

Cancer in Western Australia, 1998-2002: incidence and mortality by Statistical Local Area (SLA)

A report of the Western Australian Cancer Registry

**Health Data Collections, Health Information Centre
Department of Health
Perth, Western Australia**

August 2004

Statistical Series number 72

ISSN: 0816-2999

© 2004 Health Information Centre, Department of Health, Western Australia

Material in this publication may be reproduced and used, with acknowledgment, for genuine educational and health research purposes; no part may be published elsewhere nor copied and stored in any electronic retrieval system without the consent of the copyright holders.

Contact regarding enquiries, additional information and further copies:

Principal Medical Officer/Manager
Western Australian Cancer Registry
Health Information Centre
Department of Health
1st Floor, C Block
189 Royal St
East Perth WA 6004
AUSTRALIA

Fax : +61 (0)8 9222 4236

Phone: +61 (0)8 9222 4022

E-mail - wacanreg@health.wa.gov.au

No "spam" or commercial offers; cancer-related enquiries only please.

Internet - Department of Health home page

www.health.wa.gov.au

- Western Australian Cancer Registry home page -

www.health.wa.gov.au/wacr/

Cancer Registry Staff, 2003-2004

Timothy Threlfall	Principal medical officer/ manager	John Langley	Analyst/Programmer
Judith Thompson	Medical officer / coding advisor	Cathy Johnston	Clerical officer
Kaye Garrod	Research assistant	Colleen Kontor	Clerical officer
Charmaine Brewster	Clerical officer	Nola Olsen	Research officer (mesothelioma)

Cancer Registry Scientific Advisory Committee, 2001-2004

Dr Michael Byrne	Oncologist	Dr Christobel Saunders	Surgeon
Dr James Semmens	Epidemiologist	Dr Yee Leung	Gynaecologic oncologist
Dr Peter Heenan	Pathologist	Dr Gordon Harloe	Pathologist
Dr Cecily Metcalf	Pathologist	Dr Judith Thompson	Cancer Registry
Dr Chris Harper	Radiation oncologist	Dr Timothy Threlfall	Cancer Registry

Citation

The following citation is suggested in referring to this report:

Threlfall TJ, Powers KA, Langley J (2004) *Cancer in Western Australia, 1998-2002: incidence and mortality by Statistical Local Area (SLA)*. Department of Health, Western Australia, Perth. Statistical series number 72.

Contents

	Page
Contents	i
List of tables	ii
List of figures	ii
Summary	iii
Acknowledgements	iv
1 Introduction	
1.1 Background	1
1.1.1 Local concerns and cancer enquiries	1
1.1.2 The Western Australian Cancer Registry	1
1.1.3 Techniques available: geo-coding cancer data	2
1.1.4 This report	2
1.2 Localization of disease risks	2
1.2.1 Types of statistics	2
1.2.2 Other risk factors	3
1.2.3 Data limitations	3
1.2.4 Statistical limitations	4
1.2.5 Overview	4
2 Methods	5
2.1 Data files	5
2.2 Address information	5
2.3 Tabulations	5
2.4 Statistical methods	6
3 Technical notes and examples	6
3.1 Reference data and terminology	7
3.2 Difficult areas	7
3.3 Interpretation of SRRs: examples	7
3.4 Abbreviations used	8
3.5 Conventions regarding commonly-used words:	9
3.6 Area names and maps	9
4 Incidence and mortality SRRs by Statistical Local Area	14
4.1 Overview of results	14
4.2 State overview (a): All-cancers incidence by area - alphabetic	15
4.3 State overview (b): All-cancers incidence by area - DOH areas	16
4.4 State overview (c): All-cancers mortality by area - alphabetic	16
4.5 Incidence SRRs for common cancers - comments	27
4.6 Incidence and mortality by Statistical Local Area	28
5 References	62
Appendix 1	*
<i>Cancer incidence in individual SLAs (alphabetic)</i> <i>(odd-numbered pages)</i>	
Appendix 2	*
<i>Cancer mortality in individual SLAs (alphabetic)</i> <i>(even-numbered pages)</i>	
 * see http://www.health.wa.gov.au/wacr/ or the CD intended to be attached to this original printed report	

List of tables		Page
1	List of Statistical Local Area names and codes used in this report	10
2	Total cancer incidence by area, 1998-2002: All SLAs (alphabetic)	17
3	Total cancer incidence by area, 1998-2002: All SLAs (DOH areas)	20
4	Total cancer mortality by area, 1998-2002: All SLAs (alphabetic)	24

List of figures		Page
1	Western Australian SLA Boundaries – Map 1.	11
2	Western Australian SLA Boundaries – Map 2 (South West)	12
3	Western Australian SLA Boundaries – Map 3 (Perth Metropolitan)	13

Acknowledgments

This report is based on data recorded and maintained by the Western Australian Cancer Registry staff, and it is largely their attention to detail that underpins the operations of a high-standard case-based disease registry.

We acknowledge the invaluable contribution of the Western Australian pathologists, haematologists and radiation oncologists who supply the vast majority of the Registry's primary notifications, and the health professionals and organizations who supply additional information in response to our enquiries. Cooperation of other Australian Cancer Registries in discussions regarding procedures, coding, duplication and demarcation issues, and of the National Cancer Statistics Clearing House at AIHW, Canberra, has also played a vital part in ensuring data quality and comparability.

The Registry relies on a variety of supporting services in order to produce reports on cancer; these include population figures and projections, mapping, hospitalization data, legal advice, computing services and general support and encouragement. In this particular report, advice and discussion on statistical issues with staff of the Epidemiology Branch, HIC, and Dr Mike Philips, has been particularly helpful. Dr Paul Jelfs of the South Australian Department of Human Services provided extensive and useful comments. Thanks are also due to staff of the Health Promotion Branch for assistance with cover design and printing arrangements.

Summary

This report was written to inform Western Australians about some of the issues involved in the assessment of health issues, and cancer in particular, in different areas. These issues include disease risks other than those due to location, the natural variability of disease rates, the realities of data collection, and the statistical limitations on analysis in a State where populations are, by world standards, small and thinly-distributed.

Western Australian Cancer Registry (WACR) reports usually present cancer incidence and mortality data at a level relevant to the (W.A.) Department of Health's administrative boundaries, the Health Regions or Health Districts, so as to support the planning and operation of health services.. This report deals with a far smaller geographic unit, the Statistical Local Area (SLA), in response to growing concerns among Western Australians about perceived cancer risks in more localized areas, arising to some degree from concerns about industry in areas south of Perth.

The Registry has in recent years released data on such relatively small areas, together with material which documents the inherent limitations of the data, and the various types of information required to permit a proper assessment of "risk" due to residence in particular areas. Representation of such information in the news media has often been incomplete and inconsistent, and has appeared to focus on statistics which have sometimes, in isolation, been interpreted as indicating an elevated cancer risk in some areas.

Based on the State-wide analysis of cancer incidence and mortality for 1998-2002, there are areas where the incidence of, or mortality due to, individual cancers, or all cancers combined, has appeared higher than in the State as a whole. Likewise, there are areas where cancer incidence or mortality appeared lower than expected. In many cases, the result was based on a very small number of expected cases or deaths (less than 5) and such findings should be regarded with caution. However, in the vast majority of areas, even when based on all cancers combined, and higher numbers of expected cases, the majority of results (81% for incidence, 67% mortality) showed what appeared to be a reliable indication that results were within the range expected.

Overall, these results do not provide evidence that would support a view that there are particular areas or groups of adjacent areas in the State, where there is a systematic or consistent tendency for cancer to occur more commonly, or to cause death more commonly, than in the State as a whole.

In the analyses reported here, the numbers of cancer cases or deaths in particular areas were compared with the numbers expected based on the whole State data, to produce standardized rate ratios (SRRs) and statistical 95% confidence intervals (95% c.i.). Based on SRRs greater than 1, and confidence intervals not including 1, an assessment was made and a brief summary written to supplement the detailed statistical tables.

There were 6 Statistical Local Areas (SLAs) in which all-cancers incidence in males appeared significantly higher than in Western Australia as a whole, and all-cancers incidence in females appeared higher in 3 SLAs. All-cancers incidence in males appeared lower than expected in 16 SLAs, and for females rates appeared lower in 17 SLAs. In the remaining 86% (268) of all-

cancers comparisons made, incidence was statistically similar to the all-Western Australian rate.

In the Perth metropolitan area, there was no apparent pattern of consistently or commonly raised or lowered comparative incidence rates in any area or group of adjacent areas. There were rural areas where results appeared particularly polarized (elevated or reduced, but most often reduced) but all-cancers incidence appeared more often to be lower than average in the south of the State.

In a wide geographic area with large variations in climate, population density, work and leisure activity, cultural background, diet and access to health services, there are few measures of population health that can be expected to be distributed absolutely evenly. Despite the lack of an apparent pattern or association between groups of adjacent areas, there do appear to be variations in cancer rates within Western Australia. Difficulties with the quality of address information, which may be related in some cases to the subdivision of large areas into different SLAs with similar names, may also contribute to this variation.

In the analysis of cancer incidence, much of the data one would wish to include - socioeconomic status, residential, occupational and family history, and risks related to tobacco and alcohol consumption - are not accessible to a population-based disease registry such as the WACR. Accordingly, the reliable attribution of risk to residence in any particular area, without such additional knowledge, is beyond the capacity of this, or any other, report based only on the data currently available. Rather, it is hoped that this report has highlighted some difficulties to be addressed concerning data quality, and confirmed that the lifestyle and personal factors still need to be addressed, as the issues are far more complex than those concerning address alone.

1. Introduction

1.1 Background

1.1.1 Local concerns and cancer enquiries

Since late 2001, concerns about possible industry-related health problems have been responsible for a growing series of cancer-related data requests relating to particular areas, usually just south of Perth. The Western Australian Cancer Registry operates within the Department of Health (W.A.) (DOH), and has logged over 175 tasks related to provision of such data, or related advice to local action groups and individuals, journalists, doctors and politicians, and from the Minister for Health and Department of Health senior staff.

These sorts of issues pose a significant challenge for health information registers of all kinds. For example, there have been anecdotal reports of persons moving away from particular residential areas because of concerns over cancer risks. When no objective evidence for such risks can be found with the data available, this is a cause for great concern. In the course of dealing with such issues, the Registry must walk a fine line between making data freely available, and ensuring that the public are not alarmed without adequate scientific reasons.

The recent series of area-related tasks began with a request for time-series of cancer data for the Rockingham-Kwinana (Health Service) area. Graphs were produced, with interpretation concerning confidence intervals and a lack of statistical evidence that they showed any significant difference between State and local rates. The data were passed on by the recipient to other persons including journalists, and this has since been followed by a series of related newspaper articles and guest-editorials. Only a few of such publications have referred in any way to the Registry's initial advice concerning the limitations of such data.

In the succeeding years, the Registry has been asked to produce data for small areas based on locality name or postcode. Because of a lack of appropriate population data, and the significant risk that the Registry's advice (about the impossibility of drawing useful conclusions from case counts alone) would be disregarded, such data have not always been provided. It is regrettable that this has appeared to be interpreted, by some, as being due to a bias towards industry, or an unwillingness to reveal facts.

1.1.2 The Western Australian Cancer Registry

The Western Australian Cancer Registry (WACR) (Department of Health, Western Australia), has collected and collated information about cancers diagnosed in W.A. since 1981, supported by a legal requirement for notification under the Health Act. It is one of several State and Territory legislatively-supported population-based data collections across Australia, and produces State reports and contributes to Australian cancer reports produced by the Australian Institute of Health and Welfare (AIHW). Details of the Registry's operations can be found in current and previous reports such as) *Cancer incidence and mortality in Western Australia, 2002*, and on the Registry's Internet site at www.health.wa.gov.au/wacr/.

1.1.3 Techniques available: geo-coding cancer data

Geo-coding, or the assignment of events to a geographic area, can be done at various levels. State cancer data are routinely reported at the level of Health Region, but the Registry also produces data at Health District area level, based on postcode. Production of data at Local Government Area (LGA) or Statistical Local Area (SLA) level usually relies upon mapping an exact address.

Based on a series of methodologies detailed below, the Department has presented cancer data for various Statistical Local Areas (SLAs) south of Perth. In most of the State, SLA boundaries are the same as those of Local Government Areas, or LGAs. There have been requests from local industry and other interested parties, urging the Department of Health to examine other areas.

1.1.4 This report

This report arises out of a perceived need to inform Western Australian health workers and the public, about the variation of cancer rates across the whole State, the limitations to the conclusions that can be drawn from the statistics, and the various issues that must be considered when comparing disease rates in different areas. The report presents information in addition to the more "routine" data for Health Regions and Health Districts found in the Registry's annual reports.

This sort of information can serve as an indicator of possible risk at a broad level, and support the effective targeting of more detailed studies that also include known risk factors such as smoking and socioeconomic status. Dealing with these issues is time consuming, but necessary so as to ensure that the high-quality information contained within the Registry is used as productively as possible. In addition to the actual data, interpretation and information about limitations are necessary but all too often ignored.

1.2 Localization of disease risks

1.2.1 Localization of disease risk – Types of statistics

Interpretation of small-area statistics must always be done with caution. Risks for cancer may be sustained in one area but people may move to another area, after a diagnosis, for family reasons, or to access services related to hospitalization or support in older age. Alternatively, they may have moved for any number of reasons, before the disease became apparent.

Thus neither hospitalization data nor mortality data mapping necessarily represent the true "location" of any increased risk of disease. Mortality data are crucial in the planning of health services, and are considered in this report. However, even more so than mortality, hospitalization data are affected by the services already available, and are not presented as an independent issue in this report.

Among these types of statistics - incidence, mortality and hospitalization - only cancer incidence data may be directly related to disease risks. However, there are important limitations to the interpretation of such data, and these are presented in the summary which follows.

1.2.2 Localization of disease risk – Other risk factors

Factors other than location itself are known to be important: while lung cancer incidence, for example, is commonly higher in areas of low average socioeconomic status, the large mid-1990s increase in the apparent incidence of prostate cancer in Western Australia occurred primarily in males in areas of higher average socioeconomic status.¹ Other issues such as previous residential and occupational histories, family history and genetic predisposition, and lifestyle factors such as tobacco, alcohol and diet, are likely to be more important disease risk factors than the location where one lives when a disease is diagnosed.

Incidence data are less likely to suffer the biases inherent in the use of mortality and hospitalization data, but interpretation remains problematic. One of the greatest limitations is the variable and usually unknown time delay between “causes” of cancer and its onset or detection, and the duration for which a “cause” has to be present. The time delay between cause and cancer is often referred to as “lag time” or “lead time” and may be as long as 40 or 50 years in the case of mesothelioma.

In communities which are common destinations amongst persons of retirement age, there are other issues that might affect reported cancer incidence, independent of the fact that incidence rates, or ASRs, are adjusted for age. These may include the availability of free time to seek medical advice about existing symptoms, the chance of a coincidental finding of cancer when seeking attention for other health complaints, and the concentration of screening programmes in areas of high population density for the sake of efficiency.

1.2.3 Localization of disease risk – Data limitations

Ideally, a study of disease by area would be based on complete and accurate information, however many population-based registries must accept substantial variation in the quality of data supplied. With the use of up-to-date directories and maps, many exact street-based addresses can be plotted accurately on an electronic grid, and assigned to a locality name, Local Government Area, Health District or any chosen boundary-set.

However, postal addresses are used primarily to ensure the delivery of mail, and not to facilitate epidemiological analysis. These include address-types such as PO Boxes, Roadside Mail stops (RMB or RSM), and institutions such as retirement complexes that may be so large as to overlap some boundaries. In these cases, the true geographic location of an individual’s usual place of residence may not be able to be determined, and results in the assigning of a locality code that is divorced from the real location of a home.

In this context - comparing rates in different areas - a major concern is that is that un-mappable addresses cannot be assumed to be evenly distributed, as people in rural areas appear more likely to use a PO Box , RMB or a farm name as part of an address. For example, Cancer Registry locality data for 1998-2002 were based on postcode-only in 1.5% of residents of the SLA of Nedlands, 24% for Hall’s Creek, and 28% for Waroona.

1.2.4 Localization of disease risk – Statistical limitations

Whenever a large number of related statistical tests are done, with any given "confidence interval", it can be expected that some may yield a "significant" result due to chance alone (up to 5 in 100, if using a 0.05 significance level). This may not be due to a health problem but rather can be the outcome of the statistical processing and chance itself. There is a risk that recipients of such data will concentrate on the unusual results and ignore the vast majority that indicate no significant difference, or even a reduction in risk.

This has previously occurred for the areas south of Perth, for which standardized incidence rate ratios based on 1996-2000 data were calculated for 57 cancer types, for males and females, for 8 areas, a total of over 900 comparisons. Among these, there were approximately 3% of results that appeared "significant", and of these, the majority showed a deficit of cases when compared to the State as a whole. Selective reporting of such information, supplied by the Registry on request, can seriously mislead the public.

In addition, even "statistically significant" results must be interpreted with caution or disregarded if based on unrealistically small numbers of "events".

1.2.5 Localization of disease risk – Overview

The data presented here are robust and the most recent available, and should support other work on the relevant issues. However, the preceding points suggest that the data in this report should be read critically and with due regard to the numbers of cases involved, and the reader should consider that the best possible analysis would ideally take into account far more than residence, age and sex, and include other factors related to history, occupation and lifestyle. Such information is not practicable to obtain on a population-wide basis.

2. Methods

2.1 Data files

The data used for this report were based on the same files as used for the WACR's most recent report, *Cancer incidence and mortality in Western Australia, 2002*,² and include cancer diagnoses and cancer-related deaths in Western Australian residents in the years 1998-2002 combined. As for routine reports, cancers are grouped according to body location and/or tumour type. In the tables in this report, cancers are shown in descending order of frequency based on the data for 1998-2002. Population data files for the State and for each SLA were sourced from the Australian Bureau of Statistics (Population by age and sex, Catalogue number 3201.0, June 2003).

2.2 Address information

Addresses for incident cancer notifications, and addresses of residence at date of death, are geocoded within the Health Information Centre using a combination of methods, by Data Linkage Unit and Cancer Registry staff. The most precise processes include exact address mapping to a latitude and longitude using electronic directories from the (W.A.) Department of Land Administration (DOLA), and matching of institutional type addresses to reference files compiled within the HIC.

In a less exact process, for mis-spelled, vague or otherwise un-mappable addresses, the assignment of a SLA and/or LGA was based on reference tables compiled with the assistance of maps and 2001 Census data, in which locality names and/or postcodes were assigned to an area on a "best fit" basis, with reference to proportional overlap of boundaries in terms of area and population size.

Australia Post's delivery areas or Postcodes are the most usual basis for assignment to the Department of Health's Regions and Districts, and can be used for much SLA-related work. The majority of place names and postcodes can be mapped to SLA level without major error. For example, just over 80% of the 465 postcodes in the data files "fitted" into an SLA on the basis of an 80% or better overlap. The proportion of addresses that required these methods was low: for the State overall, 94% of 1998-2002 cases could be coded without such methods, and just over 91% of addresses were able to be coded to a Census Collector's District (CD) level.

2.3 Tabulations

Data were tabulated using Cancer Registry software and the various blocks of data (cases and population, for each SLA and for the whole State) were used to calculate Standardized Rate ratios (SRRs) based on what might have been expected based on the whole-State rates for each cancer type. The results were transferred back to original files, which were then used to produce the summary tables presented in this report using various remote cell-reference formulae and macros in MS Excel.

The data used include sex and 5-year age group information, but do not take into account indigenous status or other factors referred to in the Introduction.

2.4 Statistical methods

Age-standardized rates (ASR in Tables) are calculated by the direct method³ and represent a summation of weighted age-specific rates (weighting being determined by the relative proportion of the population in each age group compared with the proportion in the World Standard Population⁴).

The **standard deviation** is used as a measure of variability for rates in tables; an approximate 95% confidence interval for a rate is (rate \pm 1.96 ESE).

Formulae:

$$\text{ASR} = 10^5 \times \sum_i r_i \times w_i ; \quad \text{SD} = 10^5 / W \times [\sum_i \{ r_i \times (1 - r_i) \times w_i^2 / n_i \}]^{1/2} ,$$

where w_i is the Standard Population for the i th age group, $W = \sum_i w_i$ and \sum_i denoted summation over all (relevant) age groups.

Comparison of rates between different areas in this report is based on **indirect standardization**. Sex and 5-year age group are used in calculating the expected case numbers for each area: the State age-specific rates have been used to calculate an expected number of cases in different areas, based on their populations. The ratio of the observed and expected numbers is the **Standardized Rate Ratio** (SRR), and a **95% confidence interval** (95% c.i.) is one of the other results of the calculation, giving an indication of the statistical reliability of the SRR. The method for calculating confidence intervals involves use of both the Normal and Poisson probability distributions depending on absolute number of observed cases involved.

Analysis of statistics with small numbers of "cases" presents difficulties in interpretation, and in statistical comparisons Chi-square statistics based on tables with less than 5 observations in any cell are usually subject to a "continuity correction" (Yates correction).^{5,6,7} For related reasons, indirect standardization may not be regarded as reliable where there are very small numbers of "expected" cases in an analysis. Results based on less than 5 expected cases should be treated with caution even if statistically-significant.

Most results based on less than 5 expected cases are marked with "*" in tables in this report, with two types of exceptions. In special situations, other methods have been used as noted here:

- (1) For the situation in which there are no (0) cases recorded, and none were expected, "." indicates that no statistical test was possible. Neither an SRR or 95% c.i. are shown.
- (2) For the situation in which there were no (0) cases recorded, but some were expected, a meaningful SRR and confidence interval cannot be calculated. A Chi-square statistic was calculated using the formula $[(\text{Observed} - \text{Expected})^2 / \text{Expected}]$. For zero observed cases, this statistic is equal to the expected number of cases, and using 1 degree of freedom this yields a statistically-significant result for situations where the expected number of cases is 4 or more.

Thus while 0 cases observed and 3 expected yields a p-value of greater than 0.05 (indicated with "-" in tables), for 4 or more expected cases this would yield $p < 0.05$ (shown as "v" in tables). In either case, the SRR is shown as 0 and the correct (but un-informative) confidence interval (0 - 0) is replaced with "n/a".

3. Technical notes and examples

3.1 Reference data and terminology

The incidence and mortality data from the Western Australian Cancer Registry from 1998 to 2002 were allocated into 55 different cancer groups. For each of these groups the standardized rate ratio (SRR) was calculated using the ratio of local cancer cases (or deaths) to an expected number based on all-W.A. rates, the expected numbers being calculated using State age-specific rates in 5-year age groups. The "reference" to which all individual-area data was compared, was in effect the cancer incidence or mortality rate for the whole of Western Australia, variously referred to as the "all-W.A. rate", "State rate" or rates "in the State as a whole". The "Cancer incidence" and "Cancer mortality" headings set the context for the words which follow them, in which "rates" may be used alone for simplicity. The term "SRR" (standardized rate ratio) is used to refer to both incidence and mortality in the relevant sections.

3.2 Difficult areas

Some of the limitations to the "placement" of individual events (incidence, deaths) due to poor-quality address information have been mentioned. These appear more likely to affect the distribution of cancer rates in particular pairs of related/adjoining areas which share parts of their names, such as Fremantle (Inner vs Remainder), Albany (Central vs Balance), Perth (Inner vs Remainder), and Narrogin (Shire vs Town). For example, an apparently low incidence of cancers in males in Narrogin (Shire), and an apparently-high rate in Narrogin (Town), seem likely to be due to artefact, rather than to true area-based differences in cancer risk.

3.3 Interpretation of SRRs: examples

First impressions may be misleading and even though SRRs are available for many comparisons made here, they are "point estimates" that should not be assessed in isolation from the confidence intervals, and the numbers of cases expected.

Standardized rate ratios (SRRs) with wide 95% confidence intervals (which include 1) are not regarded as indicating a statistically-significant difference in disease rates between the areas (or groups) concerned. Accordingly, high (or low) SRRs with very wide confidence intervals are not routinely discussed in the results sections of this report.

SRRs, even with confidence intervals not including 1, can be of questionable reliability in situations where there is a very low expected number of cases (see "Statistical methods").

An example from this report is total cancer incidence in males in the SLA of Cue (Section 4.6). The SRR was 1.79, suggesting cancer incidence to be 79% higher than average – but the 95% c.i. was 0.56 to 3.34, and the total number of cases was 7, against an expectation of 4 (in a 5 year period). In this case, both the wide confidence interval and the small expected number of cases indicates these data should not be interpreted as indicating a significant excess risk of cancer.

In another example, with more "expected" cases (9 in males, 8 in females), the all-cancers incidence SRRs for the SLA of Dowerin suggested incidence rate elevations of 40% in males

and 93% in females, but the wide 95% confidence intervals (0.67-2.26 for males, 0.99-3.03 for females) indicate that these estimates are not statistically reliable.

In some instances where there were no cancer cases observed, and none expected, no assessment can be made - for example breast cancer in males in Albany, with a flag of "." in tables.

In other cases, where no cancers were found but some were expected, tables show an unremarkable result ("-") or a significant deficit of cases ("v") - depending on the number of cases expected. For Albany (Central) males, 3 cases of lip cancer were expected but none were observed, a statistically non-significant difference. However for females in the Ngaanyatjaraku SLA, the total number of cancer cases expected was 8 and none were observed, indicating that the local incidence rate was significantly lower than the State rate.

3.4 Abbreviations used

DOH - Department of Health (W.A.)

WACR - Western Australian Cancer Registry

SLA names: (C) refers to City, (T) refers to Town (or Municipality), (S) refers to Shire.

W.A. - Western Australia.

95% c.i. - the statistical 95% confidence interval, indicating the range of values within which the true measure represented by a statistical estimate (e.g. an SRR) should lie, with 95% confidence.

ASR - age-standardized rate per 100,000 population, representing a summation of weighted age-specific rates (weighting being determined by the relative proportion of the population in each age group compared with the proportion in the (1960) World Standard Population.

SRR - standardized rate ratio; applied to incidence or mortality rates in this report. This is effectively a ratio of disease rates in two areas, with adjustment based on the relative proportions of persons in each 5-year age group in the populations of the areas. In this report, SRRs are calculated separately for males and females.

Cancer types - some cancer types listed in the tables, are referred to in the text by more simple terms, for example:

Lung includes lung, bronchus and trachea;

Bladder refers to "Urinary bladder";

Myeloma refers to "Myeloma/plasma cell tumours"; and

Kidney refers to "Kidney & other renal tract".

Ovarian and **Ovary** refer to "Ovary & uterine adnexa"

Gallbladder refers to "Gallbladder & bile ducts"

The text should be read in conjunction with the tables so that the terminology is clear.

3.5 Conventions regarding commonly-used words:

"Similar" means statistically similar, referring to a difference (e.g. an SRR) that has a 95% confidence interval that includes 1.

"Significant" means statistically significant, referring to a difference or a ratio (e.g. an SRR) that has a 95% confidence interval that does NOT include 1.

"Expected" means the case numbers or rates that would have been expected in a given area, on the basis of how the area's population compares to the whole State population (numbers of each sex and 5-year age group), if age-and-sex-specific risks were similar over the whole State. It does NOT imply any aspect of "prediction" or forecasting of future events based on past data.

"Average" is used on occasion to refer to the State-based predicted/expected incidence or death rates based on 1998-2002 data for all SLAs combined.

3.6 Area names and maps

On the next 4 pages there appear a list of all the SLA names for which data were examined, which are those used for the 2001 Australian census reporting; and a set of outline maps showing the area boundaries.

Table 1. List of Statistical Local Area names and codes used in this report

SLA name	ABS code	SLA name	ABS code	SLA name	ABS code
Albany (C) - Central	50081	Fremantle (C) - Remainder	53432	Northam (S)	56720
Albany (C) Bal	50084	Geraldton (C)	53500	Northam (T)	56650
Armadale (C)	50210	Gingin (S)	53570	Northampton (S)	56790
Ashburton (S)	50250	Gnowangerup (S)	53640	Nungarin (S)	56860
Augusta-Margaret River (S)	50280	Goomalling (S)	53710	Peppermint Grove (S)	56930
Bassendean (T)	50350	Gosnells (C)	53780	Perenjori (S)	57000
Bayswater (C)	50420	Greenough (S) - Pt A	53851	Perth (C) - Inner	57081
Belmont (C)	50490	Greenough (S) - Pt B	53854	Perth (C) - Remainder	57082
Beverley (S)	50560	Halls Creek (S)	53920	Pingelly (S)	57140
Boddington (S)	50630	Harvey (S) - Pt A	53991	Plantagenet (S)	57210
Boyup Brook (S)	50770	Harvey (S) - Pt B	53994	Port Hedland (T)	57280
Bridgetown-Greenbushes (S)	50840	Irwin (S)	54060	Quairading (S)	57350
Brookton (S)	50910	Jerramungup (S)	54130	Ravensthorpe (S)	57420
Broome (S)	50980	Joondalup (C) - North	54171	Rockingham (C)	57490
Broomehill (S)	51050	Joondalup (C) - South	54174	Roebourne (S)	57560
Bruce Rock (S)	51120	Kalamunda (S)	54200	Sandstone (S)	57630
Bunbury (C)	51190	Kalgoorlie/Boulder (C) - Pt A	54281	Serpentine-Jarrahdale (S)	57700
Busselton (S)	51260	Kalgoorlie/Boulder (C) - Pt B	54284	Shark Bay (S)	57770
Cambridge (T)	51310	Katanning (S)	54340	South Perth (C)	57840
Canning (C)	51330	Kellerberrin (S)	54410	Stirling (C) - Central	57914
Capel (S) - Pt A	51401	Kent (S)	54480	Stirling (C) - Coastal	57915
Capel (S) - Pt B	51404	Kojonup (S)	54550	Stirling (C) - South-Eastern	57916
Carnamah (S)	51470	Kondinin (S)	54620	Subiaco (C)	57980
Carnarvon (S)	51540	Koorda (S)	54690	Swan (C)	58050
Chapman Valley (S)	51610	Kulin (S)	54760	Tambellup (S)	58120
Chittering (S)	51680	Kwinana (T)	54830	Tammin (S)	58190
Claremont (T)	51750	Lake Grace (S)	54900	Three Springs (S)	58260
Cockburn (C)	51820	Laverton (S)	54970	Toodyay (S)	58330
Collie (S)	51890	Leonora (S)	55040	Trayning (S)	58400
Coolgardie (S)	51960	Mandurah (C)	55110	Upper Gascoyne (S)	58470
Coorow (S)	52030	Manjimup (S)	55180	Victoria Park (T)	58510
Corrigin (S)	52100	Meekatharra (S)	55250	Victoria Plains (S)	58540
Cottesloe (T)	52170	Melville (C)	55320	Vincent (T)	58570
Cranbrook (S)	52240	Menzies (S)	55390	Wagin (S)	58610
Cuballing (S)	52310	Merredin (S)	55460	Wandering (S)	58680
Cue (S)	52380	Mingenew (S)	55530	Wanneroo (C) - North-East	58761
Cunderdin (S)	52450	Moora (S)	55600	Wanneroo (C) - North-West	58764
Dalwallinu (S)	52520	Morawa (S)	55670	Wanneroo (C) - South	58767
Dandaragan (S)	52590	Mosman Park (T)	55740	Waroona (S)	58820
Dardanup (S) - Pt A	52661	Mount Magnet (S)	55810	West Arthur (S)	58890
Dardanup (S) - Pt B	52664	Mount Marshall (S)	55880	Westonia (S)	59030
Denmark (S)	52730	Mukinbudin (S)	55950	Wickepin (S)	59100
Derby-West Kimberley (S)	52800	Mullewa (S)	56020	Williams (S)	59170
Donnybrook-Balingup (S)	52870	Mundaring (S)	56090	Wiluna (S)	59250
Dowerin (S)	52940	Murchison (S)	56160	Wongan-Ballidu (S)	59310
Dumbleyung (S)	53010	Murray (S)	56230	Woodanilling (S)	59380
Dundas (S)	53080	Nannup (S)	56300	Wyalkatchem (S)	59450
East Fremantle (T)	53150	Narembeen (S)	56370	Wyndham-East Kimberley (S)	59520
East Pilbara (S)	53220	Narrogin (S)	56510	Yalgoo (S)	59590
Esperance (S)	53290	Narrogin (T)	56440	Yilgarn (S)	59660
Exmouth (S)	53360	Nedlands (C)	56580	York (S)	59730
Fremantle (C) - Inner	53431	Ngaanyatjarraku (S)	56620		

Figure 1. Western Australian SLA Boundaries – Map 1




Figure 2. Western Australian SLA Boundaries – Map 2 (South West)





Figure 3. Western Australian SLA Boundaries – Map 3 (Perth Metropolitan)



4. Incidence and mortality SRRs by Statistical Local Area

4.1 Overview of results

This report shows, based on a Statewide analysis of cancer incidence and mortality for 1998-2002, that in the vast majority of areas, even when based on all cancers combined, and on reasonably high expected numbers of cases, the majority of results (81% for incidence, 67% mortality) appear to indicate that cancer incidence and mortality rates were similar to all-Western Australian rates.

There were areas where the incidence of, or mortality due to, individual cancers, or all cancers combined, has appeared higher than in the State as a whole. Likewise, there are areas where cancer incidence or mortality appeared lower than expected. In many of these findings, the result was based on a very small number of expected cases or deaths (less than 5) and should be regarded with caution.

The results of incidence and mortality comparisons, for individual cancer types across the State, show a wide range of results. As discussed in the Methods sections of this report, when disease categories become more specific and areas become smaller, the chance of a statistically-significant result is decreased, and there are more comparisons that cannot be performed because of a lack of data. Accordingly, a greater proportion of cancer incidence results were "statistically significant" in the all-cancers analyses (14%), than in the comparisons for individual cancer types (1%). For mortality (based on smaller numbers), the corresponding figures were 11% and 0.6%.

Conversely, the proportion of comparisons for which no data were available was highest where data were most scarce - 75% for mortality for individual cancer types, 65% for incidence of individual cancer types, 0.6% for all-cancers mortality, and 0 for all-cancers incidence. This could be addressed by aggregating cancer types into larger groups - or by not showing results for very uncommon cancer types.

A statistically-significant lack of cases was more common than a significant excess of cases (or deaths). In assessment of incidence of individual cancer types, only 0.3% of comparisons showed a significant incidence rate elevation in a particular area (although a quarter of these were based on very small expected numbers of cases). In all-cancers analyses, 3% of comparisons showed an excess.

In assessment of incidence of individual cancer types, only 0.8% of comparisons showed a significantly reduced incidence rate in a particular area (although 10% of these were based on very small expected numbers of cases). In all-cancers analyses, 11% of comparisons showed such a deficit.

Overall, 6% of all-cancer incidence comparisons, and 23% of all-cancers mortality comparisons, were based on expected case/death numbers less than 5, and have been flagged in tables with "*" indicating a possible lack of reliability in the indirect-standardization method.

For individual cancer type analyses, the corresponding numbers were 19% for incidence, and 14% for mortality (but many more mortality comparisons fell into the "not assessable" category).

The results summarized here and presented in tables represent a total of 34,100 statistical comparisons based on an area (SLA), a cancer type or all-cancers, and males or females. It might be suggested that there are too many areas with small populations, and too many cancer types seen only rarely, to justify analysing the Western Australian data at this level of detail routinely, as a high proportion of results were based on numbers that are insufficient to permit reliable assessment. Although the summary statistics are not easy to explain in simple terms, this summary warrants some attention as it demonstrates some of the concerns foreshadowed in the Methods sections of this report.

Routine analysis at the level of Health Regions may obscure differences within large areas, but even analysis at Health District level may be unsatisfactory (i.e. give inconclusive results) when looking at individual, uncommon cancer types. The all-cancers results are generally more satisfactory than many individual-cancers results, as expected case numbers were sufficient to permit a reasonable assessment in most comparisons (94% for incidence, 77% for mortality).

4.2 State overview (a): All-cancers incidence by area - alphabetic

Table 2 shows the all-cancers incidence results for all SLAs in Western Australia, listed in alphabetic order.

Based on SRRs greater than 1, and 95% confidence intervals (95% c.i.) not including 1, there were 6 Statistical Local Areas (SLAs) in which all-cancers incidence in males appeared significantly higher than in Western Australia as a whole: Fremantle (Remainder), Geraldton, Meekatharra, Narrogin (Town), Stirling (Coastal) and Wanneroo (North-West). In the case of Narrogin, the problem of accurately allocating addresses to Town or Shire is most likely responsible for this. In females, incidence appeared higher in Geraldton, Nedlands and Victoria Plains.

All-cancers incidence in males appeared lower than expected in 16 SLAs - Albany (Balance), Armadale, Boyup Brook, Capel (Part A), Chapman Valley, Coolgardie, Denmark, Laverton, Menzies, Mount Magnet, Narrogin (Shire), Ngaanyatjarraku, Shark Bay, Wandering, Wiluna and Woodanilling. Address artefact most likely accounts for much of the Albany and Narrogin result, and the Woodanilling result, based on only 4 cases expected, must be regarded with caution.

All-cancers incidence in females appeared lower than average in 17 SLAs - Ashburton, Capel (Part A), Dardanup (Part B), East Pilbara, Goomalling, Greenough (A and B), Jerramungup, Kulin, Manjimup, Narrogin (Shire), Ngaanyatjarraku, Perth (remainder), Pingelly, Tammin, Victoria Park and West Arthur. Narrogin and probably Capel data seem likely to be due to address artefacts, and the Tammin result was based on an expectation of only 4 cases and should be considered with caution.

In the remaining 86% (268) of all-cancers comparisons made, incidence was statistically similar to the all-Western Australian rate; however in 17 comparisons the "similar" result was based on less than 5 cases expected and must be regarded with caution.

4.3 State overview (b): All-cancers incidence by area - Department of Health (DOH) areas

Table 3 shows the all-cancers incidence results for all SLAs in Western Australia, listed in an order reflecting the current Department of Health (DOH) administrative boundaries.

In the Perth metropolitan area, there was no apparent pattern of consistently or commonly raised or lowered comparative incidence rates.

In rural areas, an apparent feature was a highly variable set of results for males and females in the Murchison and Geraldton Health District areas. In the case of Geraldton, there is likely to have been considerable address artefact in the Geraldton and Greenough SLAs; in the Murchison, the variable results are likely a result of small and mobile or otherwise rapidly changing populations; most comparisons in females were based on very small case numbers.

In the Northern Goldfields area, a lower than expected all-cancers rate appeared common, especially in males. In the Lower Great Southern area, a lower than expected all-cancers rate appeared common, especially in females. In the South West Region there were fewer statistically-significant results, however all of these indicated a lower than expected cancer incidence rate in this area.

4.4 State overview (c): All-cancers mortality by area - alphabetic

Table 4 shows the all-cancers mortality results for all SLAs in Western Australia, listed in alphabetic order. As noted in Section 1.2.1, cancer mortality is more likely than incidence to be related to availability of health services, and less likely to indicate a real risk of disease in particular areas.

In males, all-cancers mortality was statistically higher than the State rate in the 6 SLAs of Belmont, Geraldton, Kwinana, Narrogin (Town), Perth (Remainder) and Victoria Park. In females, mortality was higher than the State rate in the 4 SLAs of Bassendean, Joondalup (North), Murray and Nedlands.

Rates were lower than expected in males in the 13 SLAs of Albany (Balance), Ashburton, Boyup Brook, Fremantle (Inner), Goomalling, Jerramungup, Joondalup (South), Laverton, Narrogin (Shire), Ngaanyatjarraku, Shark Bay, West Arthur and Williams. In females, rates were lower than State rates in the 10 SLAs of Augusta-Margaret river, Capel (Part A), Chittering, Cottesloe, Dalwallinu, Goomalling, Nannup and Narrogin (Shire), Roebourne and Serpentine-Jarrahdale.

In particular, Nannup and Laverton results were based on very small numbers of expected deaths and should be regarded with caution; the Narrogin Shire vs Town results, as for all-cancers incidence, are likely to be unreliable due to poor quality of address information.

Table 2. Total cancer incidence⁽¹⁾ by area, 1998-2002: All SLAs (alphabetic)

Area	Males					Sig(2)	Females					Sig(2)
	Cases	ASR	95% c.i.	SRR	95% c.i.		Cases	ASR	95% c.i.	SRR	95% c.i.	
Albany (C) - Central	239	404.0	(349.8 - 458.1)	0.98	(0.86 - 1.11)	-	225	301.9	(255.7 - 348.0)	1.05	(0.92 - 1.20)	-
Albany (C) Bal	110	220.2	(178.4 - 262.1)	0.65	(0.54 - 0.79)	V	99	219.0	(175.3 - 262.7)	0.86	(0.70 - 1.05)	-
Armadale (C)	458	296.1	(268.8 - 323.4)	0.87	(0.79 - 0.96)	V	461	271.9	(246.3 - 297.5)	1.04	(0.95 - 1.14)	-
Ashburton (S)	27	275.4	(151.4 - 399.5)	0.84	(0.53 - 1.18)	-	13	113.0	(30.6 - 195.3)	0.59	(0.28 - 0.94)	V
Augusta-Margaret River (S)	106	299.5	(239.8 - 359.1)	0.93	(0.76 - 1.13)	-	84	245.6	(189.8 - 301.3)	1.00	(0.80 - 1.24)	-
Bassendean (T)	173	340.8	(288.8 - 392.8)	1.00	(0.86 - 1.16)	-	136	240.0	(197.1 - 283.0)	0.91	(0.77 - 1.08)	-
Bayswater (C)	678	316.0	(291.4 - 340.7)	0.93	(0.86 - 1.00)	-	626	269.9	(246.8 - 293.1)	1.03	(0.95 - 1.12)	-
Belmont (C)	425	353.2	(317.5 - 388.8)	1.04	(0.95 - 1.15)	-	360	278.7	(246.6 - 310.8)	1.07	(0.97 - 1.19)	-
Beverley (S)	24	320.2	(184.9 - 455.5)	0.90	(0.55 - 1.29)	-	13	170.0	(69.8 - 270.3)	0.72	(0.34 - 1.16)	-
Boddington (S)	12	257.4	(95.3 - 419.6)	0.85	(0.39 - 1.39)	-	11	315.5	(126.3 - 504.7)	1.09	(0.48 - 1.82)	-
Boyup Brook (S)	14	205.9	(96.1 - 315.7)	0.61	(0.30 - 0.97)	V	17	226.6	(98.3 - 355.0)	0.94	(0.50 - 1.43)	-
Bridgetown-Greenbushes (S)	45	310.6	(216.3 - 404.8)	0.87	(0.62 - 1.14)	-	45	307.3	(215.7 - 398.9)	1.12	(0.80 - 1.47)	-
Brookton (S)	14	242.8	(99.3 - 386.2)	0.84	(0.42 - 1.33)	-	18	449.9	(228.9 - 670.9)	1.73	(0.95 - 2.61)	-
Broome (S)	71	270.4	(205.2 - 335.7)	0.86	(0.68 - 1.09)	-	58	221.5	(160.7 - 282.2)	0.95	(0.73 - 1.24)	-
Broomehill (S)	5	269.0	(28.7 - 509.3)	0.88	(0.19 - 1.79)	-	3	132.6	(0.0 - 282.6)	0.67	(0.05 - 1.56)	-*
Bruce Rock (S)	19	411.7	(218.7 - 604.7)	1.21	(0.68 - 1.81)	-	11	231.9	(88.9 - 375.0)	0.93	(0.41 - 1.56)	-
Bunbury (C)	330	323.7	(287.0 - 360.3)	0.93	(0.83 - 1.03)	-	316	282.9	(248.8 - 316.9)	1.06	(0.95 - 1.18)	-
Busseton (S)	284	324.5	(284.6 - 364.4)	0.97	(0.86 - 1.09)	-	215	242.7	(207.0 - 278.4)	0.91	(0.80 - 1.05)	-
Cambridge (T)	332	338.9	(299.7 - 378.0)	1.00	(0.90 - 1.12)	-	306	265.7	(231.1 - 300.4)	1.04	(0.93 - 1.17)	-
Canning (C)	766	331.1	(307.3 - 354.9)	0.97	(0.90 - 1.04)	-	697	250.7	(231.2 - 270.2)	0.99	(0.92 - 1.07)	-
Capel (S) - Pt A	12	174.0	(72.8 - 275.2)	0.56	(0.25 - 0.91)	V	9	151.1	(46.9 - 255.3)	0.51	(0.20 - 0.90)	V
Capel (S) - Pt B	38	278.6	(188.2 - 369.1)	0.79	(0.54 - 1.06)	-	39	321.9	(217.5 - 426.3)	1.15	(0.79 - 1.53)	-
Carnamah (S)	6	210.9	(43.3 - 378.5)	0.75	(0.20 - 1.45)	-	6	280.3	(52.9 - 507.7)	1.14	(0.31 - 2.22)	-
Carnarvon (S)	59	268.6	(199.7 - 337.5)	0.80	(0.61 - 1.03)	-	44	256.7	(179.3 - 334.1)	0.93	(0.66 - 1.23)	-
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	0.20	(0.00 - 0.57)	V	5	134.3	(13.9 - 254.8)	0.75	(0.16 - 1.54)	-
Chittering (S)	35	342.7	(220.8 - 464.7)	0.97	(0.66 - 1.32)	-	17	199.7	(103.0 - 296.4)	0.74	(0.40 - 1.13)	-
Claremont (T)	140	387.9	(313.7 - 462.1)	1.08	(0.91 - 1.28)	-	146	266.4	(208.7 - 324.1)	1.09	(0.92 - 1.28)	-
Cockburn (C)	647	340.4	(314.1 - 366.7)	1.01	(0.93 - 1.09)	-	560	271.6	(248.6 - 294.7)	1.04	(0.96 - 1.13)	-
Collie (S)	127	395.3	(322.7 - 467.9)	1.16	(0.97 - 1.38)	-	94	308.7	(242.8 - 374.6)	1.13	(0.92 - 1.39)	-
Coolgardie (S)	17	162.6	(74.2 - 251.1)	0.65	(0.35 - 0.99)	V	16	264.7	(117.6 - 411.8)	0.87	(0.46 - 1.35)	-
Coorow (S)	25	491.5	(300.0 - 683.0)	1.47	(0.91 - 2.10)	-	13	302.6	(136.7 - 468.6)	1.19	(0.57 - 1.93)	-
Corrigin (S)	12	252.5	(107.6 - 397.5)	0.68	(0.31 - 1.12)	-	13	230.2	(94.7 - 365.7)	0.93	(0.44 - 1.50)	-
Cottesloe (T)	98	333.8	(265.4 - 402.2)	1.01	(0.83 - 1.24)	-	98	308.5	(234.1 - 382.9)	1.10	(0.90 - 1.35)	-
Cranbrook (S)	11	287.1	(108.7 - 465.4)	0.72	(0.31 - 1.20)	-	8	224.8	(58.2 - 391.4)	0.92	(0.32 - 1.66)	-
Cuballing (S)	10	352.8	(136.9 - 568.7)	1.13	(0.47 - 1.94)	-	5	236.4	(21.4 - 451.4)	0.83	(0.18 - 1.69)	-
Cue (S)	7	856.5	(255.0 - 1,458.1)	1.79	(0.56 - 3.34)	-*	1	114.3	(0.0 - 335.1)	0.41	(0.00 - 1.52)	-*
Cunderdin (S)	15	300.3	(148.1 - 452.4)	0.86	(0.44 - 1.35)	-	8	135.8	(28.5 - 243.0)	0.62	(0.22 - 1.12)	-
Dalwallinu (S)	19	320.2	(175.4 - 465.0)	0.94	(0.53 - 1.40)	-	12	228.1	(94.5 - 361.7)	0.83	(0.38 - 1.37)	-
Dandaragan (S)	42	326.1	(221.7 - 430.4)	1.01	(0.71 - 1.34)	-	23	252.2	(147.7 - 356.7)	0.91	(0.55 - 1.32)	-
Dardanup (S) - Pt A	47	314.9	(224.1 - 405.6)	0.93	(0.66 - 1.21)	-	41	239.6	(164.9 - 314.3)	0.99	(0.69 - 1.32)	-
Dardanup (S) - Pt B	25	299.5	(181.4 - 417.6)	0.90	(0.55 - 1.29)	-	10	144.8	(53.8 - 235.7)	0.56	(0.23 - 0.96)	V
Denmark (S)	51	244.8	(176.4 - 313.3)	0.75	(0.56 - 0.99)	V	40	240.5	(157.8 - 323.3)	0.83	(0.58 - 1.11)	-
Derby-West Kimberley (S)	51	329.3	(237.7 - 420.8)	0.94	(0.70 - 1.24)	-	33	237.2	(153.0 - 321.4)	0.88	(0.58 - 1.20)	-
Donnybrook-Balingup (S)	42	255.3	(177.9 - 332.7)	0.77	(0.54 - 1.02)	-	45	278.1	(195.4 - 360.8)	1.10	(0.78 - 1.44)	-
Dowerin (S)	13	493.7	(222.8 - 764.6)	1.40	(0.67 - 2.26)	-	15	460.0	(217.5 - 702.6)	1.93	(0.99 - 3.03)	-
Dumbleyung (S)	8	297.4	(86.7 - 508.2)	0.79	(0.28 - 1.42)	-	3	122.5	(0.0 - 261.9)	0.44	(0.04 - 1.03)	-
Dundas (S)	13	328.2	(148.4 - 508.0)	0.92	(0.44 - 1.49)	-	7	240.0	(51.9 - 428.1)	0.77	(0.24 - 1.43)	-
East Fremantle (T)	88	331.8	(259.0 - 404.5)	1.02	(0.82 - 1.26)	-	74	269.3	(199.6 - 339.1)	1.00	(0.79 - 1.26)	-
East Pilbara (S)	27	217.3	(118.0 - 316.5)	0.71	(0.45 - 1.01)	-	10	99.4	(29.6 - 169.3)	0.41	(0.17 - 0.70)	V
Esperance (S)	138	334.3	(278.1 - 390.5)	0.97	(0.82 - 1.15)	-	106	253.6	(203.8 - 303.3)	0.97	(0.80 - 1.18)	-
Exmouth (S)	23	374.6	(209.0 - 540.2)	1.08	(0.65 - 1.57)	-	11	209.2	(84.5 - 333.9)	0.76	(0.33 - 1.28)	-
Fremantle (C) - Inner	12	317.5	(131.0 - 504.0)	0.87	(0.40 - 1.43)	-	8	383.2	(105.2 - 661.1)	1.34	(0.47 - 2.42)	-
Fremantle (C) - Remainder	404	402.9	(361.7 - 444.1)	1.17	(1.06 - 1.30)	^	295	271.4	(237.5 - 305.2)	1.03	(0.91 - 1.15)	-
Geraldton (C)	287	419.2	(369.7 - 468.7)	1.21	(1.08 - 1.36)	^	233	314.6	(271.5 - 357.7)	1.19	(1.05 - 1.36)	^
Gingin (S)	73	429.4	(327.1 - 531.7)	1.23	(0.97 - 1.55)	-	40	265.1	(179.3 - 350.8)	1.01	(0.70 - 1.35)	-
Gnowangerup (S)	26	530.7	(325.7 - 735.7)	1.51	(0.94 - 2.14)	-	12	221.9	(92.2 - 351.7)	0.93	(0.43 - 1.53)	-
Goornallin (S)	10	254.9	(99.4 - 410.5)	0.75	(0.31 - 1.29)	-	4	91.9	(0.0 - 190.8)	0.42	(0.06 - 0.91)	V

Table 2 (cont.) Total cancer incidence⁽¹⁾ by area, 1998-2002: All SLAs (alphabetic)

Area	Males					Sig(2)	Females					Sig(2)
	Cases	ASR	95% c.i.	SRR	95% c.i.		Cases	ASR	95% c.i.	SRR	95% c.i.	
Gosnells (C)	728	328.3	(304.2 - 352.4)	0.97	(0.90 - 1.04)	-	611	249.4	(229.0 - 269.8)	0.95	(0.88 - 1.03)	-
Greenough (S) - Pt A	72	273.2	(208.9 - 337.5)	0.83	(0.65 - 1.05)	-	49	186.5	(132.4 - 240.5)	0.72	(0.52 - 0.94)	V
Greenough (S) - Pt B	9	248.2	(67.8 - 428.6)	0.61	(0.23 - 1.07)	-	2	56.3	(0.0 - 134.5)	0.23	(0.00 - 0.64)	V
Halls Creek (S)	16	225.5	(112.0 - 339.1)	0.65	(0.34 - 1.01)	-	15	221.4	(105.4 - 337.5)	0.83	(0.42 - 1.30)	-
Harvey (S) - Pt A	93	348.9	(275.3 - 422.5)	1.02	(0.83 - 1.26)	-	64	242.6	(182.1 - 303.1)	0.91	(0.70 - 1.17)	-
Harvey (S) - Pt B	103	355.4	(285.3 - 425.4)	1.06	(0.87 - 1.29)	-	77	279.9	(214.3 - 345.4)	1.07	(0.85 - 1.34)	-
Irwin (S)	40	290.0	(199.5 - 380.4)	0.92	(0.63 - 1.22)	-	37	383.4	(253.4 - 513.4)	1.35	(0.92 - 1.82)	-
Jerramungup (S)	11	282.0	(113.3 - 450.6)	0.81	(0.35 - 1.36)	-	3	85.5	(0.0 - 186.1)	0.35	(0.03 - 0.82)	V
Joondalup (C) - North	348	344.5	(307.2 - 381.9)	1.02	(0.92 - 1.14)	-	289	247.7	(218.1 - 277.4)	0.95	(0.84 - 1.07)	-
Joondalup (C) - South	1042	326.6	(305.9 - 347.3)	0.97	(0.91 - 1.03)	-	933	268.6	(250.3 - 286.9)	1.03	(0.96 - 1.10)	-
Kalamunda (S)	494	311.4	(283.4 - 339.3)	0.91	(0.83 - 1.00)	-	434	249.2	(224.8 - 273.7)	0.96	(0.87 - 1.05)	-
Kalgoorlie/Boulder (C) - Pt A	226	384.3	(331.6 - 436.9)	1.14	(1.00 - 1.30)	-	165	253.5	(211.5 - 295.5)	1.02	(0.88 - 1.20)	-
Kalgoorlie/Boulder (C) - Pt B	5	677.3	(57.1 - 1,297.5)	1.35	(0.30 - 2.77)	-*	3	857.1	(19.4 - 1,694.9)	1.81	(0.15 - 4.23)	-*
Katanning (S)	49	333.7	(239.2 - 428.1)	1.03	(0.74 - 1.33)	-	42	267.8	(182.9 - 352.7)	1.05	(0.74 - 1.39)	-
Kellerberrin (S)	17	318.2	(160.6 - 475.9)	0.88	(0.47 - 1.34)	-	18	347.0	(160.8 - 533.2)	1.26	(0.69 - 1.91)	-
Kent (S)	5	256.8	(23.8 - 489.8)	0.84	(0.18 - 1.72)	-	2	231.2	(0.0 - 554.7)	0.52	(0.01 - 1.46)	-*
Kojonup (S)	30	344.7	(210.9 - 478.4)	1.00	(0.65 - 1.39)	-	19	187.7	(97.7 - 277.7)	0.88	(0.50 - 1.32)	-
Kondinin (S)	14	411.5	(198.7 - 624.3)	1.25	(0.62 - 1.98)	-	10	338.9	(127.3 - 550.5)	1.37	(0.56 - 2.35)	-
Koorda (S)	3	204.0	(0.0 - 444.3)	0.46	(0.04 - 1.08)	-	2	99.5	(0.0 - 240.0)	0.43	(0.01 - 1.21)	-
Kulin (S)	6	159.8	(23.2 - 296.5)	0.52	(0.14 - 1.01)	-	3	89.2	(0.0 - 190.5)	0.37	(0.03 - 0.87)	V
Kwinana (T)	235	364.7	(317.6 - 411.8)	1.09	(0.96 - 1.24)	-	167	256.3	(216.7 - 296.0)	1.00	(0.86 - 1.17)	-
Lake Grace (S)	17	367.9	(179.7 - 556.0)	1.04	(0.56 - 1.59)	-	18	408.3	(217.3 - 599.4)	1.52	(0.84 - 2.30)	-
Laverton (S)	4	121.5	(0.0 - 244.9)	0.39	(0.06 - 0.85)	V	3	264.9	(0.0 - 605.9)	0.67	(0.05 - 1.57)	-*
Leonora (S)	13	325.2	(129.6 - 520.8)	0.81	(0.39 - 1.30)	-	7	187.9	(44.3 - 331.5)	0.94	(0.30 - 1.76)	-
Mandurah (C)	817	360.9	(333.9 - 387.9)	1.07	(1.00 - 1.14)	-	563	260.3	(236.4 - 284.1)	1.01	(0.93 - 1.10)	-
Manjimup (S)	106	292.2	(235.5 - 348.9)	0.87	(0.71 - 1.05)	-	68	198.4	(148.4 - 248.4)	0.77	(0.60 - 0.98)	V
Meekatharra (S)	21	690.1	(399.1 - 981.2)	1.73	(1.01 - 2.55)	^	8	298.1	(90.6 - 505.7)	1.01	(0.35 - 1.82)	-
Melville (C)	1306	349.6	(329.5 - 369.6)	1.06	(1.00 - 1.12)	-	1166	273.7	(256.3 - 291.2)	1.06	(1.00 - 1.12)	-
Menzies (S)	0	-	-	0	n/a	V	0	-	-	0	n/a	-
Merredin (S)	44	354.0	(247.8 - 460.3)	1.06	(0.75 - 1.40)	-	33	283.0	(181.4 - 384.6)	1.08	(0.71 - 1.47)	-
Mingenew (S)	3	152.1	(0.0 - 322.7)	0.47	(0.04 - 1.10)	-	8	577.6	(179.9 - 975.2)	1.84	(0.65 - 3.31)	-*
Moora (S)	24	353.3	(209.1 - 497.4)	0.89	(0.54 - 1.28)	-	20	273.6	(143.0 - 404.2)	0.96	(0.55 - 1.42)	-
Morawa (S)	7	187.7	(47.8 - 327.5)	0.54	(0.17 - 1.01)	-	8	323.3	(89.7 - 556.9)	1.03	(0.36 - 1.85)	-
Mosman Park (T)	120	362.4	(293.9 - 431.0)	1.13	(0.94 - 1.36)	-	101	247.7	(190.4 - 305.0)	1.04	(0.85 - 1.26)	-
Mount Magnet (S)	3	99.4	(0.0 - 211.8)	0.42	(0.03 - 0.97)	V	5	333.7	(32.9 - 634.4)	1.25	(0.27 - 2.56)	-*
Mount Marshall (S)	4	171.9	(5.3 - 338.5)	0.52	(0.08 - 1.14)	-	3	172.1	(0.0 - 364.4)	0.61	(0.05 - 1.43)	-
Mukinbudin (S)	8	298.1	(87.8 - 508.4)	0.88	(0.31 - 1.58)	-	3	128.5	(0.0 - 274.9)	0.47	(0.04 - 1.10)	-
Mullewa (S)	12	402.9	(176.6 - 629.2)	1.11	(0.51 - 1.82)	-	6	275.5	(37.5 - 513.5)	0.90	(0.24 - 1.74)	-
Mundaring (S)	376	339.4	(304.4 - 374.4)	1.01	(0.91 - 1.11)	-	345	287.9	(256.2 - 319.7)	1.10	(0.99 - 1.22)	-
Murchison (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Murray (S)	152	298.5	(248.0 - 349.0)	0.90	(0.77 - 1.06)	-	124	308.4	(251.4 - 365.4)	1.14	(0.95 - 1.37)	-
Nannup (S)	16	320.0	(161.6 - 478.4)	1.04	(0.55 - 1.61)	-	9	294.3	(69.1 - 519.4)	0.79	(0.30 - 1.39)	-
Narembeen (S)	12	316.4	(135.6 - 497.2)	0.95	(0.43 - 1.56)	-	10	272.8	(99.4 - 446.3)	1.06	(0.43 - 1.81)	-
Narrogin (S)	3	67.3	(0.0 - 144.2)	0.17	(0.01 - 0.39)	V	1	23.1	(0.0 - 68.3)	0.07	(0.00 - 0.27)	V
Narrogin (T)	69	538.6	(404.9 - 672.4)	1.54	(1.21 - 1.96)	^	49	324.2	(220.0 - 428.5)	1.25	(0.90 - 1.63)	-
Nedlands (C)	301	343.1	(300.5 - 385.8)	1.06	(0.95 - 1.19)	-	337	335.0	(292.5 - 377.6)	1.21	(1.08 - 1.34)	^
Ngaanyatjarraku (S)	1	21.5	(0.0 - 63.4)	0.10	(0.00 - 0.38)	V	0	-	-	0	n/a	V
Northam (S)	34	263.8	(172.5 - 355.1)	0.79	(0.53 - 1.08)	-	23	195.6	(115.6 - 275.6)	0.78	(0.46 - 1.12)	-
Northam (T)	95	436.8	(345.2 - 528.4)	1.17	(0.95 - 1.43)	-	74	278.6	(207.1 - 350.1)	1.06	(0.84 - 1.34)	-
Northampton (S)	52	384.6	(276.5 - 492.7)	1.10	(0.83 - 1.45)	-	27	214.8	(133.7 - 295.9)	0.86	(0.54 - 1.22)	-
Nungarin (S)	2	142.9	(0.0 - 333.6)	0.55	(0.01 - 1.53)	-*	2	163.7	(0.0 - 388.3)	0.89	(0.01 - 2.48)	-*
Peppermint Grove (S)	18	270.8	(140.9 - 400.7)	0.84	(0.46 - 1.26)	-	16	234.7	(111.0 - 358.5)	0.92	(0.48 - 1.41)	-
Perenjori (S)	10	650.5	(263.6 - 1,037.4)	1.66	(0.68 - 2.84)	-	4	227.6	(0.0 - 456.1)	0.84	(0.13 - 1.85)	-
Perth (C) - Inner	7	305.5	(65.3 - 545.8)	0.71	(0.22 - 1.33)	-	4	212.2	(0.0 - 425.8)	0.89	(0.14 - 1.95)	-*
Perth (C) - Remainder	110	399.8	(323.4 - 476.1)	1.17	(0.97 - 1.42)	-	39	193.2	(126.7 - 259.7)	0.72	(0.50 - 0.96)	V
Pingelly (S)	20	369.3	(195.5 - 543.0)	1.09	(0.63 - 1.62)	-	7	144.0	(29.1 - 258.9)	0.52	(0.16 - 0.97)	V
Plantagenet (S)	76	425.1	(327.9 - 522.2)	1.25	(0.99 - 1.57)	-	49	283.8	(200.3 - 367.3)	1.11	(0.80 - 1.45)	-

Table 2 (cont.) Total cancer incidence⁽¹⁾ by area, 1998-2002: All SLAs (alphabetic)

Area	Males						Sig(2)	Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.			Cases	ASR	95% c.i.	SRR	95% c.i.	
Port Hedland (T)	63	248.6	(177.3 - 319.9)	0.80	(0.62 - 1.03)	-	53	279.9	(193.3 - 366.6)	0.96	(0.73 - 1.27)	-	
Quairading (S)	14	298.0	(142.7 - 453.2)	0.95	(0.47 - 1.51)	-	11	217.4	(70.4 - 364.3)	0.91	(0.40 - 1.52)	-	
Ravensthorpe (S)	17	264.0	(138.9 - 389.0)	0.88	(0.47 - 1.35)	-	9	211.4	(73.5 - 349.3)	0.73	(0.28 - 1.29)	-	
Rockingham (C)	818	331.0	(307.6 - 354.4)	0.99	(0.93 - 1.06)	-	702	276.1	(254.6 - 297.6)	1.07	(0.99 - 1.15)	-	
Roebourne (S)	78	349.3	(247.8 - 450.7)	1.01	(0.80 - 1.27)	-	55	245.6	(160.0 - 331.1)	0.93	(0.71 - 1.22)	-	
Sandstone (S)	1	100.0	(0.0 - 294.0)	0.45	(0.00 - 1.67)	-*	0	-	-	0	n/a	-	
Serpentine-Jarrahdale (S)	124	356.2	(293.0 - 419.3)	1.10	(0.92 - 1.31)	-	82	244.8	(191.0 - 298.5)	0.97	(0.78 - 1.21)	-	
Shark Bay (S)	7	196.0	(35.4 - 356.7)	0.48	(0.15 - 0.89)	V	5	229.5	(16.6 - 442.5)	0.62	(0.13 - 1.26)	-	
South Perth (C)	477	358.5	(323.6 - 393.4)	1.06	(0.97 - 1.16)	-	429	266.0	(236.2 - 295.9)	0.96	(0.87 - 1.06)	-	
Stirling (C) - Central	1238	331.8	(312.7 - 350.9)	0.99	(0.93 - 1.04)	-	1035	245.9	(229.8 - 261.9)	0.96	(0.91 - 1.02)	-	
Stirling (C) - Coastal	864	376.3	(350.1 - 402.4)	1.12	(1.04 - 1.20)	^	691	266.9	(245.2 - 288.6)	1.01	(0.93 - 1.09)	-	
Stirling (C) - South-Eastern	220	351.0	(296.8 - 405.2)	1.01	(0.88 - 1.15)	-	212	249.7	(206.5 - 292.8)	0.99	(0.87 - 1.14)	-	
Subiaco (C)	185	393.3	(334.1 - 452.4)	1.13	(0.97 - 1.31)	-	175	293.8	(243.7 - 343.8)	1.10	(0.95 - 1.28)	-	
Swan (C)	708	336.1	(311.0 - 361.1)	1.00	(0.93 - 1.08)	-	579	251.7	(230.5 - 272.9)	0.97	(0.89 - 1.05)	-	
Tambellup (S)	4	190.9	(1.8 - 379.9)	0.51	(0.08 - 1.11)	-	5	212.0	(24.2 - 399.8)	0.90	(0.20 - 1.84)	-	
Tammin (S)	6	580.9	(27.8 - 1,133.9)	1.14	(0.31 - 2.21)	-	1	74.6	(0.0 - 219.8)	0.26	(0.00 - 0.96)	V*	
Three Springs (S)	6	188.6	(31.2 - 346.1)	0.59	(0.16 - 1.14)	-	8	351.1	(100.5 - 601.6)	1.22	(0.43 - 2.20)	-	
Toodyay (S)	50	381.4	(260.8 - 502.0)	1.00	(0.72 - 1.29)	-	25	179.5	(108.4 - 250.5)	0.72	(0.44 - 1.03)	-	
Trayning (S)	8	457.9	(140.1 - 775.7)	1.31	(0.46 - 2.36)	-	3	155.1	(0.0 - 329.2)	0.66	(0.05 - 1.53)	-	
Upper Gascoyne (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-	
Victoria Park (T)	386	360.3	(319.1 - 401.4)	1.05	(0.95 - 1.16)	-	315	237.5	(202.9 - 272.1)	0.87	(0.78 - 0.97)	V	
Victoria Plains (S)	16	414.8	(203.0 - 626.6)	1.13	(0.59 - 1.75)	-	16	562.1	(279.6 - 844.7)	2.13	(1.12 - 3.30)	^	
Vincent (T)	330	345.8	(305.6 - 386.1)	1.03	(0.93 - 1.15)	-	253	251.4	(215.5 - 287.3)	0.93	(0.82 - 1.06)	-	
Wagin (S)	27	352.8	(204.3 - 501.3)	1.03	(0.65 - 1.45)	-	22	307.2	(169.5 - 445.0)	1.04	(0.61 - 1.52)	-	
Wandering (S)	0	-	-	0	n/a	V	1	83.3	(0.0 - 232.4)	0.36	(0.00 - 1.33)	-*	
Wanneroo (C) - North-East	210	355.5	(306.7 - 404.3)	1.07	(0.93 - 1.22)	-	162	252.6	(212.3 - 292.9)	0.99	(0.85 - 1.16)	-	
Wanneroo (C) - North-West	261	386.2	(338.4 - 434.0)	1.15	(1.01 - 1.30)	^	166	252.7	(213.6 - 291.7)	0.95	(0.82 - 1.11)	-	
Wanneroo (C) - South	286	339.3	(299.8 - 378.9)	1.00	(0.89 - 1.12)	-	242	248.5	(216.6 - 280.4)	0.96	(0.85 - 1.09)	-	
Waroona (S)	42	304.0	(211.0 - 396.9)	0.93	(0.65 - 1.23)	-	27	232.9	(139.6 - 326.3)	0.83	(0.52 - 1.17)	-	
West Arthur (S)	8	203.2	(62.4 - 344.0)	0.61	(0.21 - 1.10)	-	3	102.3	(0.0 - 217.1)	0.35	(0.03 - 0.81)	V	
Westonia (S)	5	469.9	(60.8 - 879.0)	1.43	(0.31 - 2.93)	-*	0	-	-	0	n/a	-	
Wickepin (S)	14	500.3	(208.2 - 792.5)	1.34	(0.66 - 2.13)	-	5	203.4	(27.5 - 379.4)	0.72	(0.16 - 1.48)	-	
Williams (S)	6	181.5	(36.4 - 326.7)	0.54	(0.15 - 1.04)	-	6	215.4	(37.4 - 393.4)	0.76	(0.21 - 1.48)	-	
Wiluna (S)	1	100.0	(0.0 - 292.7)	0.14	(0.00 - 0.50)	V	5	390.4	(32.8 - 748.0)	1.61	(0.35 - 3.30)	-*	
Wongan-Ballidu (S)	22	461.1	(266.8 - 655.4)	1.42	(0.84 - 2.08)	-	12	215.6	(85.7 - 345.4)	0.97	(0.44 - 1.59)	-	
Woodanilling (S)	1	66.7	(0.0 - 196.2)	0.26	(0.00 - 0.95)	V*	0	-	-	0	n/a	-	
Wyalkatchem (S)	7	259.5	(60.1 - 458.9)	0.70	(0.22 - 1.31)	-	10	411.8	(137.4 - 686.2)	1.52	(0.63 - 2.61)	-	
Wyndham-East Kimberley (S)	36	223.7	(145.6 - 301.8)	0.75	(0.51 - 1.02)	-	31	227.0	(137.5 - 316.5)	0.96	(0.62 - 1.32)	-	
Yalgoo (S)	1	62.5	(0.0 - 184.2)	0.29	(0.00 - 1.07)	-*	0	-	-	0	n/a	-	
Yilgarn (S)	19	397.2	(216.0 - 578.5)	1.07	(0.60 - 1.60)	-	8	171.6	(49.7 - 293.5)	0.69	(0.24 - 1.24)	-	
York (S)	47	369.2	(254.7 - 483.7)	1.00	(0.72 - 1.30)	-	31	223.5	(138.4 - 308.5)	0.89	(0.58 - 1.23)	-	
Total State	20827	338.1	(333.4 - 342.7)	1.00	(0.99 - 1.01)	-	17314	260.1	(255.9 - 264.2)	1.00	(0.99 - 1.02)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

Table 3. Total cancer incidence⁽¹⁾ by area, 1998-2002: All SLAs (DOH areas)

Area	Males					Sig(2)	Females					Sig(2)
	Cases	ASR	95% c.i.	SRR	95% c.i.		Cases	ASR	95% c.i.	SRR	95% c.i.	
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	332	338.9	(299.7 - 378.0)	1.00	(0.90 - 1.12)	-	306	265.7	(231.1 - 300.4)	1.04	(0.93 - 1.17)	-
Claremont (T)	140	387.9	(313.7 - 462.1)	1.08	(0.91 - 1.28)	-	146	266.4	(208.7 - 324.1)	1.09	(0.92 - 1.28)	-
Cottesloe (T)	98	333.8	(265.4 - 402.2)	1.01	(0.83 - 1.24)	-	98	308.5	(234.1 - 382.9)	1.10	(0.90 - 1.35)	-
Joondalup (C) - North	348	344.5	(307.2 - 381.9)	1.02	(0.92 - 1.14)	-	289	247.7	(218.1 - 277.4)	0.95	(0.84 - 1.07)	-
Joondalup (C) - South	1042	326.6	(305.9 - 347.3)	0.97	(0.91 - 1.03)	-	933	268.6	(250.3 - 286.9)	1.03	(0.96 - 1.10)	-
Mosman Park (T)	120	362.4	(293.9 - 431.0)	1.13	(0.94 - 1.36)	-	101	247.7	(190.4 - 305.0)	1.04	(0.85 - 1.26)	-
Nedlands (C)	301	343.1	(300.5 - 385.8)	1.06	(0.95 - 1.19)	-	337	335.0	(292.5 - 377.6)	1.21	(1.08 - 1.34)	^
Peppermint Grove (S)	18	270.8	(140.9 - 400.7)	0.84	(0.46 - 1.26)	-	16	234.7	(111.0 - 358.5)	0.92	(0.48 - 1.41)	-
Stirling (C) - Central	1238	331.8	(312.7 - 350.9)	0.99	(0.93 - 1.04)	-	1035	245.9	(229.8 - 261.9)	0.96	(0.91 - 1.02)	-
Stirling (C) - Coastal	864	376.3	(350.1 - 402.4)	1.12	(1.04 - 1.20)	^	691	266.9	(245.2 - 288.6)	1.01	(0.93 - 1.09)	-
Subiaco (C)	185	393.3	(334.1 - 452.4)	1.13	(0.97 - 1.31)	-	175	293.8	(243.7 - 343.8)	1.10	(0.95 - 1.28)	-
Wanneroo (C) - North-East	210	355.5	(306.7 - 404.3)	1.07	(0.93 - 1.22)	-	162	252.6	(212.3 - 292.9)	0.99	(0.85 - 1.16)	-
Wanneroo (C) - North-West	261	386.2	(338.4 - 434.0)	1.15	(1.01 - 1.30)	^	166	252.7	(213.6 - 291.7)	0.95	(0.82 - 1.11)	-
Wanneroo (C) - South	286	339.3	(299.8 - 378.9)	1.00	(0.89 - 1.12)	-	242	248.5	(216.6 - 280.4)	0.96	(0.85 - 1.09)	-
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	425	353.2	(317.5 - 388.8)	1.04	(0.95 - 1.15)	-	360	278.7	(246.6 - 310.8)	1.07	(0.97 - 1.19)	-
Canning (C)	766	331.1	(307.3 - 354.9)	0.97	(0.90 - 1.04)	-	697	250.7	(231.2 - 270.2)	0.99	(0.92 - 1.07)	-
South Perth (C)	477	358.5	(323.6 - 393.4)	1.06	(0.97 - 1.16)	-	429	266.0	(236.2 - 295.9)	0.96	(0.87 - 1.06)	-
Victoria Park (T)	386	360.3	(319.1 - 401.4)	1.05	(0.95 - 1.16)	-	315	237.5	(202.9 - 272.1)	0.87	(0.78 - 0.97)	v
Inner City HD												
Perth (C) - Inner	7	305.5	(65.3 - 545.8)	0.71	(0.22 - 1.33)	-	4	212.2	(0.0 - 425.8)	0.89	(0.14 - 1.95)	-*
Perth (C) - Remainder	110	399.8	(323.4 - 476.1)	1.17	(0.97 - 1.42)	-	39	193.2	(126.7 - 259.7)	0.72	(0.50 - 0.96)	v
Stirling (C) - South-Eastern	220	351.0	(296.8 - 405.2)	1.01	(0.88 - 1.15)	-	212	249.7	(206.5 - 292.8)	0.99	(0.87 - 1.14)	-
Vincent (T)	330	345.8	(305.6 - 386.1)	1.03	(0.93 - 1.15)	-	253	251.4	(215.5 - 287.3)	0.93	(0.82 - 1.06)	-
Kalamunda HD												
Kalamunda (S)	494	311.4	(283.4 - 339.3)	0.91	(0.83 - 1.00)	-	434	249.2	(224.8 - 273.7)	0.96	(0.87 - 1.05)	-
Swan HD												
Bassendean (T)	173	340.8	(288.8 - 392.8)	1.00	(0.86 - 1.16)	-	136	240.0	(197.1 - 283.0)	0.91	(0.77 - 1.08)	-
Bayswater (C)	678	316.0	(291.4 - 340.7)	0.93	(0.86 - 1.00)	-	626	269.9	(246.8 - 293.1)	1.03	(0.95 - 1.12)	-
Mundaring (S)	376	339.4	(304.4 - 374.4)	1.01	(0.91 - 1.11)	-	345	287.9	(256.2 - 319.7)	1.10	(0.99 - 1.22)	-
Swan (C)	708	336.1	(311.0 - 361.1)	1.00	(0.93 - 1.08)	-	579	251.7	(230.5 - 272.9)	0.97	(0.89 - 1.05)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	458	296.1	(268.8 - 323.4)	0.87	(0.79 - 0.96)	v	461	271.9	(246.3 - 297.5)	1.04	(0.95 - 1.14)	-
Gosnells (C)	728	328.3	(304.2 - 352.4)	0.97	(0.90 - 1.04)	-	611	249.4	(229.0 - 269.8)	0.95	(0.88 - 1.03)	-
Serpentine-Jarrahdale (S)	124	356.2	(293.0 - 419.3)	1.10	(0.92 - 1.31)	-	82	244.8	(191.0 - 298.5)	0.97	(0.78 - 1.21)	-
Fremantle HD												
Cockburn (C)	647	340.4	(314.1 - 366.7)	1.01	(0.93 - 1.09)	-	560	271.6	(248.6 - 294.7)	1.04	(0.96 - 1.13)	-
East Fremantle (T)	88	331.8	(259.0 - 404.5)	1.02	(0.82 - 1.26)	-	74	269.3	(199.6 - 339.1)	1.00	(0.79 - 1.26)	-
Fremantle (C) - Inner	12	317.5	(131.0 - 504.0)	0.87	(0.40 - 1.43)	-	8	383.2	(105.2 - 661.1)	1.34	(0.47 - 2.42)	-
Fremantle (C) - Remainder	404	402.9	(361.7 - 444.1)	1.17	(1.06 - 1.30)	^	295	271.4	(237.5 - 305.2)	1.03	(0.91 - 1.15)	-
Melville (C)	1306	349.6	(329.5 - 369.6)	1.06	(1.00 - 1.12)	-	1166	273.7	(256.3 - 291.2)	1.06	(1.00 - 1.12)	-
Rockingham-Kwinana HD												
Kwinana (T)	235	364.7	(317.6 - 411.8)	1.09	(0.96 - 1.24)	-	167	256.3	(216.7 - 296.0)	1.00	(0.86 - 1.17)	-
Rockingham (C)	818	331.0	(307.6 - 354.4)	0.99	(0.93 - 1.06)	-	702	276.1	(254.6 - 297.6)	1.07	(0.99 - 1.15)	-
Peel HD												
Mandurah (C)	817	360.9	(333.9 - 387.9)	1.07	(1.00 - 1.14)	-	563	260.3	(236.4 - 284.1)	1.01	(0.93 - 1.10)	-
Murray (S)	152	298.5	(248.0 - 349.0)	0.90	(0.77 - 1.06)	-	124	308.4	(251.4 - 365.4)	1.14	(0.95 - 1.37)	-
Waroona (S)	42	304.0	(211.0 - 396.9)	0.93	(0.65 - 1.23)	-	27	232.9	(139.6 - 326.3)	0.83	(0.52 - 1.17)	-

Table 3 (cont.) Total cancer incidence⁽¹⁾ by area, 1998-2002:All SLAs (DOH areas)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	71	270.4	(205.2 - 335.7)	0.86	(0.68 - 1.09)	-	58	221.5	(160.7 - 282.2)	0.95	(0.73 - 1.24)	-
Derby-West Kimberley (S)	51	329.3	(237.7 - 420.8)	0.94	(0.70 - 1.24)	-	33	237.2	(153.0 - 321.4)	0.88	(0.58 - 1.20)	-
Halls Creek (S)	16	225.5	(112.0 - 339.1)	0.65	(0.34 - 1.01)	-	15	221.4	(105.4 - 337.5)	0.83	(0.42 - 1.30)	-
Wyndham-East Kimberley (S)	36	223.7	(145.6 - 301.8)	0.75	(0.51 - 1.02)	-	31	227.0	(137.5 - 316.5)	0.96	(0.62 - 1.32)	-
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	27	275.4	(151.4 - 399.5)	0.84	(0.53 - 1.18)	-	13	113.0	(30.6 - 195.3)	0.59	(0.28 - 0.94)	V
Roebourne (S)	78	349.3	(247.8 - 450.7)	1.01	(0.80 - 1.27)	-	55	245.6	(160.0 - 331.1)	0.93	(0.71 - 1.22)	-
Gascoyne HD												
Carnarvon (S)	59	268.6	(199.7 - 337.5)	0.80	(0.61 - 1.03)	-	44	256.7	(179.3 - 334.1)	0.93	(0.66 - 1.23)	-
Exmouth (S)	23	374.6	(209.0 - 540.2)	1.08	(0.65 - 1.57)	-	11	209.2	(84.5 - 333.9)	0.76	(0.33 - 1.28)	-
Shark Bay (S)	7	196.0	(35.4 - 356.7)	0.48	(0.15 - 0.89)	V	5	229.5	(16.6 - 442.5)	0.62	(0.13 - 1.26)	-
Upper Gascoyne (S)	0	-	-	0	n/a	-	0	-	-	0	-	-
East Pilbara HD												
East Pilbara (S)	27	217.3	(118.0 - 316.5)	0.71	(0.45 - 1.01)	-	10	99.4	(29.6 - 169.3)	0.41	(0.17 - 0.70)	V
Port Hedland (T)	63	248.6	(177.3 - 319.9)	0.80	(0.62 - 1.03)	-	53	279.9	(193.3 - 366.6)	0.96	(0.73 - 1.27)	-
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	6	210.9	(43.3 - 378.5)	0.75	(0.20 - 1.45)	-	6	280.3	(52.9 - 507.7)	1.14	(0.31 - 2.22)	-
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	0.20	(0.00 - 0.57)	V	5	134.3	(13.9 - 254.8)	0.75	(0.16 - 1.54)	-
Coorow (S)	25	491.5	(300.0 - 683.0)	1.47	(0.91 - 2.10)	-	13	302.6	(136.7 - 468.6)	1.19	(0.57 - 1.93)	-
Irwin (S)	40	290.0	(199.5 - 380.4)	0.92	(0.63 - 1.22)	-	37	383.4	(253.4 - 513.4)	1.35	(0.92 - 1.82)	-
Mingenew (S)	3	152.1	(0.0 - 322.7)	0.47	(0.04 - 1.10)	-	8	577.6	(179.9 - 975.2)	1.84	(0.65 - 3.31)	-*
Morawa (S)	7	187.7	(47.8 - 327.5)	0.54	(0.17 - 1.01)	-	8	323.3	(89.7 - 556.9)	1.03	(0.36 - 1.85)	-
Mullewa (S)	12	402.9	(176.6 - 629.2)	1.11	(0.51 - 1.82)	-	6	275.5	(37.5 - 513.5)	0.90	(0.24 - 1.74)	-
Murchison (S)	0	-	-	0	n/a	-	0	-	-	0	-	-
Northampton (S)	52	384.6	(276.5 - 492.7)	1.10	(0.83 - 1.45)	-	27	214.8	(133.7 - 295.9)	0.86	(0.54 - 1.22)	-
Perenjori (S)	10	650.5	(263.6 - 1,037.4)	1.66	(0.68 - 2.84)	-	4	227.6	(0.0 - 456.1)	0.84	(0.13 - 1.85)	-
Three Springs (S)	6	188.6	(31.2 - 346.1)	0.59	(0.16 - 1.14)	-	8	351.1	(100.5 - 601.6)	1.22	(0.43 - 2.20)	-
Yalgoo (S)	1	62.5	(0.0 - 184.2)	0.29	(0.00 - 1.07)	-*	0	-	-	0	-	-
Murchison HD												
Cue (S)	7	856.5	(255.0 - 1,458.1)	1.79	(0.56 - 3.34)	-*	1	114.3	(0.0 - 335.1)	0.41	(0.00 - 1.52)	-*
Meekatharra (S)	21	690.1	(399.1 - 981.2)	1.73	(1.01 - 2.55)	^	8	298.1	(90.6 - 505.7)	1.01	(0.35 - 1.82)	-
Mount Magnet (S)	3	99.4	(0.0 - 211.8)	0.42	(0.03 - 0.97)	V	5	333.7	(32.9 - 634.4)	1.25	(0.27 - 2.56)	-*
Sandstone (S)	1	100.0	(0.0 - 294.0)	0.45	(0.00 - 1.67)	-*	0	-	-	0	n/a	-
Wiluna (S)	1	100.0	(0.0 - 292.7)	0.14	(0.00 - 0.50)	V	5	390.4	(32.8 - 748.0)	1.61	(0.35 - 3.30)	-*
Geraldton HD												
Geraldton (C)	287	419.2	(369.7 - 468.7)	1.21	(1.08 - 1.36)	^	233	314.6	(271.5 - 357.7)	1.19	(1.05 - 1.36)	^
Greenough (S) - Pt A	72	273.2	(208.9 - 337.5)	0.83	(0.65 - 1.05)	-	49	186.5	(132.4 - 240.5)	0.72	(0.52 - 0.94)	V
Greenough (S) - Pt B	9	248.2	(67.8 - 428.6)	0.61	(0.23 - 1.07)	-	2	56.3	(0.0 - 134.5)	0.23	(0.00 - 0.64)	V
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	24	320.2	(184.9 - 455.5)	0.90	(0.55 - 1.29)	-	13	170.0	(69.8 - 270.3)	0.72	(0.34 - 1.16)	-
Bruce Rock (S)	19	411.7	(218.7 - 604.7)	1.21	(0.68 - 1.81)	-	11	231.9	(88.9 - 375.0)	0.93	(0.41 - 1.56)	-
Corrigin (S)	12	252.5	(107.6 - 397.5)	0.68	(0.31 - 1.12)	-	13	230.2	(94.7 - 365.7)	0.93	(0.44 - 1.50)	-
Cunderdin (S)	15	300.3	(148.1 - 452.4)	0.86	(0.44 - 1.35)	-	8	135.8	(28.5 - 243.0)	0.62	(0.22 - 1.12)	-
Quairading (S)	14	298.0	(142.7 - 453.2)	0.95	(0.47 - 1.51)	-	11	217.4	(70.4 - 364.3)	0.91	(0.40 - 1.52)	-
Tammin (S)	6	580.9	(27.8 - 1,133.9)	1.14	(0.31 - 2.21)	-	1	74.6	(0.0 - 219.8)	0.26	(0.00 - 0.96)	V*
Upper Great Southern HD												
Boddington (S)	12	257.4	(95.3 - 419.6)	0.85	(0.39 - 1.39)	-	11	315.5	(126.3 - 504.7)	1.09	(0.48 - 1.82)	-
Brookton (S)	14	242.8	(99.3 - 386.2)	0.84	(0.42 - 1.33)	-	18	449.9	(228.9 - 670.9)	1.73	(0.95 - 2.61)	-
Cuballing (S)	10	352.8	(136.9 - 568.7)	1.13	(0.47 - 1.94)	-	5	236.4	(21.4 - 451.4)	0.83	(0.18 - 1.69)	-
Dumbleyung (S)	8	297.4	(86.7 - 508.2)	0.79	(0.28 - 1.42)	-	3	122.5	(0.0 - 261.9)	0.44	(0.04 - 1.03)	-
Kondinin (S)	14	411.5	(198.7 - 624.3)	1.25	(0.62 - 1.98)	-	10	338.9	(127.3 - 550.5)	1.37	(0.56 - 2.35)	-
Kulin (S)	6	159.8	(23.2 - 296.5)	0.52	(0.14 - 1.01)	-	3	89.2	(0.0 - 190.5)	0.37	(0.03 - 0.87)	V
Lake Grace (S)	17	367.9	(179.7 - 556.0)	1.04	(0.56 - 1.59)	-	18	408.3	(217.3 - 599.4)	1.52	(0.84 - 2.30)	-
Narrogin (S)	3	67.3	(0.0 - 144.2)	0.17	(0.01 - 0.39)	V	1	23.1	(0.0 - 68.3)	0.07	(0.00 - 0.27)	V
Narrogin (T)	69	538.6	(404.9 - 672.4)	1.54	(1.21 - 1.96)	^	49	324.2	(220.0 - 428.5)	1.25	(0.90 - 1.63)	-
Pingelly (S)	20	369.3	(195.5 - 543.0)	1.09	(0.63 - 1.62)	-	7	144.0	(29.1 - 258.9)	0.52	(0.16 - 0.97)	V
Wagin (S)	27	352.8	(204.3 - 501.3)	1.03	(0.65 - 1.45)	-	22	307.2	(169.5 - 445.0)	1.04	(0.61 - 1.52)	-
Wandering (S)	0	-	-	0	n/a	V	1	83.3	(0.0 - 232.4)	0.36	(0.00 - 1.33)	-*
West Arthur (S)	8	203.2	(62.4 - 344.0)	0.61	(0.21 - 1.10)	-	3	102.3	(0.0 - 217.1)	0.35	(0.03 - 0.81)	V
Wickepin (S)	14	500.3	(208.2 - 792.5)	1.34	(0.66 - 2.13)	-	5	203.4	(27.5 - 379.4)	0.72	(0.16 - 1.48)	-
Williams (S)	6	181.5	(36.4 - 326.7)	0.54	(0.15 - 1.04)	-	6	215.4	(37.4 - 393.4)	0.76	(0.21 - 1.48)	-

Table 3 (cont.) Total cancer incidence⁽¹⁾ by area, 1998-2002:All SLAs (DOH areas)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
WHEATBELT HEALTH REGION (cont.)												
Western HD												
Chittering (S)	35	342.7	(220.8 - 464.7)	0.97	(0.66 - 1.32)	-	17	199.7	(103.0 - 296.4)	0.74	(0.40 - 1.13)	-
Dalwallinu (S)	19	320.2	(175.4 - 465.0)	0.94	(0.53 - 1.40)	-	12	228.1	(94.5 - 361.7)	0.83	(0.38 - 1.37)	-
Dandaragan (S)	42	326.1	(221.7 - 430.4)	1.01	(0.71 - 1.34)	-	23	252.2	(147.7 - 356.7)	0.91	(0.55 - 1.32)	-
Dowerin (S)	13	493.7	(222.8 - 764.6)	1.40	(0.67 - 2.26)	-	15	460.0	(217.5 - 702.6)	1.93	(0.99 - 3.03)	-
Gingin (S)	73	429.4	(327.1 - 531.7)	1.23	(0.97 - 1.55)	-	40	265.1	(179.3 - 350.8)	1.01	(0.70 - 1.35)	-
Goomalling (S)	10	254.9	(99.4 - 410.5)	0.75	(0.31 - 1.29)	-	4	91.9	(0.0 - 190.8)	0.42	(0.06 - 0.91)	V
Moora (S)	24	353.3	(209.1 - 497.4)	0.89	(0.54 - 1.28)	-	20	273.6	(143.0 - 404.2)	0.96	(0.55 - 1.42)	-
Victoria Plains (S)	16	414.8	(203.0 - 626.6)	1.13	(0.59 - 1.75)	-	16	562.1	(279.6 - 844.7)	2.13	(1.12 - 3.30)	^
Wongan-Ballidu (S)	22	461.1	(266.8 - 655.4)	1.42	(0.84 - 2.08)	-	12	215.6	(85.7 - 345.4)	0.97	(0.44 - 1.59)	-
Eastern Wheatbelt HD												
Kellerberrin (S)	17	318.2	(160.6 - 475.9)	0.88	(0.47 - 1.34)	-	18	347.0	(160.8 - 533.2)	1.26	(0.69 - 1.91)	-
Koorda (S)	3	204.0	(0.0 - 444.3)	0.46	(0.04 - 1.08)	-	2	99.5	(0.0 - 240.0)	0.43	(0.01 - 1.21)	-
Merredin (S)	44	354.0	(247.8 - 460.3)	1.06	(0.75 - 1.40)	-	33	283.0	(181.4 - 384.6)	1.08	(0.71 - 1.47)	-
Mount Marshall (S)	4	171.9	(5.3 - 338.5)	0.52	(0.08 - 1.14)	-	3	172.1	(0.0 - 364.4)	0.61	(0.05 - 1.43)	-
Mukinbudin (S)	8	298.1	(87.8 - 508.4)	0.88	(0.31 - 1.58)	-	3	128.5	(0.0 - 274.9)	0.47	(0.04 - 1.10)	-
Narembeen (S)	12	316.4	(135.6 - 497.2)	0.95	(0.43 - 1.56)	-	10	272.8	(99.4 - 446.3)	1.06	(0.43 - 1.81)	-
Nungarin (S)	2	142.9	(0.0 - 333.6)	0.55	(0.01 - 1.53)	-*	2	163.7	(0.0 - 388.3)	0.89	(0.01 - 2.48)	-*
Trayning (S)	8	457.9	(140.1 - 775.7)	1.31	(0.46 - 2.36)	-	3	155.1	(0.0 - 329.2)	0.66	(0.05 - 1.53)	-
Westonia (S)	5	469.9	(60.8 - 879.0)	1.43	(0.31 - 2.93)	-*	0	-	-	0	n/a	-
Wyalkatchem (S)	7	259.5	(60.1 - 458.9)	0.70	(0.22 - 1.31)	-	10	411.8	(137.4 - 686.2)	1.52	(0.63 - 2.61)	-
Yilgarn (S)	19	397.2	(216.0 - 578.5)	1.07	(0.60 - 1.60)	-	8	171.6	(49.7 - 293.5)	0.69	(0.24 - 1.24)	-
Avon HD												
Northam (S)	34	263.8	(172.5 - 355.1)	0.79	(0.53 - 1.08)	-	23	195.6	(115.6 - 275.6)	0.78	(0.46 - 1.12)	-
Northam (T)	95	436.8	(345.2 - 528.4)	1.17	(0.95 - 1.43)	-	74	278.6	(207.1 - 350.1)	1.06	(0.84 - 1.34)	-
Toodyay (S)	50	381.4	(260.8 - 502.0)	1.00	(0.72 - 1.29)	-	25	179.5	(108.4 - 250.5)	0.72	(0.44 - 1.03)	-
York (S)	47	369.2	(254.7 - 483.7)	1.00	(0.72 - 1.30)	-	31	223.5	(138.4 - 308.5)	0.89	(0.58 - 1.23)	-
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	17	162.6	(74.2 - 251.1)	0.65	(0.35 - 0.99)	V	16	264.7	(117.6 - 411.8)	0.87	(0.46 - 1.35)	-
Kalgoorlie/Boulder (C) - Pt A	226	384.3	(331.6 - 436.9)	1.14	(1.00 - 1.30)	-	165	253.5	(211.5 - 295.5)	1.02	(0.88 - 1.20)	-
Kalgoorlie/Boulder (C) - Pt B	5	677.3	(57.1 - 1,297.5)	1.35	(0.30 - 2.77)	-*	3	857.1	(19.4 - 1,694.9)	1.81	(0.15 - 4.23)	-*
Laverton (S)	4	121.5	(0.0 - 244.9)	0.39	(0.06 - 0.85)	V	3	264.9	(0.0 - 605.9)	0.67	(0.05 - 1.57)	-*
Leonora (S)	13	325.2	(129.6 - 520.8)	0.81	(0.39 - 1.30)	-	7	187.9	(44.3 - 331.5)	0.94	(0.30 - 1.76)	-
Menzies (S)	0	-	-	0	n/a	V	0	-	-	0	-	-
Ngaanyatjarraku (S)	1	21.5	(0.0 - 63.4)	0.10	(0.00 - 0.38)	V	0	-	-	0	-	V
South East Coastal HD												
Dundas (S)	13	328.2	(148.4 - 508.0)	0.92	(0.44 - 1.49)	-	7	240.0	(51.9 - 428.1)	0.77	(0.24 - 1.43)	-
Esperance (S)	138	334.3	(278.1 - 390.5)	0.97	(0.82 - 1.15)	-	106	253.6	(203.8 - 303.3)	0.97	(0.80 - 1.18)	-
Ravensthorpe (S)	17	264.0	(138.9 - 389.0)	0.88	(0.47 - 1.35)	-	9	211.4	(73.5 - 349.3)	0.73	(0.28 - 1.29)	-
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	239	404.0	(349.8 - 458.1)	0.98	(0.86 - 1.11)	-	225	301.9	(255.7 - 348.0)	1.05	(0.92 - 1.20)	-
Albany (C) Bal	110	220.2	(178.4 - 262.1)	0.65	(0.54 - 0.79)	V	99	219.0	(175.3 - 262.7)	0.86	(0.70 - 1.05)	-
Cranbrook (S)	11	287.1	(108.7 - 465.4)	0.72	(0.31 - 1.20)	-	8	224.8	(58.2 - 391.4)	0.92	(0.32 - 1.66)	-
Denmark (S)	51	244.8	(176.4 - 313.3)	0.75	(0.56 - 0.99)	V	40	240.5	(157.8 - 323.3)	0.83	(0.58 - 1.11)	-
Jerramungup (S)	11	282.0	(113.3 - 450.6)	0.81	(0.35 - 1.36)	-	3	85.5	(0.0 - 186.1)	0.35	(0.03 - 0.82)	V
Plantagenet (S)	76	425.1	(327.9 - 522.2)	1.25	(0.99 - 1.57)	-	49	283.8	(200.3 - 367.3)	1.11	(0.80 - 1.45)	-
Central Great Southern HD												
Broomehill (S)	5	269.0	(28.7 - 509.3)	0.88	(0.19 - 1.79)	-	3	132.6	(0.0 - 282.6)	0.67	(0.05 - 1.56)	-*
Gnowangerup (S)	26	530.7	(325.7 - 735.7)	1.51	(0.94 - 2.14)	-	12	221.9	(92.2 - 351.7)	0.93	(0.43 - 1.53)	-
Katanning (S)	49	333.7	(239.2 - 428.1)	1.03	(0.74 - 1.33)	-	42	267.8	(182.9 - 352.7)	1.05	(0.74 - 1.39)	-
Kent (S)	5	256.8	(23.8 - 489.8)	0.84	(0.18 - 1.72)	-	2	231.2	(0.0 - 554.7)	0.52	(0.01 - 1.46)	-*
Kojonup (S)	30	344.7	(210.9 - 478.4)	1.00	(0.65 - 1.39)	-	19	187.7	(97.7 - 277.7)	0.88	(0.50 - 1.32)	-
Tambellup (S)	4	190.9	(1.8 - 379.9)	0.51	(0.08 - 1.11)	-	5	212.0	(24.2 - 399.8)	0.90	(0.20 - 1.84)	-
Woodanilling (S)	1	66.7	(0.0 - 196.2)	0.26	(0.00 - 0.95)	V*	0	-	-	0	n/a	-

Table 3 (cont.) Total cancer incidence⁽¹⁾ by area, 1998-2002:All SLAs (DOH areas)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	106	299.5	(239.8 - 359.1)	0.93	(0.76 - 1.13)	-	84	245.6	(189.8 - 301.3)	1.00	(0.80 - 1.24)	-
Busselton (S)	284	324.5	(284.6 - 364.4)	0.97	(0.86 - 1.09)	-	215	242.7	(207.0 - 278.4)	0.91	(0.80 - 1.05)	-
Warren-Blackwood HD												
Boyup Brook (S)	14	205.9	(96.1 - 315.7)	0.61	(0.30 - 0.97)	V	17	226.6	(98.3 - 355.0)	0.94	(0.50 - 1.43)	-
Bridgetown-Greenbushes (S)	45	310.6	(216.3 - 404.8)	0.87	(0.62 - 1.14)	-	45	307.3	(215.7 - 398.9)	1.12	(0.80 - 1.47)	-
Manjimup (S)	106	292.2	(235.5 - 348.9)	0.87	(0.71 - 1.05)	-	68	198.4	(148.4 - 248.4)	0.77	(0.60 - 0.98)	V
Nannup (S)	16	320.0	(161.6 - 478.4)	1.04	(0.55 - 1.61)	-	9	294.3	(69.1 - 519.4)	0.79	(0.30 - 1.39)	-
Bunbury HD												
Bunbury (C)	330	323.7	(287.0 - 360.3)	0.93	(0.83 - 1.03)	-	316	282.9	(248.8 - 316.9)	1.06	(0.95 - 1.18)	-
Capel (S) - Pt A	12	174.0	(72.8 - 275.2)	0.56	(0.25 - 0.91)	V	9	151.1	(46.9 - 255.3)	0.51	(0.20 - 0.90)	V
Capel (S) - Pt B	38	278.6	(188.2 - 369.1)	0.79	(0.54 - 1.06)	-	39	321.9	(217.5 - 426.3)	1.15	(0.79 - 1.53)	-
Dardanup (S) - Pt A	47	314.9	(224.1 - 405.6)	0.93	(0.66 - 1.21)	-	41	239.6	(164.9 - 314.3)	0.99	(0.69 - 1.32)	-
Dardanup (S) - Pt B	25	299.5	(181.4 - 417.6)	0.90	(0.55 - 1.29)	-	10	144.8	(53.8 - 235.7)	0.56	(0.23 - 0.96)	V
Wellington HD												
Collie (S)	127	395.3	(322.7 - 467.9)	1.16	(0.97 - 1.38)	-	94	308.7	(242.8 - 374.6)	1.13	(0.92 - 1.39)	-
Donnybrook-Balingup (S)	42	255.3	(177.9 - 332.7)	0.77	(0.54 - 1.02)	-	45	278.1	(195.4 - 360.8)	1.10	(0.78 - 1.44)	-
Harvey-Yarloop HD												
Harvey (S) - Pt A	93	348.9	(275.3 - 422.5)	1.02	(0.83 - 1.26)	-	64	242.6	(182.1 - 303.1)	0.91	(0.70 - 1.17)	-
Harvey (S) - Pt B	103	355.4	(285.3 - 425.4)	1.06	(0.87 - 1.29)	-	77	279.9	(214.3 - 345.4)	1.07	(0.85 - 1.34)	-
Total State	20827	338.1	(333.4 - 342.7)	1.00	(0.99 - 1.01)	-	17314	260.1	(255.9 - 264.2)	1.00	(0.99 - 1.02)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

Table 4. Total cancer mortality⁽¹⁾ by area, 1998-2002: All SLAs (alphabetic)

Area	Males					Sig(2)	Females					Sig(2)
	Cases	ASR	95% c.i.	SRR	95% c.i.		Cases	ASR	95% c.i.	SRR	95% c.i.	
Albany (C) - Central	114	157.6	(125.4 - 189.8)	0.99	(0.82 - 1.19)	-	87	83.7	(61.8 - 105.6)	0.91	(0.73 - 1.13)	-
Albany (C) Bal	41	83.3	(57.3 - 109.3)	0.58	(0.41 - 0.78)	V	43	92.9	(64.8 - 121.0)	1.10	(0.78 - 1.45)	-
Armadale (C)	188	118.7	(101.6 - 135.9)	0.87	(0.75 - 1.01)	-	177	99.1	(83.8 - 114.3)	1.10	(0.94 - 1.27)	-
Ashburton (S)	4	63.5	(0.0 - 137.6)	0.38	(0.06 - 0.84)	V	6	124.6	(5.6 - 243.6)	1.11	(0.30 - 2.16)	-
Augusta-Margaret River (S)	49	122.5	(86.1 - 159.0)	0.98	(0.71 - 1.27)	-	22	51.9	(28.6 - 75.3)	0.68	(0.40 - 0.99)	V
Bassendean (T)	91	167.9	(132.3 - 203.6)	1.20	(0.97 - 1.48)	-	78	125.6	(94.9 - 156.4)	1.30	(1.03 - 1.63)	^
Bayswater (C)	291	125.0	(110.0 - 140.0)	0.90	(0.80 - 1.02)	-	268	92.1	(79.6 - 104.6)	1.07	(0.94 - 1.20)	-
Belmont (C)	217	161.2	(138.3 - 184.1)	1.19	(1.04 - 1.37)	^	135	86.7	(70.1 - 103.2)	0.96	(0.81 - 1.14)	-
Beverley (S)	7	80.0	(20.3 - 139.6)	0.59	(0.19 - 1.10)	-	4	27.9	(0.0 - 55.8)	0.55	(0.08 - 1.19)	-
Boddington (S)	5	126.2	(2.2 - 250.1)	0.85	(0.19 - 1.75)	-	4	115.5	(1.2 - 229.8)	1.17	(0.18 - 2.57)	-*
Boyup Brook (S)	2	17.4	(0.0 - 41.3)	0.20	(0.00 - 0.56)	V	7	74.8	(7.7 - 141.9)	0.93	(0.29 - 1.73)	-
Bridgetown-Greenbushes (S)	19	127.2	(67.9 - 186.4)	0.88	(0.49 - 1.32)	-	14	78.5	(36.3 - 120.6)	0.95	(0.47 - 1.50)	-
Brookton (S)	7	133.5	(26.2 - 240.7)	0.88	(0.28 - 1.64)	-	8	161.6	(35.9 - 287.3)	1.84	(0.65 - 3.32)	-*
Broome (S)	21	96.8	(54.0 - 139.6)	0.70	(0.41 - 1.03)	-	16	67.9	(32.9 - 103.0)	0.91	(0.48 - 1.40)	-
Broomehill (S)	2	109.7	(0.0 - 258.5)	0.83	(0.01 - 2.32)	-*	0	-	-	0	n/a	-
Bruce Rock (S)	9	168.2	(55.0 - 281.4)	1.30	(0.50 - 2.27)	-	4	70.2	(0.0 - 145.1)	0.86	(0.13 - 1.89)	-
Bunbury (C)	164	149.5	(124.9 - 174.1)	1.03	(0.88 - 1.21)	-	122	94.0	(75.2 - 112.9)	0.99	(0.82 - 1.18)	-
Busselton (S)	122	120.0	(97.6 - 142.4)	0.94	(0.78 - 1.12)	-	102	93.3	(73.2 - 113.4)	1.06	(0.87 - 1.30)	-
Cambridge (T)	127	108.1	(87.0 - 129.1)	0.84	(0.70 - 1.00)	-	117	83.8	(65.5 - 102.1)	0.91	(0.76 - 1.09)	-
Canning (C)	330	135.9	(120.9 - 150.8)	1.00	(0.90 - 1.12)	-	256	80.8	(70.2 - 91.4)	0.95	(0.84 - 1.08)	-
Capel (S) - Pt A	6	106.4	(13.4 - 199.5)	0.76	(0.20 - 1.47)	-	1	21.7	(0.0 - 64.2)	0.19	(0.00 - 0.71)	V
Capel (S) - Pt B	22	144.0	(83.8 - 204.2)	1.10	(0.65 - 1.60)	-	10	78.8	(29.2 - 128.5)	0.86	(0.35 - 1.46)	-
Carnamah (S)	2	89.3	(0.0 - 211.6)	0.63	(0.01 - 1.77)	-*	2	118.3	(0.0 - 276.8)	1.12	(0.01 - 3.13)	-*
Carnarvon (S)	34	144.7	(95.6 - 193.7)	1.10	(0.74 - 1.50)	-	11	60.1	(23.9 - 96.3)	0.66	(0.29 - 1.10)	-
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	0.53	(0.01 - 1.49)	-*	3	95.1	(0.0 - 208.7)	1.43	(0.12 - 3.33)	-*
Chittering (S)	19	169.4	(92.0 - 246.9)	1.33	(0.75 - 1.99)	-	3	27.4	(0.0 - 58.6)	0.40	(0.03 - 0.93)	V
Claremont (T)	59	143.7	(102.6 - 184.9)	0.97	(0.75 - 1.26)	-	59	77.4	(50.1 - 104.8)	0.92	(0.71 - 1.20)	-
Cockburn (C)	287	153.1	(135.3 - 171.0)	1.10	(0.98 - 1.24)	-	211	95.6	(82.3 - 109.0)	1.09	(0.95 - 1.25)	-
Collie (S)	48	142.1	(100.0 - 184.1)	1.00	(0.72 - 1.30)	-	30	85.9	(52.8 - 119.0)	0.93	(0.60 - 1.29)	-
Coolgardie (S)	7	113.9	(21.5 - 206.4)	0.79	(0.25 - 1.48)	-	6	83.2	(9.5 - 156.9)	1.22	(0.33 - 2.37)	-
Coorow (S)	6	126.5	(24.6 - 228.5)	0.88	(0.24 - 1.71)	-	2	35.7	(0.0 - 88.5)	0.53	(0.01 - 1.47)	-*
Corrigin (S)	4	57.9	(0.0 - 116.2)	0.52	(0.08 - 1.13)	-	7	128.9	(28.1 - 229.7)	1.21	(0.38 - 2.25)	-
Cottesloe (T)	42	126.4	(85.6 - 167.3)	0.98	(0.68 - 1.29)	-	25	54.9	(18.3 - 91.4)	0.65	(0.40 - 0.94)	V
Cranbrook (S)	5	106.9	(10.6 - 203.2)	0.75	(0.16 - 1.53)	-	3	69.5	(0.0 - 151.0)	0.94	(0.08 - 2.20)	-*
Cuballing (S)	4	148.8	(3.5 - 294.1)	1.17	(0.18 - 2.56)	-*	2	86.5	(0.0 - 206.3)	0.98	(0.01 - 2.72)	-*
Cue (S)	3	373.2	(0.0 - 792.4)	2.07	(0.17 - 4.83)	-*	3	478.3	(0.0 - 1,018.1)	3.52	(0.28 - 8.22)	-*
Cunderdin (S)	4	78.3	(2.2 - 154.5)	0.54	(0.08 - 1.17)	-	6	108.9	(13.3 - 204.5)	1.16	(0.31 - 2.25)	-
Dalwallinu (S)	8	129.3	(40.1 - 218.4)	0.95	(0.33 - 1.71)	-	1	10.6	(0.0 - 31.3)	0.18	(0.00 - 0.65)	V
Dandaragan (S)	14	102.5	(48.5 - 156.5)	0.82	(0.41 - 1.31)	-	7	73.4	(18.7 - 128.1)	0.80	(0.25 - 1.49)	-
Dardanup (S) - Pt A	24	166.2	(99.1 - 233.2)	1.19	(0.72 - 1.71)	-	8	44.3	(12.7 - 75.9)	0.57	(0.20 - 1.03)	-
Dardanup (S) - Pt B	7	83.9	(19.3 - 148.5)	0.62	(0.19 - 1.16)	-	5	75.0	(8.0 - 141.9)	0.86	(0.19 - 1.76)	-
Denmark (S)	22	92.3	(53.0 - 131.7)	0.73	(0.43 - 1.07)	-	20	92.5	(50.1 - 134.9)	1.09	(0.62 - 1.61)	-
Derby-West Kimberley (S)	29	192.5	(121.4 - 263.6)	1.37	(0.88 - 1.91)	-	14	114.9	(52.1 - 177.7)	1.13	(0.56 - 1.79)	-
Donnybrook-Balingup (S)	17	99.4	(51.9 - 146.8)	0.75	(0.40 - 1.15)	-	14	82.6	(37.8 - 127.4)	0.94	(0.47 - 1.50)	-
Dowerin (S)	3	109.0	(0.0 - 238.4)	0.77	(0.06 - 1.79)	-*	2	54.4	(0.0 - 128.6)	0.68	(0.01 - 1.88)	-*
Dumbleyung (S)	6	172.1	(35.1 - 309.1)	1.39	(0.38 - 2.71)	-*	0	-	-	0	n/a	-
Dundas (S)	5	124.0	(17.5 - 230.5)	0.89	(0.19 - 1.83)	-	2	61.2	(0.0 - 147.6)	0.63	(0.01 - 1.74)	-*
East Fremantle (T)	31	108.9	(68.6 - 149.1)	0.80	(0.52 - 1.10)	-	29	61.4	(33.2 - 89.6)	0.93	(0.59 - 1.29)	-
East Pilbara (S)	10	139.3	(46.4 - 232.2)	0.79	(0.33 - 1.35)	-	4	53.3	(0.0 - 112.9)	0.59	(0.09 - 1.29)	-
Esperance (S)	54	129.0	(94.4 - 163.7)	0.91	(0.69 - 1.20)	-	39	88.5	(59.9 - 117.2)	0.96	(0.66 - 1.29)	-
Exmouth (S)	6	121.9	(8.8 - 234.9)	0.74	(0.20 - 1.44)	-	6	96.7	(16.9 - 176.4)	1.30	(0.35 - 2.53)	-
Fremantle (C) - Inner	1	33.9	(0.0 - 100.1)	0.17	(0.00 - 0.63)	V	1	74.1	(0.0 - 216.5)	0.51	(0.00 - 1.87)	-*
Fremantle (C) - Remainder	166	153.6	(129.4 - 177.9)	1.09	(0.93 - 1.27)	-	128	100.7	(80.4 - 120.9)	1.06	(0.89 - 1.26)	-
Geraldton (C)	149	198.5	(166.1 - 231.0)	1.45	(1.23 - 1.70)	^	96	109.5	(85.5 - 133.5)	1.21	(0.99 - 1.49)	-
Gingin (S)	32	186.4	(120.7 - 252.1)	1.33	(0.87 - 1.83)	-	12	74.3	(32.3 - 116.3)	0.85	(0.39 - 1.39)	-
Gnowangerup (S)	7	167.8	(44.9 - 290.7)	0.97	(0.30 - 1.81)	-	2	24.1	(0.0 - 57.1)	0.41	(0.01 - 1.15)	-
Goomalling (S)	1	25.0	(0.0 - 72.8)	0.18	(0.00 - 0.65)	V	1	15.4	(0.0 - 45.3)	0.26	(0.00 - 0.94)	V*

Table 4 (cont.) Total cancer mortality⁽¹⁾ by area, 1998-2002: All SLAs (alphabetic)

Area	Males					Sig(2)	Females					Sig(2)
	Cases	ASR	95% c.i.	SRR	95% c.i.		Cases	ASR	95% c.i.	SRR	95% c.i.	
Gosnells (C)	308	139.6	(123.8 - 155.4)	1.02	(0.91 - 1.14)	-	217	83.5	(71.9 - 95.1)	0.95	(0.83 - 1.08)	-
Greenough (S) - Pt A	33	129.9	(84.4 - 175.3)	1.00	(0.67 - 1.37)	-	23	102.6	(59.8 - 145.5)	1.11	(0.67 - 1.61)	-
Greenough (S) - Pt B	4	81.2	(1.1 - 161.3)	0.67	(0.10 - 1.47)	-	2	54.8	(0.0 - 130.4)	0.72	(0.01 - 2.01)	-*
Halls Creek (S)	10	146.2	(51.9 - 240.4)	1.02	(0.42 - 1.75)	-	7	116.3	(26.4 - 206.1)	1.17	(0.37 - 2.18)	-
Harvey (S) - Pt A	32	119.6	(76.4 - 162.8)	0.87	(0.57 - 1.20)	-	29	114.8	(72.3 - 157.2)	1.22	(0.78 - 1.71)	-
Harvey (S) - Pt B	49	160.8	(115.4 - 206.2)	1.18	(0.85 - 1.54)	-	26	77.7	(45.2 - 110.2)	0.93	(0.58 - 1.33)	-
Irwin (S)	24	172.0	(101.9 - 242.1)	1.28	(0.78 - 1.84)	-	10	88.7	(33.1 - 144.3)	0.99	(0.41 - 1.70)	-
Jerramungup (S)	1	71.4	(0.0 - 201.0)	0.18	(0.00 - 0.68)	V	1	22.8	(0.0 - 67.5)	0.35	(0.00 - 1.31)	-*
Joondalup (C) - North	124	129.5	(106.0 - 153.1)	0.95	(0.80 - 1.14)	-	125	113.5	(93.0 - 134.1)	1.25	(1.04 - 1.49)	^
Joondalup (C) - South	362	115.0	(102.7 - 127.3)	0.83	(0.75 - 0.92)	V	304	81.5	(71.7 - 91.3)	0.96	(0.85 - 1.07)	-
Kalamunda (S)	227	138.8	(120.4 - 157.2)	1.01	(0.88 - 1.15)	-	162	83.3	(69.7 - 96.8)	0.95	(0.82 - 1.12)	-
Kalgoorlie/Boulder (C) - Pt A	88	169.5	(133.1 - 205.9)	1.20	(0.96 - 1.48)	-	67	114.7	(84.9 - 144.6)	1.22	(0.95 - 1.56)	-
Kalgoorlie/Boulder (C) - Pt B	3	597.2	(0.0 - 1,233.6)	1.99	(0.16 - 4.66)	-*	2	357.1	(0.0 - 828.0)	3.71	(0.05 - 10.33)	-*
Katanning (S)	23	148.3	(85.8 - 210.8)	1.12	(0.67 - 1.62)	-	17	85.4	(41.0 - 129.8)	1.09	(0.58 - 1.66)	-
Kellerberrin (S)	7	112.6	(27.9 - 197.3)	0.80	(0.25 - 1.49)	-	10	138.5	(38.7 - 238.2)	1.63	(0.67 - 2.78)	-
Kent (S)	1	74.1	(0.0 - 216.5)	0.46	(0.00 - 1.68)	-*	0	-	-	0	n/a	-
Kojonup (S)	12	105.9	(43.0 - 168.7)	0.92	(0.42 - 1.50)	-	10	72.1	(23.3 - 120.9)	1.18	(0.48 - 2.01)	-
Kondinin (S)	2	58.9	(0.0 - 140.7)	0.46	(0.01 - 1.27)	-*	2	84.1	(0.0 - 199.9)	0.82	(0.01 - 2.29)	-*
Koorda (S)	2	121.4	(0.0 - 280.9)	0.78	(0.01 - 2.16)	-*	1	62.5	(0.0 - 183.1)	0.60	(0.00 - 2.20)	-*
Kulin (S)	3	72.4	(0.0 - 156.7)	0.62	(0.05 - 1.44)	-	2	62.3	(0.0 - 148.8)	0.67	(0.01 - 1.86)	-*
Kwinana (T)	112	168.4	(136.7 - 200.1)	1.27	(1.05 - 1.54)	^	63	90.5	(67.5 - 113.4)	1.04	(0.81 - 1.34)	-
Lake Grace (S)	8	180.9	(53.4 - 308.4)	1.26	(0.44 - 2.27)	-	6	138.4	(25.0 - 251.8)	1.51	(0.41 - 2.93)	-*
Laverton (S)	1	38.1	(0.0 - 112.7)	0.27	(0.00 - 0.99)	V*	1	46.5	(0.0 - 137.3)	0.76	(0.00 - 2.79)	-*
Leonora (S)	5	142.6	(0.0 - 290.5)	0.87	(0.19 - 1.78)	-	1	33.3	(0.0 - 96.5)	0.49	(0.00 - 1.80)	-*
Mandurah (C)	350	139.9	(124.1 - 155.6)	1.01	(0.91 - 1.13)	-	230	86.7	(74.2 - 99.1)	1.01	(0.89 - 1.15)	-
Manjimup (S)	59	152.5	(112.3 - 192.7)	1.12	(0.86 - 1.45)	-	29	70.5	(43.1 - 97.9)	0.86	(0.55 - 1.21)	-
Meekatharra (S)	8	273.5	(81.4 - 465.5)	1.87	(0.66 - 3.37)	-*	4	164.9	(3.9 - 325.8)	1.53	(0.24 - 3.35)	-*
Melville (C)	502	123.9	(112.4 - 135.4)	0.91	(0.84 - 1.00)	-	418	76.9	(68.4 - 85.3)	0.92	(0.84 - 1.02)	-
Menzies (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Merredin (S)	18	138.5	(72.1 - 204.8)	1.02	(0.56 - 1.54)	-	19	162.2	(87.0 - 237.3)	1.62	(0.91 - 2.43)	-
Mingenew (S)	2	105.3	(0.0 - 249.2)	0.79	(0.01 - 2.20)	-*	1	60.6	(0.0 - 177.6)	0.64	(0.00 - 2.35)	-*
Moora (S)	10	139.8	(49.5 - 230.2)	0.88	(0.36 - 1.51)	-	4	48.9	(0.0 - 104.2)	0.50	(0.08 - 1.10)	-
Morawa (S)	4	118.1	(2.5 - 233.6)	0.71	(0.11 - 1.56)	-	2	52.5	(0.0 - 132.7)	0.68	(0.01 - 1.89)	-*
Mosman Park (T)	49	138.7	(97.7 - 179.7)	1.03	(0.74 - 1.34)	-	36	63.8	(35.9 - 91.7)	0.83	(0.56 - 1.13)	-
Mount Magnet (S)	0	-	-	0	n/a	-	1	58.8	(0.0 - 170.7)	0.77	(0.00 - 2.83)	-*
Mount Marshall (S)	1	43.5	(0.0 - 128.1)	0.34	(0.00 - 1.24)	-*	0	-	-	0	n/a	-
Mukinbudin (S)	1	23.5	(0.0 - 69.4)	0.27	(0.00 - 1.00)	-*	0	-	-	0	n/a	-
Mullewa (S)	4	126.6	(2.3 - 251.0)	0.89	(0.14 - 1.96)	-*	2	121.1	(0.0 - 304.9)	0.88	(0.01 - 2.44)	-*
Mundaring (S)	135	122.1	(101.1 - 143.1)	0.88	(0.74 - 1.05)	-	118	84.7	(68.8 - 100.6)	1.04	(0.86 - 1.25)	-
Murchison (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Murray (S)	63	126.5	(91.3 - 161.7)	0.87	(0.68 - 1.13)	-	59	135.2	(99.2 - 171.2)	1.47	(1.13 - 1.91)	^
Nannup (S)	4	77.3	(2.4 - 152.2)	0.63	(0.10 - 1.39)	-	1	13.5	(0.0 - 39.6)	0.24	(0.00 - 0.89)	V*
Narembeen (S)	7	156.8	(37.0 - 276.6)	1.29	(0.40 - 2.40)	-	1	10.6	(0.0 - 31.3)	0.27	(0.00 - 1.00)	-*
Narrogin (S)	0	-	-	0	n/a	V	0	-	-	0	n/a	V
Narrogin (T)	34	209.1	(133.5 - 284.8)	1.67	(1.12 - 2.28)	^	20	120.6	(58.2 - 183.0)	1.19	(0.68 - 1.76)	-
Nedlands (C)	124	109.2	(87.4 - 130.9)	0.93	(0.78 - 1.12)	-	155	94.9	(75.0 - 114.8)	1.21	(1.03 - 1.41)	^
Ngaanyatjarraku (S)	0	-	-	0	n/a	V	1	32.0	(0.0 - 94.5)	0.38	(0.00 - 1.39)	-*
Northam (S)	18	145.4	(74.6 - 216.1)	1.05	(0.58 - 1.58)	-	8	73.2	(22.5 - 123.8)	0.81	(0.28 - 1.46)	-
Northam (T)	44	179.2	(122.3 - 236.1)	1.21	(0.86 - 1.60)	-	41	108.1	(68.4 - 147.7)	1.39	(0.97 - 1.85)	-
Northampton (S)	20	147.2	(81.5 - 213.0)	0.99	(0.56 - 1.46)	-	7	46.6	(12.0 - 81.3)	0.61	(0.19 - 1.14)	-
Nungarin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Peppermint Grove (S)	8	128.5	(37.2 - 219.7)	0.82	(0.29 - 1.48)	-	8	81.6	(15.0 - 148.1)	1.15	(0.40 - 2.07)	-
Perenjori (S)	3	175.9	(0.0 - 377.3)	1.27	(0.10 - 2.97)	-*	1	33.3	(0.0 - 97.6)	0.56	(0.00 - 2.08)	-*
Perth (C) - Inner	5	301.6	(57.0 - 546.3)	1.33	(0.29 - 2.72)	-*	1	83.3	(0.0 - 245.5)	0.58	(0.00 - 2.14)	-*
Perth (C) - Remainder	57	198.4	(145.1 - 251.8)	1.38	(1.06 - 1.80)	^	18	73.6	(34.7 - 112.5)	0.81	(0.45 - 1.23)	-
Pingelly (S)	9	188.2	(53.4 - 323.0)	1.11	(0.42 - 1.94)	-	7	120.4	(22.2 - 218.6)	1.24	(0.39 - 2.31)	-
Plantagenet (S)	30	170.2	(109.2 - 231.3)	1.17	(0.76 - 1.62)	-	15	77.2	(35.8 - 118.6)	0.89	(0.45 - 1.39)	-

Table 4 (cont.) Total cancer mortality⁽¹⁾ by area, 1998-2002: All SLAs (alphabetic)

Area	Males					Sig(2)	Females					Sig(2)
	Cases	ASR	95% c.i.	SRR	95% c.i.		Cases	ASR	95% c.i.	SRR	95% c.i.	
Port Hedland (T)	24	118.7	(65.4 - 172.1)	0.89	(0.54 - 1.27)	-	14	78.2	(35.4 - 121.1)	0.92	(0.46 - 1.46)	-
Quairading (S)	5	112.1	(13.9 - 210.4)	0.81	(0.18 - 1.66)	-	7	132.7	(21.7 - 243.8)	1.38	(0.43 - 2.57)	-
Ravensthorpe (S)	4	62.3	(1.4 - 123.1)	0.51	(0.08 - 1.12)	-	4	87.1	(0.7 - 173.6)	0.91	(0.14 - 2.00)	-*
Rockingham (C)	392	152.8	(137.1 - 168.4)	1.10	(1.00 - 1.22)	-	271	94.0	(82.1 - 105.9)	1.08	(0.95 - 1.22)	-
Roebourne (S)	23	131.0	(66.9 - 195.0)	0.95	(0.57 - 1.37)	-	8	38.8	(2.3 - 75.2)	0.54	(0.19 - 0.97)	V
Sandstone (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Serpentine-Jarrahdale (S)	40	120.7	(82.8 - 158.7)	0.91	(0.63 - 1.21)	-	18	56.8	(30.3 - 83.4)	0.64	(0.35 - 0.96)	V
Shark Bay (S)	1	24.8	(0.0 - 73.4)	0.16	(0.00 - 0.59)	V	1	48.8	(0.0 - 143.8)	0.33	(0.00 - 1.23)	-*
South Perth (C)	192	123.3	(103.9 - 142.7)	0.93	(0.80 - 1.07)	-	189	86.4	(70.7 - 102.1)	0.94	(0.82 - 1.09)	-
Stirling (C) - Central	575	146.3	(133.8 - 158.8)	1.04	(0.96 - 1.13)	-	413	82.7	(73.9 - 91.5)	0.96	(0.87 - 1.05)	-
Stirling (C) - Coastal	338	131.6	(116.7 - 146.5)	0.99	(0.89 - 1.10)	-	266	87.4	(75.7 - 99.2)	0.94	(0.83 - 1.06)	-
Stirling (C) - South-Eastern	112	126.8	(98.5 - 155.2)	1.07	(0.88 - 1.29)	-	109	84.4	(61.6 - 107.3)	1.06	(0.87 - 1.28)	-
Subiaco (C)	81	158.5	(122.0 - 195.0)	1.14	(0.91 - 1.42)	-	79	94.1	(69.0 - 119.3)	1.20	(0.95 - 1.50)	-
Swan (C)	290	140.5	(124.1 - 156.9)	1.02	(0.90 - 1.14)	-	217	90.3	(77.8 - 102.9)	1.03	(0.90 - 1.18)	-
Tambellup (S)	2	92.6	(0.0 - 220.7)	0.64	(0.01 - 1.78)	-*	1	50.0	(0.0 - 147.4)	0.50	(0.00 - 1.83)	-*
Tammin (S)	4	310.9	(20.3 - 601.4)	1.78	(0.27 - 3.89)	-*	2	48.8	(0.0 - 114.8)	1.31	(0.02 - 3.64)	-*
Three Springs (S)	5	147.0	(12.4 - 281.7)	1.11	(0.24 - 2.27)	-	4	126.3	(0.0 - 265.2)	1.55	(0.24 - 3.41)	-*
Toodyay (S)	20	130.3	(73.2 - 187.3)	1.00	(0.57 - 1.48)	-	14	96.7	(45.3 - 148.1)	1.20	(0.59 - 1.90)	-
Trayning (S)	3	168.1	(0.0 - 376.3)	1.13	(0.09 - 2.64)	-*	2	95.2	(0.0 - 224.1)	1.07	(0.01 - 2.98)	-*
Upper Gascoyne (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Victoria Park (T)	227	193.7	(163.4 - 224.0)	1.29	(1.13 - 1.47)	^	182	91.0	(71.9 - 110.1)	1.02	(0.88 - 1.18)	-
Victoria Plains (S)	8	171.6	(52.0 - 291.3)	1.29	(0.45 - 2.33)	-	1	62.5	(0.0 - 181.1)	0.39	(0.00 - 1.43)	-*
Vincent (T)	145	137.3	(112.9 - 161.7)	1.01	(0.86 - 1.20)	-	99	72.3	(54.5 - 90.1)	0.84	(0.69 - 1.03)	-
Wagin (S)	15	153.1	(60.3 - 245.8)	1.24	(0.63 - 1.94)	-	11	131.1	(44.6 - 217.5)	1.22	(0.53 - 2.04)	-
Wandering (S)	1	75.0	(0.0 - 220.2)	0.62	(0.00 - 2.28)	-*	1	83.3	(0.0 - 232.4)	1.04	(0.00 - 3.84)	-*
Wanneroo (C) - North-East	93	158.0	(125.3 - 190.6)	1.15	(0.93 - 1.41)	-	63	91.1	(67.2 - 115.0)	1.05	(0.81 - 1.35)	-
Wanneroo (C) - North-West	82	119.2	(92.6 - 145.8)	0.88	(0.70 - 1.09)	-	56	78.5	(57.4 - 99.6)	0.94	(0.71 - 1.22)	-
Wanneroo (C) - South	115	137.2	(111.9 - 162.5)	1.03	(0.86 - 1.25)	-	77	79.4	(61.3 - 97.6)	0.90	(0.71 - 1.13)	-
Waroona (S)	14	107.2	(47.5 - 167.0)	0.72	(0.36 - 1.15)	-	16	127.8	(62.9 - 192.6)	1.26	(0.66 - 1.95)	-
West Arthur (S)	1	20.4	(0.0 - 60.0)	0.18	(0.00 - 0.65)	V	0	-	-	0	n/a	-
Westonia (S)	1	102.0	(0.0 - 300.0)	0.68	(0.00 - 2.50)	-*	0	-	-	0	n/a	-
Wickepin (S)	3	99.7	(0.0 - 223.9)	0.66	(0.05 - 1.54)	-	2	80.9	(0.0 - 192.5)	0.78	(0.01 - 2.18)	-*
Williams (S)	1	34.5	(0.0 - 101.7)	0.22	(0.00 - 0.81)	V	4	167.4	(4.6 - 330.2)	1.39	(0.21 - 3.04)	-*
Wiluna (S)	1	24.0	(0.0 - 70.9)	0.40	(0.00 - 1.47)	-*	2	195.8	(0.0 - 476.2)	2.16	(0.03 - 6.03)	-*
Wongan-Ballidu (S)	8	193.3	(57.2 - 329.5)	1.30	(0.46 - 2.34)	-	7	122.2	(20.9 - 223.4)	1.51	(0.47 - 2.81)	-
Woodanilling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Wyalkatchem (S)	5	147.6	(16.1 - 279.0)	1.17	(0.25 - 2.39)	-*	3	105.4	(0.0 - 236.7)	1.17	(0.09 - 2.74)	-*
Wyndham-East Kimberley (S)	13	87.9	(36.4 - 139.4)	0.74	(0.35 - 1.19)	-	8	68.1	(17.1 - 119.0)	0.84	(0.30 - 1.52)	-
Yalgoo (S)	1	62.5	(0.0 - 184.2)	0.77	(0.00 - 2.83)	-*	0	-	-	0	n/a	-
Yilgarn (S)	10	195.1	(73.6 - 316.7)	1.46	(0.60 - 2.49)	-	2	44.2	(0.0 - 105.4)	0.48	(0.01 - 1.33)	-*
York (S)	20	146.9	(81.1 - 212.6)	0.96	(0.55 - 1.43)	-	14	77.8	(32.7 - 122.8)	1.02	(0.51 - 1.63)	-
Total State	8892	137.0	(134.1 - 139.9)	1.00	(0.98 - 1.02)	-	6757	87.4	(85.1 - 89.6)	1.00	(0.98 - 1.02)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

4.5 Incidence SRRs for common cancers - comments

"Statistically significant" differences between local and State rates were seen most often for the most common cancers, and some warrant comment here. The tables showing the results are found in the Appendix, on the attached CD or on the WACR Website at www.health.wa.gov.au/wacr/ under a link labelled "Cancer statistics for Western Australia", and only comments on issues of particular note are recorded here.

Breast cancer in females:

The incidence of breast cancer in females appeared very evenly distributed throughout Western Australia, with a lower than expected incidence found for only 4 SLAs: Bassendean, Ashburton, East Pilbara and Greenough (Part A). The only statistically-significant increased incidence was in the SLA of Victoria Plains, based on only 8 cases seen in 5 years, where 2 were expected.

Prostate cancer:

Prostate cancer incidence rates in males appeared higher than average in the North Metropolitan Health Region (Nedlands, Stirling[Coastal] and Wanneroo [North West]), and in several other metropolitan areas. Rates were lower than expected in most areas in the Kimberley and East Pilbara areas, most likely because of the relatively-high proportion of indigenous persons in these areas (who have a far lower prostate cancer incidence rate than non-indigenous males). In the South West Region, incidence appeared lower than expected for residents of the Bunbury, Capel (Part A) and Dardanup (Part B) areas.

Colorectal cancer:

There were no particular regions in which residents appeared to have had a systematically raised or lowered incidence of colorectal cancer.

Melanoma of the skin:

Incidence of melanoma in males appeared higher than average in 1/3 of the SLAs in the North Metropolitan Region; similar SRRs were seen in females but these did not appear statistically-significant. Elsewhere, rates were in keeping with State-based expectations.

Lung cancer:

In the North Metropolitan Region, lung cancer incidence in males was significantly lower than the State rate in the SLAs of Cambridge and Joondalup (South), and the "point estimate" SRR of 0.70 was of borderline significance (95% c.i. 0.42-1.00) in Nedlands. In the East Metropolitan Region, incidence appeared higher than expected in Belmont, Vincent and Swan but was lower than expected in Mundaring.

In females, lung cancer incidence appeared similar to State rates in the North Metropolitan Region, but was less common than expected in South Perth (in the East Metropolitan Region). In the South Metropolitan Region, lung cancer incidence appeared higher than average in females in the Kwinana SLA, lower than average in the Melville SLA in males, and similar to State rates in other SLAs.

4.6 Incidence and mortality SRRs by Statistical Local Area

Albany (C) - Central

Cancer incidence: Incidence rates for all individual cancer types and for all cancers combined, did not differ significantly from the all-West Australian (all-W.A.) rates, for males or for females.

Cancer mortality: There were significantly fewer breast cancer deaths among females than in the State as a whole, with a standardized mortality rate ratio (SRR) of 0.49 (95% confidence interval (c.i.) 0.15–0.92). Otherwise, in males and in females, rates for all individual cancer types and for all cancers combined were statistically similar to the all-W.A. rates.

Albany (C) - Balance

Cancer incidence: Rates of lung, prostate and stomach cancers for males were significantly lower than the all-W.A. rates, but the calculation for stomach cancer was based on an expectation of only 4 cases and may be unreliable. The combined all-cancers incidence rate for males was also significantly lower than expected (SRR 0.65, 95% c.i. 0.54-0.79). Rates of other individual types of cancer in males were not significantly different from the all-W.A. rates. In females, there was a lower than average rate of uterine cancer (but based on an expectation of only 4 cases), while the other individual cancers and the all-cancers rate showed no significant departure from the all-W.A. rates.

Cancer mortality: The male colorectal cancer mortality rate and the male lung cancer mortality rate differed significantly from State rates, being lower than average. All-cancers rates in males were also significantly lower than in WA as a whole. Rates for all other types of cancers and the all-cancers combined mortality rates for females were similar to all-W.A. rates.

Armadale (C)

Cancer incidence: Males had a rate of mesothelioma (only two cases, SRR 0.27, 95% c.i. 0.00-0.76) and an all-cancers rate significantly lower than the all-W.A. rates (SRR 0.87, 95% c.i. 0.79-0.96). Other individual types of cancers in males had rates similar to the all-W.A. rate. In females there was a lower than expected rate of non-melanoma skin cancer, but otherwise there was no statistically significant difference of either the individual cancer rates or the all-cancers combined rate, from the all-W.A. rates.

Cancer mortality: The male colorectal cancer mortality rate and the male mesothelioma mortality rate differed significantly from State rates, being lower. Kidney (renal) cancers in females were statistically increased (SRR 3.22, 95% c.i. 1.33-5.51) but rates of other types of cancers were similar to the all-W.A. rates. All-cancers rates were similar to State rates for males and females.

Ashburton (S)

Cancer incidence: Males had rates for all individual cancer types and for all cancers combined, that were statistically similar to the all-W.A. rates. There were three cases of breast cancer in females, with a rate of breast cancer that was significantly lower than the State rate. The all-cancers combined incidence rate was also significantly lower for females than in the State as a whole.

Cancer mortality: The male all-cancers mortality SRR was only 0.38 with a 95% c.i. of 0.06-0.84, but rates for individual cancers were similar to State rates. Cancer mortality rates for females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Augusta-Margaret River (S)

Cancer incidence: Rates for all individual cancer types and for all cancers combined, were statistically similar to the all-W.A. rates for both males and females.

Cancer mortality: There was a marginally smaller all-cancers combined mortality rate for females when compared with the State combined rate (SRR 0.68, 95% c.i. 0.40-0.99), otherwise cancer mortality rates for males and females did not differ significantly from the all-W.A. rates.

Bassendean (T)

Cancer incidence: In males the rate for other lymphohaematopoietic cancer was significantly higher than the State rate (SRR 4.18 c.i. 1.72-7.15). However, this was based on an expectation of only 2 cases and may accordingly be unreliable. In females, incidence of breast cancer was significantly lower than the State rate, but the incidence rate for pancreatic cancer was elevated (SRR 3.00, 95% c.i. 1.31-5.02) (but based on an expectation of only 4 cases). Otherwise, rates for all individual cancer types and for all cancers combined, were statistically similar to the all-W.A. rates.

Cancer mortality: In females, the pancreatic cancer mortality rate was elevated (SRR 3.28, 95% c.i. 1.43 – 5.49), as well as the all-cancers rate (SRR 1.30). Cancer mortality rates for males, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Bayswater (C)

Cancer incidence: The rates of bladder cancer and myeloma in males were statistically lower than the State rates, as was the rate of cancer of the lip in females (SRR 0.34, 95% c.i. 0.00-0.95). Rates for all cancers combined, for males and females, were statistically similar to the all-W.A. rates.

Cancer mortality: There was significantly less prostate cancer mortality in males (SRR 0.64, 95% c.i. 0.38-0.92), but more uterine cancer mortality in females (SRR 2.37, 95% c.i. 1.08-3.89) than in the State as a whole. Otherwise cancer mortality rates for males and females were similar to all-W.A. rates.

Belmont (C)

Cancer incidence: The rate of prostate cancer was significantly lower than the all-W.A. rate, whilst the rate of lung cancer in males was significantly higher. Rates of other individual types of cancer, and the all-cancers incidence rate, in males were not significantly different from the all-W.A. rates. In females, individual cancers and the all-cancers rate showed no significant departure from the all-W.A. rates.

Cancer mortality: The male lung cancer mortality rate was significantly higher than the State rate (SRR 1.42, 95% c.i. 1.10 – 1.83). All-cancers rates in males were also significantly higher than in W.A. as a whole (SRR 1.19, 95% c.i. 1.04-1.37). Rates for all other types of cancers and the all-cancers combined mortality rates for females were similar to all-W.A. rates.

Beverley (S)

Cancer incidence: Cancer of the tonsil/oropharynx in males was more common than in the State as a whole (SRR 23.0, 95% c.i. 1.86 – 53.69) but, based on only three cases and none expected, this cannot not be regarded, in isolation, as a reliable indication of any excess risk. Otherwise in females and males, individual cancer rates and the all-cancers rate showed no significant departures from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Boddington (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Boyup Brook (S)

Cancer incidence: Individual cancer rates for males were not significantly different from the all-W.A. rates. However, the combined all-cancers rate for males was significantly lower than expected (SRR 0.61, 95% c.i. 0.30-0.97). In females, individual cancer rates and the all-cancers rate showed no significant departure from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. In males, individual cancer mortality rates were not significantly different from all-W.A. rates but the all-cancers SRR was only 0.20 (0.00-0.56).

Bridgetown-Greenbushes (S)

Cancer incidence: The incidence of colorectal cancer for males was significantly lower than the all-W.A. rate but was based on a small number of expected cases (SRR 0.14, 95% c.i. 0.00-0.52). However the combined all-cancers rate for males was not significantly different from the expected rate. In females, individual cancer rates and the all-cancers rate showed no significant departure from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Brookton (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Broome (S)

Cancer incidence: The rate of prostate cancer for males was significantly lower than the all-W.A. rate (SRR 0.25, 95% c.i. 0.04-0.54). There were more tonsil/oropharyngeal cancers than expected however this was based on only six cases over five years (expected: only 1). The combined all-cancers rate for males was not significantly different from the all-W.A. rate. In females, individual cancer rates and the all-cancers rate were similar to the all-W.A. rates.

Cancer mortality: The male lung cancer mortality rate was significantly lower than the State rate, however the expected number of cases was small. Rates for all other types of cancers and the all-cancers combined mortality rates for males and females were similar to all-W.A. rates.

Broomehill (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There were only four cancer deaths expected in females, and reliable SRRs cannot be produced.

Cancer mortality: There were no cancer-related deaths in females in 1998-2002. Cancer mortality rates for males, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There were only two deaths expected in males and in females, and SRR analysis cannot give a reliable result.

Bruce Rock (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Bunbury (C)

Cancer incidence: The rate of prostate cancer for males was significantly lower than the all-W.A. rate (SRR 0.76, 95% c.i. 0.58-0.98), as was the incidence of myeloma (no cases, 4 expected). However the combined all-cancers rate for males was not significantly different from the expected rate. In females, brain cancers were significantly less common than in the State as a whole (although based on only 4 cases expected), while other individual cancer rates and the all-cancers rate showed no significant departure from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Busselton (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: There was only one case of lymphoma in females and a significantly lower mortality rate for this disease was recorded when compared with the all-WA mortality rate (SRR 0.22, 95% c.i. 0.00-0.82). Otherwise cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cambridge (T)

Cancer incidence: Rates of lung cancer (SRR 0.64, 95% c.i. 0.40-0.90) and leukaemia (SRR 0.35, 95% c.i. 0.03-0.81) for males were significantly lower than the all-W.A. rates. Melanoma was significantly more common than in the State as a whole (SRR 1.44, 95% c.i. 1.09-1.90). Rates of other individual types of cancer in males, and the all-cancers incidence rate, were not significantly different from the all-W.A. rates. In females, apart from the colorectal cancer rate, which was significantly higher than the State rate, individual cancer rates and the all-cancers rate showed no significant departure from the all-W.A. rates.

Cancer mortality: In males there were significantly lower lung (SRR 0.68, 95% c.i. 0.42-0.98), kidney (SRR 0.26, 95% c.i. 0.00-0.95), bladder (SRR 0.23, 95% c.i. 0.00-0.86) cancer mortality rates than in W.A. as a whole. Individual and combined cancer mortality rates for females, and the all-cancers rate for males, were not significantly different from the all-W.A. rates.

Canning (C)

Cancer incidence: In males, incidence rates were significantly lower than the all-W.A. rates for testicular cancer (SRR 0.45, 95% c.i. 0.10-0.91) and tonsil/oropharyngeal cancers (SRR 0.23, 95% c.i. 0.00-0.85) (based on only 4 expected cases). Rates of other individual types of cancer in males, and the all-cancers incidence rate were not significantly different from the all-W.A. rates. In females, rates of individual cancers and the all-cancers rate were similar to the all-W.A. rates.

Cancer mortality: There were significantly lower colorectal cancer and melanoma mortality rates in males when compared with State rates. Otherwise individual and combined cancer mortality rates for males and females were not significantly different from the all-W.A. rates.

Capel (S) - Part A

Cancer incidence: The incidence of prostate cancer was significantly lower than the all-W.A. rate, and the all-cancers rate for males was also significantly lower than expected (SRR 0.56, 95% c.i. 0.25-0.91). Rates of other individual types of cancer in males were not significantly different from the all-W.A. rates. In females, individual cancer rates were similar to the all-W.A. rates. However, the all-cancers incidence rate for females was significantly lower than expected (SRR 0.51, 95% c.i. 0.20-0.90).

Cancer mortality: Individual cancer mortality rates for females and males were not significantly different from the all-W.A. rates. The all-cancers combined mortality rate for females was significantly lower than that of the State, whilst for males it was not statistically different.

Capel (S) - Part B

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Carnamah (S)

Cancer incidence: In females and males, individual cancer rates and the all-cancers rates were similar to the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. However only 3 deaths were expected in males and 2 in females, and SRR analysis cannot give a reliable result.

Carnarvon (S)

Cancer incidence: The rate of prostate cancer was significantly lower than the all-W.A. rate, however the combined all-cancers rate for males was not significantly different from the all-W.A. rate. In females, individual cancer rates and the all-cancers rate were similar to the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Chapman Valley (S)

Cancer incidence: In females and males, individual cancer rates were similar to the all-W.A. rates. The all-cancers rate was lower than expected in males, and all-cancers incidence in females was similar to the State rate.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Chittering (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers, and for all cancers combined in males, were not significantly different from the all-W.A. rates. There were fewer than expected cancer-related deaths in females (SRR 0.40, 95% c.i. 0.03-0.93)

Claremont (T)

Cancer incidence: The rate of melanoma in males was significantly higher than the all-W.A. rate (SRR 1.70, 95% c.i. 1.03-2.45). However the combined all-cancers rate for males was not significantly different from expectation, and in females, individual cancer rates and the all-cancers rate were similar to the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cockburn (C)

Cancer incidence: The rate of prostate cancer for males was lower than the all-W.A. rate (SRR 0.82, 95% c.i. 0.68-0.99), and the incidence of kidney cancer was higher than the all-WA rate (SRR 1.75, 95% c.i. 1.15-2.40). All-cancers incidence in males was not significantly different from the expected rate, and rates of other individual types of cancer in males were similar to the all-W.A. rates. In females, there was a lower than average rate of kidney cancer (SRR 0.47, 95% c.i. 0.10-0.97) and brain cancers (SRR 0.40, 95% c.i. 0.03-0.93). Other female individual cancer rates and the all-cancers rate were similar to the all-W.A. rates.

Cancer mortality: There were two deaths related to brain cancer in females which resulted in a significantly lower mortality rate than that of the State rate (SRR 0.32, 95% c.i. 0.00-0.89). The male mortality rate for leukemia was significantly higher than the State rate (SRR 1.99, 95% c.i. 1.16-2.92). Otherwise cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Collie (S)

Cancer incidence: In males, rates for all individual cancer types and for all cancers combined, were statistically similar to the all-W.A. rates. In females there was a significantly higher rate of melanoma (SRR 1.90, 95% c.i. 1.02-2.91) and primary liver cancer (SRR 10.38, 95 c.i. 1.61-22.75), but a reduced rate of cancer of the lung (SRR 0.15, 95% c.i. 0.00-0.57) compared with the State rate. The liver cancer assessment was based on an expectation of less than 1 case only and must be considered unreliable. The all-cancers incidence rate for females was not significantly different from the State rate.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Coolgardie (S)

Cancer incidence: In males there was a significantly lower rate of melanoma (SRR 0.23, 95% c.i. 0.00-0.83) (although based on only 4 cases expected) and a lower than expected all-cancers incidence rate (SRR 0.65, 95% c.i. 0.35-0.99). In females, rates for all individual cancer types and for all cancers combined were statistically similar to the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Coorow (S)

Cancer incidence: The incidence of male oesophageal cancer was significantly higher than the State rate (SRR 15.67, 95% c.i. 2.42-34.34) however this was based on only 4 cases in 5 years (expected: less than 1). Otherwise, in males and females, individual cancer rates and all-cancers rates showed no significant departure from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Corrigin (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cottesloe (T)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers, were not significantly different from the all-W.A. rates. There were significantly fewer cancer-related deaths than expected in females (SRR 0.65, 95% c.i. 0.40-0.94), but all-cancers mortality rates in males were similar to the State rate.

Cranbrook (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cuballing (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cue (S)

Cancer incidence: In females and males, individual cancer rates and the all-cancers rate showed no significant departure from the all-W.A. rates. As noted in the examples in a preceding section of this report, for males in this area both the wide 95% confidence interval, and the expectation of only 4 cases in 5 years, indicate the “crude” SRR of 1.79 to be unreliable. The expected number of cases in females was only 2 and should similarly be regarded as unreliable.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There were no cancer deaths expected in males, and one in females, and SRR analysis cannot give reliable results.

Cunderdin (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Dalwallinu (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for each type of cancer, were not significantly different from the all-W.A. rates. The male all-cancers combined mortality rate was not significantly different from the all-W.A. all-cancers combined mortality rate. However the female all-cancers combined mortality rate was significantly lower than the all-cancers combined State mortality rate (SRR 0.18, 95% c.i. 0.00-0.65).

Dandaragan (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Dardanup (S) - Part A

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Dardanup (S) - Part B

Cancer incidence: Incidence of prostate cancer was significantly lower than the all-W.A. rate (SRR 0.16, 95% c.i. 0.00-0.61) (1 case recorded, 6 expected). The combined all-cancers rate for males was statistically similar to expectation. Rates of other individual types of cancer in males were not significantly different from the all-W.A. rates. In females, rates for individual cancers were similar to State rates, but, the all-cancers incidence rate was significantly lower than the all-W.A. rate (SRR 0.56, 95% c.i. 0.23-0.96).

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Denmark (S)

Cancer incidence: In females and males, individual cancer rates showed no significant departure from the all-W.A. rates. The all-cancers incidence rate for males was significantly lower than the State rate, although the significance of this was marginal (SRR 0.75, 95% c.i. 0.56-0.99). The all-cancers rate for females was statistically similar to the State rate.

Cancer mortality: There was one death related to colorectal cancer in males which gave a significantly lower mortality rate than that of the State rate (SRR 0.25, 95% c.i. 0.00-0.94). Otherwise cancer mortality rates for females, for individual cancers and for all cancers combined for both sexes, were not significantly different from the all-W.A. rates.

Derby-West Kimberley (S)

Cancer incidence: The rate of prostate cancer was significantly lower than the all-W.A. rates (SRR 0.37, 95% c.i. 0.06-0.81). Rates of other individual types of cancer in males were not significantly different from the all-W.A. rates, and the all-cancers incidence rate for males was statistically similar to the expected. In females, individual cancers and the all-cancers rate showed no significant departure from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Donnybrook-Balingup (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Dowerin (S)

Cancer incidence: In females and males, individual cancer rates and the all-cancers rates showed no significant departure from the all-W.A. rates. As noted in an example in Section 3.3, while the SRRs suggested incidence rate elevations of 40% in males and 93% in females, the wide 95% confidence intervals indicate that these estimates are not statistically reliable.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Dumbleyung (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: There were no cancer-related deaths in females (3 expected), and no reliable SRRs can be produced. Cancer mortality rates for males, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Dundas (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

East Fremantle (T)

Cancer incidence: Colorectal cancer in females occurred at a lower rate than in the State as a whole (SRR 0.40, 95% c.i. 0.06-0.87). Otherwise, incidence rates for all individual cancer types and for all cancers combined, did not differ significantly from the all-Western Australian rates, for males or for females.

Cancer mortality: There were significantly fewer colorectal cancer deaths among females than the State rate, with SRR of 0.23 (95% c.i. 0.00 – 0.83). Otherwise, for males and females, rates for all individual cancer types and for all cancers combined were statistically similar to the all-W.A. rates.

East Pilbara (S)

Cancer incidence: The incidence of prostate cancer was significantly lower than in the State as a whole. Rates of other individual types of cancer in males were not significantly different from the all-W.A. rates. The combined all-cancers incidence rate for males was similar to the State rate. In females, there was a lower than average rate of breast cancer (SRR 0.36, 95% c.i. 0.03-0.84) and melanoma, whilst incidence of other individual cancers showed no significant departure from the all-W.A. rates. The all-cancers incidence rate in females was significantly lower than in the State as a whole (SRR 0.41, 95% c.i. 0.17-0.70).

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Esperance (S)

Cancer incidence: Rates for all individual cancer types and for all cancers combined, were statistically similar to the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Exmouth (S)

Cancer incidence: Rates for all individual cancer types and for all cancers combined, were statistically similar to the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Fremantle (C) - Inner

Cancer incidence: Rates for all individual cancer types and for all cancers combined, were statistically similar to the all-W.A. rates.

Cancer mortality: There was a statistically smaller all-cancers combined mortality rate for males when compared with the State combined rate (SRR 0.17, 95% c.i. 0.00-0.63) otherwise cancer mortality rates for males and females did not differ significantly from the all-W.A. rates. These data were based on only two expected deaths in females, and no reliable SRRs can be produced.

Fremantle (C) - Remainder

Cancer incidence: In males, individual cancer rates were not significantly different from the State rates. However the all-cancers rate for males was elevated (SRR 1.17, 95% c.i. 1.06-1.30). In females, incidence rates for kidney cancer and ovarian cancer were significantly lower than State rates, but the incidence of cancer of the lip was elevated (SRR 3.23, 95% c.i. 1.24–5.66, but based on only 3 expected cases, hence unreliable). In females, the all-cancers incidence rate was statistically similar to the all-W.A. rate.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Geraldton (C)

Cancer incidence: In males, rates of lung cancer and pancreatic cancer were higher than in the State as a whole, and the all-cancers rate was elevated (SRR 1.21, 95% c.i. 1.08-1.36). In females, whilst individual cancer incidence rates did not significantly depart from State rates, the all-cancers combined rate was increased (SRR 1.19, 95% c.i. 1.05-1.36).

Cancer mortality: The mortality rate of lymphoma in males was statistically lower than the State rate with a SRR of 0.27 (95% c.i. 0.00-0.98). Melanoma mortality in males was significantly higher (SRR 3.63, 95% c.i. 1.49-6.20) than expected, as was lung cancer mortality. Colorectal cancer in females was significantly less common (SRR 0.45, 95% c.i. 0.10-0.93) when compared with the State rate. The male all-cancers combined mortality rate was elevated when compared with all-W.A. rate with SRR of 1.45 (95% c.i. 1.23-1.70). Rates for all cancers combined, in females, were similar to the all-W.A. rates.

Gingin (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Gnowangerup (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Goomalling (S)

Cancer incidence: In females and males, individual cancer rates showed no significant departure from the all-W.A. rates. Whilst the male combined cancers rate was similar to the all-W.A. rate, all-cancers incidence in females was significantly lower than expected (SRR 0.42, 95% c.i. 0.06-0.91; but based on an expected 10 cases only.).

Cancer mortality: Individual cancer mortality rates did not statistically differ from State rates for males or females, but all-cancers mortality rates in both sexes were lower than the all-W.A. rates. These data were based on only one death in males and one in females (expected six and four respectively).

Gosnells (C)

Cancer incidence: In males, melanoma incidence was significantly lower than the State rate (SRR 0.70, 95% c.i. 0.55-0.89). The all-cancers rate in males showed no significant departure from the all-W.A. rates. Females also experienced a significantly lower incidence rate of melanoma (SRR 0.60, 95% c.i. 0.43-0.79). Other significantly less common cancers in females were lymphoma, oesophageal cancer and non-melanotic skin cancers. The all-cancers rate in females, however, was similar to the State average.

Cancer mortality: Stomach cancer mortality in males was significantly lower than expected (SRR 0.53, 95% c.i. 0.17-0.99). Otherwise cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Greenough (S) - Part A

Cancer incidence: The rate of breast cancer for females was significantly lower than the all-W.A. rate (SRR 0.60 95% c.i. 0.30-0.95). The all-cancers incidence rate for females was significantly lower than the expected rate. In males, individual cancer rates and the all-cancers rate were similar to the all-W.A. rates.

Cancer mortality: The rate of lung cancer mortality among females was increased compared with State rate (SRR 2.85, 95% c.i. 1.09-4.99). Otherwise cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Greenough (S) - Part B

Cancer incidence: In males and females, individual cancer rates showed no significant departure from the all-W.A. rates. Males had an all-cancers rate similar to the State average, but females had a lower rate with an SRR of 0.23 (95% c.i. 0.00-0.64); however this was based on an expectation of only 9 cases.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Halls Creek (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Harvey (S) - Part A

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Harvey (S) - Part B

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: There was a significantly lower lung cancer mortality rate in females than expected (SRR 0.23, 95% c.i. 0.00-0.85). Otherwise cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Irwin (S)

Cancer incidence: There was a significantly lower than expected rate of colorectal cancer in males (SRR 0.33, 95% c.i. 0.00-0.92). In females, non-melanotic skin cancer was more common than expected (SRR 14.06, 95% c.i. 1.13-32.82), but, based on only three cases (and less than 1 expected), this cannot not be regarded, in isolation, as a reliable indication of any excess risk. Otherwise individual cancer rates and the all-cancers rate, for males and females, showed no significant departure from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Jerramungup (S)

Cancer incidence: In males and females, rates for all individual cancer types were similar to the all-W.A. rates. The all-cancers incidence rate for females was lower than expected, but the rate for males was similar to the State rate.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. Based on only one death among males and one among females, the all-cancers SRR was reduced in males, but not significantly so for females.

Joondalup (C) - North

Cancer incidence: In males, leukaemia incidence was lower than the State average (SRR 0.41, 95% c.i. 0.06-0.89). Cervical cancer in females was also significantly less common than in the State as a whole (SRR 0.22, 95% c.i. 0.00-0.61). Otherwise, rates for other individual cancers and all-cancers combined were similar to the all-W.A. rates.

Cancer mortality: In males, the melanoma mortality rate was less than expected (SRR 0.26, 95% c.i. 0.00 – 0.94). Otherwise, cancer mortality rates, for individual cancers and all cancers combined in males, were not significantly different from the all-W.A. rates. The all-cancers SRR was elevated for females (1.25, 95% c.i. 1.04-1.49).

Joondalup (C) - South

Cancer incidence: The rate of lung cancer in males was lower than the State rate, although this was of marginal statistical significance (SRR 0.81, 95% c.i. 0.66–0.99). Thyroid and laryngeal cancer incidence in males was also significantly lower than expected. The incidence of melanoma was significantly elevated for both males (SRR 1.33, 95% c.i. 1.15-1.53) and females (SRR 1.29, 95% c.i. 1.09-1.53). Leukaemia incidence in females was significantly lower than the all-W.A. rate (SRR 0.56, 95% c.i. 0.23-0.95). Rates for all cancers combined, for males and females, were similar to the all-W.A. rates.

Cancer mortality: In males there was significantly less mortality due to colorectal cancer, lymphoma, mesothelioma and cancers of unknown primary site. All-cancers combined mortality in males was also significantly lower than the State rate (SRR 0.83, 95% c.i. 0.75-0.92). Cancer mortality rates for females were not significantly different from the all-W.A. rates.

Kalamunda (S)

Cancer incidence: The rates of colorectal, lip and non-melanotic skin cancers in males were significantly lower than the all-W.A. rates. The all-cancers rate for males was not significantly different to the State rate. In females, there was a lower incidence rate of brain and bladder cancers than expected, but other individual cancers and the all-cancers rate showed no significant departure from the all-W.A. rates.

Cancer mortality: The male kidney cancer mortality rate was significantly lower than the State rate (SRR 0.17, 95% c.i. 0.00 – 0.63). The all-cancers mortality rate in males was similar to the State rate. In females, mortality rates for lymphoma, pancreatic cancer and stomach cancer were all significantly less than expected. However the all-cancers combined mortality rate for females was similar to the all-W.A. rate.

Kalgoorlie/Boulder (C) - Part A

Cancer incidence: Cancer of the lung in males was significantly more common than in the State as a whole (SRR 1.59, 95% c.i. 1.05–2.19), as were cancers of unknown primary site (SRR 2.44, 95% c.i. 1.24–3.81). Otherwise in females and males, individual cancer rates and the all-cancers rate showed no significant departures from the all-W.A. rates.

Cancer mortality: In females the lung cancer mortality rate was significantly higher than expected (SRR 1.99, 95% c.i. 1.05–3.08). Otherwise mortality rates for individual cancers in males and females, were not significantly different from the all-W.A. rates. All-cancers mortality rates for males and females were similar to State rates.

Kalgoorlie/Boulder (C) - Part B

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. However, there were only four cases expected in males and two in females, rendering the SRR analysis unreliable.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Katanning (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Kellerberrin (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Kent (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates, but all were based on very low expected numbers of cases and should not be considered reliable.

Cancer mortality: Cancer mortality rates for males, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There was no cancer-related mortality in females and meaningful SRRs cannot be produced as there was only 1 case expected.

Kojonup (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Kondinin (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Koorda (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates, but were based on very low expected numbers of cases.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Kulin (S)

Cancer incidence: In females and males, individual cancer rates were similar to the all-W.A. rates. Whilst male all-cancers incidence was similar to the State rate, females had a lower rate with an SRR of 0.37 (95% c.i. 0.03-0.87).

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Kwinana (T)

Cancer incidence: The incidence of melanoma for males was significantly lower than in the State as a whole (SRR 0.66, 95% c.i. 0.36-0.99). However the combined all-cancers rate for males was not significantly different from the expected rate. In females, lung cancer was significantly more common than in the State as a whole (SRR 1.87, 95% c.i. 1.12-2.70). Otherwise, cancer incidence rates for males and females, for all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: The male all-cancers mortality rate was increased compared with the State value with an SRR of 1.27 (95% c.i. 1.05-1.54). Individual cancer mortality rates for males and females, and female all cancers combined, were not significantly different from the all-W.A. rates.

Lake Grace (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Laverton (S)

Cancer incidence: There was no significant difference between all-W.A. rates and local rates for individual cancers in males or females, nor the all-cancers rate in females. The all-cancers combined incidence rate in males was significantly lower than the State rate with an SRR of 0.39 (95% c.i. 0.06-0.85). However, all these comparisons, male and female, were based on a total of 7 cancer cases in 5 years, with 14 expected. While the results show no sign of any local excess cancer risk, statistics based on such small numbers can be unreliable.

Cancer mortality: These data were based on only one death in males and one in females, and the all-cancers mortality SRR in males was reduced. Otherwise, cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There was only one death expected in females, and four in males, and the SRRs should not be considered reliable.

Leonora (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Mandurah (C)

Cancer incidence: The melanoma incidence rate in females was higher than the all-W.A. rates, although statistical significance was marginal (SRR 1.29, 95% c.i. 1.02-1.64). Bladder cancer in females was significantly lower than expected (SRR 0.41, 95% c.i. 0.03-0.95). Rates of other individual types of cancer in males and females were not significantly different from the all-W.A. rates. The combined all-cancers rates for males and females were similar to those expected.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Manjimup (S)

Cancer incidence: The incidence rates of melanoma in females and males were significantly lower than the corresponding State rates. The all-cancers incidence rate in females was also significantly lower than expected (SRR 0.77, 95% c.i. 0.60-0.98), whilst in males there was no significant departure from the State rate.

Cancer mortality: There was significantly less than expected lung cancer mortality in females (SRR 0.19, c.i. 0.00-0.69). Otherwise cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Meekatharra (S)

Cancer incidence: In females and males, individual cancer rates showed no significant departure from the all-W.A. rates. Males had a significantly elevated all-cancers incidence (although the significance was marginal, and many individual-cancer “high” SRRs were based on only 1 case) (SRR 1.73, 95% c.i. 1.01-2.55). In females, all-cancers incidence was similar to the all-W.A. rate.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Melville (C)

Cancer incidence: In males the rates of prostate cancer and melanoma were significantly higher than the all-W.A. rates, whilst rates of lung cancer and brain cancer were lower than average. In females there was significantly higher incidence of colorectal cancer and lymphoma, whilst rates were lower than average for pancreatic and cervical cancers, and cancers of unknown primary site. In both males and females, the all-cancers incidence rates showed no significant deviation from the all-W.A. rates.

Cancer mortality: The leukaemia mortality rate (SRR 0.50, 95% c.i. 0.22-0.83) was significantly lower than the State rate in males. Other cancer mortality rates for males, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. In females deaths due to cancers of unknown primary site, cervical and liver cancers, and other lymphohaematopoietic neoplasms were all significantly less common than expected. All-cancers combined mortality in females was similar to the State rate.

Menzies (S)

Cancer incidence: There were no incident cancers recorded for this area, although expectation based on State data was 4 cases in males and 2 in females. SRR analysis cannot give a reliable result, however other methods suggest the male case numbers represent a significantly lower rate than expected, but the female rates were similar to the State rate.

Cancer mortality: There was no cancer-related mortality recorded in either males or females. There were only two cancer deaths expected in males and one in females, and reliable SRRs cannot be produced.

Merredin (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Mingenew (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. However, there were only four cases expected in females, rendering the SRR analysis unreliable.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Moora (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Morawa (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Mosman Park (T)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: There was a significantly lower than expected lung cancer mortality rate in females (SRR 0.16, 95% c.i. 0.00-0.57). All other cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Mount Magnet (S)

Cancer incidence: In males, combined incidence of all cancers was significantly lower than the State rate (SRR 0.42, 95% c.i. 0.03-0.97), although this was based on 3 cases whereas only 7 were expected. Otherwise, in males and females, individual cancer rates and the all-cancers rates showed no significant departure from the all-W.A. rates. However, there were only four cases expected in females.

Cancer mortality: There was only one cancer-related death in this area (a female). There were only three cancer deaths expected in males and one in females, and reliable SRRs cannot be produced.

Mount Marshall (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: There was only one cancer-related death in this area (a male). There were only three cancer deaths expected in males and two in females, and reliable SRRs cannot be produced.

Mukinbudin (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: There was only one cancer-related death in this area (a male). There were only four cancer deaths expected in males and two in females, and reliable SRRs cannot be produced.

Mullewa (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There were only four cancer deaths expected in males and two in females, and reliable SRRs cannot be produced.

Mundaring (S)

Cancer incidence: In males, there were lower incidence rates of lung cancer, “other lymphohaematopoietic” cancers (SRR 0.22, 95% c.i. 0.00-0.80) and liver cancers (SRR 0.25, 95% c.i. 0.00-0.94) (based on only 4 cases expected). Otherwise in males and females individual cancer incidence rates were statistically similar to State rates. In females and males, the all-cancers rates were also similar to all-W.A. rates.

Cancer mortality: The male lung cancer mortality rate was significantly lower than the all-W.A. rate. Otherwise cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the State rates.

Murchison (S)

Cancer incidence: There were no incident cancers recorded for this area, although expectation based on State data was 2 cases in males and 1 in females. SRR analysis cannot give a reliable result.

Cancer mortality: There were no cancer-related deaths in this area. There was only one cancer death expected in males and none in females, and reliable SRRs cannot be produced.

Murray (S)

Cancer incidence: There was a lower than average rate of melanoma in males (SRR 0.48, 95% c.i. 0.18-0.83). Otherwise in females and males, individual cancer rates and the all-cancers rates showed no significant departure from the all-W.A. rates.

Cancer mortality: The female lung cancer mortality rate (SRR 2.45, 95% c.i. 1.29-3.79) and the all-cancers combined mortality rate (SRR 1.47, 95% c.i. 1.13-1.91) were significantly higher than the all-W.A. rates. However the male individual cancer mortality rates and the all-cancers mortality rate were similar to the State mortality rates.

Nannup (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers, were not significantly different from the all-W.A. rates, however there was a lower all-cancers SRR in females (0.24, 95% c.i. 0.00-0.89).

Narembeen (S)

Cancer incidence: Rates for all individual cancer types and for all cancers combined, did not differ significantly from the all-West Australian rates, for males or for females.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Narrogin (S)

Cancer incidence: Males experienced a significantly lower incidence of prostate cancer than expected (SRR 0.26, 95% c.i. 0.00-0.94; although this was based on only 4 expected cases). Breast cancer incidence in women was significantly lower than expected. However, incidence rates of all other individual cancers in males and females were statistically similar to State rates. Male and female all-cancers incidence rates were significantly lower than State rates with SRRs of 0.17 (95% c.i. 0.01-0.39) and 0.07 (95% c.i. 0.00-0.27) respectively. These Narrogin (Shire) data are likely to be underestimated due to difficulty in properly localizing addresses, as indicated in the examples in an earlier section of this report.

Cancer mortality: There were no cancer-related deaths in this area, likely a result of the same issues noted for incidence.

Narrogin (T)

Cancer incidence: The rate of testicular cancer was significantly higher than the all-W.A. rate (SRR 7.52, 95% c.i. 1.16-16.47), but the comparison was based on an expectation of only 1 case and must be considered unreliable. The combined all-cancers rate for males was also significantly higher than expected (SRR 1.54, 95% c.i. 1.21-1.96). Rates of other individual types of cancer in males were not significantly different from the all-W.A. rates. In females, individual and all-cancers incidence rates showed no significant departure from State rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers, were not significantly different from the all-W.A. rates. Whilst the female all-cancers combined mortality rate was statistically similar to the State rate, the corresponding male rate was significantly higher with an SRR of 1.67 (95% c.i. 1.12-2.28).

Nedlands (C)

Cancer incidence: In males there were lower than average incidence rates of colorectal cancer and mesothelioma, but elevated rates of prostate cancer and melanoma. The expected number of mesothelioma cases was only 4 and the result may be unreliable. In females, there were elevated rates of stomach cancer (SRR 2.23, 95% c.i. 1.02-3.66), and ovarian cancer (SRR 2.06, 95% c.i. 1.11-3.15). The all-cancers incidence rate for females was significantly higher than average (SRR 1.21, 95% c.i. 1.08-1.34), whilst all-cancers incidence for males was statistically similar to the State rate.

Cancer mortality: There was one death related to mesothelioma in males, with a significantly lower mortality rate than that of the State rate (SRR 0.26, 95% c.i. 0.00-0.94). The lung cancer mortality rate for males was also lower than the State rate. The all-cancers mortality rate for males was similar to the expected rate. In females, there were significantly higher colorectal cancer and all-cancers mortality rates. Otherwise cancer mortality rates for individual cancers were not significantly different from the all-W.A. rates.

Ngaanyatjarraku (S)

Cancer incidence: Where assessment could be made, rates of individual types of cancer in males were not significantly different from the all-W.A. rates, but the data are limited to 1 case in males, but only 10 expected. All-cancers incidence was significantly lower than expected on the basis of these data. There were no cases for females (expected cases: 8), representing a significant lower than expected number of cases in this area. Addresses and other technical issues are thought to influence these data. There are no suggestions, from the available data, of any increased risk of cancer in this area

Cancer mortality: There was only one cancer-related death, a female. There were only four cancer deaths expected in males, and three in females, and SRR analysis cannot give reliable results.

Northam (S)

Cancer incidence: Apart from a lower than average prostate cancer incidence (SRR 0.41, 95% c.i. 0.06-0.89), incidence of individual cancer types and of all cancers combined, did not differ significantly from the all-West Australian rates, for males or for females.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Northam (T)

Cancer incidence: Rates for all individual cancer types and for all cancers combined, did not differ significantly from the all-West Australian rates, for males or for females.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Northampton (S)

Cancer incidence: Rates for all individual cancer types and for all cancers combined, did not differ significantly from the all-West Australian rates, for males or for females.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Nungarin (S)

Cancer incidence: Rates for all individual cancer types and for all cancers combined, did not differ significantly from the all-West Australian rates, for males or for females; expected case numbers were extremely small (4 males, 2 females) and these results may be unreliable.

Cancer mortality: There were no cancer-related deaths in this area. There were only two cancer deaths expected in males and one in females, and reliable SRRs cannot be produced.

Peppermint Grove (S)

Cancer incidence: Rates for all individual cancer types and for all cancers combined, did not differ significantly from the all-West Australian rates, for males or for females.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Perenjori (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates, although expected numbers of cases were low, only 6 males and 5 females over 5 years.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There were only two cancer death expected in males and two in females, and SRR analysis cannot give reliable results.

Perth (C) - Inner

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates, although expected numbers of cases were very low and for females (expected: 4) these results should be treated with caution..

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Perth (C) - Remainder

Cancer incidence: Males and females had rates for all individual cancer types and for all cancers combined, that were statistically similar to the all-W.A. rates. The all-cancers incidence rate was significantly lower than average for females (SRR 0.72, p5% c.i. 0.50-0.96), but showed no departure from expectation in males.

Cancer mortality: In males there was a higher rate of colorectal cancer mortality (SRR 2.24, c.i. 1.02-3.67) and all-cancers combined mortality (SRR 1.38, c.i. 1.06-1.80) that was of marginal statistical significance. Cancer mortality rates for females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Pingelly (S)

Cancer incidence: Rates for all individual cancer types were similar to the all-W.A. rates for males and females. All-cancers incidence was similar to the State rate in males, but the female rate was lower with an SRR of 0.52 (95% c.i. 0.16-0.97).

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Plantagenet (S)

Cancer incidence: Females had a significantly elevated rate of melanoma (SRR 2.81, 95% c.i. 1.34-4.52). Otherwise in females and males, individual cancer rates and the all-cancers rates were similar to all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Port Hedland (T)

Cancer incidence: Incidence rates of colorectal cancer, prostate cancer and melanoma in males were lower than the corresponding State rates. Melanoma incidence in females was also significantly lower (SRR 0.24, 95% c.i. 0.00-0.68). Rates for all cancers combined and other individual cancers, for males and females, were statistically similar to the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Quairading (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Ravensthorpe (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Rockingham (C)

Cancer incidence: Excluding lymphoma in females, which had a significantly lower incidence rate than expected (SRR 0.60, 95% c.i. 0.32-0.93), individual cancer rates and the all-cancers rate showed no significant departure from the all-W.A. rates.

Cancer mortality: The pancreatic cancer mortality rate in males was higher than expected with an SRR of 1.66 (95% c.i. 1.02-2.38). Otherwise cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Roebourne (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers, were not significantly different from the all-W.A. rates. In females there was significantly less all-cancers mortality than expected but males had a similar rate to the State rate.

Sandstone (S)

Cancer incidence: There were no cancer cases in females (expected: 1) and only 1 in males (expected: 2), and no reliable SRRs can be produced.

Cancer mortality: There were no cancer-related deaths in this area. There was only one cancer death expected in males and none in females, and reliable SRRs cannot be produced.

Serpentine-Jarrahdale (S)

Cancer incidence: Prostate cancer was more common than in the State as a whole but this was of marginal statistical significance (SRR 1.51, 95% c.i. 1.03 –2.03). Otherwise in males and females, individual cancer rates and the all-cancers rates showed no significant departures from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. In females, the all-cancers mortality rate was reduced (SRR 0.64, 95% c.i. 0.35-0.96).

Shark Bay (S)

Cancer incidence: In males and females, individual cancer rates showed no significant departure from the all-W.A. rates. The combined all-cancers incidence rate in males was lower than expected (SRR 0.48, 95% c.i. 0.15-0.89) but was similar to that for the State for females.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers, were not significantly different from the all-W.A. rates. There was only one cancer death in either sex, and the male all-cancers rate was significantly lower than the all-W.A. rate. SRR analysis in females may be unreliable as there were only 3 cancer-related deaths expected.

South Perth (C)

Cancer incidence: Individual cancer rates for males were not significantly different from the all-W.A. rates apart from a significantly raised incidence rate of melanoma (SRR 1.37, 95% c.i. 1.08-1.73). Females had lower than average rates of lung cancer and cancers of the lip (the expected number of lip cancers was only 4 and the result may be unreliable). The combined all-cancers rates for males and females were statistically similar to State rates.

Cancer mortality: Cancer mortality rates for males, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. In females there was a significantly lower mortality rate for leukaemia than expected (SRR 0.30, 95% c.i. 0.00-0.84). The all-cancers combined mortality rate did not depart significantly from the State rate.

Stirling (C) - Central

Cancer incidence: In males, there were no cases of either eye or pharyngeal cancers, representing significantly lower incidence rates than expected. Other individual cancer rates and the all-cancers incidence rate showed no significant departure from the all-W.A. rates. Incidence of melanoma in females was significantly lower than the all-W.A. rate. There was a higher than average rate of lymphoma in females (SRR 1.34, 95% c.i. 1.03-1.74). The all-cancers incidence rate for females was not significantly different from the expected rate.

Cancer mortality: Cancer mortality rates for males, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. Females had a significantly lower mortality rate for myeloma and cervical cancer but the overall all-cancers combined mortality rate was similar to the all-W.A. rate.

Stirling (C) - Coastal

Cancer incidence: In males, prostate cancer and melanoma were significantly more common than expected, and the all-cancers incidence rate was significantly higher than the all-W.A. rate (SRR 1.12, 95% c.i. 1.04-1.20). In females there was a significantly lower than expected rate of pancreatic cancer, however cancers of the floor of the mouth appeared more common (SRR 5.24, 95% c.i. 1.14-10.72) (but this was based on an expectation of only 1 case). The female all-cancers incidence rate was statistically similar to the all-W.A. rate.

Cancer mortality: In males there was a significantly lower lung cancer mortality rate than expected and females had significantly lower gallbladder cancer mortality than expected. Otherwise individual cancer death rates in males and females were similar to the State rate. Cancer mortality rates for males and females, for all cancers combined, were not significantly different from the all-W.A. rates.

Stirling (C) - South-Eastern

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Subiaco (C)

Cancer incidence: There were no cases of cervical cancer observed, representing a significantly lower incidence than expected. Excluding ovarian cancer, which had a higher than average incidence rate (SRR 3.00, 95% c.i. 1.49-4.77), individual cancer rates and the all-cancers rates showed no significant differences from the all-W.A. rates.

Cancer mortality: There was a significantly higher mortality rate for ovarian cancer (SRR 3.35, 95% c.i. 1.38-5.72) than expected. Otherwise cancer mortality rates for males and females, for individual cancers, were not significantly different from the all-W.A. rates. The all-cancers combined mortality rates for males and females were similar to State rates.

Swan (C)

Cancer incidence: There was a higher than average incidence of lung cancer in males (SRR 1.36, 95% c.i. 1.12-1.65). Otherwise in females and males, individual cancer rates and the all-cancers rates were similar to all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Tambellup (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There were only three cancer deaths expected in males and two in females, and the SRR analysis may not give reliable results.

Tammin (S)

Cancer incidence: In males and females, individual cancer rates showed no significant departure from the all-W.A. rates. The all-cancers incidence rate in males was statistically similar to that expected. However, in females, only one case resulted in a significantly lower rate than the State average (based on an expectation of only 4 cases, hence these data cannot be considered reliable).

Cancer mortality: Cancer mortality rates for males and females, for individual cancers were not significantly different from the all-W.A. rates. There were only two cancer deaths expected in males and two in females, and the SRR analysis may not give reliable results.

Three Springs (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Toodyay (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Trayning (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There were only three cancer deaths expected in males and two in females, and the SRR analysis may not give reliable results.

Upper Gascoyne (S)

Cancer incidence: There were no cancer cases in either males or females during the period of analysis, and only 5 cases expected (3 males, 2 females); no reliable assessment can be made.

Cancer mortality: There were no cancer-related deaths in this area. There was only one cancer death expected in males and one in females, and meaningful SRRs cannot be produced.

Victoria Park (T)

Cancer incidence: In males, individual cancer rates and the all-cancers rate showed no significant departure from the all-W.A. rates. Females experienced a significantly lower gallbladder cancer incidence rate than expected (though based on only 4 cases expected) and a significantly lower all-cancers combined incidence rate (SRR 0.87, 95% c.i. 0.78-0.97).

Cancer mortality: There was a significantly higher mortality rate for leukaemia in males (SRR 2.37, 95% c.i. 1.27-3.62) than expected. Otherwise cancer mortality rates for males and females, for individual cancers, were not significantly different from the all-W.A. rates. The all-cancers combined mortality rate for males (SRR 1.29, 95% c.i. 1.13-1.47) was elevated.

Victoria Plains (S)

Cancer incidence: In males, individual cancer and all-cancers incidence was similar to all-W.A. rates. In females there was a higher rate of breast cancer than expected with an SRR of 3.21 (95% c.i. 1.13-5.79) (based on an expectation of only 2 cases, and hence unreliable) and an elevated all-cancers incidence rate (SRR 2.13, 95% c.i. 1.12-3.30).

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Vincent (T)

Cancer incidence: There were significantly lower rates of prostate cancer and leukaemia in males than expected whilst there was a significantly increased rate of lung cancer in males (SRR 1.59, c.i. 1.22-2.05). Females had significantly lower kidney cancer, leukaemia and bladder cancer incidence than the State averages. In males and females, the all-cancers incidence rates showed no significant departure from the all-W.A. rates.

Cancer mortality: There were less lymphoma-related deaths in females than expected (SRR 0.18, 95% c.i. 0.00-0.68, based on one death). Otherwise cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Wagin (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: There was a significantly raised mortality rate for lung cancer in males when compared with State rate (SRR 3.12, 95% c.i. 1.20-5.47). Otherwise cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Wandering (S)

Cancer incidence: In males there were no cases recorded but only 4 were expected, indicating a significantly lower incidence rate than in the State as a whole. Rates for individual cancers could not be assessed. In females, rates for individual cancers and all cancers combined, were non-assessable, or not significantly different from the all-W.A. rates.

Cancer mortality: There was only one cancer-related death in males and one in females. There were only two cancer deaths expected in males and one in females, and the SRR analysis may not give reliable results.

Wanneroo (C) - North-East

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Wanneroo (C) - North-West

Cancer incidence: The rate of prostate cancer was higher than average (SRR 1.57, 95% c.i. 1.25-1.98). The all-cancers rate for males had a marginally significant excess when compared to the all-W.A. rates (SRR 1.15, 95% c.i. 1.01-1.30). Rates of other individual types of cancer in males were not significantly different from the all-W.A. rates. In females, there was a lower than average rate of colorectal cancer, while the rates of other individual cancer and all cancers combined showed no significant departure from the all-W.A. rates.

Cancer mortality: Males had significantly lower rates of mortality for lung and stomach cancer than expected but no significant departure from the State mortality rate for all-cancers mortality. Cancer mortality rates for females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Wanneroo (C) - South

Cancer incidence: Males had lower than average rates of melanoma (SRR 0.54, 95% c.i. 0.31-0.79) and mesothelioma (SRR 0.26, 95% c.i. 0.00-0.97). The expected number of mesothelioma cases was only 4 and the result may be unreliable. The thyroid cancer rate in males was significantly raised compared to that expected (SRR 4.12, 95% c.i. 1.58-7.21) (but was based on an expectation of only 2 cases and must be considered unreliable). The all-cancers incidence rate for males was statistically similar to that expected. In females there was no statistically significant difference of either individual cancer rates or the all-cancers combined rate, from the all-W.A. rates.

Cancer mortality: There was a significantly lower mortality rate for pancreatic cancer in females than expected. All other cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Waroona (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: There was a lower mortality rate for lung cancer in males than expected (SRR 0.21, 95% c.i. 0.00-0.77). All other cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

West Arthur (S)

Cancer incidence: In males and females, incidence rates for individual cancer types were statistically similar to the all-W.A. rates. All-cancers incidence was similar to expectation for males, but was lower than expected for females (SRR 0.35, 95% c.i. 0.03-0.81).

Cancer mortality: There was a statistically smaller all-cancers combined mortality rate for males when compared with the State combined rate (SRR 0.18, 95% c.i. 0.00-0.65) otherwise cancer mortality rates for males and females did not differ significantly from the all-W.A. rates. There were no cancer-related deaths in females, and only 3 were expected.

Westonia (S)

Cancer incidence: Cancer incidence rates for males, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There were no incident cancers recorded among females, though there might have been expected to be up to 2 cases in 5 years. With only 3 cases expected in males, the SRR analysis cannot give reliable results.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There was only one cancer-related death (a male). There was only one cancer death expected in males and one in females, and reliable SRRs cannot be produced.

Wickepin (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Williams (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Whilst the individual cancer mortality rates were statistically-similar to State rates, there was a significantly lower all-cancers combined mortality rate than expected for males with an SRR of 0.22 (95% c.i. 0.00-0.81). Cancer mortality rates for females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Wiluna (S)

Cancer incidence: Males and females had individual cancer rates that showed no significant departures from the all-W.A. rates. The all-cancers rate in males was significantly lower than expected (SRR 0.14, 95% c.i. 0.00-0.50) (but cannot be considered reliable, being based on 1 case, with an expectation of only 7 cases). Although also based on very small case numbers, and hence somewhat unreliable, female individual and all-cancers rates were similar to State rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There were only three cancer deaths expected in males and one in females, and the SRR analysis may not give reliable results.

Wongan-Ballidu (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Woodanilling (S)

Cancer incidence: There was only one cancer case recorded in this area (4 expected) in males, and none in females (1 expected). With such low expected numbers, SRR analysis cannot provide reliable information and there is no indication, from these data, of any excess cancer risk among residents of this area.

Cancer mortality: There were no cancer-related deaths in this area. There were only two cancer deaths expected in males and one in females, and reliable SRRs cannot be produced.

Wyalkatchem (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates. There were only four cancer deaths expected in males and three in females, and the SRR analysis may not give reliable results.

Wyndham-East Kimberley (S)

Cancer incidence: Among males, there was a lower than expected rate of prostate cancer (SRR 0.43, 95% c.i. 0.07-0.94). Incidence of cancers of the tongue was elevated (SRR 10.12, 95% c.i. 1.57-22.18) but this assessment was based on an expectation of less than 1 case and must be considered unreliable. Otherwise, in males and in females, individual cancer rates and the all-cancers incidence rates showed no significant departure from all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Yalgoo (S)

Cancer incidence: There were no incident cancers recorded among females, though there might have been expected to be up to 2 cases in 5 years. There were only three cases expected in males, and one observed. SRR analysis cannot provide reliable results with such low expected numbers of cases.

Cancer mortality: There was only one cancer-related death (a male). There was only one cancer death expected in males and one in females, and reliable SRRs cannot be produced.

Yilgarn (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

York (S)

Cancer incidence: Cancer incidence rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

Cancer mortality: Cancer mortality rates for males and females, for individual cancers and all cancers combined, were not significantly different from the all-W.A. rates.

5. References

1. Threlfall TJ, English DR, Rouse IL (1998) Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. *Medical Journal of Australia* 169(1), 21-24.
2. Threlfall TJ, Thompson JR (2004) *Cancer incidence and mortality in Western Australia, 2002*. Department of Health, Western Australia, Perth. Statistical series number 71.
3. Rothman KJ (1986) *Modern epidemiology*. Little, Brown & Company, Boston.
4. Segi M (1960) *Cancer mortality for selected sites in 24 countries (1950-1957)*. Sendai, Japan, Tohoku University Press.
5. Snedecor WG, Cochran WG (1976) *Statistical methods*, 6th edition. Iowa State University Press, Ames.
6. Yates F (1934) Contingency tables involving small numbers and the X^2 test. *J. Roy. Statist. Soc. Suppl.* 1:217-235.
7. Zar JH (1974) *Biostatistical analysis*. Prentice-Hall, Englewood Cliffs NJ.

SLA: Albany (C) - Central 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	56	81.4	(57.9 - 105.0)	0.98	(0.74 - 1.28)	-
Colorectal cancer	42	70.8	(48.0 - 93.5)	1.23	(0.86 - 1.63)	-	42	44.5	(28.0 - 61.0)	1.37	(0.96 - 1.81)	-
Prostate gland	60	91.7	(67.3 - 116.2)	1.07	(0.82 - 1.38)	-	0	-	-	-	-	.
Melanoma (skin)	24	48.7	(28.5 - 69.0)	0.92	(0.56 - 1.32)	-	28	51.7	(30.9 - 72.4)	1.39	(0.88 - 1.95)	-
Lung, bronchus & trachea	29	47.3	(29.4 - 65.2)	0.93	(0.60 - 1.30)	-	15	14.7	(5.7 - 23.7)	0.82	(0.42 - 1.28)	-
Lymphoma	5	9.8	(0.9 - 18.6)	0.50	(0.11 - 1.02)	-	8	11.5	(2.6 - 20.4)	0.90	(0.32 - 1.63)	-
Unknown primary site	7	13.0	(2.9 - 23.1)	0.77	(0.24 - 1.43)	-	7	3.6	(0.7 - 6.4)	0.85	(0.27 - 1.59)	-
Kidney & other renal tract	5	7.9	(0.7 - 15.1)	0.74	(0.16 - 1.51)	-	2	2.5	(0.0 - 6.7)	0.46	(0.01 - 1.29)	-*
Leukaemia	12	20.1	(7.5 - 32.8)	1.87	(0.86 - 3.07)	-	7	5.7	(0.3 - 11.2)	1.50	(0.47 - 2.79)	-
Pancreas	4	6.7	(0.0 - 13.8)	0.85	(0.13 - 1.86)	-	8	4.9	(0.4 - 9.4)	1.34	(0.47 - 2.42)	-
Urinary bladder	7	8.3	(1.9 - 14.7)	0.88	(0.28 - 1.65)	-	2	0.8	(0.0 - 1.8)	0.61	(0.01 - 1.70)	-*
Stomach	4	6.2	(0.0 - 12.6)	0.63	(0.10 - 1.38)	-	2	3.5	(0.0 - 8.5)	0.50	(0.01 - 1.39)	-*
Corpus uteri	0	-	-	-	-	.	9	12.9	(3.6 - 22.1)	1.25	(0.48 - 2.19)	-
Brain	3	5.5	(0.0 - 12.1)	0.88	(0.07 - 2.05)	-*	6	12.3	(0.1 - 24.6)	2.11	(0.57 - 4.11)	-*
Lip	0	-	-	0	n/a	-	1	0.4	(0.0 - 1.1)	0.47	(0.00 - 1.74)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	7	9.4	(1.3 - 17.5)	1.09	(0.34 - 2.03)	-
Other lymphohaematopoietic	3	3.5	(0.0 - 7.5)	0.78	(0.06 - 1.81)	-*	4	8.2	(0.2 - 16.2)	1.29	(0.20 - 2.82)	-*
Oesophagus	6	9.0	(1.6 - 16.4)	1.50	(0.41 - 2.93)	-*	3	4.1	(0.0 - 9.4)	1.33	(0.11 - 3.10)	-*
Thyroid gland	1	1.4	(0.0 - 4.1)	0.90	(0.00 - 3.31)	-*	4	9.5	(0.1 - 18.9)	1.30	(0.20 - 2.84)	-*
Myeloma/plasma cell tumours	5	8.5	(0.6 - 16.4)	1.65	(0.36 - 3.39)	-*	1	2.0	(0.0 - 5.9)	0.39	(0.00 - 1.44)	-*
Cervix uteri	0	-	-	-	-	.	4	8.9	(0.2 - 17.7)	0.97	(0.15 - 2.12)	-*
Non-mel. skin (exc BCC/SCC)	3	5.8	(0.0 - 12.8)	0.96	(0.08 - 2.25)	-*	0	-	-	0	n/a	-
Mesothelioma	1	2.1	(0.0 - 6.1)	0.27	(0.00 - 1.01)	-*	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	1	1.4	(0.0 - 4.1)	0.39	(0.00 - 1.45)	-*	0	-	-	0	n/a	-
Testis	4	11.6	(0.2 - 22.9)	1.90	(0.29 - 4.17)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	1	1.7	(0.0 - 5.1)	0.64	(0.00 - 2.38)	-*	2	2.3	(0.0 - 5.9)	0.97	(0.01 - 2.70)	-*
Larynx	1	2.1	(0.0 - 6.1)	0.41	(0.00 - 1.51)	-*	0	-	-	-	-	.
Tongue	2	3.5	(0.0 - 8.7)	1.49	(0.02 - 4.16)	-*	0	-	-	0	n/a	-
Connective & soft tissues	2	6.1	(0.0 - 14.5)	1.87	(0.02 - 5.22)	-*	1	2.0	(0.0 - 5.9)	1.40	(0.00 - 5.18)	-*
Tonsil & oropharynx	1	2.4	(0.0 - 7.0)	0.94	(0.00 - 3.45)	-*	1	1.0	(0.0 - 2.8)	3.51	(0.00 - 12.94)	-*
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	1	1.0	(0.0 - 3.0)	1.40	(0.00 - 5.17)	-*	1	0.3	(0.0 - 1.0)	1.69	(0.00 - 6.22)	-*
Eye & lacrimal gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Major Salivary Gland	1	1.0	(0.0 - 3.1)	1.52	(0.00 - 5.62)	-*	0	-	-	-	-	.
Anus	1	1.0	(0.0 - 3.0)	2.20	(0.00 - 8.12)	-*	2	2.9	(0.0 - 7.2)	2.93	(0.04 - 8.16)	-*
Mouth, other & unspecified	0	-	-	0	n/a	-	0	-	-	-	-	.
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	1.7	(0.0 - 5.1)	2.21	(0.00 - 8.17)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	1	2.4	(0.0 - 7.2)	3.81	(0.00 - 14.06)	-*	1	0.5	(0.0 - 1.5)	10.29	(0.00 - 37.95)	-*
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	1	1.7	(0.0 - 5.1)	5.60	(0.00 - 20.64)	-*	1	0.4	(0.0 - 1.1)	4.94	(0.00 - 18.21)	-*
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	239	404.0	(349.8 - 458.1)	0.98	(0.86 - 1.11)	-	225	301.9	(255.7 - 348.0)	1.05	(0.92 - 1.20)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

A-2 Albany (C) - Central 1998-2002: Cancer incidence

Cancer in Western Australia, 1998-2002: incidence and mortality by Statistical Local Area

SLA: Albany (C) Bal 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	2.0	(0.0 - 6.0)	3.70	(0.00 - 13.64)	-*	39	87.2	(59.3 - 115.1)	1.02	(0.71 - 1.37)	-
Colorectal cancer	19	36.1	(19.8 - 52.4)	0.83	(0.46 - 1.24)	-	12	29.0	(12.3 - 45.7)	0.90	(0.41 - 1.48)	-
Prostate gland	25	49.7	(30.1 - 69.3)	0.66	(0.40 - 0.94)	V	0	-	-	-	-	.
Melanoma (skin)	19	42.9	(22.6 - 63.3)	0.92	(0.52 - 1.38)	-	15	32.4	(15.9 - 48.9)	1.14	(0.58 - 1.78)	-
Lung, bronchus & trachea	8	15.1	(4.5 - 25.7)	0.40	(0.14 - 0.71)	V	6	12.1	(2.4 - 21.9)	0.72	(0.20 - 1.41)	-
Lymphoma	7	14.5	(3.3 - 25.6)	0.96	(0.30 - 1.79)	-	7	14.0	(3.6 - 24.5)	1.56	(0.49 - 2.90)	-*
Unknown primary site	3	5.0	(0.0 - 10.6)	0.53	(0.04 - 1.24)	-	2	3.9	(0.0 - 9.3)	0.69	(0.01 - 1.92)	-*
Kidney & other renal tract	2	3.5	(0.0 - 8.4)	0.42	(0.01 - 1.16)	-	2	3.9	(0.0 - 9.4)	0.87	(0.01 - 2.41)	-*
Leukaemia	5	9.9	(1.2 - 18.6)	1.13	(0.25 - 2.31)	-*	3	8.4	(0.0 - 18.2)	1.31	(0.11 - 3.05)	-*
Pancreas	2	3.8	(0.0 - 9.1)	0.63	(0.01 - 1.74)	-*	3	6.7	(0.0 - 14.3)	1.30	(0.10 - 3.03)	-*
Urinary bladder	2	4.4	(0.0 - 10.6)	0.44	(0.01 - 1.23)	-	1	1.9	(0.0 - 5.6)	0.92	(0.00 - 3.40)	-*
Stomach	1	1.6	(0.0 - 4.7)	0.24	(0.00 - 0.90)	V*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	1	1.9	(0.0 - 5.6)	0.25	(0.00 - 0.92)	V*
Brain	1	1.8	(0.0 - 5.5)	0.36	(0.00 - 1.32)	-*	1	1.8	(0.0 - 5.4)	0.63	(0.00 - 2.31)	-*
Lip	3	6.4	(0.0 - 13.6)	1.06	(0.09 - 2.48)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	1	2.6	(0.0 - 7.7)	0.30	(0.00 - 1.10)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Oesophagus	1	1.6	(0.0 - 4.7)	0.38	(0.00 - 1.41)	-*	1	2.1	(0.0 - 6.2)	1.09	(0.00 - 4.03)	-*
Thyroid gland	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	1	2.5	(0.0 - 7.3)	0.52	(0.00 - 1.90)	-*	1	2.2	(0.0 - 6.5)	0.91	(0.00 - 3.36)	-*
Cervix uteri	0	-	-	-	-	.	2	4.6	(0.0 - 10.9)	0.69	(0.01 - 1.92)	-*
Non-mel. skin (exc BCC/SCC)	2	4.0	(0.0 - 9.7)	1.03	(0.01 - 2.87)	-*	0	-	-	0	n/a	-
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Testis	1	1.9	(0.0 - 5.7)	0.49	(0.00 - 1.79)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Larynx	2	3.5	(0.0 - 8.4)	1.04	(0.01 - 2.90)	-*	0	-	-	-	-	.
Tongue	1	2.0	(0.0 - 5.8)	0.88	(0.00 - 3.24)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	0	-	-	0	n/a	-	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Major Salivary Gland	1	2.2	(0.0 - 6.7)	2.32	(0.00 - 8.55)	-*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	2.0	(0.0 - 6.1)	4.32	(0.00 - 15.93)	-*
Floor of mouth	1	2.2	(0.0 - 6.7)	1.73	(0.00 - 6.36)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	1	1.8	(0.0 - 5.5)	7.88	(0.00 - 29.05)	-*	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	1	2.0	(0.0 - 6.1)	8.56	(0.00 - 31.57)	-*
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	1.6	(0.0 - 4.6)	4.64	(0.00 - 17.10)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	110	220.2	(178.4 - 262.1)	0.65	(0.54 - 0.79)	V	99	219.0	(175.3 - 262.7)	0.86	(0.70 - 1.05)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

A-4 Albany (C) Bal 1998-2002: Cancer incidence

Cancer in Western Australia, 1998-2002: incidence and mortality by Statistical Local Area

SLA: Armadale (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	0	n/a	-	149	90.1	(75.4 - 104.8)	1.07	(0.91 - 1.26)	-
Colorectal cancer	63	41.5	(31.1 - 51.8)	0.89	(0.69 - 1.15)	-	54	30.6	(22.1 - 39.1)	1.01	(0.76 - 1.32)	-
Prostate gland	95	61.3	(48.8 - 73.8)	0.82	(0.67 - 1.01)	-	0	-	-	-	-	.
Melanoma (skin)	58	36.7	(27.1 - 46.2)	0.88	(0.67 - 1.14)	-	39	24.5	(16.6 - 32.4)	0.78	(0.54 - 1.05)	-
Lung, bronchus & trachea	56	35.6	(26.2 - 45.0)	0.92	(0.70 - 1.20)	-	40	21.9	(14.8 - 29.0)	1.23	(0.86 - 1.64)	-
Lymphoma	20	13.9	(7.8 - 20.1)	0.85	(0.49 - 1.26)	-	20	10.6	(5.8 - 15.4)	1.14	(0.65 - 1.70)	-
Unknown primary site	20	12.4	(6.9 - 17.8)	1.14	(0.65 - 1.69)	-	14	7.5	(3.4 - 11.7)	1.09	(0.54 - 1.73)	-
Kidney & other renal tract	16	9.3	(4.7 - 13.9)	1.07	(0.56 - 1.65)	-	14	7.4	(3.3 - 11.4)	1.60	(0.79 - 2.54)	-
Leukaemia	14	10.0	(4.6 - 15.3)	0.98	(0.49 - 1.56)	-	11	7.6	(2.8 - 12.3)	1.19	(0.52 - 1.99)	-
Pancreas	10	5.9	(2.2 - 9.6)	1.02	(0.42 - 1.75)	-	10	5.9	(2.1 - 9.7)	1.04	(0.43 - 1.78)	-
Urinary bladder	11	7.2	(2.9 - 11.5)	0.79	(0.34 - 1.32)	-	6	3.2	(0.5 - 6.0)	1.25	(0.34 - 2.43)	-
Stomach	13	8.9	(4.0 - 13.8)	1.03	(0.49 - 1.66)	-	7	4.1	(0.9 - 7.2)	1.07	(0.34 - 2.00)	-
Corpus uteri	0	-	-	-	-	.	19	11.0	(5.9 - 16.1)	1.26	(0.71 - 1.89)	-
Brain	7	4.2	(1.1 - 7.4)	0.77	(0.24 - 1.44)	-	5	2.7	(0.3 - 5.1)	0.81	(0.18 - 1.66)	-
Lip	5	3.2	(0.4 - 5.9)	0.55	(0.12 - 1.13)	-	3	1.3	(0.0 - 2.8)	0.74	(0.06 - 1.73)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	12	8.1	(3.3 - 12.9)	0.93	(0.43 - 1.53)	-
Other lymphohaematopoietic	5	3.7	(0.4 - 6.9)	0.77	(0.17 - 1.57)	-	4	2.5	(0.0 - 5.0)	0.84	(0.13 - 1.83)	-
Oesophagus	8	4.7	(1.4 - 8.0)	1.00	(0.35 - 1.80)	-	5	2.4	(0.2 - 4.5)	1.34	(0.29 - 2.74)	-*
Thyroid gland	1	0.5	(0.0 - 1.5)	0.30	(0.00 - 1.10)	-*	9	5.5	(1.8 - 9.3)	1.01	(0.39 - 1.77)	-
Myeloma/plasma cell tumours	10	6.5	(2.4 - 10.5)	1.68	(0.69 - 2.86)	-	6	3.5	(0.6 - 6.3)	1.35	(0.37 - 2.63)	-*
Cervix uteri	0	-	-	-	-	.	12	7.7	(3.3 - 12.2)	1.11	(0.51 - 1.82)	-
Non-mel. skin (exc BCC/SCC)	6	4.0	(0.8 - 7.2)	0.98	(0.26 - 1.90)	-	0	-	-	0	n/a	V
Mesothelioma	2	1.5	(0.0 - 3.6)	0.27	(0.00 - 0.76)	V	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	2	1.0	(0.0 - 2.5)	0.36	(0.00 - 1.01)	-	1	0.8	(0.0 - 2.2)	0.51	(0.00 - 1.87)	-*
Testis	5	3.7	(0.4 - 7.0)	0.67	(0.15 - 1.37)	-	0	-	-	-	-	.
Gallbladder & bile ducts	6	3.5	(0.7 - 6.4)	1.85	(0.50 - 3.60)	-*	1	0.4	(0.0 - 1.1)	0.31	(0.00 - 1.14)	-*
Larynx	7	4.6	(1.2 - 8.1)	1.18	(0.37 - 2.19)	-	1	0.4	(0.0 - 1.1)	1.18	(0.00 - 4.37)	-*
Tongue	1	0.6	(0.0 - 1.9)	0.28	(0.00 - 1.02)	-*	1	0.6	(0.0 - 1.7)	0.76	(0.00 - 2.82)	-*
Connective & soft tissues	1	0.9	(0.0 - 2.6)	0.36	(0.00 - 1.32)	-*	2	1.4	(0.0 - 3.4)	1.12	(0.01 - 3.11)	-*
Tonsil & oropharynx	3	1.7	(0.0 - 3.6)	1.02	(0.08 - 2.39)	-*	0	-	-	0	n/a	-
Vulva/vagina	0	-	-	-	-	.	4	2.7	(0.0 - 5.3)	1.33	(0.21 - 2.92)	-*
Small intestine	1	0.6	(0.0 - 1.9)	0.61	(0.00 - 2.27)	-*	3	2.0	(0.0 - 4.2)	2.74	(0.22 - 6.39)	-*
Eye & lacrimal gland	1	0.6	(0.0 - 1.9)	0.59	(0.00 - 2.17)	-*	1	1.3	(0.0 - 3.8)	1.23	(0.00 - 4.55)	-*
Major Salivary Gland	1	0.6	(0.0 - 1.9)	0.71	(0.00 - 2.63)	-*	3	2.0	(0.0 - 4.4)	2.91	(0.23 - 6.80)	-*
Anus	1	0.6	(0.0 - 1.9)	0.96	(0.00 - 3.53)	-*	2	1.2	(0.0 - 2.8)	1.50	(0.02 - 4.18)	-*
Mouth, other & unspecified	0	-	-	0	n/a	-	2	0.9	(0.0 - 2.2)	2.30	(0.03 - 6.41)	-*
Floor of mouth	1	0.6	(0.0 - 1.9)	0.55	(0.00 - 2.02)	-*	0	-	-	0	n/a	-
Bones, joints & articular cart.	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	2	1.4	(0.0 - 3.4)	1.23	(0.02 - 3.43)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.6	(0.0 - 1.9)	0.95	(0.00 - 3.52)	-*	1	0.4	(0.0 - 1.1)	2.56	(0.00 - 9.45)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	0	n/a	-
Adrenal & other endocrine	1	0.6	(0.0 - 1.9)	1.49	(0.00 - 5.49)	-*	0	-	-	-	-	.
Nasopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	-	.
Penis & other male genital	0	-	-	0	n/a	-	0	-	-	-	-	.
Gum	2	1.5	(0.0 - 3.6)	5.32	(0.07 - 14.83)	-*	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	1	0.9	(0.0 - 2.6)	6.42	(0.00 - 23.70)	-*	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	1	0.9	(0.0 - 2.7)	17.99	(0.00 - 66.35)	-*	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	458	296.1	(268.8 - 323.4)	0.87	(0.79 - 0.96)	V	461	271.9	(246.3 - 297.5)	1.04	(0.95 - 1.14)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Ashburton (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	25.3	(0.0 - 57.7)	0.39	(0.03 - 0.92)	V
Colorectal cancer	4	33.2	(0.0 - 73.5)	1.07	(0.17 - 2.34)	-*	2	12.6	(0.0 - 31.8)	1.10	(0.01 - 3.07)	-*
Prostate gland	10	113.4	(32.8 - 194.1)	1.91	(0.78 - 3.26)	-	0	-	-	-	-	.
Melanoma (skin)	3	16.7	(0.0 - 36.6)	0.51	(0.04 - 1.20)	-	4	51.8	(0.0 - 121.1)	1.08	(0.17 - 2.37)	-*
Lung, bronchus & trachea	1	13.7	(0.0 - 40.5)	0.36	(0.00 - 1.34)	-*	1	5.5	(0.0 - 16.2)	1.01	(0.00 - 3.74)	-*
Lymphoma	1	7.9	(0.0 - 23.4)	0.53	(0.00 - 1.97)	-*	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	1	6.0	(0.0 - 17.8)	1.80	(0.00 - 6.64)	-*
Pancreas	0	-	-	0	n/a	-	0	-	-	-	-	.
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	1	22.5	(0.0 - 66.3)	1.53	(0.00 - 5.65)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	0	-	-	0	n/a	-	0	-	-	-	-	.
Lip	0	-	-	0	n/a	-	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	1	2.9	(0.0 - 8.6)	2.50	(0.00 - 9.22)	-*	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	3.8	(0.0 - 11.2)	1.05	(0.00 - 3.86)	-*
Non-mel. skin (exc BCC/SCC)	1	7.9	(0.0 - 23.4)	2.64	(0.00 - 9.73)	-*	0	-	-	-	-	.
Mesothelioma	1	26.3	(0.0 - 77.7)	2.94	(0.00 - 10.83)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	8.0	(0.0 - 23.7)	11.26	(0.00 - 41.55)	-*
Testis	2	13.3	(0.0 - 34.5)	1.59	(0.02 - 4.43)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	1	3.8	(0.0 - 11.2)	3.82	(0.00 - 14.08)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	13.7	(0.0 - 40.5)	7.29	(0.00 - 26.90)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	27	275.4	(151.4 - 399.5)	0.84	(0.53 - 1.18)	-	13	113.0	(30.6 - 195.3)	0.59	(0.28 - 0.94)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

A-8 Ashburton (S) 1998-2002: Cancer incidence

Cancer in Western Australia, 1998-2002: incidence and mortality by Statistical Local Area

SLA: Augusta-Margaret River (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	26	85.2	(51.1 - 119.3)	1.03	(0.64 - 1.46)	-
Colorectal cancer	16	49.0	(24.0 - 74.1)	1.03	(0.54 - 1.60)	-	11	25.8	(9.6 - 42.0)	1.04	(0.45 - 1.73)	-
Prostate gland	27	74.1	(44.6 - 103.5)	1.08	(0.68 - 1.53)	-	0	-	-	-	-	.
Melanoma (skin)	16	44.0	(21.1 - 67.0)	1.15	(0.60 - 1.78)	-	16	52.4	(25.3 - 79.6)	1.72	(0.90 - 2.66)	-
Lung, bronchus & trachea	11	35.3	(13.5 - 57.1)	0.80	(0.35 - 1.34)	-	6	12.8	(1.9 - 23.7)	0.95	(0.26 - 1.85)	-
Lymphoma	3	8.1	(0.0 - 17.3)	0.60	(0.05 - 1.39)	-	5	16.8	(1.3 - 32.2)	1.48	(0.32 - 3.04)	-*
Unknown primary site	2	5.1	(0.0 - 12.2)	0.50	(0.01 - 1.38)	-*	2	3.8	(0.0 - 9.2)	0.74	(0.01 - 2.07)	-*
Kidney & other renal tract	1	2.6	(0.0 - 7.8)	0.31	(0.00 - 1.14)	-*	0	-	-	0	n/a	-
Leukaemia	8	22.0	(5.9 - 38.1)	2.58	(0.91 - 4.65)	-*	1	1.9	(0.0 - 5.7)	0.56	(0.00 - 2.05)	-*
Pancreas	2	6.0	(0.0 - 14.5)	0.93	(0.01 - 2.59)	-*	1	1.9	(0.0 - 5.7)	0.51	(0.00 - 1.89)	-*
Urinary bladder	4	10.4	(0.0 - 21.0)	1.20	(0.19 - 2.64)	-*	0	-	-	0	n/a	-
Stomach	2	3.4	(0.0 - 8.1)	0.70	(0.01 - 1.96)	-*	1	1.4	(0.0 - 4.2)	0.75	(0.00 - 2.77)	-*
Corpus uteri	0	-	-	-	-	.	3	9.8	(0.0 - 21.8)	1.08	(0.09 - 2.52)	-*
Brain	2	7.7	(0.0 - 18.3)	1.09	(0.01 - 3.04)	-*	0	-	-	0	n/a	-
Lip	1	2.7	(0.0 - 8.0)	0.53	(0.00 - 1.95)	-*	4	12.3	(0.0 - 24.6)	5.15	(0.80 - 11.29)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	0	n/a	-	1	1.3	(0.0 - 3.7)	1.00	(0.00 - 3.69)	-*
Oesophagus	1	1.5	(0.0 - 4.5)	0.56	(0.00 - 2.05)	-*	0	-	-	0	n/a	-
Thyroid gland	1	3.0	(0.0 - 8.8)	1.45	(0.00 - 5.34)	-*	1	3.5	(0.0 - 10.3)	0.61	(0.00 - 2.26)	-*
Myeloma/plasma cell tumours	2	5.3	(0.0 - 12.6)	1.48	(0.02 - 4.12)	-*	0	-	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	1	2.8	(0.0 - 8.2)	0.48	(0.00 - 1.77)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	3	8.2	(0.0 - 18.1)	4.16	(0.34 - 9.72)	-*
Mesothelioma	1	2.5	(0.0 - 7.3)	0.62	(0.00 - 2.29)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	2	4.2	(0.0 - 10.1)	1.69	(0.02 - 4.72)	-*	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Larynx	1	4.6	(0.0 - 13.5)	0.84	(0.00 - 3.11)	-*	0	-	-	-	-	.
Tongue	0	-	-	0	n/a	-	0	-	-	-	-	.
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	2.8	(0.0 - 8.2)	1.63	(0.00 - 6.02)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	2.9	(0.0 - 8.7)	6.12	(0.00 - 22.56)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	1	3.9	(0.0 - 11.5)	5.40	(0.00 - 19.92)	-*	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	2.6	(0.0 - 7.8)	3.05	(0.00 - 11.25)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	1.5	(0.0 - 4.5)	6.87	(0.00 - 25.33)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	106	299.5	(239.8 - 359.1)	0.93	(0.76 - 1.13)	-	84	245.6	(189.8 - 301.3)	1.00	(0.80 - 1.24)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Bassendean (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	30	60.3	(38.1 - 82.5)	0.69	(0.45 - 0.95)	V
Colorectal cancer	32	61.1	(39.2 - 83.0)	1.35	(0.89 - 1.85)	-	17	29.2	(14.4 - 43.9)	0.86	(0.46 - 1.32)	-
Prostate gland	30	64.4	(41.0 - 87.8)	0.77	(0.50 - 1.07)	-	0	-	-	-	-	.
Melanoma (skin)	13	25.2	(11.0 - 39.3)	0.63	(0.30 - 1.02)	-	11	22.5	(8.5 - 36.5)	0.70	(0.31 - 1.18)	-
Lung, bronchus & trachea	23	44.0	(25.4 - 62.6)	1.08	(0.65 - 1.57)	-	15	25.5	(11.7 - 39.3)	1.25	(0.64 - 1.95)	-
Lymphoma	7	15.3	(3.7 - 27.0)	0.95	(0.30 - 1.76)	-	6	11.4	(1.9 - 20.8)	0.98	(0.27 - 1.91)	-
Unknown primary site	10	21.0	(7.7 - 34.3)	1.65	(0.68 - 2.82)	-	6	7.4	(1.0 - 13.8)	1.23	(0.33 - 2.39)	-
Kidney & other renal tract	5	8.9	(0.7 - 17.1)	1.02	(0.22 - 2.09)	-	4	5.4	(0.0 - 11.0)	1.33	(0.21 - 2.92)	-*
Leukaemia	5	8.0	(0.6 - 15.4)	1.09	(0.24 - 2.24)	-	1	0.9	(0.0 - 2.6)	0.32	(0.00 - 1.19)	-*
Pancreas	4	6.9	(0.0 - 14.0)	1.21	(0.19 - 2.65)	-*	11	12.7	(4.3 - 21.1)	3.00	(1.31 - 5.02)	^*
Urinary bladder	5	7.3	(0.7 - 13.9)	1.00	(0.22 - 2.04)	-	0	-	-	0	n/a	-
Stomach	2	3.9	(0.0 - 9.3)	0.46	(0.01 - 1.28)	-*	1	2.2	(0.0 - 6.5)	0.40	(0.00 - 1.48)	-*
Corpus uteri	0	-	-	-	-	.	6	10.5	(1.7 - 19.4)	1.19	(0.32 - 2.31)	-
Brain	2	5.1	(0.0 - 12.1)	0.74	(0.01 - 2.06)	-*	2	3.8	(0.0 - 9.4)	0.99	(0.01 - 2.75)	-*
Lip	2	3.9	(0.0 - 9.2)	0.72	(0.01 - 2.01)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	6	9.5	(1.2 - 17.7)	1.36	(0.37 - 2.65)	-*
Other lymphohaematopoietic	10	16.0	(5.8 - 26.2)	4.18	(1.72 - 7.15)	^*	1	0.9	(0.0 - 2.7)	0.54	(0.00 - 1.99)	-*
Oesophagus	2	3.4	(0.0 - 8.2)	0.73	(0.01 - 2.03)	-*	1	1.4	(0.0 - 4.1)	0.71	(0.00 - 2.61)	-*
Thyroid gland	0	-	-	0	n/a	-	2	4.6	(0.0 - 10.9)	0.77	(0.01 - 2.16)	-*
Myeloma/plasma cell tumours	1	1.2	(0.0 - 3.4)	0.49	(0.00 - 1.81)	-*	1	2.3	(0.0 - 6.9)	0.61	(0.00 - 2.27)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	3	7.7	(0.0 - 16.5)	1.43	(0.12 - 3.35)	-*	1	2.0	(0.0 - 5.9)	0.78	(0.00 - 2.89)	-*
Mesothelioma	3	4.5	(0.0 - 9.8)	1.20	(0.10 - 2.81)	-*	1	1.4	(0.0 - 4.1)	2.51	(0.00 - 9.26)	-*
Liver & intrahepatic bile duct	2	4.8	(0.0 - 11.6)	1.10	(0.01 - 3.06)	-*	1	2.0	(0.0 - 5.9)	1.42	(0.00 - 5.22)	-*
Testis	1	2.3	(0.0 - 6.9)	0.47	(0.00 - 1.73)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	1	2.7	(0.0 - 7.9)	0.93	(0.00 - 3.42)	-*	2	3.8	(0.0 - 9.4)	1.60	(0.02 - 4.46)	-*
Larynx	1	2.1	(0.0 - 6.3)	0.54	(0.00 - 1.98)	-*	0	-	-	-	-	.
Tongue	0	-	-	0	n/a	-	2	2.3	(0.0 - 5.5)	4.24	(0.05 - 11.82)	-*
Connective & soft tissues	1	2.2	(0.0 - 6.4)	1.20	(0.00 - 4.41)	-*	3	6.5	(0.0 - 14.0)	5.52	(0.45 - 12.88)	-*
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	1.4	(0.0 - 4.1)	0.92	(0.00 - 3.41)	-*
Small intestine	0	-	-	0	n/a	-	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	0	n/a	-	1	1.4	(0.0 - 4.1)	3.62	(0.00 - 13.34)	-*
Major Salivary Gland	2	4.9	(0.0 - 11.8)	4.38	(0.05 - 12.20)	-*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	1	2.3	(0.0 - 6.9)	2.14	(0.00 - 7.91)	-*
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	2.3	(0.0 - 6.9)	1.92	(0.00 - 7.08)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	2	6.6	(0.0 - 15.9)	6.45	(0.08 - 17.98)	-*
Pyriform sinus & hypopharynx	2	4.3	(0.0 - 10.3)	3.89	(0.05 - 10.83)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	2.7	(0.0 - 7.9)	2.99	(0.00 - 11.02)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	1	2.4	(0.0 - 7.1)	5.50	(0.00 - 20.29)	-*	0	-	-	-	-	.
Nasopharynx	1	2.3	(0.0 - 6.9)	4.53	(0.00 - 16.71)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	173	340.8	(288.8 - 392.8)	1.00	(0.86 - 1.16)	-	136	240.0	(197.1 - 283.0)	0.91	(0.77 - 1.08)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Bayswater (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	3	1.5	(0.0 - 3.2)	2.54	(0.21 - 5.94)	-*	189	91.4	(77.7 - 105.2)	1.09	(0.94 - 1.26)	-
Colorectal cancer	86	39.7	(31.0 - 48.4)	0.86	(0.69 - 1.07)	-	81	30.3	(22.9 - 37.7)	1.00	(0.80 - 1.24)	-
Prostate gland	149	70.5	(58.7 - 82.3)	0.91	(0.77 - 1.07)	-	0	-	-	-	-	.
Melanoma (skin)	70	34.3	(25.9 - 42.6)	0.82	(0.64 - 1.04)	-	59	28.0	(20.3 - 35.7)	0.94	(0.72 - 1.22)	-
Lung, bronchus & trachea	84	36.4	(28.3 - 44.5)	0.95	(0.76 - 1.18)	-	48	16.8	(11.4 - 22.2)	1.00	(0.72 - 1.30)	-
Lymphoma	36	16.2	(10.6 - 21.8)	1.15	(0.78 - 1.56)	-	28	13.2	(7.8 - 18.6)	1.14	(0.73 - 1.60)	-
Unknown primary site	21	8.2	(4.6 - 11.9)	0.81	(0.47 - 1.20)	-	25	8.5	(4.8 - 12.2)	1.17	(0.72 - 1.68)	-
Kidney & other renal tract	21	8.8	(4.9 - 12.8)	1.02	(0.60 - 1.51)	-	11	3.5	(1.1 - 5.9)	0.92	(0.40 - 1.54)	-
Leukaemia	24	10.6	(6.2 - 15.1)	1.26	(0.76 - 1.81)	-	17	7.1	(3.1 - 11.1)	1.33	(0.72 - 2.04)	-
Pancreas	16	6.9	(3.4 - 10.3)	1.15	(0.61 - 1.78)	-	16	4.4	(1.9 - 6.8)	1.04	(0.55 - 1.61)	-
Urinary bladder	13	5.3	(2.3 - 8.4)	0.60	(0.29 - 0.97)	V	7	2.3	(0.4 - 4.1)	0.85	(0.27 - 1.59)	-
Stomach	20	9.8	(5.4 - 14.2)	1.09	(0.63 - 1.62)	-	14	5.4	(2.3 - 8.6)	1.34	(0.66 - 2.13)	-
Corpus uteri	0	-	-	-	-	.	20	9.9	(5.3 - 14.4)	0.98	(0.56 - 1.46)	-
Brain	10	6.5	(2.0 - 11.0)	0.89	(0.37 - 1.52)	-	8	3.4	(0.8 - 5.9)	0.98	(0.35 - 1.77)	-
Lip	10	5.1	(1.8 - 8.4)	0.87	(0.36 - 1.48)	-	2	1.1	(0.0 - 2.5)	0.34	(0.00 - 0.95)	V
Ovary & uterine adnexa	0	-	-	-	-	.	15	6.1	(2.7 - 9.5)	0.84	(0.43 - 1.31)	-
Other lymphohaematopoietic	9	4.2	(1.4 - 7.0)	0.87	(0.33 - 1.53)	-	9	3.0	(0.8 - 5.2)	1.13	(0.43 - 1.98)	-
Oesophagus	13	6.4	(2.8 - 9.9)	1.13	(0.54 - 1.82)	-	4	1.5	(0.0 - 3.1)	0.68	(0.11 - 1.49)	-
Thyroid gland	3	1.4	(0.0 - 3.2)	0.74	(0.06 - 1.73)	-*	12	7.8	(3.3 - 12.3)	1.15	(0.53 - 1.89)	-
Myeloma/plasma cell tumours	3	1.4	(0.0 - 3.0)	0.35	(0.03 - 0.81)	V	9	3.4	(0.9 - 5.9)	1.33	(0.51 - 2.33)	-
Cervix uteri	0	-	-	-	-	.	14	7.3	(3.4 - 11.2)	1.05	(0.52 - 1.67)	-
Non-mel. skin (exc BCC/SCC)	10	4.6	(1.6 - 7.5)	1.12	(0.46 - 1.91)	-	5	2.2	(0.0 - 4.4)	0.92	(0.20 - 1.89)	-
Mesothelioma	7	2.6	(0.6 - 4.7)	0.67	(0.21 - 1.24)	-	4	1.3	(0.0 - 2.9)	2.53	(0.39 - 5.54)	-*
Liver & intrahepatic bile duct	9	4.3	(1.4 - 7.2)	1.18	(0.45 - 2.08)	-	3	1.1	(0.0 - 2.5)	1.04	(0.08 - 2.43)	-*
Testis	8	4.7	(1.4 - 8.0)	0.89	(0.31 - 1.60)	-	0	-	-	-	-	.
Gallbladder & bile ducts	5	2.1	(0.2 - 4.0)	1.10	(0.24 - 2.24)	-	3	1.6	(0.0 - 3.5)	0.57	(0.05 - 1.34)	-
Larynx	6	3.3	(0.6 - 5.9)	0.78	(0.21 - 1.51)	-	2	0.8	(0.0 - 2.0)	1.64	(0.02 - 4.58)	-*
Tongue	3	1.4	(0.0 - 3.0)	0.67	(0.05 - 1.55)	-	2	0.3	(0.0 - 0.7)	1.08	(0.01 - 3.01)	-*
Connective & soft tissues	3	1.4	(0.0 - 3.0)	0.86	(0.07 - 2.00)	-*	2	1.1	(0.0 - 2.6)	0.93	(0.01 - 2.58)	-*
Tonsil & oropharynx	7	4.1	(1.0 - 7.1)	1.94	(0.61 - 3.62)	-*	4	2.1	(0.0 - 4.2)	4.83	(0.75 - 10.59)	-*
Vulva/vagina	0	-	-	-	-	.	3	0.6	(0.0 - 1.3)	0.68	(0.05 - 1.58)	-*
Small intestine	3	1.1	(0.0 - 2.5)	1.37	(0.11 - 3.20)	-*	1	0.2	(0.0 - 0.5)	0.63	(0.00 - 2.32)	-*
Eye & lacrimal gland	4	1.9	(0.0 - 3.7)	1.83	(0.28 - 4.00)	-*	1	0.2	(0.0 - 0.6)	0.88	(0.00 - 3.26)	-*
Major Salivary Gland	0	-	-	0	n/a	-	2	0.8	(0.0 - 2.1)	1.45	(0.02 - 4.03)	-*
Anus	2	1.2	(0.0 - 2.9)	1.42	(0.02 - 3.95)	-*	2	0.8	(0.0 - 2.0)	1.06	(0.01 - 2.95)	-*
Mouth, other & unspecified	3	1.4	(0.0 - 3.1)	1.55	(0.13 - 3.62)	-*	0	-	-	0	n/a	-
Floor of mouth	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bones, joints & articular cart.	0	-	-	0	n/a	-	3	2.4	(0.0 - 5.2)	2.40	(0.19 - 5.59)	-*
Pyriform sinus & hypopharynx	2	0.9	(0.0 - 2.2)	0.93	(0.01 - 2.60)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	2	1.1	(0.0 - 2.6)	1.43	(0.02 - 3.97)	-*	0	-	-	0	n/a	-
Peritoneum & retroperitoneum	2	1.1	(0.0 - 2.6)	3.74	(0.05 - 10.43)	-*	0	-	-	0	n/a	-
Adrenal & other endocrine	1	0.6	(0.0 - 1.7)	1.40	(0.00 - 5.15)	-*	0	-	-	-	-	.
Nasopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Pharynx, other & ill-def.	1	0.5	(0.0 - 1.5)	1.05	(0.00 - 3.89)	-*	0	-	-	-	-	.
Penis & other male genital	2	0.9	(0.0 - 2.3)	1.74	(0.02 - 4.85)	-*	0	-	-	-	-	.
Gum	2	0.9	(0.0 - 2.3)	3.82	(0.05 - 10.64)	-*	0	-	-	0	n/a	-
Kaposi sarcoma	4	2.0	(0.0 - 4.1)	6.37	(0.99 - 13.95)	-*	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	1	0.6	(0.0 - 1.8)	5.26	(0.00 - 19.39)	-*	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	1	0.2	(0.0 - 0.4)	2.70	(0.00 - 9.95)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	678	316.0	(291.4 - 340.7)	0.93	(0.86 - 1.00)	-	626	269.9	(246.8 - 293.1)	1.03	(0.95 - 1.12)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Belmont (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	0	n/a	-	107	92.9	(73.9 - 111.8)	1.14	(0.94 - 1.38)	-
Colorectal cancer	63	51.9	(38.5 - 65.4)	1.12	(0.87 - 1.45)	-	47	30.5	(20.5 - 40.5)	1.02	(0.73 - 1.34)	-
Prostate gland	68	54.9	(41.2 - 68.5)	0.73	(0.57 - 0.93)	V	0	-	-	-	-	.
Melanoma (skin)	43	42.0	(29.0 - 55.0)	0.93	(0.65 - 1.23)	-	34	30.1	(19.0 - 41.2)	1.01	(0.67 - 1.37)	-
Lung, bronchus & trachea	67	48.1	(35.9 - 60.3)	1.32	(1.03 - 1.68)	^	30	17.6	(10.6 - 24.5)	1.08	(0.70 - 1.49)	-
Lymphoma	18	13.2	(6.6 - 19.9)	1.06	(0.58 - 1.61)	-	14	12.3	(4.6 - 19.9)	1.01	(0.50 - 1.60)	-
Unknown primary site	19	12.9	(6.8 - 19.1)	1.31	(0.74 - 1.96)	-	16	9.8	(4.3 - 15.3)	1.38	(0.73 - 2.14)	-
Kidney & other renal tract	6	4.2	(0.6 - 7.8)	0.53	(0.14 - 1.03)	-	4	2.9	(0.0 - 6.0)	0.59	(0.09 - 1.30)	-
Leukaemia	11	11.6	(3.9 - 19.3)	1.03	(0.45 - 1.73)	-	9	8.6	(1.9 - 15.3)	1.27	(0.49 - 2.23)	-
Pancreas	8	5.8	(1.6 - 10.0)	1.03	(0.36 - 1.85)	-	12	6.9	(2.6 - 11.1)	1.38	(0.63 - 2.26)	-
Urinary bladder	12	8.4	(3.3 - 13.5)	0.98	(0.45 - 1.61)	-	2	0.9	(0.0 - 2.2)	0.43	(0.01 - 1.20)	-
Stomach	10	5.9	(2.0 - 9.8)	0.97	(0.40 - 1.66)	-	6	3.9	(0.4 - 7.4)	1.02	(0.28 - 1.99)	-
Corpus uteri	0	-	-	-	-	.	13	10.0	(3.9 - 16.2)	1.14	(0.54 - 1.84)	-
Brain	7	8.7	(1.3 - 16.0)	1.16	(0.37 - 2.17)	-	4	3.4	(0.0 - 7.2)	0.89	(0.14 - 1.96)	-*
Lip	10	9.6	(3.4 - 15.8)	1.64	(0.67 - 2.79)	-	2	1.9	(0.0 - 4.5)	0.62	(0.01 - 1.74)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	5	4.3	(0.3 - 8.4)	0.50	(0.11 - 1.02)	-
Other lymphohaematopoietic	6	4.5	(0.7 - 8.4)	1.03	(0.28 - 2.00)	-	7	3.5	(0.6 - 6.4)	1.58	(0.50 - 2.96)	-*
Oesophagus	6	3.5	(0.6 - 6.5)	0.92	(0.25 - 1.79)	-	1	1.0	(0.0 - 3.1)	0.30	(0.00 - 1.11)	-*
Thyroid gland	2	1.5	(0.0 - 3.7)	0.95	(0.01 - 2.64)	-*	8	8.1	(2.3 - 13.9)	1.49	(0.52 - 2.69)	-
Myeloma/plasma cell tumours	6	5.7	(0.8 - 10.5)	1.25	(0.34 - 2.43)	-	2	0.7	(0.0 - 1.6)	0.53	(0.01 - 1.47)	-*
Cervix uteri	0	-	-	-	-	.	5	5.6	(0.6 - 10.6)	0.72	(0.16 - 1.47)	-
Non-mel. skin (exc BCC/SCC)	7	5.9	(1.4 - 10.5)	1.42	(0.45 - 2.65)	-	4	2.4	(0.0 - 5.1)	1.36	(0.21 - 2.98)	-*
Mesothelioma	9	8.5	(2.9 - 14.1)	1.50	(0.58 - 2.64)	-	2	1.2	(0.0 - 3.0)	2.19	(0.03 - 6.09)	-*
Liver & intrahepatic bile duct	6	5.4	(0.9 - 10.0)	1.40	(0.38 - 2.72)	-*	3	1.7	(0.0 - 4.0)	1.85	(0.15 - 4.33)	-*
Testis	9	11.7	(3.8 - 19.6)	1.98	(0.76 - 3.46)	-	0	-	-	-	-	.
Gallbladder & bile ducts	2	1.8	(0.0 - 4.7)	0.79	(0.01 - 2.19)	-*	5	3.4	(0.1 - 6.8)	1.69	(0.37 - 3.45)	-*
Larynx	6	4.6	(0.7 - 8.4)	1.40	(0.38 - 2.72)	-*	2	1.2	(0.0 - 3.0)	2.85	(0.04 - 7.93)	-*
Tongue	3	3.0	(0.0 - 6.5)	1.27	(0.10 - 2.96)	-*	4	3.9	(0.1 - 7.8)	3.75	(0.58 - 8.22)	-*
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Tonsil & oropharynx	6	6.6	(1.3 - 11.9)	3.19	(0.86 - 6.20)	-*	1	1.0	(0.0 - 3.1)	2.13	(0.00 - 7.84)	-*
Vulva/vagina	0	-	-	-	-	.	3	2.4	(0.0 - 5.4)	1.23	(0.10 - 2.87)	-*
Small intestine	2	1.3	(0.0 - 3.1)	1.65	(0.02 - 4.60)	-*	1	0.3	(0.0 - 1.0)	1.11	(0.00 - 4.09)	-*
Eye & lacrimal gland	3	2.5	(0.0 - 5.7)	2.54	(0.20 - 5.92)	-*	0	-	-	0	n/a	-
Major Salivary Gland	2	2.3	(0.0 - 5.6)	1.87	(0.02 - 5.20)	-*	0	-	-	0	n/a	-
Anus	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Mouth, other & unspecified	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Floor of mouth	1	1.1	(0.0 - 3.4)	0.88	(0.00 - 3.26)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	1	1.1	(0.0 - 3.2)	1.81	(0.00 - 6.68)	-*	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	1	0.4	(0.0 - 1.3)	0.84	(0.00 - 3.10)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.5	(0.0 - 1.3)	1.33	(0.00 - 4.90)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	2	1.5	(0.0 - 3.8)	2.82	(0.04 - 7.86)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	1	1.1	(0.0 - 3.4)	2.09	(0.00 - 7.73)	-*	1	1.0	(0.0 - 3.0)	6.26	(0.00 - 23.09)	-*
Pharynx, other & ill-def.	0	-	-	0	n/a	-	1	0.3	(0.0 - 0.8)	9.17	(0.00 - 33.84)	-*
Penis & other male genital	1	0.9	(0.0 - 2.8)	1.54	(0.00 - 5.70)	-*	0	-	-	-	-	.
Gum	1	1.1	(0.0 - 3.2)	3.53	(0.00 - 13.01)	-*	0	-	-	-	-	.
Kaposi sarcoma	1	0.7	(0.0 - 2.1)	2.95	(0.00 - 10.88)	-*	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	1	1.1	(0.0 - 3.4)	7.10	(0.00 - 26.21)	-*
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	2	2.2	(0.0 - 5.2)	24.35	(0.30 - 67.84)	-*
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	425	353.2	(317.5 - 388.8)	1.04	(0.95 - 1.15)	-	360	278.7	(246.6 - 310.8)	1.07	(0.97 - 1.19)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Beverley (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	40.0	(0.0 - 89.1)	0.55	(0.04 - 1.29)	-
Colorectal cancer	4	42.4	(0.7 - 84.1)	1.07	(0.17 - 2.34)	-*	2	16.1	(0.0 - 39.0)	0.84	(0.01 - 2.34)	-*
Prostate gland	5	64.0	(7.3 - 120.8)	0.80	(0.17 - 1.63)	-	0	-	-	-	-	.
Melanoma (skin)	2	25.5	(0.0 - 60.8)	0.68	(0.01 - 1.89)	-*	2	35.1	(0.0 - 84.7)	1.12	(0.01 - 3.12)	-*
Lung, bronchus & trachea	3	35.8	(0.0 - 76.7)	0.91	(0.07 - 2.11)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	1	19.4	(0.0 - 57.2)	1.43	(0.00 - 5.28)	-*
Unknown primary site	1	14.1	(0.0 - 41.6)	1.05	(0.00 - 3.86)	-*	0	-	-	0	n/a	-
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	0	-	-	-	-	.
Pancreas	0	-	-	0	n/a	-	1	13.7	(0.0 - 40.5)	2.26	(0.00 - 8.32)	-*
Urinary bladder	1	13.2	(0.0 - 38.9)	1.26	(0.00 - 4.63)	-*	0	-	-	-	-	.
Stomach	1	14.1	(0.0 - 41.6)	1.49	(0.00 - 5.50)	-*	1	5.9	(0.0 - 17.3)	3.30	(0.00 - 12.16)	-*
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	1	30.8	(0.0 - 91.0)	2.51	(0.00 - 9.26)	-*	0	-	-	-	-	.
Lip	1	9.3	(0.0 - 27.6)	2.56	(0.00 - 9.46)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	14.1	(0.0 - 41.6)	1.85	(0.00 - 6.81)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	1	24.1	(0.0 - 71.2)	7.92	(0.00 - 29.23)	-*	1	20.0	(0.0 - 59.1)	3.52	(0.00 - 12.97)	-*
Myeloma/plasma cell tumours	1	12.3	(0.0 - 36.5)	3.11	(0.00 - 11.45)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	1	5.9	(0.0 - 17.3)	18.70	(0.00 - 68.97)	-*
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	3	34.6	(0.0 - 75.5)	23.00	(1.86 - 53.69)	^*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	24	320.2	(184.9 - 455.5)	0.90	(0.55 - 1.29)	-	13	170.0	(69.8 - 270.3)	0.72	(0.34 - 1.16)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Boddington (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	60.0	(0.0 - 129.8)	0.92	(0.07 - 2.15)	-*
Colorectal cancer	2	33.4	(0.0 - 80.7)	1.07	(0.01 - 2.97)	-*	1	36.7	(0.0 - 108.3)	0.87	(0.00 - 3.23)	-*
Prostate gland	1	11.6	(0.0 - 34.2)	0.33	(0.00 - 1.23)	-*	0	-	-	-	-	.
Melanoma (skin)	1	15.6	(0.0 - 46.1)	0.54	(0.00 - 1.98)	-*	1	36.7	(0.0 - 108.3)	0.82	(0.00 - 3.02)	-*
Lung, bronchus & trachea	2	63.6	(0.0 - 158.8)	1.27	(0.02 - 3.53)	-*	1	29.0	(0.0 - 85.4)	1.45	(0.00 - 5.36)	-*
Lymphoma	1	11.6	(0.0 - 34.2)	1.51	(0.00 - 5.58)	-*	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	1	21.7	(0.0 - 63.4)	4.99	(0.00 - 18.42)	-*
Urinary bladder	1	21.7	(0.0 - 63.4)	2.63	(0.00 - 9.70)	-*	1	36.7	(0.0 - 108.3)	10.56	(0.00 - 38.95)	-*
Stomach	0	-	-	-	-	.	1	29.0	(0.0 - 85.4)	7.52	(0.00 - 27.74)	-*
Corpus uteri	0	-	-	-	-	.	1	36.7	(0.0 - 108.3)	2.96	(0.00 - 10.93)	-*
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	1	45.5	(0.0 - 133.9)	3.80	(0.00 - 14.03)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	1	29.0	(0.0 - 85.4)	10.31	(0.00 - 38.02)	-*
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	1	18.2	(0.0 - 53.5)	6.27	(0.00 - 23.12)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	1	11.6	(0.0 - 34.2)	12.86	(0.00 - 47.43)	-*	0	-	-	-	-	.
Tonsil & oropharynx	1	24.6	(0.0 - 72.7)	12.47	(0.00 - 46.01)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	12	257.4	(95.3 - 419.6)	0.85	(0.39 - 1.39)	-	11	315.5	(126.3 - 504.7)	1.09	(0.48 - 1.82)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Boyup Brook (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	38.7	(0.0 - 86.5)	0.57	(0.05 - 1.33)	-
Colorectal cancer	4	58.3	(0.0 - 117.1)	1.26	(0.19 - 2.76)	-*	5	48.8	(0.6 - 96.9)	2.07	(0.45 - 4.24)	-*
Prostate gland	6	97.5	(19.8 - 175.2)	1.15	(0.31 - 2.23)	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lymphoma	1	8.8	(0.0 - 25.8)	1.03	(0.00 - 3.80)	-*	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Kidney & other renal tract	0	-	-	0	n/a	-	3	54.5	(0.0 - 118.4)	8.38	(0.68 - 19.55)	-*
Leukaemia	0	-	-	0	n/a	-	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	1	4.9	(0.0 - 14.3)	2.20	(0.00 - 8.11)	-*
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	1	4.3	(0.0 - 12.8)	3.23	(0.00 - 11.91)	-*
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	4.9	(0.0 - 14.3)	1.88	(0.00 - 6.94)	-*
Other lymphohaematopoietic	1	8.6	(0.0 - 25.4)	3.12	(0.00 - 11.51)	-*	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	1	18.7	(0.0 - 55.3)	3.61	(0.00 - 13.32)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	2	53.5	(0.0 - 133.8)	5.10	(0.06 - 14.21)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	1	17.1	(0.0 - 50.6)	28.74	(0.00 - 106.01)	-*
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	1	14.0	(0.0 - 41.4)	29.68	(0.00 - 109.49)	-*	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	14	205.9	(96.1 - 315.7)	0.61	(0.30 - 0.97)	V	17	226.6	(98.3 - 355.0)	0.94	(0.50 - 1.43)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Bridgetown-Greenbushes (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	19	133.5	(73.2 - 193.7)	1.48	(0.83 - 2.22)	-
Colorectal cancer	1	6.4	(0.0 - 19.0)	0.14	(0.00 - 0.52)	V	7	46.9	(11.1 - 82.7)	1.41	(0.44 - 2.64)	-
Prostate gland	14	89.2	(42.2 - 136.1)	1.19	(0.59 - 1.88)	-	0	-	-	-	-	.
Melanoma (skin)	8	54.0	(16.4 - 91.6)	1.27	(0.45 - 2.30)	-	2	16.6	(0.0 - 39.9)	0.46	(0.01 - 1.29)	-*
Lung, bronchus & trachea	7	45.1	(11.6 - 78.5)	1.13	(0.36 - 2.11)	-	5	30.5	(3.4 - 57.6)	1.67	(0.36 - 3.42)	-*
Lymphoma	4	32.0	(0.0 - 66.2)	1.80	(0.28 - 3.95)	-*	2	14.1	(0.0 - 33.7)	1.28	(0.02 - 3.56)	-*
Unknown primary site	2	12.7	(0.0 - 30.2)	1.14	(0.01 - 3.19)	-*	0	-	-	0	n/a	-
Kidney & other renal tract	0	-	-	0	n/a	-	2	14.1	(0.0 - 33.7)	2.49	(0.03 - 6.94)	-*
Leukaemia	1	7.1	(0.0 - 20.9)	0.74	(0.00 - 2.74)	-*	1	3.5	(0.0 - 10.3)	1.23	(0.00 - 4.55)	-*
Pancreas	1	6.4	(0.0 - 19.0)	1.01	(0.00 - 3.74)	-*	2	8.6	(0.0 - 20.4)	2.24	(0.03 - 6.24)	-*
Urinary bladder	1	6.4	(0.0 - 19.0)	0.71	(0.00 - 2.64)	-*	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	1	7.1	(0.0 - 21.0)	1.17	(0.00 - 4.31)	-*	1	7.1	(0.0 - 20.9)	1.86	(0.00 - 6.85)	-*
Lip	1	6.5	(0.0 - 19.2)	1.16	(0.00 - 4.28)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	5.8	(0.0 - 17.3)	0.84	(0.00 - 3.10)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	2	19.6	(0.0 - 47.9)	2.70	(0.03 - 7.53)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	1	6.4	(0.0 - 19.0)	1.34	(0.00 - 4.96)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	1	7.0	(0.0 - 20.8)	5.54	(0.00 - 20.43)	-*
Testis	1	17.7	(0.0 - 52.2)	1.68	(0.00 - 6.18)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	1	6.5	(0.0 - 19.2)	3.10	(0.00 - 11.42)	-*	0	-	-	-	-	.
Larynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	1	7.1	(0.0 - 20.9)	12.99	(0.00 - 47.90)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	45	310.6	(216.3 - 404.8)	0.87	(0.62 - 1.14)	-	45	307.3	(215.7 - 398.9)	1.12	(0.80 - 1.47)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Brookton (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	35.7	(0.0 - 105.4)	0.33	(0.00 - 1.22)	-*
Colorectal cancer	3	37.0	(0.0 - 80.0)	1.28	(0.10 - 2.98)	-*	3	76.6	(0.0 - 167.8)	2.14	(0.17 - 4.99)	-*
Prostate gland	4	52.3	(0.0 - 109.3)	1.05	(0.16 - 2.30)	-*	0	-	-	-	-	.
Melanoma (skin)	3	89.3	(0.0 - 191.3)	1.67	(0.13 - 3.89)	-*	3	30.9	(0.0 - 66.2)	2.83	(0.23 - 6.61)	-*
Lung, bronchus & trachea	1	7.1	(0.0 - 21.0)	0.49	(0.00 - 1.80)	-*	2	62.3	(0.0 - 148.3)	2.45	(0.03 - 6.84)	-*
Lymphoma	0	-	-	0	n/a	-	1	29.4	(0.0 - 86.9)	2.43	(0.00 - 8.98)	-*
Unknown primary site	0	-	-	0	n/a	-	1	36.4	(0.0 - 107.4)	2.68	(0.00 - 9.90)	-*
Kidney & other renal tract	0	-	-	-	-	.	1	35.7	(0.0 - 105.4)	4.82	(0.00 - 17.78)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	2	29.7	(0.0 - 75.9)	4.62	(0.06 - 12.86)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	1	26.1	(0.0 - 77.0)	7.27	(0.00 - 26.81)	-*
Lip	0	-	-	-	-	.	1	26.1	(0.0 - 77.0)	9.90	(0.00 - 36.51)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	2	41.7	(0.0 - 102.9)	6.52	(0.08 - 18.16)	-*
Other lymphohaematopoietic	1	27.4	(0.0 - 80.7)	3.63	(0.00 - 13.39)	-*	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	2	49.0	(0.0 - 123.4)	9.11	(0.11 - 25.37)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	14	242.8	(99.3 - 386.2)	0.84	(0.42 - 1.33)	-	18	449.9	(228.9 - 670.9)	1.73	(0.95 - 2.61)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Broome (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	26	87.9	(52.5 - 123.3)	1.27	(0.79 - 1.81)	-
Colorectal cancer	11	51.7	(20.7 - 82.6)	1.06	(0.46 - 1.77)	-	4	19.1	(0.0 - 38.7)	0.67	(0.10 - 1.47)	-
Prostate gland	4	19.2	(0.4 - 38.0)	0.25	(0.04 - 0.54)	V	0	-	-	-	-	.
Melanoma (skin)	11	37.2	(14.2 - 60.3)	0.87	(0.38 - 1.46)	-	5	14.4	(1.1 - 27.6)	0.57	(0.13 - 1.18)	-
Lung, bronchus & trachea	9	32.5	(10.6 - 54.4)	1.06	(0.41 - 1.86)	-	1	7.1	(0.0 - 21.1)	0.29	(0.00 - 1.06)	-*
Lymphoma	3	11.3	(0.0 - 24.5)	0.71	(0.06 - 1.66)	-*	3	13.8	(0.0 - 30.1)	1.26	(0.10 - 2.95)	-*
Unknown primary site	2	9.3	(0.0 - 22.3)	0.80	(0.01 - 2.23)	-*	5	22.5	(1.9 - 43.1)	3.70	(0.81 - 7.59)	-*
Kidney & other renal tract	3	13.1	(0.0 - 28.5)	1.24	(0.10 - 2.90)	-*	0	-	-	0	n/a	-
Leukaemia	1	3.5	(0.0 - 10.4)	0.40	(0.00 - 1.49)	-*	0	-	-	0	n/a	-
Pancreas	1	5.0	(0.0 - 14.6)	0.69	(0.00 - 2.53)	-*	1	5.9	(0.0 - 17.6)	1.03	(0.00 - 3.79)	-*
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	1	3.4	(0.0 - 10.1)	1.47	(0.00 - 5.42)	-*
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	1	3.5	(0.0 - 10.4)	0.57	(0.00 - 2.11)	-*	1	2.1	(0.0 - 6.3)	1.08	(0.00 - 4.00)	-*
Lip	1	2.5	(0.0 - 7.3)	0.55	(0.00 - 2.03)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	1	4.7	(0.0 - 13.8)	1.21	(0.00 - 4.45)	-*	2	11.4	(0.0 - 27.2)	4.03	(0.05 - 11.22)	-*
Oesophagus	4	14.7	(0.0 - 30.1)	3.48	(0.54 - 7.64)	-*	2	10.2	(0.0 - 25.0)	5.25	(0.07 - 14.62)	-*
Thyroid gland	0	-	-	0	n/a	-	1	3.4	(0.0 - 10.1)	0.56	(0.00 - 2.05)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	3	9.6	(0.0 - 20.9)	1.44	(0.12 - 3.36)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	1	4.7	(0.0 - 13.8)	0.98	(0.00 - 3.60)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	4	9.3	(0.0 - 18.6)	1.82	(0.28 - 3.98)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	1	3.4	(0.0 - 10.0)	2.12	(0.00 - 7.81)	-*	0	-	-	-	-	.
Larynx	1	4.7	(0.0 - 13.8)	1.07	(0.00 - 3.97)	-*	1	2.0	(0.0 - 5.8)	9.34	(0.00 - 34.45)	-*
Tongue	1	2.0	(0.0 - 5.9)	1.51	(0.00 - 5.57)	-*	0	-	-	-	-	.
Connective & soft tissues	1	3.4	(0.0 - 10.0)	1.78	(0.00 - 6.56)	-*	1	5.9	(0.0 - 17.6)	3.39	(0.00 - 12.50)	-*
Tonsil & oropharynx	6	17.9	(2.9 - 32.9)	11.18	(3.02 - 21.74)	^*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	2.6	(0.0 - 7.7)	2.43	(0.00 - 8.98)	-*
Small intestine	1	4.7	(0.0 - 13.8)	4.06	(0.00 - 14.98)	-*	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	5.2	(0.0 - 15.5)	3.13	(0.00 - 11.55)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	3.1	(0.0 - 9.3)	4.05	(0.00 - 14.95)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	1	3.9	(0.0 - 11.6)	6.38	(0.00 - 23.52)	-*	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	71	270.4	(205.2 - 335.7)	0.86	(0.68 - 1.09)	-	58	221.5	(160.7 - 282.2)	0.95	(0.73 - 1.24)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Broomehill (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	132.6	(0.0 - 282.6)	2.08	(0.17 - 4.85)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	3	140.2	(0.0 - 294.3)	2.43	(0.20 - 5.67)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	1	45.5	(0.0 - 134.2)	13.20	(0.00 - 48.69)	-*	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	83.3	(0.0 - 245.0)	16.15	(0.00 - 59.58)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	5	269.0	(28.7 - 509.3)	0.88	(0.19 - 1.79)	-	3	132.6	(0.0 - 282.6)	0.67	(0.05 - 1.56)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Bruce Rock (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	80.3	(0.0 - 171.2)	0.85	(0.07 - 1.98)	-*
Colorectal cancer	5	122.5	(11.8 - 233.2)	2.31	(0.50 - 4.74)	-*	2	29.7	(0.0 - 72.2)	1.31	(0.02 - 3.64)	-*
Prostate gland	3	54.9	(0.0 - 118.6)	0.85	(0.07 - 1.99)	-*	0	-	-	-	-	.
Melanoma (skin)	1	12.0	(0.0 - 35.5)	0.54	(0.00 - 2.00)	-*	3	72.5	(0.0 - 154.5)	2.45	(0.20 - 5.71)	-*
Lung, bronchus & trachea	1	11.9	(0.0 - 35.0)	0.52	(0.00 - 1.93)	-*	0	-	-	0	n/a	-
Lymphoma	1	12.0	(0.0 - 35.5)	1.49	(0.00 - 5.50)	-*	1	26.9	(0.0 - 79.5)	2.11	(0.00 - 7.79)	-*
Unknown primary site	1	21.4	(0.0 - 63.2)	1.80	(0.00 - 6.63)	-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	1	34.2	(0.0 - 100.9)	2.17	(0.00 - 7.99)	-*	0	-	-	-	-	.
Stomach	1	11.9	(0.0 - 35.0)	2.52	(0.00 - 9.29)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	1	11.1	(0.0 - 32.8)	8.98	(0.00 - 33.13)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	1	11.4	(0.0 - 33.4)	2.86	(0.00 - 10.54)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	25.4	(0.0 - 75.0)	3.99	(0.00 - 14.72)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	1	25.4	(0.0 - 75.0)	32.04	(0.00 - 118.20)	-*	0	-	-	-	-	.
Mouth, other & unspecified	1	20.3	(0.0 - 60.1)	22.88	(0.00 - 84.39)	-*	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	25.4	(0.0 - 75.0)	21.45	(0.00 - 79.13)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	1	34.2	(0.0 - 100.9)	48.03	(0.00 - 177.19)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	19	411.7	(218.7 - 604.7)	1.21	(0.68 - 1.81)	-	11	231.9	(88.9 - 375.0)	0.93	(0.41 - 1.56)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Bunbury (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	1.2	(0.0 - 3.7)	1.74	(0.00 - 6.43)	-*	93	93.2	(73.3 - 113.1)	1.09	(0.89 - 1.34)	-
Colorectal cancer	53	49.1	(35.0 - 63.1)	1.09	(0.82 - 1.43)	-	44	35.2	(23.5 - 47.0)	1.10	(0.78 - 1.45)	-
Prostate gland	60	59.5	(43.7 - 75.3)	0.76	(0.58 - 0.98)	V	0	-	-	-	-	.
Melanoma (skin)	49	51.8	(36.8 - 66.8)	1.17	(0.85 - 1.52)	-	37	38.1	(25.1 - 51.0)	1.20	(0.82 - 1.62)	-
Lung, bronchus & trachea	43	40.3	(27.5 - 53.2)	1.00	(0.70 - 1.31)	-	27	26.1	(15.7 - 36.5)	1.13	(0.71 - 1.60)	-
Lymphoma	21	21.9	(12.1 - 31.7)	1.36	(0.79 - 2.00)	-	12	8.8	(3.0 - 14.6)	0.99	(0.45 - 1.62)	-
Unknown primary site	13	12.5	(5.4 - 19.5)	1.02	(0.49 - 1.64)	-	10	5.1	(1.4 - 8.9)	0.96	(0.39 - 1.64)	-
Kidney & other renal tract	10	11.5	(4.1 - 19.0)	1.00	(0.41 - 1.71)	-	5	5.6	(0.0 - 11.7)	0.84	(0.18 - 1.73)	-
Leukaemia	9	9.6	(3.1 - 16.2)	0.95	(0.36 - 1.66)	-	8	7.3	(1.4 - 13.2)	1.24	(0.44 - 2.24)	-
Pancreas	6	4.5	(0.7 - 8.3)	0.89	(0.24 - 1.73)	-	7	5.2	(0.9 - 9.6)	0.93	(0.29 - 1.73)	-
Urinary bladder	10	9.9	(3.4 - 16.4)	0.94	(0.39 - 1.60)	-	5	2.7	(0.2 - 5.2)	1.24	(0.27 - 2.53)	-*
Stomach	9	7.8	(2.4 - 13.1)	1.01	(0.39 - 1.76)	-	4	2.9	(0.0 - 6.2)	0.78	(0.12 - 1.71)	-
Corpus uteri	0	-	-	-	-	.	9	6.4	(1.6 - 11.2)	0.90	(0.35 - 1.58)	-
Brain	5	5.5	(0.0 - 11.3)	0.90	(0.20 - 1.85)	-	1	0.8	(0.0 - 2.2)	0.25	(0.00 - 0.91)	V*
Lip	3	3.3	(0.0 - 7.0)	0.54	(0.04 - 1.25)	-	1	0.3	(0.0 - 0.9)	0.35	(0.00 - 1.29)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	5	4.2	(0.1 - 8.2)	0.57	(0.12 - 1.16)	-
Other lymphohaematopoietic	7	5.6	(1.2 - 10.1)	1.35	(0.42 - 2.52)	-	3	1.3	(0.0 - 2.7)	0.77	(0.06 - 1.79)	-*
Oesophagus	4	2.6	(0.0 - 5.2)	0.71	(0.11 - 1.56)	-	2	1.1	(0.0 - 2.7)	0.69	(0.01 - 1.93)	-*
Thyroid gland	1	1.0	(0.0 - 3.1)	0.51	(0.00 - 1.87)	-*	7	7.0	(1.7 - 12.4)	1.35	(0.43 - 2.52)	-
Myeloma/plasma cell tumours	0	-	-	0	n/a	V	4	4.2	(0.0 - 8.3)	1.21	(0.19 - 2.64)	-*
Cervix uteri	0	-	-	-	-	.	9	8.8	(2.7 - 15.0)	1.37	(0.53 - 2.40)	-
Non-mel. skin (exc BCC/SCC)	4	2.9	(0.0 - 6.2)	0.90	(0.14 - 1.96)	-*	5	6.1	(0.6 - 11.5)	1.89	(0.41 - 3.86)	-*
Mesothelioma	3	2.9	(0.0 - 6.3)	0.59	(0.05 - 1.37)	-	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	2	2.2	(0.0 - 5.4)	0.54	(0.01 - 1.51)	-*	2	1.5	(0.0 - 3.9)	1.41	(0.02 - 3.94)	-*
Testis	3	3.4	(0.0 - 7.2)	0.68	(0.06 - 1.59)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	2	2.5	(0.0 - 6.0)	0.89	(0.01 - 2.49)	-*	3	1.9	(0.0 - 4.4)	1.16	(0.09 - 2.71)	-*
Larynx	3	3.1	(0.0 - 6.8)	0.81	(0.07 - 1.90)	-*	0	-	-	0	n/a	-
Tongue	2	1.1	(0.0 - 2.7)	0.91	(0.01 - 2.55)	-*	0	-	-	0	n/a	-
Connective & soft tissues	0	-	-	0	n/a	-	1	1.2	(0.0 - 3.5)	0.92	(0.00 - 3.40)	-*
Tonsil & oropharynx	1	1.0	(0.0 - 3.1)	0.57	(0.00 - 2.09)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	3	1.4	(0.0 - 3.1)	1.37	(0.11 - 3.20)	-*
Small intestine	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Eye & lacrimal gland	0	-	-	0	n/a	-	1	0.8	(0.0 - 2.2)	1.78	(0.00 - 6.56)	-*
Major Salivary Gland	0	-	-	0	n/a	-	1	0.3	(0.0 - 0.9)	1.46	(0.00 - 5.39)	-*
Anus	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Mouth, other & unspecified	2	2.3	(0.0 - 5.5)	2.13	(0.03 - 5.94)	-*	2	1.2	(0.0 - 2.9)	3.40	(0.04 - 9.47)	-*
Floor of mouth	1	0.9	(0.0 - 2.6)	0.98	(0.00 - 3.61)	-*	1	1.1	(0.0 - 3.3)	2.39	(0.00 - 8.83)	-*
Bones, joints & articular cart.	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	1	0.4	(0.0 - 1.2)	8.61	(0.00 - 31.76)	-*
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	0	n/a	-
Adrenal & other endocrine	2	2.0	(0.0 - 4.8)	5.32	(0.07 - 14.83)	-*	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	0	n/a	-	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	1	0.4	(0.0 - 1.2)	12.57	(0.00 - 46.36)	-*
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	1	1.1	(0.0 - 3.3)	10.00	(0.00 - 36.90)	-*
Spinal cord & cranial nerves	1	1.6	(0.0 - 4.6)	8.90	(0.00 - 32.83)	-*	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	1	1.2	(0.0 - 3.5)	34.27	(0.00 - 126.42)	-*
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	330	323.7	(287.0 - 360.3)	0.93	(0.83 - 1.03)	-	316	282.9	(248.8 - 316.9)	1.06	(0.95 - 1.18)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Busselton (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	51	62.2	(44.1 - 80.3)	0.75	(0.57 - 1.00)	-
Colorectal cancer	53	61.8	(44.3 - 79.3)	1.32	(1.00 - 1.74)	-	28	25.9	(15.2 - 36.6)	0.89	(0.57 - 1.25)	-
Prostate gland	52	49.7	(35.4 - 64.0)	0.78	(0.59 - 1.03)	-	0	-	-	-	-	.
Melanoma (skin)	34	48.4	(31.3 - 65.4)	1.02	(0.68 - 1.39)	-	33	48.2	(30.5 - 65.8)	1.38	(0.91 - 1.88)	-
Lung, bronchus & trachea	30	31.3	(19.5 - 43.2)	0.82	(0.53 - 1.14)	-	25	25.4	(14.7 - 36.1)	1.31	(0.81 - 1.87)	-
Lymphoma	11	15.7	(6.2 - 25.2)	0.90	(0.39 - 1.50)	-	9	10.7	(3.1 - 18.3)	0.94	(0.36 - 1.64)	-
Unknown primary site	11	12.2	(4.4 - 19.9)	1.06	(0.46 - 1.78)	-	12	11.0	(4.0 - 17.9)	1.52	(0.69 - 2.49)	-
Kidney & other renal tract	9	9.0	(2.6 - 15.4)	1.10	(0.42 - 1.93)	-	3	4.1	(0.0 - 8.8)	0.63	(0.05 - 1.48)	-
Leukaemia	5	8.3	(0.5 - 16.1)	0.65	(0.14 - 1.33)	-	2	1.9	(0.0 - 4.9)	0.40	(0.00 - 1.11)	-
Pancreas	8	8.0	(2.3 - 13.7)	1.42	(0.50 - 2.56)	-	5	4.6	(0.1 - 9.2)	0.85	(0.19 - 1.74)	-
Urinary bladder	9	7.8	(2.4 - 13.1)	1.03	(0.39 - 1.80)	-	4	2.5	(0.0 - 4.9)	1.28	(0.20 - 2.81)	-*
Stomach	6	6.3	(1.1 - 11.6)	0.81	(0.22 - 1.58)	-	4	4.1	(0.0 - 9.5)	1.00	(0.16 - 2.20)	-*
Corpus uteri	0	-	-	-	-	.	4	4.4	(0.0 - 9.0)	0.50	(0.08 - 1.10)	-
Brain	5	6.8	(0.6 - 12.9)	1.14	(0.25 - 2.33)	-*	0	-	-	0	n/a	-
Lip	4	5.4	(0.0 - 10.8)	0.90	(0.14 - 1.97)	-*	3	2.6	(0.0 - 5.8)	1.35	(0.11 - 3.16)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	5	5.3	(0.2 - 10.4)	0.72	(0.16 - 1.47)	-
Other lymphohaematopoietic	8	7.9	(2.1 - 13.7)	1.91	(0.67 - 3.44)	-*	5	5.6	(0.4 - 10.9)	1.69	(0.37 - 3.45)	-*
Oesophagus	4	5.1	(0.0 - 10.2)	0.86	(0.13 - 1.88)	-	2	1.3	(0.0 - 3.3)	0.89	(0.01 - 2.47)	-*
Thyroid gland	1	1.4	(0.0 - 4.1)	0.65	(0.00 - 2.40)	-*	3	5.9	(0.0 - 13.0)	0.76	(0.06 - 1.78)	-*
Myeloma/plasma cell tumours	3	3.2	(0.0 - 7.0)	0.86	(0.07 - 2.01)	-*	3	1.5	(0.0 - 3.2)	1.16	(0.09 - 2.70)	-*
Cervix uteri	0	-	-	-	-	.	4	3.8	(0.0 - 7.9)	0.78	(0.12 - 1.71)	-
Non-mel. skin (exc BCC/SCC)	4	4.1	(0.0 - 8.3)	1.12	(0.17 - 2.46)	-*	1	1.6	(0.0 - 4.7)	0.50	(0.00 - 1.84)	-*
Mesothelioma	5	4.8	(0.4 - 9.3)	1.18	(0.26 - 2.41)	-*	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	2	2.0	(0.0 - 5.0)	0.65	(0.01 - 1.82)	-*	1	0.5	(0.0 - 1.3)	0.89	(0.00 - 3.30)	-*
Testis	4	6.3	(0.0 - 12.6)	1.27	(0.20 - 2.79)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	1	1.5	(0.0 - 4.5)	0.55	(0.00 - 2.01)	-*	2	2.0	(0.0 - 5.0)	1.00	(0.01 - 2.78)	-*
Larynx	2	3.3	(0.0 - 7.8)	0.65	(0.01 - 1.82)	-*	0	-	-	-	-	.
Tongue	1	1.3	(0.0 - 3.8)	0.58	(0.00 - 2.13)	-*	0	-	-	0	n/a	-
Connective & soft tissues	1	1.6	(0.0 - 4.6)	0.74	(0.00 - 2.71)	-*	2	2.6	(0.0 - 6.1)	2.33	(0.03 - 6.50)	-*
Tonsil & oropharynx	1	0.7	(0.0 - 2.0)	0.71	(0.00 - 2.62)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	1	0.7	(0.0 - 2.0)	1.15	(0.00 - 4.25)	-*	0	-	-	0	n/a	-
Eye & lacrimal gland	1	1.7	(0.0 - 5.1)	1.13	(0.00 - 4.18)	-*	0	-	-	-	-	.
Major Salivary Gland	2	1.3	(0.0 - 3.2)	2.64	(0.03 - 7.35)	-*	0	-	-	0	n/a	-
Anus	1	1.3	(0.0 - 3.8)	1.74	(0.00 - 6.44)	-*	1	1.5	(0.0 - 4.4)	1.37	(0.00 - 5.05)	-*
Mouth, other & unspecified	1	1.3	(0.0 - 3.8)	1.32	(0.00 - 4.87)	-*	0	-	-	-	-	.
Floor of mouth	3	3.7	(0.0 - 8.1)	3.62	(0.29 - 8.45)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	0.7	(0.0 - 2.0)	1.18	(0.00 - 4.34)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	1	0.5	(0.0 - 1.4)	4.53	(0.00 - 16.71)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	1	1.6	(0.0 - 4.8)	5.61	(0.00 - 20.71)	-*
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	1	1.5	(0.0 - 4.4)	42.30	(0.00 - 156.06)	-*
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	284	324.5	(284.6 - 364.4)	0.97	(0.86 - 1.09)	-	215	242.7	(207.0 - 278.4)	0.91	(0.80 - 1.05)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cambridge (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	1.4	(0.0 - 4.1)	1.85	(0.00 - 6.84)	-*	87	94.4	(73.3 - 115.5)	1.07	(0.86 - 1.33)	-
Colorectal cancer	46	49.7	(34.4 - 65.1)	1.00	(0.71 - 1.31)	-	55	37.5	(25.0 - 50.0)	1.34	(1.02 - 1.76)	^
Prostate gland	87	90.0	(70.0 - 110.1)	1.17	(0.94 - 1.45)	-	0	-	-	-	-	.
Melanoma (skin)	54	64.6	(46.1 - 83.0)	1.44	(1.09 - 1.90)	^	35	36.8	(22.7 - 51.0)	1.21	(0.82 - 1.65)	-
Lung, bronchus & trachea	26	18.7	(11.0 - 26.5)	0.64	(0.40 - 0.90)	V	20	11.4	(5.2 - 17.5)	0.84	(0.48 - 1.25)	-
Lymphoma	14	15.7	(6.9 - 24.6)	1.00	(0.49 - 1.58)	-	9	7.0	(1.8 - 12.3)	0.76	(0.29 - 1.33)	-
Unknown primary site	12	10.6	(4.1 - 17.0)	0.98	(0.45 - 1.62)	-	6	3.9	(0.0 - 7.8)	0.53	(0.14 - 1.03)	-
Kidney & other renal tract	6	6.4	(0.9 - 11.9)	0.65	(0.17 - 1.26)	-	6	4.6	(0.3 - 9.0)	1.04	(0.28 - 2.01)	-
Leukaemia	3	3.7	(0.0 - 7.8)	0.35	(0.03 - 0.81)	V	5	3.9	(0.0 - 7.9)	0.78	(0.17 - 1.60)	-
Pancreas	4	3.2	(0.0 - 6.9)	0.63	(0.10 - 1.38)	-	8	4.4	(0.5 - 8.2)	1.02	(0.36 - 1.83)	-
Urinary bladder	9	8.0	(2.4 - 13.5)	0.87	(0.33 - 1.52)	-	3	1.8	(0.0 - 4.4)	0.69	(0.06 - 1.62)	-*
Stomach	8	5.7	(1.4 - 9.9)	0.94	(0.33 - 1.70)	-	6	4.6	(0.2 - 9.0)	1.12	(0.30 - 2.18)	-
Corpus uteri	0	-	-	-	-	.	5	5.9	(0.4 - 11.4)	0.51	(0.11 - 1.05)	-
Brain	6	6.5	(1.0 - 12.0)	1.22	(0.33 - 2.38)	-	4	2.8	(0.0 - 5.9)	1.03	(0.16 - 2.25)	-*
Lip	7	7.4	(1.5 - 13.3)	1.40	(0.44 - 2.61)	-	2	2.3	(0.0 - 5.7)	0.69	(0.01 - 1.91)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	11	9.2	(3.0 - 15.3)	1.27	(0.55 - 2.12)	-
Other lymphohaematopoietic	5	4.5	(0.1 - 8.9)	0.99	(0.22 - 2.03)	-	5	2.5	(0.0 - 5.3)	1.19	(0.26 - 2.44)	-*
Oesophagus	4	2.4	(0.0 - 4.9)	0.75	(0.12 - 1.65)	-	5	3.3	(0.0 - 6.8)	1.67	(0.36 - 3.42)	-*
Thyroid gland	1	1.5	(0.0 - 4.6)	0.59	(0.00 - 2.16)	-*	3	4.0	(0.0 - 9.2)	0.65	(0.05 - 1.51)	-
Myeloma/plasma cell tumours	3	3.3	(0.0 - 7.3)	0.74	(0.06 - 1.72)	-*	2	0.7	(0.0 - 1.6)	0.59	(0.01 - 1.63)	-*
Cervix uteri	0	-	-	-	-	.	5	6.0	(0.7 - 11.4)	0.82	(0.18 - 1.68)	-
Non-mel. skin (exc BCC/SCC)	7	6.1	(1.2 - 10.9)	1.65	(0.52 - 3.08)	-*	5	5.5	(0.3 - 10.7)	1.84	(0.40 - 3.76)	-*
Mesothelioma	4	3.7	(0.0 - 7.7)	0.83	(0.13 - 1.82)	-	1	0.4	(0.0 - 1.2)	1.30	(0.00 - 4.79)	-*
Liver & intrahepatic bile duct	4	2.6	(0.0 - 5.3)	1.17	(0.18 - 2.56)	-*	2	1.1	(0.0 - 2.9)	1.39	(0.02 - 3.89)	-*
Testis	3	3.8	(0.0 - 8.2)	0.87	(0.07 - 2.03)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	2	2.0	(0.0 - 4.9)	0.95	(0.01 - 2.65)	-*	4	1.2	(0.0 - 2.4)	1.48	(0.23 - 3.25)	-*
Larynx	3	2.4	(0.0 - 5.4)	0.88	(0.07 - 2.06)	-*	0	-	-	0	n/a	-
Tongue	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Connective & soft tissues	2	3.8	(0.0 - 9.1)	1.31	(0.02 - 3.64)	-*	2	1.6	(0.0 - 4.2)	2.01	(0.03 - 5.60)	-*
Tonsil & oropharynx	1	0.6	(0.0 - 1.7)	0.62	(0.00 - 2.30)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	1.2	(0.0 - 3.6)	0.45	(0.00 - 1.65)	-*
Small intestine	0	-	-	0	n/a	-	1	1.5	(0.0 - 4.4)	1.27	(0.00 - 4.69)	-*
Eye & lacrimal gland	2	2.9	(0.0 - 6.8)	2.02	(0.03 - 5.64)	-*	0	-	-	0	n/a	-
Major Salivary Gland	2	1.5	(0.0 - 3.6)	2.20	(0.03 - 6.13)	-*	1	1.2	(0.0 - 3.6)	1.50	(0.00 - 5.52)	-*
Anus	1	0.5	(0.0 - 1.4)	1.61	(0.00 - 5.95)	-*	1	1.2	(0.0 - 3.7)	1.08	(0.00 - 3.98)	-*
Mouth, other & unspecified	1	1.3	(0.0 - 3.9)	1.16	(0.00 - 4.28)	-*	2	0.5	(0.0 - 1.3)	3.49	(0.04 - 9.73)	-*
Floor of mouth	0	-	-	0	n/a	-	1	0.3	(0.0 - 0.8)	2.26	(0.00 - 8.35)	-*
Bones, joints & articular cart.	1	1.3	(0.0 - 3.8)	2.15	(0.00 - 7.91)	-*	1	1.5	(0.0 - 4.4)	1.78	(0.00 - 6.56)	-*
Pyriform sinus & hypopharynx	1	1.3	(0.0 - 3.8)	1.06	(0.00 - 3.91)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.5	(0.0 - 1.4)	1.55	(0.00 - 5.72)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	1.2	(0.0 - 3.7)	1.69	(0.00 - 6.22)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	1.3	(0.0 - 3.8)	2.30	(0.00 - 8.47)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	0	n/a	-	0	-	-	-	-	.
Gum	0	-	-	-	-	.	1	0.3	(0.0 - 0.8)	3.53	(0.00 - 13.02)	-*
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	332	338.9	(299.7 - 378.0)	1.00	(0.90 - 1.12)	-	306	265.7	(231.1 - 300.4)	1.04	(0.93 - 1.17)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Canning (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	0.3	(0.0 - 0.9)	0.81	(0.00 - 3.00)	-*	212	82.8	(71.3 - 94.3)	0.99	(0.86 - 1.13)	-
Colorectal cancer	87	36.7	(28.8 - 44.5)	0.82	(0.66 - 1.01)	-	86	27.9	(21.6 - 34.1)	0.97	(0.78 - 1.21)	-
Prostate gland	163	71.6	(60.4 - 82.8)	0.94	(0.81 - 1.10)	-	0	-	-	-	-	.
Melanoma (skin)	93	41.1	(32.6 - 49.6)	0.94	(0.77 - 1.16)	-	72	29.3	(22.3 - 36.3)	0.93	(0.74 - 1.18)	-
Lung, bronchus & trachea	106	44.3	(35.6 - 52.9)	1.15	(0.94 - 1.39)	-	64	20.5	(15.3 - 25.8)	1.20	(0.93 - 1.54)	-
Lymphoma	41	18.3	(12.6 - 24.0)	1.17	(0.81 - 1.55)	-	33	12.2	(7.7 - 16.7)	1.17	(0.78 - 1.60)	-
Unknown primary site	18	8.0	(4.3 - 11.8)	0.68	(0.37 - 1.02)	-	25	7.8	(4.5 - 11.2)	1.15	(0.71 - 1.64)	-
Kidney & other renal tract	26	11.5	(7.0 - 16.0)	1.16	(0.72 - 1.64)	-	12	4.7	(1.9 - 7.4)	0.86	(0.39 - 1.41)	-
Leukaemia	25	12.0	(6.9 - 17.1)	1.18	(0.72 - 1.68)	-	10	3.6	(1.2 - 6.0)	0.69	(0.28 - 1.18)	-
Pancreas	21	8.9	(5.0 - 12.8)	1.42	(0.82 - 2.08)	-	16	4.8	(2.3 - 7.4)	0.99	(0.52 - 1.54)	-
Urinary bladder	22	8.5	(4.8 - 12.2)	1.03	(0.61 - 1.50)	-	12	2.8	(1.1 - 4.5)	1.45	(0.66 - 2.38)	-
Stomach	21	9.3	(5.3 - 13.4)	1.10	(0.64 - 1.61)	-	11	3.3	(1.2 - 5.5)	1.00	(0.44 - 1.68)	-
Corpus uteri	0	-	-	-	-	.	21	7.3	(4.0 - 10.6)	0.88	(0.51 - 1.29)	-
Brain	18	8.4	(4.4 - 12.5)	1.36	(0.75 - 2.05)	-	9	3.5	(1.2 - 5.9)	0.93	(0.36 - 1.62)	-
Lip	13	5.4	(2.4 - 8.3)	0.97	(0.46 - 1.56)	-	10	3.4	(1.1 - 5.6)	1.53	(0.63 - 2.62)	-
Ovary & uterine adnexa	0	-	-	-	-	.	14	5.0	(2.2 - 7.7)	0.68	(0.34 - 1.08)	-
Other lymphohaematopoietic	8	3.2	(1.0 - 5.5)	0.79	(0.28 - 1.43)	-	9	2.1	(0.6 - 3.5)	1.11	(0.43 - 1.94)	-
Oesophagus	15	5.8	(2.8 - 8.8)	1.24	(0.63 - 1.94)	-	6	2.0	(0.3 - 3.7)	0.96	(0.26 - 1.87)	-
Thyroid gland	5	2.2	(0.2 - 4.1)	1.02	(0.22 - 2.08)	-	10	4.3	(1.6 - 6.9)	0.74	(0.30 - 1.26)	-
Myeloma/plasma cell tumours	11	4.2	(1.6 - 6.7)	1.22	(0.53 - 2.03)	-	6	1.9	(0.3 - 3.5)	0.82	(0.22 - 1.59)	-
Cervix uteri	0	-	-	-	-	.	18	7.7	(4.0 - 11.4)	1.08	(0.59 - 1.63)	-
Non-mel. skin (exc BCC/SCC)	7	2.9	(0.7 - 5.1)	0.74	(0.23 - 1.39)	-	8	2.2	(0.6 - 3.8)	1.35	(0.47 - 2.43)	-
Mesothelioma	12	5.1	(2.2 - 8.0)	1.09	(0.50 - 1.79)	-	3	1.1	(0.0 - 2.4)	1.68	(0.14 - 3.91)	-*
Liver & intrahepatic bile duct	6	2.4	(0.4 - 4.4)	0.73	(0.20 - 1.41)	-	3	1.0	(0.0 - 2.3)	0.94	(0.08 - 2.20)	-*
Testis	5	2.4	(0.3 - 4.5)	0.45	(0.10 - 0.91)	V	0	-	-	-	-	.
Gallbladder & bile ducts	3	1.1	(0.0 - 2.3)	0.61	(0.05 - 1.43)	-	9	2.6	(0.8 - 4.4)	1.64	(0.63 - 2.87)	-
Larynx	6	2.5	(0.4 - 4.5)	0.69	(0.19 - 1.33)	-	2	0.7	(0.0 - 1.7)	1.46	(0.02 - 4.05)	-*
Tongue	3	1.3	(0.0 - 2.7)	0.56	(0.05 - 1.32)	-	2	1.0	(0.0 - 2.4)	0.95	(0.01 - 2.64)	-*
Connective & soft tissues	6	2.7	(0.5 - 4.8)	1.46	(0.39 - 2.83)	-*	1	0.4	(0.0 - 1.2)	0.36	(0.00 - 1.34)	-*
Tonsil & oropharynx	1	0.4	(0.0 - 1.2)	0.23	(0.00 - 0.85)	V*	0	-	-	0	n/a	-
Vulva/vagina	0	-	-	-	-	.	2	0.4	(0.0 - 0.9)	0.41	(0.01 - 1.14)	-
Small intestine	1	0.4	(0.0 - 1.2)	0.41	(0.00 - 1.53)	-*	0	-	-	0	n/a	-
Eye & lacrimal gland	2	1.2	(0.0 - 2.9)	0.79	(0.01 - 2.21)	-*	1	0.5	(0.0 - 1.6)	0.77	(0.00 - 2.84)	-*
Major Salivary Gland	3	1.2	(0.0 - 2.5)	1.43	(0.12 - 3.34)	-*	1	0.4	(0.0 - 1.1)	0.62	(0.00 - 2.29)	-*
Anus	1	0.4	(0.0 - 1.2)	0.64	(0.00 - 2.34)	-*	1	0.4	(0.0 - 1.2)	0.47	(0.00 - 1.73)	-*
Mouth, other & unspecified	3	1.2	(0.0 - 2.7)	1.31	(0.11 - 3.07)	-*	0	-	-	0	n/a	-
Floor of mouth	2	1.1	(0.0 - 2.6)	0.76	(0.01 - 2.11)	-*	1	0.2	(0.0 - 0.6)	1.10	(0.00 - 4.04)	-*
Bones, joints & articular cart.	1	0.5	(0.0 - 1.4)	0.70	(0.00 - 2.60)	-*	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	2	1.0	(0.0 - 2.3)	1.27	(0.02 - 3.54)	-*	0	-	-	0	n/a	-
Peritoneum & retroperitoneum	0	-	-	0	n/a	-	2	0.6	(0.0 - 1.4)	1.41	(0.02 - 3.93)	-*
Adrenal & other endocrine	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Nasopharynx	2	1.0	(0.0 - 2.3)	1.70	(0.02 - 4.72)	-*	2	1.0	(0.0 - 2.4)	6.09	(0.08 - 16.96)	-*
Pharynx, other & ill-def.	1	0.3	(0.0 - 0.9)	0.97	(0.00 - 3.57)	-*	1	0.5	(0.0 - 1.6)	4.89	(0.00 - 18.05)	-*
Penis & other male genital	4	1.8	(0.0 - 3.5)	3.33	(0.51 - 7.29)	-*	0	-	-	-	-	.
Gum	1	0.6	(0.0 - 1.6)	1.77	(0.00 - 6.55)	-*	1	0.4	(0.0 - 1.1)	2.02	(0.00 - 7.45)	-*
Kaposi sarcoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	1	0.4	(0.0 - 1.2)	3.04	(0.00 - 11.23)	-*
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	766	331.1	(307.3 - 354.9)	0.97	(0.90 - 1.04)	-	697	250.7	(231.2 - 270.2)	0.99	(0.92 - 1.07)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Capel (S) - Pt A 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	60.2	(5.6 - 114.7)	0.80	(0.17 - 1.63)	-
Colorectal cancer	4	55.0	(0.0 - 111.3)	1.41	(0.22 - 3.09)	-*	1	22.0	(0.0 - 64.9)	0.56	(0.00 - 2.07)	-*
Prostate gland	1	18.9	(0.0 - 55.7)	0.22	(0.00 - 0.81)	V	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	1	27.8	(0.0 - 82.1)	0.45	(0.00 - 1.66)	-*
Lung, bronchus & trachea	2	28.3	(0.0 - 69.4)	0.86	(0.01 - 2.39)	-*	0	-	-	0	n/a	-
Lymphoma	1	17.3	(0.0 - 51.2)	0.98	(0.00 - 3.60)	-*	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	0	-	-	-	-	.
Kidney & other renal tract	1	11.7	(0.0 - 34.5)	1.58	(0.00 - 5.81)	-*	0	-	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	1	19.2	(0.0 - 56.2)	8.01	(0.00 - 29.57)	-*
Stomach	1	15.9	(0.0 - 46.9)	2.04	(0.00 - 7.52)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	2	27.0	(0.0 - 65.8)	4.57	(0.06 - 12.72)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	1	22.0	(0.0 - 64.9)	7.67	(0.00 - 28.31)	-*
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	12	174.0	(72.8 - 275.2)	0.56	(0.25 - 0.91)	V	9	151.1	(46.9 - 255.3)	0.51	(0.20 - 0.90)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Capel (S) - Pt B 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	8	58.5	(17.5 - 99.6)	0.72	(0.25 - 1.29)	-
Colorectal cancer	4	28.2	(0.4 - 56.1)	0.61	(0.09 - 1.34)	-	7	57.7	(14.5 - 100.9)	1.78	(0.56 - 3.32)	-*
Prostate gland	11	78.6	(31.7 - 125.4)	1.03	(0.45 - 1.71)	-	0	-	-	-	-	.
Melanoma (skin)	3	22.7	(0.0 - 48.5)	0.51	(0.04 - 1.18)	-	5	37.9	(4.3 - 71.5)	1.27	(0.28 - 2.60)	-*
Lung, bronchus & trachea	6	38.5	(7.4 - 69.7)	1.06	(0.29 - 2.05)	-	4	35.5	(0.5 - 70.5)	1.68	(0.26 - 3.68)	-*
Lymphoma	0	-	-	0	n/a	-	3	24.4	(0.0 - 52.4)	2.28	(0.18 - 5.32)	-*
Unknown primary site	1	6.4	(0.0 - 18.9)	0.62	(0.00 - 2.28)	-*	0	-	-	0	n/a	-
Kidney & other renal tract	1	6.4	(0.0 - 18.9)	0.73	(0.00 - 2.69)	-*	0	-	-	0	n/a	-
Leukaemia	0	-	-	0	n/a	-	2	24.3	(0.0 - 59.6)	2.88	(0.04 - 8.03)	-*
Pancreas	1	8.4	(0.0 - 25.0)	1.11	(0.00 - 4.09)	-*	1	9.9	(0.0 - 29.4)	1.45	(0.00 - 5.37)	-*
Urinary bladder	0	-	-	0	n/a	-	1	8.4	(0.0 - 24.7)	3.07	(0.00 - 11.31)	-*
Stomach	1	8.4	(0.0 - 25.0)	0.86	(0.00 - 3.16)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	7.4	(0.0 - 21.9)	0.85	(0.00 - 3.14)	-*
Brain	3	21.1	(0.0 - 45.1)	3.74	(0.30 - 8.73)	-*	0	-	-	-	-	.
Lip	1	7.0	(0.0 - 20.6)	1.23	(0.00 - 4.53)	-*	1	7.3	(0.0 - 21.6)	3.30	(0.00 - 12.17)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	17.5	(0.0 - 51.7)	1.40	(0.00 - 5.15)	-*
Myeloma/plasma cell tumours	1	7.9	(0.0 - 23.5)	1.80	(0.00 - 6.64)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	6.6	(0.0 - 19.6)	1.15	(0.00 - 4.23)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	1	16.2	(0.0 - 47.8)	4.10	(0.00 - 15.13)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	6.3	(0.0 - 18.5)	4.53	(0.00 - 16.70)	-*
Small intestine	0	-	-	-	-	.	1	6.3	(0.0 - 18.5)	12.28	(0.00 - 45.28)	-*
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	1	7.9	(0.0 - 23.5)	7.87	(0.00 - 29.04)	-*	0	-	-	-	-	.
Anus	1	7.0	(0.0 - 20.6)	10.46	(0.00 - 38.57)	-*	0	-	-	-	-	.
Mouth, other & unspecified	1	7.9	(0.0 - 23.5)	7.13	(0.00 - 26.29)	-*	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	1	7.3	(0.0 - 21.6)	24.92	(0.00 - 91.92)	-*
Bones, joints & articular cart.	0	-	-	-	-	.	1	6.6	(0.0 - 19.5)	12.26	(0.00 - 45.21)	-*
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	1	6.1	(0.0 - 17.9)	27.52	(0.00 - 101.53)	-*	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	38	278.6	(188.2 - 369.1)	0.79	(0.54 - 1.06)	-	39	321.9	(217.5 - 426.3)	1.15	(0.79 - 1.53)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Carnamah (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	248.9	(29.9 - 467.8)	2.99	(0.65 - 6.13)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	3	103.7	(0.0 - 220.8)	1.78	(0.14 - 4.15)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	1	41.7	(0.0 - 121.6)	3.92	(0.00 - 14.47)	-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	1	30.5	(0.0 - 90.1)	5.03	(0.00 - 18.57)	-*	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	1	35.1	(0.0 - 103.3)	11.19	(0.00 - 41.29)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	31.4	(0.0 - 92.8)	6.58	(0.00 - 24.28)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	6	210.9	(43.3 - 378.5)	0.75	(0.20 - 1.45)	-	6	280.3	(52.9 - 507.7)	1.14	(0.31 - 2.22)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Carnarvon (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	12	70.5	(30.0 - 111.0)	0.80	(0.37 - 1.32)	-
Colorectal cancer	7	31.3	(7.8 - 54.7)	0.70	(0.22 - 1.30)	-	5	29.3	(2.8 - 55.7)	0.90	(0.20 - 1.85)	-
Prostate gland	9	42.9	(14.7 - 71.2)	0.55	(0.21 - 0.96)	V	0	-	-	-	-	.
Melanoma (skin)	5	21.9	(2.4 - 41.4)	0.55	(0.12 - 1.12)	-	9	53.3	(17.4 - 89.2)	1.62	(0.62 - 2.84)	-
Lung, bronchus & trachea	11	54.6	(22.2 - 86.9)	1.26	(0.55 - 2.10)	-	2	10.5	(0.0 - 26.0)	0.60	(0.01 - 1.66)	-*
Lymphoma	2	8.8	(0.0 - 21.0)	0.62	(0.01 - 1.72)	-*	1	5.4	(0.0 - 16.1)	0.54	(0.00 - 1.98)	-*
Unknown primary site	2	7.7	(0.0 - 18.4)	0.80	(0.01 - 2.24)	-*	2	10.2	(0.0 - 24.4)	1.53	(0.02 - 4.26)	-*
Kidney & other renal tract	1	3.3	(0.0 - 9.7)	0.48	(0.00 - 1.76)	-*	0	-	-	0	n/a	-
Leukaemia	0	-	-	0	n/a	-	2	13.8	(0.0 - 33.6)	1.96	(0.02 - 5.47)	-*
Pancreas	1	3.9	(0.0 - 11.6)	0.71	(0.00 - 2.63)	-*	0	-	-	0	n/a	-
Urinary bladder	4	16.9	(0.1 - 33.8)	1.99	(0.31 - 4.36)	-*	2	12.5	(0.0 - 30.0)	4.20	(0.05 - 11.71)	-*
Stomach	6	27.3	(5.0 - 49.5)	3.34	(0.90 - 6.50)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	2	12.2	(0.0 - 29.3)	1.26	(0.02 - 3.50)	-*
Brain	3	13.3	(0.0 - 28.3)	2.42	(0.20 - 5.66)	-*	0	-	-	0	n/a	-
Lip	2	9.0	(0.0 - 21.5)	1.59	(0.02 - 4.44)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	12.6	(0.0 - 30.2)	1.47	(0.02 - 4.08)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	1	3.9	(0.0 - 11.6)	0.88	(0.00 - 3.26)	-*	0	-	-	-	-	.
Thyroid gland	1	3.9	(0.0 - 11.6)	2.20	(0.00 - 8.13)	-*	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	2	10.5	(0.0 - 25.2)	1.63	(0.02 - 4.55)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	1	5.1	(0.0 - 15.2)	2.59	(0.00 - 9.54)	-*
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	1	5.3	(0.0 - 15.6)	4.75	(0.00 - 17.52)	-*
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	5.4	(0.0 - 16.1)	1.21	(0.00 - 4.46)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	1	5.4	(0.0 - 16.1)	8.94	(0.00 - 33.00)	-*
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	4.5	(0.0 - 13.2)	4.07	(0.00 - 15.01)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	5.4	(0.0 - 15.9)	4.48	(0.00 - 16.52)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	4.5	(0.0 - 13.4)	6.83	(0.00 - 25.21)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	59	268.6	(199.7 - 337.5)	0.80	(0.61 - 1.03)	-	44	256.7	(179.3 - 334.1)	0.93	(0.66 - 1.23)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Chapman Valley (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	70.5	(0.0 - 149.9)	1.26	(0.10 - 2.95)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	-
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	2	60.0	(0.0 - 145.0)	1.82	(0.02 - 5.08)	-*	0	-	-	-	-	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	-
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	-
Kidney & other renal tract	0	-	-	-	-	.	1	39.5	(0.0 - 116.6)	7.92	(0.00 - 29.22)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	-
Pancreas	0	-	-	-	-	.	0	-	-	-	-	-
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	-
Stomach	0	-	-	-	-	.	0	-	-	-	-	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	-
Brain	0	-	-	-	-	.	0	-	-	-	-	-
Lip	0	-	-	-	-	.	0	-	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	1	24.4	(0.0 - 72.0)	5.21	(0.00 - 19.24)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	-
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	-
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	-
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	-
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	-
Testis	0	-	-	-	-	.	0	-	-	-	-	-
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	-
Larynx	0	-	-	-	-	.	0	-	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	-
All cancers	2	60.0	(0.0 - 145.0)	0.20	(0.00 - 0.57)	V	5	134.3	(13.9 - 254.8)	0.75	(0.16 - 1.54)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Chittering (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	60.9	(6.7 - 115.0)	0.63	(0.14 - 1.29)	-
Colorectal cancer	7	56.1	(14.5 - 97.8)	1.43	(0.45 - 2.66)	-	1	10.2	(0.0 - 30.2)	0.39	(0.00 - 1.43)	-*
Prostate gland	5	44.3	(5.5 - 83.1)	0.60	(0.13 - 1.22)	-	0	-	-	-	-	.
Melanoma (skin)	3	52.9	(0.0 - 120.0)	0.69	(0.06 - 1.61)	-*	3	41.1	(0.0 - 88.1)	1.13	(0.09 - 2.63)	-*
Lung, bronchus & trachea	6	50.0	(9.9 - 90.0)	1.39	(0.38 - 2.71)	-*	3	36.2	(0.0 - 77.2)	1.91	(0.15 - 4.45)	-*
Lymphoma	3	28.4	(0.0 - 61.0)	1.99	(0.16 - 4.65)	-*	1	10.2	(0.0 - 30.2)	1.15	(0.00 - 4.24)	-*
Unknown primary site	1	9.2	(0.0 - 27.1)	0.86	(0.00 - 3.18)	-*	0	-	-	0	n/a	-
Kidney & other renal tract	2	17.2	(0.0 - 41.0)	1.96	(0.02 - 5.46)	-*	1	7.8	(0.0 - 23.0)	2.20	(0.00 - 8.11)	-*
Leukaemia	1	16.5	(0.0 - 48.8)	1.10	(0.00 - 4.06)	-*	1	16.1	(0.0 - 47.2)	2.25	(0.00 - 8.30)	-*
Pancreas	0	-	-	0	n/a	-	0	-	-	-	-	.
Urinary bladder	1	9.3	(0.0 - 27.2)	1.11	(0.00 - 4.09)	-*	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	1	13.3	(0.0 - 39.3)	1.66	(0.00 - 6.14)	-*	0	-	-	-	-	.
Lip	0	-	-	0	n/a	-	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	9.4	(0.0 - 28.0)	2.11	(0.00 - 7.77)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	1	7.2	(0.0 - 21.4)	1.90	(0.00 - 7.01)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	9.5	(0.0 - 28.2)	2.57	(0.00 - 9.47)	-*	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	1	9.6	(0.0 - 28.3)	12.95	(0.00 - 47.76)	-*	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	1	7.2	(0.0 - 21.4)	17.62	(0.00 - 64.99)	-*	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	1	12.0	(0.0 - 35.6)	20.61	(0.00 - 76.05)	-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	1	7.8	(0.0 - 23.0)	110.85	(0.00 - 408.91)	-*
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	35	342.7	(220.8 - 464.7)	0.97	(0.66 - 1.32)	-	17	199.7	(103.0 - 296.4)	0.74	(0.40 - 1.13)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Claremont (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	32	66.9	(38.8 - 94.9)	0.91	(0.60 - 1.25)	-
Colorectal cancer	16	41.5	(19.5 - 63.6)	0.88	(0.46 - 1.37)	-	22	41.6	(20.6 - 62.5)	1.11	(0.66 - 1.62)	-
Prostate gland	38	98.8	(64.6 - 133.1)	1.28	(0.88 - 1.72)	-	0	-	-	-	-	.
Melanoma (skin)	24	68.7	(38.0 - 99.3)	1.70	(1.03 - 2.45)	^	21	43.7	(21.7 - 65.7)	1.72	(1.00 - 2.53)	-
Lung, bronchus & trachea	10	25.3	(7.7 - 42.8)	0.63	(0.26 - 1.07)	-	9	6.0	(1.0 - 11.0)	0.81	(0.31 - 1.42)	-
Lymphoma	4	12.7	(0.2 - 25.3)	0.73	(0.11 - 1.61)	-	3	8.1	(0.0 - 18.9)	0.56	(0.05 - 1.31)	-
Unknown primary site	5	10.2	(0.1 - 20.2)	1.02	(0.22 - 2.10)	-	7	7.9	(0.0 - 16.4)	1.18	(0.37 - 2.21)	-
Kidney & other renal tract	3	9.2	(0.0 - 21.0)	0.83	(0.07 - 1.94)	^*	5	6.0	(0.0 - 12.8)	1.91	(0.42 - 3.91)	^*
Leukaemia	3	9.5	(0.0 - 20.4)	0.90	(0.07 - 2.09)	^*	2	3.2	(0.0 - 8.6)	0.66	(0.01 - 1.84)	^*
Pancreas	4	9.0	(0.0 - 18.8)	1.62	(0.25 - 3.54)	^*	6	7.9	(0.1 - 15.6)	1.54	(0.42 - 2.99)	^*
Urinary bladder	4	9.7	(0.0 - 20.0)	0.96	(0.15 - 2.10)	^*	3	2.3	(0.0 - 5.1)	1.35	(0.11 - 3.16)	^*
Stomach	3	9.0	(0.0 - 19.9)	0.90	(0.07 - 2.10)	^*	2	3.5	(0.0 - 9.5)	0.74	(0.01 - 2.07)	^*
Corpus uteri	0	-	-	-	-	.	4	9.8	(0.0 - 20.2)	0.90	(0.14 - 1.98)	^*
Brain	2	9.1	(0.0 - 21.8)	1.07	(0.01 - 2.98)	^*	3	4.6	(0.0 - 11.3)	1.75	(0.14 - 4.08)	^*
Lip	1	1.4	(0.0 - 4.0)	0.55	(0.00 - 2.01)	^*	1	0.5	(0.0 - 1.5)	0.72	(0.00 - 2.65)	^*
Ovary & uterine adnexa	0	-	-	-	-	.	3	1.7	(0.0 - 3.9)	0.75	(0.06 - 1.74)	^*
Other lymphohaematopoietic	2	4.0	(0.0 - 10.1)	0.98	(0.01 - 2.73)	^*	1	0.4	(0.0 - 1.1)	0.47	(0.00 - 1.72)	^*
Oesophagus	1	3.9	(0.0 - 11.5)	0.48	(0.00 - 1.77)	^*	0	-	-	0	n/a	-
Thyroid gland	2	4.8	(0.0 - 12.4)	3.22	(0.04 - 8.98)	^*	1	3.3	(0.0 - 9.7)	0.54	(0.00 - 1.99)	^*
Myeloma/plasma cell tumours	2	4.4	(0.0 - 10.9)	1.24	(0.02 - 3.45)	^*	5	8.6	(0.0 - 18.2)	2.97	(0.65 - 6.09)	^*
Cervix uteri	0	-	-	-	-	.	1	2.1	(0.0 - 6.1)	0.41	(0.00 - 1.50)	^*
Non-mel. skin (exc BCC/SCC)	1	1.0	(0.0 - 3.1)	0.60	(0.00 - 2.20)	^*	5	2.0	(0.2 - 3.7)	3.74	(0.82 - 7.66)	^*
Mesothelioma	3	3.8	(0.0 - 8.1)	1.56	(0.13 - 3.64)	^*	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	1.5	(0.0 - 4.3)	0.75	(0.00 - 2.75)	^*	1	3.7	(0.0 - 11.0)	1.46	(0.00 - 5.40)	^*
Testis	3	13.8	(0.0 - 29.5)	2.61	(0.21 - 6.08)	^*	0	-	-	-	-	.
Gallbladder & bile ducts	1	5.2	(0.0 - 15.3)	1.21	(0.00 - 4.46)	^*	2	4.1	(0.0 - 9.8)	1.50	(0.02 - 4.17)	^*
Larynx	4	7.7	(0.0 - 16.4)	3.01	(0.47 - 6.61)	^*	0	-	-	-	-	.
Tongue	0	-	-	0	n/a	-	1	2.1	(0.0 - 6.1)	2.48	(0.00 - 9.14)	^*
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	3	7.0	(0.0 - 15.6)	2.84	(0.23 - 6.62)	^*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	1	14.9	(0.0 - 43.9)	2.76	(0.00 - 10.19)	^*	1	13.3	(0.0 - 39.3)	3.90	(0.00 - 14.39)	^*
Major Salivary Gland	1	5.2	(0.0 - 15.3)	2.77	(0.00 - 10.20)	^*	1	2.7	(0.0 - 8.0)	3.19	(0.00 - 11.75)	^*
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	1	3.8	(0.0 - 11.1)	3.01	(0.00 - 11.10)	^*	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	1	3.6	(0.0 - 10.7)	4.12	(0.00 - 15.19)	^*
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	140	387.9	(313.7 - 462.1)	1.08	(0.91 - 1.28)	-	146	266.4	(208.7 - 324.1)	1.09	(0.92 - 1.28)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cockburn (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	0.5	(0.0 - 1.6)	1.00	(0.00 - 3.69)	-*	175	86.3	(73.3 - 99.3)	1.04	(0.90 - 1.21)	-
Colorectal cancer	91	49.1	(39.0 - 59.3)	1.06	(0.86 - 1.31)	-	74	34.9	(26.6 - 43.1)	1.15	(0.91 - 1.45)	-
Prostate gland	115	62.8	(51.2 - 74.3)	0.82	(0.68 - 0.99)	V	0	-	-	-	-	.
Melanoma (skin)	66	33.6	(25.4 - 41.7)	0.79	(0.62 - 1.02)	-	63	32.1	(24.1 - 40.2)	1.01	(0.78 - 1.30)	-
Lung, bronchus & trachea	69	36.8	(28.0 - 45.5)	0.93	(0.73 - 1.19)	-	47	22.5	(15.8 - 29.2)	1.21	(0.87 - 1.58)	-
Lymphoma	28	13.6	(8.5 - 18.6)	0.96	(0.61 - 1.35)	-	16	7.8	(3.8 - 11.8)	0.75	(0.39 - 1.16)	-
Unknown primary site	16	8.2	(4.1 - 12.2)	0.76	(0.40 - 1.17)	-	20	7.8	(4.2 - 11.4)	1.30	(0.74 - 1.93)	-
Kidney & other renal tract	32	16.3	(10.6 - 22.0)	1.75	(1.15 - 2.40)	^	5	2.2	(0.2 - 4.1)	0.47	(0.10 - 0.97)	V
Leukaemia	21	11.5	(6.4 - 16.6)	1.20	(0.70 - 1.76)	-	11	6.4	(2.4 - 10.3)	0.98	(0.43 - 1.64)	-
Pancreas	14	7.3	(3.5 - 11.1)	1.18	(0.58 - 1.87)	-	17	7.7	(3.9 - 11.6)	1.48	(0.80 - 2.26)	-
Urinary bladder	20	10.5	(5.8 - 15.2)	1.21	(0.69 - 1.79)	-	5	2.2	(0.2 - 4.2)	0.87	(0.19 - 1.78)	-
Stomach	16	8.2	(4.2 - 12.3)	1.05	(0.55 - 1.62)	-	13	6.6	(2.9 - 10.3)	1.66	(0.79 - 2.68)	-
Corpus uteri	0	-	-	-	-	.	17	8.0	(4.1 - 12.0)	0.95	(0.51 - 1.44)	-
Brain	16	9.0	(4.5 - 13.4)	1.41	(0.74 - 2.19)	-	3	1.4	(0.0 - 3.1)	0.40	(0.03 - 0.93)	V
Lip	16	7.9	(4.0 - 11.8)	1.39	(0.73 - 2.15)	-	6	2.7	(0.4 - 4.9)	1.24	(0.33 - 2.41)	-
Ovary & uterine adnexa	0	-	-	-	-	.	14	7.1	(3.3 - 10.9)	0.90	(0.45 - 1.43)	-
Other lymphohaematopoietic	13	6.7	(3.0 - 10.4)	1.68	(0.80 - 2.71)	-	4	1.6	(0.0 - 3.2)	0.70	(0.11 - 1.53)	-
Oesophagus	14	7.4	(3.5 - 11.3)	1.45	(0.72 - 2.30)	-	6	3.0	(0.6 - 5.4)	1.35	(0.36 - 2.62)	-*
Thyroid gland	3	1.5	(0.0 - 3.3)	0.69	(0.06 - 1.61)	-*	12	6.7	(2.8 - 10.5)	1.06	(0.48 - 1.73)	-
Myeloma/plasma cell tumours	8	4.4	(1.3 - 7.4)	1.12	(0.39 - 2.01)	-	4	2.2	(0.0 - 4.3)	0.76	(0.12 - 1.66)	-
Cervix uteri	0	-	-	-	-	.	13	6.1	(2.7 - 9.5)	0.94	(0.45 - 1.51)	-
Non-mel. skin (exc BCC/SCC)	6	3.0	(0.6 - 5.5)	0.81	(0.22 - 1.58)	-	3	1.5	(0.0 - 3.3)	0.67	(0.05 - 1.57)	-*
Mesothelioma	14	7.2	(3.4 - 11.0)	1.58	(0.78 - 2.51)	-	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	13	6.7	(3.0 - 10.3)	1.94	(0.93 - 3.13)	-	4	2.4	(0.0 - 4.8)	1.66	(0.26 - 3.65)	-*
Testis	6	2.9	(0.5 - 5.2)	0.56	(0.15 - 1.10)	-	0	-	-	-	-	.
Gallbladder & bile ducts	2	1.0	(0.0 - 2.4)	0.52	(0.01 - 1.44)	-*	9	3.0	(1.0 - 5.1)	2.34	(0.90 - 4.10)	-*
Larynx	9	4.6	(1.6 - 7.6)	1.25	(0.48 - 2.19)	-	2	0.9	(0.0 - 2.3)	1.93	(0.02 - 5.38)	-*
Tongue	4	2.0	(0.0 - 3.9)	0.90	(0.14 - 1.97)	-*	2	0.9	(0.0 - 2.2)	1.27	(0.02 - 3.53)	-*
Connective & soft tissues	3	1.7	(0.0 - 3.6)	0.85	(0.07 - 1.99)	-*	1	0.5	(0.0 - 1.3)	0.46	(0.00 - 1.68)	-*
Tonsil & oropharynx	5	2.5	(0.3 - 4.8)	1.40	(0.31 - 2.87)	-*	0	-	-	0	n/a	-
Vulva/vagina	0	-	-	-	-	.	5	2.1	(0.2 - 4.0)	1.35	(0.30 - 2.77)	-*
Small intestine	5	2.6	(0.3 - 4.8)	2.56	(0.56 - 5.25)	-*	2	0.9	(0.0 - 2.1)	1.52	(0.02 - 4.25)	-*
Eye & lacrimal gland	2	1.0	(0.0 - 2.4)	0.93	(0.01 - 2.60)	-*	1	0.6	(0.0 - 1.8)	1.02	(0.00 - 3.75)	-*
Major Salivary Gland	1	0.6	(0.0 - 1.8)	0.58	(0.00 - 2.15)	-*	1	0.8	(0.0 - 2.4)	0.80	(0.00 - 2.94)	-*
Anus	1	0.5	(0.0 - 1.6)	0.76	(0.00 - 2.79)	-*	1	0.3	(0.0 - 0.8)	0.62	(0.00 - 2.28)	-*
Mouth, other & unspecified	2	0.9	(0.0 - 2.3)	1.08	(0.01 - 3.00)	-*	0	-	-	0	n/a	-
Floor of mouth	4	2.1	(0.0 - 4.2)	1.81	(0.28 - 3.97)	-*	0	-	-	0	n/a	-
Bones, joints & articular cart.	0	-	-	0	n/a	-	2	1.4	(0.0 - 3.5)	1.52	(0.02 - 4.23)	-*
Pyriform sinus & hypopharynx	3	1.5	(0.0 - 3.3)	1.53	(0.12 - 3.58)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	0	-	-	-	-	.
Peritoneum & retroperitoneum	1	0.5	(0.0 - 1.3)	1.90	(0.00 - 7.02)	-*	0	-	-	0	n/a	-
Adrenal & other endocrine	1	0.9	(0.0 - 2.7)	1.17	(0.00 - 4.32)	-*	0	-	-	0	n/a	-
Nasopharynx	1	0.5	(0.0 - 1.6)	1.04	(0.00 - 3.85)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	1	0.5	(0.0 - 1.5)	1.22	(0.00 - 4.50)	-*	0	-	-	-	-	.
Penis & other male genital	2	0.9	(0.0 - 2.1)	2.11	(0.03 - 5.88)	-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	2	0.9	(0.0 - 2.3)	3.65	(0.05 - 10.17)	-*	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	1	0.7	(0.0 - 1.9)	3.97	(0.00 - 14.66)	-*
Pleura, heart & mediastinum	0	-	-	-	-	.	1	0.5	(0.0 - 1.3)	5.07	(0.00 - 18.72)	-*
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	647	340.4	(314.1 - 366.7)	1.01	(0.93 - 1.09)	-	560	271.6	(248.6 - 294.7)	1.04	(0.96 - 1.13)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Collie (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	23	81.2	(47.2 - 115.3)	0.93	(0.56 - 1.34)	-
Colorectal cancer	21	54.4	(29.9 - 79.0)	1.40	(0.82 - 2.06)	-	15	43.3	(19.8 - 66.7)	1.41	(0.72 - 2.21)	-
Prostate gland	26	77.3	(45.5 - 109.0)	1.07	(0.67 - 1.52)	-	0	-	-	-	-	.
Melanoma (skin)	15	56.0	(26.2 - 85.7)	1.14	(0.58 - 1.79)	-	17	57.9	(28.7 - 87.1)	1.90	(1.02 - 2.91)	^
Lung, bronchus & trachea	21	73.0	(40.2 - 105.9)	1.59	(0.92 - 2.34)	-	1	1.9	(0.0 - 5.7)	0.15	(0.00 - 0.57)	V
Lymphoma	7	21.2	(4.8 - 37.5)	1.47	(0.46 - 2.74)	-	4	14.0	(0.0 - 28.0)	1.19	(0.18 - 2.60)	-*
Unknown primary site	4	10.3	(0.0 - 20.9)	1.04	(0.16 - 2.28)	-*	5	12.6	(0.4 - 24.7)	1.93	(0.42 - 3.95)	-*
Kidney & other renal tract	1	3.0	(0.0 - 9.0)	0.32	(0.00 - 1.18)	-*	2	6.3	(0.0 - 16.1)	1.20	(0.01 - 3.34)	-*
Leukaemia	8	21.2	(6.0 - 36.4)	2.71	(0.95 - 4.89)	-*	1	4.7	(0.0 - 14.0)	0.57	(0.00 - 2.10)	-*
Pancreas	1	3.0	(0.0 - 8.9)	0.48	(0.00 - 1.77)	-*	0	-	-	0	n/a	-
Urinary bladder	1	3.1	(0.0 - 9.1)	0.32	(0.00 - 1.16)	-*	1	3.8	(0.0 - 11.1)	0.99	(0.00 - 3.64)	-*
Stomach	3	12.6	(0.0 - 27.2)	1.09	(0.09 - 2.55)	-*	2	5.3	(0.0 - 13.3)	1.52	(0.02 - 4.22)	-*
Corpus uteri	0	-	-	-	-	.	3	12.1	(0.0 - 25.8)	1.07	(0.09 - 2.50)	-*
Brain	1	4.8	(0.0 - 14.1)	0.57	(0.00 - 2.11)	-*	1	3.9	(0.0 - 11.4)	0.87	(0.00 - 3.19)	-*
Lip	2	8.9	(0.0 - 22.0)	1.12	(0.01 - 3.11)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	3	6.9	(0.0 - 15.5)	1.24	(0.10 - 2.88)	-*
Other lymphohaematopoietic	1	1.8	(0.0 - 5.2)	0.66	(0.00 - 2.43)	-*	3	7.5	(0.0 - 16.7)	3.04	(0.25 - 7.09)	-*
Oesophagus	1	1.7	(0.0 - 5.2)	0.58	(0.00 - 2.13)	-*	2	6.0	(0.0 - 15.6)	2.67	(0.03 - 7.43)	-*
Thyroid gland	0	-	-	0	n/a	-	1	3.5	(0.0 - 10.5)	0.65	(0.00 - 2.40)	-*
Myeloma/plasma cell tumours	2	4.4	(0.0 - 10.6)	1.54	(0.02 - 4.29)	-*	0	-	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	4	14.5	(0.3 - 28.8)	2.06	(0.32 - 4.52)	-*
Non-mel. skin (exc BCC/SCC)	2	6.0	(0.0 - 14.3)	1.48	(0.02 - 4.12)	-*	0	-	-	0	n/a	-
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	4	16.7	(0.0 - 34.8)	10.38	(1.61 - 22.75)	^*
Testis	2	7.2	(0.0 - 17.3)	1.50	(0.02 - 4.17)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	1	3.0	(0.0 - 9.0)	1.45	(0.00 - 5.35)	-*	0	-	-	-	n/a	-
Larynx	2	3.5	(0.0 - 8.4)	1.71	(0.02 - 4.76)	-*	0	-	-	-	-	.
Tongue	1	3.0	(0.0 - 8.9)	1.43	(0.00 - 5.26)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	1	3.8	(0.0 - 11.2)	8.79	(0.00 - 32.41)	-*
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	1	2.7	(0.0 - 8.1)	3.90	(0.00 - 14.39)	-*
Mouth, other & unspecified	1	3.5	(0.0 - 10.4)	3.28	(0.00 - 12.12)	-*	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	3.8	(0.0 - 11.2)	3.09	(0.00 - 11.39)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	1	3.0	(0.0 - 9.0)	23.52	(0.00 - 86.77)	-*	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	1	5.5	(0.0 - 16.2)	28.60	(0.00 - 105.51)	-*	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	127	395.3	(322.7 - 467.9)	1.16	(0.97 - 1.38)	-	94	308.7	(242.8 - 374.6)	1.13	(0.92 - 1.39)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Coolgardie (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	96.1	(1.6 - 190.7)	0.80	(0.17 - 1.63)	-
Colorectal cancer	2	24.5	(0.0 - 59.9)	0.63	(0.01 - 1.76)	-*	0	-	-	0	n/a	-
Prostate gland	2	24.7	(0.0 - 60.6)	0.43	(0.01 - 1.19)	-	0	-	-	-	-	-
Melanoma (skin)	1	7.3	(0.0 - 21.6)	0.23	(0.00 - 0.83)	V*	2	24.0	(0.0 - 58.2)	0.71	(0.01 - 1.99)	-*
Lung, bronchus & trachea	2	31.3	(0.0 - 81.9)	0.83	(0.01 - 2.32)	-*	1	9.1	(0.0 - 27.0)	1.08	(0.00 - 3.99)	-*
Lymphoma	0	-	-	0	n/a	-	2	36.4	(0.0 - 96.6)	2.86	(0.04 - 7.97)	-*
Unknown primary site	2	10.5	(0.0 - 25.2)	2.66	(0.03 - 7.42)	-*	0	-	-	-	-	.
Kidney & other renal tract	1	4.3	(0.0 - 12.6)	1.27	(0.00 - 4.67)	-*	0	-	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	1	16.1	(0.0 - 47.5)	2.01	(0.00 - 7.42)	-*	0	-	-	-	-	.
Stomach	1	7.3	(0.0 - 21.6)	1.82	(0.00 - 6.73)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	0	-	-	0	n/a	-	1	9.1	(0.0 - 27.0)	3.43	(0.00 - 12.64)	-*
Lip	0	-	-	0	n/a	-	1	27.6	(0.0 - 81.5)	6.68	(0.00 - 24.63)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	7.3	(0.0 - 21.6)	2.93	(0.00 - 10.81)	-*	0	-	-	-	-	.
Thyroid gland	1	7.1	(0.0 - 21.0)	3.48	(0.00 - 12.85)	-*	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	2	24.9	(0.0 - 59.9)	2.88	(0.04 - 8.03)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	1	6.3	(0.0 - 18.8)	1.14	(0.00 - 4.20)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	1	10.0	(0.0 - 29.6)	5.02	(0.00 - 18.51)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	1	27.6	(0.0 - 81.5)	164.58	(0.00 - 607.13)	-*
Nasal cavity, sinuses, int. ear	1	5.9	(0.0 - 17.6)	15.92	(0.00 - 58.72)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	1	9.8	(0.0 - 29.1)	23.50	(0.00 - 86.69)	-*
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	17	162.6	(74.2 - 251.1)	0.65	(0.35 - 0.99)	V	16	264.7	(117.6 - 411.8)	0.87	(0.46 - 1.35)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Coorow (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	95.3	(1.5 - 189.1)	1.14	(0.18 - 2.50)	-*
Colorectal cancer	3	60.9	(0.0 - 129.8)	1.31	(0.11 - 3.06)	-*	2	47.9	(0.0 - 113.9)	1.57	(0.02 - 4.38)	-*
Prostate gland	3	65.9	(0.0 - 140.1)	0.79	(0.06 - 1.84)	-*	0	-	-	-	-	.
Melanoma (skin)	5	108.8	(12.6 - 204.9)	2.34	(0.51 - 4.79)	-*	1	24.8	(0.0 - 73.3)	0.79	(0.00 - 2.90)	-*
Lung, bronchus & trachea	1	17.1	(0.0 - 50.5)	0.50	(0.00 - 1.85)	-*	1	26.7	(0.0 - 78.8)	1.31	(0.00 - 4.82)	-*
Lymphoma	2	39.0	(0.0 - 93.3)	2.71	(0.03 - 7.55)	-*	2	48.3	(0.0 - 114.9)	4.71	(0.06 - 13.13)	-*
Unknown primary site	2	35.6	(0.0 - 84.9)	3.61	(0.05 - 10.07)	-*	1	26.1	(0.0 - 77.0)	3.41	(0.00 - 12.56)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	1	15.9	(0.0 - 47.1)	2.25	(0.00 - 8.29)	-*	1	10.9	(0.0 - 31.9)	4.40	(0.00 - 16.24)	-*
Pancreas	1	20.3	(0.0 - 60.1)	3.14	(0.00 - 11.58)	-*	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	1	22.7	(0.0 - 66.2)	9.29	(0.00 - 34.28)	-*
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	4	71.4	(1.7 - 141.1)	15.67	(2.42 - 34.34)	^*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	2	34.7	(0.0 - 82.5)	10.12	(0.13 - 28.19)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	21.9	(0.0 - 64.7)	16.66	(0.00 - 61.46)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	25	491.5	(300.0 - 683.0)	1.47	(0.91 - 2.10)	-	13	302.6	(136.7 - 468.6)	1.19	(0.57 - 1.93)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Corrigin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	91.1	(1.9 - 180.2)	0.98	(0.15 - 2.16)	-*
Colorectal cancer	2	46.0	(0.0 - 109.8)	0.82	(0.01 - 2.29)	-*	3	41.8	(0.0 - 95.1)	1.60	(0.13 - 3.73)	-*
Prostate gland	6	114.1	(19.4 - 208.7)	1.51	(0.41 - 2.94)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	2	17.4	(0.0 - 41.3)	1.41	(0.02 - 3.94)	-*
Lung, bronchus & trachea	1	25.0	(0.0 - 73.8)	0.47	(0.00 - 1.75)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	1	6.8	(0.0 - 19.9)	2.03	(0.00 - 7.50)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	3	67.5	(0.0 - 143.7)	10.72	(0.86 - 25.02)	-*	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	23.8	(0.0 - 70.4)	2.40	(0.00 - 8.87)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	27.6	(0.0 - 81.7)	4.33	(0.00 - 15.96)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	21.7	(0.0 - 64.1)	8.29	(0.00 - 30.59)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	12	252.5	(107.6 - 397.5)	0.68	(0.31 - 1.12)	-	13	230.2	(94.7 - 365.7)	0.93	(0.44 - 1.50)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cottesloe (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	32	118.4	(75.3 - 161.5)	1.28	(0.84 - 1.75)	-
Colorectal cancer	18	63.1	(32.7 - 93.4)	1.35	(0.74 - 2.04)	-	7	10.1	(1.5 - 18.6)	0.57	(0.18 - 1.07)	-
Prostate gland	17	60.3	(30.7 - 89.8)	0.78	(0.42 - 1.20)	-	0	-	-	-	-	.
Melanoma (skin)	19	66.7	(35.2 - 98.2)	1.68	(0.94 - 2.51)	-	15	56.2	(24.7 - 87.6)	1.68	(0.86 - 2.63)	-
Lung, bronchus & trachea	7	22.7	(4.9 - 40.6)	0.60	(0.19 - 1.13)	-	6	7.7	(0.7 - 14.6)	0.84	(0.23 - 1.63)	-
Lymphoma	7	25.2	(5.8 - 44.5)	1.68	(0.53 - 3.13)	-*	4	10.6	(0.0 - 21.4)	1.12	(0.17 - 2.45)	-*
Unknown primary site	3	8.7	(0.0 - 19.4)	0.86	(0.07 - 2.01)	-*	3	6.9	(0.0 - 17.0)	0.91	(0.07 - 2.12)	-*
Kidney & other renal tract	3	7.2	(0.0 - 15.7)	1.10	(0.09 - 2.57)	-*	1	5.0	(0.0 - 14.8)	0.57	(0.00 - 2.12)	-*
Leukaemia	1	2.2	(0.0 - 6.6)	0.40	(0.00 - 1.48)	-*	4	28.3	(0.0 - 65.6)	2.13	(0.33 - 4.68)	-*
Pancreas	0	-	-	0	n/a	-	2	1.8	(0.0 - 4.4)	0.86	(0.01 - 2.39)	-*
Urinary bladder	4	16.2	(0.0 - 32.6)	1.39	(0.21 - 3.04)	-*	3	5.7	(0.0 - 13.1)	2.37	(0.19 - 5.54)	-*
Stomach	1	3.9	(0.0 - 11.6)	0.41	(0.00 - 1.53)	-*	2	3.6	(0.0 - 9.3)	1.27	(0.02 - 3.54)	-*
Corpus uteri	0	-	-	-	-	.	5	14.1	(0.0 - 28.3)	1.67	(0.37 - 3.43)	-*
Brain	2	6.1	(0.0 - 15.0)	1.33	(0.02 - 3.70)	-*	0	-	-	0	n/a	-
Lip	1	4.5	(0.0 - 13.3)	0.66	(0.00 - 2.42)	-*	4	15.5	(0.0 - 32.0)	4.55	(0.70 - 9.96)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	1	0.9	(0.0 - 2.7)	0.38	(0.00 - 1.40)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	4	7.0	(0.0 - 14.9)	3.25	(0.50 - 7.12)	-*
Oesophagus	1	3.9	(0.0 - 11.6)	0.66	(0.00 - 2.43)	-*	0	-	-	0	n/a	-
Thyroid gland	0	-	-	0	n/a	-	1	3.8	(0.0 - 11.1)	0.68	(0.00 - 2.52)	-*
Myeloma/plasma cell tumours	2	5.6	(0.0 - 13.9)	1.71	(0.02 - 4.77)	-*	0	-	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	4	13.0	(0.0 - 26.3)	3.30	(0.51 - 7.23)	-*	0	-	-	0	n/a	-
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	3	11.1	(0.0 - 23.6)	2.99	(0.24 - 6.97)	-*	0	-	-	-	-	.
Testis	1	3.2	(0.0 - 9.5)	0.89	(0.00 - 3.29)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Larynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Tongue	1	3.2	(0.0 - 9.5)	1.60	(0.00 - 5.89)	-*	2	5.9	(0.0 - 15.9)	7.35	(0.09 - 20.47)	-*
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	1	2.4	(0.0 - 7.0)	2.01	(0.00 - 7.41)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	3.8	(0.0 - 11.1)	5.70	(0.00 - 21.03)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	2.4	(0.0 - 7.0)	5.27	(0.00 - 19.45)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	2.2	(0.0 - 6.6)	7.69	(0.00 - 28.38)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	1	3.5	(0.0 - 10.2)	51.51	(0.00 - 190.03)	-*
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	98	333.8	(265.4 - 402.2)	1.01	(0.83 - 1.24)	-	98	308.5	(234.1 - 382.9)	1.10	(0.90 - 1.35)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cranbrook (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	53.9	(0.0 - 136.9)	0.72	(0.01 - 2.01)	-*
Colorectal cancer	3	92.2	(0.0 - 195.7)	1.42	(0.11 - 3.32)	-*	1	39.0	(0.0 - 114.8)	0.96	(0.00 - 3.53)	-*
Prostate gland	3	54.7	(0.0 - 115.1)	0.87	(0.07 - 2.03)	-*	0	-	-	-	-	.
Melanoma (skin)	2	50.3	(0.0 - 120.2)	1.11	(0.01 - 3.08)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	3	78.0	(0.0 - 169.6)	9.04	(0.73 - 21.10)	-*
Unknown primary site	0	-	-	0	n/a	-	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	1	40.4	(0.0 - 119.2)	5.83	(0.00 - 21.50)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	22.2	(0.0 - 65.7)	6.16	(0.00 - 22.71)	-*	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	13.5	(0.0 - 39.6)	16.76	(0.00 - 61.82)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	1	18.0	(0.0 - 53.2)	23.44	(0.00 - 86.47)	-*	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	1	49.7	(0.0 - 146.9)	44.11	(0.00 - 162.73)	-*	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	11	287.1	(108.7 - 465.4)	0.72	(0.31 - 1.20)	-	8	224.8	(58.2 - 391.4)	0.92	(0.32 - 1.66)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cuballing (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	1	38.2	(0.0 - 112.9)	0.84	(0.00 - 3.08)	-*	0	-	-	0	n/a	-
Prostate gland	2	63.5	(0.0 - 152.0)	0.99	(0.01 - 2.77)	-*	0	-	-	-	-	.
Melanoma (skin)	2	77.0	(0.0 - 182.9)	1.80	(0.02 - 5.01)	-*	1	42.0	(0.0 - 123.9)	1.47	(0.00 - 5.41)	-*
Lung, bronchus & trachea	1	38.2	(0.0 - 112.9)	0.98	(0.00 - 3.61)	-*	0	-	-	-	-	.
Lymphoma	1	27.4	(0.0 - 80.9)	2.63	(0.00 - 9.70)	-*	1	34.2	(0.0 - 100.9)	4.27	(0.00 - 15.77)	-*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	1	36.1	(0.0 - 106.6)	3.95	(0.00 - 14.58)	-*	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	1	75.0	(0.0 - 220.2)	8.54	(0.00 - 31.51)	-*
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	1	36.1	(0.0 - 106.6)	10.49	(0.00 - 38.71)	-*	0	-	-	-	-	.
Oesophagus	1	36.1	(0.0 - 106.6)	7.55	(0.00 - 27.84)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	36.5	(0.0 - 107.8)	8.16	(0.00 - 30.10)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	1	48.8	(0.0 - 143.2)	88.03	(0.00 - 324.75)	-*
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	10	352.8	(136.9 - 568.7)	1.13	(0.47 - 1.94)	-	5	236.4	(21.4 - 451.4)	0.83	(0.18 - 1.69)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cue (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	114.3	(0.0 - 335.1)	1.26	(0.00 - 4.64)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	1	133.3	(0.0 - 385.8)	1.28	(0.00 - 4.73)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	-	.
Lung, bronchus & trachea	3	339.9	(0.0 - 727.8)	7.49	(0.60 - 17.49)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	1	133.3	(0.0 - 385.8)	8.73	(0.00 - 32.21)	-*	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	1	166.7	(0.0 - 464.9)	11.38	(0.00 - 41.99)	-*	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	83.3	(0.0 - 232.4)	18.26	(0.00 - 67.34)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	7	856.5	(255.0 - 1,458.1)	1.79	(0.56 - 3.34)	-*	1	114.3	(0.0 - 335.1)	0.41	(0.00 - 1.52)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

A-72 Cue (S) 1998-2002: Cancer incidence

Cancer in Western Australia, 1998-2002: incidence and mortality by Statistical Local Area

SLA: Cunderdin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	89.5	(0.0 - 184.1)	1.05	(0.16 - 2.31)	-*
Colorectal cancer	2	35.5	(0.0 - 85.0)	0.84	(0.01 - 2.35)	-*	2	18.3	(0.0 - 44.3)	1.18	(0.01 - 3.29)	-*
Prostate gland	2	37.4	(0.0 - 89.2)	0.51	(0.01 - 1.43)	-*	0	-	-	-	-	.
Melanoma (skin)	3	58.0	(0.0 - 123.6)	1.44	(0.12 - 3.35)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	2	37.2	(0.0 - 88.3)	0.97	(0.01 - 2.70)	-*	1	21.3	(0.0 - 62.9)	1.00	(0.00 - 3.70)	-*
Lymphoma	2	38.8	(0.0 - 92.5)	2.64	(0.03 - 7.36)	-*	0	-	-	0	n/a	-
Unknown primary site	1	26.1	(0.0 - 77.2)	1.67	(0.00 - 6.18)	-*	1	6.7	(0.0 - 19.6)	2.29	(0.00 - 8.44)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	20.5	(0.0 - 60.7)	2.33	(0.00 - 8.61)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	1	20.5	(0.0 - 60.5)	4.52	(0.00 - 16.68)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	26.1	(0.0 - 77.2)	5.35	(0.00 - 19.73)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	15	300.3	(148.1 - 452.4)	0.86	(0.44 - 1.35)	-	8	135.8	(28.5 - 243.0)	0.62	(0.22 - 1.12)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dalwallinu (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	77.7	(5.5 - 150.0)	1.17	(0.26 - 2.40)	-*
Colorectal cancer	4	67.8	(0.0 - 135.8)	1.47	(0.23 - 3.21)	-*	0	-	-	0	n/a	-
Prostate gland	4	64.5	(0.7 - 128.3)	0.89	(0.14 - 1.95)	-*	0	-	-	-	-	.
Melanoma (skin)	1	19.5	(0.0 - 57.7)	0.40	(0.00 - 1.47)	-*	3	67.7	(0.0 - 144.8)	1.91	(0.15 - 4.45)	-*
Lung, bronchus & trachea	3	54.4	(0.0 - 116.2)	1.24	(0.10 - 2.90)	-*	0	-	-	0	n/a	-
Lymphoma	1	12.8	(0.0 - 37.8)	1.12	(0.00 - 4.14)	-*	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	1	23.0	(0.0 - 68.0)	2.10	(0.00 - 7.73)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	0	-	-	-	-	.
Pancreas	1	19.2	(0.0 - 56.2)	2.61	(0.00 - 9.65)	-*	0	-	-	-	-	.
Urinary bladder	1	12.8	(0.0 - 37.6)	1.83	(0.00 - 6.75)	-*	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	1	16.0	(0.0 - 47.4)	2.91	(0.00 - 10.74)	-*	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	19.0	(0.0 - 56.3)	3.20	(0.00 - 11.80)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	23.0	(0.0 - 68.0)	6.55	(0.00 - 24.16)	-*
Cervix uteri	0	-	-	-	-	.	1	23.0	(0.0 - 68.0)	2.88	(0.00 - 10.62)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	1	15.0	(0.0 - 44.4)	8.12	(0.00 - 29.96)	-*	1	13.7	(0.0 - 40.4)	8.97	(0.00 - 33.08)	-*
Larynx	1	19.0	(0.0 - 56.3)	4.52	(0.00 - 16.66)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	19	320.2	(175.4 - 465.0)	0.94	(0.53 - 1.40)	-	12	228.1	(94.5 - 361.7)	0.83	(0.38 - 1.37)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dandaragan (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	40.9	(0.4 - 81.4)	0.49	(0.08 - 1.06)	-
Colorectal cancer	6	42.3	(8.5 - 76.1)	1.06	(0.29 - 2.06)	-	2	20.7	(0.0 - 49.3)	0.66	(0.01 - 1.84)	-*
Prostate gland	10	86.4	(24.1 - 148.6)	1.04	(0.43 - 1.78)	-	0	-	-	-	-	.
Melanoma (skin)	4	28.0	(0.5 - 55.6)	0.81	(0.13 - 1.79)	-	3	32.0	(0.0 - 68.5)	1.08	(0.09 - 2.51)	-*
Lung, bronchus & trachea	7	52.1	(13.4 - 90.7)	1.38	(0.43 - 2.58)	-	1	12.5	(0.0 - 37.0)	0.52	(0.00 - 1.92)	-*
Lymphoma	2	12.5	(0.0 - 29.7)	1.16	(0.01 - 3.24)	-*	1	10.1	(0.0 - 29.9)	1.00	(0.00 - 3.68)	-*
Unknown primary site	0	-	-	0	n/a	-	1	12.4	(0.0 - 36.7)	1.58	(0.00 - 5.83)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Leukaemia	0	-	-	0	n/a	-	2	17.4	(0.0 - 41.5)	4.04	(0.05 - 11.25)	-*
Pancreas	0	-	-	0	n/a	-	1	10.6	(0.0 - 31.3)	1.89	(0.00 - 6.96)	-*
Urinary bladder	1	8.1	(0.0 - 24.0)	0.91	(0.00 - 3.36)	-*	0	-	-	-	-	.
Stomach	3	20.8	(0.0 - 44.5)	2.98	(0.24 - 6.97)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	0	-	-	0	n/a	-	1	8.7	(0.0 - 25.7)	2.93	(0.00 - 10.81)	-*
Lip	2	13.7	(0.0 - 32.5)	3.01	(0.04 - 8.38)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	2	21.3	(0.0 - 50.9)	4.23	(0.05 - 11.79)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	12.5	(0.0 - 37.0)	4.02	(0.00 - 14.84)	-*
Cervix uteri	0	-	-	-	-	.	2	30.4	(0.0 - 73.3)	3.40	(0.04 - 9.46)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	1	6.8	(0.0 - 20.2)	1.65	(0.00 - 6.09)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	2	25.8	(0.0 - 62.3)	4.40	(0.06 - 12.27)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	3	23.3	(0.0 - 49.6)	6.17	(0.50 - 14.39)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	12.5	(0.0 - 37.0)	18.75	(0.00 - 69.16)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	6.3	(0.0 - 18.5)	7.48	(0.00 - 27.60)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	10.1	(0.0 - 29.9)	18.79	(0.00 - 69.31)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	42	326.1	(221.7 - 430.4)	1.01	(0.71 - 1.34)	-	23	252.2	(147.7 - 356.7)	0.91	(0.55 - 1.32)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dardanup (S) - Pt A 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	16	96.0	(48.3 - 143.8)	1.22	(0.64 - 1.88)	-
Colorectal cancer	5	32.1	(3.6 - 60.5)	0.75	(0.16 - 1.53)	-	3	18.9	(0.0 - 40.8)	0.64	(0.05 - 1.49)	-
Prostate gland	9	57.6	(19.5 - 95.7)	0.84	(0.32 - 1.47)	-	0	-	-	-	-	.
Melanoma (skin)	10	67.1	(25.0 - 109.2)	1.47	(0.60 - 2.51)	-	10	54.3	(19.6 - 88.9)	1.97	(0.81 - 3.37)	-
Lung, bronchus & trachea	6	40.2	(7.6 - 72.9)	1.06	(0.29 - 2.06)	-	4	23.4	(0.4 - 46.5)	1.40	(0.22 - 3.07)	-*
Lymphoma	2	16.0	(0.0 - 38.2)	0.84	(0.01 - 2.35)	-*	1	6.5	(0.0 - 19.1)	0.61	(0.00 - 2.23)	-*
Unknown primary site	1	5.0	(0.0 - 14.9)	0.61	(0.00 - 2.24)	-*	0	-	-	0	n/a	-
Kidney & other renal tract	3	21.5	(0.0 - 46.3)	2.05	(0.17 - 4.78)	-*	1	7.9	(0.0 - 23.3)	1.22	(0.00 - 4.50)	-*
Leukaemia	3	22.7	(0.0 - 48.6)	2.09	(0.17 - 4.89)	-*	0	-	-	0	n/a	-
Pancreas	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Urinary bladder	1	8.8	(0.0 - 25.8)	0.79	(0.00 - 2.90)	-*	1	4.7	(0.0 - 14.0)	2.52	(0.00 - 9.31)	-*
Stomach	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	1	5.8	(0.0 - 17.1)	1.06	(0.00 - 3.91)	-*	0	-	-	0	n/a	-
Lip	0	-	-	0	n/a	-	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	4.5	(0.0 - 13.2)	1.04	(0.00 - 3.85)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	2	11.6	(0.0 - 28.6)	5.23	(0.07 - 14.58)	-*
Cervix uteri	0	-	-	-	-	.	2	11.8	(0.0 - 28.1)	1.72	(0.02 - 4.80)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	2	15.9	(0.0 - 37.8)	2.93	(0.04 - 8.16)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	1	7.7	(0.0 - 22.7)	1.08	(0.00 - 3.97)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	1	5.1	(0.0 - 15.1)	3.36	(0.00 - 12.41)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	1	4.7	(0.0 - 13.8)	7.18	(0.00 - 26.50)	-*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	1	4.8	(0.0 - 14.2)	12.92	(0.00 - 47.66)	-*	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	47	314.9	(224.1 - 405.6)	0.93	(0.66 - 1.21)	-	41	239.6	(164.9 - 314.3)	0.99	(0.69 - 1.32)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dardanup (S) - Pt B 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	36.2	(0.0 - 77.8)	0.50	(0.04 - 1.17)	-
Colorectal cancer	5	62.3	(8.2 - 116.5)	1.34	(0.29 - 2.75)	-*	2	33.2	(0.0 - 79.0)	1.00	(0.01 - 2.80)	-*
Prostate gland	1	11.7	(0.0 - 34.6)	0.16	(0.00 - 0.61)	V	0	-	-	-	-	.
Melanoma (skin)	4	46.0	(0.7 - 91.3)	1.14	(0.18 - 2.50)	-*	1	12.1	(0.0 - 35.8)	0.47	(0.00 - 1.73)	-*
Lung, bronchus & trachea	4	50.0	(0.0 - 100.9)	1.23	(0.19 - 2.71)	-*	1	20.8	(0.0 - 60.8)	0.81	(0.00 - 3.00)	-*
Lymphoma	3	37.9	(0.0 - 83.2)	2.44	(0.20 - 5.70)	-*	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	1	15.2	(0.0 - 44.7)	2.31	(0.00 - 8.51)	-*
Kidney & other renal tract	1	13.6	(0.0 - 40.1)	1.25	(0.00 - 4.62)	-*	0	-	-	-	-	.
Leukaemia	1	12.2	(0.0 - 36.0)	1.35	(0.00 - 4.96)	-*	0	-	-	-	-	.
Pancreas	0	-	-	0	n/a	-	0	-	-	-	-	.
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	1	12.2	(0.0 - 36.0)	1.50	(0.00 - 5.53)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	1	11.7	(0.0 - 34.6)	2.11	(0.00 - 7.79)	-*	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	15.2	(0.0 - 44.7)	1.94	(0.00 - 7.17)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	2	21.2	(0.0 - 50.7)	6.83	(0.09 - 19.03)	-*	0	-	-	-	-	.
Testis	2	20.7	(0.0 - 49.3)	5.16	(0.06 - 14.36)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	12.1	(0.0 - 35.8)	8.95	(0.00 - 33.03)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	25	299.5	(181.4 - 417.6)	0.90	(0.55 - 1.29)	-	10	144.8	(53.8 - 235.7)	0.56	(0.23 - 0.96)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Denmark (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	10	53.0	(19.4 - 86.7)	0.68	(0.28 - 1.16)	-
Colorectal cancer	5	19.5	(1.4 - 37.5)	0.53	(0.12 - 1.08)	-	7	40.8	(9.6 - 71.9)	1.14	(0.36 - 2.12)	-
Prostate gland	13	57.4	(26.0 - 88.8)	0.82	(0.39 - 1.33)	-	0	-	-	-	-	.
Melanoma (skin)	6	35.7	(6.9 - 64.6)	0.79	(0.21 - 1.53)	-	5	47.4	(0.0 - 98.0)	1.00	(0.22 - 2.06)	-
Lung, bronchus & trachea	5	26.9	(3.2 - 50.7)	0.59	(0.13 - 1.21)	-	3	14.3	(0.0 - 30.7)	0.79	(0.06 - 1.84)	-*
Lymphoma	2	8.0	(0.0 - 19.3)	0.72	(0.01 - 2.00)	-*	0	-	-	0	n/a	-
Unknown primary site	3	16.0	(0.0 - 34.2)	1.24	(0.10 - 2.90)	-*	2	13.2	(0.0 - 33.1)	1.38	(0.02 - 3.86)	-*
Kidney & other renal tract	2	11.2	(0.0 - 26.6)	1.05	(0.01 - 2.92)	-*	1	6.3	(0.0 - 18.8)	1.03	(0.00 - 3.80)	-*
Leukaemia	2	10.7	(0.0 - 25.6)	1.16	(0.01 - 3.22)	-*	0	-	-	0	n/a	-
Pancreas	0	-	-	0	n/a	-	2	10.5	(0.0 - 25.2)	1.77	(0.02 - 4.94)	-*
Urinary bladder	1	5.1	(0.0 - 15.2)	0.50	(0.00 - 1.84)	-*	2	10.9	(0.0 - 26.1)	3.53	(0.04 - 9.83)	-*
Stomach	1	3.4	(0.0 - 10.2)	0.58	(0.00 - 2.16)	-*	1	4.7	(0.0 - 13.9)	1.32	(0.00 - 4.88)	-*
Corpus uteri	0	-	-	-	-	.	1	5.8	(0.0 - 17.1)	0.60	(0.00 - 2.20)	-*
Brain	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lip	0	-	-	0	n/a	-	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	5.8	(0.0 - 17.1)	0.70	(0.00 - 2.58)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	1	3.8	(0.0 - 11.2)	1.82	(0.00 - 6.73)	-*
Oesophagus	3	13.7	(0.0 - 29.9)	2.75	(0.22 - 6.42)	-*	0	-	-	-	-	.
Thyroid gland	1	5.9	(0.0 - 17.3)	2.94	(0.00 - 10.84)	-*	1	6.1	(0.0 - 18.1)	1.22	(0.00 - 4.51)	-*
Myeloma/plasma cell tumours	1	3.4	(0.0 - 10.2)	1.23	(0.00 - 4.54)	-*	1	5.8	(0.0 - 17.1)	1.97	(0.00 - 7.28)	-*
Cervix uteri	0	-	-	-	-	.	1	6.3	(0.0 - 18.8)	0.95	(0.00 - 3.49)	-*
Non-mel. skin (exc BCC/SCC)	1	4.6	(0.0 - 13.6)	1.25	(0.00 - 4.60)	-*	1	5.8	(0.0 - 17.1)	2.60	(0.00 - 9.61)	-*
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	5.1	(0.0 - 15.2)	1.34	(0.00 - 4.96)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	1	3.4	(0.0 - 10.2)	3.25	(0.00 - 11.99)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	1	6.1	(0.0 - 18.0)	4.86	(0.00 - 17.92)	-*	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	1	5.1	(0.0 - 15.2)	5.67	(0.00 - 20.93)	-*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	3.4	(0.0 - 10.2)	4.79	(0.00 - 17.67)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	51	244.8	(176.4 - 313.3)	0.75	(0.56 - 0.99)	V	40	240.5	(157.8 - 323.3)	0.83	(0.58 - 1.11)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Derby-West Kimberley (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	13	86.4	(37.4 - 135.5)	1.11	(0.53 - 1.79)	-
Colorectal cancer	4	29.5	(0.4 - 58.7)	0.58	(0.09 - 1.27)	-	3	15.7	(0.0 - 34.5)	0.74	(0.06 - 1.72)	-*
Prostate gland	4	32.6	(0.7 - 64.5)	0.37	(0.06 - 0.81)	V	0	-	-	-	-	.
Melanoma (skin)	4	19.3	(0.0 - 38.7)	0.51	(0.08 - 1.12)	-	3	23.2	(0.0 - 50.3)	0.59	(0.05 - 1.39)	-
Lung, bronchus & trachea	10	68.3	(25.5 - 111.1)	1.74	(0.71 - 2.97)	-	4	33.8	(0.0 - 68.0)	1.73	(0.27 - 3.79)	-*
Lymphoma	2	11.1	(0.0 - 26.5)	0.72	(0.01 - 2.02)	-*	1	7.1	(0.0 - 20.9)	0.67	(0.00 - 2.46)	-*
Unknown primary site	5	31.8	(3.8 - 59.8)	2.87	(0.63 - 5.88)	-*	3	21.1	(0.0 - 46.5)	2.93	(0.24 - 6.85)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	2	14.2	(0.0 - 33.7)	2.73	(0.03 - 7.60)	-*
Leukaemia	3	19.5	(0.0 - 41.8)	1.79	(0.14 - 4.18)	-*	0	-	-	0	n/a	-
Pancreas	1	5.7	(0.0 - 16.9)	1.04	(0.00 - 3.83)	-*	0	-	-	0	n/a	-
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	2	10.8	(0.0 - 26.8)	1.63	(0.02 - 4.53)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	2	17.6	(0.0 - 42.3)	1.73	(0.02 - 4.82)	-*
Brain	1	4.4	(0.0 - 13.0)	0.90	(0.00 - 3.32)	-*	0	-	-	0	n/a	-
Lip	2	11.7	(0.0 - 27.9)	1.83	(0.02 - 5.09)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-	.
Thyroid gland	3	21.2	(0.0 - 45.3)	6.54	(0.53 - 15.26)	-*	1	10.5	(0.0 - 31.0)	0.98	(0.00 - 3.62)	-*
Myeloma/plasma cell tumours	1	8.3	(0.0 - 24.6)	1.71	(0.00 - 6.32)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	2	11.1	(0.0 - 26.5)	3.70	(0.05 - 10.31)	-*	1	7.6	(0.0 - 22.6)	5.90	(0.00 - 21.75)	-*
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	1	8.3	(0.0 - 24.6)	3.21	(0.00 - 11.84)	-*	0	-	-	-	-	.
Larynx	2	11.7	(0.0 - 27.9)	3.51	(0.04 - 9.76)	-*	0	-	-	-	-	.
Tongue	1	5.3	(0.0 - 15.6)	2.54	(0.00 - 9.35)	-*	0	-	-	-	-	.
Connective & soft tissues	2	11.1	(0.0 - 26.5)	5.46	(0.07 - 15.22)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	1	7.4	(0.0 - 21.8)	12.16	(0.00 - 44.84)	-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	51	329.3	(237.7 - 420.8)	0.94	(0.70 - 1.24)	-	33	237.2	(153.0 - 321.4)	0.88	(0.58 - 1.20)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Donnybrook-Balingup (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	17	109.6	(56.9 - 162.2)	1.29	(0.69 - 1.97)	-
Colorectal cancer	4	23.0	(0.2 - 45.7)	0.54	(0.08 - 1.19)	-	6	34.4	(6.5 - 62.2)	1.22	(0.33 - 2.36)	-
Prostate gland	13	78.0	(35.3 - 120.7)	1.07	(0.51 - 1.72)	-	0	-	-	-	-	.
Melanoma (skin)	4	24.1	(0.4 - 47.8)	0.60	(0.09 - 1.32)	-	5	29.6	(2.7 - 56.4)	1.10	(0.24 - 2.26)	-
Lung, bronchus & trachea	5	33.5	(4.2 - 62.9)	0.78	(0.17 - 1.60)	-	2	15.3	(0.0 - 36.4)	0.68	(0.01 - 1.89)	-*
Lymphoma	1	5.8	(0.0 - 17.2)	0.42	(0.00 - 1.57)	-*	1	7.7	(0.0 - 22.9)	0.63	(0.00 - 2.34)	-*
Unknown primary site	1	5.2	(0.0 - 15.3)	0.55	(0.00 - 2.01)	-*	1	4.9	(0.0 - 14.5)	0.84	(0.00 - 3.09)	-*
Kidney & other renal tract	2	10.8	(0.0 - 26.0)	1.29	(0.02 - 3.60)	-*	0	-	-	0	n/a	-
Leukaemia	1	4.4	(0.0 - 12.9)	0.71	(0.00 - 2.61)	-*	0	-	-	0	n/a	-
Pancreas	0	-	-	0	n/a	-	2	10.6	(0.0 - 26.6)	2.27	(0.03 - 6.33)	-*
Urinary bladder	3	18.7	(0.0 - 40.0)	2.06	(0.17 - 4.80)	-*	1	5.9	(0.0 - 17.5)	2.30	(0.00 - 8.50)	-*
Stomach	1	5.2	(0.0 - 15.3)	0.76	(0.00 - 2.80)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	3	15.9	(0.0 - 34.8)	2.11	(0.17 - 4.92)	-*
Brain	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lip	0	-	-	0	n/a	-	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	6.6	(0.0 - 19.6)	0.83	(0.00 - 3.07)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	1	5.2	(0.0 - 15.3)	1.19	(0.00 - 4.40)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	1	6.4	(0.0 - 19.0)	1.59	(0.00 - 5.88)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	8.0	(0.0 - 23.6)	1.01	(0.00 - 3.73)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	1	6.4	(0.0 - 19.0)	1.29	(0.00 - 4.77)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	1	5.3	(0.0 - 15.5)	5.57	(0.00 - 20.55)	-*
Testis	1	8.3	(0.0 - 24.6)	1.51	(0.00 - 5.58)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	2	12.4	(0.0 - 30.0)	6.86	(0.09 - 19.11)	-*
Larynx	1	6.7	(0.0 - 19.9)	1.62	(0.00 - 5.96)	-*	0	-	-	-	-	.
Tongue	1	6.7	(0.0 - 19.9)	2.65	(0.00 - 9.79)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	1	6.7	(0.0 - 20.0)	5.74	(0.00 - 21.19)	-*	1	6.0	(0.0 - 17.8)	14.00	(0.00 - 51.66)	-*
Major Salivary Gland	0	-	-	-	-	.	1	5.9	(0.0 - 17.5)	10.50	(0.00 - 38.73)	-*
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	42	255.3	(177.9 - 332.7)	0.77	(0.54 - 1.02)	-	45	278.1	(195.4 - 360.8)	1.10	(0.78 - 1.44)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dowerin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	7	224.3	(51.5 - 397.2)	2.99	(0.94 - 5.58)	-*
Colorectal cancer	2	82.7	(0.0 - 197.9)	1.60	(0.02 - 4.47)	-*	2	57.2	(0.0 - 141.9)	2.02	(0.03 - 5.64)	-*
Prostate gland	6	203.9	(33.1 - 374.7)	2.95	(0.80 - 5.74)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	1	43.8	(0.0 - 129.3)	1.20	(0.00 - 4.44)	-*
Lung, bronchus & trachea	1	42.6	(0.0 - 125.1)	0.91	(0.00 - 3.35)	-*	2	50.0	(0.0 - 118.4)	3.25	(0.04 - 9.06)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	1	42.6	(0.0 - 125.1)	3.17	(0.00 - 11.70)	-*	0	-	-	-	-	.
Kidney & other renal tract	1	43.2	(0.0 - 127.5)	3.74	(0.00 - 13.80)	-*	0	-	-	-	-	.
Leukaemia	1	36.2	(0.0 - 107.0)	3.93	(0.00 - 14.50)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	2	42.5	(0.0 - 102.0)	7.55	(0.09 - 21.04)	-*
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	42.6	(0.0 - 125.1)	6.85	(0.00 - 25.28)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	42.1	(0.0 - 124.2)	12.32	(0.00 - 45.46)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	13	493.7	(222.8 - 764.6)	1.40	(0.67 - 2.26)	-	15	460.0	(217.5 - 702.6)	1.93	(0.99 - 3.03)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

A-90 Dowerin (S) 1998-2002: Cancer incidence

Cancer in Western Australia, 1998-2002: incidence and mortality by Statistical Local Area

SLA: Dumbleyung (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	1	22.7	(0.0 - 66.2)	0.72	(0.00 - 2.66)	-*	0	-	-	0	n/a	-
Prostate gland	2	69.5	(0.0 - 166.1)	0.88	(0.01 - 2.44)	-*	0	-	-	0	-	.
Melanoma (skin)	1	57.1	(0.0 - 168.7)	0.82	(0.00 - 3.02)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	1	37.0	(0.0 - 109.2)	0.82	(0.00 - 3.03)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	1	44.6	(0.0 - 131.8)	3.70	(0.00 - 13.66)	-*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	1	38.0	(0.0 - 112.2)	3.49	(0.00 - 12.87)	-*	2	77.9	(0.0 - 186.7)	14.54	(0.18 - 40.51)	-*
Leukaemia	1	36.0	(0.0 - 106.3)	3.76	(0.00 - 13.89)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	1	37.0	(0.0 - 109.2)	3.53	(0.00 - 13.04)	-*	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	8	297.4	(86.7 - 508.2)	0.79	(0.28 - 1.42)	-	3	122.5	(0.0 - 261.9)	0.44	(0.04 - 1.03)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dundas (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	38.5	(0.0 - 113.1)	0.34	(0.00 - 1.26)	-*
Colorectal cancer	3	70.6	(0.0 - 151.0)	1.61	(0.13 - 3.76)	-*	1	14.3	(0.0 - 41.9)	0.95	(0.00 - 3.50)	-*
Prostate gland	4	112.5	(0.0 - 225.1)	1.33	(0.21 - 2.92)	-*	0	-	-	-	-	.
Melanoma (skin)	2	53.8	(0.0 - 128.0)	1.06	(0.01 - 2.95)	-*	1	22.9	(0.0 - 67.8)	0.91	(0.00 - 3.37)	-*
Lung, bronchus & trachea	2	47.0	(0.0 - 113.0)	1.29	(0.02 - 3.58)	-*	1	48.4	(0.0 - 142.5)	1.61	(0.00 - 5.96)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	1	44.6	(0.0 - 131.9)	5.69	(0.00 - 20.97)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	48.4	(0.0 - 142.5)	15.99	(0.00 - 58.99)	-*
Larynx	1	18.4	(0.0 - 54.5)	6.26	(0.00 - 23.10)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	1	22.9	(0.0 - 67.8)	40.06	(0.00 - 147.77)	-*
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	26.0	(0.0 - 76.7)	34.29	(0.00 - 126.48)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	13	328.2	(148.4 - 508.0)	0.92	(0.44 - 1.49)	-	7	240.0	(51.9 - 428.1)	0.77	(0.24 - 1.43)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: East Fremantle (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	25	109.3	(64.9 - 153.8)	1.19	(0.73 - 1.70)	-
Colorectal cancer	18	63.9	(32.8 - 95.0)	1.51	(0.83 - 2.28)	-	4	14.9	(0.0 - 31.1)	0.40	(0.06 - 0.87)	V
Prostate gland	23	92.2	(52.4 - 132.0)	1.20	(0.72 - 1.74)	-	0	-	-	-	-	.
Melanoma (skin)	14	49.9	(22.1 - 77.7)	1.37	(0.68 - 2.18)	-	8	29.8	(7.6 - 51.9)	1.05	(0.37 - 1.90)	-
Lung, bronchus & trachea	9	34.5	(10.6 - 58.4)	0.86	(0.33 - 1.51)	-	4	12.3	(0.0 - 26.3)	0.68	(0.11 - 1.50)	-
Lymphoma	3	9.8	(0.0 - 21.3)	0.81	(0.07 - 1.88)	-*	1	1.1	(0.0 - 3.4)	0.34	(0.00 - 1.24)	-*
Unknown primary site	4	17.1	(0.3 - 33.9)	1.28	(0.20 - 2.80)	-*	1	1.1	(0.0 - 3.1)	0.37	(0.00 - 1.36)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	3	7.6	(0.0 - 17.6)	2.05	(0.17 - 4.78)	-*
Leukaemia	2	7.4	(0.0 - 17.7)	0.89	(0.01 - 2.47)	-*	1	1.1	(0.0 - 3.4)	0.63	(0.00 - 2.32)	-*
Pancreas	1	6.1	(0.0 - 18.1)	0.60	(0.00 - 2.23)	-*	4	14.9	(0.0 - 31.8)	2.11	(0.33 - 4.62)	-*
Urinary bladder	1	2.1	(0.0 - 6.3)	0.38	(0.00 - 1.41)	-*	0	-	-	0	n/a	-
Stomach	2	7.5	(0.0 - 18.4)	0.91	(0.01 - 2.54)	-*	2	3.0	(0.0 - 7.3)	1.54	(0.02 - 4.28)	-*
Corpus uteri	0	-	-	-	-	.	5	18.4	(0.3 - 36.5)	2.04	(0.45 - 4.18)	-*
Brain	1	4.2	(0.0 - 12.5)	0.75	(0.00 - 2.76)	-*	1	4.7	(0.0 - 13.8)	1.01	(0.00 - 3.74)	-*
Lip	1	3.7	(0.0 - 11.0)	0.72	(0.00 - 2.66)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	3	7.0	(0.0 - 16.9)	1.38	(0.11 - 3.23)	-*
Other lymphohaematopoietic	2	7.1	(0.0 - 17.6)	1.55	(0.02 - 4.33)	-*	1	4.7	(0.0 - 13.8)	1.00	(0.00 - 3.68)	-*
Oesophagus	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Thyroid gland	0	-	-	-	-	.	1	9.5	(0.0 - 28.0)	0.80	(0.00 - 2.96)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	1	1.1	(0.0 - 3.4)	1.19	(0.00 - 4.40)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	1	1.1	(0.0 - 3.1)	1.48	(0.00 - 5.47)	-*
Mesothelioma	4	12.9	(0.0 - 26.4)	3.24	(0.50 - 7.10)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	1	1.1	(0.0 - 3.4)	2.79	(0.00 - 10.28)	-*
Testis	1	3.8	(0.0 - 11.3)	0.94	(0.00 - 3.48)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	1	4.9	(0.0 - 14.4)	1.55	(0.00 - 5.70)	-*
Larynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Tongue	1	6.7	(0.0 - 19.9)	1.84	(0.00 - 6.77)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	1	9.5	(0.0 - 28.0)	3.88	(0.00 - 14.33)	-*
Tonsil & oropharynx	0	-	-	-	-	.	1	4.7	(0.0 - 13.9)	10.18	(0.00 - 37.56)	-*
Vulva/vagina	0	-	-	-	-	.	1	1.1	(0.0 - 3.1)	1.79	(0.00 - 6.61)	-*
Small intestine	0	-	-	-	-	.	1	1.9	(0.0 - 5.7)	5.18	(0.00 - 19.12)	-*
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	2	4.8	(0.0 - 12.3)	11.83	(0.15 - 32.97)	-*
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	2.7	(0.0 - 7.9)	3.96	(0.00 - 14.62)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	88	331.8	(259.0 - 404.5)	1.02	(0.82 - 1.26)	-	74	269.3	(199.6 - 339.1)	1.00	(0.79 - 1.26)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: East Pilbara (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	34.8	(0.0 - 79.1)	0.36	(0.03 - 0.84)	V
Colorectal cancer	6	57.1	(0.0 - 114.6)	1.32	(0.36 - 2.57)	-	1	12.3	(0.0 - 36.5)	0.44	(0.00 - 1.63)	-*
Prostate gland	1	4.7	(0.0 - 14.0)	0.15	(0.00 - 0.56)	V	0	-	-	0	-	.
Melanoma (skin)	3	12.2	(0.0 - 26.1)	0.46	(0.04 - 1.08)	-	0	-	-	0	n/a	V
Lung, bronchus & trachea	4	40.5	(0.0 - 87.5)	1.18	(0.18 - 2.60)	-*	1	5.8	(0.0 - 17.2)	0.78	(0.00 - 2.89)	-*
Lymphoma	3	22.3	(0.0 - 49.9)	1.42	(0.11 - 3.31)	-*	0	-	-	0	n/a	-
Unknown primary site	1	3.3	(0.0 - 9.7)	0.92	(0.00 - 3.39)	-*	1	20.1	(0.0 - 59.5)	1.85	(0.00 - 6.83)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pancreas	1	17.8	(0.0 - 52.4)	1.57	(0.00 - 5.78)	-*	0	-	-	-	-	.
Urinary bladder	1	5.9	(0.0 - 17.5)	1.42	(0.00 - 5.24)	-*	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	1	7.9	(0.0 - 23.3)	3.85	(0.00 - 14.22)	-*
Corpus uteri	0	-	-	-	-	.	1	4.8	(0.0 - 14.2)	1.36	(0.00 - 5.03)	-*
Brain	1	6.3	(0.0 - 18.6)	1.11	(0.00 - 4.09)	-*	0	-	-	-	-	.
Lip	1	4.7	(0.0 - 14.0)	1.02	(0.00 - 3.77)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	6.8	(0.0 - 20.2)	1.54	(0.00 - 5.68)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	15.4	(0.0 - 45.3)	2.04	(0.00 - 7.53)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	1	3.3	(0.0 - 9.7)	0.79	(0.00 - 2.91)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	11.9	(0.0 - 35.2)	2.31	(0.00 - 8.54)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	1	5.9	(0.0 - 17.5)	3.43	(0.00 - 12.65)	-*	1	6.8	(0.0 - 20.2)	8.07	(0.00 - 29.78)	-*
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	5.9	(0.0 - 17.5)	8.99	(0.00 - 33.16)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	27	217.3	(118.0 - 316.5)	0.71	(0.45 - 1.01)	-	10	99.4	(29.6 - 169.3)	0.41	(0.17 - 0.70)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Esperance (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	34	85.6	(56.4 - 114.7)	1.01	(0.68 - 1.38)	-
Colorectal cancer	23	55.2	(32.4 - 78.0)	1.20	(0.72 - 1.74)	-	11	21.4	(8.3 - 34.5)	0.82	(0.36 - 1.37)	-
Prostate gland	36	85.0	(57.1 - 112.9)	1.15	(0.78 - 1.55)	-	0	-	-	-	-	.
Melanoma (skin)	21	56.6	(31.8 - 81.5)	1.20	(0.70 - 1.76)	-	10	22.9	(8.0 - 37.7)	0.82	(0.34 - 1.40)	-
Lung, bronchus & trachea	15	36.4	(17.9 - 55.0)	0.90	(0.46 - 1.41)	-	13	31.5	(14.1 - 48.9)	1.60	(0.77 - 2.59)	-
Lymphoma	4	8.8	(0.0 - 17.7)	0.64	(0.10 - 1.40)	-	5	13.7	(1.4 - 26.0)	1.15	(0.25 - 2.37)	-*
Unknown primary site	4	9.5	(0.2 - 18.8)	0.83	(0.13 - 1.82)	-	3	8.6	(0.0 - 18.3)	0.92	(0.07 - 2.15)	-*
Kidney & other renal tract	3	6.7	(0.0 - 14.3)	0.75	(0.06 - 1.74)	-*	4	9.9	(0.0 - 20.1)	1.84	(0.28 - 4.03)	-*
Leukaemia	6	13.2	(2.5 - 23.9)	1.58	(0.43 - 3.07)	-*	3	5.7	(0.0 - 12.2)	1.29	(0.10 - 3.01)	-*
Pancreas	2	4.8	(0.0 - 11.4)	0.76	(0.01 - 2.11)	-*	3	6.7	(0.0 - 14.4)	1.23	(0.10 - 2.88)	-*
Urinary bladder	3	7.0	(0.0 - 15.0)	0.78	(0.06 - 1.81)	-*	1	2.4	(0.0 - 7.0)	0.81	(0.00 - 2.99)	-*
Stomach	3	6.6	(0.0 - 14.0)	0.88	(0.07 - 2.04)	-*	1	1.6	(0.0 - 4.6)	0.61	(0.00 - 2.23)	-*
Corpus uteri	0	-	-	-	-	.	4	9.9	(0.2 - 19.7)	1.09	(0.17 - 2.39)	-*
Brain	1	2.1	(0.0 - 6.2)	0.42	(0.00 - 1.54)	-*	2	7.0	(0.0 - 17.0)	1.32	(0.02 - 3.69)	-*
Lip	1	2.6	(0.0 - 7.8)	0.42	(0.00 - 1.54)	-*	1	1.1	(0.0 - 3.4)	1.00	(0.00 - 3.71)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	2	4.8	(0.0 - 11.9)	0.63	(0.01 - 1.76)	-*
Other lymphohaematopoietic	2	4.3	(0.0 - 10.5)	1.09	(0.01 - 3.03)	-*	0	-	-	0	n/a	-
Oesophagus	5	11.8	(1.4 - 22.2)	2.30	(0.50 - 4.71)	-*	0	-	-	0	n/a	-
Thyroid gland	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	1	2.4	(0.0 - 7.1)	0.61	(0.00 - 2.26)	-*	1	2.5	(0.0 - 7.5)	0.90	(0.00 - 3.32)	-*
Cervix uteri	0	-	-	-	-	.	2	5.9	(0.0 - 14.1)	0.75	(0.01 - 2.09)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	1	1.4	(0.0 - 4.1)	1.10	(0.00 - 4.06)	-*
Mesothelioma	0	-	-	0	n/a	-	2	2.9	(0.0 - 7.0)	7.30	(0.09 - 20.34)	-*
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Testis	2	6.3	(0.0 - 15.3)	1.00	(0.01 - 2.80)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Larynx	1	2.7	(0.0 - 7.9)	0.64	(0.00 - 2.35)	-*	0	-	-	-	-	.
Tongue	1	2.3	(0.0 - 6.7)	1.05	(0.00 - 3.87)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-	.
Tonsil & oropharynx	1	2.7	(0.0 - 7.9)	1.33	(0.00 - 4.90)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	1	2.8	(0.0 - 8.3)	3.56	(0.00 - 13.14)	-*	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	1	2.2	(0.0 - 6.4)	3.92	(0.00 - 14.47)	-*
Pyriform sinus & hypopharynx	1	2.3	(0.0 - 6.7)	2.32	(0.00 - 8.55)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	1	3.4	(0.0 - 10.0)	10.62	(0.00 - 39.17)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	2.3	(0.0 - 6.7)	5.56	(0.00 - 20.53)	-*	1	2.6	(0.0 - 7.8)	32.86	(0.00 - 121.22)	-*
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	138	334.3	(278.1 - 390.5)	0.97	(0.82 - 1.15)	-	106	253.6	(203.8 - 303.3)	0.97	(0.80 - 1.18)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Exmouth (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	6	109.7	(20.2 - 199.2)	1.25	(0.34 - 2.43)	-
Colorectal cancer	3	48.5	(0.0 - 104.0)	1.08	(0.09 - 2.52)	-*	2	40.1	(0.0 - 96.2)	1.27	(0.02 - 3.55)	-*
Prostate gland	4	54.5	(0.9 - 108.0)	0.89	(0.14 - 1.95)	-*	0	-	-	-	-	.
Melanoma (skin)	5	76.1	(7.4 - 144.8)	1.70	(0.37 - 3.48)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	5	80.6	(9.6 - 151.6)	2.12	(0.46 - 4.35)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	0	-	-	-	-	.
Kidney & other renal tract	1	12.6	(0.0 - 37.2)	1.63	(0.00 - 6.00)	-*	0	-	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	1	21.7	(0.0 - 64.1)	3.74	(0.00 - 13.81)	-*
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	1	50.0	(0.0 - 143.0)	4.35	(0.00 - 16.03)	-*	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	2	25.3	(0.0 - 60.2)	6.99	(0.09 - 19.47)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	15.9	(0.0 - 46.7)	16.21	(0.00 - 59.80)	-*
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	1	21.7	(0.0 - 64.1)	24.00	(0.00 - 88.55)	-*
Connective & soft tissues	1	10.7	(0.0 - 31.5)	8.18	(0.00 - 30.18)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	1	16.4	(0.0 - 48.4)	14.97	(0.00 - 55.23)	-*	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	23	374.6	(209.0 - 540.2)	1.08	(0.65 - 1.57)	-	11	209.2	(84.5 - 333.9)	0.76	(0.33 - 1.28)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Fremantle (C) - Inner 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	203.6	(0.0 - 414.5)	1.98	(0.31 - 4.35)	-*
Colorectal cancer	2	77.5	(0.0 - 184.9)	1.06	(0.01 - 2.96)	-*	0	-	-	0	n/a	-
Prostate gland	4	97.1	(0.0 - 195.6)	1.28	(0.20 - 2.80)	-*	0	-	-	0	n/a	-
Melanoma (skin)	1	23.4	(0.0 - 69.1)	0.60	(0.00 - 2.22)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	1	74.1	(0.0 - 216.5)	2.48	(0.00 - 9.15)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	1	27.5	(0.0 - 81.2)	2.90	(0.00 - 10.68)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	42.6	(0.0 - 125.5)	4.78	(0.00 - 17.64)	-*
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	2	42.2	(0.0 - 103.0)	9.12	(0.11 - 25.40)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	1	15.9	(0.0 - 46.7)	6.38	(0.00 - 23.54)	-*	1	31.3	(0.0 - 91.5)	18.19	(0.00 - 67.11)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	1	33.9	(0.0 - 100.1)	11.34	(0.00 - 41.82)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	1	31.6	(0.0 - 93.5)	239.10	(0.00 - 882.03)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	12	317.5	(131.0 - 504.0)	0.87	(0.40 - 1.43)	-	8	383.2	(105.2 - 661.1)	1.34	(0.47 - 2.42)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Fremantle (C) - Remainder 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	0.6	(0.0 - 1.7)	1.78	(0.00 - 6.57)	-*	83	90.0	(69.8 - 110.2)	1.02	(0.82 - 1.27)	-
Colorectal cancer	56	58.3	(42.2 - 74.5)	1.18	(0.90 - 1.55)	-	37	30.7	(19.6 - 41.8)	0.95	(0.65 - 1.28)	-
Prostate gland	75	70.8	(54.1 - 87.4)	0.96	(0.76 - 1.22)	-	0	-	-	-	-	.
Melanoma (skin)	39	42.6	(28.9 - 56.4)	0.98	(0.67 - 1.31)	-	29	29.6	(18.0 - 41.2)	0.99	(0.63 - 1.38)	-
Lung, bronchus & trachea	49	45.1	(31.9 - 58.4)	1.16	(0.83 - 1.50)	-	26	20.5	(12.0 - 29.0)	1.12	(0.70 - 1.59)	-
Lymphoma	23	24.0	(13.8 - 34.1)	1.59	(0.95 - 2.30)	-	8	9.2	(2.5 - 15.9)	0.69	(0.24 - 1.24)	-
Unknown primary site	21	20.1	(11.1 - 29.2)	1.73	(1.00 - 2.54)	-	9	5.9	(1.3 - 10.6)	0.87	(0.34 - 1.53)	-
Kidney & other renal tract	15	16.1	(6.4 - 25.8)	1.55	(0.79 - 2.43)	-	2	1.5	(0.0 - 4.0)	0.35	(0.00 - 0.98)	V
Leukaemia	13	14.1	(6.1 - 22.1)	1.46	(0.70 - 2.35)	-	5	3.7	(0.0 - 7.4)	0.83	(0.18 - 1.70)	-
Pancreas	8	7.8	(2.2 - 13.4)	1.21	(0.43 - 2.19)	-	9	5.7	(1.5 - 10.0)	1.22	(0.47 - 2.14)	-
Urinary bladder	15	13.6	(6.5 - 20.7)	1.47	(0.75 - 2.30)	-	5	2.5	(0.1 - 4.8)	1.25	(0.27 - 2.57)	-*
Stomach	10	9.2	(3.2 - 15.2)	1.15	(0.47 - 1.97)	-	10	7.2	(2.1 - 12.3)	1.99	(0.82 - 3.41)	-
Corpus uteri	0	-	-	-	-	.	15	12.0	(5.2 - 18.7)	1.55	(0.79 - 2.43)	-
Brain	7	8.4	(2.1 - 14.7)	1.36	(0.43 - 2.53)	-	4	4.3	(0.0 - 8.9)	1.04	(0.16 - 2.28)	-*
Lip	7	7.0	(1.7 - 12.3)	1.30	(0.41 - 2.43)	-	9	8.1	(2.5 - 13.7)	3.23	(1.24 - 5.66)	^*
Ovary & uterine adnexa	0	-	-	-	-	.	2	0.8	(0.0 - 1.9)	0.24	(0.00 - 0.66)	V
Other lymphohaematopoietic	7	4.4	(1.1 - 7.8)	1.43	(0.45 - 2.67)	-	5	5.7	(0.3 - 11.1)	1.31	(0.29 - 2.68)	-*
Oesophagus	2	2.0	(0.0 - 4.8)	0.36	(0.00 - 1.01)	-	2	0.8	(0.0 - 1.9)	0.71	(0.01 - 1.97)	-*
Thyroid gland	0	-	-	0	n/a	-	8	8.9	(2.5 - 15.2)	1.67	(0.59 - 3.01)	-
Myeloma/plasma cell tumours	6	5.5	(1.0 - 9.9)	1.47	(0.40 - 2.86)	-*	3	2.2	(0.0 - 5.0)	0.92	(0.07 - 2.16)	-*
Cervix uteri	0	-	-	-	-	.	8	8.2	(2.2 - 14.2)	1.28	(0.45 - 2.31)	-
Non-mel. skin (exc BCC/SCC)	6	5.9	(0.8 - 11.1)	1.42	(0.38 - 2.77)	-*	5	4.3	(0.0 - 9.0)	1.94	(0.42 - 3.98)	-*
Mesothelioma	8	7.7	(2.2 - 13.2)	1.61	(0.56 - 2.90)	-	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	1	0.8	(0.0 - 2.4)	0.28	(0.00 - 1.02)	-*	0	-	-	0	n/a	-
Testis	5	6.4	(0.7 - 12.0)	1.27	(0.28 - 2.60)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	3	2.9	(0.0 - 6.4)	1.38	(0.11 - 3.23)	-*	2	1.9	(0.0 - 4.8)	0.79	(0.01 - 2.20)	-*
Larynx	5	3.4	(0.2 - 6.5)	1.37	(0.30 - 2.81)	-*	0	-	-	0	n/a	-
Tongue	3	3.8	(0.0 - 8.1)	1.43	(0.12 - 3.34)	-*	1	0.8	(0.0 - 2.3)	1.14	(0.00 - 4.20)	-*
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Tonsil & oropharynx	3	3.0	(0.0 - 6.5)	1.76	(0.14 - 4.11)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	2	1.1	(0.0 - 2.7)	0.95	(0.01 - 2.64)	-*
Small intestine	1	0.8	(0.0 - 2.4)	0.97	(0.00 - 3.58)	-*	0	-	-	0	n/a	-
Eye & lacrimal gland	2	2.0	(0.0 - 4.9)	1.94	(0.02 - 5.41)	-*	0	-	-	0	n/a	-
Major Salivary Gland	0	-	-	0	n/a	-	1	0.3	(0.0 - 0.9)	1.55	(0.00 - 5.70)	-*
Anus	0	-	-	0	n/a	-	1	0.3	(0.0 - 1.0)	1.12	(0.00 - 4.13)	-*
Mouth, other & unspecified	2	2.6	(0.0 - 6.2)	2.19	(0.03 - 6.10)	-*	0	-	-	0	n/a	-
Floor of mouth	2	2.0	(0.0 - 4.8)	1.99	(0.02 - 5.56)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	1	1.6	(0.0 - 4.8)	2.06	(0.00 - 7.60)	-*	1	1.8	(0.0 - 5.5)	1.78	(0.00 - 6.56)	-*
Pyriform sinus & hypopharynx	1	0.6	(0.0 - 1.7)	0.99	(0.00 - 3.65)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	0.8	(0.0 - 2.3)	1.70	(0.00 - 6.26)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	3	4.1	(0.0 - 8.7)	6.95	(0.56 - 16.23)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	0	n/a	-	0	-	-	-	-	.
Gum	1	1.2	(0.0 - 3.5)	4.13	(0.00 - 15.25)	-*	0	-	-	-	-	.
Kaposi sarcoma	2	1.7	(0.0 - 4.3)	6.77	(0.08 - 18.87)	-*	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	1	1.2	(0.0 - 3.5)	7.85	(0.00 - 28.96)	-*
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	1	2.9	(0.0 - 8.5)	13.12	(0.00 - 48.39)	-*	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	1	1.3	(0.0 - 3.8)	5.75	(0.00 - 21.23)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	404	402.9	(361.7 - 444.1)	1.17	(1.06 - 1.30)	^	295	271.4	(237.5 - 305.2)	1.03	(0.91 - 1.15)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Geraldton (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	61	91.5	(67.6 - 115.5)	1.09	(0.84 - 1.40)	-
Colorectal cancer	31	45.5	(29.1 - 61.8)	0.95	(0.62 - 1.32)	-	23	24.0	(13.1 - 34.8)	0.89	(0.53 - 1.29)	-
Prostate gland	53	77.4	(56.1 - 98.7)	0.98	(0.74 - 1.30)	-	0	-	-	-	-	.
Melanoma (skin)	32	47.4	(30.5 - 64.2)	1.16	(0.76 - 1.59)	-	23	33.7	(19.2 - 48.1)	1.13	(0.68 - 1.64)	-
Lung, bronchus & trachea	50	70.2	(50.3 - 90.1)	1.72	(1.25 - 2.23)	^	21	25.7	(13.8 - 37.6)	1.35	(0.79 - 1.98)	-
Lymphoma	9	15.2	(4.8 - 25.7)	0.90	(0.34 - 1.57)	-	12	18.5	(7.6 - 29.5)	1.51	(0.69 - 2.47)	-
Unknown primary site	9	11.9	(4.0 - 19.8)	1.09	(0.42 - 1.92)	-	8	10.2	(2.9 - 17.4)	1.22	(0.43 - 2.20)	-
Kidney & other renal tract	11	18.3	(6.9 - 29.7)	1.66	(0.72 - 2.78)	-	6	9.0	(1.4 - 16.6)	1.53	(0.41 - 2.98)	-*
Leukaemia	10	14.8	(5.3 - 24.3)	1.60	(0.66 - 2.73)	-	4	6.3	(0.0 - 13.9)	0.94	(0.15 - 2.06)	-*
Pancreas	11	14.2	(5.7 - 22.8)	2.43	(1.06 - 4.05)	^	9	11.1	(3.3 - 18.8)	1.86	(0.71 - 3.26)	-
Urinary bladder	3	3.6	(0.0 - 7.8)	0.44	(0.04 - 1.02)	-	2	1.4	(0.0 - 3.3)	0.78	(0.01 - 2.17)	-*
Stomach	9	11.2	(3.8 - 18.6)	1.53	(0.59 - 2.67)	-	2	2.3	(0.0 - 5.5)	0.61	(0.01 - 1.69)	-*
Corpus uteri	0	-	-	-	-	.	6	6.5	(0.7 - 12.3)	0.92	(0.25 - 1.78)	-
Brain	8	13.6	(4.0 - 23.3)	2.16	(0.76 - 3.89)	-*	3	3.8	(0.0 - 8.1)	1.13	(0.09 - 2.64)	-*
Lip	8	12.5	(3.7 - 21.2)	2.17	(0.76 - 3.90)	-*	3	4.0	(0.0 - 8.9)	1.63	(0.13 - 3.81)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	5	6.0	(0.2 - 11.8)	0.86	(0.19 - 1.77)	-
Other lymphohaematopoietic	1	1.0	(0.0 - 3.0)	0.30	(0.00 - 1.12)	-*	4	3.6	(0.0 - 7.6)	1.62	(0.25 - 3.56)	-*
Oesophagus	5	6.6	(0.7 - 12.5)	1.35	(0.29 - 2.76)	-*	4	5.8	(0.0 - 11.7)	2.15	(0.33 - 4.72)	-*
Thyroid gland	2	2.8	(0.0 - 6.8)	1.53	(0.02 - 4.26)	-*	2	2.3	(0.0 - 5.8)	0.59	(0.01 - 1.64)	-*
Myeloma/plasma cell tumours	2	3.0	(0.0 - 7.3)	0.71	(0.01 - 1.99)	-*	4	4.7	(0.0 - 9.6)	1.87	(0.29 - 4.11)	-*
Cervix uteri	0	-	-	-	-	.	9	13.3	(4.3 - 22.4)	2.09	(0.80 - 3.66)	-*
Non-mel. skin (exc BCC/SCC)	4	6.4	(0.1 - 12.6)	1.42	(0.22 - 3.11)	-*	2	2.4	(0.0 - 6.3)	1.18	(0.01 - 3.29)	-*
Mesothelioma	3	4.0	(0.0 - 8.6)	0.88	(0.07 - 2.05)	-*	1	1.8	(0.0 - 5.4)	1.94	(0.00 - 7.16)	-*
Liver & intrahepatic bile duct	3	4.7	(0.0 - 10.2)	1.22	(0.10 - 2.84)	-*	2	1.7	(0.0 - 4.1)	2.15	(0.03 - 5.99)	-*
Testis	4	7.3	(0.1 - 14.4)	1.41	(0.22 - 3.10)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	2	3.3	(0.0 - 7.9)	1.36	(0.02 - 3.79)	-*	2	2.5	(0.0 - 6.2)	1.22	(0.02 - 3.40)	-*
Larynx	6	9.0	(1.5 - 16.4)	2.37	(0.64 - 4.62)	-*	0	-	-	-	-	.
Tongue	3	4.9	(0.0 - 10.6)	2.08	(0.17 - 4.85)	-*	3	2.2	(0.0 - 4.9)	4.99	(0.40 - 11.65)	-*
Connective & soft tissues	0	-	-	0	n/a	-	3	5.1	(0.0 - 11.0)	4.11	(0.33 - 9.60)	-*
Tonsil & oropharynx	2	2.9	(0.0 - 7.2)	1.74	(0.02 - 4.84)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Eye & lacrimal gland	0	-	-	0	n/a	-	1	1.1	(0.0 - 3.4)	2.74	(0.00 - 10.10)	-*
Major Salivary Gland	2	2.3	(0.0 - 5.4)	3.21	(0.04 - 8.95)	-*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	1	1.5	(0.0 - 4.4)	1.65	(0.00 - 6.10)	-*
Mouth, other & unspecified	1	1.7	(0.0 - 5.0)	1.60	(0.00 - 5.89)	-*	2	3.7	(0.0 - 8.9)	5.12	(0.06 - 14.27)	-*
Floor of mouth	1	1.0	(0.0 - 3.0)	1.41	(0.00 - 5.21)	-*	1	1.8	(0.0 - 5.4)	3.81	(0.00 - 14.07)	-*
Bones, joints & articular cart.	0	-	-	-	-	.	1	2.4	(0.0 - 7.0)	2.31	(0.00 - 8.51)	-*
Pyriform sinus & hypopharynx	1	1.5	(0.0 - 4.3)	1.43	(0.00 - 5.26)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	1	1.8	(0.0 - 5.4)	5.44	(0.00 - 20.07)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	2	3.0	(0.0 - 7.2)	4.95	(0.06 - 13.78)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	1	1.0	(0.0 - 3.0)	2.74	(0.00 - 10.12)	-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	287	419.2	(369.7 - 468.7)	1.21	(1.08 - 1.36)	^	233	314.6	(271.5 - 357.7)	1.19	(1.05 - 1.36)	^

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Gingin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	9	56.2	(19.2 - 93.1)	0.70	(0.27 - 1.23)	-
Colorectal cancer	10	60.6	(21.8 - 99.4)	1.22	(0.50 - 2.08)	-	4	27.1	(0.3 - 54.0)	0.83	(0.13 - 1.82)	-
Prostate gland	22	114.7	(66.6 - 162.9)	1.57	(0.93 - 2.29)	-	0	-	-	-	-	.
Melanoma (skin)	4	26.0	(0.0 - 52.0)	0.57	(0.09 - 1.25)	-	6	41.2	(7.6 - 74.8)	1.40	(0.38 - 2.73)	-*
Lung, bronchus & trachea	8	47.6	(13.1 - 82.1)	1.10	(0.39 - 1.98)	-	1	6.4	(0.0 - 18.9)	0.34	(0.00 - 1.25)	-*
Lymphoma	2	18.7	(0.0 - 46.9)	0.82	(0.01 - 2.29)	-*	0	-	-	0	n/a	-
Unknown primary site	3	16.8	(0.0 - 35.7)	1.55	(0.13 - 3.62)	-*	1	5.5	(0.0 - 16.2)	0.93	(0.00 - 3.44)	-*
Kidney & other renal tract	3	26.5	(0.0 - 60.0)	1.78	(0.14 - 4.16)	-*	0	-	-	0	n/a	-
Leukaemia	3	16.0	(0.0 - 34.3)	2.03	(0.16 - 4.74)	-*	2	23.9	(0.0 - 60.4)	2.55	(0.03 - 7.11)	-*
Pancreas	2	9.9	(0.0 - 23.6)	1.76	(0.02 - 4.90)	-*	2	11.4	(0.0 - 27.2)	2.34	(0.03 - 6.52)	-*
Urinary bladder	2	10.0	(0.0 - 23.9)	1.30	(0.02 - 3.61)	-*	0	-	-	-	-	.
Stomach	3	20.8	(0.0 - 45.9)	2.09	(0.17 - 4.87)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	1	5.3	(0.0 - 15.7)	1.05	(0.00 - 3.86)	-*	1	9.1	(0.0 - 26.9)	1.92	(0.00 - 7.07)	-*
Lip	1	5.3	(0.0 - 15.7)	1.05	(0.00 - 3.87)	-*	3	18.2	(0.0 - 38.8)	8.47	(0.68 - 19.77)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	3	18.1	(0.0 - 38.7)	2.55	(0.21 - 5.94)	-*
Other lymphohaematopoietic	1	6.8	(0.0 - 20.2)	1.42	(0.00 - 5.24)	-*	0	-	-	-	-	.
Oesophagus	1	5.3	(0.0 - 15.7)	1.08	(0.00 - 3.98)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	9.1	(0.0 - 26.9)	1.41	(0.00 - 5.20)	-*
Myeloma/plasma cell tumours	2	11.5	(0.0 - 27.8)	2.97	(0.04 - 8.28)	-*	1	5.6	(0.0 - 16.4)	2.50	(0.00 - 9.23)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	3	15.0	(0.0 - 32.2)	9.77	(0.79 - 22.80)	-*
Mesothelioma	0	-	-	0	n/a	-	1	6.7	(0.0 - 19.7)	9.77	(0.00 - 36.05)	-*
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	2	9.4	(0.0 - 22.4)	2.80	(0.04 - 7.81)	-*	0	-	-	-	-	.
Tongue	3	18.1	(0.0 - 39.2)	7.52	(0.61 - 17.55)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	1	6.2	(0.0 - 18.4)	14.37	(0.00 - 53.02)	-*
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	1	5.6	(0.0 - 16.4)	12.21	(0.00 - 45.03)	-*
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	73	429.4	(327.1 - 531.7)	1.23	(0.97 - 1.55)	-	40	265.1	(179.3 - 350.8)	1.01	(0.70 - 1.35)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Gnowangerup (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	7	153.7	(39.1 - 268.3)	1.78	(0.56 - 3.32)	-*
Colorectal cancer	4	83.9	(0.6 - 167.1)	1.73	(0.27 - 3.80)	-*	4	56.2	(0.0 - 112.8)	2.50	(0.39 - 5.48)	-*
Prostate gland	7	144.1	(36.2 - 252.1)	1.88	(0.59 - 3.51)	-*	0	-	-	-	-	.
Melanoma (skin)	3	58.2	(0.0 - 126.8)	1.38	(0.11 - 3.22)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	1	24.2	(0.0 - 71.4)	0.50	(0.00 - 1.84)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	0	-	-	-	-	.
Kidney & other renal tract	3	59.8	(0.0 - 129.4)	6.10	(0.49 - 14.24)	-*	0	-	-	-	-	.
Leukaemia	1	27.6	(0.0 - 81.5)	2.09	(0.00 - 7.70)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	2	43.4	(0.0 - 103.4)	4.79	(0.06 - 13.36)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	2	42.7	(0.0 - 102.1)	6.63	(0.08 - 18.46)	-*	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	1	16.1	(0.0 - 47.5)	4.45	(0.00 - 16.41)	-*	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	1	14.5	(0.0 - 43.0)	3.89	(0.00 - 14.33)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	12.0	(0.0 - 35.5)	10.33	(0.00 - 38.09)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	1	16.1	(0.0 - 47.5)	37.98	(0.00 - 140.12)	-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	26	530.7	(325.7 - 735.7)	1.51	(0.94 - 2.14)	-	12	221.9	(92.2 - 351.7)	0.93	(0.43 - 1.53)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Goomalling (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	47.1	(0.0 - 116.0)	0.71	(0.01 - 1.98)	-*
Colorectal cancer	1	25.0	(0.0 - 73.7)	0.55	(0.00 - 2.03)	-*	1	35.0	(0.0 - 103.3)	0.79	(0.00 - 2.93)	-*
Prostate gland	4	101.3	(3.0 - 199.7)	1.33	(0.21 - 2.91)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lymphoma	1	25.0	(0.0 - 72.8)	1.77	(0.00 - 6.54)	-*	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	29.9	(0.0 - 88.1)	3.06	(0.00 - 11.30)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	9.8	(0.0 - 28.8)	22.16	(0.00 - 81.76)	-*
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	1	24.4	(0.0 - 72.1)	11.49	(0.00 - 42.39)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	1	25.0	(0.0 - 73.7)	24.62	(0.00 - 90.83)	-*	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	24.4	(0.0 - 72.1)	22.96	(0.00 - 84.68)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	10	254.9	(99.4 - 410.5)	0.75	(0.31 - 1.29)	-	4	91.9	(0.0 - 190.8)	0.42	(0.06 - 0.91)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Gosnells (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	0.6	(0.0 - 1.7)	0.87	(0.00 - 3.21)	-*	201	84.1	(72.2 - 96.0)	0.99	(0.86 - 1.14)	-
Colorectal cancer	110	50.6	(40.9 - 60.2)	1.10	(0.91 - 1.33)	-	74	29.5	(22.5 - 36.4)	0.97	(0.77 - 1.23)	-
Prostate gland	140	64.7	(53.8 - 75.6)	0.87	(0.73 - 1.03)	-	0	-	-	-	-	.
Melanoma (skin)	69	30.5	(23.2 - 37.8)	0.70	(0.55 - 0.89)	V	45	18.6	(13.0 - 24.1)	0.60	(0.43 - 0.79)	V
Lung, bronchus & trachea	87	40.1	(31.5 - 48.7)	1.02	(0.82 - 1.26)	-	45	17.1	(11.9 - 22.3)	0.99	(0.70 - 1.30)	-
Lymphoma	38	16.4	(11.1 - 21.7)	1.10	(0.75 - 1.48)	-	14	5.9	(2.6 - 9.1)	0.55	(0.27 - 0.88)	V
Unknown primary site	23	10.4	(6.0 - 14.7)	0.93	(0.56 - 1.35)	-	16	5.3	(2.6 - 8.0)	0.88	(0.46 - 1.35)	-
Kidney & other renal tract	23	10.1	(5.9 - 14.3)	1.06	(0.64 - 1.54)	-	16	7.2	(3.5 - 10.9)	1.27	(0.67 - 1.97)	-
Leukaemia	21	9.1	(5.0 - 13.1)	1.01	(0.59 - 1.49)	-	16	7.3	(3.6 - 11.1)	1.19	(0.62 - 1.84)	-
Pancreas	16	6.7	(3.3 - 10.0)	1.15	(0.60 - 1.78)	-	15	6.2	(2.9 - 9.6)	1.11	(0.56 - 1.73)	-
Urinary bladder	27	12.6	(7.8 - 17.4)	1.40	(0.88 - 1.98)	-	6	2.3	(0.3 - 4.3)	0.89	(0.24 - 1.73)	-
Stomach	16	6.9	(3.5 - 10.4)	0.90	(0.47 - 1.39)	-	8	3.5	(1.0 - 6.0)	0.87	(0.31 - 1.56)	-
Corpus uteri	0	-	-	-	-	.	25	9.3	(5.5 - 13.1)	1.16	(0.72 - 1.66)	-
Brain	10	4.6	(1.7 - 7.5)	0.74	(0.31 - 1.27)	-	10	4.1	(1.5 - 6.7)	1.11	(0.46 - 1.90)	-
Lip	22	9.2	(5.3 - 13.2)	1.61	(0.95 - 2.35)	-	6	1.9	(0.3 - 3.4)	1.03	(0.28 - 2.01)	-
Ovary & uterine adnexa	0	-	-	-	-	.	25	10.2	(6.1 - 14.4)	1.35	(0.83 - 1.93)	-
Other lymphohaematopoietic	7	3.5	(0.9 - 6.1)	0.78	(0.24 - 1.45)	-	8	3.7	(1.0 - 6.4)	1.17	(0.41 - 2.12)	-
Oesophagus	10	4.8	(1.8 - 7.8)	0.88	(0.36 - 1.51)	-	1	0.4	(0.0 - 1.3)	0.19	(0.00 - 0.70)	V
Thyroid gland	8	3.4	(1.0 - 5.8)	1.54	(0.54 - 2.78)	-	12	5.1	(2.2 - 8.1)	0.87	(0.40 - 1.43)	-
Myeloma/plasma cell tumours	11	5.2	(2.1 - 8.3)	1.31	(0.57 - 2.19)	-	7	2.4	(0.5 - 4.2)	1.12	(0.35 - 2.08)	-
Cervix uteri	0	-	-	-	-	.	20	8.5	(4.7 - 12.3)	1.21	(0.69 - 1.80)	-
Non-mel. skin (exc BCC/SCC)	8	3.6	(1.1 - 6.1)	0.91	(0.32 - 1.64)	-	1	0.4	(0.0 - 1.1)	0.19	(0.00 - 0.69)	V
Mesothelioma	15	7.0	(3.4 - 10.5)	1.47	(0.75 - 2.30)	-	3	1.1	(0.0 - 2.4)	1.93	(0.16 - 4.52)	-*
Liver & intrahepatic bile duct	9	3.5	(1.2 - 5.9)	1.15	(0.44 - 2.01)	-	3	1.1	(0.0 - 2.5)	1.06	(0.09 - 2.46)	-*
Testis	14	6.0	(2.8 - 9.2)	1.12	(0.55 - 1.78)	-	0	-	-	-	-	.
Gallbladder & bile ducts	4	1.7	(0.0 - 3.5)	0.87	(0.13 - 1.91)	-	5	2.0	(0.1 - 3.9)	1.10	(0.24 - 2.25)	-
Larynx	11	5.0	(2.0 - 8.0)	1.30	(0.57 - 2.17)	-	0	-	-	0	n/a	-
Tongue	8	3.5	(1.0 - 6.0)	1.51	(0.53 - 2.71)	-	2	0.8	(0.0 - 1.8)	1.07	(0.01 - 2.99)	-*
Connective & soft tissues	2	0.7	(0.0 - 1.8)	0.48	(0.01 - 1.32)	-*	2	0.8	(0.0 - 1.9)	0.76	(0.01 - 2.11)	-*
Tonsil & oropharynx	2	0.7	(0.0 - 1.8)	0.46	(0.01 - 1.28)	-*	1	0.4	(0.0 - 1.3)	1.11	(0.00 - 4.09)	-*
Vulva/vagina	0	-	-	-	-	.	10	3.9	(1.4 - 6.4)	2.29	(0.94 - 3.91)	-*
Small intestine	0	-	-	0	n/a	-	1	0.4	(0.0 - 1.3)	0.64	(0.00 - 2.37)	-*
Eye & lacrimal gland	1	0.6	(0.0 - 1.7)	0.39	(0.00 - 1.45)	-*	1	0.2	(0.0 - 0.6)	0.84	(0.00 - 3.11)	-*
Major Salivary Gland	0	-	-	0	n/a	-	1	0.6	(0.0 - 1.8)	0.66	(0.00 - 2.43)	-*
Anus	2	0.9	(0.0 - 2.3)	1.32	(0.02 - 3.68)	-*	1	0.6	(0.0 - 1.7)	0.52	(0.00 - 1.92)	-*
Mouth, other & unspecified	0	-	-	0	n/a	-	1	0.6	(0.0 - 1.7)	0.81	(0.00 - 2.98)	-*
Floor of mouth	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bones, joints & articular cart.	4	1.8	(0.0 - 3.7)	2.69	(0.42 - 5.91)	-*	4	1.8	(0.0 - 3.7)	2.48	(0.38 - 5.44)	-*
Pyriform sinus & hypopharynx	2	0.8	(0.0 - 1.8)	0.87	(0.01 - 2.43)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.4	(0.0 - 1.0)	0.65	(0.00 - 2.41)	-*	1	0.4	(0.0 - 1.1)	1.76	(0.00 - 6.49)	-*
Peritoneum & retroperitoneum	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Adrenal & other endocrine	2	1.1	(0.0 - 2.8)	1.93	(0.02 - 5.37)	-*	1	0.4	(0.0 - 1.1)	1.42	(0.00 - 5.23)	-*
Nasopharynx	2	0.9	(0.0 - 2.1)	1.70	(0.02 - 4.73)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	-	.
Penis & other male genital	1	0.4	(0.0 - 1.1)	0.89	(0.00 - 3.30)	-*	0	-	-	-	-	.
Gum	0	-	-	0	n/a	-	1	0.3	(0.0 - 0.8)	2.50	(0.00 - 9.23)	-*
Kaposi sarcoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Thymus	1	0.4	(0.0 - 1.2)	3.30	(0.00 - 12.16)	-*	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	1	0.4	(0.0 - 1.3)	4.37	(0.00 - 16.10)	-*
Spinal cord & cranial nerves	0	-	-	-	-	.	1	0.5	(0.0 - 1.5)	4.47	(0.00 - 16.50)	-*
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	728	328.3	(304.2 - 352.4)	0.97	(0.90 - 1.04)	-	611	249.4	(229.0 - 269.8)	0.95	(0.88 - 1.03)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Greenough (S) - Pt A 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	14	47.5	(21.7 - 73.2)	0.60	(0.30 - 0.95)	V
Colorectal cancer	14	58.3	(26.8 - 89.9)	1.23	(0.61 - 1.96)	-	5	20.0	(2.1 - 37.9)	0.71	(0.16 - 1.46)	-
Prostate gland	13	52.7	(23.9 - 81.5)	0.71	(0.34 - 1.15)	-	0	-	-	-	-	.
Melanoma (skin)	12	42.7	(17.7 - 67.7)	0.99	(0.45 - 1.62)	-	6	18.4	(3.1 - 33.8)	0.68	(0.18 - 1.33)	-
Lung, bronchus & trachea	6	22.7	(4.3 - 41.2)	0.63	(0.17 - 1.23)	-	6	29.0	(5.6 - 52.3)	1.43	(0.39 - 2.79)	-*
Lymphoma	4	14.2	(0.0 - 28.4)	0.97	(0.15 - 2.12)	-*	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	1	4.1	(0.0 - 12.2)	0.64	(0.00 - 2.36)	-*
Kidney & other renal tract	3	10.9	(0.0 - 23.3)	1.18	(0.10 - 2.76)	-*	1	2.9	(0.0 - 8.6)	0.75	(0.00 - 2.78)	-*
Leukaemia	2	6.9	(0.0 - 16.5)	0.82	(0.01 - 2.28)	-*	1	5.1	(0.0 - 15.2)	0.69	(0.00 - 2.56)	-*
Pancreas	3	9.9	(0.0 - 21.5)	1.90	(0.15 - 4.43)	-*	1	5.0	(0.0 - 14.8)	0.86	(0.00 - 3.16)	-*
Urinary bladder	1	2.8	(0.0 - 8.3)	0.50	(0.00 - 1.84)	-*	0	-	-	0	n/a	-
Stomach	1	4.5	(0.0 - 13.3)	0.50	(0.00 - 1.86)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	0	-	-	0	n/a	-	3	12.7	(0.0 - 27.7)	3.02	(0.24 - 7.06)	-*
Lip	2	6.9	(0.0 - 16.5)	1.16	(0.01 - 3.22)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	1	3.4	(0.0 - 10.1)	0.53	(0.00 - 1.95)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Oesophagus	1	4.0	(0.0 - 11.8)	0.79	(0.00 - 2.91)	-*	1	3.4	(0.0 - 10.1)	2.17	(0.00 - 8.02)	-*
Thyroid gland	1	2.8	(0.0 - 8.3)	1.46	(0.00 - 5.38)	-*	3	7.8	(0.0 - 16.8)	1.72	(0.14 - 4.01)	-*
Myeloma/plasma cell tumours	1	3.2	(0.0 - 9.5)	1.06	(0.00 - 3.93)	-*	3	13.4	(0.0 - 28.8)	5.21	(0.42 - 12.17)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	2	8.8	(0.0 - 21.0)	2.05	(0.03 - 5.72)	-*	0	-	-	0	n/a	-
Mesothelioma	1	4.9	(0.0 - 14.3)	0.87	(0.00 - 3.21)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	2	7.2	(0.0 - 17.3)	3.86	(0.05 - 10.75)	-*	0	-	-	-	-	.
Larynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Tongue	0	-	-	0	n/a	-	0	-	-	-	-	.
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-	.
Tonsil & oropharynx	1	2.5	(0.0 - 7.4)	1.83	(0.00 - 6.73)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	1	2.8	(0.0 - 8.3)	3.15	(0.00 - 11.62)	-*	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	1	4.5	(0.0 - 13.3)	5.48	(0.00 - 20.22)	-*	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	1	5.3	(0.0 - 15.6)	13.79	(0.00 - 50.88)	-*
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	1	3.4	(0.0 - 10.1)	34.85	(0.00 - 128.57)	-*
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	5.0	(0.0 - 14.8)	7.79	(0.00 - 28.73)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	72	273.2	(208.9 - 337.5)	0.83	(0.65 - 1.05)	-	49	186.5	(132.4 - 240.5)	0.72	(0.52 - 0.94)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Greenough (S) - Pt B 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	31.0	(0.0 - 91.5)	0.33	(0.00 - 1.23)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	2	49.4	(0.0 - 117.4)	0.63	(0.01 - 1.76)	-*	0	-	-	-	-	.
Melanoma (skin)	2	41.1	(0.0 - 98.1)	1.04	(0.01 - 2.89)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	2	41.1	(0.0 - 98.3)	1.18	(0.01 - 3.29)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	1	25.3	(0.0 - 74.8)	5.72	(0.00 - 21.11)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	1	33.0	(0.0 - 97.2)	3.61	(0.00 - 13.30)	-*	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	1	19.0	(0.0 - 56.3)	3.74	(0.00 - 13.79)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	1	64.5	(0.0 - 190.6)	12.61	(0.00 - 46.53)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	9	248.2	(67.8 - 428.6)	0.61	(0.23 - 1.07)	-	2	56.3	(0.0 - 134.5)	0.23	(0.00 - 0.64)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Halls Creek (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	73.4	(6.6 - 140.1)	0.88	(0.19 - 1.81)	-
Colorectal cancer	2	24.4	(0.0 - 58.0)	0.63	(0.01 - 1.76)	-*	0	-	-	0	n/a	-
Prostate gland	4	59.9	(0.7 - 119.2)	0.79	(0.12 - 1.74)	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	3	39.7	(0.0 - 84.8)	1.14	(0.09 - 2.66)	-*	3	41.9	(0.0 - 89.3)	2.66	(0.21 - 6.21)	-*
Lymphoma	1	12.8	(0.0 - 37.6)	0.82	(0.00 - 3.02)	-*	1	8.9	(0.0 - 26.2)	1.39	(0.00 - 5.11)	-*
Unknown primary site	1	21.3	(0.0 - 62.8)	1.25	(0.00 - 4.62)	-*	1	23.8	(0.0 - 70.2)	2.04	(0.00 - 7.52)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	2	30.1	(0.0 - 73.8)	4.27	(0.05 - 11.90)	-*
Pancreas	2	28.5	(0.0 - 72.3)	4.56	(0.06 - 12.71)	-*	0	-	-	-	-	.
Urinary bladder	1	17.5	(0.0 - 51.9)	1.62	(0.00 - 5.99)	-*	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	13.1	(0.0 - 38.7)	1.75	(0.00 - 6.47)	-*
Brain	0	-	-	0	n/a	-	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	17.2	(0.0 - 50.7)	1.93	(0.00 - 7.12)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	13.1	(0.0 - 38.7)	2.09	(0.00 - 7.70)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	1	9.1	(0.0 - 26.9)	6.03	(0.00 - 22.23)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	1	12.3	(0.0 - 36.4)	52.87	(0.00 - 195.02)	-*	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	16	225.5	(112.0 - 339.1)	0.65	(0.34 - 1.01)	-	15	221.4	(105.4 - 337.5)	0.83	(0.42 - 1.30)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Harvey (S) - Pt A 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	2.5	(0.0 - 7.4)	7.35	(0.00 - 27.11)	-*	21	75.5	(42.5 - 108.5)	0.92	(0.53 - 1.35)	-
Colorectal cancer	18	65.4	(34.6 - 96.3)	1.50	(0.82 - 2.26)	-	10	41.0	(15.2 - 66.9)	1.25	(0.51 - 2.13)	-
Prostate gland	19	75.4	(41.1 - 109.7)	0.98	(0.55 - 1.47)	-	0	-	-	-	-	.
Melanoma (skin)	12	45.9	(17.9 - 73.9)	1.01	(0.46 - 1.66)	-	6	20.2	(3.6 - 36.7)	0.71	(0.19 - 1.38)	-
Lung, bronchus & trachea	7	23.3	(5.6 - 40.9)	0.67	(0.21 - 1.25)	-	9	37.4	(12.7 - 62.2)	1.83	(0.70 - 3.20)	-
Lymphoma	5	15.6	(1.8 - 29.4)	1.20	(0.26 - 2.45)	-*	2	6.4	(0.0 - 15.3)	0.72	(0.01 - 2.00)	-*
Unknown primary site	1	2.6	(0.0 - 7.6)	0.34	(0.00 - 1.24)	-*	2	7.1	(0.0 - 17.0)	1.10	(0.01 - 3.06)	-*
Kidney & other renal tract	6	19.8	(3.6 - 36.1)	2.28	(0.62 - 4.44)	-*	0	-	-	0	n/a	-
Leukaemia	2	8.8	(0.0 - 22.0)	0.79	(0.01 - 2.19)	-*	0	-	-	0	n/a	-
Pancreas	1	4.7	(0.0 - 13.8)	0.59	(0.00 - 2.19)	-*	2	9.2	(0.0 - 21.9)	1.44	(0.02 - 4.01)	-*
Urinary bladder	3	9.9	(0.0 - 21.6)	1.29	(0.10 - 3.00)	-*	0	-	-	0	n/a	-
Stomach	1	8.1	(0.0 - 23.7)	0.46	(0.00 - 1.70)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	2	9.6	(0.0 - 23.0)	0.85	(0.01 - 2.36)	-*
Brain	1	4.7	(0.0 - 13.8)	0.62	(0.00 - 2.29)	-*	0	-	-	0	n/a	-
Lip	2	7.7	(0.0 - 18.7)	1.20	(0.02 - 3.35)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	2	9.2	(0.0 - 21.8)	0.99	(0.01 - 2.77)	-*
Other lymphohaematopoietic	2	7.4	(0.0 - 17.6)	1.84	(0.02 - 5.13)	-*	0	-	-	0	n/a	-
Oesophagus	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Thyroid gland	1	2.6	(0.0 - 7.8)	1.57	(0.00 - 5.78)	-*	2	7.3	(0.0 - 17.5)	1.25	(0.02 - 3.48)	-*
Myeloma/plasma cell tumours	2	7.4	(0.0 - 18.1)	1.99	(0.02 - 5.53)	-*	0	-	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	2	6.7	(0.0 - 16.4)	1.02	(0.01 - 2.85)	-*
Non-mel. skin (exc BCC/SCC)	2	7.3	(0.0 - 17.9)	1.88	(0.02 - 5.24)	-*	1	4.3	(0.0 - 12.8)	1.82	(0.00 - 6.73)	-*
Mesothelioma	2	9.5	(0.0 - 22.6)	1.62	(0.02 - 4.50)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	-	-	-	.
Larynx	1	3.7	(0.0 - 11.0)	0.98	(0.00 - 3.60)	-*	0	-	-	-	-	.
Tongue	0	-	-	0	n/a	-	0	-	-	-	-	.
Connective & soft tissues	2	11.2	(0.0 - 28.0)	4.05	(0.05 - 11.28)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	1	3.5	(0.0 - 10.3)	8.14	(0.00 - 30.04)	-*
Major Salivary Gland	1	3.1	(0.0 - 9.3)	4.24	(0.00 - 15.63)	-*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	2.7	(0.0 - 8.0)	7.50	(0.00 - 27.65)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	2.5	(0.0 - 7.4)	5.28	(0.00 - 19.49)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	1	2.6	(0.0 - 7.8)	12.86	(0.00 - 47.44)	-*
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	93	348.9	(275.3 - 422.5)	1.02	(0.83 - 1.26)	-	64	242.6	(182.1 - 303.1)	0.91	(0.70 - 1.17)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Harvey (S) - Pt B 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	24	97.5	(58.1 - 136.9)	1.09	(0.66 - 1.57)	-
Colorectal cancer	16	54.5	(27.4 - 81.7)	1.21	(0.63 - 1.87)	-	6	20.8	(3.7 - 38.0)	0.66	(0.18 - 1.28)	-
Prostate gland	26	85.7	(52.4 - 119.0)	1.19	(0.74 - 1.69)	-	0	-	-	-	-	.
Melanoma (skin)	12	45.2	(18.9 - 71.5)	1.04	(0.48 - 1.71)	-	8	27.0	(7.2 - 46.8)	1.03	(0.36 - 1.86)	-
Lung, bronchus & trachea	10	32.0	(11.9 - 52.2)	0.86	(0.35 - 1.47)	-	4	12.2	(0.0 - 25.0)	0.74	(0.11 - 1.61)	-
Lymphoma	8	28.2	(7.1 - 49.3)	1.92	(0.68 - 3.47)	-*	5	18.5	(1.6 - 35.4)	1.75	(0.38 - 3.59)	-*
Unknown primary site	2	6.1	(0.0 - 14.7)	0.60	(0.01 - 1.67)	-*	3	8.0	(0.0 - 17.9)	1.31	(0.11 - 3.05)	-*
Kidney & other renal tract	1	3.9	(0.0 - 11.4)	0.37	(0.00 - 1.35)	-*	1	4.1	(0.0 - 12.1)	0.70	(0.00 - 2.58)	-*
Leukaemia	3	13.3	(0.0 - 30.5)	1.17	(0.09 - 2.74)	-*	3	18.7	(0.0 - 40.7)	1.94	(0.16 - 4.53)	-*
Pancreas	3	9.6	(0.0 - 20.6)	1.64	(0.13 - 3.82)	-*	1	3.7	(0.0 - 10.8)	0.60	(0.00 - 2.20)	-*
Urinary bladder	2	6.7	(0.0 - 16.0)	0.73	(0.01 - 2.04)	-*	2	3.4	(0.0 - 8.2)	2.33	(0.03 - 6.50)	-*
Stomach	2	6.7	(0.0 - 16.0)	0.84	(0.01 - 2.34)	-*	2	3.4	(0.0 - 8.2)	1.76	(0.02 - 4.90)	-*
Corpus uteri	0	-	-	-	-	.	5	17.6	(1.5 - 33.7)	2.02	(0.44 - 4.15)	-*
Brain	1	4.0	(0.0 - 11.8)	0.64	(0.00 - 2.37)	-*	0	-	-	0	n/a	-
Lip	0	-	-	0	n/a	-	1	4.1	(0.0 - 12.1)	1.49	(0.00 - 5.49)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	1	3.8	(0.0 - 11.1)	0.47	(0.00 - 1.72)	-*
Other lymphohaematopoietic	3	9.3	(0.0 - 20.1)	2.33	(0.19 - 5.43)	-*	1	4.3	(0.0 - 12.6)	1.19	(0.00 - 4.38)	-*
Oesophagus	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Thyroid gland	0	-	-	0	n/a	-	2	8.0	(0.0 - 19.2)	1.50	(0.02 - 4.17)	-*
Myeloma/plasma cell tumours	2	6.7	(0.0 - 16.4)	1.77	(0.02 - 4.94)	-*	1	4.4	(0.0 - 13.1)	1.32	(0.00 - 4.87)	-*
Cervix uteri	0	-	-	-	-	.	3	8.7	(0.0 - 18.9)	1.81	(0.15 - 4.23)	-*
Non-mel. skin (exc BCC/SCC)	2	7.2	(0.0 - 17.2)	1.75	(0.02 - 4.89)	-*	2	3.9	(0.0 - 9.3)	3.30	(0.04 - 9.19)	-*
Mesothelioma	2	6.4	(0.0 - 15.5)	1.43	(0.02 - 3.99)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	2	7.0	(0.0 - 16.6)	1.97	(0.02 - 5.49)	-*	0	-	-	-	-	.
Testis	2	7.9	(0.0 - 18.9)	1.68	(0.02 - 4.68)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Larynx	1	3.8	(0.0 - 11.2)	0.94	(0.00 - 3.45)	-*	0	-	-	-	-	.
Tongue	1	3.9	(0.0 - 11.4)	1.60	(0.00 - 5.89)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	1	4.1	(0.0 - 12.1)	9.27	(0.00 - 34.21)	-*
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	1	3.8	(0.0 - 11.2)	3.75	(0.00 - 13.83)	-*	1	3.6	(0.0 - 10.8)	6.93	(0.00 - 25.55)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	3.5	(0.0 - 10.3)	5.32	(0.00 - 19.62)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	103	355.4	(285.3 - 425.4)	1.06	(0.87 - 1.29)	-	77	279.9	(214.3 - 345.4)	1.07	(0.85 - 1.34)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Irwin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	8	85.7	(25.7 - 145.7)	0.92	(0.33 - 1.67)	-
Colorectal cancer	2	14.9	(0.0 - 35.8)	0.33	(0.00 - 0.92)	V	4	35.6	(0.1 - 71.2)	1.18	(0.18 - 2.58)	-*
Prostate gland	9	73.4	(25.2 - 121.5)	0.88	(0.34 - 1.55)	-	0	-	-	-	-	.
Melanoma (skin)	5	40.7	(4.6 - 76.9)	1.00	(0.22 - 2.05)	-	8	88.4	(24.9 - 151.9)	2.73	(0.96 - 4.91)	-*
Lung, bronchus & trachea	9	57.1	(19.4 - 94.8)	1.65	(0.63 - 2.89)	-	3	21.3	(0.0 - 45.3)	1.43	(0.12 - 3.33)	-*
Lymphoma	3	22.6	(0.0 - 48.4)	1.68	(0.14 - 3.92)	-*	2	37.1	(0.0 - 93.7)	1.84	(0.02 - 5.13)	-*
Unknown primary site	0	-	-	0	n/a	-	2	16.5	(0.0 - 39.8)	2.60	(0.03 - 7.25)	-*
Kidney & other renal tract	3	21.6	(0.0 - 46.1)	2.45	(0.20 - 5.72)	-*	0	-	-	0	n/a	-
Leukaemia	1	7.7	(0.0 - 22.8)	0.89	(0.00 - 3.29)	-*	1	8.0	(0.0 - 23.7)	1.81	(0.00 - 6.68)	-*
Pancreas	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Urinary bladder	3	17.3	(0.0 - 37.0)	2.42	(0.20 - 5.66)	-*	1	8.0	(0.0 - 23.7)	3.40	(0.00 - 12.53)	-*
Stomach	2	15.6	(0.0 - 37.1)	1.84	(0.02 - 5.14)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	9.8	(0.0 - 29.0)	1.03	(0.00 - 3.79)	-*
Brain	0	-	-	0	n/a	-	0	-	-	-	-	.
Lip	1	6.2	(0.0 - 18.3)	1.50	(0.00 - 5.54)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	22.5	(0.0 - 53.5)	2.44	(0.03 - 6.79)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	1	5.0	(0.0 - 14.8)	1.45	(0.00 - 5.33)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	2	19.8	(0.0 - 47.1)	3.23	(0.04 - 9.01)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	3	30.7	(0.0 - 65.5)	14.06	(1.13 - 32.82)	^*
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	7.8	(0.0 - 23.2)	2.03	(0.00 - 7.48)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	40	290.0	(199.5 - 380.4)	0.92	(0.63 - 1.22)	-	37	383.4	(253.4 - 513.4)	1.35	(0.92 - 1.82)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Jerramungup (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	2	54.3	(0.0 - 129.6)	1.10	(0.01 - 3.07)	-*	0	-	-	0	n/a	-
Prostate gland	3	69.0	(0.0 - 149.3)	1.03	(0.08 - 2.39)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	1	40.4	(0.0 - 119.2)	0.97	(0.00 - 3.59)	-*
Lung, bronchus & trachea	1	24.0	(0.0 - 70.8)	0.65	(0.00 - 2.38)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	1	20.5	(0.0 - 60.8)	2.55	(0.00 - 9.41)	-*	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	2	62.3	(0.0 - 148.3)	5.83	(0.07 - 16.23)	-*	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	1	22.8	(0.0 - 67.5)	8.19	(0.00 - 30.20)	-*
Lip	1	32.0	(0.0 - 94.5)	3.98	(0.00 - 14.68)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	22.3	(0.0 - 65.9)	4.24	(0.00 - 15.63)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	19.9	(0.0 - 58.7)	6.44	(0.00 - 23.75)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	11	282.0	(113.3 - 450.6)	0.81	(0.35 - 1.36)	-	3	85.5	(0.0 - 186.1)	0.35	(0.03 - 0.82)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Joondalup (C) - North 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	91	74.7	(58.6 - 90.8)	0.91	(0.74 - 1.12)	-
Colorectal cancer	47	46.4	(32.6 - 60.3)	1.07	(0.77 - 1.40)	-	32	28.1	(18.0 - 38.3)	0.96	(0.63 - 1.32)	-
Prostate gland	76	79.7	(61.3 - 98.1)	1.10	(0.87 - 1.39)	-	0	-	-	-	-	.
Melanoma (skin)	49	43.2	(30.4 - 56.0)	1.01	(0.73 - 1.31)	-	41	31.6	(21.5 - 41.6)	1.07	(0.74 - 1.42)	-
Lung, bronchus & trachea	35	38.2	(25.3 - 51.1)	0.95	(0.64 - 1.29)	-	20	19.7	(10.8 - 28.6)	1.01	(0.58 - 1.49)	-
Lymphoma	18	17.7	(9.2 - 26.1)	1.09	(0.60 - 1.64)	-	13	10.1	(4.4 - 15.7)	1.10	(0.52 - 1.77)	-
Unknown primary site	12	10.8	(4.5 - 17.1)	1.12	(0.51 - 1.84)	-	11	8.6	(3.3 - 13.9)	1.38	(0.60 - 2.31)	-
Kidney & other renal tract	14	12.4	(5.6 - 19.1)	1.40	(0.69 - 2.23)	-	5	4.0	(0.3 - 7.8)	0.84	(0.18 - 1.73)	-
Leukaemia	4	4.8	(0.0 - 9.7)	0.41	(0.06 - 0.89)	V	7	7.3	(1.7 - 12.8)	1.08	(0.34 - 2.02)	-
Pancreas	7	7.2	(1.7 - 12.8)	1.13	(0.36 - 2.11)	-	4	3.4	(0.0 - 6.9)	0.70	(0.11 - 1.53)	-
Urinary bladder	10	12.7	(4.7 - 20.8)	1.25	(0.52 - 2.14)	-	1	0.7	(0.0 - 2.2)	0.36	(0.00 - 1.31)	-*
Stomach	11	10.6	(4.3 - 17.0)	1.40	(0.61 - 2.34)	-	4	3.9	(0.0 - 7.8)	1.00	(0.16 - 2.20)	-*
Corpus uteri	0	-	-	-	-	.	6	6.6	(1.3 - 11.9)	0.61	(0.16 - 1.18)	-
Brain	3	2.8	(0.0 - 6.1)	0.45	(0.04 - 1.05)	-	6	4.8	(0.9 - 8.7)	1.35	(0.37 - 2.63)	-*
Lip	6	5.4	(0.8 - 10.0)	0.86	(0.23 - 1.67)	-	5	5.0	(0.5 - 9.4)	1.87	(0.41 - 3.84)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	9	8.3	(2.7 - 13.8)	1.06	(0.41 - 1.86)	-
Other lymphohaematopoietic	5	6.3	(0.6 - 11.9)	1.35	(0.29 - 2.76)	-*	0	-	-	0	n/a	-
Oesophagus	7	6.3	(1.6 - 11.0)	1.40	(0.44 - 2.62)	-	4	2.8	(0.0 - 5.6)	1.80	(0.28 - 3.94)	-*
Thyroid gland	5	3.2	(0.4 - 6.0)	1.79	(0.39 - 3.66)	-*	12	10.2	(4.2 - 16.1)	1.60	(0.73 - 2.62)	-
Myeloma/plasma cell tumours	2	2.8	(0.0 - 6.8)	0.54	(0.01 - 1.51)	-*	1	1.0	(0.0 - 3.1)	0.37	(0.00 - 1.35)	-*
Cervix uteri	0	-	-	-	-	.	2	2.3	(0.0 - 5.5)	0.22	(0.00 - 0.61)	V
Non-mel. skin (exc BCC/SCC)	2	1.9	(0.0 - 4.6)	0.50	(0.01 - 1.40)	-*	0	-	-	0	n/a	-
Mesothelioma	7	7.0	(1.7 - 12.3)	1.60	(0.50 - 2.99)	-*	1	0.7	(0.0 - 2.0)	1.45	(0.00 - 5.34)	-*
Liver & intrahepatic bile duct	4	3.7	(0.0 - 7.5)	1.14	(0.18 - 2.50)	-*	1	1.0	(0.0 - 3.0)	0.76	(0.00 - 2.81)	-*
Testis	6	4.9	(0.8 - 8.9)	0.85	(0.23 - 1.65)	-	0	-	-	-	-	.
Gallbladder & bile ducts	1	1.3	(0.0 - 3.8)	0.49	(0.00 - 1.81)	-*	2	1.5	(0.0 - 3.5)	1.05	(0.01 - 2.93)	-*
Larynx	2	2.0	(0.0 - 5.0)	0.52	(0.01 - 1.45)	-*	0	-	-	0	n/a	-
Tongue	3	2.0	(0.0 - 4.3)	1.15	(0.09 - 2.68)	-*	2	2.5	(0.0 - 6.1)	2.33	(0.03 - 6.48)	-*
Connective & soft tissues	1	0.7	(0.0 - 1.9)	0.48	(0.00 - 1.78)	-*	3	3.4	(0.0 - 7.2)	2.24	(0.18 - 5.22)	-*
Tonsil & oropharynx	1	1.3	(0.0 - 4.0)	0.45	(0.00 - 1.67)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Eye & lacrimal gland	1	0.6	(0.0 - 1.7)	0.78	(0.00 - 2.89)	-*	1	0.8	(0.0 - 2.3)	1.88	(0.00 - 6.93)	-*
Major Salivary Gland	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Anus	0	-	-	0	n/a	-	2	1.7	(0.0 - 4.2)	2.23	(0.03 - 6.21)	-*
Mouth, other & unspecified	2	2.2	(0.0 - 5.3)	1.85	(0.02 - 5.16)	-*	0	-	-	0	n/a	-
Floor of mouth	1	0.7	(0.0 - 1.9)	0.78	(0.00 - 2.87)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	1	0.7	(0.0 - 2.1)	1.27	(0.00 - 4.70)	-*	1	1.1	(0.0 - 3.3)	1.20	(0.00 - 4.42)	-*
Pyriform sinus & hypopharynx	2	2.6	(0.0 - 6.5)	1.94	(0.02 - 5.39)	-*	1	1.0	(0.0 - 3.0)	9.09	(0.00 - 33.53)	-*
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	0	-	-	-	-	.
Peritoneum & retroperitoneum	1	0.9	(0.0 - 2.8)	3.20	(0.00 - 11.82)	-*	0	-	-	0	n/a	-
Adrenal & other endocrine	1	0.9	(0.0 - 2.7)	1.79	(0.00 - 6.60)	-*	1	1.0	(0.0 - 3.0)	2.65	(0.00 - 9.76)	-*
Nasopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Pharynx, other & ill-def.	1	0.7	(0.0 - 2.1)	2.27	(0.00 - 8.36)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	0	n/a	-	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	348	344.5	(307.2 - 381.9)	1.02	(0.92 - 1.14)	-	289	247.7	(218.1 - 277.4)	0.95	(0.84 - 1.07)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Joondalup (C) - South 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	0	n/a	-	303	87.0	(76.7 - 97.4)	1.02	(0.91 - 1.15)	-
Colorectal cancer	130	39.5	(32.4 - 46.5)	0.91	(0.76 - 1.08)	-	103	28.2	(22.4 - 34.0)	0.98	(0.80 - 1.19)	-
Prostate gland	243	78.6	(68.3 - 89.0)	1.06	(0.93 - 1.20)	-	0	-	-	-	-	-
Melanoma (skin)	186	55.9	(47.5 - 64.3)	1.33	(1.15 - 1.53)	^	135	40.9	(33.6 - 48.2)	1.29	(1.09 - 1.53)	^
Lung, bronchus & trachea	99	30.6	(24.3 - 36.9)	0.81	(0.66 - 0.99)	V	67	18.7	(14.0 - 23.5)	1.06	(0.83 - 1.35)	-
Lymphoma	45	14.0	(9.6 - 18.4)	0.91	(0.65 - 1.20)	-	29	8.1	(5.0 - 11.2)	0.83	(0.53 - 1.16)	-
Unknown primary site	27	8.8	(5.3 - 12.2)	0.76	(0.48 - 1.07)	-	24	5.6	(3.2 - 7.9)	0.95	(0.58 - 1.36)	-
Kidney & other renal tract	32	11.3	(7.2 - 15.5)	1.03	(0.68 - 1.41)	-	16	5.4	(2.5 - 8.3)	0.91	(0.48 - 1.41)	-
Leukaemia	33	11.3	(7.2 - 15.4)	1.13	(0.75 - 1.55)	-	10	3.2	(0.9 - 5.4)	0.56	(0.23 - 0.95)	V
Pancreas	20	5.7	(3.1 - 8.3)	1.00	(0.57 - 1.49)	-	24	6.1	(3.5 - 8.7)	1.29	(0.79 - 1.86)	-
Urinary bladder	24	8.0	(4.7 - 11.3)	0.87	(0.53 - 1.25)	-	6	2.2	(0.3 - 4.1)	0.65	(0.18 - 1.27)	-
Stomach	25	8.0	(4.8 - 11.3)	0.97	(0.60 - 1.39)	-	12	3.6	(1.4 - 5.7)	0.95	(0.43 - 1.56)	-
Corpus uteri	0	-	-	-	-	.	32	8.9	(5.7 - 12.1)	1.04	(0.69 - 1.43)	-
Brain	19	6.6	(3.3 - 9.9)	1.00	(0.56 - 1.50)	-	11	3.0	(1.2 - 4.8)	0.86	(0.38 - 1.44)	-
Lip	22	6.1	(3.4 - 8.8)	1.13	(0.67 - 1.64)	-	7	1.8	(0.4 - 3.3)	0.85	(0.27 - 1.58)	-
Ovary & uterine adnexa	0	-	-	-	-	.	29	8.8	(5.4 - 12.2)	1.12	(0.72 - 1.57)	-
Other lymphohaematopoietic	7	2.4	(0.6 - 4.2)	0.54	(0.17 - 1.02)	-	14	3.1	(1.4 - 4.9)	1.51	(0.74 - 2.39)	-
Oesophagus	14	4.0	(1.8 - 6.2)	0.85	(0.42 - 1.36)	-	6	1.6	(0.2 - 3.1)	0.84	(0.23 - 1.63)	-
Thyroid gland	3	0.9	(0.0 - 1.9)	0.41	(0.03 - 0.97)	V	16	4.7	(2.3 - 7.1)	0.82	(0.43 - 1.27)	-
Myeloma/plasma cell tumours	15	4.7	(2.2 - 7.2)	1.24	(0.63 - 1.94)	-	9	2.7	(0.8 - 4.6)	1.03	(0.39 - 1.80)	-
Cervix uteri	0	-	-	-	-	.	21	6.5	(3.6 - 9.4)	0.90	(0.52 - 1.32)	-
Non-mel. skin (exc BCC/SCC)	12	3.3	(1.4 - 5.3)	0.93	(0.43 - 1.53)	-	11	2.8	(1.0 - 4.6)	1.49	(0.65 - 2.50)	-
Mesothelioma	9	2.4	(0.7 - 4.1)	0.62	(0.24 - 1.08)	-	3	0.6	(0.0 - 1.3)	1.39	(0.11 - 3.24)	-*
Liver & intrahepatic bile duct	9	3.0	(1.0 - 5.0)	0.79	(0.30 - 1.39)	-	5	1.6	(0.0 - 3.5)	1.29	(0.28 - 2.64)	-*
Testis	17	6.5	(3.3 - 9.7)	1.07	(0.57 - 1.63)	-	0	-	-	-	-	.
Gallbladder & bile ducts	3	0.8	(0.0 - 1.8)	0.45	(0.04 - 1.04)	-	4	1.1	(0.0 - 2.3)	0.63	(0.10 - 1.39)	-
Larynx	4	1.1	(0.0 - 2.2)	0.32	(0.05 - 0.71)	V	2	0.7	(0.0 - 1.6)	1.22	(0.02 - 3.39)	-*
Tongue	4	1.0	(0.0 - 1.9)	0.51	(0.08 - 1.12)	-	1	0.4	(0.0 - 1.3)	0.38	(0.00 - 1.41)	-*
Connective & soft tissues	3	0.7	(0.0 - 1.5)	0.51	(0.04 - 1.20)	-	9	2.9	(0.9 - 4.8)	2.42	(0.93 - 4.25)	-*
Tonsil & oropharynx	4	0.9	(0.0 - 1.8)	0.60	(0.09 - 1.32)	-	2	0.7	(0.0 - 1.6)	1.59	(0.02 - 4.43)	-*
Vulva/vagina	0	-	-	-	-	.	8	2.7	(0.7 - 4.6)	1.32	(0.46 - 2.38)	-
Small intestine	4	1.1	(0.0 - 2.2)	1.19	(0.18 - 2.62)	-*	1	0.2	(0.0 - 0.7)	0.46	(0.00 - 1.68)	-*
Eye & lacrimal gland	3	1.3	(0.0 - 2.9)	0.84	(0.07 - 1.96)	-*	0	-	-	0	n/a	-
Major Salivary Gland	4	1.3	(0.0 - 2.7)	1.41	(0.22 - 3.09)	-*	3	1.1	(0.0 - 2.3)	1.44	(0.12 - 3.36)	-*
Anus	2	0.7	(0.0 - 1.7)	0.93	(0.01 - 2.59)	-*	0	-	-	0	n/a	-
Mouth, other & unspecified	3	1.1	(0.0 - 2.4)	0.88	(0.07 - 2.06)	-*	2	0.8	(0.0 - 1.9)	1.18	(0.01 - 3.29)	-*
Floor of mouth	5	1.5	(0.1 - 3.0)	1.26	(0.27 - 2.58)	-*	1	0.2	(0.0 - 0.6)	0.89	(0.00 - 3.28)	-*
Bones, joints & articular cart.	2	0.6	(0.0 - 1.4)	0.95	(0.01 - 2.64)	-*	1	0.5	(0.0 - 1.6)	0.47	(0.00 - 1.73)	-*
Pyriform sinus & hypopharynx	1	0.2	(0.0 - 0.6)	0.30	(0.00 - 1.10)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.3	(0.0 - 0.8)	0.44	(0.00 - 1.63)	-*	0	-	-	0	n/a	-
Peritoneum & retroperitoneum	1	0.2	(0.0 - 0.7)	1.23	(0.00 - 4.55)	-*	3	1.6	(0.0 - 3.6)	1.73	(0.14 - 4.03)	-*
Adrenal & other endocrine	0	-	-	0	n/a	-	1	0.3	(0.0 - 0.9)	1.17	(0.00 - 4.32)	-*
Nasopharynx	2	0.5	(0.0 - 1.1)	1.12	(0.01 - 3.12)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	-	.
Penis & other male genital	2	0.9	(0.0 - 2.1)	1.24	(0.02 - 3.45)	-*	0	-	-	-	-	.
Gum	1	0.4	(0.0 - 1.2)	1.35	(0.00 - 4.99)	-*	0	-	-	0	n/a	-
Kaposi sarcoma	1	0.3	(0.0 - 0.8)	1.02	(0.00 - 3.78)	-*	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	1	0.2	(0.0 - 0.6)	2.98	(0.00 - 11.00)	-*	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	0	n/a	-	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	1	0.2	(0.0 - 0.7)	1.53	(0.00 - 5.64)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	1	0.2	(0.0 - 0.5)	24.92	(0.00 - 91.94)	-*
All cancers	1042	326.6	(305.9 - 347.3)	0.97	(0.91 - 1.03)	-	933	268.6	(250.3 - 286.9)	1.03	(0.96 - 1.10)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kalamunda (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	2	1.2	(0.0 - 3.0)	2.33	(0.03 - 6.51)	-*	150	88.0	(73.5 - 102.5)	1.06	(0.90 - 1.24)	-
Colorectal cancer	49	30.4	(21.8 - 39.1)	0.67	(0.48 - 0.86)	V	48	24.9	(17.4 - 32.4)	0.86	(0.62 - 1.12)	-
Prostate gland	108	67.2	(54.4 - 80.0)	0.89	(0.73 - 1.08)	-	0	-	-	-	-	.
Melanoma (skin)	75	49.3	(37.9 - 60.7)	1.13	(0.89 - 1.42)	-	38	23.2	(15.6 - 30.8)	0.77	(0.53 - 1.03)	-
Lung, bronchus & trachea	50	29.7	(21.3 - 38.0)	0.78	(0.57 - 1.01)	-	25	14.1	(8.3 - 19.8)	0.74	(0.46 - 1.06)	-
Lymphoma	30	19.8	(12.3 - 27.2)	1.27	(0.82 - 1.76)	-	18	12.0	(6.2 - 17.8)	1.01	(0.56 - 1.53)	-
Unknown primary site	18	10.9	(5.8 - 16.0)	0.99	(0.54 - 1.49)	-	18	8.1	(4.1 - 12.1)	1.31	(0.72 - 1.99)	-
Kidney & other renal tract	15	8.9	(4.3 - 13.5)	0.97	(0.50 - 1.52)	-	12	7.7	(3.2 - 12.2)	1.34	(0.62 - 2.21)	-
Leukaemia	14	7.9	(3.7 - 12.1)	0.98	(0.49 - 1.56)	-	11	7.6	(2.9 - 12.3)	1.19	(0.52 - 1.98)	-
Pancreas	8	5.2	(1.5 - 8.9)	0.79	(0.28 - 1.42)	-	6	3.8	(0.4 - 7.1)	0.59	(0.16 - 1.15)	-
Urinary bladder	11	6.2	(2.5 - 10.0)	0.75	(0.33 - 1.26)	-	0	-	-	0	n/a	V
Stomach	14	8.8	(4.1 - 13.4)	1.07	(0.53 - 1.69)	-	3	1.2	(0.0 - 2.7)	0.44	(0.04 - 1.02)	-
Corpus uteri	0	-	-	-	-	.	14	7.6	(3.5 - 11.7)	0.90	(0.44 - 1.43)	-
Brain	9	7.4	(1.9 - 12.8)	1.00	(0.38 - 1.75)	-	2	1.5	(0.0 - 3.5)	0.32	(0.00 - 0.90)	V
Lip	3	1.9	(0.0 - 4.0)	0.33	(0.03 - 0.77)	V	2	1.5	(0.0 - 3.7)	0.48	(0.01 - 1.33)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	16	8.3	(4.0 - 12.6)	1.20	(0.63 - 1.86)	-
Other lymphohaematopoietic	6	3.7	(0.7 - 6.8)	0.88	(0.24 - 1.71)	-	4	1.4	(0.0 - 2.9)	0.78	(0.12 - 1.72)	-
Oesophagus	7	4.5	(1.1 - 7.8)	0.84	(0.26 - 1.56)	-	5	2.7	(0.3 - 5.1)	1.27	(0.28 - 2.60)	-*
Thyroid gland	2	1.4	(0.0 - 3.4)	0.61	(0.01 - 1.71)	-*	16	10.3	(5.1 - 15.6)	1.84	(0.97 - 2.85)	-
Myeloma/plasma cell tumours	6	3.8	(0.7 - 6.9)	0.97	(0.26 - 1.88)	-	5	2.4	(0.2 - 4.7)	1.07	(0.23 - 2.20)	-
Cervix uteri	0	-	-	-	-	.	12	7.1	(2.8 - 11.4)	1.13	(0.52 - 1.86)	-
Non-mel. skin (exc BCC/SCC)	2	1.2	(0.0 - 2.8)	0.32	(0.00 - 0.88)	V	3	1.5	(0.0 - 3.3)	0.80	(0.06 - 1.86)	-*
Mesothelioma	13	8.3	(3.7 - 12.8)	1.69	(0.81 - 2.73)	-	2	1.2	(0.0 - 2.8)	1.76	(0.02 - 4.91)	-*
Liver & intrahepatic bile duct	8	4.3	(1.3 - 7.2)	1.40	(0.49 - 2.52)	-	2	1.4	(0.0 - 3.3)	0.98	(0.01 - 2.72)	-*
Testis	11	9.2	(3.6 - 14.7)	1.61	(0.70 - 2.69)	-	0	-	-	-	-	.
Gallbladder & bile ducts	6	3.6	(0.7 - 6.5)	1.78	(0.48 - 3.47)	-*	3	2.0	(0.0 - 4.4)	0.88	(0.07 - 2.05)	-*
Larynx	3	1.5	(0.0 - 3.1)	0.49	(0.04 - 1.14)	-	0	-	-	0	n/a	-
Tongue	4	2.5	(0.0 - 4.9)	1.09	(0.17 - 2.38)	-*	0	-	-	0	n/a	-
Connective & soft tissues	4	2.6	(0.0 - 5.1)	1.45	(0.22 - 3.17)	-*	2	1.6	(0.0 - 3.9)	1.11	(0.01 - 3.10)	-*
Tonsil & oropharynx	5	3.2	(0.4 - 6.0)	1.67	(0.36 - 3.42)	-*	2	0.9	(0.0 - 2.2)	3.02	(0.04 - 8.41)	-*
Vulva/vagina	0	-	-	-	-	.	4	2.3	(0.0 - 4.7)	1.30	(0.20 - 2.84)	-*
Small intestine	2	1.2	(0.0 - 2.9)	1.19	(0.01 - 3.32)	-*	1	0.5	(0.0 - 1.6)	0.88	(0.00 - 3.24)	-*
Eye & lacrimal gland	2	1.3	(0.0 - 3.2)	1.18	(0.01 - 3.29)	-*	0	-	-	0	n/a	-
Major Salivary Gland	0	-	-	0	n/a	-	3	1.2	(0.0 - 2.6)	2.87	(0.23 - 6.69)	-*
Anus	0	-	-	0	n/a	-	2	1.1	(0.0 - 2.8)	1.45	(0.02 - 4.04)	-*
Mouth, other & unspecified	1	0.7	(0.0 - 2.0)	0.63	(0.00 - 2.32)	-*	1	0.3	(0.0 - 0.8)	1.11	(0.00 - 4.11)	-*
Floor of mouth	2	1.2	(0.0 - 2.9)	1.07	(0.01 - 2.98)	-*	0	-	-	0	n/a	-
Bones, joints & articular cart.	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	2	1.4	(0.0 - 3.3)	1.86	(0.02 - 5.19)	-*	1	0.6	(0.0 - 1.9)	2.49	(0.00 - 9.17)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	2	0.9	(0.0 - 2.3)	2.22	(0.03 - 6.19)	-*
Adrenal & other endocrine	0	-	-	0	n/a	-	0	-	-	-	-	.
Nasopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	-	.
Penis & other male genital	0	-	-	0	n/a	-	0	-	-	-	-	.
Gum	1	0.7	(0.0 - 2.0)	2.54	(0.00 - 9.37)	-*	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	1	0.6	(0.0 - 1.9)	4.98	(0.00 - 18.36)	-*	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	1	0.3	(0.0 - 0.8)	3.41	(0.00 - 12.59)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	494	311.4	(283.4 - 339.3)	0.91	(0.83 - 1.00)	-	434	249.2	(224.8 - 273.7)	0.96	(0.87 - 1.05)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kalgoorlie-Boulder (C) - Pt A 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	48	71.6	(50.2 - 92.9)	0.97	(0.70 - 1.26)	-
Colorectal cancer	29	57.7	(35.9 - 79.5)	1.17	(0.75 - 1.63)	-	19	35.5	(18.1 - 52.8)	1.07	(0.60 - 1.60)	-
Prostate gland	42	82.6	(56.9 - 108.2)	1.10	(0.77 - 1.46)	-	0	-	-	-	-	.
Melanoma (skin)	22	25.5	(14.2 - 36.8)	0.72	(0.43 - 1.06)	-	22	25.2	(14.2 - 36.1)	1.03	(0.61 - 1.50)	-
Lung, bronchus & trachea	32	67.5	(43.7 - 91.4)	1.59	(1.05 - 2.19)	^	17	29.0	(14.1 - 43.9)	1.67	(0.90 - 2.56)	-
Lymphoma	10	12.0	(4.0 - 19.9)	0.98	(0.40 - 1.67)	-	7	10.2	(1.9 - 18.4)	1.10	(0.34 - 2.05)	-
Unknown primary site	15	24.9	(11.5 - 38.3)	2.44	(1.24 - 3.81)	^	5	9.2	(0.3 - 18.0)	1.08	(0.24 - 2.22)	-
Kidney & other renal tract	7	10.4	(1.9 - 18.9)	1.21	(0.38 - 2.26)	-	1	1.0	(0.0 - 2.9)	0.32	(0.00 - 1.20)	-*
Leukaemia	7	10.8	(2.3 - 19.4)	1.18	(0.37 - 2.20)	-	5	7.7	(0.1 - 15.3)	1.32	(0.29 - 2.71)	-*
Pancreas	4	7.2	(0.0 - 14.4)	1.16	(0.18 - 2.54)	-*	4	8.3	(0.0 - 16.6)	1.28	(0.20 - 2.80)	-*
Urinary bladder	5	8.7	(0.9 - 16.6)	1.12	(0.24 - 2.30)	-*	2	3.9	(0.0 - 9.8)	1.25	(0.02 - 3.49)	-*
Stomach	3	5.5	(0.0 - 11.9)	0.68	(0.06 - 1.60)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	3	6.8	(0.0 - 15.1)	0.61	(0.05 - 1.42)	-
Brain	5	8.3	(0.5 - 16.2)	1.19	(0.26 - 2.45)	-*	1	1.7	(0.0 - 5.0)	0.42	(0.00 - 1.54)	-*
Lip	6	7.0	(1.3 - 12.8)	1.38	(0.37 - 2.68)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	4	5.7	(0.0 - 11.6)	0.90	(0.14 - 1.97)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	1	2.0	(0.0 - 5.9)	0.59	(0.00 - 2.18)	-*
Oesophagus	1	2.7	(0.0 - 7.9)	0.36	(0.00 - 1.34)	-*	2	5.1	(0.0 - 12.3)	1.66	(0.02 - 4.62)	-*
Thyroid gland	1	0.9	(0.0 - 2.7)	0.55	(0.00 - 2.01)	-*	5	6.0	(0.6 - 11.4)	1.17	(0.26 - 2.40)	-*
Myeloma/plasma cell tumours	1	1.9	(0.0 - 5.6)	0.48	(0.00 - 1.78)	-*	1	2.9	(0.0 - 8.5)	0.68	(0.00 - 2.53)	-*
Cervix uteri	0	-	-	-	-	.	9	10.8	(3.3 - 18.3)	1.78	(0.68 - 3.13)	-
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	2	2.5	(0.0 - 6.0)	1.39	(0.02 - 3.88)	-*
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	3	4.1	(0.0 - 8.8)	1.52	(0.12 - 3.54)	-*	1	1.0	(0.0 - 2.9)	1.41	(0.00 - 5.20)	-*
Testis	9	8.0	(2.7 - 13.3)	1.63	(0.63 - 2.86)	-	0	-	-	-	-	.
Gallbladder & bile ducts	1	1.5	(0.0 - 4.3)	0.88	(0.00 - 3.24)	-*	0	-	-	0	n/a	-
Larynx	3	5.2	(0.0 - 11.3)	1.38	(0.11 - 3.22)	-*	0	-	-	-	-	.
Tongue	5	7.4	(0.8 - 14.1)	3.18	(0.69 - 6.52)	-*	0	-	-	-	-	.
Connective & soft tissues	1	0.9	(0.0 - 2.7)	0.74	(0.00 - 2.73)	-*	0	-	-	0	n/a	-
Tonsil & oropharynx	2	3.6	(0.0 - 9.2)	1.59	(0.02 - 4.42)	-*	1	2.9	(0.0 - 8.5)	5.09	(0.00 - 18.76)	-*
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	0	-	-	0	n/a	-	1	0.8	(0.0 - 2.3)	2.77	(0.00 - 10.22)	-*
Eye & lacrimal gland	0	-	-	0	n/a	-	1	1.5	(0.0 - 4.3)	3.22	(0.00 - 11.89)	-*
Major Salivary Gland	2	3.3	(0.0 - 8.1)	3.38	(0.04 - 9.41)	-*	0	-	-	-	-	.
Anus	3	6.0	(0.0 - 13.1)	7.42	(0.60 - 17.31)	-*	2	1.8	(0.0 - 4.2)	4.26	(0.05 - 11.88)	-*
Mouth, other & unspecified	1	1.2	(0.0 - 3.5)	1.63	(0.00 - 6.01)	-*	1	0.8	(0.0 - 2.3)	3.53	(0.00 - 13.01)	-*
Floor of mouth	3	4.1	(0.0 - 8.7)	4.09	(0.33 - 9.54)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	1	1.7	(0.0 - 5.2)	5.10	(0.00 - 18.81)	-*	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	1	1.5	(0.0 - 4.3)	2.89	(0.00 - 10.65)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	1	2.1	(0.0 - 6.3)	3.98	(0.00 - 14.67)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	226	384.3	(331.6 - 436.9)	1.14	(1.00 - 1.30)	-	165	253.5	(211.5 - 295.5)	1.02	(0.88 - 1.20)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kalgoorlie-Boulder (C) - Pt B 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	1	97.6	(0.0 - 286.4)	1.33	(0.00 - 4.92)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	-	.
Lung, bronchus & trachea	2	319.8	(0.0 - 771.8)	4.97	(0.06 - 13.85)	-*	1	333.3	(0.0 - 929.7)	10.05	(0.00 - 37.07)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	1	187.5	(0.0 - 543.3)	9.79	(0.00 - 36.10)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	333.3	(0.0 - 929.7)	21.18	(0.00 - 78.14)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	190.5	(0.0 - 554.8)	137.32	(0.00 - 506.58)	-*
Testis	1	72.5	(0.0 - 213.5)	13.45	(0.00 - 49.60)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	5	677.3	(57.1 - 1,297.5)	1.35	(0.30 - 2.77)	-*	3	857.1	(19.4 - 1,694.9)	1.81	(0.15 - 4.23)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Katanning (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	9	67.3	(22.6 - 111.9)	0.76	(0.29 - 1.33)	-
Colorectal cancer	5	33.3	(3.0 - 63.5)	0.77	(0.17 - 1.59)	-	4	19.7	(0.0 - 40.5)	0.78	(0.12 - 1.71)	-
Prostate gland	17	110.8	(57.0 - 164.5)	1.62	(0.87 - 2.48)	-	0	-	-	-	-	.
Melanoma (skin)	3	24.1	(0.0 - 51.8)	0.51	(0.04 - 1.20)	-	6	47.9	(9.4 - 86.3)	1.39	(0.38 - 2.70)	-*
Lung, bronchus & trachea	7	46.1	(11.2 - 81.0)	1.25	(0.39 - 2.32)	-	5	37.9	(4.5 - 71.4)	1.63	(0.36 - 3.35)	-*
Lymphoma	1	7.0	(0.0 - 20.7)	0.47	(0.00 - 1.74)	-*	1	6.1	(0.0 - 17.9)	0.62	(0.00 - 2.30)	-*
Unknown primary site	2	14.0	(0.0 - 33.4)	1.20	(0.02 - 3.35)	-*	0	-	-	0	n/a	-
Kidney & other renal tract	1	8.9	(0.0 - 26.2)	0.74	(0.00 - 2.72)	-*	2	5.9	(0.0 - 14.0)	2.52	(0.03 - 7.01)	-*
Leukaemia	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pancreas	0	-	-	0	n/a	-	2	11.1	(0.0 - 28.4)	2.11	(0.03 - 5.89)	-*
Urinary bladder	2	12.6	(0.0 - 30.1)	1.48	(0.02 - 4.11)	-*	2	6.8	(0.0 - 16.3)	4.07	(0.05 - 11.35)	-*
Stomach	1	8.2	(0.0 - 24.1)	0.86	(0.00 - 3.16)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	1	6.1	(0.0 - 17.9)	0.74	(0.00 - 2.74)	-*
Brain	2	12.1	(0.0 - 28.9)	2.51	(0.03 - 6.99)	-*	1	6.1	(0.0 - 17.9)	1.83	(0.00 - 6.74)	-*
Lip	1	5.6	(0.0 - 16.4)	1.26	(0.00 - 4.65)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	8.4	(0.0 - 24.8)	0.85	(0.00 - 3.12)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	1	6.8	(0.0 - 20.0)	1.35	(0.00 - 4.98)	-*	0	-	-	-	-	.
Thyroid gland	1	11.0	(0.0 - 32.6)	3.42	(0.00 - 12.61)	-*	2	10.6	(0.0 - 26.0)	2.68	(0.03 - 7.46)	-*
Myeloma/plasma cell tumours	2	14.0	(0.0 - 33.4)	3.57	(0.04 - 9.96)	-*	1	3.7	(0.0 - 10.9)	2.36	(0.00 - 8.72)	-*
Cervix uteri	0	-	-	-	-	.	2	15.1	(0.0 - 36.2)	2.15	(0.03 - 6.00)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	8.3	(0.0 - 24.6)	3.13	(0.00 - 11.54)	-*
Larynx	1	5.6	(0.0 - 16.4)	1.96	(0.00 - 7.24)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	1	3.7	(0.0 - 10.9)	6.45	(0.00 - 23.78)	-*
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	3.1	(0.0 - 9.2)	3.56	(0.00 - 13.13)	-*
Small intestine	1	6.8	(0.0 - 20.0)	7.00	(0.00 - 25.82)	-*	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	7.0	(0.0 - 20.7)	16.23	(0.00 - 59.87)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	49	333.7	(239.2 - 428.1)	1.03	(0.74 - 1.33)	-	42	267.8	(182.9 - 352.7)	1.05	(0.74 - 1.39)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kellerberrin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	118.8	(0.0 - 252.7)	1.01	(0.16 - 2.20)	-*
Colorectal cancer	5	96.4	(7.7 - 185.0)	1.85	(0.40 - 3.80)	-*	2	32.6	(0.0 - 79.9)	1.01	(0.01 - 2.81)	-*
Prostate gland	5	79.2	(7.6 - 150.8)	1.11	(0.24 - 2.28)	-	0	-	-	-	-	.
Melanoma (skin)	1	28.7	(0.0 - 84.9)	0.47	(0.00 - 1.73)	-*	3	45.6	(0.0 - 101.3)	2.16	(0.17 - 5.04)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	1	19.7	(0.0 - 58.3)	0.86	(0.00 - 3.16)	-*
Lymphoma	1	17.1	(0.0 - 50.6)	1.26	(0.00 - 4.66)	-*	1	27.0	(0.0 - 79.8)	1.74	(0.00 - 6.41)	-*
Unknown primary site	2	28.0	(0.0 - 68.6)	2.86	(0.04 - 7.98)	-*	1	5.3	(0.0 - 15.7)	1.89	(0.00 - 6.97)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	1	15.3	(0.0 - 45.1)	2.65	(0.00 - 9.78)	-*
Urinary bladder	0	-	-	0	n/a	-	1	15.3	(0.0 - 45.1)	4.90	(0.00 - 18.06)	-*
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	27.0	(0.0 - 79.8)	2.08	(0.00 - 7.67)	-*
Brain	1	18.7	(0.0 - 55.2)	3.53	(0.00 - 13.01)	-*	0	-	-	-	-	.
Lip	1	26.3	(0.0 - 77.8)	3.53	(0.00 - 13.03)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	1	11.1	(0.0 - 32.8)	6.83	(0.00 - 25.18)	-*
Thyroid gland	0	-	-	-	-	.	1	6.2	(0.0 - 18.2)	4.64	(0.00 - 17.11)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	23.0	(0.0 - 68.0)	3.42	(0.00 - 12.62)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	23.8	(0.0 - 70.4)	4.88	(0.00 - 18.00)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	17	318.2	(160.6 - 475.9)	0.88	(0.47 - 1.34)	-	18	347.0	(160.8 - 533.2)	1.26	(0.69 - 1.91)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kent (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	64.5	(0.0 - 189.9)	0.75	(0.00 - 2.75)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	2	115.3	(0.0 - 278.9)	1.63	(0.02 - 4.54)	-*	0	-	-	-	-	.
Melanoma (skin)	1	30.2	(0.0 - 89.1)	1.17	(0.00 - 4.31)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	1	74.1	(0.0 - 216.5)	1.58	(0.00 - 5.84)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	1	166.7	(0.0 - 464.9)	11.73	(0.00 - 43.25)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	1	37.3	(0.0 - 110.1)	8.01	(0.00 - 29.55)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	5	256.8	(23.8 - 489.8)	0.84	(0.18 - 1.72)	-	2	231.2	(0.0 - 554.7)	0.52	(0.01 - 1.46)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kojonup (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	62.6	(6.6 - 118.6)	0.78	(0.17 - 1.60)	-
Colorectal cancer	4	36.0	(0.0 - 73.5)	0.97	(0.15 - 2.14)	-*	2	14.5	(0.0 - 34.4)	0.72	(0.01 - 2.01)	-*
Prostate gland	11	117.2	(45.6 - 188.8)	1.63	(0.71 - 2.72)	-	0	-	-	-	-	.
Melanoma (skin)	4	69.6	(0.0 - 143.8)	1.14	(0.18 - 2.50)	-*	1	7.2	(0.0 - 21.4)	0.43	(0.00 - 1.60)	-*
Lung, bronchus & trachea	1	5.7	(0.0 - 16.9)	0.28	(0.00 - 1.02)	-*	1	11.4	(0.0 - 33.8)	0.60	(0.00 - 2.22)	-*
Lymphoma	1	9.9	(0.0 - 29.2)	0.78	(0.00 - 2.88)	-*	1	5.1	(0.0 - 14.9)	1.17	(0.00 - 4.30)	-*
Unknown primary site	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Kidney & other renal tract	1	5.7	(0.0 - 16.9)	1.19	(0.00 - 4.37)	-*	0	-	-	-	-	.
Leukaemia	2	19.6	(0.0 - 46.6)	2.52	(0.03 - 7.01)	-*	2	16.5	(0.0 - 40.9)	4.35	(0.05 - 12.11)	-*
Pancreas	0	-	-	0	n/a	-	1	5.2	(0.0 - 15.2)	1.95	(0.00 - 7.19)	-*
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	15.2	(0.0 - 44.9)	1.38	(0.00 - 5.09)	-*
Brain	0	-	-	-	-	.	2	18.2	(0.0 - 45.6)	6.84	(0.09 - 19.05)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	1	9.7	(0.0 - 28.6)	2.37	(0.00 - 8.75)	-*	0	-	-	-	-	.
Oesophagus	1	13.2	(0.0 - 38.9)	2.12	(0.00 - 7.82)	-*	0	-	-	-	-	.
Thyroid gland	1	10.4	(0.0 - 30.8)	5.97	(0.00 - 22.01)	-*	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	13.8	(0.0 - 40.7)	4.34	(0.00 - 16.00)	-*
Cervix uteri	0	-	-	-	-	.	1	13.1	(0.0 - 38.7)	2.00	(0.00 - 7.38)	-*
Non-mel. skin (exc BCC/SCC)	1	13.6	(0.0 - 40.2)	2.78	(0.00 - 10.26)	-*	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	5.1	(0.0 - 14.9)	9.83	(0.00 - 36.28)	-*
Testis	1	22.7	(0.0 - 67.0)	2.84	(0.00 - 10.49)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	1	11.4	(0.0 - 33.6)	11.07	(0.00 - 40.83)	-*	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	30	344.7	(210.9 - 478.4)	1.00	(0.65 - 1.39)	-	19	187.7	(97.7 - 277.7)	0.88	(0.50 - 1.32)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kondinin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	21.3	(0.0 - 62.5)	0.42	(0.00 - 1.55)	-*
Colorectal cancer	2	66.7	(0.0 - 157.9)	1.33	(0.02 - 3.72)	-*	1	37.4	(0.0 - 110.3)	1.20	(0.00 - 4.43)	-*
Prostate gland	3	90.5	(0.0 - 192.2)	1.23	(0.10 - 2.86)	-*	0	-	-	-	-	.
Melanoma (skin)	4	116.0	(2.0 - 230.0)	2.69	(0.42 - 5.90)	-*	3	94.7	(0.0 - 201.7)	3.47	(0.28 - 8.10)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lymphoma	1	28.0	(0.0 - 82.9)	1.97	(0.00 - 7.28)	-*	1	48.4	(0.0 - 142.5)	3.49	(0.00 - 12.88)	-*
Unknown primary site	1	28.6	(0.0 - 84.3)	2.79	(0.00 - 10.31)	-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	1	44.4	(0.0 - 130.6)	6.96	(0.00 - 25.69)	-*
Leukaemia	1	28.6	(0.0 - 84.3)	3.33	(0.00 - 12.29)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	1	25.2	(0.0 - 74.3)	3.67	(0.00 - 13.53)	-*	1	35.7	(0.0 - 103.2)	14.65	(0.00 - 54.06)	-*
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	2	57.0	(0.0 - 136.1)	19.54	(0.24 - 54.43)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	1	28.0	(0.0 - 82.9)	124.85	(0.00 - 460.59)	-*	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	14	411.5	(198.7 - 624.3)	1.25	(0.62 - 1.98)	-	10	338.9	(127.3 - 550.5)	1.37	(0.56 - 2.35)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Koorda (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	37.0	(0.0 - 109.2)	0.68	(0.00 - 2.50)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	3	204.0	(0.0 - 444.3)	2.00	(0.16 - 4.68)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	62.5	(0.0 - 183.1)	6.31	(0.00 - 23.28)	-*
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	3	204.0	(0.0 - 444.3)	0.46	(0.04 - 1.08)	-	2	99.5	(0.0 - 240.0)	0.43	(0.01 - 1.21)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kulin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	0	-	-	0	n/a	-	1	25.0	(0.0 - 73.7)	1.01	(0.00 - 3.72)	-*
Prostate gland	3	98.6	(0.0 - 217.1)	1.17	(0.09 - 2.73)	-*	0	-	-	-	-	.
Melanoma (skin)	1	23.5	(0.0 - 69.5)	0.71	(0.00 - 2.61)	-*	1	33.9	(0.0 - 100.1)	1.15	(0.00 - 4.23)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	1	18.9	(0.0 - 55.5)	5.28	(0.00 - 19.49)	-*	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	30.3	(0.0 - 89.5)	5.18	(0.00 - 19.09)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	1	18.9	(0.0 - 55.5)	27.60	(0.00 - 101.82)	-*	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	6	159.8	(23.2 - 296.5)	0.52	(0.14 - 1.01)	-	3	89.2	(0.0 - 190.5)	0.37	(0.03 - 0.87)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kwinana (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	47	74.8	(53.1 - 96.5)	0.91	(0.65 - 1.18)	-
Colorectal cancer	31	48.2	(30.9 - 65.6)	1.08	(0.70 - 1.49)	-	18	26.5	(13.9 - 39.2)	0.89	(0.49 - 1.34)	-
Prostate gland	37	60.9	(40.8 - 81.0)	0.78	(0.53 - 1.05)	-	0	-	-	-	-	.
Melanoma (skin)	18	26.7	(14.2 - 39.3)	0.66	(0.36 - 0.99)	V	12	19.4	(8.3 - 30.6)	0.63	(0.29 - 1.03)	-
Lung, bronchus & trachea	32	48.0	(31.2 - 64.8)	1.27	(0.84 - 1.75)	-	23	33.8	(19.6 - 48.0)	1.87	(1.12 - 2.70)	^
Lymphoma	7	11.6	(2.9 - 20.3)	0.73	(0.23 - 1.35)	-	4	6.5	(0.1 - 12.8)	0.60	(0.09 - 1.30)	-
Unknown primary site	11	16.3	(6.5 - 26.1)	1.55	(0.67 - 2.58)	-	7	9.0	(2.0 - 16.0)	1.49	(0.47 - 2.79)	-
Kidney & other renal tract	8	11.9	(3.5 - 20.3)	1.30	(0.46 - 2.35)	-	5	7.3	(0.8 - 13.8)	1.50	(0.33 - 3.08)	.*
Leukaemia	4	6.2	(0.1 - 12.3)	0.68	(0.10 - 1.48)	-	4	7.7	(0.0 - 15.5)	1.12	(0.17 - 2.46)	.*
Pancreas	7	9.8	(2.5 - 17.2)	1.75	(0.55 - 3.27)	.*	4	5.3	(0.0 - 10.9)	1.09	(0.17 - 2.40)	.*
Urinary bladder	12	18.2	(7.8 - 28.6)	2.13	(0.97 - 3.49)	-	2	2.1	(0.0 - 5.2)	1.12	(0.01 - 3.11)	.*
Stomach	9	14.2	(4.6 - 23.7)	1.75	(0.67 - 3.06)	-	1	1.8	(0.0 - 5.3)	0.41	(0.00 - 1.51)	.*
Corpus uteri	0	-	-	-	-	.	7	11.3	(2.9 - 19.7)	1.23	(0.39 - 2.30)	-
Brain	7	11.1	(2.8 - 19.5)	1.87	(0.59 - 3.50)	.*	3	4.7	(0.0 - 10.0)	1.29	(0.10 - 3.01)	.*
Lip	6	9.8	(1.9 - 17.7)	1.59	(0.43 - 3.09)	.*	4	5.6	(0.0 - 11.1)	2.67	(0.41 - 5.85)	.*
Ovary & uterine adnexa	0	-	-	-	-	.	6	9.7	(1.8 - 17.5)	1.22	(0.33 - 2.37)	-
Other lymphohaematopoietic	3	4.4	(0.0 - 9.3)	1.14	(0.09 - 2.67)	.*	2	2.7	(0.0 - 6.7)	1.12	(0.01 - 3.11)	.*
Oesophagus	3	4.2	(0.0 - 9.0)	0.91	(0.07 - 2.13)	.*	0	-	-	0	n/a	-
Thyroid gland	2	3.0	(0.0 - 7.3)	1.40	(0.02 - 3.90)	.*	1	1.8	(0.0 - 5.3)	0.29	(0.00 - 1.09)	.*
Myeloma/plasma cell tumours	1	1.7	(0.0 - 4.9)	0.42	(0.00 - 1.54)	.*	1	1.3	(0.0 - 3.9)	0.60	(0.00 - 2.23)	.*
Cervix uteri	0	-	-	-	-	.	3	4.8	(0.0 - 10.2)	0.73	(0.06 - 1.70)	.*
Non-mel. skin (exc BCC/SCC)	4	6.4	(0.1 - 12.6)	1.63	(0.25 - 3.56)	.*	3	5.8	(0.0 - 12.3)	2.21	(0.18 - 5.15)	.*
Mesothelioma	6	8.7	(1.7 - 15.8)	1.99	(0.54 - 3.87)	.*	1	0.8	(0.0 - 2.4)	2.38	(0.00 - 8.77)	.*
Liver & intrahepatic bile duct	1	1.2	(0.0 - 3.4)	0.44	(0.00 - 1.63)	.*	0	-	-	0	n/a	-
Testis	4	6.1	(0.1 - 12.2)	1.15	(0.18 - 2.51)	.*	0	-	-	-	-	.
Gallbladder & bile ducts	1	1.5	(0.0 - 4.5)	0.77	(0.00 - 2.84)	.*	1	1.6	(0.0 - 4.8)	0.82	(0.00 - 3.04)	.*
Larynx	3	4.9	(0.0 - 10.4)	1.25	(0.10 - 2.91)	.*	0	-	-	-	-	.
Tongue	3	4.0	(0.0 - 8.5)	2.07	(0.17 - 4.84)	.*	1	1.4	(0.0 - 4.1)	1.99	(0.00 - 7.35)	.*
Connective & soft tissues	3	5.3	(0.0 - 11.3)	2.59	(0.21 - 6.05)	.*	2	3.6	(0.0 - 8.6)	2.90	(0.04 - 8.07)	.*
Tonsil & oropharynx	1	1.2	(0.0 - 3.4)	0.87	(0.00 - 3.21)	.*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	0.8	(0.0 - 2.4)	0.89	(0.00 - 3.27)	.*
Small intestine	1	1.2	(0.0 - 3.4)	1.54	(0.00 - 5.67)	.*	1	1.6	(0.0 - 4.6)	2.39	(0.00 - 8.82)	.*
Eye & lacrimal gland	1	2.6	(0.0 - 7.8)	1.42	(0.00 - 5.24)	.*	0	-	-	-	-	.
Major Salivary Gland	2	3.3	(0.0 - 7.9)	3.49	(0.04 - 9.72)	.*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	1	1.4	(0.0 - 4.1)	1.96	(0.00 - 7.24)	.*
Mouth, other & unspecified	1	1.5	(0.0 - 4.5)	1.66	(0.00 - 6.11)	.*	1	1.8	(0.0 - 5.3)	2.98	(0.00 - 10.98)	.*
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	-	.
Bones, joints & articular cart.	1	2.1	(0.0 - 6.3)	2.55	(0.00 - 9.40)	.*	1	1.5	(0.0 - 4.4)	2.40	(0.00 - 8.85)	.*
Pyriform sinus & hypopharynx	2	3.6	(0.0 - 8.6)	3.05	(0.04 - 8.48)	.*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	1.2	(0.0 - 3.4)	3.65	(0.00 - 13.46)	.*	0	-	-	-	-	.
Penis & other male genital	1	1.7	(0.0 - 5.0)	3.14	(0.00 - 11.60)	.*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	1	2.0	(0.0 - 5.8)	14.92	(0.00 - 55.05)	.*	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	235	364.7	(317.6 - 411.8)	1.09	(0.96 - 1.24)	-	167	256.3	(216.7 - 296.0)	1.00	(0.86 - 1.17)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Lake Grace (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	94.3	(8.5 - 180.1)	1.28	(0.28 - 2.63)	-*
Colorectal cancer	1	19.8	(0.0 - 58.4)	0.47	(0.00 - 1.72)	-*	4	88.6	(1.3 - 175.9)	2.99	(0.46 - 6.56)	-*
Prostate gland	2	47.4	(0.0 - 114.1)	0.58	(0.01 - 1.62)	-*	0	-	-	-	-	.
Melanoma (skin)	1	15.7	(0.0 - 46.3)	0.45	(0.00 - 1.66)	-*	4	103.4	(3.2 - 203.6)	2.81	(0.44 - 6.16)	-*
Lung, bronchus & trachea	3	88.4	(0.0 - 203.7)	1.65	(0.13 - 3.85)	-*	3	61.5	(0.0 - 129.9)	3.71	(0.30 - 8.67)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	1	17.2	(0.0 - 50.7)	1.92	(0.00 - 7.09)	-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	2	47.4	(0.0 - 114.1)	5.02	(0.06 - 13.97)	-*	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	24.2	(0.0 - 71.5)	2.50	(0.00 - 9.24)	-*
Brain	2	29.6	(0.0 - 70.5)	6.70	(0.08 - 18.67)	-*	1	36.4	(0.0 - 107.5)	5.97	(0.00 - 22.03)	-*
Lip	1	16.2	(0.0 - 47.8)	3.17	(0.00 - 11.68)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	1	28.6	(0.0 - 84.3)	4.63	(0.00 - 17.09)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	1	18.8	(0.0 - 55.5)	8.14	(0.00 - 30.05)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	1	21.7	(0.0 - 64.2)	17.01	(0.00 - 62.75)	-*	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	17.2	(0.0 - 50.7)	47.61	(0.00 - 175.63)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	17	367.9	(179.7 - 556.0)	1.04	(0.56 - 1.59)	-	18	408.3	(217.3 - 599.4)	1.52	(0.84 - 2.30)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Laverton (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	0	-	-	0	n/a	-	1	46.5	(0.0 - 137.3)	2.26	(0.00 - 8.35)	-*
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	1	38.1	(0.0 - 112.7)	1.85	(0.00 - 6.82)	-*	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	1	17.1	(0.0 - 50.7)	3.37	(0.00 - 12.42)	-*	0	-	-	-	-	.
Leukaemia	1	38.1	(0.0 - 112.7)	3.46	(0.00 - 12.75)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	28.1	(0.0 - 83.0)	4.54	(0.00 - 16.74)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	166.7	(0.0 - 479.4)	7.11	(0.00 - 26.22)	-*
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	1	51.7	(0.0 - 152.7)	26.39	(0.00 - 97.34)	-*
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	4	121.5	(0.0 - 244.9)	0.39	(0.06 - 0.85)	V	3	264.9	(0.0 - 605.9)	0.67	(0.05 - 1.57)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Leonora (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	25.8	(0.0 - 76.1)	0.40	(0.00 - 1.48)	-*
Colorectal cancer	2	68.5	(0.0 - 166.5)	1.03	(0.01 - 2.87)	-*	1	33.3	(0.0 - 96.5)	1.48	(0.00 - 5.47)	-*
Prostate gland	1	24.4	(0.0 - 71.6)	0.36	(0.00 - 1.34)	-*	0	-	-	-	-	.
Melanoma (skin)	1	14.2	(0.0 - 42.0)	0.36	(0.00 - 1.35)	-*	1	25.8	(0.0 - 76.1)	0.87	(0.00 - 3.21)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	1	42.6	(0.0 - 125.5)	2.63	(0.00 - 9.70)	-*
Lymphoma	2	76.4	(0.0 - 182.8)	2.26	(0.03 - 6.28)	-*	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	1	6.2	(0.0 - 18.3)	2.12	(0.00 - 7.81)	-*	1	17.3	(0.0 - 51.3)	5.57	(0.00 - 20.56)	-*
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	2	62.6	(0.0 - 155.8)	9.46	(0.12 - 26.36)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	21.6	(0.0 - 63.8)	3.55	(0.00 - 13.09)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	20.0	(0.0 - 58.4)	6.69	(0.00 - 24.69)	-*	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	21.6	(0.0 - 63.8)	19.56	(0.00 - 72.14)	-*
Small intestine	1	7.1	(0.0 - 21.0)	21.88	(0.00 - 80.71)	-*	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	32.3	(0.0 - 95.2)	16.27	(0.00 - 60.01)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	1	13.5	(0.0 - 40.0)	34.50	(0.00 - 127.26)	-*	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	13	325.2	(129.6 - 520.8)	0.81	(0.39 - 1.30)	-	7	187.9	(44.3 - 331.5)	0.94	(0.30 - 1.76)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mandurah (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	3	1.0	(0.0 - 2.2)	2.33	(0.19 - 5.44)	-*	174	85.6	(72.1 - 99.2)	1.08	(0.92 - 1.25)	-
Colorectal cancer	110	45.1	(36.0 - 54.1)	1.03	(0.85 - 1.25)	-	73	30.0	(22.5 - 37.4)	0.97	(0.76 - 1.22)	-
Prostate gland	197	80.6	(68.7 - 92.5)	1.09	(0.95 - 1.26)	-	0	-	-	-	-	.
Melanoma (skin)	91	46.1	(35.7 - 56.6)	1.11	(0.90 - 1.36)	-	71	39.6	(29.3 - 49.8)	1.29	(1.02 - 1.64)	^
Lung, bronchus & trachea	92	38.2	(29.9 - 46.6)	0.93	(0.76 - 1.15)	-	53	20.0	(14.1 - 25.9)	1.13	(0.85 - 1.49)	-
Lymphoma	31	15.8	(9.5 - 22.1)	1.01	(0.66 - 1.40)	-	23	8.7	(4.5 - 13.0)	1.00	(0.60 - 1.45)	-
Unknown primary site	30	11.2	(7.0 - 15.5)	1.10	(0.71 - 1.52)	-	14	6.6	(2.1 - 11.0)	0.77	(0.38 - 1.23)	-
Kidney & other renal tract	16	7.9	(3.7 - 12.1)	0.75	(0.40 - 1.16)	-	9	3.2	(1.0 - 5.3)	0.79	(0.30 - 1.38)	-
Leukaemia	27	12.5	(6.6 - 18.3)	1.37	(0.86 - 1.93)	-	15	7.1	(2.7 - 11.5)	1.30	(0.66 - 2.04)	-
Pancreas	12	6.0	(2.4 - 9.5)	0.80	(0.37 - 1.32)	-	14	4.9	(2.1 - 7.7)	1.00	(0.49 - 1.58)	-
Urinary bladder	29	10.1	(6.2 - 14.1)	1.24	(0.79 - 1.73)	-	3	0.7	(0.0 - 1.5)	0.41	(0.03 - 0.95)	V
Stomach	29	11.4	(6.9 - 15.9)	1.48	(0.95 - 2.06)	-	9	3.4	(1.0 - 5.7)	0.95	(0.36 - 1.66)	-
Corpus uteri	0	-	-	-	-	.	15	6.9	(3.1 - 10.7)	0.77	(0.39 - 1.21)	-
Brain	11	5.7	(2.1 - 9.3)	1.03	(0.45 - 1.72)	-	6	3.9	(0.3 - 7.4)	0.81	(0.22 - 1.57)	-
Lip	15	8.3	(3.9 - 12.8)	1.40	(0.71 - 2.19)	-	2	0.5	(0.0 - 1.1)	0.38	(0.00 - 1.07)	-
Ovary & uterine adnexa	0	-	-	-	-	.	15	7.2	(3.3 - 11.1)	0.89	(0.46 - 1.40)	-
Other lymphohaematopoietic	12	4.0	(1.7 - 6.3)	1.07	(0.49 - 1.76)	-	9	3.5	(0.9 - 6.2)	1.31	(0.50 - 2.30)	-
Oesophagus	15	5.6	(2.6 - 8.6)	1.20	(0.61 - 1.88)	-	4	1.8	(0.0 - 3.8)	0.73	(0.11 - 1.61)	-
Thyroid gland	4	2.9	(0.0 - 5.9)	1.15	(0.18 - 2.51)	-*	5	4.8	(0.3 - 9.4)	0.58	(0.13 - 1.19)	-
Myeloma/plasma cell tumours	9	3.4	(1.0 - 5.8)	0.98	(0.38 - 1.72)	-	6	2.5	(0.4 - 4.7)	0.96	(0.26 - 1.87)	-
Cervix uteri	0	-	-	-	-	.	10	5.7	(1.9 - 9.4)	0.88	(0.36 - 1.51)	-
Non-mel. skin (exc BCC/SCC)	5	2.8	(0.3 - 5.3)	0.55	(0.12 - 1.12)	-	5	2.4	(0.1 - 4.6)	1.09	(0.24 - 2.24)	-
Mesothelioma	13	5.3	(2.2 - 8.4)	1.13	(0.54 - 1.83)	-	2	0.7	(0.0 - 1.7)	1.28	(0.02 - 3.57)	-*
Liver & intrahepatic bile duct	4	2.2	(0.0 - 4.5)	0.49	(0.08 - 1.07)	-	3	0.8	(0.0 - 1.7)	1.13	(0.09 - 2.64)	-*
Testis	3	2.6	(0.0 - 5.6)	0.50	(0.04 - 1.16)	-	0	-	-	-	-	.
Gallbladder & bile ducts	4	2.0	(0.0 - 3.9)	0.83	(0.13 - 1.81)	-	3	0.8	(0.0 - 1.7)	0.63	(0.05 - 1.47)	-
Larynx	9	4.3	(1.3 - 7.4)	1.11	(0.42 - 1.94)	-	0	-	-	0	n/a	-
Tongue	8	3.9	(1.0 - 6.7)	1.88	(0.66 - 3.38)	-*	4	2.1	(0.0 - 4.3)	2.25	(0.35 - 4.93)	-*
Connective & soft tissues	7	3.0	(0.6 - 5.5)	2.16	(0.68 - 4.03)	-*	3	1.8	(0.0 - 3.9)	1.48	(0.12 - 3.46)	-*
Tonsil & oropharynx	3	1.2	(0.0 - 2.6)	0.88	(0.07 - 2.04)	-*	2	1.2	(0.0 - 2.8)	2.42	(0.03 - 6.75)	-*
Vulva/vagina	0	-	-	-	-	.	2	1.0	(0.0 - 2.6)	0.51	(0.01 - 1.43)	-*
Small intestine	5	2.6	(0.2 - 5.0)	2.18	(0.48 - 4.47)	-*	1	0.2	(0.0 - 0.7)	0.67	(0.00 - 2.48)	-*
Eye & lacrimal gland	4	3.9	(0.0 - 7.9)	1.87	(0.29 - 4.10)	-*	0	-	-	0	n/a	-
Major Salivary Gland	2	0.9	(0.0 - 2.3)	1.05	(0.01 - 2.92)	-*	0	-	-	0	n/a	-
Anus	1	0.7	(0.0 - 2.1)	0.67	(0.00 - 2.46)	-*	0	-	-	0	n/a	-
Mouth, other & unspecified	2	1.2	(0.0 - 2.8)	1.05	(0.01 - 2.92)	-*	1	0.6	(0.0 - 1.7)	0.86	(0.00 - 3.15)	-*
Floor of mouth	3	1.9	(0.0 - 4.0)	1.43	(0.12 - 3.34)	-*	3	0.9	(0.0 - 1.8)	4.20	(0.34 - 9.80)	-*
Bones, joints & articular cart.	2	0.6	(0.0 - 1.5)	2.14	(0.03 - 5.97)	-*	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	1	0.5	(0.0 - 1.3)	0.44	(0.00 - 1.62)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.6	(0.0 - 1.8)	0.73	(0.00 - 2.69)	-*	0	-	-	0	n/a	-
Peritoneum & retroperitoneum	0	-	-	0	n/a	-	2	0.9	(0.0 - 2.1)	1.67	(0.02 - 4.67)	-*
Adrenal & other endocrine	3	2.4	(0.0 - 5.8)	4.38	(0.35 - 10.23)	-*	0	-	-	-	-	.
Nasopharynx	1	0.8	(0.0 - 2.3)	1.19	(0.00 - 4.38)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	0	n/a	-	1	0.2	(0.0 - 0.7)	6.02	(0.00 - 22.21)	-*
Penis & other male genital	2	1.4	(0.0 - 3.6)	1.65	(0.02 - 4.61)	-*	0	-	-	-	-	.
Gum	0	-	-	0	n/a	-	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Thymus	1	0.3	(0.0 - 0.9)	3.50	(0.00 - 12.91)	-*	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	1	0.2	(0.0 - 0.7)	3.41	(0.00 - 12.60)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	817	360.9	(333.9 - 387.9)	1.07	(1.00 - 1.14)	-	563	260.3	(236.4 - 284.1)	1.01	(0.93 - 1.10)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Manjimup (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	2.1	(0.0 - 6.1)	5.11	(0.00 - 18.84)	-*	23	70.3	(40.9 - 99.8)	0.86	(0.52 - 1.25)	-
Colorectal cancer	11	33.9	(13.7 - 54.1)	0.66	(0.29 - 1.10)	-	10	25.5	(8.6 - 42.4)	0.90	(0.37 - 1.54)	-
Prostate gland	27	74.5	(46.0 - 103.0)	0.99	(0.62 - 1.39)	-	0	-	-	-	-	.
Melanoma (skin)	5	14.2	(1.6 - 26.8)	0.34	(0.07 - 0.70)	V	4	13.6	(0.2 - 27.1)	0.42	(0.06 - 0.91)	V
Lung, bronchus & trachea	17	40.6	(20.7 - 60.4)	1.16	(0.62 - 1.77)	-	4	9.5	(0.0 - 19.5)	0.60	(0.09 - 1.31)	-
Lymphoma	4	11.9	(0.2 - 23.6)	0.76	(0.12 - 1.66)	-	2	6.3	(0.0 - 15.1)	0.57	(0.01 - 1.58)	-*
Unknown primary site	7	18.5	(4.4 - 32.6)	1.66	(0.52 - 3.09)	-*	1	1.8	(0.0 - 5.2)	0.37	(0.00 - 1.37)	-*
Kidney & other renal tract	1	3.2	(0.0 - 9.6)	0.29	(0.00 - 1.07)	-*	1	6.1	(0.0 - 17.9)	0.57	(0.00 - 2.10)	-*
Leukaemia	2	4.6	(0.0 - 11.3)	0.61	(0.01 - 1.71)	-*	1	1.3	(0.0 - 3.8)	0.53	(0.00 - 1.96)	-*
Pancreas	3	8.3	(0.0 - 17.7)	1.28	(0.10 - 2.99)	-*	3	6.3	(0.0 - 14.1)	1.47	(0.12 - 3.43)	-*
Urinary bladder	6	14.5	(2.7 - 26.3)	1.72	(0.47 - 3.35)	-*	1	3.7	(0.0 - 10.8)	0.96	(0.00 - 3.55)	-*
Stomach	3	6.0	(0.0 - 12.9)	0.99	(0.08 - 2.31)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	2	4.8	(0.0 - 11.8)	0.67	(0.01 - 1.87)	-*
Brain	5	17.4	(1.6 - 33.3)	2.53	(0.55 - 5.19)	-*	2	6.9	(0.0 - 16.5)	1.64	(0.02 - 4.57)	-*
Lip	2	7.7	(0.0 - 18.9)	1.00	(0.01 - 2.79)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	2	5.4	(0.0 - 13.4)	0.77	(0.01 - 2.15)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Oesophagus	2	5.9	(0.0 - 14.3)	1.06	(0.01 - 2.95)	-*	1	1.8	(0.0 - 5.2)	1.28	(0.00 - 4.74)	-*
Thyroid gland	0	-	-	0	n/a	-	4	11.2	(0.0 - 22.5)	2.39	(0.37 - 5.25)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	1	1.8	(0.0 - 5.2)	1.10	(0.00 - 4.05)	-*
Cervix uteri	0	-	-	-	-	.	1	6.1	(0.0 - 18.2)	0.48	(0.00 - 1.77)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Mesothelioma	2	5.0	(0.0 - 12.2)	1.15	(0.01 - 3.21)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	3.2	(0.0 - 9.6)	0.79	(0.00 - 2.91)	-*	0	-	-	-	-	.
Testis	1	2.8	(0.0 - 8.3)	0.66	(0.00 - 2.43)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	1	2.5	(0.0 - 7.4)	1.31	(0.00 - 4.83)	-*	3	9.9	(0.0 - 21.2)	4.36	(0.35 - 10.17)	-*
Larynx	2	5.8	(0.0 - 14.0)	1.50	(0.02 - 4.19)	-*	0	-	-	-	-	.
Tongue	0	-	-	0	n/a	-	0	-	-	-	-	.
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	1.3	(0.0 - 3.8)	1.62	(0.00 - 5.97)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	1	2.9	(0.0 - 8.6)	4.14	(0.00 - 15.25)	-*	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	1	4.9	(0.0 - 14.4)	5.01	(0.00 - 18.47)	-*
Pyriform sinus & hypopharynx	1	3.4	(0.0 - 10.2)	2.76	(0.00 - 10.19)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	3.0	(0.0 - 9.0)	4.11	(0.00 - 15.15)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	106	292.2	(235.5 - 348.9)	0.87	(0.71 - 1.05)	-	68	198.4	(148.4 - 248.4)	0.77	(0.60 - 0.98)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Meekatharra (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	97.9	(0.0 - 208.2)	1.19	(0.10 - 2.77)	-*
Colorectal cancer	1	42.6	(0.0 - 125.1)	0.66	(0.00 - 2.43)	-*	0	-	-	0	n/a	-
Prostate gland	4	148.2	(4.5 - 292.0)	1.69	(0.26 - 3.69)	-*	0	-	-	-	-	.
Melanoma (skin)	3	96.5	(0.0 - 209.9)	1.60	(0.13 - 3.73)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	3	109.8	(0.0 - 234.1)	2.47	(0.20 - 5.76)	-*	1	46.2	(0.0 - 135.9)	1.93	(0.00 - 7.11)	-*
Lymphoma	2	61.2	(0.0 - 151.3)	3.23	(0.04 - 8.99)	-*	1	33.3	(0.0 - 98.5)	3.19	(0.00 - 11.75)	-*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	2	60.3	(0.0 - 146.5)	5.69	(0.07 - 15.84)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	42.6	(0.0 - 125.1)	3.80	(0.00 - 14.02)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	21.8	(0.0 - 64.5)	6.04	(0.00 - 22.27)	-*	0	-	-	-	-	.
Thyroid gland	1	27.9	(0.0 - 82.4)	8.66	(0.00 - 31.96)	-*	0	-	-	-	-	.
Myeloma/plasma cell tumours	1	18.2	(0.0 - 53.9)	8.18	(0.00 - 30.17)	-*	2	81.5	(0.0 - 195.8)	27.96	(0.35 - 77.89)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	39.2	(0.0 - 115.3)	19.98	(0.00 - 73.70)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	1	18.6	(0.0 - 55.0)	12.56	(0.00 - 46.33)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	42.6	(0.0 - 125.1)	27.32	(0.00 - 100.78)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	21	690.1	(399.1 - 981.2)	1.73	(1.01 - 2.55)	^	8	298.1	(90.6 - 505.7)	1.01	(0.35 - 1.82)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Melville (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	3	0.6	(0.0 - 1.3)	1.51	(0.12 - 3.52)	-*	339	87.5	(77.6 - 97.4)	1.07	(0.96 - 1.19)	-
Colorectal cancer	195	49.2	(42.0 - 56.5)	1.15	(0.99 - 1.32)	-	180	35.2	(29.4 - 41.0)	1.22	(1.05 - 1.42)	^
Prostate gland	329	84.3	(74.7 - 93.9)	1.18	(1.06 - 1.32)	^	0	-	-	-	-	.
Melanoma (skin)	188	54.7	(46.6 - 62.9)	1.32	(1.14 - 1.53)	^	126	37.4	(30.5 - 44.3)	1.13	(0.95 - 1.35)	-
Lung, bronchus & trachea	123	30.9	(25.1 - 36.6)	0.81	(0.68 - 0.98)	V	82	16.9	(12.9 - 21.0)	0.93	(0.74 - 1.16)	-
Lymphoma	47	13.5	(9.3 - 17.6)	0.90	(0.64 - 1.17)	-	61	13.2	(9.3 - 17.0)	1.37	(1.06 - 1.77)	^
Unknown primary site	45	11.5	(8.0 - 15.1)	1.02	(0.73 - 1.34)	-	21	4.1	(2.1 - 6.2)	0.56	(0.32 - 0.82)	V
Kidney & other renal tract	31	7.9	(4.9 - 10.9)	0.89	(0.58 - 1.23)	-	28	6.6	(3.5 - 9.6)	1.28	(0.81 - 1.80)	-
Leukaemia	23	8.0	(4.3 - 11.8)	0.71	(0.43 - 1.03)	-	17	4.2	(1.9 - 6.5)	0.75	(0.40 - 1.14)	-
Pancreas	19	5.4	(2.9 - 7.9)	0.81	(0.45 - 1.21)	-	15	2.6	(1.1 - 4.2)	0.54	(0.28 - 0.85)	V
Urinary bladder	36	8.0	(5.2 - 10.8)	0.98	(0.66 - 1.32)	-	21	3.4	(1.7 - 5.1)	1.43	(0.83 - 2.10)	-
Stomach	27	7.1	(4.2 - 9.9)	0.87	(0.55 - 1.22)	-	23	4.9	(2.7 - 7.2)	1.23	(0.74 - 1.78)	-
Corpus uteri	0	-	-	-	-	.	45	10.0	(6.9 - 13.2)	1.21	(0.86 - 1.59)	-
Brain	9	2.8	(0.8 - 4.8)	0.48	(0.18 - 0.84)	V	17	4.6	(1.8 - 7.4)	1.15	(0.62 - 1.75)	-
Lip	29	8.0	(4.9 - 11.0)	1.53	(0.98 - 2.13)	-	17	3.5	(1.6 - 5.4)	1.61	(0.87 - 2.47)	-
Ovary & uterine adnexa	0	-	-	-	-	.	44	11.0	(7.4 - 14.5)	1.36	(0.96 - 1.79)	-
Other lymphohaematopoietic	18	4.3	(2.2 - 6.4)	1.02	(0.56 - 1.54)	-	13	1.6	(0.6 - 2.6)	0.92	(0.44 - 1.48)	-
Oesophagus	20	5.0	(2.7 - 7.4)	1.02	(0.58 - 1.51)	-	13	2.6	(1.1 - 4.1)	1.23	(0.59 - 1.98)	-
Thyroid gland	11	3.9	(1.5 - 6.2)	1.68	(0.73 - 2.82)	-	21	5.8	(3.1 - 8.5)	1.14	(0.66 - 1.68)	-
Myeloma/plasma cell tumours	17	4.2	(2.1 - 6.3)	1.15	(0.62 - 1.76)	-	10	1.6	(0.5 - 2.7)	0.82	(0.34 - 1.40)	-
Cervix uteri	0	-	-	-	-	.	14	3.8	(1.7 - 6.0)	0.59	(0.29 - 0.94)	V
Non-mel. skin (exc BCC/SCC)	23	5.4	(3.0 - 7.7)	1.50	(0.90 - 2.17)	-	9	1.6	(0.4 - 2.7)	0.94	(0.36 - 1.65)	-
Mesothelioma	22	6.1	(3.4 - 8.7)	1.23	(0.73 - 1.80)	-	2	0.7	(0.0 - 1.7)	0.69	(0.01 - 1.92)	-*
Liver & intrahepatic bile duct	12	4.0	(1.7 - 6.3)	0.93	(0.42 - 1.52)	-	4	0.9	(0.0 - 1.9)	0.77	(0.12 - 1.69)	-
Testis	9	3.4	(1.1 - 5.6)	0.68	(0.26 - 1.20)	-	0	-	-	-	-	.
Gallbladder & bile ducts	6	1.4	(0.2 - 2.5)	0.77	(0.21 - 1.49)	-	7	0.8	(0.2 - 1.4)	0.74	(0.23 - 1.38)	-
Larynx	10	2.6	(1.0 - 4.3)	0.76	(0.31 - 1.30)	-	0	-	-	0	n/a	-
Tongue	5	1.9	(0.2 - 3.6)	0.66	(0.14 - 1.35)	-	1	0.4	(0.0 - 1.1)	0.29	(0.00 - 1.08)	-*
Connective & soft tissues	6	2.5	(0.5 - 4.4)	1.03	(0.28 - 2.01)	-	3	0.8	(0.0 - 1.7)	0.76	(0.06 - 1.78)	-*
Tonsil & oropharynx	8	2.6	(0.8 - 4.3)	1.29	(0.45 - 2.32)	-	1	0.3	(0.0 - 0.9)	0.67	(0.00 - 2.46)	-*
Vulva/vagina	0	-	-	-	-	.	7	1.2	(0.2 - 2.3)	0.88	(0.28 - 1.64)	-
Small intestine	5	1.6	(0.1 - 3.0)	1.34	(0.29 - 2.75)	-*	2	0.5	(0.0 - 1.2)	0.69	(0.01 - 1.92)	-*
Eye & lacrimal gland	5	1.1	(0.1 - 2.2)	1.36	(0.30 - 2.79)	-*	1	0.1	(0.0 - 0.3)	0.49	(0.00 - 1.81)	-*
Major Salivary Gland	3	0.6	(0.0 - 1.3)	0.91	(0.07 - 2.13)	-*	3	1.4	(0.0 - 3.0)	1.23	(0.10 - 2.86)	-*
Anus	0	-	-	0	n/a	-	3	1.0	(0.0 - 2.1)	0.88	(0.07 - 2.05)	-*
Mouth, other & unspecified	0	-	-	0	n/a	-	2	0.3	(0.0 - 0.7)	0.92	(0.01 - 2.56)	-*
Floor of mouth	1	0.3	(0.0 - 0.8)	0.27	(0.00 - 1.01)	-*	0	-	-	0	n/a	-
Bones, joints & articular cart.	2	0.7	(0.0 - 1.6)	1.08	(0.01 - 3.01)	-*	5	1.3	(0.0 - 2.8)	2.24	(0.49 - 4.58)	-*
Pyriform sinus & hypopharynx	2	0.7	(0.0 - 1.6)	0.55	(0.01 - 1.53)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	4	1.1	(0.0 - 2.2)	1.68	(0.26 - 3.68)	-*	1	0.1	(0.0 - 0.3)	0.95	(0.00 - 3.50)	-*
Peritoneum & retroperitoneum	1	0.2	(0.0 - 0.6)	1.14	(0.00 - 4.21)	-*	4	0.9	(0.0 - 1.8)	1.78	(0.28 - 3.90)	-*
Adrenal & other endocrine	1	1.0	(0.0 - 2.9)	0.84	(0.00 - 3.09)	-*	0	-	-	0	n/a	-
Nasopharynx	5	1.6	(0.2 - 3.0)	3.08	(0.67 - 6.32)	-*	1	0.3	(0.0 - 0.9)	2.02	(0.00 - 7.44)	-*
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	-	.
Penis & other male genital	3	0.8	(0.0 - 1.8)	1.52	(0.12 - 3.56)	-*	0	-	-	-	-	.
Gum	1	0.4	(0.0 - 1.0)	1.14	(0.00 - 4.19)	-*	1	0.1	(0.0 - 0.2)	1.11	(0.00 - 4.11)	-*
Kaposi sarcoma	1	0.4	(0.0 - 1.0)	0.94	(0.00 - 3.46)	-*	1	0.2	(0.0 - 0.6)	3.35	(0.00 - 12.37)	-*
Thymus	1	0.3	(0.0 - 1.0)	2.22	(0.00 - 8.17)	-*	1	0.4	(0.0 - 1.1)	2.01	(0.00 - 7.42)	-*
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	0	n/a	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1306	349.6	(329.5 - 369.6)	1.06	(1.00 - 1.12)	-	1166	273.7	(256.3 - 291.2)	1.06	(1.00 - 1.12)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Menzies (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	V	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Merredin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	7.9	(0.0 - 23.4)	15.33	(0.00 - 56.57)	-*	8	75.8	(22.8 - 128.7)	0.87	(0.31 - 1.56)	-
Colorectal cancer	10	76.6	(27.9 - 125.3)	1.79	(0.74 - 3.06)	-	3	28.4	(0.0 - 60.8)	0.78	(0.06 - 1.81)	-*
Prostate gland	12	105.5	(45.1 - 165.8)	1.32	(0.60 - 2.17)	-	0	-	-	-	-	.
Melanoma (skin)	3	21.5	(0.0 - 48.0)	0.59	(0.05 - 1.38)	-	2	12.5	(0.0 - 31.0)	0.59	(0.01 - 1.65)	-*
Lung, bronchus & trachea	5	46.1	(5.3 - 86.9)	1.02	(0.22 - 2.09)	-	6	50.2	(8.2 - 92.2)	2.58	(0.70 - 5.02)	-*
Lymphoma	1	4.9	(0.0 - 14.3)	0.55	(0.00 - 2.02)	-*	1	8.0	(0.0 - 23.6)	0.81	(0.00 - 2.99)	-*
Unknown primary site	1	5.2	(0.0 - 15.2)	0.70	(0.00 - 2.60)	-*	2	10.4	(0.0 - 24.8)	2.10	(0.03 - 5.86)	-*
Kidney & other renal tract	2	12.8	(0.0 - 30.7)	1.70	(0.02 - 4.74)	-*	1	10.5	(0.0 - 31.0)	1.64	(0.00 - 6.05)	-*
Leukaemia	2	12.4	(0.0 - 29.8)	1.78	(0.02 - 4.95)	-*	1	17.9	(0.0 - 52.9)	1.51	(0.00 - 5.56)	-*
Pancreas	1	10.1	(0.0 - 29.8)	1.29	(0.00 - 4.76)	-*	2	15.2	(0.0 - 37.3)	2.83	(0.04 - 7.87)	-*
Urinary bladder	0	-	-	0	n/a	-	1	10.0	(0.0 - 29.6)	2.76	(0.00 - 10.17)	-*
Stomach	1	7.9	(0.0 - 23.4)	0.99	(0.00 - 3.64)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	2	14.9	(0.0 - 36.5)	1.94	(0.02 - 5.40)	-*
Brain	0	-	-	0	n/a	-	0	-	-	-	-	.
Lip	0	-	-	0	n/a	-	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	10.3	(0.0 - 30.5)	1.11	(0.00 - 4.09)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	11.2	(0.0 - 33.1)	1.70	(0.00 - 6.28)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	3.8	(0.0 - 11.4)	3.14	(0.00 - 11.59)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	1	3.8	(0.0 - 11.4)	3.87	(0.00 - 14.29)	-*
Mesothelioma	1	7.9	(0.0 - 23.4)	1.72	(0.00 - 6.34)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	8.7	(0.0 - 25.8)	2.32	(0.00 - 8.56)	-*	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	1	10.1	(0.0 - 29.8)	3.76	(0.00 - 13.86)	-*	0	-	-	-	-	.
Connective & soft tissues	1	8.7	(0.0 - 25.8)	4.73	(0.00 - 17.43)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	1	7.9	(0.0 - 23.4)	19.68	(0.00 - 72.58)	-*	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	44	354.0	(247.8 - 460.3)	1.06	(0.75 - 1.40)	-	33	283.0	(181.4 - 384.6)	1.08	(0.71 - 1.47)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mingenew (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	355.5	(46.2 - 664.8)	3.66	(0.80 - 7.49)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	1	52.6	(0.0 - 155.1)	0.71	(0.00 - 2.63)	-*	0	-	-	-	-	.
Melanoma (skin)	1	46.9	(0.0 - 138.4)	1.23	(0.00 - 4.54)	-*	1	76.9	(0.0 - 227.0)	2.00	(0.00 - 7.36)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	1	60.6	(0.0 - 177.6)	10.80	(0.00 - 39.86)	-*
Urinary bladder	1	52.6	(0.0 - 155.1)	6.25	(0.00 - 23.04)	-*	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	84.5	(0.0 - 249.0)	8.94	(0.00 - 32.96)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	3	152.1	(0.0 - 322.7)	0.47	(0.04 - 1.10)	-	8	577.6	(179.9 - 975.2)	1.84	(0.65 - 3.31)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Moora (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	84.0	(6.7 - 161.4)	0.79	(0.17 - 1.62)	-
Colorectal cancer	3	38.4	(0.0 - 84.4)	0.83	(0.07 - 1.95)	-*	5	73.2	(4.5 - 141.9)	1.93	(0.42 - 3.96)	-*
Prostate gland	4	63.0	(0.0 - 126.8)	0.70	(0.11 - 1.53)	-	0	-	-	-	-	-
Melanoma (skin)	4	54.5	(0.6 - 108.3)	1.17	(0.18 - 2.56)	-*	1	13.2	(0.0 - 39.0)	0.43	(0.00 - 1.57)	-*
Lung, bronchus & trachea	5	87.5	(10.7 - 164.3)	1.62	(0.35 - 3.32)	-*	0	-	-	0	n/a	-
Lymphoma	1	8.2	(0.0 - 24.2)	0.82	(0.00 - 3.01)	-*	4	30.9	(0.0 - 65.8)	4.85	(0.75 - 10.62)	-*
Unknown primary site	1	9.8	(0.0 - 28.8)	1.09	(0.00 - 4.03)	-*	0	-	-	0	n/a	-
Kidney & other renal tract	0	-	-	0	n/a	-	1	20.6	(0.0 - 60.9)	2.43	(0.00 - 8.98)	-*
Leukaemia	1	11.2	(0.0 - 33.2)	1.34	(0.00 - 4.95)	-*	1	7.9	(0.0 - 23.2)	2.17	(0.00 - 8.01)	-*
Pancreas	1	19.0	(0.0 - 56.0)	1.99	(0.00 - 7.35)	-*	1	18.0	(0.0 - 53.1)	2.10	(0.00 - 7.76)	-*
Urinary bladder	1	13.8	(0.0 - 40.7)	1.36	(0.00 - 5.02)	-*	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	1	16.9	(0.0 - 49.8)	2.13	(0.00 - 7.88)	-*	1	7.9	(0.0 - 23.2)	3.44	(0.00 - 12.68)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	1	18.0	(0.0 - 53.1)	5.47	(0.00 - 20.16)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	19.0	(0.0 - 56.0)	3.63	(0.00 - 13.39)	-*	0	-	-	-	-	.
Testis	1	12.1	(0.0 - 35.7)	2.36	(0.00 - 8.71)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	24	353.3	(209.1 - 497.4)	0.89	(0.54 - 1.28)	-	20	273.6	(143.0 - 404.2)	0.96	(0.55 - 1.42)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Morawa (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	111.0	(0.0 - 237.6)	1.25	(0.10 - 2.92)	-*
Colorectal cancer	1	32.3	(0.0 - 95.2)	0.56	(0.00 - 2.08)	-*	1	31.7	(0.0 - 93.8)	1.04	(0.00 - 3.84)	-*
Prostate gland	2	52.3	(0.0 - 126.0)	0.68	(0.01 - 1.89)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	3	131.4	(0.0 - 291.2)	3.44	(0.28 - 8.02)	-*
Lung, bronchus & trachea	1	28.8	(0.0 - 85.1)	0.63	(0.00 - 2.34)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	1	49.1	(0.0 - 145.0)	3.35	(0.00 - 12.37)	-*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	1	24.7	(0.0 - 72.9)	4.87	(0.00 - 17.95)	-*	0	-	-	-	-	.
Lip	1	27.4	(0.0 - 81.0)	4.89	(0.00 - 18.04)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	22.2	(0.0 - 65.3)	41.11	(0.00 - 151.66)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	7	187.7	(47.8 - 327.5)	0.54	(0.17 - 1.01)	-	8	323.3	(89.7 - 556.9)	1.03	(0.36 - 1.85)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mosman Park (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	27	94.1	(57.0 - 131.2)	1.01	(0.63 - 1.42)	-
Colorectal cancer	18	52.3	(26.8 - 77.8)	1.23	(0.68 - 1.87)	-	17	31.1	(12.3 - 50.0)	1.25	(0.67 - 1.91)	-
Prostate gland	28	84.8	(51.4 - 118.3)	1.18	(0.75 - 1.66)	-	0	-	-	-	-	.
Melanoma (skin)	15	52.8	(24.9 - 80.7)	1.22	(0.62 - 1.91)	-	15	34.2	(12.9 - 55.6)	1.56	(0.80 - 2.45)	-
Lung, bronchus & trachea	13	45.0	(19.3 - 70.7)	1.01	(0.48 - 1.63)	-	4	7.0	(0.0 - 16.4)	0.52	(0.08 - 1.13)	-
Lymphoma	4	10.6	(0.0 - 21.4)	0.88	(0.14 - 1.94)	-	5	6.6	(0.0 - 14.3)	1.29	(0.28 - 2.64)	-*
Unknown primary site	7	15.4	(3.3 - 27.4)	1.82	(0.57 - 3.40)	-*	6	5.5	(0.9 - 10.1)	1.54	(0.42 - 2.99)	-*
Kidney & other renal tract	2	4.1	(0.0 - 9.8)	0.67	(0.01 - 1.87)	-*	0	-	-	0	n/a	-
Leukaemia	1	1.9	(0.0 - 5.7)	0.36	(0.00 - 1.34)	-*	1	3.5	(0.0 - 10.4)	0.46	(0.00 - 1.71)	-*
Pancreas	2	7.9	(0.0 - 18.9)	1.00	(0.01 - 2.77)	-*	0	-	-	0	n/a	-
Urinary bladder	6	16.6	(2.3 - 30.9)	1.87	(0.51 - 3.64)	-*	3	1.8	(0.0 - 3.9)	2.06	(0.17 - 4.80)	-*
Stomach	3	6.8	(0.0 - 15.1)	1.12	(0.09 - 2.62)	-*	1	3.4	(0.0 - 10.0)	0.56	(0.00 - 2.06)	-*
Corpus uteri	0	-	-	-	-	.	3	7.3	(0.0 - 16.7)	0.93	(0.08 - 2.17)	-*
Brain	1	3.5	(0.0 - 10.2)	0.62	(0.00 - 2.30)	-*	1	3.8	(0.0 - 11.2)	0.78	(0.00 - 2.88)	-*
Lip	3	9.9	(0.0 - 21.6)	1.82	(0.15 - 4.25)	-*	1	4.5	(0.0 - 13.2)	1.02	(0.00 - 3.76)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	3	6.4	(0.0 - 15.7)	1.04	(0.08 - 2.42)	-*
Other lymphohaematopoietic	4	10.4	(0.0 - 21.4)	2.57	(0.40 - 5.63)	-*	1	0.6	(0.0 - 1.8)	0.70	(0.00 - 2.59)	-*
Oesophagus	1	1.4	(0.0 - 4.2)	0.59	(0.00 - 2.19)	-*	1	4.5	(0.0 - 13.4)	1.00	(0.00 - 3.68)	-*
Thyroid gland	0	-	-	0	n/a	-	1	0.9	(0.0 - 2.5)	0.63	(0.00 - 2.34)	-*
Myeloma/plasma cell tumours	3	11.2	(0.0 - 24.4)	2.35	(0.19 - 5.48)	-*	0	-	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	5	21.6	(2.6 - 40.6)	2.52	(0.55 - 5.17)	-*
Non-mel. skin (exc BCC/SCC)	4	12.1	(0.0 - 24.9)	3.00	(0.46 - 6.58)	-*	2	4.4	(0.0 - 11.5)	2.16	(0.03 - 6.01)	-*
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	1	3.4	(0.0 - 10.0)	2.12	(0.00 - 7.80)	-*
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	1	0.9	(0.0 - 2.5)	1.11	(0.00 - 4.09)	-*
Larynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Tongue	1	4.1	(0.0 - 12.0)	1.51	(0.00 - 5.57)	-*	0	-	-	-	-	.
Connective & soft tissues	1	2.2	(0.0 - 6.5)	2.00	(0.00 - 7.38)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	1.3	(0.0 - 3.8)	1.37	(0.00 - 5.04)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	1	0.9	(0.0 - 2.5)	4.31	(0.00 - 15.88)	-*
Anus	2	5.6	(0.0 - 13.8)	10.02	(0.13 - 27.91)	-*	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	3.7	(0.0 - 11.0)	3.24	(0.00 - 11.95)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	120	362.4	(293.9 - 431.0)	1.13	(0.94 - 1.36)	-	101	247.7	(190.4 - 305.0)	1.04	(0.85 - 1.26)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mount Magnet (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	130.4	(0.0 - 322.7)	1.59	(0.02 - 4.42)	-*
Colorectal cancer	1	41.7	(0.0 - 119.9)	1.07	(0.00 - 3.93)	-*	0	-	-	-	-	.
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	2	145.0	(0.0 - 346.4)	8.00	(0.10 - 22.29)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	1	58.3	(0.0 - 171.9)	12.85	(0.00 - 47.42)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	1	24.8	(0.0 - 73.3)	6.87	(0.00 - 25.33)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	1	33.0	(0.0 - 97.4)	17.44	(0.00 - 64.35)	-*	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	3	99.4	(0.0 - 211.8)	0.42	(0.03 - 0.97)	V	5	333.7	(32.9 - 634.4)	1.25	(0.27 - 2.56)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mount Marshall (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	54.8	(0.0 - 161.5)	0.62	(0.00 - 2.30)	-*
Colorectal cancer	1	40.4	(0.0 - 119.2)	0.97	(0.00 - 3.58)	-*	0	-	-	0	n/a	-
Prostate gland	1	40.4	(0.0 - 119.2)	0.58	(0.00 - 2.14)	-*	0	-	-	-	-	-
Melanoma (skin)	0	-	-	0	n/a	-	1	54.8	(0.0 - 161.5)	1.74	(0.00 - 6.43)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	1	62.5	(0.0 - 183.1)	3.01	(0.00 - 11.10)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	43.5	(0.0 - 128.1)	12.36	(0.00 - 45.61)	-*	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	47.6	(0.0 - 138.7)	10.90	(0.00 - 40.20)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	4	171.9	(5.3 - 338.5)	0.52	(0.08 - 1.14)	-	3	172.1	(0.0 - 364.4)	0.61	(0.05 - 1.43)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mukinbudin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	1	45.1	(0.0 - 133.2)	0.80	(0.00 - 2.96)	-*	0	-	-	0	n/a	-
Prostate gland	1	38.1	(0.0 - 112.4)	0.47	(0.00 - 1.74)	-*	0	-	-	-	-	.
Melanoma (skin)	1	38.1	(0.0 - 112.4)	0.92	(0.00 - 3.38)	-*	2	76.8	(0.0 - 183.3)	2.93	(0.04 - 8.16)	-*
Lung, bronchus & trachea	1	23.5	(0.0 - 69.4)	0.88	(0.00 - 3.26)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	2	62.0	(0.0 - 149.9)	9.05	(0.11 - 25.23)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	1	46.2	(0.0 - 136.3)	6.87	(0.00 - 25.34)	-*	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	51.7	(0.0 - 152.2)	5.21	(0.00 - 19.22)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	1	45.1	(0.0 - 133.2)	9.79	(0.00 - 36.10)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	8	298.1	(87.8 - 508.4)	0.88	(0.31 - 1.58)	-	3	128.5	(0.0 - 274.9)	0.47	(0.04 - 1.10)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mullewa (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	31.3	(0.0 - 92.0)	56.62	(0.00 - 208.87)	-*	3	110.5	(0.0 - 235.1)	1.38	(0.11 - 3.23)	-*
Colorectal cancer	1	47.6	(0.0 - 138.7)	0.68	(0.00 - 2.52)	-*	2	134.9	(0.0 - 328.9)	2.64	(0.03 - 7.36)	-*
Prostate gland	1	31.6	(0.0 - 93.1)	0.42	(0.00 - 1.53)	-*	0	-	-	-	-	.
Melanoma (skin)	2	78.9	(0.0 - 188.4)	1.50	(0.02 - 4.19)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	1	27.6	(0.0 - 81.5)	0.81	(0.00 - 2.98)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	1	31.6	(0.0 - 93.1)	5.54	(0.00 - 20.43)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	1	30.3	(0.0 - 89.5)	7.17	(0.00 - 26.44)	-*	0	-	-	-	-	.
Oesophagus	1	33.7	(0.0 - 99.6)	6.33	(0.00 - 23.33)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	30.2	(0.0 - 89.1)	5.63	(0.00 - 20.77)	-*
Non-mel. skin (exc BCC/SCC)	1	31.3	(0.0 - 92.0)	7.97	(0.00 - 29.42)	-*	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	31.6	(0.0 - 93.1)	8.38	(0.00 - 30.93)	-*	0	-	-	-	-	.
Tongue	1	27.6	(0.0 - 81.5)	13.56	(0.00 - 50.03)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	12	402.9	(176.6 - 629.2)	1.11	(0.51 - 1.82)	-	6	275.5	(37.5 - 513.5)	0.90	(0.24 - 1.74)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mundaring (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	2	1.9	(0.0 - 4.7)	3.44	(0.04 - 9.60)	-*	111	93.5	(75.9 - 111.2)	1.10	(0.91 - 1.33)	-
Colorectal cancer	55	50.7	(37.1 - 64.3)	1.09	(0.83 - 1.43)	-	45	35.3	(24.3 - 46.3)	1.19	(0.85 - 1.57)	-
Prostate gland	99	87.1	(69.6 - 104.5)	1.20	(0.98 - 1.47)	-	0	-	-	-	-	.
Melanoma (skin)	42	36.8	(25.4 - 48.3)	0.89	(0.62 - 1.18)	-	36	34.1	(22.3 - 45.9)	1.03	(0.70 - 1.39)	-
Lung, bronchus & trachea	29	25.1	(15.8 - 34.5)	0.67	(0.43 - 0.93)	V	18	13.3	(6.9 - 19.7)	0.79	(0.44 - 1.20)	-
Lymphoma	23	23.6	(13.4 - 33.7)	1.38	(0.83 - 2.00)	-	14	11.3	(5.2 - 17.5)	1.15	(0.57 - 1.83)	-
Unknown primary site	12	11.7	(4.8 - 18.7)	0.96	(0.44 - 1.58)	-	8	6.2	(1.7 - 10.7)	0.88	(0.31 - 1.59)	-
Kidney & other renal tract	8	7.2	(2.1 - 12.2)	0.74	(0.26 - 1.34)	-	8	6.8	(2.0 - 11.7)	1.30	(0.46 - 2.34)	-
Leukaemia	10	10.5	(3.6 - 17.4)	1.01	(0.41 - 1.72)	-	11	11.2	(4.1 - 18.3)	1.74	(0.76 - 2.91)	-
Pancreas	10	9.2	(3.4 - 15.0)	1.43	(0.59 - 2.44)	-	4	3.0	(0.0 - 6.1)	0.60	(0.09 - 1.30)	-
Urinary bladder	10	8.5	(3.1 - 13.9)	1.02	(0.42 - 1.74)	-	6	3.7	(0.5 - 7.0)	1.81	(0.49 - 3.51)	-*
Stomach	5	5.1	(0.6 - 9.7)	0.56	(0.12 - 1.14)	-	4	2.6	(0.0 - 5.5)	0.87	(0.14 - 1.91)	-
Corpus uteri	0	-	-	-	-	.	16	15.1	(7.6 - 22.6)	1.49	(0.78 - 2.30)	-
Brain	5	4.8	(0.5 - 9.2)	0.78	(0.17 - 1.60)	-	8	6.6	(2.0 - 11.3)	1.86	(0.65 - 3.35)	-*
Lip	4	3.1	(0.0 - 6.2)	0.61	(0.09 - 1.34)	-	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	9	6.8	(2.1 - 11.5)	0.99	(0.38 - 1.73)	-
Other lymphohaematopoietic	1	0.9	(0.0 - 2.7)	0.22	(0.00 - 0.80)	V	3	1.6	(0.0 - 3.5)	0.90	(0.07 - 2.09)	-*
Oesophagus	6	5.0	(0.9 - 9.0)	1.05	(0.28 - 2.04)	-	4	2.4	(0.0 - 4.8)	1.52	(0.24 - 3.33)	-*
Thyroid gland	0	-	-	0	n/a	-	9	9.7	(2.9 - 16.4)	1.45	(0.56 - 2.54)	-
Myeloma/plasma cell tumours	5	4.4	(0.5 - 8.3)	1.17	(0.26 - 2.40)	-*	3	2.0	(0.0 - 4.3)	0.96	(0.08 - 2.23)	-*
Cervix uteri	0	-	-	-	-	.	6	4.4	(0.8 - 8.0)	0.79	(0.21 - 1.53)	-
Non-mel. skin (exc BCC/SCC)	4	3.2	(0.1 - 6.2)	0.91	(0.14 - 2.00)	-*	3	2.1	(0.0 - 4.6)	1.18	(0.10 - 2.75)	-*
Mesothelioma	11	9.9	(4.0 - 15.8)	2.11	(0.92 - 3.53)	-	1	1.1	(0.0 - 3.3)	1.30	(0.00 - 4.78)	-*
Liver & intrahepatic bile duct	1	1.8	(0.0 - 5.2)	0.25	(0.00 - 0.94)	V*	0	-	-	0	n/a	-
Testis	6	4.7	(0.9 - 8.5)	1.19	(0.32 - 2.31)	-	0	-	-	-	-	.
Gallbladder & bile ducts	4	2.8	(0.1 - 5.6)	1.72	(0.27 - 3.76)	-*	4	2.7	(0.0 - 5.4)	1.78	(0.27 - 3.89)	-*
Larynx	3	2.6	(0.0 - 5.7)	0.70	(0.06 - 1.64)	-*	0	-	-	0	n/a	-
Tongue	2	1.4	(0.0 - 3.4)	0.76	(0.01 - 2.12)	-*	1	0.9	(0.0 - 2.7)	1.08	(0.00 - 3.98)	-*
Connective & soft tissues	4	4.0	(0.0 - 8.1)	2.05	(0.32 - 4.50)	-*	2	1.2	(0.0 - 2.9)	1.59	(0.02 - 4.44)	-*
Tonsil & oropharynx	2	1.7	(0.0 - 4.0)	0.92	(0.01 - 2.56)	-*	1	0.8	(0.0 - 2.4)	2.19	(0.00 - 8.07)	-*
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	1	0.9	(0.0 - 2.7)	0.86	(0.00 - 3.16)	-*	1	0.8	(0.0 - 2.4)	1.30	(0.00 - 4.78)	-*
Eye & lacrimal gland	2	1.9	(0.0 - 4.5)	1.65	(0.02 - 4.60)	-*	1	0.9	(0.0 - 2.7)	1.80	(0.00 - 6.63)	-*
Major Salivary Gland	1	0.7	(0.0 - 2.0)	1.02	(0.00 - 3.75)	-*	0	-	-	0	n/a	-
Anus	1	0.7	(0.0 - 2.0)	1.34	(0.00 - 4.94)	-*	0	-	-	0	n/a	-
Mouth, other & unspecified	0	-	-	0	n/a	-	1	0.8	(0.0 - 2.4)	1.63	(0.00 - 6.00)	-*
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	-	.
Bones, joints & articular cart.	2	1.8	(0.0 - 4.4)	2.97	(0.04 - 8.27)	-*	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	2	1.9	(0.0 - 4.7)	1.72	(0.02 - 4.79)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	0	-	-	-	-	.
Peritoneum & retroperitoneum	1	0.9	(0.0 - 2.6)	3.51	(0.00 - 12.96)	-*	1	0.8	(0.0 - 2.4)	1.61	(0.00 - 5.93)	-*
Adrenal & other endocrine	1	1.3	(0.0 - 3.8)	2.22	(0.00 - 8.17)	-*	1	0.7	(0.0 - 2.1)	3.42	(0.00 - 12.63)	-*
Nasopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Pharynx, other & ill-def.	1	0.9	(0.0 - 2.7)	2.00	(0.00 - 7.36)	-*	0	-	-	-	-	.
Penis & other male genital	1	0.7	(0.0 - 2.1)	1.82	(0.00 - 6.73)	-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	2	1.2	(0.0 - 2.9)	12.66	(0.16 - 35.28)	-*
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	1	2.2	(0.0 - 6.5)	10.61	(0.00 - 39.13)	-*
Uterus, nos	0	-	-	-	-	.	1	0.8	(0.0 - 2.3)	4.74	(0.00 - 17.49)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	1	1.0	(0.0 - 3.0)	33.90	(0.00 - 125.05)	-*
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	376	339.4	(304.4 - 374.4)	1.01	(0.91 - 1.11)	-	345	287.9	(256.2 - 319.7)	1.10	(0.99 - 1.22)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Murchison (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	-	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Murray (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	1.6	(0.0 - 4.6)	3.59	(0.00 - 13.24)	-*	33	84.8	(55.3 - 114.4)	0.95	(0.63 - 1.31)	-
Colorectal cancer	20	38.3	(20.6 - 56.1)	0.85	(0.49 - 1.27)	-	12	26.1	(11.2 - 41.1)	0.88	(0.40 - 1.45)	-
Prostate gland	49	84.6	(60.5 - 108.6)	1.23	(0.89 - 1.60)	-	0	-	-	-	-	.
Melanoma (skin)	9	19.1	(6.2 - 31.9)	0.48	(0.18 - 0.83)	V	8	21.9	(5.1 - 38.8)	0.70	(0.25 - 1.27)	-
Lung, bronchus & trachea	21	35.7	(20.2 - 51.1)	0.99	(0.58 - 1.46)	-	16	34.5	(17.4 - 51.7)	1.90	(1.00 - 2.93)	-
Lymphoma	5	15.0	(1.0 - 29.0)	0.74	(0.16 - 1.51)	-	9	23.0	(7.6 - 38.5)	2.10	(0.80 - 3.67)	-*
Unknown primary site	4	9.3	(0.0 - 18.6)	0.70	(0.11 - 1.53)	-	4	9.0	(0.0 - 18.1)	1.32	(0.20 - 2.89)	-*
Kidney & other renal tract	3	5.7	(0.0 - 12.3)	0.64	(0.05 - 1.48)	-	3	7.0	(0.0 - 15.0)	1.36	(0.11 - 3.18)	-*
Leukaemia	6	16.9	(0.0 - 33.8)	1.42	(0.38 - 2.76)	-*	4	15.2	(0.0 - 32.4)	1.86	(0.29 - 4.08)	-*
Pancreas	2	4.1	(0.0 - 9.7)	0.61	(0.01 - 1.70)	-*	4	8.5	(0.1 - 16.8)	1.64	(0.25 - 3.60)	-*
Urinary bladder	3	5.7	(0.0 - 12.2)	0.63	(0.05 - 1.48)	-	0	-	-	0	n/a	-
Stomach	4	8.7	(0.0 - 17.4)	0.95	(0.15 - 2.09)	-*	2	4.6	(0.0 - 11.1)	1.22	(0.02 - 3.39)	-*
Corpus uteri	0	-	-	-	-	.	2	4.5	(0.0 - 10.8)	0.51	(0.01 - 1.42)	-*
Brain	1	2.2	(0.0 - 6.5)	0.40	(0.00 - 1.47)	-*	3	7.7	(0.0 - 16.5)	2.09	(0.17 - 4.88)	-*
Lip	2	3.9	(0.0 - 9.4)	0.79	(0.01 - 2.21)	-*	2	4.3	(0.0 - 10.4)	2.04	(0.03 - 5.68)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	5	11.0	(1.4 - 20.6)	1.52	(0.33 - 3.12)	-*
Other lymphohaematopoietic	1	1.6	(0.0 - 4.6)	0.45	(0.00 - 1.68)	-*	0	-	-	0	n/a	-
Oesophagus	3	6.4	(0.0 - 13.5)	1.12	(0.09 - 2.61)	-*	2	3.8	(0.0 - 9.2)	2.07	(0.03 - 5.76)	-*
Thyroid gland	0	-	-	0	n/a	-	2	7.2	(0.0 - 17.2)	1.07	(0.01 - 2.97)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	1	2.4	(0.0 - 7.0)	0.89	(0.00 - 3.28)	-*
Cervix uteri	0	-	-	-	-	.	4	15.3	(0.0 - 31.1)	1.71	(0.27 - 3.76)	-*
Non-mel. skin (exc BCC/SCC)	2	4.5	(0.0 - 10.6)	1.05	(0.01 - 2.93)	-*	0	-	-	0	n/a	-
Mesothelioma	2	4.3	(0.0 - 10.2)	0.80	(0.01 - 2.23)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	1.6	(0.0 - 4.6)	0.55	(0.00 - 2.03)	-*	1	2.4	(0.0 - 7.0)	2.04	(0.00 - 7.52)	-*
Testis	3	8.7	(0.0 - 19.2)	2.11	(0.17 - 4.91)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	3	4.5	(0.0 - 9.7)	2.85	(0.23 - 6.64)	-*	2	3.4	(0.0 - 8.1)	2.49	(0.03 - 6.94)	-*
Larynx	2	3.7	(0.0 - 9.0)	1.04	(0.01 - 2.88)	-*	0	-	-	-	-	.
Tongue	1	1.3	(0.0 - 3.9)	0.96	(0.00 - 3.56)	-*	1	1.8	(0.0 - 5.4)	3.02	(0.00 - 11.13)	-*
Connective & soft tissues	1	1.9	(0.0 - 5.5)	1.33	(0.00 - 4.92)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	3	7.5	(0.0 - 16.0)	4.31	(0.35 - 10.05)	-*
Small intestine	0	-	-	0	n/a	-	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	1	2.5	(0.0 - 7.4)	3.02	(0.00 - 11.13)	-*
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	-	.
Bones, joints & articular cart.	1	5.0	(0.0 - 14.9)	4.55	(0.00 - 16.77)	-*	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	2.1	(0.0 - 6.2)	1.87	(0.00 - 6.92)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	2.4	(0.0 - 7.0)	4.70	(0.00 - 17.34)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	152	298.5	(248.0 - 349.0)	0.90	(0.77 - 1.06)	-	124	308.4	(251.4 - 365.4)	1.14	(0.95 - 1.37)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Nannup (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	102.6	(0.0 - 205.4)	1.09	(0.17 - 2.38)	-*
Colorectal cancer	4	65.5	(1.4 - 129.6)	1.90	(0.29 - 4.16)	-*	1	22.2	(0.0 - 65.7)	0.73	(0.00 - 2.69)	-*
Prostate gland	3	61.9	(0.0 - 133.1)	0.86	(0.07 - 2.00)	-*	0	-	-	-	-	.
Melanoma (skin)	4	87.0	(0.5 - 173.6)	2.14	(0.33 - 4.68)	-*	1	87.9	(0.0 - 259.3)	0.81	(0.00 - 2.99)	-*
Lung, bronchus & trachea	1	22.6	(0.0 - 66.8)	0.56	(0.00 - 2.05)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	1	18.2	(0.0 - 53.5)	2.33	(0.00 - 8.60)	-*
Unknown primary site	0	-	-	0	n/a	-	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	1	22.6	(0.0 - 66.8)	3.89	(0.00 - 14.35)	-*	0	-	-	-	-	.
Lip	1	14.7	(0.0 - 43.5)	3.88	(0.00 - 14.31)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	34.8	(0.0 - 102.7)	3.78	(0.00 - 13.96)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	1	20.0	(0.0 - 58.4)	4.54	(0.00 - 16.74)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	28.6	(0.0 - 84.3)	13.33	(0.00 - 49.18)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	1	25.6	(0.0 - 75.6)	25.31	(0.00 - 93.36)	-*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	16	320.0	(161.6 - 478.4)	1.04	(0.55 - 1.61)	-	9	294.3	(69.1 - 519.4)	0.79	(0.30 - 1.39)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Narembeen (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	57.7	(0.0 - 138.7)	0.70	(0.01 - 1.94)	-*
Colorectal cancer	1	28.3	(0.0 - 83.5)	0.57	(0.00 - 2.12)	-*	1	23.8	(0.0 - 70.4)	0.83	(0.00 - 3.05)	-*
Prostate gland	2	54.7	(0.0 - 131.6)	0.70	(0.01 - 1.95)	-*	0	-	-	-	-	.
Melanoma (skin)	2	60.8	(0.0 - 145.0)	1.33	(0.02 - 3.70)	-*	2	67.2	(0.0 - 160.1)	1.98	(0.02 - 5.52)	-*
Lung, bronchus & trachea	2	43.5	(0.0 - 105.9)	1.32	(0.02 - 3.68)	-*	2	31.0	(0.0 - 75.7)	2.79	(0.03 - 7.78)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	1	15.2	(0.0 - 44.4)	5.76	(0.00 - 21.26)	-*	0	-	-	-	-	.
Oesophagus	1	32.5	(0.0 - 96.0)	5.17	(0.00 - 19.08)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	1	28.3	(0.0 - 83.5)	5.55	(0.00 - 20.48)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	1	33.3	(0.0 - 98.4)	54.56	(0.00 - 201.27)	-*
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	1	28.2	(0.0 - 83.5)	25.48	(0.00 - 93.98)	-*	0	-	-	-	-	.
Eye & lacrimal gland	1	24.9	(0.0 - 73.6)	25.10	(0.00 - 92.60)	-*	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	1	29.9	(0.0 - 87.9)	46.89	(0.00 - 172.98)	-*
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	1	29.9	(0.0 - 87.9)	138.23	(0.00 - 509.94)	-*
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	12	316.4	(135.6 - 497.2)	0.95	(0.43 - 1.56)	-	10	272.8	(99.4 - 446.3)	1.06	(0.43 - 1.81)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

A-200 Narembeen (S) 1998-2002: Cancer incidence

Cancer in Western Australia, 1998-2002: incidence and mortality by Statistical Local Area

SLA: Narrogin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	V
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	1	26.3	(0.0 - 77.7)	0.26	(0.00 - 0.94)	V*	0	-	-	-	-	.
Melanoma (skin)	1	23.8	(0.0 - 70.2)	0.46	(0.00 - 1.71)	-*	1	23.1	(0.0 - 68.3)	0.67	(0.00 - 2.49)	-*
Lung, bronchus & trachea	1	17.2	(0.0 - 50.7)	0.48	(0.00 - 1.78)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	3	67.3	(0.0 - 144.2)	0.17	(0.01 - 0.39)	V	1	23.1	(0.0 - 68.3)	0.07	(0.00 - 0.27)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Narrogin (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	7	50.5	(10.9 - 90.1)	0.65	(0.20 - 1.21)	-
Colorectal cancer	10	92.3	(34.6 - 149.9)	1.63	(0.67 - 2.78)	-	7	33.7	(4.2 - 63.3)	1.30	(0.41 - 2.43)	-
Prostate gland	10	66.6	(22.2 - 111.0)	1.00	(0.41 - 1.71)	-	0	-	-	-	-	.
Melanoma (skin)	9	84.6	(29.1 - 140.1)	1.74	(0.67 - 3.05)	-	6	52.0	(7.8 - 96.2)	1.52	(0.41 - 2.95)	-*
Lung, bronchus & trachea	7	52.7	(10.4 - 95.0)	1.29	(0.41 - 2.41)	-	4	31.9	(0.0 - 64.4)	1.27	(0.20 - 2.78)	-*
Lymphoma	2	16.0	(0.0 - 39.8)	1.03	(0.01 - 2.86)	-*	1	9.0	(0.0 - 26.6)	0.63	(0.00 - 2.32)	-*
Unknown primary site	1	3.5	(0.0 - 10.4)	0.61	(0.00 - 2.26)	-*	3	14.9	(0.0 - 35.5)	2.04	(0.16 - 4.77)	-*
Kidney & other renal tract	3	19.5	(0.0 - 44.3)	2.39	(0.19 - 5.59)	-*	1	10.2	(0.0 - 30.0)	1.29	(0.00 - 4.77)	-*
Leukaemia	2	9.1	(0.0 - 21.8)	1.65	(0.02 - 4.60)	-*	4	30.9	(0.0 - 69.0)	4.50	(0.70 - 9.86)	-*
Pancreas	1	3.5	(0.0 - 10.4)	1.18	(0.00 - 4.36)	-*	2	10.7	(0.0 - 28.3)	1.95	(0.02 - 5.43)	-*
Urinary bladder	5	25.3	(0.3 - 50.3)	3.64	(0.79 - 7.45)	-*	2	5.1	(0.0 - 12.4)	3.55	(0.04 - 9.89)	-*
Stomach	2	20.0	(0.0 - 47.8)	1.77	(0.02 - 4.94)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	4	25.3	(0.0 - 53.9)	3.10	(0.48 - 6.80)	-*
Brain	1	4.3	(0.0 - 12.7)	1.43	(0.00 - 5.28)	-*	1	11.3	(0.0 - 33.3)	1.88	(0.00 - 6.92)	-*
Lip	2	14.6	(0.0 - 35.9)	2.91	(0.04 - 8.11)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	3.2	(0.0 - 9.3)	0.86	(0.00 - 3.18)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Oesophagus	1	11.2	(0.0 - 33.0)	1.42	(0.00 - 5.23)	-*	0	-	-	-	-	.
Thyroid gland	2	13.6	(0.0 - 33.3)	8.15	(0.10 - 22.69)	-*	1	8.6	(0.0 - 25.3)	1.53	(0.00 - 5.63)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	1	9.8	(0.0 - 29.1)	2.23	(0.00 - 8.23)	-*
Cervix uteri	0	-	-	-	-	.	1	1.9	(0.0 - 5.8)	1.19	(0.00 - 4.41)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	1	1.9	(0.0 - 5.8)	2.80	(0.00 - 10.31)	-*
Mesothelioma	1	3.5	(0.0 - 10.4)	1.55	(0.00 - 5.72)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	7.6	(0.0 - 22.4)	2.18	(0.00 - 8.02)	-*	0	-	-	-	-	.
Testis	4	42.8	(0.3 - 85.4)	7.52	(1.16 - 16.47)	^*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	11.5	(0.0 - 33.9)	2.83	(0.00 - 10.43)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	1	8.7	(0.0 - 25.9)	3.65	(0.00 - 13.45)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	1.9	(0.0 - 5.8)	3.38	(0.00 - 12.48)	-*
Small intestine	1	11.2	(0.0 - 33.0)	7.53	(0.00 - 27.77)	-*	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	1	8.8	(0.0 - 26.1)	8.55	(0.00 - 31.54)	-*	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	1	8.7	(0.0 - 25.9)	17.56	(0.00 - 64.76)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	1	10.4	(0.0 - 30.8)	82.23	(0.00 - 303.35)	-*	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	69	538.6	(404.9 - 672.4)	1.54	(1.21 - 1.96)	^	49	324.2	(220.0 - 428.5)	1.25	(0.90 - 1.63)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Nedlands (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	93	109.3	(85.4 - 133.1)	1.23	(1.00 - 1.52)	-
Colorectal cancer	23	22.2	(11.9 - 32.5)	0.58	(0.35 - 0.84)	V	51	43.3	(28.2 - 58.4)	1.28	(0.96 - 1.69)	-
Prostate gland	83	100.0	(76.6 - 123.4)	1.30	(1.04 - 1.62)	^	0	-	-	-	-	.
Melanoma (skin)	53	68.6	(48.8 - 88.4)	1.67	(1.27 - 2.21)	^	35	42.2	(25.8 - 58.5)	1.33	(0.89 - 1.80)	-
Lung, bronchus & trachea	24	21.5	(11.8 - 31.1)	0.70	(0.42 - 1.00)	-	19	13.4	(5.9 - 20.9)	0.84	(0.47 - 1.26)	-
Lymphoma	14	14.8	(6.5 - 23.1)	1.15	(0.57 - 1.83)	-	15	15.1	(5.7 - 24.4)	1.36	(0.70 - 2.13)	-
Unknown primary site	10	11.5	(3.6 - 19.3)	0.93	(0.38 - 1.59)	-	15	9.9	(3.2 - 16.6)	1.27	(0.65 - 1.99)	-
Kidney & other renal tract	9	10.5	(2.8 - 18.1)	1.13	(0.44 - 1.99)	-	4	3.0	(0.0 - 6.2)	0.74	(0.11 - 1.61)	-
Leukaemia	12	15.8	(5.8 - 25.7)	1.62	(0.74 - 2.65)	-	5	2.8	(0.0 - 6.0)	0.80	(0.17 - 1.64)	-
Pancreas	3	2.9	(0.0 - 6.7)	0.55	(0.04 - 1.29)	-	4	1.1	(0.0 - 2.3)	0.51	(0.08 - 1.12)	-
Urinary bladder	8	5.3	(1.3 - 9.3)	0.88	(0.31 - 1.58)	-	4	1.1	(0.0 - 2.3)	0.91	(0.14 - 1.99)	-*
Stomach	5	2.8	(0.3 - 5.3)	0.69	(0.15 - 1.40)	-	12	8.7	(1.2 - 16.2)	2.23	(1.02 - 3.66)	^
Corpus uteri	0	-	-	-	-	.	14	16.4	(6.7 - 26.1)	1.53	(0.76 - 2.43)	-
Brain	5	8.7	(0.5 - 16.9)	1.18	(0.26 - 2.41)	-*	1	1.0	(0.0 - 3.1)	0.27	(0.00 - 1.01)	-*
Lip	2	1.9	(0.0 - 4.9)	0.48	(0.01 - 1.33)	-*	3	1.5	(0.0 - 3.6)	1.05	(0.08 - 2.44)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	17	18.1	(8.7 - 27.5)	2.06	(1.11 - 3.15)	^
Other lymphohaematopoietic	4	3.7	(0.0 - 7.6)	0.88	(0.14 - 1.94)	-	6	2.2	(0.0 - 4.7)	1.39	(0.38 - 2.71)	-*
Oesophagus	4	3.9	(0.0 - 8.0)	0.89	(0.14 - 1.94)	-	3	2.1	(0.0 - 5.4)	1.00	(0.08 - 2.34)	-*
Thyroid gland	4	5.8	(0.0 - 11.6)	2.83	(0.44 - 6.21)	-*	4	9.0	(0.0 - 18.0)	0.96	(0.15 - 2.11)	-*
Myeloma/plasma cell tumours	3	5.1	(0.0 - 11.0)	0.83	(0.07 - 1.94)	-*	4	1.9	(0.0 - 4.3)	1.18	(0.18 - 2.58)	-*
Cervix uteri	0	-	-	-	-	.	8	11.6	(2.9 - 20.2)	1.47	(0.52 - 2.65)	-
Non-mel. skin (exc BCC/SCC)	8	6.7	(1.6 - 11.7)	2.14	(0.75 - 3.85)	-*	1	1.6	(0.0 - 4.8)	0.37	(0.00 - 1.35)	-*
Mesothelioma	1	0.5	(0.0 - 1.5)	0.24	(0.00 - 0.89)	V*	1	1.0	(0.0 - 3.1)	1.39	(0.00 - 5.14)	-*
Liver & intrahepatic bile duct	5	6.4	(0.4 - 12.4)	1.74	(0.38 - 3.55)	-*	3	2.3	(0.0 - 5.1)	2.15	(0.17 - 5.02)	-*
Testis	2	3.2	(0.0 - 7.9)	0.73	(0.01 - 2.03)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	4	2.3	(0.0 - 4.6)	2.20	(0.34 - 4.82)	-*	2	0.7	(0.0 - 1.7)	0.74	(0.01 - 2.07)	-*
Larynx	4	5.3	(0.0 - 10.6)	1.39	(0.22 - 3.06)	-*	1	0.2	(0.0 - 0.6)	1.85	(0.00 - 6.84)	-*
Tongue	1	0.5	(0.0 - 1.5)	0.57	(0.00 - 2.10)	-*	0	-	-	0	n/a	-
Connective & soft tissues	0	-	-	0	n/a	-	1	2.3	(0.0 - 6.9)	1.11	(0.00 - 4.11)	-*
Tonsil & oropharynx	1	1.3	(0.0 - 3.9)	0.72	(0.00 - 2.65)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	2.0	(0.0 - 5.9)	0.46	(0.00 - 1.68)	-*
Small intestine	0	-	-	0	n/a	-	3	3.2	(0.0 - 7.1)	4.02	(0.32 - 9.39)	-*
Eye & lacrimal gland	0	-	-	0	n/a	-	1	0.5	(0.0 - 1.4)	1.89	(0.00 - 6.97)	-*
Major Salivary Gland	2	1.7	(0.0 - 4.4)	2.45	(0.03 - 6.83)	-*	0	-	-	0	n/a	-
Anus	0	-	-	0	n/a	-	1	0.2	(0.0 - 0.7)	1.13	(0.00 - 4.19)	-*
Mouth, other & unspecified	1	0.5	(0.0 - 1.5)	1.33	(0.00 - 4.90)	-*	1	2.0	(0.0 - 5.9)	1.86	(0.00 - 6.85)	-*
Floor of mouth	1	1.8	(0.0 - 5.5)	1.26	(0.00 - 4.65)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	2	3.2	(0.0 - 7.9)	4.74	(0.06 - 13.20)	-*	2	2.4	(0.0 - 5.7)	3.86	(0.05 - 10.76)	-*
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	1.0	(0.0 - 3.1)	1.81	(0.00 - 6.66)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	1	1.3	(0.0 - 3.9)	2.65	(0.00 - 9.77)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	1	1.8	(0.0 - 5.5)	2.63	(0.00 - 9.69)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	1	1.6	(0.0 - 4.7)	11.29	(0.00 - 41.65)	-*	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	1	2.0	(0.0 - 5.9)	12.79	(0.00 - 47.19)	-*
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	301	343.1	(300.5 - 385.8)	1.06	(0.95 - 1.19)	-	337	335.0	(292.5 - 377.6)	1.21	(1.08 - 1.34)	^

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Ngaanyatjarraku (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	1	21.5	(0.0 - 63.4)	17.83	(0.00 - 65.78)	.*	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	21.5	(0.0 - 63.4)	0.10	(0.00 - 0.38)	V	0	-	-	0	n/a	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Northam (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	6	52.8	(10.6 - 95.1)	0.60	(0.16 - 1.17)	-
Colorectal cancer	8	72.5	(17.9 - 127.1)	1.37	(0.48 - 2.47)	-	4	35.1	(0.6 - 69.6)	1.18	(0.18 - 2.58)	-*
Prostate gland	4	28.6	(0.6 - 56.6)	0.41	(0.06 - 0.89)	V	0	-	-	-	-	.
Melanoma (skin)	4	30.8	(0.6 - 61.0)	0.76	(0.12 - 1.67)	-	3	24.1	(0.0 - 51.4)	0.88	(0.07 - 2.06)	-*
Lung, bronchus & trachea	3	23.3	(0.0 - 49.6)	0.58	(0.05 - 1.36)	-	2	19.5	(0.0 - 46.4)	0.96	(0.01 - 2.67)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	2	17.6	(0.0 - 42.2)	2.72	(0.03 - 7.58)	-*
Kidney & other renal tract	1	7.0	(0.0 - 20.7)	0.82	(0.00 - 3.02)	-*	2	15.1	(0.0 - 36.0)	3.40	(0.04 - 9.46)	-*
Leukaemia	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pancreas	1	7.5	(0.0 - 22.2)	1.23	(0.00 - 4.55)	-*	0	-	-	0	n/a	-
Urinary bladder	3	22.0	(0.0 - 46.8)	2.75	(0.22 - 6.43)	-*	0	-	-	-	-	.
Stomach	2	13.9	(0.0 - 33.3)	1.95	(0.02 - 5.42)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	0	-	-	0	n/a	-	0	-	-	-	-	.
Lip	1	7.5	(0.0 - 22.2)	1.39	(0.00 - 5.12)	-*	1	8.4	(0.0 - 24.9)	3.84	(0.00 - 14.16)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	7.1	(0.0 - 21.1)	1.51	(0.00 - 5.56)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	7.3	(0.0 - 21.5)	1.36	(0.00 - 5.02)	-*
Non-mel. skin (exc BCC/SCC)	1	7.4	(0.0 - 21.8)	2.16	(0.00 - 7.97)	-*	0	-	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	7.0	(0.0 - 20.6)	2.17	(0.00 - 8.00)	-*	0	-	-	-	-	.
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Tongue	1	7.4	(0.0 - 21.8)	3.38	(0.00 - 12.47)	-*	0	-	-	-	-	.
Connective & soft tissues	1	7.5	(0.0 - 22.2)	4.63	(0.00 - 17.10)	-*	1	8.4	(0.0 - 25.0)	7.92	(0.00 - 29.20)	-*
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	1	7.0	(0.0 - 20.6)	10.86	(0.00 - 40.07)	-*	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	7.5	(0.0 - 22.2)	6.36	(0.00 - 23.46)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	7.3	(0.0 - 21.5)	16.80	(0.00 - 61.97)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	34	263.8	(172.5 - 355.1)	0.79	(0.53 - 1.08)	-	23	195.6	(115.6 - 275.6)	0.78	(0.46 - 1.12)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Northam (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	17	70.9	(34.4 - 107.4)	0.87	(0.47 - 1.33)	-
Colorectal cancer	12	46.4	(18.2 - 74.7)	1.07	(0.49 - 1.76)	-	7	22.9	(2.5 - 43.3)	0.73	(0.23 - 1.37)	-
Prostate gland	24	110.3	(64.3 - 156.4)	1.30	(0.79 - 1.87)	-	0	-	-	-	-	.
Melanoma (skin)	13	62.9	(27.1 - 98.8)	1.40	(0.67 - 2.25)	-	5	18.4	(0.2 - 36.7)	0.72	(0.16 - 1.47)	-
Lung, bronchus & trachea	14	56.8	(25.8 - 87.8)	1.39	(0.69 - 2.20)	-	9	32.5	(9.1 - 55.9)	1.58	(0.61 - 2.76)	-
Lymphoma	2	7.5	(0.0 - 17.9)	0.58	(0.01 - 1.62)	-*	1	8.1	(0.0 - 24.1)	0.35	(0.00 - 1.29)	-*
Unknown primary site	3	18.2	(0.0 - 38.7)	1.04	(0.08 - 2.42)	-*	4	7.4	(0.0 - 15.2)	1.60	(0.25 - 3.51)	-*
Kidney & other renal tract	4	18.3	(0.1 - 36.4)	1.75	(0.27 - 3.83)	-*	2	2.6	(0.0 - 6.3)	1.44	(0.02 - 4.01)	-*
Leukaemia	1	7.2	(0.0 - 21.2)	0.46	(0.00 - 1.69)	-*	2	4.4	(0.0 - 11.1)	1.32	(0.02 - 3.67)	-*
Pancreas	2	11.2	(0.0 - 26.7)	1.28	(0.02 - 3.56)	-*	1	1.3	(0.0 - 4.0)	0.55	(0.00 - 2.04)	-*
Urinary bladder	1	3.8	(0.0 - 11.3)	0.41	(0.00 - 1.52)	-*	1	5.5	(0.0 - 16.3)	1.02	(0.00 - 3.77)	-*
Stomach	3	6.8	(0.0 - 14.5)	1.45	(0.12 - 3.40)	-*	2	6.6	(0.0 - 17.3)	1.64	(0.02 - 4.57)	-*
Corpus uteri	0	-	-	-	-	.	4	15.5	(0.0 - 32.1)	1.71	(0.26 - 3.75)	-*
Brain	3	17.9	(0.0 - 38.3)	2.42	(0.20 - 5.65)	-*	2	7.7	(0.0 - 20.1)	2.12	(0.03 - 5.90)	-*
Lip	4	20.5	(0.0 - 41.6)	3.23	(0.50 - 7.08)	-*	2	6.4	(0.0 - 16.7)	2.97	(0.04 - 8.27)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	2	6.7	(0.0 - 17.2)	0.96	(0.01 - 2.69)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Oesophagus	2	9.5	(0.0 - 22.7)	1.53	(0.02 - 4.28)	-*	0	-	-	0	n/a	-
Thyroid gland	0	-	-	-	-	.	3	15.8	(0.0 - 33.7)	2.63	(0.21 - 6.14)	-*
Myeloma/plasma cell tumours	1	5.6	(0.0 - 16.6)	1.03	(0.00 - 3.81)	-*	0	-	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	4	21.5	(0.3 - 42.7)	2.72	(0.42 - 5.97)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Mesothelioma	1	4.8	(0.0 - 14.1)	0.85	(0.00 - 3.13)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	1	7.3	(0.0 - 21.6)	1.15	(0.00 - 4.23)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Larynx	1	6.3	(0.0 - 18.5)	1.17	(0.00 - 4.31)	-*	1	1.6	(0.0 - 4.8)	6.96	(0.00 - 25.69)	-*
Tongue	1	4.8	(0.0 - 14.1)	2.07	(0.00 - 7.62)	-*	1	4.9	(0.0 - 14.5)	4.62	(0.00 - 17.06)	-*
Connective & soft tissues	0	-	-	-	-	.	1	6.1	(0.0 - 18.1)	4.01	(0.00 - 14.80)	-*
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	2	4.4	(0.0 - 11.1)	3.90	(0.05 - 10.86)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	1	7.1	(0.0 - 20.9)	6.31	(0.00 - 23.29)	-*
Anus	2	10.8	(0.0 - 25.8)	12.53	(0.16 - 34.92)	-*	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	95	436.8	(345.2 - 528.4)	1.17	(0.95 - 1.43)	-	74	278.6	(207.1 - 350.1)	1.06	(0.84 - 1.34)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Northampton (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	10	79.0	(29.9 - 128.2)	1.01	(0.41 - 1.72)	-
Colorectal cancer	8	70.0	(17.0 - 123.0)	1.22	(0.43 - 2.20)	-	2	14.1	(0.0 - 33.6)	0.52	(0.01 - 1.44)	-*
Prostate gland	9	55.6	(18.4 - 92.7)	0.82	(0.32 - 1.44)	-	0	-	-	-	-	.
Melanoma (skin)	10	79.4	(29.8 - 129.0)	1.82	(0.75 - 3.11)	-	6	50.6	(9.8 - 91.3)	1.78	(0.48 - 3.46)	-*
Lung, bronchus & trachea	6	44.8	(8.4 - 81.3)	1.02	(0.28 - 1.99)	-	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	1	7.4	(0.0 - 22.0)	0.80	(0.00 - 2.96)	-*
Unknown primary site	2	14.1	(0.0 - 34.1)	1.24	(0.02 - 3.45)	-*	0	-	-	0	n/a	-
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Leukaemia	1	8.6	(0.0 - 25.5)	0.82	(0.00 - 3.03)	-*	0	-	-	0	n/a	-
Pancreas	1	8.6	(0.0 - 25.3)	1.09	(0.00 - 4.01)	-*	1	7.4	(0.0 - 21.7)	1.45	(0.00 - 5.34)	-*
Urinary bladder	1	7.2	(0.0 - 21.2)	0.75	(0.00 - 2.75)	-*	1	8.6	(0.0 - 25.6)	2.96	(0.00 - 10.94)	-*
Stomach	2	12.2	(0.0 - 29.3)	1.69	(0.02 - 4.72)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	2	15.8	(0.0 - 37.8)	2.74	(0.03 - 7.64)	-*	1	7.4	(0.0 - 21.7)	2.38	(0.00 - 8.79)	-*
Lip	1	5.5	(0.0 - 16.4)	1.34	(0.00 - 4.96)	-*	2	18.7	(0.0 - 44.6)	7.17	(0.09 - 19.99)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	1	6.8	(0.0 - 20.0)	1.08	(0.00 - 3.98)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	1	7.4	(0.0 - 21.7)	3.66	(0.00 - 13.51)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	1	7.5	(0.0 - 22.0)	1.81	(0.00 - 6.67)	-*	0	-	-	-	-	.
Mesothelioma	1	4.7	(0.0 - 13.9)	1.45	(0.00 - 5.34)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	2	12.7	(0.0 - 30.5)	6.71	(0.08 - 18.69)	-*	0	-	-	-	-	.
Larynx	1	8.6	(0.0 - 25.3)	1.88	(0.00 - 6.94)	-*	1	7.4	(0.0 - 22.0)	16.24	(0.00 - 59.89)	-*
Tongue	1	8.9	(0.0 - 26.2)	3.36	(0.00 - 12.40)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	1	4.7	(0.0 - 13.9)	6.83	(0.00 - 25.19)	-*	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	1	7.2	(0.0 - 21.3)	8.42	(0.00 - 31.05)	-*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	1	8.6	(0.0 - 25.5)	7.57	(0.00 - 27.91)	-*	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	52	384.6	(276.5 - 492.7)	1.10	(0.83 - 1.45)	-	27	214.8	(133.7 - 295.9)	0.86	(0.54 - 1.22)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Nungarin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	1	71.4	(0.0 - 208.9)	1.23	(0.00 - 4.52)	^*	0	-	-	-	-	.
Melanoma (skin)	1	71.4	(0.0 - 208.9)	2.30	(0.00 - 8.49)	^*	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	92.3	(0.0 - 271.8)	22.52	(0.00 - 83.07)	^*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	71.4	(0.0 - 206.3)	60.86	(0.00 - 224.51)	^*
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	2	142.9	(0.0 - 333.6)	0.55	(0.01 - 1.53)	^*	2	163.7	(0.0 - 388.3)	0.89	(0.01 - 2.48)	^*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Peppermint Grove (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	55.7	(0.0 - 119.7)	0.57	(0.05 - 1.33)	-
Colorectal cancer	1	11.9	(0.0 - 35.0)	0.33	(0.00 - 1.23)	-*	3	44.6	(0.0 - 98.4)	1.33	(0.11 - 3.10)	-*
Prostate gland	5	64.8	(2.8 - 126.8)	1.01	(0.22 - 2.07)	-	0	-	-	-	-	.
Melanoma (skin)	2	27.1	(0.0 - 66.5)	0.84	(0.01 - 2.33)	-*	1	15.4	(0.0 - 45.5)	0.56	(0.00 - 2.05)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lymphoma	3	43.7	(0.0 - 96.6)	3.32	(0.27 - 7.76)	-*	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	2	10.8	(0.0 - 25.5)	3.45	(0.04 - 9.62)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	-	.
Leukaemia	1	17.2	(0.0 - 50.9)	1.79	(0.00 - 6.61)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	1	17.2	(0.0 - 50.9)	1.53	(0.00 - 5.63)	-*	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	16.4	(0.0 - 48.5)	1.67	(0.00 - 6.17)	-*
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	44.8	(0.0 - 106.8)	3.84	(0.05 - 10.71)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	1	6.4	(0.0 - 18.9)	4.59	(0.00 - 16.95)	-*
Oesophagus	0	-	-	-	-	.	1	7.8	(0.0 - 23.1)	6.21	(0.00 - 22.92)	-*
Thyroid gland	2	34.0	(0.0 - 81.2)	19.46	(0.24 - 54.21)	-*	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	1	16.3	(0.0 - 48.3)	7.30	(0.00 - 26.94)	-*	0	-	-	-	-	.
Larynx	1	17.2	(0.0 - 50.9)	4.31	(0.00 - 15.90)	-*	1	16.4	(0.0 - 48.5)	30.13	(0.00 - 111.16)	-*
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	1	21.2	(0.0 - 62.5)	15.37	(0.00 - 56.71)	-*	1	16.4	(0.0 - 48.5)	22.03	(0.00 - 81.28)	-*
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	18	270.8	(140.9 - 400.7)	0.84	(0.46 - 1.26)	-	16	234.7	(111.0 - 358.5)	0.92	(0.48 - 1.41)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Perenjori (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	1	73.2	(0.0 - 214.8)	1.26	(0.00 - 4.64)	-*	1	48.8	(0.0 - 143.2)	1.72	(0.00 - 6.33)	-*
Prostate gland	4	262.5	(9.1 - 515.9)	3.16	(0.49 - 6.92)	-*	0	-	-	-	-	.
Melanoma (skin)	2	122.2	(0.0 - 285.4)	2.45	(0.03 - 6.82)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	2	132.9	(0.0 - 316.1)	3.03	(0.04 - 8.44)	-*	0	-	-	-	-	.
Lymphoma	1	59.7	(0.0 - 175.8)	3.58	(0.00 - 13.21)	-*	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	1	33.3	(0.0 - 97.6)	6.90	(0.00 - 25.47)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	72.7	(0.0 - 214.0)	6.39	(0.00 - 23.57)	-*
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	72.7	(0.0 - 214.0)	20.84	(0.00 - 76.88)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	n/a	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	10	650.5	(263.6 - 1,037.4)	1.66	(0.68 - 2.84)	-	4	227.6	(0.0 - 456.1)	0.84	(0.13 - 1.85)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Perth (C) - Inner 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	61.2	(0.0 - 180.6)	0.74	(0.00 - 2.72)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	-
Melanoma (skin)	0	-	-	0	n/a	-	1	74.1	(0.0 - 218.6)	1.98	(0.00 - 7.31)	-*
Lung, bronchus & trachea	3	163.2	(0.0 - 360.4)	2.75	(0.22 - 6.42)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	1	38.5	(0.0 - 112.4)	5.60	(0.00 - 20.67)	-*
Unknown primary site	1	30.2	(0.0 - 89.1)	3.22	(0.00 - 11.89)	-*	0	-	-	-	-	.
Kidney & other renal tract	1	38.5	(0.0 - 113.1)	3.58	(0.00 - 13.20)	-*	1	38.5	(0.0 - 112.4)	11.72	(0.00 - 43.24)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	2	73.8	(0.0 - 175.4)	10.69	(0.13 - 29.79)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	7	305.5	(65.3 - 545.8)	0.71	(0.22 - 1.33)	-	4	212.2	(0.0 - 425.8)	0.89	(0.14 - 1.95)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Perth (C) - Remainder 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	9	46.8	(13.5 - 80.2)	0.59	(0.23 - 1.04)	-
Colorectal cancer	16	56.6	(27.7 - 85.5)	1.25	(0.65 - 1.93)	-	6	25.3	(3.1 - 47.4)	0.84	(0.23 - 1.63)	-
Prostate gland	24	85.9	(50.6 - 121.2)	1.15	(0.70 - 1.65)	-	0	-	-	-	-	.
Melanoma (skin)	15	54.1	(25.7 - 82.5)	1.33	(0.68 - 2.08)	-	3	18.4	(0.0 - 39.4)	0.50	(0.04 - 1.17)	-
Lung, bronchus & trachea	12	45.6	(19.5 - 71.7)	1.08	(0.49 - 1.77)	-	2	8.8	(0.0 - 22.3)	0.47	(0.01 - 1.31)	-*
Lymphoma	6	17.8	(3.0 - 32.7)	1.46	(0.40 - 2.85)	-*	1	5.3	(0.0 - 15.7)	0.44	(0.00 - 1.63)	-*
Unknown primary site	1	4.7	(0.0 - 14.0)	0.30	(0.00 - 1.10)	-*	1	1.9	(0.0 - 5.6)	0.54	(0.00 - 2.00)	-*
Kidney & other renal tract	3	10.4	(0.0 - 22.8)	1.16	(0.09 - 2.70)	-*	1	4.6	(0.0 - 13.7)	0.96	(0.00 - 3.55)	-*
Leukaemia	1	4.5	(0.0 - 13.3)	0.42	(0.00 - 1.53)	-*	1	2.3	(0.0 - 6.9)	0.90	(0.00 - 3.30)	-*
Pancreas	2	6.4	(0.0 - 15.4)	1.13	(0.01 - 3.15)	-*	1	1.7	(0.0 - 5.0)	0.74	(0.00 - 2.73)	-*
Urinary bladder	3	11.0	(0.0 - 23.4)	1.09	(0.09 - 2.54)	-*	1	1.9	(0.0 - 5.6)	1.40	(0.00 - 5.15)	-*
Stomach	0	-	-	0	n/a	-	2	7.5	(0.0 - 19.3)	2.18	(0.03 - 6.08)	-*
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	0	-	-	0	n/a	-	3	16.0	(0.0 - 35.6)	4.10	(0.33 - 9.58)	-*
Lip	1	4.4	(0.0 - 12.9)	0.67	(0.00 - 2.46)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	2	10.2	(0.0 - 26.3)	1.24	(0.02 - 3.45)	-*
Other lymphohaematopoietic	1	3.7	(0.0 - 11.0)	0.75	(0.00 - 2.75)	-*	0	-	-	0	n/a	-
Oesophagus	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Thyroid gland	1	2.7	(0.0 - 7.9)	1.86	(0.00 - 6.87)	-*	2	14.5	(0.0 - 34.9)	1.93	(0.02 - 5.39)	-*
Myeloma/plasma cell tumours	3	7.8	(0.0 - 16.9)	2.68	(0.22 - 6.25)	-*	0	-	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	1	4.9	(0.0 - 14.6)	0.85	(0.00 - 3.15)	-*	0	-	-	0	n/a	-
Mesothelioma	2	5.3	(0.0 - 12.7)	1.49	(0.02 - 4.16)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	3	11.8	(0.0 - 25.3)	3.15	(0.25 - 7.35)	-*	0	-	-	-	-	.
Testis	2	9.3	(0.0 - 22.2)	1.46	(0.02 - 4.06)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	1	6.6	(0.0 - 19.5)	2.17	(0.00 - 8.01)	-*
Larynx	2	6.9	(0.0 - 17.0)	2.03	(0.03 - 5.66)	-*	0	-	-	-	-	.
Tongue	2	9.2	(0.0 - 22.0)	3.35	(0.04 - 9.35)	-*	0	-	-	-	-	.
Connective & soft tissues	1	4.7	(0.0 - 14.0)	2.14	(0.00 - 7.89)	-*	1	7.8	(0.0 - 22.9)	4.81	(0.00 - 17.75)	-*
Tonsil & oropharynx	1	2.7	(0.0 - 7.9)	2.19	(0.00 - 8.07)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	1	5.8	(0.0 - 17.1)	7.08	(0.00 - 26.10)	-*
Eye & lacrimal gland	0	-	-	-	-	.	1	7.9	(0.0 - 23.3)	9.53	(0.00 - 35.14)	-*
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	4.5	(0.0 - 13.3)	3.59	(0.00 - 13.23)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	2	8.1	(0.0 - 19.4)	7.37	(0.09 - 20.53)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	2	9.3	(0.0 - 22.2)	11.20	(0.14 - 31.21)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	3.7	(0.0 - 11.0)	8.42	(0.00 - 31.07)	-*	0	-	-	-	-	.
Penis & other male genital	1	3.7	(0.0 - 11.0)	6.86	(0.00 - 25.32)	-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	110	399.8	(323.4 - 476.1)	1.17	(0.97 - 1.42)	-	39	193.2	(126.7 - 259.7)	0.72	(0.50 - 0.96)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Pingelly (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	51.4	(0.0 - 123.1)	0.51	(0.01 - 1.43)	-*
Colorectal cancer	3	47.5	(0.0 - 103.1)	1.18	(0.09 - 2.75)	-*	0	-	-	0	n/a	-
Prostate gland	6	106.3	(19.9 - 192.6)	1.41	(0.38 - 2.74)	-*	0	-	-	-	-	.
Melanoma (skin)	1	19.6	(0.0 - 57.9)	0.49	(0.00 - 1.82)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	4	66.7	(3.6 - 129.9)	1.75	(0.27 - 3.84)	-*	1	22.7	(0.0 - 67.0)	0.93	(0.00 - 3.44)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	3	45.0	(0.0 - 106.3)	6.24	(0.50 - 14.56)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	0	n/a	-	1	24.9	(0.0 - 73.5)	5.44	(0.00 - 20.09)	-*
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	2	21.3	(0.0 - 50.6)	7.46	(0.09 - 20.77)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	1	9.9	(0.0 - 29.2)	3.90	(0.00 - 14.38)	-*	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	n/a	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	21.4	(0.0 - 63.3)	4.94	(0.00 - 18.24)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	1	29.4	(0.0 - 86.9)	20.80	(0.00 - 76.73)	-*	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	1	47.2	(0.0 - 139.4)	59.69	(0.00 - 220.19)	-*	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	20	369.3	(195.5 - 543.0)	1.09	(0.63 - 1.62)	-	7	144.0	(29.1 - 258.9)	0.52	(0.16 - 0.97)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Plantagenet (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	17	107.3	(53.1 - 161.5)	1.26	(0.68 - 1.93)	-
Colorectal cancer	11	61.8	(25.0 - 98.5)	1.32	(0.57 - 2.20)	-	6	32.6	(5.7 - 59.5)	1.07	(0.29 - 2.08)	-
Prostate gland	16	83.9	(42.5 - 125.3)	1.15	(0.60 - 1.78)	-	0	-	-	-	-	.
Melanoma (skin)	10	55.0	(20.5 - 89.5)	1.39	(0.57 - 2.38)	-	13	75.8	(33.1 - 118.6)	2.81	(1.34 - 4.52)	^
Lung, bronchus & trachea	7	35.4	(9.0 - 61.8)	0.95	(0.30 - 1.76)	-	1	2.6	(0.0 - 7.7)	0.29	(0.00 - 1.09)	-*
Lymphoma	2	10.8	(0.0 - 26.1)	0.78	(0.01 - 2.18)	-*	2	14.6	(0.0 - 34.9)	1.15	(0.01 - 3.19)	-*
Unknown primary site	3	24.8	(0.0 - 56.4)	1.45	(0.12 - 3.39)	-*	1	7.0	(0.0 - 20.7)	0.74	(0.00 - 2.72)	-*
Kidney & other renal tract	2	11.2	(0.0 - 26.9)	1.17	(0.01 - 3.25)	-*	0	-	-	0	n/a	-
Leukaemia	2	9.7	(0.0 - 23.3)	1.27	(0.02 - 3.54)	-*	1	6.0	(0.0 - 17.8)	1.10	(0.00 - 4.06)	-*
Pancreas	4	24.5	(0.5 - 48.6)	3.45	(0.53 - 7.56)	-*	1	5.5	(0.0 - 16.3)	0.98	(0.00 - 3.60)	-*
Urinary bladder	1	4.0	(0.0 - 11.7)	0.59	(0.00 - 2.19)	-*	0	-	-	0	n/a	-
Stomach	1	4.0	(0.0 - 11.7)	0.67	(0.00 - 2.47)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	3	12.6	(0.0 - 27.2)	1.97	(0.16 - 4.60)	-*
Brain	2	11.7	(0.0 - 27.8)	2.07	(0.03 - 5.77)	-*	0	-	-	0	n/a	-
Lip	2	10.7	(0.0 - 25.6)	2.06	(0.03 - 5.73)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	1	5.9	(0.0 - 17.4)	1.27	(0.00 - 4.70)	-*	0	-	-	0	n/a	-
Oesophagus	2	11.1	(0.0 - 26.7)	2.10	(0.03 - 5.86)	-*	0	-	-	-	-	.
Thyroid gland	1	5.5	(0.0 - 16.2)	2.96	(0.00 - 10.92)	-*	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	1	5.0	(0.0 - 14.6)	1.42	(0.00 - 5.25)	-*	3	12.0	(0.0 - 26.7)	6.46	(0.52 - 15.07)	-*
Cervix uteri	0	-	-	-	-	.	1	7.7	(0.0 - 22.6)	1.02	(0.00 - 3.74)	-*
Non-mel. skin (exc BCC/SCC)	1	7.7	(0.0 - 22.7)	1.43	(0.00 - 5.27)	-*	0	-	-	-	-	.
Mesothelioma	1	6.2	(0.0 - 18.3)	1.13	(0.00 - 4.18)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	3	18.9	(0.0 - 40.3)	4.64	(0.37 - 10.83)	-*	0	-	-	-	-	.
Testis	1	6.6	(0.0 - 19.4)	1.49	(0.00 - 5.51)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	5.0	(0.0 - 14.6)	1.45	(0.00 - 5.35)	-*	0	-	-	-	-	.
Tongue	1	5.9	(0.0 - 17.4)	2.52	(0.00 - 9.31)	-*	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	76	425.1	(327.9 - 522.2)	1.25	(0.99 - 1.57)	-	49	283.8	(200.3 - 367.3)	1.11	(0.80 - 1.45)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Port Hedland (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	18	109.4	(52.4 - 166.3)	0.96	(0.53 - 1.45)	-
Colorectal cancer	4	17.7	(0.0 - 37.2)	0.41	(0.06 - 0.91)	V	2	5.0	(0.0 - 12.2)	0.39	(0.00 - 1.10)	-
Prostate gland	7	40.6	(7.4 - 73.8)	0.49	(0.15 - 0.91)	V	0	-	-	-	-	.
Melanoma (skin)	6	15.4	(2.8 - 27.9)	0.46	(0.12 - 0.89)	V	2	6.3	(0.0 - 15.2)	0.24	(0.00 - 0.68)	V
Lung, bronchus & trachea	8	38.1	(7.7 - 68.4)	1.09	(0.38 - 1.97)	-	6	37.1	(3.0 - 71.2)	2.12	(0.57 - 4.12)	-*
Lymphoma	2	4.7	(0.0 - 11.3)	0.46	(0.01 - 1.30)	-*	3	24.7	(0.0 - 54.5)	1.43	(0.12 - 3.33)	-*
Unknown primary site	5	21.1	(1.6 - 40.5)	2.16	(0.47 - 4.42)	-*	1	8.2	(0.0 - 24.1)	0.83	(0.00 - 3.06)	-*
Kidney & other renal tract	2	4.3	(0.0 - 10.3)	0.85	(0.01 - 2.36)	-*	0	-	-	0	n/a	-
Leukaemia	2	3.7	(0.0 - 8.9)	0.83	(0.01 - 2.31)	-*	0	-	-	0	n/a	-
Pancreas	0	-	-	0	n/a	-	3	12.1	(0.0 - 25.9)	3.70	(0.30 - 8.63)	-*
Urinary bladder	3	18.7	(0.0 - 41.5)	1.93	(0.16 - 4.51)	-*	2	16.6	(0.0 - 41.7)	5.60	(0.07 - 15.60)	-*
Stomach	5	18.4	(1.0 - 35.8)	3.01	(0.66 - 6.16)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	2	5.7	(0.0 - 14.0)	1.21	(0.02 - 3.37)	-*
Brain	1	2.0	(0.0 - 5.8)	0.55	(0.00 - 2.02)	-*	1	3.5	(0.0 - 10.3)	1.17	(0.00 - 4.32)	-*
Lip	0	-	-	0	n/a	-	1	3.7	(0.0 - 11.1)	2.21	(0.00 - 8.15)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	2	11.8	(0.0 - 28.1)	1.37	(0.02 - 3.81)	-*
Other lymphohaematopoietic	1	6.0	(0.0 - 17.8)	1.40	(0.00 - 5.15)	-*	0	-	-	-	-	.
Oesophagus	2	4.7	(0.0 - 11.2)	1.92	(0.02 - 5.35)	-*	1	8.2	(0.0 - 24.1)	3.19	(0.00 - 11.76)	-*
Thyroid gland	1	1.7	(0.0 - 5.0)	1.21	(0.00 - 4.46)	-*	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	5	11.5	(1.4 - 21.6)	2.48	(0.54 - 5.07)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	4	16.2	(0.0 - 35.4)	4.37	(0.68 - 9.57)	-*	1	4.5	(0.0 - 13.3)	9.67	(0.00 - 35.67)	-*
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	1	3.1	(0.0 - 9.1)	4.52	(0.00 - 16.67)	-*
Testis	4	9.8	(0.0 - 20.0)	1.63	(0.25 - 3.57)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	8.0	(0.0 - 23.6)	1.10	(0.00 - 4.04)	-*	0	-	-	-	-	.
Tongue	0	-	-	0	n/a	-	0	-	-	-	-	.
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-	.
Tonsil & oropharynx	1	2.3	(0.0 - 6.9)	1.72	(0.00 - 6.36)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	1	1.7	(0.0 - 5.0)	2.93	(0.00 - 10.80)	-*	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	1	6.0	(0.0 - 17.5)	6.45	(0.00 - 23.80)	-*
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	1	2.6	(0.0 - 7.6)	5.04	(0.00 - 18.59)	-*
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	2	11.5	(0.0 - 29.6)	19.21	(0.24 - 53.52)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	1	2.0	(0.0 - 5.8)	27.09	(0.00 - 99.93)	-*	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	63	248.6	(177.3 - 319.9)	0.80	(0.62 - 1.03)	-	53	279.9	(193.3 - 366.6)	0.96	(0.73 - 1.27)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Quairading (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	32.3	(0.0 - 85.5)	0.57	(0.01 - 1.60)	-*
Colorectal cancer	3	69.2	(0.0 - 147.4)	1.49	(0.12 - 3.48)	-*	1	34.2	(0.0 - 101.1)	0.61	(0.00 - 2.27)	-*
Prostate gland	7	140.8	(37.8 - 243.9)	2.09	(0.66 - 3.90)	-*	0	-	-	-	-	.
Melanoma (skin)	1	20.8	(0.0 - 61.4)	0.57	(0.00 - 2.09)	-*	1	18.7	(0.0 - 55.2)	0.81	(0.00 - 3.00)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	2	43.2	(0.0 - 103.5)	4.01	(0.05 - 11.16)	-*	2	20.3	(0.0 - 51.0)	4.53	(0.06 - 12.62)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	1	32.0	(0.0 - 94.5)	3.28	(0.00 - 12.10)	-*
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	1	24.0	(0.0 - 70.9)	4.15	(0.00 - 15.33)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	10.2	(0.0 - 30.0)	2.79	(0.00 - 10.30)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	5.6	(0.0 - 16.6)	7.31	(0.00 - 26.98)	-*
Cervix uteri	0	-	-	-	-	.	1	32.0	(0.0 - 94.5)	3.75	(0.00 - 13.82)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	32.0	(0.0 - 94.5)	11.31	(0.00 - 41.73)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	14	298.0	(142.7 - 453.2)	0.95	(0.47 - 1.51)	-	11	217.4	(70.4 - 364.3)	0.91	(0.40 - 1.52)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Ravensthorpe (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	67.2	(0.0 - 143.6)	0.76	(0.06 - 1.78)	-*
Colorectal cancer	1	16.6	(0.0 - 49.1)	0.38	(0.00 - 1.40)	-*	1	25.3	(0.0 - 74.6)	0.68	(0.00 - 2.51)	-*
Prostate gland	10	157.9	(60.0 - 255.8)	2.26	(0.93 - 3.86)	-*	0	-	-	-	-	.
Melanoma (skin)	1	15.6	(0.0 - 46.2)	0.43	(0.00 - 1.58)	-*	1	20.4	(0.0 - 60.3)	0.73	(0.00 - 2.70)	-*
Lung, bronchus & trachea	3	46.8	(0.0 - 99.8)	1.33	(0.11 - 3.11)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	0	-	-	0	n/a	-	1	24.1	(0.0 - 71.2)	2.90	(0.00 - 10.70)	-*
Kidney & other renal tract	1	13.5	(0.0 - 39.6)	1.84	(0.00 - 6.80)	-*	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	1	24.1	(0.0 - 71.2)	5.70	(0.00 - 21.01)	-*
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	50.3	(0.0 - 119.9)	5.54	(0.07 - 15.44)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	13.6	(0.0 - 40.1)	3.48	(0.00 - 12.85)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	17	264.0	(138.9 - 389.0)	0.88	(0.47 - 1.35)	-	9	211.4	(73.5 - 349.3)	0.73	(0.28 - 1.29)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Rockingham (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	2	0.9	(0.0 - 2.2)	1.51	(0.02 - 4.19)	-*	200	83.8	(71.9 - 95.8)	1.02	(0.88 - 1.17)	-
Colorectal cancer	117	46.7	(38.0 - 55.4)	1.04	(0.87 - 1.25)	-	92	31.5	(24.7 - 38.3)	1.10	(0.89 - 1.36)	-
Prostate gland	192	73.8	(63.0 - 84.5)	1.04	(0.90 - 1.20)	-	0	-	-	-	-	.
Melanoma (skin)	90	39.1	(30.7 - 47.5)	0.92	(0.74 - 1.13)	-	67	30.4	(22.8 - 38.0)	0.94	(0.74 - 1.21)	-
Lung, bronchus & trachea	96	36.6	(29.1 - 44.2)	0.95	(0.78 - 1.17)	-	59	21.1	(15.5 - 26.7)	1.15	(0.89 - 1.50)	-
Lymphoma	30	14.5	(9.1 - 19.9)	0.85	(0.55 - 1.18)	-	16	6.6	(3.2 - 9.9)	0.60	(0.32 - 0.93)	V
Unknown primary site	35	13.0	(8.5 - 17.4)	1.23	(0.83 - 1.67)	-	17	5.8	(2.9 - 8.7)	0.85	(0.46 - 1.30)	-
Kidney & other renal tract	25	10.2	(6.1 - 14.3)	1.08	(0.66 - 1.54)	-	20	7.9	(4.2 - 11.6)	1.52	(0.87 - 2.25)	-
Leukaemia	17	8.7	(4.2 - 13.2)	0.77	(0.41 - 1.17)	-	20	9.8	(5.0 - 14.6)	1.44	(0.82 - 2.13)	-
Pancreas	23	9.4	(5.5 - 13.4)	1.47	(0.88 - 2.13)	-	17	5.9	(2.9 - 8.8)	1.11	(0.60 - 1.70)	-
Urinary bladder	23	8.2	(4.7 - 11.7)	0.98	(0.59 - 1.42)	-	8	2.6	(0.7 - 4.5)	1.02	(0.36 - 1.84)	-
Stomach	16	6.6	(3.3 - 9.9)	0.78	(0.41 - 1.21)	-	14	4.3	(1.9 - 6.7)	1.35	(0.67 - 2.15)	-
Corpus uteri	0	-	-	-	-	.	21	8.2	(4.5 - 11.9)	0.94	(0.55 - 1.39)	-
Brain	18	8.0	(4.1 - 11.9)	1.37	(0.76 - 2.08)	-	14	5.5	(2.4 - 8.6)	1.55	(0.77 - 2.46)	-
Lip	11	4.5	(1.7 - 7.2)	0.83	(0.36 - 1.39)	-	11	3.5	(1.3 - 5.7)	1.83	(0.80 - 3.06)	-
Ovary & uterine adnexa	0	-	-	-	-	.	25	10.4	(6.0 - 14.7)	1.29	(0.80 - 1.85)	-
Other lymphohaematopoietic	9	3.2	(1.1 - 5.3)	0.81	(0.31 - 1.42)	-	9	2.9	(0.9 - 4.9)	1.19	(0.46 - 2.08)	-
Oesophagus	16	5.9	(2.9 - 8.9)	1.23	(0.65 - 1.91)	-	11	3.8	(1.4 - 6.2)	1.86	(0.81 - 3.11)	-
Thyroid gland	2	0.7	(0.0 - 1.7)	0.42	(0.01 - 1.17)	-	12	5.2	(2.1 - 8.2)	0.99	(0.45 - 1.62)	-
Myeloma/plasma cell tumours	7	2.5	(0.6 - 4.4)	0.73	(0.23 - 1.37)	-	8	2.5	(0.7 - 4.3)	1.16	(0.41 - 2.10)	-
Cervix uteri	0	-	-	-	-	.	20	8.8	(4.7 - 12.9)	1.30	(0.75 - 1.93)	-
Non-mel. skin (exc BCC/SCC)	11	4.2	(1.6 - 6.7)	1.13	(0.49 - 1.88)	-	3	0.9	(0.0 - 2.1)	0.55	(0.04 - 1.29)	-
Mesothelioma	12	5.3	(2.2 - 8.3)	1.01	(0.46 - 1.66)	-	2	1.0	(0.0 - 2.3)	1.17	(0.01 - 3.25)	-*
Liver & intrahepatic bile duct	12	4.6	(1.9 - 7.3)	1.38	(0.63 - 2.27)	-	3	1.4	(0.0 - 3.0)	0.99	(0.08 - 2.30)	-*
Testis	9	4.8	(1.6 - 8.0)	0.87	(0.33 - 1.52)	-	0	-	-	-	-	.
Gallbladder & bile ducts	3	1.2	(0.0 - 2.6)	0.59	(0.05 - 1.37)	-	4	1.2	(0.0 - 2.4)	0.78	(0.12 - 1.70)	-
Larynx	7	2.8	(0.7 - 5.0)	0.79	(0.25 - 1.47)	-	3	1.0	(0.0 - 2.2)	2.26	(0.18 - 5.27)	-*
Tongue	2	0.9	(0.0 - 2.1)	0.39	(0.00 - 1.09)	-	2	0.7	(0.0 - 1.6)	0.99	(0.01 - 2.75)	-*
Connective & soft tissues	3	1.6	(0.0 - 3.5)	0.74	(0.06 - 1.74)	-*	2	0.7	(0.0 - 1.8)	0.79	(0.01 - 2.19)	-*
Tonsil & oropharynx	3	1.2	(0.0 - 2.6)	0.73	(0.06 - 1.70)	-*	2	1.0	(0.0 - 2.3)	2.15	(0.03 - 5.98)	-*
Vulva/vagina	0	-	-	-	-	.	5	1.5	(0.1 - 2.9)	1.09	(0.24 - 2.22)	-
Small intestine	2	1.0	(0.0 - 2.4)	0.81	(0.01 - 2.25)	-*	4	1.0	(0.0 - 2.0)	2.39	(0.37 - 5.23)	-*
Eye & lacrimal gland	5	2.0	(0.2 - 3.8)	1.96	(0.43 - 4.01)	-*	1	0.2	(0.0 - 0.7)	0.83	(0.00 - 3.05)	-*
Major Salivary Gland	3	1.2	(0.0 - 2.7)	1.40	(0.11 - 3.26)	-*	1	0.4	(0.0 - 1.3)	0.67	(0.00 - 2.47)	-*
Anus	0	-	-	0	n/a	-	2	0.9	(0.0 - 2.1)	0.99	(0.01 - 2.77)	-*
Mouth, other & unspecified	4	1.8	(0.0 - 3.5)	1.82	(0.28 - 3.99)	-*	1	0.3	(0.0 - 1.0)	0.76	(0.00 - 2.79)	-*
Floor of mouth	3	1.2	(0.0 - 2.6)	1.20	(0.10 - 2.81)	-*	1	0.6	(0.0 - 1.9)	1.23	(0.00 - 4.53)	-*
Bones, joints & articular cart.	2	1.4	(0.0 - 3.3)	1.53	(0.02 - 4.27)	-*	1	0.3	(0.0 - 1.0)	0.67	(0.00 - 2.47)	-*
Pyriform sinus & hypopharynx	2	0.8	(0.0 - 2.0)	0.82	(0.01 - 2.28)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	3	1.2	(0.0 - 2.6)	1.91	(0.15 - 4.45)	-*	1	0.5	(0.0 - 1.6)	1.69	(0.00 - 6.24)	-*
Peritoneum & retroperitoneum	2	0.6	(0.0 - 1.4)	3.12	(0.04 - 8.68)	-*	1	0.4	(0.0 - 1.2)	0.73	(0.00 - 2.70)	-*
Adrenal & other endocrine	1	0.9	(0.0 - 2.6)	1.05	(0.00 - 3.86)	-*	2	1.5	(0.0 - 3.7)	3.36	(0.04 - 9.35)	-*
Nasopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	-	.
Penis & other male genital	0	-	-	0	n/a	-	0	-	-	-	-	.
Gum	0	-	-	0	n/a	-	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	818	331.0	(307.6 - 354.4)	0.99	(0.93 - 1.06)	-	702	276.1	(254.6 - 297.6)	1.07	(0.99 - 1.15)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Roebourne (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	23	84.3	(37.5 - 131.0)	1.10	(0.66 - 1.59)	-
Colorectal cancer	7	51.7	(8.3 - 95.1)	0.77	(0.24 - 1.44)	-	4	12.0	(0.0 - 24.5)	0.81	(0.12 - 1.77)	-
Prostate gland	10	59.1	(12.1 - 106.0)	0.78	(0.32 - 1.33)	-	0	-	-	-	-	.
Melanoma (skin)	12	23.0	(9.8 - 36.2)	0.86	(0.39 - 1.41)	-	9	42.9	(5.4 - 80.5)	0.96	(0.37 - 1.67)	-
Lung, bronchus & trachea	13	90.4	(30.9 - 149.8)	1.97	(0.94 - 3.18)	-	3	18.0	(0.0 - 40.9)	1.09	(0.09 - 2.56)	-*
Lymphoma	7	37.8	(5.2 - 70.5)	1.56	(0.49 - 2.91)	-*	3	15.1	(0.0 - 36.4)	1.35	(0.11 - 3.15)	-*
Unknown primary site	1	10.5	(0.0 - 31.1)	0.47	(0.00 - 1.74)	-*	0	-	-	0	n/a	-
Kidney & other renal tract	1	2.0	(0.0 - 5.9)	0.42	(0.00 - 1.56)	-*	1	2.6	(0.0 - 7.6)	0.92	(0.00 - 3.39)	-*
Leukaemia	3	6.8	(0.0 - 14.9)	1.21	(0.10 - 2.82)	-*	0	-	-	0	n/a	-
Pancreas	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Urinary bladder	1	2.8	(0.0 - 8.2)	0.77	(0.00 - 2.86)	-*	0	-	-	-	-	.
Stomach	2	4.7	(0.0 - 11.4)	1.29	(0.02 - 3.59)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	2	13.0	(0.0 - 33.4)	1.16	(0.01 - 3.23)	-*
Brain	1	3.4	(0.0 - 9.9)	0.51	(0.00 - 1.89)	-*	1	2.6	(0.0 - 7.6)	1.05	(0.00 - 3.88)	-*
Lip	0	-	-	0	n/a	-	1	3.0	(0.0 - 8.9)	2.10	(0.00 - 7.74)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	1	8.6	(0.0 - 25.4)	1.71	(0.00 - 6.31)	-*	0	-	-	-	-	.
Oesophagus	1	2.0	(0.0 - 5.9)	1.02	(0.00 - 3.76)	-*	0	-	-	-	-	.
Thyroid gland	2	3.0	(0.0 - 7.3)	2.15	(0.03 - 5.98)	-*	1	4.8	(0.0 - 14.1)	0.48	(0.00 - 1.78)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	4	8.3	(0.0 - 16.6)	1.67	(0.26 - 3.67)	-*
Non-mel. skin (exc BCC/SCC)	1	2.1	(0.0 - 6.1)	1.12	(0.00 - 4.11)	-*	1	10.3	(0.0 - 30.3)	2.04	(0.00 - 7.54)	-*
Mesothelioma	3	8.3	(0.0 - 17.6)	3.65	(0.29 - 8.51)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	2	3.0	(0.0 - 7.3)	0.70	(0.01 - 1.95)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	2	4.8	(0.0 - 11.6)	4.65	(0.06 - 12.96)	-*	0	-	-	-	-	.
Larynx	2	4.8	(0.0 - 11.6)	2.22	(0.03 - 6.19)	-*	0	-	-	-	-	.
Tongue	1	10.5	(0.0 - 31.1)	1.34	(0.00 - 4.95)	-*	1	14.4	(0.0 - 42.5)	7.01	(0.00 - 25.87)	-*
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-	.
Tonsil & oropharynx	1	2.8	(0.0 - 8.2)	1.60	(0.00 - 5.89)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	1	2.0	(0.0 - 5.9)	2.73	(0.00 - 10.07)	-*	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	1	14.4	(0.0 - 42.5)	6.15	(0.00 - 22.68)	-*
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	1.6	(0.0 - 4.7)	2.82	(0.00 - 10.41)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	1	2.0	(0.0 - 5.9)	3.89	(0.00 - 14.36)	-*	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	1.6	(0.0 - 4.7)	5.12	(0.00 - 18.90)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	78	349.3	(247.8 - 450.7)	1.01	(0.80 - 1.27)	-	55	245.6	(160.0 - 331.1)	0.93	(0.71 - 1.22)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Sandstone (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	1	100.0	(0.0 - 294.0)	117.87	(0.00 - 434.81)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	100.0	(0.0 - 294.0)	0.45	(0.00 - 1.67)	-*	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Serpentine-Jarrahdale (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	24	69.4	(41.2 - 97.5)	0.85	(0.52 - 1.23)	-
Colorectal cancer	14	40.4	(18.6 - 62.1)	0.93	(0.46 - 1.48)	-	10	31.1	(11.4 - 50.7)	1.05	(0.43 - 1.80)	-
Prostate gland	37	110.0	(74.2 - 145.8)	1.51	(1.03 - 2.03)	^	0	-	-	-	-	.
Melanoma (skin)	12	33.4	(13.9 - 52.8)	0.81	(0.37 - 1.32)	-	14	40.1	(18.6 - 61.6)	1.39	(0.69 - 2.21)	-
Lung, bronchus & trachea	12	35.4	(15.2 - 55.6)	0.94	(0.43 - 1.54)	-	4	14.0	(0.2 - 27.8)	0.70	(0.11 - 1.53)	-
Lymphoma	4	12.1	(0.1 - 24.0)	0.78	(0.12 - 1.72)	-	5	14.3	(1.7 - 26.8)	1.55	(0.34 - 3.17)	-*
Unknown primary site	4	11.0	(0.0 - 22.0)	1.11	(0.17 - 2.43)	-*	1	3.6	(0.0 - 10.5)	0.46	(0.00 - 1.69)	-*
Kidney & other renal tract	3	8.1	(0.0 - 17.3)	0.92	(0.07 - 2.14)	-*	0	-	-	0	n/a	-
Leukaemia	5	14.0	(1.6 - 26.3)	1.66	(0.36 - 3.39)	-*	2	6.9	(0.0 - 16.5)	1.17	(0.01 - 3.26)	-*
Pancreas	2	6.3	(0.0 - 15.0)	0.95	(0.01 - 2.65)	-*	0	-	-	0	n/a	-
Urinary bladder	4	10.5	(0.2 - 20.9)	1.45	(0.22 - 3.18)	-*	2	5.9	(0.0 - 14.0)	2.61	(0.03 - 7.28)	-*
Stomach	6	17.1	(3.3 - 31.0)	2.26	(0.61 - 4.40)	-*	2	7.7	(0.0 - 18.3)	1.78	(0.02 - 4.97)	-*
Corpus uteri	0	-	-	-	-	.	4	13.2	(0.1 - 26.3)	1.39	(0.21 - 3.05)	-*
Brain	3	8.3	(0.0 - 17.8)	1.48	(0.12 - 3.45)	-*	1	2.5	(0.0 - 7.3)	0.85	(0.00 - 3.12)	-*
Lip	1	2.4	(0.0 - 7.1)	0.48	(0.00 - 1.76)	-*	2	4.8	(0.0 - 11.6)	2.68	(0.03 - 7.47)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	2	5.4	(0.0 - 13.1)	0.82	(0.01 - 2.30)	-*
Other lymphohaematopoietic	1	3.0	(0.0 - 9.0)	0.79	(0.00 - 2.92)	-*	0	-	-	0	n/a	-
Oesophagus	4	12.0	(0.2 - 23.7)	2.37	(0.37 - 5.19)	-*	0	-	-	0	n/a	-
Thyroid gland	0	-	-	0	n/a	-	1	2.7	(0.0 - 8.1)	0.53	(0.00 - 1.97)	-*
Myeloma/plasma cell tumours	1	3.0	(0.0 - 9.0)	0.80	(0.00 - 2.95)	-*	2	7.1	(0.0 - 16.9)	2.54	(0.03 - 7.07)	-*
Cervix uteri	0	-	-	-	-	.	3	7.3	(0.0 - 15.5)	1.33	(0.11 - 3.10)	-*
Non-mel. skin (exc BCC/SCC)	1	3.0	(0.0 - 8.8)	0.78	(0.00 - 2.88)	-*	0	-	-	0	n/a	-
Mesothelioma	2	4.8	(0.0 - 11.5)	1.30	(0.02 - 3.62)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	1	2.3	(0.0 - 6.8)	0.57	(0.00 - 2.11)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Larynx	1	2.2	(0.0 - 6.4)	0.75	(0.00 - 2.76)	-*	0	-	-	-	-	.
Tongue	1	2.3	(0.0 - 6.8)	1.20	(0.00 - 4.41)	-*	0	-	-	-	-	.
Connective & soft tissues	1	2.4	(0.0 - 7.1)	1.62	(0.00 - 5.98)	-*	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	2.7	(0.0 - 8.1)	1.79	(0.00 - 6.62)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	1	2.5	(0.0 - 7.3)	2.62	(0.00 - 9.66)	-*	1	2.7	(0.0 - 8.1)	6.79	(0.00 - 25.05)	-*
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	2	4.9	(0.0 - 11.6)	8.51	(0.11 - 23.71)	-*	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	4.9	(0.0 - 14.5)	4.22	(0.00 - 15.57)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	3.6	(0.0 - 10.5)	6.06	(0.00 - 22.34)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	124	356.2	(293.0 - 419.3)	1.10	(0.92 - 1.31)	-	82	244.8	(191.0 - 298.5)	0.97	(0.78 - 1.21)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Shark Bay (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	20.8	(0.0 - 60.8)	0.40	(0.00 - 1.47)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	1	24.8	(0.0 - 73.4)	0.30	(0.00 - 1.09)	-*	0	-	-	-	-	-
Melanoma (skin)	0	-	-	0	n/a	-	1	38.0	(0.0 - 111.9)	1.10	(0.00 - 4.07)	-*
Lung, bronchus & trachea	2	50.9	(0.0 - 121.3)	1.10	(0.01 - 3.06)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	-
Unknown primary site	0	-	-	0	n/a	-	0	-	-	-	-	-
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	-
Leukaemia	2	72.3	(0.0 - 190.3)	5.36	(0.07 - 14.94)	-*	2	97.6	(0.0 - 231.1)	12.04	(0.15 - 33.54)	-*
Pancreas	0	-	-	-	-	.	0	-	-	-	-	-
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	-
Stomach	0	-	-	-	-	.	0	-	-	-	-	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	-
Brain	0	-	-	-	-	.	0	-	-	-	-	-
Lip	0	-	-	-	-	.	0	-	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	-
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	-
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	-
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	-
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	-
Testis	1	29.6	(0.0 - 87.3)	6.98	(0.00 - 25.75)	-*	0	-	-	-	-	-
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	-
Larynx	0	-	-	-	-	.	0	-	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	1	73.2	(0.0 - 216.1)	18.06	(0.00 - 66.61)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	-
Eye & lacrimal gland	1	18.3	(0.0 - 54.1)	22.92	(0.00 - 84.57)	-*	0	-	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	-
All cancers	7	196.0	(35.4 - 356.7)	0.48	(0.15 - 0.89)	V	5	229.5	(16.6 - 442.5)	0.62	(0.13 - 1.26)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: South Perth (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	0	n/a	-	132	95.9	(78.0 - 113.8)	1.10	(0.93 - 1.31)	-
Colorectal cancer	60	45.9	(33.3 - 58.5)	0.97	(0.75 - 1.26)	-	64	30.5	(21.5 - 39.5)	1.02	(0.79 - 1.30)	-
Prostate gland	116	86.1	(68.8 - 103.4)	1.17	(0.97 - 1.41)	-	0	-	-	-	-	.
Melanoma (skin)	72	58.7	(44.4 - 73.0)	1.37	(1.08 - 1.73)	^	45	33.4	(22.8 - 43.9)	1.02	(0.72 - 1.33)	-
Lung, bronchus & trachea	42	27.5	(18.1 - 36.9)	0.77	(0.54 - 1.03)	-	25	14.4	(7.5 - 21.2)	0.69	(0.42 - 0.98)	V
Lymphoma	16	11.9	(5.4 - 18.3)	0.81	(0.43 - 1.25)	-	21	14.5	(6.6 - 22.3)	1.16	(0.67 - 1.71)	-
Unknown primary site	23	15.0	(8.2 - 21.9)	1.38	(0.83 - 2.00)	-	12	3.7	(0.9 - 6.6)	0.67	(0.31 - 1.10)	-
Kidney & other renal tract	21	17.1	(9.2 - 25.0)	1.67	(0.97 - 2.45)	-	6	6.8	(0.0 - 13.7)	0.69	(0.19 - 1.34)	-
Leukaemia	8	5.5	(1.3 - 9.6)	0.67	(0.23 - 1.20)	-	10	5.5	(0.0 - 11.2)	1.03	(0.42 - 1.75)	-
Pancreas	8	4.3	(1.0 - 7.5)	0.94	(0.33 - 1.69)	-	12	5.4	(1.6 - 9.2)	0.98	(0.45 - 1.61)	-
Urinary bladder	8	4.9	(1.1 - 8.7)	0.57	(0.20 - 1.02)	-	4	1.7	(0.0 - 4.2)	0.58	(0.09 - 1.28)	-
Stomach	8	4.8	(1.1 - 8.5)	0.70	(0.25 - 1.26)	-	6	1.8	(0.0 - 3.7)	0.72	(0.19 - 1.40)	-
Corpus uteri	0	-	-	-	-	.	17	13.0	(6.1 - 19.9)	1.17	(0.63 - 1.78)	-
Brain	7	6.1	(1.4 - 10.9)	1.02	(0.32 - 1.91)	-	6	3.6	(0.4 - 6.8)	1.01	(0.27 - 1.97)	-
Lip	4	3.5	(0.0 - 7.2)	0.57	(0.09 - 1.26)	-	1	0.1	(0.0 - 0.4)	0.22	(0.00 - 0.82)	V*
Ovary & uterine adnexa	0	-	-	-	-	.	16	9.0	(3.7 - 14.4)	1.22	(0.64 - 1.88)	-
Other lymphohaematopoietic	8	6.1	(1.3 - 10.9)	1.15	(0.41 - 2.08)	-	5	2.1	(0.0 - 4.3)	0.75	(0.16 - 1.54)	-
Oesophagus	7	5.4	(1.0 - 9.8)	0.98	(0.31 - 1.83)	-	2	0.4	(0.0 - 1.0)	0.43	(0.01 - 1.20)	-
Thyroid gland	3	3.3	(0.0 - 7.1)	1.21	(0.10 - 2.83)	-*	5	3.5	(0.3 - 6.8)	0.70	(0.15 - 1.43)	-
Myeloma/plasma cell tumours	7	6.3	(1.4 - 11.1)	1.27	(0.40 - 2.37)	-	5	2.4	(0.0 - 4.8)	0.94	(0.21 - 1.94)	-
Cervix uteri	0	-	-	-	-	.	7	4.3	(0.6 - 7.9)	0.76	(0.24 - 1.41)	-
Non-mel. skin (exc BCC/SCC)	12	8.6	(3.3 - 14.0)	2.04	(0.93 - 3.34)	-	3	1.2	(0.0 - 3.1)	0.69	(0.06 - 1.62)	-*
Mesothelioma	3	1.1	(0.0 - 2.5)	0.47	(0.04 - 1.09)	-	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	5	3.0	(0.2 - 5.8)	1.09	(0.24 - 2.23)	-	3	0.7	(0.0 - 1.5)	1.37	(0.11 - 3.19)	-*
Testis	8	7.4	(2.2 - 12.6)	1.37	(0.48 - 2.47)	-	0	-	-	-	-	.
Gallbladder & bile ducts	3	1.7	(0.0 - 3.8)	1.06	(0.09 - 2.46)	-*	3	1.6	(0.0 - 3.7)	0.71	(0.06 - 1.66)	-*
Larynx	4	4.7	(0.1 - 9.4)	0.89	(0.14 - 1.95)	-*	0	-	-	0	n/a	-
Tongue	5	5.2	(0.6 - 9.9)	1.83	(0.40 - 3.75)	-*	2	1.5	(0.0 - 3.6)	1.47	(0.02 - 4.10)	-*
Connective & soft tissues	4	4.4	(0.0 - 9.0)	1.83	(0.28 - 4.00)	-*	3	1.8	(0.0 - 4.2)	2.02	(0.16 - 4.72)	-*
Tonsil & oropharynx	3	1.9	(0.0 - 4.2)	1.38	(0.11 - 3.22)	-*	0	-	-	0	n/a	-
Vulva/vagina	0	-	-	-	-	.	3	0.9	(0.0 - 2.1)	0.87	(0.07 - 2.03)	-*
Small intestine	3	2.0	(0.0 - 4.4)	2.26	(0.18 - 5.28)	-*	2	0.8	(0.0 - 2.1)	1.67	(0.02 - 4.66)	-*
Eye & lacrimal gland	0	-	-	0	n/a	-	1	0.9	(0.0 - 2.8)	1.17	(0.00 - 4.30)	-*
Major Salivary Gland	0	-	-	0	n/a	-	2	2.1	(0.0 - 5.1)	1.94	(0.02 - 5.40)	-*
Anus	1	0.4	(0.0 - 1.2)	1.22	(0.00 - 4.50)	-*	0	-	-	0	n/a	-
Mouth, other & unspecified	1	0.4	(0.0 - 1.2)	0.86	(0.00 - 3.19)	-*	1	0.6	(0.0 - 1.7)	1.16	(0.00 - 4.27)	-*
Floor of mouth	0	-	-	0	n/a	-	1	0.1	(0.0 - 0.4)	1.42	(0.00 - 5.23)	-*
Bones, joints & articular cart.	1	0.9	(0.0 - 2.8)	1.41	(0.00 - 5.19)	-*	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	2	1.2	(0.0 - 3.2)	1.60	(0.02 - 4.46)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.9	(0.0 - 2.8)	1.14	(0.00 - 4.21)	-*	1	0.2	(0.0 - 0.5)	2.17	(0.00 - 8.02)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	2	1.2	(0.0 - 3.1)	2.23	(0.03 - 6.21)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	0	n/a	-	1	0.3	(0.0 - 0.8)	5.38	(0.00 - 19.83)	-*
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	-	.
Penis & other male genital	1	0.4	(0.0 - 1.2)	1.34	(0.00 - 4.93)	-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	1	0.8	(0.0 - 2.4)	7.00	(0.00 - 25.82)	-*	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	1	0.8	(0.0 - 2.4)	32.05	(0.00 - 118.23)	-*	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	477	358.5	(323.6 - 393.4)	1.06	(0.97 - 1.16)	-	429	266.0	(236.2 - 295.9)	0.96	(0.87 - 1.06)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Stirling (C) - Central 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	0.3	(0.0 - 0.7)	0.49	(0.00 - 1.80)	-*	284	75.1	(66.0 - 84.2)	0.91	(0.81 - 1.02)	-
Colorectal cancer	173	44.8	(37.9 - 51.7)	1.00	(0.86 - 1.17)	-	134	26.6	(21.7 - 31.5)	0.94	(0.79 - 1.12)	-
Prostate gland	263	68.9	(60.3 - 77.4)	0.92	(0.81 - 1.04)	-	0	-	-	-	-	.
Melanoma (skin)	122	34.7	(28.4 - 41.0)	0.84	(0.70 - 1.00)	-	87	24.8	(19.4 - 30.3)	0.78	(0.63 - 0.96)	V
Lung, bronchus & trachea	180	45.0	(38.2 - 51.9)	1.16	(1.00 - 1.35)	-	84	18.9	(14.5 - 23.2)	0.97	(0.78 - 1.20)	-
Lymphoma	59	16.0	(11.7 - 20.3)	1.11	(0.86 - 1.45)	-	59	13.8	(10.0 - 17.7)	1.34	(1.03 - 1.74)	^
Unknown primary site	47	12.6	(8.9 - 16.3)	1.07	(0.76 - 1.39)	-	35	6.8	(4.3 - 9.3)	1.01	(0.68 - 1.37)	-
Kidney & other renal tract	29	7.9	(4.7 - 11.1)	0.83	(0.53 - 1.15)	-	20	3.9	(2.0 - 5.8)	0.93	(0.53 - 1.38)	-
Leukaemia	35	10.1	(6.7 - 13.6)	1.07	(0.72 - 1.45)	-	23	6.0	(3.1 - 8.8)	1.04	(0.62 - 1.50)	-
Pancreas	23	6.4	(3.7 - 9.1)	0.96	(0.58 - 1.39)	-	25	4.7	(2.6 - 6.7)	0.94	(0.58 - 1.35)	-
Urinary bladder	36	8.8	(5.9 - 11.8)	0.98	(0.66 - 1.32)	-	16	2.8	(1.3 - 4.2)	1.16	(0.61 - 1.79)	-
Stomach	34	9.3	(6.1 - 12.6)	1.08	(0.72 - 1.48)	-	24	4.1	(2.3 - 5.9)	1.34	(0.82 - 1.93)	-
Corpus uteri	0	-	-	-	-	.	37	9.8	(6.5 - 13.1)	1.00	(0.68 - 1.35)	-
Brain	18	5.2	(2.6 - 7.7)	0.94	(0.52 - 1.42)	-	18	4.9	(2.4 - 7.4)	1.25	(0.69 - 1.88)	-
Lip	16	5.1	(2.6 - 7.6)	0.83	(0.43 - 1.28)	-	10	2.1	(0.7 - 3.5)	0.99	(0.41 - 1.69)	-
Ovary & uterine adnexa	0	-	-	-	-	.	28	6.8	(4.2 - 9.5)	0.87	(0.56 - 1.23)	-
Other lymphohaematopoietic	18	3.8	(1.9 - 5.6)	1.03	(0.57 - 1.56)	-	14	2.9	(1.2 - 4.6)	1.06	(0.52 - 1.68)	-
Oesophagus	17	4.2	(2.1 - 6.3)	0.86	(0.46 - 1.31)	-	12	2.3	(0.9 - 3.7)	1.17	(0.54 - 1.93)	-
Thyroid gland	7	2.1	(0.5 - 3.7)	1.03	(0.33 - 1.93)	-	18	5.4	(2.8 - 8.1)	0.98	(0.54 - 1.48)	-
Myeloma/plasma cell tumours	18	4.8	(2.5 - 7.1)	1.22	(0.67 - 1.85)	-	7	1.5	(0.3 - 2.7)	0.60	(0.19 - 1.11)	-
Cervix uteri	0	-	-	-	-	.	17	5.2	(2.7 - 7.7)	0.73	(0.39 - 1.11)	-
Non-mel. skin (exc BCC/SCC)	15	3.6	(1.7 - 5.5)	1.00	(0.51 - 1.56)	-	8	1.9	(0.5 - 3.2)	0.87	(0.31 - 1.57)	-
Mesothelioma	16	4.0	(2.0 - 6.1)	0.88	(0.46 - 1.35)	-	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	20	5.7	(3.2 - 8.3)	1.52	(0.87 - 2.25)	-	3	0.9	(0.0 - 1.9)	0.60	(0.05 - 1.39)	-
Testis	12	4.2	(1.8 - 6.6)	0.80	(0.37 - 1.31)	-	0	-	-	-	-	.
Gallbladder & bile ducts	11	3.1	(1.2 - 5.0)	1.41	(0.61 - 2.36)	-	12	2.1	(0.8 - 3.4)	1.33	(0.61 - 2.19)	-
Larynx	16	4.8	(2.4 - 7.1)	1.19	(0.62 - 1.84)	-	4	0.9	(0.0 - 1.9)	1.80	(0.28 - 3.93)	-*
Tongue	8	2.6	(0.7 - 4.4)	1.05	(0.37 - 1.90)	-	1	0.3	(0.0 - 0.8)	0.30	(0.00 - 1.10)	-*
Connective & soft tissues	8	3.2	(0.7 - 5.6)	1.35	(0.47 - 2.43)	-	4	1.1	(0.0 - 2.3)	1.01	(0.16 - 2.21)	-*
Tonsil & oropharynx	5	1.3	(0.1 - 2.6)	0.83	(0.18 - 1.71)	-	1	0.1	(0.0 - 0.4)	0.64	(0.00 - 2.37)	-*
Vulva/vagina	0	-	-	-	-	.	13	2.6	(1.0 - 4.1)	1.72	(0.82 - 2.77)	-
Small intestine	5	1.3	(0.1 - 2.5)	1.33	(0.29 - 2.72)	-*	1	0.1	(0.0 - 0.4)	0.35	(0.00 - 1.30)	-*
Eye & lacrimal gland	0	-	-	0	n/a	V	4	0.8	(0.0 - 1.6)	1.99	(0.31 - 4.35)	-*
Major Salivary Gland	2	0.6	(0.0 - 1.4)	0.60	(0.01 - 1.67)	-*	2	0.2	(0.0 - 0.5)	0.83	(0.01 - 2.31)	-*
Anus	2	0.5	(0.0 - 1.1)	0.81	(0.01 - 2.27)	-*	6	1.2	(0.1 - 2.2)	1.80	(0.49 - 3.50)	-*
Mouth, other & unspecified	5	1.5	(0.1 - 2.9)	1.53	(0.33 - 3.13)	-*	3	0.8	(0.0 - 1.8)	1.36	(0.11 - 3.16)	-*
Floor of mouth	4	1.2	(0.0 - 2.4)	1.09	(0.17 - 2.38)	-*	3	0.4	(0.0 - 0.8)	2.11	(0.17 - 4.92)	-*
Bones, joints & articular cart.	2	0.7	(0.0 - 1.6)	1.09	(0.01 - 3.05)	-*	3	0.7	(0.0 - 1.6)	1.32	(0.11 - 3.07)	-*
Pyriform sinus & hypopharynx	0	-	-	0	n/a	V	2	0.6	(0.0 - 1.4)	4.24	(0.05 - 11.81)	-*
Nasal cavity, sinuses, int. ear	3	0.8	(0.0 - 1.8)	1.28	(0.10 - 2.98)	-*	4	0.8	(0.0 - 1.6)	3.94	(0.61 - 8.63)	-*
Peritoneum & retroperitoneum	0	-	-	0	n/a	-	1	0.2	(0.0 - 0.6)	0.44	(0.00 - 1.64)	-*
Adrenal & other endocrine	1	0.8	(0.0 - 2.4)	0.82	(0.00 - 3.01)	-*	0	-	-	0	n/a	-
Nasopharynx	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pharynx, other & ill-def.	2	0.5	(0.0 - 1.2)	1.25	(0.02 - 3.49)	-*	0	-	-	-	-	.
Penis & other male genital	3	0.9	(0.0 - 2.0)	1.54	(0.12 - 3.58)	-*	0	-	-	-	-	.
Gum	1	0.3	(0.0 - 0.7)	1.11	(0.00 - 4.08)	-*	4	0.9	(0.0 - 1.7)	4.99	(0.77 - 10.95)	-*
Kaposi sarcoma	1	0.3	(0.0 - 1.0)	0.97	(0.00 - 3.57)	-*	1	0.1	(0.0 - 0.3)	3.72	(0.00 - 13.74)	-*
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	1	0.1	(0.0 - 0.4)	2.70	(0.00 - 9.96)	-*
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	1	0.3	(0.0 - 1.0)	1.65	(0.00 - 6.07)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	1	0.4	(0.0 - 1.1)	8.39	(0.00 - 30.95)	-*
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1238	331.8	(312.7 - 350.9)	0.99	(0.93 - 1.04)	-	1035	245.9	(229.8 - 261.9)	0.96	(0.91 - 1.02)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Stirling (C) - Coastal 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	2	0.9	(0.0 - 2.1)	1.60	(0.02 - 4.47)	-*	207	87.0	(74.6 - 99.5)	1.05	(0.91 - 1.20)	-
Colorectal cancer	117	48.5	(39.3 - 57.7)	1.10	(0.92 - 1.33)	-	81	27.1	(20.6 - 33.6)	0.88	(0.70 - 1.10)	-
Prostate gland	215	91.9	(79.2 - 104.7)	1.24	(1.08 - 1.42)	^	0	-	-	-	-	.
Melanoma (skin)	133	63.2	(52.2 - 74.3)	1.47	(1.23 - 1.74)	^	78	34.6	(26.3 - 42.9)	1.11	(0.88 - 1.39)	-
Lung, bronchus & trachea	80	31.8	(24.6 - 39.1)	0.85	(0.68 - 1.06)	-	45	13.9	(9.4 - 18.4)	0.82	(0.58 - 1.07)	-
Lymphoma	38	19.2	(12.9 - 25.6)	1.15	(0.79 - 1.54)	-	31	10.9	(6.7 - 15.1)	1.11	(0.73 - 1.54)	-
Unknown primary site	31	12.2	(7.7 - 16.8)	1.13	(0.74 - 1.56)	-	22	6.0	(3.1 - 8.9)	0.93	(0.55 - 1.36)	-
Kidney & other renal tract	22	9.7	(5.5 - 13.9)	1.02	(0.60 - 1.48)	-	16	6.2	(2.9 - 9.4)	1.18	(0.62 - 1.82)	-
Leukaemia	22	9.6	(4.9 - 14.3)	1.09	(0.64 - 1.59)	-	16	5.9	(2.6 - 9.3)	1.12	(0.59 - 1.74)	-
Pancreas	10	4.0	(1.4 - 6.7)	0.68	(0.28 - 1.16)	-	10	3.5	(1.2 - 5.8)	0.58	(0.24 - 0.99)	V
Urinary bladder	23	10.4	(5.5 - 15.2)	1.01	(0.60 - 1.46)	-	9	2.8	(0.7 - 4.9)	0.98	(0.38 - 1.72)	-
Stomach	15	6.5	(3.1 - 10.0)	0.78	(0.40 - 1.22)	-	16	4.9	(2.1 - 7.7)	1.37	(0.72 - 2.11)	-
Corpus uteri	0	-	-	-	-	.	16	6.2	(3.0 - 9.4)	0.69	(0.36 - 1.06)	-
Brain	13	6.1	(2.7 - 9.5)	1.09	(0.52 - 1.77)	-	6	1.9	(0.2 - 3.5)	0.65	(0.18 - 1.27)	-
Lip	12	5.7	(2.4 - 9.1)	0.99	(0.45 - 1.63)	-	4	1.6	(0.0 - 3.3)	0.61	(0.09 - 1.34)	-
Ovary & uterine adnexa	0	-	-	-	-	.	19	8.2	(4.1 - 12.3)	0.94	(0.53 - 1.40)	-
Other lymphohaematopoietic	19	7.0	(3.7 - 10.3)	1.73	(0.97 - 2.59)	-	14	4.3	(1.7 - 6.9)	1.58	(0.78 - 2.51)	-
Oesophagus	9	3.3	(1.0 - 5.5)	0.74	(0.28 - 1.29)	-	9	3.7	(1.2 - 6.1)	1.35	(0.52 - 2.37)	-
Thyroid gland	5	2.4	(0.2 - 4.5)	1.18	(0.26 - 2.41)	-*	13	6.6	(2.9 - 10.3)	1.12	(0.54 - 1.81)	-
Myeloma/plasma cell tumours	12	4.9	(2.0 - 7.8)	1.31	(0.60 - 2.15)	-	9	3.4	(1.0 - 5.8)	1.18	(0.45 - 2.07)	-
Cervix uteri	0	-	-	-	-	.	19	7.5	(3.8 - 11.2)	1.29	(0.72 - 1.93)	-
Non-mel. skin (exc BCC/SCC)	14	5.9	(2.7 - 9.2)	1.48	(0.73 - 2.34)	-	8	3.3	(0.7 - 5.8)	1.33	(0.47 - 2.39)	-
Mesothelioma	12	4.5	(1.9 - 7.1)	1.08	(0.49 - 1.76)	-	4	1.3	(0.0 - 2.8)	2.20	(0.34 - 4.83)	-*
Liver & intrahepatic bile duct	5	1.4	(0.2 - 2.7)	0.62	(0.14 - 1.27)	-	1	0.5	(0.0 - 1.5)	0.31	(0.00 - 1.14)	-*
Testis	10	5.6	(2.1 - 9.1)	1.06	(0.43 - 1.80)	-	0	-	-	-	-	.
Gallbladder & bile ducts	2	0.8	(0.0 - 2.0)	0.41	(0.01 - 1.15)	-	3	0.8	(0.0 - 1.8)	0.51	(0.04 - 1.19)	-
Larynx	7	3.5	(0.9 - 6.1)	0.85	(0.27 - 1.59)	-	2	1.0	(0.0 - 2.4)	1.44	(0.02 - 4.01)	-*
Tongue	3	1.4	(0.0 - 3.0)	0.63	(0.05 - 1.47)	-	3	0.9	(0.0 - 2.0)	1.41	(0.11 - 3.29)	-*
Connective & soft tissues	5	2.5	(0.3 - 4.8)	1.35	(0.29 - 2.76)	-*	1	0.5	(0.0 - 1.6)	0.41	(0.00 - 1.50)	-*
Tonsil & oropharynx	3	1.4	(0.0 - 3.1)	0.79	(0.06 - 1.85)	-*	0	-	-	0	n/a	-
Vulva/vagina	0	-	-	-	-	.	4	1.9	(0.0 - 3.8)	0.81	(0.12 - 1.77)	-
Small intestine	1	0.6	(0.0 - 1.7)	0.43	(0.00 - 1.59)	-*	3	1.2	(0.0 - 2.7)	1.66	(0.13 - 3.87)	-*
Eye & lacrimal gland	5	2.3	(0.2 - 4.4)	2.17	(0.47 - 4.45)	-*	3	0.8	(0.0 - 1.7)	2.34	(0.19 - 5.46)	-*
Major Salivary Gland	2	1.1	(0.0 - 2.6)	0.96	(0.01 - 2.67)	-*	2	0.7	(0.0 - 1.6)	1.29	(0.02 - 3.60)	-*
Anus	1	0.6	(0.0 - 1.6)	0.68	(0.00 - 2.49)	-*	3	1.0	(0.0 - 2.2)	1.40	(0.11 - 3.28)	-*
Mouth, other & unspecified	5	2.0	(0.2 - 3.8)	2.44	(0.53 - 5.01)	-*	2	1.0	(0.0 - 2.4)	1.44	(0.02 - 4.01)	-*
Floor of mouth	2	1.1	(0.0 - 2.7)	0.88	(0.01 - 2.45)	-*	5	1.9	(0.0 - 3.8)	5.24	(1.14 - 10.72)	^*
Bones, joints & articular cart.	0	-	-	0	n/a	-	2	0.8	(0.0 - 2.0)	1.41	(0.02 - 3.94)	-*
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.4	(0.0 - 1.0)	0.68	(0.00 - 2.52)	-*	0	-	-	0	n/a	-
Peritoneum & retroperitoneum	0	-	-	0	n/a	-	1	0.2	(0.0 - 0.6)	0.71	(0.00 - 2.61)	-*
Adrenal & other endocrine	1	0.6	(0.0 - 1.6)	1.34	(0.00 - 4.96)	-*	1	1.5	(0.0 - 4.5)	2.16	(0.00 - 7.96)	-*
Nasopharynx	1	0.4	(0.0 - 1.1)	0.99	(0.00 - 3.65)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	2	0.5	(0.0 - 1.3)	2.01	(0.03 - 5.60)	-*	1	0.5	(0.0 - 1.6)	4.76	(0.00 - 17.54)	-*
Penis & other male genital	1	0.3	(0.0 - 0.8)	0.83	(0.00 - 3.05)	-*	0	-	-	-	-	.
Gum	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Kaposi sarcoma	1	0.4	(0.0 - 1.1)	1.51	(0.00 - 5.56)	-*	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	2	1.6	(0.0 - 3.9)	9.22	(0.12 - 25.69)	-*	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	2	1.1	(0.0 - 2.6)	4.93	(0.06 - 13.74)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	864	376.3	(350.1 - 402.4)	1.12	(1.04 - 1.20)	^	691	266.9	(245.2 - 288.6)	1.01	(0.93 - 1.09)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Stirling (C) - South-Eastern 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	66	106.1	(76.2 - 135.9)	1.24	(0.96 - 1.58)	-
Colorectal cancer	33	48.8	(28.8 - 68.9)	1.09	(0.72 - 1.49)	-	31	25.2	(12.4 - 37.9)	0.98	(0.64 - 1.35)	-
Prostate gland	45	76.8	(50.7 - 102.9)	0.94	(0.67 - 1.23)	-	0	-	-	-	-	.
Melanoma (skin)	17	33.3	(16.5 - 50.2)	0.70	(0.37 - 1.07)	-	17	23.0	(10.3 - 35.6)	0.85	(0.46 - 1.30)	-
Lung, bronchus & trachea	30	44.7	(26.4 - 63.0)	1.12	(0.73 - 1.56)	-	11	10.7	(2.8 - 18.5)	0.62	(0.27 - 1.04)	-
Lymphoma	11	16.9	(5.5 - 28.2)	1.17	(0.51 - 1.96)	-	7	8.6	(0.0 - 17.4)	0.81	(0.26 - 1.52)	-
Unknown primary site	7	6.5	(1.2 - 11.7)	0.83	(0.26 - 1.55)	-	7	4.9	(0.0 - 10.0)	0.72	(0.23 - 1.34)	-
Kidney & other renal tract	4	3.4	(0.0 - 7.2)	0.66	(0.10 - 1.45)	-	5	7.9	(0.0 - 16.0)	1.21	(0.26 - 2.48)	-*
Leukaemia	6	12.0	(0.4 - 23.6)	1.04	(0.28 - 2.02)	-	6	7.3	(0.0 - 14.9)	1.21	(0.33 - 2.35)	-
Pancreas	4	6.5	(0.0 - 14.1)	0.96	(0.15 - 2.10)	-*	9	4.4	(0.7 - 8.2)	1.43	(0.55 - 2.51)	-
Urinary bladder	4	4.7	(0.0 - 9.7)	0.55	(0.08 - 1.20)	-	3	1.4	(0.0 - 2.9)	0.82	(0.07 - 1.91)	-*
Stomach	7	6.5	(0.5 - 12.5)	1.23	(0.39 - 2.29)	-	3	2.3	(0.0 - 5.8)	0.69	(0.06 - 1.61)	-*
Corpus uteri	0	-	-	-	-	.	3	5.7	(0.0 - 13.4)	0.45	(0.04 - 1.04)	-
Brain	2	6.5	(0.0 - 17.6)	0.64	(0.01 - 1.78)	-*	3	5.9	(0.0 - 12.7)	1.07	(0.09 - 2.51)	-*
Lip	3	3.9	(0.0 - 8.6)	0.92	(0.07 - 2.16)	-*	5	4.8	(0.0 - 11.4)	2.24	(0.49 - 4.59)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	5	4.2	(0.0 - 10.3)	0.80	(0.17 - 1.63)	-
Other lymphohaematopoietic	6	3.7	(0.7 - 6.7)	1.63	(0.44 - 3.17)	-*	5	4.5	(0.2 - 8.8)	1.41	(0.31 - 2.89)	-*
Oesophagus	4	6.4	(0.0 - 13.8)	1.14	(0.18 - 2.50)	-*	1	0.2	(0.0 - 0.6)	0.42	(0.00 - 1.55)	-*
Thyroid gland	3	5.8	(0.0 - 12.3)	2.69	(0.22 - 6.29)	-*	2	1.7	(0.0 - 4.4)	0.64	(0.01 - 1.78)	-*
Myeloma/plasma cell tumours	2	1.2	(0.0 - 2.9)	0.71	(0.01 - 1.99)	-*	2	1.7	(0.0 - 4.4)	0.75	(0.01 - 2.08)	-*
Cervix uteri	0	-	-	-	-	.	4	2.3	(0.0 - 5.0)	0.94	(0.15 - 2.06)	-*
Non-mel. skin (exc BCC/SCC)	8	14.0	(2.9 - 25.2)	2.67	(0.94 - 4.82)	-*	3	6.7	(0.0 - 14.3)	1.37	(0.11 - 3.20)	-*
Mesothelioma	2	3.2	(0.0 - 8.5)	0.64	(0.01 - 1.77)	-*	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	2	3.5	(0.0 - 9.1)	0.92	(0.01 - 2.57)	-*	0	-	-	0	n/a	-
Testis	4	8.5	(0.1 - 16.9)	1.61	(0.25 - 3.53)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	2	2.2	(0.0 - 5.5)	1.43	(0.02 - 3.99)	-*	3	1.3	(0.0 - 2.8)	1.37	(0.11 - 3.20)	-*
Larynx	1	3.3	(0.0 - 9.8)	0.49	(0.00 - 1.81)	-*	0	-	-	-	-	.
Tongue	2	3.3	(0.0 - 8.5)	1.59	(0.02 - 4.43)	-*	1	0.3	(0.0 - 0.9)	1.56	(0.00 - 5.75)	-*
Connective & soft tissues	3	6.5	(0.0 - 13.9)	2.96	(0.24 - 6.91)	-*	0	-	-	0	n/a	-
Tonsil & oropharynx	3	5.4	(0.0 - 12.0)	2.97	(0.24 - 6.94)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	3	3.9	(0.0 - 8.9)	1.70	(0.14 - 3.97)	-*
Small intestine	1	3.3	(0.0 - 9.8)	1.59	(0.00 - 5.85)	-*	0	-	-	0	n/a	-
Eye & lacrimal gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Major Salivary Gland	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Anus	1	0.8	(0.0 - 2.5)	2.60	(0.00 - 9.59)	-*	3	1.3	(0.0 - 2.8)	4.42	(0.36 - 10.32)	-*
Mouth, other & unspecified	0	-	-	0	n/a	-	0	-	-	-	-	.
Floor of mouth	2	6.0	(0.0 - 14.4)	3.83	(0.05 - 10.67)	-*	2	3.0	(0.0 - 8.4)	5.45	(0.07 - 15.20)	-*
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	3.3	(0.0 - 9.8)	1.74	(0.00 - 6.43)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	1	0.2	(0.0 - 0.6)	3.81	(0.00 - 14.06)	-*
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	1	0.2	(0.0 - 0.6)	10.10	(0.00 - 37.25)	-*
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	220	351.0	(296.8 - 405.2)	1.01	(0.88 - 1.15)	-	212	249.7	(206.5 - 292.8)	0.99	(0.87 - 1.14)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Subiaco (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	52	99.8	(70.9 - 128.6)	1.16	(0.87 - 1.53)	-
Colorectal cancer	17	36.3	(18.4 - 54.3)	0.77	(0.41 - 1.17)	-	22	29.0	(14.9 - 43.1)	1.04	(0.62 - 1.52)	-
Prostate gland	44	105.6	(73.8 - 137.5)	1.24	(0.87 - 1.63)	-	0	-	-	-	-	.
Melanoma (skin)	26	52.0	(31.2 - 72.9)	1.27	(0.79 - 1.81)	-	12	24.0	(10.0 - 38.0)	0.70	(0.32 - 1.15)	-
Lung, bronchus & trachea	26	49.1	(28.9 - 69.4)	1.37	(0.85 - 1.94)	-	11	16.3	(6.1 - 26.6)	0.90	(0.39 - 1.51)	-
Lymphoma	9	20.7	(6.8 - 34.5)	1.22	(0.47 - 2.14)	-	8	14.5	(3.7 - 25.3)	1.25	(0.44 - 2.26)	-
Unknown primary site	7	12.8	(2.4 - 23.1)	1.21	(0.38 - 2.26)	-	9	9.1	(1.8 - 16.5)	1.56	(0.60 - 2.74)	-
Kidney & other renal tract	2	4.0	(0.0 - 9.6)	0.43	(0.01 - 1.21)	-	3	3.5	(0.0 - 8.1)	0.99	(0.08 - 2.30)	-*
Leukaemia	5	11.9	(0.0 - 25.3)	1.15	(0.25 - 2.35)	-*	4	10.8	(0.0 - 25.9)	1.19	(0.18 - 2.61)	-*
Pancreas	6	15.5	(3.0 - 28.1)	1.97	(0.53 - 3.84)	-*	5	9.0	(0.5 - 17.5)	1.25	(0.27 - 2.57)	-*
Urinary bladder	2	3.5	(0.0 - 8.7)	0.42	(0.01 - 1.18)	-	3	4.2	(0.0 - 10.0)	1.39	(0.11 - 3.25)	-*
Stomach	2	3.3	(0.0 - 7.9)	0.50	(0.01 - 1.39)	-*	3	4.5	(0.0 - 10.1)	1.10	(0.09 - 2.57)	-*
Corpus uteri	0	-	-	-	-	.	7	11.2	(1.6 - 20.8)	1.34	(0.42 - 2.51)	-
Brain	1	2.9	(0.0 - 8.7)	0.37	(0.00 - 1.36)	-*	2	2.5	(0.0 - 6.7)	0.94	(0.01 - 2.61)	-*
Lip	2	3.9	(0.0 - 9.2)	0.72	(0.01 - 2.01)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	14	23.5	(9.9 - 37.1)	3.00	(1.49 - 4.77)	^
Other lymphohaematopoietic	5	9.6	(0.7 - 18.5)	2.19	(0.48 - 4.48)	-*	1	0.6	(0.0 - 1.7)	0.47	(0.00 - 1.73)	-*
Oesophagus	3	4.3	(0.0 - 9.3)	1.20	(0.10 - 2.79)	-*	2	2.5	(0.0 - 6.7)	1.31	(0.02 - 3.64)	-*
Thyroid gland	0	-	-	0	n/a	-	3	11.7	(0.0 - 26.1)	1.01	(0.08 - 2.37)	-*
Myeloma/plasma cell tumours	2	4.4	(0.0 - 10.6)	1.03	(0.01 - 2.88)	-*	1	0.5	(0.0 - 1.4)	0.57	(0.00 - 2.10)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	v
Non-mel. skin (exc BCC/SCC)	3	4.9	(0.0 - 10.6)	1.46	(0.12 - 3.42)	-*	4	7.7	(0.0 - 15.8)	2.68	(0.41 - 5.87)	-*
Mesothelioma	1	2.9	(0.0 - 8.7)	0.43	(0.00 - 1.60)	-*	1	1.7	(0.0 - 5.0)	2.51	(0.00 - 9.26)	-*
Liver & intrahepatic bile duct	3	6.7	(0.0 - 14.9)	1.80	(0.15 - 4.20)	-*	0	-	-	0	n/a	-
Testis	3	5.5	(0.0 - 11.8)	1.15	(0.09 - 2.69)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	4	6.6	(0.0 - 13.2)	3.95	(0.61 - 8.67)	-*	0	-	-	0	n/a	-
Larynx	4	8.3	(0.1 - 16.5)	2.32	(0.36 - 5.09)	-*	0	-	-	-	-	.
Tongue	0	-	-	0	n/a	-	1	0.6	(0.0 - 1.7)	2.14	(0.00 - 7.89)	-*
Connective & soft tissues	1	2.4	(0.0 - 7.1)	1.17	(0.00 - 4.30)	-*	1	1.6	(0.0 - 4.7)	1.74	(0.00 - 6.40)	-*
Tonsil & oropharynx	1	2.4	(0.0 - 7.1)	1.17	(0.00 - 4.33)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	0.6	(0.0 - 1.7)	0.85	(0.00 - 3.14)	-*
Small intestine	2	4.9	(0.0 - 11.8)	4.07	(0.05 - 11.34)	-*	1	0.8	(0.0 - 2.5)	2.43	(0.00 - 8.96)	-*
Eye & lacrimal gland	1	1.9	(0.0 - 5.8)	1.95	(0.00 - 7.20)	-*	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	2	2.5	(0.0 - 6.3)	5.33	(0.07 - 14.84)	-*
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	2	4.4	(0.0 - 10.5)	4.43	(0.06 - 12.34)	-*	0	-	-	-	-	.
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	1	0.5	(0.0 - 1.4)	6.24	(0.00 - 23.00)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	1	0.5	(0.0 - 1.4)	6.99	(0.00 - 25.78)	-*
Kaposi sarcoma	1	2.4	(0.0 - 7.1)	6.81	(0.00 - 25.10)	-*	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	185	393.3	(334.1 - 452.4)	1.13	(0.97 - 1.31)	-	175	293.8	(243.7 - 343.8)	1.10	(0.95 - 1.28)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Swan (C) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	2	0.8	(0.0 - 2.0)	1.85	(0.02 - 5.16)	-*	166	76.0	(64.1 - 87.8)	0.89	(0.76 - 1.04)	-
Colorectal cancer	86	39.5	(31.0 - 48.0)	0.92	(0.74 - 1.14)	-	76	32.7	(25.0 - 40.4)	1.09	(0.86 - 1.37)	-
Prostate gland	125	62.0	(51.0 - 73.0)	0.83	(0.70 - 1.00)	-	0	-	-	-	-	.
Melanoma (skin)	75	33.0	(25.4 - 40.6)	0.80	(0.63 - 1.01)	-	63	27.9	(20.8 - 35.0)	0.88	(0.68 - 1.13)	-
Lung, bronchus & trachea	109	53.2	(43.0 - 63.3)	1.36	(1.12 - 1.65)	^	40	17.1	(11.6 - 22.6)	0.96	(0.66 - 1.28)	-
Lymphoma	35	16.5	(10.9 - 22.1)	1.06	(0.72 - 1.44)	-	20	8.6	(4.6 - 12.6)	0.84	(0.48 - 1.25)	-
Unknown primary site	25	11.3	(6.8 - 15.9)	1.08	(0.66 - 1.54)	-	20	6.4	(3.4 - 9.4)	1.18	(0.68 - 1.75)	-
Kidney & other renal tract	23	10.4	(6.1 - 14.7)	1.13	(0.68 - 1.64)	-	16	7.2	(3.6 - 10.8)	1.36	(0.72 - 2.11)	-
Leukaemia	19	9.8	(5.3 - 14.3)	0.95	(0.53 - 1.42)	-	13	5.9	(2.6 - 9.3)	1.01	(0.48 - 1.62)	-
Pancreas	14	7.7	(3.6 - 11.7)	1.08	(0.53 - 1.71)	-	12	5.6	(2.3 - 8.9)	0.97	(0.44 - 1.58)	-
Urinary bladder	21	10.4	(5.9 - 14.9)	1.16	(0.67 - 1.70)	-	5	2.2	(0.2 - 4.2)	0.81	(0.18 - 1.66)	-
Stomach	18	8.5	(4.5 - 12.5)	1.08	(0.59 - 1.63)	-	6	2.3	(0.3 - 4.3)	0.71	(0.19 - 1.37)	-
Corpus uteri	0	-	-	-	-	.	23	10.3	(6.0 - 14.7)	1.17	(0.70 - 1.70)	-
Brain	17	8.0	(4.1 - 11.9)	1.32	(0.71 - 2.02)	-	8	3.1	(0.9 - 5.4)	0.94	(0.33 - 1.70)	-
Lip	9	4.1	(1.4 - 6.9)	0.68	(0.26 - 1.20)	-	4	1.7	(0.0 - 3.5)	0.75	(0.12 - 1.64)	-
Ovary & uterine adnexa	0	-	-	-	-	.	20	9.1	(5.0 - 13.2)	1.17	(0.67 - 1.74)	-
Other lymphohaematopoietic	8	4.2	(1.3 - 7.2)	0.94	(0.33 - 1.69)	-	4	1.6	(0.0 - 3.3)	0.63	(0.10 - 1.39)	-
Oesophagus	11	5.4	(2.2 - 8.7)	1.04	(0.45 - 1.74)	-	6	2.7	(0.4 - 4.9)	1.24	(0.34 - 2.42)	-
Thyroid gland	6	2.4	(0.5 - 4.3)	1.17	(0.32 - 2.28)	-	10	4.1	(1.5 - 6.7)	0.75	(0.31 - 1.27)	-
Myeloma/plasma cell tumours	7	3.6	(0.9 - 6.4)	0.89	(0.28 - 1.66)	-	7	2.9	(0.6 - 5.2)	1.22	(0.38 - 2.27)	-
Cervix uteri	0	-	-	-	-	.	17	6.6	(3.4 - 9.7)	1.04	(0.56 - 1.59)	-
Non-mel. skin (exc BCC/SCC)	7	3.3	(0.8 - 5.9)	0.84	(0.26 - 1.57)	-	7	2.8	(0.6 - 5.1)	1.41	(0.44 - 2.62)	-
Mesothelioma	11	5.5	(2.2 - 8.9)	1.15	(0.50 - 1.92)	-	2	0.8	(0.0 - 2.1)	1.40	(0.02 - 3.90)	-*
Liver & intrahepatic bile duct	10	4.6	(1.7 - 7.4)	1.37	(0.56 - 2.34)	-	2	0.9	(0.0 - 2.2)	0.75	(0.01 - 2.09)	-*
Testis	18	7.2	(3.8 - 10.6)	1.40	(0.77 - 2.12)	-	0	-	-	-	-	.
Gallbladder & bile ducts	6	2.9	(0.6 - 5.2)	1.41	(0.38 - 2.74)	-*	8	3.4	(0.9 - 5.8)	1.92	(0.68 - 3.46)	-*
Larynx	9	4.6	(1.6 - 7.6)	1.15	(0.44 - 2.02)	-	4	1.4	(0.0 - 2.7)	3.52	(0.54 - 7.72)	-*
Tongue	2	0.8	(0.0 - 1.9)	0.40	(0.01 - 1.12)	-	1	0.3	(0.0 - 0.9)	0.58	(0.00 - 2.12)	-*
Connective & soft tissues	4	1.9	(0.0 - 3.8)	0.99	(0.15 - 2.18)	-*	0	-	-	0	n/a	-
Tonsil & oropharynx	4	2.1	(0.0 - 4.2)	0.99	(0.15 - 2.17)	-*	1	0.5	(0.0 - 1.4)	1.23	(0.00 - 4.53)	-*
Vulva/vagina	0	-	-	-	-	.	6	2.3	(0.4 - 4.2)	1.43	(0.39 - 2.79)	-*
Small intestine	2	1.0	(0.0 - 2.3)	0.94	(0.01 - 2.61)	-*	0	-	-	0	n/a	-
Eye & lacrimal gland	2	1.1	(0.0 - 2.5)	0.80	(0.01 - 2.24)	-*	2	0.9	(0.0 - 2.2)	1.82	(0.02 - 5.08)	-*
Major Salivary Gland	3	1.3	(0.0 - 2.7)	1.56	(0.13 - 3.63)	-*	2	1.2	(0.0 - 3.0)	1.39	(0.02 - 3.87)	-*
Anus	1	0.4	(0.0 - 1.3)	0.70	(0.00 - 2.57)	-*	3	1.3	(0.0 - 2.8)	1.67	(0.13 - 3.91)	-*
Mouth, other & unspecified	2	0.8	(0.0 - 1.9)	0.97	(0.01 - 2.70)	-*	0	-	-	0	n/a	-
Floor of mouth	3	1.5	(0.0 - 3.2)	1.24	(0.10 - 2.90)	-*	0	-	-	0	n/a	-
Bones, joints & articular cart.	1	0.4	(0.0 - 1.3)	0.70	(0.00 - 2.59)	-*	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	5	2.2	(0.2 - 4.2)	2.37	(0.52 - 4.85)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.6	(0.0 - 1.8)	0.69	(0.00 - 2.55)	-*	0	-	-	0	n/a	-
Peritoneum & retroperitoneum	2	1.0	(0.0 - 2.3)	3.24	(0.04 - 9.01)	-*	2	0.6	(0.0 - 1.3)	1.68	(0.02 - 4.69)	-*
Adrenal & other endocrine	1	0.4	(0.0 - 1.1)	0.94	(0.00 - 3.47)	-*	0	-	-	0	n/a	-
Nasopharynx	1	0.4	(0.0 - 1.1)	0.94	(0.00 - 3.47)	-*	1	0.6	(0.0 - 1.8)	3.48	(0.00 - 12.85)	-*
Pharynx, other & ill-def.	1	0.4	(0.0 - 1.1)	1.11	(0.00 - 4.08)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	0	n/a	-	0	-	-	-	-	.
Gum	1	0.6	(0.0 - 1.8)	2.01	(0.00 - 7.40)	-*	0	-	-	-	-	.
Kaposi sarcoma	1	0.4	(0.0 - 1.1)	1.58	(0.00 - 5.84)	-*	1	0.2	(0.0 - 0.7)	8.89	(0.00 - 32.80)	-*
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	1	0.3	(0.0 - 0.9)	2.40	(0.00 - 8.85)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	708	336.1	(311.0 - 361.1)	1.00	(0.93 - 1.08)	-	579	251.7	(230.5 - 272.9)	0.97	(0.89 - 1.05)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Tambellup (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	38.1	(0.0 - 112.4)	0.57	(0.00 - 2.12)	-*
Colorectal cancer	0	-	-	0	n/a	-	1	54.5	(0.0 - 160.5)	1.47	(0.00 - 5.42)	-*
Prostate gland	2	98.3	(0.0 - 237.8)	1.12	(0.01 - 3.11)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	1	38.1	(0.0 - 112.4)	1.60	(0.00 - 5.90)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	1	37.0	(0.0 - 109.2)	2.94	(0.00 - 10.83)	-*	1	50.0	(0.0 - 147.4)	4.50	(0.00 - 16.58)	-*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	31.3	(0.0 - 91.5)	5.97	(0.00 - 22.01)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	55.6	(0.0 - 161.4)	39.98	(0.00 - 147.50)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	4	190.9	(1.8 - 379.9)	0.51	(0.08 - 1.11)	-	5	212.0	(24.2 - 399.8)	0.90	(0.20 - 1.84)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Tammin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	1	50.0	(0.0 - 143.0)	1.38	(0.00 - 5.09)	-*	0	-	-	-	-	.
Prostate gland	1	64.5	(0.0 - 189.9)	0.84	(0.00 - 3.11)	-*	0	-	-	-	-	.
Melanoma (skin)	1	50.0	(0.0 - 147.6)	1.58	(0.00 - 5.81)	-*	0	-	-	-	-	.
Lung, bronchus & trachea	2	173.9	(0.0 - 404.2)	3.28	(0.04 - 9.14)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	74.6	(0.0 - 219.8)	7.70	(0.00 - 28.40)	-*
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	1	242.4	(0.0 - 710.3)	100.25	(0.00 - 369.82)	-*	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	6	580.9	(27.8 - 1,133.9)	1.14	(0.31 - 2.21)	-	1	74.6	(0.0 - 219.8)	0.26	(0.00 - 0.96)	V*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Three Springs (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	187.4	(0.0 - 375.4)	2.03	(0.31 - 4.46)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	-
Melanoma (skin)	1	35.5	(0.0 - 104.9)	0.83	(0.00 - 3.05)	-*	1	44.8	(0.0 - 132.2)	1.39	(0.00 - 5.12)	-*
Lung, bronchus & trachea	1	44.4	(0.0 - 131.1)	0.82	(0.00 - 3.02)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	2	47.9	(0.0 - 115.0)	5.52	(0.07 - 15.37)	-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	1	35.1	(0.0 - 103.7)	7.06	(0.00 - 26.05)	-*
Pancreas	0	-	-	-	-	.	1	25.0	(0.0 - 72.8)	6.60	(0.00 - 24.36)	-*
Urinary bladder	1	18.5	(0.0 - 54.1)	3.33	(0.00 - 12.27)	-*	1	58.8	(0.0 - 173.0)	12.51	(0.00 - 46.16)	-*
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	42.3	(0.0 - 124.8)	6.26	(0.00 - 23.10)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	6	188.6	(31.2 - 346.1)	0.59	(0.16 - 1.14)	-	8	351.1	(100.5 - 601.6)	1.22	(0.43 - 2.20)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Toodyay (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	9	65.9	(22.1 - 109.6)	0.76	(0.29 - 1.34)	-
Colorectal cancer	6	41.2	(8.0 - 74.5)	0.88	(0.24 - 1.70)	-	2	13.2	(0.0 - 31.5)	0.50	(0.01 - 1.40)	-*
Prostate gland	9	58.3	(19.8 - 96.7)	0.78	(0.30 - 1.37)	-	0	-	-	-	-	.
Melanoma (skin)	11	127.0	(36.9 - 217.1)	1.79	(0.78 - 2.99)	-	2	18.4	(0.0 - 44.0)	0.51	(0.01 - 1.43)	-*
Lung, bronchus & trachea	6	37.0	(7.4 - 66.6)	1.01	(0.27 - 1.96)	-	2	12.0	(0.0 - 28.6)	0.82	(0.01 - 2.30)	-*
Lymphoma	3	22.8	(0.0 - 49.8)	1.41	(0.11 - 3.30)	-*	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	2	14.9	(0.0 - 35.5)	2.27	(0.03 - 6.34)	-*
Kidney & other renal tract	2	11.7	(0.0 - 27.9)	1.39	(0.02 - 3.88)	-*	1	5.6	(0.0 - 16.5)	1.46	(0.00 - 5.37)	-*
Leukaemia	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pancreas	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Urinary bladder	1	6.6	(0.0 - 19.6)	0.79	(0.00 - 2.90)	-*	2	15.0	(0.0 - 35.9)	6.48	(0.08 - 18.05)	-*
Stomach	2	13.0	(0.0 - 30.9)	1.67	(0.02 - 4.65)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	7.8	(0.0 - 23.1)	0.80	(0.00 - 2.97)	-*
Brain	0	-	-	0	n/a	-	0	-	-	-	-	.
Lip	1	5.4	(0.0 - 15.8)	1.17	(0.00 - 4.33)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	7.2	(0.0 - 21.4)	0.98	(0.00 - 3.61)	-*
Other lymphohaematopoietic	2	11.7	(0.0 - 27.9)	3.46	(0.04 - 9.65)	-*	0	-	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	1	6.0	(0.0 - 17.5)	3.62	(0.00 - 13.35)	-*
Thyroid gland	0	-	-	-	-	.	1	7.5	(0.0 - 22.2)	1.44	(0.00 - 5.30)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	3	19.0	(0.0 - 40.4)	4.18	(0.34 - 9.76)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	6.3	(0.0 - 18.8)	1.86	(0.00 - 6.86)	-*	0	-	-	-	-	.
Testis	1	7.2	(0.0 - 21.3)	1.77	(0.00 - 6.53)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	6.0	(0.0 - 17.5)	4.43	(0.00 - 16.33)	-*
Larynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	1	7.2	(0.0 - 21.3)	7.93	(0.00 - 29.25)	-*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	7.1	(0.0 - 21.0)	15.38	(0.00 - 56.75)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	50	381.4	(260.8 - 502.0)	1.00	(0.72 - 1.29)	-	25	179.5	(108.4 - 250.5)	0.72	(0.44 - 1.03)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Trayning (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	98.8	(0.0 - 233.9)	1.48	(0.02 - 4.13)	-*
Colorectal cancer	1	45.5	(0.0 - 133.5)	1.18	(0.00 - 4.36)	-*	0	-	-	0	n/a	-
Prostate gland	5	309.9	(36.8 - 582.9)	3.52	(0.77 - 7.21)	-*	0	-	-	-	-	.
Melanoma (skin)	1	45.5	(0.0 - 133.5)	1.44	(0.00 - 5.33)	-*	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	1	56.3	(0.0 - 166.0)	6.41	(0.00 - 23.66)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	57.1	(0.0 - 168.3)	6.55	(0.00 - 24.15)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	8	457.9	(140.1 - 775.7)	1.31	(0.46 - 2.36)	-	3	155.1	(0.0 - 329.2)	0.66	(0.05 - 1.53)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Upper Gascoyne (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	-	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Victoria Park (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	0	n/a	-	75	77.1	(56.8 - 97.4)	0.86	(0.68 - 1.08)	-
Colorectal cancer	44	37.6	(24.5 - 50.6)	0.87	(0.61 - 1.14)	-	43	28.2	(16.2 - 40.2)	0.78	(0.55 - 1.03)	-
Prostate gland	82	72.5	(54.2 - 90.8)	1.01	(0.81 - 1.26)	-	0	-	-	-	-	.
Melanoma (skin)	43	42.9	(28.3 - 57.5)	1.05	(0.74 - 1.38)	-	33	27.7	(15.9 - 39.4)	0.97	(0.64 - 1.33)	-
Lung, bronchus & trachea	54	46.3	(31.6 - 60.9)	1.20	(0.91 - 1.57)	-	29	17.9	(9.0 - 26.7)	0.94	(0.60 - 1.31)	-
Lymphoma	9	9.5	(2.6 - 16.5)	0.57	(0.22 - 1.00)	-	12	6.8	(1.6 - 12.0)	0.80	(0.37 - 1.32)	-
Unknown primary site	14	13.0	(5.0 - 20.9)	0.99	(0.49 - 1.58)	-	16	7.7	(1.8 - 13.6)	0.95	(0.50 - 1.47)	-
Kidney & other renal tract	15	13.5	(5.8 - 21.3)	1.49	(0.76 - 2.33)	-	7	7.3	(1.3 - 13.3)	0.99	(0.31 - 1.86)	-
Leukaemia	11	11.5	(3.5 - 19.5)	1.13	(0.49 - 1.89)	-	6	6.3	(0.0 - 13.9)	0.71	(0.19 - 1.37)	-
Pancreas	5	5.3	(0.0 - 10.6)	0.71	(0.16 - 1.46)	-	10	2.9	(0.8 - 5.1)	0.91	(0.38 - 1.56)	-
Urinary bladder	14	10.3	(3.9 - 16.6)	1.14	(0.56 - 1.81)	-	7	2.7	(0.0 - 5.4)	1.09	(0.34 - 2.03)	-
Stomach	16	16.6	(7.5 - 25.7)	1.67	(0.88 - 2.59)	-	5	3.1	(0.0 - 6.5)	0.66	(0.14 - 1.35)	-
Corpus uteri	0	-	-	-	-	.	11	10.0	(2.7 - 17.3)	0.96	(0.42 - 1.61)	-
Brain	8	9.8	(2.5 - 17.1)	1.53	(0.54 - 2.76)	-	6	5.0	(0.3 - 9.6)	1.27	(0.34 - 2.47)	-
Lip	4	5.0	(0.0 - 9.9)	0.74	(0.11 - 1.63)	-	5	2.3	(0.0 - 5.7)	1.31	(0.29 - 2.69)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	6	4.4	(0.1 - 8.7)	0.56	(0.15 - 1.09)	-
Other lymphohaematopoietic	6	3.9	(0.3 - 7.6)	0.97	(0.26 - 1.88)	-	8	2.1	(0.2 - 4.0)	1.30	(0.46 - 2.34)	-
Oesophagus	5	7.3	(0.5 - 14.1)	0.85	(0.19 - 1.75)	-	4	1.2	(0.0 - 2.5)	0.96	(0.15 - 2.11)	-*
Thyroid gland	1	0.9	(0.0 - 2.6)	0.54	(0.00 - 1.97)	-*	5	5.0	(0.5 - 9.5)	0.96	(0.21 - 1.98)	-
Myeloma/plasma cell tumours	2	0.7	(0.0 - 1.8)	0.43	(0.01 - 1.19)	-	4	1.6	(0.0 - 3.5)	0.86	(0.13 - 1.89)	-
Cervix uteri	0	-	-	-	-	.	4	2.2	(0.0 - 4.9)	0.56	(0.09 - 1.24)	-
Non-mel. skin (exc BCC/SCC)	2	0.7	(0.0 - 1.8)	0.40	(0.00 - 1.11)	-	4	2.9	(0.0 - 6.6)	1.05	(0.16 - 2.31)	-*
Mesothelioma	4	1.6	(0.0 - 3.2)	0.75	(0.12 - 1.65)	-	1	1.2	(0.0 - 3.6)	1.04	(0.00 - 3.85)	-*
Liver & intrahepatic bile duct	4	3.2	(0.0 - 6.8)	1.10	(0.17 - 2.41)	-*	1	0.3	(0.0 - 0.9)	0.53	(0.00 - 1.96)	-*
Testis	8	9.1	(2.7 - 15.5)	1.73	(0.61 - 3.12)	-	0	-	-	-	-	.
Gallbladder & bile ducts	6	5.2	(0.5 - 9.9)	2.57	(0.70 - 5.00)	-*	1	0.2	(0.0 - 0.5)	0.26	(0.00 - 0.97)	V*
Larynx	2	3.5	(0.0 - 8.3)	0.59	(0.01 - 1.64)	-*	0	-	-	0	n/a	-
Tongue	5	6.0	(0.5 - 11.5)	2.45	(0.54 - 5.03)	-*	1	0.1	(0.0 - 0.4)	0.91	(0.00 - 3.36)	-*
Connective & soft tissues	1	0.4	(0.0 - 1.1)	0.58	(0.00 - 2.15)	-*	1	1.6	(0.0 - 4.6)	0.92	(0.00 - 3.40)	-*
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	2	1.2	(0.0 - 3.2)	0.66	(0.01 - 1.85)	-*
Small intestine	3	1.7	(0.0 - 3.8)	2.85	(0.23 - 6.66)	-*	0	-	-	0	n/a	-
Eye & lacrimal gland	2	1.8	(0.0 - 4.2)	1.84	(0.02 - 5.13)	-*	1	1.8	(0.0 - 5.4)	1.40	(0.00 - 5.15)	-*
Major Salivary Gland	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Anus	2	3.5	(0.0 - 8.3)	3.10	(0.04 - 8.64)	-*	1	0.2	(0.0 - 0.5)	0.87	(0.00 - 3.19)	-*
Mouth, other & unspecified	1	0.9	(0.0 - 2.6)	1.16	(0.00 - 4.29)	-*	0	-	-	0	n/a	-
Floor of mouth	3	3.6	(0.0 - 7.7)	3.61	(0.29 - 8.42)	-*	0	-	-	0	n/a	-
Bones, joints & articular cart.	3	4.7	(0.0 - 10.2)	5.78	(0.47 - 13.48)	-*	1	0.2	(0.0 - 0.5)	1.43	(0.00 - 5.29)	-*
Pyriform sinus & hypopharynx	2	3.5	(0.0 - 8.3)	2.10	(0.03 - 5.86)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	2	2.2	(0.0 - 5.5)	2.71	(0.03 - 7.56)	-*
Adrenal & other endocrine	0	-	-	-	-	.	1	3.5	(0.0 - 10.3)	5.68	(0.00 - 20.97)	-*
Nasopharynx	1	1.4	(0.0 - 4.2)	2.43	(0.00 - 8.97)	-*	1	0.6	(0.0 - 1.9)	7.09	(0.00 - 26.15)	-*
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	1	0.4	(0.0 - 1.1)	1.59	(0.00 - 5.86)	-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	1	0.1	(0.0 - 0.4)	2.18	(0.00 - 8.05)	-*
Kaposi sarcoma	2	1.7	(0.0 - 4.1)	5.94	(0.07 - 16.55)	-*	0	-	-	-	-	.
Thymus	1	0.9	(0.0 - 2.6)	8.20	(0.00 - 30.25)	-*	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	386	360.3	(319.1 - 401.4)	1.05	(0.95 - 1.16)	-	315	237.5	(202.9 - 272.1)	0.87	(0.78 - 0.97)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Victoria Plains (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	8	295.8	(82.5 - 509.0)	3.21	(1.13 - 5.79)	^*
Colorectal cancer	0	-	-	0	n/a	-	2	43.8	(0.0 - 103.9)	2.33	(0.03 - 6.49)	-*
Prostate gland	6	146.2	(30.0 - 262.3)	1.84	(0.50 - 3.58)	-*	0	-	-	-	-	.
Melanoma (skin)	1	23.3	(0.0 - 68.7)	0.61	(0.00 - 2.26)	-*	3	121.7	(0.0 - 259.1)	3.42	(0.28 - 7.99)	-*
Lung, bronchus & trachea	4	92.0	(2.3 - 181.6)	2.35	(0.36 - 5.15)	-*	1	41.7	(0.0 - 122.8)	1.99	(0.00 - 7.34)	-*
Lymphoma	0	-	-	0	n/a	-	1	29.6	(0.0 - 87.4)	3.59	(0.00 - 13.24)	-*
Unknown primary site	1	25.3	(0.0 - 74.6)	2.01	(0.00 - 7.40)	-*	0	-	-	-	-	.
Kidney & other renal tract	1	24.2	(0.0 - 71.6)	2.54	(0.00 - 9.36)	-*	0	-	-	-	-	.
Leukaemia	1	58.8	(0.0 - 173.8)	2.78	(0.00 - 10.26)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	1	23.3	(0.0 - 68.7)	4.53	(0.00 - 16.72)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	29.6	(0.0 - 87.4)	6.37	(0.00 - 23.50)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	21.7	(0.0 - 63.4)	6.94	(0.00 - 25.60)	-*	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	16	414.8	(203.0 - 626.6)	1.13	(0.59 - 1.75)	-	16	562.1	(279.6 - 844.7)	2.13	(1.12 - 3.30)	^

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Vincent (T) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	0	n/a	-	75	90.5	(68.2 - 112.8)	1.04	(0.82 - 1.31)	-
Colorectal cancer	48	50.3	(34.7 - 65.8)	1.11	(0.80 - 1.45)	-	41	35.4	(22.5 - 48.2)	1.09	(0.76 - 1.45)	-
Prostate gland	51	54.5	(38.4 - 70.6)	0.73	(0.55 - 0.97)	V	0	-	-	-	-	.
Melanoma (skin)	32	33.1	(20.9 - 45.2)	0.83	(0.55 - 1.14)	-	23	19.8	(10.8 - 28.8)	0.80	(0.48 - 1.17)	-
Lung, bronchus & trachea	61	64.6	(47.1 - 82.2)	1.59	(1.22 - 2.05)	^	16	12.3	(5.3 - 19.4)	0.73	(0.38 - 1.13)	-
Lymphoma	17	17.2	(8.5 - 25.9)	1.22	(0.66 - 1.86)	-	7	9.1	(2.0 - 16.3)	0.63	(0.20 - 1.17)	-
Unknown primary site	11	13.9	(5.2 - 22.6)	0.96	(0.42 - 1.60)	-	10	4.5	(1.0 - 8.0)	0.96	(0.40 - 1.65)	-
Kidney & other renal tract	7	10.5	(2.6 - 18.4)	0.79	(0.25 - 1.47)	-	1	0.4	(0.0 - 1.3)	0.19	(0.00 - 0.70)	V
Leukaemia	3	2.3	(0.0 - 5.0)	0.36	(0.03 - 0.83)	V	2	0.8	(0.0 - 1.8)	0.34	(0.00 - 0.94)	V
Pancreas	5	4.1	(0.3 - 8.0)	0.83	(0.18 - 1.70)	-	9	11.6	(3.2 - 20.1)	1.25	(0.48 - 2.19)	-
Urinary bladder	12	9.5	(3.7 - 15.3)	1.24	(0.57 - 2.04)	-	0	-	-	0	n/a	V
Stomach	9	6.8	(2.1 - 11.6)	1.12	(0.43 - 1.96)	-	6	3.7	(0.0 - 7.6)	1.21	(0.33 - 2.36)	-
Corpus uteri	0	-	-	-	-	.	9	9.4	(2.3 - 16.6)	1.04	(0.40 - 1.82)	-
Brain	5	6.9	(0.6 - 13.2)	1.02	(0.22 - 2.09)	-	6	6.6	(0.0 - 13.5)	1.65	(0.44 - 3.20)	-*
Lip	4	4.5	(0.0 - 9.1)	0.77	(0.12 - 1.68)	-	1	1.3	(0.0 - 3.9)	0.38	(0.00 - 1.39)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	5	4.3	(0.0 - 8.7)	0.63	(0.14 - 1.30)	-
Other lymphohaematopoietic	6	3.8	(0.8 - 6.9)	1.26	(0.34 - 2.46)	-	7	5.9	(0.4 - 11.5)	1.81	(0.57 - 3.38)	-*
Oesophagus	8	8.8	(2.2 - 15.4)	1.60	(0.56 - 2.88)	-	2	0.5	(0.0 - 1.3)	0.73	(0.01 - 2.04)	-*
Thyroid gland	2	2.8	(0.0 - 6.6)	1.05	(0.01 - 2.94)	-*	4	5.4	(0.0 - 10.9)	0.84	(0.13 - 1.85)	-
Myeloma/plasma cell tumours	7	6.9	(1.3 - 12.4)	1.83	(0.58 - 3.42)	-*	5	3.4	(0.0 - 7.1)	1.61	(0.35 - 3.30)	-*
Cervix uteri	0	-	-	-	-	.	10	12.1	(4.1 - 20.1)	1.60	(0.66 - 2.73)	-
Non-mel. skin (exc BCC/SCC)	3	3.5	(0.0 - 7.6)	0.74	(0.06 - 1.72)	-*	1	1.3	(0.0 - 3.9)	0.39	(0.00 - 1.43)	-*
Mesothelioma	5	4.3	(0.3 - 8.2)	1.11	(0.24 - 2.27)	-	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	5	8.1	(0.0 - 16.4)	1.55	(0.34 - 3.18)	-*	0	-	-	0	n/a	-
Testis	5	4.3	(0.5 - 8.1)	1.01	(0.22 - 2.06)	-	0	-	-	-	-	.
Gallbladder & bile ducts	2	1.5	(0.0 - 3.6)	1.01	(0.01 - 2.83)	-*	3	1.6	(0.0 - 3.5)	1.21	(0.10 - 2.83)	-*
Larynx	4	6.0	(0.0 - 12.0)	1.27	(0.20 - 2.78)	-*	0	-	-	0	n/a	-
Tongue	2	1.7	(0.0 - 4.2)	1.05	(0.01 - 2.91)	-*	1	0.4	(0.0 - 1.3)	1.22	(0.00 - 4.50)	-*
Connective & soft tissues	0	-	-	0	n/a	-	1	0.8	(0.0 - 2.4)	1.09	(0.00 - 4.01)	-*
Tonsil & oropharynx	2	2.5	(0.0 - 6.0)	1.32	(0.02 - 3.68)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	0.3	(0.0 - 0.8)	0.48	(0.00 - 1.75)	-*
Small intestine	1	0.5	(0.0 - 1.6)	1.09	(0.00 - 4.01)	-*	1	0.4	(0.0 - 1.3)	1.41	(0.00 - 5.19)	-*
Eye & lacrimal gland	1	0.5	(0.0 - 1.6)	1.01	(0.00 - 3.72)	-*	0	-	-	0	n/a	-
Major Salivary Gland	3	2.3	(0.0 - 4.9)	3.30	(0.27 - 7.70)	-*	1	1.3	(0.0 - 3.9)	1.59	(0.00 - 5.86)	-*
Anus	0	-	-	0	n/a	-	2	1.6	(0.0 - 4.3)	2.36	(0.03 - 6.57)	-*
Mouth, other & unspecified	1	1.6	(0.0 - 4.6)	1.25	(0.00 - 4.63)	-*	0	-	-	0	n/a	-
Floor of mouth	1	1.4	(0.0 - 4.2)	1.19	(0.00 - 4.38)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	0	n/a	-
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	1	1.4	(0.0 - 4.2)	1.63	(0.00 - 6.03)	-*	2	3.0	(0.0 - 7.3)	7.23	(0.09 - 20.15)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	0	n/a	-
Adrenal & other endocrine	0	-	-	-	-	.	1	3.3	(0.0 - 9.8)	5.52	(0.00 - 20.38)	-*
Nasopharynx	2	3.1	(0.0 - 7.5)	5.24	(0.07 - 14.60)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	2	1.5	(0.0 - 3.6)	3.85	(0.05 - 10.72)	-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	1	0.5	(0.0 - 1.6)	3.43	(0.00 - 12.66)	-*	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	1	0.5	(0.0 - 1.6)	9.97	(0.00 - 36.79)	-*	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	330	345.8	(305.6 - 386.1)	1.03	(0.93 - 1.15)	-	253	251.4	(215.5 - 287.3)	0.93	(0.82 - 1.06)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wagin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	8	113.4	(30.0 - 196.8)	1.35	(0.48 - 2.44)	-
Colorectal cancer	4	69.2	(0.0 - 139.1)	1.10	(0.17 - 2.41)	-*	1	19.5	(0.0 - 57.7)	0.34	(0.00 - 1.26)	-*
Prostate gland	4	57.5	(0.0 - 121.8)	0.68	(0.10 - 1.49)	-	0	-	-	-	-	.
Melanoma (skin)	3	55.7	(0.0 - 120.9)	1.01	(0.08 - 2.35)	-*	1	19.5	(0.0 - 57.7)	0.48	(0.00 - 1.78)	-*
Lung, bronchus & trachea	7	67.8	(7.9 - 127.6)	2.18	(0.69 - 4.07)	-*	2	35.6	(0.0 - 85.0)	1.14	(0.01 - 3.18)	-*
Lymphoma	2	26.0	(0.0 - 62.0)	1.77	(0.02 - 4.93)	-*	1	9.9	(0.0 - 29.1)	1.16	(0.00 - 4.26)	-*
Unknown primary site	0	-	-	0	n/a	-	1	4.5	(0.0 - 13.2)	1.31	(0.00 - 4.83)	-*
Kidney & other renal tract	1	18.5	(0.0 - 54.6)	1.34	(0.00 - 4.93)	-*	0	-	-	-	-	.
Leukaemia	2	23.7	(0.0 - 62.1)	2.83	(0.04 - 7.90)	-*	1	19.5	(0.0 - 57.7)	2.18	(0.00 - 8.03)	-*
Pancreas	1	4.7	(0.0 - 13.8)	2.01	(0.00 - 7.43)	-*	2	14.3	(0.0 - 35.5)	3.59	(0.04 - 10.01)	-*
Urinary bladder	2	13.4	(0.0 - 32.8)	2.43	(0.03 - 6.76)	-*	1	9.9	(0.0 - 29.1)	3.33	(0.00 - 12.29)	-*
Stomach	0	-	-	0	n/a	-	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	0	-	-	-	-	.	1	4.9	(0.0 - 14.6)	3.49	(0.00 - 12.87)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	19.5	(0.0 - 57.7)	1.59	(0.00 - 5.85)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	17.3	(0.0 - 51.3)	4.15	(0.00 - 15.29)	-*
Cervix uteri	0	-	-	-	-	.	1	19.5	(0.0 - 57.5)	2.27	(0.00 - 8.39)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	1	16.4	(0.0 - 48.6)	3.77	(0.00 - 13.92)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	27	352.8	(204.3 - 501.3)	1.03	(0.65 - 1.45)	-	22	307.2	(169.5 - 445.0)	1.04	(0.61 - 1.52)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wandering (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	83.3	(0.0 - 232.4)	1.09	(0.00 - 4.02)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	V	1	83.3	(0.0 - 232.4)	0.36	(0.00 - 1.33)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wanneroo (C) - North-East 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	41	68.8	(47.2 - 90.5)	0.80	(0.56 - 1.06)	-
Colorectal cancer	32	51.5	(33.2 - 69.8)	1.21	(0.80 - 1.66)	-	19	29.0	(15.3 - 42.6)	0.96	(0.54 - 1.43)	-
Prostate gland	51	87.1	(62.8 - 111.4)	1.19	(0.89 - 1.57)	-	0	-	-	-	-	.
Melanoma (skin)	23	38.3	(22.4 - 54.1)	0.92	(0.55 - 1.33)	-	26	38.6	(23.2 - 54.1)	1.41	(0.88 - 2.00)	-
Lung, bronchus & trachea	28	47.8	(29.8 - 65.9)	1.24	(0.79 - 1.74)	-	14	22.6	(10.3 - 34.9)	1.18	(0.59 - 1.88)	-
Lymphoma	10	19.9	(7.2 - 32.7)	1.13	(0.46 - 1.92)	-	6	8.2	(1.2 - 15.1)	0.94	(0.25 - 1.82)	-
Unknown primary site	3	5.7	(0.0 - 12.3)	0.45	(0.04 - 1.06)	-	3	4.6	(0.0 - 10.2)	0.62	(0.05 - 1.44)	-
Kidney & other renal tract	5	10.0	(0.7 - 19.3)	0.89	(0.19 - 1.81)	-	1	1.6	(0.0 - 4.7)	0.31	(0.00 - 1.15)	-*
Leukaemia	4	5.8	(0.1 - 11.5)	0.75	(0.12 - 1.64)	-	2	1.9	(0.0 - 4.5)	0.59	(0.01 - 1.64)	-*
Pancreas	2	3.7	(0.0 - 8.8)	0.55	(0.01 - 1.52)	-*	4	4.7	(0.0 - 9.9)	1.12	(0.17 - 2.46)	-*
Urinary bladder	5	8.0	(0.8 - 15.1)	0.96	(0.21 - 1.96)	-	3	3.5	(0.0 - 7.5)	1.68	(0.14 - 3.92)	-*
Stomach	6	9.7	(1.7 - 17.7)	1.27	(0.34 - 2.47)	-	2	3.6	(0.0 - 8.5)	0.83	(0.01 - 2.30)	-*
Corpus uteri	0	-	-	-	-	.	9	13.8	(4.7 - 22.8)	1.62	(0.62 - 2.84)	-
Brain	3	5.3	(0.0 - 11.3)	0.88	(0.07 - 2.05)	-*	2	2.3	(0.0 - 5.7)	0.88	(0.01 - 2.46)	-*
Lip	4	6.1	(0.1 - 12.1)	1.16	(0.18 - 2.54)	-*	0	-	-	0	n/a	-
Ovary & uterine adnexa	0	-	-	-	-	.	4	8.1	(0.1 - 16.2)	0.84	(0.13 - 1.84)	-
Other lymphohaematopoietic	2	2.5	(0.0 - 6.1)	0.82	(0.01 - 2.27)	-*	0	-	-	0	n/a	-
Oesophagus	2	3.2	(0.0 - 7.7)	0.67	(0.01 - 1.86)	-*	3	5.3	(0.0 - 11.5)	2.17	(0.17 - 5.06)	-*
Thyroid gland	1	1.6	(0.0 - 4.8)	0.78	(0.00 - 2.89)	-*	6	9.4	(1.9 - 16.9)	1.80	(0.49 - 3.51)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	2	2.1	(0.0 - 5.0)	1.22	(0.02 - 3.39)	-*
Cervix uteri	0	-	-	-	-	.	5	7.1	(0.8 - 13.4)	1.24	(0.27 - 2.54)	-*
Non-mel. skin (exc BCC/SCC)	2	4.3	(0.0 - 10.2)	0.86	(0.01 - 2.39)	-*	1	0.8	(0.0 - 2.4)	0.73	(0.00 - 2.70)	-*
Mesothelioma	2	3.3	(0.0 - 7.9)	0.73	(0.01 - 2.04)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	1	2.2	(0.0 - 6.5)	1.37	(0.00 - 5.05)	-*
Testis	4	7.0	(0.0 - 13.9)	1.37	(0.21 - 3.01)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	3	4.1	(0.0 - 8.6)	2.47	(0.20 - 5.75)	-*	0	-	-	0	n/a	-
Larynx	5	8.1	(0.9 - 15.3)	2.25	(0.49 - 4.60)	-*	2	3.7	(0.0 - 8.8)	6.44	(0.08 - 17.95)	-*
Tongue	2	3.8	(0.0 - 9.2)	1.45	(0.02 - 4.03)	-*	0	-	-	-	-	.
Connective & soft tissues	3	6.1	(0.0 - 13.1)	2.83	(0.23 - 6.61)	-*	1	1.1	(0.0 - 3.1)	1.52	(0.00 - 5.61)	-*
Tonsil & oropharynx	1	1.6	(0.0 - 4.8)	0.89	(0.00 - 3.29)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	1.6	(0.0 - 4.7)	0.90	(0.00 - 3.31)	-*
Small intestine	0	-	-	0	n/a	-	2	4.4	(0.0 - 10.4)	4.93	(0.06 - 13.75)	-*
Eye & lacrimal gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Major Salivary Gland	1	1.8	(0.0 - 5.3)	1.88	(0.00 - 6.94)	-*	0	-	-	-	-	.
Anus	1	2.2	(0.0 - 6.6)	2.57	(0.00 - 9.49)	-*	2	3.8	(0.0 - 9.0)	4.05	(0.05 - 11.29)	-*
Mouth, other & unspecified	1	1.4	(0.0 - 4.3)	1.70	(0.00 - 6.27)	-*	0	-	-	-	-	.
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	2	2.7	(0.0 - 6.4)	3.31	(0.04 - 9.21)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	1	1.4	(0.0 - 4.0)	6.56	(0.00 - 24.21)	-*	0	-	-	-	-	.
Adrenal & other endocrine	1	1.4	(0.0 - 4.3)	4.01	(0.00 - 14.80)	-*	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	210	355.5	(306.7 - 404.3)	1.07	(0.93 - 1.22)	-	162	252.6	(212.3 - 292.9)	0.99	(0.85 - 1.16)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wanneroo (C) - North-West 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	63	96.6	(72.4 - 120.8)	1.15	(0.89 - 1.49)	-
Colorectal cancer	29	46.8	(29.0 - 64.6)	0.96	(0.62 - 1.34)	-	12	17.8	(7.6 - 28.1)	0.59	(0.27 - 0.97)	V
Prostate gland	78	114.9	(88.9 - 140.9)	1.57	(1.25 - 1.98)	^	0	-	-	-	-	.
Melanoma (skin)	33	44.9	(29.0 - 60.7)	1.15	(0.76 - 1.57)	-	17	25.3	(12.9 - 37.6)	0.81	(0.43 - 1.23)	-
Lung, bronchus & trachea	22	35.5	(20.4 - 50.6)	0.82	(0.48 - 1.19)	-	13	16.8	(7.4 - 26.2)	1.04	(0.50 - 1.68)	-
Lymphoma	11	16.3	(6.4 - 26.1)	1.08	(0.47 - 1.81)	-	7	10.7	(2.6 - 18.9)	0.99	(0.31 - 1.85)	-
Unknown primary site	4	5.5	(0.1 - 11.0)	0.53	(0.08 - 1.16)	-	4	6.2	(0.0 - 12.4)	0.88	(0.14 - 1.93)	-
Kidney & other renal tract	10	12.9	(4.6 - 21.2)	1.55	(0.64 - 2.64)	-	3	4.3	(0.0 - 9.2)	0.86	(0.07 - 2.01)	-*
Leukaemia	5	8.0	(0.7 - 15.4)	0.77	(0.17 - 1.58)	-	3	4.5	(0.0 - 9.8)	0.78	(0.06 - 1.82)	-*
Pancreas	7	10.9	(2.4 - 19.4)	1.65	(0.52 - 3.08)	-*	2	2.9	(0.0 - 7.0)	0.56	(0.01 - 1.56)	-*
Urinary bladder	6	8.9	(1.5 - 16.3)	0.99	(0.27 - 1.93)	-	1	1.7	(0.0 - 4.9)	0.58	(0.00 - 2.13)	-*
Stomach	5	7.1	(0.8 - 13.4)	0.91	(0.20 - 1.87)	-	3	4.8	(0.0 - 10.3)	1.24	(0.10 - 2.89)	-*
Corpus uteri	0	-	-	-	-	.	7	11.5	(2.9 - 20.2)	1.21	(0.38 - 2.25)	-
Brain	5	7.4	(0.9 - 14.0)	1.27	(0.28 - 2.60)	-*	2	3.0	(0.0 - 7.2)	0.80	(0.01 - 2.23)	-*
Lip	5	7.8	(0.8 - 14.7)	1.26	(0.27 - 2.58)	-*	1	1.7	(0.0 - 4.9)	0.66	(0.00 - 2.43)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	6	10.2	(2.0 - 18.4)	1.19	(0.32 - 2.31)	-
Other lymphohaematopoietic	4	5.4	(0.0 - 10.8)	1.42	(0.22 - 3.10)	-*	0	-	-	0	n/a	-
Oesophagus	4	5.5	(0.1 - 10.9)	1.15	(0.18 - 2.52)	-*	2	3.1	(0.0 - 7.5)	1.44	(0.02 - 4.02)	-*
Thyroid gland	0	-	-	0	n/a	-	5	8.1	(1.0 - 15.3)	1.28	(0.28 - 2.63)	-*
Myeloma/plasma cell tumours	2	2.3	(0.0 - 5.4)	0.79	(0.01 - 2.21)	-*	1	1.9	(0.0 - 5.5)	0.61	(0.00 - 2.24)	-*
Cervix uteri	0	-	-	-	-	.	5	8.2	(1.0 - 15.4)	1.05	(0.23 - 2.15)	-
Non-mel. skin (exc BCC/SCC)	4	6.4	(0.1 - 12.8)	1.53	(0.24 - 3.34)	-*	1	1.7	(0.0 - 4.9)	0.72	(0.00 - 2.66)	-*
Mesothelioma	5	6.7	(0.7 - 12.7)	1.58	(0.35 - 3.25)	-*	2	2.4	(0.0 - 5.8)	4.64	(0.06 - 12.93)	-*
Liver & intrahepatic bile duct	7	10.8	(2.7 - 18.8)	2.95	(0.93 - 5.50)	-*	1	1.1	(0.0 - 3.2)	1.28	(0.00 - 4.73)	-*
Testis	5	6.3	(0.7 - 11.9)	1.34	(0.29 - 2.74)	-*	0	-	-	-	-	-
Gallbladder & bile ducts	0	-	-	0	n/a	-	1	1.3	(0.0 - 4.0)	0.85	(0.00 - 3.12)	-*
Larynx	1	1.7	(0.0 - 5.1)	0.41	(0.00 - 1.49)	-*	0	-	-	-	-	.
Tongue	1	1.3	(0.0 - 3.8)	0.68	(0.00 - 2.52)	-*	0	-	-	0	n/a	-
Connective & soft tissues	2	3.2	(0.0 - 7.6)	1.63	(0.02 - 4.54)	-*	0	-	-	0	n/a	-
Tonsil & oropharynx	2	3.1	(0.0 - 7.3)	1.70	(0.02 - 4.73)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	0	n/a	-
Small intestine	0	-	-	0	n/a	-	0	-	-	-	-	.
Eye & lacrimal gland	2	3.1	(0.0 - 7.4)	2.58	(0.03 - 7.19)	-*	1	1.8	(0.0 - 5.3)	3.10	(0.00 - 11.43)	-*
Major Salivary Gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Anus	0	-	-	-	-	.	1	1.8	(0.0 - 5.3)	1.91	(0.00 - 7.04)	-*
Mouth, other & unspecified	0	-	-	0	n/a	-	0	-	-	-	-	.
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	1	2.4	(0.0 - 7.0)	2.13	(0.00 - 7.87)	-*
Pyriform sinus & hypopharynx	1	1.9	(0.0 - 5.5)	1.49	(0.00 - 5.51)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	1.0	(0.0 - 3.0)	2.76	(0.00 - 10.20)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	1.9	(0.0 - 5.5)	3.55	(0.00 - 13.09)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	261	386.2	(338.4 - 434.0)	1.15	(1.01 - 1.30)	^	166	252.7	(213.6 - 291.7)	0.95	(0.82 - 1.11)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wanneroo (C) - South 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	1	1.0	(0.0 - 3.1)	2.32	(0.00 - 8.56)	-*	76	78.1	(60.2 - 96.1)	0.94	(0.75 - 1.19)	-
Colorectal cancer	27	33.5	(20.6 - 46.4)	0.72	(0.46 - 1.02)	-	30	30.3	(19.3 - 41.3)	1.05	(0.68 - 1.46)	-
Prostate gland	66	80.3	(60.8 - 99.8)	1.10	(0.86 - 1.41)	-	0	-	-	-	-	.
Melanoma (skin)	21	21.4	(12.1 - 30.8)	0.54	(0.31 - 0.79)	V	24	24.1	(14.3 - 34.0)	0.78	(0.47 - 1.12)	-
Lung, bronchus & trachea	42	52.7	(36.7 - 68.8)	1.33	(0.93 - 1.76)	-	19	18.9	(10.2 - 27.6)	1.11	(0.62 - 1.66)	-
Lymphoma	10	11.9	(4.4 - 19.5)	0.74	(0.30 - 1.26)	-	7	6.8	(1.6 - 12.0)	0.71	(0.22 - 1.32)	-
Unknown primary site	7	8.3	(2.1 - 14.6)	0.77	(0.24 - 1.44)	-	4	3.9	(0.0 - 7.8)	0.59	(0.09 - 1.29)	-
Kidney & other renal tract	6	6.6	(1.3 - 12.0)	0.73	(0.20 - 1.41)	-	5	5.7	(0.6 - 10.8)	1.02	(0.22 - 2.08)	-
Leukaemia	10	12.1	(4.6 - 19.7)	1.22	(0.50 - 2.09)	-	8	9.1	(2.7 - 15.5)	1.47	(0.52 - 2.66)	-
Pancreas	7	8.8	(2.1 - 15.4)	1.34	(0.42 - 2.51)	-	2	2.5	(0.0 - 6.0)	0.40	(0.01 - 1.12)	-
Urinary bladder	14	17.4	(8.1 - 26.6)	2.02	(1.00 - 3.20)	-	2	2.0	(0.0 - 5.0)	0.82	(0.01 - 2.28)	-*
Stomach	7	6.9	(1.8 - 12.1)	1.06	(0.33 - 1.97)	-	3	3.2	(0.0 - 7.0)	0.87	(0.07 - 2.03)	-*
Corpus uteri	0	-	-	-	-	.	11	12.5	(5.0 - 20.0)	1.32	(0.58 - 2.21)	-
Brain	2	2.0	(0.0 - 4.7)	0.37	(0.00 - 1.03)	-	3	3.3	(0.0 - 7.2)	0.84	(0.07 - 1.95)	-*
Lip	4	4.3	(0.0 - 8.6)	0.72	(0.11 - 1.59)	-	1	0.9	(0.0 - 2.8)	0.45	(0.00 - 1.66)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	8	8.3	(2.4 - 14.1)	1.12	(0.39 - 2.01)	-
Other lymphohaematopoietic	5	6.6	(0.8 - 12.5)	1.55	(0.34 - 3.18)	-*	1	1.2	(0.0 - 3.4)	0.40	(0.00 - 1.48)	-*
Oesophagus	2	2.3	(0.0 - 5.5)	0.48	(0.01 - 1.33)	-*	4	3.1	(0.1 - 6.2)	2.05	(0.32 - 4.48)	-*
Thyroid gland	9	9.0	(2.9 - 15.1)	4.12	(1.58 - 7.21)	^*	8	8.1	(2.4 - 13.8)	1.37	(0.48 - 2.48)	-
Myeloma/plasma cell tumours	6	6.6	(1.3 - 12.0)	1.93	(0.52 - 3.76)	-*	2	1.9	(0.0 - 4.5)	0.85	(0.01 - 2.37)	-*
Cervix uteri	0	-	-	-	-	.	12	12.5	(5.3 - 19.7)	1.72	(0.79 - 2.82)	-
Non-mel. skin (exc BCC/SCC)	3	3.3	(0.0 - 7.1)	0.92	(0.07 - 2.14)	-*	1	1.0	(0.0 - 2.9)	0.48	(0.00 - 1.79)	-*
Mesothelioma	1	1.4	(0.0 - 4.2)	0.26	(0.00 - 0.97)	V*	0	-	-	0	n/a	-
Liver & intrahepatic bile duct	6	8.1	(1.6 - 14.5)	2.03	(0.55 - 3.95)	-*	1	0.8	(0.0 - 2.3)	0.91	(0.00 - 3.35)	-*
Testis	5	5.1	(0.5 - 9.7)	0.89	(0.19 - 1.82)	-	0	-	-	-	-	.
Gallbladder & bile ducts	4	4.1	(0.0 - 8.1)	2.35	(0.36 - 5.15)	-*	1	0.9	(0.0 - 2.8)	0.61	(0.00 - 2.24)	-*
Larynx	5	5.7	(0.7 - 10.7)	1.55	(0.34 - 3.17)	-*	0	-	-	-	-	.
Tongue	2	2.8	(0.0 - 6.7)	0.96	(0.01 - 2.67)	-*	1	0.9	(0.0 - 2.6)	1.41	(0.00 - 5.21)	-*
Connective & soft tissues	1	1.4	(0.0 - 4.1)	0.59	(0.00 - 2.17)	-*	0	-	-	0	n/a	-
Tonsil & oropharynx	1	0.9	(0.0 - 2.8)	0.59	(0.00 - 2.18)	-*	1	0.7	(0.0 - 2.1)	2.83	(0.00 - 10.46)	-*
Vulva/vagina	0	-	-	-	-	.	2	1.9	(0.0 - 4.6)	1.18	(0.01 - 3.28)	-*
Small intestine	0	-	-	0	n/a	-	3	3.5	(0.0 - 7.5)	5.10	(0.41 - 11.91)	-*
Eye & lacrimal gland	1	1.2	(0.0 - 3.7)	0.97	(0.00 - 3.57)	-*	0	-	-	-	-	.
Major Salivary Gland	0	-	-	0	n/a	-	1	0.9	(0.0 - 2.8)	1.63	(0.00 - 6.03)	-*
Anus	1	1.4	(0.0 - 4.1)	1.69	(0.00 - 6.24)	-*	0	-	-	0	n/a	-
Mouth, other & unspecified	0	-	-	0	n/a	-	0	-	-	-	-	.
Floor of mouth	3	3.4	(0.0 - 7.2)	2.90	(0.23 - 6.77)	-*	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	0	n/a	-	1	1.3	(0.0 - 4.0)	1.47	(0.00 - 5.42)	-*
Pyriform sinus & hypopharynx	4	5.2	(0.1 - 10.3)	4.61	(0.71 - 10.10)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	0	-	-	-	-	.
Peritoneum & retroperitoneum	1	1.4	(0.0 - 4.2)	3.87	(0.00 - 14.29)	-*	0	-	-	0	n/a	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	1	1.0	(0.0 - 3.0)	2.75	(0.00 - 10.14)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	1	1.0	(0.0 - 3.0)	8.12	(0.00 - 29.95)	-*	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	286	339.3	(299.8 - 378.9)	1.00	(0.89 - 1.12)	-	242	248.5	(216.6 - 280.4)	0.96	(0.85 - 1.09)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Waroona (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	7	58.8	(13.7 - 103.9)	0.72	(0.22 - 1.33)	-
Colorectal cancer	7	52.0	(13.0 - 91.0)	1.12	(0.35 - 2.10)	-	3	25.3	(0.0 - 54.1)	0.72	(0.06 - 1.68)	-*
Prostate gland	11	75.7	(30.5 - 121.0)	1.06	(0.46 - 1.77)	-	0	-	-	-	-	.
Melanoma (skin)	8	56.9	(17.0 - 96.8)	1.52	(0.53 - 2.73)	-	1	9.6	(0.0 - 28.5)	0.29	(0.00 - 1.08)	-*
Lung, bronchus & trachea	3	21.1	(0.0 - 45.5)	0.54	(0.04 - 1.26)	-	1	4.7	(0.0 - 13.9)	0.40	(0.00 - 1.47)	-*
Lymphoma	0	-	-	0	n/a	-	2	18.0	(0.0 - 43.4)	1.55	(0.02 - 4.33)	-*
Unknown primary site	1	6.0	(0.0 - 17.8)	0.64	(0.00 - 2.38)	-*	1	7.3	(0.0 - 21.5)	0.96	(0.00 - 3.55)	-*
Kidney & other renal tract	3	21.2	(0.0 - 45.4)	2.37	(0.19 - 5.53)	-*	1	9.5	(0.0 - 28.0)	1.55	(0.00 - 5.72)	-*
Leukaemia	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pancreas	1	6.0	(0.0 - 17.8)	1.15	(0.00 - 4.24)	-*	0	-	-	0	n/a	-
Urinary bladder	2	12.3	(0.0 - 29.4)	1.56	(0.02 - 4.35)	-*	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	1	4.7	(0.0 - 13.9)	1.92	(0.00 - 7.09)	-*
Corpus uteri	0	-	-	-	-	.	1	10.7	(0.0 - 31.7)	0.90	(0.00 - 3.33)	-*
Brain	0	-	-	0	n/a	-	1	10.7	(0.0 - 31.7)	2.27	(0.00 - 8.39)	-*
Lip	1	9.2	(0.0 - 27.1)	1.40	(0.00 - 5.17)	-*	1	7.3	(0.0 - 21.5)	3.29	(0.00 - 12.13)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	1	9.5	(0.0 - 28.0)	1.04	(0.00 - 3.85)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	1	4.7	(0.0 - 13.9)	2.61	(0.00 - 9.62)	-*
Oesophagus	1	6.4	(0.0 - 18.9)	1.41	(0.00 - 5.20)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	7.3	(0.0 - 21.5)	1.73	(0.00 - 6.38)	-*
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	1	6.0	(0.0 - 17.8)	1.53	(0.00 - 5.63)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	12.9	(0.0 - 38.2)	2.12	(0.00 - 7.82)	-*	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	2	18.1	(0.0 - 43.1)	8.73	(0.11 - 24.33)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	2	14.3	(0.0 - 35.2)	8.90	(0.11 - 24.80)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	9.5	(0.0 - 28.0)	15.61	(0.00 - 57.58)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	1	21.1	(0.0 - 62.4)	36.28	(0.00 - 133.84)	-*
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	42	304.0	(211.0 - 396.9)	0.93	(0.65 - 1.23)	-	27	232.9	(139.6 - 326.3)	0.83	(0.52 - 1.17)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: West Arthur (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	67.2	(0.0 - 159.6)	0.75	(0.01 - 2.09)	-*
Colorectal cancer	2	46.1	(0.0 - 109.7)	1.11	(0.01 - 3.09)	-*	0	-	-	0	n/a	-
Prostate gland	3	77.9	(0.0 - 165.2)	1.00	(0.08 - 2.34)	-*	0	-	-	0	-	.
Melanoma (skin)	1	26.0	(0.0 - 76.7)	0.65	(0.00 - 2.40)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	1	32.8	(0.0 - 96.9)	0.63	(0.00 - 2.31)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	1	20.4	(0.0 - 60.0)	2.18	(0.00 - 8.05)	-*	1	35.1	(0.0 - 103.3)	3.71	(0.00 - 13.70)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	n/a	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	8	203.2	(62.4 - 344.0)	0.61	(0.21 - 1.10)	-	3	102.3	(0.0 - 217.1)	0.35	(0.03 - 0.81)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Westonia (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	2	176.1	(0.0 - 420.0)	4.19	(0.05 - 11.68)	^-*	0	-	-	-	-	.
Prostate gland	2	191.7	(0.0 - 459.9)	2.56	(0.03 - 7.14)	^-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	1	102.0	(0.0 - 300.0)	8.37	(0.00 - 30.88)	^-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	5	469.9	(60.8 - 879.0)	1.43	(0.31 - 2.93)	^-*	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wickepin (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	80.9	(0.0 - 192.5)	0.92	(0.01 - 2.57)	-*
Colorectal cancer	2	50.4	(0.0 - 119.9)	1.40	(0.02 - 3.90)	-*	0	-	-	0	n/a	-
Prostate gland	6	176.1	(25.3 - 326.8)	2.58	(0.70 - 5.02)	-*	0	-	-	-	-	.
Melanoma (skin)	3	176.8	(0.0 - 390.9)	2.42	(0.19 - 5.64)	-*	1	39.2	(0.0 - 115.7)	1.33	(0.00 - 4.89)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	1	41.7	(0.0 - 122.9)	4.91	(0.00 - 18.11)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	1	44.4	(0.0 - 131.1)	3.27	(0.00 - 12.05)	-*	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	1	41.7	(0.0 - 122.9)	10.76	(0.00 - 39.68)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	1	26.3	(0.0 - 77.2)	7.68	(0.00 - 28.33)	-*	0	-	-	-	-	.
Mesothelioma	1	26.3	(0.0 - 77.2)	6.67	(0.00 - 24.59)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	14	500.3	(208.2 - 792.5)	1.34	(0.66 - 2.13)	-	5	203.4	(27.5 - 379.4)	0.72	(0.16 - 1.48)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Williams (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	64.7	(0.0 - 164.4)	0.79	(0.01 - 2.20)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	1	29.0	(0.0 - 85.4)	0.40	(0.00 - 1.48)	-*	0	-	-	-	-	.
Melanoma (skin)	1	26.7	(0.0 - 78.8)	0.71	(0.00 - 2.63)	-*	1	42.9	(0.0 - 126.3)	1.14	(0.00 - 4.20)	-*
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	1	25.6	(0.0 - 75.8)	2.70	(0.00 - 9.98)	-*	1	37.4	(0.0 - 110.3)	4.13	(0.00 - 15.25)	-*
Kidney & other renal tract	0	-	-	-	-	.	1	34.8	(0.0 - 102.7)	6.54	(0.00 - 24.14)	-*
Leukaemia	0	-	-	-	-	.	1	35.7	(0.0 - 105.5)	6.09	(0.00 - 22.46)	-*
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	1	31.3	(0.0 - 92.3)	6.76	(0.00 - 24.92)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	1	34.5	(0.0 - 101.7)	33.79	(0.00 - 124.64)	-*	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	34.5	(0.0 - 101.7)	28.74	(0.00 - 106.00)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	6	181.5	(36.4 - 326.7)	0.54	(0.15 - 1.04)	-	6	215.4	(37.4 - 393.4)	0.76	(0.21 - 1.48)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wiluna (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	0	-	-	0	n/a	-	1	62.5	(0.0 - 184.4)	3.26	(0.00 - 12.03)	-*
Prostate gland	1	100.0	(0.0 - 292.7)	0.78	(0.00 - 2.89)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	1	133.3	(0.0 - 385.8)	13.45	(0.00 - 49.63)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	50.4	(0.0 - 148.8)	10.79	(0.00 - 39.80)	-*
Brain	0	-	-	-	-	.	1	81.6	(0.0 - 240.0)	21.37	(0.00 - 78.85)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	62.5	(0.0 - 184.4)	10.17	(0.00 - 37.51)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	100.0	(0.0 - 292.7)	0.14	(0.00 - 0.50)	V	5	390.4	(32.8 - 748.0)	1.61	(0.35 - 3.30)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wongan-Ballidu (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	43.7	(0.0 - 109.8)	0.53	(0.01 - 1.47)	-*
Colorectal cancer	4	77.4	(2.1 - 152.7)	1.97	(0.30 - 4.31)	-*	0	-	-	0	n/a	-
Prostate gland	6	122.0	(24.4 - 219.7)	1.84	(0.50 - 3.57)	-*	0	-	-	-	-	.
Melanoma (skin)	1	14.9	(0.0 - 44.0)	0.49	(0.00 - 1.79)	-*	3	53.4	(0.0 - 113.9)	2.14	(0.17 - 5.00)	-*
Lung, bronchus & trachea	4	88.8	(0.8 - 176.8)	2.27	(0.35 - 4.98)	-*	1	20.5	(0.0 - 60.6)	1.12	(0.00 - 4.12)	-*
Lymphoma	2	52.5	(0.0 - 127.5)	2.82	(0.04 - 7.84)	-*	0	-	-	-	-	.
Unknown primary site	2	44.0	(0.0 - 106.2)	4.00	(0.05 - 11.14)	-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	19.6	(0.0 - 57.9)	2.73	(0.00 - 10.09)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	1	9.7	(0.0 - 28.6)	5.79	(0.00 - 21.35)	-*
Lip	1	16.8	(0.0 - 49.6)	3.43	(0.00 - 12.65)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	9.6	(0.0 - 28.3)	2.80	(0.00 - 10.33)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	28.1	(0.0 - 83.0)	3.95	(0.00 - 14.58)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	1	25.2	(0.0 - 74.4)	3.66	(0.00 - 13.50)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	9.6	(0.0 - 28.3)	10.52	(0.00 - 38.83)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	20.5	(0.0 - 60.6)	44.37	(0.00 - 163.69)	-*
Floor of mouth	0	-	-	-	-	.	1	20.5	(0.0 - 60.6)	61.43	(0.00 - 226.62)	-*
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	22	461.1	(266.8 - 655.4)	1.42	(0.84 - 2.08)	-	12	215.6	(85.7 - 345.4)	0.97	(0.44 - 1.59)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Woodanilling (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	1	66.7	(0.0 - 196.2)	1.92	(0.00 - 7.07)	-*	0	-	-	-	-	.
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	66.7	(0.0 - 196.2)	0.26	(0.00 - 0.95)	V*	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wyalkatchem (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	165.5	(0.0 - 355.1)	1.48	(0.12 - 3.45)	-*
Colorectal cancer	0	-	-	0	n/a	-	2	66.6	(0.0 - 174.8)	2.39	(0.03 - 6.66)	-*
Prostate gland	2	63.0	(0.0 - 153.2)	0.86	(0.01 - 2.39)	-*	0	-	-	-	-	.
Melanoma (skin)	2	89.2	(0.0 - 219.4)	1.76	(0.02 - 4.91)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	1	40.3	(0.0 - 119.0)	0.82	(0.00 - 3.01)	-*	0	-	-	-	-	.
Lymphoma	1	29.2	(0.0 - 86.2)	2.44	(0.00 - 9.00)	-*	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	2	74.3	(0.0 - 176.9)	15.67	(0.20 - 43.64)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	1	12.5	(0.0 - 36.7)	6.45	(0.00 - 23.80)	-*
Urinary bladder	1	37.7	(0.0 - 111.0)	3.55	(0.00 - 13.09)	-*	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	92.9	(0.0 - 222.0)	10.06	(0.13 - 28.02)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	7	259.5	(60.1 - 458.9)	0.70	(0.22 - 1.31)	-	10	411.8	(137.4 - 686.2)	1.52	(0.63 - 2.61)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wyndham-East Kimberley (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	14	116.5	(48.5 - 184.5)	1.29	(0.64 - 2.06)	-
Colorectal cancer	3	24.3	(0.0 - 52.0)	0.50	(0.04 - 1.16)	-	3	33.4	(0.0 - 73.9)	0.95	(0.08 - 2.22)	-*
Prostate gland	4	37.4	(0.4 - 74.5)	0.43	(0.07 - 0.94)	V	0	-	-	-	-	.
Melanoma (skin)	8	36.4	(10.2 - 62.6)	1.10	(0.39 - 1.98)	-	5	23.2	(1.7 - 44.7)	1.08	(0.24 - 2.21)	-
Lung, bronchus & trachea	3	14.3	(0.0 - 30.6)	0.63	(0.05 - 1.46)	-	2	11.9	(0.0 - 29.2)	1.09	(0.01 - 3.04)	-*
Lymphoma	2	9.9	(0.0 - 23.9)	0.81	(0.01 - 2.27)	-*	2	12.6	(0.0 - 30.1)	1.60	(0.02 - 4.45)	-*
Unknown primary site	2	16.6	(0.0 - 43.1)	1.35	(0.02 - 3.77)	-*	1	6.3	(0.0 - 18.7)	1.35	(0.00 - 4.97)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Leukaemia	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Pancreas	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-	.
Stomach	1	3.9	(0.0 - 11.7)	0.95	(0.00 - 3.51)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Brain	1	4.5	(0.0 - 13.2)	0.97	(0.00 - 3.59)	-*	0	-	-	0	n/a	-
Lip	0	-	-	0	n/a	-	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	-	-	.	2	8.6	(0.0 - 20.5)	7.45	(0.09 - 20.76)	-*
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	0	n/a	-
Myeloma/plasma cell tumours	1	5.2	(0.0 - 15.3)	1.98	(0.00 - 7.30)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	7.9	(0.0 - 23.3)	7.34	(0.00 - 27.07)	-*
Testis	0	-	-	0	n/a	-	0	-	-	-	-	.
Gallbladder & bile ducts	1	5.2	(0.0 - 15.3)	3.65	(0.00 - 13.45)	-*	0	-	-	-	-	.
Larynx	2	15.4	(0.0 - 36.7)	3.68	(0.05 - 10.25)	-*	0	-	-	-	-	.
Tongue	4	29.6	(0.0 - 59.5)	10.12	(1.57 - 22.18)	^*	0	-	-	-	-	.
Connective & soft tissues	1	4.5	(0.0 - 13.2)	3.04	(0.00 - 11.20)	-*	0	-	-	-	-	.
Tonsil & oropharynx	2	11.3	(0.0 - 27.9)	6.37	(0.08 - 17.75)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	1	5.2	(0.0 - 15.3)	6.88	(0.00 - 25.38)	-*	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	1	6.6	(0.0 - 19.6)	15.44	(0.00 - 56.95)	-*
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	36	223.7	(145.6 - 301.8)	0.75	(0.51 - 1.02)	-	31	227.0	(137.5 - 316.5)	0.96	(0.62 - 1.32)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Yalgoo (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	0	n/a	-
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	1	62.5	(0.0 - 184.2)	14.09	(0.00 - 51.97)	-*	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	62.5	(0.0 - 184.2)	0.29	(0.00 - 1.07)	-*	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Yilgarn (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	71.6	(0.0 - 153.5)	0.85	(0.07 - 1.97)	-*
Colorectal cancer	3	84.5	(0.0 - 181.0)	1.30	(0.10 - 3.04)	-*	1	24.8	(0.0 - 73.4)	0.73	(0.00 - 2.71)	-*
Prostate gland	6	127.2	(25.1 - 229.2)	1.62	(0.44 - 3.16)	-*	0	-	-	-	-	.
Melanoma (skin)	2	28.6	(0.0 - 70.0)	0.80	(0.01 - 2.22)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	2	35.6	(0.0 - 84.9)	1.02	(0.01 - 2.85)	-*	1	24.8	(0.0 - 73.4)	1.26	(0.00 - 4.64)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	1	20.2	(0.0 - 59.7)	1.77	(0.00 - 6.54)	-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	0	n/a	-	1	20.4	(0.0 - 60.3)	4.43	(0.00 - 16.35)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	1	16.2	(0.0 - 47.8)	3.12	(0.00 - 11.50)	-*	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	25.0	(0.0 - 73.7)	2.44	(0.00 - 8.99)	-*	1	20.4	(0.0 - 60.3)	5.89	(0.00 - 21.72)	-*
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	16.2	(0.0 - 47.8)	3.85	(0.00 - 14.20)	-*	0	-	-	-	-	.
Thyroid gland	1	25.0	(0.0 - 73.7)	6.98	(0.00 - 25.74)	-*	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	9.4	(0.0 - 27.7)	8.80	(0.00 - 32.47)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	18.9	(0.0 - 55.7)	5.07	(0.00 - 18.71)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	19	397.2	(216.0 - 578.5)	1.07	(0.60 - 1.60)	-	8	171.6	(49.7 - 293.5)	0.69	(0.24 - 1.24)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: York (S) 1998-2002: Cancer incidence(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	10	68.8	(24.3 - 113.3)	0.94	(0.39 - 1.61)	-
Colorectal cancer	10	67.2	(24.1 - 110.3)	1.53	(0.63 - 2.61)	-	2	13.8	(0.0 - 33.3)	0.44	(0.01 - 1.24)	-*
Prostate gland	8	49.9	(14.6 - 85.2)	0.74	(0.26 - 1.33)	-	0	-	-	-	-	.
Melanoma (skin)	8	73.5	(15.4 - 131.6)	1.51	(0.53 - 2.72)	-	3	25.1	(0.0 - 55.0)	0.85	(0.07 - 1.98)	-*
Lung, bronchus & trachea	6	47.0	(9.4 - 84.6)	1.04	(0.28 - 2.02)	-	2	11.3	(0.0 - 28.7)	0.74	(0.01 - 2.06)	-*
Lymphoma	2	19.8	(0.0 - 47.8)	1.03	(0.01 - 2.86)	-*	1	18.2	(0.0 - 53.9)	0.74	(0.00 - 2.71)	-*
Unknown primary site	1	4.7	(0.0 - 13.8)	0.60	(0.00 - 2.20)	-*	0	-	-	0	n/a	-
Kidney & other renal tract	2	15.8	(0.0 - 37.8)	1.52	(0.02 - 4.24)	-*	0	-	-	0	n/a	-
Leukaemia	1	9.2	(0.0 - 27.3)	0.83	(0.00 - 3.08)	-*	1	10.3	(0.0 - 30.3)	1.41	(0.00 - 5.21)	-*
Pancreas	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Urinary bladder	0	-	-	0	n/a	-	2	11.7	(0.0 - 29.4)	4.74	(0.06 - 13.20)	-*
Stomach	1	9.2	(0.0 - 27.3)	0.85	(0.00 - 3.13)	-*	0	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	1	8.3	(0.0 - 24.6)	0.83	(0.00 - 3.05)	-*
Brain	0	-	-	0	n/a	-	1	5.4	(0.0 - 16.0)	2.19	(0.00 - 8.08)	-*
Lip	1	9.7	(0.0 - 28.7)	1.41	(0.00 - 5.22)	-*	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	7.1	(0.0 - 21.1)	0.97	(0.00 - 3.58)	-*
Other lymphohaematopoietic	1	7.1	(0.0 - 21.1)	1.47	(0.00 - 5.43)	-*	0	-	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	8.9	(0.0 - 26.4)	1.74	(0.00 - 6.42)	-*
Myeloma/plasma cell tumours	2	14.1	(0.0 - 33.5)	3.49	(0.04 - 9.72)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	2	11.7	(0.0 - 29.4)	2.69	(0.03 - 7.50)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mesothelioma	1	4.0	(0.0 - 11.7)	1.44	(0.00 - 5.31)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	1	22.1	(0.0 - 65.4)	2.28	(0.00 - 8.40)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	2.9	(0.0 - 8.7)	3.64	(0.00 - 13.42)	-*
Larynx	0	-	-	0	n/a	-	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	1	5.4	(0.0 - 16.0)	11.42	(0.00 - 42.13)	-*
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	1	7.1	(0.0 - 21.1)	9.28	(0.00 - 34.24)	-*
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	8.8	(0.0 - 25.9)	7.03	(0.00 - 25.95)	-*	1	7.1	(0.0 - 21.1)	65.55	(0.00 - 241.81)	-*
Nasal cavity, sinuses, int. ear	1	7.1	(0.0 - 21.1)	11.36	(0.00 - 41.89)	-*	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	47	369.2	(254.7 - 483.7)	1.00	(0.72 - 1.30)	-	31	223.5	(138.4 - 308.5)	0.89	(0.58 - 1.23)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Total State 1998-2002: Cancer incidence(1)

Cancer type	Males			Females		
	Cases	ASR	95% c.i.	Cases	ASR	95% c.i.
Breast	33	0.5	(0.3 - 0.7)	5171	83.7	(81.3 - 86.1)
Colorectal cancer	2822	45.1	(43.4 - 46.8)	2209	29.7	(28.4 - 31.1)
Prostate gland	4600	74.3	(72.1 - 76.5)	0	-	-
Melanoma (skin)	2548	42.7	(41.0 - 44.4)	1879	30.9	(29.4 - 32.3)
Lung, bronchus & trachea	2473	39.0	(37.4 - 40.6)	1320	18.2	(17.2 - 19.3)
Lymphoma	915	15.3	(14.3 - 16.4)	693	10.4	(9.6 - 11.2)
Unknown primary site	717	11.1	(10.3 - 12.0)	558	6.5	(5.9 - 7.1)
Kidney & other renal tract	590	9.6	(8.8 - 10.3)	342	5.3	(4.7 - 5.9)
Leukaemia	558	9.7	(8.9 - 10.6)	366	6.0	(5.3 - 6.7)
Pancreas	392	6.3	(5.6 - 6.9)	407	5.2	(4.6 - 5.7)
Urinary bladder	584	8.7	(8.0 - 9.5)	212	2.4	(2.1 - 2.8)
Stomach	511	8.0	(7.3 - 8.7)	277	3.6	(3.1 - 4.0)
Corpus uteri	0	-	-	581	8.9	(8.1 - 9.6)
Brain	341	6.2	(5.5 - 6.9)	237	3.7	(3.2 - 4.2)
Lip	347	5.8	(5.2 - 6.4)	162	2.2	(1.9 - 2.6)
Ovary & uterine adnexa	0	-	-	506	7.6	(6.9 - 8.4)
Other lymphohaematopoietic	278	4.1	(3.6 - 4.6)	208	2.4	(2.1 - 2.8)
Oesophagus	323	5.0	(4.5 - 5.6)	157	2.0	(1.7 - 2.4)
Thyroid gland	126	2.2	(1.8 - 2.6)	326	5.8	(5.1 - 6.4)
Myeloma/plasma cell tumours	242	3.8	(3.3 - 4.3)	183	2.4	(2.0 - 2.8)
Cervix uteri	0	-	-	407	6.7	(6.0 - 7.3)
Non-mel. skin (exc BCC/SCC)	251	3.8	(3.3 - 4.3)	149	2.0	(1.7 - 2.4)
Mesothelioma	294	4.7	(4.1 - 5.2)	44	0.6	(0.4 - 0.8)
Liver & intrahepatic bile duct	217	3.5	(3.0 - 4.0)	80	1.2	(0.9 - 1.5)
Testis	286	5.3	(4.7 - 5.9)	0	-	-
Gallbladder & bile ducts	129	2.0	(1.7 - 2.4)	138	1.7	(1.4 - 2.0)
Larynx	226	3.8	(3.3 - 4.3)	34	0.5	(0.3 - 0.7)
Tongue	136	2.3	(1.9 - 2.7)	52	0.7	(0.5 - 0.9)
Connective & soft tissues	106	2.0	(1.6 - 2.4)	66	1.2	(0.9 - 1.5)
Tonsil & oropharynx	110	1.8	(1.5 - 2.2)	24	0.4	(0.2 - 0.6)
Vulva/vagina	0	-	-	123	1.6	(1.3 - 2.0)
Small intestine	63	1.0	(0.8 - 1.3)	44	0.6	(0.4 - 0.8)
Eye & lacrimal gland	66	1.2	(0.9 - 1.5)	32	0.5	(0.3 - 0.7)
Major Salivary Gland	56	0.9	(0.7 - 1.1)	40	0.6	(0.4 - 0.9)
Anus	41	0.7	(0.5 - 0.9)	53	0.8	(0.5 - 1.0)
Mouth, other & unspecified	58	1.0	(0.7 - 1.2)	34	0.5	(0.3 - 0.7)
Floor of mouth	66	1.2	(0.9 - 1.5)	23	0.3	(0.2 - 0.4)
Bones, joints & articular cart.	35	0.7	(0.4 - 0.9)	39	0.8	(0.5 - 1.0)
Pyriform sinus & hypopharynx	62	1.0	(0.8 - 1.3)	7	0.1	(0.0 - 0.2)
Nasal cavity, sinuses, int. ear	41	0.7	(0.4 - 0.9)	16	0.2	(0.1 - 0.3)
Peritoneum & retroperitoneum	16	0.3	(0.1 - 0.4)	35	0.5	(0.3 - 0.7)
Adrenal & other endocrine	24	0.6	(0.3 - 0.8)	15	0.4	(0.2 - 0.6)
Nasopharynx	29	0.5	(0.3 - 0.7)	8	0.1	(0.0 - 0.2)
Pharynx, other & ill-def.	27	0.4	(0.3 - 0.6)	5	0.1	(0.0 - 0.2)
Penis & other male genital	32	0.5	(0.3 - 0.7)	0	-	-
Gum	15	0.3	(0.1 - 0.4)	13	0.1	(0.1 - 0.2)
Kaposi sarcoma	18	0.3	(0.1 - 0.4)	4	0.0	(0.0 - 0.1)
Thymus	8	0.1	(0.0 - 0.2)	8	0.1	(0.0 - 0.2)
Pleura, heart & mediastinum	6	0.1	(0.0 - 0.2)	6	0.1	(0.0 - 0.2)
Spinal cord & cranial nerves	7	0.2	(0.0 - 0.3)	5	0.1	(0.0 - 0.2)
Uterus, nos	0	-	-	11	0.2	(0.1 - 0.3)
Nervous, periph./autonomic	2	0.0	(0.0 - 0.1)	2	0.0	(0.0 - 0.1)
Placenta	0	-	-	2	0.0	(0.0 - 0.1)
Meninges (cerebral & spinal)	0	-	-	1	0.0	(0.0 - 0.0)
All cancers	20827	338.1	(333.4 - 342.7)	17314	260.1	(255.9 - 264.2)

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC;
SRRs not shown, as all are 1.00 by definition.

SLA: Albany (C) - Central 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	7	8.0 (0.8 - 15.2)	0.49	(0.15 - 0.92)	V
Colorectal cancer	21	29.2	(15.1 - 43.3)	1.42	(0.83 - 2.09)	-	18	16.3 (6.8 - 25.9)	1.32	(0.73 - 2.00)	-
Prostate gland	9	9.8	(2.7 - 17.0)	0.63	(0.24 - 1.11)	-	0	-	-	-	.
Melanoma (skin)	4	5.6	(0.0 - 11.9)	1.34	(0.21 - 2.93)	-*	3	4.1 (0.0 - 9.4)	1.54	(0.12 - 3.59)	-*
Lung, bronchus & trachea	26	42.8	(25.2 - 60.4)	0.93	(0.58 - 1.32)	-	15	17.4 (7.0 - 27.8)	0.99	(0.50 - 1.55)	-
Lymphoma	2	1.3	(0.0 - 3.0)	0.48	(0.01 - 1.34)	-*	4	5.5 (0.0 - 11.3)	0.89	(0.14 - 1.96)	-*
Unknown primary site	7	10.4	(1.8 - 19.1)	1.00	(0.32 - 1.87)	-	7	3.6 (0.7 - 6.4)	0.99	(0.31 - 1.85)	-
Kidney & other renal tract	4	4.8	(0.0 - 10.2)	1.37	(0.21 - 3.00)	-*	0	-	0	n/a	-
Leukaemia	4	3.1	(0.0 - 6.3)	0.87	(0.14 - 1.92)	-	4	1.6 (0.0 - 3.1)	1.31	(0.20 - 2.87)	-*
Pancreas	8	13.6	(3.5 - 23.6)	1.74	(0.61 - 3.14)	-	8	4.9 (0.5 - 9.4)	1.43	(0.50 - 2.58)	-
Urinary bladder	5	5.0	(0.0 - 10.2)	1.51	(0.33 - 3.10)	-*	2	0.8 (0.0 - 1.8)	1.23	(0.02 - 3.42)	-*
Stomach	6	9.4	(1.4 - 17.3)	1.21	(0.33 - 2.35)	-	1	0.3 (0.0 - 1.0)	0.32	(0.00 - 1.20)	-*
Corpus uteri	0	-	-	-	-	.	2	0.8 (0.0 - 2.0)	1.00	(0.01 - 2.79)	-*
Brain	3	5.0	(0.0 - 11.2)	0.97	(0.08 - 2.26)	-*	3	2.6 (0.0 - 5.9)	1.17	(0.09 - 2.73)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	4.1 (0.0 - 9.9)	0.46	(0.01 - 1.29)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	2	4.2 (0.0 - 10.1)	1.65	(0.02 - 4.58)	-*
Oesophagus	4	5.2	(0.0 - 10.6)	1.32	(0.20 - 2.90)	-*	2	1.9 (0.0 - 5.1)	1.05	(0.01 - 2.93)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	1	0.7	(0.0 - 2.0)	0.52	(0.00 - 1.92)	-*	1	2.0 (0.0 - 5.9)	0.55	(0.00 - 2.01)	-*
Cervix uteri	0	-	-	-	-	.	1	1.8 (0.0 - 5.3)	0.57	(0.00 - 2.09)	-*
Non-mel. skin (exc BCC/SCC)	1	0.7	(0.0 - 2.0)	1.81	(0.00 - 6.67)	-*	0	-	-	-	.
Mesothelioma	3	5.1	(0.0 - 11.3)	0.87	(0.07 - 2.04)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	1	1.3	(0.0 - 3.8)	0.44	(0.00 - 1.63)	-*	0	-	0	n/a	-
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	2	2.4	(0.0 - 6.1)	1.53	(0.02 - 4.26)	-*	1	0.3 (0.0 - 1.0)	0.61	(0.00 - 2.26)	-*
Larynx	0	-	-	0	n/a	-	0	-	-	-	.
Tongue	0	-	-	0	n/a	-	0	-	-	-	.
Connective & soft tissues	1	4.3	(0.0 - 12.6)	2.67	(0.00 - 9.85)	-*	0	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	1	0.7	(0.0 - 2.0)	2.30	(0.00 - 8.49)	-*	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	1	0.9	(0.0 - 2.6)	4.01	(0.00 - 14.78)	-*	0	-	-	-	.
Anus	1	0.7	(0.0 - 2.0)	6.08	(0.00 - 22.44)	-*	1	2.1 (0.0 - 6.3)	2.70	(0.00 - 9.96)	-*
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	1	0.5 (0.0 - 1.5)	9.39	(0.00 - 34.64)	-*
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	1	0.4 (0.0 - 1.1)	7.47	(0.00 - 27.55)	-*
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	115	157.6	(125.4 - 189.8)	0.99	(0.82 - 1.19)	-	87	83.7 (61.8 - 105.6)	0.91	(0.73 - 1.13)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Albany (C) Bal 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	8	18.0 (5.3 - 30.6)	1.11	(0.39 - 2.01)	-
Colorectal cancer	4	8.3	(0.1 - 16.5)	0.43	(0.07 - 0.95)	V	4	10.8 (0.1 - 21.5)	0.79	(0.12 - 1.72)	-
Prostate gland	6	14.3	(2.9 - 25.8)	0.88	(0.24 - 1.70)	-	0	-	-	-	-
Melanoma (skin)	2	4.0	(0.0 - 9.5)	1.04	(0.01 - 2.90)	-*	1	2.3 (0.0 - 6.7)	1.13	(0.00 - 4.15)	-*
Lung, bronchus & trachea	9	17.5	(6.0 - 29.1)	0.52	(0.20 - 0.90)	V	7	14.2 (3.6 - 24.7)	1.10	(0.35 - 2.06)	-
Lymphoma	2	3.8	(0.0 - 9.2)	0.77	(0.01 - 2.14)	-*	5	10.6 (1.3 - 20.0)	2.73	(0.59 - 5.59)	-*
Unknown primary site	3	5.0	(0.0 - 10.6)	0.73	(0.06 - 1.70)	-*	3	6.2 (0.0 - 13.2)	1.29	(0.10 - 3.02)	-*
Kidney & other renal tract	3	5.4	(0.0 - 11.5)	1.66	(0.13 - 3.86)	-*	1	1.9 (0.0 - 5.6)	1.35	(0.00 - 4.98)	-*
Leukaemia	3	5.6	(0.0 - 12.0)	1.08	(0.09 - 2.52)	-*	2	3.9 (0.0 - 9.3)	1.66	(0.02 - 4.62)	-*
Pancreas	0	-	-	0	n/a	-	3	6.5 (0.0 - 13.9)	1.50	(0.12 - 3.51)	-*
Urinary bladder	2	3.5	(0.0 - 8.5)	1.16	(0.01 - 3.22)	-*	2	3.3 (0.0 - 7.9)	4.22	(0.05 - 11.75)	-*
Stomach	0	-	-	0	n/a	-	0	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	0	-	0	n/a	-
Brain	2	3.7	(0.0 - 8.8)	0.81	(0.01 - 2.27)	-*	1	2.0 (0.0 - 6.1)	0.74	(0.00 - 2.74)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	2	5.0 (0.0 - 11.8)	1.06	(0.01 - 2.96)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	1	1.9 (0.0 - 5.6)	3.09	(0.00 - 11.39)	-*
Oesophagus	0	-	-	0	n/a	-	1	2.1 (0.0 - 6.2)	1.51	(0.00 - 5.56)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	1	2.2 (0.0 - 6.5)	1.53	(0.00 - 5.65)	-*
Cervix uteri	0	-	-	-	-	.	1	2.0 (0.0 - 6.1)	1.12	(0.00 - 4.14)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	0	n/a	-
Larynx	0	-	-	0	n/a	-	0	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-
Connective & soft tissues	1	4.3	(0.0 - 12.6)	3.88	(0.00 - 14.30)	-*	0	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-
Mouth, other & unspecified	1	1.9	(0.0 - 5.7)	5.01	(0.00 - 18.48)	-*	0	-	-	-	-
Floor of mouth	1	2.0	(0.0 - 6.0)	5.03	(0.00 - 18.54)	-*	0	-	-	-	-
Bones, joints & articular cart.	1	2.0	(0.0 - 5.8)	6.98	(0.00 - 25.74)	-*	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	1	1.8	(0.0 - 5.5)	7.80	(0.00 - 28.76)	-*	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	41	83.3	(57.3 - 109.3)	0.58	(0.41 - 0.78)	V	43	92.9 (64.8 - 121.0)	1.10	(0.78 - 1.45)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Armadale (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	27	15.9 (9.7 - 22.1)	0.96	(0.60 - 1.36)	-
Colorectal cancer	15	8.9 (4.4 - 13.5)	0.53	(0.27 - 0.83)	V		23	12.8 (7.3 - 18.3)	1.06	(0.64 - 1.54)	-
Prostate gland	17	10.0 (5.2 - 14.9)	0.80	(0.43 - 1.22)	-		0	-	-	-	.
Melanoma (skin)	7	4.3 (1.1 - 7.5)	1.15	(0.36 - 2.15)	-		6	3.7 (0.7 - 6.8)	1.67	(0.45 - 3.25)	-*
Lung, bronchus & trachea	53	33.8 (24.6 - 43.0)	1.00	(0.76 - 1.32)	-		34	17.5 (11.3 - 23.6)	1.33	(0.89 - 1.82)	-
Lymphoma	7	4.7 (1.2 - 8.1)	0.86	(0.27 - 1.60)	-		11	5.9 (2.2 - 9.7)	1.48	(0.64 - 2.47)	-
Unknown primary site	16	9.8 (5.0 - 14.7)	1.26	(0.66 - 1.95)	-		10	5.5 (2.0 - 9.1)	0.95	(0.39 - 1.62)	-
Kidney & other renal tract	6	3.7 (0.7 - 6.8)	1.06	(0.29 - 2.07)	-		10	5.2 (1.8 - 8.7)	3.22	(1.33 - 5.51)	^*
Leukaemia	9	5.9 (2.0 - 9.7)	1.02	(0.39 - 1.79)	-		3	2.7 (0.0 - 5.8)	0.58	(0.05 - 1.35)	-
Pancreas	10	6.2 (2.3 - 10.1)	1.07	(0.44 - 1.83)	-		8	4.2 (1.1 - 7.4)	0.94	(0.33 - 1.69)	-
Urinary bladder	6	3.8 (0.7 - 6.8)	1.13	(0.31 - 2.20)	-		1	0.4 (0.0 - 1.1)	0.45	(0.00 - 1.65)	-*
Stomach	8	5.5 (1.6 - 9.3)	0.85	(0.30 - 1.54)	-		6	3.8 (0.7 - 7.0)	1.27	(0.34 - 2.47)	-
Corpus uteri	0	-	-	-	-	.	1	0.3 (0.0 - 0.9)	0.32	(0.00 - 1.19)	-*
Brain	5	3.3 (0.3 - 6.3)	0.64	(0.14 - 1.31)	-		4	2.1 (0.0 - 4.1)	0.77	(0.12 - 1.69)	-
Lip	0	-	-	-	-	.	1	0.3 (0.0 - 0.9)	11.75	(0.00 - 43.35)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	7	4.0 (0.9 - 7.0)	0.93	(0.29 - 1.73)	-
Other lymphohaematopoietic	3	2.2 (0.0 - 4.8)	1.12	(0.09 - 2.62)	-*		1	0.8 (0.0 - 2.4)	0.61	(0.00 - 2.26)	-*
Oesophagus	6	3.5 (0.7 - 6.3)	1.02	(0.28 - 1.99)	-		4	1.8 (0.0 - 3.7)	1.38	(0.21 - 3.03)	-*
Thyroid gland	1	0.8 (0.0 - 2.2)	2.72	(0.00 - 10.02)	-*		0	-	0	n/a	-
Myeloma/plasma cell tumours	6	3.9 (0.7 - 7.0)	1.77	(0.48 - 3.45)	-*		0	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	9	5.9 (2.0 - 9.8)	2.58	(0.99 - 4.52)	-*
Non-mel. skin (exc BCC/SCC)	1	0.6 (0.0 - 1.9)	1.12	(0.00 - 4.12)	-*		0	-	-	-	.
Mesothelioma	1	0.8 (0.0 - 2.2)	0.15	(0.00 - 0.54)	V		0	-	0	n/a	-
Liver & intrahepatic bile duct	2	1.3 (0.0 - 3.0)	0.42	(0.01 - 1.18)	-		2	1.1 (0.0 - 2.7)	1.20	(0.02 - 3.35)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	3	1.7 (0.0 - 3.6)	1.23	(0.10 - 2.88)	-*		1	0.4 (0.0 - 1.1)	0.40	(0.00 - 1.49)	-*
Larynx	0	-	-	0	n/a	-	0	-	-	-	.
Tongue	0	-	-	0	n/a	-	1	0.6 (0.0 - 1.7)	1.74	(0.00 - 6.42)	-*
Connective & soft tissues	1	0.6 (0.0 - 1.7)	1.14	(0.00 - 4.20)	-*		1	0.8 (0.0 - 2.5)	1.59	(0.00 - 5.87)	-*
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	0	n/a	-
Small intestine	0	-	-	0	n/a	-	2	1.4 (0.0 - 3.2)	3.37	(0.04 - 9.38)	-*
Eye & lacrimal gland	1	0.5 (0.0 - 1.5)	2.07	(0.00 - 7.64)	-*		0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	1	0.6 (0.0 - 1.9)	2.85	(0.00 - 10.51)	-*		0	-	0	n/a	-
Mouth, other & unspecified	0	-	-	0	n/a	-	1	0.5 (0.0 - 1.6)	2.17	(0.00 - 7.99)	-*
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	1	0.8 (0.0 - 2.2)	0.99	(0.00 - 3.64)	-*		0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	1	0.4 (0.0 - 1.1)	7.50	(0.00 - 27.68)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	0	n/a	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	1	0.7 (0.0 - 2.2)	11.08	(0.00 - 40.87)	-*		0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	1	0.6 (0.0 - 1.8)	5.62	(0.00 - 20.72)	-*
Pleura, heart & mediastinum	1	0.9 (0.0 - 2.6)	3.83	(0.00 - 14.15)	-*		0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	188	118.7 (101.6 - 135.9)	0.87	(0.75 - 1.01)	-		177	99.1 (83.8 - 114.3)	1.10	(0.94 - 1.27)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Ashburton (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	71.5 (0.0 - 169.6)	1.63	(0.02 - 4.55)	-*
Colorectal cancer	1	7.9	(0.0 - 23.4)	0.73	(0.00 - 2.68)	-*	0	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-
Melanoma (skin)	0	-	-	-	-	.	1	5.1 (0.0 - 15.1)	5.76	(0.00 - 21.24)	-*
Lung, bronchus & trachea	1	26.3	(0.0 - 77.7)	0.44	(0.00 - 1.62)	-*	1	5.5 (0.0 - 16.2)	1.39	(0.00 - 5.14)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-
Unknown primary site	0	-	-	0	n/a	-	0	-	-	-	-
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-
Leukaemia	0	-	-	-	-	.	0	-	-	-	-
Pancreas	0	-	-	-	-	.	0	-	-	-	-
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-
Stomach	1	2.9	(0.0 - 8.6)	2.20	(0.00 - 8.11)	-*	0	-	-	-	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-
Brain	0	-	-	0	n/a	-	1	8.0 (0.0 - 23.7)	3.97	(0.00 - 14.65)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-
Oesophagus	0	-	-	-	-	.	0	-	-	-	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-
Mesothelioma	1	26.3	(0.0 - 77.7)	3.13	(0.00 - 11.56)	-*	0	-	-	-	-
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-
Larynx	0	-	-	-	-	.	0	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	1	34.5 (0.0 - 100.9)	256.74	(0.00 - 947.10)	-*
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	4	63.5	(0.0 - 137.6)	0.38	(0.06 - 0.84)	V	6	124.6 (5.6 - 243.6)	1.11	(0.30 - 2.16)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Augusta-Margaret River (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	12.2 (0.0 - 24.4)	0.74	(0.11 - 1.63)	-
Colorectal cancer	7	19.5 (3.8 - 35.2)	1.08	(0.34 - 2.02)	-		3	10.2 (0.0 - 21.9)	0.67	(0.05 - 1.58)	-*
Prostate gland	7	15.4 (2.9 - 27.9)	1.25	(0.39 - 2.33)	-		0	-	-	-	.
Melanoma (skin)	1	1.5 (0.0 - 4.5)	0.73	(0.00 - 2.68)	-*		1	1.3 (0.0 - 3.7)	1.39	(0.00 - 5.13)	-*
Lung, bronchus & trachea	7	20.1 (4.4 - 35.7)	0.58	(0.18 - 1.08)	-		7	14.6 (2.7 - 26.6)	1.38	(0.44 - 2.58)	-
Lymphoma	1	2.5 (0.0 - 7.3)	0.54	(0.00 - 1.99)	-*		1	2.9 (0.0 - 8.7)	0.67	(0.00 - 2.46)	-*
Unknown primary site	2	5.1 (0.0 - 12.2)	0.67	(0.01 - 1.86)	-*		2	3.8 (0.0 - 9.2)	0.90	(0.01 - 2.50)	-*
Kidney & other renal tract	1	2.6 (0.0 - 7.8)	0.78	(0.00 - 2.89)	-*		0	-	0	n/a	-
Leukaemia	2	4.2 (0.0 - 10.1)	0.99	(0.01 - 2.76)	-*		0	-	0	n/a	-
Pancreas	3	7.9 (0.0 - 17.1)	1.44	(0.12 - 3.37)	-*		0	-	0	n/a	-
Urinary bladder	2	5.3 (0.0 - 13.2)	1.49	(0.02 - 4.15)	-*		0	-	-	-	.
Stomach	2	3.4 (0.0 - 8.1)	0.92	(0.01 - 2.57)	-*		1	1.4 (0.0 - 4.2)	1.01	(0.00 - 3.71)	-*
Corpus uteri	0	-	-	-	-	.	1	1.3 (0.0 - 3.7)	1.58	(0.00 - 5.84)	-*
Brain	2	5.4 (0.0 - 13.6)	1.25	(0.02 - 3.48)	-*		0	-	0	n/a	-
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	0	n/a	-
Other lymphohaematopoietic	1	2.6 (0.0 - 7.8)	1.47	(0.00 - 5.41)	-*		1	1.4 (0.0 - 4.2)	2.78	(0.00 - 10.24)	-*
Oesophagus	2	5.3 (0.0 - 13.2)	1.51	(0.02 - 4.20)	-*		0	-	0	n/a	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	2	4.2 (0.0 - 10.1)	2.47	(0.03 - 6.87)	-*		0	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	1	2.7 (0.0 - 8.0)	1.44	(0.00 - 5.32)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	1	2.5 (0.0 - 7.3)	0.66	(0.00 - 2.44)	-*		0	-	-	-	.
Liver & intrahepatic bile duct	2	4.2 (0.0 - 10.1)	1.94	(0.02 - 5.40)	-*		0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	1	3.8 (0.0 - 11.1)	1.79	(0.00 - 6.61)	-*		0	-	0	n/a	-
Larynx	1	3.8 (0.0 - 11.1)	2.25	(0.00 - 8.30)	-*		0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	1	1.9 (0.0 - 5.5)	4.66	(0.00 - 17.19)	-*		0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	1	1.5 (0.0 - 4.5)	9.11	(0.00 - 33.61)	-*		0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	49	122.5 (86.1 - 159.0)	0.98	(0.71 - 1.27)	-		22	51.9 (28.6 - 75.3)	0.68	(0.40 - 0.99)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Bassendean (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	11	20.2 (7.7 - 32.7)	1.15	(0.50 - 1.92)	-
Colorectal cancer	6	8.9 (1.6 - 16.1)	0.61	(0.16 - 1.19)	-	8	9.5 (2.4 - 16.5)	0.97	(0.34 - 1.74)	-	
Prostate gland	6	10.3 (1.9 - 18.6)	0.73	(0.20 - 1.43)	-	0	-	-	-	-	
Melanoma (skin)	4	5.2 (0.0 - 10.4)	1.95	(0.30 - 4.28)	-*	2	4.4 (0.0 - 10.5)	1.57	(0.02 - 4.36)	-*	
Lung, bronchus & trachea	26	48.0 (29.0 - 67.0)	1.39	(0.87 - 1.98)	-	12	19.3 (7.5 - 31.1)	1.24	(0.57 - 2.04)	-	
Lymphoma	4	8.2 (0.0 - 16.7)	1.43	(0.22 - 3.13)	-*	5	9.0 (0.7 - 17.4)	1.77	(0.39 - 3.63)	-*	
Unknown primary site	8	17.2 (5.2 - 29.2)	1.78	(0.63 - 3.21)	-*	2	2.3 (0.0 - 5.5)	0.49	(0.01 - 1.36)	-*	
Kidney & other renal tract	3	4.1 (0.0 - 8.7)	1.55	(0.13 - 3.62)	-*	2	1.5 (0.0 - 3.7)	1.65	(0.02 - 4.60)	-*	
Leukaemia	4	5.6 (0.0 - 11.4)	1.33	(0.21 - 2.90)	-*	1	0.9 (0.0 - 2.6)	0.53	(0.00 - 1.95)	-*	
Pancreas	4	6.9 (0.0 - 14.0)	1.26	(0.19 - 2.76)	-*	11	13.0 (4.5 - 21.4)	3.28	(1.43 - 5.49)	^*	
Urinary bladder	3	5.7 (0.0 - 12.2)	1.51	(0.12 - 3.52)	-*	0	-	0	n/a	-	
Stomach	2	2.9 (0.0 - 7.0)	0.61	(0.01 - 1.70)	-*	1	2.2 (0.0 - 6.5)	0.54	(0.00 - 2.00)	-*	
Corpus uteri	0	-	-	-	-	2	2.3 (0.0 - 5.5)	1.66	(0.02 - 4.62)	-*	
Brain	3	7.4 (0.0 - 15.8)	1.26	(0.10 - 2.94)	-*	3	5.9 (0.0 - 12.8)	1.71	(0.14 - 3.98)	-*	
Lip	0	-	-	-	-	0	-	-	-	-	
Ovary & uterine adnexa	0	-	-	-	-	3	4.1 (0.0 - 9.1)	1.08	(0.09 - 2.53)	-*	
Other lymphohaematopoietic	2	3.3 (0.0 - 8.1)	1.99	(0.02 - 5.54)	-*	2	6.6 (0.0 - 15.9)	3.05	(0.04 - 8.51)	-*	
Oesophagus	3	5.6 (0.0 - 12.1)	1.48	(0.12 - 3.46)	-*	0	-	0	n/a	-	
Thyroid gland	0	-	-	-	-	0	-	-	-	-	
Myeloma/plasma cell tumours	1	1.2 (0.0 - 3.4)	0.83	(0.00 - 3.05)	-*	3	4.1 (0.0 - 9.3)	2.72	(0.22 - 6.35)	-*	
Cervix uteri	0	-	-	-	-	1	2.4 (0.0 - 7.2)	0.82	(0.00 - 3.03)	-*	
Non-mel. skin (exc BCC/SCC)	1	2.7 (0.0 - 7.9)	2.95	(0.00 - 10.90)	-*	0	-	-	-	-	
Mesothelioma	4	7.5 (0.0 - 15.0)	1.71	(0.26 - 3.75)	-*	1	2.4 (0.0 - 7.2)	3.07	(0.00 - 11.32)	-*	
Liver & intrahepatic bile duct	1	2.7 (0.0 - 7.9)	0.63	(0.00 - 2.31)	-*	1	2.0 (0.0 - 5.9)	1.62	(0.00 - 5.98)	-*	
Testis	0	-	-	-	-	0	-	-	-	-	
Gallbladder & bile ducts	1	2.7 (0.0 - 7.9)	1.18	(0.00 - 4.36)	-*	1	2.4 (0.0 - 7.2)	1.03	(0.00 - 3.80)	-*	
Larynx	0	-	-	0	n/a	-	-	-	-	-	
Tongue	0	-	-	-	-	0	-	-	-	-	
Connective & soft tissues	1	2.2 (0.0 - 6.4)	3.73	(0.00 - 13.76)	-*	2	2.8 (0.0 - 6.6)	9.17	(0.11 - 25.55)	-*	
Tonsil & oropharynx	0	-	-	-	-	0	-	-	-	-	
Vulva/vagina	0	-	-	-	-	1	0.9 (0.0 - 2.7)	3.88	(0.00 - 14.30)	-*	
Small intestine	0	-	-	-	-	1	0.9 (0.0 - 2.7)	4.69	(0.00 - 17.30)	-*	
Eye & lacrimal gland	0	-	-	-	-	0	-	-	-	-	
Major Salivary Gland	1	2.7 (0.0 - 7.9)	6.38	(0.00 - 23.53)	-*	0	-	-	-	-	
Anus	0	-	-	-	-	1	2.3 (0.0 - 6.9)	4.32	(0.00 - 15.95)	-*	
Mouth, other & unspecified	0	-	-	-	-	0	-	-	-	-	
Floor of mouth	0	-	-	-	-	0	-	-	-	-	
Bones, joints & articular cart.	0	-	-	-	-	1	4.1 (0.0 - 12.2)	9.68	(0.00 - 35.73)	-*	
Pyriform sinus & hypopharynx	1	2.2 (0.0 - 6.4)	2.92	(0.00 - 10.76)	-*	0	-	-	-	-	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	0	-	-	-	-	
Peritoneum & retroperitoneum	0	-	-	-	-	0	-	-	-	-	
Adrenal & other endocrine	1	2.7 (0.0 - 7.9)	13.79	(0.00 - 50.87)	-*	0	-	-	-	-	
Nasopharynx	1	2.3 (0.0 - 6.9)	9.32	(0.00 - 34.37)	-*	0	-	-	-	-	
Pharynx, other & ill-def.	0	-	-	-	-	0	-	-	-	-	
Penis & other male genital	0	-	-	-	-	0	-	-	-	-	
Gum	0	-	-	-	-	0	-	-	-	-	
Kaposi sarcoma	0	-	-	-	-	0	-	-	-	-	
Thymus	0	-	-	-	-	0	-	-	-	-	
Pleura, heart & mediastinum	0	-	-	-	-	0	-	-	-	-	
Spinal cord & cranial nerves	0	-	-	-	-	0	-	-	-	-	
Uterus, nos	0	-	-	-	-	0	-	-	-	-	
Nervous, periph./autonomic	0	-	-	-	-	0	-	-	-	-	
Placenta	0	-	-	-	-	0	-	-	-	-	
Meninges (cerebral & spinal)	0	-	-	-	-	0	-	-	-	-	
All cancers	91	167.9 (132.3 - 203.6)	1.20	(0.97 - 1.48)	-	78	125.6 (94.9 - 156.4)	1.30	(1.03 - 1.63)	^	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Bayswater (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	46	19.6 (13.4 - 25.8)	1.16	(0.83 - 1.52)	-
Colorectal cancer	35	15.0	(9.8 - 20.2)	0.84	(0.56 - 1.14)	-	30	10.6 (6.2 - 14.9)	0.85	(0.55 - 1.18)	-
Prostate gland	23	9.6	(5.5 - 13.7)	0.64	(0.38 - 0.92)	V	0	-	-	-	.
Melanoma (skin)	7	3.7	(0.9 - 6.5)	0.80	(0.25 - 1.49)	-	5	2.0 (0.1 - 3.9)	0.94	(0.20 - 1.92)	-
Lung, bronchus & trachea	81	33.2	(25.6 - 40.7)	1.03	(0.82 - 1.29)	-	37	10.7 (6.8 - 14.7)	0.94	(0.64 - 1.27)	-
Lymphoma	9	3.4	(1.1 - 5.7)	0.76	(0.29 - 1.32)	-	12	4.3 (1.6 - 6.9)	1.03	(0.47 - 1.69)	-
Unknown primary site	16	6.2	(3.0 - 9.4)	0.83	(0.44 - 1.29)	-	22	6.4 (3.3 - 9.5)	1.22	(0.72 - 1.78)	-
Kidney & other renal tract	7	2.7	(0.6 - 4.9)	0.85	(0.27 - 1.58)	-	5	1.6 (0.0 - 3.2)	0.99	(0.22 - 2.03)	-
Leukaemia	13	5.2	(2.2 - 8.2)	1.01	(0.48 - 1.63)	-	7	2.1 (0.3 - 3.8)	0.86	(0.27 - 1.60)	-
Pancreas	18	7.9	(4.1 - 11.7)	1.35	(0.74 - 2.04)	-	16	3.8 (1.7 - 5.8)	1.13	(0.59 - 1.75)	-
Urinary bladder	6	2.4	(0.4 - 4.4)	0.70	(0.19 - 1.35)	-	6	1.8 (0.2 - 3.4)	1.48	(0.40 - 2.89)	-*
Stomach	16	7.5	(3.8 - 11.3)	1.15	(0.60 - 1.77)	-	15	5.6 (2.4 - 8.7)	1.90	(0.97 - 2.98)	-
Corpus uteri	0	-	-	-	-	.	12	5.4 (2.1 - 8.7)	2.37	(1.08 - 3.89)	^
Brain	8	4.6	(1.0 - 8.2)	0.81	(0.28 - 1.45)	-	9	3.0 (0.8 - 5.3)	1.28	(0.49 - 2.24)	-
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	9	2.9 (0.7 - 5.1)	0.78	(0.30 - 1.37)	-
Other lymphohaematopoietic	2	0.7	(0.0 - 1.7)	0.45	(0.01 - 1.26)	-*	4	0.6 (0.0 - 1.2)	1.31	(0.20 - 2.88)	-*
Oesophagus	8	3.8	(1.1 - 6.5)	0.93	(0.33 - 1.68)	-	5	1.5 (0.0 - 3.1)	1.03	(0.23 - 2.12)	-
Thyroid gland	0	-	-	0	n/a	-	0	-	0	n/a	-
Myeloma/plasma cell tumours	0	-	-	0	n/a	V	7	2.5 (0.5 - 4.4)	1.50	(0.47 - 2.80)	-
Cervix uteri	0	-	-	-	-	.	5	2.2 (0.2 - 4.2)	1.01	(0.22 - 2.06)	-
Non-mel. skin (exc BCC/SCC)	2	0.8	(0.0 - 2.1)	1.38	(0.02 - 3.83)	-*	0	-	0	n/a	-
Mesothelioma	11	4.2	(1.6 - 6.8)	1.11	(0.49 - 1.86)	-	3	1.1 (0.0 - 2.5)	2.31	(0.19 - 5.39)	-*
Liver & intrahepatic bile duct	6	2.7	(0.5 - 5.0)	0.90	(0.24 - 1.75)	-	1	0.2 (0.0 - 0.5)	0.39	(0.00 - 1.45)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	3	0.9	(0.0 - 2.0)	0.83	(0.07 - 1.93)	-*	2	1.0 (0.0 - 2.3)	0.49	(0.01 - 1.36)	-*
Larynx	3	1.6	(0.0 - 3.5)	1.04	(0.08 - 2.42)	-*	0	-	-	-	.
Tongue	3	1.7	(0.0 - 3.6)	1.72	(0.14 - 4.02)	-*	0	-	0	n/a	-
Connective & soft tissues	0	-	-	0	n/a	-	0	-	0	n/a	-
Tonsil & oropharynx	5	2.6	(0.3 - 4.9)	3.21	(0.70 - 6.58)	-*	2	0.6 (0.0 - 1.5)	8.82	(0.11 - 24.57)	-*
Vulva/vagina	0	-	-	-	-	.	2	0.4 (0.0 - 0.9)	1.77	(0.02 - 4.94)	-*
Small intestine	2	0.6	(0.0 - 1.3)	1.61	(0.02 - 4.49)	-*	1	0.6 (0.0 - 1.7)	1.15	(0.00 - 4.23)	-*
Eye & lacrimal gland	2	0.9	(0.0 - 2.2)	3.06	(0.04 - 8.53)	-*	0	-	0	n/a	-
Major Salivary Gland	0	-	-	0	n/a	-	0	-	-	-	.
Anus	1	0.6	(0.0 - 1.9)	2.04	(0.00 - 7.51)	-*	1	0.2 (0.0 - 0.5)	1.00	(0.00 - 3.70)	-*
Mouth, other & unspecified	2	1.2	(0.0 - 2.8)	2.42	(0.03 - 6.73)	-*	0	-	0	n/a	-
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	.
Bones, joints & articular cart.	1	0.5	(0.0 - 1.5)	1.57	(0.00 - 5.78)	-*	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	1	0.6	(0.0 - 1.7)	1.80	(0.00 - 6.65)	-*	2	1.0 (0.0 - 2.3)	2.39	(0.03 - 6.65)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	1	0.2 (0.0 - 0.6)	3.75	(0.00 - 13.83)	-*
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	291	125.0	(110.0 - 140.0)	0.90	(0.80 - 1.02)	-	268	92.1 (79.6 - 104.6)	1.07	(0.94 - 1.20)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Belmont (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	21	15.4 (8.0 - 22.8)	0.97	(0.56 - 1.43)	-
Colorectal cancer	31	23.5	(14.7 - 32.4)	1.31	(0.86 - 1.82)	-	19	12.1 (5.8 - 18.5)	0.97	(0.54 - 1.45)	-
Prostate gland	17	13.0	(6.5 - 19.6)	0.84	(0.45 - 1.28)	-	0	-	-	-	.
Melanoma (skin)	6	5.2	(0.9 - 9.6)	1.24	(0.34 - 2.41)	-	2	1.5 (0.0 - 3.6)	0.68	(0.01 - 1.89)	-*
Lung, bronchus & trachea	64	44.3	(32.7 - 55.9)	1.42	(1.10 - 1.83)	^	20	10.2 (5.1 - 15.3)	0.88	(0.51 - 1.31)	-
Lymphoma	13	8.5	(3.5 - 13.4)	1.95	(0.93 - 3.14)	-	7	4.5 (0.8 - 8.2)	1.05	(0.33 - 1.97)	-
Unknown primary site	11	7.7	(2.9 - 12.6)	1.01	(0.44 - 1.69)	-	10	5.2 (1.5 - 8.9)	1.02	(0.42 - 1.74)	-
Kidney & other renal tract	3	1.7	(0.0 - 3.7)	0.65	(0.05 - 1.51)	-	0	-	0	n/a	-
Leukaemia	8	7.2	(2.0 - 12.4)	1.11	(0.39 - 2.00)	-	8	6.2 (1.5 - 10.8)	1.79	(0.63 - 3.23)	-*
Pancreas	7	4.8	(1.0 - 8.7)	0.93	(0.29 - 1.74)	-	8	4.4 (1.0 - 7.8)	1.00	(0.35 - 1.79)	-
Urinary bladder	4	2.8	(0.0 - 5.6)	0.82	(0.13 - 1.80)	-	2	1.2 (0.0 - 3.0)	0.89	(0.01 - 2.49)	-*
Stomach	10	6.2	(2.2 - 10.2)	1.27	(0.52 - 2.17)	-	6	3.8 (0.2 - 7.4)	1.37	(0.37 - 2.66)	-*
Corpus uteri	0	-	-	-	-	.	2	1.3 (0.0 - 3.4)	0.69	(0.01 - 1.93)	-*
Brain	5	5.2	(0.0 - 10.5)	0.94	(0.20 - 1.92)	-	2	0.9 (0.0 - 2.2)	0.50	(0.01 - 1.40)	-*
Lip	1	1.1	(0.0 - 3.2)	11.44	(0.00 - 42.21)	-*	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	4	2.9 (0.0 - 6.0)	0.62	(0.10 - 1.35)	-
Other lymphohaematopoietic	4	3.0	(0.0 - 6.1)	1.63	(0.25 - 3.57)	-*	2	0.6 (0.0 - 1.5)	1.24	(0.02 - 3.45)	-*
Oesophagus	9	7.2	(2.2 - 12.1)	1.85	(0.71 - 3.24)	-	3	1.8 (0.0 - 3.9)	1.11	(0.09 - 2.59)	-*
Thyroid gland	1	0.9	(0.0 - 2.8)	3.19	(0.00 - 11.75)	-*	2	0.6 (0.0 - 1.4)	3.05	(0.04 - 8.51)	-*
Myeloma/plasma cell tumours	2	1.6	(0.0 - 4.0)	0.68	(0.01 - 1.91)	-*	1	0.6 (0.0 - 1.8)	0.38	(0.00 - 1.41)	-*
Cervix uteri	0	-	-	-	-	.	0	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	1	0.5	(0.0 - 1.3)	1.21	(0.00 - 4.45)	-*	0	-	-	-	.
Mesothelioma	4	4.0	(0.0 - 8.0)	0.71	(0.11 - 1.57)	-	1	0.6 (0.0 - 1.8)	1.33	(0.00 - 4.92)	-*
Liver & intrahepatic bile duct	7	5.9	(1.3 - 10.5)	1.85	(0.58 - 3.45)	-*	3	1.6 (0.0 - 3.8)	2.08	(0.17 - 4.86)	-*
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	1	0.5	(0.0 - 1.3)	0.49	(0.00 - 1.81)	-*	3	2.0 (0.0 - 4.5)	1.30	(0.11 - 3.04)	-*
Larynx	2	1.1	(0.0 - 2.7)	1.22	(0.02 - 3.39)	-*	1	0.9 (0.0 - 2.6)	4.08	(0.00 - 15.05)	-*
Tongue	0	-	-	0	n/a	-	3	3.1 (0.0 - 6.6)	6.35	(0.51 - 14.82)	-*
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	.
Tonsil & oropharynx	2	2.2	(0.0 - 5.2)	2.36	(0.03 - 6.58)	-*	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	0	n/a	-
Small intestine	0	-	-	0	n/a	-	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	1	0.4	(0.0 - 1.3)	2.65	(0.00 - 9.78)	-*	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	0	n/a	-
Mouth, other & unspecified	0	-	-	-	-	.	1	0.9 (0.0 - 2.6)	2.50	(0.00 - 9.21)	-*
Floor of mouth	1	1.1	(0.0 - 3.4)	2.33	(0.00 - 8.59)	-*	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	1	1.1	(0.0 - 3.3)	1.22	(0.00 - 4.52)	-*	0	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.5	(0.0 - 1.3)	3.51	(0.00 - 12.96)	-*	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	1.1 (0.0 - 3.4)	2.08	(0.00 - 7.67)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	1	1.1 (0.0 - 3.4)	7.53	(0.00 - 27.78)	-*
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	1	1.0 (0.0 - 3.1)	15.93	(0.00 - 58.77)	-*
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	217	161.2	(138.3 - 184.1)	1.19	(1.04 - 1.37)	^	135	86.7 (70.1 - 103.2)	0.96	(0.81 - 1.14)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Beverley (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	0	n/a	-
Colorectal cancer	0	-	-	0	n/a	-	1	5.9 (0.0 - 17.3)	0.97	(0.00 - 3.56)	-*
Prostate gland	1	9.3 (0.0 - 27.6)	0.76	(0.00 - 2.82)	-*	0	-	-	-	-	.
Melanoma (skin)	1	12.3 (0.0 - 36.5)	3.19	(0.00 - 11.76)	-*	0	-	-	-	-	.
Lung, bronchus & trachea	1	9.3 (0.0 - 27.6)	0.34	(0.00 - 1.27)	-*	0	-	0	n/a	-	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	1	14.1 (0.0 - 41.6)	1.42	(0.00 - 5.24)	-*	0	-	0	n/a	-	-
Kidney & other renal tract	0	-	-	-	-	.	1	10.2 (0.0 - 30.1)	6.82	(0.00 - 25.14)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	1	12.3 (0.0 - 36.5)	2.02	(0.00 - 7.46)	-*	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	0	n/a	-	1	5.9 (0.0 - 17.3)	4.44	(0.00 - 16.36)	-*
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	1	9.3 (0.0 - 27.6)	5.16	(0.00 - 19.04)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	1	5.9 (0.0 - 17.3)	43.16	(0.00 - 159.23)	-*
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	1	13.2 (0.0 - 38.9)	17.14	(0.00 - 63.23)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	7	80.0 (20.3 - 139.6)	0.59 (0.19 - 1.10)	-	-	-	4	27.9 (0.0 - 55.8)	0.55 (0.08 - 1.19)	-	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Boddington (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	1	28.1 (0.0 - 83.0)	1.60	(0.00 - 5.90)	-*	
Colorectal cancer	1	21.7	(0.0 - 63.4)	1.30	(0.00 - 4.79)	-*	0	-	-	-	.	
Prostate gland	1	35.7	(0.0 - 105.1)	1.61	(0.00 - 5.94)	-*	0	-	-	-	.	
Melanoma (skin)	1	11.6	(0.0 - 34.2)	5.83	(0.00 - 21.52)	-*	0	-	-	-	.	
Lung, bronchus & trachea	1	45.5	(0.0 - 133.9)	0.72	(0.00 - 2.66)	-*	0	-	0	n/a	-	
Lymphoma	0	-	-	-	-	.	0	-	-	-	.	
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.	
Leukaemia	0	-	-	-	-	.	0	-	-	-	.	
Pancreas	0	-	-	-	-	.	1	21.7 (0.0 - 63.4)	5.77	(0.00 - 21.29)	-*	
Urinary bladder	0	-	-	-	-	.	1	36.7 (0.0 - 108.3)	23.70	(0.00 - 87.41)	-*	
Stomach	0	-	-	-	-	.	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.	
Other lymphohaematopoietic	0	-	-	-	-	.	1	29.0 (0.0 - 85.4)	33.08	(0.00 - 122.02)	-*	
Oesophagus	0	-	-	-	-	.	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	1	11.6	(0.0 - 34.2)	10.77	(0.00 - 39.72)	-*	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	5	126.2	(2.2 - 250.1)	0.85	(0.19 - 1.75)	-	4	115.5 (1.2 - 229.8)	1.17	(0.18 - 2.57)	-*	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Boyup Brook (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	0	n/a	-
Colorectal cancer	0	-	-	0	n/a	-	2	21.1 (0.0 - 54.3)	1.89	(0.02 - 5.27)	-*
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	0	n/a	-	0	-	0	n/a	-
Kidney & other renal tract	0	-	-	-	-	.	1	15.4 (0.0 - 45.5)	6.61	(0.00 - 24.39)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	1	4.9 (0.0 - 14.3)	2.37	(0.00 - 8.74)	-*
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	1	4.3 (0.0 - 12.8)	4.27	(0.00 - 15.75)	-*
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	4.9 (0.0 - 14.3)	2.92	(0.00 - 10.79)	-*
Other lymphohaematopoietic	2	17.4	(0.0 - 41.3)	14.10	(0.18 - 39.29)	-*	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	24.2 (0.0 - 71.6)	7.06	(0.00 - 26.03)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	2	17.4	(0.0 - 41.3)	0.20	(0.00 - 0.56)	V	7	74.8 (7.7 - 141.9)	0.93	(0.29 - 1.73)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Bridgetown-Greenbushes (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	4	22.8 (0.1 - 45.5)	1.55	(0.24 - 3.40)	-*	
Colorectal cancer	0	-	-	0	n/a	-	2	11.3 (0.0 - 27.5)	1.00	(0.01 - 2.79)	-*	
Prostate gland	1	4.9 (0.0 - 14.6)	0.47	(0.00 - 1.74)	-*	0	-	-	-	-	.	
Melanoma (skin)	1	4.9 (0.0 - 14.6)	1.69	(0.00 - 6.24)	-*	0	-	-	-	-	.	
Lung, bronchus & trachea	5	32.4 (3.9 - 60.8)	0.94	(0.20 - 1.92)	-	4	25.3 (0.1 - 50.5)	1.70	(0.26 - 3.73)	-*		
Lymphoma	2	20.0 (0.0 - 49.7)	2.50	(0.03 - 6.97)	-*	0	-	-	0	n/a	-	
Unknown primary site	2	12.7 (0.0 - 30.2)	1.59	(0.02 - 4.42)	-*	0	-	-	0	n/a	-	
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	.	
Leukaemia	1	6.0 (0.0 - 17.7)	1.18	(0.00 - 4.36)	-*	1	3.5 (0.0 - 10.3)	2.19	(0.00 - 8.09)	-*		
Pancreas	0	-	-	0	n/a	-	2	8.6 (0.0 - 20.4)	2.52	(0.03 - 7.03)	-*	
Urinary bladder	2	12.2 (0.0 - 29.4)	3.76	(0.05 - 10.47)	-*	0	-	-	-	-	.	
Stomach	0	-	-	0	n/a	-	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	1	7.1 (0.0 - 21.0)	1.32	(0.00 - 4.88)	-*	0	-	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	
Other lymphohaematopoietic	1	7.3 (0.0 - 21.5)	3.68	(0.00 - 13.59)	-*	0	-	-	-	-	.	
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	7.0 (0.0 - 20.8)	6.48	(0.00 - 23.90)	-*	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	1	6.5 (0.0 - 19.2)	4.11	(0.00 - 15.16)	-*	0	-	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	1	7.3 (0.0 - 21.5)	25.35	(0.00 - 93.52)	-*	0	-	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	1	6.0 (0.0 - 17.7)	26.18	(0.00 - 96.57)	-*	0	-	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	19	127.2	(67.9 - 186.4)	0.88	(0.49 - 1.32)	-	14	78.5	(36.3 - 120.6)	0.95	(0.47 - 1.50)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Brookton (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	1	14.9	(0.0 - 44.0)	0.97	(0.00 - 3.59)	-*	3	34.5	4.86	(0.39 - 11.35)	-*	
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	3	60.6	(0.0 - 134.5)	1.61	(0.13 - 3.77)	-*	1	13.3	1.50	(0.00 - 5.53)	-*	
Lymphoma	0	-	-	-	-	.	0	-	-	-	.	
Unknown primary site	0	-	-	-	-	.	1	36.4	3.18	(0.00 - 11.73)	-*	
Kidney & other renal tract	0	-	-	-	-	.	1	28.4	11.35	(0.00 - 41.87)	-*	
Leukaemia	1	28.3	(0.0 - 83.6)	3.21	(0.00 - 11.83)	-*	0	-	-	-	.	
Pancreas	0	-	-	-	-	.	0	-	-	-	.	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.	
Stomach	2	29.7	(0.0 - 75.9)	5.79	(0.07 - 16.14)	-*	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	1	35.7	4.99	(0.00 - 18.41)	-*	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	0	-	-	-	-	.	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	1	13.3	11.75	(0.00 - 43.34)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	7	133.5	(26.2 - 240.7)	0.88	(0.28 - 1.64)	-	8	161.6	(35.9 - 287.3)	1.84	(0.65 - 3.32)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Broome (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	11.7 (0.0 - 23.4)	1.12	(0.17 - 2.46)	-*
Colorectal cancer	2	11.6 (0.0 - 27.8)	0.50	(0.01 - 1.40)	-*	0	-	0	n/a	-	
Prostate gland	2	11.3 (0.0 - 27.1)	0.83	(0.01 - 2.31)	-*	0	-	-	-	.	
Melanoma (skin)	2	5.4 (0.0 - 13.0)	2.08	(0.03 - 5.79)	-*	0	-	-	-	.	
Lung, bronchus & trachea	2	7.8 (0.0 - 18.8)	0.28	(0.00 - 0.78)	V	2	8.9 (0.0 - 21.4)	0.77	(0.01 - 2.13)	-*	
Lymphoma	0	-	0	n/a	-	3	13.8 (0.0 - 30.1)	3.81	(0.31 - 8.89)	-*	
Unknown primary site	1	4.7 (0.0 - 13.8)	0.58	(0.00 - 2.14)	-*	3	13.0 (0.0 - 28.5)	2.91	(0.23 - 6.80)	-*	
Kidney & other renal tract	1	4.9 (0.0 - 14.6)	1.27	(0.00 - 4.69)	-*	0	-	-	-	.	
Leukaemia	1	3.8 (0.0 - 11.1)	0.77	(0.00 - 2.85)	-*	0	-	0	n/a	-	
Pancreas	1	5.0 (0.0 - 14.6)	0.73	(0.00 - 2.69)	-*	0	-	0	n/a	-	
Urinary bladder	0	-	0	n/a	-	0	-	-	-	.	
Stomach	1	7.0 (0.0 - 20.7)	0.76	(0.00 - 2.82)	-*	0	-	-	-	.	
Corpus uteri	0	-	-	-	.	1	6.6 (0.0 - 19.6)	3.39	(0.00 - 12.52)	-*	
Brain	0	-	0	n/a	-	0	-	0	n/a	-	
Lip	0	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	.	0	-	0	n/a	-	
Other lymphohaematopoietic	1	4.7 (0.0 - 13.8)	3.11	(0.00 - 11.47)	-*	0	-	-	-	.	
Oesophagus	1	2.3 (0.0 - 6.7)	1.25	(0.00 - 4.60)	-*	1	3.6 (0.0 - 10.6)	3.70	(0.00 - 13.66)	-*	
Thyroid gland	0	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	1	4.9 (0.0 - 14.6)	2.27	(0.00 - 8.38)	-*	0	-	-	-	.	
Cervix uteri	0	-	-	-	.	1	4.4 (0.0 - 13.1)	1.98	(0.00 - 7.30)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	.	0	-	-	-	.	
Mesothelioma	1	3.1 (0.0 - 9.3)	1.05	(0.00 - 3.87)	-*	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	0	n/a	-	0	-	-	-	.	
Testis	0	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	.	0	-	-	-	.	
Tongue	1	6.4 (0.0 - 18.9)	5.18	(0.00 - 19.11)	-*	0	-	-	-	.	
Connective & soft tissues	1	3.4 (0.0 - 10.0)	6.03	(0.00 - 22.23)	-*	1	5.9 (0.0 - 17.6)	11.89	(0.00 - 43.85)	-*	
Tonsil & oropharynx	0	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	.	0	-	-	-	.	
Small intestine	1	5.2 (0.0 - 15.5)	7.50	(0.00 - 27.68)	-*	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	.	0	-	-	-	.	
Floor of mouth	1	5.2 (0.0 - 15.5)	10.78	(0.00 - 39.76)	-*	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	.	0	-	-	-	.	
All cancers	21	96.8 (54.0 - 139.6)	0.70 (0.41 - 1.03)	-	16	67.9 (32.9 - 103.0)	0.91 (0.48 - 1.40)	-			

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Broomehill (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	-	.
Colorectal cancer	1	59.7	(0.0 - 175.8)	3.21	(0.00 - 11.83)	-*	0	-	-	-	.
Prostate gland	1	50.0	(0.0 - 143.0)	4.00	(0.00 - 14.74)	-*	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	.	0	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	2	109.7	(0.0 - 258.5)	0.83	(0.01 - 2.32)	-*	0	-	-	0	n/a

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Bruce Rock (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	29.9	(0.0 - 88.1)	1.32	(0.00 - 4.85)	-*
Colorectal cancer	1	25.4	(0.0 - 75.0)	1.11	(0.00 - 4.09)	-*	2	29.7	(0.0 - 72.2)	3.15	(0.04 - 8.77)	-*
Prostate gland	2	29.3	(0.0 - 70.0)	2.56	(0.03 - 7.14)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	1	11.9	(0.0 - 35.0)	0.59	(0.00 - 2.18)	-*	1	10.6	(0.0 - 31.3)	1.33	(0.00 - 4.92)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	11.9	(0.0 - 35.0)	3.31	(0.00 - 12.23)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	1	21.5	(0.0 - 63.4)	10.45	(0.00 - 38.55)	-*	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	1	21.4	(0.0 - 63.2)	8.88	(0.00 - 32.75)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	1	21.4	(0.0 - 63.2)	190.37	(0.00 - 702.26)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	1	25.4	(0.0 - 75.0)	97.17	(0.00 - 358.45)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	9	168.2	(55.0 - 281.4)	1.30	(0.50 - 2.27)	-	4	70.2	(0.0 - 145.1)	0.86	(0.13 - 1.89)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Bunbury (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	21	18.5 (9.9 - 27.1)	1.08	(0.63 - 1.58)	-
Colorectal cancer	18	14.8 (7.4 - 22.1)	0.88	(0.48 - 1.33)	-		15	11.2 (4.5 - 17.9)	0.87	(0.44 - 1.36)	-
Prostate gland	26	18.1 (10.8 - 25.3)	1.41	(0.88 - 2.01)	-		0	-	-	-	-
Melanoma (skin)	5	6.0 (0.7 - 11.3)	1.16	(0.25 - 2.38)	-*		2	1.5 (0.0 - 3.9)	0.77	(0.01 - 2.13)	-*
Lung, bronchus & trachea	44	41.9 (28.7 - 55.0)	1.15	(0.81 - 1.51)	-		25	22.6 (13.1 - 32.2)	1.29	(0.79 - 1.84)	-
Lymphoma	5	5.5 (0.5 - 10.4)	0.85	(0.19 - 1.75)	-		6	5.3 (0.7 - 9.9)	1.05	(0.28 - 2.04)	-
Unknown primary site	12	11.1 (4.6 - 17.7)	1.26	(0.57 - 2.06)	-		9	3.2 (1.1 - 5.3)	1.02	(0.39 - 1.79)	-
Kidney & other renal tract	4	5.7 (0.1 - 11.3)	0.98	(0.15 - 2.15)	-*		2	2.1 (0.0 - 5.2)	0.80	(0.01 - 2.24)	-*
Leukaemia	9	7.5 (2.3 - 12.6)	1.40	(0.54 - 2.45)	-		2	1.8 (0.0 - 4.7)	0.50	(0.01 - 1.39)	-*
Pancreas	4	2.7 (0.0 - 5.4)	0.61	(0.09 - 1.34)	-		6	3.7 (0.4 - 7.0)	0.86	(0.23 - 1.68)	-
Urinary bladder	3	2.5 (0.0 - 5.5)	0.69	(0.06 - 1.61)	-*		2	1.1 (0.0 - 2.7)	1.01	(0.01 - 2.82)	-*
Stomach	6	5.6 (0.9 - 10.3)	0.87	(0.24 - 1.69)	-		4	2.9 (0.0 - 6.2)	1.03	(0.16 - 2.26)	-*
Corpus uteri	0	-	-	-	-	.	1	0.3 (0.0 - 0.9)	0.40	(0.00 - 1.48)	-*
Brain	6	8.2 (0.4 - 15.9)	1.23	(0.33 - 2.40)	-		2	1.9 (0.0 - 4.5)	0.57	(0.01 - 1.58)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	4	2.6 (0.0 - 5.8)	0.71	(0.11 - 1.56)	-
Other lymphohaematopoietic	4	2.7 (0.0 - 5.3)	1.78	(0.28 - 3.90)	-*		2	0.8 (0.0 - 2.0)	1.35	(0.02 - 3.76)	-*
Oesophagus	3	2.0 (0.0 - 4.3)	0.71	(0.06 - 1.66)	-*		1	0.3 (0.0 - 0.9)	0.42	(0.00 - 1.55)	-*
Thyroid gland	0	-	-	-	-	.	0	-	0	n/a	-
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	2	2.6 (0.0 - 6.3)	0.82	(0.01 - 2.29)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-
Mesothelioma	2	1.7 (0.0 - 4.3)	0.42	(0.01 - 1.16)	-		0	-	0	n/a	-
Liver & intrahepatic bile duct	1	1.1 (0.0 - 3.4)	0.31	(0.00 - 1.14)	-*		2	1.5 (0.0 - 3.9)	1.60	(0.02 - 4.46)	-*
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	2	2.5 (0.0 - 6.0)	1.12	(0.01 - 3.12)	-*		3	1.5 (0.0 - 3.3)	1.48	(0.12 - 3.46)	-*
Larynx	1	1.2 (0.0 - 3.7)	0.71	(0.00 - 2.62)	-*		0	-	-	-	-
Tongue	1	0.7 (0.0 - 2.0)	1.17	(0.00 - 4.31)	-*		0	-	-	-	-
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-
Tonsil & oropharynx	1	1.1 (0.0 - 3.2)	1.33	(0.00 - 4.89)	-*		0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	1	0.3 (0.0 - 0.9)	1.81	(0.00 - 6.68)	-*
Small intestine	0	-	-	0	n/a	-	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	1	1.1 (0.0 - 3.4)	3.85	(0.00 - 14.20)	-*
Major Salivary Gland	1	1.2 (0.0 - 3.4)	2.90	(0.00 - 10.70)	-*		1	0.3 (0.0 - 0.9)	13.05	(0.00 - 48.13)	-*
Anus	0	-	-	-	-	.	0	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	1	0.8 (0.0 - 2.2)	2.90	(0.00 - 10.70)	-*
Floor of mouth	1	0.5 (0.0 - 1.4)	2.67	(0.00 - 9.85)	-*		2	1.9 (0.0 - 4.5)	10.49	(0.13 - 29.22)	-*
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	1	0.6 (0.0 - 1.7)	1.48	(0.00 - 5.47)	-*		1	0.4 (0.0 - 1.2)	12.20	(0.00 - 44.99)	-*
Nasal cavity, sinuses, int. ear	1	1.2 (0.0 - 3.7)	4.11	(0.00 - 15.17)	-*		1	0.3 (0.0 - 0.9)	8.47	(0.00 - 31.24)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	1.1 (0.0 - 3.3)	2.38	(0.00 - 8.78)	-*
Adrenal & other endocrine	1	0.9 (0.0 - 2.6)	6.71	(0.00 - 24.73)	-*		0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	1	1.2 (0.0 - 3.4)	6.91	(0.00 - 25.51)	-*		0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	1	1.6 (0.0 - 4.6)	26.62	(0.00 - 98.21)	-*		0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	164	149.5 (124.9 - 174.1)	1.03	(0.88 - 1.21)	-		122	94.0 (75.2 - 112.9)	0.99	(0.82 - 1.18)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Busseton (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	12	14.3 (5.7 - 23.0)	0.79	(0.36 - 1.29)	-
Colorectal cancer	16	16.8 (8.2 - 25.5)	0.95	(0.50 - 1.47)	-	15	14.3 (6.4 - 22.3)	1.13	(0.57 - 1.76)	-	
Prostate gland	18	15.0 (7.7 - 22.3)	1.24	(0.68 - 1.87)	-	0	-	-	-	-	
Melanoma (skin)	3	3.3 (0.0 - 7.1)	0.87	(0.07 - 2.03)	-*	3	4.0 (0.0 - 8.6)	1.49	(0.12 - 3.47)	-*	
Lung, bronchus & trachea	23	23.2 (13.4 - 33.1)	0.72	(0.43 - 1.04)	-	23	20.2 (11.2 - 29.1)	1.50	(0.90 - 2.17)	-	
Lymphoma	6	6.5 (1.1 - 11.8)	1.26	(0.34 - 2.45)	-	1	0.5 (0.0 - 1.3)	0.22	(0.00 - 0.82)	V	
Unknown primary site	8	7.4 (1.9 - 12.9)	1.03	(0.36 - 1.85)	-	10	8.9 (2.7 - 15.1)	1.50	(0.62 - 2.56)	-	
Kidney & other renal tract	3	2.3 (0.0 - 5.0)	0.91	(0.07 - 2.12)	-*	2	1.4 (0.0 - 3.5)	1.03	(0.01 - 2.87)	-*	
Leukaemia	4	5.5 (0.0 - 11.5)	0.77	(0.12 - 1.69)	-	4	3.0 (0.0 - 6.4)	1.31	(0.20 - 2.88)	-*	
Pancreas	8	7.7 (2.2 - 13.2)	1.47	(0.52 - 2.66)	-	5	4.3 (0.1 - 8.6)	0.93	(0.20 - 1.90)	-	
Urinary bladder	3	3.2 (0.0 - 7.0)	0.85	(0.07 - 1.98)	-*	2	1.0 (0.0 - 2.4)	1.34	(0.02 - 3.74)	-*	
Stomach	5	4.7 (0.5 - 9.0)	0.89	(0.19 - 1.81)	-	3	1.4 (0.0 - 3.0)	1.01	(0.08 - 2.35)	-*	
Corpus uteri	0	-	-	-	-	2	1.8 (0.0 - 4.2)	1.03	(0.01 - 2.86)	-*	
Brain	3	2.6 (0.0 - 5.6)	0.77	(0.06 - 1.79)	-*	0	-	0	n/a	-	
Lip	0	-	-	-	-	0	-	-	-	-	
Ovary & uterine adnexa	0	-	-	-	-	5	5.6 (0.4 - 10.8)	1.13	(0.25 - 2.32)	-*	
Other lymphohaematopoietic	4	3.5 (0.0 - 7.3)	2.23	(0.35 - 4.89)	-*	0	-	0	n/a	-	
Oesophagus	5	4.5 (0.4 - 8.5)	1.44	(0.31 - 2.95)	-*	3	1.5 (0.0 - 3.2)	1.64	(0.13 - 3.84)	-*	
Thyroid gland	0	-	-	-	-	0	-	-	-	-	
Myeloma/plasma cell tumours	1	0.9 (0.0 - 2.8)	0.47	(0.00 - 1.75)	-*	2	2.2 (0.0 - 5.6)	1.14	(0.01 - 3.17)	-*	
Cervix uteri	0	-	-	-	-	2	1.0 (0.0 - 2.5)	1.05	(0.01 - 2.91)	-*	
Non-mel. skin (exc BCC/SCC)	1	1.0 (0.0 - 2.9)	1.64	(0.00 - 6.06)	-*	0	-	-	-	-	
Mesothelioma	3	2.9 (0.0 - 6.2)	0.75	(0.06 - 1.76)	-*	0	-	0	n/a	-	
Liver & intrahepatic bile duct	2	2.4 (0.0 - 6.0)	0.74	(0.01 - 2.06)	-*	2	1.3 (0.0 - 3.3)	2.03	(0.03 - 5.67)	-*	
Testis	0	-	-	-	-	0	-	-	-	-	
Gallbladder & bile ducts	1	1.7 (0.0 - 5.1)	0.70	(0.00 - 2.57)	-*	2	1.9 (0.0 - 4.9)	1.30	(0.02 - 3.63)	-*	
Larynx	0	-	-	0	n/a	-	-	-	-	-	
Tongue	0	-	-	0	n/a	-	-	-	-	-	
Connective & soft tissues	0	-	-	-	-	1	0.9 (0.0 - 2.6)	2.86	(0.00 - 10.56)	-*	
Tonsil & oropharynx	1	0.7 (0.0 - 2.0)	1.63	(0.00 - 6.03)	-*	0	-	-	-	-	
Vulva/vagina	0	-	-	-	-	1	0.5 (0.0 - 1.4)	2.43	(0.00 - 8.98)	-*	
Small intestine	1	0.7 (0.0 - 2.0)	1.98	(0.00 - 7.30)	-*	0	-	-	-	-	
Eye & lacrimal gland	0	-	-	-	-	0	-	-	-	-	
Major Salivary Gland	1	0.7 (0.0 - 2.0)	3.72	(0.00 - 13.73)	-*	0	-	-	-	-	
Anus	1	1.3 (0.0 - 3.8)	4.83	(0.00 - 17.83)	-*	0	-	-	-	-	
Mouth, other & unspecified	0	-	-	-	-	0	-	-	-	-	
Floor of mouth	1	1.5 (0.0 - 4.5)	3.28	(0.00 - 12.09)	-*	0	-	-	-	-	
Bones, joints & articular cart.	0	-	-	-	-	0	-	-	-	-	
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	-	-	-	-	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	0	-	-	-	-	
Peritoneum & retroperitoneum	0	-	-	-	-	0	-	-	-	-	
Adrenal & other endocrine	0	-	-	-	-	1	1.6 (0.0 - 4.8)	8.68	(0.00 - 32.03)	-*	
Nasopharynx	0	-	-	-	-	0	-	-	-	-	
Pharynx, other & ill-def.	0	-	-	-	-	0	-	-	-	-	
Penis & other male genital	0	-	-	-	-	0	-	-	-	-	
Gum	0	-	-	-	-	0	-	-	-	-	
Kaposi sarcoma	0	-	-	-	-	0	-	-	-	-	
Thymus	0	-	-	-	-	0	-	-	-	-	
Pleura, heart & mediastinum	0	-	-	-	-	0	-	-	-	-	
Spinal cord & cranial nerves	0	-	-	-	-	1	1.6 (0.0 - 4.8)	20.85	(0.00 - 76.92)	-*	
Uterus, nos	0	-	-	-	-	0	-	-	-	-	
Nervous, periph./autonomic	0	-	-	-	-	0	-	-	-	-	
Placenta	0	-	-	-	-	0	-	-	-	-	
Meninges (cerebral & spinal)	0	-	-	-	-	0	-	-	-	-	
All cancers	122	120.0 (97.6 - 142.4)	0.94	(0.78 - 1.12)	-	102	93.3 (73.2 - 113.4)	1.06	(0.87 - 1.30)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cambridge (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	16	13.5 (6.2 - 20.8)	0.81	(0.43 - 1.25)	-
Colorectal cancer	16	15.1 (7.1 - 23.1)	0.82	(0.43 - 1.26)	-	-	25	20.6 (10.8 - 30.4)	1.36	(0.84 - 1.95)	-
Prostate gland	18	11.6 (6.1 - 17.1)	0.98	(0.54 - 1.48)	-	-	0	-	-	-	-
Melanoma (skin)	6	6.6 (1.1 - 12.2)	1.48	(0.40 - 2.87)	-*	-	2	1.5 (0.0 - 3.9)	0.74	(0.01 - 2.07)	-*
Lung, bronchus & trachea	25	17.2 (9.9 - 24.5)	0.68	(0.42 - 0.98)	V	-	17	11.8 (5.0 - 18.5)	0.86	(0.46 - 1.32)	-
Lymphoma	8	10.3 (2.9 - 17.8)	1.44	(0.51 - 2.60)	-	-	5	3.1 (0.0 - 6.3)	0.85	(0.19 - 1.74)	-
Unknown primary site	11	12.4 (3.3 - 21.5)	1.20	(0.52 - 2.00)	-	-	5	3.5 (0.0 - 7.1)	0.52	(0.11 - 1.06)	-
Kidney & other renal tract	1	1.0 (0.0 - 2.9)	0.26	(0.00 - 0.95)	V*	-	2	0.5 (0.0 - 1.2)	0.76	(0.01 - 2.13)	-*
Leukaemia	4	2.3 (0.0 - 4.5)	0.66	(0.10 - 1.45)	-	-	0	-	0	n/a	V
Pancreas	3	2.6 (0.0 - 6.0)	0.49	(0.04 - 1.13)	-	-	6	4.0 (0.0 - 8.0)	0.81	(0.22 - 1.58)	-
Urinary bladder	1	0.6 (0.0 - 1.7)	0.23	(0.00 - 0.86)	V*	-	2	0.5 (0.0 - 1.2)	0.92	(0.01 - 2.55)	-*
Stomach	8	6.3 (1.5 - 11.0)	1.21	(0.43 - 2.19)	-	-	3	1.8 (0.0 - 4.4)	0.72	(0.06 - 1.69)	-*
Corpus uteri	0	-	-	-	-	.	0	-	0	n/a	-
Brain	5	5.3 (0.3 - 10.2)	1.13	(0.25 - 2.31)	-*	-	6	4.4 (0.5 - 8.4)	1.75	(0.47 - 3.41)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	6	6.9 (1.1 - 12.6)	1.04	(0.28 - 2.02)	-
Other lymphohaematopoietic	2	1.2 (0.0 - 2.8)	0.89	(0.01 - 2.49)	-*	-	2	0.7 (0.0 - 1.6)	1.18	(0.01 - 3.28)	-*
Oesophagus	2	1.0 (0.0 - 2.3)	0.50	(0.01 - 1.39)	-*	-	2	0.7 (0.0 - 1.6)	0.79	(0.01 - 2.20)	-*
Thyroid gland	0	-	-	-	-	.	0	-	0	n/a	-
Myeloma/plasma cell tumours	2	2.8 (0.0 - 6.6)	0.79	(0.01 - 2.19)	-*	-	1	0.3 (0.0 - 0.8)	0.41	(0.00 - 1.51)	-*
Cervix uteri	0	-	-	-	-	.	2	1.7 (0.0 - 4.4)	0.83	(0.01 - 2.30)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	-
Mesothelioma	5	4.4 (0.2 - 8.5)	1.10	(0.24 - 2.25)	-	-	1	0.4 (0.0 - 1.2)	1.58	(0.00 - 5.84)	-*
Liver & intrahepatic bile duct	5	3.2 (0.3 - 6.1)	1.66	(0.36 - 3.41)	-*	-	2	0.7 (0.0 - 1.6)	1.55	(0.02 - 4.31)	-*
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	2	2.0 (0.0 - 4.9)	1.16	(0.01 - 3.22)	-*	-	3	0.9 (0.0 - 2.0)	1.39	(0.11 - 3.25)	-*
Larynx	0	-	-	0	n/a	-	0	-	-	-	-
Tongue	0	-	-	0	n/a	-	1	1.2 (0.0 - 3.6)	2.40	(0.00 - 8.87)	-*
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	-
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	1	0.9 (0.0 - 2.6)	1.61	(0.00 - 5.95)	-*
Small intestine	0	-	-	0	n/a	-	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	1	0.2 (0.0 - 0.7)	3.55	(0.00 - 13.10)	-*
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	1	1.2 (0.0 - 3.7)	1.90	(0.00 - 7.03)	-*
Mouth, other & unspecified	0	-	-	-	-	.	2	1.1 (0.0 - 2.9)	5.68	(0.07 - 15.82)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-
Bones, joints & articular cart.	2	1.9 (0.0 - 4.7)	6.95	(0.09 - 19.37)	-*	-	1	1.3 (0.0 - 3.9)	5.26	(0.00 - 19.40)	-*
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	0.2 (0.0 - 0.7)	2.42	(0.00 - 8.94)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	1	0.3 (0.0 - 0.8)	5.50	(0.00 - 20.27)	-*
Kaposi sarcoma	1	0.5 (0.0 - 1.4)	46.81	(0.00 - 172.68)	-*	-	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	127	108.1 (87.0 - 129.1)	0.84 (0.70 - 1.00)	-	-	-	117	83.8 (65.5 - 102.1)	0.91 (0.76 - 1.09)	-	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Canning (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	40	14.3 (9.7 - 19.0)	0.88	(0.61 - 1.18)	-
Colorectal cancer	31	13.1 (8.4 - 17.8)	0.72	(0.47 - 0.99)	V		36	9.8 (6.4 - 13.2)	0.99	(0.67 - 1.33)	-
Prostate gland	37	14.7 (9.8 - 19.5)	1.10	(0.75 - 1.48)	-		0	-	-	-	.
Melanoma (skin)	3	1.5 (0.0 - 3.2)	0.33	(0.03 - 0.76)	V		4	1.1 (0.0 - 2.3)	0.69	(0.11 - 1.50)	-
Lung, bronchus & trachea	95	39.1 (31.0 - 47.1)	1.18	(0.96 - 1.45)	-		43	13.3 (9.1 - 17.6)	1.01	(0.71 - 1.34)	-
Lymphoma	12	4.8 (2.1 - 7.6)	0.97	(0.44 - 1.58)	-		14	5.0 (2.2 - 7.8)	1.13	(0.56 - 1.79)	-
Unknown primary site	17	7.4 (3.8 - 10.9)	0.88	(0.47 - 1.34)	-		24	7.1 (4.0 - 10.2)	1.33	(0.81 - 1.91)	-
Kidney & other renal tract	8	3.3 (1.0 - 5.7)	0.94	(0.33 - 1.69)	-		3	1.3 (0.0 - 2.9)	0.57	(0.05 - 1.34)	-
Leukaemia	18	7.5 (3.9 - 11.1)	1.34	(0.74 - 2.02)	-		8	2.5 (0.6 - 4.3)	0.93	(0.33 - 1.67)	-
Pancreas	17	7.2 (3.7 - 10.7)	1.20	(0.65 - 1.84)	-		10	3.2 (1.1 - 5.4)	0.69	(0.28 - 1.18)	-
Urinary bladder	5	1.6 (0.2 - 3.0)	0.60	(0.13 - 1.23)	-		6	1.2 (0.2 - 2.2)	1.53	(0.41 - 2.98)	-*
Stomach	16	6.9 (3.4 - 10.3)	1.12	(0.59 - 1.73)	-		11	3.9 (1.4 - 6.3)	1.37	(0.60 - 2.28)	-
Corpus uteri	0	-	-	-	.		5	1.4 (0.1 - 2.7)	0.95	(0.21 - 1.94)	-
Brain	10	4.6 (1.7 - 7.5)	0.87	(0.36 - 1.48)	-		7	2.8 (0.7 - 4.9)	0.85	(0.27 - 1.59)	-
Lip	0	-	-	-	.		0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	.		9	2.5 (0.8 - 4.2)	0.72	(0.28 - 1.27)	-
Other lymphohaematopoietic	3	1.2 (0.0 - 2.5)	0.71	(0.06 - 1.67)	-*		4	0.7 (0.0 - 1.5)	1.39	(0.21 - 3.04)	-*
Oesophagus	16	6.1 (3.1 - 9.2)	1.80	(0.95 - 2.79)	-		3	1.1 (0.0 - 2.4)	0.61	(0.05 - 1.42)	-
Thyroid gland	0	-	-	0	n/a	-	1	0.5 (0.0 - 1.4)	0.79	(0.00 - 2.92)	-*
Myeloma/plasma cell tumours	7	2.6 (0.7 - 4.6)	1.34	(0.42 - 2.51)	-		2	0.7 (0.0 - 1.8)	0.42	(0.01 - 1.16)	-
Cervix uteri	0	-	-	-	.		4	1.6 (0.0 - 3.3)	0.71	(0.11 - 1.56)	-
Non-mel. skin (exc BCC/SCC)	4	1.5 (0.0 - 3.1)	2.84	(0.44 - 6.21)	-*		1	0.2 (0.0 - 0.5)	1.38	(0.00 - 5.08)	-*
Mesothelioma	11	4.6 (1.9 - 7.4)	1.07	(0.47 - 1.79)	-		2	0.5 (0.0 - 1.3)	1.35	(0.02 - 3.77)	-*
Liver & intrahepatic bile duct	6	2.5 (0.4 - 4.5)	0.84	(0.23 - 1.64)	-		2	0.5 (0.0 - 1.3)	0.73	(0.01 - 2.03)	-*
Testis	1	0.4 (0.0 - 1.2)	2.92	(0.00 - 10.77)	-*		0	-	-	-	.
Gallbladder & bile ducts	2	0.6 (0.0 - 1.4)	0.54	(0.01 - 1.50)	-*		7	2.1 (0.5 - 3.8)	1.66	(0.52 - 3.10)	-*
Larynx	1	0.3 (0.0 - 0.9)	0.33	(0.00 - 1.22)	-*		0	-	-	-	.
Tongue	2	0.8 (0.0 - 2.0)	1.05	(0.01 - 2.93)	-*		0	-	0	n/a	-
Connective & soft tissues	0	-	-	0	n/a	-	1	0.5 (0.0 - 1.6)	0.98	(0.00 - 3.62)	-*
Tonsil & oropharynx	1	0.5 (0.0 - 1.6)	0.58	(0.00 - 2.14)	-*		1	0.2 (0.0 - 0.6)	4.18	(0.00 - 15.43)	-*
Vulva/vagina	0	-	-	-	.		1	0.2 (0.0 - 0.6)	0.95	(0.00 - 3.49)	-*
Small intestine	2	0.7 (0.0 - 1.7)	1.53	(0.02 - 4.27)	-*		0	-	0	n/a	-
Eye & lacrimal gland	1	0.4 (0.0 - 1.1)	1.41	(0.00 - 5.21)	-*		1	0.4 (0.0 - 1.1)	1.84	(0.00 - 6.80)	-*
Major Salivary Gland	0	-	-	0	n/a	-	1	0.4 (0.0 - 1.1)	6.67	(0.00 - 24.62)	-*
Anus	0	-	-	0	n/a	-	1	0.4 (0.0 - 1.2)	0.93	(0.00 - 3.43)	-*
Mouth, other & unspecified	1	0.6 (0.0 - 1.6)	1.09	(0.00 - 4.02)	-*		0	-	0	n/a	-
Floor of mouth	0	-	-	0	n/a	-	1	0.2 (0.0 - 0.6)	2.56	(0.00 - 9.44)	-*
Bones, joints & articular cart.	0	-	-	0	n/a	-	0	-	0	n/a	-
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	1	0.2 (0.0 - 0.6)	4.31	(0.00 - 15.89)	-*
Peritoneum & retroperitoneum	0	-	-	0	n/a	-	0	-	0	n/a	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	1	0.4 (0.0 - 1.2)	1.78	(0.00 - 6.57)	-*		0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	.
Penis & other male genital	1	0.4 (0.0 - 1.1)	4.44	(0.00 - 16.36)	-*		0	-	-	-	.
Gum	1	0.6 (0.0 - 1.6)	7.01	(0.00 - 25.87)	-*		0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	1	0.4 (0.0 - 1.2)	5.93	(0.00 - 21.87)	-*
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	330	135.9 (120.9 - 150.8)	1.00	(0.90 - 1.12)	-		256	80.8 (70.2 - 91.4)	0.95	(0.84 - 1.08)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Capel (S) - Pt A 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	21.7	(0.0 - 64.2)	0.91	(0.00 - 3.37)	-*
Colorectal cancer	2	18.8	(0.0 - 44.7)	1.89	(0.02 - 5.25)	-*	0	-	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	1	15.9	(0.0 - 46.9)	4.21	(0.00 - 15.54)	-*	0	-	-	-	-	.
Lung, bronchus & trachea	1	17.2	(0.0 - 50.7)	0.52	(0.00 - 1.90)	-*	0	-	-	0	n/a	-
Lymphoma	1	18.9	(0.0 - 55.7)	3.23	(0.00 - 11.92)	-*	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	1	35.7	(0.0 - 103.2)	3.08	(0.00 - 11.35)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	6	106.4	(13.4 - 199.5)	0.76	(0.20 - 1.47)	-	1	21.7	(0.0 - 64.2)	0.19	(0.00 - 0.71)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Capel (S) - Pt B 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	6.6 (0.0 - 19.6)	0.47	(0.00 - 1.72)	-*
Colorectal cancer	2	14.7	(0.0 - 35.3)	0.76	(0.01 - 2.11)	-*	2	16.7 (0.0 - 39.7)	1.30	(0.02 - 3.62)	-*
Prostate gland	5	30.1	(3.7 - 56.6)	2.50	(0.55 - 5.13)	-*	0	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	.
Lung, bronchus & trachea	4	23.7	(0.6 - 46.9)	0.81	(0.13 - 1.78)	-	1	7.3 (0.0 - 21.6)	0.54	(0.00 - 2.01)	-*
Lymphoma	0	-	-	0	n/a	-	1	6.1 (0.0 - 18.0)	1.85	(0.00 - 6.84)	-*
Unknown primary site	0	-	-	0	n/a	-	0	-	0	n/a	-
Kidney & other renal tract	2	12.6	(0.0 - 29.9)	3.85	(0.05 - 10.74)	-*	0	-	-	-	.
Leukaemia	1	6.1	(0.0 - 17.9)	1.26	(0.00 - 4.64)	-*	0	-	-	-	.
Pancreas	1	8.4	(0.0 - 25.0)	1.16	(0.00 - 4.28)	-*	1	9.9 (0.0 - 29.4)	1.67	(0.00 - 6.17)	-*
Urinary bladder	1	4.9	(0.0 - 14.3)	2.01	(0.00 - 7.40)	-*	0	-	-	-	.
Stomach	1	8.4	(0.0 - 25.0)	1.15	(0.00 - 4.23)	-*	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	3	20.6	(0.0 - 43.9)	4.27	(0.34 - 9.96)	-*	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	19.9 (0.0 - 47.3)	3.60	(0.04 - 10.02)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	1	8.4	(0.0 - 25.0)	57.94	(0.00 - 213.76)	-*	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	6.1 (0.0 - 18.0)	5.96	(0.00 - 21.98)	-*
Larynx	1	6.1	(0.0 - 17.9)	5.34	(0.00 - 19.70)	-*	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	1	6.3 (0.0 - 18.5)	23.18	(0.00 - 85.51)	-*
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	22	144.0	(83.8 - 204.2)	1.10	(0.65 - 1.60)	-	10	78.8 (29.2 - 128.5)	0.86	(0.35 - 1.46)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Carnamah (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	1	71.4 (0.0 - 201.0)	24.09	(0.00 - 88.85)	-*	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	1	46.9 (0.0 - 138.0)	3.60	(0.00 - 13.29)	-*	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	1	41.7 (0.0 - 121.6)	20.58	(0.00 - 75.92)	-*	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	1	47.6 (0.0 - 140.2)	51.15	(0.00 - 188.70)	-*	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	2	89.3	(0.0 - 211.6)	0.63	(0.01 - 1.77)	-*	2	118.3	(0.0 - 276.8)	1.12	(0.01 - 3.13)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Carnarvon (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	5.1 (0.0 - 15.2)	0.34	(0.00 - 1.25)	-*
Colorectal cancer	7	31.5 (7.9 - 55.1)	1.74	(0.55 - 3.24)	-*		1	7.0 (0.0 - 20.7)	0.45	(0.00 - 1.66)	-*
Prostate gland	6	23.2 (4.5 - 41.9)	1.94	(0.52 - 3.77)	-*		0	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	-
Lung, bronchus & trachea	6	29.4 (5.7 - 53.2)	0.79	(0.21 - 1.54)	-		4	20.8 (0.0 - 41.9)	1.54	(0.24 - 3.37)	-*
Lymphoma	1	4.4 (0.0 - 13.0)	0.87	(0.00 - 3.20)	-*		0	-	-	0	n/a
Unknown primary site	2	7.7 (0.0 - 18.4)	1.10	(0.01 - 3.08)	-*		2	10.2 (0.0 - 24.4)	1.88	(0.02 - 5.25)	-*
Kidney & other renal tract	1	3.3 (0.0 - 9.7)	1.26	(0.00 - 4.64)	-*		0	-	-	-	-
Leukaemia	0	-	-	0	n/a	-	0	-	-	0	n/a
Pancreas	2	9.3 (0.0 - 22.5)	1.49	(0.02 - 4.16)	-*		0	-	-	0	n/a
Urinary bladder	2	7.7 (0.0 - 18.4)	2.57	(0.03 - 7.15)	-*		0	-	-	-	-
Stomach	4	14.8 (0.2 - 29.5)	2.97	(0.46 - 6.52)	-*		0	-	-	-	-
Corpus uteri	0	-	-	-	-	.	1	7.0 (0.0 - 20.7)	3.17	(0.00 - 11.68)	-*
Brain	3	13.3 (0.0 - 28.3)	2.81	(0.23 - 6.55)	-*		0	-	-	0	n/a
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-
Cervix uteri	0	-	-	-	-	.	1	4.7 (0.0 - 13.8)	2.64	(0.00 - 9.75)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	1	5.3 (0.0 - 15.6)	5.82	(0.00 - 21.48)	-*
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-
Larynx	0	-	-	-	-	.	0	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	34	144.7 (95.6 - 193.7)	1.10 (0.74 - 1.50)	-			11	60.1 (23.9 - 96.3)	0.66 (0.29 - 1.10)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Chapman Valley (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	70.7 (0.0 - 173.8)	4.61	(0.06 - 12.85)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	2	60.0	(0.0 - 145.0)	2.17	(0.03 - 6.04)	-*	0	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	24.4 (0.0 - 72.0)	9.66	(0.00 - 35.65)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	2	60.0	(0.0 - 145.0)	0.53	(0.01 - 1.49)	-*	3	95.1 (0.0 - 208.7)	1.43	(0.12 - 3.33)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Chittering (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	9.4 (0.0 - 28.0)	0.69	(0.00 - 2.55)	-*
Colorectal cancer	5	41.5 (5.1 - 77.9)	2.60	(0.57 - 5.33)	-*	.	0	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	1	9.6 (0.0 - 28.3)	2.56	(0.00 - 9.46)	-*	.	0	-	-	-	.
Lung, bronchus & trachea	7	59.4 (15.3 - 103.5)	1.91	(0.60 - 3.56)	-*	.	1	10.2 (0.0 - 30.2)	0.84	(0.00 - 3.10)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	.
Unknown primary site	1	9.2 (0.0 - 27.1)	1.22	(0.00 - 4.51)	-*	.	0	-	-	-	.
Kidney & other renal tract	1	9.3 (0.0 - 27.2)	2.69	(0.00 - 9.92)	-*	.	0	-	-	-	.
Leukaemia	1	16.5 (0.0 - 48.8)	1.82	(0.00 - 6.72)	-*	.	0	-	-	-	.
Pancreas	0	-	-	0	n/a	-	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	0	n/a	-	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	1	9.6 (0.0 - 28.3)	2.52	(0.00 - 9.30)	-*	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	1	7.2 (0.0 - 21.4)	2.97	(0.00 - 10.97)	-*	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	1	7.2 (0.0 - 21.4)	35.46	(0.00 - 130.83)	-*	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	1	7.8 (0.0 - 23.0)	260.12	(0.00 - 959.59)	-*
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	19	169.4 (92.0 - 246.9)	1.33 (0.75 - 1.99)	-	-	-	3	27.4 (0.0 - 58.6)	0.40 (0.03 - 0.93)	V	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Claremont (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	11	9.7 (1.5 - 18.0)	1.17	(0.51 - 1.95)	-
Colorectal cancer	8	21.3 (5.4 - 37.2)	1.02	(0.36 - 1.84)	-	-	6	15.2 (2.0 - 28.5)	0.64	(0.17 - 1.24)	-
Prostate gland	9	15.3 (4.6 - 26.1)	1.18	(0.45 - 2.08)	-	-	0	-	-	-	-
Melanoma (skin)	3	3.9 (0.0 - 8.3)	1.87	(0.15 - 4.36)	-*	-	3	9.1 (0.0 - 21.6)	2.31	(0.19 - 5.39)	-*
Lung, bronchus & trachea	13	27.0 (9.8 - 44.1)	0.90	(0.43 - 1.45)	-	-	8	7.7 (1.2 - 14.2)	0.85	(0.30 - 1.54)	-
Lymphoma	2	6.9 (0.0 - 16.6)	0.91	(0.01 - 2.53)	-*	-	1	3.6 (0.0 - 10.7)	0.35	(0.00 - 1.29)	-*
Unknown primary site	2	6.4 (0.0 - 16.6)	0.54	(0.01 - 1.51)	-*	-	7	7.9 (0.0 - 16.4)	1.38	(0.43 - 2.57)	-
Kidney & other renal tract	0	-	-	0	n/a	-	3	1.4 (0.0 - 2.9)	2.28	(0.18 - 5.32)	-*
Leukaemia	2	6.8 (0.0 - 16.4)	0.82	(0.01 - 2.29)	-*	-	1	3.6 (0.0 - 10.7)	0.47	(0.00 - 1.75)	-*
Pancreas	4	9.0 (0.0 - 18.8)	1.66	(0.26 - 3.64)	-*	-	5	4.9 (0.0 - 9.9)	1.33	(0.29 - 2.73)	-*
Urinary bladder	0	-	-	0	n/a	-	1	0.4 (0.0 - 1.1)	0.85	(0.00 - 3.15)	-*
Stomach	3	7.8 (0.0 - 17.3)	1.14	(0.09 - 2.67)	-*	-	1	1.0 (0.0 - 2.9)	0.47	(0.00 - 1.73)	-*
Corpus uteri	0	-	-	-	-	.	0	-	0	n/a	-
Brain	3	13.4 (0.0 - 28.6)	1.76	(0.14 - 4.10)	-*	-	1	1.0 (0.0 - 2.9)	0.65	(0.00 - 2.38)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	3	1.7 (0.0 - 3.9)	1.06	(0.09 - 2.48)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	1	0.4 (0.0 - 1.1)	1.04	(0.00 - 3.83)	-*
Oesophagus	2	7.6 (0.0 - 18.2)	1.26	(0.02 - 3.50)	-*	-	1	0.4 (0.0 - 1.1)	0.76	(0.00 - 2.81)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	3	1.8 (0.0 - 4.1)	2.40	(0.19 - 5.60)	-*
Cervix uteri	0	-	-	-	-	.	1	2.1 (0.0 - 6.1)	0.89	(0.00 - 3.30)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-
Mesothelioma	2	2.4 (0.0 - 5.8)	1.10	(0.01 - 3.07)	-*	-	0	-	-	-	-
Liver & intrahepatic bile duct	1	2.9 (0.0 - 8.7)	0.85	(0.00 - 3.13)	-*	-	1	3.7 (0.0 - 11.0)	1.58	(0.00 - 5.82)	-*
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	0	-	-	0	n/a	-	1	2.1 (0.0 - 6.1)	0.92	(0.00 - 3.38)	-*
Larynx	2	4.8 (0.0 - 12.4)	3.79	(0.05 - 10.57)	-*	-	0	-	-	-	-
Tongue	1	3.0 (0.0 - 9.0)	3.13	(0.00 - 11.56)	-*	-	0	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-
Small intestine	1	1.4 (0.0 - 4.0)	4.36	(0.00 - 16.07)	-*	-	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-
Mouth, other & unspecified	1	3.8 (0.0 - 11.1)	6.55	(0.00 - 24.18)	-*	-	0	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	59	143.7 (102.6 - 184.9)	0.97	(0.75 - 1.26)	-	-	59	77.4 (50.1 - 104.8)	0.92	(0.71 - 1.20)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cockburn (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	31	14.6 (9.3 - 20.0)	0.92	(0.60 - 1.27)	-
Colorectal cancer	35	19.6	(13.0 - 26.2)	1.02	(0.69 - 1.39)	-	34	15.5 (10.1 - 20.9)	1.31	(0.88 - 1.79)	-
Prostate gland	25	13.1	(7.9 - 18.4)	1.01	(0.62 - 1.44)	-	0	-	-	-	.
Melanoma (skin)	6	3.1	(0.6 - 5.7)	0.81	(0.22 - 1.57)	-	9	4.2 (1.4 - 6.9)	2.05	(0.79 - 3.59)	-*
Lung, bronchus & trachea	69	36.5	(27.8 - 45.2)	1.08	(0.85 - 1.38)	-	40	19.3 (13.1 - 25.5)	1.31	(0.91 - 1.75)	-
Lymphoma	8	3.7	(1.1 - 6.3)	0.81	(0.29 - 1.47)	-	5	1.9 (0.2 - 3.7)	0.56	(0.12 - 1.14)	-
Unknown primary site	10	5.1	(1.9 - 8.3)	0.66	(0.27 - 1.13)	-	16	6.1 (3.0 - 9.1)	1.27	(0.67 - 1.97)	-
Kidney & other renal tract	9	4.6	(1.5 - 7.6)	1.34	(0.51 - 2.34)	-	3	1.5 (0.0 - 3.2)	0.81	(0.07 - 1.90)	-*
Leukaemia	21	12.1	(6.8 - 17.4)	1.99	(1.16 - 2.92)	^	9	4.5 (1.4 - 7.7)	1.43	(0.55 - 2.50)	-
Pancreas	15	7.7	(3.8 - 11.6)	1.33	(0.68 - 2.08)	-	11	4.9 (1.9 - 7.9)	1.08	(0.47 - 1.81)	-
Urinary bladder	10	5.3	(2.0 - 8.7)	1.60	(0.66 - 2.73)	-	0	-	0	n/a	-
Stomach	13	6.5	(2.9 - 10.1)	1.15	(0.55 - 1.86)	-	8	3.5 (1.0 - 6.1)	1.41	(0.50 - 2.54)	-
Corpus uteri	0	-	-	-	-	.	1	0.3 (0.0 - 0.9)	0.27	(0.00 - 1.00)	-*
Brain	10	5.7	(2.1 - 9.3)	1.04	(0.43 - 1.78)	-	2	0.9 (0.0 - 2.1)	0.32	(0.00 - 0.89)	V
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	9	4.4 (1.4 - 7.3)	1.00	(0.38 - 1.74)	-
Other lymphohaematopoietic	2	0.9	(0.0 - 2.1)	0.64	(0.01 - 1.78)	-*	3	1.7 (0.0 - 3.6)	1.55	(0.13 - 3.62)	-*
Oesophagus	9	4.9	(1.7 - 8.2)	1.28	(0.49 - 2.25)	-	2	0.8 (0.0 - 2.0)	0.58	(0.01 - 1.62)	-*
Thyroid gland	1	0.6	(0.0 - 1.7)	2.21	(0.00 - 8.15)	-*	1	0.3 (0.0 - 0.9)	1.09	(0.00 - 4.02)	-*
Myeloma/plasma cell tumours	5	2.5	(0.3 - 4.8)	1.25	(0.27 - 2.56)	-*	3	1.5 (0.0 - 3.2)	0.90	(0.07 - 2.09)	-*
Cervix uteri	0	-	-	-	-	.	8	3.8 (1.1 - 6.5)	1.85	(0.65 - 3.33)	-*
Non-mel. skin (exc BCC/SCC)	3	1.8	(0.0 - 3.9)	2.82	(0.23 - 6.58)	-*	1	0.3 (0.0 - 0.9)	1.98	(0.00 - 7.31)	-*
Mesothelioma	12	6.5	(2.8 - 10.2)	1.45	(0.66 - 2.38)	-	0	-	0	n/a	-
Liver & intrahepatic bile duct	4	2.1	(0.0 - 4.2)	0.70	(0.11 - 1.53)	-	4	1.9 (0.0 - 3.8)	2.00	(0.31 - 4.38)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	1	0.4	(0.0 - 1.3)	0.34	(0.00 - 1.27)	-*	5	1.6 (0.2 - 2.9)	1.71	(0.37 - 3.51)	-*
Larynx	7	3.7	(0.9 - 6.5)	2.88	(0.91 - 5.37)	-*	0	-	-	-	.
Tongue	2	1.2	(0.0 - 2.8)	1.31	(0.02 - 3.64)	-*	2	0.7 (0.0 - 1.8)	2.92	(0.04 - 8.14)	-*
Connective & soft tissues	0	-	-	0	n/a	-	1	0.5 (0.0 - 1.5)	1.31	(0.00 - 4.82)	-*
Tonsil & oropharynx	2	1.0	(0.0 - 2.3)	1.43	(0.02 - 3.97)	-*	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	0	n/a	-
Small intestine	1	0.5	(0.0 - 1.6)	0.96	(0.00 - 3.53)	-*	1	0.3 (0.0 - 1.0)	1.41	(0.00 - 5.19)	-*
Eye & lacrimal gland	2	1.0	(0.0 - 2.4)	3.31	(0.04 - 9.23)	-*	0	-	-	-	.
Major Salivary Gland	1	0.6	(0.0 - 1.8)	1.84	(0.00 - 6.79)	-*	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	0	n/a	-
Mouth, other & unspecified	0	-	-	0	n/a	-	0	-	0	n/a	-
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	.
Bones, joints & articular cart.	1	0.7	(0.0 - 2.0)	1.64	(0.00 - 6.06)	-*	0	-	-	-	.
Pyriform sinus & hypopharynx	1	0.6	(0.0 - 1.8)	0.81	(0.00 - 2.98)	-*	0	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.5	(0.0 - 1.6)	2.38	(0.00 - 8.79)	-*	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	0	n/a	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	1	0.4	(0.0 - 1.2)	1.65	(0.00 - 6.07)	-*	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	287	153.1	(135.3 - 171.0)	1.10	(0.98 - 1.24)	-	211	95.6 (82.3 - 109.0)	1.09	(0.95 - 1.25)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Collie (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	4	12.1 (0.0 - 25.1)	0.76	(0.12 - 1.66)	-	
Colorectal cancer	8	19.5 (5.4 - 33.5)	1.29	(0.45 - 2.32)	-		3	7.1 (0.0 - 15.3)	0.69	(0.06 - 1.60)	-*	
Prostate gland	8	22.8 (6.5 - 39.1)	1.51	(0.53 - 2.72)	-		0	-	-	-	.	
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lung, bronchus & trachea	15	46.3 (21.7 - 70.8)	1.29	(0.66 - 2.02)	-		4	13.2 (0.0 - 26.5)	0.77	(0.12 - 1.69)	-	
Lymphoma	2	5.7 (0.0 - 13.6)	1.12	(0.01 - 3.12)	-*		1	2.7 (0.0 - 8.1)	0.66	(0.00 - 2.45)	-*	
Unknown primary site	3	8.6 (0.0 - 18.6)	1.05	(0.08 - 2.45)	-*		5	12.6 (0.4 - 24.7)	2.32	(0.51 - 4.75)	-*	
Kidney & other renal tract	1	3.0 (0.0 - 9.0)	0.81	(0.00 - 3.00)	-*		1	1.6 (0.0 - 4.7)	1.56	(0.00 - 5.74)	-*	
Leukaemia	1	3.0 (0.0 - 9.0)	0.52	(0.00 - 1.91)	-*		1	3.2 (0.0 - 9.4)	0.97	(0.00 - 3.59)	-*	
Pancreas	1	3.0 (0.0 - 8.9)	0.50	(0.00 - 1.84)	-*		0	-	0	n/a	-	
Urinary bladder	0	-	-	0	n/a	-	1	3.8 (0.0 - 11.1)	2.09	(0.00 - 7.71)	-*	
Stomach	2	6.5 (0.0 - 16.5)	0.96	(0.01 - 2.68)	-*		0	-	0	n/a	-	
Corpus uteri	0	-	-	-	-	.	1	4.7 (0.0 - 14.0)	1.57	(0.00 - 5.80)	-*	
Brain	2	8.9 (0.0 - 22.0)	1.29	(0.02 - 3.59)	-*		1	3.9 (0.0 - 11.4)	1.01	(0.00 - 3.73)	-*	
Lip	0	-	-	-	-	.	0	-	-	-	-	
Ovary & uterine adnexa	0	-	-	-	-	.	1	1.2 (0.0 - 3.7)	0.67	(0.00 - 2.48)	-*	
Other lymphohaematopoietic	0	-	-	0	n/a	-	1	1.2 (0.0 - 3.7)	2.97	(0.00 - 10.94)	-*	
Oesophagus	1	1.7 (0.0 - 5.2)	0.78	(0.00 - 2.89)	-*		2	6.0 (0.0 - 15.6)	3.36	(0.04 - 9.36)	-*	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	
Myeloma/plasma cell tumours	2	5.7 (0.0 - 13.6)	2.59	(0.03 - 7.22)	-*		0	-	0	n/a	-	
Cervix uteri	0	-	-	-	-	.	1	3.2 (0.0 - 9.4)	1.49	(0.00 - 5.50)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	3	9.4 (0.0 - 20.5)	9.05	(0.73 - 21.13)	-*	
Testis	0	-	-	-	-	.	0	-	-	-	-	
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	-	0	n/a	
Larynx	0	-	-	-	-	.	0	-	-	-	-	
Tongue	0	-	-	-	-	.	0	-	-	-	-	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	
Small intestine	0	-	-	-	-	.	0	-	-	-	-	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	
Anus	0	-	-	-	-	.	0	-	-	-	-	
Mouth, other & unspecified	1	3.5 (0.0 - 10.4)	7.99	(0.00 - 29.47)	-*		0	-	-	-	-	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	
Pyriform sinus & hypopharynx	1	3.8 (0.0 - 11.2)	4.73	(0.00 - 17.46)	-*		0	-	-	-	-	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	
Gum	0	-	-	-	-	.	0	-	-	-	-	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	
Thymus	0	-	-	-	-	.	0	-	-	-	-	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	
Placenta	0	-	-	-	-	.	0	-	-	-	-	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	
All cancers	48	142.1 (100.0 - 184.1)	1.00	(0.72 - 1.30)	-		30	85.9 (52.8 - 119.0)	0.93	(0.60 - 1.29)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Coolgardie (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	14.7 (0.0 - 43.5)	0.94	(0.00 - 3.48)	-*
Colorectal cancer	1	24.6	(0.0 - 72.6)	0.86	(0.00 - 3.16)	-*	0	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	2	40.9	(0.0 - 98.6)	6.41	(0.08 - 17.86)	-*	0	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	0	n/a	-
Lymphoma	1	8.4	(0.0 - 24.8)	2.69	(0.00 - 9.94)	-*	1	7.9 (0.0 - 23.4)	4.78	(0.00 - 17.62)	-*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	1	9.1 (0.0 - 27.0)	4.75	(0.00 - 17.54)	-*
Lip	1	8.4	(0.0 - 24.8)	92.29	(0.00 - 340.46)	-*	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	1	24.6	(0.0 - 72.6)	4.31	(0.00 - 15.88)	-*	0	-	-	-	.
Thyroid gland	1	7.1	(0.0 - 21.0)	61.35	(0.00 - 226.32)	-*	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	14.7 (0.0 - 43.5)	6.38	(0.00 - 23.54)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	1	27.6 (0.0 - 81.5)	205.41	(0.00 - 757.74)	-*
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	1	9.1 (0.0 - 27.0)	49.65	(0.00 - 183.17)	-*
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	7	113.9	(21.5 - 206.4)	0.79	(0.25 - 1.48)	-	6	83.2 (9.5 - 156.9)	1.22	(0.33 - 2.37)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Coorow (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	24.8 (0.0 - 73.3)	1.48	(0.00 - 5.46)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	1	16.5 (0.0 - 48.8)	2.53	(0.00 - 9.34)	-*	.	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	1	25.0 (0.0 - 72.8)	3.74	(0.00 - 13.81)	-*	.	1	10.9 (0.0 - 31.9)	8.34	(0.00 - 30.77)	-*
Pancreas	1	20.3 (0.0 - 60.1)	3.29	(0.00 - 12.15)	-*	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	1	18.2 (0.0 - 53.5)	12.17	(0.00 - 44.90)	-*	.	0	-	-	-	.
Oesophagus	1	17.1 (0.0 - 50.5)	5.37	(0.00 - 19.80)	-*	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	1	29.4 (0.0 - 85.3)	27.26	(0.00 - 100.55)	-*	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	6	126.5 (24.6 - 228.5)	0.88 (0.24 - 1.71)	-	-	-	2	35.7 (0.0 - 88.5)	0.53 (0.01 - 1.47)	-*	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Corrigin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	0	n/a	-
Colorectal cancer	0	-	-	0	n/a	-	3	54.8 (0.0 - 120.8)	3.69	(0.30 - 8.61)	-*
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	-	-	.	1	6.8 (0.0 - 19.9)	2.40	(0.00 - 8.87)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	2	32.9	(0.0 - 80.0)	8.05	(0.10 - 22.42)	-*	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	45.5 (0.0 - 108.5)	7.49	(0.09 - 20.88)	-*
Other lymphohaematopoietic	1	13.2	(0.0 - 38.6)	9.25	(0.00 - 34.11)	-*	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	21.7 (0.0 - 64.1)	10.71	(0.00 - 39.50)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	1	11.9	(0.0 - 35.1)	35.47	(0.00 - 130.83)	-*	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	4	57.9	(0.0 - 116.2)	0.52	(0.08 - 1.13)	-	7	128.9 (28.1 - 229.7)	1.21	(0.38 - 2.25)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cottesloe (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	11.2 (0.0 - 23.0)	0.84	(0.18 - 1.72)	-
Colorectal cancer	12	40.6	(16.2 - 65.0)	2.14	(0.98 - 3.51)	-	3	2.7 (0.0 - 5.8)	0.56	(0.04 - 1.30)	-
Prostate gland	4	7.7	(0.1 - 15.3)	0.80	(0.12 - 1.76)	-	0	-	-	-	-
Melanoma (skin)	4	12.1	(0.0 - 24.3)	3.39	(0.52 - 7.43)	-*	1	5.0 (0.0 - 14.8)	1.25	(0.00 - 4.62)	-*
Lung, bronchus & trachea	5	15.4	(0.8 - 30.0)	0.49	(0.11 - 1.00)	-	4	3.7 (0.1 - 7.2)	0.68	(0.10 - 1.48)	-
Lymphoma	1	5.0	(0.0 - 14.7)	0.63	(0.00 - 2.33)	-*	0	-	0	n/a	-
Unknown primary site	4	15.2	(0.0 - 30.9)	1.55	(0.24 - 3.40)	-*	3	6.9 (0.0 - 17.0)	1.07	(0.09 - 2.49)	-*
Kidney & other renal tract	1	1.6	(0.0 - 4.8)	0.90	(0.00 - 3.33)	-*	0	-	0	n/a	-
Leukaemia	1	2.2	(0.0 - 6.6)	0.58	(0.00 - 2.15)	-*	1	0.9 (0.0 - 2.7)	0.81	(0.00 - 2.98)	-*
Pancreas	0	-	-	0	n/a	-	2	1.8 (0.0 - 4.4)	0.92	(0.01 - 2.57)	-*
Urinary bladder	1	1.6	(0.0 - 4.8)	0.86	(0.00 - 3.16)	-*	0	-	0	n/a	-
Stomach	1	2.4	(0.0 - 7.0)	0.54	(0.00 - 1.98)	-*	0	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	1	0.9 (0.0 - 2.7)	1.29	(0.00 - 4.76)	-*
Brain	2	6.1	(0.0 - 15.0)	1.49	(0.02 - 4.15)	-*	0	-	0	n/a	-
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	1	0.9 (0.0 - 2.7)	0.58	(0.00 - 2.14)	-*
Other lymphohaematopoietic	2	4.4	(0.0 - 10.6)	3.28	(0.04 - 9.12)	-*	0	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	1	2.7 (0.0 - 8.1)	1.34	(0.00 - 4.94)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	1	1.3 (0.0 - 3.9)	1.37	(0.00 - 5.06)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	1	1.6	(0.0 - 4.8)	0.76	(0.00 - 2.81)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	2	7.1	(0.0 - 17.1)	2.30	(0.03 - 6.41)	-*	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	0	n/a	-
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	1	3.2	(0.0 - 9.5)	4.19	(0.00 - 15.47)	-*	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	1.3 (0.0 - 3.9)	9.50	(0.00 - 35.06)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	1	15.5 (0.0 - 45.8)	17.58	(0.00 - 64.84)	-*
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	42	126.4	(85.6 - 167.3)	0.98	(0.68 - 1.29)	-	25	54.9 (18.3 - 91.4)	0.65	(0.40 - 0.94)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cranbrook (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	0	n/a	-
Colorectal cancer	1	21.2	(0.0 - 62.6)	1.15	(0.00 - 4.23)	-*	0	-	-	-	.
Prostate gland	1	14.7	(0.0 - 43.3)	1.36	(0.00 - 5.03)	-*	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	1	30.8	(0.0 - 90.8)	0.61	(0.00 - 2.25)	-*	0	-	-	-	.
Lymphoma	1	18.0	(0.0 - 53.2)	4.00	(0.00 - 14.76)	-*	2	46.4	(0.0 - 114.1)	13.86	(0.17 - 38.62) -*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	1	23.1	(0.0 - 68.4)	10.01	(0.00 - 36.91) -*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	1	22.2	(0.0 - 65.7)	7.09	(0.00 - 26.15)	-*	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	5	106.9	(10.6 - 203.2)	0.75	(0.16 - 1.53)	-	3	69.5	(0.0 - 151.0)	0.94	(0.08 - 2.20) -*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cuballing (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	1	38.2	(0.0 - 112.9)	1.16	(0.00 - 4.27)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	1	37.7	(0.0 - 111.3)	8.04	(0.00 - 29.65)	-*
Kidney & other renal tract	1	36.1	(0.0 - 106.6)	11.09	(0.00 - 40.92)	-*	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	33.6	(0.0 - 99.2)	10.48	(0.00 - 38.66)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	1	48.8	(0.0 - 143.2)	285.51	(0.00 - 1,053.24)	-*
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	1	40.8	(0.0 - 120.0)	73.68	(0.00 - 271.80)	-*	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	4	148.8	(3.5 - 294.1)	1.17	(0.18 - 2.56)	-*	2	86.5	(0.0 - 206.3)	0.98	(0.01 - 2.72)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cue (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	3	373.2	(0.0 - 792.4)	8.86	(0.71 - 20.68)	-*	2	301.8	(0.0 - 720.5)	16.67	(0.21 - 46.45)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	1	176.5	(0.0 - 517.2)	66.27	(0.00 - 244.46)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	3	373.2	(0.0 - 792.4)	2.07	(0.17 - 4.83)	-*	3	478.3	(0.0 - 1,018.1)	3.52	(0.28 - 8.22)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Cunderdin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	32.8 (0.0 - 85.6)	2.38	(0.03 - 6.63)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	2	37.2	(0.0 - 88.3)	1.11	(0.01 - 3.09)	-*	1	21.3 (0.0 - 62.9)	1.25	(0.00 - 4.62)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	1	20.5	(0.0 - 60.7)	2.26	(0.00 - 8.35)	-*	1	6.7 (0.0 - 19.6)	2.73	(0.00 - 10.06)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	1	26.8 (0.0 - 79.3)	6.77	(0.00 - 24.98)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	1	20.5	(0.0 - 60.7)	8.20	(0.00 - 30.25)	-*	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	4	78.3	(2.2 - 154.5)	0.54	(0.08 - 1.17)	-	6	108.9 (13.3 - 204.5)	1.16	(0.31 - 2.25)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dalwallinu (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	1	15.0	(0.0 - 44.4)	0.90	(0.00 - 3.33)	-*	0	-	0	n/a	-	
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	0	n/a	-	
Lymphoma	1	12.8	(0.0 - 37.8)	3.19	(0.00 - 11.77)	-*	0	-	-	-	.	
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.	
Leukaemia	0	-	-	-	-	.	0	-	-	-	.	
Pancreas	1	19.2	(0.0 - 56.2)	2.74	(0.00 - 10.11)	-*	0	-	-	-	.	
Urinary bladder	2	32.1	(0.0 - 76.6)	9.45	(0.12 - 26.32)	-*	0	-	-	-	.	
Stomach	0	-	-	-	-	.	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	1	16.0	(0.0 - 47.4)	3.41	(0.00 - 12.58)	-*	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	1	10.6	(0.0 - 31.3)	3.86	(0.00 - 14.25) -*	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	1	19.0	(0.0 - 56.3)	4.40	(0.00 - 16.24)	-*	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	1	15.0	(0.0 - 44.4)	10.86	(0.00 - 40.07)	-*	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	8	129.3	(40.1 - 218.4)	0.95	(0.33 - 1.71)	-	1	10.6	(0.0 - 31.3)	0.18	(0.00 - 0.65)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dandaragan (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	3	20.3	(0.0 - 43.2)	1.33	(0.11 - 3.09)	-*	0	-	0	n/a	-	
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	
Melanoma (skin)	1	6.3	(0.0 - 18.5)	2.17	(0.00 - 7.99)	-*	1	10.9	5.17	(0.00 - 19.07)	-*	
Lung, bronchus & trachea	4	29.3	(0.5 - 58.2)	0.92	(0.14 - 2.01)	-*	0	-	0	n/a	-	
Lymphoma	0	-	-	0	n/a	-	1	10.1	2.36	(0.00 - 8.71)	-*	
Unknown primary site	1	8.1	(0.0 - 24.0)	1.01	(0.00 - 3.74)	-*	1	12.4	1.95	(0.00 - 7.20)	-*	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	
Leukaemia	0	-	-	0	n/a	-	2	17.4	7.64	(0.10 - 21.29)	-*	
Pancreas	0	-	-	0	n/a	-	1	10.6	2.18	(0.00 - 8.03)	-*	
Urinary bladder	1	8.1	(0.0 - 24.0)	2.49	(0.00 - 9.18)	-*	0	-	-	-	-	
Stomach	2	13.1	(0.0 - 31.2)	2.71	(0.03 - 7.54)	-*	0	-	-	-	-	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	
Brain	1	10.5	(0.0 - 31.0)	1.71	(0.00 - 6.32)	-*	0	-	-	-	-	
Lip	0	-	-	-	-	.	0	-	-	-	-	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	
Other lymphohaematopoietic	1	6.8	(0.0 - 20.2)	5.17	(0.00 - 19.07)	-*	0	-	-	-	-	
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	
Cervix uteri	0	-	-	-	-	.	1	12.0	5.15	(0.00 - 19.01)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	
Testis	0	-	-	-	-	.	0	-	-	-	-	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	
Larynx	0	-	-	-	-	.	0	-	-	-	-	
Tongue	0	-	-	-	-	.	0	-	-	-	-	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	
Small intestine	0	-	-	-	-	.	0	-	-	-	-	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	
Anus	0	-	-	-	-	.	0	-	-	-	-	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	
Gum	0	-	-	-	-	.	0	-	-	-	-	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	
Thymus	0	-	-	-	-	.	0	-	-	-	-	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	
Placenta	0	-	-	-	-	.	0	-	-	-	-	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	
All cancers	14	102.5	(48.5 - 156.5)	0.82	(0.41 - 1.31)	-	7	73.4	(18.7 - 128.1)	0.80	(0.25 - 1.49)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dardanup (S) - Pt A 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	1	6.1	(0.0 - 18.2)	98.35	(0.00 - 362.82)	-*	0	-	0	n/a	-	
Colorectal cancer	5	32.4	(3.7 - 61.0)	1.88	(0.41 - 3.85)	-*	0	-	0	n/a	-	
Prostate gland	2	16.0	(0.0 - 38.2)	1.05	(0.01 - 2.93)	-*	0	-	-	-	-	
Melanoma (skin)	1	5.1	(0.0 - 15.1)	1.70	(0.00 - 6.27)	-*	1	3.7	3.05	(0.00 - 11.24)	-*	
Lung, bronchus & trachea	5	33.1	(3.7 - 62.5)	1.02	(0.22 - 2.09)	-	2	11.4	0.90	(0.01 - 2.52)	-*	
Lymphoma	1	8.3	(0.0 - 24.6)	1.29	(0.00 - 4.75)	-*	1	6.5	1.54	(0.00 - 5.69)	-*	
Unknown primary site	1	5.0	(0.0 - 14.9)	0.85	(0.00 - 3.13)	-*	0	-	0	n/a	-	
Kidney & other renal tract	1	8.8	(0.0 - 25.8)	1.89	(0.00 - 6.98)	-*	0	-	-	-	-	
Leukaemia	2	13.8	(0.0 - 33.1)	2.40	(0.03 - 6.68)	-*	0	-	-	-	-	
Pancreas	0	-	-	0	n/a	-	0	-	0	n/a	-	
Urinary bladder	1	8.8	(0.0 - 25.8)	2.09	(0.00 - 7.69)	-*	2	11.2	11.32	(0.14 - 31.54)	-*	
Stomach	0	-	-	0	n/a	-	0	-	-	-	-	
Corpus uteri	0	-	-	-	-	-	0	-	-	-	-	
Brain	1	5.8	(0.0 - 17.1)	1.26	(0.00 - 4.67)	-*	0	-	-	-	-	
Lip	0	-	-	-	-	-	0	-	-	-	-	
Ovary & uterine adnexa	0	-	-	-	-	-	0	-	0	n/a	-	
Other lymphohaematopoietic	1	7.7	(0.0 - 22.7)	4.17	(0.00 - 15.38)	-*	0	-	-	-	-	
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-	
Thyroid gland	0	-	-	-	-	-	0	-	-	-	-	
Myeloma/plasma cell tumours	0	-	-	-	-	-	2	11.6	8.51	(0.11 - 23.71)	-*	
Cervix uteri	0	-	-	-	-	-	0	-	-	-	-	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	-	0	-	-	-	-	
Mesothelioma	1	7.7	(0.0 - 22.7)	1.57	(0.00 - 5.80)	-*	0	-	-	-	-	
Liver & intrahepatic bile duct	0	-	-	-	-	-	0	-	-	-	-	
Testis	0	-	-	-	-	-	0	-	-	-	-	
Gallbladder & bile ducts	0	-	-	-	-	-	0	-	-	-	-	
Larynx	1	7.5	(0.0 - 22.3)	5.32	(0.00 - 19.61)	-*	0	-	-	-	-	
Tongue	0	-	-	-	-	-	0	-	-	-	-	
Connective & soft tissues	0	-	-	-	-	-	0	-	-	-	-	
Tonsil & oropharynx	0	-	-	-	-	-	0	-	-	-	-	
Vulva/vagina	0	-	-	-	-	-	0	-	-	-	-	
Small intestine	0	-	-	-	-	-	0	-	-	-	-	
Eye & lacrimal gland	0	-	-	-	-	-	0	-	-	-	-	
Major Salivary Gland	0	-	-	-	-	-	0	-	-	-	-	
Anus	0	-	-	-	-	-	0	-	-	-	-	
Mouth, other & unspecified	0	-	-	-	-	-	0	-	-	-	-	
Floor of mouth	0	-	-	-	-	-	0	-	-	-	-	
Bones, joints & articular cart.	0	-	-	-	-	-	0	-	-	-	-	
Pyriform sinus & hypopharynx	0	-	-	-	-	-	0	-	-	-	-	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	-	0	-	-	-	-	
Peritoneum & retroperitoneum	0	-	-	-	-	-	0	-	-	-	-	
Adrenal & other endocrine	0	-	-	-	-	-	0	-	-	-	-	
Nasopharynx	0	-	-	-	-	-	0	-	-	-	-	
Pharynx, other & ill-def.	0	-	-	-	-	-	0	-	-	-	-	
Penis & other male genital	0	-	-	-	-	-	0	-	-	-	-	
Gum	0	-	-	-	-	-	0	-	-	-	-	
Kaposi sarcoma	0	-	-	-	-	-	0	-	-	-	-	
Thymus	0	-	-	-	-	-	0	-	-	-	-	
Pleura, heart & mediastinum	0	-	-	-	-	-	0	-	-	-	-	
Spinal cord & cranial nerves	0	-	-	-	-	-	0	-	-	-	-	
Uterus, nos	0	-	-	-	-	-	0	-	-	-	-	
Nervous, periph./autonomic	0	-	-	-	-	-	0	-	-	-	-	
Placenta	0	-	-	-	-	-	0	-	-	-	-	
Meninges (cerebral & spinal)	0	-	-	-	-	-	0	-	-	-	-	
All cancers	24	166.2	(99.1 - 233.2)	1.19	(0.72 - 1.71)	-	8	44.3	(12.7 - 75.9)	0.57	(0.20 - 1.03)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dardanup (S) - Pt B 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	10.5 (0.0 - 31.0)	0.91	(0.00 - 3.35)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	0	n/a	-
Prostate gland	1	14.6	(0.0 - 43.2)	0.93	(0.00 - 3.42)	-*	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	2	27.4	(0.0 - 67.6)	0.72	(0.01 - 1.99)	-*	1	20.8 (0.0 - 60.8)	1.07	(0.00 - 3.94)	-*
Lymphoma	1	13.6	(0.0 - 40.1)	2.34	(0.00 - 8.62)	-*	0	-	-	-	.
Unknown primary site	0	-	-	0	n/a	-	0	-	-	-	.
Kidney & other renal tract	1	8.1	(0.0 - 24.0)	3.40	(0.00 - 12.54)	-*	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	15.2 (0.0 - 44.7)	3.59	(0.00 - 13.24)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	16.4 (0.0 - 48.5)	7.17	(0.00 - 26.45)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	2	20.2	(0.0 - 48.1)	7.99	(0.10 - 22.25)	-*	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	12.1 (0.0 - 35.8)	12.47	(0.00 - 46.00)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	7	83.9	(19.3 - 148.5)	0.62	(0.19 - 1.16)	-	5	75.0 (8.0 - 141.9)	0.86	(0.19 - 1.76)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Denmark (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	3	15.6 (0.0 - 33.9)	0.98	(0.08 - 2.28)	-*	
Colorectal cancer	1	3.4 (0.0 - 10.2)	0.25	(0.00 - 0.94)	V*	4	19.3 (0.0 - 39.1)	1.60	(0.25 - 3.51)	-*		
Prostate gland	6	22.1 (4.1 - 40.0)	1.83	(0.50 - 3.57)	-*	0	-	-	-	.		
Melanoma (skin)	1	4.6 (0.0 - 13.7)	1.26	(0.00 - 4.66)	-*	1	3.1 (0.0 - 9.0)	2.52	(0.00 - 9.31)	-*		
Lung, bronchus & trachea	7	31.4 (7.9 - 54.9)	0.94	(0.30 - 1.75)	-	3	12.7 (0.0 - 27.5)	1.00	(0.08 - 2.33)	-*		
Lymphoma	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Kidney & other renal tract	1	5.1 (0.0 - 15.2)	1.29	(0.00 - 4.77)	-*	1	6.3 (0.0 - 18.8)	2.70	(0.00 - 9.96)	-*		
Leukaemia	1	4.6 (0.0 - 13.6)	0.86	(0.00 - 3.16)	-*	1	2.4 (0.0 - 7.1)	1.78	(0.00 - 6.56)	-*		
Pancreas	1	6.1 (0.0 - 18.0)	0.80	(0.00 - 2.95)	-*	2	8.9 (0.0 - 21.8)	1.97	(0.02 - 5.49)	-*		
Urinary bladder	1	2.5 (0.0 - 7.4)	1.27	(0.00 - 4.67)	-*	1	3.1 (0.0 - 9.0)	3.83	(0.00 - 14.12)	-*		
Stomach	1	3.4 (0.0 - 10.2)	0.77	(0.00 - 2.83)	-*	0	-	-	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	-	-	.	1	3.8 (0.0 - 11.2)	5.46	(0.00 - 20.16)	-*	
Oesophagus	1	5.6 (0.0 - 16.5)	1.23	(0.00 - 4.55)	-*	0	-	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	5.8 (0.0 - 17.1)	3.04	(0.00 - 11.21)	-*	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	1	5.8 (0.0 - 17.1)	21.11	(0.00 - 77.87)	-*	
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	1	3.4 (0.0 - 10.2)	10.10	(0.00 - 37.25)	-*	0	-	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	5.8 (0.0 - 17.1)	18.66	(0.00 - 68.84)	-*	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	22	92.3 (53.0 - 131.7)	0.73 (0.43 - 1.07)	-	20	92.5 (50.1 - 134.9)	1.09 (0.62 - 1.61)	-				

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Derby-West Kimberley (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	10.1 (0.0 - 29.9)	0.44	(0.00 - 1.63)	-*
Colorectal cancer	1	7.4 (0.0 - 21.8)	0.36	(0.00 - 1.34)	-*		2	8.0 (0.0 - 19.1)	1.22	(0.02 - 3.41)	-*
Prostate gland	1	8.3 (0.0 - 24.6)	0.49	(0.00 - 1.81)	-*		0	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	.
Lung, bronchus & trachea	9	65.5 (22.4 - 108.6)	1.81	(0.70 - 3.17)	-		3	28.3 (0.0 - 60.8)	1.66	(0.13 - 3.88)	-*
Lymphoma	1	5.8 (0.0 - 17.3)	1.22	(0.00 - 4.50)	-*		1	7.1 (0.0 - 20.9)	1.80	(0.00 - 6.65)	-*
Unknown primary site	4	26.0 (0.3 - 51.7)	3.22	(0.50 - 7.06)	-*		1	4.1 (0.0 - 12.2)	1.23	(0.00 - 4.52)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	.
Leukaemia	3	22.1 (0.0 - 47.5)	3.20	(0.26 - 7.46)	-*		0	-	-	-	.
Pancreas	1	5.7 (0.0 - 16.9)	1.10	(0.00 - 4.05)	-*		1	7.1 (0.0 - 20.9)	1.61	(0.00 - 5.95)	-*
Urinary bladder	0	-	-	0	n/a	-	1	10.5 (0.0 - 31.0)	6.06	(0.00 - 22.37)	-*
Stomach	1	7.4 (0.0 - 21.8)	1.09	(0.00 - 4.03)	-*		0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	2	21.5 (0.0 - 51.1)	8.96	(0.11 - 24.95)	-*
Brain	2	7.8 (0.0 - 18.8)	2.30	(0.03 - 6.41)	-*		0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.
Liver & intrahepatic bile duct	2	11.1 (0.0 - 26.5)	4.40	(0.06 - 12.26)	-*		2	18.1 (0.0 - 43.5)	15.59	(0.19 - 43.42)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	1	8.3 (0.0 - 24.6)	4.28	(0.00 - 15.77)	-*		0	-	-	-	.
Larynx	1	5.9 (0.0 - 17.3)	5.21	(0.00 - 19.23)	-*		0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	1	5.3 (0.0 - 15.6)	8.69	(0.00 - 32.05)	-*		0	-	-	-	.
Tonsil & oropharynx	1	5.8 (0.0 - 17.3)	8.65	(0.00 - 31.90)	-*		0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	29	192.5 (121.4 - 263.6)	1.37	(0.88 - 1.91)	-		14	114.9 (52.1 - 177.7)	1.13	(0.56 - 1.79)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Donnybrook-Balingup (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	19.4 (0.0 - 41.5)	1.13	(0.09 - 2.64)	-*
Colorectal cancer	4	21.6	(0.3 - 43.0)	1.34	(0.21 - 2.94)	-*	3	14.4 (0.0 - 31.1)	1.49	(0.12 - 3.49)	-*
Prostate gland	5	29.2	(3.5 - 54.8)	2.23	(0.49 - 4.57)	-*	0	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	-
Lung, bronchus & trachea	4	26.8	(0.6 - 53.0)	0.72	(0.11 - 1.58)	-	2	15.3 (0.0 - 36.4)	0.87	(0.01 - 2.42)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	0	n/a
Unknown primary site	1	5.2	(0.0 - 15.3)	0.76	(0.00 - 2.79)	-*	0	-	-	0	n/a
Kidney & other renal tract	1	4.4	(0.0 - 12.9)	1.72	(0.00 - 6.33)	-*	0	-	-	-	-
Leukaemia	0	-	-	0	n/a	-	0	-	-	-	-
Pancreas	0	-	-	0	n/a	-	2	10.6 (0.0 - 26.6)	2.57	(0.03 - 7.15)	-*
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	-
Stomach	0	-	-	0	n/a	-	0	-	-	-	-
Corpus uteri	0	-	-	-	-	.	1	3.1 (0.0 - 9.1)	3.53	(0.00 - 13.03)	-*
Brain	0	-	-	0	n/a	-	0	-	-	-	-
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	1	6.4	(0.0 - 19.0)	2.82	(0.00 - 10.40)	-*	0	-	-	-	-
Cervix uteri	0	-	-	-	-	.	2	12.3 (0.0 - 29.4)	6.28	(0.08 - 17.49)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	0	-	-	-	-	.	1	7.5 (0.0 - 22.3)	4.63	(0.00 - 17.09)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-
Major Salivary Gland	1	5.8	(0.0 - 17.2)	20.16	(0.00 - 74.38)	-*	0	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	17	99.4	(51.9 - 146.8)	0.75	(0.40 - 1.15)	-	14	82.6 (37.8 - 127.4)	0.94	(0.47 - 1.50)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dowerin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	29.4	(0.0 - 85.3)	2.04	(0.00 - 7.53)	-*
Colorectal cancer	1	47.6	(0.0 - 140.2)	1.95	(0.00 - 7.21)	-*	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	1	42.6	(0.0 - 125.1)	9.09	(0.00 - 33.53)	-*	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	1	25.0	(0.0 - 73.7)	2.05	(0.00 - 7.56)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	1	18.9	(0.0 - 55.5)	9.49	(0.00 - 35.00)	-*	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	3	109.0	(0.0 - 238.4)	0.77	(0.06 - 1.79)	-*	2	54.4	(0.0 - 128.6)	0.68	(0.01 - 1.88)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dumbleyung (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	-	.
Colorectal cancer	1	22.7	(0.0 - 66.2)	1.77	(0.00 - 6.52)	-*	0	-	-	-	.
Prostate gland	2	52.6	(0.0 - 123.6)	4.49	(0.06 - 12.50)	-*	0	-	-	-	.
Melanoma (skin)	1	29.9	(0.0 - 87.9)	8.49	(0.00 - 31.30)	-*	0	-	-	-	.
Lung, bronchus & trachea	1	37.0	(0.0 - 109.2)	0.94	(0.00 - 3.48)	-*	0	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.
Kidney & other renal tract	1	29.9	(0.0 - 87.9)	8.93	(0.00 - 32.94)	-*	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	6	172.1	(35.1 - 309.1)	1.39	(0.38 - 2.71)	-*	0	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Dundas (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	1	26.3	(0.0 - 76.5)	1.34	(0.00 - 4.96)	-*	0	-	-	-	.	
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	1	19.2	(0.0 - 56.9)	0.74	(0.00 - 2.74)	-*	0	-	-	-	.	
Lymphoma	0	-	-	-	-	.	0	-	-	-	.	
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.	
Leukaemia	0	-	-	-	-	.	1	22.7	(0.0 - 66.2)	9.39	(0.00 - 34.64)	-*
Pancreas	0	-	-	-	-	.	0	-	-	-	.	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.	
Stomach	1	24.4	(0.0 - 71.6)	4.11	(0.00 - 15.16)	-*	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	1	27.8	(0.0 - 82.0)	6.67	(0.00 - 24.60)	-*	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	1	26.3	(0.0 - 76.5)	11.68	(0.00 - 43.07)	-*	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	1	38.5	(0.0 - 113.1)	1,688.23	(0.00 - 9,916.88)	-*
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	5	124.0	(17.5 - 230.5)	0.89	(0.19 - 1.83)	-	2	61.2	(0.0 - 147.6)	0.63	(0.01 - 1.74)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: East Fremantle (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	6	13.8 (0.0 - 27.6)	1.22	(0.33 - 2.37)	-
Colorectal cancer	6	19.8 (3.2 - 36.4)	1.19	(0.32 - 2.32)	-	1	1.9 (0.0 - 5.7)	0.23	(0.00 - 0.83)	v*	
Prostate gland	3	9.7 (0.0 - 21.4)	0.65	(0.05 - 1.52)	-	0	-	-	-	.	
Melanoma (skin)	1	2.2 (0.0 - 6.4)	0.95	(0.00 - 3.50)	-*	1	1.1 (0.0 - 3.1)	1.50	(0.00 - 5.53)	-*	
Lung, bronchus & trachea	7	22.6 (4.6 - 40.6)	0.76	(0.24 - 1.41)	-	2	2.3 (0.0 - 5.4)	0.42	(0.01 - 1.16)	-	
Lymphoma	0	-	0	n/a	-	1	1.1 (0.0 - 3.4)	0.70	(0.00 - 2.58)	-*	
Unknown primary site	3	12.2 (0.0 - 26.0)	1.28	(0.10 - 2.98)	-*	1	1.1 (0.0 - 3.1)	0.43	(0.00 - 1.60)	-*	
Kidney & other renal tract	1	2.2 (0.0 - 6.4)	1.01	(0.00 - 3.71)	-*	2	3.0 (0.0 - 7.3)	3.17	(0.04 - 8.84)	-*	
Leukaemia	1	3.7 (0.0 - 11.0)	0.65	(0.00 - 2.38)	-*	0	-	0	n/a	-	
Pancreas	1	6.1 (0.0 - 18.1)	0.62	(0.00 - 2.30)	-*	4	14.9 (0.0 - 31.8)	2.26	(0.35 - 4.95)	-*	
Urinary bladder	0	-	0	n/a	-	0	-	0	n/a	-	
Stomach	2	6.4 (0.0 - 15.3)	1.18	(0.01 - 3.28)	-*	1	1.9 (0.0 - 5.7)	1.00	(0.00 - 3.69)	-*	
Corpus uteri	0	-	-	-	.	0	-	0	n/a	-	
Brain	1	4.2 (0.0 - 12.5)	0.84	(0.00 - 3.11)	-*	0	-	0	n/a	-	
Lip	0	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	.	2	2.1 (0.0 - 5.0)	1.41	(0.02 - 3.94)	-*	
Other lymphohaematopoietic	0	-	0	n/a	-	1	4.7 (0.0 - 13.9)	2.50	(0.00 - 9.23)	-*	
Oesophagus	0	-	0	n/a	-	1	3.3 (0.0 - 9.8)	1.63	(0.00 - 6.01)	-*	
Thyroid gland	0	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	0	n/a	-	1	1.1 (0.0 - 3.1)	1.70	(0.00 - 6.26)	-*	
Cervix uteri	0	-	-	-	.	0	-	0	n/a	-	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	.	0	-	-	-	.	
Mesothelioma	3	10.8 (0.0 - 23.5)	2.57	(0.21 - 6.01)	-*	0	-	-	-	.	
Liver & intrahepatic bile duct	1	4.9 (0.0 - 14.4)	1.30	(0.00 - 4.78)	-*	1	1.1 (0.0 - 3.4)	3.15	(0.00 - 11.62)	-*	
Testis	0	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	.	2	5.9 (0.0 - 15.6)	3.87	(0.05 - 10.77)	-*	
Larynx	0	-	-	-	.	0	-	-	-	.	
Tongue	1	4.2 (0.0 - 12.5)	4.60	(0.00 - 16.98)	-*	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	.	1	1.1 (0.0 - 3.1)	6.84	(0.00 - 25.25)	-*	
Small intestine	0	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	.	1	1.1 (0.0 - 3.4)	7.82	(0.00 - 28.85)	-*	
Mouth, other & unspecified	0	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	.	0	-	-	-	.	
All cancers	31	108.9 (68.6 - 149.1)	0.80	(0.52 - 1.10)	-	29	61.4 (33.2 - 89.6)	0.93	(0.59 - 1.29)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: East Pilbara (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	27.3	(0.0 - 70.8)	1.39	(0.02 - 3.88)	-*
Colorectal cancer	1	17.8	(0.0 - 52.4)	0.60	(0.00 - 2.20)	-*	0	-	-	0	n/a	-
Prostate gland	1	21.7	(0.0 - 64.1)	1.08	(0.00 - 4.00)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	3	36.4	(0.0 - 82.7)	1.07	(0.09 - 2.51)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	.
Unknown primary site	0	-	-	0	n/a	-	1	20.1	(0.0 - 59.5)	2.47	(0.00 - 9.12)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	0	-	-	-	-	.
Pancreas	0	-	-	0	n/a	-	0	-	-	-	-	.
Urinary bladder	1	21.7	(0.0 - 64.1)	4.04	(0.00 - 14.89)	-*	0	-	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	0	n/a	-	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	1	11.9	(0.0 - 35.2)	5.51	(0.00 - 20.32)	-*	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	5.8	(0.0 - 17.2)	4.80	(0.00 - 17.71)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	1	5.9	(0.0 - 17.5)	2.55	(0.00 - 9.41)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	11.9	(0.0 - 35.2)	8.42	(0.00 - 31.06)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	1	11.9	(0.0 - 35.2)	17.50	(0.00 - 64.55)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	10	139.3	(46.4 - 232.2)	0.79	(0.33 - 1.35)	-	4	53.3	(0.0 - 112.9)	0.59	(0.09 - 1.29)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Esperance (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	6	13.8 (2.6 - 24.9)	0.87	(0.24 - 1.69)	-
Colorectal cancer	14	33.8	(15.9 - 51.6)	1.80	(0.89 - 2.85)	-	6	12.5 (1.9 - 23.1)	1.09	(0.30 - 2.12)	-
Prostate gland	9	19.4	(6.6 - 32.3)	1.49	(0.57 - 2.61)	-	0	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	0	n/a	-
Lung, bronchus & trachea	9	22.6	(7.8 - 37.4)	0.62	(0.24 - 1.09)	-	8	19.2 (5.5 - 32.8)	1.25	(0.44 - 2.25)	-
Lymphoma	0	-	-	0	n/a	-	1	3.4 (0.0 - 10.0)	0.53	(0.00 - 1.96)	-*
Unknown primary site	2	4.6	(0.0 - 11.0)	0.57	(0.01 - 1.59)	-*	3	8.1 (0.0 - 17.3)	1.12	(0.09 - 2.61)	-*
Kidney & other renal tract	1	2.1	(0.0 - 6.2)	0.65	(0.00 - 2.39)	-*	3	7.8 (0.0 - 16.6)	3.78	(0.31 - 8.83)	-*
Leukaemia	4	9.5	(0.2 - 18.9)	1.68	(0.26 - 3.69)	-*	1	1.6 (0.0 - 4.6)	0.77	(0.00 - 2.83)	-*
Pancreas	3	7.1	(0.0 - 15.3)	1.19	(0.10 - 2.77)	-*	3	6.4 (0.0 - 13.9)	1.38	(0.11 - 3.21)	-*
Urinary bladder	0	-	-	0	n/a	-	0	-	0	n/a	-
Stomach	2	5.1	(0.0 - 12.1)	0.77	(0.01 - 2.16)	-*	1	1.6 (0.0 - 4.6)	0.83	(0.00 - 3.06)	-*
Corpus uteri	0	-	-	-	-	.	1	2.4 (0.0 - 7.1)	1.28	(0.00 - 4.72)	-*
Brain	2	4.5	(0.0 - 10.7)	0.97	(0.01 - 2.70)	-*	1	2.5 (0.0 - 7.4)	0.78	(0.00 - 2.88)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	0	n/a	-
Other lymphohaematopoietic	2	4.3	(0.0 - 10.5)	2.64	(0.03 - 7.36)	-*	0	-	-	-	.
Oesophagus	2	4.2	(0.0 - 10.0)	1.25	(0.02 - 3.48)	-*	1	1.4 (0.0 - 4.1)	1.36	(0.00 - 5.02)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	0	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	1	2.8	(0.0 - 8.3)	0.54	(0.00 - 1.98)	-*	2	2.9 (0.0 - 7.0)	9.10	(0.11 - 25.35)	-*
Liver & intrahepatic bile duct	1	2.3	(0.0 - 6.7)	0.78	(0.00 - 2.88)	-*	0	-	-	-	.
Testis	1	3.6	(0.0 - 10.7)	19.09	(0.00 - 70.43)	-*	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	0	n/a	-
Larynx	0	-	-	0	n/a	-	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	1	3.2	(0.0 - 9.3)	7.90	(0.00 - 29.13)	-*	1	2.4 (0.0 - 7.0)	11.83	(0.00 - 43.65)	-*
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	1	2.6 (0.0 - 7.8)	40.72	(0.00 - 150.23)	-*
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	54	129.0	(94.4 - 163.7)	0.91	(0.69 - 1.20)	-	39	88.5 (59.9 - 117.2)	0.96	(0.66 - 1.29)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Exmouth (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	11.3 (0.0 - 33.5)	1.14	(0.00 - 4.22)	-*
Colorectal cancer	1	13.0	(0.0 - 38.6)	0.92	(0.00 - 3.41)	-*	1	13.2 (0.0 - 38.6)	1.70	(0.00 - 6.25)	-*
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	1	19.4	(0.0 - 57.4)	4.12	(0.00 - 15.19)	-*	0	-	-	-	.
Lung, bronchus & trachea	2	28.7	(0.0 - 68.8)	1.00	(0.01 - 2.78)	-*	0	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	1	14.2 (0.0 - 41.9)	4.69	(0.00 - 17.31)	-*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	2	44.9 (0.0 - 106.8)	8.78	(0.11 - 24.47)	-*
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	1	50.0	(0.0 - 143.0)	11.74	(0.00 - 43.31)	-*	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	13.2 (0.0 - 38.6)	20.51	(0.00 - 75.64)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	1	10.7	(0.0 - 31.5)	27.27	(0.00 - 100.61)	-*	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	6	121.9	(8.8 - 234.9)	0.74	(0.20 - 1.44)	-	6	96.7 (16.9 - 176.4)	1.30	(0.35 - 2.53)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Fremantle (C) - Inner 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	1	74.1 (0.0 - 216.5)	3.21 (0.00 - 11.85)		-*	
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	1	33.9 (0.0 - 100.1)		65.30 (0.00 - 240.89)		-*	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	33.9 (0.0 - 100.1)		0.17 (0.00 - 0.63)		V	1	74.1 (0.0 - 216.5)	0.51 (0.00 - 1.87)		-*	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Fremantle (C) - Remainder 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	27	24.1 (14.2 - 34.1)	1.43	(0.90 - 2.01)	-	
Colorectal cancer	22	22.2	(12.6 - 31.8)	1.11	(0.66 - 1.62)	-	19	15.2 (7.5 - 22.8)	1.12	(0.63 - 1.67)	-	
Prostate gland	20	15.7	(8.7 - 22.7)	1.18	(0.67 - 1.75)	-	0	-	-	-	.	
Melanoma (skin)	3	2.2	(0.0 - 4.8)	0.73	(0.06 - 1.71)	-*	0	-	0	n/a	-	
Lung, bronchus & trachea	45	41.8	(29.0 - 54.6)	1.20	(0.85 - 1.58)	-	21	16.8 (8.8 - 24.8)	1.11	(0.65 - 1.63)	-	
Lymphoma	7	6.1	(1.3 - 10.8)	1.25	(0.39 - 2.32)	-	4	2.6 (0.0 - 6.0)	0.72	(0.11 - 1.57)	-	
Unknown primary site	13	12.9	(5.6 - 20.2)	1.43	(0.68 - 2.31)	-	8	4.8 (0.7 - 8.8)	0.92	(0.32 - 1.65)	-	
Kidney & other renal tract	4	4.0	(0.0 - 7.9)	1.03	(0.16 - 2.26)	-*	0	-	0	n/a	-	
Leukaemia	6	5.3	(0.9 - 9.8)	0.99	(0.27 - 1.93)	-	2	1.7 (0.0 - 4.6)	0.51	(0.01 - 1.43)	-*	
Pancreas	6	5.7	(1.0 - 10.4)	0.94	(0.26 - 1.84)	-	6	4.5 (0.5 - 8.6)	0.88	(0.24 - 1.71)	-	
Urinary bladder	3	2.9	(0.0 - 6.2)	0.73	(0.06 - 1.71)	-*	3	1.4 (0.0 - 3.1)	1.53	(0.12 - 3.57)	-*	
Stomach	6	5.1	(0.7 - 9.6)	0.91	(0.25 - 1.77)	-	8	6.1 (1.3 - 11.0)	2.09	(0.74 - 3.77)	-*	
Corpus uteri	0	-	-	-	-	.	4	1.7 (0.0 - 3.5)	1.62	(0.25 - 3.56)	-*	
Brain	5	6.1	(0.7 - 11.5)	1.09	(0.24 - 2.22)	-	4	6.0 (0.0 - 12.9)	1.20	(0.19 - 2.63)	-*	
Lip	0	-	-	-	-	.	1	0.8 (0.0 - 2.3)	12.59	(0.00 - 46.45)	-*	
Ovary & uterine adnexa	0	-	-	-	-	.	4	2.1 (0.0 - 4.7)	0.73	(0.11 - 1.59)	-	
Other lymphohaematopoietic	1	0.6	(0.0 - 1.7)	0.48	(0.00 - 1.78)	-*	2	1.5 (0.0 - 4.0)	1.35	(0.02 - 3.77)	-*	
Oesophagus	2	2.3	(0.0 - 5.5)	0.49	(0.01 - 1.37)	-*	1	0.3 (0.0 - 1.0)	0.43	(0.00 - 1.57)	-*	
Thyroid gland	0	-	-	-	-	.	1	0.3 (0.0 - 1.0)	1.73	(0.00 - 6.39)	-*	
Myeloma/plasma cell tumours	4	3.0	(0.0 - 6.1)	1.62	(0.25 - 3.55)	-*	3	3.2 (0.0 - 6.8)	1.33	(0.11 - 3.11)	-*	
Cervix uteri	0	-	-	-	-	.	2	0.9 (0.0 - 2.1)	0.84	(0.01 - 2.35)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	.	
Mesothelioma	7	5.9	(1.3 - 10.5)	1.50	(0.47 - 2.80)	-	0	-	0	n/a	-	
Liver & intrahepatic bile duct	1	0.8	(0.0 - 2.4)	0.32	(0.00 - 1.16)	-*	0	-	0	n/a	-	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	5	4.9	(0.5 - 9.4)	2.94	(0.64 - 6.02)	-*	1	0.4 (0.0 - 1.3)	0.51	(0.00 - 1.86)	-*	
Larynx	1	0.5	(0.0 - 1.6)	0.73	(0.00 - 2.68)	-*	0	-	-	-	.	
Tongue	0	-	-	0	n/a	-	0	-	-	-	.	
Connective & soft tissues	1	0.5	(0.0 - 1.6)	1.92	(0.00 - 7.07)	-*	0	-	-	-	.	
Tonsil & oropharynx	1	1.2	(0.0 - 3.5)	1.37	(0.00 - 5.07)	-*	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	0	n/a	-	
Small intestine	0	-	-	0	n/a	-	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	3	2.0 (0.0 - 4.6)	6.32	(0.51 - 14.76)	-*	
Mouth, other & unspecified	1	1.2	(0.0 - 3.4)	2.57	(0.00 - 9.49)	-*	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	1	1.8 (0.0 - 5.5)	5.45	(0.00 - 20.12)	-*	
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	1	1.2	(0.0 - 3.6)	3.82	(0.00 - 14.08)	-*	1	0.8 (0.0 - 2.3)	2.43	(0.00 - 8.95)	-*	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	1	1.4	(0.0 - 4.2)	2.95	(0.00 - 10.90)	-*	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	1	1.2 (0.0 - 3.6)	8.52	(0.00 - 31.44)	-*	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	1	0.3 (0.0 - 0.9)	12.75	(0.00 - 47.05)	-*	
All cancers	166	153.6	(129.4 - 177.9)	1.09	(0.93 - 1.27)	-	128	100.7	(80.4 - 120.9)	1.06	(0.89 - 1.26)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Geraldton (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	21	26.7 (14.3 - 39.1)	1.67	(0.97 - 2.46)	-
Colorectal cancer	13	18.8 (8.3 - 29.2)	0.97	(0.46 - 1.56)	-		5	4.0 (0.2 - 7.8)	0.45	(0.10 - 0.93)	v
Prostate gland	13	15.5 (7.0 - 24.0)	1.17	(0.56 - 1.89)	-		0	-	-	-	.
Melanoma (skin)	10	12.8 (4.6 - 21.0)	3.63	(1.49 - 6.20)	^*		1	1.5 (0.0 - 4.4)	0.59	(0.00 - 2.19)	-*
Lung, bronchus & trachea	47	64.0 (45.3 - 82.7)	1.85	(1.32 - 2.41)	^		17	19.0 (9.1 - 28.8)	1.35	(0.73 - 2.07)	-
Lymphoma	1	1.0 (0.0 - 3.0)	0.27	(0.00 - 0.98)	v*		1	0.7 (0.0 - 2.1)	0.27	(0.00 - 1.00)	-*
Unknown primary site	5	6.1 (0.7 - 11.5)	0.82	(0.18 - 1.67)	-		10	13.1 (4.5 - 21.6)	1.81	(0.75 - 3.10)	-
Kidney & other renal tract	1	1.5 (0.0 - 4.3)	0.38	(0.00 - 1.40)	-*		1	0.5 (0.0 - 1.5)	0.62	(0.00 - 2.31)	-*
Leukaemia	3	4.5 (0.0 - 9.6)	0.73	(0.06 - 1.69)	-*		3	1.9 (0.0 - 4.2)	1.17	(0.09 - 2.74)	-*
Pancreas	6	7.9 (1.4 - 14.3)	1.38	(0.37 - 2.68)	-*		9	12.4 (3.7 - 21.0)	2.02	(0.78 - 3.55)	-*
Urinary bladder	4	4.2 (0.1 - 8.4)	1.46	(0.23 - 3.20)	-*		1	0.5 (0.0 - 1.5)	0.81	(0.00 - 2.99)	-*
Stomach	10	12.4 (4.6 - 20.2)	2.23	(0.92 - 3.81)	-*		0	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	2	1.3 (0.0 - 3.0)	1.25	(0.02 - 3.49)	-*
Brain	7	11.1 (2.8 - 19.4)	2.16	(0.68 - 4.03)	-*		2	2.6 (0.0 - 6.3)	0.87	(0.01 - 2.42)	-*
Lip	1	1.0 (0.0 - 3.0)	20.24	(0.00 - 74.67)	-*		1	0.6 (0.0 - 1.6)	20.38	(0.00 - 75.17)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	5	5.7 (0.3 - 11.1)	1.37	(0.30 - 2.81)	-*
Other lymphohaematopoietic	0	-	-	0	n/a	-	1	0.7 (0.0 - 2.1)	1.10	(0.00 - 4.04)	-*
Oesophagus	6	8.3 (1.5 - 15.0)	2.18	(0.59 - 4.23)	-*		4	5.4 (0.0 - 11.1)	2.66	(0.41 - 5.83)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	3	3.6 (0.0 - 7.8)	1.80	(0.15 - 4.20)	-*		2	1.7 (0.0 - 4.2)	1.38	(0.02 - 3.84)	-*
Cervix uteri	0	-	-	-	-	.	2	2.1 (0.0 - 5.2)	1.26	(0.02 - 3.52)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	6	8.6 (1.5 - 15.7)	1.88	(0.51 - 3.65)	-*		0	-	-	-	.
Liver & intrahepatic bile duct	2	2.2 (0.0 - 5.2)	0.92	(0.01 - 2.55)	-*		2	1.7 (0.0 - 4.1)	2.46	(0.03 - 6.86)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	1	1.9 (0.0 - 5.5)	0.90	(0.00 - 3.31)	-*		1	1.8 (0.0 - 5.3)	0.79	(0.00 - 2.91)	-*
Larynx	3	3.2 (0.0 - 6.8)	3.21	(0.26 - 7.50)	-*		0	-	-	-	.
Tongue	3	4.7 (0.0 - 10.1)	5.14	(0.41 - 11.99)	-*		2	1.7 (0.0 - 4.1)	7.56	(0.09 - 21.07)	-*
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	1	1.0 (0.0 - 3.0)	2.02	(0.00 - 7.44)	-*		0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	1	1.8 (0.0 - 5.3)	3.57	(0.00 - 13.17)	-*
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	1	1.1 (0.0 - 3.1)	3.82	(0.00 - 14.10)	-*		1	1.8 (0.0 - 5.4)	8.62	(0.00 - 31.79)	-*
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	1	1.5 (0.0 - 4.3)	2.16	(0.00 - 7.96)	-*		0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	1	0.5 (0.0 - 1.5)	11.97	(0.00 - 44.17)	-*
Pharynx, other & ill-def.	1	1.9 (0.0 - 5.5)	4.52	(0.00 - 16.66)	-*		0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	149	198.5 (166.1 - 231.0)	1.45	(1.23 - 1.70)	^		96	109.5 (85.5 - 133.5)	1.21	(0.99 - 1.49)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Gingin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	6.4 (0.0 - 18.9)	0.40	(0.00 - 1.47)	-*
Colorectal cancer	8	48.5	(13.4 - 83.7)	2.48	(0.87 - 4.47)	-*	2	12.1 (0.0 - 28.9)	1.05	(0.01 - 2.91)	-*
Prostate gland	4	23.3	(0.3 - 46.3)	1.91	(0.30 - 4.18)	-*	0	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	.
Lung, bronchus & trachea	5	27.6	(3.2 - 52.0)	0.81	(0.18 - 1.65)	-	1	6.7 (0.0 - 19.7)	0.44	(0.00 - 1.62)	-*
Lymphoma	2	11.0	(0.0 - 26.3)	2.26	(0.03 - 6.30)	-*	1	5.5 (0.0 - 16.2)	1.49	(0.00 - 5.48)	-*
Unknown primary site	3	16.8	(0.0 - 35.7)	2.16	(0.17 - 5.05)	-*	1	5.5 (0.0 - 16.2)	1.15	(0.00 - 4.24)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	.
Leukaemia	1	6.1	(0.0 - 18.1)	1.09	(0.00 - 4.01)	-*	0	-	-	-	.
Pancreas	2	9.9	(0.0 - 23.6)	1.86	(0.02 - 5.17)	-*	1	5.7 (0.0 - 16.9)	1.33	(0.00 - 4.89)	-*
Urinary bladder	1	5.3	(0.0 - 15.7)	1.78	(0.00 - 6.57)	-*	0	-	-	-	.
Stomach	2	16.2	(0.0 - 39.7)	1.90	(0.02 - 5.29)	-*	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	1	5.3	(0.0 - 15.7)	1.18	(0.00 - 4.36)	-*	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	12.5 (0.0 - 30.0)	2.88	(0.04 - 8.03)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	1	5.3	(0.0 - 15.7)	1.49	(0.00 - 5.50)	-*	1	7.0 (0.0 - 20.8)	3.99	(0.00 - 14.71)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	6.2 (0.0 - 18.4)	3.29	(0.00 - 12.14)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	1	5.3	(0.0 - 15.7)	1.24	(0.00 - 4.58)	-*	1	6.7 (0.0 - 19.7)	12.27	(0.00 - 45.26)	-*
Liver & intrahepatic bile duct	1	5.7	(0.0 - 16.9)	1.78	(0.00 - 6.56)	-*	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	32	186.4	(120.7 - 252.1)	1.33	(0.87 - 1.83)	-	12	74.3 (32.3 - 116.3)	0.85	(0.39 - 1.39)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Gnowangerup (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	0	n/a	-
Colorectal cancer	2	51.8	(0.0 - 123.4)	2.12	(0.03 - 5.90)	-*	1	12.0	1.50	(0.00 - 5.55)	-*
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	1	24.2	(0.0 - 71.4)	0.57	(0.00 - 2.11)	-*	0	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	1	24.2	(0.0 - 71.4)	2.33	(0.00 - 8.60)	-*	0	-	-	-	.
Kidney & other renal tract	1	24.2	(0.0 - 71.4)	5.37	(0.00 - 19.80)	-*	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	1	19.2	(0.0 - 56.7)	3.20	(0.00 - 11.82)	-*	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	1	24.2	(0.0 - 71.4)	3.88	(0.00 - 14.31)	-*	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	12.0	13.61	(0.00 - 50.22)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	7	167.8	(44.9 - 290.7)	0.97	(0.30 - 1.81)	-	2	24.1	0.41	(0.01 - 1.15)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Goomalling (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	15.4	(0.0 - 45.3)	1.57	(0.00 - 5.79)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lymphoma	1	25.0	(0.0 - 72.8)	4.79	(0.00 - 17.68)	-*	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	25.0	(0.0 - 72.8)	0.18	(0.00 - 0.65)	V	1	15.4	(0.0 - 45.3)	0.26	(0.00 - 0.94)	V*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Gosnells (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	44	17.4 (12.1 - 22.7)	1.09	(0.77 - 1.43)	-
Colorectal cancer	50	24.1	(17.3 - 30.9)	1.26	(0.91 - 1.63)	-	23	8.4 (4.8 - 11.9)	0.75	(0.45 - 1.09)	-
Prostate gland	23	9.7	(5.7 - 13.8)	0.79	(0.47 - 1.14)	-	0	-	-	-	.
Melanoma (skin)	5	2.3	(0.2 - 4.3)	0.57	(0.12 - 1.17)	-	5	1.9 (0.2 - 3.6)	0.96	(0.21 - 1.97)	-
Lung, bronchus & trachea	75	34.8	(26.8 - 42.8)	1.02	(0.81 - 1.28)	-	27	10.1 (6.2 - 14.1)	0.75	(0.47 - 1.06)	-
Lymphoma	15	6.9	(3.3 - 10.5)	1.29	(0.66 - 2.02)	-	7	3.0 (0.7 - 5.3)	0.67	(0.21 - 1.24)	-
Unknown primary site	22	9.9	(5.7 - 14.2)	1.24	(0.73 - 1.81)	-	10	3.6 (1.2 - 6.0)	0.67	(0.28 - 1.15)	-
Kidney & other renal tract	8	3.3	(1.0 - 5.6)	1.01	(0.36 - 1.82)	-	0	-	0	n/a	V
Leukaemia	14	5.2	(2.5 - 7.9)	1.12	(0.55 - 1.78)	-	12	5.2 (2.2 - 8.2)	1.60	(0.73 - 2.62)	-
Pancreas	14	5.4	(2.5 - 8.3)	1.06	(0.52 - 1.68)	-	13	4.9 (2.1 - 7.8)	1.09	(0.52 - 1.75)	-
Urinary bladder	7	3.0	(0.7 - 5.2)	0.96	(0.30 - 1.79)	-	3	1.1 (0.0 - 2.4)	0.96	(0.08 - 2.23)	-*
Stomach	7	3.2	(0.8 - 5.6)	0.53	(0.17 - 0.99)	V	5	2.4 (0.2 - 4.5)	0.75	(0.16 - 1.54)	-
Corpus uteri	0	-	-	-	-	.	4	1.2 (0.0 - 2.4)	0.92	(0.14 - 2.03)	-*
Brain	10	4.4	(1.6 - 7.2)	0.87	(0.36 - 1.49)	-	4	1.7 (0.0 - 3.4)	0.54	(0.08 - 1.17)	-
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	17	6.8 (3.4 - 10.2)	1.59	(0.86 - 2.43)	-
Other lymphohaematopoietic	3	1.4	(0.0 - 3.0)	0.82	(0.07 - 1.91)	-*	4	1.6 (0.0 - 3.3)	1.74	(0.27 - 3.80)	-*
Oesophagus	4	2.2	(0.0 - 4.3)	0.49	(0.08 - 1.07)	-	2	1.0 (0.0 - 2.4)	0.49	(0.01 - 1.38)	-*
Thyroid gland	0	-	-	0	n/a	-	1	0.4 (0.0 - 1.3)	0.92	(0.00 - 3.40)	-*
Myeloma/plasma cell tumours	7	3.6	(0.9 - 6.2)	1.49	(0.47 - 2.79)	-	7	2.2 (0.5 - 3.8)	1.77	(0.56 - 3.29)	-*
Cervix uteri	0	-	-	-	-	.	6	1.9 (0.2 - 3.5)	1.18	(0.32 - 2.29)	-
Non-mel. skin (exc BCC/SCC)	2	1.0	(0.0 - 2.5)	1.63	(0.02 - 4.54)	-*	0	-	0	n/a	-
Mesothelioma	17	8.2	(4.3 - 12.2)	1.78	(0.96 - 2.73)	-	2	0.8 (0.0 - 1.8)	1.58	(0.02 - 4.41)	-*
Liver & intrahepatic bile duct	7	3.1	(0.8 - 5.5)	1.05	(0.33 - 1.96)	-	4	1.4 (0.0 - 2.8)	1.70	(0.26 - 3.72)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	1	0.4	(0.0 - 1.2)	0.29	(0.00 - 1.07)	-*	4	1.3 (0.0 - 2.6)	1.15	(0.18 - 2.52)	-*
Larynx	5	2.3	(0.3 - 4.4)	1.77	(0.38 - 3.62)	-*	0	-	-	-	.
Tongue	4	1.8	(0.0 - 3.6)	2.23	(0.34 - 4.88)	-*	1	0.4 (0.0 - 1.3)	1.22	(0.00 - 4.49)	-*
Connective & soft tissues	0	-	-	0	n/a	-	1	0.4 (0.0 - 1.1)	1.12	(0.00 - 4.12)	-*
Tonsil & oropharynx	1	0.3	(0.0 - 1.0)	0.60	(0.00 - 2.22)	-*	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	0.2 (0.0 - 0.6)	1.19	(0.00 - 4.39)	-*
Small intestine	0	-	-	0	n/a	-	1	0.6 (0.0 - 1.6)	1.19	(0.00 - 4.40)	-*
Eye & lacrimal gland	1	0.4	(0.0 - 1.1)	1.43	(0.00 - 5.26)	-*	1	0.4 (0.0 - 1.3)	2.22	(0.00 - 8.20)	-*
Major Salivary Gland	1	0.6	(0.0 - 1.7)	1.56	(0.00 - 5.75)	-*	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	0	n/a	-
Mouth, other & unspecified	0	-	-	0	n/a	-	1	0.6 (0.0 - 1.7)	1.55	(0.00 - 5.71)	-*
Floor of mouth	0	-	-	0	n/a	-	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	0	n/a	-	1	0.4 (0.0 - 1.1)	1.84	(0.00 - 6.79)	-*
Pyriform sinus & hypopharynx	3	1.2	(0.0 - 2.6)	2.12	(0.17 - 4.94)	-*	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	0	n/a	-	0	-	0	n/a	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	1	0.4	(0.0 - 1.2)	1.77	(0.00 - 6.53)	-*	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	.
Penis & other male genital	1	0.4	(0.0 - 1.1)	4.72	(0.00 - 17.43)	-*	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	1	0.4 (0.0 - 1.3)	9.51	(0.00 - 35.10)	-*
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	308	139.6	(123.8 - 155.4)	1.02	(0.91 - 1.14)	-	217	83.5 (71.9 - 95.1)	0.95	(0.83 - 1.08)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Greenough (S) - Pt A 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	15.0 (0.0 - 29.9)	0.96	(0.15 - 2.11)	-*
Colorectal cancer	7	29.4	(7.6 - 51.2)	1.60	(0.50 - 2.99)	-*	2	10.5 (0.0 - 25.1)	0.77	(0.01 - 2.15)	-*
Prostate gland	1	4.5	(0.0 - 13.3)	0.37	(0.00 - 1.37)	-*	0	-	-	-	.
Melanoma (skin)	1	7.6	(0.0 - 22.3)	1.02	(0.00 - 3.76)	-*	0	-	0	n/a	-
Lung, bronchus & trachea	6	22.3	(4.1 - 40.5)	0.75	(0.20 - 1.45)	-	9	43.9 (14.8 - 73.0)	2.85	(1.09 - 4.99)	^*
Lymphoma	5	15.9	(1.7 - 30.1)	3.94	(0.86 - 8.06)	-*	1	5.0 (0.0 - 14.8)	1.07	(0.00 - 3.96)	-*
Unknown primary site	0	-	-	0	n/a	-	0	-	0	n/a	-
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	.
Leukaemia	2	5.8	(0.0 - 13.9)	1.48	(0.02 - 4.12)	-*	1	3.1 (0.0 - 9.3)	1.44	(0.00 - 5.32)	-*
Pancreas	3	11.4	(0.0 - 24.5)	2.01	(0.16 - 4.69)	-*	0	-	0	n/a	-
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	0	n/a	-	3	13.2 (0.0 - 28.6)	3.82	(0.31 - 8.91)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	3.4 (0.0 - 10.1)	1.02	(0.00 - 3.75)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	1	4.0	(0.0 - 11.8)	1.11	(0.00 - 4.10)	-*	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	1	4.0	(0.0 - 11.7)	2.04	(0.00 - 7.51)	-*	1	5.0 (0.0 - 14.8)	3.09	(0.00 - 11.38)	-*
Cervix uteri	0	-	-	-	-	.	0	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	1	4.8	(0.0 - 14.2)	8.02	(0.00 - 29.57)	-*	0	-	-	-	.
Mesothelioma	1	4.9	(0.0 - 14.3)	0.94	(0.00 - 3.47)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	2	8.0	(0.0 - 19.4)	5.52	(0.07 - 15.37)	-*	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	1	4.5	(0.0 - 13.3)	17.20	(0.00 - 63.45)	-*	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	1	2.8	(0.0 - 8.3)	9.44	(0.00 - 34.82)	-*	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	1	3.4 (0.0 - 10.1)	47.39	(0.00 - 174.81)	-*
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	33	129.9	(84.4 - 175.3)	1.00	(0.67 - 1.37)	-	23	102.6 (59.8 - 145.5)	1.11	(0.67 - 1.61)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Greenough (S) - Pt B 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	27.0	(0.0 - 79.9)	1.83	(0.00 - 6.74)	-*
Colorectal cancer	1	20.2	(0.0 - 59.6)	1.28	(0.00 - 4.74)	-*	0	-	-	-	-	.
Prostate gland	2	44.9	(0.0 - 107.2)	3.50	(0.04 - 9.76)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	1	16.1	(0.0 - 47.5)	0.69	(0.00 - 2.54)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	27.8	(0.0 - 81.8)	119.75	(0.00 - 441.77)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	4	81.2	(1.1 - 161.3)	0.67	(0.10 - 1.47)	-	2	54.8	(0.0 - 130.4)	0.72	(0.01 - 2.01)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Halls Creek (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	47.0 (0.0 - 104.7)	2.75	(0.22 - 6.41)	-*
Colorectal cancer	1	12.3	(0.0 - 36.4)	0.79	(0.00 - 2.90)	-*	1	15.2 (0.0 - 44.6)	1.26	(0.00 - 4.65)	-*
Prostate gland	1	21.3	(0.0 - 62.8)	1.02	(0.00 - 3.77)	-*	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	1	15.6	(0.0 - 46.2)	0.44	(0.00 - 1.61)	-*	0	-	0	n/a	-
Lymphoma	1	12.8	(0.0 - 37.6)	2.69	(0.00 - 9.91)	-*	0	-	-	-	.
Unknown primary site	2	33.5	(0.0 - 81.5)	3.47	(0.04 - 9.68)	-*	1	23.8 (0.0 - 70.2)	2.55	(0.00 - 9.41)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	2	28.5	(0.0 - 72.3)	4.82	(0.06 - 13.42)	-*	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	17.2 (0.0 - 50.7)	3.60	(0.00 - 13.26)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	13.1 (0.0 - 38.7)	33.66	(0.00 - 124.18)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	1	9.7	(0.0 - 28.7)	19.04	(0.00 - 70.26)	-*	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	1	12.3	(0.0 - 36.4)	198.93	(0.00 - 733.85)	-*	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	10	146.2	(51.9 - 240.4)	1.02	(0.42 - 1.75)	-	7	116.3 (26.4 - 206.1)	1.17	(0.37 - 2.18)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Harvey (S) - Pt A 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	9	35.0 (11.7 - 58.3)	2.06	(0.79 - 3.61)	-*
Colorectal cancer	7	23.7	(5.6 - 41.9)	1.45	(0.46 - 2.71)	-	2	8.9 (0.0 - 21.3)	0.65	(0.01 - 1.82)	-*
Prostate gland	2	5.7	(0.0 - 13.6)	0.57	(0.01 - 1.60)	-*	0	-	-	-	.
Melanoma (skin)	1	2.6	(0.0 - 7.8)	0.95	(0.00 - 3.52)	-*	0	-	0	n/a	-
Lung, bronchus & trachea	5	17.6	(1.9 - 33.2)	0.55	(0.12 - 1.13)	-	9	36.0 (12.1 - 59.9)	2.37	(0.91 - 4.16)	-*
Lymphoma	3	12.2	(0.0 - 26.1)	2.13	(0.17 - 4.97)	-*	0	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	2	7.0 (0.0 - 16.9)	1.38	(0.02 - 3.83)	-*
Kidney & other renal tract	3	9.9	(0.0 - 21.7)	3.15	(0.25 - 7.34)	-*	0	-	-	-	.
Leukaemia	1	2.5	(0.0 - 7.4)	0.66	(0.00 - 2.45)	-*	0	-	0	n/a	-
Pancreas	1	4.8	(0.0 - 14.2)	0.62	(0.00 - 2.30)	-*	2	9.2 (0.0 - 21.9)	1.66	(0.02 - 4.63)	-*
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	1	4.7	(0.0 - 13.8)	0.72	(0.00 - 2.64)	-*	1	4.8 (0.0 - 14.2)	1.22	(0.00 - 4.49)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	4.8 (0.0 - 14.2)	0.90	(0.00 - 3.33)	-*
Other lymphohaematopoietic	2	7.3	(0.0 - 17.4)	4.71	(0.06 - 13.12)	-*	0	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	2.9 (0.0 - 8.7)	8.64	(0.00 - 31.86)	-*
Myeloma/plasma cell tumours	2	12.9	(0.0 - 31.2)	3.58	(0.04 - 9.96)	-*	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	2	9.5	(0.0 - 22.6)	1.74	(0.02 - 4.84)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	1	3.7	(0.0 - 10.8)	2.91	(0.00 - 10.73)	-*	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	1	2.5	(0.0 - 7.4)	5.01	(0.00 - 18.50)	-*	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	3.5 (0.0 - 10.3)	13.14	(0.00 - 48.46)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	1	2.6 (0.0 - 7.8)	22.09	(0.00 - 81.50)	-*
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	32	119.6	(76.4 - 162.8)	0.87	(0.57 - 1.20)	-	29	114.8 (72.3 - 157.2)	1.22	(0.78 - 1.71)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Harvey (S) - Pt B 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	5	12.5 (0.2 - 24.7)	1.07	(0.23 - 2.20)	-
Colorectal cancer	4	14.3	(0.0 - 28.6)	0.74	(0.11 - 1.61)	-	3	11.0 (0.0 - 23.8)	0.78	(0.06 - 1.82)	-*
Prostate gland	10	31.8	(11.8 - 51.7)	2.30	(0.95 - 3.93)	-*	0	-	-	-	-
Melanoma (skin)	2	7.5	(0.0 - 17.8)	1.77	(0.02 - 4.93)	-*	1	3.9 (0.0 - 11.5)	1.64	(0.00 - 6.06)	-*
Lung, bronchus & trachea	7	22.9	(5.7 - 40.1)	0.69	(0.22 - 1.28)	-	1	2.0 (0.0 - 5.8)	0.23	(0.00 - 0.85)	V*
Lymphoma	4	10.5	(0.0 - 20.9)	2.62	(0.41 - 5.74)	-*	3	10.0 (0.0 - 22.1)	2.33	(0.19 - 5.44)	-*
Unknown primary site	2	6.1	(0.0 - 14.7)	0.82	(0.01 - 2.27)	-*	1	1.5 (0.0 - 4.3)	0.52	(0.00 - 1.94)	-*
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	0	n/a	-
Leukaemia	2	5.8	(0.0 - 13.9)	1.21	(0.02 - 3.38)	-*	1	6.0 (0.0 - 17.8)	1.11	(0.00 - 4.10)	-*
Pancreas	3	10.5	(0.0 - 22.4)	1.71	(0.14 - 3.99)	-*	1	3.7 (0.0 - 10.8)	0.66	(0.00 - 2.43)	-*
Urinary bladder	4	12.9	(0.1 - 25.7)	3.75	(0.58 - 8.22)	-*	2	3.4 (0.0 - 8.2)	4.90	(0.06 - 13.66)	-*
Stomach	2	6.5	(0.0 - 15.4)	1.11	(0.01 - 3.10)	-*	2	3.4 (0.0 - 8.2)	2.38	(0.03 - 6.62)	-*
Corpus uteri	0	-	-	-	-	.	1	2.3 (0.0 - 6.8)	1.82	(0.00 - 6.71)	-*
Brain	2	7.5	(0.0 - 17.8)	1.46	(0.02 - 4.07)	-*	0	-	0	n/a	-
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	2	7.8 (0.0 - 18.7)	1.53	(0.02 - 4.27)	-*
Other lymphohaematopoietic	1	3.2	(0.0 - 9.6)	1.84	(0.00 - 6.78)	-*	1	4.3 (0.0 - 12.6)	3.18	(0.00 - 11.73)	-*
Oesophagus	0	-	-	0	n/a	-	0	-	0	n/a	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	1	4.3	(0.0 - 12.8)	1.52	(0.00 - 5.60)	-*	1	3.8 (0.0 - 11.1)	2.03	(0.00 - 7.48)	-*
Cervix uteri	0	-	-	-	-	.	1	2.3 (0.0 - 6.8)	1.74	(0.00 - 6.43)	-*
Non-mel. skin (exc BCC/SCC)	1	3.5	(0.0 - 10.3)	5.54	(0.00 - 20.43)	-*	0	-	-	-	.
Mesothelioma	1	2.4	(0.0 - 7.1)	0.77	(0.00 - 2.83)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	2	7.5	(0.0 - 17.8)	2.26	(0.03 - 6.31)	-*	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	1	3.8	(0.0 - 11.2)	2.62	(0.00 - 9.68)	-*	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	49	160.8	(115.4 - 206.2)	1.18	(0.85 - 1.54)	-	26	77.7 (45.2 - 110.2)	0.93	(0.58 - 1.33)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Irwin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	30.8 (0.0 - 65.7)	1.72	(0.14 - 4.02)	-*
Colorectal cancer	2	14.0 (0.0 - 33.6)	0.81	(0.01 - 2.26)	-*	.	2	16.7 (0.0 - 40.0)	1.48	(0.02 - 4.11)	-*
Prostate gland	3	21.8 (0.0 - 47.6)	1.59	(0.13 - 3.72)	-*	.	0	-	-	-	.
Melanoma (skin)	1	6.2 (0.0 - 18.3)	2.02	(0.00 - 7.44)	-*	.	0	-	-	-	.
Lung, bronchus & trachea	8	55.6 (16.0 - 95.2)	1.69	(0.59 - 3.04)	-	.	1	7.0 (0.0 - 20.7)	0.61	(0.00 - 2.26)	-*
Lymphoma	2	13.9 (0.0 - 33.2)	2.93	(0.04 - 8.15)	-*	.	1	9.9 (0.0 - 29.2)	2.10	(0.00 - 7.74)	-*
Unknown primary site	0	-	-	0	n/a	-	2	16.5 (0.0 - 39.8)	3.16	(0.04 - 8.81)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	1	7.7 (0.0 - 22.8)	1.38	(0.00 - 5.07)	-*	.	0	-	-	-	.
Pancreas	0	-	-	0	n/a	-	0	-	-	0	n/a
Urinary bladder	2	11.2 (0.0 - 26.7)	4.22	(0.05 - 11.76)	-*	.	0	-	-	-	.
Stomach	2	15.6 (0.0 - 37.1)	2.46	(0.03 - 6.84)	-*	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	0	n/a	-	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	7.8 (0.0 - 22.9)	2.05	(0.00 - 7.56)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	1	5.0 (0.0 - 14.8)	1.96	(0.00 - 7.22)	-*	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	1	10.4 (0.0 - 30.9)	5.68	(0.00 - 20.94)	-*	.	0	-	-	-	.
Tongue	1	10.6 (0.0 - 31.3)	9.50	(0.00 - 35.04)	-*	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	24	172.0 (101.9 - 242.1)	1.28	(0.78 - 1.84)	-	.	10	88.7 (33.1 - 144.3)	0.99	(0.41 - 1.70)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Jerramungup (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	.	
Prostate gland	1	71.4	(0.0 - 201.0)	1.99	(0.00 - 7.33)	-*	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	.	
Lymphoma	0	-	-	-	-	.	0	-	-	-	.	
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.	
Leukaemia	0	-	-	-	-	.	0	-	-	-	.	
Pancreas	0	-	-	-	-	.	0	-	-	-	.	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.	
Stomach	0	-	-	-	-	.	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	1	22.8	(0.0 - 67.5)	10.17	(0.00 - 37.52)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	0	-	-	-	-	.	0	-	-	n/a	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	1	71.4	(0.0 - 201.0)	0.18	(0.00 - 0.68)	V	1	22.8	(0.0 - 67.5)	0.35	(0.00 - 1.31)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Joondalup (C) - North 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	26	23.1 (13.8 - 32.4)	1.38	(0.86 - 1.96)	-	
Colorectal cancer	16	15.7	(7.9 - 23.6)	0.94	(0.49 - 1.45)	-	15	13.5 (6.4 - 20.6)	1.16	(0.59 - 1.81)	-	
Prostate gland	11	10.6	(4.3 - 16.9)	0.97	(0.42 - 1.62)	-	0	-	-	-	.	
Melanoma (skin)	1	0.9	(0.0 - 2.6)	0.26	(0.00 - 0.94)	V*	1	0.7 (0.0 - 2.1)	0.41	(0.00 - 1.53)	-*	
Lung, bronchus & trachea	30	32.7	(20.6 - 44.8)	0.96	(0.62 - 1.33)	-	21	21.4 (11.9 - 30.9)	1.37	(0.80 - 2.01)	-	
Lymphoma	6	6.3	(1.1 - 11.6)	1.17	(0.32 - 2.28)	-	7	5.9 (1.4 - 10.5)	1.55	(0.49 - 2.89)	-	
Unknown primary site	8	8.3	(2.4 - 14.2)	1.06	(0.37 - 1.91)	-	10	9.5 (3.4 - 15.6)	1.58	(0.65 - 2.70)	-	
Kidney & other renal tract	3	2.4	(0.0 - 5.1)	0.88	(0.07 - 2.06)	-*	3	2.2 (0.0 - 4.8)	1.67	(0.13 - 3.89)	-*	
Leukaemia	2	2.8	(0.0 - 6.9)	0.36	(0.00 - 1.02)	-	2	1.1 (0.0 - 2.7)	0.59	(0.01 - 1.64)	-*	
Pancreas	7	6.5	(1.5 - 11.6)	1.20	(0.38 - 2.23)	-	4	3.5 (0.0 - 7.0)	0.81	(0.12 - 1.77)	-	
Urinary bladder	2	2.9	(0.0 - 7.1)	0.68	(0.01 - 1.89)	-*	1	0.7 (0.0 - 2.2)	0.79	(0.00 - 2.91)	-*	
Stomach	4	3.9	(0.1 - 7.7)	0.71	(0.11 - 1.55)	-	2	1.8 (0.0 - 4.3)	0.70	(0.01 - 1.95)	-*	
Corpus uteri	0	-	-	-	-	.	2	1.8 (0.0 - 4.3)	1.12	(0.01 - 3.13)	-*	
Brain	4	3.5	(0.0 - 7.1)	0.72	(0.11 - 1.57)	-	9	8.3 (2.7 - 13.9)	2.57	(0.99 - 4.51)	-*	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	5	4.9 (0.6 - 9.3)	1.08	(0.24 - 2.22)	-	
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	0	n/a	-	
Oesophagus	3	2.9	(0.0 - 6.3)	0.85	(0.07 - 1.99)	-*	2	1.5 (0.0 - 3.5)	1.18	(0.01 - 3.30)	-*	
Thyroid gland	0	-	-	-	-	.	1	1.0 (0.0 - 3.1)	1.99	(0.00 - 7.32)	-*	
Myeloma/plasma cell tumours	5	6.5	(0.4 - 12.6)	2.56	(0.56 - 5.25)	-*	1	0.7 (0.0 - 2.2)	0.60	(0.00 - 2.22)	-*	
Cervix uteri	0	-	-	-	-	.	1	1.0 (0.0 - 3.1)	0.40	(0.00 - 1.48)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	.	
Mesothelioma	7	7.2	(1.7 - 12.6)	1.72	(0.54 - 3.21)	-*	1	0.7 (0.0 - 2.0)	1.82	(0.00 - 6.72)	-*	
Liver & intrahepatic bile duct	1	1.3	(0.0 - 3.8)	0.34	(0.00 - 1.25)	-*	2	2.2 (0.0 - 5.2)	1.92	(0.02 - 5.35)	-*	
Testis	1	1.1	(0.0 - 3.2)	5.77	(0.00 - 21.29)	-*	0	-	-	-	.	
Gallbladder & bile ducts	2	2.4	(0.0 - 5.7)	1.38	(0.02 - 3.83)	-*	4	2.8 (0.0 - 5.6)	2.76	(0.43 - 6.05)	-*	
Larynx	1	1.9	(0.0 - 5.6)	0.82	(0.00 - 3.03)	-*	1	1.0 (0.0 - 3.1)	6.73	(0.00 - 24.84)	-*	
Tongue	2	1.4	(0.0 - 3.2)	2.51	(0.03 - 6.99)	-*	0	-	-	-	.	
Connective & soft tissues	0	-	-	0	n/a	-	1	1.0 (0.0 - 3.1)	2.40	(0.00 - 8.87)	-*	
Tonsil & oropharynx	1	1.9	(0.0 - 5.6)	1.31	(0.00 - 4.84)	-*	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	1	0.7	(0.0 - 1.9)	1.78	(0.00 - 6.58)	-*	0	-	-	-	.	
Eye & lacrimal gland	2	2.1	(0.0 - 5.0)	6.19	(0.08 - 17.25)	-*	1	0.7 (0.0 - 2.1)	5.37	(0.00 - 19.80)	-*	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	2	2.3 (0.0 - 5.5)	4.49	(0.06 - 12.50)	-*	
Mouth, other & unspecified	1	0.9	(0.0 - 2.8)	2.55	(0.00 - 9.41)	-*	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	1	0.9	(0.0 - 2.8)	3.56	(0.00 - 13.13)	-*	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	2	1.9	(0.0 - 4.6)	6.65	(0.08 - 18.53)	-*	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	124	129.5	(106.0 - 153.1)	0.95	(0.80 - 1.14)	-	125	113.5	(93.0 - 134.1)	1.25	(1.04 - 1.49)	^

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Joondalup (C) - South 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	51	14.6 (10.4 - 18.9)	0.88	(0.66 - 1.16)	-	
Colorectal cancer	41	12.2	(8.3 - 16.1)	0.72	(0.50 - 0.95)	V	39	10.5 (7.0 - 14.0)	0.93	(0.64 - 1.24)	-	
Prostate gland	41	12.4	(8.4 - 16.4)	0.97	(0.68 - 1.29)	-	0	-	-	-	.	
Melanoma (skin)	10	3.1	(1.1 - 5.2)	0.80	(0.33 - 1.36)	-	9	2.6 (0.8 - 4.4)	1.25	(0.48 - 2.20)	-	
Lung, bronchus & trachea	87	27.5	(21.4 - 33.5)	0.83	(0.67 - 1.02)	-	42	11.5 (7.8 - 15.2)	0.84	(0.59 - 1.12)	-	
Lymphoma	8	2.4	(0.7 - 4.2)	0.48	(0.17 - 0.86)	V	11	2.4 (0.9 - 3.9)	0.77	(0.33 - 1.28)	-	
Unknown primary site	15	4.9	(2.3 - 7.4)	0.59	(0.30 - 0.92)	V	19	4.4 (2.3 - 6.6)	0.93	(0.52 - 1.39)	-	
Kidney & other renal tract	19	6.8	(3.7 - 10.0)	1.67	(0.94 - 2.50)	-	6	1.6 (0.3 - 3.0)	1.02	(0.28 - 1.99)	-	
Leukaemia	19	6.1	(3.3 - 9.0)	1.06	(0.60 - 1.59)	-	12	3.2 (1.3 - 5.1)	1.17	(0.54 - 1.93)	-	
Pancreas	18	5.1	(2.7 - 7.5)	0.95	(0.52 - 1.43)	-	24	6.2 (3.5 - 8.8)	1.48	(0.90 - 2.13)	-	
Urinary bladder	9	3.9	(1.3 - 6.4)	0.87	(0.33 - 1.52)	-	4	1.2 (0.0 - 2.5)	0.94	(0.15 - 2.06)	-*	
Stomach	24	7.8	(4.5 - 11.1)	1.27	(0.77 - 1.83)	-	6	1.5 (0.2 - 2.8)	0.66	(0.18 - 1.28)	-	
Corpus uteri	0	-	-	-	-	.	5	1.4 (0.1 - 2.7)	0.86	(0.19 - 1.75)	-	
Brain	15	4.4	(2.1 - 6.7)	0.90	(0.46 - 1.41)	-	8	2.2 (0.6 - 3.8)	0.77	(0.27 - 1.38)	-	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	20	5.7 (3.0 - 8.4)	1.36	(0.78 - 2.02)	-	
Other lymphohaematopoietic	3	0.9	(0.0 - 1.9)	0.58	(0.05 - 1.35)	-	3	0.6 (0.0 - 1.2)	0.96	(0.08 - 2.23)	-*	
Oesophagus	11	3.4	(1.3 - 5.6)	0.93	(0.40 - 1.55)	-	3	0.6 (0.0 - 1.2)	0.54	(0.04 - 1.26)	-	
Thyroid gland	1	0.2	(0.0 - 0.6)	1.32	(0.00 - 4.86)	-*	1	0.2 (0.0 - 0.5)	0.66	(0.00 - 2.43)	-*	
Myeloma/plasma cell tumours	6	2.1	(0.4 - 3.9)	0.89	(0.24 - 1.73)	-	7	1.9 (0.4 - 3.4)	1.28	(0.40 - 2.39)	-	
Cervix uteri	0	-	-	-	-	.	9	2.4 (0.7 - 4.2)	1.27	(0.49 - 2.23)	-	
Non-mel. skin (exc BCC/SCC)	1	0.4	(0.0 - 1.3)	0.59	(0.00 - 2.17)	-*	1	0.3 (0.0 - 1.0)	1.21	(0.00 - 4.45)	-*	
Mesothelioma	7	2.4	(0.5 - 4.3)	0.52	(0.16 - 0.96)	V	4	1.2 (0.0 - 2.4)	2.25	(0.35 - 4.94)	-*	
Liver & intrahepatic bile duct	6	1.9	(0.3 - 3.5)	0.63	(0.17 - 1.22)	-	2	0.5 (0.0 - 1.1)	0.62	(0.01 - 1.72)	-*	
Testis	1	0.2	(0.0 - 0.7)	1.98	(0.00 - 7.30)	-*	0	-	-	-	.	
Gallbladder & bile ducts	2	0.7	(0.0 - 1.7)	0.40	(0.00 - 1.10)	-	4	1.0 (0.0 - 2.1)	0.83	(0.13 - 1.81)	-	
Larynx	2	0.7	(0.0 - 1.7)	0.49	(0.01 - 1.37)	-*	1	0.3 (0.0 - 1.0)	2.16	(0.00 - 7.95)	-*	
Tongue	0	-	-	0	n/a	-	1	0.2 (0.0 - 0.7)	0.85	(0.00 - 3.14)	-*	
Connective & soft tissues	1	0.3	(0.0 - 0.8)	0.54	(0.00 - 2.00)	-*	1	0.3 (0.0 - 1.0)	0.83	(0.00 - 3.07)	-*	
Tonsil & oropharynx	1	0.4	(0.0 - 1.2)	0.41	(0.00 - 1.50)	-*	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	1	0.4 (0.0 - 1.1)	0.89	(0.00 - 3.29)	-*	
Small intestine	1	0.5	(0.0 - 1.3)	0.58	(0.00 - 2.12)	-*	3	1.0 (0.0 - 2.1)	2.53	(0.20 - 5.90)	-*	
Eye & lacrimal gland	1	0.4	(0.0 - 1.3)	1.08	(0.00 - 3.97)	-*	0	-	0	n/a	-	
Major Salivary Gland	1	0.5	(0.0 - 1.3)	1.06	(0.00 - 3.90)	-*	0	-	-	-	.	
Anus	3	1.2	(0.0 - 2.5)	4.34	(0.35 - 10.12)	-*	1	0.2 (0.0 - 0.6)	0.71	(0.00 - 2.61)	-*	
Mouth, other & unspecified	1	0.2	(0.0 - 0.6)	0.79	(0.00 - 2.92)	-*	0	-	0	n/a	-	
Floor of mouth	2	0.6	(0.0 - 1.6)	1.59	(0.02 - 4.44)	-*	0	-	-	-	.	
Bones, joints & articular cart.	1	0.4	(0.0 - 1.1)	0.98	(0.00 - 3.62)	-*	1	0.2 (0.0 - 0.7)	1.27	(0.00 - 4.69)	-*	
Pyriform sinus & hypopharynx	1	0.2	(0.0 - 0.6)	0.49	(0.00 - 1.83)	-*	1	0.2 (0.0 - 0.7)	3.71	(0.00 - 13.67)	-*	
Nasal cavity, sinuses, int. ear	1	0.2	(0.0 - 0.7)	1.43	(0.00 - 5.27)	-*	0	-	-	-	.	
Peritoneum & retroperitoneum	1	0.2	(0.0 - 0.7)	1.17	(0.00 - 4.32)	-*	0	-	0	n/a	-	
Adrenal & other endocrine	0	-	-	-	-	.	1	0.3 (0.0 - 0.9)	2.10	(0.00 - 7.76)	-*	
Nasopharynx	0	-	-	0	n/a	-	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	0	n/a	-	1	0.2 (0.0 - 0.6)	5.16	(0.00 - 19.03)	-*	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	0	n/a	-	0	-	-	-	.	
Pleura, heart & mediastinum	1	0.3	(0.0 - 0.8)	1.80	(0.00 - 6.66)	-*	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	1	0.2 (0.0 - 0.5)	6.27	(0.00 - 23.11)	-*	
All cancers	362	115.0	(102.7 - 127.3)	0.83	(0.75 - 0.92)	V	304	81.5	(71.7 - 91.3)	0.96	(0.85 - 1.07)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kalamunda (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	32	17.4 (11.1 - 23.7)	1.09	(0.72 - 1.50)	-
Colorectal cancer	25	15.3 (9.2 - 21.3)	0.84	(0.52 - 1.20)	-	26	13.3 (7.9 - 18.7)	1.13	(0.70 - 1.60)	-	
Prostate gland	26	15.6 (9.5 - 21.7)	1.16	(0.72 - 1.64)	-	0	-	-	-	.	
Melanoma (skin)	11	7.0 (2.7 - 11.3)	1.76	(0.77 - 2.95)	-	6	2.8 (0.3 - 5.2)	1.61	(0.43 - 3.12)	-*	
Lung, bronchus & trachea	47	28.3 (20.1 - 36.6)	0.85	(0.61 - 1.11)	-	19	10.2 (5.4 - 15.0)	0.71	(0.40 - 1.07)	-	
Lymphoma	14	7.5 (3.5 - 11.5)	1.65	(0.82 - 2.63)	-	3	1.3 (0.0 - 3.0)	0.38	(0.03 - 0.90)	V	
Unknown primary site	16	9.8 (4.9 - 14.6)	1.21	(0.64 - 1.87)	-	14	6.9 (2.9 - 10.9)	1.24	(0.61 - 1.97)	-	
Kidney & other renal tract	1	0.7 (0.0 - 2.2)	0.17	(0.00 - 0.63)	V	3	2.3 (0.0 - 4.9)	0.91	(0.07 - 2.12)	-*	
Leukaemia	7	3.9 (1.0 - 6.9)	0.77	(0.24 - 1.44)	-	5	2.8 (0.3 - 5.4)	0.92	(0.20 - 1.89)	-	
Pancreas	9	5.6 (1.9 - 9.4)	0.93	(0.36 - 1.62)	-	3	1.2 (0.0 - 2.7)	0.33	(0.03 - 0.77)	V	
Urinary bladder	8	4.6 (1.3 - 7.8)	1.44	(0.51 - 2.59)	-	0	-	0	n/a	-	
Stomach	12	7.3 (3.1 - 11.5)	1.23	(0.56 - 2.01)	-	1	0.3 (0.0 - 0.8)	0.20	(0.00 - 0.74)	V	
Corpus uteri	0	-	-	-	.	5	2.2 (0.1 - 4.4)	1.54	(0.33 - 3.15)	-*	
Brain	9	6.9 (1.9 - 11.9)	1.13	(0.44 - 1.99)	-	3	1.8 (0.0 - 4.0)	0.57	(0.05 - 1.32)	-	
Lip	0	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	.	9	4.3 (1.3 - 7.2)	1.13	(0.44 - 1.99)	-	
Other lymphohaematopoietic	1	0.6 (0.0 - 1.9)	0.36	(0.00 - 1.31)	-*	2	0.6 (0.0 - 1.4)	1.11	(0.01 - 3.08)	-*	
Oesophagus	5	2.9 (0.3 - 5.6)	0.82	(0.18 - 1.67)	-	5	2.6 (0.2 - 4.9)	1.63	(0.36 - 3.34)	-*	
Thyroid gland	0	-	-	-	.	0	-	0	n/a	-	
Myeloma/plasma cell tumours	3	1.9 (0.0 - 4.1)	0.85	(0.07 - 1.98)	-*	5	2.7 (0.3 - 5.2)	1.66	(0.36 - 3.41)	-*	
Cervix uteri	0	-	-	-	.	5	2.0 (0.1 - 3.9)	1.41	(0.31 - 2.89)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	1	0.3 (0.0 - 0.9)	2.19	(0.00 - 8.09)	-*	
Mesothelioma	11	7.1 (2.9 - 11.4)	1.54	(0.67 - 2.57)	-	2	1.2 (0.0 - 2.8)	2.16	(0.03 - 6.02)	-*	
Liver & intrahepatic bile duct	6	3.0 (0.6 - 5.4)	1.22	(0.33 - 2.37)	-	2	1.4 (0.0 - 3.3)	1.14	(0.01 - 3.19)	-*	
Testis	0	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	5	2.9 (0.3 - 5.6)	1.96	(0.43 - 4.01)	-*	3	1.5 (0.0 - 3.4)	1.14	(0.09 - 2.66)	-*	
Larynx	1	0.5 (0.0 - 1.6)	0.48	(0.00 - 1.75)	-*	0	-	-	-	.	
Tongue	2	1.4 (0.0 - 3.4)	1.51	(0.02 - 4.21)	-*	0	-	0	n/a	-	
Connective & soft tissues	3	2.0 (0.0 - 4.3)	3.46	(0.28 - 8.07)	-*	1	0.6 (0.0 - 1.9)	1.56	(0.00 - 5.75)	-*	
Tonsil & oropharynx	1	0.6 (0.0 - 1.9)	0.83	(0.00 - 3.06)	-*	0	-	-	-	.	
Vulva/vagina	0	-	-	-	.	0	-	0	n/a	-	
Small intestine	0	-	-	0	n/a	1	0.5 (0.0 - 1.6)	1.61	(0.00 - 5.95)	-*	
Eye & lacrimal gland	0	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	.	1	0.3 (0.0 - 0.9)	10.14	(0.00 - 37.39)	-*	
Anus	0	-	-	-	.	0	-	0	n/a	-	
Mouth, other & unspecified	0	-	-	0	n/a	0	-	-	-	.	
Floor of mouth	0	-	-	0	n/a	0	-	-	-	.	
Bones, joints & articular cart.	2	1.7 (0.0 - 4.1)	4.09	(0.05 - 11.39)	-*	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	0	n/a	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	1	0.7 (0.0 - 2.1)	2.78	(0.00 - 10.25)	-*	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	.	2	0.9 (0.0 - 2.3)	3.57	(0.04 - 9.96)	-*	
Adrenal & other endocrine	0	-	-	-	.	1	0.7 (0.0 - 2.2)	4.38	(0.00 - 16.17)	-*	
Nasopharynx	0	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	0	n/a	0	-	-	-	.	
Penis & other male genital	0	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	.	0	-	-	-	.	
Thymus	1	0.6 (0.0 - 1.9)	4.03	(0.00 - 14.87)	-*	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	.	1	0.3 (0.0 - 0.8)	21.90	(0.00 - 80.79)	-*	
Nervous, periph./autonomic	0	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	.	0	-	-	-	.	
All cancers	227	138.8 (120.4 - 157.2)	1.01	(0.88 - 1.15)	-	162	83.3 (69.7 - 96.8)	0.95	(0.82 - 1.12)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kalgoorlie-Boulder (C) - Pt A 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	14	24.9 (11.1 - 38.7)	1.42	(0.70 - 2.26)	-
Colorectal cancer	15	29.6	(14.1 - 45.0)	1.55	(0.79 - 2.42)	-	8	17.2 (4.4 - 29.9)	1.10	(0.39 - 1.98)	-
Prostate gland	5	9.4	(0.8 - 18.0)	0.77	(0.17 - 1.58)	-	0	-	-	-	.
Melanoma (skin)	2	3.6	(0.0 - 8.6)	0.84	(0.01 - 2.34)	-*	0	-	0	n/a	-
Lung, bronchus & trachea	27	58.4	(36.1 - 80.8)	1.57	(0.99 - 2.22)	-	16	28.9 (13.5 - 44.2)	1.99	(1.05 - 3.08)	^
Lymphoma	3	3.4	(0.0 - 7.2)	1.02	(0.08 - 2.39)	-*	3	5.0 (0.0 - 11.5)	1.23	(0.10 - 2.87)	-*
Unknown primary site	7	12.6	(2.8 - 22.4)	1.64	(0.51 - 3.05)	-*	5	9.2 (0.3 - 18.0)	1.34	(0.29 - 2.75)	-*
Kidney & other renal tract	3	6.0	(0.0 - 13.1)	1.55	(0.12 - 3.61)	-*	0	-	0	n/a	-
Leukaemia	1	0.9	(0.0 - 2.7)	0.31	(0.00 - 1.15)	-*	2	1.8 (0.0 - 4.2)	1.00	(0.01 - 2.77)	-*
Pancreas	5	9.5	(1.0 - 18.0)	1.54	(0.34 - 3.15)	-*	3	5.3 (0.0 - 11.4)	1.09	(0.09 - 2.53)	-*
Urinary bladder	2	3.3	(0.0 - 8.0)	1.21	(0.02 - 3.38)	-*	0	-	0	n/a	-
Stomach	3	3.7	(0.0 - 8.0)	0.94	(0.08 - 2.19)	-*	1	1.5 (0.0 - 4.3)	0.61	(0.00 - 2.26)	-*
Corpus uteri	0	-	-	-	-	.	1	1.0 (0.0 - 2.9)	1.00	(0.00 - 3.69)	-*
Brain	3	6.9	(0.0 - 14.8)	0.91	(0.07 - 2.11)	-*	1	1.7 (0.0 - 5.0)	0.54	(0.00 - 1.99)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	3	4.0 (0.0 - 8.8)	1.21	(0.10 - 2.82)	-*
Other lymphohaematopoietic	1	1.9	(0.0 - 5.6)	1.22	(0.00 - 4.49)	-*	0	-	0	n/a	-
Oesophagus	1	2.1	(0.0 - 6.3)	0.51	(0.00 - 1.90)	-*	1	2.2 (0.0 - 6.5)	1.04	(0.00 - 3.84)	-*
Thyroid gland	0	-	-	-	-	.	2	2.8 (0.0 - 6.7)	6.95	(0.09 - 19.35)	-*
Myeloma/plasma cell tumours	1	1.9	(0.0 - 5.6)	0.91	(0.00 - 3.36)	-*	0	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	3	3.6 (0.0 - 8.0)	2.19	(0.18 - 5.11)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.
Liver & intrahepatic bile duct	3	4.8	(0.0 - 10.3)	1.85	(0.15 - 4.31)	-*	0	-	0	n/a	-
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	0	-	0	n/a	-
Larynx	1	1.9	(0.0 - 5.6)	1.46	(0.00 - 5.37)	-*	0	-	-	-	.
Tongue	2	3.8	(0.0 - 9.1)	4.44	(0.06 - 12.37)	-*	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	1.3 (0.0 - 3.9)	4.77	(0.00 - 17.60)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	1	1.5	(0.0 - 4.3)	6.30	(0.00 - 23.24)	-*	0	-	-	-	.
Anus	1	2.3	(0.0 - 6.9)	8.42	(0.00 - 31.05)	-*	2	1.6 (0.0 - 3.7)	8.30	(0.10 - 23.11)	-*
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	1	2.9 (0.0 - 8.7)	23.86	(0.00 - 88.02)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	1	2.1	(0.0 - 6.3)	5.87	(0.00 - 21.65)	-*	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	88	169.5	(133.1 - 205.9)	1.20	(0.96 - 1.48)	-	67	114.7 (84.9 - 144.6)	1.22	(0.95 - 1.56)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kalgoorlie-Boulder (C) - Pt B 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	1	222.2	(0.0 - 632.9)	6.39	(0.00 - 23.57)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	1	187.5	(0.0 - 543.3)	2.83	(0.00 - 10.44)	-*	1	166.7	(0.0 - 464.9)	12.84	(0.00 - 47.36)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	1	187.5	(0.0 - 543.3)	11.26	(0.00 - 41.55)	-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	190.5	(0.0 - 554.8)	176.99	(0.00 - 652.91)	-*
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	3	597.2	(0.0 - 1,233.6)	1.99	(0.16 - 4.66)	-*	2	357.1	(0.0 - 828.0)	3.71	(0.05 - 10.33)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Katanning (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	6.4 (0.0 - 15.4)	0.78	(0.01 - 2.17)	.*
Colorectal cancer	3	15.5	(0.0 - 34.3)	1.12	(0.09 - 2.62)	.*	1	2.7 (0.0 - 8.1)	0.46	(0.00 - 1.71)	.*
Prostate gland	4	18.7	(0.1 - 37.2)	1.79	(0.28 - 3.91)	.*	0	-	-	-	.
Melanoma (skin)	2	17.1	(0.0 - 41.2)	3.51	(0.04 - 9.79)	.*	1	2.7 (0.0 - 8.1)	2.95	(0.00 - 10.88)	.*
Lung, bronchus & trachea	5	38.4	(4.1 - 72.6)	1.01	(0.22 - 2.07)	-	4	29.6 (0.5 - 58.8)	1.64	(0.25 - 3.58)	.*
Lymphoma	0	-	-	0	n/a	-	2	11.1 (0.0 - 28.2)	2.76	(0.03 - 7.68)	.*
Unknown primary site	2	14.0	(0.0 - 33.4)	1.64	(0.02 - 4.56)	.*	0	-	0	n/a	-
Kidney & other renal tract	1	7.0	(0.0 - 20.7)	1.89	(0.00 - 6.97)	.*	1	2.7 (0.0 - 8.1)	3.24	(0.00 - 11.96)	.*
Leukaemia	0	-	-	0	n/a	-	0	-	0	n/a	-
Pancreas	0	-	-	0	n/a	-	2	11.1 (0.0 - 28.4)	2.33	(0.03 - 6.48)	.*
Urinary bladder	0	-	-	0	n/a	-	2	9.2 (0.0 - 22.5)	8.52	(0.11 - 23.75)	.*
Stomach	1	7.0	(0.0 - 20.7)	1.13	(0.00 - 4.16)	.*	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	6.1 (0.0 - 17.9)	3.21	(0.00 - 11.84)	.*
Brain	1	5.6	(0.0 - 16.4)	1.46	(0.00 - 5.37)	.*	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	3.7 (0.0 - 10.9)	13.60	(0.00 - 50.16)	.*
Myeloma/plasma cell tumours	2	12.6	(0.0 - 30.1)	6.04	(0.08 - 16.84)	.*	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	1	5.6	(0.0 - 16.4)	5.38	(0.00 - 19.86)	.*	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	1	7.0	(0.0 - 20.7)	22.02	(0.00 - 81.23)	.*	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	23	148.3	(85.8 - 210.8)	1.12	(0.67 - 1.62)	-	17	85.4 (41.0 - 129.8)	1.09	(0.58 - 1.66)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kellerberrin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	10.6 (0.0 - 25.2)	2.12	(0.03 - 5.90)	-*
Colorectal cancer	3	58.3	(0.0 - 124.0)	2.63	(0.21 - 6.14)	-*	3	37.9 (0.0 - 86.3)	3.41	(0.28 - 7.97)	-*
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	1	13.2	(0.0 - 38.6)	0.46	(0.00 - 1.71)	-*	0	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	1	27.0 (0.0 - 79.8)	3.49	(0.00 - 12.88)	-*
Unknown primary site	1	9.3	(0.0 - 27.2)	1.91	(0.00 - 7.04)	-*	1	5.3 (0.0 - 15.7)	2.23	(0.00 - 8.21)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	1	15.3 (0.0 - 45.1)	2.83	(0.00 - 10.43)	-*
Urinary bladder	0	-	-	-	-	.	1	15.3 (0.0 - 45.1)	9.85	(0.00 - 36.35)	-*
Stomach	1	13.2	(0.0 - 38.6)	2.64	(0.00 - 9.74)	-*	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	1	18.7	(0.0 - 55.2)	3.91	(0.00 - 14.42)	-*	1	27.0 (0.0 - 79.8)	6.07	(0.00 - 22.38)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	7	112.6	(27.9 - 197.3)	0.80	(0.25 - 1.49)	-	10	138.5 (38.7 - 238.2)	1.63	(0.67 - 2.78)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kent (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	1	74.1	(0.0 - 216.5)	1.89	(0.00 - 6.97)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	74.1	(0.0 - 216.5)	0.46	(0.00 - 1.68)	-*	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kojonup (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	12.3 (0.0 - 29.5)	1.44	(0.02 - 4.01)	-*
Colorectal cancer	2	28.5 (0.0 - 67.8)	1.17	(0.01 - 3.26)	-*		4	39.5 (0.0 - 80.8)	3.40	(0.53 - 7.46)	-*
Prostate gland	3	20.3 (0.0 - 43.5)	2.09	(0.17 - 4.88)	-*		0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	1	5.7 (0.0 - 16.9)	0.31	(0.00 - 1.16)	-*		0	-	0	n/a	-
Lymphoma	1	9.9 (0.0 - 29.2)	2.08	(0.00 - 7.67)	-*		0	-	-	-	.
Unknown primary site	0	-	-	0	n/a	-	1	5.1 (0.0 - 14.9)	1.71	(0.00 - 6.29)	-*
Kidney & other renal tract	1	5.7 (0.0 - 16.9)	2.98	(0.00 - 10.98)	-*		0	-	-	-	.
Leukaemia	2	19.6 (0.0 - 46.6)	3.85	(0.05 - 10.74)	-*		0	-	-	-	.
Pancreas	0	-	-	0	n/a	-	2	10.2 (0.0 - 24.3)	4.28	(0.05 - 11.92)	-*
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	1	5.7 (0.0 - 16.9)	5.64	(0.00 - 20.82)	-*		0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	1	10.4 (0.0 - 30.8)	47.30	(0.00 - 174.50)	-*		0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	5.1 (0.0 - 14.9)	11.43	(0.00 - 42.15)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	12	105.9 (43.0 - 168.7)	0.92 (0.42 - 1.50)	-			10	72.1 (23.3 - 120.9)	1.18 (0.48 - 2.01)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kondinin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	48.4 (0.0 - 142.5)	2.23	(0.00 - 8.23)	-*
Colorectal cancer	1	33.3	(0.0 - 98.1)	1.71	(0.00 - 6.32)	-*	0	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	1	35.7 (0.0 - 103.2)	11.80	(0.00 - 43.52)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	1	25.5	(0.0 - 75.5)	56.55	(0.00 - 208.61)	-*	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	2	58.9	(0.0 - 140.7)	0.46	(0.01 - 1.27)	-*	2	84.1 (0.0 - 199.9)	0.82	(0.01 - 2.29)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Koorda (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	1	50.0	(0.0 - 143.0)	4.41	(0.00 - 16.27)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	1	71.4	(0.0 - 201.0)	10.17	(0.00 - 37.52)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	1	62.5	(0.0 - 183.1)	139.59	(0.00 - 514.96)	-*
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	2	121.4	(0.0 - 280.9)	0.78	(0.01 - 2.16)	-*	1	62.5	(0.0 - 183.1)	0.60	(0.00 - 2.20)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kulin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	28.4	(0.0 - 84.0)	1.94	(0.00 - 7.15)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	1	20.0	(0.0 - 58.4)	1.98	(0.00 - 7.30)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	1	33.5	(0.0 - 99.0)	5.16	(0.00 - 19.03)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	1	18.9	(0.0 - 55.5)	6.03	(0.00 - 22.24)	-*	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	1	33.9	(0.0 - 100.1)	33.54	(0.00 - 123.73)	-*
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	3	72.4	(0.0 - 156.7)	0.62	(0.05 - 1.44)	-	2	62.3	(0.0 - 148.8)	0.67	(0.01 - 1.86)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Kwinana (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	8	13.2 (4.0 - 22.4)	0.77	(0.27 - 1.39)	-
Colorectal cancer	9	12.9 (4.4 - 21.5)	0.78	(0.30 - 1.36)	-	11	15.7 (6.1 - 25.2)	1.37	(0.60 - 2.28)	-	
Prostate gland	6	8.1 (1.5 - 14.7)	0.71	(0.19 - 1.39)	-	0	-	-	-	.	
Melanoma (skin)	1	1.2 (0.0 - 3.4)	0.40	(0.00 - 1.49)	-*	0	-	-	0	n/a	-
Lung, bronchus & trachea	32	50.1 (32.3 - 67.8)	1.47	(0.97 - 2.02)	-	15	18.9 (9.0 - 28.7)	1.55	(0.79 - 2.42)	-	
Lymphoma	4	5.9 (0.1 - 11.7)	1.20	(0.19 - 2.64)	-*	2	3.1 (0.0 - 7.4)	0.70	(0.01 - 1.96)	-*	
Unknown primary site	6	8.6 (1.6 - 15.6)	1.17	(0.32 - 2.27)	-	5	6.6 (0.6 - 12.6)	1.30	(0.28 - 2.67)	-*	
Kidney & other renal tract	6	9.0 (1.7 - 16.3)	2.64	(0.71 - 5.13)	-*	3	5.1 (0.0 - 10.9)	2.54	(0.21 - 5.93)	-*	
Leukaemia	3	4.6 (0.0 - 9.7)	0.84	(0.07 - 1.96)	-*	0	-	-	0	n/a	-
Pancreas	7	9.8 (2.5 - 17.2)	1.85	(0.58 - 3.44)	-*	5	7.1 (0.6 - 13.7)	1.55	(0.34 - 3.17)	-*	
Urinary bladder	4	6.1 (0.1 - 12.0)	1.89	(0.29 - 4.14)	-*	1	0.8 (0.0 - 2.4)	1.23	(0.00 - 4.53)	-*	
Stomach	7	11.5 (2.7 - 20.2)	1.84	(0.58 - 3.43)	-*	1	1.8 (0.0 - 5.3)	0.57	(0.00 - 2.11)	-*	
Corpus uteri	0	-	-	-	.	1	1.3 (0.0 - 3.9)	0.85	(0.00 - 3.15)	-*	
Brain	4	5.7 (0.1 - 11.4)	1.26	(0.20 - 2.77)	-*	2	3.1 (0.0 - 7.5)	1.01	(0.01 - 2.81)	-*	
Lip	0	-	-	-	.	0	-	-	-	-	
Ovary & uterine adnexa	0	-	-	-	.	1	1.6 (0.0 - 4.6)	0.35	(0.00 - 1.29)	-*	
Other lymphohaematopoietic	1	1.2 (0.0 - 3.4)	0.96	(0.00 - 3.53)	-*	0	-	-	0	n/a	-
Oesophagus	4	5.4 (0.1 - 10.7)	1.68	(0.26 - 3.69)	-*	0	-	-	0	n/a	-
Thyroid gland	0	-	-	-	.	0	-	-	-	-	
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	2	2.1 (0.0 - 5.2)	1.92	(0.02 - 5.36)	-*
Cervix uteri	0	-	-	-	.	2	3.5 (0.0 - 8.4)	1.51	(0.02 - 4.21)	-*	
Non-mel. skin (exc BCC/SCC)	1	1.7 (0.0 - 4.9)	2.80	(0.00 - 10.31)	-*	0	-	-	-	-	
Mesothelioma	5	7.6 (0.9 - 14.2)	1.78	(0.39 - 3.65)	-*	0	-	-	-	-	
Liver & intrahepatic bile duct	1	1.2 (0.0 - 3.4)	0.51	(0.00 - 1.89)	-*	0	-	-	0	n/a	-
Testis	0	-	-	-	.	0	-	-	-	-	
Gallbladder & bile ducts	1	1.5 (0.0 - 4.5)	1.02	(0.00 - 3.76)	-*	1	1.6 (0.0 - 4.8)	1.10	(0.00 - 4.06)	-*	
Larynx	2	3.3 (0.0 - 8.0)	2.42	(0.03 - 6.73)	-*	0	-	-	-	-	
Tongue	2	2.7 (0.0 - 6.4)	3.97	(0.05 - 11.07)	-*	0	-	-	-	-	
Connective & soft tissues	1	1.7 (0.0 - 5.0)	2.81	(0.00 - 10.37)	-*	0	-	-	-	-	
Tonsil & oropharynx	0	-	-	-	.	1	1.7 (0.0 - 5.0)	20.25	(0.00 - 74.69)	-*	
Vulva/vagina	0	-	-	-	.	0	-	-	-	-	
Small intestine	0	-	-	-	.	0	-	-	-	-	
Eye & lacrimal gland	1	2.6 (0.0 - 7.8)	4.92	(0.00 - 18.13)	-*	0	-	-	-	-	
Major Salivary Gland	0	-	-	-	.	0	-	-	-	-	
Anus	0	-	-	-	.	0	-	-	-	-	
Mouth, other & unspecified	0	-	-	-	.	0	-	-	-	-	
Floor of mouth	0	-	-	-	.	0	-	-	-	-	
Bones, joints & articular cart.	0	-	-	-	.	0	-	-	-	-	
Pyriform sinus & hypopharynx	1	1.5 (0.0 - 4.5)	2.37	(0.00 - 8.73)	-*	0	-	-	-	-	
Nasal cavity, sinuses, int. ear	0	-	-	-	.	0	-	-	-	-	
Peritoneum & retroperitoneum	0	-	-	-	.	0	-	-	-	-	
Adrenal & other endocrine	0	-	-	-	.	1	1.4 (0.0 - 4.1)	9.62	(0.00 - 35.47)	-*	
Nasopharynx	1	1.5 (0.0 - 4.5)	6.86	(0.00 - 25.29)	-*	0	-	-	-	-	
Pharynx, other & ill-def.	1	1.2 (0.0 - 3.4)	4.79	(0.00 - 17.69)	-*	0	-	-	-	-	
Penis & other male genital	0	-	-	-	.	0	-	-	-	-	
Gum	0	-	-	-	.	0	-	-	-	-	
Kaposi sarcoma	0	-	-	-	.	0	-	-	-	-	
Thymus	0	-	-	-	.	0	-	-	-	-	
Pleura, heart & mediastinum	1	2.0 (0.0 - 5.8)	8.61	(0.00 - 31.75)	-*	0	-	-	-	-	
Spinal cord & cranial nerves	0	-	-	-	.	0	-	-	-	-	
Uterus, nos	0	-	-	-	.	0	-	-	-	-	
Nervous, periph./autonomic	0	-	-	-	.	0	-	-	-	-	
Placenta	0	-	-	-	.	0	-	-	-	-	
Meninges (cerebral & spinal)	0	-	-	-	.	0	-	-	-	-	
All cancers	112	168.4 (136.7 - 200.1)	1.27	(1.05 - 1.54)	^	63	90.5 (67.5 - 113.4)	1.04	(0.81 - 1.34)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Lake Grace (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	20.4 (0.0 - 60.0)	1.35	(0.00 - 5.00)	-*
Colorectal cancer	0	-	-	0	n/a	-	1	20.1 (0.0 - 59.4)	1.93	(0.00 - 7.12)	-*
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	2	53.0	(0.0 - 128.3)	1.29	(0.02 - 3.60)	-*	3	61.5 (0.0 - 129.9)	4.81	(0.39 - 11.22)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	1	17.2	(0.0 - 50.7)	2.72	(0.00 - 10.02)	-*	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	1	18.8	(0.0 - 55.5)	6.72	(0.00 - 24.80)	-*	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	1	36.4 (0.0 - 107.5)	7.26	(0.00 - 26.79)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	1	19.8	(0.0 - 58.4)	4.96	(0.00 - 18.30)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	1	28.6	(0.0 - 84.3)	7.02	(0.00 - 25.91)	-*	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	1	26.3	(0.0 - 76.5)	54.37	(0.00 - 200.58)	-*	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	1	17.2	(0.0 - 50.7)	67.71	(0.00 - 249.78)	-*	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	8	180.9	(53.4 - 308.4)	1.26	(0.44 - 2.27)	-	6	138.4 (25.0 - 251.8)	1.51	(0.41 - 2.93)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Laverton (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	-	-
Colorectal cancer	0	-	-	-	-	.	1	46.5 (0.0 - 137.3)	5.87	(0.00 - 21.65)	-*
Prostate gland	0	-	-	-	-	.	0	-	-	-	-
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	-
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-
Leukaemia	1	38.1	(0.0 - 112.7)	6.40	(0.00 - 23.61)	-*	0	-	-	-	-
Pancreas	0	-	-	-	-	.	0	-	-	-	-
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-
Stomach	0	-	-	-	-	.	0	-	-	-	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-
Brain	0	-	-	-	-	.	0	-	-	-	-
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-
Oesophagus	0	-	-	-	-	.	0	-	-	-	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-
Larynx	0	-	-	-	-	.	0	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	1	38.1	(0.0 - 112.7)	0.27	(0.00 - 0.99)	V*	1	46.5 (0.0 - 137.3)	0.76	(0.00 - 2.79)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Leonora (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	-	-
Colorectal cancer	1	57.1	(0.0 - 167.5)	1.33	(0.00 - 4.89)	-*	1	33.3	(0.0 - 96.5)	4.01	(0.00 - 14.78) -*
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-
Lymphoma	1	44.1	(0.0 - 130.0)	4.26	(0.00 - 15.73)	-*	0	-	-	-	-
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-
Leukaemia	0	-	-	-	-	.	0	-	-	-	-
Pancreas	0	-	-	-	-	.	0	-	-	-	-
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-
Stomach	0	-	-	-	-	.	0	-	-	-	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-
Brain	0	-	-	-	-	.	0	-	-	-	-
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-
Oesophagus	1	18.5	(0.0 - 54.7)	6.84	(0.00 - 25.23)	-*	0	-	-	-	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-
Liver & intrahepatic bile duct	1	9.3	(0.0 - 27.5)	8.41	(0.00 - 31.03)	-*	0	-	-	-	-
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-
Larynx	0	-	-	-	-	.	0	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-
Floor of mouth	1	13.5	(0.0 - 40.0)	61.08	(0.00 - 225.32)	-*	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	5	142.6	(0.0 - 290.5)	0.87	(0.19 - 1.78)	-	1	33.3	(0.0 - 96.5)	0.49	(0.00 - 1.80) -*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mandurah (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	37	17.0 (11.0 - 23.1)	1.03	(0.70 - 1.39)	-
Colorectal cancer	53	21.6 (15.3 - 27.9)	1.18	(0.89 - 1.56)	-	26	9.0 (5.3 - 12.6)	0.83	(0.51 - 1.17)	-	
Prostate gland	47	16.0 (11.2 - 20.8)	1.23	(0.88 - 1.60)	-	0	-	-	-	.	
Melanoma (skin)	8	2.9 (0.8 - 5.0)	0.90	(0.32 - 1.62)	-	3	1.1 (0.0 - 2.4)	0.64	(0.05 - 1.50)	-	
Lung, bronchus & trachea	73	28.3 (21.4 - 35.3)	0.84	(0.66 - 1.06)	-	48	17.5 (12.1 - 23.0)	1.28	(0.92 - 1.67)	-	
Lymphoma	7	3.0 (0.6 - 5.5)	0.56	(0.18 - 1.04)	-	14	4.3 (1.9 - 6.7)	1.29	(0.64 - 2.04)	-	
Unknown primary site	20	6.9 (3.8 - 10.1)	0.97	(0.55 - 1.44)	-	15	4.8 (2.2 - 7.5)	0.98	(0.50 - 1.54)	-	
Kidney & other renal tract	8	3.9 (1.1 - 6.8)	0.91	(0.32 - 1.65)	-	0	-	0	n/a	V	
Leukaemia	12	3.7 (1.5 - 5.9)	0.89	(0.41 - 1.45)	-	10	2.9 (1.0 - 4.8)	1.43	(0.59 - 2.45)	-	
Pancreas	16	7.7 (3.8 - 11.7)	1.11	(0.58 - 1.72)	-	16	5.5 (2.6 - 8.5)	1.25	(0.65 - 1.93)	-	
Urinary bladder	13	4.8 (2.1 - 7.5)	1.39	(0.66 - 2.24)	-	2	0.5 (0.0 - 1.1)	0.58	(0.01 - 1.62)	-*	
Stomach	24	8.6 (4.9 - 12.4)	1.60	(0.97 - 2.30)	-	9	3.3 (1.1 - 5.6)	1.29	(0.49 - 2.26)	-	
Corpus uteri	0	-	-	-	.	9	2.7 (0.9 - 4.5)	1.92	(0.74 - 3.36)	-	
Brain	14	8.0 (3.3 - 12.7)	1.43	(0.71 - 2.28)	-	5	2.4 (0.1 - 4.7)	0.76	(0.16 - 1.55)	-	
Lip	0	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	.	9	4.2 (1.2 - 7.2)	0.85	(0.32 - 1.48)	-	
Other lymphohaematopoietic	3	1.3 (0.0 - 2.9)	0.64	(0.05 - 1.50)	-	0	-	0	n/a	-	
Oesophagus	11	4.3 (1.7 - 6.9)	1.18	(0.51 - 1.97)	-	2	1.0 (0.0 - 2.5)	0.46	(0.01 - 1.29)	-*	
Thyroid gland	0	-	-	0	n/a	-	-	0	n/a	-	
Myeloma/plasma cell tumours	3	0.8 (0.0 - 1.7)	0.54	(0.04 - 1.25)	-	3	0.8 (0.0 - 1.7)	0.72	(0.06 - 1.68)	-*	
Cervix uteri	0	-	-	-	.	5	2.9 (0.0 - 6.0)	1.12	(0.24 - 2.30)	-*	
Non-mel. skin (exc BCC/SCC)	2	0.6 (0.0 - 1.4)	1.23	(0.02 - 3.43)	-*	0	-	0	n/a	-	
Mesothelioma	10	4.0 (1.4 - 6.7)	0.93	(0.38 - 1.59)	-	1	0.3 (0.0 - 1.0)	0.78	(0.00 - 2.87)	-*	
Liver & intrahepatic bile duct	4	1.9 (0.0 - 3.8)	0.55	(0.08 - 1.20)	-	5	1.9 (0.0 - 3.8)	2.13	(0.46 - 4.36)	-*	
Testis	0	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	2	0.8 (0.0 - 1.8)	0.53	(0.01 - 1.47)	-*	4	0.9 (0.0 - 1.8)	1.11	(0.17 - 2.43)	-*	
Larynx	3	1.4 (0.0 - 3.0)	0.95	(0.08 - 2.23)	-*	0	-	-	-	.	
Tongue	1	0.6 (0.0 - 1.8)	0.55	(0.00 - 2.03)	-*	0	-	0	n/a	-	
Connective & soft tissues	1	0.3 (0.0 - 0.7)	0.96	(0.00 - 3.53)	-*	2	1.2 (0.0 - 2.8)	2.34	(0.03 - 6.53)	-*	
Tonsil & oropharynx	4	2.9 (0.0 - 5.7)	2.55	(0.39 - 5.59)	-*	0	-	-	-	.	
Vulva/vagina	0	-	-	-	.	0	-	0	n/a	-	
Small intestine	3	1.3 (0.0 - 2.8)	2.31	(0.19 - 5.38)	-*	1	0.2 (0.0 - 0.7)	1.21	(0.00 - 4.45)	-*	
Eye & lacrimal gland	0	-	-	0	n/a	-	-	-	-	.	
Major Salivary Gland	1	0.3 (0.0 - 0.9)	1.42	(0.00 - 5.25)	-*	0	-	-	-	.	
Anus	1	0.7 (0.0 - 2.1)	1.79	(0.00 - 6.61)	-*	1	0.3 (0.0 - 1.0)	1.24	(0.00 - 4.58)	-*	
Mouth, other & unspecified	2	1.2 (0.0 - 3.0)	2.36	(0.03 - 6.58)	-*	0	-	0	n/a	-	
Floor of mouth	0	-	-	0	n/a	-	-	-	-	.	
Bones, joints & articular cart.	0	-	-	0	n/a	-	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	0	n/a	-	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	0	n/a	-	-	0	n/a	-	
Adrenal & other endocrine	2	0.8 (0.0 - 2.1)	6.09	(0.08 - 16.96)	-*	0	-	-	-	.	
Nasopharynx	1	0.8 (0.0 - 2.3)	2.43	(0.00 - 8.96)	-*	0	-	-	-	.	
Pharynx, other & ill-def.	1	0.3 (0.0 - 0.7)	1.29	(0.00 - 4.75)	-*	1	0.7 (0.0 - 2.0)	7.53	(0.00 - 27.79)	-*	
Penis & other male genital	0	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	.	1	0.3 (0.0 - 1.0)	6.81	(0.00 - 25.13)	-*	
All cancers	350	139.9 (124.1 - 155.6)	1.01	(0.91 - 1.13)	-	230	86.7 (74.2 - 99.1)	1.01	(0.89 - 1.15)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Manjimup (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	11.7 (0.0 - 23.6)	0.71 (0.11 - 1.57)	-	-
Colorectal cancer	7	18.9 (4.7 - 33.1)	1.02 (0.32 - 1.91)	-	-	-	6	14.1 (1.7 - 26.4)	1.32 (0.36 - 2.56)	-	-
Prostate gland	9	17.5 (6.0 - 29.0)	1.59 (0.61 - 2.79)	-	-	-	0	-	-	-	-
Melanoma (skin)	2	5.3 (0.0 - 12.8)	1.40 (0.02 - 3.89)	-*	-	-	0	-	0 n/a	-	-
Lung, bronchus & trachea	12	29.0 (12.1 - 45.8)	0.93 (0.43 - 1.53)	-	-	-	1	3.6 (0.0 - 10.8)	0.19 (0.00 - 0.69)	V	-
Lymphoma	3	11.1 (0.0 - 24.5)	1.54 (0.12 - 3.60)	-*	-	-	2	4.5 (0.0 - 11.2)	1.28 (0.02 - 3.56)	-*	-
Unknown primary site	4	10.7 (0.0 - 21.5)	1.28 (0.20 - 2.81)	-*	-	-	2	3.3 (0.0 - 7.9)	0.89 (0.01 - 2.49)	-*	-
Kidney & other renal tract	0	-	-	0 n/a	-	-	0	-	0 n/a	-	-
Leukaemia	1	3.2 (0.0 - 9.6)	0.47 (0.00 - 1.75)	-*	-	-	1	1.5 (0.0 - 4.6)	0.93 (0.00 - 3.43)	-*	-
Pancreas	1	2.5 (0.0 - 7.4)	0.44 (0.00 - 1.64)	-*	-	-	2	3.0 (0.0 - 7.3)	1.09 (0.01 - 3.04)	-*	-
Urinary bladder	2	5.7 (0.0 - 13.7)	1.44 (0.02 - 4.00)	-*	-	-	0	-	-	-	-
Stomach	3	6.7 (0.0 - 14.7)	1.30 (0.11 - 3.04)	-*	-	-	0	-	0 n/a	-	-
Corpus uteri	0	-	-	-	-	-	2	4.8 (0.0 - 11.8)	3.05 (0.04 - 8.50)	-*	-
Brain	6	18.8 (3.7 - 33.9)	3.46 (0.94 - 6.73)	-*	-	-	2	6.9 (0.0 - 16.5)	1.91 (0.02 - 5.33)	-*	-
Lip	1	2.9 (0.0 - 8.6)	35.85 (0.00 - 132.26)	-*	-	-	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	-	1	1.5 (0.0 - 4.6)	0.64 (0.00 - 2.36)	-*	-
Other lymphohaematopoietic	1	2.1 (0.0 - 6.1)	1.38 (0.00 - 5.10)	-*	-	-	0	-	-	-	-
Oesophagus	2	5.5 (0.0 - 13.3)	1.42 (0.02 - 3.97)	-*	-	-	3	7.2 (0.0 - 15.8)	4.94 (0.40 - 11.53)	-*	-
Thyroid gland	0	-	-	-	-	-	0	-	-	-	-
Myeloma/plasma cell tumours	1	1.7 (0.0 - 5.1)	1.17 (0.00 - 4.32)	-*	-	-	1	1.8 (0.0 - 5.2)	1.68 (0.00 - 6.19)	-*	-
Cervix uteri	0	-	-	-	-	-	0	-	0 n/a	-	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	-	0	-	-	-	-
Mesothelioma	1	3.2 (0.0 - 9.6)	0.61 (0.00 - 2.26)	-*	-	-	0	-	-	-	-
Liver & intrahepatic bile duct	1	3.2 (0.0 - 9.6)	0.91 (0.00 - 3.34)	-*	-	-	0	-	-	-	-
Testis	0	-	-	-	-	-	0	-	-	-	-
Gallbladder & bile ducts	1	2.5 (0.0 - 7.4)	1.71 (0.00 - 6.30)	-*	-	-	1	3.2 (0.0 - 9.6)	1.90 (0.00 - 7.01)	-*	-
Larynx	0	-	-	-	-	-	0	-	-	-	-
Tongue	0	-	-	-	-	-	0	-	-	-	-
Connective & soft tissues	0	-	-	-	-	-	0	-	-	-	-
Tonsil & oropharynx	1	1.7 (0.0 - 5.1)	3.78 (0.00 - 13.93)	-*	-	-	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	-	0	-	-	-	-
Small intestine	0	-	-	-	-	-	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	-	0	-	-	-	-
Major Salivary Gland	0	-	-	-	-	-	0	-	-	-	-
Anus	0	-	-	-	-	-	0	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	-	1	3.2 (0.0 - 9.6)	10.65 (0.00 - 39.27)	-*	-
Floor of mouth	0	-	-	-	-	-	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	-	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	-	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	-	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	-	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	-	0	-	-	-	-
Nasopharynx	0	-	-	-	-	-	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	-	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	-	0	-	-	-	-
Gum	0	-	-	-	-	-	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	-	0	-	-	-	-
Thymus	0	-	-	-	-	-	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	-	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	-	0	-	-	-	-
Uterus, nos	0	-	-	-	-	-	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	-	0	-	-	-	-
Placenta	0	-	-	-	-	-	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	-	0	-	-	-	-
All cancers	59	152.5 (112.3 - 192.7)	1.12 (0.86 - 1.45)	-	-	-	29	70.5 (43.1 - 97.9)	0.86 (0.55 - 1.21)	-	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Meekatharra (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	1	42.6	(0.0 - 125.1)	1.75	(0.00 - 6.46)	-*	0	-	-	-	-	.
Prostate gland	1	41.7	(0.0 - 119.9)	3.14	(0.00 - 11.59)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	2	77.8	(0.0 - 185.3)	1.96	(0.02 - 5.47)	-*	1	46.2	(0.0 - 135.9)	2.50	(0.00 - 9.21)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	1	18.6	(0.0 - 55.0)	8.84	(0.00 - 32.60)	-*	0	-	-	-	-	.
Leukaemia	1	32.0	(0.0 - 94.5)	5.45	(0.00 - 20.09)	-*	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	42.6	(0.0 - 125.1)	5.40	(0.00 - 19.90)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	1	18.2	(0.0 - 53.9)	16.60	(0.00 - 61.24)	-*	2	79.5	(0.0 - 190.4)	46.98	(0.59 - 130.88)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	39.2	(0.0 - 115.3)	26.98	(0.00 - 99.55)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	8	273.5	(81.4 - 465.5)	1.87	(0.66 - 3.37)	-*	4	164.9	(3.9 - 325.8)	1.53	(0.24 - 3.35)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Melville (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	63	13.0 (9.5 - 16.6)	0.88	(0.68 - 1.13)	-
Colorectal cancer	74	19.2 (14.6 - 23.8)	1.04	(0.82 - 1.31)	-		76	13.0 (9.6 - 16.4)	1.21	(0.96 - 1.52)	-
Prostate gland	61	12.2 (8.9 - 15.4)	0.98	(0.75 - 1.26)	-		0	-	-	-	.
Melanoma (skin)	16	4.0 (1.9 - 6.0)	1.08	(0.57 - 1.68)	-		7	1.3 (0.1 - 2.5)	0.74	(0.23 - 1.38)	-
Lung, bronchus & trachea	121	30.2 (24.5 - 35.9)	0.90	(0.75 - 1.09)	-		60	11.6 (8.3 - 14.9)	0.84	(0.64 - 1.08)	-
Lymphoma	15	3.1 (1.5 - 4.8)	0.74	(0.38 - 1.15)	-		27	4.2 (2.4 - 6.0)	1.29	(0.81 - 1.82)	-
Unknown primary site	35	8.3 (5.4 - 11.2)	1.06	(0.72 - 1.44)	-		14	2.2 (0.9 - 3.6)	0.44	(0.22 - 0.70)	V
Kidney & other renal tract	9	2.1 (0.7 - 3.6)	0.64	(0.25 - 1.12)	-		6	0.8 (0.1 - 1.6)	0.66	(0.18 - 1.28)	-
Leukaemia	11	2.8 (1.1 - 4.5)	0.50	(0.22 - 0.83)	V		14	2.3 (0.9 - 3.8)	0.97	(0.48 - 1.55)	-
Pancreas	19	5.2 (2.8 - 7.7)	0.83	(0.47 - 1.25)	-		17	2.6 (1.2 - 4.0)	0.67	(0.36 - 1.02)	-
Urinary bladder	19	4.1 (2.2 - 6.0)	1.28	(0.72 - 1.91)	-		9	1.3 (0.3 - 2.4)	1.26	(0.48 - 2.20)	-
Stomach	18	5.3 (2.8 - 7.8)	0.76	(0.42 - 1.14)	-		18	2.6 (1.2 - 4.0)	1.28	(0.70 - 1.94)	-
Corpus uteri	0	-	-	-	-	.	12	2.1 (0.8 - 3.4)	1.32	(0.60 - 2.16)	-
Brain	12	3.1 (1.2 - 5.0)	0.71	(0.33 - 1.17)	-		18	4.7 (2.2 - 7.3)	1.39	(0.77 - 2.11)	-
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	27	5.3 (3.0 - 7.5)	1.31	(0.82 - 1.85)	-
Other lymphohaematopoietic	6	1.5 (0.2 - 2.8)	0.79	(0.21 - 1.53)	-		1	0.1 (0.0 - 0.2)	0.19	(0.00 - 0.70)	V
Oesophagus	11	2.6 (0.9 - 4.2)	0.75	(0.33 - 1.25)	-		8	1.5 (0.4 - 2.7)	0.92	(0.32 - 1.66)	-
Thyroid gland	0	-	-	0	n/a	-	3	0.6 (0.0 - 1.5)	1.40	(0.11 - 3.28)	-*
Myeloma/plasma cell tumours	14	3.2 (1.4 - 5.0)	1.56	(0.77 - 2.48)	-		5	0.6 (0.1 - 1.2)	0.60	(0.13 - 1.22)	-
Cervix uteri	0	-	-	-	-	.	4	1.0 (0.0 - 2.0)	0.45	(0.07 - 0.99)	V
Non-mel. skin (exc BCC/SCC)	4	0.9 (0.0 - 1.9)	1.60	(0.25 - 3.50)	-*		1	0.1 (0.0 - 0.2)	0.77	(0.00 - 2.82)	-*
Mesothelioma	17	4.5 (2.2 - 6.7)	1.02	(0.55 - 1.55)	-		2	0.7 (0.0 - 1.7)	0.83	(0.01 - 2.32)	-*
Liver & intrahepatic bile duct	10	3.3 (1.2 - 5.4)	0.88	(0.36 - 1.51)	-		1	0.1 (0.0 - 0.2)	0.22	(0.00 - 0.80)	V
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	4	0.6 (0.0 - 1.2)	0.64	(0.10 - 1.41)	-		5	0.6 (0.0 - 1.2)	0.67	(0.15 - 1.38)	-
Larynx	4	0.8 (0.0 - 1.5)	0.81	(0.13 - 1.78)	-		0	-	0	n/a	-
Tongue	1	0.3 (0.0 - 0.7)	0.34	(0.00 - 1.24)	-*		2	0.4 (0.0 - 1.0)	1.30	(0.02 - 3.63)	-*
Connective & soft tissues	3	1.0 (0.0 - 2.2)	1.55	(0.12 - 3.61)	-*		2	0.5 (0.0 - 1.2)	1.27	(0.02 - 3.53)	-*
Tonsil & oropharynx	2	0.7 (0.0 - 1.6)	0.75	(0.01 - 2.10)	-*		0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	4	0.5 (0.0 - 1.0)	2.00	(0.31 - 4.39)	-*
Small intestine	3	0.9 (0.0 - 2.0)	1.42	(0.11 - 3.32)	-*		2	0.3 (0.0 - 0.7)	1.26	(0.02 - 3.51)	-*
Eye & lacrimal gland	1	0.3 (0.0 - 1.0)	0.93	(0.00 - 3.44)	-*		0	-	0	n/a	-
Major Salivary Gland	1	0.2 (0.0 - 0.5)	0.84	(0.00 - 3.11)	-*		0	-	-	-	.
Anus	0	-	-	0	n/a	-	2	0.4 (0.0 - 1.0)	1.10	(0.01 - 3.08)	-*
Mouth, other & unspecified	0	-	-	0	n/a	-	0	-	0	n/a	-
Floor of mouth	1	0.4 (0.0 - 1.0)	0.75	(0.00 - 2.77)	-*		1	0.1 (0.0 - 0.3)	1.43	(0.00 - 5.29)	-*
Bones, joints & articular cart.	1	0.2 (0.0 - 0.5)	0.92	(0.00 - 3.40)	-*		2	0.6 (0.0 - 1.6)	2.56	(0.03 - 7.12)	-*
Pyriform sinus & hypopharynx	3	1.0 (0.0 - 2.2)	1.25	(0.10 - 2.93)	-*		0	-	-	-	.
Nasal cavity, sinuses, int. ear	2	0.6 (0.0 - 1.3)	2.34	(0.03 - 6.53)	-*		0	-	-	-	.
Peritoneum & retroperitoneum	1	0.2 (0.0 - 0.6)	1.06	(0.00 - 3.91)	-*		1	0.3 (0.0 - 0.9)	0.65	(0.00 - 2.39)	-*
Adrenal & other endocrine	1	0.7 (0.0 - 2.0)	2.04	(0.00 - 7.54)	-*		1	0.4 (0.0 - 1.2)	2.16	(0.00 - 7.97)	-*
Nasopharynx	0	-	-	0	n/a	-	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	.
Penis & other male genital	1	0.3 (0.0 - 0.7)	2.66	(0.00 - 9.80)	-*		0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	0	n/a	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	1	0.3 (0.0 - 1.0)	1.94	(0.00 - 7.16)	-*		1	0.4 (0.0 - 1.1)	2.24	(0.00 - 8.26)	-*
Pleura, heart & mediastinum	0	-	-	0	n/a	-	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	502	123.9 (112.4 - 135.4)	0.91	(0.84 - 1.00)	-		418	76.9 (68.4 - 85.3)	0.92	(0.84 - 1.02)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Menzies (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	-	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Merredin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	2	13.2	(0.0 - 31.9)	0.87	(0.01 - 2.43)	-*	3	28.4	1.87	(0.15 - 4.37)	-*	
Prostate gland	1	11.5	(0.0 - 34.1)	0.53	(0.00 - 1.97)	-*	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	1	10.0	3.87	(0.00 - 14.29)	-*	
Lung, bronchus & trachea	3	29.5	(0.0 - 63.2)	0.70	(0.06 - 1.63)	-*	5	45.0	2.70	(0.59 - 5.54)	-*	
Lymphoma	1	4.9	(0.0 - 14.3)	1.51	(0.00 - 5.55)	-*	2	20.3	3.66	(0.05 - 10.19)	-*	
Unknown primary site	1	5.2	(0.0 - 15.2)	0.96	(0.00 - 3.53)	-*	3	14.8	3.80	(0.31 - 8.88)	-*	
Kidney & other renal tract	0	-	-	-	-	.	1	10.5	4.31	(0.00 - 15.91)	-*	
Leukaemia	2	12.4	(0.0 - 29.8)	2.78	(0.03 - 7.75)	-*	0	-	-	-	.	
Pancreas	0	-	-	0	n/a	-	2	15.2	3.12	(0.04 - 8.70)	-*	
Urinary bladder	0	-	-	-	-	.	1	10.0	5.82	(0.00 - 21.47)	-*	
Stomach	2	16.2	(0.0 - 38.6)	2.62	(0.03 - 7.30)	-*	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	1	7.5	(0.0 - 22.2)	1.69	(0.00 - 6.24)	-*	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	0	n/a	-	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	0	-	-	-	-	.	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	1	7.9	(0.0 - 23.4)	1.84	(0.00 - 6.78)	-*	0	-	-	-	.	
Liver & intrahepatic bile duct	2	13.9	(0.0 - 33.7)	5.37	(0.07 - 14.95)	-*	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	1	11.5	(0.0 - 34.1)	6.22	(0.00 - 22.96)	-*	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	1	4.9	(0.0 - 14.3)	26.39	(0.00 - 97.35)	-*	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	8.0	24.88	(0.00 - 91.80)	-*	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	18	138.5	(72.1 - 204.8)	1.02	(0.56 - 1.54)	-	19	162.2	(87.0 - 237.3)	1.62	(0.91 - 2.43)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mingenew (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	1	60.6 (0.0 - 177.6)	12.10 (0.00 - 44.65)		-*	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	52.6 (0.0 - 155.1)		9.02 (0.00 - 33.29)		-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	52.6 (0.0 - 155.1)		17.83 (0.00 - 65.76)		-*	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	2	105.3 (0.0 - 249.2)		0.79 (0.01 - 2.20)		-*	1	60.6 (0.0 - 177.6)	0.64 (0.00 - 2.35)		-*	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Moora (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	1	9.3	(0.0 - 27.2)	0.68	(0.00 - 2.52)	-*	1	20.6	0.91	(0.00 - 3.37)	-*	
Prostate gland	2	16.4	(0.0 - 38.9)	1.66	(0.02 - 4.61)	-*	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	4	66.5	(1.2 - 131.7)	1.48	(0.23 - 3.25)	-*	0	-	0	n/a	-	
Lymphoma	0	-	-	-	-	.	2	10.3	5.52	(0.07 - 15.37)	-*	
Unknown primary site	2	28.8	(0.0 - 70.4)	2.98	(0.04 - 8.31)	-*	0	-	0	n/a	-	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.	
Leukaemia	0	-	-	-	-	.	0	-	-	-	.	
Pancreas	0	-	-	-	-	.	1	18.0	2.32	(0.00 - 8.56)	-*	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.	
Stomach	0	-	-	-	-	.	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	0	-	-	-	-	.	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	1	19.0	(0.0 - 56.0)	4.27	(0.00 - 15.73)	-*	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	10	139.8	(49.5 - 230.2)	0.88	(0.36 - 1.51)	-	4	48.9	(0.0 - 104.2)	0.50	(0.08 - 1.10)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Morawa (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	13.5	(0.0 - 39.6)	1.99	(0.00 - 7.35)	-*
Colorectal cancer	1	32.3	(0.0 - 95.2)	1.37	(0.00 - 5.04)	-*	0	-	-	-	-	.
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	1	28.8	(0.0 - 85.1)	0.73	(0.00 - 2.68)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	1	24.7	(0.0 - 72.9)	5.57	(0.00 - 20.55)	-*	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	39.0	(0.0 - 114.8)	19.25	(0.00 - 71.01)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	1	32.3	(0.0 - 95.2)	16.46	(0.00 - 60.72)	-*	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	4	118.1	(2.5 - 233.6)	0.71	(0.11 - 1.56)	-	2	52.5	(0.0 - 132.7)	0.68	(0.01 - 1.89)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mosman Park (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	11	32.6 (10.4 - 54.7)	1.65	(0.72 - 2.77)	-
Colorectal cancer	5	13.5	(1.1 - 25.8)	0.81	(0.18 - 1.66)	-	7	4.8 (1.2 - 8.3)	1.12	(0.35 - 2.09)	-
Prostate gland	6	15.9	(2.5 - 29.4)	1.08	(0.29 - 2.09)	-	0	-	-	-	.
Melanoma (skin)	5	17.0	(1.7 - 32.3)	3.87	(0.84 - 7.93)	-*	1	1.3 (0.0 - 3.8)	1.11	(0.00 - 4.09)	-*
Lung, bronchus & trachea	13	39.5	(16.5 - 62.4)	1.13	(0.54 - 1.83)	-	1	0.6 (0.0 - 1.8)	0.16	(0.00 - 0.57)	V
Lymphoma	1	1.9	(0.0 - 5.7)	0.57	(0.00 - 2.10)	-*	2	5.3 (0.0 - 14.5)	1.03	(0.01 - 2.86)	-*
Unknown primary site	5	10.1	(0.7 - 19.6)	1.75	(0.38 - 3.58)	-*	4	3.2 (0.0 - 6.3)	1.20	(0.19 - 2.63)	-*
Kidney & other renal tract	1	4.1	(0.0 - 12.0)	0.82	(0.00 - 3.02)	-*	0	-	0	n/a	-
Leukaemia	1	3.3	(0.0 - 9.8)	0.53	(0.00 - 1.94)	-*	0	-	0	n/a	-
Pancreas	1	4.4	(0.0 - 13.0)	0.51	(0.00 - 1.90)	-*	0	-	0	n/a	-
Urinary bladder	2	4.7	(0.0 - 11.8)	1.53	(0.02 - 4.27)	-*	1	0.6 (0.0 - 1.8)	1.33	(0.00 - 4.92)	-*
Stomach	1	1.9	(0.0 - 5.7)	0.48	(0.00 - 1.79)	-*	0	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	0	-	0	n/a	-
Brain	2	7.0	(0.0 - 16.8)	1.39	(0.02 - 3.87)	-*	1	3.4 (0.0 - 10.0)	0.89	(0.00 - 3.28)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	1.2 (0.0 - 2.9)	1.04	(0.01 - 2.88)	-*
Other lymphohaematopoietic	2	5.5	(0.0 - 13.3)	2.97	(0.04 - 8.26)	-*	3	2.5 (0.0 - 5.5)	4.89	(0.39 - 11.42)	-*
Oesophagus	0	-	-	0	n/a	-	1	3.0 (0.0 - 9.0)	1.17	(0.00 - 4.31)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	1	4.5 (0.0 - 13.4)	1.25	(0.00 - 4.63)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	0	n/a	-	1	0.9 (0.0 - 2.5)	1.39	(0.00 - 5.13)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	1	2.2	(0.0 - 6.5)	3.93	(0.00 - 14.51)	-*	0	-	-	-	.
Connective & soft tissues	1	2.2	(0.0 - 6.5)	5.82	(0.00 - 21.47)	-*	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	2	5.4	(0.0 - 13.2)	29.14	(0.36 - 81.19)	-*	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	49	138.7	(97.7 - 179.7)	1.03	(0.74 - 1.34)	-	36	63.8 (35.9 - 91.7)	0.83	(0.56 - 1.13)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mount Magnet (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	1	58.8 (0.0 - 170.7)	5.20 (0.00 - 19.17)		-*	
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	-	1	58.8 (0.0 - 170.7)	0.77 (0.00 - 2.83)		-*	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mount Marshall (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	43.5	(0.0 - 128.1)	14.49	(0.00 - 53.45)	-*	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	43.5	(0.0 - 128.1)	0.34	(0.00 - 1.24)	-*	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mukinbudin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	1	23.5	(0.0 - 69.4)	1.04	(0.00 - 3.84)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	23.5	(0.0 - 69.4)	0.27	(0.00 - 1.00)	-*	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mullewa (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	-	-
Colorectal cancer	0	-	-	0	n/a	-	1	90.9 (0.0 - 265.0)	3.27	(0.00 - 12.05)	-*
Prostate gland	0	-	-	-	-	.	0	-	-	-	-
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-
Lung, bronchus & trachea	1	27.6	(0.0 - 81.5)	0.94	(0.00 - 3.45)	-*	0	-	-	-	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	-
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-
Leukaemia	1	30.3	(0.0 - 89.5)	5.53	(0.00 - 20.39)	-*	0	-	-	-	-
Pancreas	0	-	-	-	-	.	0	-	-	-	-
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-
Stomach	0	-	-	-	-	.	0	-	-	-	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-
Brain	0	-	-	-	-	.	0	-	-	-	-
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-
Oesophagus	1	37.5	(0.0 - 110.8)	8.45	(0.00 - 31.15)	-*	0	-	-	-	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-
Cervix uteri	0	-	-	-	-	.	1	30.2 (0.0 - 89.1)	18.94	(0.00 - 69.89)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-
Larynx	1	31.3	(0.0 - 92.0)	24.49	(0.00 - 90.34)	-*	0	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	4	126.6	(2.3 - 251.0)	0.89	(0.14 - 1.96)	-*	2	121.1 (0.0 - 304.9)	0.88	(0.01 - 2.44)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Mundaring (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	22	15.9 (9.1 - 22.7)	1.09	(0.65 - 1.59)	-
Colorectal cancer	21	20.3 (11.5 - 29.1)	1.04	(0.61 - 1.53)	-	12	8.4 (3.4 - 13.5)	0.79	(0.36 - 1.29)	-	
Prostate gland	11	9.1 (3.6 - 14.6)	0.73	(0.32 - 1.22)	-	0	-	-	-	.	
Melanoma (skin)	4	3.3 (0.0 - 6.5)	0.93	(0.14 - 2.04)	-*	1	0.8 (0.0 - 2.3)	0.39	(0.00 - 1.45)	-*	
Lung, bronchus & trachea	25	21.5 (12.9 - 30.2)	0.67	(0.41 - 0.95)	V	14	9.3 (4.2 - 14.3)	0.79	(0.39 - 1.25)	-	
Lymphoma	6	5.1 (1.0 - 9.3)	1.03	(0.28 - 2.01)	-	3	2.3 (0.0 - 5.1)	0.58	(0.05 - 1.35)	-	
Unknown primary site	8	6.4 (1.8 - 10.9)	0.89	(0.31 - 1.61)	-	9	6.0 (1.8 - 10.2)	1.22	(0.47 - 2.13)	-	
Kidney & other renal tract	2	1.6 (0.0 - 3.9)	0.50	(0.01 - 1.40)	-*	2	1.6 (0.0 - 4.0)	0.92	(0.01 - 2.57)	-*	
Leukaemia	9	8.6 (2.9 - 14.3)	1.46	(0.56 - 2.56)	-	5	3.5 (0.4 - 6.6)	1.39	(0.30 - 2.86)	-*	
Pancreas	6	5.8 (1.1 - 10.6)	0.90	(0.24 - 1.75)	-	5	3.6 (0.2 - 6.9)	0.84	(0.18 - 1.72)	-	
Urinary bladder	2	1.6 (0.0 - 3.9)	0.53	(0.01 - 1.49)	-*	2	1.7 (0.0 - 4.1)	1.28	(0.02 - 3.57)	-*	
Stomach	4	4.7 (0.0 - 9.4)	0.60	(0.09 - 1.31)	-	4	3.2 (0.0 - 6.5)	1.21	(0.19 - 2.66)	-*	
Corpus uteri	0	-	-	-	-	0	-	0	n/a	-	
Brain	7	6.3 (1.6 - 10.9)	1.24	(0.39 - 2.32)	-	5	4.1 (0.4 - 7.8)	1.38	(0.30 - 2.82)	-*	
Lip	0	-	-	-	-	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	4	3.0 (0.0 - 6.3)	0.75	(0.12 - 1.65)	-	
Other lymphohaematopoietic	0	-	-	0	n/a	-	2	1.7 (0.0 - 4.2)	1.73	(0.02 - 4.82)	-*
Oesophagus	2	1.6 (0.0 - 3.9)	0.48	(0.01 - 1.34)	-*	4	2.8 (0.0 - 5.7)	1.97	(0.30 - 4.32)	-*	
Thyroid gland	0	-	-	-	-	2	1.4 (0.0 - 3.3)	3.84	(0.05 - 10.70)	-*	
Myeloma/plasma cell tumours	4	3.6 (0.0 - 7.2)	1.67	(0.26 - 3.66)	-*	4	2.5 (0.0 - 5.0)	2.01	(0.31 - 4.41)	-*	
Cervix uteri	0	-	-	-	-	1	0.6 (0.0 - 1.8)	0.41	(0.00 - 1.50)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	1	0.9 (0.0 - 2.7)	3.30	(0.00 - 12.18)	-*
Mesothelioma	10	9.8 (3.6 - 16.0)	2.07	(0.85 - 3.53)	-	2	1.9 (0.0 - 4.6)	3.19	(0.04 - 8.88)	-*	
Liver & intrahepatic bile duct	1	1.8 (0.0 - 5.2)	0.30	(0.00 - 1.10)	-*	0	-	0	n/a	-	
Testis	0	-	-	-	-	0	-	-	-	.	
Gallbladder & bile ducts	3	2.2 (0.0 - 4.6)	1.72	(0.14 - 4.02)	-*	3	1.9 (0.0 - 4.2)	1.73	(0.14 - 4.03)	-*	
Larynx	0	-	-	0	n/a	-	0	-	-	.	
Tongue	1	1.1 (0.0 - 3.3)	1.09	(0.00 - 4.03)	-*	2	1.3 (0.0 - 3.1)	4.88	(0.06 - 13.59)	-*	
Connective & soft tissues	0	-	-	0	n/a	-	2	1.2 (0.0 - 2.9)	4.55	(0.06 - 12.66)	-*
Tonsil & oropharynx	0	-	-	0	n/a	-	0	-	-	.	
Vulva/vagina	0	-	-	-	-	0	-	-	-	.	
Small intestine	1	1.1 (0.0 - 3.3)	1.64	(0.00 - 6.06)	-*	0	-	-	-	.	
Eye & lacrimal gland	1	1.1 (0.0 - 3.3)	2.97	(0.00 - 10.94)	-*	1	1.1 (0.0 - 3.3)	4.42	(0.00 - 16.32)	-*	
Major Salivary Gland	0	-	-	-	-	0	-	-	-	.	
Anus	0	-	-	-	-	2	1.4 (0.0 - 3.3)	4.24	(0.05 - 11.81)	-*	
Mouth, other & unspecified	1	0.9 (0.0 - 2.7)	2.25	(0.00 - 8.30)	-*	0	-	-	-	.	
Floor of mouth	1	0.7 (0.0 - 2.0)	2.25	(0.00 - 8.31)	-*	0	-	-	-	.	
Bones, joints & articular cart.	1	0.7 (0.0 - 2.0)	2.98	(0.00 - 11.00)	-*	0	-	-	-	.	
Pyriform sinus & hypopharynx	2	1.8 (0.0 - 4.4)	2.79	(0.03 - 7.78)	-*	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	1	0.6 (0.0 - 1.8)	2.61	(0.00 - 9.64)	-*	
Adrenal & other endocrine	0	-	-	-	-	0	-	-	-	.	
Nasopharynx	1	0.7 (0.0 - 2.0)	3.49	(0.00 - 12.89)	-*	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	0	-	-	-	.	
Gum	0	-	-	-	-	1	0.6 (0.0 - 1.8)	8.53	(0.00 - 31.48)	-*	
Kaposi sarcoma	0	-	-	-	-	0	-	-	-	.	
Thymus	1	0.7 (0.0 - 2.0)	5.59	(0.00 - 20.62)	-*	2	1.2 (0.0 - 2.9)	15.43	(0.19 - 42.98)	-*	
Pleura, heart & mediastinum	0	-	-	-	-	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	0	-	-	-	.	
Placenta	0	-	-	-	-	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	0	-	-	-	.	
All cancers	135	122.1 (101.1 - 143.1)	0.88	(0.74 - 1.05)	-	118	84.7 (68.8 - 100.6)	1.04	(0.86 - 1.25)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Murchison (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	=	0	-	-	-	-	.

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Murray (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	7	21.8 (4.3 - 39.2)	1.01	(0.32 - 1.89)	-
Colorectal cancer	8	13.3 (4.0 - 22.7)	0.84	(0.30 - 1.52)	-	4	9.4 (0.0 - 18.8)	0.74	(0.11 - 1.62)	-	
Prostate gland	6	10.1 (1.9 - 18.2)	0.84	(0.23 - 1.64)	-	0	-	-	-	-	
Melanoma (skin)	2	8.5 (0.0 - 21.8)	1.06	(0.01 - 2.96)	-*	2	4.6 (0.0 - 11.4)	2.32	(0.03 - 6.46)	-*	
Lung, bronchus & trachea	15	26.1 (12.7 - 39.5)	0.82	(0.42 - 1.28)	-	16	33.2 (16.8 - 49.7)	2.45	(1.29 - 3.79)	^	
Lymphoma	1	1.8 (0.0 - 5.3)	0.38	(0.00 - 1.40)	-*	4	7.7 (0.1 - 15.2)	2.10	(0.32 - 4.60)	-*	
Unknown primary site	4	8.8 (0.0 - 17.8)	0.95	(0.15 - 2.08)	-*	5	11.5 (1.2 - 21.8)	2.00	(0.44 - 4.11)	-*	
Kidney & other renal tract	1	2.1 (0.0 - 6.2)	0.54	(0.00 - 1.99)	-*	1	2.4 (0.0 - 7.0)	1.26	(0.00 - 4.64)	-*	
Leukaemia	3	10.3 (0.0 - 25.5)	1.08	(0.09 - 2.51)	-*	4	9.5 (0.0 - 19.5)	3.32	(0.51 - 7.28)	-*	
Pancreas	1	2.2 (0.0 - 6.5)	0.32	(0.00 - 1.18)	-*	3	6.6 (0.0 - 14.1)	1.39	(0.11 - 3.25)	-*	
Urinary bladder	2	2.9 (0.0 - 6.9)	1.11	(0.01 - 3.08)	-*	0	-	0	n/a	-	
Stomach	3	6.8 (0.0 - 14.7)	0.96	(0.08 - 2.23)	-*	2	4.4 (0.0 - 10.5)	1.74	(0.02 - 4.83)	-*	
Corpus uteri	0	-	-	-	-	1	2.3 (0.0 - 6.7)	1.26	(0.00 - 4.65)	-*	
Brain	0	-	-	0	n/a	-	2	5.4 (0.0 - 13.1)	1.58	(0.02 - 4.39)	-*
Lip	0	-	-	-	-	.	0	-	-	-	
Ovary & uterine adnexa	0	-	-	-	-	.	3	6.4 (0.0 - 13.7)	1.54	(0.12 - 3.60)	-*
Other lymphohaematopoietic	2	3.4 (0.0 - 8.0)	2.22	(0.03 - 6.19)	-*	0	-	-	-	-	
Oesophagus	3	6.0 (0.0 - 12.8)	1.52	(0.12 - 3.54)	-*	0	-	0	n/a	-	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	0	n/a	
Cervix uteri	0	-	-	-	-	.	0	-	0	n/a	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	
Mesothelioma	3	6.1 (0.0 - 13.1)	1.29	(0.10 - 3.01)	-*	0	-	-	-	-	
Liver & intrahepatic bile duct	2	3.1 (0.0 - 7.5)	1.24	(0.02 - 3.47)	-*	1	2.4 (0.0 - 7.0)	2.37	(0.00 - 8.76)	-*	
Testis	0	-	-	-	-	.	0	-	-	-	
Gallbladder & bile ducts	1	1.3 (0.0 - 3.9)	1.27	(0.00 - 4.70)	-*	2	3.4 (0.0 - 8.1)	3.38	(0.04 - 9.42)	-*	
Larynx	3	5.6 (0.0 - 12.0)	4.40	(0.36 - 10.28)	-*	0	-	-	-	-	
Tongue	1	1.3 (0.0 - 3.9)	2.41	(0.00 - 8.91)	-*	1	1.8 (0.0 - 5.4)	7.29	(0.00 - 26.90)	-*	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	
Vulva/vagina	0	-	-	-	-	.	1	2.4 (0.0 - 7.0)	7.46	(0.00 - 27.52)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	
Anus	0	-	-	-	-	.	0	-	-	-	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	
Bones, joints & articular cart.	2	6.6 (0.0 - 16.9)	15.75	(0.20 - 43.88)	-*	0	-	-	-	-	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	
Gum	0	-	-	-	-	.	0	-	-	-	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	
Thymus	0	-	-	-	-	.	0	-	-	-	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	
Placenta	0	-	-	-	-	.	0	-	-	-	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	
All cancers	63	126.5 (91.3 - 161.7)	0.87	(0.68 - 1.13)	-		59	135.2 (99.2 - 171.2)	1.47	(1.13 - 1.91)	^

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Nannup (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	2	34.7	(0.0 - 82.7)	2.40	(0.03 - 6.67)	-*	0	-	0	n/a	-	
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	0	n/a	-	
Lymphoma	0	-	-	-	-	.	1	13.5	(0.0 - 39.6)	5.30	(0.00 - 19.56)	-*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.	
Leukaemia	0	-	-	-	-	.	0	-	-	-	.	
Pancreas	0	-	-	-	-	.	0	-	-	-	.	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.	
Stomach	0	-	-	-	-	.	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	1	22.6	(0.0 - 66.8)	4.35	(0.00 - 16.04)	-*	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	0	-	-	-	-	.	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	1	20.0	(0.0 - 58.4)	4.89	(0.00 - 18.03)	-*	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	4	77.3	(2.4 - 152.2)	0.63	(0.10 - 1.39)	-	1	13.5	(0.0 - 39.6)	0.24	(0.00 - 0.89)	v*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Narembeen (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	2	60.8	(0.0 - 145.0)	2.82	(0.04 - 7.87)	-*	0	-	0	n/a	-	
Prostate gland	2	37.4	(0.0 - 89.6)	3.40	(0.04 - 9.48)	-*	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	1	15.2	(0.0 - 44.4)	0.76	(0.00 - 2.80)	-*	1	10.6	(0.0 - 31.3)	1.75	(0.00 - 6.45) -*	
Lymphoma	0	-	-	-	-	.	0	-	-	-	.	
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.	
Leukaemia	0	-	-	-	-	.	0	-	-	-	.	
Pancreas	0	-	-	-	-	.	0	-	-	-	.	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.	
Stomach	0	-	-	-	-	.	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.	
Other lymphohaematopoietic	1	15.2	(0.0 - 44.4)	12.77	(0.00 - 47.10)	-*	0	-	-	-	.	
Oesophagus	0	-	-	-	-	.	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	1	28.3	(0.0 - 83.5)	5.91	(0.00 - 21.81)	-*	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	7	156.8	(37.0 - 276.6)	1.29	(0.40 - 2.40)	-	1	10.6	(0.0 - 31.3)	0.27	(0.00 - 1.00) -*	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Narrogin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	0	-	-	0	n/a	-	0	-	0	n/a	-	
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	0	n/a	-	
Lymphoma	0	-	-	-	-	.	0	-	-	-	.	
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.	
Leukaemia	0	-	-	-	-	.	0	-	-	-	.	
Pancreas	0	-	-	-	-	.	0	-	-	-	.	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.	
Stomach	0	-	-	-	-	.	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	0	-	-	-	-	.	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	n/a	.	
All cancers	0	-	-	0	n/a	V	0	-	0	n/a	V	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Narrogin (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	4	22.9 (0.0 - 49.4)	1.55	(0.24 - 3.39)	-*
Colorectal cancer	2	11.1 (0.0 - 27.4)	0.76	(0.01 - 2.13)	-*		1	2.2 (0.0 - 6.4)	0.42	(0.00 - 1.54)	-*
Prostate gland	7	35.6 (8.1 - 63.2)	2.88	(0.90 - 5.36)	-*		0	-	-	-	.
Melanoma (skin)	1	7.6 (0.0 - 22.4)	1.83	(0.00 - 6.73)	-*		0	-	-	-	.
Lung, bronchus & trachea	7	44.7 (9.0 - 80.5)	1.45	(0.46 - 2.70)	-		3	20.4 (0.0 - 46.3)	1.16	(0.09 - 2.70)	-*
Lymphoma	2	18.7 (0.0 - 45.2)	2.69	(0.03 - 7.50)	-*		0	-	0	n/a	-
Unknown primary site	2	7.0 (0.0 - 16.7)	1.63	(0.02 - 4.54)	-*		3	14.9 (0.0 - 35.5)	2.40	(0.19 - 5.61)	-*
Kidney & other renal tract	1	11.2 (0.0 - 33.0)	1.92	(0.00 - 7.07)	-*		1	9.8 (0.0 - 29.1)	2.93	(0.00 - 10.80)	-*
Leukaemia	1	4.3 (0.0 - 12.7)	1.21	(0.00 - 4.47)	-*		1	8.6 (0.0 - 25.3)	1.78	(0.00 - 6.58)	-*
Pancreas	1	3.5 (0.0 - 10.4)	1.22	(0.00 - 4.49)	-*		1	1.9 (0.0 - 5.8)	1.04	(0.00 - 3.84)	-*
Urinary bladder	2	7.8 (0.0 - 18.7)	3.51	(0.04 - 9.78)	-*		0	-	-	-	.
Stomach	2	19.2 (0.0 - 45.9)	2.27	(0.03 - 6.33)	-*		0	-	0	n/a	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	1	4.3 (0.0 - 12.7)	1.63	(0.00 - 6.00)	-*		0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	3.2 (0.0 - 9.3)	1.32	(0.00 - 4.89)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	1	1.9 (0.0 - 5.8)	4.57	(0.00 - 16.84)	-*
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	.
Thyroid gland	1	4.8 (0.0 - 14.3)	31.44	(0.00 - 115.96)	-*		0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	9.8 (0.0 - 29.1)	3.14	(0.00 - 11.59)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	1	3.5 (0.0 - 10.4)	1.65	(0.00 - 6.07)	-*		0	-	-	-	.
Liver & intrahepatic bile duct	1	7.6 (0.0 - 22.4)	2.48	(0.00 - 9.16)	-*		0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	11.5 (0.0 - 33.9)	3.56	(0.00 - 13.14)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	1.9 (0.0 - 5.8)	12.55	(0.00 - 46.29)	-*
Small intestine	1	7.6 (0.0 - 22.4)	12.62	(0.00 - 46.57)	-*		0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	1	11.5 (0.0 - 33.9)	27.33	(0.00 - 100.83)	-*
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	1	10.4 (0.0 - 30.8)	50.69	(0.00 - 187.01)	-*		0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	34	209.1 (133.5 - 284.8)	1.67	(1.12 - 2.28)	^		20	120.6 (58.2 - 183.0)	1.19	(0.68 - 1.76)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Nedlands (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	22	19.2 (9.1 - 29.4)	1.13	(0.67 - 1.65)	-
Colorectal cancer	14	8.4 (3.9 - 12.8)	0.82	(0.40 - 1.30)	-	31	17.1 (9.1 - 25.1)	1.65	(1.08 - 2.28)	^	
Prostate gland	14	8.8 (3.7 - 13.8)	0.83	(0.41 - 1.31)	-	0	-	-	-	.	
Melanoma (skin)	4	5.1 (0.0 - 10.4)	1.13	(0.17 - 2.47)	-*	1	0.2 (0.0 - 0.6)	0.38	(0.00 - 1.39)	-*	
Lung, bronchus & trachea	19	16.8 (8.4 - 25.3)	0.61	(0.34 - 0.92)	V	14	8.1 (2.4 - 13.8)	0.74	(0.36 - 1.17)	-	
Lymphoma	8	7.2 (1.8 - 12.7)	1.66	(0.58 - 3.00)	-	9	6.5 (0.8 - 12.1)	1.57	(0.60 - 2.74)	-	
Unknown primary site	7	6.5 (0.8 - 12.2)	0.86	(0.27 - 1.61)	-	13	8.3 (2.6 - 14.0)	1.28	(0.61 - 2.07)	-	
Kidney & other renal tract	5	4.6 (0.0 - 9.2)	1.46	(0.32 - 2.99)	-*	3	1.1 (0.0 - 2.5)	1.14	(0.09 - 2.67)	-*	
Leukaemia	5	4.4 (0.1 - 8.7)	0.94	(0.20 - 1.92)	-	6	2.0 (0.3 - 3.8)	1.41	(0.38 - 2.75)	-*	
Pancreas	5	5.5 (0.0 - 11.0)	0.94	(0.21 - 1.93)	-	5	1.4 (0.1 - 2.7)	0.67	(0.15 - 1.37)	-	
Urinary bladder	5	4.4 (0.0 - 8.8)	1.29	(0.28 - 2.65)	-*	3	0.9 (0.0 - 2.0)	1.29	(0.10 - 3.02)	-*	
Stomach	5	3.5 (0.0 - 7.0)	0.87	(0.19 - 1.77)	-	10	7.9 (0.6 - 15.2)	2.35	(0.97 - 4.02)	-*	
Corpus uteri	0	-	-	-	-	1	1.0 (0.0 - 3.1)	0.39	(0.00 - 1.42)	-*	
Brain	5	6.8 (0.6 - 13.0)	1.30	(0.28 - 2.66)	-*	2	2.1 (0.0 - 4.9)	0.62	(0.01 - 1.72)	-*	
Lip	0	-	-	-	-	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	12	8.0 (2.6 - 13.4)	2.11	(0.97 - 3.47)	-	
Other lymphohaematopoietic	2	2.4 (0.0 - 6.1)	0.96	(0.01 - 2.68)	-*	2	0.4 (0.0 - 0.9)	1.06	(0.01 - 2.96)	-*	
Oesophagus	3	2.6 (0.0 - 5.7)	0.87	(0.07 - 2.03)	-*	2	0.4 (0.0 - 1.0)	0.76	(0.01 - 2.12)	-*	
Thyroid gland	0	-	-	-	-	1	0.5 (0.0 - 1.4)	1.62	(0.00 - 5.98)	-*	
Myeloma/plasma cell tumours	2	2.0 (0.0 - 5.0)	0.87	(0.01 - 2.43)	-*	4	2.6 (0.0 - 5.8)	1.59	(0.25 - 3.49)	-*	
Cervix uteri	0	-	-	-	-	3	1.5 (0.0 - 3.6)	1.29	(0.10 - 3.02)	-*	
Non-mel. skin (exc BCC/SCC)	3	3.4 (0.0 - 7.5)	4.68	(0.38 - 10.92)	-*	0	-	-	-	.	
Mesothelioma	1	0.5 (0.0 - 1.5)	0.26	(0.00 - 0.94)	V*	1	0.2 (0.0 - 0.7)	1.69	(0.00 - 6.23)	-*	
Liver & intrahepatic bile duct	4	5.0 (0.0 - 10.3)	1.59	(0.25 - 3.48)	-*	1	0.2 (0.0 - 0.6)	0.78	(0.00 - 2.89)	-*	
Testis	0	-	-	-	-	0	-	-	-	.	
Gallbladder & bile ducts	5	2.8 (0.3 - 5.3)	3.26	(0.71 - 6.69)	-*	2	0.7 (0.0 - 1.7)	0.90	(0.01 - 2.52)	-*	
Larynx	1	0.8 (0.0 - 2.2)	0.88	(0.00 - 3.25)	-*	1	0.2 (0.0 - 0.6)	5.22	(0.00 - 19.25)	-*	
Tongue	0	-	-	0	n/a	-	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	0	n/a	-	-	-	-	.	
Vulva/vagina	0	-	-	-	-	0	-	0	n/a	-	
Small intestine	0	-	-	0	n/a	-	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	1	0.5 (0.0 - 1.4)	3.43	(0.00 - 12.66)	-*	
Major Salivary Gland	1	0.5 (0.0 - 1.5)	3.18	(0.00 - 11.73)	-*	0	-	-	-	.	
Anus	0	-	-	-	-	1	0.2 (0.0 - 0.7)	1.83	(0.00 - 6.74)	-*	
Mouth, other & unspecified	1	1.8 (0.0 - 5.5)	2.90	(0.00 - 10.68)	-*	0	-	-	-	.	
Floor of mouth	1	1.3 (0.0 - 3.9)	3.28	(0.00 - 12.09)	-*	1	1.0 (0.0 - 3.1)	4.34	(0.00 - 16.00)	-*	
Bones, joints & articular cart.	0	-	-	-	-	1	1.0 (0.0 - 3.1)	5.63	(0.00 - 20.78)	-*	
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	0	-	-	-	.	
Peritoneum & retroperitoneum	1	0.5 (0.0 - 1.5)	4.64	(0.00 - 17.10)	-*	1	1.0 (0.0 - 3.1)	2.57	(0.00 - 9.48)	-*	
Adrenal & other endocrine	0	-	-	-	-	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	0	-	-	-	.	
Pharynx, other & ill-def.	1	1.8 (0.0 - 5.5)	3.68	(0.00 - 13.56)	-*	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	0	-	-	-	.	
Gum	0	-	-	-	-	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	0	-	-	-	.	
Thymus	1	1.4 (0.0 - 4.2)	9.39	(0.00 - 34.63)	-*	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	0	-	-	-	.	
Placenta	0	-	-	-	-	0	-	-	-	.	
Meninges (cerebral & spinal)	1	0.5 (0.0 - 1.5)	35.05	(0.00 - 129.30)	-*	0	-	-	-	.	
All cancers	124	109.2 (87.4 - 130.9)	0.93	(0.78 - 1.12)	-	155	94.9 (75.0 - 114.8)	1.21	(1.03 - 1.41)	^	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Ngaanyatjarraku (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	1	32.0 (0.0 - 94.5)	7.82 (0.00 - 28.83)		-*	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	V	1	32.0 (0.0 - 94.5)	0.38 (0.00 - 1.39)		-*	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Northam (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	18.4	(0.0 - 43.9)	1.07	(0.01 - 2.99)	-*
Colorectal cancer	4	42.5	(0.0 - 88.5)	1.74	(0.27 - 3.81)	-*	0	-	-	0	n/a	-
Prostate gland	2	14.6	(0.0 - 34.8)	1.34	(0.02 - 3.72)	-*	0	-	-	-	-	-
Melanoma (skin)	1	7.0	(0.0 - 20.6)	2.13	(0.00 - 7.85)	-*	1	8.4	(0.0 - 24.9)	4.41	(0.00 - 16.29)	-*
Lung, bronchus & trachea	5	38.1	(4.8 - 71.5)	1.14	(0.25 - 2.34)	-*	3	28.7	(0.0 - 61.1)	1.89	(0.15 - 4.42)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	-	-
Unknown primary site	0	-	-	0	n/a	-	2	17.6	(0.0 - 42.2)	3.42	(0.04 - 9.52)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	-
Leukaemia	0	-	-	0	n/a	-	0	-	-	-	-	-
Pancreas	2	14.5	(0.0 - 34.6)	2.61	(0.03 - 7.28)	-*	0	-	-	0	n/a	-
Urinary bladder	1	7.1	(0.0 - 21.1)	2.54	(0.00 - 9.35)	-*	0	-	-	-	-	-
Stomach	0	-	-	0	n/a	-	0	-	-	-	-	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	-
Brain	0	-	-	0	n/a	-	0	-	-	-	-	-
Lip	0	-	-	-	-	.	0	-	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	-
Oesophagus	1	7.1	(0.0 - 21.1)	2.09	(0.00 - 7.72)	-*	0	-	-	-	-	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	-
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	-
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	-	-
Liver & intrahepatic bile duct	1	7.0	(0.0 - 20.6)	2.50	(0.00 - 9.21)	-*	0	-	-	-	-	-
Testis	0	-	-	-	-	.	0	-	-	-	-	-
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	-
Larynx	0	-	-	-	-	.	0	-	-	-	-	-
Tongue	1	7.5	(0.0 - 22.2)	9.58	(0.00 - 35.33)	-*	0	-	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	-
All cancers	18	145.4	(74.6 - 216.1)	1.05	(0.58 - 1.58)	-	8	73.2	(22.5 - 123.8)	0.81	(0.28 - 1.46)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Northam (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	6	21.2 (1.4 - 41.0)	1.31	(0.36 - 2.56)	-
Colorectal cancer	8	26.8 (7.0 - 46.6)	1.70	(0.60 - 3.07)	-	-	6	13.6 (0.0 - 27.3)	1.45	(0.39 - 2.82)	-*
Prostate gland	6	16.5 (2.9 - 30.1)	1.47	(0.40 - 2.86)	-*	.	0	-	-	-	.
Melanoma (skin)	3	10.5 (0.0 - 24.1)	3.10	(0.25 - 7.24)	-*	.	1	1.3 (0.0 - 3.9)	1.63	(0.00 - 6.02)	-*
Lung, bronchus & trachea	12	50.1 (19.9 - 80.4)	1.34	(0.61 - 2.20)	-	.	5	16.8 (0.5 - 33.0)	1.07	(0.23 - 2.20)	-
Lymphoma	1	3.7 (0.0 - 11.1)	0.75	(0.00 - 2.76)	-*	.	0	-	0	n/a	-
Unknown primary site	1	6.3 (0.0 - 18.5)	0.46	(0.00 - 1.70)	-*	.	4	5.9 (0.1 - 11.7)	1.89	(0.29 - 4.14)	-*
Kidney & other renal tract	2	6.1 (0.0 - 14.8)	2.16	(0.03 - 6.01)	-*	.	2	2.6 (0.0 - 6.3)	3.34	(0.04 - 9.31)	-*
Leukaemia	1	7.2 (0.0 - 21.2)	0.69	(0.00 - 2.53)	-*	.	2	4.4 (0.0 - 11.1)	2.10	(0.03 - 5.85)	-*
Pancreas	1	6.3 (0.0 - 18.5)	0.66	(0.00 - 2.45)	-*	.	1	1.3 (0.0 - 3.9)	0.60	(0.00 - 2.20)	-*
Urinary bladder	0	-	0	n/a	-	.	1	1.3 (0.0 - 3.9)	2.09	(0.00 - 7.72)	-*
Stomach	2	8.6 (0.0 - 21.7)	1.27	(0.02 - 3.55)	-*	.	2	6.6 (0.0 - 17.3)	2.15	(0.03 - 6.00)	-*
Corpus uteri	0	-	-	-	-	.	1	1.3 (0.0 - 3.9)	1.66	(0.00 - 6.12)	-*
Brain	2	12.8 (0.0 - 30.6)	1.82	(0.02 - 5.06)	-*	.	1	1.6 (0.0 - 4.8)	1.21	(0.00 - 4.46)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	3	12.8 (0.0 - 28.7)	2.24	(0.18 - 5.23)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-
Oesophagus	2	8.5 (0.0 - 20.4)	2.07	(0.03 - 5.76)	-*	.	0	-	0	n/a	-
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	1	6.3 (0.0 - 18.5)	1.71	(0.00 - 6.31)	-*	.	0	-	0	n/a	-
Cervix uteri	0	-	-	-	-	.	1	1.3 (0.0 - 3.9)	1.77	(0.00 - 6.52)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-
Mesothelioma	1	4.8 (0.0 - 14.1)	0.90	(0.00 - 3.33)	-*	.	0	-	-	-	-
Liver & intrahepatic bile duct	0	-	0	n/a	-	.	0	-	-	-	-
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-
Larynx	0	-	-	-	-	.	1	1.6 (0.0 - 4.8)	20.20	(0.00 - 74.52)	-*
Tongue	1	4.8 (0.0 - 14.1)	5.22	(0.00 - 19.27)	-*	.	1	4.9 (0.0 - 14.5)	10.31	(0.00 - 38.04)	-*
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	1	3.1 (0.0 - 9.2)	7.48	(0.00 - 27.60)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	1	4.9 (0.0 - 14.5)	16.07	(0.00 - 59.27)	-*
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	0	-	-	-	-
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	44	179.2 (122.3 - 236.1)	1.21	(0.86 - 1.60)	-	-	41	108.1 (68.4 - 147.7)	1.39	(0.97 - 1.85)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Northampton (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	7.4 (0.0 - 21.7)	0.51	(0.00 - 1.87)	-*
Colorectal cancer	3	23.4 (0.0 - 51.0)	1.13	(0.09 - 2.64)	-*		2	13.5 (0.0 - 32.1)	1.30	(0.02 - 3.63)	-*
Prostate gland	1	6.9 (0.0 - 20.5)	0.48	(0.00 - 1.79)	-*		0	-	-	-	.
Melanoma (skin)	1	8.9 (0.0 - 26.2)	1.85	(0.00 - 6.82)	-*		0	-	-	-	.
Lung, bronchus & trachea	6	43.4 (8.1 - 78.7)	1.18	(0.32 - 2.29)	-		1	4.3 (0.0 - 12.7)	0.54	(0.00 - 1.98)	-*
Lymphoma	1	8.6 (0.0 - 25.5)	1.34	(0.00 - 4.95)	-*		0	-	0	n/a	-
Unknown primary site	1	5.5 (0.0 - 16.4)	0.84	(0.00 - 3.09)	-*		0	-	0	n/a	-
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	.
Leukaemia	1	8.6 (0.0 - 25.5)	1.27	(0.00 - 4.67)	-*		0	-	-	-	.
Pancreas	1	8.6 (0.0 - 25.3)	1.14	(0.00 - 4.19)	-*		1	7.4 (0.0 - 21.7)	1.63	(0.00 - 6.02)	-*
Urinary bladder	1	5.5 (0.0 - 16.4)	1.92	(0.00 - 7.07)	-*		0	-	-	-	.
Stomach	1	4.7 (0.0 - 13.9)	1.13	(0.00 - 4.16)	-*		0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	2	15.8 (0.0 - 37.8)	3.07	(0.04 - 8.55)	-*		1	7.4 (0.0 - 21.7)	2.73	(0.00 - 10.07)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	1	7.2 (0.0 - 21.3)	24.20	(0.00 - 89.27)	-*		0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	20	147.2 (81.5 - 213.0)	0.99	(0.56 - 1.46)	-		7	46.6 (12.0 - 81.3)	0.61	(0.19 - 1.14)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Nungarin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	-	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Peppermint Grove (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	23.4 (0.0 - 69.1)	0.87	(0.00 - 3.21)	-*
Colorectal cancer	0	-	-	0	n/a	-	1	5.4 (0.0 - 15.9)	1.04	(0.00 - 3.85)	-*
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	2	34.5	(0.0 - 81.9)	0.84	(0.01 - 2.35)	-*	1	5.4 (0.0 - 15.9)	0.92	(0.00 - 3.38)	-*
Lymphoma	3	43.7	(0.0 - 96.6)	8.41	(0.68 - 19.64)	-*	0	-	-	-	.
Unknown primary site	1	11.9	(0.0 - 35.0)	1.71	(0.00 - 6.31)	-*	3	24.9 (0.0 - 56.2)	6.22	(0.50 - 14.52)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	1	17.2	(0.0 - 50.9)	2.59	(0.00 - 9.55)	-*	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	1	6.4 (0.0 - 18.9)	9.39	(0.00 - 34.65)	-*
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	1	16.1 (0.0 - 47.6)	7.73	(0.00 - 28.53)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	1	21.2	(0.0 - 62.5)	26.95	(0.00 - 99.44)	-*	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	8	128.5	(37.2 - 219.7)	0.82	(0.29 - 1.48)	-	8	81.6 (15.0 - 148.1)	1.15	(0.40 - 2.07)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Perenjori (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	-	.
Colorectal cancer	1	43.0	(0.0 - 126.9)	3.20	(0.00 - 11.81)	-*	0	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	2	132.9	(0.0 - 316.1)	3.54	(0.04 - 9.85)	-*	0	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	-	-	.	1	33.3	(0.0 - 97.6)	8.37	(0.00 - 30.88) -*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	3	175.9	(0.0 - 377.3)	1.27	(0.10 - 2.97)	-*	1	33.3	(0.0 - 97.6)	0.56	(0.00 - 2.08) -*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Perth (C) - Inner 1998-2002: Cancer mortality(1)

Cancer type	Males					Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	0	-	-	-	.
Colorectal cancer	1	21.5	(0.0 - 63.5)	1.98	(0.00 - 7.32)	-*	0	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	.
Melanoma (skin)	1	100.0	(0.0 - 275.3)	8.92	(0.00 - 32.92)	-*	0	-	-	-	.
Lung, bronchus & trachea	3	180.1	(0.0 - 386.9)	3.26	(0.26 - 7.60)	-*	0	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	1	83.3	(0.0 - 245.5)	932.09	(0.00 - 3,438.49) -*
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	5	301.6	(57.0 - 546.3)	1.33	(0.29 - 2.72)	-*	1	83.3	(0.0 - 245.5)	0.58	(0.00 - 2.14) -*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Perth (C) - Remainder 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	10.8 (0.0 - 27.1)	0.58	(0.01 - 1.61)	.*
Colorectal cancer	12	40.8 (16.5 - 65.2)	2.24	(1.02 - 3.67)	^	4	13.0 (0.0 - 27.8)	1.30	(0.20 - 2.84)	.*	
Prostate gland	9	27.6 (8.6 - 46.5)	1.90	(0.73 - 3.33)	-	0	-	-	-	.	
Melanoma (skin)	2	5.9 (0.0 - 14.3)	1.75	(0.02 - 4.88)	.*	1	6.6 (0.0 - 19.5)	2.09	(0.00 - 7.71)	.*	
Lung, bronchus & trachea	11	41.8 (16.8 - 66.8)	1.12	(0.49 - 1.86)	-	2	8.9 (0.0 - 22.6)	0.58	(0.01 - 1.61)	.*	
Lymphoma	1	2.1 (0.0 - 6.3)	0.66	(0.00 - 2.43)	.*	0	-	0	n/a	-	
Unknown primary site	1	4.7 (0.0 - 14.0)	0.40	(0.00 - 1.49)	.*	1	1.9 (0.0 - 5.6)	0.64	(0.00 - 2.37)	.*	
Kidney & other renal tract	2	7.4 (0.0 - 18.0)	1.88	(0.02 - 5.24)	.*	1	4.6 (0.0 - 13.7)	2.24	(0.00 - 8.28)	.*	
Leukaemia	1	4.5 (0.0 - 13.3)	0.60	(0.00 - 2.20)	.*	0	-	0	n/a	-	
Pancreas	0	-	-	0	n/a	-	1	1.7 (0.0 - 5.0)	0.80	(0.00 - 2.96)	.*
Urinary bladder	0	-	-	0	n/a	-	1	1.9 (0.0 - 5.6)	2.84	(0.00 - 10.49)	.*
Stomach	0	-	-	0	n/a	-	1	1.7 (0.0 - 5.0)	1.46	(0.00 - 5.38)	.*
Corpus uteri	0	-	-	-	-	.	0	-	-	-	
Brain	1	4.8 (0.0 - 14.1)	0.79	(0.00 - 2.91)	.*	2	8.1 (0.0 - 20.3)	3.17	(0.04 - 8.83)	.*	
Lip	0	-	-	-	-	.	0	-	-	-	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	0	n/a	
Other lymphohaematopoietic	1	4.5 (0.0 - 13.3)	1.68	(0.00 - 6.21)	.*	0	-	-	-	.	
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	
Thyroid gland	1	2.7 (0.0 - 7.9)	15.67	(0.00 - 57.80)	.*	0	-	-	-	.	
Myeloma/plasma cell tumours	2	5.7 (0.0 - 13.9)	2.92	(0.04 - 8.14)	.*	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	1	6.6 (0.0 - 19.5)	2.28	(0.00 - 8.43)	.*
Non-mel. skin (exc BCC/SCC)	1	4.9 (0.0 - 14.6)	5.21	(0.00 - 19.21)	.*	0	-	-	-	.	
Mesothelioma	2	4.8 (0.0 - 11.4)	1.59	(0.02 - 4.43)	.*	0	-	-	-	.	
Liver & intrahepatic bile duct	2	8.1 (0.0 - 19.4)	2.39	(0.03 - 6.65)	.*	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	
Gallbladder & bile ducts	1	2.1 (0.0 - 6.3)	2.16	(0.00 - 7.98)	.*	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	
Tongue	1	4.5 (0.0 - 13.3)	4.30	(0.00 - 15.85)	.*	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	1	7.8 (0.0 - 22.9)	12.28	(0.00 - 45.31)	.*
Tonsil & oropharynx	1	2.7 (0.0 - 7.9)	5.02	(0.00 - 18.51)	.*	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	
Small intestine	0	-	-	-	-	.	0	-	-	-	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	
Anus	0	-	-	-	-	.	0	-	-	-	
Mouth, other & unspecified	1	4.5 (0.0 - 13.3)	8.98	(0.00 - 33.11)	.*	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	
Pyriform sinus & hypopharynx	2	7.2 (0.0 - 17.4)	11.30	(0.14 - 31.48)	.*	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	
Pharynx, other & ill-def.	2	7.4 (0.0 - 17.5)	22.75	(0.28 - 63.39)	.*	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	
Gum	0	-	-	-	-	.	0	-	-	-	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	
Thymus	0	-	-	-	-	.	0	-	-	-	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	
Placenta	0	-	-	-	-	.	0	-	-	-	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	
All cancers	57	198.4 (145.1 - 251.8)	1.38	(1.06 - 1.80)	^	18	73.6 (34.7 - 112.5)	0.81	(0.45 - 1.23)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Pingelly (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	21.4 (0.0 - 63.2)	1.12	(0.00 - 4.14)	-*
Colorectal cancer	3	57.2	(0.0 - 121.9)	2.83	(0.23 - 6.60)	-*	0	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	3	50.6	(0.0 - 106.7)	1.49	(0.12 - 3.48)	-*	1	22.7 (0.0 - 67.0)	1.14	(0.00 - 4.21)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	-	-	.	3	45.0 (0.0 - 106.3)	7.37	(0.59 - 17.20)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	1	22.1 (0.0 - 65.3)	11.14	(0.00 - 41.08)	-*
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	1	9.9	(0.0 - 29.2)	9.04	(0.00 - 33.33)	-*	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	9.2 (0.0 - 27.1)	38.90	(0.00 - 143.51)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	1	23.4	(0.0 - 69.1)	25.35	(0.00 - 93.51)	-*	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	1	47.2	(0.0 - 139.4)	128.47	(0.00 - 473.93)	-*	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	9	188.2	(53.4 - 323.0)	1.11	(0.42 - 1.94)	-	7	120.4 (22.2 - 218.6)	1.24	(0.39 - 2.31)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Plantagenet (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	1	2.6 (0.0 - 7.7)	0.35	(0.00 - 1.30)	-*	
Colorectal cancer	5	29.6 (3.7 - 55.6)	1.48	(0.32 - 3.03)	-*		2	10.1 (0.0 - 25.1)	0.86	(0.01 - 2.41)	-*	
Prostate gland	5	27.7 (3.4 - 52.1)	1.94	(0.42 - 3.98)	-*		0	-	-	-	.	
Melanoma (skin)	0	-	-	0	n/a	-	1	3.2 (0.0 - 9.3)	2.73	(0.00 - 10.06)	-*	
Lung, bronchus & trachea	4	21.2 (0.2 - 42.2)	0.62	(0.10 - 1.36)	-		1	2.6 (0.0 - 7.7)	0.37	(0.00 - 1.37)	-*	
Lymphoma	1	6.3 (0.0 - 18.5)	1.06	(0.00 - 3.90)	-*		1	7.0 (0.0 - 20.7)	1.26	(0.00 - 4.66)	-*	
Unknown primary site	1	5.0 (0.0 - 14.6)	0.66	(0.00 - 2.45)	-*		3	18.5 (0.0 - 39.5)	2.67	(0.22 - 6.23)	-*	
Kidney & other renal tract	1	6.3 (0.0 - 18.5)	1.51	(0.00 - 5.58)	-*		1	6.0 (0.0 - 17.8)	2.96	(0.00 - 10.93)	-*	
Leukaemia	0	-	-	0	n/a	-	0	-	0	n/a	-	
Pancreas	3	18.8 (0.0 - 40.0)	2.71	(0.22 - 6.32)	-*		0	-	0	n/a	-	
Urinary bladder	1	5.0 (0.0 - 14.6)	1.55	(0.00 - 5.72)	-*		0	-	-	-	.	
Stomach	1	4.0 (0.0 - 11.7)	0.89	(0.00 - 3.30)	-*		0	-	0	n/a	-	
Corpus uteri	0	-	-	-	-	.	1	3.2 (0.0 - 9.3)	3.01	(0.00 - 11.12)	-*	
Brain	0	-	-	0	n/a	-	1	7.7 (0.0 - 22.6)	1.94	(0.00 - 7.14)	-*	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	0	n/a	-	
Other lymphohaematopoietic	1	5.9 (0.0 - 17.4)	3.09	(0.00 - 11.38)	-*		0	-	-	-	.	
Oesophagus	2	11.1 (0.0 - 26.7)	2.86	(0.04 - 7.97)	-*		0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	3.2 (0.0 - 9.3)	3.30	(0.00 - 12.19)	-*	
Cervix uteri	0	-	-	-	-	.	1	6.5 (0.0 - 19.2)	2.87	(0.00 - 10.60)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	1	6.6 (0.0 - 19.4)	1.22	(0.00 - 4.49)	-*		0	-	-	-	.	
Liver & intrahepatic bile duct	3	18.9 (0.0 - 40.3)	5.32	(0.43 - 12.41)	-*		0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	1	6.8 (0.0 - 20.0)	3.81	(0.00 - 14.07)	-*	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	1	4.0 (0.0 - 11.7)	8.09	(0.00 - 29.84)	-*		0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	30	170.2 (109.2 - 231.3)	1.17	(0.76 - 1.62)	-		15	77.2 (35.8 - 118.6)	0.89	(0.45 - 1.39)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Port Hedland (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	14.7 (0.0 - 35.3)	0.62	(0.01 - 1.73)	-*
Colorectal cancer	1	2.3 (0.0 - 6.9)	0.28	(0.00 - 1.03)	-*	.	0	-	0	n/a	-
Prostate gland	2	14.0 (0.0 - 33.6)	0.98	(0.01 - 2.73)	-*	.	0	-	-	-	-
Melanoma (skin)	0	-	-	0	n/a	-	1	2.6 (0.0 - 7.7)	2.34	(0.00 - 8.61)	-*
Lung, bronchus & trachea	7	34.2 (5.8 - 62.5)	1.15	(0.36 - 2.14)	-	.	1	5.9 (0.0 - 17.3)	0.47	(0.00 - 1.73)	-*
Lymphoma	0	-	-	0	n/a	-	2	12.7 (0.0 - 30.9)	3.07	(0.04 - 8.56)	-*
Unknown primary site	2	11.0 (0.0 - 26.3)	1.30	(0.02 - 3.62)	-*	.	0	-	0	n/a	-
Kidney & other renal tract	1	2.3 (0.0 - 6.9)	1.38	(0.00 - 5.08)	-*	.	0	-	-	-	-
Leukaemia	0	-	-	0	n/a	-	0	-	0	n/a	-
Pancreas	0	-	-	0	n/a	-	0	-	0	n/a	-
Urinary bladder	1	8.0 (0.0 - 23.6)	1.85	(0.00 - 6.81)	-*	.	0	-	-	-	-
Stomach	2	14.8 (0.0 - 35.7)	1.70	(0.02 - 4.72)	-*	.	0	-	-	-	-
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-
Brain	0	-	-	0	n/a	-	0	-	0	n/a	-
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	1	5.9 (0.0 - 17.3)	1.42	(0.00 - 5.25)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-
Oesophagus	2	4.7 (0.0 - 11.2)	2.78	(0.03 - 7.74)	-*	.	1	8.2 (0.0 - 24.1)	4.47	(0.00 - 16.51)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	1	2.1 (0.0 - 6.3)	27.44	(0.00 - 101.24)	-*
Mesothelioma	2	11.5 (0.0 - 29.6)	2.35	(0.03 - 6.55)	-*	.	1	4.5 (0.0 - 13.3)	12.33	(0.00 - 45.50)	-*
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	1	3.7 (0.0 - 11.1)	6.38	(0.00 - 23.52)	-*
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	1	2.3 (0.0 - 6.9)	3.17	(0.00 - 11.69)	-*	.	0	-	-	-	-
Larynx	0	-	-	-	-	.	0	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	1	6.0 (0.0 - 17.5)	13.81	(0.00 - 50.96)	-*
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-
Small intestine	0	-	-	-	-	.	0	-	-	-	-
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	1	6.0 (0.0 - 17.5)	13.17	(0.00 - 48.57)	-*
Mouth, other & unspecified	0	-	-	-	-	.	1	6.0 (0.0 - 17.5)	26.81	(0.00 - 98.92)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	2	11.5 (0.0 - 29.6)	31.37	(0.39 - 87.40)	-*	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	1	2.0 (0.0 - 5.8)	14.02	(0.00 - 51.73)	-*	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	24	118.7 (65.4 - 172.1)	0.89 (0.54 - 1.27)	-	-	-	14	78.2 (35.4 - 121.1)	0.92 (0.46 - 1.46)	-	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Quairading (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	32.0 (0.0 - 94.5)	1.24	(0.00 - 4.56)	-*
Colorectal cancer	2	47.0	(0.0 - 112.0)	2.46	(0.03 - 6.85)	-*	0	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	2	43.2	(0.0 - 103.5)	5.52	(0.07 - 15.39)	-*	3	39.3 (0.0 - 87.5)	8.04	(0.65 - 18.76)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	1	32.0 (0.0 - 94.5)	3.52	(0.00 - 12.99)	-*
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	5.6 (0.0 - 16.6)	10.68	(0.00 - 39.40)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	1	22.0	(0.0 - 64.9)	17.26	(0.00 - 63.67)	-*	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	23.8 (0.0 - 70.3)	45.29	(0.00 - 167.09)	-*
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	5	112.1	(13.9 - 210.4)	0.81	(0.18 - 1.66)	-	7	132.7 (21.7 - 243.8)	1.38	(0.43 - 2.57)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Ravensthorpe (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	20.6	(0.0 - 60.8)	1.28	(0.00 - 4.72)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Prostate gland	2	29.6	(0.0 - 70.4)	2.66	(0.03 - 7.42)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	2	32.7	(0.0 - 77.9)	1.04	(0.01 - 2.89)	-*	0	-	-	0	n/a	-
Lymphoma	0	-	-	-	-	.	1	16.3	(0.0 - 48.1)	4.91	(0.00 - 18.11)	-*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	1	24.1	(0.0 - 71.2)	7.92	(0.00 - 29.23)	-*
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	26.2	(0.0 - 77.4)	4.70	(0.00 - 17.34)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	4	62.3	(1.4 - 123.1)	0.51	(0.08 - 1.12)	-	4	87.1	(0.7 - 173.6)	0.91	(0.14 - 2.00)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Rockingham (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	45	16.6 (11.5 - 21.7)	1.09	(0.77 - 1.43)	-
Colorectal cancer	52	20.5	(14.7 - 26.2)	1.12	(0.85 - 1.49)	-	44	14.8 (10.2 - 19.4)	1.29	(0.91 - 1.69)	-
Prostate gland	34	11.7	(7.6 - 15.7)	0.91	(0.61 - 1.24)	-	0	-	-	-	.
Melanoma (skin)	9	3.9	(1.3 - 6.4)	0.94	(0.36 - 1.64)	-	10	3.4 (1.2 - 5.7)	1.83	(0.76 - 3.13)	-
Lung, bronchus & trachea	96	36.6	(29.1 - 44.2)	1.09	(0.89 - 1.34)	-	41	13.7 (9.3 - 18.1)	1.01	(0.71 - 1.34)	-
Lymphoma	19	8.3	(4.3 - 12.2)	1.44	(0.81 - 2.16)	-	8	3.0 (0.9 - 5.1)	0.68	(0.24 - 1.22)	-
Unknown primary site	26	9.5	(5.7 - 13.3)	1.24	(0.77 - 1.75)	-	12	4.0 (1.6 - 6.4)	0.72	(0.33 - 1.18)	-
Kidney & other renal tract	14	5.4	(2.5 - 8.4)	1.54	(0.76 - 2.45)	-	9	2.7 (0.8 - 4.5)	1.80	(0.69 - 3.15)	-
Leukaemia	13	4.7	(1.9 - 7.5)	0.91	(0.44 - 1.47)	-	7	3.0 (0.5 - 5.4)	0.88	(0.28 - 1.63)	-
Pancreas	25	9.7	(5.8 - 13.7)	1.66	(1.02 - 2.38)	^	14	4.4 (2.0 - 6.8)	1.02	(0.50 - 1.61)	-
Urinary bladder	8	3.0	(0.9 - 5.2)	0.87	(0.31 - 1.57)	-	4	1.0 (0.0 - 2.0)	1.10	(0.17 - 2.40)	-*
Stomach	16	6.6	(3.3 - 9.9)	1.04	(0.55 - 1.61)	-	9	3.0 (0.9 - 5.0)	1.19	(0.46 - 2.09)	-
Corpus uteri	0	-	-	-	-	.	4	1.4 (0.0 - 3.0)	0.80	(0.12 - 1.75)	-
Brain	11	4.6	(1.8 - 7.3)	0.96	(0.42 - 1.61)	-	13	5.0 (2.1 - 7.9)	1.68	(0.80 - 2.70)	-
Lip	0	-	-	-	-	.	1	0.2 (0.0 - 0.7)	6.94	(0.00 - 25.60)	-*
Ovary & uterine adnexa	0	-	-	-	-	.	10	3.9 (1.4 - 6.4)	0.85	(0.35 - 1.46)	-
Other lymphohaematopoietic	3	1.2	(0.0 - 2.6)	0.65	(0.05 - 1.52)	-	1	0.2 (0.0 - 0.7)	0.39	(0.00 - 1.43)	-*
Oesophagus	12	4.5	(1.9 - 7.1)	1.26	(0.58 - 2.06)	-	9	3.0 (0.9 - 5.1)	1.94	(0.74 - 3.39)	-
Thyroid gland	1	0.3	(0.0 - 0.8)	1.63	(0.00 - 6.01)	-*	1	0.6 (0.0 - 1.9)	0.85	(0.00 - 3.15)	-*
Myeloma/plasma cell tumours	4	1.5	(0.0 - 3.0)	0.71	(0.11 - 1.56)	-	4	1.3 (0.0 - 2.6)	0.89	(0.14 - 1.95)	-*
Cervix uteri	0	-	-	-	-	.	7	3.1 (0.7 - 5.4)	1.32	(0.42 - 2.47)	-
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	2	0.4 (0.0 - 1.0)	2.99	(0.04 - 8.34)	-*
Mesothelioma	12	5.3	(2.2 - 8.3)	1.09	(0.50 - 1.78)	-	2	1.0 (0.0 - 2.3)	1.43	(0.02 - 3.99)	-*
Liver & intrahepatic bile duct	9	3.5	(1.2 - 5.9)	1.18	(0.45 - 2.07)	-	2	1.0 (0.0 - 2.3)	0.77	(0.01 - 2.14)	-*
Testis	1	0.7	(0.0 - 2.2)	3.67	(0.00 - 13.54)	-*	0	-	-	-	.
Gallbladder & bile ducts	4	1.4	(0.0 - 2.8)	1.02	(0.16 - 2.23)	-*	5	1.5 (0.2 - 2.9)	1.27	(0.28 - 2.61)	-*
Larynx	5	2.1	(0.2 - 4.0)	1.54	(0.33 - 3.15)	-*	1	0.2 (0.0 - 0.7)	2.29	(0.00 - 8.44)	-*
Tongue	4	1.6	(0.0 - 3.2)	2.05	(0.32 - 4.50)	-*	1	0.2 (0.0 - 0.5)	1.14	(0.00 - 4.21)	-*
Connective & soft tissues	1	0.9	(0.0 - 2.6)	0.79	(0.00 - 2.90)	-*	0	-	0	n/a	-
Tonsil & oropharynx	2	0.8	(0.0 - 1.9)	1.15	(0.01 - 3.21)	-*	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	0.2 (0.0 - 0.5)	1.00	(0.00 - 3.69)	-*
Small intestine	0	-	-	0	n/a	-	1	0.2 (0.0 - 0.5)	1.09	(0.00 - 4.04)	-*
Eye & lacrimal gland	1	0.3	(0.0 - 1.0)	1.33	(0.00 - 4.90)	-*	1	0.2 (0.0 - 0.7)	1.96	(0.00 - 7.24)	-*
Major Salivary Gland	1	0.3	(0.0 - 0.8)	1.37	(0.00 - 5.05)	-*	0	-	-	-	.
Anus	0	-	-	0	n/a	-	1	0.2 (0.0 - 0.5)	1.06	(0.00 - 3.91)	-*
Mouth, other & unspecified	0	-	-	0	n/a	-	0	-	0	n/a	-
Floor of mouth	1	0.5	(0.0 - 1.6)	1.12	(0.00 - 4.15)	-*	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	0	n/a	-	0	-	-	-	.
Pyriform sinus & hypopharynx	1	0.5	(0.0 - 1.4)	0.61	(0.00 - 2.27)	-*	0	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.3	(0.0 - 0.8)	1.74	(0.00 - 6.43)	-*	0	-	-	-	.
Peritoneum & retroperitoneum	2	0.6	(0.0 - 1.4)	3.18	(0.04 - 8.87)	-*	0	-	0	n/a	-
Adrenal & other endocrine	1	0.6	(0.0 - 1.9)	2.58	(0.00 - 9.53)	-*	0	-	-	-	.
Nasopharynx	0	-	-	0	n/a	-	1	0.5 (0.0 - 1.4)	3.81	(0.00 - 14.05)	-*
Pharynx, other & ill-def.	0	-	-	0	n/a	-	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	1	0.5	(0.0 - 1.4)	2.87	(0.00 - 10.58)	-*	0	-	-	-	.
Pleura, heart & mediastinum	2	1.1	(0.0 - 2.7)	5.53	(0.07 - 15.41)	-*	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	392	152.8	(137.1 - 168.4)	1.10	(1.00 - 1.22)	-	271	94.0 (82.1 - 105.9)	1.08	(0.95 - 1.22)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Roebourne (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	3	7.9 (0.0 - 17.1)	0.88	(0.07 - 2.04)	-*
Colorectal cancer	1	1.6	(0.0 - 4.7)	0.31	(0.00 - 1.14)	-*	0	-	0	n/a	-
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	.
Lung, bronchus & trachea	9	56.4	(13.1 - 99.8)	1.68	(0.64 - 2.94)	-	3	27.2 (0.0 - 62.1)	1.50	(0.12 - 3.49)	-*
Lymphoma	1	10.5	(0.0 - 31.1)	0.94	(0.00 - 3.47)	-*	0	-	0	n/a	-
Unknown primary site	2	12.6	(0.0 - 33.6)	1.47	(0.02 - 4.10)	-*	0	-	0	n/a	-
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	0	-	0	n/a	-
Pancreas	1	10.9	(0.0 - 32.1)	0.85	(0.00 - 3.15)	-*	0	-	0	n/a	-
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	0	n/a	-	1	1.7 (0.0 - 5.0)	1.50	(0.00 - 5.54)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	0	n/a	-
Other lymphohaematopoietic	2	12.0	(0.0 - 30.8)	10.17	(0.13 - 28.34)	-*	0	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	1.9 (0.0 - 5.7)	1.97	(0.00 - 7.28)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	3	16.7	(0.0 - 38.3)	3.94	(0.32 - 9.21)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	1	2.8	(0.0 - 8.2)	3.50	(0.00 - 12.91)	-*	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	1	2.8	(0.0 - 8.2)	5.44	(0.00 - 20.08)	-*	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	1	2.0	(0.0 - 5.9)	8.45	(0.00 - 31.16)	-*	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	1	2.8	(0.0 - 8.2)	14.31	(0.00 - 52.79)	-*	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	23	131.0	(66.9 - 195.0)	0.95	(0.57 - 1.37)	-	8	38.8 (2.3 - 75.2)	0.54	(0.19 - 0.97)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Sandstone (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	=	0	-	-	-	-	.

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Serpentine-Jarrahdale (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	V	
Colorectal cancer	5	16.0	(1.6 - 30.5)	0.85	(0.19 - 1.75)	-	3	8.2	0.81	(0.07 - 1.90)	-*	
Prostate gland	2	6.5	(0.0 - 15.4)	0.52	(0.01 - 1.44)	-*	0	-	-	-	.	
Melanoma (skin)	0	-	-	0	n/a	-	0	-	0	n/a	-	
Lung, bronchus & trachea	11	33.7	(13.6 - 53.8)	1.01	(0.44 - 1.69)	-	3	8.8	0.68	(0.06 - 1.60)	-*	
Lymphoma	1	3.0	(0.0 - 9.0)	0.59	(0.00 - 2.18)	-*	0	-	0	n/a	-	
Unknown primary site	3	8.8	(0.0 - 19.0)	1.18	(0.10 - 2.75)	-*	1	3.6	0.58	(0.00 - 2.12)	-*	
Kidney & other renal tract	1	3.2	(0.0 - 9.6)	0.86	(0.00 - 3.19)	-*	0	-	0	n/a	-	
Leukaemia	1	3.2	(0.0 - 9.6)	0.56	(0.00 - 2.08)	-*	3	11.3	3.33	(0.27 - 7.78)	-*	
Pancreas	2	5.9	(0.0 - 14.1)	1.01	(0.01 - 2.80)	-*	0	-	0	n/a	-	
Urinary bladder	4	12.6	(0.0 - 25.6)	3.97	(0.61 - 8.69)	-*	0	-	-	-	.	
Stomach	3	8.3	(0.0 - 17.7)	1.55	(0.13 - 3.63)	-*	1	3.2	1.28	(0.00 - 4.70)	-*	
Corpus uteri	0	-	-	-	-	.	1	3.2	1.95	(0.00 - 7.21)	-*	
Brain	3	8.3	(0.0 - 17.8)	1.70	(0.14 - 3.98)	-*	2	6.7	2.05	(0.03 - 5.71)	-*	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	1	3.2	0.75	(0.00 - 2.75)	-*	
Other lymphohaematopoietic	0	-	-	0	n/a	-	0	-	-	-	.	
Oesophagus	3	8.9	(0.0 - 19.3)	2.47	(0.20 - 5.77)	-*	1	3.6	2.07	(0.00 - 7.64)	-*	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	2	5.3	3.02	(0.04 - 8.43)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	1	2.2	(0.0 - 6.4)	0.70	(0.00 - 2.58)	-*	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	0	n/a	-	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	40	120.7	(82.8 - 158.7)	0.91	(0.63 - 1.21)	-	18	56.8	(30.3 - 83.4)	0.64	(0.35 - 0.96)	V

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Shark Bay (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	48.8	(0.0 - 143.8)	1.95	(0.00 - 7.19)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	1	24.8	(0.0 - 73.4)	0.63	(0.00 - 2.33)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	24.8	(0.0 - 73.4)	0.16	(0.00 - 0.59)	V	1	48.8	(0.0 - 143.8)	0.33	(0.00 - 1.23)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: South Perth (C) 1998-2002: Cancer mortality(1)

Cancer type	Males					Females						
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	1	0.3	(0.0 - 0.9)	11.52	(0.00 - 42.49)	-*	32	20.1	1.06	(0.70 - 1.46)	-	
Colorectal cancer	21	14.3	(7.6 - 21.0)	0.79	(0.46 - 1.16)	-	32	12.7	1.11	(0.73 - 1.52)	-	
Prostate gland	25	13.3	(7.4 - 19.2)	0.98	(0.60 - 1.39)	-	0	-	-	-	.	
Melanoma (skin)	8	5.7	(1.2 - 10.2)	1.42	(0.50 - 2.55)	-	2	1.1	0.48	(0.01 - 1.34)	-*	
Lung, bronchus & trachea	38	24.1	(15.5 - 32.7)	0.78	(0.53 - 1.04)	-	26	11.3	0.86	(0.53 - 1.22)	-	
Lymphoma	10	6.7	(2.2 - 11.3)	1.31	(0.54 - 2.24)	-	12	5.8	1.32	(0.60 - 2.16)	-	
Unknown primary site	16	11.3	(5.1 - 17.6)	1.27	(0.67 - 1.97)	-	9	3.0	0.59	(0.23 - 1.03)	-	
Kidney & other renal tract	6	3.2	(0.4 - 6.0)	1.13	(0.31 - 2.20)	-	4	1.6	0.98	(0.15 - 2.15)	-*	
Leukaemia	6	4.5	(0.5 - 8.5)	0.71	(0.19 - 1.38)	-	2	0.4	0.30	(0.00 - 0.84)	v	
Pancreas	8	4.6	(1.0 - 8.1)	0.97	(0.34 - 1.74)	-	13	5.2	1.12	(0.54 - 1.81)	-	
Urinary bladder	3	1.1	(0.0 - 2.5)	0.51	(0.04 - 1.19)	-	0	-	0	n/a	v	
Stomach	5	2.6	(0.1 - 5.1)	0.56	(0.12 - 1.14)	-	6	1.1	0.92	(0.25 - 1.78)	-	
Corpus uteri	0	-	-	-	-	.	5	2.2	1.22	(0.27 - 2.51)	-*	
Brain	4	3.8	(0.0 - 7.5)	0.66	(0.10 - 1.45)	-	6	5.0	1.16	(0.31 - 2.25)	-	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	6	3.6	0.67	(0.18 - 1.31)	-	
Other lymphohaematopoietic	6	3.2	(0.2 - 6.2)	1.94	(0.52 - 3.77)	-*	5	1.1	1.81	(0.39 - 3.70)	-*	
Oesophagus	4	3.0	(0.0 - 6.2)	0.74	(0.11 - 1.62)	-	3	2.1	0.75	(0.06 - 1.74)	-*	
Thyroid gland	0	-	-	-	-	.	0	-	0	n/a	-	
Myeloma/plasma cell tumours	3	2.0	(0.0 - 4.4)	0.86	(0.07 - 2.01)	-*	5	1.6	1.30	(0.28 - 2.65)	-*	
Cervix uteri	0	-	-	-	-	.	3	1.6	0.80	(0.06 - 1.88)	-*	
Non-mel. skin (exc BCC/SCC)	1	0.3	(0.0 - 0.9)	1.02	(0.00 - 3.77)	-*	1	0.1	1.53	(0.00 - 5.65)	-*	
Mesothelioma	3	1.1	(0.0 - 2.5)	0.49	(0.04 - 1.15)	-	1	0.8	1.04	(0.00 - 3.85)	-*	
Liver & intrahepatic bile duct	5	3.4	(0.3 - 6.5)	1.25	(0.27 - 2.55)	-*	2	0.5	1.00	(0.01 - 2.80)	-*	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	4	2.7	(0.0 - 5.5)	1.68	(0.26 - 3.68)	-*	3	1.6	0.88	(0.07 - 2.05)	-*	
Larynx	1	1.3	(0.0 - 3.8)	0.56	(0.00 - 2.07)	-*	1	1.2	3.21	(0.00 - 11.86)	-*	
Tongue	1	0.9	(0.0 - 2.7)	0.93	(0.00 - 3.43)	-*	0	-	0	n/a	-	
Connective & soft tissues	3	2.1	(0.0 - 4.6)	3.85	(0.31 - 8.98)	-*	1	0.1	1.54	(0.00 - 5.70)	-*	
Tonsil & oropharynx	1	0.3	(0.0 - 0.9)	1.04	(0.00 - 3.85)	-*	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	1	0.1	1.00	(0.00 - 3.67)	-*	
Small intestine	3	2.8	(0.0 - 6.1)	3.76	(0.30 - 8.78)	-*	2	0.4	3.02	(0.04 - 8.41)	-*	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	0	n/a	-	
Mouth, other & unspecified	0	-	-	0	n/a	-	2	0.3	3.68	(0.05 - 10.25)	-*	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	1	0.4	(0.0 - 1.2)	2.28	(0.00 - 8.40)	-*	0	-	-	-	.	
Pyriform sinus & hypopharynx	2	1.2	(0.0 - 3.2)	2.41	(0.03 - 6.70)	-*	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	1	1.2	(0.0 - 3.6)	3.38	(0.00 - 12.45)	-*	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	2	1.1	3.13	(0.04 - 8.71)	-*	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	1	0.1	4.67	(0.00 - 17.23)	-*	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	1	0.8	(0.0 - 2.4)	7.04	(0.00 - 25.95)	-*	0	-	-	-	.	
Gum	0	-	-	-	-	.	1	0.2	3.37	(0.00 - 12.42)	-*	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	1	0.9	(0.0 - 2.7)	5.95	(0.00 - 21.94)	-*	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	192	123.3	(103.9 - 142.7)	0.93	(0.80 - 1.07)	-	189	86.4	(70.7 - 102.1)	0.94	(0.82 - 1.09)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Stirling (C) - Central 1998-2002: Cancer mortality(1)

Cancer type	Males					Females						
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	2	0.6	(0.0 - 1.5)	8.91	(0.11 - 24.83)	-*	61	15.1	(11.1 - 19.1)	0.89	(0.68 - 1.15)	-
Colorectal cancer	80	19.9	(15.4 - 24.5)	1.12	(0.89 - 1.40)	-	50	9.2	(6.4 - 12.1)	0.84	(0.61 - 1.09)	-
Prostate gland	49	10.4	(7.4 - 13.4)	0.82	(0.59 - 1.06)	-	0	-	-	-	-	-
Melanoma (skin)	13	3.4	(1.5 - 5.4)	0.88	(0.42 - 1.41)	-	5	1.2	(0.1 - 2.4)	0.55	(0.12 - 1.12)	-
Lung, bronchus & trachea	153	37.7	(31.5 - 44.0)	1.12	(0.96 - 1.32)	-	61	12.6	(9.2 - 16.0)	0.88	(0.68 - 1.13)	-
Lymphoma	21	5.2	(2.9 - 7.5)	1.04	(0.60 - 1.52)	-	29	5.8	(3.5 - 8.0)	1.42	(0.91 - 1.98)	-
Unknown primary site	38	10.2	(6.8 - 13.6)	1.16	(0.80 - 1.56)	-	37	6.7	(4.3 - 9.1)	1.26	(0.86 - 1.70)	-
Kidney & other renal tract	10	2.7	(1.0 - 4.5)	0.71	(0.29 - 1.21)	-	10	1.6	(0.5 - 2.7)	1.15	(0.47 - 1.96)	-
Leukaemia	24	6.3	(3.7 - 9.0)	1.09	(0.66 - 1.57)	-	16	3.3	(1.4 - 5.2)	1.17	(0.61 - 1.81)	-
Pancreas	19	5.0	(2.7 - 7.4)	0.83	(0.46 - 1.24)	-	22	3.5	(1.9 - 5.1)	0.91	(0.54 - 1.33)	-
Urinary bladder	14	3.5	(1.6 - 5.4)	0.96	(0.48 - 1.53)	-	5	1.0	(0.1 - 1.9)	0.76	(0.17 - 1.56)	-
Stomach	29	7.7	(4.7 - 10.6)	1.21	(0.78 - 1.69)	-	17	2.6	(1.3 - 4.0)	1.29	(0.69 - 1.97)	-
Corpus uteri	0	-	-	-	-	.	6	1.2	(0.1 - 2.2)	0.68	(0.18 - 1.33)	-
Brain	23	7.5	(4.2 - 10.9)	1.37	(0.82 - 1.98)	-	15	4.0	(1.7 - 6.2)	1.19	(0.61 - 1.86)	-
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	17	3.7	(1.8 - 5.5)	0.84	(0.45 - 1.29)	-
Other lymphohaematopoietic	8	1.7	(0.5 - 2.8)	1.08	(0.38 - 1.95)	-	6	0.7	(0.1 - 1.2)	1.28	(0.35 - 2.49)	-
Oesophagus	16	4.4	(2.2 - 6.6)	1.09	(0.57 - 1.68)	-	11	1.5	(0.6 - 2.5)	1.35	(0.59 - 2.26)	-
Thyroid gland	2	0.5	(0.0 - 1.1)	2.15	(0.03 - 5.99)	-*	4	0.7	(0.0 - 1.4)	2.00	(0.31 - 4.39)	-*
Myeloma/plasma cell tumours	11	2.8	(1.1 - 4.4)	1.24	(0.54 - 2.08)	-	3	0.4	(0.0 - 0.9)	0.38	(0.03 - 0.89)	V
Cervix uteri	0	-	-	-	-	.	3	0.8	(0.0 - 1.8)	0.35	(0.03 - 0.81)	V
Non-mel. skin (exc BCC/SCC)	1	0.3	(0.0 - 0.9)	0.40	(0.00 - 1.48)	-*	0	-	-	0	n/a	-
Mesothelioma	18	4.5	(2.3 - 6.7)	1.05	(0.58 - 1.59)	-	1	0.2	(0.0 - 0.6)	0.42	(0.00 - 1.55)	-*
Liver & intrahepatic bile duct	9	2.6	(0.9 - 4.3)	0.78	(0.30 - 1.36)	-	3	0.7	(0.0 - 1.5)	0.68	(0.05 - 1.58)	-*
Testis	1	0.4	(0.0 - 1.2)	2.32	(0.00 - 8.55)	-*	0	-	-	-	-	.
Gallbladder & bile ducts	8	2.0	(0.6 - 3.5)	1.30	(0.46 - 2.35)	-	8	1.5	(0.4 - 2.6)	1.16	(0.41 - 2.10)	-
Larynx	5	1.5	(0.2 - 2.8)	1.00	(0.22 - 2.04)	-	0	-	-	0	n/a	-
Tongue	2	0.5	(0.0 - 1.2)	0.67	(0.01 - 1.86)	-*	0	-	-	0	n/a	-
Connective & soft tissues	2	0.5	(0.0 - 1.3)	1.04	(0.01 - 2.90)	-*	2	0.4	(0.0 - 1.1)	1.25	(0.02 - 3.49)	-*
Tonsil & oropharynx	3	0.7	(0.0 - 1.5)	1.14	(0.09 - 2.65)	-*	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	0.1	(0.0 - 0.4)	0.56	(0.00 - 2.05)	-*
Small intestine	0	-	-	0	n/a	-	1	0.3	(0.0 - 0.8)	0.65	(0.00 - 2.39)	-*
Eye & lacrimal gland	1	0.3	(0.0 - 0.9)	0.88	(0.00 - 3.26)	-*	1	0.1	(0.0 - 0.4)	1.11	(0.00 - 4.08)	-*
Major Salivary Gland	1	0.2	(0.0 - 0.5)	0.86	(0.00 - 3.19)	-*	0	-	-	-	-	.
Anus	0	-	-	0	n/a	-	2	0.4	(0.0 - 1.1)	1.25	(0.02 - 3.49)	-*
Mouth, other & unspecified	0	-	-	0	n/a	-	2	0.5	(0.0 - 1.2)	1.61	(0.02 - 4.48)	-*
Floor of mouth	1	0.3	(0.0 - 0.9)	0.73	(0.00 - 2.71)	-*	1	0.1	(0.0 - 0.3)	1.62	(0.00 - 5.99)	-*
Bones, joints & articular cart.	2	0.7	(0.0 - 1.6)	1.83	(0.02 - 5.11)	-*	2	0.7	(0.0 - 1.8)	2.77	(0.03 - 7.72)	-*
Pyriiform sinus & hypopharynx	0	-	-	0	n/a	-	1	0.3	(0.0 - 0.9)	3.05	(0.00 - 11.25)	-*
Nasal cavity, sinuses, int. ear	1	0.2	(0.0 - 0.5)	1.15	(0.00 - 4.25)	-*	1	0.1	(0.0 - 0.4)	2.50	(0.00 - 9.21)	-*
Peritoneum & retroperitoneum	2	0.6	(0.0 - 1.5)	2.14	(0.03 - 5.95)	-*	2	0.4	(0.0 - 0.9)	1.34	(0.02 - 3.73)	-*
Adrenal & other endocrine	0	-	-	0	n/a	-	1	0.2	(0.0 - 0.6)	1.98	(0.00 - 7.30)	-*
Nasopharynx	1	0.4	(0.0 - 1.1)	1.33	(0.00 - 4.90)	-*	0	-	-	-	-	.
Pharynx, other & ill-def.	1	0.3	(0.0 - 1.0)	0.80	(0.00 - 2.96)	-*	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	1	0.3	(0.0 - 0.7)	4.02	(0.00 - 14.83)	-*	2	0.4	(0.0 - 1.0)	3.93	(0.05 - 10.96)	-*
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	1	0.2	(0.0 - 0.7)	1.97	(0.00 - 7.25)	-*	0	-	-	-	-	.
Pleura, heart & mediastinum	1	0.3	(0.0 - 0.9)	1.78	(0.00 - 6.57)	-*	1	0.1	(0.0 - 0.4)	4.86	(0.00 - 17.92)	-*
Spinal cord & cranial nerves	1	0.2	(0.0 - 0.5)	9.25	(0.00 - 34.13)	-*	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	575	146.3	(133.8 - 158.8)	1.04	(0.96 - 1.13)	-	413	82.7	(73.9 - 91.5)	0.96	(0.87 - 1.05)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Stirling (C) - Coastal 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	45	17.7 (12.2 - 23.3)	1.01	(0.71 - 1.32)	-
Colorectal cancer	37	14.5 (9.6 - 19.5)	0.84	(0.57 - 1.13)	-		35	11.3 (7.1 - 15.5)	0.89	(0.60 - 1.20)	-
Prostate gland	44	14.8 (10.3 - 19.3)	1.15	(0.82 - 1.52)	-		0	-	-	-	.
Melanoma (skin)	11	4.2 (1.6 - 6.8)	1.19	(0.52 - 1.99)	-		9	3.2 (0.9 - 5.6)	1.51	(0.58 - 2.64)	-
Lung, bronchus & trachea	58	22.4 (16.4 - 28.5)	0.70	(0.53 - 0.91)	V		43	13.7 (9.2 - 18.1)	0.96	(0.68 - 1.27)	-
Lymphoma	12	4.8 (2.0 - 7.6)	0.95	(0.44 - 1.56)	-		11	3.3 (1.2 - 5.3)	0.84	(0.36 - 1.40)	-
Unknown primary site	23	8.0 (4.6 - 11.5)	1.13	(0.68 - 1.64)	-		18	4.0 (1.8 - 6.2)	0.91	(0.50 - 1.37)	-
Kidney & other renal tract	14	6.2 (2.8 - 9.6)	1.60	(0.79 - 2.54)	-		9	2.5 (0.7 - 4.4)	1.58	(0.60 - 2.76)	-
Leukaemia	17	7.4 (3.2 - 11.7)	1.24	(0.67 - 1.90)	-		8	3.3 (0.6 - 5.9)	0.89	(0.31 - 1.60)	-
Pancreas	13	5.8 (2.5 - 9.0)	0.92	(0.44 - 1.48)	-		10	3.6 (1.2 - 6.1)	0.63	(0.26 - 1.07)	-
Urinary bladder	11	5.3 (1.5 - 9.2)	1.20	(0.52 - 2.01)	-		6	1.2 (0.1 - 2.4)	1.34	(0.36 - 2.61)	-*
Stomach	14	5.7 (2.6 - 8.8)	0.95	(0.47 - 1.50)	-		9	2.1 (0.5 - 3.8)	1.03	(0.39 - 1.80)	-
Corpus uteri	0	-	-	-	-	.	8	3.2 (0.8 - 5.7)	1.40	(0.49 - 2.53)	-
Brain	12	4.9 (2.0 - 7.8)	1.15	(0.52 - 1.88)	-		4	1.3 (0.0 - 2.6)	0.50	(0.08 - 1.09)	-
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	14	5.2 (2.2 - 8.1)	1.08	(0.53 - 1.71)	-
Other lymphohaematopoietic	6	2.1 (0.4 - 3.9)	1.28	(0.35 - 2.50)	-		3	1.1 (0.0 - 2.4)	0.91	(0.07 - 2.12)	-*
Oesophagus	7	2.0 (0.5 - 3.6)	0.77	(0.24 - 1.43)	-		4	1.6 (0.0 - 3.3)	0.74	(0.11 - 1.62)	-
Thyroid gland	2	0.6 (0.0 - 1.5)	3.55	(0.04 - 9.89)	-*		0	-	0	n/a	-
Myeloma/plasma cell tumours	5	1.8 (0.2 - 3.5)	0.90	(0.20 - 1.85)	-		4	1.1 (0.0 - 2.4)	0.76	(0.12 - 1.68)	-
Cervix uteri	0	-	-	-	-	.	6	1.7 (0.2 - 3.2)	1.08	(0.29 - 2.10)	-
Non-mel. skin (exc BCC/SCC)	3	1.3 (0.0 - 2.9)	1.93	(0.16 - 4.50)	-*		3	0.7 (0.0 - 1.7)	3.70	(0.30 - 8.63)	-*
Mesothelioma	13	4.9 (2.1 - 7.8)	1.24	(0.59 - 2.01)	-		3	0.9 (0.0 - 2.0)	2.01	(0.16 - 4.69)	-*
Liver & intrahepatic bile duct	7	2.8 (0.6 - 5.0)	0.99	(0.31 - 1.84)	-		2	0.7 (0.0 - 1.7)	0.69	(0.01 - 1.94)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	4	1.7 (0.0 - 3.4)	1.05	(0.16 - 2.29)	-*		1	0.5 (0.0 - 1.6)	0.22	(0.00 - 0.80)	V
Larynx	3	0.8 (0.0 - 1.7)	0.98	(0.08 - 2.28)	-*		2	1.0 (0.0 - 2.4)	4.26	(0.05 - 11.86)	-*
Tongue	3	1.3 (0.0 - 2.9)	1.62	(0.13 - 3.78)	-*		1	0.1 (0.0 - 0.4)	1.06	(0.00 - 3.90)	-*
Connective & soft tissues	4	1.9 (0.0 - 3.8)	3.25	(0.50 - 7.13)	-*		0	-	0	n/a	-
Tonsil & oropharynx	1	0.3 (0.0 - 0.8)	0.61	(0.00 - 2.26)	-*		0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	0	n/a	-
Small intestine	2	0.8 (0.0 - 2.0)	1.52	(0.02 - 4.25)	-*		0	-	0	n/a	-
Eye & lacrimal gland	0	-	-	0	n/a	-	1	0.2 (0.0 - 0.4)	1.69	(0.00 - 6.23)	-*
Major Salivary Gland	1	0.6 (0.0 - 1.7)	1.36	(0.00 - 5.02)	-*		0	-	-	-	.
Anus	0	-	-	0	n/a	-	0	-	0	n/a	-
Mouth, other & unspecified	2	0.6 (0.0 - 1.5)	2.27	(0.03 - 6.31)	-*		0	-	0	n/a	-
Floor of mouth	2	1.1 (0.0 - 2.6)	2.41	(0.03 - 6.71)	-*		2	0.3 (0.0 - 0.7)	4.66	(0.06 - 12.97)	-*
Bones, joints & articular cart.	0	-	-	0	n/a	-	0	-	-	-	.
Pyriform sinus & hypopharynx	1	0.4 (0.0 - 1.0)	0.67	(0.00 - 2.46)	-*		0	-	-	-	.
Nasal cavity, sinuses, int. ear	2	0.7 (0.0 - 1.8)	3.80	(0.05 - 10.59)	-*		0	-	-	-	.
Peritoneum & retroperitoneum	1	0.5 (0.0 - 1.5)	1.73	(0.00 - 6.37)	-*		2	0.5 (0.0 - 1.3)	2.11	(0.03 - 5.87)	-*
Adrenal & other endocrine	1	0.6 (0.0 - 1.6)	3.34	(0.00 - 12.31)	-*		0	-	-	-	.
Nasopharynx	1	0.4 (0.0 - 1.1)	2.08	(0.00 - 7.68)	-*		0	-	-	-	.
Pharynx, other & ill-def.	1	0.3 (0.0 - 0.8)	1.32	(0.00 - 4.88)	-*		0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	1	0.3 (0.0 - 1.0)	5.64	(0.00 - 20.81)	-*
All cancers	338	131.6 (116.7 - 146.5)	0.99	(0.89 - 1.10)	-		266	87.4 (75.7 - 99.2)	0.94	(0.83 - 1.06)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Stirling (C) - South-Eastern 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	16	10.5 (3.3 - 17.7)	1.07	(0.56 - 1.66)	-
Colorectal cancer	17	20.5	(8.8 - 32.2)	1.27	(0.69 - 1.95)	-	12	8.6 (1.6 - 15.6)	0.79	(0.36 - 1.29)	-
Prostate gland	18	13.2	(6.8 - 19.5)	1.28	(0.71 - 1.94)	-	0	-	-	-	-
Melanoma (skin)	0	-	-	0	n/a	-	4	2.6 (0.0 - 6.1)	1.89	(0.29 - 4.15)	-*
Lung, bronchus & trachea	31	42.9	(25.4 - 60.4)	1.27	(0.83 - 1.76)	-	12	9.0 (2.3 - 15.7)	0.80	(0.36 - 1.31)	-
Lymphoma	4	2.9	(0.0 - 5.8)	1.05	(0.16 - 2.31)	-*	6	4.3 (0.0 - 8.7)	1.30	(0.35 - 2.54)	-
Unknown primary site	5	4.3	(0.2 - 8.4)	0.77	(0.17 - 1.59)	-	8	5.5 (0.3 - 10.7)	0.95	(0.33 - 1.71)	-
Kidney & other renal tract	2	1.2	(0.0 - 2.9)	0.75	(0.01 - 2.09)	-*	3	3.3 (0.0 - 8.2)	1.42	(0.11 - 3.31)	-*
Leukaemia	5	3.2	(0.4 - 6.1)	1.18	(0.26 - 2.42)	-*	5	7.5 (0.0 - 16.0)	1.43	(0.31 - 2.93)	-*
Pancreas	6	8.7	(0.4 - 16.9)	1.46	(0.39 - 2.84)	-*	9	3.7 (0.6 - 6.7)	1.48	(0.57 - 2.59)	-
Urinary bladder	2	3.3	(0.0 - 8.7)	0.63	(0.01 - 1.75)	-*	3	3.9 (0.0 - 8.9)	1.54	(0.12 - 3.60)	-*
Stomach	2	1.3	(0.0 - 3.0)	0.44	(0.01 - 1.22)	-	4	5.6 (0.0 - 12.8)	1.14	(0.18 - 2.49)	-*
Corpus uteri	0	-	-	-	-	.	0	-	0	n/a	-
Brain	1	0.8	(0.0 - 2.5)	0.35	(0.00 - 1.31)	-*	2	2.3 (0.0 - 6.3)	0.82	(0.01 - 2.28)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	3	4.0 (0.0 - 10.4)	0.67	(0.05 - 1.57)	-*
Other lymphohaematopoietic	2	1.3	(0.0 - 3.0)	1.17	(0.01 - 3.27)	-*	1	0.3 (0.0 - 0.9)	0.63	(0.00 - 2.32)	-*
Oesophagus	2	4.0	(0.0 - 10.6)	0.74	(0.01 - 2.07)	-*	2	0.5 (0.0 - 1.2)	0.93	(0.01 - 2.60)	-*
Thyroid gland	0	-	-	-	-	.	2	2.3 (0.0 - 5.8)	3.88	(0.05 - 10.82)	-*
Myeloma/plasma cell tumours	2	2.2	(0.0 - 5.5)	1.09	(0.01 - 3.04)	-*	3	1.8 (0.0 - 4.3)	1.47	(0.12 - 3.43)	-*
Cervix uteri	0	-	-	-	-	.	2	0.5 (0.0 - 1.2)	1.08	(0.01 - 3.02)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	0	-	-	-	.
Mesothelioma	1	2.6	(0.0 - 7.7)	0.33	(0.00 - 1.23)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	1	0.8	(0.0 - 2.5)	0.52	(0.00 - 1.92)	-*	0	-	0	n/a	-
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	1	0.6	(0.0 - 1.9)	0.84	(0.00 - 3.09)	-*	3	1.0 (0.0 - 2.3)	1.67	(0.13 - 3.89)	-*
Larynx	1	0.8	(0.0 - 2.5)	1.15	(0.00 - 4.25)	-*	0	-	-	-	.
Tongue	1	0.6	(0.0 - 1.9)	1.86	(0.00 - 6.88)	-*	1	0.3 (0.0 - 0.9)	3.28	(0.00 - 12.10)	-*
Connective & soft tissues	1	0.6	(0.0 - 1.9)	2.70	(0.00 - 9.95)	-*	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	1	0.3 (0.0 - 0.9)	1.79	(0.00 - 6.59)	-*
Small intestine	1	0.6	(0.0 - 1.9)	2.40	(0.00 - 8.87)	-*	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	1	3.2 (0.0 - 9.6)	4.17	(0.00 - 15.37)	-*
Major Salivary Gland	1	0.6	(0.0 - 1.8)	4.18	(0.00 - 15.41)	-*	0	-	-	-	.
Anus	0	-	-	-	-	.	1	0.3 (0.0 - 0.9)	2.29	(0.00 - 8.45)	-*
Mouth, other & unspecified	2	3.2	(0.0 - 8.5)	7.93	(0.10 - 22.10)	-*	0	-	-	-	.
Floor of mouth	1	1.6	(0.0 - 4.6)	4.86	(0.00 - 17.92)	-*	1	0.2 (0.0 - 0.6)	5.28	(0.00 - 19.47)	-*
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	1	3.3	(0.0 - 9.8)	2.56	(0.00 - 9.44)	-*	0	-	-	-	.
Nasal cavity, sinuses, int. ear	1	1.6	(0.0 - 4.6)	6.72	(0.00 - 24.79)	-*	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	1	0.2 (0.0 - 0.6)	5.87	(0.00 - 21.66)	-*
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	1	0.2 (0.0 - 0.6)	10.63	(0.00 - 39.22)	-*
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	112	126.8	(98.5 - 155.2)	1.07	(0.88 - 1.29)	-	109	84.4 (61.6 - 107.3)	1.06	(0.87 - 1.28)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Subiaco (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	9	8.8 (2.0 - 15.7)	0.86	(0.33 - 1.51)	-
Colorectal cancer	7	15.0	(3.3 - 26.6)	0.76	(0.24 - 1.41)	-	9	7.3 (1.8 - 12.9)	0.96	(0.37 - 1.69)	-
Prostate gland	6	9.6	(1.6 - 17.6)	0.74	(0.20 - 1.44)	-	0	-	-	-	-
Melanoma (skin)	0	-	-	0	n/a	-	3	3.8 (0.0 - 9.3)	2.10	(0.17 - 4.90)	-*
Lung, bronchus & trachea	22	41.8	(23.1 - 60.5)	1.31	(0.77 - 1.91)	-	12	17.2 (6.2 - 28.2)	1.20	(0.55 - 1.97)	-
Lymphoma	6	10.7	(1.5 - 19.9)	2.26	(0.61 - 4.39)	-*	3	6.2 (0.0 - 14.0)	1.00	(0.08 - 2.33)	-*
Unknown primary site	5	8.9	(0.4 - 17.3)	1.17	(0.26 - 2.40)	-*	7	6.3 (0.6 - 12.0)	1.44	(0.45 - 2.68)	-
Kidney & other renal tract	1	2.9	(0.0 - 8.7)	0.54	(0.00 - 2.01)	-*	4	2.4 (0.0 - 4.8)	3.06	(0.47 - 6.70)	-*
Leukaemia	7	14.2	(3.1 - 25.2)	2.42	(0.76 - 4.51)	-*	1	2.1 (0.0 - 6.1)	0.45	(0.00 - 1.67)	-*
Pancreas	5	12.5	(1.2 - 23.7)	1.71	(0.37 - 3.51)	-*	3	5.1 (0.0 - 11.6)	0.81	(0.07 - 1.89)	-*
Urinary bladder	0	-	-	0	n/a	-	0	-	0	n/a	-
Stomach	1	1.3	(0.0 - 4.0)	0.32	(0.00 - 1.20)	-*	2	2.2 (0.0 - 5.6)	0.96	(0.01 - 2.66)	-*
Corpus uteri	0	-	-	-	-	.	1	2.7 (0.0 - 8.0)	0.75	(0.00 - 2.78)	-*
Brain	1	2.5	(0.0 - 7.3)	0.43	(0.00 - 1.59)	-*	3	5.3 (0.0 - 12.0)	1.65	(0.13 - 3.84)	-*
Lip	0	-	-	-	-	.	0	-	-	-	-
Ovary & uterine adnexa	0	-	-	-	-	.	10	12.9 (3.1 - 22.7)	3.35	(1.38 - 5.72)	^*
Other lymphohaematopoietic	2	2.4	(0.0 - 5.7)	2.01	(0.03 - 5.60)	-*	2	2.2 (0.0 - 5.6)	2.36	(0.03 - 6.56)	-*
Oesophagus	3	5.3	(0.0 - 11.9)	1.60	(0.13 - 3.74)	-*	2	2.5 (0.0 - 6.7)	1.56	(0.02 - 4.35)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-
Myeloma/plasma cell tumours	2	3.2	(0.0 - 7.8)	1.72	(0.02 - 4.79)	-*	3	1.6 (0.0 - 3.5)	2.44	(0.20 - 5.70)	-*
Cervix uteri	0	-	-	-	-	.	0	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	1	0.5 (0.0 - 1.4)	4.96	(0.00 - 18.28)	-*
Mesothelioma	2	4.0	(0.0 - 9.6)	0.93	(0.01 - 2.58)	-*	1	1.7 (0.0 - 5.0)	3.04	(0.00 - 11.23)	-*
Liver & intrahepatic bile duct	4	8.3	(0.0 - 17.1)	2.79	(0.43 - 6.11)	-*	0	-	0	n/a	-
Testis	0	-	-	-	-	.	0	-	-	-	-
Gallbladder & bile ducts	2	4.4	(0.0 - 10.7)	2.44	(0.03 - 6.81)	-*	0	-	0	n/a	-
Larynx	3	7.3	(0.0 - 15.6)	4.73	(0.38 - 11.05)	-*	0	-	-	-	-
Tongue	0	-	-	-	-	.	0	-	-	-	-
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-
Small intestine	1	1.9	(0.0 - 5.8)	3.59	(0.00 - 13.25)	-*	1	0.6 (0.0 - 1.7)	4.52	(0.00 - 16.66)	-*
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-
Anus	0	-	-	-	-	.	1	2.3 (0.0 - 6.7)	3.74	(0.00 - 13.78)	-*
Mouth, other & unspecified	1	2.5	(0.0 - 7.3)	5.21	(0.00 - 19.22)	-*	0	-	-	-	-
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	1	0.5 (0.0 - 1.4)	15.82	(0.00 - 58.35)	-*
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-
Gum	0	-	-	-	-	.	0	-	-	-	-
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-
Thymus	0	-	-	-	-	.	0	-	-	-	-
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-
Placenta	0	-	-	-	-	.	0	-	-	-	-
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-
All cancers	81	158.5	(122.0 - 195.0)	1.14	(0.91 - 1.42)	-	79	94.1 (69.0 - 119.3)	1.20	(0.95 - 1.50)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Swan (C) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	30	12.2 (7.7 - 16.7)	0.81	(0.52 - 1.12)	-
Colorectal cancer	35	16.4 (10.8 - 21.9)	0.94	(0.63 - 1.27)	-		35	14.7 (9.6 - 19.9)	1.25	(0.84 - 1.69)	-
Prostate gland	27	12.9 (8.0 - 17.9)	0.98	(0.61 - 1.38)	-		0	-	-	-	.
Melanoma (skin)	9	4.3 (1.4 - 7.2)	1.09	(0.42 - 1.91)	-		4	1.9 (0.0 - 3.8)	0.82	(0.13 - 1.79)	-
Lung, bronchus & trachea	84	41.5 (32.5 - 50.5)	1.21	(0.97 - 1.51)	-		33	14.4 (9.3 - 19.5)	1.01	(0.67 - 1.38)	-
Lymphoma	8	4.0 (1.2 - 6.9)	0.73	(0.26 - 1.32)	-		13	5.6 (2.4 - 8.8)	1.34	(0.64 - 2.16)	-
Unknown primary site	14	6.0 (2.8 - 9.2)	0.84	(0.41 - 1.33)	-		12	4.0 (1.6 - 6.4)	0.87	(0.40 - 1.43)	-
Kidney & other renal tract	9	4.6 (1.5 - 7.6)	1.22	(0.47 - 2.13)	-		5	2.1 (0.2 - 3.9)	1.26	(0.27 - 2.57)	-*
Leukaemia	7	3.8 (1.0 - 6.7)	0.59	(0.19 - 1.11)	-		5	2.2 (0.2 - 4.3)	0.71	(0.15 - 1.46)	-
Pancreas	12	6.7 (2.9 - 10.5)	0.97	(0.44 - 1.59)	-		13	5.9 (2.6 - 9.2)	1.18	(0.56 - 1.91)	-
Urinary bladder	12	5.8 (2.4 - 9.1)	1.73	(0.79 - 2.84)	-		1	0.5 (0.0 - 1.4)	0.35	(0.00 - 1.28)	-*
Stomach	9	4.6 (1.6 - 7.7)	0.73	(0.28 - 1.27)	-		4	1.5 (0.0 - 2.9)	0.65	(0.10 - 1.42)	-
Corpus uteri	0	-	-	-	-	.	4	1.5 (0.0 - 2.9)	1.00	(0.16 - 2.20)	-*
Brain	8	3.7 (1.1 - 6.3)	0.74	(0.26 - 1.33)	-		5	2.2 (0.2 - 4.2)	0.72	(0.16 - 1.47)	-
Lip	1	0.3 (0.0 - 1.0)	5.27	(0.00 - 19.45)	-*		0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	13	5.4 (2.4 - 8.4)	1.33	(0.63 - 2.14)	-
Other lymphohaematopoietic	3	1.4 (0.0 - 3.0)	0.87	(0.07 - 2.02)	-*		0	-	0	n/a	-
Oesophagus	7	3.3 (0.8 - 5.8)	0.92	(0.29 - 1.71)	-		7	2.8 (0.6 - 4.9)	1.87	(0.59 - 3.50)	-*
Thyroid gland	0	-	-	-	-	.	0	-	0	n/a	-
Myeloma/plasma cell tumours	3	1.3 (0.0 - 2.9)	0.68	(0.05 - 1.59)	-*		7	3.0 (0.6 - 5.3)	1.93	(0.61 - 3.60)	-*
Cervix uteri	0	-	-	-	-	.	5	2.3 (0.2 - 4.4)	1.02	(0.22 - 2.10)	-
Non-mel. skin (exc BCC/SCC)	2	1.0 (0.0 - 2.3)	1.70	(0.02 - 4.74)	-*		3	1.4 (0.0 - 2.9)	5.37	(0.43 - 12.54)	-*
Mesothelioma	15	7.3 (3.5 - 11.0)	1.68	(0.86 - 2.63)	-		1	0.5 (0.0 - 1.4)	0.87	(0.00 - 3.20)	-*
Liver & intrahepatic bile duct	9	4.2 (1.4 - 7.0)	1.45	(0.55 - 2.53)	-		1	0.6 (0.0 - 1.8)	0.46	(0.00 - 1.69)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	3	1.3 (0.0 - 2.7)	0.94	(0.08 - 2.19)	-*		5	1.7 (0.1 - 3.3)	1.57	(0.34 - 3.21)	-*
Larynx	3	1.5 (0.0 - 3.1)	1.13	(0.09 - 2.65)	-*		1	0.3 (0.0 - 0.9)	3.03	(0.00 - 11.18)	-*
Tongue	0	-	-	0	n/a	-	0	-	0	n/a	-
Connective & soft tissues	0	-	-	0	n/a	-	1	0.5 (0.0 - 1.4)	1.16	(0.00 - 4.30)	-*
Tonsil & oropharynx	1	0.6 (0.0 - 1.8)	0.65	(0.00 - 2.39)	-*		1	0.5 (0.0 - 1.4)	5.55	(0.00 - 20.47)	-*
Vulva/vagina	0	-	-	-	-	.	1	0.2 (0.0 - 0.7)	1.28	(0.00 - 4.71)	-*
Small intestine	1	0.6 (0.0 - 1.8)	0.86	(0.00 - 3.17)	-*		0	-	0	n/a	-
Eye & lacrimal gland	0	-	-	0	n/a	-	0	-	-	-	.
Major Salivary Gland	0	-	-	0	n/a	-	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	0	n/a	-
Mouth, other & unspecified	0	-	-	0	n/a	-	1	0.4 (0.0 - 1.3)	1.71	(0.00 - 6.31)	-*
Floor of mouth	1	0.6 (0.0 - 1.8)	1.27	(0.00 - 4.70)	-*		0	-	-	-	.
Bones, joints & articular cart.	0	-	-	0	n/a	-	1	0.4 (0.0 - 1.1)	1.93	(0.00 - 7.12)	-*
Pyriform sinus & hypopharynx	2	0.9 (0.0 - 2.1)	1.52	(0.02 - 4.24)	-*		0	-	-	-	.
Nasal cavity, sinuses, int. ear	1	0.5 (0.0 - 1.4)	2.18	(0.00 - 8.03)	-*		0	-	-	-	.
Peritoneum & retroperitoneum	2	0.7 (0.0 - 1.8)	3.59	(0.04 - 9.99)	-*		2	0.6 (0.0 - 1.3)	2.66	(0.03 - 7.42)	-*
Adrenal & other endocrine	1	0.4 (0.0 - 1.1)	2.81	(0.00 - 10.38)	-*		0	-	-	-	.
Nasopharynx	0	-	-	0	n/a	-	1	0.6 (0.0 - 1.8)	4.77	(0.00 - 17.61)	-*
Pharynx, other & ill-def.	1	0.4 (0.0 - 1.1)	1.52	(0.00 - 5.62)	-*		0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	290	140.5 (124.1 - 156.9)	1.02	(0.90 - 1.14)	-		217	90.3 (77.8 - 102.9)	1.03	(0.90 - 1.18)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Tambellup (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	1	37.0	(0.0 - 109.2)	8.73	(0.00 - 32.19)	-*	1	50.0	(0.0 - 147.4)	10.45	(0.00 - 38.54)	-*
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriiform sinus & hypopharynx	1	55.6	(0.0 - 161.4)	61.60	(0.00 - 227.24)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	2	92.6	(0.0 - 220.7)	0.64	(0.01 - 1.78)	-*	1	50.0	(0.0 - 147.4)	0.50	(0.00 - 1.83)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Tammin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	1	87.0	(0.0 - 253.6)	4.07	(0.00 - 15.00)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	2	173.9	(0.0 - 404.2)	3.75	(0.05 - 10.45)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	1	25.0	(0.0 - 72.8)	36.05	(0.00 - 132.97)	-*
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	1	50.0	(0.0 - 143.0)	48.55	(0.00 - 179.09)	-*	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	1	23.8	(0.0 - 69.4)	,873.54	(0.00 - 6,911.47)	-*
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	4	310.9	(20.3 - 601.4)	1.78	(0.27 - 3.89)	-*	2	48.8	(0.0 - 114.8)	1.31	(0.02 - 3.64)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Three Springs (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	1	44.4	(0.0 - 131.1)	0.93	(0.00 - 3.42)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	2	47.9	(0.0 - 115.0)	7.40	(0.09 - 20.63)	-*	0	-	-	-	-	.
Kidney & other renal tract	1	36.1	(0.0 - 106.6)	8.53	(0.00 - 31.45)	-*	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	1	12.2	(0.0 - 35.8)	11.94	(0.00 - 44.04)	-*
Pancreas	0	-	-	-	-	.	1	25.0	(0.0 - 72.8)	7.23	(0.00 - 26.67)	-*
Urinary bladder	1	18.5	(0.0 - 54.1)	8.13	(0.00 - 29.98)	-*	1	58.8	(0.0 - 173.0)	25.47	(0.00 - 93.95)	-*
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	1	30.3	(0.0 - 88.8)	174.33	(0.00 - 643.09)	-*
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	5	147.0	(12.4 - 281.7)	1.11	(0.24 - 2.27)	-	4	126.3	(0.0 - 265.2)	1.55	(0.24 - 3.41)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Toodyay (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	7	49.8 (12.3 - 87.4)	3.17	(1.00 - 5.90)	-*
Colorectal cancer	4	28.2	(0.2 - 56.3)	1.50	(0.23 - 3.28)	-*	2	15.8 (0.0 - 38.2)	1.31	(0.02 - 3.64)	-*
Prostate gland	1	6.6	(0.0 - 19.6)	0.57	(0.00 - 2.12)	-*	0	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	.
Lung, bronchus & trachea	5	31.6	(3.9 - 59.3)	0.99	(0.22 - 2.03)	-	2	12.0 (0.0 - 28.6)	1.08	(0.01 - 3.01)	-*
Lymphoma	0	-	-	0	n/a	-	0	-	-	n/a	-
Unknown primary site	0	-	-	0	n/a	-	1	7.2 (0.0 - 21.4)	1.43	(0.00 - 5.26)	-*
Kidney & other renal tract	1	6.6	(0.0 - 19.6)	1.91	(0.00 - 7.04)	-*	0	-	-	-	.
Leukaemia	1	6.0	(0.0 - 17.8)	1.29	(0.00 - 4.76)	-*	1	6.0 (0.0 - 17.5)	2.84	(0.00 - 10.49)	-*
Pancreas	0	-	-	0	n/a	-	0	-	-	n/a	-
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	2	13.0	(0.0 - 30.9)	2.28	(0.03 - 6.35)	-*	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	0	n/a	-	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	0	n/a
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	1	6.0 (0.0 - 17.5)	5.05	(0.00 - 18.63)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	3	19.9	(0.0 - 42.2)	4.53	(0.37 - 10.56)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	1	6.3	(0.0 - 18.8)	2.16	(0.00 - 7.97)	-*	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	1	5.3	(0.0 - 15.8)	27.99	(0.00 - 103.25)	-*	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	1	6.6	(0.0 - 19.6)	9.74	(0.00 - 35.95)	-*	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	20	130.3	(73.2 - 187.3)	1.00	(0.57 - 1.48)	-	14	96.7 (45.3 - 148.1)	1.20	(0.59 - 1.90)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Trayning (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	1	22.7	(0.0 - 66.8)	2.91	(0.00 - 10.75)	-*	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	1	47.6	(0.0 - 139.8)	3.47	(0.00 - 12.80)	-*
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	1	88.2	(0.0 - 258.6)	6.41	(0.00 - 23.65)	-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	57.1	(0.0 - 168.3)	8.69	(0.00 - 32.06)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	47.6	(0.0 - 139.8)	25.62	(0.00 - 94.50)	-*
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	3	168.1	(0.0 - 376.3)	1.13	(0.09 - 2.64)	-*	2	95.2	(0.0 - 224.1)	1.07	(0.01 - 2.98)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Upper Gascoyne (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	-	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Victoria Park (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	32	13.4 (6.4 - 20.3)	1.27	(0.84 - 1.75)	-
Colorectal cancer	27	19.1 (10.4 - 27.8)	1.20	(0.76 - 1.70)	-	29	13.9 (6.2 - 21.6)	1.09	(0.70 - 1.52)	-	
Prostate gland	27	16.1 (8.5 - 23.7)	1.15	(0.72 - 1.62)	-	0	-	-	-	.	
Melanoma (skin)	4	3.6 (0.0 - 7.9)	0.85	(0.13 - 1.86)	-	9	4.5 (0.3 - 8.7)	2.47	(0.95 - 4.33)	-*	
Lung, bronchus & trachea	50	44.2 (29.8 - 58.6)	1.21	(0.88 - 1.57)	-	30	18.9 (9.8 - 28.1)	1.14	(0.74 - 1.58)	-	
Lymphoma	5	3.8 (0.0 - 7.6)	0.78	(0.17 - 1.60)	-	7	2.2 (0.0 - 4.4)	0.87	(0.27 - 1.62)	-	
Unknown primary site	12	9.1 (3.0 - 15.3)	1.10	(0.51 - 1.81)	-	9	4.5 (0.0 - 9.1)	0.62	(0.24 - 1.08)	-	
Kidney & other renal tract	8	5.9 (1.0 - 10.8)	1.79	(0.63 - 3.23)	-*	5	3.8 (0.0 - 8.0)	1.35	(0.29 - 2.76)	-*	
Leukaemia	17	18.1 (8.3 - 28.0)	2.37	(1.27 - 3.62)	^	6	3.0 (0.0 - 6.2)	0.99	(0.27 - 1.92)	-	
Pancreas	5	5.2 (0.0 - 10.5)	0.72	(0.16 - 1.48)	-	10	2.9 (0.8 - 5.1)	0.94	(0.39 - 1.60)	-	
Urinary bladder	3	1.6 (0.0 - 3.6)	0.56	(0.05 - 1.31)	-	4	1.6 (0.0 - 4.1)	1.17	(0.18 - 2.56)	-*	
Stomach	15	12.5 (4.9 - 20.1)	1.96	(1.00 - 3.06)	-	5	3.2 (0.0 - 6.6)	0.81	(0.18 - 1.67)	-	
Corpus uteri	0	-	-	-	.	3	1.1 (0.0 - 2.5)	0.80	(0.06 - 1.87)	-*	
Brain	9	14.3 (3.9 - 24.8)	1.95	(0.75 - 3.41)	-	5	4.1 (0.0 - 8.5)	1.20	(0.26 - 2.46)	-*	
Lip	0	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	.	5	3.6 (0.0 - 7.8)	0.65	(0.14 - 1.32)	-	
Other lymphohaematopoietic	3	1.2 (0.0 - 2.7)	1.04	(0.08 - 2.44)	-*	4	1.0 (0.0 - 2.3)	1.44	(0.22 - 3.16)	-*	
Oesophagus	5	7.8 (0.6 - 15.0)	1.11	(0.24 - 2.27)	-	4	1.2 (0.0 - 2.5)	1.06	(0.16 - 2.33)	-*	
Thyroid gland	0	-	-	-	.	1	1.8 (0.0 - 5.4)	1.12	(0.00 - 4.14)	-*	
Myeloma/plasma cell tumours	4	4.0 (0.0 - 8.2)	1.30	(0.20 - 2.84)	-*	2	0.3 (0.0 - 0.7)	0.56	(0.01 - 1.57)	-*	
Cervix uteri	0	-	-	-	.	1	0.1 (0.0 - 0.4)	0.31	(0.00 - 1.16)	-*	
Non-mel. skin (exc BCC/SCC)	2	0.9 (0.0 - 2.1)	2.19	(0.03 - 6.11)	-*	0	-	0	n/a	-	
Mesothelioma	4	1.5 (0.0 - 3.0)	0.79	(0.12 - 1.73)	-	0	-	0	n/a	-	
Liver & intrahepatic bile duct	4	3.2 (0.0 - 6.8)	1.23	(0.19 - 2.70)	-*	1	0.3 (0.0 - 0.9)	0.57	(0.00 - 2.10)	-*	
Testis	0	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	4	2.9 (0.0 - 6.4)	2.01	(0.31 - 4.41)	-*	1	0.2 (0.0 - 0.5)	0.32	(0.00 - 1.18)	-*	
Larynx	1	0.5 (0.0 - 1.5)	0.68	(0.00 - 2.52)	-*	0	-	-	-	.	
Tongue	1	0.5 (0.0 - 1.5)	1.12	(0.00 - 4.12)	-*	1	0.2 (0.0 - 0.5)	1.95	(0.00 - 7.18)	-*	
Connective & soft tissues	1	0.4 (0.0 - 1.1)	1.59	(0.00 - 5.86)	-*	1	1.8 (0.0 - 5.4)	1.82	(0.00 - 6.71)	-*	
Tonsil & oropharynx	0	-	-	0	n/a	-	-	-	-	.	
Vulva/vagina	0	-	-	-	.	2	0.5 (0.0 - 1.2)	2.03	(0.03 - 5.66)	-*	
Small intestine	2	1.4 (0.0 - 3.7)	2.91	(0.04 - 8.10)	-*	0	-	0	n/a	-	
Eye & lacrimal gland	1	1.9 (0.0 - 5.7)	2.93	(0.00 - 10.81)	-*	0	-	-	-	.	
Major Salivary Gland	1	0.9 (0.0 - 2.6)	2.51	(0.00 - 9.24)	-*	1	0.2 (0.0 - 0.5)	6.50	(0.00 - 23.96)	-*	
Anus	1	1.6 (0.0 - 4.6)	4.18	(0.00 - 15.41)	-*	0	-	0	n/a	-	
Mouth, other & unspecified	3	1.6 (0.0 - 3.6)	7.18	(0.58 - 16.75)	-*	1	0.2 (0.0 - 0.5)	2.09	(0.00 - 7.70)	-*	
Floor of mouth	2	2.4 (0.0 - 5.9)	5.88	(0.07 - 16.38)	-*	0	-	-	-	.	
Bones, joints & articular cart.	1	1.6 (0.0 - 4.6)	2.81	(0.00 - 10.38)	-*	0	-	-	-	.	
Pyriform sinus & hypopharynx	2	2.8 (0.0 - 6.9)	3.04	(0.04 - 8.46)	-*	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	.	2	1.9 (0.0 - 5.0)	3.57	(0.04 - 9.93)	-*	
Adrenal & other endocrine	0	-	-	-	.	0	-	-	-	.	
Nasopharynx	2	2.3 (0.0 - 6.1)	10.21	(0.13 - 28.46)	-*	1	0.6 (0.0 - 1.9)	5.23	(0.00 - 19.29)	-*	
Pharynx, other & ill-def.	0	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	.	0	-	-	-	.	
Thymus	1	0.9 (0.0 - 2.6)	8.06	(0.00 - 29.73)	-*	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	.	0	-	-	-	.	
All cancers	227	193.7 (163.4 - 224.0)	1.29	(1.13 - 1.47)	^	182	91.0 (71.9 - 110.1)	1.02	(0.88 - 1.18)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Victoria Plains (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	3	62.9	(0.0 - 136.3)	4.37	(0.35 - 10.19)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	3	67.7	(0.0 - 144.2)	2.01	(0.16 - 4.69)	-*	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	1	19.2	(0.0 - 56.6)	3.68	(0.00 - 13.58)	-*	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	1	62.5	(0.0 - 181.1)	21.46	(0.00 - 79.17)	-*
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	1	21.7	(0.0 - 63.4)	7.90	(0.00 - 29.16)	-*	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	8	171.6	(52.0 - 291.3)	1.29	(0.45 - 2.33)	-	1	62.5	(0.0 - 181.1)	0.39	(0.00 - 1.43)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Vincent (T) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	20	18.5 (8.6 - 28.3)	1.13	(0.65 - 1.67)	-
Colorectal cancer	19	17.3	(8.7 - 25.8)	1.03	(0.58 - 1.54)	-	15	10.8 (4.2 - 17.5)	0.89	(0.46 - 1.40)	-
Prostate gland	13	9.6	(4.2 - 15.0)	0.77	(0.37 - 1.23)	-	0	-	-	-	.
Melanoma (skin)	4	3.1	(0.0 - 6.4)	1.01	(0.16 - 2.21)	-*	1	0.4 (0.0 - 1.3)	0.40	(0.00 - 1.47)	-*
Lung, bronchus & trachea	45	44.2	(29.9 - 58.5)	1.31	(0.93 - 1.72)	-	13	8.1 (3.1 - 13.2)	0.72	(0.34 - 1.16)	-
Lymphoma	6	4.0	(0.7 - 7.3)	1.14	(0.31 - 2.21)	-	1	1.6 (0.0 - 4.7)	0.18	(0.00 - 0.68)	V
Unknown primary site	5	3.8	(0.4 - 7.2)	0.58	(0.13 - 1.19)	-	6	2.1 (0.2 - 4.1)	0.68	(0.18 - 1.32)	-
Kidney & other renal tract	4	6.6	(0.1 - 13.1)	1.10	(0.17 - 2.42)	-*	2	0.9 (0.0 - 2.1)	0.84	(0.01 - 2.34)	-*
Leukaemia	4	3.9	(0.0 - 8.2)	0.69	(0.11 - 1.52)	-	6	3.6 (0.5 - 6.6)	1.52	(0.41 - 2.95)	-*
Pancreas	3	2.9	(0.0 - 6.3)	0.51	(0.04 - 1.20)	-	8	9.9 (2.1 - 17.7)	1.18	(0.42 - 2.13)	-
Urinary bladder	3	2.6	(0.0 - 5.9)	0.75	(0.06 - 1.75)	-*	1	0.3 (0.0 - 0.9)	0.49	(0.00 - 1.82)	-*
Stomach	8	6.6	(1.6 - 11.6)	1.29	(0.45 - 2.32)	-	6	2.7 (0.4 - 5.0)	1.56	(0.42 - 3.03)	-*
Corpus uteri	0	-	-	-	-	.	3	2.7 (0.0 - 6.4)	1.24	(0.10 - 2.89)	-*
Brain	4	5.8	(0.0 - 11.5)	0.95	(0.15 - 2.07)	-*	5	3.8 (0.0 - 7.9)	1.61	(0.35 - 3.29)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	2	0.6 (0.0 - 1.4)	0.38	(0.00 - 1.06)	-
Other lymphohaematopoietic	0	-	-	0	n/a	-	1	0.3 (0.0 - 0.9)	0.65	(0.00 - 2.39)	-*
Oesophagus	5	5.1	(0.3 - 9.9)	1.34	(0.29 - 2.74)	-*	1	0.3 (0.0 - 0.8)	0.43	(0.00 - 1.58)	-*
Thyroid gland	0	-	-	-	-	.	0	-	0	n/a	-
Myeloma/plasma cell tumours	1	0.6	(0.0 - 1.8)	0.42	(0.00 - 1.56)	-*	3	2.3 (0.0 - 5.7)	1.34	(0.11 - 3.14)	-*
Cervix uteri	0	-	-	-	-	.	0	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	0	n/a	-	1	0.3 (0.0 - 0.8)	2.69	(0.00 - 9.92)	-*
Mesothelioma	4	3.3	(0.0 - 6.9)	0.94	(0.15 - 2.06)	-*	0	-	0	n/a	-
Liver & intrahepatic bile duct	8	8.8	(2.5 - 15.2)	2.82	(0.99 - 5.08)	-*	0	-	0	n/a	-
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	1	0.5	(0.0 - 1.6)	0.63	(0.00 - 2.31)	-*	2	0.6 (0.0 - 1.4)	1.02	(0.01 - 2.84)	-*
Larynx	0	-	-	0	n/a	-	0	-	-	-	.
Tongue	0	-	-	0	n/a	-	1	1.3 (0.0 - 3.9)	2.71	(0.00 - 10.01)	-*
Connective & soft tissues	1	1.4	(0.0 - 4.0)	1.89	(0.00 - 6.95)	-*	0	-	-	-	.
Tonsil & oropharynx	2	2.7	(0.0 - 6.4)	3.04	(0.04 - 8.47)	-*	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	0	n/a	-
Small intestine	2	1.6	(0.0 - 3.9)	3.55	(0.04 - 9.90)	-*	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	1	1.3 (0.0 - 3.9)	2.15	(0.00 - 7.92)	-*
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	0	n/a	-	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	1	1.8	(0.0 - 5.3)	5.50	(0.00 - 20.28)	-*	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	1	0.5	(0.0 - 1.6)	10.47	(0.00 - 38.64)	-*	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	1	0.5	(0.0 - 1.6)	5.86	(0.00 - 21.63)	-*	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	145	137.3	(112.9 - 161.7)	1.01	(0.86 - 1.20)	-	99	72.3 (54.5 - 90.1)	0.84	(0.69 - 1.03)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wagin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	1	4.2 (0.0 - 12.5)	0.72	(0.00 - 2.65)	-*	
Colorectal cancer	0	-	-	0	n/a	-	1	9.9 (0.0 - 29.1)	0.79	(0.00 - 2.92)	-*	
Prostate gland	1	8.8	(0.0 - 25.8)	0.68	(0.00 - 2.51)	-*	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	9	91.5	(20.4 - 162.5)	3.12	(1.20 - 5.47)	^*	2	39.0 (0.0 - 92.9)	1.39	(0.02 - 3.88)	-*	
Lymphoma	1	13.8	(0.0 - 40.7)	2.23	(0.00 - 8.24)	-*	0	-	-	-	.	
Unknown primary site	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Kidney & other renal tract	0	-	-	-	-	.	1	9.9 (0.0 - 29.1)	5.46	(0.00 - 20.13)	-*	
Leukaemia	1	4.7	(0.0 - 13.8)	2.07	(0.00 - 7.63)	-*	1	19.5 (0.0 - 57.7)	3.46	(0.00 - 12.78)	-*	
Pancreas	2	29.7	(0.0 - 79.3)	4.13	(0.05 - 11.51)	-*	2	14.3 (0.0 - 35.5)	3.88	(0.05 - 10.80)	-*	
Urinary bladder	1	4.7	(0.0 - 13.8)	2.98	(0.00 - 10.99)	-*	0	-	-	-	.	
Stomach	0	-	-	0	n/a	-	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	1	4.9 (0.0 - 14.6)	3.97	(0.00 - 14.65)	-*	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	1	19.5 (0.0 - 57.7)	2.45	(0.00 - 9.04)	-*	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	0	-	-	-	-	.	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	1	9.9 (0.0 - 29.1)	5.81	(0.00 - 21.44)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	15	153.1	(60.3 - 245.8)	1.24	(0.63 - 1.94)	-	11	131.1 (44.6 - 217.5)	1.22	(0.53 - 2.04)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wandering (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	83.3 (0.0 - 232.4)	5.68	(0.00 - 20.96)	-*
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.
Lung, bronchus & trachea	1	75.0	(0.0 - 220.2)	2.55	(0.00 - 9.40)	-*	0	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	1	75.0	(0.0 - 220.2)	0.62	(0.00 - 2.28)	-*	1	83.3 (0.0 - 232.4)	1.04	(0.00 - 3.84)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wanneroo (C) - North-East 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	12	17.2 (6.9 - 27.5)	1.15	(0.52 - 1.88)	-
Colorectal cancer	13	20.3 (9.1 - 31.6)	1.22	(0.58 - 1.97)	-	6	7.4 (1.0 - 13.8)	0.74	(0.20 - 1.44)	-	
Prostate gland	10	19.3 (7.2 - 31.4)	1.23	(0.51 - 2.11)	-	0	-	-	-	.	
Melanoma (skin)	3	5.2 (0.0 - 11.2)	1.30	(0.11 - 3.04)	-*	1	2.2 (0.0 - 6.5)	0.74	(0.00 - 2.75)	-*	
Lung, bronchus & trachea	30	51.4 (32.6 - 70.3)	1.53	(0.99 - 2.12)	-	13	19.9 (8.6 - 31.2)	1.39	(0.66 - 2.24)	-	
Lymphoma	3	5.3 (0.0 - 11.3)	0.98	(0.08 - 2.28)	-*	3	3.9 (0.0 - 8.7)	1.09	(0.09 - 2.54)	-*	
Unknown primary site	3	4.5 (0.0 - 9.6)	0.63	(0.05 - 1.47)	-	2	2.5 (0.0 - 6.0)	0.50	(0.01 - 1.40)	-*	
Kidney & other renal tract	2	3.4 (0.0 - 8.3)	0.95	(0.01 - 2.64)	-*	0	-	0	n/a	-	
Leukaemia	6	10.7 (2.0 - 19.4)	1.82	(0.49 - 3.53)	-*	1	0.8 (0.0 - 2.4)	0.51	(0.00 - 1.89)	-*	
Pancreas	2	3.7 (0.0 - 8.8)	0.57	(0.01 - 1.60)	-*	5	6.9 (0.2 - 13.6)	1.57	(0.34 - 3.22)	-*	
Urinary bladder	4	5.9 (0.1 - 11.8)	2.00	(0.31 - 4.39)	-*	0	-	0	n/a	-	
Stomach	2	4.3 (0.0 - 10.2)	0.57	(0.01 - 1.58)	-*	1	1.8 (0.0 - 5.3)	0.57	(0.00 - 2.09)	-*	
Corpus uteri	0	-	-	-	.	3	4.8 (0.0 - 10.3)	2.62	(0.21 - 6.12)	-*	
Brain	3	5.3 (0.0 - 11.3)	1.01	(0.08 - 2.37)	-*	3	3.1 (0.0 - 6.8)	1.58	(0.13 - 3.68)	-*	
Lip	0	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	.	2	3.7 (0.0 - 8.8)	0.71	(0.01 - 1.99)	-*	
Other lymphohaematopoietic	1	2.1 (0.0 - 6.1)	0.99	(0.00 - 3.64)	-*	0	-	0	n/a	-	
Oesophagus	1	1.3 (0.0 - 4.0)	0.46	(0.00 - 1.69)	-*	2	3.8 (0.0 - 9.1)	1.86	(0.02 - 5.18)	-*	
Thyroid gland	1	1.2 (0.0 - 3.5)	7.33	(0.00 - 27.05)	-*	1	2.2 (0.0 - 6.5)	3.57	(0.00 - 13.16)	-*	
Myeloma/plasma cell tumours	0	-	-	0	n/a	-	-	-	-	.	
Cervix uteri	0	-	-	-	.	4	4.8 (0.0 - 9.6)	3.09	(0.48 - 6.77)	-*	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	.	0	-	-	-	.	
Mesothelioma	1	1.4 (0.0 - 4.3)	0.39	(0.00 - 1.45)	-*	0	-	-	-	.	
Liver & intrahepatic bile duct	2	3.7 (0.0 - 8.8)	1.14	(0.01 - 3.17)	-*	0	-	0	n/a	-	
Testis	0	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	4	5.3 (0.1 - 10.6)	4.33	(0.67 - 9.48)	-*	0	-	0	n/a	-	
Larynx	0	-	-	0	n/a	-	-	-	-	.	
Tongue	1	2.2 (0.0 - 6.6)	2.09	(0.00 - 7.71)	-*	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	.	1	2.2 (0.0 - 6.5)	4.57	(0.00 - 16.85)	-*	
Eye & lacrimal gland	0	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	1	1.4 (0.0 - 4.0)	2.67	(0.00 - 9.86)	-*	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	.	0	-	-	-	.	
All cancers	93	158.0 (125.3 - 190.6)	1.15	(0.93 - 1.41)	-	63	91.1 (67.2 - 115.0)	1.05	(0.81 - 1.35)	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wanneroo (C) - North-West 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	16	22.1 (11.1 - 33.2)	1.52	(0.80 - 2.35)	-
Colorectal cancer	12	17.3	(7.3 - 27.4)	0.98	(0.45 - 1.61)	-	6	8.2 (1.5 - 15.0)	0.77	(0.21 - 1.49)	-
Prostate gland	9	12.8	(4.0 - 21.5)	0.98	(0.38 - 1.72)	-	0	-	-	-	.
Melanoma (skin)	3	4.0	(0.0 - 8.7)	1.14	(0.09 - 2.67)	-*	1	1.7 (0.0 - 4.9)	0.72	(0.00 - 2.65)	-*
Lung, bronchus & trachea	14	21.7	(10.0 - 33.5)	0.60	(0.30 - 0.95)	V	14	18.0 (8.2 - 27.7)	1.45	(0.72 - 2.30)	-
Lymphoma	3	5.0	(0.0 - 10.6)	0.85	(0.07 - 1.98)	-*	1	1.3 (0.0 - 4.0)	0.35	(0.00 - 1.30)	-*
Unknown primary site	3	4.2	(0.0 - 9.0)	0.55	(0.04 - 1.27)	-	2	2.7 (0.0 - 6.6)	0.55	(0.01 - 1.52)	-*
Kidney & other renal tract	3	2.9	(0.0 - 6.3)	1.25	(0.10 - 2.91)	-*	0	-	0	n/a	-
Leukaemia	3	3.5	(0.0 - 7.5)	0.78	(0.06 - 1.83)	-*	3	5.8 (0.0 - 12.5)	1.52	(0.12 - 3.56)	-*
Pancreas	7	10.9	(2.4 - 19.3)	1.73	(0.54 - 3.23)	-*	2	2.9 (0.0 - 7.0)	0.64	(0.01 - 1.79)	-*
Urinary bladder	0	-	-	0	n/a	-	1	1.1 (0.0 - 3.2)	1.31	(0.00 - 4.84)	-*
Stomach	1	1.7	(0.0 - 5.1)	0.25	(0.00 - 0.91)	V*	1	1.8 (0.0 - 5.3)	0.59	(0.00 - 2.16)	-*
Corpus uteri	0	-	-	-	-	.	1	1.7 (0.0 - 4.9)	0.87	(0.00 - 3.21)	-*
Brain	3	4.5	(0.0 - 9.6)	0.91	(0.07 - 2.12)	-*	0	-	0	n/a	-
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	3	5.1 (0.0 - 10.9)	1.06	(0.09 - 2.47)	-*
Other lymphohaematopoietic	3	3.5	(0.0 - 7.5)	2.63	(0.21 - 6.15)	-*	0	-	0	n/a	-
Oesophagus	4	5.5	(0.1 - 10.9)	1.59	(0.25 - 3.49)	-*	1	1.3 (0.0 - 4.0)	0.97	(0.00 - 3.57)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	2	3.8	(0.0 - 9.3)	1.39	(0.02 - 3.88)	-*	1	1.1 (0.0 - 3.2)	1.00	(0.00 - 3.67)	-*
Cervix uteri	0	-	-	-	-	.	0	-	0	n/a	-
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	4	6.0	(0.0 - 12.0)	1.36	(0.21 - 2.97)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	4	6.6	(0.1 - 13.2)	1.95	(0.30 - 4.27)	-*	1	1.1 (0.0 - 3.2)	1.59	(0.00 - 5.88)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	1	1.2	(0.0 - 3.6)	0.97	(0.00 - 3.56)	-*	0	-	0	n/a	-
Larynx	1	1.3	(0.0 - 3.8)	1.15	(0.00 - 4.24)	-*	0	-	-	-	.
Tongue	0	-	-	0	n/a	-	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	1	1.6 (0.0 - 4.9)	3.89	(0.00 - 14.36)	-*
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	2	2.8	(0.0 - 6.9)	4.51	(0.06 - 12.57)	-*	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	1	1.0 (0.0 - 3.0)	4.44	(0.00 - 16.39)	-*
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	82	119.2	(92.6 - 145.8)	0.88	(0.70 - 1.09)	-	56	78.5 (57.4 - 99.6)	0.94	(0.71 - 1.22)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wanneroo (C) - South 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	13	13.7 (6.0 - 21.3)	0.84	(0.40 - 1.35)	-
Colorectal cancer	14	17.9	(8.4 - 27.4)	0.96	(0.47 - 1.52)	-	6	5.9 (1.1 - 10.7)	0.53	(0.14 - 1.03)	-
Prostate gland	7	8.1	(2.1 - 14.2)	0.70	(0.22 - 1.31)	-	0	-	-	-	.
Melanoma (skin)	2	2.0	(0.0 - 4.7)	0.61	(0.01 - 1.70)	-*	1	1.0 (0.0 - 3.0)	0.50	(0.00 - 1.83)	-*
Lung, bronchus & trachea	32	39.2	(25.5 - 52.8)	1.18	(0.78 - 1.63)	-	13	13.6 (6.1 - 21.1)	0.98	(0.47 - 1.58)	-
Lymphoma	5	5.3	(0.6 - 10.0)	1.16	(0.25 - 2.38)	-*	6	6.3 (1.1 - 11.4)	1.53	(0.41 - 2.97)	-*
Unknown primary site	8	9.7	(2.9 - 16.4)	1.24	(0.44 - 2.24)	-	3	2.7 (0.0 - 5.8)	0.55	(0.04 - 1.28)	-
Kidney & other renal tract	0	-	-	0	n/a	-	1	1.4 (0.0 - 4.1)	0.63	(0.00 - 2.33)	-*
Leukaemia	4	4.9	(0.1 - 9.8)	0.86	(0.13 - 1.89)	-	4	4.5 (0.0 - 9.1)	1.38	(0.21 - 3.04)	-*
Pancreas	7	8.4	(2.0 - 14.8)	1.42	(0.45 - 2.65)	-	1	1.1 (0.0 - 3.3)	0.23	(0.00 - 0.85)	v*
Urinary bladder	3	3.7	(0.0 - 7.9)	1.16	(0.09 - 2.72)	-*	1	0.7 (0.0 - 2.1)	0.89	(0.00 - 3.30)	-*
Stomach	2	1.8	(0.0 - 4.3)	0.41	(0.01 - 1.15)	-	2	1.8 (0.0 - 4.4)	0.81	(0.01 - 2.25)	-*
Corpus uteri	0	-	-	-	-	.	1	1.3 (0.0 - 3.9)	0.63	(0.00 - 2.31)	-*
Brain	5	5.2	(0.6 - 9.9)	1.11	(0.24 - 2.27)	-	2	2.4 (0.0 - 5.8)	0.69	(0.01 - 1.92)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	6	6.3 (1.1 - 11.4)	1.49	(0.40 - 2.91)	-*
Other lymphohaematopoietic	3	4.6	(0.0 - 9.9)	2.35	(0.19 - 5.48)	-*	0	-	0	n/a	-
Oesophagus	4	5.1	(0.1 - 10.1)	1.33	(0.21 - 2.92)	-*	2	1.6 (0.0 - 3.9)	1.35	(0.02 - 3.76)	-*
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	1	1.4	(0.0 - 4.2)	0.60	(0.00 - 2.19)	-*	2	2.3 (0.0 - 5.5)	1.39	(0.02 - 3.87)	-*
Cervix uteri	0	-	-	-	-	.	2	1.9 (0.0 - 4.6)	0.98	(0.01 - 2.74)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	3	3.2	(0.0 - 7.0)	0.85	(0.07 - 1.98)	-*	0	-	-	-	.
Liver & intrahepatic bile duct	5	6.7	(0.8 - 12.5)	2.00	(0.44 - 4.11)	-*	4	3.9 (0.0 - 7.8)	4.51	(0.70 - 9.88)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	2	1.8	(0.0 - 4.4)	1.61	(0.02 - 4.49)	-*	0	-	0	n/a	-
Larynx	2	1.8	(0.0 - 4.4)	1.90	(0.02 - 5.30)	-*	0	-	-	-	.
Tongue	0	-	-	0	n/a	-	0	-	-	-	.
Connective & soft tissues	0	-	-	0	n/a	-	0	-	-	-	.
Tonsil & oropharynx	0	-	-	0	n/a	-	1	0.7 (0.0 - 2.1)	13.37	(0.00 - 49.34)	-*
Vulva/vagina	0	-	-	-	-	.	1	0.8 (0.0 - 2.3)	3.44	(0.00 - 12.70)	-*
Small intestine	0	-	-	-	-	.	2	2.2 (0.0 - 5.3)	6.30	(0.08 - 17.56)	-*
Eye & lacrimal gland	1	1.0	(0.0 - 3.1)	3.55	(0.00 - 13.08)	-*	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	1	1.1	(0.0 - 3.1)	3.02	(0.00 - 11.14)	-*	1	0.9 (0.0 - 2.5)	4.09	(0.00 - 15.09)	-*
Floor of mouth	1	1.0	(0.0 - 3.1)	3.04	(0.00 - 11.21)	-*	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	2	2.2	(0.0 - 5.4)	3.77	(0.05 - 10.50)	-*	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	1	0.9	(0.0 - 2.8)	4.57	(0.00 - 16.86)	-*	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	115	137.2	(111.9 - 162.5)	1.03	(0.86 - 1.25)	-	77	79.4 (61.3 - 97.6)	0.90	(0.71 - 1.13)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Waroona (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	16.8 (0.0 - 40.4)	0.95	(0.01 - 2.65)	-*
Colorectal cancer	4	27.1 (0.1 - 54.2)	1.57	(0.24 - 3.45)	-*		5	34.2 (2.8 - 65.6)	2.86	(0.62 - 5.87)	-*
Prostate gland	3	18.8 (0.0 - 39.9)	1.49	(0.12 - 3.48)	-*		0	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	.
Lung, bronchus & trachea	1	6.0 (0.0 - 17.7)	0.21	(0.00 - 0.77)	V		0	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	2	16.9 (0.0 - 40.6)	3.41	(0.04 - 9.50)	-*
Unknown primary site	1	6.0 (0.0 - 17.8)	0.87	(0.00 - 3.21)	-*		2	18.0 (0.0 - 43.4)	2.31	(0.03 - 6.42)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	1	10.7 (0.0 - 31.7)	2.47	(0.00 - 9.12)	-*
Pancreas	1	6.0 (0.0 - 17.8)	1.20	(0.00 - 4.43)	-*		0	-	0	n/a	-
Urinary bladder	0	-	-	0	n/a	-	0	-	-	-	.
Stomach	1	9.2 (0.0 - 27.1)	1.18	(0.00 - 4.34)	-*		0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	1	11.3 (0.0 - 33.4)	1.59	(0.00 - 5.88)	-*		1	9.6 (0.0 - 28.5)	2.64	(0.00 - 9.75)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	0	n/a	-
Other lymphohaematopoietic	0	-	-	-	-	.	1	3.4 (0.0 - 10.1)	7.07	(0.00 - 26.09)	-*
Oesophagus	1	6.4 (0.0 - 18.9)	1.91	(0.00 - 7.04)	-*		0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	7.3 (0.0 - 21.5)	17.06	(0.00 - 62.95)	-*
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.
Liver & intrahepatic bile duct	1	16.4 (0.0 - 48.6)	2.40	(0.00 - 8.84)	-*		0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	1	10.7 (0.0 - 31.7)	27.36	(0.00 - 100.92)	-*
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	14	107.2 (47.5 - 167.0)	0.72 (0.36 - 1.15)	-	-	-	16	127.8 (62.9 - 192.6)	1.26 (0.66 - 1.95)	-	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: West Arthur (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	.	
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	0	n/a	-	
Lymphoma	0	-	-	-	-	.	0	-	-	-	.	
Unknown primary site	1	20.4	(0.0 - 60.0)	2.98	(0.00 - 11.01)	-*	0	-	-	-	.	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.	
Leukaemia	0	-	-	-	-	.	0	-	-	-	.	
Pancreas	0	-	-	-	-	.	0	-	-	-	.	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.	
Stomach	0	-	-	-	-	.	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	0	-	-	-	-	.	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	1	20.4	(0.0 - 60.0)	0.18	(0.00 - 0.65)	V	0	-	0	n/a	-	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Westonia (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	1	102.0	(0.0 - 300.0)	11.44	(0.00 - 42.21)	-*	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	102.0	(0.0 - 300.0)	0.68	(0.00 - 2.50)	-*	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wickepin (S) 1998-2002: Cancer mortality(1)

Cancer type	Males					Females						
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	1	17.9	(0.0 - 52.2)	1.97	(0.00 - 7.27)	-*	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	1	41.7	(0.0 - 122.9)	5.96	(0.00 - 21.98)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	1	55.6	(0.0 - 163.4)	8.18	(0.00 - 30.19)	-*	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	1	26.3	(0.0 - 77.2)	7.18	(0.00 - 26.48)	-*	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	3	99.7	(0.0 - 223.9)	0.66	(0.05 - 1.54)	-	2	80.9	(0.0 - 192.5)	0.78	(0.01 - 2.18)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Williams (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	47.6	(0.0 - 139.8)	1.95	(0.00 - 7.18)	-*
Colorectal cancer	0	-	-	0	n/a	-	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	2	85.0	(0.0 - 202.6)	10.17	(0.13 - 28.35)	-*
Kidney & other renal tract	0	-	-	-	-	.	1	34.8	(0.0 - 102.7)	18.16	(0.00 - 66.97)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriiform sinus & hypopharynx	1	34.5	(0.0 - 101.7)	47.61	(0.00 - 175.62)	-*	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	34.5	(0.0 - 101.7)	0.22	(0.00 - 0.81)	V	4	167.4	(4.6 - 330.2)	1.39	(0.21 - 3.04)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wiluna (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	0	n/a	-	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	1	133.3 (0.0 - 385.8)	17.40 (0.00 - 64.18)		-*	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	1	62.5 (0.0 - 184.4)	192.63 (0.00 - 710.62)		-*	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	1	24.0 (0.0 - 70.9)		469.44 (0.00 - 1,731.78)		-*	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	24.0 (0.0 - 70.9)		0.40 (0.00 - 1.47)		-*	2	195.8 (0.0 - 476.2)	2.16 (0.03 - 6.03)		-*	

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wongan-Ballidu (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	1	19.6	(0.0 - 57.9)	1.24	(0.00 - 4.56)	-*	0	-	0	n/a	-	
Prostate gland	0	-	-	0	n/a	-	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	4	101.5	(1.3 - 201.6)	2.64	(0.41 - 5.79)	-*	2	30.2	(0.0 - 74.5)	2.77	(0.03 - 7.72)	-*
Lymphoma	1	35.7	(0.0 - 103.2)	4.23	(0.00 - 15.62)	-*	0	-	-	-	.	
Unknown primary site	1	16.9	(0.0 - 49.9)	2.78	(0.00 - 10.25)	-*	0	-	-	-	.	
Kidney & other renal tract	0	-	-	-	-	.	1	33.0	(0.0 - 97.2)	11.31	(0.00 - 41.71)	-*
Leukaemia	0	-	-	-	-	.	0	-	-	-	.	
Pancreas	0	-	-	-	-	.	0	-	-	-	.	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.	
Stomach	1	19.6	(0.0 - 57.9)	3.72	(0.00 - 13.71)	-*	0	-	-	-	.	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	1	9.7	(0.0 - 28.6)	6.99	(0.00 - 25.78)	-*
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	2	37.4	(0.0 - 94.6)	9.39	(0.12 - 26.15)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	0	-	-	-	-	.	0	-	-	-	.	
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.	
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	1	11.9	(0.0 - 35.0)	9.99	(0.00 - 36.87)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	0	-	-	-	.	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	8	193.3	(57.2 - 329.5)	1.30	(0.46 - 2.34)	-	7	122.2	(20.9 - 223.4)	1.51	(0.47 - 2.81)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Woodanilling (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	0	-	-	0	n/a	-	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wyalkatchem (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	54.1 (0.0 - 158.6)	2.30	(0.00 - 8.48)	-*
Colorectal cancer	1	32.6	(0.0 - 96.2)	1.76	(0.00 - 6.50)	-*	1	12.5 (0.0 - 36.7)	2.79	(0.00 - 10.30)	-*
Prostate gland	1	22.7	(0.0 - 66.8)	2.28	(0.00 - 8.42)	-*	0	-	-	-	.
Melanoma (skin)	1	22.7	(0.0 - 66.8)	8.68	(0.00 - 32.01)	-*	0	-	-	-	.
Lung, bronchus & trachea	2	69.5	(0.0 - 166.7)	1.86	(0.02 - 5.18)	-*	0	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	-	-	.	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	38.8 (0.0 - 114.6)	8.27	(0.00 - 30.49)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	5	147.6	(16.1 - 279.0)	1.17	(0.25 - 2.39)	-*	3	105.4 (0.0 - 236.7)	1.17	(0.09 - 2.74)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Wyndham-East Kimberley (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	1	4.0 (0.0 - 11.9)	0.52	(0.00 - 1.93)	-*
Colorectal cancer	0	-	-	0	n/a	-	1	13.7 (0.0 - 40.5)	0.85	(0.00 - 3.12)	-*
Prostate gland	3	20.5	(0.0 - 45.0)	2.01	(0.16 - 4.69)	-*	0	-	-	-	.
Melanoma (skin)	0	-	-	0	n/a	-	0	-	-	-	.
Lung, bronchus & trachea	5	34.3	(3.0 - 65.6)	1.23	(0.27 - 2.52)	-*	0	-	0	n/a	-
Lymphoma	0	-	-	0	n/a	-	0	-	-	-	.
Unknown primary site	2	16.6	(0.0 - 43.1)	1.98	(0.02 - 5.50)	-*	1	6.3 (0.0 - 18.7)	1.76	(0.00 - 6.48)	-*
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.
Leukaemia	0	-	-	0	n/a	-	2	14.8 (0.0 - 35.3)	5.67	(0.07 - 15.80)	-*
Pancreas	0	-	-	0	n/a	-	0	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.
Stomach	0	-	-	0	n/a	-	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	0	-	-	0	n/a	-	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	14.8 (0.0 - 43.6)	2.27	(0.00 - 8.36)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	1	7.9 (0.0 - 23.3)	10.16	(0.00 - 37.48)	-*
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	1	5.2	(0.0 - 15.3)	4.96	(0.00 - 18.31)	-*	0	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	2	11.3	(0.0 - 27.9)	18.24	(0.23 - 50.81)	-*	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	1	6.6 (0.0 - 19.6)	31.49	(0.00 - 116.17)	-*
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	13	87.9	(36.4 - 139.4)	0.74	(0.35 - 1.19)	-	8	68.1 (17.1 - 119.0)	0.84	(0.30 - 1.52)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Yalgoo (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	-	-	-	.
Colorectal cancer	0	-	-	-	-	.	0	-	-	-	-	.
Prostate gland	0	-	-	-	-	.	0	-	-	-	-	.
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	-	.
Lung, bronchus & trachea	0	-	-	-	-	.	0	-	-	-	-	.
Lymphoma	0	-	-	-	-	.	0	-	-	-	-	.
Unknown primary site	0	-	-	-	-	.	0	-	-	-	-	.
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	-	.
Leukaemia	0	-	-	-	-	.	0	-	-	-	-	.
Pancreas	0	-	-	-	-	.	0	-	-	-	-	.
Urinary bladder	0	-	-	-	-	.	0	-	-	-	-	.
Stomach	0	-	-	-	-	.	0	-	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	-	.
Brain	1	62.5	(0.0 - 184.2)	17.26	(0.00 - 63.68)	-*	0	-	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	-	.
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	-	.
Oesophagus	0	-	-	-	-	.	0	-	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	-	.
Cervix uteri	0	-	-	-	-	.	0	-	-	-	-	.
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	-	.
Mesothelioma	0	-	-	-	-	.	0	-	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	-	.
Larynx	0	-	-	-	-	.	0	-	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	-	.
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	-	.
All cancers	1	62.5	(0.0 - 184.2)	0.77	(0.00 - 2.83)	-*	0	-	-	0	n/a	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Yilgarn (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)	
Breast	0	-	-	-	-	.	0	-	0	n/a	-	
Colorectal cancer	1	18.9	(0.0 - 55.7)	1.10	(0.00 - 4.05)	-*	0	-	0	n/a	-	
Prostate gland	1	16.7	(0.0 - 49.1)	1.65	(0.00 - 6.08)	-*	0	-	-	-	.	
Melanoma (skin)	0	-	-	-	-	.	0	-	-	-	.	
Lung, bronchus & trachea	3	52.2	(0.0 - 111.2)	1.79	(0.14 - 4.17)	-*	0	-	0	n/a	-	
Lymphoma	0	-	-	-	-	.	0	-	-	-	.	
Unknown primary site	0	-	-	-	-	.	0	-	-	-	.	
Kidney & other renal tract	0	-	-	-	-	.	0	-	-	-	.	
Leukaemia	0	-	-	-	-	.	0	-	-	-	.	
Pancreas	1	16.2	(0.0 - 47.8)	3.31	(0.00 - 12.23)	-*	0	-	-	-	.	
Urinary bladder	0	-	-	-	-	.	0	-	-	-	.	
Stomach	1	25.0	(0.0 - 73.7)	3.35	(0.00 - 12.37)	-*	1	20.4	(0.0 - 60.3)	7.97	(0.00 - 29.38) -*	
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.	
Brain	0	-	-	-	-	.	0	-	-	-	.	
Lip	0	-	-	-	-	.	0	-	-	-	.	
Ovary & uterine adnexa	0	-	-	-	-	.	0	-	-	-	.	
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.	
Oesophagus	1	16.2	(0.0 - 47.8)	5.45	(0.00 - 20.10)	-*	0	-	-	-	.	
Thyroid gland	1	25.0	(0.0 - 73.7)	76.83	(0.00 - 283.44)	-*	0	-	-	-	.	
Myeloma/plasma cell tumours	1	25.0	(0.0 - 73.7)	9.89	(0.00 - 36.47)	-*	0	-	-	-	.	
Cervix uteri	0	-	-	-	-	.	0	-	-	-	.	
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.	
Mesothelioma	0	-	-	-	-	.	0	-	-	-	.	
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.	
Testis	0	-	-	-	-	.	0	-	-	-	.	
Gallbladder & bile ducts	0	-	-	-	-	.	0	-	-	-	.	
Larynx	0	-	-	-	-	.	0	-	-	-	.	
Tongue	0	-	-	-	-	.	0	-	-	-	.	
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.	
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.	
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.	
Small intestine	0	-	-	-	-	.	0	-	-	-	.	
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.	
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.	
Anus	0	-	-	-	-	.	0	-	-	-	.	
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.	
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.	
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.	
Pyriform sinus & hypopharynx	0	-	-	-	-	.	0	-	-	-	.	
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.	
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.	
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.	
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.	
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.	
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.	
Gum	0	-	-	-	-	.	1	23.8	(0.0 - 70.2)	213.58	(0.00 - 787.89) -*	
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.	
Thymus	0	-	-	-	-	.	0	-	-	-	.	
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.	
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.	
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.	
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.	
Placenta	0	-	-	-	-	.	0	-	-	-	.	
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.	
All cancers	10	195.1	(73.6 - 316.7)	1.46	(0.60 - 2.49)	-	2	44.2	(0.0 - 105.4)	0.48	(0.01 - 1.33)	-*

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "V" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: York (S) 1998-2002: Cancer mortality(1)

Cancer type	Males						Females				
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	SRR	95% c.i.	Sig(2)
Breast	0	-	-	-	-	.	2	10.1 (0.0 - 25.2)	0.88	(0.01 - 2.46)	-*
Colorectal cancer	4	23.1	(0.0 - 46.8)	1.47	(0.23 - 3.22)	-*	1	8.4 (0.0 - 24.8)	0.53	(0.00 - 1.95)	-*
Prostate gland	5	30.8	(3.6 - 58.0)	2.16	(0.47 - 4.43)	-*	0	-	-	-	.
Melanoma (skin)	1	8.8	(0.0 - 25.9)	1.82	(0.00 - 6.70)	-*	2	13.8 (0.0 - 33.3)	6.81	(0.09 - 18.97)	-*
Lung, bronchus & trachea	5	39.8	(4.9 - 74.8)	0.98	(0.21 - 2.02)	-	2	6.3 (0.0 - 15.0)	0.93	(0.01 - 2.59)	-*
Lymphoma	1	8.1	(0.0 - 23.9)	1.33	(0.00 - 4.89)	-*	0	-	0	n/a	-
Unknown primary site	0	-	-	0	n/a	-	0	-	0	n/a	-
Kidney & other renal tract	0	-	-	0	n/a	-	0	-	-	-	.
Leukaemia	1	9.2	(0.0 - 27.3)	1.23	(0.00 - 4.54)	-*	2	13.6 (0.0 - 34.7)	4.73	(0.06 - 13.19)	-*
Pancreas	0	-	-	0	n/a	-	0	-	0	n/a	-
Urinary bladder	0	-	-	0	n/a	-	1	8.4 (0.0 - 24.8)	4.89	(0.00 - 18.05)	-*
Stomach	1	10.2	(0.0 - 30.3)	1.10	(0.00 - 4.07)	-*	0	-	-	-	.
Corpus uteri	0	-	-	-	-	.	0	-	-	-	.
Brain	1	8.1	(0.0 - 23.9)	1.56	(0.00 - 5.75)	-*	0	-	-	-	.
Lip	0	-	-	-	-	.	0	-	-	-	.
Ovary & uterine adnexa	0	-	-	-	-	.	1	2.9 (0.0 - 8.7)	1.57	(0.00 - 5.78)	-*
Other lymphohaematopoietic	0	-	-	-	-	.	0	-	-	-	.
Oesophagus	0	-	-	0	n/a	-	0	-	-	-	.
Thyroid gland	0	-	-	-	-	.	0	-	-	-	.
Myeloma/plasma cell tumours	0	-	-	-	-	.	0	-	-	-	.
Cervix uteri	0	-	-	-	-	.	1	8.4 (0.0 - 24.8)	3.65	(0.00 - 13.46)	-*
Non-mel. skin (exc BCC/SCC)	0	-	-	-	-	.	0	-	-	-	.
Mesothelioma	0	-	-	0	n/a	-	0	-	-	-	.
Liver & intrahepatic bile duct	0	-	-	-	-	.	0	-	-	-	.
Testis	0	-	-	-	-	.	0	-	-	-	.
Gallbladder & bile ducts	0	-	-	-	-	.	1	2.9 (0.0 - 8.7)	4.67	(0.00 - 17.22)	-*
Larynx	0	-	-	-	-	.	0	-	-	-	.
Tongue	0	-	-	-	-	.	0	-	-	-	.
Connective & soft tissues	0	-	-	-	-	.	0	-	-	-	.
Tonsil & oropharynx	0	-	-	-	-	.	0	-	-	-	.
Vulva/vagina	0	-	-	-	-	.	0	-	-	-	.
Small intestine	0	-	-	-	-	.	0	-	-	-	.
Eye & lacrimal gland	0	-	-	-	-	.	0	-	-	-	.
Major Salivary Gland	0	-	-	-	-	.	0	-	-	-	.
Anus	0	-	-	-	-	.	0	-	-	-	.
Mouth, other & unspecified	0	-	-	-	-	.	0	-	-	-	.
Floor of mouth	0	-	-	-	-	.	0	-	-	-	.
Bones, joints & articular cart.	0	-	-	-	-	.	0	-	-	-	.
Pyriform sinus & hypopharynx	1	8.8	(0.0 - 25.9)	11.05	(0.00 - 40.76)	-*	0	-	-	-	.
Nasal cavity, sinuses, int. ear	0	-	-	-	-	.	0	-	-	-	.
Peritoneum & retroperitoneum	0	-	-	-	-	.	0	-	-	-	.
Adrenal & other endocrine	0	-	-	-	-	.	0	-	-	-	.
Nasopharynx	0	-	-	-	-	.	0	-	-	-	.
Pharynx, other & ill-def.	0	-	-	-	-	.	0	-	-	-	.
Penis & other male genital	0	-	-	-	-	.	0	-	-	-	.
Gum	0	-	-	-	-	.	0	-	-	-	.
Kaposi sarcoma	0	-	-	-	-	.	0	-	-	-	.
Thymus	0	-	-	-	-	.	0	-	-	-	.
Pleura, heart & mediastinum	0	-	-	-	-	.	0	-	-	-	.
Spinal cord & cranial nerves	0	-	-	-	-	.	0	-	-	-	.
Uterus, nos	0	-	-	-	-	.	0	-	-	-	.
Nervous, periph./autonomic	0	-	-	-	-	.	0	-	-	-	.
Placenta	0	-	-	-	-	.	0	-	-	-	.
Meninges (cerebral & spinal)	0	-	-	-	-	.	0	-	-	-	.
All cancers	20	146.9	(81.1 - 212.6)	0.96	(0.55 - 1.43)	-	14	77.8 (32.7 - 122.8)	1.02	(0.51 - 1.63)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"A" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

SLA: Total State 1998-2002: Cancer mortality(1)

Cancer type	Males			Females		
	Cases	ASR	95% c.i.	Cases	ASR	
Breast	4	0.1	(0.0 - 0.1)	1115	15.9	(14.9 - 16.8)
Colorectal cancer	1159	18.0	(16.9 - 19.1)	929	11.5	(10.6 - 12.3)
Prostate gland	945	13.0	(12.2 - 13.9)	0	-	-
Melanoma (skin)	246	3.8	(3.3 - 4.3)	147	2.0	(1.7 - 2.4)
Lung, bronchus & trachea	2166	33.6	(32.1 - 35.0)	1058	13.9	(13.0 - 14.8)
Lymphoma	332	5.1	(4.5 - 5.6)	312	4.1	(3.6 - 4.6)
Unknown primary site	527	8.0	(7.3 - 8.7)	465	5.2	(4.7 - 5.8)
Kidney & other renal tract	229	3.6	(3.1 - 4.1)	133	1.7	(1.3 - 2.0)
Leukaemia	359	5.7	(5.1 - 6.3)	219	2.9	(2.5 - 3.3)
Pancreas	376	5.9	(5.3 - 6.6)	370	4.5	(4.0 - 5.0)
Urinary bladder	230	3.3	(2.9 - 3.8)	102	1.1	(0.8 - 1.3)
Stomach	386	6.0	(5.3 - 6.6)	206	2.5	(2.1 - 2.8)
Corpus uteri	0	-	-	133	1.7	(1.3 - 2.0)
Brain	297	5.1	(4.5 - 5.7)	202	3.1	(2.6 - 3.5)
Lip	5	0.1	(0.0 - 0.1)	4	0.0	(0.0 - 0.1)
Ovary & uterine adnexa	0	-	-	311	4.2	(3.7 - 4.7)
Other lymphohaematopoietic	117	1.7	(1.4 - 2.0)	76	0.8	(0.6 - 1.0)
Oesophagus	238	3.7	(3.2 - 4.2)	126	1.5	(1.2 - 1.8)
Thyroid gland	15	0.2	(0.1 - 0.3)	32	0.4	(0.2 - 0.5)
Myeloma/plasma cell tumours	142	2.1	(1.8 - 2.5)	122	1.4	(1.2 - 1.7)
Cervix uteri	0	-	-	140	2.0	(1.7 - 2.4)
Non-mel. skin (exc BCC/SCC)	39	0.6	(0.4 - 0.8)	19	0.2	(0.1 - 0.3)
Mesothelioma	275	4.4	(3.8 - 4.9)	36	0.5	(0.3 - 0.7)
Liver & intrahepatic bile duct	188	3.0	(2.6 - 3.5)	69	0.9	(0.7 - 1.2)
Testis	8	0.2	(0.0 - 0.3)	0	-	-
Gallbladder & bile ducts	100	1.5	(1.2 - 1.8)	107	1.2	(1.0 - 1.5)
Larynx	81	1.3	(1.0 - 1.6)	11	0.2	(0.1 - 0.3)
Tongue	50	0.8	(0.6 - 1.1)	23	0.3	(0.2 - 0.4)
Connective & soft tissues	34	0.6	(0.4 - 0.8)	25	0.4	(0.2 - 0.6)
Tonsil & oropharynx	45	0.7	(0.5 - 0.9)	6	0.1	(0.0 - 0.1)
Vulva/vagina	0	-	-	28	0.3	(0.2 - 0.4)
Small intestine	35	0.6	(0.4 - 0.7)	24	0.3	(0.2 - 0.5)
Eye & lacrimal gland	19	0.3	(0.2 - 0.5)	14	0.2	(0.1 - 0.3)
Major Salivary Gland	19	0.3	(0.2 - 0.4)	4	0.0	(0.0 - 0.1)
Anus	14	0.2	(0.1 - 0.4)	27	0.3	(0.2 - 0.5)
Mouth, other & unspecified	24	0.4	(0.2 - 0.6)	19	0.3	(0.1 - 0.4)
Floor of mouth	23	0.4	(0.2 - 0.6)	10	0.1	(0.0 - 0.2)
Bones, joints & articular cart.	19	0.3	(0.2 - 0.5)	13	0.3	(0.1 - 0.4)
Pyriform sinus & hypopharynx	40	0.7	(0.4 - 0.9)	5	0.1	(0.0 - 0.2)
Nasal cavity, sinuses, int. ear	14	0.2	(0.1 - 0.3)	6	0.1	(0.0 - 0.1)
Peritoneum & retroperitoneum	16	0.2	(0.1 - 0.4)	23	0.3	(0.2 - 0.4)
Adrenal & other endocrine	9	0.2	(0.1 - 0.3)	9	0.2	(0.1 - 0.3)
Nasopharynx	14	0.2	(0.1 - 0.4)	7	0.1	(0.0 - 0.2)
Pharynx, other & ill-def.	20	0.3	(0.2 - 0.4)	4	0.1	(0.0 - 0.1)
Penis & other male genital	6	0.1	(0.0 - 0.2)	0	-	-
Gum	4	0.1	(0.0 - 0.1)	8	0.1	(0.0 - 0.1)
Kaposi sarcoma	1	0.0	(0.0 - 0.0)	1	0.0	(0.0 - 0.0)
Thymus	9	0.2	(0.1 - 0.3)	7	0.1	(0.0 - 0.2)
Pleura, heart & mediastinum	10	0.2	(0.1 - 0.3)	3	0.0	(0.0 - 0.1)
Spinal cord & cranial nerves	2	0.0	(0.0 - 0.1)	4	0.1	(0.0 - 0.1)
Uterus, nos	0	-	-	2	0.0	(0.0 - 0.0)
Nervous, periph./autonomic	0	-	-	0	-	-
Placenta	0	-	-	0	-	-
Meninges (cerebral & spinal)	1	0.0	(0.0 - 0.0)	4	0.0	(0.0 - 0.1)
All cancers	8892	137.0	(134.1 - 139.9)	6757	87.4	(85.1 - 89.6)

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; SRRs not shown, as all are 1.00 by definition.

W.A. Cancer by SLA (alphabetic)
Cancer type: Breast 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	0	-	-	-	-	.	56	81.4	(57.9 - 105.0)	0.98	(0.74 - 1.28)	-
Albany (C) Bal	1	2.0	(0.0 - 6.0)	3.70	(0.00 - 13.64)	-*	39	87.2	(59.3 - 115.1)	1.02	(0.71 - 1.37)	-
Armadale (C)	0	-	-	0	n/a	-	149	90.1	(75.4 - 104.8)	1.07	(0.91 - 1.26)	-
Ashburton (S)	0	-	-	-	-	.	3	25.3	(0.0 - 57.7)	0.39	(0.03 - 0.92)	V
Augusta-Margaret River (S)	0	-	-	-	-	.	26	85.2	(51.1 - 119.3)	1.03	(0.64 - 1.46)	-
Bassendean (T)	0	-	-	-	-	.	30	60.3	(38.1 - 82.5)	0.69	(0.45 - 0.95)	V
Bayswater (C)	3	1.5	(0.0 - 3.2)	2.54	(0.21 - 5.94)	-*	189	91.4	(77.7 - 105.2)	1.09	(0.94 - 1.26)	-
Belmont (C)	0	-	-	0	n/a	-	107	92.9	(73.9 - 111.8)	1.14	(0.94 - 1.38)	-
Beverley (S)	0	-	-	-	-	.	3	40.0	(0.0 - 89.1)	0.55	(0.04 - 1.29)	-
Boddington (S)	0	-	-	-	-	.	3	60.0	(0.0 - 129.8)	0.92	(0.07 - 2.15)	-*
Boyup Brook (S)	0	-	-	-	-	.	3	38.7	(0.0 - 86.5)	0.57	(0.05 - 1.33)	-
Bridgetown-Greenbushes (S)	0	-	-	-	-	.	19	133.5	(73.2 - 193.7)	1.48	(0.83 - 2.22)	-
Brookton (S)	0	-	-	-	-	.	1	35.7	(0.0 - 105.4)	0.33	(0.00 - 1.22)	-*
Broome (S)	0	-	-	-	-	.	26	87.9	(52.5 - 123.3)	1.27	(0.79 - 1.81)	-
Broomehill (S)	0	-	-	-	-	.	3	132.6	(0.0 - 282.6)	2.08	(0.17 - 4.85)	-*
Bruce Rock (S)	0	-	-	-	-	.	3	80.3	(0.0 - 171.2)	0.85	(0.07 - 1.98)	-*
Bunbury (C)	1	1.2	(0.0 - 3.7)	1.74	(0.00 - 6.43)	-*	93	93.2	(73.3 - 113.1)	1.09	(0.89 - 1.34)	-
Busselton (S)	0	-	-	-	-	.	51	62.2	(44.1 - 80.3)	0.75	(0.57 - 1.00)	-
Cambridge (T)	1	1.4	(0.0 - 4.1)	1.85	(0.00 - 6.84)	-*	87	94.4	(73.3 - 115.5)	1.07	(0.86 - 1.33)	-
Canning (C)	1	0.3	(0.0 - 0.9)	0.81	(0.00 - 3.00)	-*	212	82.8	(71.3 - 94.3)	0.99	(0.86 - 1.13)	-
Capel (S) - Pt A	0	-	-	-	-	.	5	60.2	(5.6 - 114.7)	0.80	(0.17 - 1.63)	-
Capel (S) - Pt B	0	-	-	-	-	.	8	58.5	(17.5 - 99.6)	0.72	(0.25 - 1.29)	-
Carnamah (S)	0	-	-	-	-	.	5	248.9	(29.9 - 467.8)	2.99	(0.65 - 6.13)	-*
Carnarvon (S)	0	-	-	-	-	.	12	70.5	(30.0 - 111.0)	0.80	(0.37 - 1.32)	-
Chapman Valley (S)	0	-	-	-	-	.	3	70.5	(0.0 - 149.9)	1.26	(0.10 - 2.95)	-*
Chittering (S)	0	-	-	-	-	.	5	60.9	(6.7 - 115.0)	0.63	(0.14 - 1.29)	-
Claremont (T)	0	-	-	-	-	.	32	66.9	(38.8 - 94.9)	0.91	(0.60 - 1.25)	-
Cockburn (C)	1	0.5	(0.0 - 1.6)	1.00	(0.00 - 3.69)	-*	175	86.3	(73.3 - 99.3)	1.04	(0.90 - 1.21)	-
Collie (S)	0	-	-	-	-	.	23	81.2	(47.2 - 115.3)	0.93	(0.56 - 1.34)	-
Coolgardie (S)	0	-	-	-	-	.	5	96.1	(1.6 - 190.7)	0.80	(0.17 - 1.63)	-
Coorow (S)	0	-	-	-	-	.	4	95.3	(1.5 - 189.1)	1.14	(0.18 - 2.50)	-*
Corrigin (S)	0	-	-	-	-	.	4	91.1	(1.9 - 180.2)	0.98	(0.15 - 2.16)	-*
Cottesloe (T)	0	-	-	-	-	.	32	118.4	(75.3 - 161.5)	1.28	(0.84 - 1.75)	-
Cranbrook (S)	0	-	-	-	-	.	2	53.9	(0.0 - 136.9)	0.72	(0.01 - 2.01)	-*
Cuballing (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Cue (S)	0	-	-	-	-	.	1	114.3	(0.0 - 335.1)	1.26	(0.00 - 4.64)	-*
Cunderdin (S)	0	-	-	-	-	.	4	89.5	(0.0 - 184.1)	1.05	(0.16 - 2.31)	-*
Dalwallinu (S)	0	-	-	-	-	.	5	77.7	(5.5 - 150.0)	1.17	(0.26 - 2.40)	-*
Dandaragan (S)	0	-	-	-	-	.	4	40.9	(0.4 - 81.4)	0.49	(0.08 - 1.06)	-
Dardanup (S) - Pt A	0	-	-	-	-	.	16	96.0	(48.3 - 143.8)	1.22	(0.64 - 1.88)	-
Dardanup (S) - Pt B	0	-	-	-	-	.	3	36.2	(0.0 - 77.8)	0.50	(0.04 - 1.17)	-
Denmark (S)	0	-	-	-	-	.	10	53.0	(19.4 - 86.7)	0.68	(0.28 - 1.16)	-
Derby-West Kimberley (S)	0	-	-	-	-	.	13	86.4	(37.4 - 135.5)	1.11	(0.53 - 1.79)	-
Donnybrook-Balingup (S)	0	-	-	-	-	.	17	109.6	(56.9 - 162.2)	1.29	(0.69 - 1.97)	-
Dowerin (S)	0	-	-	-	-	.	7	224.3	(51.5 - 397.2)	2.99	(0.94 - 5.58)	-*
Dumbleyung (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Dundas (S)	0	-	-	-	-	.	1	38.5	(0.0 - 113.1)	0.34	(0.00 - 1.26)	-*
East Fremantle (T)	0	-	-	-	-	.	25	109.3	(64.9 - 153.8)	1.19	(0.73 - 1.70)	-
East Pilbara (S)	0	-	-	-	-	.	3	34.8	(0.0 - 79.1)	0.36	(0.03 - 0.84)	V
Esperance (S)	0	-	-	-	-	.	34	85.6	(56.4 - 114.7)	1.01	(0.68 - 1.38)	-
Exmouth (S)	0	-	-	-	-	.	6	109.7	(20.2 - 199.2)	1.25	(0.34 - 2.43)	-
Fremantle (C) - Inner	0	-	-	-	-	.	4	203.6	(0.0 - 414.5)	1.98	(0.31 - 4.35)	-*
Fremantle (C) - Remainder	1	0.6	(0.0 - 1.7)	1.78	(0.00 - 6.57)	-*	83	90.0	(69.8 - 110.2)	1.02	(0.82 - 1.27)	-
Geraldton (C)	0	-	-	-	-	.	61	91.5	(67.6 - 115.5)	1.09	(0.84 - 1.40)	-
Gingin (S)	0	-	-	-	-	.	9	56.2	(19.2 - 93.1)	0.70	(0.27 - 1.23)	-
Gnowangerup (S)	0	-	-	-	-	.	7	153.7	(39.1 - 268.3)	1.78	(0.56 - 3.32)	-*
Goomalling (S)	0	-	-	-	-	.	2	47.1	(0.0 - 116.0)	0.71	(0.01 - 1.98)	-*
Gosnells (C)	1	0.6	(0.0 - 1.7)	0.87	(0.00 - 3.21)	-*	201	84.1	(72.2 - 96.0)	0.99	(0.86 - 1.14)	-
Greenough (S) - Pt A	0	-	-	-	-	.	14	47.5	(21.7 - 73.2)	0.60	(0.30 - 0.95)	V
Greenough (S) - Pt B	0	-	-	-	-	.	1	31.0	(0.0 - 91.5)	0.33	(0.00 - 1.23)	-*
Halls Creek (S)	0	-	-	-	-	.	5	73.4	(6.6 - 140.1)	0.88	(0.19 - 1.81)	-
Harvey (S) - Pt A	1	2.5	(0.0 - 7.4)	7.35	(0.00 - 27.11)	-*	21	75.5	(42.5 - 108.5)	0.92	(0.53 - 1.35)	-
Harvey (S) - Pt B	0	-	-	-	-	.	24	97.5	(58.1 - 136.9)	1.09	(0.66 - 1.57)	-

Cancer type: Breast 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	0	-	-	-	-	.	8	85.7	(25.7 - 145.7)	0.92	(0.33 - 1.67)	-
Jerramungup (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Joondalup (C) - North	0	-	-	-	-	.	91	74.7	(58.6 - 90.8)	0.91	(0.74 - 1.12)	-
Joondalup (C) - South	0	-	-	0	n/a	-	303	87.0	(76.7 - 97.4)	1.02	(0.91 - 1.15)	-
Kalamunda (S)	2	1.2	(0.0 - 3.0)	2.33	(0.03 - 6.51)	-*	150	88.0	(73.5 - 102.5)	1.06	(0.90 - 1.24)	-
Kalgoorlie/Boulder (C) - Pt A	0	-	-	-	-	.	48	71.6	(50.2 - 92.9)	0.97	(0.70 - 1.26)	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	-	-	.	0	-	-	0	n/a	-
Katanning (S)	0	-	-	-	-	.	9	67.3	(22.6 - 111.9)	0.76	(0.29 - 1.33)	-
Kellerberrin (S)	0	-	-	-	-	.	4	118.8	(0.0 - 252.7)	1.01	(0.16 - 2.20)	-*
Kent (S)	0	-	-	-	-	.	1	64.5	(0.0 - 189.9)	0.75	(0.00 - 2.75)	-*
Kojonup (S)	0	-	-	-	-	.	5	62.6	(6.6 - 118.6)	0.78	(0.17 - 1.60)	-
Kondinin (S)	0	-	-	-	-	.	1	21.3	(0.0 - 62.5)	0.42	(0.00 - 1.55)	-*
Koorda (S)	0	-	-	-	-	.	1	37.0	(0.0 - 109.2)	0.68	(0.00 - 2.50)	-*
Kulin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Kwinana (T)	0	-	-	-	-	.	47	74.8	(53.1 - 96.5)	0.91	(0.65 - 1.18)	-
Lake Grace (S)	0	-	-	-	-	.	5	94.3	(8.5 - 180.1)	1.28	(0.28 - 2.63)	-*
Laverton (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Leonora (S)	0	-	-	-	-	.	1	25.8	(0.0 - 76.1)	0.40	(0.00 - 1.48)	-*
Mandurah (C)	3	1.0	(0.0 - 2.2)	2.33	(0.19 - 5.44)	-*	174	85.6	(72.1 - 99.2)	1.08	(0.92 - 1.25)	-
Manjimup (S)	1	2.1	(0.0 - 6.1)	5.11	(0.00 - 18.84)	-*	23	70.3	(40.9 - 99.8)	0.86	(0.52 - 1.25)	-
Meekatharra (S)	0	-	-	-	-	.	3	97.9	(0.0 - 208.2)	1.19	(0.10 - 2.77)	-*
Melville (C)	3	0.6	(0.0 - 1.3)	1.51	(0.12 - 3.52)	-*	339	87.5	(77.6 - 97.4)	1.07	(0.96 - 1.19)	-
Menzies (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Merredin (S)	1	7.9	(0.0 - 23.4)	15.33	(0.00 - 56.57)	-*	8	75.8	(22.8 - 128.7)	0.87	(0.31 - 1.56)	-
Mingenew (S)	0	-	-	-	-	.	5	355.5	(46.2 - 664.8)	3.66	(0.80 - 7.49)	-*
Moora (S)	0	-	-	-	-	.	5	84.0	(6.7 - 161.4)	0.79	(0.17 - 1.62)	-
Morawa (S)	0	-	-	-	-	.	3	111.0	(0.0 - 237.6)	1.25	(0.10 - 2.92)	-*
Mosman Park (T)	0	-	-	-	-	.	27	94.1	(57.0 - 131.2)	1.01	(0.63 - 1.42)	-
Mount Magnet (S)	0	-	-	-	-	.	2	130.4	(0.0 - 322.7)	1.59	(0.02 - 4.42)	-*
Mount Marshall (S)	0	-	-	-	-	.	1	54.8	(0.0 - 161.5)	0.62	(0.00 - 2.30)	-*
Mukinbudin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Mullewa (S)	1	31.3	(0.0 - 92.0)	56.62	(0.00 - 208.87)	-*	3	110.5	(0.0 - 235.1)	1.38	(0.11 - 3.23)	-*
Mundaring (S)	2	1.9	(0.0 - 4.7)	3.44	(0.04 - 9.60)	-*	111	93.5	(75.9 - 111.2)	1.10	(0.91 - 1.33)	-
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	-
Murray (S)	1	1.6	(0.0 - 4.6)	3.59	(0.00 - 13.24)	-*	33	84.8	(55.3 - 114.4)	0.95	(0.63 - 1.31)	-
Nannup (S)	0	-	-	-	-	.	4	102.6	(0.0 - 205.4)	1.09	(0.17 - 2.38)	-*
Narembeen (S)	0	-	-	-	-	.	2	57.7	(0.0 - 138.7)	0.70	(0.01 - 1.94)	-*
Narrogin (S)	0	-	-	-	-	.	0	-	-	0	n/a	V
Narrogin (T)	0	-	-	-	-	.	7	50.5	(10.9 - 90.1)	0.65	(0.20 - 1.21)	-
Nedlands (C)	0	-	-	-	-	.	93	109.3	(85.4 - 133.1)	1.23	(1.00 - 1.52)	-
Ngaanyatjarraku (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Northam (S)	0	-	-	-	-	.	6	52.8	(10.6 - 95.1)	0.60	(0.16 - 1.17)	-
Northam (T)	0	-	-	-	-	.	17	70.9	(34.4 - 107.4)	0.87	(0.47 - 1.33)	-
Northampton (S)	0	-	-	-	-	.	10	79.0	(29.9 - 128.2)	1.01	(0.41 - 1.72)	-
Nungarin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Peppermint Grove (S)	0	-	-	-	-	.	3	55.7	(0.0 - 119.7)	0.57	(0.05 - 1.33)	-
Perenjori (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Perth (C) - Inner	0	-	-	-	-	.	1	61.2	(0.0 - 180.6)	0.74	(0.00 - 2.72)	-*
Perth (C) - Remainder	0	-	-	-	-	.	9	46.8	(13.5 - 80.2)	0.59	(0.23 - 1.04)	-
Pingelly (S)	0	-	-	-	-	.	2	51.4	(0.0 - 123.1)	0.51	(0.01 - 1.43)	-*
Plantagenet (S)	0	-	-	-	-	.	17	107.3	(53.1 - 161.5)	1.26	(0.68 - 1.93)	-
Port Hedland (T)	0	-	-	-	-	.	18	109.4	(52.4 - 166.3)	0.96	(0.53 - 1.45)	-
Quairading (S)	0	-	-	-	-	.	2	32.3	(0.0 - 85.5)	0.57	(0.01 - 1.60)	-*
Ravensthorpe (S)	0	-	-	-	-	.	3	67.2	(0.0 - 143.6)	0.76	(0.06 - 1.78)	-*
Rockingham (C)	2	0.9	(0.0 - 2.2)	1.51	(0.02 - 4.19)	-*	200	83.8	(71.9 - 95.8)	1.02	(0.88 - 1.17)	-
Roebourne (S)	0	-	-	-	-	.	23	84.3	(37.5 - 131.0)	1.10	(0.66 - 1.59)	-
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	-
Serpentine-Jarrahdale (S)	0	-	-	-	-	.	24	69.4	(41.2 - 97.5)	0.85	(0.52 - 1.23)	-
Shark Bay (S)	0	-	-	-	-	.	1	20.8	(0.0 - 60.8)	0.40	(0.00 - 1.47)	-*
South Perth (C)	0	-	-	0	n/a	-	132	95.9	(78.0 - 113.8)	1.10	(0.93 - 1.31)	-
Stirling (C) - Central	1	0.3	(0.0 - 0.7)	0.49	(0.00 - 1.80)	-*	284	75.1	(66.0 - 84.2)	0.91	(0.81 - 1.02)	-
Stirling (C) - Coastal	2	0.9	(0.0 - 2.1)	1.60	(0.02 - 4.47)	-*	207	87.0	(74.6 - 99.5)	1.05	(0.91 - 1.20)	-
Stirling (C) - South-Eastern	0	-	-	-	-	.	66	106.1	(76.2 - 135.9)	1.24	(0.96 - 1.58)	-
Subiaco (C)	0	-	-	-	-	.	52	99.8	(70.9 - 128.6)	1.16	(0.87 - 1.53)	-
Swan (C)	2	0.8	(0.0 - 2.0)	1.85	(0.02 - 5.16)	-*	166	76.0	(64.1 - 87.8)	0.89	(0.76 - 1.04)	-

Cancer type: Breast 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	0	-	-	-	-	.	1	38.1	(0.0 - 112.4)	0.57	(0.00 - 2.12)	-*
Tammin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Three Springs (S)	0	-	-	-	-	.	4	187.4	(0.0 - 375.4)	2.03	(0.31 - 4.46)	-*
Toodyay (S)	0	-	-	-	-	.	9	65.9	(22.1 - 109.6)	0.76	(0.29 - 1.34)	-
Trayning (S)	0	-	-	-	-	.	2	98.8	(0.0 - 233.9)	1.48	(0.02 - 4.13)	-*
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Victoria Park (T)	0	-	-	0	n/a	-	75	77.1	(56.8 - 97.4)	0.86	(0.68 - 1.08)	-
Victoria Plains (S)	0	-	-	-	-	.	8	295.8	(82.5 - 509.0)	3.21	(1.13 - 5.79)	^*
Vincent (T)	0	-	-	0	n/a	-	75	90.5	(68.2 - 112.8)	1.04	(0.82 - 1.31)	-
Wagin (S)	0	-	-	-	-	.	8	113.4	(30.0 - 196.8)	1.35	(0.48 - 2.44)	-
Wandering (S)	0	-	-	-	-	.	1	83.3	(0.0 - 232.4)	1.09	(0.00 - 4.02)	-*
Wanneroo (C) - North-East	0	-	-	-	-	.	41	68.8	(47.2 - 90.5)	0.80	(0.56 - 1.06)	-
Wanneroo (C) - North-West	0	-	-	-	-	.	63	96.6	(72.4 - 120.8)	1.15	(0.89 - 1.49)	-
Wanneroo (C) - South	1	1.0	(0.0 - 3.1)	2.32	(0.00 - 8.56)	-*	76	78.1	(60.2 - 96.1)	0.94	(0.75 - 1.19)	-
Waroona (S)	0	-	-	-	-	.	7	58.8	(13.7 - 103.9)	0.72	(0.22 - 1.33)	-
West Arthur (S)	0	-	-	-	-	.	2	67.2	(0.0 - 159.6)	0.75	(0.01 - 2.09)	-*
Westonia (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Wickepin (S)	0	-	-	-	-	.	2	80.9	(0.0 - 192.5)	0.92	(0.01 - 2.57)	-*
Williams (S)	0	-	-	-	-	.	2	64.7	(0.0 - 164.4)	0.79	(0.01 - 2.20)	-*
Wiluna (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Wongan-Ballidu (S)	0	-	-	-	-	.	2	43.7	(0.0 - 109.8)	0.53	(0.01 - 1.47)	-*
Woodanilling (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Wyalkatchem (S)	0	-	-	-	-	.	3	165.5	(0.0 - 355.1)	1.48	(0.12 - 3.45)	-*
Wyndham-East Kimberley (S)	0	-	-	-	-	.	14	116.5	(48.5 - 184.5)	1.29	(0.64 - 2.06)	-
Yalgoo (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Yilgarn (S)	0	-	-	-	-	.	3	71.6	(0.0 - 153.5)	0.85	(0.07 - 1.97)	-*
York (S)	0	-	-	-	-	.	10	68.8	(24.3 - 113.3)	0.94	(0.39 - 1.61)	-
Total State	33	0.5	(0.3 - 0.7)	1.00	(0.66 - 1.37)	-	5171	83.7	(81.3 - 86.1)	1.00	(0.97 - 1.03)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (alphabetic)
Cancer type: Colorectal cancer 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	42	70.8	(48.0 - 93.5)	1.23	(0.86 - 1.63)	-	42	44.5	(28.0 - 61.0)	1.37	(0.96 - 1.81)	-
Albany (C) Bal	19	36.1	(19.8 - 52.4)	0.83	(0.46 - 1.24)	-	12	29.0	(12.3 - 45.7)	0.90	(0.41 - 1.48)	-
Armadale (C)	63	41.5	(31.1 - 51.8)	0.89	(0.69 - 1.15)	-	54	30.6	(22.1 - 39.1)	1.01	(0.76 - 1.32)	-
Ashburton (S)	4	33.2	(0.0 - 73.5)	1.07	(0.17 - 2.34)	-*	2	12.6	(0.0 - 31.8)	1.10	(0.01 - 3.07)	-*
Augusta-Margaret River (S)	16	49.0	(24.0 - 74.1)	1.03	(0.54 - 1.60)	-	11	25.8	(9.6 - 42.0)	1.04	(0.45 - 1.73)	-
Bassendean (T)	32	61.1	(39.2 - 83.0)	1.35	(0.89 - 1.85)	-	17	29.2	(14.4 - 43.9)	0.86	(0.46 - 1.32)	-
Bayswater (C)	86	39.7	(31.0 - 48.4)	0.86	(0.69 - 1.07)	-	81	30.3	(22.9 - 37.7)	1.00	(0.80 - 1.24)	-
Belmont (C)	63	51.9	(38.5 - 65.4)	1.12	(0.87 - 1.45)	-	47	30.5	(20.5 - 40.5)	1.02	(0.73 - 1.34)	-
Beverley (S)	4	42.4	(0.7 - 84.1)	1.07	(0.17 - 2.34)	-*	2	16.1	(0.0 - 39.0)	0.84	(0.01 - 2.34)	-*
Boddington (S)	2	33.4	(0.0 - 80.7)	1.07	(0.01 - 2.97)	-*	1	36.7	(0.0 - 108.3)	0.87	(0.00 - 3.23)	-*
Boyup Brook (S)	4	58.3	(0.0 - 117.1)	1.26	(0.19 - 2.76)	-*	5	48.8	(0.6 - 96.9)	2.07	(0.45 - 4.24)	-*
Bridgetown-Greenbushes (S)	1	6.4	(0.0 - 19.0)	0.14	(0.00 - 0.52)	V	7	46.9	(11.1 - 82.7)	1.41	(0.44 - 2.64)	-
Brookton (S)	3	37.0	(0.0 - 80.0)	1.28	(0.10 - 2.98)	-*	3	76.6	(0.0 - 167.8)	2.14	(0.17 - 4.99)	-*
Broome (S)	11	51.7	(20.7 - 82.6)	1.06	(0.46 - 1.77)	-	4	19.1	(0.0 - 38.7)	0.67	(0.10 - 1.47)	-
Broomehill (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bruce Rock (S)	5	122.5	(11.8 - 233.2)	2.31	(0.50 - 4.74)	-*	2	29.7	(0.0 - 72.2)	1.31	(0.02 - 3.64)	-*
Bunbury (C)	53	49.1	(35.0 - 63.1)	1.09	(0.82 - 1.43)	-	44	35.2	(23.5 - 47.0)	1.10	(0.78 - 1.45)	-
Busselton (S)	53	61.8	(44.3 - 79.3)	1.32	(1.00 - 1.74)	-	28	25.9	(15.2 - 36.6)	0.89	(0.57 - 1.25)	-
Cambridge (T)	46	49.7	(34.4 - 65.1)	1.00	(0.71 - 1.31)	-	55	37.5	(25.0 - 50.0)	1.34	(1.02 - 1.76)	^
Canning (C)	87	36.7	(28.8 - 44.5)	0.82	(0.66 - 1.01)	-	86	27.9	(21.6 - 34.1)	0.97	(0.78 - 1.21)	-
Capel (S) - Pt A	4	55.0	(0.0 - 111.3)	1.41	(0.22 - 3.09)	-*	1	22.0	(0.0 - 64.9)	0.56	(0.00 - 2.07)	-*
Capel (S) - Pt B	4	28.2	(0.4 - 56.1)	0.61	(0.09 - 1.34)	-	7	57.7	(14.5 - 100.9)	1.78	(0.56 - 3.32)	-*
Carnamah (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Carnarvon (S)	7	31.3	(7.8 - 54.7)	0.70	(0.22 - 1.30)	-	5	29.3	(2.8 - 55.7)	0.90	(0.20 - 1.85)	-
Chapman Valley (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Chittering (S)	7	56.1	(14.5 - 97.8)	1.43	(0.45 - 2.66)	-	1	10.2	(0.0 - 30.2)	0.39	(0.00 - 1.43)	-*
Claremont (T)	16	41.5	(19.5 - 63.6)	0.88	(0.46 - 1.37)	-	22	41.6	(20.6 - 62.5)	1.11	(0.66 - 1.62)	-
Cockburn (C)	91	49.1	(39.0 - 59.3)	1.06	(0.86 - 1.31)	-	74	34.9	(26.6 - 43.1)	1.15	(0.91 - 1.45)	-
Collie (S)	21	54.4	(29.9 - 79.0)	1.40	(0.82 - 2.06)	-	15	43.3	(19.8 - 66.7)	1.41	(0.72 - 2.21)	-
Coolgardie (S)	2	24.5	(0.0 - 59.9)	0.63	(0.01 - 1.76)	-*	0	-	-	0	n/a	-
Coorow (S)	3	60.9	(0.0 - 129.8)	1.31	(0.11 - 3.06)	-*	2	47.9	(0.0 - 113.9)	1.57	(0.02 - 4.38)	-*
Corrigin (S)	2	46.0	(0.0 - 109.8)	0.82	(0.01 - 2.29)	-*	3	41.8	(0.0 - 95.1)	1.60	(0.13 - 3.73)	-*
Cottesloe (T)	18	63.1	(32.7 - 93.4)	1.35	(0.74 - 2.04)	-	7	10.1	(1.5 - 18.6)	0.57	(0.18 - 1.07)	-
Cranbrook (S)	3	92.2	(0.0 - 195.7)	1.42	(0.11 - 3.32)	-*	1	39.0	(0.0 - 114.8)	0.96	(0.00 - 3.53)	-*
Cuballing (S)	1	38.2	(0.0 - 112.9)	0.84	(0.00 - 3.08)	-*	0	-	-	0	n/a	-
Cue (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Cunderdin (S)	2	35.5	(0.0 - 85.0)	0.84	(0.01 - 2.35)	-*	2	18.3	(0.0 - 44.3)	1.18	(0.01 - 3.29)	-*
Dalwallinu (S)	4	67.8	(0.0 - 135.8)	1.47	(0.23 - 3.21)	-*	0	-	-	0	n/a	-
Dandaragan (S)	6	42.3	(8.5 - 76.1)	1.06	(0.29 - 2.06)	-	2	20.7	(0.0 - 49.3)	0.66	(0.01 - 1.84)	-*
Dardanup (S) - Pt A	5	32.1	(3.6 - 60.5)	0.75	(0.16 - 1.53)	-	3	18.9	(0.0 - 40.8)	0.64	(0.05 - 1.49)	-
Dardanup (S) - Pt B	5	62.3	(8.2 - 116.5)	1.34	(0.29 - 2.75)	-*	2	33.2	(0.0 - 79.0)	1.00	(0.01 - 2.80)	-*
Denmark (S)	5	19.5	(1.4 - 37.5)	0.53	(0.12 - 1.08)	-	7	40.8	(9.6 - 71.9)	1.14	(0.36 - 2.12)	-
Derby-West Kimberley (S)	4	29.5	(0.4 - 58.7)	0.58	(0.09 - 1.27)	-	3	15.7	(0.0 - 34.5)	0.74	(0.06 - 1.72)	-*
Donnybrook-Balingup (S)	4	23.0	(0.2 - 45.7)	0.54	(0.08 - 1.19)	-	6	34.4	(6.5 - 62.2)	1.22	(0.33 - 2.36)	-
Dowerin (S)	2	82.7	(0.0 - 197.9)	1.60	(0.02 - 4.47)	-*	2	57.2	(0.0 - 141.9)	2.02	(0.03 - 5.64)	-*
Dumbleyung (S)	1	22.7	(0.0 - 66.2)	0.72	(0.00 - 2.66)	-*	0	-	-	0	n/a	-
Dundas (S)	3	70.6	(0.0 - 151.0)	1.61	(0.13 - 3.76)	-*	1	14.3	(0.0 - 41.9)	0.95	(0.00 - 3.50)	-*
East Fremantle (T)	18	63.9	(32.8 - 95.0)	1.51	(0.83 - 2.28)	-	4	14.9	(0.0 - 31.1)	0.40	(0.06 - 0.87)	V
East Pilbara (S)	6	57.1	(0.0 - 114.6)	1.32	(0.36 - 2.57)	-	1	12.3	(0.0 - 36.5)	0.44	(0.00 - 1.63)	-*
Esperance (S)	23	55.2	(32.4 - 78.0)	1.20	(0.72 - 1.74)	-	11	21.4	(8.3 - 34.5)	0.82	(0.36 - 1.37)	-
Exmouth (S)	3	48.5	(0.0 - 104.0)	1.08	(0.09 - 2.52)	-*	2	40.1	(0.0 - 96.2)	1.27	(0.02 - 3.55)	-*
Fremantle (C) - Inner	2	77.5	(0.0 - 184.9)	1.06	(0.01 - 2.96)	-*	0	-	-	0	n/a	-
Fremantle (C) - Remainder	56	58.3	(42.2 - 74.5)	1.18	(0.90 - 1.55)	-	37	30.7	(19.6 - 41.8)	0.95	(0.65 - 1.28)	-
Geraldton (C)	31	45.5	(29.1 - 61.8)	0.95	(0.62 - 1.32)	-	23	24.0	(13.1 - 34.8)	0.89	(0.53 - 1.29)	-
Gingin (S)	10	60.6	(21.8 - 99.4)	1.22	(0.50 - 2.08)	-	4	27.1	(0.3 - 54.0)	0.83	(0.13 - 1.82)	-
Gnowangerup (S)	4	83.9	(0.6 - 167.1)	1.73	(0.27 - 3.80)	-*	4	56.2	(0.0 - 112.8)	2.50	(0.39 - 5.48)	-*
Goomalling (S)	1	25.0	(0.0 - 73.7)	0.55	(0.00 - 2.03)	-*	1	35.0	(0.0 - 103.3)	0.79	(0.00 - 2.93)	-*
Gosnells (C)	110	50.6	(40.9 - 60.2)	1.10	(0.91 - 1.33)	-	74	29.5	(22.5 - 36.4)	0.97	(0.77 - 1.23)	-
Greenough (S) - Pt A	14	58.3	(26.8 - 89.9)	1.23	(0.61 - 1.96)	-	5	20.0	(2.1 - 37.9)	0.71	(0.16 - 1.46)	-
Greenough (S) - Pt B	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Halls Creek (S)	2	24.4	(0.0 - 58.0)	0.63	(0.01 - 1.76)	-*	0	-	-	0	n/a	-
Harvey (S) - Pt A	18	65.4	(34.6 - 96.3)	1.50	(0.82 - 2.26)	-	10	41.0	(15.2 - 66.9)	1.25	(0.51 - 2.13)	-
Harvey (S) - Pt B	16	54.5	(27.4 - 81.7)	1.21	(0.63 - 1.87)	-	6	20.8	(3.7 - 38.0)	0.66	(0.18 - 1.28)	-

Cancer type: Colorectal cancer 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	2	14.9	(0.0 - 35.8)	0.33	(0.00 - 0.92)	V	4	35.6	(0.1 - 71.2)	1.18	(0.18 - 2.58)	-*
Jerramungup (S)	2	54.3	(0.0 - 129.6)	1.10	(0.01 - 3.07)	-*	0	-	-	0	n/a	-
Joondalup (C) - North	47	46.4	(32.6 - 60.3)	1.07	(0.77 - 1.40)	-	32	28.1	(18.0 - 38.3)	0.96	(0.63 - 1.32)	-
Joondalup (C) - South	130	39.5	(32.4 - 46.5)	0.91	(0.76 - 1.08)	-	103	28.2	(22.4 - 34.0)	0.98	(0.80 - 1.19)	-
Kalamunda (S)	49	30.4	(21.8 - 39.1)	0.67	(0.48 - 0.86)	V	48	24.9	(17.4 - 32.4)	0.86	(0.62 - 1.12)	-
Kalgoorlie/Boulder (C) - Pt A	29	57.7	(35.9 - 79.5)	1.17	(0.75 - 1.63)	-	19	35.5	(18.1 - 52.8)	1.07	(0.60 - 1.60)	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	-	-	-	0	-	-	-	-	-
Katanning (S)	5	33.3	(3.0 - 63.5)	0.77	(0.17 - 1.59)	-	4	19.7	(0.0 - 40.5)	0.78	(0.12 - 1.71)	-
Kellerberrin (S)	5	96.4	(7.7 - 185.0)	1.85	(0.40 - 3.80)	-*	2	32.6	(0.0 - 79.9)	1.01	(0.01 - 2.81)	-*
Kent (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Kojonup (S)	4	36.0	(0.0 - 73.5)	0.97	(0.15 - 2.14)	-*	2	14.5	(0.0 - 34.4)	0.72	(0.01 - 2.01)	-*
Kondinin (S)	2	66.7	(0.0 - 157.9)	1.33	(0.02 - 3.72)	-*	1	37.4	(0.0 - 110.3)	1.20	(0.00 - 4.43)	-*
Koorda (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Kulin (S)	0	-	-	0	n/a	-	1	25.0	(0.0 - 73.7)	1.01	(0.00 - 3.72)	-*
Kwinana (T)	31	48.2	(30.9 - 65.6)	1.08	(0.70 - 1.49)	-	18	26.5	(13.9 - 39.2)	0.89	(0.49 - 1.34)	-
Lake Grace (S)	1	19.8	(0.0 - 58.4)	0.47	(0.00 - 1.72)	-*	4	88.6	(1.3 - 175.9)	2.99	(0.46 - 6.56)	-*
Laverton (S)	0	-	-	0	n/a	-	1	46.5	(0.0 - 137.3)	2.26	(0.00 - 8.35)	-*
Leonora (S)	2	68.5	(0.0 - 166.5)	1.03	(0.01 - 2.87)	-*	1	33.3	(0.0 - 96.5)	1.48	(0.00 - 5.47)	-*
Mandurah (C)	110	45.1	(36.0 - 54.1)	1.03	(0.85 - 1.25)	-	73	30.0	(22.5 - 37.4)	0.97	(0.76 - 1.22)	-
Manjimup (S)	11	33.9	(13.7 - 54.1)	0.66	(0.29 - 1.10)	-	10	25.5	(8.6 - 42.4)	0.90	(0.37 - 1.54)	-
Meekatharra (S)	1	42.6	(0.0 - 125.1)	0.66	(0.00 - 2.43)	-*	0	-	-	0	n/a	-
Melville (C)	195	49.2	(42.0 - 56.5)	1.15	(0.99 - 1.32)	-	180	35.2	(29.4 - 41.0)	1.22	(1.05 - 1.42)	^
Menzies (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Merredin (S)	10	76.6	(27.9 - 125.3)	1.79	(0.74 - 3.06)	-	3	28.4	(0.0 - 60.8)	0.78	(0.06 - 1.81)	-*
Mingenew (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Moora (S)	3	38.4	(0.0 - 84.4)	0.83	(0.07 - 1.95)	-*	5	73.2	(4.5 - 141.9)	1.93	(0.42 - 3.96)	-*
Morawa (S)	1	32.3	(0.0 - 95.2)	0.56	(0.00 - 2.08)	-*	1	31.7	(0.0 - 93.8)	1.04	(0.00 - 3.84)	-*
Mosman Park (T)	18	52.3	(26.8 - 77.8)	1.23	(0.68 - 1.87)	-	17	31.1	(12.3 - 50.0)	1.25	(0.67 - 1.91)	-
Mount Magnet (S)	1	41.7	(0.0 - 119.9)	1.07	(0.00 - 3.93)	-*	0	-	-	-	-	-
Mount Marshall (S)	1	40.4	(0.0 - 119.2)	0.97	(0.00 - 3.58)	-*	0	-	-	0	n/a	-
Mukinbudin (S)	1	45.1	(0.0 - 133.2)	0.80	(0.00 - 2.96)	-*	0	-	-	0	n/a	-
Mullewa (S)	1	47.6	(0.0 - 138.7)	0.68	(0.00 - 2.52)	-*	2	134.9	(0.0 - 328.9)	2.64	(0.03 - 7.36)	-*
Mundaring (S)	55	50.7	(37.1 - 64.3)	1.09	(0.83 - 1.43)	-	45	35.3	(24.3 - 46.3)	1.19	(0.85 - 1.57)	-
Murchison (S)	0	-	-	-	-	-	0	-	-	-	-	-
Murray (S)	20	38.3	(20.6 - 56.1)	0.85	(0.49 - 1.27)	-	12	26.1	(11.2 - 41.1)	0.88	(0.40 - 1.45)	-
Nannup (S)	4	65.5	(1.4 - 129.6)	1.90	(0.29 - 4.16)	-*	1	22.2	(0.0 - 65.7)	0.73	(0.00 - 2.69)	-*
Narembeen (S)	1	28.3	(0.0 - 83.5)	0.57	(0.00 - 2.12)	-*	1	23.8	(0.0 - 70.4)	0.83	(0.00 - 3.05)	-*
Narrogin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Narrogin (T)	10	92.3	(34.6 - 149.9)	1.63	(0.67 - 2.78)	-	7	33.7	(4.2 - 63.3)	1.30	(0.41 - 2.43)	-
Nedlands (C)	23	22.2	(11.9 - 32.5)	0.58	(0.35 - 0.84)	V	51	43.3	(28.2 - 58.4)	1.28	(0.96 - 1.69)	-
Ngaanyatjarraku (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Northam (S)	8	72.5	(17.9 - 127.1)	1.37	(0.48 - 2.47)	-	4	35.1	(0.6 - 69.6)	1.18	(0.18 - 2.58)	-*
Northam (T)	12	46.4	(18.2 - 74.7)	1.07	(0.49 - 1.76)	-	7	22.9	(2.5 - 43.3)	0.73	(0.23 - 1.37)	-
Northampton (S)	8	70.0	(17.0 - 123.0)	1.22	(0.43 - 2.20)	-	2	14.1	(0.0 - 33.6)	0.52	(0.01 - 1.44)	-*
Nungarin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Peppermint Grove (S)	1	11.9	(0.0 - 35.0)	0.33	(0.00 - 1.23)	-*	3	44.6	(0.0 - 98.4)	1.33	(0.11 - 3.10)	-*
Perenjori (S)	1	73.2	(0.0 - 214.8)	1.26	(0.00 - 4.64)	-*	1	48.8	(0.0 - 143.2)	1.72	(0.00 - 6.33)	-*
Perth (C) - Inner	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Perth (C) - Remainder	16	56.6	(27.7 - 85.5)	1.25	(0.65 - 1.93)	-	6	25.3	(3.1 - 47.4)	0.84	(0.23 - 1.63)	-
Pingelly (S)	3	47.5	(0.0 - 103.1)	1.18	(0.09 - 2.75)	-*	0	-	-	0	n/a	-
Plantagenet (S)	11	61.8	(25.0 - 98.5)	1.32	(0.57 - 2.20)	-	6	32.6	(5.7 - 59.5)	1.07	(0.29 - 2.08)	-
Port Hedland (T)	4	17.7	(0.0 - 37.2)	0.41	(0.06 - 0.91)	V	2	5.0	(0.0 - 12.2)	0.39	(0.00 - 1.10)	-
Quairading (S)	3	69.2	(0.0 - 147.4)	1.49	(0.12 - 3.48)	-*	1	34.2	(0.0 - 101.1)	0.61	(0.00 - 2.27)	-*
Ravensthorpe (S)	1	16.6	(0.0 - 49.1)	0.38	(0.00 - 1.40)	-*	1	25.3	(0.0 - 74.6)	0.68	(0.00 - 2.51)	-*
Rockingham (C)	117	46.7	(38.0 - 55.4)	1.04	(0.87 - 1.25)	-	92	31.5	(24.7 - 38.3)	1.10	(0.89 - 1.36)	-
Roebourne (S)	7	51.7	(8.3 - 95.1)	0.77	(0.24 - 1.44)	-	4	12.0	(0.0 - 24.5)	0.81	(0.12 - 1.77)	-
Sandstone (S)	0	-	-	-	-	-	0	-	-	-	-	-
Serpentine-Jarrahdale (S)	14	40.4	(18.6 - 62.1)	0.93	(0.46 - 1.48)	-	10	31.1	(11.4 - 50.7)	1.05	(0.43 - 1.80)	-
Shark Bay (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
South Perth (C)	60	45.9	(33.3 - 58.5)	0.97	(0.75 - 1.26)	-	64	30.5	(21.5 - 39.5)	1.02	(0.79 - 1.30)	-
Stirling (C) - Central	173	44.8	(37.9 - 51.7)	1.00	(0.86 - 1.17)	-	134	26.6	(21.7 - 31.5)	0.94	(0.79 - 1.12)	-
Stirling (C) - Coastal	117	48.5	(39.3 - 57.7)	1.10	(0.92 - 1.33)	-	81	27.1	(20.6 - 33.6)	0.88	(0.70 - 1.10)	-
Stirling (C) - South-Eastern	33	48.8	(28.8 - 68.9)	1.09	(0.72 - 1.49)	-	31	25.2	(12.4 - 37.9)	0.98	(0.64 - 1.35)	-
Subiaco (C)	17	36.3	(18.4 - 54.3)	0.77	(0.41 - 1.17)	-	22	29.0	(14.9 - 43.1)	1.04	(0.62 - 1.52)	-
Swan (C)	86	39.5	(31.0 - 48.0)	0.92	(0.74 - 1.14)	-	76	32.7	(25.0 - 40.4)	1.09	(0.86 - 1.37)	-

Cancer type: Colorectal cancer 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	0	-	-	0	n/a	-	1	54.5	(0.0 - 160.5)	1.47	(0.00 - 5.42)	-*
Tammin (S)	1	50.0	(0.0 - 143.0)	1.38	(0.00 - 5.09)	-*	0	-	-	-	-	.
Three Springs (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Toodyay (S)	6	41.2	(8.0 - 74.5)	0.88	(0.24 - 1.70)	-	2	13.2	(0.0 - 31.5)	0.50	(0.01 - 1.40)	-*
Trayning (S)	1	45.5	(0.0 - 133.5)	1.18	(0.00 - 4.36)	-*	0	-	-	0	n/a	-
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
Victoria Park (T)	44	37.6	(24.5 - 50.6)	0.87	(0.61 - 1.14)	-	43	28.2	(16.2 - 40.2)	0.78	(0.55 - 1.03)	-
Victoria Plains (S)	0	-	-	0	n/a	-	2	43.8	(0.0 - 103.9)	2.33	(0.03 - 6.49)	-*
Vincent (T)	48	50.3	(34.7 - 65.8)	1.11	(0.80 - 1.45)	-	41	35.4	(22.5 - 48.2)	1.09	(0.76 - 1.45)	-
Wagin (S)	4	69.2	(0.0 - 139.1)	1.10	(0.17 - 2.41)	-*	1	19.5	(0.0 - 57.7)	0.34	(0.00 - 1.26)	-*
Wandering (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wanneroo (C) - North-East	32	51.5	(33.2 - 69.8)	1.21	(0.80 - 1.66)	-	19	29.0	(15.3 - 42.6)	0.96	(0.54 - 1.43)	-
Wanneroo (C) - North-West	29	46.8	(29.0 - 64.6)	0.96	(0.62 - 1.34)	-	12	17.8	(7.6 - 28.1)	0.59	(0.27 - 0.97)	V
Wanneroo (C) - South	27	33.5	(20.6 - 46.4)	0.72	(0.46 - 1.02)	-	30	30.3	(19.3 - 41.3)	1.05	(0.68 - 1.46)	-
Waroona (S)	7	52.0	(13.0 - 91.0)	1.12	(0.35 - 2.10)	-	3	25.3	(0.0 - 54.1)	0.72	(0.06 - 1.68)	-*
West Arthur (S)	2	46.1	(0.0 - 109.7)	1.11	(0.01 - 3.09)	-*	0	-	-	0	n/a	-
Westonia (S)	2	176.1	(0.0 - 420.0)	4.19	(0.05 - 11.68)	-*	0	-	-	-	-	.
Wickepin (S)	2	50.4	(0.0 - 119.9)	1.40	(0.02 - 3.90)	-*	0	-	-	0	n/a	-
Williams (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Wiluna (S)	0	-	-	0	n/a	-	1	62.5	(0.0 - 184.4)	3.26	(0.00 - 12.03)	-*
Wongan-Ballidu (S)	4	77.4	(2.1 - 152.7)	1.97	(0.30 - 4.31)	-*	0	-	-	0	n/a	-
Woodanilling (S)	1	66.7	(0.0 - 196.2)	1.92	(0.00 - 7.07)	-*	0	-	-	-	-	.
Wyalkatchem (S)	0	-	-	0	n/a	-	2	66.6	(0.0 - 174.8)	2.39	(0.03 - 6.66)	-*
Wyndham-East Kimberley (S)	3	24.3	(0.0 - 52.0)	0.50	(0.04 - 1.16)	-	3	33.4	(0.0 - 73.9)	0.95	(0.08 - 2.22)	-*
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Yilgarn (S)	3	84.5	(0.0 - 181.0)	1.30	(0.10 - 3.04)	-*	1	24.8	(0.0 - 73.4)	0.73	(0.00 - 2.71)	-*
York (S)	10	67.2	(24.1 - 110.3)	1.53	(0.63 - 2.61)	-	2	13.8	(0.0 - 33.3)	0.44	(0.01 - 1.24)	-*
Total State	2822	45.1	(43.4 - 46.8)	1.00	(0.96 - 1.04)	-	2209	29.7	(28.4 - 31.1)	1.00	(0.96 - 1.04)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (alphabetic)
Cancer type: Prostate gland 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	60	91.7	(67.3 - 116.2)	1.07	(0.82 - 1.38)	-	0	-	-	-	-	.
Albany (C) Bal	25	49.7	(30.1 - 69.3)	0.66	(0.40 - 0.94)	V	0	-	-	-	-	.
Armadale (C)	95	61.3	(48.8 - 73.8)	0.82	(0.67 - 1.01)	-	0	-	-	-	-	.
Ashburton (S)	10	113.4	(32.8 - 194.1)	1.91	(0.78 - 3.26)	-	0	-	-	-	-	.
Augusta-Margaret River (S)	27	74.1	(44.6 - 103.5)	1.08	(0.68 - 1.53)	-	0	-	-	-	-	.
Bassendean (T)	30	64.4	(41.0 - 87.8)	0.77	(0.50 - 1.07)	-	0	-	-	-	-	.
Bayswater (C)	149	70.5	(58.7 - 82.3)	0.91	(0.77 - 1.07)	-	0	-	-	-	-	.
Belmont (C)	68	54.9	(41.2 - 68.5)	0.73	(0.57 - 0.93)	V	0	-	-	-	-	.
Beverley (S)	5	64.0	(7.3 - 120.8)	0.80	(0.17 - 1.63)	-	0	-	-	-	-	.
Boddington (S)	1	11.6	(0.0 - 34.2)	0.33	(0.00 - 1.23)	-*	0	-	-	-	-	.
Boyup Brook (S)	6	97.5	(19.8 - 175.2)	1.15	(0.31 - 2.23)	-	0	-	-	-	-	.
Bridgetown-Greenbushes (S)	14	89.2	(42.2 - 136.1)	1.19	(0.59 - 1.88)	-	0	-	-	-	-	.
Brookton (S)	4	52.3	(0.0 - 109.3)	1.05	(0.16 - 2.30)	-*	0	-	-	-	-	.
Broome (S)	4	19.2	(0.4 - 38.0)	0.25	(0.04 - 0.54)	V	0	-	-	-	-	.
Broomehill (S)	3	140.2	(0.0 - 294.3)	2.43	(0.20 - 5.67)	-*	0	-	-	-	-	.
Bruce Rock (S)	3	54.9	(0.0 - 118.6)	0.85	(0.07 - 1.99)	-*	0	-	-	-	-	.
Bunbury (C)	60	59.5	(43.7 - 75.3)	0.76	(0.58 - 0.98)	V	0	-	-	-	-	.
Busselton (S)	52	49.7	(35.4 - 64.0)	0.78	(0.59 - 1.03)	-	0	-	-	-	-	.
Cambridge (T)	87	90.0	(70.0 - 110.1)	1.17	(0.94 - 1.45)	-	0	-	-	-	-	.
Canning (C)	163	71.6	(60.4 - 82.8)	0.94	(0.81 - 1.10)	-	0	-	-	-	-	.
Capel (S) - Pt A	1	18.9	(0.0 - 55.7)	0.22	(0.00 - 0.81)	V	0	-	-	-	-	.
Capel (S) - Pt B	11	78.6	(31.7 - 125.4)	1.03	(0.45 - 1.71)	-	0	-	-	-	-	.
Carnamah (S)	3	103.7	(0.0 - 220.8)	1.78	(0.14 - 4.15)	-*	0	-	-	-	-	.
Carnarvon (S)	9	42.9	(14.7 - 71.2)	0.55	(0.21 - 0.96)	V	0	-	-	-	-	.
Chapman Valley (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Chittering (S)	5	44.3	(5.5 - 83.1)	0.60	(0.13 - 1.22)	-	0	-	-	-	-	.
Claremont (T)	38	98.8	(64.6 - 133.1)	1.28	(0.88 - 1.72)	-	0	-	-	-	-	.
Cockburn (C)	115	62.8	(51.2 - 74.3)	0.82	(0.68 - 0.99)	V	0	-	-	-	-	.
Collie (S)	26	77.3	(45.5 - 109.0)	1.07	(0.67 - 1.52)	-	0	-	-	-	-	.
Coolgardie (S)	2	24.7	(0.0 - 60.6)	0.43	(0.01 - 1.19)	-	0	-	-	-	-	.
Coorow (S)	3	65.9	(0.0 - 140.1)	0.79	(0.06 - 1.84)	-*	0	-	-	-	-	.
Corrigin (S)	6	114.1	(19.4 - 208.7)	1.51	(0.41 - 2.94)	-*	0	-	-	-	-	.
Cottesloe (T)	17	60.3	(30.7 - 89.8)	0.78	(0.42 - 1.20)	-	0	-	-	-	-	.
Cranbrook (S)	3	54.7	(0.0 - 115.1)	0.87	(0.07 - 2.03)	-*	0	-	-	-	-	.
Cuballing (S)	2	63.5	(0.0 - 152.0)	0.99	(0.01 - 2.77)	-*	0	-	-	-	-	.
Cue (S)	1	133.3	(0.0 - 385.8)	1.28	(0.00 - 4.73)	-*	0	-	-	-	-	.
Cunderdin (S)	2	37.4	(0.0 - 89.2)	0.51	(0.01 - 1.43)	-*	0	-	-	-	-	.
Dalwallinu (S)	4	64.5	(0.7 - 128.3)	0.89	(0.14 - 1.95)	-*	0	-	-	-	-	.
Dandaragan (S)	10	86.4	(24.1 - 148.6)	1.04	(0.43 - 1.78)	-	0	-	-	-	-	.
Dardanup (S) - Pt A	9	57.6	(19.5 - 95.7)	0.84	(0.32 - 1.47)	-	0	-	-	-	-	.
Dardanup (S) - Pt B	1	11.7	(0.0 - 34.6)	0.16	(0.00 - 0.61)	V	0	-	-	-	-	.
Denmark (S)	13	57.4	(26.0 - 88.8)	0.82	(0.39 - 1.33)	-	0	-	-	-	-	.
Derby-West Kimberley (S)	4	32.6	(0.7 - 64.5)	0.37	(0.06 - 0.81)	V	0	-	-	-	-	.
Donnybrook-Balingup (S)	13	78.0	(35.3 - 120.7)	1.07	(0.51 - 1.72)	-	0	-	-	-	-	.
Dowerin (S)	6	203.9	(33.1 - 374.7)	2.95	(0.80 - 5.74)	-*	0	-	-	-	-	.
Dumbleyung (S)	2	69.5	(0.0 - 166.1)	0.88	(0.01 - 2.44)	-*	0	-	-	-	-	.
Dundas (S)	4	112.5	(0.0 - 225.1)	1.33	(0.21 - 2.92)	-*	0	-	-	-	-	.
East Fremantle (T)	23	92.2	(52.4 - 132.0)	1.20	(0.72 - 1.74)	-	0	-	-	-	-	.
East Pilbara (S)	1	4.7	(0.0 - 14.0)	0.15	(0.00 - 0.56)	V	0	-	-	-	-	.
Esperance (S)	36	85.0	(57.1 - 112.9)	1.15	(0.78 - 1.55)	-	0	-	-	-	-	.
Exmouth (S)	4	54.5	(0.9 - 108.0)	0.89	(0.14 - 1.95)	-*	0	-	-	-	-	.
Fremantle (C) - Inner	4	97.1	(0.0 - 195.6)	1.28	(0.20 - 2.80)	-*	0	-	-	-	-	.
Fremantle (C) - Remainder	75	70.8	(54.1 - 87.4)	0.96	(0.76 - 1.22)	-	0	-	-	-	-	.
Geraldton (C)	53	77.4	(56.1 - 98.7)	0.98	(0.74 - 1.30)	-	0	-	-	-	-	.
Gingin (S)	22	114.7	(66.6 - 162.9)	1.57	(0.93 - 2.29)	-	0	-	-	-	-	.
Gnowangerup (S)	7	144.1	(36.2 - 252.1)	1.88	(0.59 - 3.51)	-*	0	-	-	-	-	.
Goomalling (S)	4	101.3	(3.0 - 199.7)	1.33	(0.21 - 2.91)	-*	0	-	-	-	-	.
Gosnells (C)	140	64.7	(53.8 - 75.6)	0.87	(0.73 - 1.03)	-	0	-	-	-	-	.
Greenough (S) - Pt A	13	52.7	(23.9 - 81.5)	0.71	(0.34 - 1.15)	-	0	-	-	-	-	.
Greenough (S) - Pt B	2	49.4	(0.0 - 117.4)	0.63	(0.01 - 1.76)	-*	0	-	-	-	-	.
Halls Creek (S)	4	59.9	(0.7 - 119.2)	0.79	(0.12 - 1.74)	-	0	-	-	-	-	.
Harvey (S) - Pt A	19	75.4	(41.1 - 109.7)	0.98	(0.55 - 1.47)	-	0	-	-	-	-	.
Harvey (S) - Pt B	26	85.7	(52.4 - 119.0)	1.19	(0.74 - 1.69)	-	0	-	-	-	-	.

Cancer type: Prostate gland 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	9	73.4	(25.2 - 121.5)	0.88	(0.34 - 1.55)	-	0	-	-	-	-	-
Jerramungup (S)	3	69.0	(0.0 - 149.3)	1.03	(0.08 - 2.39)	-*	0	-	-	-	-	-
Joondalup (C) - North	76	79.7	(61.3 - 98.1)	1.10	(0.87 - 1.39)	-	0	-	-	-	-	-
Joondalup (C) - South	243	78.6	(68.3 - 89.0)	1.06	(0.93 - 1.20)	-	0	-	-	-	-	-
Kalamunda (S)	108	67.2	(54.4 - 80.0)	0.89	(0.73 - 1.08)	-	0	-	-	-	-	-
Kalgoorlie/Boulder (C) - Pt A	42	82.6	(56.9 - 108.2)	1.10	(0.77 - 1.46)	-	0	-	-	-	-	-
Kalgoorlie/Boulder (C) - Pt B	1	97.6	(0.0 - 286.4)	1.33	(0.00 - 4.92)	-*	0	-	-	-	-	-
Katanning (S)	17	110.8	(57.0 - 164.5)	1.62	(0.87 - 2.48)	-	0	-	-	-	-	-
Kellerberrin (S)	5	79.2	(7.6 - 150.8)	1.11	(0.24 - 2.28)	-	0	-	-	-	-	-
Kent (S)	2	115.3	(0.0 - 278.9)	1.63	(0.02 - 4.54)	-*	0	-	-	-	-	-
Kojonup (S)	11	117.2	(45.6 - 188.8)	1.63	(0.71 - 2.72)	-	0	-	-	-	-	-
Kondinin (S)	3	90.5	(0.0 - 192.2)	1.23	(0.10 - 2.86)	-*	0	-	-	-	-	-
Koorda (S)	3	204.0	(0.0 - 444.3)	2.00	(0.16 - 4.68)	-*	0	-	-	-	-	-
Kulin (S)	3	98.6	(0.0 - 217.1)	1.17	(0.09 - 2.73)	-*	0	-	-	-	-	-
Kwinana (T)	37	60.9	(40.8 - 81.0)	0.78	(0.53 - 1.05)	-	0	-	-	-	-	-
Lake Grace (S)	2	47.4	(0.0 - 114.1)	0.58	(0.01 - 1.62)	-*	0	-	-	-	-	-
Laverton (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Leonora (S)	1	24.4	(0.0 - 71.6)	0.36	(0.00 - 1.34)	-*	0	-	-	-	-	-
Mandurah (C)	197	80.6	(68.7 - 92.5)	1.09	(0.95 - 1.26)	-	0	-	-	-	-	-
Manjimup (S)	27	74.5	(46.0 - 103.0)	0.99	(0.62 - 1.39)	-	0	-	-	-	-	-
Meekatharra (S)	4	148.2	(4.5 - 292.0)	1.69	(0.26 - 3.69)	-*	0	-	-	-	-	-
Melville (C)	329	84.3	(74.7 - 93.9)	1.18	(1.06 - 1.32)	^	0	-	-	-	-	-
Menzies (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Merredin (S)	12	105.5	(45.1 - 165.8)	1.32	(0.60 - 2.17)	-	0	-	-	-	-	-
Mingenew (S)	1	52.6	(0.0 - 155.1)	0.71	(0.00 - 2.63)	-*	0	-	-	-	-	-
Moora (S)	4	63.0	(0.0 - 126.8)	0.70	(0.11 - 1.53)	-	0	-	-	-	-	-
Morawa (S)	2	52.3	(0.0 - 126.0)	0.68	(0.01 - 1.89)	-*	0	-	-	-	-	-
Mosman Park (T)	28	84.8	(51.4 - 118.3)	1.18	(0.75 - 1.66)	-	0	-	-	-	-	-
Mount Magnet (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Mount Marshall (S)	1	40.4	(0.0 - 119.2)	0.58	(0.00 - 2.14)	-*	0	-	-	-	-	-
Mukinbudin (S)	1	38.1	(0.0 - 112.4)	0.47	(0.00 - 1.74)	-*	0	-	-	-	-	-
Mullewa (S)	1	31.6	(0.0 - 93.1)	0.42	(0.00 - 1.53)	-*	0	-	-	-	-	-
Mundaring (S)	99	87.1	(69.6 - 104.5)	1.20	(0.98 - 1.47)	-	0	-	-	-	-	-
Murchison (S)	0	-	-	0	-	-	0	-	-	-	-	-
Murray (S)	49	84.6	(60.5 - 108.6)	1.23	(0.89 - 1.60)	-	0	-	-	-	-	-
Nannup (S)	3	61.9	(0.0 - 133.1)	0.86	(0.07 - 2.00)	-*	0	-	-	-	-	-
Narembeen (S)	2	54.7	(0.0 - 131.6)	0.70	(0.01 - 1.95)	-*	0	-	-	-	-	-
Narrogin (S)	1	26.3	(0.0 - 77.7)	0.26	(0.00 - 0.94)	V*	0	-	-	-	-	-
Narrogin (T)	10	66.6	(22.2 - 111.0)	1.00	(0.41 - 1.71)	-	0	-	-	-	-	-
Nedlands (C)	83	100.0	(76.6 - 123.4)	1.30	(1.04 - 1.62)	^	0	-	-	-	-	-
Ngaanyatjarraku (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Northam (S)	4	28.6	(0.6 - 56.6)	0.41	(0.06 - 0.89)	V	0	-	-	-	-	-
Northam (T)	24	110.3	(64.3 - 156.4)	1.30	(0.79 - 1.87)	-	0	-	-	-	-	-
Northampton (S)	9	55.6	(18.4 - 92.7)	0.82	(0.32 - 1.44)	-	0	-	-	-	-	-
Nungarin (S)	1	71.4	(0.0 - 208.9)	1.23	(0.00 - 4.52)	-*	0	-	-	-	-	-
Peppermint Grove (S)	5	64.8	(2.8 - 126.8)	1.01	(0.22 - 2.07)	-	0	-	-	-	-	-
Perenjori (S)	4	262.5	(9.1 - 515.9)	3.16	(0.49 - 6.92)	-*	0	-	-	-	-	-
Perth (C) - Inner	0	-	-	0	n/a	-	0	-	-	-	-	-
Perth (C) - Remainder	24	85.9	(50.6 - 121.2)	1.15	(0.70 - 1.65)	-	0	-	-	-	-	-
Pingelly (S)	6	106.3	(19.9 - 192.6)	1.41	(0.38 - 2.74)	-*	0	-	-	-	-	-
Plantagenet (S)	16	83.9	(42.5 - 125.3)	1.15	(0.60 - 1.78)	-	0	-	-	-	-	-
Port Hedland (T)	7	40.6	(7.4 - 73.8)	0.49	(0.15 - 0.91)	V	0	-	-	-	-	-
Quairading (S)	7	140.8	(37.8 - 243.9)	2.09	(0.66 - 3.90)	-*	0	-	-	-	-	-
Ravensthorpe (S)	10	157.9	(60.0 - 255.8)	2.26	(0.93 - 3.86)	-*	0	-	-	-	-	-
Rockingham (C)	192	73.8	(63.0 - 84.5)	1.04	(0.90 - 1.20)	-	0	-	-	-	-	-
Roebourne (S)	10	59.1	(12.1 - 106.0)	0.78	(0.32 - 1.33)	-	0	-	-	-	-	-
Sandstone (S)	0	-	-	0	-	-	0	-	-	-	-	-
Serpentine-Jarrahdale (S)	37	110.0	(74.2 - 145.8)	1.51	(1.03 - 2.03)	^	0	-	-	-	-	-
Shark Bay (S)	1	24.8	(0.0 - 73.4)	0.30	(0.00 - 1.09)	-*	0	-	-	-	-	-
South Perth (C)	116	86.1	(68.8 - 103.4)	1.17	(0.97 - 1.41)	-	0	-	-	-	-	-
Stirling (C) - Central	263	68.9	(60.3 - 77.4)	0.92	(0.81 - 1.04)	-	0	-	-	-	-	-
Stirling (C) - Coastal	215	91.9	(79.2 - 104.7)	1.24	(1.08 - 1.42)	^	0	-	-	-	-	-
Stirling (C) - South-Eastern	45	76.8	(50.7 - 102.9)	0.94	(0.67 - 1.23)	-	0	-	-	-	-	-
Subiaco (C)	44	105.6	(73.8 - 137.5)	1.24	(0.87 - 1.63)	-	0	-	-	-	-	-
Swan (C)	125	62.0	(51.0 - 73.0)	0.83	(0.70 - 1.00)	-	0	-	-	-	-	-

Cancer type: Prostate gland 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	2	98.3	(0.0 - 237.8)	1.12	(0.01 - 3.11)	-*	0	-	-	-	-	.
Tammin (S)	1	64.5	(0.0 - 189.9)	0.84	(0.00 - 3.11)	-*	0	-	-	-	-	.
Three Springs (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Toodyay (S)	9	58.3	(19.8 - 96.7)	0.78	(0.30 - 1.37)	-	0	-	-	-	-	.
Trayning (S)	5	309.9	(36.8 - 582.9)	3.52	(0.77 - 7.21)	-*	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Victoria Park (T)	82	72.5	(54.2 - 90.8)	1.01	(0.81 - 1.26)	-	0	-	-	-	-	.
Victoria Plains (S)	6	146.2	(30.0 - 262.3)	1.84	(0.50 - 3.58)	-*	0	-	-	-	-	.
Vincent (T)	51	54.5	(38.4 - 70.6)	0.73	(0.55 - 0.97)	V	0	-	-	-	-	.
Wagin (S)	4	57.5	(0.0 - 121.8)	0.68	(0.10 - 1.49)	-	0	-	-	-	-	.
Wandering (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wanneroo (C) - North-East	51	87.1	(62.8 - 111.4)	1.19	(0.89 - 1.57)	-	0	-	-	-	-	.
Wanneroo (C) - North-West	78	114.9	(88.9 - 140.9)	1.57	(1.25 - 1.98)	^	0	-	-	-	-	.
Wanneroo (C) - South	66	80.3	(60.8 - 99.8)	1.10	(0.86 - 1.41)	-	0	-	-	-	-	.
Waroona (S)	11	75.7	(30.5 - 121.0)	1.06	(0.46 - 1.77)	-	0	-	-	-	-	.
West Arthur (S)	3	77.9	(0.0 - 165.2)	1.00	(0.08 - 2.34)	-*	0	-	-	-	-	.
Westonia (S)	2	191.7	(0.0 - 459.9)	2.56	(0.03 - 7.14)	-*	0	-	-	-	-	.
Wickepin (S)	6	176.1	(25.3 - 326.8)	2.58	(0.70 - 5.02)	-*	0	-	-	-	-	.
Williams (S)	1	29.0	(0.0 - 85.4)	0.40	(0.00 - 1.48)	-*	0	-	-	-	-	.
Wiluna (S)	1	100.0	(0.0 - 292.7)	0.78	(0.00 - 2.89)	-*	0	-	-	-	-	.
Wongan-Ballidu (S)	6	122.0	(24.4 - 219.7)	1.84	(0.50 - 3.57)	-*	0	-	-	-	-	.
Woodanilling (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wyalkatchem (S)	2	63.0	(0.0 - 153.2)	0.86	(0.01 - 2.39)	-*	0	-	-	-	-	.
Wyndham-East Kimberley (S)	4	37.4	(0.4 - 74.5)	0.43	(0.07 - 0.94)	V	0	-	-	-	-	.
Yalgoo (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Yilgarn (S)	6	127.2	(25.1 - 229.2)	1.62	(0.44 - 3.16)	-*	0	-	-	-	-	.
York (S)	8	49.9	(14.6 - 85.2)	0.74	(0.26 - 1.33)	-	0	-	-	-	-	.
Total State	4600	74.3	(72.1 - 76.5)	1.00	(0.97 - 1.03)	-	0	-	-	-	-	.

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (alphabetic)
Cancer type: Melanoma (skin) 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	24	48.7	(28.5 - 69.0)	0.92	(0.56 - 1.32)	-	28	51.7	(30.9 - 72.4)	1.39	(0.88 - 1.95)	-
Albany (C) Bal	19	42.9	(22.6 - 63.3)	0.92	(0.52 - 1.38)	-	15	32.4	(15.9 - 48.9)	1.14	(0.58 - 1.78)	-
Armadale (C)	58	36.7	(27.1 - 46.2)	0.88	(0.67 - 1.14)	-	39	24.5	(16.6 - 32.4)	0.78	(0.54 - 1.05)	-
Ashburton (S)	3	16.7	(0.0 - 36.6)	0.51	(0.04 - 1.20)	-	4	51.8	(0.0 - 121.1)	1.08	(0.17 - 2.37)	-*
Augusta-Margaret River (S)	16	44.0	(21.1 - 67.0)	1.15	(0.60 - 1.78)	-	16	52.4	(25.3 - 79.6)	1.72	(0.90 - 2.66)	-
Bassendean (T)	13	25.2	(11.0 - 39.3)	0.63	(0.30 - 1.02)	-	11	22.5	(8.5 - 36.5)	0.70	(0.31 - 1.18)	-
Bayswater (C)	70	34.3	(25.9 - 42.6)	0.82	(0.64 - 1.04)	-	59	28.0	(20.3 - 35.7)	0.94	(0.72 - 1.22)	-
Belmont (C)	43	42.0	(29.0 - 55.0)	0.93	(0.65 - 1.23)	-	34	30.1	(19.0 - 41.2)	1.01	(0.67 - 1.37)	-
Beverley (S)	2	25.5	(0.0 - 60.8)	0.68	(0.01 - 1.89)	-*	2	35.1	(0.0 - 84.7)	1.12	(0.01 - 3.12)	-*
Boddington (S)	1	15.6	(0.0 - 46.1)	0.54	(0.00 - 1.98)	-*	1	36.7	(0.0 - 108.3)	0.82	(0.00 - 3.02)	-*
Boyup Brook (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bridgetown-Greenbushes (S)	8	54.0	(16.4 - 91.6)	1.27	(0.45 - 2.30)	-	2	16.6	(0.0 - 39.9)	0.46	(0.01 - 1.29)	-*
Brookton (S)	3	89.3	(0.0 - 191.3)	1.67	(0.13 - 3.89)	-*	3	30.9	(0.0 - 66.2)	2.83	(0.23 - 6.61)	-*
Broome (S)	11	37.2	(14.2 - 60.3)	0.87	(0.38 - 1.46)	-	5	14.4	(1.1 - 27.6)	0.57	(0.13 - 1.18)	-
Broomehill (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bruce Rock (S)	1	12.0	(0.0 - 35.5)	0.54	(0.00 - 2.00)	-*	3	72.5	(0.0 - 154.5)	2.45	(0.20 - 5.71)	-*
Bunbury (C)	49	51.8	(36.8 - 66.8)	1.17	(0.85 - 1.52)	-	37	38.1	(25.1 - 51.0)	1.20	(0.82 - 1.62)	-
Busselton (S)	34	48.4	(31.3 - 65.4)	1.02	(0.68 - 1.39)	-	33	48.2	(30.5 - 65.8)	1.38	(0.91 - 1.88)	-
Cambridge (T)	54	64.6	(46.1 - 83.0)	1.44	(1.09 - 1.90)	^	35	36.8	(22.7 - 51.0)	1.21	(0.82 - 1.65)	-
Canning (C)	93	41.1	(32.6 - 49.6)	0.94	(0.77 - 1.16)	-	72	29.3	(22.3 - 36.3)	0.93	(0.74 - 1.18)	-
Capel (S) - Pt A	0	-	-	0	n/a	-	1	27.8	(0.0 - 82.1)	0.45	(0.00 - 1.66)	-*
Capel (S) - Pt B	3	22.7	(0.0 - 48.5)	0.51	(0.04 - 1.18)	-	5	37.9	(4.3 - 71.5)	1.27	(0.28 - 2.60)	-*
Carnamah (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Carnarvon (S)	5	21.9	(2.4 - 41.4)	0.55	(0.12 - 1.12)	-	9	53.3	(17.4 - 89.2)	1.62	(0.62 - 2.84)	-
Chapman Valley (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Chittering (S)	3	52.9	(0.0 - 120.0)	0.69	(0.06 - 1.61)	-*	3	41.1	(0.0 - 88.1)	1.13	(0.09 - 2.63)	-*
Claremont (T)	24	68.7	(38.0 - 99.3)	1.70	(1.03 - 2.45)	^	21	43.7	(21.7 - 65.7)	1.72	(1.00 - 2.53)	-
Cockburn (C)	66	33.6	(25.4 - 41.7)	0.79	(0.62 - 1.02)	-	63	32.1	(24.1 - 40.2)	1.01	(0.78 - 1.30)	-
Collie (S)	15	56.0	(26.2 - 85.7)	1.14	(0.58 - 1.79)	-	17	57.9	(28.7 - 87.1)	1.90	(1.02 - 2.91)	^
Coolgardie (S)	1	7.3	(0.0 - 21.6)	0.23	(0.00 - 0.83)	V*	2	24.0	(0.0 - 58.2)	0.71	(0.01 - 1.99)	-*
Coorow (S)	5	108.8	(12.6 - 204.9)	2.34	(0.51 - 4.79)	-*	1	24.8	(0.0 - 73.3)	0.79	(0.00 - 2.90)	-*
Corrigin (S)	0	-	-	0	n/a	-	2	17.4	(0.0 - 41.3)	1.41	(0.02 - 3.94)	-*
Cottesloe (T)	19	66.7	(35.2 - 98.2)	1.68	(0.94 - 2.51)	-	15	56.2	(24.7 - 87.6)	1.68	(0.86 - 2.63)	-
Cranbrook (S)	2	50.3	(0.0 - 120.2)	1.11	(0.01 - 3.08)	-*	0	-	-	0	n/a	-
Crabballing (S)	2	77.0	(0.0 - 182.9)	1.80	(0.02 - 5.01)	-*	1	42.0	(0.0 - 123.9)	1.47	(0.00 - 5.41)	-*
Cue (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Cunderdin (S)	3	58.0	(0.0 - 123.6)	1.44	(0.12 - 3.35)	-*	0	-	-	0	n/a	-
Dalwallinu (S)	1	19.5	(0.0 - 57.7)	0.40	(0.00 - 1.47)	-*	3	67.7	(0.0 - 144.8)	1.91	(0.15 - 4.45)	-*
Dandaragan (S)	4	28.0	(0.5 - 55.6)	0.81	(0.13 - 1.79)	-	3	32.0	(0.0 - 68.5)	1.08	(0.09 - 2.51)	-*
Dardanup (S) - Pt A	10	67.1	(25.0 - 109.2)	1.47	(0.60 - 2.51)	-	10	54.3	(19.6 - 88.9)	1.97	(0.81 - 3.37)	-
Dardanup (S) - Pt B	4	46.0	(0.7 - 91.3)	1.14	(0.18 - 2.50)	-*	1	12.1	(0.0 - 35.8)	0.47	(0.00 - 1.73)	-*
Denmark (S)	6	35.7	(6.9 - 64.6)	0.79	(0.21 - 1.53)	-	5	47.4	(0.0 - 98.0)	1.00	(0.22 - 2.06)	-
Derby-West Kimberley (S)	4	19.3	(0.0 - 38.7)	0.51	(0.08 - 1.12)	-	3	23.2	(0.0 - 50.3)	0.59	(0.05 - 1.39)	-
Donnybrook-Balingup (S)	4	24.1	(0.4 - 47.8)	0.60	(0.09 - 1.32)	-	5	29.6	(2.7 - 56.4)	1.10	(0.24 - 2.26)	-
Dowerin (S)	0	-	-	0	n/a	-	1	43.8	(0.0 - 129.3)	1.20	(0.00 - 4.44)	-*
Dumbleyung (S)	1	57.1	(0.0 - 168.7)	0.82	(0.00 - 3.02)	-*	0	-	-	0	n/a	-
Dundas (S)	2	53.8	(0.0 - 128.0)	1.06	(0.01 - 2.95)	-*	1	22.9	(0.0 - 67.8)	0.91	(0.00 - 3.37)	-*
East Fremantle (T)	14	49.9	(22.1 - 77.7)	1.37	(0.68 - 2.18)	-	8	29.8	(7.6 - 51.9)	1.05	(0.37 - 1.90)	-
East Pilbara (S)	3	12.2	(0.0 - 26.1)	0.46	(0.04 - 1.08)	-	0	-	-	0	n/a	V
Esperance (S)	21	56.6	(31.8 - 81.5)	1.20	(0.70 - 1.76)	-	10	22.9	(8.0 - 37.7)	0.82	(0.34 - 1.40)	-
Exmouth (S)	5	76.1	(7.4 - 144.8)	1.70	(0.37 - 3.48)	-*	0	-	-	0	n/a	-
Fremantle (C) - Inner	1	23.4	(0.0 - 69.1)	0.60	(0.00 - 2.22)	-*	0	-	-	0	n/a	-
Fremantle (C) - Remainder	39	42.6	(28.9 - 56.4)	0.98	(0.67 - 1.31)	-	29	29.6	(18.0 - 41.2)	0.99	(0.63 - 1.38)	-
Geraldton (C)	32	47.4	(30.5 - 64.2)	1.16	(0.76 - 1.59)	-	23	33.7	(19.2 - 48.1)	1.13	(0.68 - 1.64)	-
Gingin (S)	4	26.0	(0.0 - 52.0)	0.57	(0.09 - 1.25)	-	6	41.2	(7.6 - 74.8)	1.40	(0.38 - 2.73)	-*
Gnowangerup (S)	3	58.2	(0.0 - 126.8)	1.38	(0.11 - 3.22)	-*	0	-	-	0	n/a	-
Goomalling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Gosnells (C)	69	30.5	(23.2 - 37.8)	0.70	(0.55 - 0.89)	V	45	18.6	(13.0 - 24.1)	0.60	(0.43 - 0.79)	V
Greenough (S) - Pt A	12	42.7	(17.7 - 67.7)	0.99	(0.45 - 1.62)	-	6	18.4	(3.1 - 33.8)	0.68	(0.18 - 1.33)	-
Greenough (S) - Pt B	2	41.1	(0.0 - 98.1)	1.04	(0.01 - 2.89)	-*	0	-	-	0	n/a	-
Halls Creek (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Harvey (S) - Pt A	12	45.9	(17.9 - 73.9)	1.01	(0.46 - 1.66)	-	6	20.2	(3.6 - 36.7)	0.71	(0.19 - 1.38)	-
Harvey (S) - Pt B	12	45.2	(18.9 - 71.5)	1.04	(0.48 - 1.71)	-	8	27.0	(7.2 - 46.8)	1.03	(0.36 - 1.86)	-

Cancer type: Melanoma (skin) 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	5	40.7	(4.6 - 76.9)	1.00	(0.22 - 2.05)	-	8	88.4	(24.9 - 151.9)	2.73	(0.96 - 4.91)	-*
Jerramungup (S)	0	-	-	0	n/a	-	1	40.4	(0.0 - 119.2)	0.97	(0.00 - 3.59)	-*
Joondalup (C) - North	49	43.2	(30.4 - 56.0)	1.01	(0.73 - 1.31)	-	41	31.6	(21.5 - 41.6)	1.07	(0.74 - 1.42)	-
Joondalup (C) - South	186	55.9	(47.5 - 64.3)	1.33	(1.15 - 1.53)	^	135	40.9	(33.6 - 48.2)	1.29	(1.09 - 1.53)	^
Kalamunda (S)	75	49.3	(37.9 - 60.7)	1.13	(0.89 - 1.42)	-	38	23.2	(15.6 - 30.8)	0.77	(0.53 - 1.03)	-
Kalgoorlie/Boulder (C) - Pt A	22	25.5	(14.2 - 36.8)	0.72	(0.43 - 1.06)	-	22	25.2	(14.2 - 36.1)	1.03	(0.61 - 1.50)	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	0	n/a	-	0	-	-	-	-	-
Katanning (S)	3	24.1	(0.0 - 51.8)	0.51	(0.04 - 1.20)	-	6	47.9	(9.4 - 86.3)	1.39	(0.38 - 2.70)	-*
Kellerberrin (S)	1	28.7	(0.0 - 84.9)	0.47	(0.00 - 1.73)	-*	3	45.6	(0.0 - 101.3)	2.16	(0.17 - 5.04)	-*
Kent (S)	1	30.2	(0.0 - 89.1)	1.17	(0.00 - 4.31)	-*	0	-	-	0	n/a	-
Kojonup (S)	4	69.6	(0.0 - 143.8)	1.14	(0.18 - 2.50)	-*	1	7.2	(0.0 - 21.4)	0.43	(0.00 - 1.60)	-*
Kondinin (S)	4	116.0	(2.0 - 230.0)	2.69	(0.42 - 5.90)	-*	3	94.7	(0.0 - 201.7)	3.47	(0.28 - 8.10)	-*
Koorda (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Kulin (S)	1	23.5	(0.0 - 69.5)	0.71	(0.00 - 2.61)	-*	1	33.9	(0.0 - 100.1)	1.15	(0.00 - 4.23)	-*
Kwinana (T)	18	26.7	(14.2 - 39.3)	0.66	(0.36 - 0.99)	v	12	19.4	(8.3 - 30.6)	0.63	(0.29 - 1.03)	-
Lake Grace (S)	1	15.7	(0.0 - 46.3)	0.45	(0.00 - 1.66)	-*	4	103.4	(3.2 - 203.6)	2.81	(0.44 - 6.16)	-*
Laverton (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Leonora (S)	1	14.2	(0.0 - 42.0)	0.36	(0.00 - 1.35)	-*	1	25.8	(0.0 - 76.1)	0.87	(0.00 - 3.21)	-*
Mandurah (C)	91	46.1	(35.7 - 56.6)	1.11	(0.90 - 1.36)	-	71	39.6	(29.3 - 49.8)	1.29	(1.02 - 1.64)	^
Manjimup (S)	5	14.2	(1.6 - 26.8)	0.34	(0.07 - 0.70)	v	4	13.6	(0.2 - 27.1)	0.42	(0.06 - 0.91)	v
Meekatharra (S)	3	96.5	(0.0 - 209.9)	1.60	(0.13 - 3.73)	-*	0	-	-	0	n/a	-
Melville (C)	188	54.7	(46.6 - 62.9)	1.32	(1.14 - 1.53)	^	126	37.4	(30.5 - 44.3)	1.13	(0.95 - 1.35)	-
Menzies (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Merredin (S)	3	21.5	(0.0 - 48.0)	0.59	(0.05 - 1.38)	-	2	12.5	(0.0 - 31.0)	0.59	(0.01 - 1.65)	-*
Mingenew (S)	1	46.9	(0.0 - 138.4)	1.23	(0.00 - 4.54)	-*	1	76.9	(0.0 - 227.0)	2.00	(0.00 - 7.36)	-*
Moora (S)	4	54.5	(0.6 - 108.3)	1.17	(0.18 - 2.56)	-*	1	13.2	(0.0 - 39.0)	0.43	(0.00 - 1.57)	-*
Morawa (S)	0	-	-	0	n/a	-	3	131.4	(0.0 - 291.2)	3.44	(0.28 - 8.02)	-*
Mosman Park (T)	15	52.8	(24.9 - 80.7)	1.22	(0.62 - 1.91)	-	15	34.2	(12.9 - 55.6)	1.56	(0.80 - 2.45)	-
Mount Magnet (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Mount Marshall (S)	0	-	-	0	n/a	-	1	54.8	(0.0 - 161.5)	1.74	(0.00 - 6.43)	-*
Mukinbudin (S)	1	38.1	(0.0 - 112.4)	0.92	(0.00 - 3.38)	-*	2	76.8	(0.0 - 183.3)	2.93	(0.04 - 8.16)	-*
Mullewa (S)	2	78.9	(0.0 - 188.4)	1.50	(0.02 - 4.19)	-*	0	-	-	0	n/a	-
Mundaring (S)	42	36.8	(25.4 - 48.3)	0.89	(0.62 - 1.18)	-	36	34.1	(22.3 - 45.9)	1.03	(0.70 - 1.39)	-
Murchison (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Murray (S)	9	19.1	(6.2 - 31.9)	0.48	(0.18 - 0.83)	v	8	21.9	(5.1 - 38.8)	0.70	(0.25 - 1.27)	-
Nannup (S)	4	87.0	(0.5 - 173.6)	2.14	(0.33 - 4.68)	-*	1	87.9	(0.0 - 259.3)	0.81	(0.00 - 2.99)	-*
Narembeen (S)	2	60.8	(0.0 - 145.0)	1.33	(0.02 - 3.70)	-*	2	67.2	(0.0 - 160.1)	1.98	(0.02 - 5.52)	-*
Narrogin (S)	1	23.8	(0.0 - 70.2)	0.46	(0.00 - 1.71)	-*	1	23.1	(0.0 - 68.3)	0.67	(0.00 - 2.49)	-*
Narrogin (T)	9	84.6	(29.1 - 140.1)	1.74	(0.67 - 3.05)	-	6	52.0	(7.8 - 96.2)	1.52	(0.41 - 2.95)	-*
Nedlands (C)	53	68.6	(48.8 - 88.4)	1.67	(1.27 - 2.21)	^	35	42.2	(25.8 - 58.5)	1.33	(0.89 - 1.80)	-
Ngaanyatjarraku (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Northam (S)	4	30.8	(0.6 - 61.0)	0.76	(0.12 - 1.67)	-	3	24.1	(0.0 - 51.4)	0.88	(0.07 - 2.06)	-*
Northam (T)	13	62.9	(27.1 - 98.8)	1.40	(0.67 - 2.25)	-	5	18.4	(0.2 - 36.7)	0.72	(0.16 - 1.47)	-
Northampton (S)	10	79.4	(29.8 - 129.0)	1.82	(0.75 - 3.11)	-	6	50.6	(9.8 - 91.3)	1.78	(0.48 - 3.46)	-*
Nungarin (S)	1	71.4	(0.0 - 208.9)	2.30	(0.00 - 8.49)	-*	0	-	-	0	n/a	-
Peppermint Grove (S)	2	27.1	(0.0 - 66.5)	0.84	(0.01 - 2.33)	-*	1	15.4	(0.0 - 45.5)	0.56	(0.00 - 2.05)	-*
Perenjori (S)	2	122.2	(0.0 - 285.4)	2.45	(0.03 - 6.82)	-*	0	-	-	0	n/a	-
Perth (C) - Inner	0	-	-	0	n/a	-	1	74.1	(0.0 - 218.6)	1.98	(0.00 - 7.31)	-*
Perth (C) - Remainder	15	54.1	(25.7 - 82.5)	1.33	(0.68 - 2.08)	-	3	18.4	(0.0 - 39.4)	0.50	(0.04 - 1.17)	-
Pingelly (S)	1	19.6	(0.0 - 57.9)	0.49	(0.00 - 1.82)	-*	0	-	-	0	n/a	-
Plantagenet (S)	10	55.0	(20.5 - 89.5)	1.39	(0.57 - 2.38)	-	13	75.8	(33.1 - 118.6)	2.81	(1.34 - 4.52)	^
Port Hedland (T)	6	15.4	(2.8 - 27.9)	0.46	(0.12 - 0.89)	v	2	6.3	(0.0 - 15.2)	0.24	(0.00 - 0.68)	v
Quairading (S)	1	20.8	(0.0 - 61.4)	0.57	(0.00 - 2.09)	-*	1	18.7	(0.0 - 55.2)	0.81	(0.00 - 3.00)	-*
Ravensthorpe (S)	1	15.6	(0.0 - 46.2)	0.43	(0.00 - 1.58)	-*	1	20.4	(0.0 - 60.3)	0.73	(0.00 - 2.70)	-*
Rockingham (C)	90	39.1	(30.7 - 47.5)	0.92	(0.74 - 1.13)	-	67	30.4	(22.8 - 38.0)	0.94	(0.74 - 1.21)	-
Roebourne (S)	12	23.0	(9.8 - 36.2)	0.86	(0.39 - 1.41)	-	9	42.9	(5.4 - 80.5)	0.96	(0.37 - 1.67)	-
Sandstone (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Serpentine-Jarrahdale (S)	12	33.4	(13.9 - 52.8)	0.81	(0.37 - 1.32)	-	14	40.1	(18.6 - 61.6)	1.39	(0.69 - 2.21)	-
Shark Bay (S)	0	-	-	0	n/a	-	1	38.0	(0.0 - 111.9)	1.10	(0.00 - 4.07)	-*
South Perth (C)	72	58.7	(44.4 - 73.0)	1.37	(1.08 - 1.73)	^	45	33.4	(22.8 - 43.9)	1.02	(0.72 - 1.33)	-
Stirling (C) - Central	122	34.7	(28.4 - 41.0)	0.84	(0.70 - 1.00)	-	87	24.8	(19.4 - 30.3)	0.78	(0.63 - 0.96)	v
Stirling (C) - Coastal	133	63.2	(52.2 - 74.3)	1.47	(1.23 - 1.74)	^	78	34.6	(26.3 - 42.9)	1.11	(0.88 - 1.39)	-
Stirling (C) - South-Eastern	17	33.3	(16.5 - 50.2)	0.70	(0.37 - 1.07)	-	17	23.0	(10.3 - 35.6)	0.85	(0.46 - 1.30)	-
Subiaco (C)	26	52.0	(31.2 - 72.9)	1.27	(0.79 - 1.81)	-	12	24.0	(10.0 - 38.0)	0.70	(0.32 - 1.15)	-
Swan (C)	75	33.0	(25.4 - 40.6)	0.80	(0.63 - 1.01)	-	63	27.9	(20.8 - 35.0)	0.88	(0.68 - 1.13)	-

Cancer type: Melanoma (skin) 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	0	-	-	0	n/a	-	1	38.1	(0.0 - 112.4)	1.60	(0.00 - 5.90)	-*
Tammin (S)	1	50.0	(0.0 - 147.6)	1.58	(0.00 - 5.81)	-*	0	-	-	-	-	.
Three Springs (S)	1	35.5	(0.0 - 104.9)	0.83	(0.00 - 3.05)	-*	1	44.8	(0.0 - 132.2)	1.39	(0.00 - 5.12)	-*
Toodyay (S)	11	127.0	(36.9 - 217.1)	1.79	(0.78 - 2.99)	-	2	18.4	(0.0 - 44.0)	0.51	(0.01 - 1.43)	-*
Trayning (S)	1	45.5	(0.0 - 133.5)	1.44	(0.00 - 5.33)	-*	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
Victoria Park (T)	43	42.9	(28.3 - 57.5)	1.05	(0.74 - 1.38)	-	33	27.7	(15.9 - 39.4)	0.97	(0.64 - 1.33)	-
Victoria Plains (S)	1	23.3	(0.0 - 68.7)	0.61	(0.00 - 2.26)	-*	3	121.7	(0.0 - 259.1)	3.42	(0.28 - 7.99)	-*
Vincent (T)	32	33.1	(20.9 - 45.2)	0.83	(0.55 - 1.14)	-	23	19.8	(10.8 - 28.8)	0.80	(0.48 - 1.17)	-
Wagin (S)	3	55.7	(0.0 - 120.9)	1.01	(0.08 - 2.35)	-*	1	19.5	(0.0 - 57.7)	0.48	(0.00 - 1.78)	-*
Wandering (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wanneroo (C) - North-East	23	38.3	(22.4 - 54.1)	0.92	(0.55 - 1.33)	-	26	38.6	(23.2 - 54.1)	1.41	(0.88 - 2.00)	-
Wanneroo (C) - North-West	33	44.9	(29.0 - 60.7)	1.15	(0.76 - 1.57)	-	17	25.3	(12.9 - 37.6)	0.81	(0.43 - 1.23)	-
Wanneroo (C) - South	21	21.4	(12.1 - 30.8)	0.54	(0.31 - 0.79)	v	24	24.1	(14.3 - 34.0)	0.78	(0.47 - 1.12)	-
Waroona (S)	8	56.9	(17.0 - 96.8)	1.52	(0.53 - 2.73)	-	1	9.6	(0.0 - 28.5)	0.29	(0.00 - 1.08)	-*
West Arthur (S)	1	26.0	(0.0 - 76.7)	0.65	(0.00 - 2.40)	-*	0	-	-	0	n/a	-
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wickepin (S)	3	176.8	(0.0 - 390.9)	2.42	(0.19 - 5.64)	-*	1	39.2	(0.0 - 115.7)	1.33	(0.00 - 4.89)	-*
Williams (S)	1	26.7	(0.0 - 78.8)	0.71	(0.00 - 2.63)	-*	1	42.9	(0.0 - 126.3)	1.14	(0.00 - 4.20)	-*
Wiluna (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wongan-Ballidu (S)	1	14.9	(0.0 - 44.0)	0.49	(0.00 - 1.79)	-*	3	53.4	(0.0 - 113.9)	2.14	(0.17 - 5.00)	-*
Woodanilling (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wyalkatchem (S)	2	89.2	(0.0 - 219.4)	1.76	(0.02 - 4.91)	-*	0	-	-	0	n/a	-
Wyndham-East Kimberley (S)	8	36.4	(10.2 - 62.6)	1.10	(0.39 - 1.98)	-	5	23.2	(1.7 - 44.7)	1.08	(0.24 - 2.21)	-
Yalgoo (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Yilgarn (S)	2	28.6	(0.0 - 70.0)	0.80	(0.01 - 2.22)	-*	0	-	-	0	n/a	-
York (S)	8	73.5	(15.4 - 131.6)	1.51	(0.53 - 2.72)	-	3	25.1	(0.0 - 55.0)	0.85	(0.07 - 1.98)	-*
Total State	2548	42.7	(41.0 - 44.4)	1.00	(0.96 - 1.04)	-	1879	30.9	(29.4 - 32.3)	1.00	(0.96 - 1.05)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (alphabetic)

Cancer type: Lung, bronchus & trachea 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	29	47.3	(29.4 - 65.2)	0.93	(0.60 - 1.30)	-	15	14.7	(5.7 - 23.7)	0.82	(0.42 - 1.28)	-
Albany (C) Bal	8	15.1	(4.5 - 25.7)	0.40	(0.14 - 0.71)	V	6	12.1	(2.4 - 21.9)	0.72	(0.20 - 1.41)	-
Armadale (C)	56	35.6	(26.2 - 45.0)	0.92	(0.70 - 1.20)	-	40	21.9	(14.8 - 29.0)	1.23	(0.86 - 1.64)	-
Ashburton (S)	1	13.7	(0.0 - 40.5)	0.36	(0.00 - 1.34)	-*	1	5.5	(0.0 - 16.2)	1.01	(0.00 - 3.74)	-*
Augusta-Margaret River (S)	11	35.3	(13.5 - 57.1)	0.80	(0.35 - 1.34)	-	6	12.8	(1.9 - 23.7)	0.95	(0.26 - 1.85)	-
Bassendean (T)	23	44.0	(25.4 - 62.6)	1.08	(0.65 - 1.57)	-	15	25.5	(11.7 - 39.3)	1.25	(0.64 - 1.95)	-
Bayswater (C)	84	36.4	(28.3 - 44.5)	0.95	(0.76 - 1.18)	-	48	16.8	(11.4 - 22.2)	1.00	(0.72 - 1.30)	-
Belmont (C)	67	48.1	(35.9 - 60.3)	1.32	(1.03 - 1.68)	^	30	17.6	(10.6 - 24.5)	1.08	(0.70 - 1.49)	-
Beverley (S)	3	35.8	(0.0 - 76.7)	0.91	(0.07 - 2.11)	-*	0	-	-	0	n/a	-
Boddington (S)	2	63.6	(0.0 - 158.8)	1.27	(0.02 - 3.53)	-*	1	29.0	(0.0 - 85.4)	1.45	(0.00 - 5.36)	-*
Boyup Brook (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bridgetown-Greenbushes (S)	7	45.1	(11.6 - 78.5)	1.13	(0.36 - 2.11)	-	5	30.5	(3.4 - 57.6)	1.67	(0.36 - 3.42)	-*
Brookton (S)	1	7.1	(0.0 - 21.0)	0.49	(0.00 - 1.80)	-*	2	62.3	(0.0 - 148.3)	2.45	(0.03 - 6.84)	-*
Broome (S)	9	32.5	(10.6 - 54.4)	1.06	(0.41 - 1.86)	-	1	7.1	(0.0 - 21.1)	0.29	(0.00 - 1.06)	-*
Broomehill (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Bruce Rock (S)	1	11.9	(0.0 - 35.0)	0.52	(0.00 - 1.93)	-*	0	-	-	0	n/a	-
Bunbury (C)	43	40.3	(27.5 - 53.2)	1.00	(0.70 - 1.31)	-	27	26.1	(15.7 - 36.5)	1.13	(0.71 - 1.60)	-
Busselton (S)	30	31.3	(19.5 - 43.2)	0.82	(0.53 - 1.14)	-	25	25.4	(14.7 - 36.1)	1.31	(0.81 - 1.87)	-
Cambridge (T)	26	18.7	(11.0 - 26.5)	0.64	(0.40 - 0.90)	V	20	11.4	(5.2 - 17.5)	0.84	(0.48 - 1.25)	-
Canning (C)	106	44.3	(35.6 - 52.9)	1.15	(0.94 - 1.39)	-	64	20.5	(15.3 - 25.8)	1.20	(0.93 - 1.54)	-
Capel (S) - Pt A	2	28.3	(0.0 - 69.4)	0.86	(0.01 - 2.39)	-*	0	-	-	0	n/a	-
Capel (S) - Pt B	6	38.5	(7.4 - 69.7)	1.06	(0.29 - 2.05)	-	4	35.5	(0.5 - 70.5)	1.68	(0.26 - 3.68)	-*
Carnamah (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Carnarvon (S)	11	54.6	(22.2 - 86.9)	1.26	(0.55 - 2.10)	-	2	10.5	(0.0 - 26.0)	0.60	(0.01 - 1.66)	-*
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	1.82	(0.02 - 5.08)	-*	0	-	-	-	-	-
Chittering (S)	6	50.0	(9.9 - 90.0)	1.39	(0.38 - 2.71)	-*	3	36.2	(0.0 - 77.2)	1.91	(0.15 - 4.45)	-*
Claremont (T)	10	25.3	(7.7 - 42.8)	0.63	(0.26 - 1.07)	-	9	6.0	(1.0 - 11.0)	0.81	(0.31 - 1.42)	-
Cockburn (C)	69	36.8	(28.0 - 45.5)	0.93	(0.73 - 1.19)	-	47	22.5	(15.8 - 29.2)	1.21	(0.87 - 1.58)	-
Collie (S)	21	73.0	(40.2 - 105.9)	1.59	(0.92 - 2.34)	-	1	1.9	(0.0 - 5.7)	0.15	(0.00 - 0.57)	V
Coolgardie (S)	2	31.3	(0.0 - 81.9)	0.83	(0.01 - 2.32)	-*	1	9.1	(0.0 - 27.0)	1.08	(0.00 - 3.99)	-*
Coorow (S)	1	17.1	(0.0 - 50.5)	0.50	(0.00 - 1.85)	-*	1	26.7	(0.0 - 78.8)	1.31	(0.00 - 4.82)	-*
Corrigin (S)	1	25.0	(0.0 - 73.8)	0.47	(0.00 - 1.75)	-*	0	-	-	0	n/a	-
Cottesloe (T)	7	22.7	(4.9 - 40.6)	0.60	(0.19 - 1.13)	-	6	7.7	(0.7 - 14.6)	0.84	(0.23 - 1.63)	-
Cranbrook (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Cuballing (S)	1	38.2	(0.0 - 112.9)	0.98	(0.00 - 3.61)	-*	0	-	-	-	-	-
Cue (S)	3	339.9	(0.0 - 727.8)	7.49	(0.60 - 17.49)	-*	0	-	-	-	-	-
Cunderdin (S)	2	37.2	(0.0 - 88.3)	0.97	(0.01 - 2.70)	-*	1	21.3	(0.0 - 62.9)	1.00	(0.00 - 3.70)	-*
Dalwallinu (S)	3	54.4	(0.0 - 116.2)	1.24	(0.10 - 2.90)	-*	0	-	-	0	n/a	-
Dandaragan (S)	7	52.1	(13.4 - 90.7)	1.38	(0.43 - 2.58)	-	1	12.5	(0.0 - 37.0)	0.52	(0.00 - 1.92)	-*
Dardanup (S) - Pt A	6	40.2	(7.6 - 72.9)	1.06	(0.29 - 2.06)	-	4	23.4	(0.4 - 46.5)	1.40	(0.22 - 3.07)	-*
Dardanup (S) - Pt B	4	50.0	(0.0 - 100.9)	1.23	(0.19 - 2.71)	-*	1	20.8	(0.0 - 60.8)	0.81	(0.00 - 3.00)	-*
Denmark (S)	5	26.9	(3.2 - 50.7)	0.59	(0.13 - 1.21)	-	3	14.3	(0.0 - 30.7)	0.79	(0.06 - 1.84)	-*
Derby-West Kimberley (S)	10	68.3	(25.5 - 111.1)	1.74	(0.71 - 2.97)	-	4	33.8	(0.0 - 68.0)	1.73	(0.27 - 3.79)	-*
Donnybrook-Balingup (S)	5	33.5	(4.2 - 62.9)	0.78	(0.17 - 1.60)	-	2	15.3	(0.0 - 36.4)	0.68	(0.01 - 1.89)	-*
Dowerin (S)	1	42.6	(0.0 - 125.1)	0.91	(0.00 - 3.35)	-*	2	50.0	(0.0 - 118.4)	3.25	(0.04 - 9.06)	-*
Dumbleyung (S)	1	37.0	(0.0 - 109.2)	0.82	(0.00 - 3.03)	-*	0	-	-	0	n/a	-
Dundas (S)	2	47.0	(0.0 - 113.0)	1.29	(0.02 - 3.58)	-*	1	48.4	(0.0 - 142.5)	1.61	(0.00 - 5.96)	-*
East Fremantle (T)	9	34.5	(10.6 - 58.4)	0.86	(0.33 - 1.51)	-	4	12.3	(0.0 - 26.3)	0.68	(0.11 - 1.50)	-
East Pilbara (S)	4	40.5	(0.0 - 87.5)	1.18	(0.18 - 2.60)	-*	1	5.8	(0.0 - 17.2)	0.78	(0.00 - 2.89)	-*
Esperance (S)	15	36.4	(17.9 - 55.0)	0.90	(0.46 - 1.41)	-	13	31.5	(14.1 - 48.9)	1.60	(0.77 - 2.59)	-
Exmouth (S)	5	80.6	(9.6 - 151.6)	2.12	(0.46 - 4.35)	-*	0	-	-	0	n/a	-
Fremantle (C) - Inner	0	-	-	0	n/a	-	1	74.1	(0.0 - 216.5)	2.48	(0.00 - 9.15)	-*
Fremantle (C) - Remainder	49	45.1	(31.9 - 58.4)	1.16	(0.83 - 1.50)	-	26	20.5	(12.0 - 29.0)	1.12	(0.70 - 1.59)	-
Geraldton (C)	50	70.2	(50.3 - 90.1)	1.72	(1.25 - 2.23)	^	21	25.7	(13.8 - 37.6)	1.35	(0.79 - 1.98)	-
Gingin (S)	8	47.6	(13.1 - 82.1)	1.10	(0.39 - 1.98)	-	1	6.4	(0.0 - 18.9)	0.34	(0.00 - 1.25)	-*
Gnowangerup (S)	1	24.2	(0.0 - 71.4)	0.50	(0.00 - 1.84)	-*	0	-	-	0	n/a	-
Goomalling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Gosnells (C)	87	40.1	(31.5 - 48.7)	1.02	(0.82 - 1.26)	-	45	17.1	(11.9 - 22.3)	0.99	(0.70 - 1.30)	-
Greenough (S) - Pt A	6	22.7	(4.3 - 41.2)	0.63	(0.17 - 1.23)	-	6	29.0	(5.6 - 52.3)	1.43	(0.39 - 2.79)	-*
Greenough (S) - Pt B	2	41.1	(0.0 - 98.3)	1.18	(0.01 - 3.29)	-*	0	-	-	0	n/a	-
Halls Creek (S)	3	39.7	(0.0 - 84.8)	1.14	(0.09 - 2.66)	-*	3	41.9	(0.0 - 89.3)	2.66	(0.21 - 6.21)	-*
Harvey (S) - Pt A	7	23.3	(5.6 - 40.9)	0.67	(0.21 - 1.25)	-	9	37.4	(12.7 - 62.2)	1.83	(0.70 - 3.20)	-
Harvey (S) - Pt B	10	32.0	(11.9 - 52.2)	0.86	(0.35 - 1.47)	-	4	12.2	(0.0 - 25.0)	0.74	(0.11 - 1.61)	-

Cancer type: Lung, bronchus & trachea 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	9	57.1	(19.4 - 94.8)	1.65	(0.63 - 2.89)	-	3	21.3	(0.0 - 45.3)	1.43	(0.12 - 3.33)	-*
Jerramungup (S)	1	24.0	(0.0 - 70.8)	0.65	(0.00 - 2.38)	-*	0	-	-	0	n/a	-
Joondalup (C) - North	35	38.2	(25.3 - 51.1)	0.95	(0.64 - 1.29)	-	20	19.7	(10.8 - 28.6)	1.01	(0.58 - 1.49)	-
Joondalup (C) - South	99	30.6	(24.3 - 36.9)	0.81	(0.66 - 0.99)	V	67	18.7	(14.0 - 23.5)	1.06	(0.83 - 1.35)	-
Kalamunda (S)	50	29.7	(21.3 - 38.0)	0.78	(0.57 - 1.01)	-	25	14.1	(8.3 - 19.8)	0.74	(0.46 - 1.06)	-
Kalgoorlie/Boulder (C) - Pt A	32	67.5	(43.7 - 91.4)	1.59	(1.05 - 2.19)	^	17	29.0	(14.1 - 43.9)	1.67	(0.90 - 2.56)	-
Kalgoorlie/Boulder (C) - Pt B	2	319.8	(0.0 - 771.8)	4.97	(0.06 - 13.85)	-*	1	333.3	(0.0 - 929.7)	10.05	(0.00 - 37.07)	-*
Katanning (S)	7	46.1	(11.2 - 81.0)	1.25	(0.39 - 2.32)	-	5	37.9	(4.5 - 71.4)	1.63	(0.36 - 3.35)	-*
Kellerberrin (S)	0	-	-	0	n/a	-	1	19.7	(0.0 - 58.3)	0.86	(0.00 - 3.16)	-*
Kent (S)	1	74.1	(0.0 - 216.5)	1.58	(0.00 - 5.84)	-*	0	-	-	-	-	-
Kojonup (S)	1	5.7	(0.0 - 16.9)	0.28	(0.00 - 1.02)	-*	1	11.4	(0.0 - 33.8)	0.60	(0.00 - 2.22)	-*
Kondinin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Koorda (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Kulin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Kwinana (T)	32	48.0	(31.2 - 64.8)	1.27	(0.84 - 1.75)	-	23	33.8	(19.6 - 48.0)	1.87	(1.12 - 2.70)	^
Lake Grace (S)	3	88.4	(0.0 - 203.7)	1.65	(0.13 - 3.85)	-*	3	61.5	(0.0 - 129.9)	3.71	(0.30 - 8.67)	-*
Laverton (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Leonora (S)	0	-	-	0	n/a	-	1	42.6	(0.0 - 125.5)	2.63	(0.00 - 9.70)	-*
Mandurah (C)	92	38.2	(29.9 - 46.6)	0.93	(0.76 - 1.15)	-	53	20.0	(14.1 - 25.9)	1.13	(0.85 - 1.49)	-
Manjimup (S)	17	40.6	(20.7 - 60.4)	1.16	(0.62 - 1.77)	-	4	9.5	(0.0 - 19.5)	0.60	(0.09 - 1.31)	-
Meekatharra (S)	3	109.8	(0.0 - 234.1)	2.47	(0.20 - 5.76)	-*	1	46.2	(0.0 - 135.9)	1.93	(0.00 - 7.11)	-*
Melville (C)	123	30.9	(25.1 - 36.6)	0.81	(0.68 - 0.98)	V	82	16.9	(12.9 - 21.0)	0.93	(0.74 - 1.16)	-
Menzies (S)	0	-	-	-	-	-	0	-	-	-	-	-
Merredin (S)	5	46.1	(5.3 - 86.9)	1.02	(0.22 - 2.09)	-	6	50.2	(8.2 - 92.2)	2.58	(0.70 - 5.02)	-*
Mingenew (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Moora (S)	5	87.5	(10.7 - 164.3)	1.62	(0.35 - 3.32)	-*	0	-	-	0	n/a	-
Morawa (S)	1	28.8	(0.0 - 85.1)	0.63	(0.00 - 2.34)	-*	0	-	-	0	n/a	-
Mosman Park (T)	13	45.0	(19.3 - 70.7)	1.01	(0.48 - 1.63)	-	4	7.0	(0.0 - 16.4)	0.52	(0.08 - 1.13)	-
Mount Magnet (S)	0	-	-	0	n/a	-	2	145.0	(0.0 - 346.4)	8.00	(0.10 - 22.29)	-*
Mount Marshall (S)	0	-	-	0	n/a	-	1	62.5	(0.0 - 183.1)	3.01	(0.00 - 11.10)	-*
Mukinbudin (S)	1	23.5	(0.0 - 69.4)	0.88	(0.00 - 3.26)	-*	0	-	-	-	-	-
Mullewa (S)	1	27.6	(0.0 - 81.5)	0.81	(0.00 - 2.98)	-*	0	-	-	-	-	-
Mundaring (S)	29	25.1	(15.8 - 34.5)	0.67	(0.43 - 0.93)	V	18	13.3	(6.9 - 19.7)	0.79	(0.44 - 1.20)	-
Murchison (S)	0	-	-	-	-	-	0	-	-	-	-	-
Murray (S)	21	35.7	(20.2 - 51.1)	0.99	(0.58 - 1.46)	-	16	34.5	(17.4 - 51.7)	1.90	(1.00 - 2.93)	-
Nannup (S)	1	22.6	(0.0 - 66.8)	0.56	(0.00 - 2.05)	-*	0	-	-	0	n/a	-
Narembeen (S)	2	43.5	(0.0 - 105.9)	1.32	(0.02 - 3.68)	-*	2	31.0	(0.0 - 75.7)	2.79	(0.03 - 7.78)	-*
Narrogin (S)	1	17.2	(0.0 - 50.7)	0.48	(0.00 - 1.78)	-*	0	-	-	0	n/a	-
Narrogin (T)	7	52.7	(10.4 - 95.0)	1.29	(0.41 - 2.41)	-	4	31.9	(0.0 - 64.4)	1.27	(0.20 - 2.78)	-*
Nedlands (C)	24	21.5	(11.8 - 31.1)	0.70	(0.42 - 1.00)	-	19	13.4	(5.9 - 20.9)	0.84	(0.47 - 1.26)	-
Ngaanyatjarraku (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Northam (S)	3	23.3	(0.0 - 49.6)	0.58	(0.05 - 1.36)	-	2	19.5	(0.0 - 46.4)	0.96	(0.01 - 2.67)	-*
Northam (T)	14	56.8	(25.8 - 87.8)	1.39	(0.69 - 2.20)	-	9	32.5	(9.1 - 55.9)	1.58	(0.61 - 2.76)	-
Northampton (S)	6	44.8	(8.4 - 81.3)	1.02	(0.28 - 1.99)	-	0	-	-	0	n/a	-
Nungarin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Peppermint Grove (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Perenjori (S)	2	132.9	(0.0 - 316.1)	3.03	(0.04 - 8.44)	-*	0	-	-	-	-	-
Perth (C) - Inner	3	163.2	(0.0 - 360.4)	2.75	(0.22 - 6.42)	-*	0	-	-	-	-	-
Perth (C) - Remainder	12	45.6	(19.5 - 71.7)	1.08	(0.49 - 1.77)	-	2	8.8	(0.0 - 22.3)	0.47	(0.01 - 1.31)	-*
Pingelly (S)	4	66.7	(3.6 - 129.9)	1.75	(0.27 - 3.84)	-*	1	22.7	(0.0 - 67.0)	0.93	(0.00 - 3.44)	-*
Plantagenet (S)	7	35.4	(9.0 - 61.8)	0.95	(0.30 - 1.76)	-	1	2.6	(0.0 - 7.7)	0.29	(0.00 - 1.09)	-*
Port Hedland (T)	8	38.1	(7.7 - 68.4)	1.09	(0.38 - 1.97)	-	6	37.1	(3.0 - 71.2)	2.12	(0.57 - 4.12)	-*
Quairading (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Ravensthorpe (S)	3	46.8	(0.0 - 99.8)	1.33	(0.11 - 3.11)	-*	0	-	-	0	n/a	-
Rockingham (C)	96	36.6	(29.1 - 44.2)	0.95	(0.78 - 1.17)	-	59	21.1	(15.5 - 26.7)	1.15	(0.89 - 1.50)	-
Roebourne (S)	13	90.4	(30.9 - 149.8)	1.97	(0.94 - 3.18)	-	3	18.0	(0.0 - 40.9)	1.09	(0.09 - 2.56)	-*
Sandstone (S)	0	-	-	-	-	-	0	-	-	-	-	-
Serpentine-Jarrahdale (S)	12	35.4	(15.2 - 55.6)	0.94	(0.43 - 1.54)	-	4	14.0	(0.2 - 27.8)	0.70	(0.11 - 1.53)	-
Shark Bay (S)	2	50.9	(0.0 - 121.3)	1.10	(0.01 - 3.06)	-*	0	-	-	0	n/a	-
South Perth (C)	42	27.5	(18.1 - 36.9)	0.77	(0.54 - 1.03)	-	25	14.4	(7.5 - 21.2)	0.69	(0.42 - 0.98)	V
Stirling (C) - Central	180	45.0	(38.2 - 51.9)	1.16	(1.00 - 1.35)	-	84	18.9	(14.5 - 23.2)	0.97	(0.78 - 1.20)	-
Stirling (C) - Coastal	80	31.8	(24.6 - 39.1)	0.85	(0.68 - 1.06)	-	45	13.9	(9.4 - 18.4)	0.82	(0.58 - 1.07)	-
Stirling (C) - South-Eastern	30	44.7	(26.4 - 63.0)	1.12	(0.73 - 1.56)	-	11	10.7	(2.8 - 18.5)	0.62	(0.27 - 1.04)	-
Subiaco (C)	26	49.1	(28.9 - 69.4)	1.37	(0.85 - 1.94)	-	11	16.3	(6.1 - 26.6)	0.90	(0.39 - 1.51)	-
Swan (C)	109	53.2	(43.0 - 63.3)	1.36	(1.12 - 1.65)	^	40	17.1	(11.6 - 22.6)	0.96	(0.66 - 1.28)	-

Cancer type: Lung, bronchus & trachea 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Tammin (S)	2	173.9	(0.0 - 404.2)	3.28	(0.04 - 9.14)	-*	0	-	-	-	-	.
Three Springs (S)	1	44.4	(0.0 - 131.1)	0.82	(0.00 - 3.02)	-*	0	-	-	-	-	.
Toodyay (S)	6	37.0	(7.4 - 66.6)	1.01	(0.27 - 1.96)	-	2	12.0	(0.0 - 28.6)	0.82	(0.01 - 2.30)	-*
Trayning (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
Victoria Park (T)	54	46.3	(31.6 - 60.9)	1.20	(0.91 - 1.57)	-	29	17.9	(9.0 - 26.7)	0.94	(0.60 - 1.31)	-
Victoria Plains (S)	4	92.0	(2.3 - 181.6)	2.35	(0.36 - 5.15)	-*	1	41.7	(0.0 - 122.8)	1.99	(0.00 - 7.34)	-*
Vincent (T)	61	64.6	(47.1 - 82.2)	1.59	(1.22 - 2.05)	^	16	12.3	(5.3 - 19.4)	0.73	(0.38 - 1.13)	-
Wagin (S)	7	67.8	(7.9 - 127.6)	2.18	(0.69 - 4.07)	-*	2	35.6	(0.0 - 85.0)	1.14	(0.01 - 3.18)	-*
Wandering (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wanneroo (C) - North-East	28	47.8	(29.8 - 65.9)	1.24	(0.79 - 1.74)	-	14	22.6	(10.3 - 34.9)	1.18	(0.59 - 1.88)	-
Wanneroo (C) - North-West	22	35.5	(20.4 - 50.6)	0.82	(0.48 - 1.19)	-	13	16.8	(7.4 - 26.2)	1.04	(0.50 - 1.68)	-
Wanneroo (C) - South	42	52.7	(36.7 - 68.8)	1.33	(0.93 - 1.76)	-	19	18.9	(10.2 - 27.6)	1.11	(0.62 - 1.66)	-
Waroona (S)	3	21.1	(0.0 - 45.5)	0.54	(0.04 - 1.26)	-	1	4.7	(0.0 - 13.9)	0.40	(0.00 - 1.47)	-*
West Arthur (S)	1	32.8	(0.0 - 96.9)	0.63	(0.00 - 2.31)	-*	0	-	-	0	n/a	-
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wickepin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Williams (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Wiluna (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wongan-Ballidu (S)	4	88.8	(0.8 - 176.8)	2.27	(0.35 - 4.98)	-*	1	20.5	(0.0 - 60.6)	1.12	(0.00 - 4.12)	-*
Woodanilling (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	1	40.3	(0.0 - 119.0)	0.82	(0.00 - 3.01)	-*	0	-	-	-	-	.
Wyndham-East Kimberley (S)	3	14.3	(0.0 - 30.6)	0.63	(0.05 - 1.46)	-	2	11.9	(0.0 - 29.2)	1.09	(0.01 - 3.04)	-*
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Yilgarn (S)	2	35.6	(0.0 - 84.9)	1.02	(0.01 - 2.85)	-*	1	24.8	(0.0 - 73.4)	1.26	(0.00 - 4.64)	-*
York (S)	6	47.0	(9.4 - 84.6)	1.04	(0.28 - 2.02)	-	2	11.3	(0.0 - 28.7)	0.74	(0.01 - 2.06)	-*
Total State	2473	39.0	(37.4 - 40.6)	1.00	(0.96 - 1.04)	-	1320	18.2	(17.2 - 19.3)	1.00	(0.95 - 1.06)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (alphabetic)
Cancer type: All cancers 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	239	404.0	(349.8 - 458.1)	0.98	(0.86 - 1.11)	-	225	301.9	(255.7 - 348.0)	1.05	(0.92 - 1.20)	-
Albany (C) Bal	110	220.2	(178.4 - 262.1)	0.65	(0.54 - 0.79)	V	99	219.0	(175.3 - 262.7)	0.86	(0.70 - 1.05)	-
Armadale (C)	458	296.1	(268.8 - 323.4)	0.87	(0.79 - 0.96)	V	461	271.9	(246.3 - 297.5)	1.04	(0.95 - 1.14)	-
Ashburton (S)	27	275.4	(151.4 - 399.5)	0.84	(0.53 - 1.18)	-	13	113.0	(30.6 - 195.3)	0.59	(0.28 - 0.94)	V
Augusta-Margaret River (S)	106	299.5	(239.8 - 359.1)	0.93	(0.76 - 1.13)	-	84	245.6	(189.8 - 301.3)	1.00	(0.80 - 1.24)	-
Bassendean (T)	173	340.8	(288.8 - 392.8)	1.00	(0.86 - 1.16)	-	136	240.0	(197.1 - 283.0)	0.91	(0.77 - 1.08)	-
Bayswater (C)	678	316.0	(291.4 - 340.7)	0.93	(0.86 - 1.00)	-	626	269.9	(246.8 - 293.1)	1.03	(0.95 - 1.12)	-
Belmont (C)	425	353.2	(317.5 - 388.8)	1.04	(0.95 - 1.15)	-	360	278.7	(246.6 - 310.8)	1.07	(0.97 - 1.19)	-
Beverley (S)	24	320.2	(184.9 - 455.5)	0.90	(0.55 - 1.29)	-	13	170.0	(69.8 - 270.3)	0.72	(0.34 - 1.16)	-
Boddington (S)	12	257.4	(95.3 - 419.6)	0.85	(0.39 - 1.39)	-	11	315.5	(126.3 - 504.7)	1.09	(0.48 - 1.82)	-
Boyup Brook (S)	14	205.9	(96.1 - 315.7)	0.61	(0.30 - 0.97)	V	17	226.6	(98.3 - 355.0)	0.94	(0.50 - 1.43)	-
Bridgetown-Greenbushes (S)	45	310.6	(216.3 - 404.8)	0.87	(0.62 - 1.14)	-	45	307.3	(215.7 - 398.9)	1.12	(0.80 - 1.47)	-
Brookton (S)	14	242.8	(99.3 - 386.2)	0.84	(0.42 - 1.33)	-	18	449.9	(228.9 - 670.9)	1.73	(0.95 - 2.61)	-
Broome (S)	71	270.4	(205.2 - 335.7)	0.86	(0.68 - 1.09)	-	58	221.5	(160.7 - 282.2)	0.95	(0.73 - 1.24)	-
Broomehill (S)	5	269.0	(28.7 - 509.3)	0.88	(0.19 - 1.79)	-	3	132.6	(0.0 - 282.6)	0.67	(0.05 - 1.56)	-*
Bruce Rock (S)	19	411.7	(218.7 - 604.7)	1.21	(0.68 - 1.81)	-	11	231.9	(88.9 - 375.0)	0.93	(0.41 - 1.56)	-
Bunbury (C)	330	323.7	(287.0 - 360.3)	0.93	(0.83 - 1.03)	-	316	282.9	(248.8 - 316.9)	1.06	(0.95 - 1.18)	-
Busselton (S)	284	324.5	(284.6 - 364.4)	0.97	(0.86 - 1.09)	-	215	242.7	(207.0 - 278.4)	0.91	(0.80 - 1.05)	-
Cambridge (T)	332	338.9	(299.7 - 378.0)	1.00	(0.90 - 1.12)	-	306	265.7	(231.1 - 300.4)	1.04	(0.93 - 1.17)	-
Canning (C)	766	331.1	(307.3 - 354.9)	0.97	(0.90 - 1.04)	-	697	250.7	(231.2 - 270.2)	0.99	(0.92 - 1.07)	-
Capel (S) - Pt A	12	174.0	(72.8 - 275.2)	0.56	(0.25 - 0.91)	V	9	151.1	(46.9 - 255.3)	0.51	(0.20 - 0.90)	V
Capel (S) - Pt B	38	278.6	(188.2 - 369.1)	0.79	(0.54 - 1.06)	-	39	321.9	(217.5 - 426.3)	1.15	(0.79 - 1.53)	-
Carnamah (S)	6	210.9	(43.3 - 378.5)	0.75	(0.20 - 1.45)	-	6	280.3	(52.9 - 507.7)	1.14	(0.31 - 2.22)	-
Carnarvon (S)	59	268.6	(199.7 - 337.5)	0.80	(0.61 - 1.03)	-	44	256.7	(179.3 - 334.1)	0.93	(0.66 - 1.23)	-
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	0.20	(0.00 - 0.57)	V	5	134.3	(13.9 - 254.8)	0.75	(0.16 - 1.54)	-
Chittering (S)	35	342.7	(220.8 - 464.7)	0.97	(0.66 - 1.32)	-	17	199.7	(103.0 - 296.4)	0.74	(0.40 - 1.13)	-
Claremont (T)	140	387.9	(313.7 - 462.1)	1.08	(0.91 - 1.28)	-	146	266.4	(208.7 - 324.1)	1.09	(0.92 - 1.28)	-
Cockburn (C)	647	340.4	(314.1 - 366.7)	1.01	(0.93 - 1.09)	-	560	271.6	(248.6 - 294.7)	1.04	(0.96 - 1.13)	-
Collie (S)	127	395.3	(322.7 - 467.9)	1.16	(0.97 - 1.38)	-	94	308.7	(242.8 - 374.6)	1.13	(0.92 - 1.39)	-
Coolgardie (S)	17	162.6	(74.2 - 251.1)	0.65	(0.35 - 0.99)	V	16	264.7	(117.6 - 411.8)	0.87	(0.46 - 1.35)	-
Coorow (S)	25	491.5	(300.0 - 683.0)	1.47	(0.91 - 2.10)	-	13	302.6	(136.7 - 468.6)	1.19	(0.57 - 1.93)	-
Corrigin (S)	12	252.5	(107.6 - 397.5)	0.68	(0.31 - 1.12)	-	13	230.2	(94.7 - 365.7)	0.93	(0.44 - 1.50)	-
Cottesloe (T)	98	333.8	(265.4 - 402.2)	1.01	(0.83 - 1.24)	-	98	308.5	(234.1 - 382.9)	1.10	(0.90 - 1.35)	-
Cranbrook (S)	11	287.1	(108.7 - 465.4)	0.72	(0.31 - 1.20)	-	8	224.8	(58.2 - 391.4)	0.92	(0.32 - 1.66)	-
Cuballing (S)	10	352.8	(136.9 - 568.7)	1.13	(0.47 - 1.94)	-	5	236.4	(21.4 - 451.4)	0.83	(0.18 - 1.69)	-
Cue (S)	7	856.5	(255.0 - 1,458.1)	1.79	(0.56 - 3.34)	-*	1	114.3	(0.0 - 335.1)	0.41	(0.00 - 1.52)	-*
Cunderdin (S)	15	300.3	(148.1 - 452.4)	0.86	(0.44 - 1.35)	-	8	135.8	(28.5 - 243.0)	0.62	(0.22 - 1.12)	-
Dalwallinu (S)	19	320.2	(175.4 - 465.0)	0.94	(0.53 - 1.40)	-	12	228.1	(94.5 - 361.7)	0.83	(0.38 - 1.37)	-
Dandaragan (S)	42	326.1	(221.7 - 430.4)	1.01	(0.71 - 1.34)	-	23	252.2	(147.7 - 356.7)	0.91	(0.55 - 1.32)	-
Dardanup (S) - Pt A	47	314.9	(224.1 - 405.6)	0.93	(0.66 - 1.21)	-	41	239.6	(164.9 - 314.3)	0.99	(0.69 - 1.32)	-
Dardanup (S) - Pt B	25	299.5	(181.4 - 417.6)	0.90	(0.55 - 1.29)	-	10	144.8	(53.8 - 235.7)	0.56	(0.23 - 0.96)	V
Denmark (S)	51	244.8	(176.4 - 313.3)	0.75	(0.56 - 0.99)	V	40	240.5	(157.8 - 323.3)	0.83	(0.58 - 1.11)	-
Derby-West Kimberley (S)	51	329.3	(237.7 - 420.8)	0.94	(0.70 - 1.24)	-	33	237.2	(153.0 - 321.4)	0.88	(0.58 - 1.20)	-
Donnybrook-Balingup (S)	42	255.3	(177.9 - 332.7)	0.77	(0.54 - 1.02)	-	45	278.1	(195.4 - 360.8)	1.10	(0.78 - 1.44)	-
Dowerin (S)	13	493.7	(222.8 - 764.6)	1.40	(0.67 - 2.26)	-	15	460.0	(217.5 - 702.6)	1.93	(0.99 - 3.03)	-
Dumbleyung (S)	8	297.4	(86.7 - 508.2)	0.79	(0.28 - 1.42)	-	3	122.5	(0.0 - 261.9)	0.44	(0.04 - 1.03)	-
Dundas (S)	13	328.2	(148.4 - 508.0)	0.92	(0.44 - 1.49)	-	7	240.0	(51.9 - 428.1)	0.77	(0.24 - 1.43)	-
East Fremantle (T)	88	331.8	(259.0 - 404.5)	1.02	(0.82 - 1.26)	-	74	269.3	(199.6 - 339.1)	1.00	(0.79 - 1.26)	-
East Pilbara (S)	27	217.3	(118.0 - 316.5)	0.71	(0.45 - 1.01)	-	10	99.4	(29.6 - 169.3)	0.41	(0.17 - 0.70)	V
Esperance (S)	138	334.3	(278.1 - 390.5)	0.97	(0.82 - 1.15)	-	106	253.6	(203.8 - 303.3)	0.97	(0.80 - 1.18)	-
Exmouth (S)	23	374.6	(209.0 - 540.2)	1.08	(0.65 - 1.57)	-	11	209.2	(84.5 - 333.9)	0.76	(0.33 - 1.28)	-
Fremantle (C) - Inner	12	317.5	(131.0 - 504.0)	0.87	(0.40 - 1.43)	-	8	383.2	(105.2 - 661.1)	1.34	(0.47 - 2.42)	-
Fremantle (C) - Remainder	404	402.9	(361.7 - 444.1)	1.17	(1.06 - 1.30)	^	295	271.4	(237.5 - 305.2)	1.03	(0.91 - 1.15)	-
Geraldton (C)	287	419.2	(369.7 - 468.7)	1.21	(1.08 - 1.36)	^	233	314.6	(271.5 - 357.7)	1.19	(1.05 - 1.36)	^
Gingin (S)	73	429.4	(327.1 - 531.7)	1.23	(0.97 - 1.55)	-	40	265.1	(179.3 - 350.8)	1.01	(0.70 - 1.35)	-
Gnowangerup (S)	26	530.7	(325.7 - 735.7)	1.51	(0.94 - 2.14)	-	12	221.9	(92.2 - 351.7)	0.93	(0.43 - 1.53)	-
Goomalling (S)	10	254.9	(99.4 - 410.5)	0.75	(0.31 - 1.29)	-	4	91.9	(0.0 - 190.8)	0.42	(0.06 - 0.91)	V
Gosnells (C)	728	328.3	(304.2 - 352.4)	0.97	(0.90 - 1.04)	-	611	249.4	(229.0 - 269.8)	0.95	(0.88 - 1.03)	-
Greenough (S) - Pt A	72	273.2	(208.9 - 337.5)	0.83	(0.65 - 1.05)	-	49	186.5	(132.4 - 240.5)	0.72	(0.52 - 0.94)	V
Greenough (S) - Pt B	9	248.2	(67.8 - 428.6)	0.61	(0.23 - 1.07)	-	2	56.3	(0.0 - 134.5)	0.23	(0.00 - 0.64)	V
Halls Creek (S)	16	225.5	(112.0 - 339.1)	0.65	(0.34 - 1.01)	-	15	221.4	(105.4 - 337.5)	0.83	(0.42 - 1.30)	-
Harvey (S) - Pt A	93	348.9	(275.3 - 422.5)	1.02	(0.83 - 1.26)	-	64	242.6	(182.1 - 303.1)	0.91	(0.70 - 1.17)	-
Harvey (S) - Pt B	103	355.4	(285.3 - 425.4)	1.06	(0.87 - 1.29)	-	77	279.9	(214.3 - 345.4)	1.07	(0.85 - 1.34)	-

Cancer type: All cancers 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	40	290.0	(199.5 - 380.4)	0.92	(0.63 - 1.22)	-	37	383.4	(253.4 - 513.4)	1.35	(0.92 - 1.82)	-
Jerramungup (S)	11	282.0	(113.3 - 450.6)	0.81	(0.35 - 1.36)	-	3	85.5	(0.0 - 186.1)	0.35	(0.03 - 0.82)	V
Joondalup (C) - North	348	344.5	(307.2 - 381.9)	1.02	(0.92 - 1.14)	-	289	247.7	(218.1 - 277.4)	0.95	(0.84 - 1.07)	-
Joondalup (C) - South	1042	326.6	(305.9 - 347.3)	0.97	(0.91 - 1.03)	-	933	268.6	(250.3 - 286.9)	1.03	(0.96 - 1.10)	-
Kalamunda (S)	494	311.4	(283.4 - 339.3)	0.91	(0.83 - 1.00)	-	434	249.2	(224.8 - 273.7)	0.96	(0.87 - 1.05)	-
Kalgoorlie/Boulder (C) - Pt A	226	384.3	(331.6 - 436.9)	1.14	(1.00 - 1.30)	-	165	253.5	(211.5 - 295.5)	1.02	(0.88 - 1.20)	-
Kalgoorlie/Boulder (C) - Pt B	5	677.3	(57.1 - 1,297.5)	1.35	(0.30 - 2.77)	-*	3	857.1	(19.4 - 1,694.9)	1.81	(0.15 - 4.23)	-*
Katanning (S)	49	333.7	(239.2 - 428.1)	1.03	(0.74 - 1.33)	-	42	267.8	(182.9 - 352.7)	1.05	(0.74 - 1.39)	-
Kellerberrin (S)	17	318.2	(160.6 - 475.9)	0.88	(0.47 - 1.34)	-	18	347.0	(160.8 - 533.2)	1.26	(0.69 - 1.91)	-
Kent (S)	5	256.8	(23.8 - 489.8)	0.84	(0.18 - 1.72)	-	2	231.2	(0.0 - 554.7)	0.52	(0.01 - 1.46)	-*
Kojonup (S)	30	344.7	(210.9 - 478.4)	1.00	(0.65 - 1.39)	-	19	187.7	(97.7 - 277.7)	0.88	(0.50 - 1.32)	-
Kondinin (S)	14	411.5	(198.7 - 624.3)	1.25	(0.62 - 1.98)	-	10	338.9	(127.3 - 550.5)	1.37	(0.56 - 2.35)	-
Koorda (S)	3	204.0	(0.0 - 444.3)	0.46	(0.04 - 1.08)	-	2	99.5	(0.0 - 240.0)	0.43	(0.01 - 1.21)	-
Kulin (S)	6	159.8	(23.2 - 296.5)	0.52	(0.14 - 1.01)	-	3	89.2	(0.0 - 190.5)	0.37	(0.03 - 0.87)	V
Kwinana (T)	235	364.7	(317.6 - 411.8)	1.09	(0.96 - 1.24)	-	167	256.3	(216.7 - 296.0)	1.00	(0.86 - 1.17)	-
Lake Grace (S)	17	367.9	(179.7 - 556.0)	1.04	(0.56 - 1.59)	-	18	408.3	(217.3 - 599.4)	1.52	(0.84 - 2.30)	-
Laverton (S)	4	121.5	(0.0 - 244.9)	0.39	(0.06 - 0.85)	V	3	264.9	(0.0 - 605.9)	0.67	(0.05 - 1.57)	-*
Leonora (S)	13	325.2	(129.6 - 520.8)	0.81	(0.39 - 1.30)	-	7	187.9	(44.3 - 331.5)	0.94	(0.30 - 1.76)	-
Mandurah (C)	817	360.9	(333.9 - 387.9)	1.07	(1.00 - 1.14)	-	563	260.3	(236.4 - 284.1)	1.01	(0.93 - 1.10)	-
Manjimup (S)	106	292.2	(235.5 - 348.9)	0.87	(0.71 - 1.05)	-	68	198.4	(148.4 - 248.4)	0.77	(0.60 - 0.98)	V
Meekatharra (S)	21	690.1	(399.1 - 981.2)	1.73	(1.01 - 2.55)	^	8	298.1	(90.6 - 505.7)	1.01	(0.35 - 1.82)	-
Melville (C)	1306	349.6	(329.5 - 369.6)	1.06	(1.00 - 1.12)	-	1166	273.7	(256.3 - 291.2)	1.06	(1.00 - 1.12)	-
Menzies (S)	0	-	-	0	n/a	V	0	-	-	0	n/a	-
Merredin (S)	44	354.0	(247.8 - 460.3)	1.06	(0.75 - 1.40)	-	33	283.0	(181.4 - 384.6)	1.08	(0.71 - 1.47)	-
Mingenew (S)	3	152.1	(0.0 - 322.7)	0.47	(0.04 - 1.10)	-	8	577.6	(179.9 - 975.2)	1.84	(0.65 - 3.31)	-*
Moora (S)	24	353.3	(209.1 - 497.4)	0.89	(0.54 - 1.28)	-	20	273.6	(143.0 - 404.2)	0.96	(0.55 - 1.42)	-
Morawa (S)	7	187.7	(47.8 - 327.5)	0.54	(0.17 - 1.01)	-	8	323.3	(89.7 - 556.9)	1.03	(0.36 - 1.85)	-
Mosman Park (T)	120	362.4	(293.9 - 431.0)	1.13	(0.94 - 1.36)	-	101	247.7	(190.4 - 305.0)	1.04	(0.85 - 1.26)	-
Mount Magnet (S)	3	99.4	(0.0 - 211.8)	0.42	(0.03 - 0.97)	V	5	333.7	(32.9 - 634.4)	1.25	(0.27 - 2.56)	-*
Mount Marshall (S)	4	171.9	(5.3 - 338.5)	0.52	(0.08 - 1.14)	-	3	172.1	(0.0 - 364.4)	0.61	(0.05 - 1.43)	-
Mukinbudin (S)	8	298.1	(87.8 - 508.4)	0.88	(0.31 - 1.58)	-	3	128.5	(0.0 - 274.9)	0.47	(0.04 - 1.10)	-
Mullewa (S)	12	402.9	(176.6 - 629.2)	1.11	(0.51 - 1.82)	-	6	275.5	(37.5 - 513.5)	0.90	(0.24 - 1.74)	-
Mundaring (S)	376	339.4	(304.4 - 374.4)	1.01	(0.91 - 1.11)	-	345	287.9	(256.2 - 319.7)	1.10	(0.99 - 1.22)	-
Murchison (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Murray (S)	152	298.5	(248.0 - 349.0)	0.90	(0.77 - 1.06)	-	124	308.4	(251.4 - 365.4)	1.14	(0.95 - 1.37)	-
Nannup (S)	16	320.0	(161.6 - 478.4)	1.04	(0.55 - 1.61)	-	9	294.3	(69.1 - 519.4)	0.79	(0.30 - 1.39)	-
Narembeen (S)	12	316.4	(135.6 - 497.2)	0.95	(0.43 - 1.56)	-	10	272.8	(99.4 - 446.3)	1.06	(0.43 - 1.81)	-
Narrogin (S)	3	67.3	(0.0 - 144.2)	0.17	(0.01 - 0.39)	V	1	23.1	(0.0 - 68.3)	0.07	(0.00 - 0.27)	V
Narrogin (T)	69	538.6	(404.9 - 672.4)	1.54	(1.21 - 1.96)	^	49	324.2	(220.0 - 428.5)	1.25	(0.90 - 1.63)	-
Nedlands (C)	301	343.1	(300.5 - 385.8)	1.06	(0.95 - 1.19)	-	337	335.0	(292.5 - 377.6)	1.21	(1.08 - 1.34)	^
Ngaanyatjarraku (S)	1	21.5	(0.0 - 63.4)	0.10	(0.00 - 0.38)	V	0	-	-	0	n/a	V
Northam (S)	34	263.8	(172.5 - 355.1)	0.79	(0.53 - 1.08)	-	23	195.6	(115.6 - 275.6)	0.78	(0.46 - 1.12)	-
Northam (T)	95	436.8	(345.2 - 528.4)	1.17	(0.95 - 1.43)	-	74	278.6	(207.1 - 350.1)	1.06	(0.84 - 1.34)	-
Northampton (S)	52	384.6	(276.5 - 492.7)	1.10	(0.83 - 1.45)	-	27	214.8	(133.7 - 295.9)	0.86	(0.54 - 1.22)	-
Nungarin (S)	2	142.9	(0.0 - 333.6)	0.55	(0.01 - 1.53)	-*	2	163.7	(0.0 - 388.3)	0.89	(0.01 - 2.48)	-*
Peppermint Grove (S)	18	270.8	(140.9 - 400.7)	0.84	(0.46 - 1.26)	-	16	234.7	(111.0 - 358.5)	0.92	(0.48 - 1.41)	-
Perenjori (S)	10	650.5	(263.6 - 1,037.4)	1.66	(0.68 - 2.84)	-	4	227.6	(0.0 - 456.1)	0.84	(0.13 - 1.85)	-
Perth (C) - Inner	7	305.5	(65.3 - 545.8)	0.71	(0.22 - 1.33)	-	4	212.2	(0.0 - 425.8)	0.89	(0.14 - 1.95)	-*
Perth (C) - Remainder	110	399.8	(323.4 - 476.1)	1.17	(0.97 - 1.42)	-	39	193.2	(126.7 - 259.7)	0.72	(0.50 - 0.96)	V
Pingelly (S)	20	369.3	(195.5 - 543.0)	1.09	(0.63 - 1.62)	-	7	144.0	(29.1 - 258.9)	0.52	(0.16 - 0.97)	V
Plantagenet (S)	76	425.1	(327.9 - 522.2)	1.25	(0.99 - 1.57)	-	49	283.8	(200.3 - 367.3)	1.11	(0.80 - 1.45)	-
Port Hedland (T)	63	248.6	(177.3 - 319.9)	0.80	(0.62 - 1.03)	-	53	279.9	(193.3 - 366.6)	0.96	(0.73 - 1.27)	-
Quairading (S)	14	298.0	(142.7 - 453.2)	0.95	(0.47 - 1.51)	-	11	217.4	(70.4 - 364.3)	0.91	(0.40 - 1.52)	-
Ravensthorpe (S)	17	264.0	(138.9 - 389.0)	0.88	(0.47 - 1.35)	-	9	211.4	(73.5 - 349.3)	0.73	(0.28 - 1.29)	-
Rockingham (C)	818	331.0	(307.6 - 354.4)	0.99	(0.93 - 1.06)	-	702	276.1	(254.6 - 297.6)	1.07	(0.99 - 1.15)	-
Roebourne (S)	78	349.3	(247.8 - 450.7)	1.01	(0.80 - 1.27)	-	55	245.6	(160.0 - 331.1)	0.93	(0.71 - 1.22)	-
Sandstone (S)	1	100.0	(0.0 - 294.0)	0.45	(0.00 - 1.67)	-*	0	-	-	0	n/a	-
Serpentine-Jarrohdale (S)	124	356.2	(293.0 - 419.3)	1.10	(0.92 - 1.31)	-	82	244.8	(191.0 - 298.5)	0.97	(0.78 - 1.21)	-
Shark Bay (S)	7	196.0	(35.4 - 356.7)	0.48	(0.15 - 0.89)	V	5	229.5	(16.6 - 442.5)	0.62	(0.13 - 1.26)	-
South Perth (C)	477	358.5	(323.6 - 393.4)	1.06	(0.97 - 1.16)	-	429	266.0	(236.2 - 295.9)	0.96	(0.87 - 1.06)	-
Stirling (C) - Central	1238	331.8	(312.7 - 350.9)	0.99	(0.93 - 1.04)	-	1035	245.9	(229.8 - 261.9)	0.96	(0.91 - 1.02)	-
Stirling (C) - Coastal	864	376.3	(350.1 - 402.4)	1.12	(1.04 - 1.20)	^	691	266.9	(245.2 - 288.6)	1.01	(0.93 - 1.09)	-
Stirling (C) - South-Eastern	220	351.0	(296.8 - 405.2)	1.01	(0.88 - 1.15)	-	212	249.7	(206.5 - 292.8)	0.99	(0.87 - 1.14)	-
Subiaco (C)	185	393.3	(334.1 - 452.4)	1.13	(0.97 - 1.31)	-	175	293.8	(243.7 - 343.8)	1.10	(0.95 - 1.28)	-
Swan (C)	708	336.1	(311.0 - 361.1)	1.00	(0.93 - 1.08)	-	579	251.7	(230.5 - 272.9)	0.97	(0.89 - 1.05)	-

Cancer type: All cancers 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	4	190.9	(1.8 - 379.9)	0.51	(0.08 - 1.11)	-	5	212.0	(24.2 - 399.8)	0.90	(0.20 - 1.84)	-
Tammin (S)	6	580.9	(27.8 - 1,133.9)	1.14	(0.31 - 2.21)	-	1	74.6	(0.0 - 219.8)	0.26	(0.00 - 0.96)	V*
Three Springs (S)	6	188.6	(31.2 - 346.1)	0.59	(0.16 - 1.14)	-	8	351.1	(100.5 - 601.6)	1.22	(0.43 - 2.20)	-
Toodyay (S)	50	381.4	(260.8 - 502.0)	1.00	(0.72 - 1.29)	-	25	179.5	(108.4 - 250.5)	0.72	(0.44 - 1.03)	-
Trayning (S)	8	457.9	(140.1 - 775.7)	1.31	(0.46 - 2.36)	-	3	155.1	(0.0 - 329.2)	0.66	(0.05 - 1.53)	-
Upper Gascoyne (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Victoria Park (T)	386	360.3	(319.1 - 401.4)	1.05	(0.95 - 1.16)	-	315	237.5	(202.9 - 272.1)	0.87	(0.78 - 0.97)	V
Victoria Plains (S)	16	414.8	(203.0 - 626.6)	1.13	(0.59 - 1.75)	-	16	562.1	(279.6 - 844.7)	2.13	(1.12 - 3.30)	^
Vincent (T)	330	345.8	(305.6 - 386.1)	1.03	(0.93 - 1.15)	-	253	251.4	(215.5 - 287.3)	0.93	(0.82 - 1.06)	-
Wagin (S)	27	352.8	(204.3 - 501.3)	1.03	(0.65 - 1.45)	-	22	307.2	(169.5 - 445.0)	1.04	(0.61 - 1.52)	-
Wandering (S)	0	-	-	0	n/a	V	1	83.3	(0.0 - 232.4)	0.36	(0.00 - 1.33)	-*
Wanneroo (C) - North-East	210	355.5	(306.7 - 404.3)	1.07	(0.93 - 1.22)	-	162	252.6	(212.3 - 292.9)	0.99	(0.85 - 1.16)	-
Wanneroo (C) - North-West	261	386.2	(338.4 - 434.0)	1.15	(1.01 - 1.30)	^	166	252.7	(213.6 - 291.7)	0.95	(0.82 - 1.11)	-
Wanneroo (C) - South	286	339.3	(299.8 - 378.9)	1.00	(0.89 - 1.12)	-	242	248.5	(216.6 - 280.4)	0.96	(0.85 - 1.09)	-
Waroona (S)	42	304.0	(211.0 - 396.9)	0.93	(0.65 - 1.23)	-	27	232.9	(139.6 - 326.3)	0.83	(0.52 - 1.17)	-
West Arthur (S)	8	203.2	(62.4 - 344.0)	0.61	(0.21 - 1.10)	-	3	102.3	(0.0 - 217.1)	0.35	(0.03 - 0.81)	V
Westonia (S)	5	469.9	(60.8 - 879.0)	1.43	(0.31 - 2.93)	-*	0	-	-	0	n/a	-
Wickepin (S)	14	500.3	(208.2 - 792.5)	1.34	(0.66 - 2.13)	-	5	203.4	(27.5 - 379.4)	0.72	(0.16 - 1.48)	-
Williams (S)	6	181.5	(36.4 - 326.7)	0.54	(0.15 - 1.04)	-	6	215.4	(37.4 - 393.4)	0.76	(0.21 - 1.48)	-
Wiluna (S)	1	100.0	(0.0 - 292.7)	0.14	(0.00 - 0.50)	V	5	390.4	(32.8 - 748.0)	1.61	(0.35 - 3.30)	-*
Wongan-Ballidu (S)	22	461.1	(266.8 - 655.4)	1.42	(0.84 - 2.08)	-	12	215.6	(85.7 - 345.4)	0.97	(0.44 - 1.59)	-
Woodanilling (S)	1	66.7	(0.0 - 196.2)	0.26	(0.00 - 0.95)	V*	0	-	-	0	n/a	-
Wyalkatchem (S)	7	259.5	(60.1 - 458.9)	0.70	(0.22 - 1.31)	-	10	411.8	(137.4 - 686.2)	1.52	(0.63 - 2.61)	-
Wyndham-East Kimberley (S)	36	223.7	(145.6 - 301.8)	0.75	(0.51 - 1.02)	-	31	227.0	(137.5 - 316.5)	0.96	(0.62 - 1.32)	-
Yalgoo (S)	1	62.5	(0.0 - 184.2)	0.29	(0.00 - 1.07)	-*	0	-	-	0	n/a	-
Yilgam (S)	19	397.2	(216.0 - 578.5)	1.07	(0.60 - 1.60)	-	8	171.6	(49.7 - 293.5)	0.69	(0.24 - 1.24)	-
York (S)	47	369.2	(254.7 - 483.7)	1.00	(0.72 - 1.30)	-	31	223.5	(138.4 - 308.5)	0.89	(0.58 - 1.23)	-
Total State	20827	338.1	(333.4 - 342.7)	1.00	(0.99 - 1.01)	-	17314	260.1	(255.9 - 264.2)	1.00	(0.99 - 1.02)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (DOH Areas)
Cancer type: Breast 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	1	1.4	(0.0 - 4.1)	1.85	(0.00 - 6.84)	-*	87	94.4	(73.3 - 115.5)	1.07	(0.86 - 1.33)	-
Claremont (T)	0	-	-	-	-	.	32	66.9	(38.8 - 94.9)	0.91	(0.60 - 1.25)	-
Cottesloe (T)	0	-	-	-	-	.	32	118.4	(75.3 - 161.5)	1.28	(0.84 - 1.75)	-
Joondalup (C) - North	0	-	-	-	-	.	91	74.7	(58.6 - 90.8)	0.91	(0.74 - 1.12)	-
Joondalup (C) - South	0	-	-	0	n/a	-	303	87.0	(76.7 - 97.4)	1.02	(0.91 - 1.15)	-
Mosman Park (T)	0	-	-	-	-	.	27	94.1	(57.0 - 131.2)	1.01	(0.63 - 1.42)	-
Nedlands (C)	0	-	-	-	-	.	93	109.3	(85.4 - 133.1)	1.23	(1.00 - 1.52)	-
Peppermint Grove (S)	0	-	-	-	-	.	3	55.7	(0.0 - 119.7)	0.57	(0.05 - 1.33)	-
Stirling (C) - Central	1	0.3	(0.0 - 0.7)	0.49	(0.00 - 1.80)	-*	284	75.1	(66.0 - 84.2)	0.91	(0.81 - 1.02)	-
Stirling (C) - Coastal	2	0.9	(0.0 - 2.1)	1.60	(0.02 - 4.47)	-*	207	87.0	(74.6 - 99.5)	1.05	(0.91 - 1.20)	-
Subiaco (C)	0	-	-	-	-	.	52	99.8	(70.9 - 128.6)	1.16	(0.87 - 1.53)	-
Wanneroo (C) - North-East	0	-	-	-	-	.	41	68.8	(47.2 - 90.5)	0.80	(0.56 - 1.06)	-
Wanneroo (C) - North-West	0	-	-	-	-	.	63	96.6	(72.4 - 120.8)	1.15	(0.89 - 1.49)	-
Wanneroo (C) - South	1	1.0	(0.0 - 3.1)	2.32	(0.00 - 8.56)	-*	76	78.1	(60.2 - 96.1)	0.94	(0.75 - 1.19)	-
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	0	-	-	0	n/a	-	107	92.9	(73.9 - 111.8)	1.14	(0.94 - 1.38)	-
Canning (C)	1	0.3	(0.0 - 0.9)	0.81	(0.00 - 3.00)	-*	212	82.8	(71.3 - 94.3)	0.99	(0.86 - 1.13)	-
South Perth (C)	0	-	-	0	n/a	-	132	95.9	(78.0 - 113.8)	1.10	(0.93 - 1.31)	-
Victoria Park (T)	0	-	-	0	n/a	-	75	77.1	(56.8 - 97.4)	0.86	(0.68 - 1.08)	-
Inner City HD												
Perth (C) - Inner	0	-	-	-	-	.	1	61.2	(0.0 - 180.6)	0.74	(0.00 - 2.72)	-*
Perth (C) - Remainder	0	-	-	-	-	.	9	46.8	(13.5 - 80.2)	0.59	(0.23 - 1.04)	-
Stirling (C) - South-Eastern	0	-	-	-	-	.	66	106.1	(76.2 - 135.9)	1.24	(0.96 - 1.58)	-
Vincent (T)	0	-	-	0	n/a	-	75	90.5	(68.2 - 112.8)	1.04	(0.82 - 1.31)	-
Kalamunda HD												
Kalamunda (S)	2	1.2	(0.0 - 3.0)	2.33	(0.03 - 6.51)	-*	150	88.0	(73.5 - 102.5)	1.06	(0.90 - 1.24)	-
Swan HD												
Bassendean (T)	0	-	-	-	-	.	30	60.3	(38.1 - 82.5)	0.69	(0.45 - 0.95)	V
Bayswater (C)	3	1.5	(0.0 - 3.2)	2.54	(0.21 - 5.94)	-*	189	91.4	(77.7 - 105.2)	1.09	(0.94 - 1.26)	-
Mundaring (S)	2	1.9	(0.0 - 4.7)	3.44	(0.04 - 9.60)	-*	111	93.5	(75.9 - 111.2)	1.10	(0.91 - 1.33)	-
Swan (C)	2	0.8	(0.0 - 2.0)	1.85	(0.02 - 5.16)	-*	166	76.0	(64.1 - 87.8)	0.89	(0.76 - 1.04)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	0	-	-	0	n/a	-	149	90.1	(75.4 - 104.8)	1.07	(0.91 - 1.26)	-
Gosnells (C)	1	0.6	(0.0 - 1.7)	0.87	(0.00 - 3.21)	-*	201	84.1	(72.2 - 96.0)	0.99	(0.86 - 1.14)	-
Serpentine-Jarrahdale (S)	0	-	-	-	-	.	24	69.4	(41.2 - 97.5)	0.85	(0.52 - 1.23)	-
Fremantle HD												
Cockburn (C)	1	0.5	(0.0 - 1.6)	1.00	(0.00 - 3.69)	-*	175	86.3	(73.3 - 99.3)	1.04	(0.90 - 1.21)	-
East Fremantle (T)	0	-	-	-	-	.	25	109.3	(64.9 - 153.8)	1.19	(0.73 - 1.70)	-
Fremantle (C) - Inner	0	-	-	-	-	.	4	203.6	(0.0 - 414.5)	1.98	(0.31 - 4.35)	-*
Fremantle (C) - Remainder	1	0.6	(0.0 - 1.7)	1.78	(0.00 - 6.57)	-*	83	90.0	(69.8 - 110.2)	1.02	(0.82 - 1.27)	-
Melville (C)	3	0.6	(0.0 - 1.3)	1.51	(0.12 - 3.52)	-*	339	87.5	(77.6 - 97.4)	1.07	(0.96 - 1.19)	-
Rockingham-Kwinana HD												
Kwinana (T)	0	-	-	-	-	.	47	74.8	(53.1 - 96.5)	0.91	(0.65 - 1.18)	-
Rockingham (C)	2	0.9	(0.0 - 2.2)	1.51	(0.02 - 4.19)	-*	200	83.8	(71.9 - 95.8)	1.02	(0.88 - 1.17)	-
Peel HD												
Mandurah (C)	3	1.0	(0.0 - 2.2)	2.33	(0.19 - 5.44)	-*	174	85.6	(72.1 - 99.2)	1.08	(0.92 - 1.25)	-
Murray (S)	1	1.6	(0.0 - 4.6)	3.59	(0.00 - 13.24)	-*	33	84.8	(55.3 - 114.4)	0.95	(0.63 - 1.31)	-
Waroona (S)	0	-	-	-	-	.	7	58.8	(13.7 - 103.9)	0.72	(0.22 - 1.33)	-
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	0	-	-	-	-	.	26	87.9	(52.5 - 123.3)	1.27	(0.79 - 1.81)	-
Derby-West Kimberley (S)	0	-	-	-	-	.	13	86.4	(37.4 - 135.5)	1.11	(0.53 - 1.79)	-
Halls Creek (S)	0	-	-	-	-	.	5	73.4	(6.6 - 140.1)	0.88	(0.19 - 1.81)	-
Wyndham-East Kimberley (S)	0	-	-	-	-	.	14	116.5	(48.5 - 184.5)	1.29	(0.64 - 2.06)	-
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	0	-	-	-	-	.	3	25.3	(0.0 - 57.7)	0.39	(0.03 - 0.92)	V
Roebourne (S)	0	-	-	-	-	.	23	84.3	(37.5 - 131.0)	1.10	(0.66 - 1.59)	-

Cancer type: Breast 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	0	-	-	-	-	.	12	70.5	(30.0 - 111.0)	0.80	(0.37 - 1.32)	-
Exmouth (S)	0	-	-	-	-	.	6	109.7	(20.2 - 199.2)	1.25	(0.34 - 2.43)	-
Shark Bay (S)	0	-	-	-	-	.	1	20.8	(0.0 - 60.8)	0.40	(0.00 - 1.47)	-*
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	0	-	-
East Pilbara HD												
East Pilbara (S)	0	-	-	-	-	.	3	34.8	(0.0 - 79.1)	0.36	(0.03 - 0.84)	V
Port Hedland (T)	0	-	-	-	-	.	18	109.4	(52.4 - 166.3)	0.96	(0.53 - 1.45)	-
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	0	-	-	-	-	.	5	248.9	(29.9 - 467.8)	2.99	(0.65 - 6.13)	-*
Chapman Valley (S)	0	-	-	-	-	.	3	70.5	(0.0 - 149.9)	1.26	(0.10 - 2.95)	-*
Coorow (S)	0	-	-	-	-	.	4	95.3	(1.5 - 189.1)	1.14	(0.18 - 2.50)	-*
Irwin (S)	0	-	-	-	-	.	8	85.7	(25.7 - 145.7)	0.92	(0.33 - 1.67)	-
Mingenew (S)	0	-	-	-	-	.	5	355.5	(46.2 - 664.8)	3.66	(0.80 - 7.49)	-*
Morawa (S)	0	-	-	-	-	.	3	111.0	(0.0 - 237.6)	1.25	(0.10 - 2.92)	-*
Mullewa (S)	1	31.3	(0.0 - 92.0)	56.62	(0.00 - 208.87)	-*	3	110.5	(0.0 - 235.1)	1.38	(0.11 - 3.23)	-*
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northampton (S)	0	-	-	-	-	.	10	79.0	(29.9 - 128.2)	1.01	(0.41 - 1.72)	-
Perenjori (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Three Springs (S)	0	-	-	-	-	.	4	187.4	(0.0 - 375.4)	2.03	(0.31 - 4.46)	-*
Yalgoo (S)	0	-	-	-	-	.	0	-	-	0	-	-
Murchison HD												
Cue (S)	0	-	-	-	-	.	1	114.3	(0.0 - 335.1)	1.26	(0.00 - 4.64)	-*
Meekatharra (S)	0	-	-	-	-	.	3	97.9	(0.0 - 208.2)	1.19	(0.10 - 2.77)	-*
Mount Magnet (S)	0	-	-	-	-	.	2	130.4	(0.0 - 322.7)	1.59	(0.02 - 4.42)	-*
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Geraldton HD												
Geraldton (C)	0	-	-	-	-	.	61	91.5	(67.6 - 115.5)	1.09	(0.84 - 1.40)	-
Greenough (S) - Pt A	0	-	-	-	-	.	14	47.5	(21.7 - 73.2)	0.60	(0.30 - 0.95)	V
Greenough (S) - Pt B	0	-	-	-	-	.	1	31.0	(0.0 - 91.5)	0.33	(0.00 - 1.23)	-*
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	0	-	-	-	-	.	3	40.0	(0.0 - 89.1)	0.55	(0.04 - 1.29)	-
Bruce Rock (S)	0	-	-	-	-	.	3	80.3	(0.0 - 171.2)	0.85	(0.07 - 1.98)	-*
Corrigin (S)	0	-	-	-	-	.	4	91.1	(1.9 - 180.2)	0.98	(0.15 - 2.16)	-*
Cunderdin (S)	0	-	-	-	-	.	4	89.5	(0.0 - 184.1)	1.05	(0.16 - 2.31)	-*
Quairading (S)	0	-	-	-	-	.	2	32.3	(0.0 - 85.5)	0.57	(0.01 - 1.60)	-*
Tammin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Upper Great Southern HD												
Boddington (S)	0	-	-	-	-	.	3	60.0	(0.0 - 129.8)	0.92	(0.07 - 2.15)	-*
Brookton (S)	0	-	-	-	-	.	1	35.7	(0.0 - 105.4)	0.33	(0.00 - 1.22)	-*
Cuballing (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Dumbleyung (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Kondinin (S)	0	-	-	-	-	.	1	21.3	(0.0 - 62.5)	0.42	(0.00 - 1.55)	-*
Kulin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Lake Grace (S)	0	-	-	-	-	.	5	94.3	(8.5 - 180.1)	1.28	(0.28 - 2.63)	-*
Narrogin (S)	0	-	-	-	-	.	0	-	-	0	n/a	V
Narrogin (T)	0	-	-	-	-	.	7	50.5	(10.9 - 90.1)	0.65	(0.20 - 1.21)	-
Pingelly (S)	0	-	-	-	-	.	2	51.4	(0.0 - 123.1)	0.51	(0.01 - 1.43)	-*
Wagin (S)	0	-	-	-	-	.	8	113.4	(30.0 - 196.8)	1.35	(0.48 - 2.44)	-
Wandering (S)	0	-	-	-	-	.	1	83.3	(0.0 - 232.4)	1.09	(0.00 - 4.02)	-*
West Arthur (S)	0	-	-	-	-	.	2	67.2	(0.0 - 159.6)	0.75	(0.01 - 2.09)	-*
Wickepin (S)	0	-	-	-	-	.	2	80.9	(0.0 - 192.5)	0.92	(0.01 - 2.57)	-*
Williams (S)	0	-	-	-	-	.	2	64.7	(0.0 - 164.4)	0.79	(0.01 - 2.20)	-*
Western HD												
Chittering (S)	0	-	-	-	-	.	5	60.9	(6.7 - 115.0)	0.63	(0.14 - 1.29)	-
Dalwallinu (S)	0	-	-	-	-	.	5	77.7	(5.5 - 150.0)	1.17	(0.26 - 2.40)	-*
Dandaragan (S)	0	-	-	-	-	.	4	40.9	(0.4 - 81.4)	0.49	(0.08 - 1.06)	-
Dowerin (S)	0	-	-	-	-	.	7	224.3	(51.5 - 397.2)	2.99	(0.94 - 5.58)	-*
Gingin (S)	0	-	-	-	-	.	9	56.2	(19.2 - 93.1)	0.70	(0.27 - 1.23)	-
Goomalling (S)	0	-	-	-	-	.	2	47.1	(0.0 - 116.0)	0.71	(0.01 - 1.98)	-*
Moora (S)	0	-	-	-	-	.	5	84.0	(6.7 - 161.4)	0.79	(0.17 - 1.62)	-

Cancer type: Breast 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	0	-	-	-	-	.	8	295.8	(82.5 - 509.0)	3.21	(1.13 - 5.79)	^*
Wongan-Ballidu (S)	0	-	-	-	-	.	2	43.7	(0.0 - 109.8)	0.53	(0.01 - 1.47)	-*
Eastern Wheatbelt HD												
Kellerberrin (S)	0	-	-	-	-	.	4	118.8	(0.0 - 252.7)	1.01	(0.16 - 2.20)	-*
Koorda (S)	0	-	-	-	-	.	1	37.0	(0.0 - 109.2)	0.68	(0.00 - 2.50)	-*
Merredin (S)	1	7.9	(0.0 - 23.4)	15.33	(0.00 - 56.57)	-*	8	75.8	(22.8 - 128.7)	0.87	(0.31 - 1.56)	-
Mount Marshall (S)	0	-	-	-	-	.	1	54.8	(0.0 - 161.5)	0.62	(0.00 - 2.30)	-*
Mukinbudin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Narembeen (S)	0	-	-	-	-	.	2	57.7	(0.0 - 138.7)	0.70	(0.01 - 1.94)	-*
Nungarin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Trayning (S)	0	-	-	-	-	.	2	98.8	(0.0 - 233.9)	1.48	(0.02 - 4.13)	-*
Westonia (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Wyalkatchem (S)	0	-	-	-	-	.	3	165.5	(0.0 - 355.1)	1.48	(0.12 - 3.45)	-*
Yilgam (S)	0	-	-	-	-	.	3	71.6	(0.0 - 153.5)	0.85	(0.07 - 1.97)	-*
Avon HD												
Northam (S)	0	-	-	-	-	.	6	52.8	(10.6 - 95.1)	0.60	(0.16 - 1.17)	-
Northam (T)	0	-	-	-	-	.	17	70.9	(34.4 - 107.4)	0.87	(0.47 - 1.33)	-
Toodyay (S)	0	-	-	-	-	.	9	65.9	(22.1 - 109.6)	0.76	(0.29 - 1.34)	-
York (S)	0	-	-	-	-	.	10	68.8	(24.3 - 113.3)	0.94	(0.39 - 1.61)	-
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	0	-	-	-	-	.	5	96.1	(1.6 - 190.7)	0.80	(0.17 - 1.63)	-
Kalgoorlie/Boulder (C) - Pt A	0	-	-	-	-	.	48	71.6	(50.2 - 92.9)	0.97	(0.70 - 1.26)	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	-	-	.	0	-	-	0	n/a	-
Laverton (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Leonora (S)	0	-	-	-	-	.	1	25.8	(0.0 - 76.1)	0.40	(0.00 - 1.48)	-*
Menzies (S)	0	-	-	-	-	.	0	-	-	0	-	-
Ngaanyatjarraku (S)	0	-	-	-	-	.	0	-	-	0	-	-
South East Coastal HD												
Dundas (S)	0	-	-	-	-	.	1	38.5	(0.0 - 113.1)	0.34	(0.00 - 1.26)	-*
Esperance (S)	0	-	-	-	-	.	34	85.6	(56.4 - 114.7)	1.01	(0.68 - 1.38)	-
Ravensthorpe (S)	0	-	-	-	-	.	3	67.2	(0.0 - 143.6)	0.76	(0.06 - 1.78)	-*
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	0	-	-	-	-	.	56	81.4	(57.9 - 105.0)	0.98	(0.74 - 1.28)	-
Albany (C) Bal	1	2.0	(0.0 - 6.0)	3.70	(0.00 - 13.64)	-*	39	87.2	(59.3 - 115.1)	1.02	(0.71 - 1.37)	-
Cranbrook (S)	0	-	-	-	-	.	2	53.9	(0.0 - 136.9)	0.72	(0.01 - 2.01)	-*
Denmark (S)	0	-	-	-	-	.	10	53.0	(19.4 - 86.7)	0.68	(0.28 - 1.16)	-
Jerramungup (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Plantagenet (S)	0	-	-	-	-	.	17	107.3	(53.1 - 161.5)	1.26	(0.68 - 1.93)	-
Central Great Southern HD												
Broomehill (S)	0	-	-	-	-	.	3	132.6	(0.0 - 282.6)	2.08	(0.17 - 4.85)	-*
Gnowangerup (S)	0	-	-	-	-	.	7	153.7	(39.1 - 268.3)	1.78	(0.56 - 3.32)	-*
Katanning (S)	0	-	-	-	-	.	9	67.3	(22.6 - 111.9)	0.76	(0.29 - 1.33)	-
Kent (S)	0	-	-	-	-	.	1	64.5	(0.0 - 189.9)	0.75	(0.00 - 2.75)	-*
Kojonup (S)	0	-	-	-	-	.	5	62.6	(6.6 - 118.6)	0.78	(0.17 - 1.60)	-
Tambellup (S)	0	-	-	-	-	.	1	38.1	(0.0 - 112.4)	0.57	(0.00 - 2.12)	-*
Woodanilling (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	0	-	-	-	-	.	26	85.2	(51.1 - 119.3)	1.03	(0.64 - 1.46)	-
Busselton (S)	0	-	-	-	-	.	51	62.2	(44.1 - 80.3)	0.75	(0.57 - 1.00)	-
Warren-Blackwood HD												
Boyup Brook (S)	0	-	-	-	-	.	3	38.7	(0.0 - 86.5)	0.57	(0.05 - 1.33)	-
Bridgetown-Greenbushes (S)	0	-	-	-	-	.	19	133.5	(73.2 - 193.7)	1.48	(0.83 - 2.22)	-
Manjimup (S)	1	2.1	(0.0 - 6.1)	5.11	(0.00 - 18.84)	-*	23	70.3	(40.9 - 99.8)	0.86	(0.52 - 1.25)	-
Nannup (S)	0	-	-	-	-	.	4	102.6	(0.0 - 205.4)	1.09	(0.17 - 2.38)	-*
Bunbury HD												
Bunbury (C)	1	1.2	(0.0 - 3.7)	1.74	(0.00 - 6.43)	-*	93	93.2	(73.3 - 113.1)	1.09	(0.89 - 1.34)	-
Capel (S) - Pt A	0	-	-	-	-	.	5	60.2	(5.6 - 114.7)	0.80	(0.17 - 1.63)	-
Capel (S) - Pt B	0	-	-	-	-	.	8	58.5	(17.5 - 99.6)	0.72	(0.25 - 1.29)	-
Dardanup (S) - Pt A	0	-	-	-	-	.	16	96.0	(48.3 - 143.8)	1.22	(0.64 - 1.88)	-
Dardanup (S) - Pt B	0	-	-	-	-	.	3	36.2	(0.0 - 77.8)	0.50	(0.04 - 1.17)	-
Wellington HD												

Cancer type: Breast 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	0	-	-	-	-	.	23	81.2	(47.2 - 115.3)	0.93	(0.56 - 1.34)	-
Donnybrook-Balingup (S)	0	-	-	-	-	.	17	109.6	(56.9 - 162.2)	1.29	(0.69 - 1.97)	-
Harvey-Yarloop HD												
Harvey (S) - Pt A	1	2.5	(0.0 - 7.4)	7.35	(0.00 - 27.11)	-*	21	75.5	(42.5 - 108.5)	0.92	(0.53 - 1.35)	-
Harvey (S) - Pt B	0	-	-	-	-	.	24	97.5	(58.1 - 136.9)	1.09	(0.66 - 1.57)	-
Total State	33	0.5	(0.3 - 0.7)	1.00	(0.66 - 1.37)	-	5171	83.7	(81.3 - 86.1)	1.00	(0.97 - 1.03)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

W.A. Cancer by SLA (DOH Areas)
Cancer type: Colorectal cancer 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	46	49.7	(34.4 - 65.1)	1.00	(0.71 - 1.31)	-	55	37.5	(25.0 - 50.0)	1.34	(1.02 - 1.76)	^
Claremont (T)	16	41.5	(19.5 - 63.6)	0.88	(0.46 - 1.37)	-	22	41.6	(20.6 - 62.5)	1.11	(0.66 - 1.62)	-
Cottesloe (T)	18	63.1	(32.7 - 93.4)	1.35	(0.74 - 2.04)	-	7	10.1	(1.5 - 18.6)	0.57	(0.18 - 1.07)	-
Joondalup (C) - North	47	46.4	(32.6 - 60.3)	1.07	(0.77 - 1.40)	-	32	28.1	(18.0 - 38.3)	0.96	(0.63 - 1.32)	-
Joondalup (C) - South	130	39.5	(32.4 - 46.5)	0.91	(0.76 - 1.08)	-	103	28.2	(22.4 - 34.0)	0.98	(0.80 - 1.19)	-
Mosman Park (T)	18	52.3	(26.8 - 77.8)	1.23	(0.68 - 1.87)	-	17	31.1	(12.3 - 50.0)	1.25	(0.67 - 1.91)	-
Nedlands (C)	23	22.2	(11.9 - 32.5)	0.58	(0.35 - 0.84)	V	51	43.3	(28.2 - 58.4)	1.28	(0.96 - 1.69)	-
Peppermint Grove (S)	1	11.9	(0.0 - 35.0)	0.33	(0.00 - 1.23)	-*	3	44.6	(0.0 - 98.4)	1.33	(0.11 - 3.10)	-*
Stirling (C) - Central	173	44.8	(37.9 - 51.7)	1.00	(0.86 - 1.17)	-	134	26.6	(21.7 - 31.5)	0.94	(0.79 - 1.12)	-
Stirling (C) - Coastal	117	48.5	(39.3 - 57.7)	1.10	(0.92 - 1.33)	-	81	27.1	(20.6 - 33.6)	0.88	(0.70 - 1.10)	-
Subiaco (C)	17	36.3	(18.4 - 54.3)	0.77	(0.41 - 1.17)	-	22	29.0	(14.9 - 43.1)	1.04	(0.62 - 1.52)	-
Wanneroo (C) - North-East	32	51.5	(33.2 - 69.8)	1.21	(0.80 - 1.66)	-	19	29.0	(15.3 - 42.6)	0.96	(0.54 - 1.43)	-
Wanneroo (C) - North-West	29	46.8	(29.0 - 64.6)	0.96	(0.62 - 1.34)	-	12	17.8	(7.6 - 28.1)	0.59	(0.27 - 0.97)	V
Wanneroo (C) - South	27	33.5	(20.6 - 46.4)	0.72	(0.46 - 1.02)	-	30	30.3	(19.3 - 41.3)	1.05	(0.68 - 1.46)	-
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	63	51.9	(38.5 - 65.4)	1.12	(0.87 - 1.45)	-	47	30.5	(20.5 - 40.5)	1.02	(0.73 - 1.34)	-
Canning (C)	87	36.7	(28.8 - 44.5)	0.82	(0.66 - 1.01)	-	86	27.9	(21.6 - 34.1)	0.97	(0.78 - 1.21)	-
South Perth (C)	60	45.9	(33.3 - 58.5)	0.97	(0.75 - 1.26)	-	64	30.5	(21.5 - 39.5)	1.02	(0.79 - 1.30)	-
Victoria Park (T)	44	37.6	(24.5 - 50.6)	0.87	(0.61 - 1.14)	-	43	28.2	(16.2 - 40.2)	0.78	(0.55 - 1.03)	-
Inner City HD												
Perth (C) - Inner	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Perth (C) - Remainder	16	56.6	(27.7 - 85.5)	1.25	(0.65 - 1.93)	-	6	25.3	(3.1 - 47.4)	0.84	(0.23 - 1.63)	-
Stirling (C) - South-Eastern	33	48.8	(28.8 - 68.9)	1.09	(0.72 - 1.49)	-	31	25.2	(12.4 - 37.9)	0.98	(0.64 - 1.35)	-
Vincent (T)	48	50.3	(34.7 - 65.8)	1.11	(0.80 - 1.45)	-	41	35.4	(22.5 - 48.2)	1.09	(0.76 - 1.45)	-
Kalamunda HD												
Kalamunda (S)	49	30.4	(21.8 - 39.1)	0.67	(0.48 - 0.86)	V	48	24.9	(17.4 - 32.4)	0.86	(0.62 - 1.12)	-
Swan HD												
Bassendean (T)	32	61.1	(39.2 - 83.0)	1.35	(0.89 - 1.85)	-	17	29.2	(14.4 - 43.9)	0.86	(0.46 - 1.32)	-
Bayswater (C)	86	39.7	(31.0 - 48.4)	0.86	(0.69 - 1.07)	-	81	30.3	(22.9 - 37.7)	1.00	(0.80 - 1.24)	-
Mundaring (S)	55	50.7	(37.1 - 64.3)	1.09	(0.83 - 1.43)	-	45	35.3	(24.3 - 46.3)	1.19	(0.85 - 1.57)	-
Swan (C)	86	39.5	(31.0 - 48.0)	0.92	(0.74 - 1.14)	-	76	32.7	(25.0 - 40.4)	1.09	(0.86 - 1.37)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	63	41.5	(31.1 - 51.8)	0.89	(0.69 - 1.15)	-	54	30.6	(22.1 - 39.1)	1.01	(0.76 - 1.32)	-
Gosnells (C)	110	50.6	(40.9 - 60.2)	1.10	(0.91 - 1.33)	-	74	29.5	(22.5 - 36.4)	0.97	(0.77 - 1.23)	-
Serpentine-Jarrahdale (S)	14	40.4	(18.6 - 62.1)	0.93	(0.46 - 1.48)	-	10	31.1	(11.4 - 50.7)	1.05	(0.43 - 1.80)	-
Fremantle HD												
Cockburn (C)	91	49.1	(39.0 - 59.3)	1.06	(0.86 - 1.31)	-	74	34.9	(26.6 - 43.1)	1.15	(0.91 - 1.45)	-
East Fremantle (T)	18	63.9	(32.8 - 95.0)	1.51	(0.83 - 2.28)	-	4	14.9	(0.0 - 31.1)	0.40	(0.06 - 0.87)	V
Fremantle (C) - Inner	2	77.5	(0.0 - 184.9)	1.06	(0.01 - 2.96)	-*	0	-	-	0	n/a	-
Fremantle (C) - Remainder	56	58.3	(42.2 - 74.5)	1.18	(0.90 - 1.55)	-	37	30.7	(19.6 - 41.8)	0.95	(0.65 - 1.28)	-
Melville (C)	195	49.2	(42.0 - 56.5)	1.15	(0.99 - 1.32)	-	180	35.2	(29.4 - 41.0)	1.22	(1.05 - 1.42)	^
Rockingham-Kwinana HD												
Kwinana (T)	31	48.2	(30.9 - 65.6)	1.08	(0.70 - 1.49)	-	18	26.5	(13.9 - 39.2)	0.89	(0.49 - 1.34)	-
Rockingham (C)	117	46.7	(38.0 - 55.4)	1.04	(0.87 - 1.25)	-	92	31.5	(24.7 - 38.3)	1.10	(0.89 - 1.36)	-
Peel HD												
Mandurah (C)	110	45.1	(36.0 - 54.1)	1.03	(0.85 - 1.25)	-	73	30.0	(22.5 - 37.4)	0.97	(0.76 - 1.22)	-
Murray (S)	20	38.3	(20.6 - 56.1)	0.85	(0.49 - 1.27)	-	12	26.1	(11.2 - 41.1)	0.88	(0.40 - 1.45)	-
Waroona (S)	7	52.0	(13.0 - 91.0)	1.12	(0.35 - 2.10)	-	3	25.3	(0.0 - 54.1)	0.72	(0.06 - 1.68)	-*
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	11	51.7	(20.7 - 82.6)	1.06	(0.46 - 1.77)	-	4	19.1	(0.0 - 38.7)	0.67	(0.10 - 1.47)	-
Derby-West Kimberley (S)	4	29.5	(0.4 - 58.7)	0.58	(0.09 - 1.27)	-	3	15.7	(0.0 - 34.5)	0.74	(0.06 - 1.72)	-*
Halls Creek (S)	2	24.4	(0.0 - 58.0)	0.63	(0.01 - 1.76)	-*	0	-	-	0	n/a	-
Wyndham-East Kimberley (S)	3	24.3	(0.0 - 52.0)	0.50	(0.04 - 1.16)	-	3	33.4	(0.0 - 73.9)	0.95	(0.08 - 2.22)	-*
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	4	33.2	(0.0 - 73.5)	1.07	(0.17 - 2.34)	-*	2	12.6	(0.0 - 31.8)	1.10	(0.01 - 3.07)	-*
Roebourne (S)	7	51.7	(8.3 - 95.1)	0.77	(0.24 - 1.44)	-	4	12.0	(0.0 - 24.5)	0.81	(0.12 - 1.77)	-

Cancer type: Colorectal cancer 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	7	31.3	(7.8 - 54.7)	0.70	(0.22 - 1.30)	-	5	29.3	(2.8 - 55.7)	0.90	(0.20 - 1.85)	-
Exmouth (S)	3	48.5	(0.0 - 104.0)	1.08	(0.09 - 2.52)	-*	2	40.1	(0.0 - 96.2)	1.27	(0.02 - 3.55)	-*
Shark Bay (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
East Pilbara HD												
East Pilbara (S)	6	57.1	(0.0 - 114.6)	1.32	(0.36 - 2.57)	-	1	12.3	(0.0 - 36.5)	0.44	(0.00 - 1.63)	-*
Port Hedland (T)	4	17.7	(0.0 - 37.2)	0.41	(0.06 - 0.91)	V	2	5.0	(0.0 - 12.2)	0.39	(0.00 - 1.10)	-
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Chapman Valley (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Coorow (S)	3	60.9	(0.0 - 129.8)	1.31	(0.11 - 3.06)	-*	2	47.9	(0.0 - 113.9)	1.57	(0.02 - 4.38)	-*
Irwin (S)	2	14.9	(0.0 - 35.8)	0.33	(0.00 - 0.92)	V	4	35.6	(0.1 - 71.2)	1.18	(0.18 - 2.58)	-*
Mingenew (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Morawa (S)	1	32.3	(0.0 - 95.2)	0.56	(0.00 - 2.08)	-*	1	31.7	(0.0 - 93.8)	1.04	(0.00 - 3.84)	-*
Mullewa (S)	1	47.6	(0.0 - 138.7)	0.68	(0.00 - 2.52)	-*	2	134.9	(0.0 - 328.9)	2.64	(0.03 - 7.36)	-*
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northampton (S)	8	70.0	(17.0 - 123.0)	1.22	(0.43 - 2.20)	-	2	14.1	(0.0 - 33.6)	0.52	(0.01 - 1.44)	-*
Perenjori (S)	1	73.2	(0.0 - 214.8)	1.26	(0.00 - 4.64)	-*	1	48.8	(0.0 - 143.2)	1.72	(0.00 - 6.33)	-*
Three Springs (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murchison HD												
Cue (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Meekatharra (S)	1	42.6	(0.0 - 125.1)	0.66	(0.00 - 2.43)	-*	0	-	-	0	n/a	-
Mount Magnet (S)	1	41.7	(0.0 - 119.9)	1.07	(0.00 - 3.93)	-*	0	-	-	-	-	.
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	0	-	-	0	n/a	-	1	62.5	(0.0 - 184.4)	3.26	(0.00 - 12.03)	-*
Geraldton HD												
Geraldton (C)	31	45.5	(29.1 - 61.8)	0.95	(0.62 - 1.32)	-	23	24.0	(13.1 - 34.8)	0.89	(0.53 - 1.29)	-
Greenough (S) - Pt A	14	58.3	(26.8 - 89.9)	1.23	(0.61 - 1.96)	-	5	20.0	(2.1 - 37.9)	0.71	(0.16 - 1.46)	-
Greenough (S) - Pt B	0	-	-	0	n/a	-	0	-	-	0	n/a	-
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	4	42.4	(0.7 - 84.1)	1.07	(0.17 - 2.34)	-*	2	16.1	(0.0 - 39.0)	0.84	(0.01 - 2.34)	-*
Bruce Rock (S)	5	122.5	(11.8 - 233.2)	2.31	(0.50 - 4.74)	-*	2	29.7	(0.0 - 72.2)	1.31	(0.02 - 3.64)	-*
Corrigin (S)	2	46.0	(0.0 - 109.8)	0.82	(0.01 - 2.29)	-*	3	41.8	(0.0 - 95.1)	1.60	(0.13 - 3.73)	-*
Cunderdin (S)	2	35.5	(0.0 - 85.0)	0.84	(0.01 - 2.35)	-*	2	18.3	(0.0 - 44.3)	1.18	(0.01 - 3.29)	-*
Quairading (S)	3	69.2	(0.0 - 147.4)	1.49	(0.12 - 3.48)	-*	1	34.2	(0.0 - 101.1)	0.61	(0.00 - 2.27)	-*
Tammin (S)	1	50.0	(0.0 - 143.0)	1.38	(0.00 - 5.09)	-*	0	-	-	-	-	.
Upper Great Southern HD												
Boddington (S)	2	33.4	(0.0 - 80.7)	1.07	(0.01 - 2.97)	-*	1	36.7	(0.0 - 108.3)	0.87	(0.00 - 3.23)	-*
Brookton (S)	3	37.0	(0.0 - 80.0)	1.28	(0.10 - 2.98)	-*	3	76.6	(0.0 - 167.8)	2.14	(0.17 - 4.99)	-*
Cuballing (S)	1	38.2	(0.0 - 112.9)	0.84	(0.00 - 3.08)	-*	0	-	-	0	n/a	-
Dumbleyung (S)	1	22.7	(0.0 - 66.2)	0.72	(0.00 - 2.66)	-*	0	-	-	0	n/a	-
Kondinin (S)	2	66.7	(0.0 - 157.9)	1.33	(0.02 - 3.72)	-*	1	37.4	(0.0 - 110.3)	1.20	(0.00 - 4.43)	-*
Kulin (S)	0	-	-	0	n/a	-	1	25.0	(0.0 - 73.7)	1.01	(0.00 - 3.72)	-*
Lake Grace (S)	1	19.8	(0.0 - 58.4)	0.47	(0.00 - 1.72)	-*	4	88.6	(1.3 - 175.9)	2.99	(0.46 - 6.56)	-*
Narrogin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Narrogin (T)	10	92.3	(34.6 - 149.9)	1.63	(0.67 - 2.78)	-	7	33.7	(4.2 - 63.3)	1.30	(0.41 - 2.43)	-
Pingelly (S)	3	47.5	(0.0 - 103.1)	1.18	(0.09 - 2.75)	-*	0	-	-	0	n/a	-
Wagin (S)	4	69.2	(0.0 - 139.1)	1.10	(0.17 - 2.41)	-*	1	19.5	(0.0 - 57.7)	0.34	(0.00 - 1.26)	-*
Wandering (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
West Arthur (S)	2	46.1	(0.0 - 109.7)	1.11	(0.01 - 3.09)	-*	0	-	-	0	n/a	-
Wickepin (S)	2	50.4	(0.0 - 119.9)	1.40	(0.02 - 3.90)	-*	0	-	-	0	n/a	-
Williams (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Western HD												
Chittering (S)	7	56.1	(14.5 - 97.8)	1.43	(0.45 - 2.66)	-	1	10.2	(0.0 - 30.2)	0.39	(0.00 - 1.43)	-*
Dalwallinu (S)	4	67.8	(0.0 - 135.8)	1.47	(0.23 - 3.21)	-*	0	-	-	0	n/a	-
Dandaragan (S)	6	42.3	(8.5 - 76.1)	1.06	(0.29 - 2.06)	-	2	20.7	(0.0 - 49.3)	0.66	(0.01 - 1.84)	-*
Dowerin (S)	2	82.7	(0.0 - 197.9)	1.60	(0.02 - 4.47)	-*	2	57.2	(0.0 - 141.9)	2.02	(0.03 - 5.64)	-*
Gingin (S)	10	60.6	(21.8 - 99.4)	1.22	(0.50 - 2.08)	-	4	27.1	(0.3 - 54.0)	0.83	(0.13 - 1.82)	-
Goomalling (S)	1	25.0	(0.0 - 73.7)	0.55	(0.00 - 2.03)	-*	1	35.0	(0.0 - 103.3)	0.79	(0.00 - 2.93)	-*
Moora (S)	3	38.4	(0.0 - 84.4)	0.83	(0.07 - 1.95)	-*	5	73.2	(4.5 - 141.9)	1.93	(0.42 - 3.96)	-*

Cancer type: Colorectal cancer 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	0	-	-	0	n/a	-	2	43.8	(0.0 - 103.9)	2.33	(0.03 - 6.49)	-*
Wongan-Ballidu (S)	4	77.4	(2.1 - 152.7)	1.97	(0.30 - 4.31)	-*	0	-	-	0	n/a	-
Eastern Wheatbelt HD												
Kellerberrin (S)	5	96.4	(7.7 - 185.0)	1.85	(0.40 - 3.80)	-*	2	32.6	(0.0 - 79.9)	1.01	(0.01 - 2.81)	-*
Koorda (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Merredin (S)	10	76.6	(27.9 - 125.3)	1.79	(0.74 - 3.06)	-	3	28.4	(0.0 - 60.8)	0.78	(0.06 - 1.81)	-*
Mount Marshall (S)	1	40.4	(0.0 - 119.2)	0.97	(0.00 - 3.58)	-*	0	-	-	0	n/a	-
Mukinbudin (S)	1	45.1	(0.0 - 133.2)	0.80	(0.00 - 2.96)	-*	0	-	-	0	n/a	-
Narembeen (S)	1	28.3	(0.0 - 83.5)	0.57	(0.00 - 2.12)	-*	1	23.8	(0.0 - 70.4)	0.83	(0.00 - 3.05)	-*
Nungarin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Trayning (S)	1	45.5	(0.0 - 133.5)	1.18	(0.00 - 4.36)	-*	0	-	-	0	n/a	-
Westonia (S)	2	176.1	(0.0 - 420.0)	4.19	(0.05 - 11.68)	-*	0	-	-	-	-	-
Wyalkatchem (S)	0	-	-	0	n/a	-	2	66.6	(0.0 - 174.8)	2.39	(0.03 - 6.66)	-*
Yilgam (S)	3	84.5	(0.0 - 181.0)	1.30	(0.10 - 3.04)	-*	1	24.8	(0.0 - 73.4)	0.73	(0.00 - 2.71)	-*
Avon HD												
Northam (S)	8	72.5	(17.9 - 127.1)	1.37	(0.48 - 2.47)	-	4	35.1	(0.6 - 69.6)	1.18	(0.18 - 2.58)	-*
Northam (T)	12	46.4	(18.2 - 74.7)	1.07	(0.49 - 1.76)	-	7	22.9	(2.5 - 43.3)	0.73	(0.23 - 1.37)	-
Toodyay (S)	6	41.2	(8.0 - 74.5)	0.88	(0.24 - 1.70)	-	2	13.2	(0.0 - 31.5)	0.50	(0.01 - 1.40)	-*
York (S)	10	67.2	(24.1 - 110.3)	1.53	(0.63 - 2.61)	-	2	13.8	(0.0 - 33.3)	0.44	(0.01 - 1.24)	-*
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	2	24.5	(0.0 - 59.9)	0.63	(0.01 - 1.76)	-*	0	-	-	0	n/a	-
Kalgoorlie/Boulder (C) - Pt A	29	57.7	(35.9 - 79.5)	1.17	(0.75 - 1.63)	-	19	35.5	(18.1 - 52.8)	1.07	(0.60 - 1.60)	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	-	-	-	0	-	-	-	-	-
Laverton (S)	0	-	-	0	n/a	-	1	46.5	(0.0 - 137.3)	2.26	(0.00 - 8.35)	-*
Leonora (S)	2	68.5	(0.0 - 166.5)	1.03	(0.01 - 2.87)	-*	1	33.3	(0.0 - 96.5)	1.48	(0.00 - 5.47)	-*
Menzies (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Ngaanyatjarraku (S)	0	-	-	0	n/a	-	0	-	-	0	-	-
South East Coastal HD												
Dundas (S)	3	70.6	(0.0 - 151.0)	1.61	(0.13 - 3.76)	-*	1	14.3	(0.0 - 41.9)	0.95	(0.00 - 3.50)	-*
Esperance (S)	23	55.2	(32.4 - 78.0)	1.20	(0.72 - 1.74)	-	11	21.4	(8.3 - 34.5)	0.82	(0.36 - 1.37)	-
Ravensthorpe (S)	1	16.6	(0.0 - 49.1)	0.38	(0.00 - 1.40)	-*	1	25.3	(0.0 - 74.6)	0.68	(0.00 - 2.51)	-*
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	42	70.8	(48.0 - 93.5)	1.23	(0.86 - 1.63)	-	42	44.5	(28.0 - 61.0)	1.37	(0.96 - 1.81)	-
Albany (C) Bal	19	36.1	(19.8 - 52.4)	0.83	(0.46 - 1.24)	-	12	29.0	(12.3 - 45.7)	0.90	(0.41 - 1.48)	-
Cranbrook (S)	3	92.2	(0.0 - 195.7)	1.42	(0.11 - 3.32)	-*	1	39.0	(0.0 - 114.8)	0.96	(0.00 - 3.53)	-*
Denmark (S)	5	19.5	(1.4 - 37.5)	0.53	(0.12 - 1.08)	-	7	40.8	(9.6 - 71.9)	1.14	(0.36 - 2.12)	-
Jerramungup (S)	2	54.3	(0.0 - 129.6)	1.10	(0.01 - 3.07)	-*	0	-	-	0	n/a	-
Plantagenet (S)	11	61.8	(25.0 - 98.5)	1.32	(0.57 - 2.20)	-	6	32.6	(5.7 - 59.5)	1.07	(0.29 - 2.08)	-
Central Great Southern HD												
Broomehill (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Gnowangerup (S)	4	83.9	(0.6 - 167.1)	1.73	(0.27 - 3.80)	-*	4	56.2	(0.0 - 112.8)	2.50	(0.39 - 5.48)	-*
Katanning (S)	5	33.3	(3.0 - 63.5)	0.77	(0.17 - 1.59)	-	4	19.7	(0.0 - 40.5)	0.78	(0.12 - 1.71)	-
Kent (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Kojonup (S)	4	36.0	(0.0 - 73.5)	0.97	(0.15 - 2.14)	-*	2	14.5	(0.0 - 34.4)	0.72	(0.01 - 2.01)	-*
Tambellup (S)	0	-	-	0	n/a	-	1	54.5	(0.0 - 160.5)	1.47	(0.00 - 5.42)	-*
Woodanilling (S)	1	66.7	(0.0 - 196.2)	1.92	(0.00 - 7.07)	-*	0	-	-	-	-	-
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	16	49.0	(24.0 - 74.1)	1.03	(0.54 - 1.60)	-	11	25.8	(9.6 - 42.0)	1.04	(0.45 - 1.73)	-
Busselton (S)	53	61.8	(44.3 - 79.3)	1.32	(1.00 - 1.74)	-	28	25.9	(15.2 - 36.6)	0.89	(0.57 - 1.25)	-
Warren-Blackwood HD												
Boyup Brook (S)	4	58.3	(0.0 - 117.1)	1.26	(0.19 - 2.76)	-*	5	48.8	(0.6 - 96.9)	2.07	(0.45 - 4.24)	-*
Bridgetown-Greenbushes (S)	1	6.4	(0.0 - 19.0)	0.14	(0.00 - 0.52)	V	7	46.9	(11.1 - 82.7)	1.41	(0.44 - 2.64)	-
Manjimup (S)	11	33.9	(13.7 - 54.1)	0.66	(0.29 - 1.10)	-	10	25.5	(8.6 - 42.4)	0.90	(0.37 - 1.54)	-
Nannup (S)	4	65.5	(1.4 - 129.6)	1.90	(0.29 - 4.16)	-*	1	22.2	(0.0 - 65.7)	0.73	(0.00 - 2.69)	-*
Bunbury HD												
Bunbury (C)	53	49.1	(35.0 - 63.1)	1.09	(0.82 - 1.43)	-	44	35.2	(23.5 - 47.0)	1.10	(0.78 - 1.45)	-
Capel (S) - Pt A	4	55.0	(0.0 - 111.3)	1.41	(0.22 - 3.09)	-*	1	22.0	(0.0 - 64.9)	0.56	(0.00 - 2.07)	-*
Capel (S) - Pt B	4	28.2	(0.4 - 56.1)	0.61	(0.09 - 1.34)	-	7	57.7	(14.5 - 100.9)	1.78	(0.56 - 3.32)	-*
Dardanup (S) - Pt A	5	32.1	(3.6 - 60.5)	0.75	(0.16 - 1.53)	-	3	18.9	(0.0 - 40.8)	0.64	(0.05 - 1.49)	-
Dardanup (S) - Pt B	5	62.3	(8.2 - 116.5)	1.34	(0.29 - 2.75)	-*	2	33.2	(0.0 - 79.0)	1.00	(0.01 - 2.80)	-*
Wellington HD												

Cancer type: Colorectal cancer 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	21	54.4	(29.9 - 79.0)	1.40	(0.82 - 2.06)	-	15	43.3	(19.8 - 66.7)	1.41	(0.72 - 2.21)	-
Donnybrook-Balingup (S)	4	23.0	(0.2 - 45.7)	0.54	(0.08 - 1.19)	-	6	34.4	(6.5 - 62.2)	1.22	(0.33 - 2.36)	-
Harvey-Yarloop HD												
Harvey (S) - Pt A	18	65.4	(34.6 - 96.3)	1.50	(0.82 - 2.26)	-	10	41.0	(15.2 - 66.9)	1.25	(0.51 - 2.13)	-
Harvey (S) - Pt B	16	54.5	(27.4 - 81.7)	1.21	(0.63 - 1.87)	-	6	20.8	(3.7 - 38.0)	0.66	(0.18 - 1.28)	-
Total State	2822	45.1	(43.4 - 46.8)	1.00	(0.96 - 1.04)	-	2209	29.7	(28.4 - 31.1)	1.00	(0.96 - 1.04)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

W.A. Cancer by SLA (DOH Areas)
Cancer type: Prostate gland 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	87	90.0	(70.0 - 110.1)	1.17	(0.94 - 1.45)	-	0	-	-	-	-	.
Claremont (T)	38	98.8	(64.6 - 133.1)	1.28	(0.88 - 1.72)	-	0	-	-	-	-	.
Cottesloe (T)	17	60.3	(30.7 - 89.8)	0.78	(0.42 - 1.20)	-	0	-	-	-	-	.
Joondalup (C) - North	76	79.7	(61.3 - 98.1)	1.10	(0.87 - 1.39)	-	0	-	-	-	-	.
Joondalup (C) - South	243	78.6	(68.3 - 89.0)	1.06	(0.93 - 1.20)	-	0	-	-	-	-	.
Mosman Park (T)	28	84.8	(51.4 - 118.3)	1.18	(0.75 - 1.66)	-	0	-	-	-	-	.
Nedlands (C)	83	100.0	(76.6 - 123.4)	1.30	(1.04 - 1.62)	^	0	-	-	-	-	.
Peppermint Grove (S)	5	64.8	(2.8 - 126.8)	1.01	(0.22 - 2.07)	-	0	-	-	-	-	.
Stirling (C) - Central	263	68.9	(60.3 - 77.4)	0.92	(0.81 - 1.04)	-	0	-	-	-	-	.
Stirling (C) - Coastal	215	91.9	(79.2 - 104.7)	1.24	(1.08 - 1.42)	^	0	-	-	-	-	.
Subiaco (C)	44	105.6	(73.8 - 137.5)	1.24	(0.87 - 1.63)	-	0	-	-	-	-	.
Wanneroo (C) - North-East	51	87.1	(62.8 - 111.4)	1.19	(0.89 - 1.57)	-	0	-	-	-	-	.
Wanneroo (C) - North-West	78	114.9	(88.9 - 140.9)	1.57	(1.25 - 1.98)	^	0	-	-	-	-	.
Wanneroo (C) - South	66	80.3	(60.8 - 99.8)	1.10	(0.86 - 1.41)	-	0	-	-	-	-	.
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	68	54.9	(41.2 - 68.5)	0.73	(0.57 - 0.93)	V	0	-	-	-	-	.
Canning (C)	163	71.6	(60.4 - 82.8)	0.94	(0.81 - 1.10)	-	0	-	-	-	-	.
South Perth (C)	116	86.1	(68.8 - 103.4)	1.17	(0.97 - 1.41)	-	0	-	-	-	-	.
Victoria Park (T)	82	72.5	(54.2 - 90.8)	1.01	(0.81 - 1.26)	-	0	-	-	-	-	.
Inner City HD												
Perth (C) - Inner	0	-	-	0	n/a	-	0	-	-	-	-	.
Perth (C) - Remainder	24	85.9	(50.6 - 121.2)	1.15	(0.70 - 1.65)	-	0	-	-	-	-	.
Stirling (C) - South-Eastern	45	76.8	(50.7 - 102.9)	0.94	(0.67 - 1.23)	-	0	-	-	-	-	.
Vincent (T)	51	54.5	(38.4 - 70.6)	0.73	(0.55 - 0.97)	V	0	-	-	-	-	.
Kalamunda HD												
Kalamunda (S)	108	67.2	(54.4 - 80.0)	0.89	(0.73 - 1.08)	-	0	-	-	-	-	.
Swan HD												
Bassendean (T)	30	64.4	(41.0 - 87.8)	0.77	(0.50 - 1.07)	-	0	-	-	-	-	.
Bayswater (C)	149	70.5	(58.7 - 82.3)	0.91	(0.77 - 1.07)	-	0	-	-	-	-	.
Mundaring (S)	99	87.1	(69.6 - 104.5)	1.20	(0.98 - 1.47)	-	0	-	-	-	-	.
Swan (C)	125	62.0	(51.0 - 73.0)	0.83	(0.70 - 1.00)	-	0	-	-	-	-	.
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	95	61.3	(48.8 - 73.8)	0.82	(0.67 - 1.01)	-	0	-	-	-	-	.
Gosnells (C)	140	64.7	(53.8 - 75.6)	0.87	(0.73 - 1.03)	-	0	-	-	-	-	.
Serpentine-Jarrahdale (S)	37	110.0	(74.2 - 145.8)	1.51	(1.03 - 2.03)	^	0	-	-	-	-	.
Fremantle HD												
Cockburn (C)	115	62.8	(51.2 - 74.3)	0.82	(0.68 - 0.99)	V	0	-	-	-	-	.
East Fremantle (T)	23	92.2	(52.4 - 132.0)	1.20	(0.72 - 1.74)	-	0	-	-	-	-	.
Fremantle (C) - Inner	4	97.1	(0.0 - 195.6)	1.28	(0.20 - 2.80)	-*	0	-	-	-	-	.
Fremantle (C) - Remainder	75	70.8	(54.1 - 87.4)	0.96	(0.76 - 1.22)	-	0	-	-	-	-	.
Melville (C)	329	84.3	(74.7 - 93.9)	1.18	(1.06 - 1.32)	^	0	-	-	-	-	.
Rockingham-Kwinana HD												
Kwinana (T)	37	60.9	(40.8 - 81.0)	0.78	(0.53 - 1.05)	-	0	-	-	-	-	.
Rockingham (C)	192	73.8	(63.0 - 84.5)	1.04	(0.90 - 1.20)	-	0	-	-	-	-	.
Peel HD												
Mandurah (C)	197	80.6	(68.7 - 92.5)	1.09	(0.95 - 1.26)	-	0	-	-	-	-	.
Murray (S)	49	84.6	(60.5 - 108.6)	1.23	(0.89 - 1.60)	-	0	-	-	-	-	.
Waroona (S)	11	75.7	(30.5 - 121.0)	1.06	(0.46 - 1.77)	-	0	-	-	-	-	.
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	4	19.2	(0.4 - 38.0)	0.25	(0.04 - 0.54)	V	0	-	-	-	-	.
Derby-West Kimberley (S)	4	32.6	(0.7 - 64.5)	0.37	(0.06 - 0.81)	V	0	-	-	-	-	.
Halls Creek (S)	4	59.9	(0.7 - 119.2)	0.79	(0.12 - 1.74)	-	0	-	-	-	-	.
Wyndham-East Kimberley (S)	4	37.4	(0.4 - 74.5)	0.43	(0.07 - 0.94)	V	0	-	-	-	-	.
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	10	113.4	(32.8 - 194.1)	1.91	(0.78 - 3.26)	-	0	-	-	-	-	.
Roebourne (S)	10	59.1	(12.1 - 106.0)	0.78	(0.32 - 1.33)	-	0	-	-	-	-	.

Cancer type: Prostate gland 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	9	42.9	(14.7 - 71.2)	0.55	(0.21 - 0.96)	V	0	-	-	-	-	.
Exmouth (S)	4	54.5	(0.9 - 108.0)	0.89	(0.14 - 1.95)	-*	0	-	-	-	-	.
Shark Bay (S)	1	24.8	(0.0 - 73.4)	0.30	(0.00 - 1.09)	-*	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
East Pilbara HD												
East Pilbara (S)	1	4.7	(0.0 - 14.0)	0.15	(0.00 - 0.56)	V	0	-	-	-	-	.
Port Hedland (T)	7	40.6	(7.4 - 73.8)	0.49	(0.15 - 0.91)	V	0	-	-	-	-	.
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	3	103.7	(0.0 - 220.8)	1.78	(0.14 - 4.15)	-*	0	-	-	-	-	.
Chapman Valley (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Coorow (S)	3	65.9	(0.0 - 140.1)	0.79	(0.06 - 1.84)	-*	0	-	-	-	-	.
Irwin (S)	9	73.4	(25.2 - 121.5)	0.88	(0.34 - 1.55)	-	0	-	-	-	-	.
Mingenew (S)	1	52.6	(0.0 - 155.1)	0.71	(0.00 - 2.63)	-*	0	-	-	-	-	.
Morawa (S)	2	52.3	(0.0 - 126.0)	0.68	(0.01 - 1.89)	-*	0	-	-	-	-	.
Mullewa (S)	1	31.6	(0.0 - 93.1)	0.42	(0.00 - 1.53)	-*	0	-	-	-	-	.
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northampton (S)	9	55.6	(18.4 - 92.7)	0.82	(0.32 - 1.44)	-	0	-	-	-	-	.
Perenjori (S)	4	262.5	(9.1 - 515.9)	3.16	(0.49 - 6.92)	-*	0	-	-	-	-	.
Three Springs (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Yalgoo (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Murchison HD												
Cue (S)	1	133.3	(0.0 - 385.8)	1.28	(0.00 - 4.73)	-*	0	-	-	-	-	.
Meekatharra (S)	4	148.2	(4.5 - 292.0)	1.69	(0.26 - 3.69)	-*	0	-	-	-	-	.
Mount Magnet (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	1	100.0	(0.0 - 292.7)	0.78	(0.00 - 2.89)	-*	0	-	-	-	-	.
Geraldton HD												
Geraldton (C)	53	77.4	(56.1 - 98.7)	0.98	(0.74 - 1.30)	-	0	-	-	-	-	.
Greenough (S) - Pt A	13	52.7	(23.9 - 81.5)	0.71	(0.34 - 1.15)	-	0	-	-	-	-	.
Greenough (S) - Pt B	2	49.4	(0.0 - 117.4)	0.63	(0.01 - 1.76)	-*	0	-	-	-	-	.
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	5	64.0	(7.3 - 120.8)	0.80	(0.17 - 1.63)	-	0	-	-	-	-	.
Bruce Rock (S)	3	54.9	(0.0 - 118.6)	0.85	(0.07 - 1.99)	-*	0	-	-	-	-	.
Corrigin (S)	6	114.1	(19.4 - 208.7)	1.51	(0.41 - 2.94)	-*	0	-	-	-	-	.
Cunderdin (S)	2	37.4	(0.0 - 89.2)	0.51	(0.01 - 1.43)	-*	0	-	-	-	-	.
Quairading (S)	7	140.8	(37.8 - 243.9)	2.09	(0.66 - 3.90)	-*	0	-	-	-	-	.
Tammin (S)	1	64.5	(0.0 - 189.9)	0.84	(0.00 - 3.11)	-*	0	-	-	-	-	.
Upper Great Southern HD												
Boddington (S)	1	11.6	(0.0 - 34.2)	0.33	(0.00 - 1.23)	-*	0	-	-	-	-	.
Brookton (S)	4	52.3	(0.0 - 109.3)	1.05	(0.16 - 2.30)	-*	0	-	-	-	-	.
Cuballing (S)	2	63.5	(0.0 - 152.0)	0.99	(0.01 - 2.77)	-*	0	-	-	-	-	.
Dumbleyung (S)	2	69.5	(0.0 - 166.1)	0.88	(0.01 - 2.44)	-*	0	-	-	-	-	.
Kondinin (S)	3	90.5	(0.0 - 192.2)	1.23	(0.10 - 2.86)	-*	0	-	-	-	-	.
Kulin (S)	3	98.6	(0.0 - 217.1)	1.17	(0.09 - 2.73)	-*	0	-	-	-	-	.
Lake Grace (S)	2	47.4	(0.0 - 114.1)	0.58	(0.01 - 1.62)	-*	0	-	-	-	-	.
Narrogin (S)	1	26.3	(0.0 - 77.7)	0.26	(0.00 - 0.94)	V*	0	-	-	-	-	.
Narrogin (T)	10	66.6	(22.2 - 111.0)	1.00	(0.41 - 1.71)	-	0	-	-	-	-	.
Pingelly (S)	6	106.3	(19.9 - 192.6)	1.41	(0.38 - 2.74)	-*	0	-	-	-	-	.
Wagin (S)	4	57.5	(0.0 - 121.8)	0.68	(0.10 - 1.49)	-	0	-	-	-	-	.
Wandering (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
West Arthur (S)	3	77.9	(0.0 - 165.2)	1.00	(0.08 - 2.34)	-*	0	-	-	-	-	.
Wickepin (S)	6	176.1	(25.3 - 326.8)	2.58	(0.70 - 5.02)	-*	0	-	-	-	-	.
Williams (S)	1	29.0	(0.0 - 85.4)	0.40	(0.00 - 1.48)	-*	0	-	-	-	-	.
Western HD												
Chittering (S)	5	44.3	(5.5 - 83.1)	0.60	(0.13 - 1.22)	-	0	-	-	-	-	.
Dalwallinu (S)	4	64.5	(0.7 - 128.3)	0.89	(0.14 - 1.95)	-*	0	-	-	-	-	.
Dandaragan (S)	10	86.4	(24.1 - 148.6)	1.04	(0.43 - 1.78)	-	0	-	-	-	-	.
Dowerin (S)	6	203.9	(33.1 - 374.7)	2.95	(0.80 - 5.74)	-*	0	-	-	-	-	.
Gingin (S)	22	114.7	(66.6 - 162.9)	1.57	(0.93 - 2.29)	-	0	-	-	-	-	.
Goomalling (S)	4	101.3	(3.0 - 199.7)	1.33	(0.21 - 2.91)	-*	0	-	-	-	-	.
Moora (S)	4	63.0	(0.0 - 126.8)	0.70	(0.11 - 1.53)	-	0	-	-	-	-	.

Cancer type: Prostate gland 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	6	146.2	(30.0 - 262.3)	1.84	(0.50 - 3.58)	-*	0	-	-	-	-	.
Wongan-Ballidu (S)	6	122.0	(24.4 - 219.7)	1.84	(0.50 - 3.57)	-*	0	-	-	-	-	.
Eastern Wheatbelt HD												
Kellerberrin (S)	5	79.2	(7.6 - 150.8)	1.11	(0.24 - 2.28)	-	0	-	-	-	-	.
Koorda (S)	3	204.0	(0.0 - 444.3)	2.00	(0.16 - 4.68)	-*	0	-	-	-	-	.
Merredin (S)	12	105.5	(45.1 - 165.8)	1.32	(0.60 - 2.17)	-	0	-	-	-	-	.
Mount Marshall (S)	1	40.4	(0.0 - 119.2)	0.58	(0.00 - 2.14)	-*	0	-	-	-	-	.
Mukinbudin (S)	1	38.1	(0.0 - 112.4)	0.47	(0.00 - 1.74)	-*	0	-	-	-	-	.
Narembeen (S)	2	54.7	(0.0 - 131.6)	0.70	(0.01 - 1.95)	-*	0	-	-	-	-	.
Nungarin (S)	1	71.4	(0.0 - 208.9)	1.23	(0.00 - 4.52)	-*	0	-	-	-	-	.
Trayning (S)	5	309.9	(36.8 - 582.9)	3.52	(0.77 - 7.21)	-*	0	-	-	-	-	.
Westonia (S)	2	191.7	(0.0 - 459.9)	2.56	(0.03 - 7.14)	-*	0	-	-	-	-	.
Wyalkatchem (S)	2	63.0	(0.0 - 153.2)	0.86	(0.01 - 2.39)	-*	0	-	-	-	-	.
Yilgam (S)	6	127.2	(25.1 - 229.2)	1.62	(0.44 - 3.16)	-*	0	-	-	-	-	.
Avon HD												
Northam (S)	4	28.6	(0.6 - 56.6)	0.41	(0.06 - 0.89)	V	0	-	-	-	-	.
Northam (T)	24	110.3	(64.3 - 156.4)	1.30	(0.79 - 1.87)	-	0	-	-	-	-	.
Toodyay (S)	9	58.3	(19.8 - 96.7)	0.78	(0.30 - 1.37)	-	0	-	-	-	-	.
York (S)	8	49.9	(14.6 - 85.2)	0.74	(0.26 - 1.33)	-	0	-	-	-	-	.
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	2	24.7	(0.0 - 60.6)	0.43	(0.01 - 1.19)	-	0	-	-	-	-	.
Kalgoorlie/Boulder (C) - Pt A	42	82.6	(56.9 - 108.2)	1.10	(0.77 - 1.46)	-	0	-	-	-	-	.
Kalgoorlie/Boulder (C) - Pt B	1	97.6	(0.0 - 286.4)	1.33	(0.00 - 4.92)	-*	0	-	-	-	-	.
Laverton (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Leonora (S)	1	24.4	(0.0 - 71.6)	0.36	(0.00 - 1.34)	-*	0	-	-	-	-	.
Menzies (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Ngaanyatjarraku (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
South East Coastal HD												
Dundas (S)	4	112.5	(0.0 - 225.1)	1.33	(0.21 - 2.92)	-*	0	-	-	-	-	.
Esperance (S)	36	85.0	(57.1 - 112.9)	1.15	(0.78 - 1.55)	-	0	-	-	-	-	.
Ravensthorpe (S)	10	157.9	(60.0 - 255.8)	2.26	(0.93 - 3.86)	-*	0	-	-	-	-	.
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	60	91.7	(67.3 - 116.2)	1.07	(0.82 - 1.38)	-	0	-	-	-	-	.
Albany (C) Bal	25	49.7	(30.1 - 69.3)	0.66	(0.40 - 0.94)	V	0	-	-	-	-	.
Cranbrook (S)	3	54.7	(0.0 - 115.1)	0.87	(0.07 - 2.03)	-*	0	-	-	-	-	.
Denmark (S)	13	57.4	(26.0 - 88.8)	0.82	(0.39 - 1.33)	-	0	-	-	-	-	.
Jerramungup (S)	3	69.0	(0.0 - 149.3)	1.03	(0.08 - 2.39)	-*	0	-	-	-	-	.
Plantagenet (S)	16	83.9	(42.5 - 125.3)	1.15	(0.60 - 1.78)	-	0	-	-	-	-	.
Central Great Southern HD												
Broomehill (S)	3	140.2	(0.0 - 294.3)	2.43	(0.20 - 5.67)	-*	0	-	-	-	-	.
Gnowangerup (S)	7	144.1	(36.2 - 252.1)	1.88	(0.59 - 3.51)	-*	0	-	-	-	-	.
Katanning (S)	17	110.8	(57.0 - 164.5)	1.62	(0.87 - 2.48)	-	0	-	-	-	-	.
Kent (S)	2	115.3	(0.0 - 278.9)	1.63	(0.02 - 4.54)	-*	0	-	-	-	-	.
Kojonup (S)	11	117.2	(45.6 - 188.8)	1.63	(0.71 - 2.72)	-	0	-	-	-	-	.
Tambellup (S)	2	98.3	(0.0 - 237.8)	1.12	(0.01 - 3.11)	-*	0	-	-	-	-	.
Woodanilling (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	27	74.1	(44.6 - 103.5)	1.08	(0.68 - 1.53)	-	0	-	-	-	-	.
Busselton (S)	52	49.7	(35.4 - 64.0)	0.78	(0.59 - 1.03)	-	0	-	-	-	-	.
Warren-Blackwood HD												
Boyup Brook (S)	6	97.5	(19.8 - 175.2)	1.15	(0.31 - 2.23)	-	0	-	-	-	-	.
Bridgetown-Greenbushes (S)	14	89.2	(42.2 - 136.1)	1.19	(0.59 - 1.88)	-	0	-	-	-	-	.
Manjimup (S)	27	74.5	(46.0 - 103.0)	0.99	(0.62 - 1.39)	-	0	-	-	-	-	.
Nannup (S)	3	61.9	(0.0 - 133.1)	0.86	(0.07 - 2.00)	-*	0	-	-	-	-	.
Bunbury HD												
Bunbury (C)	60	59.5	(43.7 - 75.3)	0.76	(0.58 - 0.98)	V	0	-	-	-	-	.
Capel (S) - Pt A	1	18.9	(0.0 - 55.7)	0.22	(0.00 - 0.81)	V	0	-	-	-	-	.
Capel (S) - Pt B	11	78.6	(31.7 - 125.4)	1.03	(0.45 - 1.71)	-	0	-	-	-	-	.
Dardanup (S) - Pt A	9	57.6	(19.5 - 95.7)	0.84	(0.32 - 1.47)	-	0	-	-	-	-	.
Dardanup (S) - Pt B	1	11.7	(0.0 - 34.6)	0.16	(0.00 - 0.61)	V	0	-	-	-	-	.
Wellington HD												

Cancer type: Prostate gland 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	26	77.3	(45.5 - 109.0)	1.07	(0.67 - 1.52)	-	0	-	-	-	-	.
Donnybrook-Balingup (S)	13	78.0	(35.3 - 120.7)	1.07	(0.51 - 1.72)	-	0	-	-	-	-	.
Harvey-Yarloop HD												
Harvey (S) - Pt A	19	75.4	(41.1 - 109.7)	0.98	(0.55 - 1.47)	-	0	-	-	-	-	.
Harvey (S) - Pt B	26	85.7	(52.4 - 119.0)	1.19	(0.74 - 1.69)	-	0	-	-	-	-	.
Total State	4600	74.3	(72.1 - 76.5)	1.00	(0.97 - 1.03)	-	0	-	-	-	-	.

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

W.A. Cancer by SLA (DOH Areas)
Cancer type: Melanoma (skin) 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	54	64.6	(46.1 - 83.0)	1.44	(1.09 - 1.90)	^	35	36.8	(22.7 - 51.0)	1.21	(0.82 - 1.65)	-
Claremont (T)	24	68.7	(38.0 - 99.3)	1.70	(1.03 - 2.45)	^	21	43.7	(21.7 - 65.7)	1.72	(1.00 - 2.53)	-
Cottesloe (T)	19	66.7	(35.2 - 98.2)	1.68	(0.94 - 2.51)	-	15	56.2	(24.7 - 87.6)	1.68	(0.86 - 2.63)	-
Joondalup (C) - North	49	43.2	(30.4 - 56.0)	1.01	(0.73 - 1.31)	-	41	31.6	(21.5 - 41.6)	1.07	(0.74 - 1.42)	-
Joondalup (C) - South	186	55.9	(47.5 - 64.3)	1.33	(1.15 - 1.53)	^	135	40.9	(33.6 - 48.2)	1.29	(1.09 - 1.53)	^
Mosman Park (T)	15	52.8	(24.9 - 80.7)	1.22	(0.62 - 1.91)	-	15	34.2	(12.9 - 55.6)	1.56	(0.80 - 2.45)	-
Nedlands (C)	53	68.6	(48.8 - 88.4)	1.67	(1.27 - 2.21)	^	35	42.2	(25.8 - 58.5)	1.33	(0.89 - 1.80)	-
Peppermint Grove (S)	2	27.1	(0.0 - 66.5)	0.84	(0.01 - 2.33)	-*	1	15.4	(0.0 - 45.5)	0.56	(0.00 - 2.05)	-*
Stirling (C) - Central	122	34.7	(28.4 - 41.0)	0.84	(0.70 - 1.00)	-	87	24.8	(19.4 - 30.3)	0.78	(0.63 - 0.96)	V
Stirling (C) - Coastal	133	63.2	(52.2 - 74.3)	1.47	(1.23 - 1.74)	^	78	34.6	(26.3 - 42.9)	1.11	(0.88 - 1.39)	-
Subiaco (C)	26	52.0	(31.2 - 72.9)	1.27	(0.79 - 1.81)	-	12	24.0	(10.0 - 38.0)	0.70	(0.32 - 1.15)	-
Wanneroo (C) - North-East	23	38.3	(22.4 - 54.1)	0.92	(0.55 - 1.33)	-	26	38.6	(23.2 - 54.1)	1.41	(0.88 - 2.00)	-
Wanneroo (C) - North-West	33	44.9	(29.0 - 60.7)	1.15	(0.76 - 1.57)	-	17	25.3	(12.9 - 37.6)	0.81	(0.43 - 1.23)	-
Wanneroo (C) - South	21	21.4	(12.1 - 30.8)	0.54	(0.31 - 0.79)	V	24	24.1	(14.3 - 34.0)	0.78	(0.47 - 1.12)	-
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	43	42.0	(29.0 - 55.0)	0.93	(0.65 - 1.23)	-	34	30.1	(19.0 - 41.2)	1.01	(0.67 - 1.37)	-
Canning (C)	93	41.1	(32.6 - 49.6)	0.94	(0.77 - 1.16)	-	72	29.3	(22.3 - 36.3)	0.93	(0.74 - 1.18)	-
South Perth (C)	72	58.7	(44.4 - 73.0)	1.37	(1.08 - 1.73)	^	45	33.4	(22.8 - 43.9)	1.02	(0.72 - 1.33)	-
Victoria Park (T)	43	42.9	(28.3 - 57.5)	1.05	(0.74 - 1.38)	-	33	27.7	(15.9 - 39.4)	0.97	(0.64 - 1.33)	-
Inner City HD												
Perth (C) - Inner	0	-	-	0	n/a	-	1	74.1	(0.0 - 218.6)	1.98	(0.00 - 7.31)	-*
Perth (C) - Remainder	15	54.1	(25.7 - 82.5)	1.33	(0.68 - 2.08)	-	3	18.4	(0.0 - 39.4)	0.50	(0.04 - 1.17)	-
Stirling (C) - South-Eastern	17	33.3	(16.5 - 50.2)	0.70	(0.37 - 1.07)	-	17	23.0	(10.3 - 35.6)	0.85	(0.46 - 1.30)	-
Vincent (T)	32	33.1	(20.9 - 45.2)	0.83	(0.55 - 1.14)	-	23	19.8	(10.8 - 28.8)	0.80	(0.48 - 1.17)	-
Kalamunda HD												
Kalamunda (S)	75	49.3	(37.9 - 60.7)	1.13	(0.89 - 1.42)	-	38	23.2	(15.6 - 30.8)	0.77	(0.53 - 1.03)	-
Swan HD												
Bassendean (T)	13	25.2	(11.0 - 39.3)	0.63	(0.30 - 1.02)	-	11	22.5	(8.5 - 36.5)	0.70	(0.31 - 1.18)	-
Bayswater (C)	70	34.3	(25.9 - 42.6)	0.82	(0.64 - 1.04)	-	59	28.0	(20.3 - 35.7)	0.94	(0.72 - 1.22)	-
Mundaring (S)	42	36.8	(25.4 - 48.3)	0.89	(0.62 - 1.18)	-	36	34.1	(22.3 - 45.9)	1.03	(0.70 - 1.39)	-
Swan (C)	75	33.0	(25.4 - 40.6)	0.80	(0.63 - 1.01)	-	63	27.9	(20.8 - 35.0)	0.88	(0.68 - 1.13)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	58	36.7	(27.1 - 46.2)	0.88	(0.67 - 1.14)	-	39	24.5	(16.6 - 32.4)	0.78	(0.54 - 1.05)	-
Gosnells (C)	69	30.5	(23.2 - 37.8)	0.70	(0.55 - 0.89)	V	45	18.6	(13.0 - 24.1)	0.60	(0.43 - 0.79)	V
Serpentine-Jarrahdale (S)	12	33.4	(13.9 - 52.8)	0.81	(0.37 - 1.32)	-	14	40.1	(18.6 - 61.6)	1.39	(0.69 - 2.21)	-
Fremantle HD												
Cockburn (C)	66	33.6	(25.4 - 41.7)	0.79	(0.62 - 1.02)	-	63	32.1	(24.1 - 40.2)	1.01	(0.78 - 1.30)	-
East Fremantle (T)	14	49.9	(22.1 - 77.7)	1.37	(0.68 - 2.18)	-	8	29.8	(7.6 - 51.9)	1.05	(0.37 - 1.90)	-
Fremantle (C) - Inner	1	23.4	(0.0 - 69.1)	0.60	(0.00 - 2.22)	-*	0	-	-	0	n/a	-
Fremantle (C) - Remainder	39	42.6	(28.9 - 56.4)	0.98	(0.67 - 1.31)	-	29	29.6	(18.0 - 41.2)	0.99	(0.63 - 1.38)	-
Melville (C)	188	54.7	(46.6 - 62.9)	1.32	(1.14 - 1.53)	^	126	37.4	(30.5 - 44.3)	1.13	(0.95 - 1.35)	-
Rockingham-Kwinana HD												
Kwinana (T)	18	26.7	(14.2 - 39.3)	0.66	(0.36 - 0.99)	V	12	19.4	(8.3 - 30.6)	0.63	(0.29 - 1.03)	-
Rockingham (C)	90	39.1	(30.7 - 47.5)	0.92	(0.74 - 1.13)	-	67	30.4	(22.8 - 38.0)	0.94	(0.74 - 1.21)	-
Peel HD												
Mandurah (C)	91	46.1	(35.7 - 56.6)	1.11	(0.90 - 1.36)	-	71	39.6	(29.3 - 49.8)	1.29	(1.02 - 1.64)	^
Murray (S)	9	19.1	(6.2 - 31.9)	0.48	(0.18 - 0.83)	V	8	21.9	(5.1 - 38.8)	0.70	(0.25 - 1.27)	-
Waroona (S)	8	56.9	(17.0 - 96.8)	1.52	(0.53 - 2.73)	-	1	9.6	(0.0 - 28.5)	0.29	(0.00 - 1.08)	-*
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	11	37.2	(14.2 - 60.3)	0.87	(0.38 - 1.46)	-	5	14.4	(1.1 - 27.6)	0.57	(0.13 - 1.18)	-
Derby-West Kimberley (S)	4	19.3	(0.0 - 38.7)	0.51	(0.08 - 1.12)	-	3	23.2	(0.0 - 50.3)	0.59	(0.05 - 1.39)	-
Halls Creek (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Wyndham-East Kimberley (S)	8	36.4	(10.2 - 62.6)	1.10	(0.39 - 1.98)	-	5	23.2	(1.7 - 44.7)	1.08	(0.24 - 2.21)	-
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	3	16.7	(0.0 - 36.6)	0.51	(0.04 - 1.20)	-	4	51.8	(0.0 - 121.1)	1.08	(0.17 - 2.37)	-*
Roebourne (S)	12	23.0	(9.8 - 36.2)	0.86	(0.39 - 1.41)	-	9	42.9	(5.4 - 80.5)	0.96	(0.37 - 1.67)	-

Cancer type: Melanoma (skin) 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	5	21.9	(2.4 - 41.4)	0.55	(0.12 - 1.12)	-	9	53.3	(17.4 - 89.2)	1.62	(0.62 - 2.84)	-
Exmouth (S)	5	76.1	(7.4 - 144.8)	1.70	(0.37 - 3.48)	-*	0	-	-	0	n/a	-
Shark Bay (S)	0	-	-	0	n/a	-	1	38.0	(0.0 - 111.9)	1.10	(0.00 - 4.07)	-*
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
East Pilbara HD												
East Pilbara (S)	3	12.2	(0.0 - 26.1)	0.46	(0.04 - 1.08)	-	0	-	-	0	n/a	V
Port Hedland (T)	6	15.4	(2.8 - 27.9)	0.46	(0.12 - 0.89)	V	2	6.3	(0.0 - 15.2)	0.24	(0.00 - 0.68)	V
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Chapman Valley (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Coorow (S)	5	108.8	(12.6 - 204.9)	2.34	(0.51 - 4.79)	-*	1	24.8	(0.0 - 73.3)	0.79	(0.00 - 2.90)	-*
Irwin (S)	5	40.7	(4.6 - 76.9)	1.00	(0.22 - 2.05)	-	8	88.4	(24.9 - 151.9)	2.73	(0.96 - 4.91)	-*
Mingenew (S)	1	46.9	(0.0 - 138.4)	1.23	(0.00 - 4.54)	-*	1	76.9	(0.0 - 227.0)	2.00	(0.00 - 7.36)	-*
Morawa (S)	0	-	-	0	n/a	-	3	131.4	(0.0 - 291.2)	3.44	(0.28 - 8.02)	-*
Mullewa (S)	2	78.9	(0.0 - 188.4)	1.50	(0.02 - 4.19)	-*	0	-	-	0	n/a	-
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northampton (S)	10	79.4	(29.8 - 129.0)	1.82	(0.75 - 3.11)	-	6	50.6	(9.8 - 91.3)	1.78	(0.48 - 3.46)	-*
Perenjori (S)	2	122.2	(0.0 - 285.4)	2.45	(0.03 - 6.82)	-*	0	-	-	0	n/a	-
Three Springs (S)	1	35.5	(0.0 - 104.9)	0.83	(0.00 - 3.05)	-*	1	44.8	(0.0 - 132.2)	1.39	(0.00 - 5.12)	-*
Yalgoo (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Murchison HD												
Cue (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Meekatharra (S)	3	96.5	(0.0 - 209.9)	1.60	(0.13 - 3.73)	-*	0	-	-	0	n/a	-
Mount Magnet (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Geraldton HD												
Geraldton (C)	32	47.4	(30.5 - 64.2)	1.16	(0.76 - 1.59)	-	23	33.7	(19.2 - 48.1)	1.13	(0.68 - 1.64)	-
Greenough (S) - Pt A	12	42.7	(17.7 - 67.7)	0.99	(0.45 - 1.62)	-	6	18.4	(3.1 - 33.8)	0.68	(0.18 - 1.33)	-
Greenough (S) - Pt B	2	41.1	(0.0 - 98.1)	1.04	(0.01 - 2.89)	-*	0	-	-	0	n/a	-
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	2	25.5	(0.0 - 60.8)	0.68	(0.01 - 1.89)	-*	2	35.1	(0.0 - 84.7)	1.12	(0.01 - 3.12)	-*
Bruce Rock (S)	1	12.0	(0.0 - 35.5)	0.54	(0.00 - 2.00)	-*	3	72.5	(0.0 - 154.5)	2.45	(0.20 - 5.71)	-*
Corrigin (S)	0	-	-	0	n/a	-	2	17.4	(0.0 - 41.3)	1.41	(0.02 - 3.94)	-*
Cunderdin (S)	3	58.0	(0.0 - 123.6)	1.44	(0.12 - 3.35)	-*	0	-	-	0	n/a	-
Quairading (S)	1	20.8	(0.0 - 61.4)	0.57	(0.00 - 2.09)	-*	1	18.7	(0.0 - 55.2)	0.81	(0.00 - 3.00)	-*
Tammin (S)	1	50.0	(0.0 - 147.6)	1.58	(0.00 - 5.81)	-*	0	-	-	-	-	.
Upper Great Southern HD												
Boddington (S)	1	15.6	(0.0 - 46.1)	0.54	(0.00 - 1.98)	-*	1	36.7	(0.0 - 108.3)	0.82	(0.00 - 3.02)	-*
Brookton (S)	3	89.3	(0.0 - 191.3)	1.67	(0.13 - 3.89)	-*	3	30.9	(0.0 - 66.2)	2.83	(0.23 - 6.61)	-*
Cuballing (S)	2	77.0	(0.0 - 182.9)	1.80	(0.02 - 5.01)	-*	1	42.0	(0.0 - 123.9)	1.47	(0.00 - 5.41)	-*
Dumbleyung (S)	1	57.1	(0.0 - 168.7)	0.82	(0.00 - 3.02)	-*	0	-	-	0	n/a	-
Kondinin (S)	4	116.0	(2.0 - 230.0)	2.69	(0.42 - 5.90)	-*	3	94.7	(0.0 - 201.7)	3.47	(0.28 - 8.10)	-*
Kulin (S)	1	23.5	(0.0 - 69.5)	0.71	(0.00 - 2.61)	-*	1	33.9	(0.0 - 100.1)	1.15	(0.00 - 4.23)	-*
Lake Grace (S)	1	15.7	(0.0 - 46.3)	0.45	(0.00 - 1.66)	-*	4	103.4	(3.2 - 203.6)	2.81	(0.44 - 6.16)	-*
Narrogin (S)	1	23.8	(0.0 - 70.2)	0.46	(0.00 - 1.71)	-*	1	23.1	(0.0 - 68.3)	0.67	(0.00 - 2.49)	-*
Narrogin (T)	9	84.6	(29.1 - 140.1)	1.74	(0.67 - 3.05)	-	6	52.0	(7.8 - 96.2)	1.52	(0.41 - 2.95)	-*
Pingelly (S)	1	19.6	(0.0 - 57.9)	0.49	(0.00 - 1.82)	-*	0	-	-	0	n/a	-
Wagin (S)	3	55.7	(0.0 - 120.9)	1.01	(0.08 - 2.35)	-*	1	19.5	(0.0 - 57.7)	0.48	(0.00 - 1.78)	-*
Wandering (S)	0	-	-	-	-	.	0	-	-	-	-	.
West Arthur (S)	1	26.0	(0.0 - 76.7)	0.65	(0.00 - 2.40)	-*	0	-	-	0	n/a	-
Wickepin (S)	3	176.8	(0.0 - 390.9)	2.42	(0.19 - 5.64)	-*	1	39.2	(0.0 - 115.7)	1.33	(0.00 - 4.89)	-*
Williams (S)	1	26.7	(0.0 - 78.8)	0.71	(0.00 - 2.63)	-*	1	42.9	(0.0 - 126.3)	1.14	(0.00 - 4.20)	-*
Western HD												
Chittering (S)	3	52.9	(0.0 - 120.0)	0.69	(0.06 - 1.61)	-*	3	41.1	(0.0 - 88.1)	1.13	(0.09 - 2.63)	-*
Dalwallinu (S)	1	19.5	(0.0 - 57.7)	0.40	(0.00 - 1.47)	-*	3	67.7	(0.0 - 144.8)	1.91	(0.15 - 4.45)	-*
Dandaragan (S)	4	28.0	(0.5 - 55.6)	0.81	(0.13 - 1.79)	-	3	32.0	(0.0 - 68.5)	1.08	(0.09 - 2.51)	-*
Dowerin (S)	0	-	-	0	n/a	-	1	43.8	(0.0 - 129.3)	1.20	(0.00 - 4.44)	-*
Gingin (S)	4	26.0	(0.0 - 52.0)	0.57	(0.09 - 1.25)	-	6	41.2	(7.6 - 74.8)	1.40	(0.38 - 2.73)	-*
Goomalling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Moora (S)	4	54.5	(0.6 - 108.3)	1.17	(0.18 - 2.56)	-*	1	13.2	(0.0 - 39.0)	0.43	(0.00 - 1.57)	-*

Cancer type: Melanoma (skin) 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	1	23.3	(0.0 - 68.7)	0.61	(0.00 - 2.26)	-*	3	121.7	(0.0 - 259.1)	3.42	(0.28 - 7.99)	-*
Wongan-Ballidu (S)	1	14.9	(0.0 - 44.0)	0.49	(0.00 - 1.79)	-*	3	53.4	(0.0 - 113.9)	2.14	(0.17 - 5.00)	-*
Eastern Wheatbelt HD												
Kellerberrin (S)	1	28.7	(0.0 - 84.9)	0.47	(0.00 - 1.73)	-*	3	45.6	(0.0 - 101.3)	2.16	(0.17 - 5.04)	-*
Koorda (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Merredin (S)	3	21.5	(0.0 - 48.0)	0.59	(0.05 - 1.38)	-	2	12.5	(0.0 - 31.0)	0.59	(0.01 - 1.65)	-*
Mount Marshall (S)	0	-	-	0	n/a	-	1	54.8	(0.0 - 161.5)	1.74	(0.00 - 6.43)	-*
Mukinbudin (S)	1	38.1	(0.0 - 112.4)	0.92	(0.00 - 3.38)	-*	2	76.8	(0.0 - 183.3)	2.93	(0.04 - 8.16)	-*
Narembeen (S)	2	60.8	(0.0 - 145.0)	1.33	(0.02 - 3.70)	-*	2	67.2	(0.0 - 160.1)	1.98	(0.02 - 5.52)	-*
Nungarin (S)	1	71.4	(0.0 - 208.9)	2.30	(0.00 - 8.49)	-*	0	-	-	-	-	.
Trayning (S)	1	45.5	(0.0 - 133.5)	1.44	(0.00 - 5.33)	-*	0	-	-	-	-	.
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	2	89.2	(0.0 - 219.4)	1.76	(0.02 - 4.91)	-*	0	-	-	0	n/a	-
Yilgam (S)	2	28.6	(0.0 - 70.0)	0.80	(0.01 - 2.22)	-*	0	-	-	0	n/a	-
Avon HD												
Northam (S)	4	30.8	(0.6 - 61.0)	0.76	(0.12 - 1.67)	-	3	24.1	(0.0 - 51.4)	0.88	(0.07 - 2.06)	-*
Northam (T)	13	62.9	(27.1 - 98.8)	1.40	(0.67 - 2.25)	-	5	18.4	(0.2 - 36.7)	0.72	(0.16 - 1.47)	-
Toodyay (S)	11	127.0	(36.9 - 217.1)	1.79	(0.78 - 2.99)	-	2	18.4	(0.0 - 44.0)	0.51	(0.01 - 1.43)	-*
York (S)	8	73.5	(15.4 - 131.6)	1.51	(0.53 - 2.72)	-	3	25.1	(0.0 - 55.0)	0.85	(0.07 - 1.98)	-*
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	1	7.3	(0.0 - 21.6)	0.23	(0.00 - 0.83)	V*	2	24.0	(0.0 - 58.2)	0.71	(0.01 - 1.99)	-*
Kalgoorlie/Boulder (C) - Pt A	22	25.5	(14.2 - 36.8)	0.72	(0.43 - 1.06)	-	22	25.2	(14.2 - 36.1)	1.03	(0.61 - 1.50)	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	0	n/a	-	0	-	-	-	-	.
Laverton (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Leonora (S)	1	14.2	(0.0 - 42.0)	0.36	(0.00 - 1.35)	-*	1	25.8	(0.0 - 76.1)	0.87	(0.00 - 3.21)	-*
Menzies (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Ngaanyatjarraku (S)	0	-	-	0	n/a	-	0	-	-	0	-	-
South East Coastal HD												
Dundas (S)	2	53.8	(0.0 - 128.0)	1.06	(0.01 - 2.95)	-*	1	22.9	(0.0 - 67.8)	0.91	(0.00 - 3.37)	-*
Esperance (S)	21	56.6	(31.8 - 81.5)	1.20	(0.70 - 1.76)	-	10	22.9	(8.0 - 37.7)	0.82	(0.34 - 1.40)	-
Ravensthorpe (S)	1	15.6	(0.0 - 46.2)	0.43	(0.00 - 1.58)	-*	1	20.4	(0.0 - 60.3)	0.73	(0.00 - 2.70)	-*
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	24	48.7	(28.5 - 69.0)	0.92	(0.56 - 1.32)	-	28	51.7	(30.9 - 72.4)	1.39	(0.88 - 1.95)	-
Albany (C) Bal	19	42.9	(22.6 - 63.3)	0.92	(0.52 - 1.38)	-	15	32.4	(15.9 - 48.9)	1.14	(0.58 - 1.78)	-
Cranbrook (S)	2	50.3	(0.0 - 120.2)	1.11	(0.01 - 3.08)	-*	0	-	-	0	n/a	-
Denmark (S)	6	35.7	(6.9 - 64.6)	0.79	(0.21 - 1.53)	-	5	47.4	(0.0 - 98.0)	1.00	(0.22 - 2.06)	-
Jerramungup (S)	0	-	-	0	n/a	-	1	40.4	(0.0 - 119.2)	0.97	(0.00 - 3.59)	-*
Plantagenet (S)	10	55.0	(20.5 - 89.5)	1.39	(0.57 - 2.38)	-	13	75.8	(33.1 - 118.6)	2.81	(1.34 - 4.52)	^
Central Great Southern HD												
Broomehill (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Gnowangerup (S)	3	58.2	(0.0 - 126.8)	1.38	(0.11 - 3.22)	-*	0	-	-	0	n/a	-
Katanning (S)	3	24.1	(0.0 - 51.8)	0.51	(0.04 - 1.20)	-	6	47.9	(9.4 - 86.3)	1.39	(0.38 - 2.70)	-*
Kent (S)	1	30.2	(0.0 - 89.1)	1.17	(0.00 - 4.31)	-*	0	-	-	0	n/a	-
Kojonup (S)	4	69.6	(0.0 - 143.8)	1.14	(0.18 - 2.50)	-*	1	7.2	(0.0 - 21.4)	0.43	(0.00 - 1.60)	-*
Tambellup (S)	0	-	-	0	n/a	-	1	38.1	(0.0 - 112.4)	1.60	(0.00 - 5.90)	-*
Woodanilling (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	16	44.0	(21.1 - 67.0)	1.15	(0.60 - 1.78)	-	16	52.4	(25.3 - 79.6)	1.72	(0.90 - 2.66)	-
Busselton (S)	34	48.4	(31.3 - 65.4)	1.02	(0.68 - 1.39)	-	33	48.2	(30.5 - 65.8)	1.38	(0.91 - 1.88)	-
Warren-Blackwood HD												
Boyup Brook (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bridgetown-Greenbushes (S)	8	54.0	(16.4 - 91.6)	1.27	(0.45 - 2.30)	-	2	16.6	(0.0 - 39.9)	0.46	(0.01 - 1.29)	-*
Manjimup (S)	5	14.2	(1.6 - 26.8)	0.34	(0.07 - 0.70)	V	4	13.6	(0.2 - 27.1)	0.42	(0.06 - 0.91)	V
Nannup (S)	4	87.0	(0.5 - 173.6)	2.14	(0.33 - 4.68)	-*	1	87.9	(0.0 - 259.3)	0.81	(0.00 - 2.99)	-*
Bunbury HD												
Bunbury (C)	49	51.8	(36.8 - 66.8)	1.17	(0.85 - 1.52)	-	37	38.1	(25.1 - 51.0)	1.20	(0.82 - 1.62)	-
Capel (S) - Pt A	0	-	-	0	n/a	-	1	27.8	(0.0 - 82.1)	0.45	(0.00 - 1.66)	-*
Capel (S) - Pt B	3	22.7	(0.0 - 48.5)	0.51	(0.04 - 1.18)	-	5	37.9	(4.3 - 71.5)	1.27	(0.28 - 2.60)	-*
Dardanup (S) - Pt A	10	67.1	(25.0 - 109.2)	1.47	(0.60 - 2.51)	-	10	54.3	(19.6 - 88.9)	1.97	(0.81 - 3.37)	-
Dardanup (S) - Pt B	4	46.0	(0.7 - 91.3)	1.14	(0.18 - 2.50)	-*	1	12.1	(0.0 - 35.8)	0.47	(0.00 - 1.73)	-*
Wellington HD												

Cancer type: Melanoma (skin) 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	15	56.0	(26.2 - 85.7)	1.14	(0.58 - 1.79)	-	17	57.9	(28.7 - 87.1)	1.90	(1.02 - 2.91)	^
Donnybrook-Balingup (S)	4	24.1	(0.4 - 47.8)	0.60	(0.09 - 1.32)	-	5	29.6	(2.7 - 56.4)	1.10	(0.24 - 2.26)	-
Harvey-Yarloop HD												
Harvey (S) - Pt A	12	45.9	(17.9 - 73.9)	1.01	(0.46 - 1.66)	-	6	20.2	(3.6 - 36.7)	0.71	(0.19 - 1.38)	-
Harvey (S) - Pt B	12	45.2	(18.9 - 71.5)	1.04	(0.48 - 1.71)	-	8	27.0	(7.2 - 46.8)	1.03	(0.36 - 1.86)	-
Total State	2548	42.7	(41.0 - 44.4)	1.00	(0.96 - 1.04)	-	1879	30.9	(29.4 - 32.3)	1.00	(0.96 - 1.05)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

W.A. Cancer by SLA (DOH Areas)

Cancer type: Lung, bronchus & trachea 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	26	18.7	(11.0 - 26.5)	0.64	(0.40 - 0.90)	V	20	11.4	(5.2 - 17.5)	0.84	(0.48 - 1.25)	-
Claremont (T)	10	25.3	(7.7 - 42.8)	0.63	(0.26 - 1.07)	-	9	6.0	(1.0 - 11.0)	0.81	(0.31 - 1.42)	-
Cottesloe (T)	7	22.7	(4.9 - 40.6)	0.60	(0.19 - 1.13)	-	6	7.7	(0.7 - 14.6)	0.84	(0.23 - 1.63)	-
Joondalup (C) - North	35	38.2	(25.3 - 51.1)	0.95	(0.64 - 1.29)	-	20	19.7	(10.8 - 28.6)	1.01	(0.58 - 1.49)	-
Joondalup (C) - South	99	30.6	(24.3 - 36.9)	0.81	(0.66 - 0.99)	V	67	18.7	(14.0 - 23.5)	1.06	(0.83 - 1.35)	-
Mosman Park (T)	13	45.0	(19.3 - 70.7)	1.01	(0.48 - 1.63)	-	4	7.0	(0.0 - 16.4)	0.52	(0.08 - 1.13)	-
Nedlands (C)	24	21.5	(11.8 - 31.1)	0.70	(0.42 - 1.00)	-	19	13.4	(5.9 - 20.9)	0.84	(0.47 - 1.26)	-
Peppermint Grove (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Stirling (C) - Central	180	45.0	(38.2 - 51.9)	1.16	(1.00 - 1.35)	-	84	18.9	(14.5 - 23.2)	0.97	(0.78 - 1.20)	-
Stirling (C) - Coastal	80	31.8	(24.6 - 39.1)	0.85	(0.68 - 1.06)	-	45	13.9	(9.4 - 18.4)	0.82	(0.58 - 1.07)	-
Subiaco (C)	26	49.1	(28.9 - 69.4)	1.37	(0.85 - 1.94)	-	11	16.3	(6.1 - 26.6)	0.90	(0.39 - 1.51)	-
Wanneroo (C) - North-East	28	47.8	(29.8 - 65.9)	1.24	(0.79 - 1.74)	-	14	22.6	(10.3 - 34.9)	1.18	(0.59 - 1.88)	-
Wanneroo (C) - North-West	22	35.5	(20.4 - 50.6)	0.82	(0.48 - 1.19)	-	13	16.8	(7.4 - 26.2)	1.04	(0.50 - 1.68)	-
Wanneroo (C) - South	42	52.7	(36.7 - 68.8)	1.33	(0.93 - 1.76)	-	19	18.9	(10.2 - 27.6)	1.11	(0.62 - 1.66)	-
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	67	48.1	(35.9 - 60.3)	1.32	(1.03 - 1.68)	^	30	17.6	(10.6 - 24.5)	1.08	(0.70 - 1.49)	-
Canning (C)	106	44.3	(35.6 - 52.9)	1.15	(0.94 - 1.39)	-	64	20.5	(15.3 - 25.8)	1.20	(0.93 - 1.54)	-
South Perth (C)	42	27.5	(18.1 - 36.9)	0.77	(0.54 - 1.03)	-	25	14.4	(7.5 - 21.2)	0.69	(0.42 - 0.98)	V
Victoria Park (T)	54	46.3	(31.6 - 60.9)	1.20	(0.91 - 1.57)	-	29	17.9	(9.0 - 26.7)	0.94	(0.60 - 1.31)	-
Inner City HD												
Perth (C) - Inner	3	163.2	(0.0 - 360.4)	2.75	(0.22 - 6.42)	-*	0	-	-	-	-	-
Perth (C) - Remainder	12	45.6	(19.5 - 71.7)	1.08	(0.49 - 1.77)	-	2	8.8	(0.0 - 22.3)	0.47	(0.01 - 1.31)	-*
Stirling (C) - South-Eastern	30	44.7	(26.4 - 63.0)	1.12	(0.73 - 1.56)	-	11	10.7	(2.8 - 18.5)	0.62	(0.27 - 1.04)	-
Vincent (T)	61	64.6	(47.1 - 82.2)	1.59	(1.22 - 2.05)	^	16	12.3	(5.3 - 19.4)	0.73	(0.38 - 1.13)	-
Kalamunda HD												
Kalamunda (S)	50	29.7	(21.3 - 38.0)	0.78	(0.57 - 1.01)	-	25	14.1	(8.3 - 19.8)	0.74	(0.46 - 1.06)	-
Swan HD												
Bassendean (T)	23	44.0	(25.4 - 62.6)	1.08	(0.65 - 1.57)	-	15	25.5	(11.7 - 39.3)	1.25	(0.64 - 1.95)	-
Bayswater (C)	84	36.4	(28.3 - 44.5)	0.95	(0.76 - 1.18)	-	48	16.8	(11.4 - 22.2)	1.00	(0.72 - 1.30)	-
Mundaring (S)	29	25.1	(15.8 - 34.5)	0.67	(0.43 - 0.93)	V	18	13.3	(6.9 - 19.7)	0.79	(0.44 - 1.20)	-
Swan (C)	109	53.2	(43.0 - 63.3)	1.36	(1.12 - 1.65)	^	40	17.1	(11.6 - 22.6)	0.96	(0.66 - 1.28)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	56	35.6	(26.2 - 45.0)	0.92	(0.70 - 1.20)	-	40	21.9	(14.8 - 29.0)	1.23	(0.86 - 1.64)	-
Gosnells (C)	87	40.1	(31.5 - 48.7)	1.02	(0.82 - 1.26)	-	45	17.1	(11.9 - 22.3)	0.99	(0.70 - 1.30)	-
Serpentine-Jarrahdale (S)	12	35.4	(15.2 - 55.6)	0.94	(0.43 - 1.54)	-	4	14.0	(0.2 - 27.8)	0.70	(0.11 - 1.53)	-
Fremantle HD												
Cockburn (C)	69	36.8	(28.0 - 45.5)	0.93	(0.73 - 1.19)	-	47	22.5	(15.8 - 29.2)	1.21	(0.87 - 1.58)	-
East Fremantle (T)	9	34.5	(10.6 - 58.4)	0.86	(0.33 - 1.51)	-	4	12.3	(0.0 - 26.3)	0.68	(0.11 - 1.50)	-
Fremantle (C) - Inner	0	-	-	0	n/a	-	1	74.1	(0.0 - 216.5)	2.48	(0.00 - 9.15)	-*
Fremantle (C) - Remainder	49	45.1	(31.9 - 58.4)	1.16	(0.83 - 1.50)	-	26	20.5	(12.0 - 29.0)	1.12	(0.70 - 1.59)	-
Melville (C)	123	30.9	(25.1 - 36.6)	0.81	(0.68 - 0.98)	V	82	16.9	(12.9 - 21.0)	0.93	(0.74 - 1.16)	-
Rockingham-Kwinana HD												
Kwinana (T)	32	48.0	(31.2 - 64.8)	1.27	(0.84 - 1.75)	-	23	33.8	(19.6 - 48.0)	1.87	(1.12 - 2.70)	^
Rockingham (C)	96	36.6	(29.1 - 44.2)	0.95	(0.78 - 1.17)	-	59	21.1	(15.5 - 26.7)	1.15	(0.89 - 1.50)	-
Peel HD												
Mandurah (C)	92	38.2	(29.9 - 46.6)	0.93	(0.76 - 1.15)	-	53	20.0	(14.1 - 25.9)	1.13	(0.85 - 1.49)	-
Murray (S)	21	35.7	(20.2 - 51.1)	0.99	(0.58 - 1.46)	-	16	34.5	(17.4 - 51.7)	1.90	(1.00 - 2.93)	-
Waroona (S)	3	21.1	(0.0 - 45.5)	0.54	(0.04 - 1.26)	-	1	4.7	(0.0 - 13.9)	0.40	(0.00 - 1.47)	-*
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	9	32.5	(10.6 - 54.4)	1.06	(0.41 - 1.86)	-	1	7.1	(0.0 - 21.1)	0.29	(0.00 - 1.06)	-*
Derby-West Kimberley (S)	10	68.3	(25.5 - 111.1)	1.74	(0.71 - 2.97)	-	4	33.8	(0.0 - 68.0)	1.73	(0.27 - 3.79)	-*
Halls Creek (S)	3	39.7	(0.0 - 84.8)	1.14	(0.09 - 2.66)	-*	3	41.9	(0.0 - 89.3)	2.66	(0.21 - 6.21)	-*
Wyndham-East Kimberley (S)	3	14.3	(0.0 - 30.6)	0.63	(0.05 - 1.46)	-	2	11.9	(0.0 - 29.2)	1.09	(0.01 - 3.04)	-*
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	1	13.7	(0.0 - 40.5)	0.36	(0.00 - 1.34)	-*	1	5.5	(0.0 - 16.2)	1.01	(0.00 - 3.74)	-*
Roebourne (S)	13	90.4	(30.9 - 149.8)	1.97	(0.94 - 3.18)	-	3	18.0	(0.0 - 40.9)	1.09	(0.09 - 2.56)	-*

Cancer type: Lung, bronchus & trachea 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	11	54.6	(22.2 - 86.9)	1.26	(0.55 - 2.10)	-	2	10.5	(0.0 - 26.0)	0.60	(0.01 - 1.66)	-*
Exmouth (S)	5	80.6	(9.6 - 151.6)	2.12	(0.46 - 4.35)	-*	0	-	-	0	n/a	-
Shark Bay (S)	2	50.9	(0.0 - 121.3)	1.10	(0.01 - 3.06)	-*	0	-	-	0	n/a	-
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
East Pilbara HD												
East Pilbara (S)	4	40.5	(0.0 - 87.5)	1.18	(0.18 - 2.60)	-*	1	5.8	(0.0 - 17.2)	0.78	(0.00 - 2.89)	-*
Port Hedland (T)	8	38.1	(7.7 - 68.4)	1.09	(0.38 - 1.97)	-	6	37.1	(3.0 - 71.2)	2.12	(0.57 - 4.12)	-*
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	1.82	(0.02 - 5.08)	-*	0	-	-	-	-	.
Coorow (S)	1	17.1	(0.0 - 50.5)	0.50	(0.00 - 1.85)	-*	1	26.7	(0.0 - 78.8)	1.31	(0.00 - 4.82)	-*
Irwin (S)	9	57.1	(19.4 - 94.8)	1.65	(0.63 - 2.89)	-	3	21.3	(0.0 - 45.3)	1.43	(0.12 - 3.33)	-*
Mingenew (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Morawa (S)	1	28.8	(0.0 - 85.1)	0.63	(0.00 - 2.34)	-*	0	-	-	0	n/a	-
Mullewa (S)	1	27.6	(0.0 - 81.5)	0.81	(0.00 - 2.98)	-*	0	-	-	-	-	.
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northampton (S)	6	44.8	(8.4 - 81.3)	1.02	(0.28 - 1.99)	-	0	-	-	0	n/a	-
Perenjori (S)	2	132.9	(0.0 - 316.1)	3.03	(0.04 - 8.44)	-*	0	-	-	-	-	.
Three Springs (S)	1	44.4	(0.0 - 131.1)	0.82	(0.00 - 3.02)	-*	0	-	-	-	-	.
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murchison HD												
Cue (S)	3	339.9	(0.0 - 727.8)	7.49	(0.60 - 17.49)	-*	0	-	-	-	-	.
Meekatharra (S)	3	109.8	(0.0 - 234.1)	2.47	(0.20 - 5.76)	-*	1	46.2	(0.0 - 135.9)	1.93	(0.00 - 7.11)	-*
Mount Magnet (S)	0	-	-	0	n/a	-	2	145.0	(0.0 - 346.4)	8.00	(0.10 - 22.29)	-*
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Geraldton HD												
Geraldton (C)	50	70.2	(50.3 - 90.1)	1.72	(1.25 - 2.23)	^	21	25.7	(13.8 - 37.6)	1.35	(0.79 - 1.98)	-
Greenough (S) - Pt A	6	22.7	(4.3 - 41.2)	0.63	(0.17 - 1.23)	-	6	29.0	(5.6 - 52.3)	1.43	(0.39 - 2.79)	-*
Greenough (S) - Pt B	2	41.1	(0.0 - 98.3)	1.18	(0.01 - 3.29)	-*	0	-	-	0	n/a	-
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	3	35.8	(0.0 - 76.7)	0.91	(0.07 - 2.11)	-*	0	-	-	0	n/a	-
Bruce Rock (S)	1	11.9	(0.0 - 35.0)	0.52	(0.00 - 1.93)	-*	0	-	-	0	n/a	-
Corrigin (S)	1	25.0	(0.0 - 73.8)	0.47	(0.00 - 1.75)	-*	0	-	-	0	n/a	-
Cunderdin (S)	2	37.2	(0.0 - 88.3)	0.97	(0.01 - 2.70)	-*	1	21.3	(0.0 - 62.9)	1.00	(0.00 - 3.70)	-*
Quairading (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Tammin (S)	2	173.9	(0.0 - 404.2)	3.28	(0.04 - 9.14)	-*	0	-	-	-	-	.
Upper Great Southern HD												
Boddington (S)	2	63.6	(0.0 - 158.8)	1.27	(0.02 - 3.53)	-*	1	29.0	(0.0 - 85.4)	1.45	(0.00 - 5.36)	-*
Brookton (S)	1	7.1	(0.0 - 21.0)	0.49	(0.00 - 1.80)	-*	2	62.3	(0.0 - 148.3)	2.45	(0.03 - 6.84)	-*
Cuballing (S)	1	38.2	(0.0 - 112.9)	0.98	(0.00 - 3.61)	-*	0	-	-	-	-	.
Dumblebung (S)	1	37.0	(0.0 - 109.2)	0.82	(0.00 - 3.03)	-*	0	-	-	0	n/a	-
Kondinin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Kulin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Lake Grace (S)	3	88.4	(0.0 - 203.7)	1.65	(0.13 - 3.85)	-*	3	61.5	(0.0 - 129.9)	3.71	(0.30 - 8.67)	-*
Narrogin (S)	1	17.2	(0.0 - 50.7)	0.48	(0.00 - 1.78)	-*	0	-	-	0	n/a	-
Narrogin (T)	7	52.7	(10.4 - 95.0)	1.29	(0.41 - 2.41)	-	4	31.9	(0.0 - 64.4)	1.27	(0.20 - 2.78)	-*
Pingelly (S)	4	66.7	(3.6 - 129.9)	1.75	(0.27 - 3.84)	-*	1	22.7	(0.0 - 67.0)	0.93	(0.00 - 3.44)	-*
Wagin (S)	7	67.8	(7.9 - 127.6)	2.18	(0.69 - 4.07)	-*	2	35.6	(0.0 - 85.0)	1.14	(0.01 - 3.18)	-*
Wandering (S)	0	-	-	-	-	.	0	-	-	-	-	.
West Arthur (S)	1	32.8	(0.0 - 96.9)	0.63	(0.00 - 2.31)	-*	0	-	-	0	n/a	-
Wickepin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Williams (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Western HD												
Chittering (S)	6	50.0	(9.9 - 90.0)	1.39	(0.38 - 2.71)	-*	3	36.2	(0.0 - 77.2)	1.91	(0.15 - 4.45)	-*
Dalwallinu (S)	3	54.4	(0.0 - 116.2)	1.24	(0.10 - 2.90)	-*	0	-	-	0	n/a	-
Dandaragan (S)	7	52.1	(13.4 - 90.7)	1.38	(0.43 - 2.58)	-	1	12.5	(0.0 - 37.0)	0.52	(0.00 - 1.92)	-*
Dowerin (S)	1	42.6	(0.0 - 125.1)	0.91	(0.00 - 3.35)	-*	2	50.0	(0.0 - 118.4)	3.25	(0.04 - 9.06)	-*
Gingin (S)	8	47.6	(13.1 - 82.1)	1.10	(0.39 - 1.98)	-	1	6.4	(0.0 - 18.9)	0.34	(0.00 - 1.25)	-*
Goomalling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Moora (S)	5	87.5	(10.7 - 164.3)	1.62	(0.35 - 3.32)	-*	0	-	-	0	n/a	-

Cancer type: Lung, bronchus & trachea 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	4	92.0	(2.3 - 181.6)	2.35	(0.36 - 5.15)	-*	1	41.7	(0.0 - 122.8)	1.99	(0.00 - 7.34)	-*
Wongan-Ballidu (S)	4	88.8	(0.8 - 176.8)	2.27	(0.35 - 4.98)	-*	1	20.5	(0.0 - 60.6)	1.12	(0.00 - 4.12)	-*
Eastern Wheatbelt HD												
Kellerberrin (S)	0	-	-	0	n/a	-	1	19.7	(0.0 - 58.3)	0.86	(0.00 - 3.16)	-*
Koorda (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Merredin (S)	5	46.1	(5.3 - 86.9)	1.02	(0.22 - 2.09)	-	6	50.2	(8.2 - 92.2)	2.58	(0.70 - 5.02)	-*
Mount Marshall (S)	0	-	-	0	n/a	-	1	62.5	(0.0 - 183.1)	3.01	(0.00 - 11.10)	-*
Mukinbudin (S)	1	23.5	(0.0 - 69.4)	0.88	(0.00 - 3.26)	-*	0	-	-	-	-	.
Narembeen (S)	2	43.5	(0.0 - 105.9)	1.32	(0.02 - 3.68)	-*	2	31.0	(0.0 - 75.7)	2.79	(0.03 - 7.78)	-*
Nungarin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Trayning (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	1	40.3	(0.0 - 119.0)	0.82	(0.00 - 3.01)	-*	0	-	-	-	-	.
Yilgam (S)	2	35.6	(0.0 - 84.9)	1.02	(0.01 - 2.85)	-*	1	24.8	(0.0 - 73.4)	1.26	(0.00 - 4.64)	-*
Avon HD												
Northam (S)	3	23.3	(0.0 - 49.6)	0.58	(0.05 - 1.36)	-	2	19.5	(0.0 - 46.4)	0.96	(0.01 - 2.67)	-*
Northam (T)	14	56.8	(25.8 - 87.8)	1.39	(0.69 - 2.20)	-	9	32.5	(9.1 - 55.9)	1.58	(0.61 - 2.76)	-
Toodyay (S)	6	37.0	(7.4 - 66.6)	1.01	(0.27 - 1.96)	-	2	12.0	(0.0 - 28.6)	0.82	(0.01 - 2.30)	-*
York (S)	6	47.0	(9.4 - 84.6)	1.04	(0.28 - 2.02)	-	2	11.3	(0.0 - 28.7)	0.74	(0.01 - 2.06)	-*
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	2	31.3	(0.0 - 81.9)	0.83	(0.01 - 2.32)	-*	1	9.1	(0.0 - 27.0)	1.08	(0.00 - 3.99)	-*
Kalgoorlie/Boulder (C) - Pt A	32	67.5	(43.7 - 91.4)	1.59	(1.05 - 2.19)	^	17	29.0	(14.1 - 43.9)	1.67	(0.90 - 2.56)	-
Kalgoorlie/Boulder (C) - Pt B	2	319.8	(0.0 - 771.8)	4.97	(0.06 - 13.85)	-*	1	333.3	(0.0 - 929.7)	10.05	(0.00 - 37.07)	-*
Laverton (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Leonora (S)	0	-	-	0	n/a	-	1	42.6	(0.0 - 125.5)	2.63	(0.00 - 9.70)	-*
Menzies (S)	0	-	-	-	-	.	0	-	-	-	-	.
Ngaanyatjarraku (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
South East Coastal HD												
Dundas (S)	2	47.0	(0.0 - 113.0)	1.29	(0.02 - 3.58)	-*	1	48.4	(0.0 - 142.5)	1.61	(0.00 - 5.96)	-*
Esperance (S)	15	36.4	(17.9 - 55.0)	0.90	(0.46 - 1.41)	-	13	31.5	(14.1 - 48.9)	1.60	(0.77 - 2.59)	-
Ravensthorpe (S)	3	46.8	(0.0 - 99.8)	1.33	(0.11 - 3.11)	-*	0	-	-	0	n/a	-
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	29	47.3	(29.4 - 65.2)	0.93	(0.60 - 1.30)	-	15	14.7	(5.7 - 23.7)	0.82	(0.42 - 1.28)	-
Albany (C) Bal	8	15.1	(4.5 - 25.7)	0.40	(0.14 - 0.71)	v	6	12.1	(2.4 - 21.9)	0.72	(0.20 - 1.41)	-
Cranbrook (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Denmark (S)	5	26.9	(3.2 - 50.7)	0.59	(0.13 - 1.21)	-	3	14.3	(0.0 - 30.7)	0.79	(0.06 - 1.84)	-*
Jerramungup (S)	1	24.0	(0.0 - 70.8)	0.65	(0.00 - 2.38)	-*	0	-	-	0	n/a	-
Plantagenet (S)	7	35.4	(9.0 - 61.8)	0.95	(0.30 - 1.76)	-	1	2.6	(0.0 - 7.7)	0.29	(0.00 - 1.09)	-*
Central Great Southern HD												
Broomehill (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Gnowangerup (S)	1	24.2	(0.0 - 71.4)	0.50	(0.00 - 1.84)	-*	0	-	-	0	n/a	-
Katanning (S)	7	46.1	(11.2 - 81.0)	1.25	(0.39 - 2.32)	-	5	37.9	(4.5 - 71.4)	1.63	(0.36 - 3.35)	-*
Kent (S)	1	74.1	(0.0 - 216.5)	1.58	(0.00 - 5.84)	-*	0	-	-	-	-	.
Kojonup (S)	1	5.7	(0.0 - 16.9)	0.28	(0.00 - 1.02)	-*	1	11.4	(0.0 - 33.8)	0.60	(0.00 - 2.22)	-*
Tambellup (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Woodanilling (S)	0	-	-	-	-	.	0	-	-	-	-	.
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	11	35.3	(13.5 - 57.1)	0.80	(0.35 - 1.34)	-	6	12.8	(1.9 - 23.7)	0.95	(0.26 - 1.85)	-
Busselton (S)	30	31.3	(19.5 - 43.2)	0.82	(0.53 - 1.14)	-	25	25.4	(14.7 - 36.1)	1.31	(0.81 - 1.87)	-
Warren-Blackwood HD												
Boyup Brook (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bridgetown-Greenbushes (S)	7	45.1	(11.6 - 78.5)	1.13	(0.36 - 2.11)	-	5	30.5	(3.4 - 57.6)	1.67	(0.36 - 3.42)	-*
Manjimup (S)	17	40.6	(20.7 - 60.4)	1.16	(0.62 - 1.77)	-	4	9.5	(0.0 - 19.5)	0.60	(0.09 - 1.31)	-
Nannup (S)	1	22.6	(0.0 - 66.8)	0.56	(0.00 - 2.05)	-*	0	-	-	0	n/a	-
Bunbury HD												
Bunbury (C)	43	40.3	(27.5 - 53.2)	1.00	(0.70 - 1.31)	-	27	26.1	(15.7 - 36.5)	1.13	(0.71 - 1.60)	-
Capel (S) - Pt A	2	28.3	(0.0 - 69.4)	0.86	(0.01 - 2.39)	-*	0	-	-	0	n/a	-
Capel (S) - Pt B	6	38.5	(7.4 - 69.7)	1.06	(0.29 - 2.05)	-	4	35.5	(0.5 - 70.5)	1.68	(0.26 - 3.68)	-*
Dardanup (S) - Pt A	6	40.2	(7.6 - 72.9)	1.06	(0.29 - 2.06)	-	4	23.4	(0.4 - 46.5)	1.40	(0.22 - 3.07)	-*
Dardanup (S) - Pt B	4	50.0	(0.0 - 100.9)	1.23	(0.19 - 2.71)	-*	1	20.8	(0.0 - 60.8)	0.81	(0.00 - 3.00)	-*
Wellington HD												

Cancer type: Lung, bronchus & trachea 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	21	73.0	(40.2 - 105.9)	1.59	(0.92 - 2.34)	-	1	1.9	(0.0 - 5.7)	0.15	(0.00 - 0.57)	V
Donnybrook-Balingup (S)	5	33.5	(4.2 - 62.9)	0.78	(0.17 - 1.60)	-	2	15.3	(0.0 - 36.4)	0.68	(0.01 - 1.89)	-*
Harvey-Yarloop HD												
Harvey (S) - Pt A	7	23.3	(5.6 - 40.9)	0.67	(0.21 - 1.25)	-	9	37.4	(12.7 - 62.2)	1.83	(0.70 - 3.20)	-
Harvey (S) - Pt B	10	32.0	(11.9 - 52.2)	0.86	(0.35 - 1.47)	-	4	12.2	(0.0 - 25.0)	0.74	(0.11 - 1.61)	-
Total State	2473	39.0	(37.4 - 40.6)	1.00	(0.96 - 1.04)	-	1320	18.2	(17.2 - 19.3)	1.00	(0.95 - 1.06)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

W.A. Cancer by SLA (DOH Areas)
Cancer type: All cancers 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	332	338.9	(299.7 - 378.0)	1.00	(0.90 - 1.12)	-	306	265.7	(231.1 - 300.4)	1.04	(0.93 - 1.17)	-
Claremont (T)	140	387.9	(313.7 - 462.1)	1.08	(0.91 - 1.28)	-	146	266.4	(208.7 - 324.1)	1.09	(0.92 - 1.28)	-
Cottesloe (T)	98	333.8	(265.4 - 402.2)	1.01	(0.83 - 1.24)	-	98	308.5	(234.1 - 382.9)	1.10	(0.90 - 1.35)	-
Joondalup (C) - North	348	344.5	(307.2 - 381.9)	1.02	(0.92 - 1.14)	-	289	247.7	(218.1 - 277.4)	0.95	(0.84 - 1.07)	-
Joondalup (C) - South	1042	326.6	(305.9 - 347.3)	0.97	(0.91 - 1.03)	-	933	268.6	(250.3 - 286.9)	1.03	(0.96 - 1.10)	-
Mosman Park (T)	120	362.4	(293.9 - 431.0)	1.13	(0.94 - 1.36)	-	101	247.7	(190.4 - 305.0)	1.04	(0.85 - 1.26)	-
Nedlands (C)	301	343.1	(300.5 - 385.8)	1.06	(0.95 - 1.19)	-	337	335.0	(292.5 - 377.6)	1.21	(1.08 - 1.34)	^
Peppermint Grove (S)	18	270.8	(140.9 - 400.7)	0.84	(0.46 - 1.26)	-	16	234.7	(111.0 - 358.5)	0.92	(0.48 - 1.41)	-
Stirling (C) - Central	1238	331.8	(312.7 - 350.9)	0.99	(0.93 - 1.04)	-	1035	245.9	(229.8 - 261.9)	0.96	(0.91 - 1.02)	-
Stirling (C) - Coastal	864	376.3	(350.1 - 402.4)	1.12	(1.04 - 1.20)	^	691	266.9	(245.2 - 288.6)	1.01	(0.93 - 1.09)	-
Subiaco (C)	185	393.3	(334.1 - 452.4)	1.13	(0.97 - 1.31)	-	175	293.8	(243.7 - 343.8)	1.10	(0.95 - 1.28)	-
Wanneroo (C) - North-East	210	355.5	(306.7 - 404.3)	1.07	(0.93 - 1.22)	-	162	252.6	(212.3 - 292.9)	0.99	(0.85 - 1.16)	-
Wanneroo (C) - North-West	261	386.2	(338.4 - 434.0)	1.15	(1.01 - 1.30)	^	166	252.7	(213.6 - 291.7)	0.95	(0.82 - 1.11)	-
Wanneroo (C) - South	286	339.3	(299.8 - 378.9)	1.00	(0.89 - 1.12)	-	242	248.5	(216.6 - 280.4)	0.96	(0.85 - 1.09)	-
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	425	353.2	(317.5 - 388.8)	1.04	(0.95 - 1.15)	-	360	278.7	(246.6 - 310.8)	1.07	(0.97 - 1.19)	-
Canning (C)	766	331.1	(307.3 - 354.9)	0.97	(0.90 - 1.04)	-	697	250.7	(231.2 - 270.2)	0.99	(0.92 - 1.07)	-
South Perth (C)	477	358.5	(323.6 - 393.4)	1.06	(0.97 - 1.16)	-	429	266.0	(236.2 - 295.9)	0.96	(0.87 - 1.06)	-
Victoria Park (T)	386	360.3	(319.1 - 401.4)	1.05	(0.95 - 1.16)	-	315	237.5	(202.9 - 272.1)	0.87	(0.78 - 0.97)	V
Inner City HD												
Perth (C) - Inner	7	305.5	(65.3 - 545.8)	0.71	(0.22 - 1.33)	-	4	212.2	(0.0 - 425.8)	0.89	(0.14 - 1.95)	-*
Perth (C) - Remainder	110	399.8	(323.4 - 476.1)	1.17	(0.97 - 1.42)	-	39	193.2	(126.7 - 259.7)	0.72	(0.50 - 0.96)	V
Stirling (C) - South-Eastern	220	351.0	(296.8 - 405.2)	1.01	(0.88 - 1.15)	-	212	249.7	(206.5 - 292.8)	0.99	(0.87 - 1.14)	-
Vincent (T)	330	345.8	(305.6 - 386.1)	1.03	(0.93 - 1.15)	-	253	251.4	(215.5 - 287.3)	0.93	(0.82 - 1.06)	-
Kalamunda HD												
Kalamunda (S)	494	311.4	(283.4 - 339.3)	0.91	(0.83 - 1.00)	-	434	249.2	(224.8 - 273.7)	0.96	(0.87 - 1.05)	-
Swan HD												
Bassendean (T)	173	340.8	(288.8 - 392.8)	1.00	(0.86 - 1.16)	-	136	240.0	(197.1 - 283.0)	0.91	(0.77 - 1.08)	-
Bayswater (C)	678	316.0	(291.4 - 340.7)	0.93	(0.86 - 1.00)	-	626	269.9	(246.8 - 293.1)	1.03	(0.95 - 1.12)	-
Mundaring (S)	376	339.4	(304.4 - 374.4)	1.01	(0.91 - 1.11)	-	345	287.9	(256.2 - 319.7)	1.10	(0.99 - 1.22)	-
Swan (C)	708	336.1	(311.0 - 361.1)	1.00	(0.93 - 1.08)	-	579	251.7	(230.5 - 272.9)	0.97	(0.89 - 1.05)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	458	296.1	(268.8 - 323.4)	0.87	(0.79 - 0.96)	V	461	271.9	(246.3 - 297.5)	1.04	(0.95 - 1.14)	-
Gosnells (C)	728	328.3	(304.2 - 352.4)	0.97	(0.90 - 1.04)	-	611	249.4	(229.0 - 269.8)	0.95	(0.88 - 1.03)	-
Serpentine-Jarrahdale (S)	124	356.2	(293.0 - 419.3)	1.10	(0.92 - 1.31)	-	82	244.8	(191.0 - 298.5)	0.97	(0.78 - 1.21)	-
Fremantle HD												
Cockburn (C)	647	340.4	(314.1 - 366.7)	1.01	(0.93 - 1.09)	-	560	271.6	(248.6 - 294.7)	1.04	(0.96 - 1.13)	-
East Fremantle (T)	88	331.8	(259.0 - 404.5)	1.02	(0.82 - 1.26)	-	74	269.3	(199.6 - 339.1)	1.00	(0.79 - 1.26)	-
Fremantle (C) - Inner	12	317.5	(131.0 - 504.0)	0.87	(0.40 - 1.43)	-	8	383.2	(105.2 - 661.1)	1.34	(0.47 - 2.42)	-
Fremantle (C) - Remainder	404	402.9	(361.7 - 444.1)	1.17	(1.06 - 1.30)	^	295	271.4	(237.5 - 305.2)	1.03	(0.91 - 1.15)	-
Melville (C)	1306	349.6	(329.5 - 369.6)	1.06	(1.00 - 1.12)	-	1166	273.7	(256.3 - 291.2)	1.06	(1.00 - 1.12)	-
Rockingham-Kwinana HD												
Kwinana (T)	235	364.7	(317.6 - 411.8)	1.09	(0.96 - 1.24)	-	167	256.3	(216.7 - 296.0)	1.00	(0.86 - 1.17)	-
Rockingham (C)	818	331.0	(307.6 - 354.4)	0.99	(0.93 - 1.06)	-	702	276.1	(254.6 - 297.6)	1.07	(0.99 - 1.15)	-
Peel HD												
Mandurah (C)	817	360.9	(333.9 - 387.9)	1.07	(1.00 - 1.14)	-	563	260.3	(236.4 - 284.1)	1.01	(0.93 - 1.10)	-
Murray (S)	152	298.5	(248.0 - 349.0)	0.90	(0.77 - 1.06)	-	124	308.4	(251.4 - 365.4)	1.14	(0.95 - 1.37)	-
Waroona (S)	42	304.0	(211.0 - 396.9)	0.93	(0.65 - 1.23)	-	27	232.9	(139.6 - 326.3)	0.83	(0.52 - 1.17)	-
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	71	270.4	(205.2 - 335.7)	0.86	(0.68 - 1.09)	-	58	221.5	(160.7 - 282.2)	0.95	(0.73 - 1.24)	-
Derby-West Kimberley (S)	51	329.3	(237.7 - 420.8)	0.94	(0.70 - 1.24)	-	33	237.2	(153.0 - 321.4)	0.88	(0.58 - 1.20)	-
Halls Creek (S)	16	225.5	(112.0 - 339.1)	0.65	(0.34 - 1.01)	-	15	221.4	(105.4 - 337.5)	0.83	(0.42 - 1.30)	-
Wyndham-East Kimberley (S)	36	223.7	(145.6 - 301.8)	0.75	(0.51 - 1.02)	-	31	227.0	(137.5 - 316.5)	0.96	(0.62 - 1.32)	-
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	27	275.4	(151.4 - 399.5)	0.84	(0.53 - 1.18)	-	13	113.0	(30.6 - 195.3)	0.59	(0.28 - 0.94)	V
Roebourne (S)	78	349.3	(247.8 - 450.7)	1.01	(0.80 - 1.27)	-	55	245.6	(160.0 - 331.1)	0.93	(0.71 - 1.22)	-

Cancer type: All cancers 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	59	268.6	(199.7 - 337.5)	0.80	(0.61 - 1.03)	-	44	256.7	(179.3 - 334.1)	0.93	(0.66 - 1.23)	-
Exmouth (S)	23	374.6	(209.0 - 540.2)	1.08	(0.65 - 1.57)	-	11	209.2	(84.5 - 333.9)	0.76	(0.33 - 1.28)	-
Shark Bay (S)	7	196.0	(35.4 - 356.7)	0.48	(0.15 - 0.89)	V	5	229.5	(16.6 - 442.5)	0.62	(0.13 - 1.26)	-
Upper Gascoyne (S)	0	-	-	0	n/a	-	0	-	-	0	-	-
East Pilbara HD												
East Pilbara (S)	27	217.3	(118.0 - 316.5)	0.71	(0.45 - 1.01)	-	10	99.4	(29.6 - 169.3)	0.41	(0.17 - 0.70)	V
Port Hedland (T)	63	248.6	(177.3 - 319.9)	0.80	(0.62 - 1.03)	-	53	279.9	(193.3 - 366.6)	0.96	(0.73 - 1.27)	-
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	6	210.9	(43.3 - 378.5)	0.75	(0.20 - 1.45)	-	6	280.3	(52.9 - 507.7)	1.14	(0.31 - 2.22)	-
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	0.20	(0.00 - 0.57)	V	5	134.3	(13.9 - 254.8)	0.75	(0.16 - 1.54)	-
Coorow (S)	25	491.5	(300.0 - 683.0)	1.47	(0.91 - 2.10)	-	13	302.6	(136.7 - 468.6)	1.19	(0.57 - 1.93)	-
Irwin (S)	40	290.0	(199.5 - 380.4)	0.92	(0.63 - 1.22)	-	37	383.4	(253.4 - 513.4)	1.35	(0.92 - 1.82)	-
Mingenew (S)	3	152.1	(0.0 - 322.7)	0.47	(0.04 - 1.10)	-	8	577.6	(179.9 - 975.2)	1.84	(0.65 - 3.31)	-*
Morawa (S)	7	187.7	(47.8 - 327.5)	0.54	(0.17 - 1.01)	-	8	323.3	(89.7 - 556.9)	1.03	(0.36 - 1.85)	-
Mullewa (S)	12	402.9	(176.6 - 629.2)	1.11	(0.51 - 1.82)	-	6	275.5	(37.5 - 513.5)	0.90	(0.24 - 1.74)	-
Murchison (S)	0	-	-	0	n/a	-	0	-	-	0	-	-
Northampton (S)	52	384.6	(276.5 - 492.7)	1.10	(0.83 - 1.45)	-	27	214.8	(133.7 - 295.9)	0.86	(0.54 - 1.22)	-
Perenjori (S)	10	650.5	(263.6 - 1,037.4)	1.66	(0.68 - 2.84)	-	4	227.6	(0.0 - 456.1)	0.84	(0.13 - 1.85)	-
Three Springs (S)	6	188.6	(31.2 - 346.1)	0.59	(0.16 - 1.14)	-	8	351.1	(100.5 - 601.6)	1.22	(0.43 - 2.20)	-
Yalgoo (S)	1	62.5	(0.0 - 184.2)	0.29	(0.00 - 1.07)	-*	0	-	-	0	-	-
Murchison HD												
Cue (S)	7	856.5	(255.0 - 1,458.1)	1.79	(0.56 - 3.34)	-*	1	114.3	(0.0 - 335.1)	0.41	(0.00 - 1.52)	-*
Meekatharra (S)	21	690.1	(399.1 - 981.2)	1.73	(1.01 - 2.55)	^	8	298.1	(90.6 - 505.7)	1.01	(0.35 - 1.82)	-
Mount Magnet (S)	3	99.4	(0.0 - 211.8)	0.42	(0.03 - 0.97)	V	5	333.7	(32.9 - 634.4)	1.25	(0.27 - 2.56)	-*
Sandstone (S)	1	100.0	(0.0 - 294.0)	0.45	(0.00 - 1.67)	-*	0	-	-	0	n/a	-
Wiluna (S)	1	100.0	(0.0 - 292.7)	0.14	(0.00 - 0.50)	V	5	390.4	(32.8 - 748.0)	1.61	(0.35 - 3.30)	-*
Geraldton HD												
Geraldton (C)	287	419.2	(369.7 - 468.7)	1.21	(1.08 - 1.36)	^	233	314.6	(271.5 - 357.7)	1.19	(1.05 - 1.36)	^
Greenough (S) - Pt A	72	273.2	(208.9 - 337.5)	0.83	(0.65 - 1.05)	-	49	186.5	(132.4 - 240.5)	0.72	(0.52 - 0.94)	V
Greenough (S) - Pt B	9	248.2	(67.8 - 428.6)	0.61	(0.23 - 1.07)	-	2	56.3	(0.0 - 134.5)	0.23	(0.00 - 0.64)	V
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	24	320.2	(184.9 - 455.5)	0.90	(0.55 - 1.29)	-	13	170.0	(69.8 - 270.3)	0.72	(0.34 - 1.16)	-
Bruce Rock (S)	19	411.7	(218.7 - 604.7)	1.21	(0.68 - 1.81)	-	11	231.9	(88.9 - 375.0)	0.93	(0.41 - 1.56)	-
Corrigin (S)	12	252.5	(107.6 - 397.5)	0.68	(0.31 - 1.12)	-	13	230.2	(94.7 - 365.7)	0.93	(0.44 - 1.50)	-
Cunderdin (S)	15	300.3	(148.1 - 452.4)	0.86	(0.44 - 1.35)	-	8	135.8	(28.5 - 243.0)	0.62	(0.22 - 1.12)	-
Quairading (S)	14	298.0	(142.7 - 453.2)	0.95	(0.47 - 1.51)	-	11	217.4	(70.4 - 364.3)	0.91	(0.40 - 1.52)	-
Tammin (S)	6	580.9	(27.8 - 1,133.9)	1.14	(0.31 - 2.21)	-	1	74.6	(0.0 - 219.8)	0.26	(0.00 - 0.96)	V*
Upper Great Southern HD												
Boddington (S)	12	257.4	(95.3 - 419.6)	0.85	(0.39 - 1.39)	-	11	315.5	(126.3 - 504.7)	1.09	(0.48 - 1.82)	-
Brookton (S)	14	242.8	(99.3 - 386.2)	0.84	(0.42 - 1.33)	-	18	449.9	(228.9 - 670.9)	1.73	(0.95 - 2.61)	-
Cuballing (S)	10	352.8	(136.9 - 568.7)	1.13	(0.47 - 1.94)	-	5	236.4	(21.4 - 451.4)	0.83	(0.18 - 1.69)	-
Dumbleyung (S)	8	297.4	(86.7 - 508.2)	0.79	(0.28 - 1.42)	-	3	122.5	(0.0 - 261.9)	0.44	(0.04 - 1.03)	-
Kondinin (S)	14	411.5	(198.7 - 624.3)	1.25	(0.62 - 1.98)	-	10	338.9	(127.3 - 550.5)	1.37	(0.56 - 2.35)	-
Kulin (S)	6	159.8	(23.2 - 296.5)	0.52	(0.14 - 1.01)	-	3	89.2	(0.0 - 190.5)	0.37	(0.03 - 0.87)	V
Lake Grace (S)	17	367.9	(179.7 - 556.0)	1.04	(0.56 - 1.59)	-	18	408.3	(217.3 - 599.4)	1.52	(0.84 - 2.30)	-
Narrogin (S)	3	67.3	(0.0 - 144.2)	0.17	(0.01 - 0.39)	V	1	23.1	(0.0 - 68.3)	0.07	(0.00 - 0.27)	V
Narrogin (T)	69	538.6	(404.9 - 672.4)	1.54	(1.21 - 1.96)	^	49	324.2	(220.0 - 428.5)	1.25	(0.90 - 1.63)	-
Pingelly (S)	20	369.3	(195.5 - 543.0)	1.09	(0.63 - 1.62)	-	7	144.0	(29.1 - 258.9)	0.52	(0.16 - 0.97)	V
Wagin (S)	27	352.8	(204.3 - 501.3)	1.03	(0.65 - 1.45)	-	22	307.2	(169.5 - 445.0)	1.04	(0.61 - 1.52)	-
Wandering (S)	0	-	-	0	n/a	V	1	83.3	(0.0 - 232.4)	0.36	(0.00 - 1.33)	-*
West Arthur (S)	8	203.2	(62.4 - 344.0)	0.61	(0.21 - 1.10)	-	3	102.3	(0.0 - 217.1)	0.35	(0.03 - 0.81)	V
Wickepin (S)	14	500.3	(208.2 - 792.5)	1.34	(0.66 - 2.13)	-	5	203.4	(27.5 - 379.4)	0.72	(0.16 - 1.48)	-
Williams (S)	6	181.5	(36.4 - 326.7)	0.54	(0.15 - 1.04)	-	6	215.4	(37.4 - 393.4)	0.76	(0.21 - 1.48)	-
Western HD												
Chittering (S)	35	342.7	(220.8 - 464.7)	0.97	(0.66 - 1.32)	-	17	199.7	(103.0 - 296.4)	0.74	(0.40 - 1.13)	-
Dalwallinu (S)	19	320.2	(175.4 - 465.0)	0.94	(0.53 - 1.40)	-	12	228.1	(94.5 - 361.7)	0.83	(0.38 - 1.37)	-
Dandaragan (S)	42	326.1	(221.7 - 430.4)	1.01	(0.71 - 1.34)	-	23	252.2	(147.7 - 356.7)	0.91	(0.55 - 1.32)	-
Dowerin (S)	13	493.7	(222.8 - 764.6)	1.40	(0.67 - 2.26)	-	15	460.0	(217.5 - 702.6)	1.93	(0.99 - 3.03)	-
Gingin (S)	73	429.4	(327.1 - 531.7)	1.23	(0.97 - 1.55)	-	40	265.1	(179.3 - 350.8)	1.01	(0.70 - 1.35)	-
Goomalling (S)	10	254.9	(99.4 - 410.5)	0.75	(0.31 - 1.29)	-	4	91.9	(0.0 - 190.8)	0.42	(0.06 - 0.91)	V
Moora (S)	24	353.3	(209.1 - 497.4)	0.89	(0.54 - 1.28)	-	20	273.6	(143.0 - 404.2)	0.96	(0.55 - 1.42)	-

Cancer type: All cancers 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	16	414.8	(203.0 - 626.6)	1.13	(0.59 - 1.75)	-	16	562.1	(279.6 - 844.7)	2.13	(1.12 - 3.30)	^
Wongan-Ballidu (S)	22	461.1	(266.8 - 655.4)	1.42	(0.84 - 2.08)	-	12	215.6	(85.7 - 345.4)	0.97	(0.44 - 1.59)	-
Eastern Wheatbelt HD												
Kellerberrin (S)	17	318.2	(160.6 - 475.9)	0.88	(0.47 - 1.34)	-	18	347.0	(160.8 - 533.2)	1.26	(0.69 - 1.91)	-
Koorda (S)	3	204.0	(0.0 - 444.3)	0.46	(0.04 - 1.08)	-	2	99.5	(0.0 - 240.0)	0.43	(0.01 - 1.21)	-
Merredin (S)	44	354.0	(247.8 - 460.3)	1.06	(0.75 - 1.40)	-	33	283.0	(181.4 - 384.6)	1.08	(0.71 - 1.47)	-
Mount Marshall (S)	4	171.9	(5.3 - 338.5)	0.52	(0.08 - 1.14)	-	3	172.1	(0.0 - 364.4)	0.61	(0.05 - 1.43)	-
Mukinbudin (S)	8	298.1	(87.8 - 508.4)	0.88	(0.31 - 1.58)	-	3	128.5	(0.0 - 274.9)	0.47	(0.04 - 1.10)	-
Narembeen (S)	12	316.4	(135.6 - 497.2)	0.95	(0.43 - 1.56)	-	10	272.8	(99.4 - 446.3)	1.06	(0.43 - 1.81)	-
Nungarin (S)	2	142.9	(0.0 - 333.6)	0.55	(0.01 - 1.53)	-*	2	163.7	(0.0 - 388.3)	0.89	(0.01 - 2.48)	-*
Trayning (S)	8	457.9	(140.1 - 775.7)	1.31	(0.46 - 2.36)	-	3	155.1	(0.0 - 329.2)	0.66	(0.05 - 1.53)	-
Westonia (S)	5	469.9	(60.8 - 879.0)	1.43	(0.31 - 2.93)	-*	0	-	-	0	n/a	-
Wyalkatchem (S)	7	259.5	(60.1 - 458.9)	0.70	(0.22 - 1.31)	-	10	411.8	(137.4 - 686.2)	1.52	(0.63 - 2.61)	-
Yilgam (S)	19	397.2	(216.0 - 578.5)	1.07	(0.60 - 1.60)	-	8	171.6	(49.7 - 293.5)	0.69	(0.24 - 1.24)	-
Avon HD												
Northam (S)	34	263.8	(172.5 - 355.1)	0.79	(0.53 - 1.08)	-	23	195.6	(115.6 - 275.6)	0.78	(0.46 - 1.12)	-
Northam (T)	95	436.8	(345.2 - 528.4)	1.17	(0.95 - 1.43)	-	74	278.6	(207.1 - 350.1)	1.06	(0.84 - 1.34)	-
Toodyay (S)	50	381.4	(260.8 - 502.0)	1.00	(0.72 - 1.29)	-	25	179.5	(108.4 - 250.5)	0.72	(0.44 - 1.03)	-
York (S)	47	369.2	(254.7 - 483.7)	1.00	(0.72 - 1.30)	-	31	223.5	(138.4 - 308.5)	0.89	(0.58 - 1.23)	-
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	17	162.6	(74.2 - 251.1)	0.65	(0.35 - 0.99)	V	16	264.7	(117.6 - 411.8)	0.87	(0.46 - 1.35)	-
Kalgoorlie/Boulder (C) - Pt A	226	384.3	(331.6 - 436.9)	1.14	(1.00 - 1.30)	-	165	253.5	(211.5 - 295.5)	1.02	(0.88 - 1.20)	-
Kalgoorlie/Boulder (C) - Pt B	5	677.3	(57.1 - 1,297.5)	1.35	(0.30 - 2.77)	-*	3	857.1	(19.4 - 1,694.9)	1.81	(0.15 - 4.23)	-*
Laverton (S)	4	121.5	(0.0 - 244.9)	0.39	(0.06 - 0.85)	V	3	264.9	(0.0 - 605.9)	0.67	(0.05 - 1.57)	-*
Leonora (S)	13	325.2	(129.6 - 520.8)	0.81	(0.39 - 1.30)	-	7	187.9	(44.3 - 331.5)	0.94	(0.30 - 1.76)	-
Menzies (S)	0	-	-	0	n/a	V	0	-	-	0	-	-
Ngaanyatjarraku (S)	1	21.5	(0.0 - 63.4)	0.10	(0.00 - 0.38)	V	0	-	-	0	-	V
South East Coastal HD												
Dundas (S)	13	328.2	(148.4 - 508.0)	0.92	(0.44 - 1.49)	-	7	240.0	(51.9 - 428.1)	0.77	(0.24 - 1.43)	-
Esperance (S)	138	334.3	(278.1 - 390.5)	0.97	(0.82 - 1.15)	-	106	253.6	(203.8 - 303.3)	0.97	(0.80 - 1.18)	-
Ravensthorpe (S)	17	264.0	(138.9 - 389.0)	0.88	(0.47 - 1.35)	-	9	211.4	(73.5 - 349.3)	0.73	(0.28 - 1.29)	-
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	239	404.0	(349.8 - 458.1)	0.98	(0.86 - 1.11)	-	225	301.9	(255.7 - 348.0)	1.05	(0.92 - 1.20)	-
Albany (C) Bal	110	220.2	(178.4 - 262.1)	0.65	(0.54 - 0.79)	V	99	219.0	(175.3 - 262.7)	0.86	(0.70 - 1.05)	-
Cranbrook (S)	11	287.1	(108.7 - 465.4)	0.72	(0.31 - 1.20)	-	8	224.8	(58.2 - 391.4)	0.92	(0.32 - 1.66)	-
Denmark (S)	51	244.8	(176.4 - 313.3)	0.75	(0.56 - 0.99)	V	40	240.5	(157.8 - 323.3)	0.83	(0.58 - 1.11)	-
Jerramungup (S)	11	282.0	(113.3 - 450.6)	0.81	(0.35 - 1.36)	-	3	85.5	(0.0 - 186.1)	0.35	(0.03 - 0.82)	V
Plantagenet (S)	76	425.1	(327.9 - 522.2)	1.25	(0.99 - 1.57)	-	49	283.8	(200.3 - 367.3)	1.11	(0.80 - 1.45)	-
Central Great Southern HD												
Broomehill (S)	5	269.0	(28.7 - 509.3)	0.88	(0.19 - 1.79)	-	3	132.6	(0.0 - 282.6)	0.67	(0.05 - 1.56)	-*
Gnowangerup (S)	26	530.7	(325.7 - 735.7)	1.51	(0.94 - 2.14)	-	12	221.9	(92.2 - 351.7)	0.93	(0.43 - 1.53)	-
Katanning (S)	49	333.7	(239.2 - 428.1)	1.03	(0.74 - 1.33)	-	42	267.8	(182.9 - 352.7)	1.05	(0.74 - 1.39)	-
Kent (S)	5	256.8	(23.8 - 489.8)	0.84	(0.18 - 1.72)	-	2	231.2	(0.0 - 554.7)	0.52	(0.01 - 1.46)	-*
Kojonup (S)	30	344.7	(210.9 - 478.4)	1.00	(0.65 - 1.39)	-	19	187.7	(97.7 - 277.7)	0.88	(0.50 - 1.32)	-
Tambellup (S)	4	190.9	(1.8 - 379.9)	0.51	(0.08 - 1.11)	-	5	212.0	(24.2 - 399.8)	0.90	(0.20 - 1.84)	-
Woodanilling (S)	1	66.7	(0.0 - 196.2)	0.26	(0.00 - 0.95)	V*	0	-	-	0	n/a	-
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	106	299.5	(239.8 - 359.1)	0.93	(0.76 - 1.13)	-	84	245.6	(189.8 - 301.3)	1.00	(0.80 - 1.24)	-
Busselton (S)	284	324.5	(284.6 - 364.4)	0.97	(0.86 - 1.09)	-	215	242.7	(207.0 - 278.4)	0.91	(0.80 - 1.05)	-
Warren-Blackwood HD												
Boyup Brook (S)	14	205.9	(96.1 - 315.7)	0.61	(0.30 - 0.97)	V	17	226.6	(98.3 - 355.0)	0.94	(0.50 - 1.43)	-
Bridgetown-Greenbushes (S)	45	310.6	(216.3 - 404.8)	0.87	(0.62 - 1.14)	-	45	307.3	(215.7 - 398.9)	1.12	(0.80 - 1.47)	-
Manjimup (S)	106	292.2	(235.5 - 348.9)	0.87	(0.71 - 1.05)	-	68	198.4	(148.4 - 248.4)	0.77	(0.60 - 0.98)	V
Nannup (S)	16	320.0	(161.6 - 478.4)	1.04	(0.55 - 1.61)	-	9	294.3	(69.1 - 519.4)	0.79	(0.30 - 1.39)	-
Bunbury HD												
Bunbury (C)	330	323.7	(287.0 - 360.3)	0.93	(0.83 - 1.03)	-	316	282.9	(248.8 - 316.9)	1.06	(0.95 - 1.18)	-
Capel (S) - Pt A	12	174.0	(72.8 - 275.2)	0.56	(0.25 - 0.91)	V	9	151.1	(46.9 - 255.3)	0.51	(0.20 - 0.90)	V
Capel (S) - Pt B	38	278.6	(188.2 - 369.1)	0.79	(0.54 - 1.06)	-	39	321.9	(217.5 - 426.3)	1.15	(0.79 - 1.53)	-
Dardanup (S) - Pt A	47	314.9	(224.1 - 405.6)	0.93	(0.66 - 1.21)	-	41	239.6	(164.9 - 314.3)	0.99	(0.69 - 1.32)	-
Dardanup (S) - Pt B	25	299.5	(181.4 - 417.6)	0.90	(0.55 - 1.29)	-	10	144.8	(53.8 - 235.7)	0.56	(0.23 - 0.96)	V
Wellington HD												

Cancer type: All cancers 1998-2002: incidence(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	127	395.3	(322.7 - 467.9)	1.16	(0.97 - 1.38)	-	94	308.7	(242.8 - 374.6)	1.13	(0.92 - 1.39)	-
Donnybrook-Balingup (S)	42	255.3	(177.9 - 332.7)	0.77	(0.54 - 1.02)	-	45	278.1	(195.4 - 360.8)	1.10	(0.78 - 1.44)	-
Harvey-Yarloop HD												
Harvey (S) - Pt A	93	348.9	(275.3 - 422.5)	1.02	(0.83 - 1.26)	-	64	242.6	(182.1 - 303.1)	0.91	(0.70 - 1.17)	-
Harvey (S) - Pt B	103	355.4	(285.3 - 425.4)	1.06	(0.87 - 1.29)	-	77	279.9	(214.3 - 345.4)	1.07	(0.85 - 1.34)	-
Total State	20827	338.1	(333.4 - 342.7)	1.00	(0.99 - 1.01)	-	17314	260.1	(255.9 - 264.2)	1.00	(0.99 - 1.02)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

W.A. Cancer by SLA (alphabetic)
Cancer type: Breast 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	0	-	-	-	-	.	7	8.0	(0.8 - 15.2)	0.49	(0.15 - 0.92)	V
Albany (C) Bal	0	-	-	-	-	.	8	18.0	(5.3 - 30.6)	1.11	(0.39 - 2.01)	-
Armadale (C)	0	-	-	-	-	.	27	15.9	(9.7 - 22.1)	0.96	(0.60 - 1.36)	-
Ashburton (S)	0	-	-	-	-	.	2	71.5	(0.0 - 169.6)	1.63	(0.02 - 4.55)	-*
Augusta-Margaret River (S)	0	-	-	-	-	.	4	12.2	(0.0 - 24.4)	0.74	(0.11 - 1.63)	-
Bassendean (T)	0	-	-	-	-	.	11	20.2	(7.7 - 32.7)	1.15	(0.50 - 1.92)	-
Bayswater (C)	0	-	-	-	-	.	46	19.6	(13.4 - 25.8)	1.16	(0.83 - 1.52)	-
Belmont (C)	0	-	-	-	-	.	21	15.4	(8.0 - 22.8)	0.97	(0.56 - 1.43)	-
Beverley (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Boddington (S)	0	-	-	-	-	.	1	28.1	(0.0 - 83.0)	1.60	(0.00 - 5.90)	-*
Boyup Brook (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Bridgetown-Greenbushes (S)	0	-	-	-	-	.	4	22.8	(0.1 - 45.5)	1.55	(0.24 - 3.40)	-*
Brookton (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Broome (S)	0	-	-	-	-	.	4	11.7	(0.0 - 23.4)	1.12	(0.17 - 2.46)	-*
Broomehill (S)	0	-	-	-	-	.	0	-	-	-	-	.
Bruce Rock (S)	0	-	-	-	-	.	1	29.9	(0.0 - 88.1)	1.32	(0.00 - 4.85)	-*
Bunbury (C)	0	-	-	-	-	.	21	18.5	(9.9 - 27.1)	1.08	(0.63 - 1.58)	-
Busselton (S)	0	-	-	-	-	.	12	14.3	(5.7 - 23.0)	0.79	(0.36 - 1.29)	-
Cambridge (T)	0	-	-	-	-	.	16	13.5	(6.2 - 20.8)	0.81	(0.43 - 1.25)	-
Canning (C)	0	-	-	-	-	.	40	14.3	(9.7 - 19.0)	0.88	(0.61 - 1.18)	-
Capel (S) - Pt A	0	-	-	-	-	.	1	21.7	(0.0 - 64.2)	0.91	(0.00 - 3.37)	-*
Capel (S) - Pt B	0	-	-	-	-	.	1	6.6	(0.0 - 19.6)	0.47	(0.00 - 1.72)	-*
Carnamah (S)	0	-	-	-	-	.	0	-	-	-	-	.
Carnarvon (S)	0	-	-	-	-	.	1	5.1	(0.0 - 15.2)	0.34	(0.00 - 1.25)	-*
Chapman Valley (S)	0	-	-	-	-	.	2	70.7	(0.0 - 173.8)	4.61	(0.06 - 12.85)	-*
Chittering (S)	0	-	-	-	-	.	1	9.4	(0.0 - 28.0)	0.69	(0.00 - 2.55)	-*
Claremont (T)	0	-	-	-	-	.	11	9.7	(1.5 - 18.0)	1.17	(0.51 - 1.95)	-
Cockburn (C)	0	-	-	-	-	.	31	14.6	(9.3 - 20.0)	0.92	(0.60 - 1.27)	-
Collie (S)	0	-	-	-	-	.	4	12.1	(0.0 - 25.1)	0.76	(0.12 - 1.66)	-
Coolgardie (S)	0	-	-	-	-	.	1	14.7	(0.0 - 43.5)	0.94	(0.00 - 3.48)	-*
Coorow (S)	0	-	-	-	-	.	1	24.8	(0.0 - 73.3)	1.48	(0.00 - 5.46)	-*
Corrigin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Cottesloe (T)	0	-	-	-	-	.	5	11.2	(0.0 - 23.0)	0.84	(0.18 - 1.72)	-
Cranbrook (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Cuballing (S)	0	-	-	-	-	.	0	-	-	-	-	.
Cue (S)	0	-	-	-	-	.	0	-	-	-	-	.
Cunderdin (S)	0	-	-	-	-	.	2	32.8	(0.0 - 85.6)	2.38	(0.03 - 6.63)	-*
Dalwallinu (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Dandaragan (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Dardanup (S) - Pt A	1	6.1	(0.0 - 18.2)	98.35	(0.00 - 362.82)	-*	0	-	-	0	n/a	-
Dardanup (S) - Pt B	0	-	-	-	-	.	1	10.5	(0.0 - 31.0)	0.91	(0.00 - 3.35)	-*
Denmark (S)	0	-	-	-	-	.	3	15.6	(0.0 - 33.9)	0.98	(0.08 - 2.28)	-*
Derby-West Kimberley (S)	0	-	-	-	-	.	1	10.1	(0.0 - 29.9)	0.44	(0.00 - 1.63)	-*
Donnybrook-Balingup (S)	0	-	-	-	-	.	3	19.4	(0.0 - 41.5)	1.13	(0.09 - 2.64)	-*
Dowerin (S)	0	-	-	-	-	.	1	29.4	(0.0 - 85.3)	2.04	(0.00 - 7.53)	-*
Dumbleyung (S)	0	-	-	-	-	.	0	-	-	-	-	.
Dundas (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
East Fremantle (T)	0	-	-	-	-	.	6	13.8	(0.0 - 27.6)	1.22	(0.33 - 2.37)	-
East Pilbara (S)	0	-	-	-	-	.	2	27.3	(0.0 - 70.8)	1.39	(0.02 - 3.88)	-*
Esperance (S)	0	-	-	-	-	.	6	13.8	(2.6 - 24.9)	0.87	(0.24 - 1.69)	-
Exmouth (S)	0	-	-	-	-	.	1	11.3	(0.0 - 33.5)	1.14	(0.00 - 4.22)	-*
Fremantle (C) - Inner	0	-	-	-	-	.	0	-	-	-	-	.
Fremantle (C) - Remainder	0	-	-	-	-	.	27	24.1	(14.2 - 34.1)	1.43	(0.90 - 2.01)	-
Geraldton (C)	0	-	-	-	-	.	21	26.7	(14.3 - 39.1)	1.67	(0.97 - 2.46)	-
Gingin (S)	0	-	-	-	-	.	1	6.4	(0.0 - 18.9)	0.40	(0.00 - 1.47)	-*
Gnowangerup (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Goomalling (S)	0	-	-	-	-	.	1	15.4	(0.0 - 45.3)	1.57	(0.00 - 5.79)	-*
Gosnells (C)	0	-	-	-	-	.	44	17.4	(12.1 - 22.7)	1.09	(0.77 - 1.43)	-
Greenough (S) - Pt A	0	-	-	-	-	.	4	15.0	(0.0 - 29.9)	0.96	(0.15 - 2.11)	-*
Greenough (S) - Pt B	0	-	-	-	-	.	1	27.0	(0.0 - 79.9)	1.83	(0.00 - 6.74)	-*
Halls Creek (S)	0	-	-	-	-	.	3	47.0	(0.0 - 104.7)	2.75	(0.22 - 6.41)	-*
Harvey (S) - Pt A	0	-	-	-	-	.	9	35.0	(11.7 - 58.3)	2.06	(0.79 - 3.61)	-*
Harvey (S) - Pt B	0	-	-	-	-	.	5	12.5	(0.2 - 24.7)	1.07	(0.23 - 2.20)	-

Cancer type: Breast 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	0	-	-	-	-	.	3	30.8	(0.0 - 65.7)	1.72	(0.14 - 4.02)	-*
Jerramungup (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Joondalup (C) - North	0	-	-	-	-	.	26	23.1	(13.8 - 32.4)	1.38	(0.86 - 1.96)	-
Joondalup (C) - South	0	-	-	-	-	.	51	14.6	(10.4 - 18.9)	0.88	(0.66 - 1.16)	-
Kalamunda (S)	0	-	-	-	-	.	32	17.4	(11.1 - 23.7)	1.09	(0.72 - 1.50)	-
Kalgoorlie/Boulder (C) - Pt A	0	-	-	-	-	.	14	24.9	(11.1 - 38.7)	1.42	(0.70 - 2.26)	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	-	-	.	0	-	-	-	-	.
Katanning (S)	0	-	-	-	-	.	2	6.4	(0.0 - 15.4)	0.78	(0.01 - 2.17)	-*
Kellerberrin (S)	0	-	-	-	-	.	2	10.6	(0.0 - 25.2)	2.12	(0.03 - 5.90)	-*
Kent (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kojonup (S)	0	-	-	-	-	.	2	12.3	(0.0 - 29.5)	1.44	(0.02 - 4.01)	-*
Kondinin (S)	0	-	-	-	-	.	1	48.4	(0.0 - 142.5)	2.23	(0.00 - 8.23)	-*
Koorda (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kulin (S)	0	-	-	-	-	.	1	28.4	(0.0 - 84.0)	1.94	(0.00 - 7.15)	-*
Kwinana (T)	0	-	-	-	-	.	8	13.2	(4.0 - 22.4)	0.77	(0.27 - 1.39)	-
Lake Grace (S)	0	-	-	-	-	.	1	20.4	(0.0 - 60.0)	1.35	(0.00 - 5.00)	-*
Laverton (S)	0	-	-	-	-	.	0	-	-	-	-	.
Leonora (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mandurah (C)	0	-	-	-	-	.	37	17.0	(11.0 - 23.1)	1.03	(0.70 - 1.39)	-
Manjimup (S)	0	-	-	-	-	.	4	11.7	(0.0 - 23.6)	0.71	(0.11 - 1.57)	-
Meekatharra (S)	0	-	-	-	-	.	0	-	-	-	-	.
Melville (C)	0	-	-	-	-	.	63	13.0	(9.5 - 16.6)	0.88	(0.68 - 1.13)	-
Menzies (S)	0	-	-	-	-	.	0	-	-	-	-	.
Merredin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Mingenew (S)	0	-	-	-	-	.	0	-	-	-	-	.
Moora (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Morawa (S)	0	-	-	-	-	.	1	13.5	(0.0 - 39.6)	1.99	(0.00 - 7.35)	-*
Mosman Park (T)	0	-	-	-	-	.	11	32.6	(10.4 - 54.7)	1.65	(0.72 - 2.77)	-
Mount Magnet (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mount Marshall (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mukinbudin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mullewa (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mundaring (S)	0	-	-	-	-	.	22	15.9	(9.1 - 22.7)	1.09	(0.65 - 1.59)	-
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murray (S)	0	-	-	-	-	.	7	21.8	(4.3 - 39.2)	1.01	(0.32 - 1.89)	-
Nannup (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Narembeen (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Narrogin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Narrogin (T)	0	-	-	-	-	.	4	22.9	(0.0 - 49.4)	1.55	(0.24 - 3.39)	-*
Nedlands (C)	0	-	-	-	-	.	22	19.2	(9.1 - 29.4)	1.13	(0.67 - 1.65)	-
Ngaanyatjarraku (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northam (S)	0	-	-	-	-	.	2	18.4	(0.0 - 43.9)	1.07	(0.01 - 2.99)	-*
Northam (T)	0	-	-	-	-	.	6	21.2	(1.4 - 41.0)	1.31	(0.36 - 2.56)	-
Northampton (S)	0	-	-	-	-	.	1	7.4	(0.0 - 21.7)	0.51	(0.00 - 1.87)	-*
Nungarin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Peppermint Grove (S)	0	-	-	-	-	.	1	23.4	(0.0 - 69.1)	0.87	(0.00 - 3.21)	-*
Perenjori (S)	0	-	-	-	-	.	0	-	-	-	-	.
Perth (C) - Inner	0	-	-	-	-	.	0	-	-	-	-	.
Perth (C) - Remainder	0	-	-	-	-	.	2	10.8	(0.0 - 27.1)	0.58	(0.01 - 1.61)	-*
Pingelly (S)	0	-	-	-	-	.	1	21.4	(0.0 - 63.2)	1.12	(0.00 - 4.14)	-*
Plantagenet (S)	0	-	-	-	-	.	1	2.6	(0.0 - 7.7)	0.35	(0.00 - 1.30)	-*
Port Hedland (T)	0	-	-	-	-	.	2	14.7	(0.0 - 35.3)	0.62	(0.01 - 1.73)	-*
Quairading (S)	0	-	-	-	-	.	1	32.0	(0.0 - 94.5)	1.24	(0.00 - 4.56)	-*
Ravensthorpe (S)	0	-	-	-	-	.	1	20.6	(0.0 - 60.8)	1.28	(0.00 - 4.72)	-*
Rockingham (C)	0	-	-	-	-	.	45	16.6	(11.5 - 21.7)	1.09	(0.77 - 1.43)	-
Roebourne (S)	0	-	-	-	-	.	3	7.9	(0.0 - 17.1)	0.88	(0.07 - 2.04)	-*
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Serpentine-Jarrahdale (S)	0	-	-	-	-	.	0	-	-	0	n/a	V
Shark Bay (S)	0	-	-	-	-	.	1	48.8	(0.0 - 143.8)	1.95	(0.00 - 7.19)	-*
South Perth (C)	1	0.3	(0.0 - 0.9)	11.52	(0.00 - 42.49)	-*	32	20.1	(12.2 - 28.1)	1.06	(0.70 - 1.46)	-
Stirling (C) - Central	2	0.6	(0.0 - 1.5)	8.91	(0.11 - 24.83)	-*	61	15.1	(11.1 - 19.1)	0.89	(0.68 - 1.15)	-
Stirling (C) - Coastal	0	-	-	-	-	.	45	17.7	(12.2 - 23.3)	1.01	(0.71 - 1.32)	-
Stirling (C) - South-Eastern	0	-	-	-	-	.	16	10.5	(3.3 - 17.7)	1.07	(0.56 - 1.66)	-
Subiaco (C)	0	-	-	-	-	.	9	8.8	(2.0 - 15.7)	0.86	(0.33 - 1.51)	-
Swan (C)	0	-	-	-	-	.	30	12.2	(7.7 - 16.7)	0.81	(0.52 - 1.12)	-

Cancer type: Breast 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Tammin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Three Springs (S)	0	-	-	-	-	.	0	-	-	-	-	.
Toodyay (S)	0	-	-	-	-	.	7	49.8	(12.3 - 87.4)	3.17	(1.00 - 5.90)	-*
Trayning (S)	0	-	-	-	-	.	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
Victoria Park (T)	0	-	-	-	-	.	32	13.4	(6.4 - 20.3)	1.27	(0.84 - 1.75)	-
Victoria Plains (S)	0	-	-	-	-	.	0	-	-	-	-	.
Vincent (T)	0	-	-	-	-	.	20	18.5	(8.6 - 28.3)	1.13	(0.65 - 1.67)	-
Wagin (S)	0	-	-	-	-	.	1	4.2	(0.0 - 12.5)	0.72	(0.00 - 2.65)	-*
Wandering (S)	0	-	-	-	-	.	1	83.3	(0.0 - 232.4)	5.68	(0.00 - 20.96)	-*
Wanneroo (C) - North-East	0	-	-	-	-	.	12	17.2	(6.9 - 27.5)	1.15	(0.52 - 1.88)	-
Wanneroo (C) - North-West	0	-	-	-	-	.	16	22.1	(11.1 - 33.2)	1.52	(0.80 - 2.35)	-
Wanneroo (C) - South	0	-	-	-	-	.	13	13.7	(6.0 - 21.3)	0.84	(0.40 - 1.35)	-
Waroona (S)	0	-	-	-	-	.	2	16.8	(0.0 - 40.4)	0.95	(0.01 - 2.65)	-*
West Arthur (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wickepin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Williams (S)	0	-	-	-	-	.	1	47.6	(0.0 - 139.8)	1.95	(0.00 - 7.18)	-*
Wiluna (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wongan-Ballidu (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Woodanilling (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	0	-	-	-	-	.	1	54.1	(0.0 - 158.6)	2.30	(0.00 - 8.48)	-*
Wyndham-East Kimberley (S)	0	-	-	-	-	.	1	4.0	(0.0 - 11.9)	0.52	(0.00 - 1.93)	-*
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Yilgarn (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
York (S)	0	-	-	-	-	.	2	10.1	(0.0 - 25.2)	0.88	(0.01 - 2.46)	-*
Total State	4	0.1	(0.0 - 0.1)	1.00	(0.15 - 2.19)	-*	1115	15.9	(14.9 - 16.8)	1.00	(0.94 - 1.06)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (alphabetic)
Cancer type: Colorectal cancer 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	21	29.2	(15.1 - 43.3)	1.42	(0.83 - 2.09)	-	18	16.3	(6.8 - 25.9)	1.32	(0.73 - 2.00)	-
Albany (C) Bal	4	8.3	(0.1 - 16.5)	0.43	(0.07 - 0.95)	V	4	10.8	(0.1 - 21.5)	0.79	(0.12 - 1.72)	-
Armadale (C)	15	8.9	(4.4 - 13.5)	0.53	(0.27 - 0.83)	V	23	12.8	(7.3 - 18.3)	1.06	(0.64 - 1.54)	-
Ashburton (S)	1	7.9	(0.0 - 23.4)	0.73	(0.00 - 2.68)	-*	0	-	-	0	n/a	-
Augusta-Margaret River (S)	7	19.5	(3.8 - 35.2)	1.08	(0.34 - 2.02)	-	3	10.2	(0.0 - 21.9)	0.67	(0.05 - 1.58)	-*
Bassendean (T)	6	8.9	(1.6 - 16.1)	0.61	(0.16 - 1.19)	-	8	9.5	(2.4 - 16.5)	0.97	(0.34 - 1.74)	-
Bayswater (C)	35	15.0	(9.8 - 20.2)	0.84	(0.56 - 1.14)	-	30	10.6	(6.2 - 14.9)	0.85	(0.55 - 1.18)	-
Belmont (C)	31	23.5	(14.7 - 32.4)	1.31	(0.86 - 1.82)	-	19	12.1	(5.8 - 18.5)	0.97	(0.54 - 1.45)	-
Beverley (S)	0	-	-	0	n/a	-	1	5.9	(0.0 - 17.3)	0.97	(0.00 - 3.56)	-*
Boddington (S)	1	21.7	(0.0 - 63.4)	1.30	(0.00 - 4.79)	-*	0	-	-	-	-	-
Boyup Brook (S)	0	-	-	0	n/a	-	2	21.1	(0.0 - 54.3)	1.89	(0.02 - 5.27)	-*
Bridgetown-Greenbushes (S)	0	-	-	0	n/a	-	2	11.3	(0.0 - 27.5)	1.00	(0.01 - 2.79)	-*
Brookton (S)	1	14.9	(0.0 - 44.0)	0.97	(0.00 - 3.59)	-*	3	34.5	(0.0 - 74.0)	4.86	(0.39 - 11.35)	-*
Broome (S)	2	11.6	(0.0 - 27.8)	0.50	(0.01 - 1.40)	-*	0	-	-	0	n/a	-
Broomehill (S)	1	59.7	(0.0 - 175.8)	3.21	(0.00 - 11.83)	-*	0	-	-	-	-	-
Bruce Rock (S)	1	25.4	(0.0 - 75.0)	1.11	(0.00 - 4.09)	-*	2	29.7	(0.0 - 72.2)	3.15	(0.04 - 8.77)	-*
Bunbury (C)	18	14.8	(7.4 - 22.1)	0.88	(0.48 - 1.33)	-	15	11.2	(4.5 - 17.9)	0.87	(0.44 - 1.36)	-
Busselton (S)	16	16.8	(8.2 - 25.5)	0.95	(0.50 - 1.47)	-	15	14.3	(6.4 - 22.3)	1.13	(0.57 - 1.76)	-
Cambridge (T)	16	15.1	(7.1 - 23.1)	0.82	(0.43 - 1.26)	-	25	20.6	(10.8 - 30.4)	1.36	(0.84 - 1.95)	-
Canning (C)	31	13.1	(8.4 - 17.8)	0.72	(0.47 - 0.99)	V	36	9.8	(6.4 - 13.2)	0.99	(0.67 - 1.33)	-
Capel (S) - Pt A	2	18.8	(0.0 - 44.7)	1.89	(0.02 - 5.25)	-*	0	-	-	0	n/a	-
Capel (S) - Pt B	2	14.7	(0.0 - 35.3)	0.76	(0.01 - 2.11)	-*	2	16.7	(0.0 - 39.7)	1.30	(0.02 - 3.62)	-*
Carnamah (S)	0	-	-	-	-	-	0	-	-	-	-	-
Carnarvon (S)	7	31.5	(7.9 - 55.1)	1.74	(0.55 - 3.24)	-*	1	7.0	(0.0 - 20.7)	0.45	(0.00 - 1.66)	-*
Chapman Valley (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Chittering (S)	5	41.5	(5.1 - 77.9)	2.60	(0.57 - 5.33)	-*	0	-	-	0	n/a	-
Claremont (T)	8	21.3	(5.4 - 37.2)	1.02	(0.36 - 1.84)	-	6	15.2	(2.0 - 28.5)	0.64	(0.17 - 1.24)	-
Cockburn (C)	35	19.6	(13.0 - 26.2)	1.02	(0.69 - 1.39)	-	34	15.5	(10.1 - 20.9)	1.31	(0.88 - 1.79)	-
Collie (S)	8	19.5	(5.4 - 33.5)	1.29	(0.45 - 2.32)	-	3	7.1	(0.0 - 15.3)	0.69	(0.06 - 1.60)	-*
Coolgardie (S)	1	24.6	(0.0 - 72.6)	0.86	(0.00 - 3.16)	-*	0	-	-	0	n/a	-
Coorow (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Corrigin (S)	0	-	-	0	n/a	-	3	54.8	(0.0 - 120.8)	3.69	(0.30 - 8.61)	-*
Cottesloe (T)	12	40.6	(16.2 - 65.0)	2.14	(0.98 - 3.51)	-	3	2.7	(0.0 - 5.8)	0.56	(0.04 - 1.30)	-
Cranbrook (S)	1	21.2	(0.0 - 62.6)	1.15	(0.00 - 4.23)	-*	0	-	-	-	-	-
Cuballing (S)	0	-	-	-	-	-	0	-	-	-	-	-
Cue (S)	0	-	-	-	-	-	0	-	-	-	-	-
Cunderdin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Dalwallinu (S)	1	15.0	(0.0 - 44.4)	0.90	(0.00 - 3.33)	-*	0	-	-	0	n/a	-
Dandaragan (S)	3	20.3	(0.0 - 43.2)	1.33	(0.11 - 3.09)	-*	0	-	-	0	n/a	-
Dardanup (S) - Pt A	5	32.4	(3.7 - 61.0)	1.88	(0.41 - 3.85)	-*	0	-	-	0	n/a	-
Dardanup (S) - Pt B	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Denmark (S)	1	3.4	(0.0 - 10.2)	0.25	(0.00 - 0.94)	V*	4	19.3	(0.0 - 39.1)	1.60	(0.25 - 3.51)	-*
Derby-West Kimberley (S)	1	7.4	(0.0 - 21.8)	0.36	(0.00 - 1.34)	-*	2	8.0	(0.0 - 19.1)	1.22	(0.02 - 3.41)	-*
Donnybrook-Balingup (S)	4	21.6	(0.3 - 43.0)	1.34	(0.21 - 2.94)	-*	3	14.4	(0.0 - 31.1)	1.49	(0.12 - 3.49)	-*
Dowerin (S)	1	47.6	(0.0 - 140.2)	1.95	(0.00 - 7.21)	-*	0	-	-	-	-	-
Dumbleyung (S)	1	22.7	(0.0 - 66.2)	1.77	(0.00 - 6.52)	-*	0	-	-	-	-	-
Dundas (S)	1	26.3	(0.0 - 76.5)	1.34	(0.00 - 4.96)	-*	0	-	-	-	-	-
East Fremantle (T)	6	19.8	(3.2 - 36.4)	1.19	(0.32 - 2.32)	-	1	1.9	(0.0 - 5.7)	0.23	(0.00 - 0.83)	V*
East Pilbara (S)	1	17.8	(0.0 - 52.4)	0.60	(0.00 - 2.20)	-*	0	-	-	0	n/a	-
Esperance (S)	14	33.8	(15.9 - 51.6)	1.80	(0.89 - 2.85)	-	6	12.5	(1.9 - 23.1)	1.09	(0.30 - 2.12)	-
Exmouth (S)	1	13.0	(0.0 - 38.6)	0.92	(0.00 - 3.41)	-*	1	13.2	(0.0 - 38.6)	1.70	(0.00 - 6.25)	-*
Fremantle (C) - Inner	0	-	-	0	n/a	-	0	-	-	-	-	-
Fremantle (C) - Remainder	22	22.2	(12.6 - 31.8)	1.11	(0.66 - 1.62)	-	19	15.2	(7.5 - 22.8)	1.12	(0.63 - 1.67)	-
Geraldton (C)	13	18.8	(8.3 - 29.2)	0.97	(0.46 - 1.56)	-	5	4.0	(0.2 - 7.8)	0.45	(0.10 - 0.93)	V
Gingin (S)	8	48.5	(13.4 - 83.7)	2.48	(0.87 - 4.47)	-*	2	12.1	(0.0 - 28.9)	1.05	(0.01 - 2.91)	-*
Gnowangerup (S)	2	51.8	(0.0 - 123.4)	2.12	(0.03 - 5.90)	-*	1	12.0	(0.0 - 35.5)	1.50	(0.00 - 5.55)	-*
Goomalling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Gosnells (C)	50	24.1	(17.3 - 30.9)	1.26	(0.91 - 1.63)	-	23	8.4	(4.8 - 11.9)	0.75	(0.45 - 1.09)	-
Greenough (S) - Pt A	7	29.4	(7.6 - 51.2)	1.60	(0.50 - 2.99)	-*	2	10.5	(0.0 - 25.1)	0.77	(0.01 - 2.15)	-*
Greenough (S) - Pt B	1	20.2	(0.0 - 59.6)	1.28	(0.00 - 4.74)	-*	0	-	-	-	-	-
Halls Creek (S)	1	12.3	(0.0 - 36.4)	0.79	(0.00 - 2.90)	-*	1	15.2	(0.0 - 44.6)	1.26	(0.00 - 4.65)	-*
Harvey (S) - Pt A	7	23.7	(5.6 - 41.9)	1.45	(0.46 - 2.71)	-	2	8.9	(0.0 - 21.3)	0.65	(0.01 - 1.82)	-*
Harvey (S) - Pt B	4	14.3	(0.0 - 28.6)	0.74	(0.11 - 1.61)	-	3	11.0	(0.0 - 23.8)	0.78	(0.06 - 1.82)	-*

Cancer type: Colorectal cancer 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	2	14.0	(0.0 - 33.6)	0.81	(0.01 - 2.26)	-*	2	16.7	(0.0 - 40.0)	1.48	(0.02 - 4.11)	-*
Jerramungup (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Joondalup (C) - North	16	15.7	(7.9 - 23.6)	0.94	(0.49 - 1.45)	-	15	13.5	(6.4 - 20.6)	1.16	(0.59 - 1.81)	-
Joondalup (C) - South	41	12.2	(8.3 - 16.1)	0.72	(0.50 - 0.95)	V	39	10.5	(7.0 - 14.0)	0.93	(0.64 - 1.24)	-
Kalamunda (S)	25	15.3	(9.2 - 21.3)	0.84	(0.52 - 1.20)	-	26	13.3	(7.9 - 18.7)	1.13	(0.70 - 1.60)	-
Kalgoorlie/Boulder (C) - Pt A	15	29.6	(14.1 - 45.0)	1.55	(0.79 - 2.42)	-	8	17.2	(4.4 - 29.9)	1.10	(0.39 - 1.98)	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	-	-	.	0	-	-	-	-	.
Katanning (S)	3	15.5	(0.0 - 34.3)	1.12	(0.09 - 2.62)	-*	1	2.7	(0.0 - 8.1)	0.46	(0.00 - 1.71)	-*
Kellerberrin (S)	3	58.3	(0.0 - 124.0)	2.63	(0.21 - 6.14)	-*	3	37.9	(0.0 - 86.3)	3.41	(0.28 - 7.97)	-*
Kent (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kojonup (S)	2	28.5	(0.0 - 67.8)	1.17	(0.01 - 3.26)	-*	4	39.5	(0.0 - 80.8)	3.40	(0.53 - 7.46)	-*
Kondinin (S)	1	33.3	(0.0 - 98.1)	1.71	(0.00 - 6.32)	-*	0	-	-	-	-	.
Koorda (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kulin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Kwinana (T)	9	12.9	(4.4 - 21.5)	0.78	(0.30 - 1.36)	-	11	15.7	(6.1 - 25.2)	1.37	(0.60 - 2.28)	-
Lake Grace (S)	0	-	-	0	n/a	-	1	20.1	(0.0 - 59.4)	1.93	(0.00 - 7.12)	-*
Laverton (S)	0	-	-	-	-	.	1	46.5	(0.0 - 137.3)	5.87	(0.00 - 21.65)	-*
Leonora (S)	1	57.1	(0.0 - 167.5)	1.33	(0.00 - 4.89)	-*	1	33.3	(0.0 - 96.5)	4.01	(0.00 - 14.78)	-*
Mandurah (C)	53	21.6	(15.3 - 27.9)	1.18	(0.89 - 1.56)	-	26	9.0	(5.3 - 12.6)	0.83	(0.51 - 1.17)	-
Manjimup (S)	7	18.9	(4.7 - 33.1)	1.02	(0.32 - 1.91)	-	6	14.1	(1.7 - 26.4)	1.32	(0.36 - 2.56)	-
Meekatharra (S)	1	42.6	(0.0 - 125.1)	1.75	(0.00 - 6.46)	-*	0	-	-	-	-	.
Melville (C)	74	19.2	(14.6 - 23.8)	1.04	(0.82 - 1.31)	-	76	13.0	(9.6 - 16.4)	1.21	(0.96 - 1.52)	-
Menzies (S)	0	-	-	-	-	.	0	-	-	-	-	.
Merredin (S)	2	13.2	(0.0 - 31.9)	0.87	(0.01 - 2.43)	-*	3	28.4	(0.0 - 60.8)	1.87	(0.15 - 4.37)	-*
Mingenew (S)	0	-	-	-	-	.	0	-	-	-	-	.
Moora (S)	1	9.3	(0.0 - 27.2)	0.68	(0.00 - 2.52)	-*	1	20.6	(0.0 - 60.9)	0.91	(0.00 - 3.37)	-*
Morawa (S)	1	32.3	(0.0 - 95.2)	1.37	(0.00 - 5.04)	-*	0	-	-	-	-	.
Mosman Park (T)	5	13.5	(1.1 - 25.8)	0.81	(0.18 - 1.66)	-	7	4.8	(1.2 - 8.3)	1.12	(0.35 - 2.09)	-
Mount Magnet (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mount Marshall (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mukinbudin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mullewa (S)	0	-	-	0	n/a	-	1	90.9	(0.0 - 265.0)	3.27	(0.00 - 12.05)	-*
Mundaring (S)	21	20.3	(11.5 - 29.1)	1.04	(0.61 - 1.53)	-	12	8.4	(3.4 - 13.5)	0.79	(0.36 - 1.29)	-
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murray (S)	8	13.3	(4.0 - 22.7)	0.84	(0.30 - 1.52)	-	4	9.4	(0.0 - 18.8)	0.74	(0.11 - 1.62)	-
Nannup (S)	2	34.7	(0.0 - 82.7)	2.40	(0.03 - 6.67)	-*	0	-	-	0	n/a	-
Narembeen (S)	2	60.8	(0.0 - 145.0)	2.82	(0.04 - 7.87)	-*	0	-	-	0	n/a	-
Narrogin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Narrogin (T)	2	11.1	(0.0 - 27.4)	0.76	(0.01 - 2.13)	-*	1	2.2	(0.0 - 6.4)	0.42	(0.00 - 1.54)	-*
Nedlands (C)	14	8.4	(3.9 - 12.8)	0.82	(0.40 - 1.30)	-	31	17.1	(9.1 - 25.1)	1.65	(1.08 - 2.28)	^
Ngaanyatjarraku (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northam (S)	4	42.5	(0.0 - 88.5)	1.74	(0.27 - 3.81)	-*	0	-	-	0	n/a	-
Northam (T)	8	26.8	(7.0 - 46.6)	1.70	(0.60 - 3.07)	-	6	13.6	(0.0 - 27.3)	1.45	(0.39 - 2.82)	-*
Northampton (S)	3	23.4	(0.0 - 51.0)	1.13	(0.09 - 2.64)	-*	2	13.5	(0.0 - 32.1)	1.30	(0.02 - 3.63)	-*
Nungarin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Peppermint Grove (S)	0	-	-	0	n/a	-	1	5.4	(0.0 - 15.9)	1.04	(0.00 - 3.85)	-*
Perenjori (S)	1	43.0	(0.0 - 126.9)	3.20	(0.00 - 11.81)	-*	0	-	-	-	-	.
Perth (C) - Inner	1	21.5	(0.0 - 63.5)	1.98	(0.00 - 7.32)	-*	0	-	-	-	-	.
Perth (C) - Remainder	12	40.8	(16.5 - 65.2)	2.24	(1.02 - 3.67)	^	4	13.0	(0.0 - 27.8)	1.30	(0.20 - 2.84)	-*
Pingelly (S)	3	57.2	(0.0 - 121.9)	2.83	(0.23 - 6.60)	-*	0	-	-	0	n/a	-
Plantagenet (S)	5	29.6	(3.7 - 55.6)	1.48	(0.32 - 3.03)	-*	2	10.1	(0.0 - 25.1)	0.86	(0.01 - 2.41)	-*
Port Hedland (T)	1	2.3	(0.0 - 6.9)	0.28	(0.00 - 1.03)	-*	0	-	-	0	n/a	-
Quairading (S)	2	47.0	(0.0 - 112.0)	2.46	(0.03 - 6.85)	-*	0	-	-	0	n/a	-
Ravensthorpe (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Rockingham (C)	52	20.5	(14.7 - 26.2)	1.12	(0.85 - 1.49)	-	44	14.8	(10.2 - 19.4)	1.29	(0.91 - 1.69)	-
Roebourne (S)	1	1.6	(0.0 - 4.7)	0.31	(0.00 - 1.14)	-*	0	-	-	0	n/a	-
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Serpentine-Jarrahdale (S)	5	16.0	(1.6 - 30.5)	0.85	(0.19 - 1.75)	-	3	8.2	(0.0 - 17.7)	0.81	(0.07 - 1.90)	-*
Shark Bay (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
South Perth (C)	21	14.3	(7.6 - 21.0)	0.79	(0.46 - 1.16)	-	32	12.7	(7.1 - 18.2)	1.11	(0.73 - 1.52)	-
Stirling (C) - Central	80	19.9	(15.4 - 24.5)	1.12	(0.89 - 1.40)	-	50	9.2	(6.4 - 12.1)	0.84	(0.61 - 1.09)	-
Stirling (C) - Coastal	37	14.5	(9.6 - 19.5)	0.84	(0.57 - 1.13)	-	35	11.3	(7.1 - 15.5)	0.89	(0.60 - 1.20)	-
Stirling (C) - South-Eastern	17	20.5	(8.8 - 32.2)	1.27	(0.69 - 1.95)	-	12	8.6	(1.6 - 15.6)	0.79	(0.36 - 1.29)	-
Subiaco (C)	7	15.0	(3.3 - 26.6)	0.76	(0.24 - 1.41)	-	9	7.3	(1.8 - 12.9)	0.96	(0.37 - 1.69)	-
Swan (C)	35	16.4	(10.8 - 21.9)	0.94	(0.63 - 1.27)	-	35	14.7	(9.6 - 19.9)	1.25	(0.84 - 1.69)	-

Cancer type: Colorectal cancer 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Tammin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Three Springs (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Toodyay (S)	4	28.2	(0.2 - 56.3)	1.50	(0.23 - 3.28)	-*	2	15.8	(0.0 - 38.2)	1.31	(0.02 - 3.64)	-*
Trayning (S)	1	22.7	(0.0 - 66.8)	2.91	(0.00 - 10.75)	-*	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
Victoria Park (T)	27	19.1	(10.4 - 27.8)	1.20	(0.76 - 1.70)	-	29	13.9	(6.2 - 21.6)	1.09	(0.70 - 1.52)	-
Victoria Plains (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Vincent (T)	19	17.3	(8.7 - 25.8)	1.03	(0.58 - 1.54)	-	15	10.8	(4.2 - 17.5)	0.89	(0.46 - 1.40)	-
Wagin (S)	0	-	-	0	n/a	-	1	9.9	(0.0 - 29.1)	0.79	(0.00 - 2.92)	-*
Wandering (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wanneroo (C) - North-East	13	20.3	(9.1 - 31.6)	1.22	(0.58 - 1.97)	-	6	7.4	(1.0 - 13.8)	0.74	(0.20 - 1.44)	-
Wanneroo (C) - North-West	12	17.3	(7.3 - 27.4)	0.98	(0.45 - 1.61)	-	6	8.2	(1.5 - 15.0)	0.77	(0.21 - 1.49)	-
Wanneroo (C) - South	14	17.9	(8.4 - 27.4)	0.96	(0.47 - 1.52)	-	6	5.9	(1.1 - 10.7)	0.53	(0.14 - 1.03)	-
Waroona (S)	4	27.1	(0.1 - 54.2)	1.57	(0.24 - 3.45)	-*	5	34.2	(2.8 - 65.6)	2.86	(0.62 - 5.87)	-*
West Arthur (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wickepin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Williams (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wiluna (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wongan-Ballidu (S)	1	19.6	(0.0 - 57.9)	1.24	(0.00 - 4.56)	-*	0	-	-	0	n/a	-
Woodanilling (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	1	32.6	(0.0 - 96.2)	1.76	(0.00 - 6.50)	-*	1	12.5	(0.0 - 36.7)	2.79	(0.00 - 10.30)	-*
Wyndham-East Kimberley (S)	0	-	-	0	n/a	-	1	13.7	(0.0 - 40.5)	0.85	(0.00 - 3.12)	-*
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Yilgarn (S)	1	18.9	(0.0 - 55.7)	1.10	(0.00 - 4.05)	-*	0	-	-	0	n/a	-
York (S)	4	23.1	(0.0 - 46.8)	1.47	(0.23 - 3.22)	-*	1	8.4	(0.0 - 24.8)	0.53	(0.00 - 1.95)	-*
Total State	1159	18.0	(16.9 - 19.1)	1.00	(0.94 - 1.06)	-	929	11.5	(10.6 - 12.3)	1.00	(0.94 - 1.07)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (alphabetic)
Cancer type: Prostate gland 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	9	9.8	(2.7 - 17.0)	0.63	(0.24 - 1.11)	-	0	-	-	-	-	-
Albany (C) Bal	6	14.3	(2.9 - 25.8)	0.88	(0.24 - 1.70)	-	0	-	-	-	-	-
Armadale (C)	17	10.0	(5.2 - 14.9)	0.80	(0.43 - 1.22)	-	0	-	-	-	-	-
Ashburton (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Augusta-Margaret River (S)	7	15.4	(2.9 - 27.9)	1.25	(0.39 - 2.33)	-	0	-	-	-	-	-
Bassendean (T)	6	10.3	(1.9 - 18.6)	0.73	(0.20 - 1.43)	-	0	-	-	-	-	-
Bayswater (C)	23	9.6	(5.5 - 13.7)	0.64	(0.38 - 0.92)	V	0	-	-	-	-	-
Belmont (C)	17	13.0	(6.5 - 19.6)	0.84	(0.45 - 1.28)	-	0	-	-	-	-	-
Beverley (S)	1	9.3	(0.0 - 27.6)	0.76	(0.00 - 2.82)	-*	0	-	-	-	-	-
Boddington (S)	1	35.7	(0.0 - 105.1)	1.61	(0.00 - 5.94)	-*	0	-	-	-	-	-
Boyup Brook (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Bridgetown-Greenbushes (S)	1	4.9	(0.0 - 14.6)	0.47	(0.00 - 1.74)	-*	0	-	-	-	-	-
Brookton (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Broome (S)	2	11.3	(0.0 - 27.1)	0.83	(0.01 - 2.31)	-*	0	-	-	-	-	-
Broomehill (S)	1	50.0	(0.0 - 143.0)	4.00	(0.00 - 14.74)	-*	0	-	-	-	-	-
Bruce Rock (S)	2	29.3	(0.0 - 70.0)	2.56	(0.03 - 7.14)	-*	0	-	-	-	-	-
Bunbury (C)	26	18.1	(10.8 - 25.3)	1.41	(0.88 - 2.01)	-	0	-	-	-	-	-
Busselton (S)	18	15.0	(7.7 - 22.3)	1.24	(0.68 - 1.87)	-	0	-	-	-	-	-
Cambridge (T)	18	11.6	(6.1 - 17.1)	0.98	(0.54 - 1.48)	-	0	-	-	-	-	-
Canning (C)	37	14.7	(9.8 - 19.5)	1.10	(0.75 - 1.48)	-	0	-	-	-	-	-
Capel (S) - Pt A	0	-	-	0	n/a	-	0	-	-	-	-	-
Capel (S) - Pt B	5	30.1	(3.7 - 56.6)	2.50	(0.55 - 5.13)	-*	0	-	-	-	-	-
Carnamah (S)	0	-	-	0	-	-	0	-	-	-	-	-
Carnarvon (S)	6	23.2	(4.5 - 41.9)	1.94	(0.52 - 3.77)	-*	0	-	-	-	-	-
Chapman Valley (S)	0	-	-	0	-	-	0	-	-	-	-	-
Chittering (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Claremont (T)	9	15.3	(4.6 - 26.1)	1.18	(0.45 - 2.08)	-	0	-	-	-	-	-
Cockburn (C)	25	13.1	(7.9 - 18.4)	1.01	(0.62 - 1.44)	-	0	-	-	-	-	-
Collie (S)	8	22.8	(6.5 - 39.1)	1.51	(0.53 - 2.72)	-	0	-	-	-	-	-
Coolgardie (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Coorow (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Corrigin (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Cottesloe (T)	4	7.7	(0.1 - 15.3)	0.80	(0.12 - 1.76)	-	0	-	-	-	-	-
Cranbrook (S)	1	14.7	(0.0 - 43.3)	1.36	(0.00 - 5.03)	-*	0	-	-	-	-	-
Cuballing (S)	0	-	-	0	-	-	0	-	-	-	-	-
Cue (S)	0	-	-	0	-	-	0	-	-	-	-	-
Cunderdin (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Dalwallinu (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Dandaragan (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Dardanup (S) - Pt A	2	16.0	(0.0 - 38.2)	1.05	(0.01 - 2.93)	-*	0	-	-	-	-	-
Dardanup (S) - Pt B	1	14.6	(0.0 - 43.2)	0.93	(0.00 - 3.42)	-*	0	-	-	-	-	-
Denmark (S)	6	22.1	(4.1 - 40.0)	1.83	(0.50 - 3.57)	-*	0	-	-	-	-	-
Derby-West Kimberley (S)	1	8.3	(0.0 - 24.6)	0.49	(0.00 - 1.81)	-*	0	-	-	-	-	-
Donnybrook-Balingup (S)	5	29.2	(3.5 - 54.8)	2.23	(0.49 - 4.57)	-*	0	-	-	-	-	-
Dowerin (S)	0	-	-	0	-	-	0	-	-	-	-	-
Dumbleyung (S)	2	52.6	(0.0 - 123.6)	4.49	(0.06 - 12.50)	-*	0	-	-	-	-	-
Dundas (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
East Fremantle (T)	3	9.7	(0.0 - 21.4)	0.65	(0.05 - 1.52)	-	0	-	-	-	-	-
East Pilbara (S)	1	21.7	(0.0 - 64.1)	1.08	(0.00 - 4.00)	-*	0	-	-	-	-	-
Esperance (S)	9	19.4	(6.6 - 32.3)	1.49	(0.57 - 2.61)	-	0	-	-	-	-	-
Exmouth (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Fremantle (C) - Inner	0	-	-	0	n/a	-	0	-	-	-	-	-
Fremantle (C) - Remainder	20	15.7	(8.7 - 22.7)	1.18	(0.67 - 1.75)	-	0	-	-	-	-	-
Geraldton (C)	13	15.5	(7.0 - 24.0)	1.17	(0.56 - 1.89)	-	0	-	-	-	-	-
Gingin (S)	4	23.3	(0.3 - 46.3)	1.91	(0.30 - 4.18)	-*	0	-	-	-	-	-
Gnowangerup (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Goomalling (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Gosnells (C)	23	9.7	(5.7 - 13.8)	0.79	(0.47 - 1.14)	-	0	-	-	-	-	-
Greenough (S) - Pt A	1	4.5	(0.0 - 13.3)	0.37	(0.00 - 1.37)	-*	0	-	-	-	-	-
Greenough (S) - Pt B	2	44.9	(0.0 - 107.2)	3.50	(0.04 - 9.76)	-*	0	-	-	-	-	-
Halls Creek (S)	1	21.3	(0.0 - 62.8)	1.02	(0.00 - 3.77)	-*	0	-	-	-	-	-
Harvey (S) - Pt A	2	5.7	(0.0 - 13.6)	0.57	(0.01 - 1.60)	-*	0	-	-	-	-	-
Harvey (S) - Pt B	10	31.8	(11.8 - 51.7)	2.30	(0.95 - 3.93)	-*	0	-	-	-	-	-

Cancer type: Prostate gland 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	3	21.8	(0.0 - 47.6)	1.59	(0.13 - 3.72)	-*	0	-	-	-	-	-
Jerramungup (S)	1	71.4	(0.0 - 201.0)	1.99	(0.00 - 7.33)	-*	0	-	-	-	-	-
Joondalup (C) - North	11	10.6	(4.3 - 16.9)	0.97	(0.42 - 1.62)	-	0	-	-	-	-	-
Joondalup (C) - South	41	12.4	(8.4 - 16.4)	0.97	(0.68 - 1.29)	-	0	-	-	-	-	-
Kalamunda (S)	26	15.6	(9.5 - 21.7)	1.16	(0.72 - 1.64)	-	0	-	-	-	-	-
Kalgoorlie/Boulder (C) - Pt A	5	9.4	(0.8 - 18.0)	0.77	(0.17 - 1.58)	-	0	-	-	-	-	-
Kalgoorlie/Boulder (C) - Pt B	1	222.2	(0.0 - 632.9)	6.39	(0.00 - 23.57)	-*	0	-	-	-	-	-
Katanning (S)	4	18.7	(0.1 - 37.2)	1.79	(0.28 - 3.91)	-*	0	-	-	-	-	-
Kellerberrin (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Kent (S)	0	-	-	-	-	-	0	-	-	-	-	-
Kojonup (S)	3	20.3	(0.0 - 43.5)	2.09	(0.17 - 4.88)	-*	0	-	-	-	-	-
Kondinin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Koorda (S)	1	50.0	(0.0 - 143.0)	4.41	(0.00 - 16.27)	-*	0	-	-	-	-	-
Kulin (S)	1	20.0	(0.0 - 58.4)	1.98	(0.00 - 7.30)	-*	0	-	-	-	-	-
Kwinana (T)	6	8.1	(1.5 - 14.7)	0.71	(0.19 - 1.39)	-	0	-	-	-	-	-
Lake Grace (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Laverton (S)	0	-	-	-	-	-	0	-	-	-	-	-
Leonora (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Mandurah (C)	47	16.0	(11.2 - 20.8)	1.23	(0.88 - 1.60)	-	0	-	-	-	-	-
Manjimup (S)	9	17.5	(6.0 - 29.0)	1.59	(0.61 - 2.79)	-	0	-	-	-	-	-
Meekatharra (S)	1	41.7	(0.0 - 119.9)	3.14	(0.00 - 11.59)	-*	0	-	-	-	-	-
Melville (C)	61	12.2	(8.9 - 15.4)	0.98	(0.75 - 1.26)	-	0	-	-	-	-	-
Menzies (S)	0	-	-	-	-	-	0	-	-	-	-	-
Merredin (S)	1	11.5	(0.0 - 34.1)	0.53	(0.00 - 1.97)	-*	0	-	-	-	-	-
Mingenew (S)	0	-	-	-	-	-	0	-	-	-	-	-
Moora (S)	2	16.4	(0.0 - 38.9)	1.66	(0.02 - 4.61)	-*	0	-	-	-	-	-
Morawa (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Mosman Park (T)	6	15.9	(2.5 - 29.4)	1.08	(0.29 - 2.09)	-	0	-	-	-	-	-
Mount Magnet (S)	0	-	-	-	-	-	0	-	-	-	-	-
Mount Marshall (S)	0	-	-	-	-	-	0	-	-	-	-	-
Mukinbudin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Mullewa (S)	0	-	-	-	-	-	0	-	-	-	-	-
Mundaring (S)	11	9.1	(3.6 - 14.6)	0.73	(0.32 - 1.22)	-	0	-	-	-	-	-
Murchison (S)	0	-	-	-	-	-	0	-	-	-	-	-
Murray (S)	6	10.1	(1.9 - 18.2)	0.84	(0.23 - 1.64)	-	0	-	-	-	-	-
Nannup (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Narembeen (S)	2	37.4	(0.0 - 89.6)	3.40	(0.04 - 9.48)	-*	0	-	-	-	-	-
Narrogin (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Narrogin (T)	7	35.6	(8.1 - 63.2)	2.88	(0.90 - 5.36)	-*	0	-	-	-	-	-
Nedlands (C)	14	8.8	(3.7 - 13.8)	0.83	(0.41 - 1.31)	-	0	-	-	-	-	-
Ngaanyatjarraku (S)	0	-	-	-	-	-	0	-	-	-	-	-
Northam (S)	2	14.6	(0.0 - 34.8)	1.34	(0.02 - 3.72)	-*	0	-	-	-	-	-
Northam (T)	6	16.5	(2.9 - 30.1)	1.47	(0.40 - 2.86)	-*	0	-	-	-	-	-
Northampton (S)	1	6.9	(0.0 - 20.5)	0.48	(0.00 - 1.79)	-*	0	-	-	-	-	-
Nungarin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Peppermint Grove (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Perenjori (S)	0	-	-	-	-	-	0	-	-	-	-	-
Perth (C) - Inner	0	-	-	-	-	-	0	-	-	-	-	-
Perth (C) - Remainder	9	27.6	(8.6 - 46.5)	1.90	(0.73 - 3.33)	-	0	-	-	-	-	-
Pingelly (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Plantagenet (S)	5	27.7	(3.4 - 52.1)	1.94	(0.42 - 3.98)	-*	0	-	-	-	-	-
Port Hedland (T)	2	14.0	(0.0 - 33.6)	0.98	(0.01 - 2.73)	-*	0	-	-	-	-	-
Quairading (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Ravensthorpe (S)	2	29.6	(0.0 - 70.4)	2.66	(0.03 - 7.42)	-*	0	-	-	-	-	-
Rockingham (C)	34	11.7	(7.6 - 15.7)	0.91	(0.61 - 1.24)	-	0	-	-	-	-	-
Roebourne (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Sandstone (S)	0	-	-	-	-	-	0	-	-	-	-	-
Serpentine-Jarrahdale (S)	2	6.5	(0.0 - 15.4)	0.52	(0.01 - 1.44)	-*	0	-	-	-	-	-
Shark Bay (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
South Perth (C)	25	13.3	(7.4 - 19.2)	0.98	(0.60 - 1.39)	-	0	-	-	-	-	-
Stirling (C) - Central	49	10.4	(7.4 - 13.4)	0.82	(0.59 - 1.06)	-	0	-	-	-	-	-
Stirling (C) - Coastal	44	14.8	(10.3 - 19.3)	1.15	(0.82 - 1.52)	-	0	-	-	-	-	-
Stirling (C) - South-Eastern	18	13.2	(6.8 - 19.5)	1.28	(0.71 - 1.94)	-	0	-	-	-	-	-
Subiaco (C)	6	9.6	(1.6 - 17.6)	0.74	(0.20 - 1.44)	-	0	-	-	-	-	-
Swan (C)	27	12.9	(8.0 - 17.9)	0.98	(0.61 - 1.38)	-	0	-	-	-	-	-

Cancer type: Prostate gland 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Tammin (S)	1	87.0	(0.0 - 253.6)	4.07	(0.00 - 15.00)	-*	0	-	-	-	-	.
Three Springs (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Toodyay (S)	1	6.6	(0.0 - 19.6)	0.57	(0.00 - 2.12)	-*	0	-	-	-	-	.
Trayning (S)	0	-	-	-	-	.	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
Victoria Park (T)	27	16.1	(8.5 - 23.7)	1.15	(0.72 - 1.62)	-	0	-	-	-	-	.
Victoria Plains (S)	3	62.9	(0.0 - 136.3)	4.37	(0.35 - 10.19)	-*	0	-	-	-	-	.
Vincent (T)	13	9.6	(4.2 - 15.0)	0.77	(0.37 - 1.23)	-	0	-	-	-	-	.
Wagin (S)	1	8.8	(0.0 - 25.8)	0.68	(0.00 - 2.51)	-*	0	-	-	-	-	.
Wandering (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wanneroo (C) - North-East	10	19.3	(7.2 - 31.4)	1.23	(0.51 - 2.11)	-	0	-	-	-	-	.
Wanneroo (C) - North-West	9	12.8	(4.0 - 21.5)	0.98	(0.38 - 1.72)	-	0	-	-	-	-	.
Wanneroo (C) - South	7	8.1	(2.1 - 14.2)	0.70	(0.22 - 1.31)	-	0	-	-	-	-	.
Waroona (S)	3	18.8	(0.0 - 39.9)	1.49	(0.12 - 3.48)	-*	0	-	-	-	-	.
West Arthur (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wickepin (S)	1	17.9	(0.0 - 52.2)	1.97	(0.00 - 7.27)	-*	0	-	-	-	-	.
Williams (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wongan-Ballidu (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Woodanilling (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	1	22.7	(0.0 - 66.8)	2.28	(0.00 - 8.42)	-*	0	-	-	-	-	.
Wyndham-East Kimberley (S)	3	20.5	(0.0 - 45.0)	2.01	(0.16 - 4.69)	-*	0	-	-	-	-	.
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Yilgarn (S)	1	16.7	(0.0 - 49.1)	1.65	(0.00 - 6.08)	-*	0	-	-	-	-	.
York (S)	5	30.8	(3.6 - 58.0)	2.16	(0.47 - 4.43)	-*	0	-	-	-	-	.
Total State	945	13.0	(12.2 - 13.9)	1.00	(0.94 - 1.07)	-	0	-	-	-	-	.

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (alphabetic)
Cancer type: Melanoma (skin) 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	4	5.6	(0.0 - 11.9)	1.34	(0.21 - 2.93)	-*	3	4.1	(0.0 - 9.4)	1.54	(0.12 - 3.59)	-*
Albany (C) Bal	2	4.0	(0.0 - 9.5)	1.04	(0.01 - 2.90)	-*	1	2.3	(0.0 - 6.7)	1.13	(0.00 - 4.15)	-*
Armadale (C)	7	4.3	(1.1 - 7.5)	1.15	(0.36 - 2.15)	-	6	3.7	(0.7 - 6.8)	1.67	(0.45 - 3.25)	-*
Ashburton (S)	0	-	-	-	-	.	1	5.1	(0.0 - 15.1)	5.76	(0.00 - 21.24)	-*
Augusta-Margaret River (S)	1	1.5	(0.0 - 4.5)	0.73	(0.00 - 2.68)	-*	1	1.3	(0.0 - 3.7)	1.39	(0.00 - 5.13)	-*
Bassendean (T)	4	5.2	(0.0 - 10.4)	1.95	(0.30 - 4.28)	-*	2	4.4	(0.0 - 10.5)	1.57	(0.02 - 4.36)	-*
Bayswater (C)	7	3.7	(0.9 - 6.5)	0.80	(0.25 - 1.49)	-	5	2.0	(0.1 - 3.9)	0.94	(0.20 - 1.92)	-
Belmont (C)	6	5.2	(0.9 - 9.6)	1.24	(0.34 - 2.41)	-	2	1.5	(0.0 - 3.6)	0.68	(0.01 - 1.89)	-*
Beverley (S)	1	12.3	(0.0 - 36.5)	3.19	(0.00 - 11.76)	-*	0	-	-	-	-	.
Boddington (S)	1	11.6	(0.0 - 34.2)	5.83	(0.00 - 21.52)	-*	0	-	-	-	-	.
Boyup Brook (S)	0	-	-	-	-	.	0	-	-	-	-	.
Bridgetown-Greenbushes (S)	1	4.9	(0.0 - 14.6)	1.69	(0.00 - 6.24)	-*	0	-	-	-	-	.
Brookton (S)	0	-	-	-	-	.	0	-	-	-	-	.
Broome (S)	2	5.4	(0.0 - 13.0)	2.08	(0.03 - 5.79)	-*	0	-	-	-	-	.
Broomehill (S)	0	-	-	-	-	.	0	-	-	-	-	.
Bruce Rock (S)	0	-	-	-	-	.	0	-	-	-	-	.
Bunbury (C)	5	6.0	(0.7 - 11.3)	1.16	(0.25 - 2.38)	-*	2	1.5	(0.0 - 3.9)	0.77	(0.01 - 2.13)	-*
Busselton (S)	3	3.3	(0.0 - 7.1)	0.87	(0.07 - 2.03)	-*	3	4.0	(0.0 - 8.6)	1.49	(0.12 - 3.47)	-*
Cambridge (T)	6	6.6	(1.1 - 12.2)	1.48	(0.40 - 2.87)	-*	2	1.5	(0.0 - 3.9)	0.74	(0.01 - 2.07)	-*
Canning (C)	3	1.5	(0.0 - 3.2)	0.33	(0.03 - 0.76)	V	4	1.1	(0.0 - 2.3)	0.69	(0.11 - 1.50)	-
Capel (S) - Pt A	1	15.9	(0.0 - 46.9)	4.21	(0.00 - 15.54)	-*	0	-	-	-	-	.
Capel (S) - Pt B	0	-	-	0	n/a	-	0	-	-	-	-	.
Carnamah (S)	0	-	-	-	-	.	1	71.4	(0.0 - 201.0)	24.09	(0.00 - 88.85)	-*
Carnarvon (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Chapman Valley (S)	0	-	-	-	-	.	0	-	-	-	-	.
Chittering (S)	1	9.6	(0.0 - 28.3)	2.56	(0.00 - 9.46)	-*	0	-	-	-	-	.
Claremont (T)	3	3.9	(0.0 - 8.3)	1.87	(0.15 - 4.36)	-*	3	9.1	(0.0 - 21.6)	2.31	(0.19 - 5.39)	-*
Cockburn (C)	6	3.1	(0.6 - 5.7)	0.81	(0.22 - 1.57)	-	9	4.2	(1.4 - 6.9)	2.05	(0.79 - 3.59)	-*
Collie (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Coolgardie (S)	2	40.9	(0.0 - 98.6)	6.41	(0.08 - 17.86)	-*	0	-	-	-	-	.
Coorow (S)	0	-	-	-	-	.	0	-	-	-	-	.
Corrigin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Cottesloe (T)	4	12.1	(0.0 - 24.3)	3.39	(0.52 - 7.43)	-*	1	5.0	(0.0 - 14.8)	1.25	(0.00 - 4.62)	-*
Cranbrook (S)	0	-	-	-	-	.	0	-	-	-	-	.
Cuballing (S)	0	-	-	-	-	.	0	-	-	-	-	.
Cue (S)	0	-	-	-	-	.	0	-	-	-	-	.
Cunderdin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Dalwallinu (S)	0	-	-	-	-	.	0	-	-	-	-	.
Dandaragan (S)	1	6.3	(0.0 - 18.5)	2.17	(0.00 - 7.99)	-*	1	10.9	(0.0 - 32.2)	5.17	(0.00 - 19.07)	-*
Dardanup (S) - Pt A	1	5.1	(0.0 - 15.1)	1.70	(0.00 - 6.27)	-*	1	3.7	(0.0 - 10.9)	3.05	(0.00 - 11.24)	-*
Dardanup (S) - Pt B	0	-	-	-	-	.	0	-	-	-	-	.
Denmark (S)	1	4.6	(0.0 - 13.7)	1.26	(0.00 - 4.66)	-*	1	3.1	(0.0 - 9.0)	2.52	(0.00 - 9.31)	-*
Derby-West Kimberley (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Donnybrook-Balingup (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Dowerin (S)	1	42.6	(0.0 - 125.1)	9.09	(0.00 - 33.53)	-*	0	-	-	-	-	.
Dumbleyung (S)	1	29.9	(0.0 - 87.9)	8.49	(0.00 - 31.30)	-*	0	-	-	-	-	.
Dundas (S)	0	-	-	-	-	.	0	-	-	-	-	.
East Fremantle (T)	1	2.2	(0.0 - 6.4)	0.95	(0.00 - 3.50)	-*	1	1.1	(0.0 - 3.1)	1.50	(0.00 - 5.53)	-*
East Pilbara (S)	0	-	-	-	-	.	0	-	-	-	-	.
Esperance (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Exmouth (S)	1	19.4	(0.0 - 57.4)	4.12	(0.00 - 15.19)	-*	0	-	-	-	-	.
Fremantle (C) - Inner	0	-	-	-	-	.	0	-	-	-	-	.
Fremantle (C) - Remainder	3	2.2	(0.0 - 4.8)	0.73	(0.06 - 1.71)	-*	0	-	-	0	n/a	-
Geraldton (C)	10	12.8	(4.6 - 21.0)	3.63	(1.49 - 6.20)	^*	1	1.5	(0.0 - 4.4)	0.59	(0.00 - 2.19)	-*
Gingin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Gnowangerup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Goomalling (S)	0	-	-	-	-	.	0	-	-	-	-	.
Gosnells (C)	5	2.3	(0.2 - 4.3)	0.57	(0.12 - 1.17)	-	5	1.9	(0.2 - 3.6)	0.96	(0.21 - 1.97)	-
Greenough (S) - Pt A	1	7.6	(0.0 - 22.3)	1.02	(0.00 - 3.76)	-*	0	-	-	0	n/a	-
Greenough (S) - Pt B	0	-	-	-	-	.	0	-	-	-	-	.
Halls Creek (S)	0	-	-	-	-	.	0	-	-	-	-	.
Harvey (S) - Pt A	1	2.6	(0.0 - 7.8)	0.95	(0.00 - 3.52)	-*	0	-	-	0	n/a	-
Harvey (S) - Pt B	2	7.5	(0.0 - 17.8)	1.77	(0.02 - 4.93)	-*	1	3.9	(0.0 - 11.5)	1.64	(0.00 - 6.06)	-*

Cancer type: Melanoma (skin) 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	1	6.2	(0.0 - 18.3)	2.02	(0.00 - 7.44)	-*	0	-	-	-	-	.
Jerramungup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Joondalup (C) - North	1	0.9	(0.0 - 2.6)	0.26	(0.00 - 0.94)	V*	1	0.7	(0.0 - 2.1)	0.41	(0.00 - 1.53)	-*
Joondalup (C) - South	10	3.1	(1.1 - 5.2)	0.80	(0.33 - 1.36)	-	9	2.6	(0.8 - 4.4)	1.25	(0.48 - 2.20)	-
Kalamunda (S)	11	7.0	(2.7 - 11.3)	1.76	(0.77 - 2.95)	-	6	2.8	(0.3 - 5.2)	1.61	(0.43 - 3.12)	-*
Kalgoorlie/Boulder (C) - Pt A	2	3.6	(0.0 - 8.6)	0.84	(0.01 - 2.34)	-*	0	-	-	0	n/a	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	-	-	.	0	-	-	-	-	.
Katanning (S)	2	17.1	(0.0 - 41.2)	3.51	(0.04 - 9.79)	-*	1	2.7	(0.0 - 8.1)	2.95	(0.00 - 10.88)	-*
Kellerberrin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kent (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kojonup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kondinin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Koorda (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kulin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kwinana (T)	1	1.2	(0.0 - 3.4)	0.40	(0.00 - 1.49)	-*	0	-	-	0	n/a	-
Lake Grace (S)	0	-	-	-	-	.	0	-	-	-	-	.
Laverton (S)	0	-	-	-	-	.	0	-	-	-	-	.
Leonora (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mandurah (C)	8	2.9	(0.8 - 5.0)	0.90	(0.32 - 1.62)	-	3	1.1	(0.0 - 2.4)	0.64	(0.05 - 1.50)	-
Manjimup (S)	2	5.3	(0.0 - 12.8)	1.40	(0.02 - 3.89)	-*	0	-	-	0	n/a	-
Meekatharra (S)	0	-	-	-	-	.	0	-	-	-	-	.
Melville (C)	16	4.0	(1.9 - 6.0)	1.08	(0.57 - 1.68)	-	7	1.3	(0.1 - 2.5)	0.74	(0.23 - 1.38)	-
Menzies (S)	0	-	-	-	-	.	0	-	-	-	-	.
Merredin (S)	0	-	-	-	-	.	1	10.0	(0.0 - 29.6)	3.87	(0.00 - 14.29)	-*
Mingenew (S)	0	-	-	-	-	.	0	-	-	-	-	.
Moora (S)	0	-	-	-	-	.	0	-	-	-	-	.
Morawa (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mosman Park (T)	5	17.0	(1.7 - 32.3)	3.87	(0.84 - 7.93)	-*	1	1.3	(0.0 - 3.8)	1.11	(0.00 - 4.09)	-*
Mount Magnet (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mount Marshall (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mukinbudin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mullewa (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mundaring (S)	4	3.3	(0.0 - 6.5)	0.93	(0.14 - 2.04)	-*	1	0.8	(0.0 - 2.3)	0.39	(0.00 - 1.45)	-*
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murray (S)	2	8.5	(0.0 - 21.8)	1.06	(0.01 - 2.96)	-*	2	4.6	(0.0 - 11.4)	2.32	(0.03 - 6.46)	-*
Nannup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Narembeen (S)	0	-	-	-	-	.	0	-	-	-	-	.
Narrogin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Narrogin (T)	1	7.6	(0.0 - 22.4)	1.83	(0.00 - 6.73)	-*	0	-	-	-	-	.
Nedlands (C)	4	5.1	(0.0 - 10.4)	1.13	(0.17 - 2.47)	-*	1	0.2	(0.0 - 0.6)	0.38	(0.00 - 1.39)	-*
Ngaanyatjarraku (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northam (S)	1	7.0	(0.0 - 20.6)	2.13	(0.00 - 7.85)	-*	1	8.4	(0.0 - 24.9)	4.41	(0.00 - 16.29)	-*
Northam (T)	3	10.5	(0.0 - 24.1)	3.10	(0.25 - 7.24)	-*	1	1.3	(0.0 - 3.9)	1.63	(0.00 - 6.02)	-*
Northampton (S)	1	8.9	(0.0 - 26.2)	1.85	(0.00 - 6.82)	-*	0	-	-	-	-	.
Nungarin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Peppermint Grove (S)	0	-	-	-	-	.	0	-	-	-	-	.
Perenjori (S)	0	-	-	-	-	.	0	-	-	-	-	.
Perth (C) - Inner	1	100.0	(0.0 - 275.3)	8.92	(0.00 - 32.92)	-*	0	-	-	-	-	.
Perth (C) - Remainder	2	5.9	(0.0 - 14.3)	1.75	(0.02 - 4.88)	-*	1	6.6	(0.0 - 19.5)	2.09	(0.00 - 7.71)	-*
Pingelly (S)	0	-	-	-	-	.	0	-	-	-	-	.
Plantagenet (S)	0	-	-	0	n/a	-	1	3.2	(0.0 - 9.3)	2.73	(0.00 - 10.06)	-*
Port Hedland (T)	0	-	-	0	n/a	-	1	2.6	(0.0 - 7.7)	2.34	(0.00 - 8.61)	-*
Quairading (S)	0	-	-	-	-	.	0	-	-	-	-	.
Ravensthorpe (S)	0	-	-	-	-	.	0	-	-	-	-	.
Rockingham (C)	9	3.9	(1.3 - 6.4)	0.94	(0.36 - 1.64)	-	10	3.4	(1.2 - 5.7)	1.83	(0.76 - 3.13)	-
Roebourne (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Serpentine-Jarrahdale (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Shark Bay (S)	0	-	-	-	-	.	0	-	-	-	-	.
South Perth (C)	8	5.7	(1.2 - 10.2)	1.42	(0.50 - 2.55)	-	2	1.1	(0.0 - 2.8)	0.48	(0.01 - 1.34)	-*
Stirling (C) - Central	13	3.4	(1.5 - 5.4)	0.88	(0.42 - 1.41)	-	5	1.2	(0.1 - 2.4)	0.55	(0.12 - 1.12)	-
Stirling (C) - Coastal	11	4.2	(1.6 - 6.8)	1.19	(0.52 - 1.99)	-	9	3.2	(0.9 - 5.6)	1.51	(0.58 - 2.64)	-
Stirling (C) - South-Eastern	0	-	-	0	n/a	-	4	2.6	(0.0 - 6.1)	1.89	(0.29 - 4.15)	-*
Subiaco (C)	0	-	-	0	n/a	-	3	3.8	(0.0 - 9.3)	2.10	(0.17 - 4.90)	-*
Swan (C)	9	4.3	(1.4 - 7.2)	1.09	(0.42 - 1.91)	-	4	1.9	(0.0 - 3.8)	0.82	(0.13 - 1.79)	-

Cancer type: Melanoma (skin) 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Tammin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Three Springs (S)	0	-	-	-	-	.	0	-	-	-	-	.
Toodyay (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Trayning (S)	0	-	-	-	-	.	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
Victoria Park (T)	4	3.6	(0.0 - 7.9)	0.85	(0.13 - 1.86)	-	9	4.5	(0.3 - 8.7)	2.47	(0.95 - 4.33)	-*
Victoria Plains (S)	0	-	-	-	-	.	0	-	-	-	-	.
Vincent (T)	4	3.1	(0.0 - 6.4)	1.01	(0.16 - 2.21)	-*	1	0.4	(0.0 - 1.3)	0.40	(0.00 - 1.47)	-*
Wagin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wandering (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wanneroo (C) - North-East	3	5.2	(0.0 - 11.2)	1.30	(0.11 - 3.04)	-*	1	2.2	(0.0 - 6.5)	0.74	(0.00 - 2.75)	-*
Wanneroo (C) - North-West	3	4.0	(0.0 - 8.7)	1.14	(0.09 - 2.67)	-*	1	1.7	(0.0 - 4.9)	0.72	(0.00 - 2.65)	-*
Wanneroo (C) - South	2	2.0	(0.0 - 4.7)	0.61	(0.01 - 1.70)	-*	1	1.0	(0.0 - 3.0)	0.50	(0.00 - 1.83)	-*
Waroona (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
West Arthur (S)	0	-	-	-	-	.	0	-	-	-	-	.
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wickepin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Williams (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wongan-Ballidu (S)	0	-	-	-	-	.	0	-	-	-	-	.
Woodanilling (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	1	22.7	(0.0 - 66.8)	8.68	(0.00 - 32.01)	-*	0	-	-	-	-	.
Wyndham-East Kimberley (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Yilgarn (S)	0	-	-	-	-	.	0	-	-	-	-	.
York (S)	1	8.8	(0.0 - 25.9)	1.82	(0.00 - 6.70)	-*	2	13.8	(0.0 - 33.3)	6.81	(0.09 - 18.97)	-*
Total State	246	3.8	(3.3 - 4.3)	1.00	(0.88 - 1.14)	-	147	2.0	(1.7 - 2.4)	1.00	(0.85 - 1.18)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (alphabetic)

Cancer type: Lung, bronchus & trachea 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	26	42.8	(25.2 - 60.4)	0.93	(0.58 - 1.32)	-	15	17.4	(7.0 - 27.8)	0.99	(0.50 - 1.55)	-
Albany (C) Bal	9	17.5	(6.0 - 29.1)	0.52	(0.20 - 0.90)	V	7	14.2	(3.6 - 24.7)	1.10	(0.35 - 2.06)	-
Armadale (C)	53	33.8	(24.6 - 43.0)	1.00	(0.76 - 1.32)	-	34	17.5	(11.3 - 23.6)	1.33	(0.89 - 1.82)	-
Ashburton (S)	1	26.3	(0.0 - 77.7)	0.44	(0.00 - 1.62)	-*	1	5.5	(0.0 - 16.2)	1.39	(0.00 - 5.14)	-*
Augusta-Margaret River (S)	7	20.1	(4.4 - 35.7)	0.58	(0.18 - 1.08)	-	7	14.6	(2.7 - 26.6)	1.38	(0.44 - 2.58)	-
Bassendean (T)	26	48.0	(29.0 - 67.0)	1.39	(0.87 - 1.98)	-	12	19.3	(7.5 - 31.1)	1.24	(0.57 - 2.04)	-
Bayswater (C)	81	33.2	(25.6 - 40.7)	1.03	(0.82 - 1.29)	-	37	10.7	(6.8 - 14.7)	0.94	(0.64 - 1.27)	-
Belmont (C)	64	44.3	(32.7 - 55.9)	1.42	(1.10 - 1.83)	^	20	10.2	(5.1 - 15.3)	0.88	(0.51 - 1.31)	-
Beverley (S)	1	9.3	(0.0 - 27.6)	0.34	(0.00 - 1.27)	-*	0	-	-	0	n/a	-
Boddington (S)	1	45.5	(0.0 - 133.9)	0.72	(0.00 - 2.66)	-*	0	-	-	0	n/a	-
Boyup Brook (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bridgetown-Greenbushes (S)	5	32.4	(3.9 - 60.8)	0.94	(0.20 - 1.92)	-	4	25.3	(0.1 - 50.5)	1.70	(0.26 - 3.73)	-*
Brookton (S)	3	60.6	(0.0 - 134.5)	1.61	(0.13 - 3.77)	-*	1	13.3	(0.0 - 39.3)	1.50	(0.00 - 5.53)	-*
Broome (S)	2	7.8	(0.0 - 18.8)	0.28	(0.00 - 0.78)	V	2	8.9	(0.0 - 21.4)	0.77	(0.01 - 2.13)	-*
Broomehill (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Bruce Rock (S)	1	11.9	(0.0 - 35.0)	0.59	(0.00 - 2.18)	-*	1	10.6	(0.0 - 31.3)	1.33	(0.00 - 4.92)	-*
Bunbury (C)	44	41.9	(28.7 - 55.0)	1.15	(0.81 - 1.51)	-	25	22.6	(13.1 - 32.2)	1.29	(0.79 - 1.84)	-
Busselton (S)	23	23.2	(13.4 - 33.1)	0.72	(0.43 - 1.04)	-	23	20.2	(11.2 - 29.1)	1.50	(0.90 - 2.17)	-
Cambridge (T)	25	17.2	(9.9 - 24.5)	0.68	(0.42 - 0.98)	V	17	11.8	(5.0 - 18.5)	0.86	(0.46 - 1.32)	-
Canning (C)	95	39.1	(31.0 - 47.1)	1.18	(0.96 - 1.45)	-	43	13.3	(9.1 - 17.6)	1.01	(0.71 - 1.34)	-
Capel (S) - Pt A	1	17.2	(0.0 - 50.7)	0.52	(0.00 - 1.90)	-*	0	-	-	0	n/a	-
Capel (S) - Pt B	4	23.7	(0.6 - 46.9)	0.81	(0.13 - 1.78)	-	1	7.3	(0.0 - 21.6)	0.54	(0.00 - 2.01)	-*
Carnamah (S)	0	-	-	0	n/a	-	1	46.9	(0.0 - 138.0)	3.60	(0.00 - 13.29)	-*
Carnarvon (S)	6	29.4	(5.7 - 53.2)	0.79	(0.21 - 1.54)	-	4	20.8	(0.0 - 41.9)	1.54	(0.24 - 3.37)	-*
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	2.17	(0.03 - 6.04)	-*	0	-	-	-	-	-
Chittering (S)	7	59.4	(15.3 - 103.5)	1.91	(0.60 - 3.56)	-*	1	10.2	(0.0 - 30.2)	0.84	(0.00 - 3.10)	-*
Claremont (T)	13	27.0	(9.8 - 44.1)	0.90	(0.43 - 1.45)	-	8	7.7	(1.2 - 14.2)	0.85	(0.30 - 1.54)	-
Cockburn (C)	69	36.5	(27.8 - 45.2)	1.08	(0.85 - 1.38)	-	40	19.3	(13.1 - 25.5)	1.31	(0.91 - 1.75)	-
Collie (S)	15	46.3	(21.7 - 70.8)	1.29	(0.66 - 2.02)	-	4	13.2	(0.0 - 26.5)	0.77	(0.12 - 1.69)	-
Coolgardie (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Coorow (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Corrigin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Cottesloe (T)	5	15.4	(0.8 - 30.0)	0.49	(0.11 - 1.00)	-	4	3.7	(0.1 - 7.2)	0.68	(0.10 - 1.48)	-
Cranbrook (S)	1	30.8	(0.0 - 90.8)	0.61	(0.00 - 2.25)	-*	0	-	-	-	-	-
Cuballing (S)	1	38.2	(0.0 - 112.9)	1.16	(0.00 - 4.27)	-*	0	-	-	-	-	-
Cue (S)	3	373.2	(0.0 - 792.4)	8.86	(0.71 - 20.68)	-*	2	301.8	(0.0 - 720.5)	16.67	(0.21 - 46.45)	-*
Cunderdin (S)	2	37.2	(0.0 - 88.3)	1.11	(0.01 - 3.09)	-*	1	21.3	(0.0 - 62.9)	1.25	(0.00 - 4.62)	-*
Dalwallinu (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Dandaragan (S)	4	29.3	(0.5 - 58.2)	0.92	(0.14 - 2.01)	-*	0	-	-	0	n/a	-
Dardanup (S) - Pt A	5	33.1	(3.7 - 62.5)	1.02	(0.22 - 2.09)	-	2	11.4	(0.0 - 27.3)	0.90	(0.01 - 2.52)	-*
Dardanup (S) - Pt B	2	27.4	(0.0 - 67.6)	0.72	(0.01 - 1.99)	-*	1	20.8	(0.0 - 60.8)	1.07	(0.00 - 3.94)	-*
Denmark (S)	7	31.4	(7.9 - 54.9)	0.94	(0.30 - 1.75)	-	3	12.7	(0.0 - 27.5)	1.00	(0.08 - 2.33)	-*
Derby-West Kimberley (S)	9	65.5	(22.4 - 108.6)	1.81	(0.70 - 3.17)	-	3	28.3	(0.0 - 60.8)	1.66	(0.13 - 3.88)	-*
Donnybrook-Balingup (S)	4	26.8	(0.6 - 53.0)	0.72	(0.11 - 1.58)	-	2	15.3	(0.0 - 36.4)	0.87	(0.01 - 2.42)	-*
Dowerin (S)	0	-	-	0	n/a	-	1	25.0	(0.0 - 73.7)	2.05	(0.00 - 7.56)	-*
Dumbleyung (S)	1	37.0	(0.0 - 109.2)	0.94	(0.00 - 3.48)	-*	0	-	-	-	-	-
Dundas (S)	1	19.2	(0.0 - 56.9)	0.74	(0.00 - 2.74)	-*	0	-	-	-	-	-
East Fremantle (T)	7	22.6	(4.6 - 40.6)	0.76	(0.24 - 1.41)	-	2	2.3	(0.0 - 5.4)	0.42	(0.01 - 1.16)	-
East Pilbara (S)	3	36.4	(0.0 - 82.7)	1.07	(0.09 - 2.51)	-*	0	-	-	0	n/a	-
Esperance (S)	9	22.6	(7.8 - 37.4)	0.62	(0.24 - 1.09)	-	8	19.2	(5.5 - 32.8)	1.25	(0.44 - 2.25)	-
Exmouth (S)	2	28.7	(0.0 - 68.8)	1.00	(0.01 - 2.78)	-*	0	-	-	0	n/a	-
Fremantle (C) - Inner	0	-	-	0	n/a	-	1	74.1	(0.0 - 216.5)	3.21	(0.00 - 11.85)	-*
Fremantle (C) - Remainder	45	41.8	(29.0 - 54.6)	1.20	(0.85 - 1.58)	-	21	16.8	(8.8 - 24.8)	1.11	(0.65 - 1.63)	-
Geraldton (C)	47	64.0	(45.3 - 82.7)	1.85	(1.32 - 2.41)	^	17	19.0	(9.1 - 28.8)	1.35	(0.73 - 2.07)	-
Gingin (S)	5	27.6	(3.2 - 52.0)	0.81	(0.18 - 1.65)	-	1	6.7	(0.0 - 19.7)	0.44	(0.00 - 1.62)	-*
Gnowangerup (S)	1	24.2	(0.0 - 71.4)	0.57	(0.00 - 2.11)	-*	0	-	-	0	n/a	-
Goomalling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Gosnells (C)	75	34.8	(26.8 - 42.8)	1.02	(0.81 - 1.28)	-	27	10.1	(6.2 - 14.1)	0.75	(0.47 - 1.06)	-
Greenough (S) - Pt A	6	22.3	(4.1 - 40.5)	0.75	(0.20 - 1.45)	-	9	43.9	(14.8 - 73.0)	2.85	(1.09 - 4.99)	^*
Greenough (S) - Pt B	1	16.1	(0.0 - 47.5)	0.69	(0.00 - 2.54)	-*	0	-	-	-	-	-
Halls Creek (S)	1	15.6	(0.0 - 46.2)	0.44	(0.00 - 1.61)	-*	0	-	-	0	n/a	-
Harvey (S) - Pt A	5	17.6	(1.9 - 33.2)	0.55	(0.12 - 1.13)	-	9	36.0	(12.1 - 59.9)	2.37	(0.91 - 4.16)	-*
Harvey (S) - Pt B	7	22.9	(5.7 - 40.1)	0.69	(0.22 - 1.28)	-	1	2.0	(0.0 - 5.8)	0.23	(0.00 - 0.85)	V*

Cancer type: Lung, bronchus & trachea 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	8	55.6	(16.0 - 95.2)	1.69	(0.59 - 3.04)	-	1	7.0	(0.0 - 20.7)	0.61	(0.00 - 2.26)	-*
Jerramungup (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Joondalup (C) - North	30	32.7	(20.6 - 44.8)	0.96	(0.62 - 1.33)	-	21	21.4	(11.9 - 30.9)	1.37	(0.80 - 2.01)	-
Joondalup (C) - South	87	27.5	(21.4 - 33.5)	0.83	(0.67 - 1.02)	-	42	11.5	(7.8 - 15.2)	0.84	(0.59 - 1.12)	-
Kalamunda (S)	47	28.3	(20.1 - 36.6)	0.85	(0.61 - 1.11)	-	19	10.2	(5.4 - 15.0)	0.71	(0.40 - 1.07)	-
Kalgoorlie/Boulder (C) - Pt A	27	58.4	(36.1 - 80.8)	1.57	(0.99 - 2.22)	-	16	28.9	(13.5 - 44.2)	1.99	(1.05 - 3.08)	^
Kalgoorlie/Boulder (C) - Pt B	1	187.5	(0.0 - 543.3)	2.83	(0.00 - 10.44)	-*	1	166.7	(0.0 - 464.9)	12.84	(0.00 - 47.36)	-*
Katanning (S)	5	38.4	(4.1 - 72.6)	1.01	(0.22 - 2.07)	-	4	29.6	(0.5 - 58.8)	1.64	(0.25 - 3.58)	-*
Kellerberrin (S)	1	13.2	(0.0 - 38.6)	0.46	(0.00 - 1.71)	-*	0	-	-	0	n/a	-
Kent (S)	1	74.1	(0.0 - 216.5)	1.89	(0.00 - 6.97)	-*	0	-	-	-	-	-
Kojonup (S)	1	5.7	(0.0 - 16.9)	0.31	(0.00 - 1.16)	-*	0	-	-	0	n/a	-
Kondinin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Koorda (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Kulin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Kwinana (T)	32	50.1	(32.3 - 67.8)	1.47	(0.97 - 2.02)	-	15	18.9	(9.0 - 28.7)	1.55	(0.79 - 2.42)	-
Lake Grace (S)	2	53.0	(0.0 - 128.3)	1.29	(0.02 - 3.60)	-*	3	61.5	(0.0 - 129.9)	4.81	(0.39 - 11.22)	-*
Laverton (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Leonora (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mandurah (C)	73	28.3	(21.4 - 35.3)	0.84	(0.66 - 1.06)	-	48	17.5	(12.1 - 23.0)	1.28	(0.92 - 1.67)	-
Manjimup (S)	12	29.0	(12.1 - 45.8)	0.93	(0.43 - 1.53)	-	1	3.6	(0.0 - 10.8)	0.19	(0.00 - 0.69)	V
Meekatharra (S)	2	77.8	(0.0 - 185.3)	1.96	(0.02 - 5.47)	-*	1	46.2	(0.0 - 135.9)	2.50	(0.00 - 9.21)	-*
Melville (C)	121	30.2	(24.5 - 35.9)	0.90	(0.75 - 1.09)	-	60	11.6	(8.3 - 14.9)	0.84	(0.64 - 1.08)	-
Menzies (S)	0	-	-	-	-	.	0	-	-	-	-	.
Merredin (S)	3	29.5	(0.0 - 63.2)	0.70	(0.06 - 1.63)	-*	5	45.0	(4.3 - 85.7)	2.70	(0.59 - 5.54)	-*
Mingenew (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Moora (S)	4	66.5	(1.2 - 131.7)	1.48	(0.23 - 3.25)	-*	0	-	-	0	n/a	-
Morawa (S)	1	28.8	(0.0 - 85.1)	0.73	(0.00 - 2.68)	-*	0	-	-	-	-	.
Mosman Park (T)	13	39.5	(16.5 - 62.4)	1.13	(0.54 - 1.83)	-	1	0.6	(0.0 - 1.8)	0.16	(0.00 - 0.57)	V
Mount Magnet (S)	0	-	-	0	n/a	-	1	58.8	(0.0 - 170.7)	5.20	(0.00 - 19.17)	-*
Mount Marshall (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mukinbudin (S)	1	23.5	(0.0 - 69.4)	1.04	(0.00 - 3.84)	-*	0	-	-	-	-	.
Mullewa (S)	1	27.6	(0.0 - 81.5)	0.94	(0.00 - 3.45)	-*	0	-	-	-	-	.
Mundaring (S)	25	21.5	(12.9 - 30.2)	0.67	(0.41 - 0.95)	V	14	9.3	(4.2 - 14.3)	0.79	(0.39 - 1.25)	-
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murray (S)	15	26.1	(12.7 - 39.5)	0.82	(0.42 - 1.28)	-	16	33.2	(16.8 - 49.7)	2.45	(1.29 - 3.79)	^
Nannup (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Narembeen (S)	1	15.2	(0.0 - 44.4)	0.76	(0.00 - 2.80)	-*	1	10.6	(0.0 - 31.3)	1.75	(0.00 - 6.45)	-*
Narrogin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Narrogin (T)	7	44.7	(9.0 - 80.5)	1.45	(0.46 - 2.70)	-	3	20.4	(0.0 - 46.3)	1.16	(0.09 - 2.70)	-*
Nedlands (C)	19	16.8	(8.4 - 25.3)	0.61	(0.34 - 0.92)	V	14	8.1	(2.4 - 13.8)	0.74	(0.36 - 1.17)	-
Ngaanyatjarraku (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Northam (S)	5	38.1	(4.8 - 71.5)	1.14	(0.25 - 2.34)	-*	3	28.7	(0.0 - 61.1)	1.89	(0.15 - 4.42)	-*
Northam (T)	12	50.1	(19.9 - 80.4)	1.34	(0.61 - 2.20)	-	5	16.8	(0.5 - 33.0)	1.07	(0.23 - 2.20)	-
Northampton (S)	6	43.4	(8.1 - 78.7)	1.18	(0.32 - 2.29)	-	1	4.3	(0.0 - 12.7)	0.54	(0.00 - 1.98)	-*
Nungarin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Peppermint Grove (S)	2	34.5	(0.0 - 81.9)	0.84	(0.01 - 2.35)	-*	1	5.4	(0.0 - 15.9)	0.92	(0.00 - 3.38)	-*
Perenjori (S)	2	132.9	(0.0 - 316.1)	3.54	(0.04 - 9.85)	-*	0	-	-	-	-	.
Perth (C) - Inner	3	180.1	(0.0 - 386.9)	3.26	(0.26 - 7.60)	-*	0	-	-	-	-	.
Perth (C) - Remainder	11	41.8	(16.8 - 66.8)	1.12	(0.49 - 1.86)	-	2	8.9	(0.0 - 22.6)	0.58	(0.01 - 1.61)	-*
Pingelly (S)	3	50.6	(0.0 - 106.7)	1.49	(0.12 - 3.48)	-*	1	22.7	(0.0 - 67.0)	1.14	(0.00 - 4.21)	-*
Plantagenet (S)	4	21.2	(0.2 - 42.2)	0.62	(0.10 - 1.36)	-	1	2.6	(0.0 - 7.7)	0.37	(0.00 - 1.37)	-*
Port Hedland (T)	7	34.2	(5.8 - 62.5)	1.15	(0.36 - 2.14)	-	1	5.9	(0.0 - 17.3)	0.47	(0.00 - 1.73)	-*
Quairading (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Ravensthorpe (S)	2	32.7	(0.0 - 77.9)	1.04	(0.01 - 2.89)	-*	0	-	-	0	n/a	-
Rockingham (C)	96	36.6	(29.1 - 44.2)	1.09	(0.89 - 1.34)	-	41	13.7	(9.3 - 18.1)	1.01	(0.71 - 1.34)	-
Roebourne (S)	9	56.4	(13.1 - 99.8)	1.68	(0.64 - 2.94)	-	3	27.2	(0.0 - 62.1)	1.50	(0.12 - 3.49)	-*
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Serpentine-Jarrahdale (S)	11	33.7	(13.6 - 53.8)	1.01	(0.44 - 1.69)	-	3	8.8	(0.0 - 19.0)	0.68	(0.06 - 1.60)	-*
Shark Bay (S)	1	24.8	(0.0 - 73.4)	0.63	(0.00 - 2.33)	-*	0	-	-	-	-	.
South Perth (C)	38	24.1	(15.5 - 32.7)	0.78	(0.53 - 1.04)	-	26	11.3	(5.9 - 16.8)	0.86	(0.53 - 1.22)	-
Stirling (C) - Central	153	37.7	(31.5 - 44.0)	1.12	(0.96 - 1.32)	-	61	12.6	(9.2 - 16.0)	0.88	(0.68 - 1.13)	-
Stirling (C) - Coastal	58	22.4	(16.4 - 28.5)	0.70	(0.53 - 0.91)	V	43	13.7	(9.2 - 18.1)	0.96	(0.68 - 1.27)	-
Stirling (C) - South-Eastern	31	42.9	(25.4 - 60.4)	1.27	(0.83 - 1.76)	-	12	9.0	(2.3 - 15.7)	0.80	(0.36 - 1.31)	-
Subiaco (C)	22	41.8	(23.1 - 60.5)	1.31	(0.77 - 1.91)	-	12	17.2	(6.2 - 28.2)	1.20	(0.55 - 1.97)	-
Swan (C)	84	41.5	(32.5 - 50.5)	1.21	(0.97 - 1.51)	-	33	14.4	(9.3 - 19.5)	1.01	(0.67 - 1.38)	-

Cancer type: Lung, bronchus & trachea 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Tammin (S)	2	173.9	(0.0 - 404.2)	3.75	(0.05 - 10.45)	-*	0	-	-	-	-	.
Three Springs (S)	1	44.4	(0.0 - 131.1)	0.93	(0.00 - 3.42)	-*	0	-	-	-	-	.
Toodyay (S)	5	31.6	(3.9 - 59.3)	0.99	(0.22 - 2.03)	-	2	12.0	(0.0 - 28.6)	1.08	(0.01 - 3.01)	-*
Trayning (S)	0	-	-	0	n/a	-	1	47.6	(0.0 - 139.8)	3.47	(0.00 - 12.80)	-*
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
Victoria Park (T)	50	44.2	(29.8 - 58.6)	1.21	(0.88 - 1.57)	-	30	18.9	(9.8 - 28.1)	1.14	(0.74 - 1.58)	-
Victoria Plains (S)	3	67.7	(0.0 - 144.2)	2.01	(0.16 - 4.69)	-*	0	-	-	-	-	.
Vincent (T)	45	44.2	(29.9 - 58.5)	1.31	(0.93 - 1.72)	-	13	8.1	(3.1 - 13.2)	0.72	(0.34 - 1.16)	-
Wagin (S)	9	91.5	(20.4 - 162.5)	3.12	(1.20 - 5.47)	^*	2	39.0	(0.0 - 92.9)	1.39	(0.02 - 3.88)	-*
Wandering (S)	1	75.0	(0.0 - 220.2)	2.55	(0.00 - 9.40)	-*	0	-	-	-	-	.
Wanneroo (C) - North-East	30	51.4	(32.6 - 70.3)	1.53	(0.99 - 2.12)	-	13	19.9	(8.6 - 31.2)	1.39	(0.66 - 2.24)	-
Wanneroo (C) - North-West	14	21.7	(10.0 - 33.5)	0.60	(0.30 - 0.95)	v	14	18.0	(8.2 - 27.7)	1.45	(0.72 - 2.30)	-
Wanneroo (C) - South	32	39.2	(25.5 - 52.8)	1.18	(0.78 - 1.63)	-	13	13.6	(6.1 - 21.1)	0.98	(0.47 - 1.58)	-
Waroona (S)	1	6.0	(0.0 - 17.7)	0.21	(0.00 - 0.77)	v	0	-	-	0	n/a	-
West Arthur (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wickepin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Williams (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wiluna (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wongan-Ballidu (S)	4	101.5	(1.3 - 201.6)	2.64	(0.41 - 5.79)	-*	2	30.2	(0.0 - 74.5)	2.77	(0.03 - 7.72)	-*
Woodanilling (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	2	69.5	(0.0 - 166.7)	1.86	(0.02 - 5.18)	-*	0	-	-	-	-	.
Wyndham-East Kimberley (S)	5	34.3	(3.0 - 65.6)	1.23	(0.27 - 2.52)	-*	0	-	-	0	n/a	-
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Yilgarn (S)	3	52.2	(0.0 - 111.2)	1.79	(0.14 - 4.17)	-*	0	-	-	0	n/a	-
York (S)	5	39.8	(4.9 - 74.8)	0.98	(0.21 - 2.02)	-	2	6.3	(0.0 - 15.0)	0.93	(0.01 - 2.59)	-*
Total State	2166	33.6	(32.1 - 35.0)	1.00	(0.96 - 1.04)	-	1058	13.9	(13.0 - 14.8)	1.00	(0.94 - 1.06)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (alphabetic)
Cancer type: All cancers 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Albany (C) - Central	114	157.6	(125.4 - 189.8)	0.99	(0.82 - 1.19)	-	87	83.7	(61.8 - 105.6)	0.91	(0.73 - 1.13)	-
Albany (C) Bal	41	83.3	(57.3 - 109.3)	0.58	(0.41 - 0.78)	V	43	92.9	(64.8 - 121.0)	1.10	(0.78 - 1.45)	-
Armadale (C)	188	118.7	(101.6 - 135.9)	0.87	(0.75 - 1.01)	-	177	99.1	(83.8 - 114.3)	1.10	(0.94 - 1.27)	-
Ashburton (S)	4	63.5	(0.0 - 137.6)	0.38	(0.06 - 0.84)	V	6	124.6	(5.6 - 243.6)	1.11	(0.30 - 2.16)	-
Augusta-Margaret River (S)	49	122.5	(86.1 - 159.0)	0.98	(0.71 - 1.27)	-	22	51.9	(28.6 - 75.3)	0.68	(0.40 - 0.99)	V
Bassendean (T)	91	167.9	(132.3 - 203.6)	1.20	(0.97 - 1.48)	-	78	125.6	(94.9 - 156.4)	1.30	(1.03 - 1.63)	^
Bayswater (C)	291	125.0	(110.0 - 140.0)	0.90	(0.80 - 1.02)	-	268	92.1	(79.6 - 104.6)	1.07	(0.94 - 1.20)	-
Belmont (C)	217	161.2	(138.3 - 184.1)	1.19	(1.04 - 1.37)	^	135	86.7	(70.1 - 103.2)	0.96	(0.81 - 1.14)	-
Beverley (S)	7	80.0	(20.3 - 139.6)	0.59	(0.19 - 1.10)	-	4	27.9	(0.0 - 55.8)	0.55	(0.08 - 1.19)	-
Boddington (S)	5	126.2	(2.2 - 250.1)	0.85	(0.19 - 1.75)	-	4	115.5	(1.2 - 229.8)	1.17	(0.18 - 2.57)	-*
Boyup Brook (S)	2	17.4	(0.0 - 41.3)	0.20	(0.00 - 0.56)	V	7	74.8	(7.7 - 141.9)	0.93	(0.29 - 1.73)	-
Bridgetown-Greenbushes (S)	19	127.2	(67.9 - 186.4)	0.88	(0.49 - 1.32)	-	14	78.5	(36.3 - 120.6)	0.95	(0.47 - 1.50)	-
Brookton (S)	7	133.5	(26.2 - 240.7)	0.88	(0.28 - 1.64)	-	8	161.6	(35.9 - 287.3)	1.84	(0.65 - 3.32)	-*
Broome (S)	21	96.8	(54.0 - 139.6)	0.70	(0.41 - 1.03)	-	16	67.9	(32.9 - 103.0)	0.91	(0.48 - 1.40)	-
Broomehill (S)	2	109.7	(0.0 - 258.5)	0.83	(0.01 - 2.32)	-*	0	-	-	0	n/a	-
Bruce Rock (S)	9	168.2	(55.0 - 281.4)	1.30	(0.50 - 2.27)	-	4	70.2	(0.0 - 145.1)	0.86	(0.13 - 1.89)	-
Bunbury (C)	164	149.5	(124.9 - 174.1)	1.03	(0.88 - 1.21)	-	122	94.0	(75.2 - 112.9)	0.99	(0.82 - 1.18)	-
Busselton (S)	122	120.0	(97.6 - 142.4)	0.94	(0.78 - 1.12)	-	102	93.3	(73.2 - 113.4)	1.06	(0.87 - 1.30)	-
Cambridge (T)	127	108.1	(87.0 - 129.1)	0.84	(0.70 - 1.00)	-	117	83.8	(65.5 - 102.1)	0.91	(0.76 - 1.09)	-
Canning (C)	330	135.9	(120.9 - 150.8)	1.00	(0.90 - 1.12)	-	256	80.8	(70.2 - 91.4)	0.95	(0.84 - 1.08)	-
Capel (S) - Pt A	6	106.4	(13.4 - 199.5)	0.76	(0.20 - 1.47)	-	1	21.7	(0.0 - 64.2)	0.19	(0.00 - 0.71)	V
Capel (S) - Pt B	22	144.0	(83.8 - 204.2)	1.10	(0.65 - 1.60)	-	10	78.8	(29.2 - 128.5)	0.86	(0.35 - 1.46)	-
Carnamah (S)	2	89.3	(0.0 - 211.6)	0.63	(0.01 - 1.77)	-*	2	118.3	(0.0 - 276.8)	1.12	(0.01 - 3.13)	-*
Carnarvon (S)	34	144.7	(95.6 - 193.7)	1.10	(0.74 - 1.50)	-	11	60.1	(23.9 - 96.3)	0.66	(0.29 - 1.10)	-
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	0.53	(0.01 - 1.49)	-*	3	95.1	(0.0 - 208.7)	1.43	(0.12 - 3.33)	-*
Chittering (S)	19	169.4	(92.0 - 246.9)	1.33	(0.75 - 1.99)	-	3	27.4	(0.0 - 58.6)	0.40	(0.03 - 0.93)	V
Claremont (T)	59	143.7	(102.6 - 184.9)	0.97	(0.75 - 1.26)	-	59	77.4	(50.1 - 104.8)	0.92	(0.71 - 1.20)	-
Cockburn (C)	287	153.1	(135.3 - 171.0)	1.10	(0.98 - 1.24)	-	211	95.6	(82.3 - 109.0)	1.09	(0.95 - 1.25)	-
Collie (S)	48	142.1	(100.0 - 184.1)	1.00	(0.72 - 1.30)	-	30	85.9	(52.8 - 119.0)	0.93	(0.60 - 1.29)	-
Coolgardie (S)	7	113.9	(21.5 - 206.4)	0.79	(0.25 - 1.48)	-	6	83.2	(9.5 - 156.9)	1.22	(0.33 - 2.37)	-
Coorow (S)	6	126.5	(24.6 - 228.5)	0.88	(0.24 - 1.71)	-	2	35.7	(0.0 - 88.5)	0.53	(0.01 - 1.47)	-*
Corrigin (S)	4	57.9	(0.0 - 116.2)	0.52	(0.08 - 1.13)	-	7	128.9	(28.1 - 229.7)	1.21	(0.38 - 2.25)	-
Cottesloe (T)	42	126.4	(85.6 - 167.3)	0.98	(0.68 - 1.29)	-	25	54.9	(18.3 - 91.4)	0.65	(0.40 - 0.94)	V
Cranbrook (S)	5	106.9	(10.6 - 203.2)	0.75	(0.16 - 1.53)	-	3	69.5	(0.0 - 151.0)	0.94	(0.08 - 2.20)	-*
Cuballing (S)	4	148.8	(3.5 - 294.1)	1.17	(0.18 - 2.56)	-*	2	86.5	(0.0 - 206.3)	0.98	(0.01 - 2.72)	-*
Cue (S)	3	373.2	(0.0 - 792.4)	2.07	(0.17 - 4.83)	-*	3	478.3	(0.0 - 1,018.1)	3.52	(0.28 - 8.22)	-*
Cunderdin (S)	4	78.3	(2.2 - 154.5)	0.54	(0.08 - 1.17)	-	6	108.9	(13.3 - 204.5)	1.16	(0.31 - 2.25)	-
Dalwallinu (S)	8	129.3	(40.1 - 218.4)	0.95	(0.33 - 1.71)	-	1	10.6	(0.0 - 31.3)	0.18	(0.00 - 0.65)	V
Dandaragan (S)	14	102.5	(48.5 - 156.5)	0.82	(0.41 - 1.31)	-	7	73.4	(18.7 - 128.1)	0.80	(0.25 - 1.49)	-
Dardanup (S) - Pt A	24	166.2	(99.1 - 233.2)	1.19	(0.72 - 1.71)	-	8	44.3	(12.7 - 75.9)	0.57	(0.20 - 1.03)	-
Dardanup (S) - Pt B	7	83.9	(19.3 - 148.5)	0.62	(0.19 - 1.16)	-	5	75.0	(8.0 - 141.9)	0.86	(0.19 - 1.76)	-
Denmark (S)	22	92.3	(53.0 - 131.7)	0.73	(0.43 - 1.07)	-	20	92.5	(50.1 - 134.9)	1.09	(0.62 - 1.61)	-
Derby-West Kimberley (S)	29	192.5	(121.4 - 263.6)	1.37	(0.88 - 1.91)	-	14	114.9	(52.1 - 177.7)	1.13	(0.56 - 1.79)	-
Donnybrook-Balingup (S)	17	99.4	(51.9 - 146.8)	0.75	(0.40 - 1.15)	-	14	82.6	(37.8 - 127.4)	0.94	(0.47 - 1.50)	-
Dowerin (S)	3	109.0	(0.0 - 238.4)	0.77	(0.06 - 1.79)	-*	2	54.4	(0.0 - 128.6)	0.68	(0.01 - 1.88)	-*
Dumbleyung (S)	6	172.1	(35.1 - 309.1)	1.39	(0.38 - 2.71)	-*	0	-	-	0	n/a	-
Dundas (S)	5	124.0	(17.5 - 230.5)	0.89	(0.19 - 1.83)	-	2	61.2	(0.0 - 147.6)	0.63	(0.01 - 1.74)	-*
East Fremantle (T)	31	108.9	(68.6 - 149.1)	0.80	(0.52 - 1.10)	-	29	61.4	(33.2 - 89.6)	0.93	(0.59 - 1.29)	-
East Pilbara (S)	10	139.3	(46.4 - 232.2)	0.79	(0.33 - 1.35)	-	4	53.3	(0.0 - 112.9)	0.59	(0.09 - 1.29)	-
Esperance (S)	54	129.0	(94.4 - 163.7)	0.91	(0.69 - 1.20)	-	39	88.5	(59.9 - 117.2)	0.96	(0.66 - 1.29)	-
Exmouth (S)	6	121.9	(8.8 - 234.9)	0.74	(0.20 - 1.44)	-	6	96.7	(16.9 - 176.4)	1.30	(0.35 - 2.53)	-
Fremantle (C) - Inner	1	33.9	(0.0 - 100.1)	0.17	(0.00 - 0.63)	V	1	74.1	(0.0 - 216.5)	0.51	(0.00 - 1.87)	-*
Fremantle (C) - Remainder	166	153.6	(129.4 - 177.9)	1.09	(0.93 - 1.27)	-	128	100.7	(80.4 - 120.9)	1.06	(0.89 - 1.26)	-
Geraldton (C)	149	198.5	(166.1 - 231.0)	1.45	(1.23 - 1.70)	^	96	109.5	(85.5 - 133.5)	1.21	(0.99 - 1.49)	-
Gingin (S)	32	186.4	(120.7 - 252.1)	1.33	(0.87 - 1.83)	-	12	74.3	(32.3 - 116.3)	0.85	(0.39 - 1.39)	-
Gnowangerup (S)	7	167.8	(44.9 - 290.7)	0.97	(0.30 - 1.81)	-	2	24.1	(0.0 - 57.1)	0.41	(0.01 - 1.15)	-
Goomalling (S)	1	25.0	(0.0 - 72.8)	0.18	(0.00 - 0.65)	V	1	15.4	(0.0 - 45.3)	0.26	(0.00 - 0.94)	V*
Gosnells (C)	308	139.6	(123.8 - 155.4)	1.02	(0.91 - 1.14)	-	217	83.5	(71.9 - 95.1)	0.95	(0.83 - 1.08)	-
Greenough (S) - Pt A	33	129.9	(84.4 - 175.3)	1.00	(0.67 - 1.37)	-	23	102.6	(59.8 - 145.5)	1.11	(0.67 - 1.61)	-
Greenough (S) - Pt B	4	81.2	(1.1 - 161.3)	0.67	(0.10 - 1.47)	-	2	54.8	(0.0 - 130.4)	0.72	(0.01 - 2.01)	-*
Halls Creek (S)	10	146.2	(51.9 - 240.4)	1.02	(0.42 - 1.75)	-	7	116.3	(26.4 - 206.1)	1.17	(0.37 - 2.18)	-
Harvey (S) - Pt A	32	119.6	(76.4 - 162.8)	0.87	(0.57 - 1.20)	-	29	114.8	(72.3 - 157.2)	1.22	(0.78 - 1.71)	-
Harvey (S) - Pt B	49	160.8	(115.4 - 206.2)	1.18	(0.85 - 1.54)	-	26	77.7	(45.2 - 110.2)	0.93	(0.58 - 1.33)	-

Cancer type: All cancers 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Irwin (S)	24	172.0	(101.9 - 242.1)	1.28	(0.78 - 1.84)	-	10	88.7	(33.1 - 144.3)	0.99	(0.41 - 1.70)	-
Jerramungup (S)	1	71.4	(0.0 - 201.0)	0.18	(0.00 - 0.68)	V	1	22.8	(0.0 - 67.5)	0.35	(0.00 - 1.31)	-*
Joondalup (C) - North	124	129.5	(106.0 - 153.1)	0.95	(0.80 - 1.14)	-	125	113.5	(93.0 - 134.1)	1.25	(1.04 - 1.49)	^
Joondalup (C) - South	362	115.0	(102.7 - 127.3)	0.83	(0.75 - 0.92)	V	304	81.5	(71.7 - 91.3)	0.96	(0.85 - 1.07)	-
Kalamunda (S)	227	138.8	(120.4 - 157.2)	1.01	(0.88 - 1.15)	-	162	83.3	(69.7 - 96.8)	0.95	(0.82 - 1.12)	-
Kalgoorlie/Boulder (C) - Pt A	88	169.5	(133.1 - 205.9)	1.20	(0.96 - 1.48)	-	67	114.7	(84.9 - 144.6)	1.22	(0.95 - 1.56)	-
Kalgoorlie/Boulder (C) - Pt B	3	597.2	(0.0 - 1,233.6)	1.99	(0.16 - 4.66)	-*	2	357.1	(0.0 - 828.0)	3.71	(0.05 - 10.33)	-*
Katanning (S)	23	148.3	(85.8 - 210.8)	1.12	(0.67 - 1.62)	-	17	85.4	(41.0 - 129.8)	1.09	(0.58 - 1.66)	-
Kellerberrin (S)	7	112.6	(27.9 - 197.3)	0.80	(0.25 - 1.49)	-	10	138.5	(38.7 - 238.2)	1.63	(0.67 - 2.78)	-
Kent (S)	1	74.1	(0.0 - 216.5)	0.46	(0.00 - 1.68)	-*	0	-	-	0	n/a	-
Kojonup (S)	12	105.9	(43.0 - 168.7)	0.92	(0.42 - 1.50)	-	10	72.1	(23.3 - 120.9)	1.18	(0.48 - 2.01)	-
Kondinin (S)	2	58.9	(0.0 - 140.7)	0.46	(0.01 - 1.27)	-*	2	84.1	(0.0 - 199.9)	0.82	(0.01 - 2.29)	-*
Koorda (S)	2	121.4	(0.0 - 280.9)	0.78	(0.01 - 2.16)	-*	1	62.5	(0.0 - 183.1)	0.60	(0.00 - 2.20)	-*
Kulin (S)	3	72.4	(0.0 - 156.7)	0.62	(0.05 - 1.44)	-	2	62.3	(0.0 - 148.8)	0.67	(0.01 - 1.86)	-*
Kwinana (T)	112	168.4	(136.7 - 200.1)	1.27	(1.05 - 1.54)	^	63	90.5	(67.5 - 113.4)	1.04	(0.81 - 1.34)	-
Lake Grace (S)	8	180.9	(53.4 - 308.4)	1.26	(0.44 - 2.27)	-	6	138.4	(25.0 - 251.8)	1.51	(0.41 - 2.93)	-*
Laverton (S)	1	38.1	(0.0 - 112.7)	0.27	(0.00 - 0.99)	V*	1	46.5	(0.0 - 137.3)	0.76	(0.00 - 2.79)	-*
Leonora (S)	5	142.6	(0.0 - 290.5)	0.87	(0.19 - 1.78)	-	1	33.3	(0.0 - 96.5)	0.49	(0.00 - 1.80)	-*
Mandurah (C)	350	139.9	(124.1 - 155.6)	1.01	(0.91 - 1.13)	-	230	86.7	(74.2 - 99.1)	1.01	(0.89 - 1.15)	-
Manjimup (S)	59	152.5	(112.3 - 192.7)	1.12	(0.86 - 1.45)	-	29	70.5	(43.1 - 97.9)	0.86	(0.55 - 1.21)	-
Meekatharra (S)	8	273.5	(81.4 - 465.5)	1.87	(0.66 - 3.37)	-*	4	164.9	(3.9 - 325.8)	1.53	(0.24 - 3.35)	-*
Melville (C)	502	123.9	(112.4 - 135.4)	0.91	(0.84 - 1.00)	-	418	76.9	(68.4 - 85.3)	0.92	(0.84 - 1.02)	-
Menzies (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Merredin (S)	18	138.5	(72.1 - 204.8)	1.02	(0.56 - 1.54)	-	19	162.2	(87.0 - 237.3)	1.62	(0.91 - 2.43)	-
Mingenew (S)	2	105.3	(0.0 - 249.2)	0.79	(0.01 - 2.20)	-*	1	60.6	(0.0 - 177.6)	0.64	(0.00 - 2.35)	-*
Moora (S)	10	139.8	(49.5 - 230.2)	0.88	(0.36 - 1.51)	-	4	48.9	(0.0 - 104.2)	0.50	(0.08 - 1.10)	-
Morawa (S)	4	118.1	(2.5 - 233.6)	0.71	(0.11 - 1.56)	-	2	52.5	(0.0 - 132.7)	0.68	(0.01 - 1.89)	-*
Mosman Park (T)	49	138.7	(97.7 - 179.7)	1.03	(0.74 - 1.34)	-	36	63.8	(35.9 - 91.7)	0.83	(0.56 - 1.13)	-
Mount Magnet (S)	0	-	-	0	n/a	-	1	58.8	(0.0 - 170.7)	0.77	(0.00 - 2.83)	-*
Mount Marshall (S)	1	43.5	(0.0 - 128.1)	0.34	(0.00 - 1.24)	-*	0	-	-	0	n/a	-
Mukinbudin (S)	1	23.5	(0.0 - 69.4)	0.27	(0.00 - 1.00)	-*	0	-	-	0	n/a	-
Mullewa (S)	4	126.6	(2.3 - 251.0)	0.89	(0.14 - 1.96)	-*	2	121.1	(0.0 - 304.9)	0.88	(0.01 - 2.44)	-*
Mundaring (S)	135	122.1	(101.1 - 143.1)	0.88	(0.74 - 1.05)	-	118	84.7	(68.8 - 100.6)	1.04	(0.86 - 1.25)	-
Murchison (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Murray (S)	63	126.5	(91.3 - 161.7)	0.87	(0.68 - 1.13)	-	59	135.2	(99.2 - 171.2)	1.47	(1.13 - 1.91)	^
Nannup (S)	4	77.3	(2.4 - 152.2)	0.63	(0.10 - 1.39)	-	1	13.5	(0.0 - 39.6)	0.24	(0.00 - 0.89)	V*
Narembeen (S)	7	156.8	(37.0 - 276.6)	1.29	(0.40 - 2.40)	-	1	10.6	(0.0 - 31.3)	0.27	(0.00 - 1.00)	-*
Narrogin (S)	0	-	-	0	n/a	V	0	-	-	0	n/a	V
Narrogin (T)	34	209.1	(133.5 - 284.8)	1.67	(1.12 - 2.28)	^	20	120.6	(58.2 - 183.0)	1.19	(0.68 - 1.76)	-
Nedlands (C)	124	109.2	(87.4 - 130.9)	0.93	(0.78 - 1.12)	-	155	94.9	(75.0 - 114.8)	1.21	(1.03 - 1.41)	^
Ngaanyatjarraku (S)	0	-	-	0	n/a	V	1	32.0	(0.0 - 94.5)	0.38	(0.00 - 1.39)	-*
Northam (S)	18	145.4	(74.6 - 216.1)	1.05	(0.58 - 1.58)	-	8	73.2	(22.5 - 123.8)	0.81	(0.28 - 1.46)	-
Northam (T)	44	179.2	(122.3 - 236.1)	1.21	(0.86 - 1.60)	-	41	108.1	(68.4 - 147.7)	1.39	(0.97 - 1.85)	-
Northampton (S)	20	147.2	(81.5 - 213.0)	0.99	(0.56 - 1.46)	-	7	46.6	(12.0 - 81.3)	0.61	(0.19 - 1.14)	-
Nungarin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Peppermint Grove (S)	8	128.5	(37.2 - 219.7)	0.82	(0.29 - 1.48)	-	8	81.6	(15.0 - 148.1)	1.15	(0.40 - 2.07)	-
Perenjori (S)	3	175.9	(0.0 - 377.3)	1.27	(0.10 - 2.97)	-*	1	33.3	(0.0 - 97.6)	0.56	(0.00 - 2.08)	-*
Perth (C) - Inner	5	301.6	(57.0 - 546.3)	1.33	(0.29 - 2.72)	-*	1	83.3	(0.0 - 245.5)	0.58	(0.00 - 2.14)	-*
Perth (C) - Remainder	57	198.4	(145.1 - 251.8)	1.38	(1.06 - 1.80)	^	18	73.6	(34.7 - 112.5)	0.81	(0.45 - 1.23)	-
Pingelly (S)	9	188.2	(53.4 - 323.0)	1.11	(0.42 - 1.94)	-	7	120.4	(22.2 - 218.6)	1.24	(0.39 - 2.31)	-
Plantagenet (S)	30	170.2	(109.2 - 231.3)	1.17	(0.76 - 1.62)	-	15	77.2	(35.8 - 118.6)	0.89	(0.45 - 1.39)	-
Port Hedland (T)	24	118.7	(65.4 - 172.1)	0.89	(0.54 - 1.27)	-	14	78.2	(35.4 - 121.1)	0.92	(0.46 - 1.46)	-
Quairading (S)	5	112.1	(13.9 - 210.4)	0.81	(0.18 - 1.66)	-	7	132.7	(21.7 - 243.8)	1.38	(0.43 - 2.57)	-
Ravensthorpe (S)	4	62.3	(1.4 - 123.1)	0.51	(0.08 - 1.12)	-	4	87.1	(0.7 - 173.6)	0.91	(0.14 - 2.00)	-*
Rockingham (C)	392	152.8	(137.1 - 168.4)	1.10	(1.00 - 1.22)	-	271	94.0	(82.1 - 105.9)	1.08	(0.95 - 1.22)	-
Roebourne (S)	23	131.0	(66.9 - 195.0)	0.95	(0.57 - 1.37)	-	8	38.8	(2.3 - 75.2)	0.54	(0.19 - 0.97)	V
Sandstone (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Serpentine-Jarrahdale (S)	40	120.7	(82.8 - 158.7)	0.91	(0.63 - 1.21)	-	18	56.8	(30.3 - 83.4)	0.64	(0.35 - 0.96)	V
Shark Bay (S)	1	24.8	(0.0 - 73.4)	0.16	(0.00 - 0.59)	V	1	48.8	(0.0 - 143.8)	0.33	(0.00 - 1.23)	-*
South Perth (C)	192	123.3	(103.9 - 142.7)	0.93	(0.80 - 1.07)	-	189	86.4	(70.7 - 102.1)	0.94	(0.82 - 1.09)	-
Stirling (C) - Central	575	146.3	(133.8 - 158.8)	1.04	(0.96 - 1.13)	-	413	82.7	(73.9 - 91.5)	0.96	(0.87 - 1.05)	-
Stirling (C) - Coastal	338	131.6	(116.7 - 146.5)	0.99	(0.89 - 1.10)	-	266	87.4	(75.7 - 99.2)	0.94	(0.83 - 1.06)	-
Stirling (C) - South-Eastern	112	126.8	(98.5 - 155.2)	1.07	(0.88 - 1.29)	-	109	84.4	(61.6 - 107.3)	1.06	(0.87 - 1.28)	-
Subiaco (C)	81	158.5	(122.0 - 195.0)	1.14	(0.91 - 1.42)	-	79	94.1	(69.0 - 119.3)	1.20	(0.95 - 1.50)	-
Swan (C)	290	140.5	(124.1 - 156.9)	1.02	(0.90 - 1.14)	-	217	90.3	(77.8 - 102.9)	1.03	(0.90 - 1.18)	-

Cancer type: All cancers 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Tambellup (S)	2	92.6	(0.0 - 220.7)	0.64	(0.01 - 1.78)	-*	1	50.0	(0.0 - 147.4)	0.50	(0.00 - 1.83)	-*
Tammin (S)	4	310.9	(20.3 - 601.4)	1.78	(0.27 - 3.89)	-*	2	48.8	(0.0 - 114.8)	1.31	(0.02 - 3.64)	-*
Three Springs (S)	5	147.0	(12.4 - 281.7)	1.11	(0.24 - 2.27)	-	4	126.3	(0.0 - 265.2)	1.55	(0.24 - 3.41)	-*
Toodyay (S)	20	130.3	(73.2 - 187.3)	1.00	(0.57 - 1.48)	-	14	96.7	(45.3 - 148.1)	1.20	(0.59 - 1.90)	-
Trayning (S)	3	168.1	(0.0 - 376.3)	1.13	(0.09 - 2.64)	-*	2	95.2	(0.0 - 224.1)	1.07	(0.01 - 2.98)	-*
Upper Gascoyne (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Victoria Park (T)	227	193.7	(163.4 - 224.0)	1.29	(1.13 - 1.47)	^	182	91.0	(71.9 - 110.1)	1.02	(0.88 - 1.18)	-
Victoria Plains (S)	8	171.6	(52.0 - 291.3)	1.29	(0.45 - 2.33)	-	1	62.5	(0.0 - 181.1)	0.39	(0.00 - 1.43)	-*
Vincent (T)	145	137.3	(112.9 - 161.7)	1.01	(0.86 - 1.20)	-	99	72.3	(54.5 - 90.1)	0.84	(0.69 - 1.03)	-
Wagin (S)	15	153.1	(60.3 - 245.8)	1.24	(0.63 - 1.94)	-	11	131.1	(44.6 - 217.5)	1.22	(0.53 - 2.04)	-
Wandering (S)	1	75.0	(0.0 - 220.2)	0.62	(0.00 - 2.28)	-*	1	83.3	(0.0 - 232.4)	1.04	(0.00 - 3.84)	-*
Wanneroo (C) - North-East	93	158.0	(125.3 - 190.6)	1.15	(0.93 - 1.41)	-	63	91.1	(67.2 - 115.0)	1.05	(0.81 - 1.35)	-
Wanneroo (C) - North-West	82	119.2	(92.6 - 145.8)	0.88	(0.70 - 1.09)	-	56	78.5	(57.4 - 99.6)	0.94	(0.71 - 1.22)	-
Wanneroo (C) - South	115	137.2	(111.9 - 162.5)	1.03	(0.86 - 1.25)	-	77	79.4	(61.3 - 97.6)	0.90	(0.71 - 1.13)	-
Waroona (S)	14	107.2	(47.5 - 167.0)	0.72	(0.36 - 1.15)	-	16	127.8	(62.9 - 192.6)	1.26	(0.66 - 1.95)	-
West Arthur (S)	1	20.4	(0.0 - 60.0)	0.18	(0.00 - 0.65)	V	0	-	-	0	n/a	-
Westonia (S)	1	102.0	(0.0 - 300.0)	0.68	(0.00 - 2.50)	-*	0	-	-	0	n/a	-
Wickepin (S)	3	99.7	(0.0 - 223.9)	0.66	(0.05 - 1.54)	-	2	80.9	(0.0 - 192.5)	0.78	(0.01 - 2.18)	-*
Williams (S)	1	34.5	(0.0 - 101.7)	0.22	(0.00 - 0.81)	V	4	167.4	(4.6 - 330.2)	1.39	(0.21 - 3.04)	-*
Wiluna (S)	1	24.0	(0.0 - 70.9)	0.40	(0.00 - 1.47)	-*	2	195.8	(0.0 - 476.2)	2.16	(0.03 - 6.03)	-*
Wongan-Ballidu (S)	8	193.3	(57.2 - 329.5)	1.30	(0.46 - 2.34)	-	7	122.2	(20.9 - 223.4)	1.51	(0.47 - 2.81)	-
Woodanilling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Wyalkatchem (S)	5	147.6	(16.1 - 279.0)	1.17	(0.25 - 2.39)	-*	3	105.4	(0.0 - 236.7)	1.17	(0.09 - 2.74)	-*
Wyndham-East Kimberley (S)	13	87.9	(36.4 - 139.4)	0.74	(0.35 - 1.19)	-	8	68.1	(17.1 - 119.0)	0.84	(0.30 - 1.52)	-
Yalgoo (S)	1	62.5	(0.0 - 184.2)	0.77	(0.00 - 2.83)	-*	0	-	-	0	n/a	-
Yilgarn (S)	10	195.1	(73.6 - 316.7)	1.46	(0.60 - 2.49)	-	2	44.2	(0.0 - 105.4)	0.48	(0.01 - 1.33)	-*
York (S)	20	146.9	(81.1 - 212.6)	0.96	(0.55 - 1.43)	-	14	77.8	(32.7 - 122.8)	1.02	(0.51 - 1.63)	-
Total State	8892	137.0	(134.1 - 139.9)	1.00	(0.98 - 1.02)	-	6757	87.4	(85.1 - 89.6)	1.00	(0.98 - 1.02)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (DOH Areas)
Cancer type: Breast 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	0	-	-	-	-	.	16	13.5	(6.2 - 20.8)	0.81	(0.43 - 1.25)	-
Claremont (T)	0	-	-	-	-	.	11	9.7	(1.5 - 18.0)	1.17	(0.51 - 1.95)	-
Cottesloe (T)	0	-	-	-	-	.	5	11.2	(0.0 - 23.0)	0.84	(0.18 - 1.72)	-
Joondalup (C) - North	0	-	-	-	-	.	26	23.1	(13.8 - 32.4)	1.38	(0.86 - 1.96)	-
Joondalup (C) - South	0	-	-	-	-	.	51	14.6	(10.4 - 18.9)	0.88	(0.66 - 1.16)	-
Mosman Park (T)	0	-	-	-	-	.	11	32.6	(10.4 - 54.7)	1.65	(0.72 - 2.77)	-
Nedlands (C)	0	-	-	-	-	.	22	19.2	(9.1 - 29.4)	1.13	(0.67 - 1.65)	-
Peppermint Grove (S)	0	-	-	-	-	.	1	23.4	(0.0 - 69.1)	0.87	(0.00 - 3.21)	-*
Stirling (C) - Central	2	0.6	(0.0 - 1.5)	8.91	(0.11 - 24.83)	-*	61	15.1	(11.1 - 19.1)	0.89	(0.68 - 1.15)	-
Stirling (C) - Coastal	0	-	-	-	-	.	45	17.7	(12.2 - 23.3)	1.01	(0.71 - 1.32)	-
Subiaco (C)	0	-	-	-	-	.	9	8.8	(2.0 - 15.7)	0.86	(0.33 - 1.51)	-
Wanneroo (C) - North-East	0	-	-	-	-	.	12	17.2	(6.9 - 27.5)	1.15	(0.52 - 1.88)	-
Wanneroo (C) - North-West	0	-	-	-	-	.	16	22.1	(11.1 - 33.2)	1.52	(0.80 - 2.35)	-
Wanneroo (C) - South	0	-	-	-	-	.	13	13.7	(6.0 - 21.3)	0.84	(0.40 - 1.35)	-
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	0	-	-	-	-	.	21	15.4	(8.0 - 22.8)	0.97	(0.56 - 1.43)	-
Canning (C)	0	-	-	-	-	.	40	14.3	(9.7 - 19.0)	0.88	(0.61 - 1.18)	-
South Perth (C)	1	0.3	(0.0 - 0.9)	11.52	(0.00 - 42.49)	-*	32	20.1	(12.2 - 28.1)	1.06	(0.70 - 1.46)	-
Victoria Park (T)	0	-	-	-	-	.	32	13.4	(6.4 - 20.3)	1.27	(0.84 - 1.75)	-
Inner City HD												
Perth (C) - Inner	0	-	-	-	-	.	0	-	-	-	-	.
Perth (C) - Remainder	0	-	-	-	-	.	2	10.8	(0.0 - 27.1)	0.58	(0.01 - 1.61)	-*
Stirling (C) - South-Eastern	0	-	-	-	-	.	16	10.5	(3.3 - 17.7)	1.07	(0.56 - 1.66)	-
Vincent (T)	0	-	-	-	-	.	20	18.5	(8.6 - 28.3)	1.13	(0.65 - 1.67)	-
Kalamunda HD												
Kalamunda (S)	0	-	-	-	-	.	32	17.4	(11.1 - 23.7)	1.09	(0.72 - 1.50)	-
Swan HD												
Bassendean (T)	0	-	-	-	-	.	11	20.2	(7.7 - 32.7)	1.15	(0.50 - 1.92)	-
Bayswater (C)	0	-	-	-	-	.	46	19.6	(13.4 - 25.8)	1.16	(0.83 - 1.52)	-
Mundaring (S)	0	-	-	-	-	.	22	15.9	(9.1 - 22.7)	1.09	(0.65 - 1.59)	-
Swan (C)	0	-	-	-	-	.	30	12.2	(7.7 - 16.7)	0.81	(0.52 - 1.12)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	0	-	-	-	-	.	27	15.9	(9.7 - 22.1)	0.96	(0.60 - 1.36)	-
Gosnells (C)	0	-	-	-	-	.	44	17.4	(12.1 - 22.7)	1.09	(0.77 - 1.43)	-
Serpentine-Jarrahdale (S)	0	-	-	-	-	.	0	-	-	0	n/a	V
Fremantle HD												
Cockburn (C)	0	-	-	-	-	.	31	14.6	(9.3 - 20.0)	0.92	(0.60 - 1.27)	-
East Fremantle (T)	0	-	-	-	-	.	6	13.8	(0.0 - 27.6)	1.22	(0.33 - 2.37)	-
Fremantle (C) - Inner	0	-	-	-	-	.	0	-	-	-	-	.
Fremantle (C) - Remainder	0	-	-	-	-	.	27	24.1	(14.2 - 34.1)	1.43	(0.90 - 2.01)	-
Melville (C)	0	-	-	-	-	.	63	13.0	(9.5 - 16.6)	0.88	(0.68 - 1.13)	-
Rockingham-Kwinana HD												
Kwinana (T)	0	-	-	-	-	.	8	13.2	(4.0 - 22.4)	0.77	(0.27 - 1.39)	-
Rockingham (C)	0	-	-	-	-	.	45	16.6	(11.5 - 21.7)	1.09	(0.77 - 1.43)	-
Peel HD												
Mandurah (C)	0	-	-	-	-	.	37	17.0	(11.0 - 23.1)	1.03	(0.70 - 1.39)	-
Murray (S)	0	-	-	-	-	.	7	21.8	(4.3 - 39.2)	1.01	(0.32 - 1.89)	-
Waroona (S)	0	-	-	-	-	.	2	16.8	(0.0 - 40.4)	0.95	(0.01 - 2.65)	-*
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	0	-	-	-	-	.	4	11.7	(0.0 - 23.4)	1.12	(0.17 - 2.46)	-*
Derby-West Kimberley (S)	0	-	-	-	-	.	1	10.1	(0.0 - 29.9)	0.44	(0.00 - 1.63)	-*
Halls Creek (S)	0	-	-	-	-	.	3	47.0	(0.0 - 104.7)	2.75	(0.22 - 6.41)	-*
Wyndham-East Kimberley (S)	0	-	-	-	-	.	1	4.0	(0.0 - 11.9)	0.52	(0.00 - 1.93)	-*
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	0	-	-	-	-	.	2	71.5	(0.0 - 169.6)	1.63	(0.02 - 4.55)	-*
Roebourne (S)	0	-	-	-	-	.	3	7.9	(0.0 - 17.1)	0.88	(0.07 - 2.04)	-*

Cancer type: Breast 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	0	-	-	-	-	.	1	5.1	(0.0 - 15.2)	0.34	(0.00 - 1.25)	-*
Exmouth (S)	0	-	-	-	-	.	1	11.3	(0.0 - 33.5)	1.14	(0.00 - 4.22)	-*
Shark Bay (S)	0	-	-	-	-	.	1	48.8	(0.0 - 143.8)	1.95	(0.00 - 7.19)	-*
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
East Pilbara HD												
East Pilbara (S)	0	-	-	-	-	.	2	27.3	(0.0 - 70.8)	1.39	(0.02 - 3.88)	-*
Port Hedland (T)	0	-	-	-	-	.	2	14.7	(0.0 - 35.3)	0.62	(0.01 - 1.73)	-*
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	0	-	-	-	-	.	0	-	-	-	-	.
Chapman Valley (S)	0	-	-	-	-	.	2	70.7	(0.0 - 173.8)	4.61	(0.06 - 12.85)	-*
Coorow (S)	0	-	-	-	-	.	1	24.8	(0.0 - 73.3)	1.48	(0.00 - 5.46)	-*
Irwin (S)	0	-	-	-	-	.	3	30.8	(0.0 - 65.7)	1.72	(0.14 - 4.02)	-*
Mingenew (S)	0	-	-	-	-	.	0	-	-	-	-	.
Morawa (S)	0	-	-	-	-	.	1	13.5	(0.0 - 39.6)	1.99	(0.00 - 7.35)	-*
Mullewa (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northampton (S)	0	-	-	-	-	.	1	7.4	(0.0 - 21.7)	0.51	(0.00 - 1.87)	-*
Perenjori (S)	0	-	-	-	-	.	0	-	-	-	-	.
Three Springs (S)	0	-	-	-	-	.	0	-	-	-	-	.
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murchison HD												
Cue (S)	0	-	-	-	-	.	0	-	-	-	-	.
Meekatharra (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mount Magnet (S)	0	-	-	-	-	.	0	-	-	-	-	.
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	0	-	-	-	-	.	0	-	-	-	-	.
Geraldton HD												
Geraldton (C)	0	-	-	-	-	.	21	26.7	(14.3 - 39.1)	1.67	(0.97 - 2.46)	-
Greenough (S) - Pt A	0	-	-	-	-	.	4	15.0	(0.0 - 29.9)	0.96	(0.15 - 2.11)	-*
Greenough (S) - Pt B	0	-	-	-	-	.	1	27.0	(0.0 - 79.9)	1.83	(0.00 - 6.74)	-*
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Bruce Rock (S)	0	-	-	-	-	.	1	29.9	(0.0 - 88.1)	1.32	(0.00 - 4.85)	-*
Corrigin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Cunderdin (S)	0	-	-	-	-	.	2	32.8	(0.0 - 85.6)	2.38	(0.03 - 6.63)	-*
Quairading (S)	0	-	-	-	-	.	1	32.0	(0.0 - 94.5)	1.24	(0.00 - 4.56)	-*
Tammin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Upper Great Southern HD												
Boddington (S)	0	-	-	-	-	.	1	28.1	(0.0 - 83.0)	1.60	(0.00 - 5.90)	-*
Brookton (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Cuballing (S)	0	-	-	-	-	.	0	-	-	-	-	.
Dumbleyung (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kondinin (S)	0	-	-	-	-	.	1	48.4	(0.0 - 142.5)	2.23	(0.00 - 8.23)	-*
Kulin (S)	0	-	-	-	-	.	1	28.4	(0.0 - 84.0)	1.94	(0.00 - 7.15)	-*
Lake Grace (S)	0	-	-	-	-	.	1	20.4	(0.0 - 60.0)	1.35	(0.00 - 5.00)	-*
Narrogin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Narrogin (T)	0	-	-	-	-	.	4	22.9	(0.0 - 49.4)	1.55	(0.24 - 3.39)	-*
Pingelly (S)	0	-	-	-	-	.	1	21.4	(0.0 - 63.2)	1.12	(0.00 - 4.14)	-*
Wagin (S)	0	-	-	-	-	.	1	4.2	(0.0 - 12.5)	0.72	(0.00 - 2.65)	-*
Wandering (S)	0	-	-	-	-	.	1	83.3	(0.0 - 232.4)	5.68	(0.00 - 20.96)	-*
West Arthur (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Wickepin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Williams (S)	0	-	-	-	-	.	1	47.6	(0.0 - 139.8)	1.95	(0.00 - 7.18)	-*
Western HD												
Chittering (S)	0	-	-	-	-	.	1	9.4	(0.0 - 28.0)	0.69	(0.00 - 2.55)	-*
Dalwallinu (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Dandaragan (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Dowerin (S)	0	-	-	-	-	.	1	29.4	(0.0 - 85.3)	2.04	(0.00 - 7.53)	-*
Gingin (S)	0	-	-	-	-	.	1	6.4	(0.0 - 18.9)	0.40	(0.00 - 1.47)	-*
Goomalling (S)	0	-	-	-	-	.	1	15.4	(0.0 - 45.3)	1.57	(0.00 - 5.79)	-*
Moora (S)	0	-	-	-	-	.	0	-	-	0	n/a	-

Cancer type: Breast 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wongan-Ballidu (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Eastern Wheatbelt HD												
Kellerberrin (S)	0	-	-	-	-	.	2	10.6	(0.0 - 25.2)	2.12	(0.03 - 5.90)	-*
Koorda (S)	0	-	-	-	-	.	0	-	-	-	-	.
Merredin (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Mount Marshall (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mukinbudin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Narembeen (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Nungarin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Trayning (S)	0	-	-	-	-	.	0	-	-	-	-	.
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	0	-	-	-	-	.	1	54.1	(0.0 - 158.6)	2.30	(0.00 - 8.48)	-*
Yilgam (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Avon HD												
Northam (S)	0	-	-	-	-	.	2	18.4	(0.0 - 43.9)	1.07	(0.01 - 2.99)	-*
Northam (T)	0	-	-	-	-	.	6	21.2	(1.4 - 41.0)	1.31	(0.36 - 2.56)	-
Toodyay (S)	0	-	-	-	-	.	7	49.8	(12.3 - 87.4)	3.17	(1.00 - 5.90)	-*
York (S)	0	-	-	-	-	.	2	10.1	(0.0 - 25.2)	0.88	(0.01 - 2.46)	-*
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	0	-	-	-	-	.	1	14.7	(0.0 - 43.5)	0.94	(0.00 - 3.48)	-*
Kalgoorlie/Boulder (C) - Pt A	0	-	-	-	-	.	14	24.9	(11.1 - 38.7)	1.42	(0.70 - 2.26)	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	-	-	.	0	-	-	-	-	.
Laverton (S)	0	-	-	-	-	.	0	-	-	-	-	.
Leonora (S)	0	-	-	-	-	.	0	-	-	-	-	.
Menzies (S)	0	-	-	-	-	.	0	-	-	-	-	.
Ngaanyatjarraku (S)	0	-	-	-	-	.	0	-	-	-	-	.
South East Coastal HD												
Dundas (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Esperance (S)	0	-	-	-	-	.	6	13.8	(2.6 - 24.9)	0.87	(0.24 - 1.69)	-
Ravensthorpe (S)	0	-	-	-	-	.	1	20.6	(0.0 - 60.8)	1.28	(0.00 - 4.72)	-*
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	0	-	-	-	-	.	7	8.0	(0.8 - 15.2)	0.49	(0.15 - 0.92)	V
Albany (C) Bal	0	-	-	-	-	.	8	18.0	(5.3 - 30.6)	1.11	(0.39 - 2.01)	-
Cranbrook (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Denmark (S)	0	-	-	-	-	.	3	15.6	(0.0 - 33.9)	0.98	(0.08 - 2.28)	-*
Jerramungup (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Plantagenet (S)	0	-	-	-	-	.	1	2.6	(0.0 - 7.7)	0.35	(0.00 - 1.30)	-*
Central Great Southern HD												
Broomehill (S)	0	-	-	-	-	.	0	-	-	-	-	.
Gnowangerup (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Katanning (S)	0	-	-	-	-	.	2	6.4	(0.0 - 15.4)	0.78	(0.01 - 2.17)	-*
Kent (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kojonup (S)	0	-	-	-	-	.	2	12.3	(0.0 - 29.5)	1.44	(0.02 - 4.01)	-*
Tambellup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Woodanilling (S)	0	-	-	-	-	.	0	-	-	-	-	.
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	0	-	-	-	-	.	4	12.2	(0.0 - 24.4)	0.74	(0.11 - 1.63)	-
Busselton (S)	0	-	-	-	-	.	12	14.3	(5.7 - 23.0)	0.79	(0.36 - 1.29)	-
Warren-Blackwood HD												
Boyup Brook (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Bridgetown-Greenbushes (S)	0	-	-	-	-	.	4	22.8	(0.1 - 45.5)	1.55	(0.24 - 3.40)	-*
Manjimup (S)	0	-	-	-	-	.	4	11.7	(0.0 - 23.6)	0.71	(0.11 - 1.57)	-
Nannup (S)	0	-	-	-	-	.	0	-	-	0	n/a	-
Bunbury HD												
Bunbury (C)	0	-	-	-	-	.	21	18.5	(9.9 - 27.1)	1.08	(0.63 - 1.58)	-
Capel (S) - Pt A	0	-	-	-	-	.	1	21.7	(0.0 - 64.2)	0.91	(0.00 - 3.37)	-*
Capel (S) - Pt B	0	-	-	-	-	.	1	6.6	(0.0 - 19.6)	0.47	(0.00 - 1.72)	-*
Dardanup (S) - Pt A	1	6.1	(0.0 - 18.2)	98.35	(0.00 - 362.82)	-*	0	-	-	0	n/a	-
Dardanup (S) - Pt B	0	-	-	-	-	.	1	10.5	(0.0 - 31.0)	0.91	(0.00 - 3.35)	-*
Wellington HD												

Cancer type: Breast 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	0	-	-	-	-	.	4	12.1	(0.0 - 25.1)	0.76	(0.12 - 1.66)	-
Donnybrook-Balingup (S)	0	-	-	-	-	.	3	19.4	(0.0 - 41.5)	1.13	(0.09 - 2.64)	-*
Harvey-Yarloop HD												
Harvey (S) - Pt A	0	-	-	-	-	.	9	35.0	(11.7 - 58.3)	2.06	(0.79 - 3.61)	-*
Harvey (S) - Pt B	0	-	-	-	-	.	5	12.5	(0.2 - 24.7)	1.07	(0.23 - 2.20)	-
Total State	4	0.1	(0.0 - 0.1)	1.00	(0.15 - 2.19)	-*	1115	15.9	(14.9 - 16.8)	1.00	(0.94 - 1.06)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (DOH Areas)
Cancer type: Colorectal cancer 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	16	15.1	(7.1 - 23.1)	0.82	(0.43 - 1.26)	-	25	20.6	(10.8 - 30.4)	1.36	(0.84 - 1.95)	-
Claremont (T)	8	21.3	(5.4 - 37.2)	1.02	(0.36 - 1.84)	-	6	15.2	(2.0 - 28.5)	0.64	(0.17 - 1.24)	-
Cottesloe (T)	12	40.6	(16.2 - 65.0)	2.14	(0.98 - 3.51)	-	3	2.7	(0.0 - 5.8)	0.56	(0.04 - 1.30)	-
Joondalup (C) - North	16	15.7	(7.9 - 23.6)	0.94	(0.49 - 1.45)	-	15	13.5	(6.4 - 20.6)	1.16	(0.59 - 1.81)	-
Joondalup (C) - South	41	12.2	(8.3 - 16.1)	0.72	(0.50 - 0.95)	V	39	10.5	(7.0 - 14.0)	0.93	(0.64 - 1.24)	-
Mosman Park (T)	5	13.5	(1.1 - 25.8)	0.81	(0.18 - 1.66)	-	7	4.8	(1.2 - 8.3)	1.12	(0.35 - 2.09)	-
Nedlands (C)	14	8.4	(3.9 - 12.8)	0.82	(0.40 - 1.30)	-	31	17.1	(9.1 - 25.1)	1.65	(1.08 - 2.28)	^
Peppermint Grove (S)	0	-	-	0	n/a	-	1	5.4	(0.0 - 15.9)	1.04	(0.00 - 3.85)	-*
Stirling (C) - Central	80	19.9	(15.4 - 24.5)	1.12	(0.89 - 1.40)	-	50	9.2	(6.4 - 12.1)	0.84	(0.61 - 1.09)	-
Stirling (C) - Coastal	37	14.5	(9.6 - 19.5)	0.84	(0.57 - 1.13)	-	35	11.3	(7.1 - 15.5)	0.89	(0.60 - 1.20)	-
Subiaco (C)	7	15.0	(3.3 - 26.6)	0.76	(0.24 - 1.41)	-	9	7.3	(1.8 - 12.9)	0.96	(0.37 - 1.69)	-
Wanneroo (C) - North-East	13	20.3	(9.1 - 31.6)	1.22	(0.58 - 1.97)	-	6	7.4	(1.0 - 13.8)	0.74	(0.20 - 1.44)	-
Wanneroo (C) - North-West	12	17.3	(7.3 - 27.4)	0.98	(0.45 - 1.61)	-	6	8.2	(1.5 - 15.0)	0.77	(0.21 - 1.49)	-
Wanneroo (C) - South	14	17.9	(8.4 - 27.4)	0.96	(0.47 - 1.52)	-	6	5.9	(1.1 - 10.7)	0.53	(0.14 - 1.03)	-
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	31	23.5	(14.7 - 32.4)	1.31	(0.86 - 1.82)	-	19	12.1	(5.8 - 18.5)	0.97	(0.54 - 1.45)	-
Canning (C)	31	13.1	(8.4 - 17.8)	0.72	(0.47 - 0.99)	V	36	9.8	(6.4 - 13.2)	0.99	(0.67 - 1.33)	-
South Perth (C)	21	14.3	(7.6 - 21.0)	0.79	(0.46 - 1.16)	-	32	12.7	(7.1 - 18.2)	1.11	(0.73 - 1.52)	-
Victoria Park (T)	27	19.1	(10.4 - 27.8)	1.20	(0.76 - 1.70)	-	29	13.9	(6.2 - 21.6)	1.09	(0.70 - 1.52)	-
Inner City HD												
Perth (C) - Inner	1	21.5	(0.0 - 63.5)	1.98	(0.00 - 7.32)	-*	0	-	-	-	-	.
Perth (C) - Remainder	12	40.8	(16.5 - 65.2)	2.24	(1.02 - 3.67)	^	4	13.0	(0.0 - 27.8)	1.30	(0.20 - 2.84)	-*
Stirling (C) - South-Eastern	17	20.5	(8.8 - 32.2)	1.27	(0.69 - 1.95)	-	12	8.6	(1.6 - 15.6)	0.79	(0.36 - 1.29)	-
Vincent (T)	19	17.3	(8.7 - 25.8)	1.03	(0.58 - 1.54)	-	15	10.8	(4.2 - 17.5)	0.89	(0.46 - 1.40)	-
Kalamunda HD												
Kalamunda (S)	25	15.3	(9.2 - 21.3)	0.84	(0.52 - 1.20)	-	26	13.3	(7.9 - 18.7)	1.13	(0.70 - 1.60)	-
Swan HD												
Bassendean (T)	6	8.9	(1.6 - 16.1)	0.61	(0.16 - 1.19)	-	8	9.5	(2.4 - 16.5)	0.97	(0.34 - 1.74)	-
Bayswater (C)	35	15.0	(9.8 - 20.2)	0.84	(0.56 - 1.14)	-	30	10.6	(6.2 - 14.9)	0.85	(0.55 - 1.18)	-
Mundaring (S)	21	20.3	(11.5 - 29.1)	1.04	(0.61 - 1.53)	-	12	8.4	(3.4 - 13.5)	0.79	(0.36 - 1.29)	-
Swan (C)	35	16.4	(10.8 - 21.9)	0.94	(0.63 - 1.27)	-	35	14.7	(9.6 - 19.9)	1.25	(0.84 - 1.69)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	15	8.9	(4.4 - 13.5)	0.53	(0.27 - 0.83)	V	23	12.8	(7.3 - 18.3)	1.06	(0.64 - 1.54)	-
Gosnells (C)	50	24.1	(17.3 - 30.9)	1.26	(0.91 - 1.63)	-	23	8.4	(4.8 - 11.9)	0.75	(0.45 - 1.09)	-
Serpentine-Jarrahdale (S)	5	16.0	(1.6 - 30.5)	0.85	(0.19 - 1.75)	-	3	8.2	(0.0 - 17.7)	0.81	(0.07 - 1.90)	-*
Fremantle HD												
Cockburn (C)	35	19.6	(13.0 - 26.2)	1.02	(0.69 - 1.39)	-	34	15.5	(10.1 - 20.9)	1.31	(0.88 - 1.79)	-
East Fremantle (T)	6	19.8	(3.2 - 36.4)	1.19	(0.32 - 2.32)	-	1	1.9	(0.0 - 5.7)	0.23	(0.00 - 0.83)	V*
Fremantle (C) - Inner	0	-	-	0	n/a	-	0	-	-	-	-	.
Fremantle (C) - Remainder	22	22.2	(12.6 - 31.8)	1.11	(0.66 - 1.62)	-	19	15.2	(7.5 - 22.8)	1.12	(0.63 - 1.67)	-
Melville (C)	74	19.2	(14.6 - 23.8)	1.04	(0.82 - 1.31)	-	76	13.0	(9.6 - 16.4)	1.21	(0.96 - 1.52)	-
Rockingham-Kwinana HD												
Kwinana (T)	9	12.9	(4.4 - 21.5)	0.78	(0.30 - 1.36)	-	11	15.7	(6.1 - 25.2)	1.37	(0.60 - 2.28)	-
Rockingham (C)	52	20.5	(14.7 - 26.2)	1.12	(0.85 - 1.49)	-	44	14.8	(10.2 - 19.4)	1.29	(0.91 - 1.69)	-
Peel HD												
Mandurah (C)	53	21.6	(15.3 - 27.9)	1.18	(0.89 - 1.56)	-	26	9.0	(5.3 - 12.6)	0.83	(0.51 - 1.17)	-
Murray (S)	8	13.3	(4.0 - 22.7)	0.84	(0.30 - 1.52)	-	4	9.4	(0.0 - 18.8)	0.74	(0.11 - 1.62)	-
Waroona (S)	4	27.1	(0.1 - 54.2)	1.57	(0.24 - 3.45)	-*	5	34.2	(2.8 - 65.6)	2.86	(0.62 - 5.87)	-*
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	2	11.6	(0.0 - 27.8)	0.50	(0.01 - 1.40)	-*	0	-	-	0	n/a	-
Derby-West Kimberley (S)	1	7.4	(0.0 - 21.8)	0.36	(0.00 - 1.34)	-*	2	8.0	(0.0 - 19.1)	1.22	(0.02 - 3.41)	-*
Halls Creek (S)	1	12.3	(0.0 - 36.4)	0.79	(0.00 - 2.90)	-*	1	15.2	(0.0 - 44.6)	1.26	(0.00 - 4.65)	-*
Wyndham-East Kimberley (S)	0	-	-	0	n/a	-	1	13.7	(0.0 - 40.5)	0.85	(0.00 - 3.12)	-*
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	1	7.9	(0.0 - 23.4)	0.73	(0.00 - 2.68)	-*	0	-	-	0	n/a	-
Roebourne (S)	1	1.6	(0.0 - 4.7)	0.31	(0.00 - 1.14)	-*	0	-	-	0	n/a	-

Cancer type: Colorectal cancer 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	7	31.5	(7.9 - 55.1)	1.74	(0.55 - 3.24)	-*	1	7.0	(0.0 - 20.7)	0.45	(0.00 - 1.66)	-*
Exmouth (S)	1	13.0	(0.0 - 38.6)	0.92	(0.00 - 3.41)	-*	1	13.2	(0.0 - 38.6)	1.70	(0.00 - 6.25)	-*
Shark Bay (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
East Pilbara HD												
East Pilbara (S)	1	17.8	(0.0 - 52.4)	0.60	(0.00 - 2.20)	-*	0	-	-	0	n/a	-
Port Hedland (T)	1	2.3	(0.0 - 6.9)	0.28	(0.00 - 1.03)	-*	0	-	-	0	n/a	-
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	0	-	-	-	-	.	0	-	-	-	-	.
Chapman Valley (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Coorow (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Irwin (S)	2	14.0	(0.0 - 33.6)	0.81	(0.01 - 2.26)	-*	2	16.7	(0.0 - 40.0)	1.48	(0.02 - 4.11)	-*
Mingenew (S)	0	-	-	-	-	.	0	-	-	-	-	.
Morawa (S)	1	32.3	(0.0 - 95.2)	1.37	(0.00 - 5.04)	-*	0	-	-	-	-	.
Mullewa (S)	0	-	-	0	n/a	-	1	90.9	(0.0 - 265.0)	3.27	(0.00 - 12.05)	-*
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northampton (S)	3	23.4	(0.0 - 51.0)	1.13	(0.09 - 2.64)	-*	2	13.5	(0.0 - 32.1)	1.30	(0.02 - 3.63)	-*
Perenjori (S)	1	43.0	(0.0 - 126.9)	3.20	(0.00 - 11.81)	-*	0	-	-	-	-	.
Three Springs (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murchison HD												
Cue (S)	0	-	-	-	-	.	0	-	-	-	-	.
Meekatharra (S)	1	42.6	(0.0 - 125.1)	1.75	(0.00 - 6.46)	-*	0	-	-	-	-	.
Mount Magnet (S)	0	-	-	-	-	.	0	-	-	-	-	.
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	0	-	-	-	-	.	0	-	-	-	-	.
Geraldton HD												
Geraldton (C)	13	18.8	(8.3 - 29.2)	0.97	(0.46 - 1.56)	-	5	4.0	(0.2 - 7.8)	0.45	(0.10 - 0.93)	V
Greenough (S) - Pt A	7	29.4	(7.6 - 51.2)	1.60	(0.50 - 2.99)	-*	2	10.5	(0.0 - 25.1)	0.77	(0.01 - 2.15)	-*
Greenough (S) - Pt B	1	20.2	(0.0 - 59.6)	1.28	(0.00 - 4.74)	-*	0	-	-	-	-	.
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	0	-	-	0	n/a	-	1	5.9	(0.0 - 17.3)	0.97	(0.00 - 3.56)	-*
Bruce Rock (S)	1	25.4	(0.0 - 75.0)	1.11	(0.00 - 4.09)	-*	2	29.7	(0.0 - 72.2)	3.15	(0.04 - 8.77)	-*
Corrigin (S)	0	-	-	0	n/a	-	3	54.8	(0.0 - 120.8)	3.69	(0.30 - 8.61)	-*
Cunderdin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Quairading (S)	2	47.0	(0.0 - 112.0)	2.46	(0.03 - 6.85)	-*	0	-	-	0	n/a	-
Tammin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Upper Great Southern HD												
Boddington (S)	1	21.7	(0.0 - 63.4)	1.30	(0.00 - 4.79)	-*	0	-	-	-	-	.
Brookton (S)	1	14.9	(0.0 - 44.0)	0.97	(0.00 - 3.59)	-*	3	34.5	(0.0 - 74.0)	4.86	(0.39 - 11.35)	-*
Cuballing (S)	0	-	-	-	-	.	0	-	-	-	-	.
Dumbleyung (S)	1	22.7	(0.0 - 66.2)	1.77	(0.00 - 6.52)	-*	0	-	-	-	-	.
Kondinin (S)	1	33.3	(0.0 - 98.1)	1.71	(0.00 - 6.32)	-*	0	-	-	-	-	.
Kulin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Lake Grace (S)	0	-	-	0	n/a	-	1	20.1	(0.0 - 59.4)	1.93	(0.00 - 7.12)	-*
Narrogin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Narrogin (T)	2	11.1	(0.0 - 27.4)	0.76	(0.01 - 2.13)	-*	1	2.2	(0.0 - 6.4)	0.42	(0.00 - 1.54)	-*
Pingelly (S)	3	57.2	(0.0 - 121.9)	2.83	(0.23 - 6.60)	-*	0	-	-	0	n/a	-
Wagin (S)	0	-	-	0	n/a	-	1	9.9	(0.0 - 29.1)	0.79	(0.00 - 2.92)	-*
Wandering (S)	0	-	-	-	-	.	0	-	-	-	-	.
West Arthur (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wickepin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Williams (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Western HD												
Chittering (S)	5	41.5	(5.1 - 77.9)	2.60	(0.57 - 5.33)	-*	0	-	-	0	n/a	-
Dalwallinu (S)	1	15.0	(0.0 - 44.4)	0.90	(0.00 - 3.33)	-*	0	-	-	0	n/a	-
Dandaragan (S)	3	20.3	(0.0 - 43.2)	1.33	(0.11 - 3.09)	-*	0	-	-	0	n/a	-
Dowerin (S)	1	47.6	(0.0 - 140.2)	1.95	(0.00 - 7.21)	-*	0	-	-	-	-	.
Gingin (S)	8	48.5	(13.4 - 83.7)	2.48	(0.87 - 4.47)	-*	2	12.1	(0.0 - 28.9)	1.05	(0.01 - 2.91)	-*
Goomalling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Moora (S)	1	9.3	(0.0 - 27.2)	0.68	(0.00 - 2.52)	-*	1	20.6	(0.0 - 60.9)	0.91	(0.00 - 3.37)	-*

Cancer type: Colorectal cancer 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Wongan-Ballidu (S)	1	19.6	(0.0 - 57.9)	1.24	(0.00 - 4.56)	-*	0	-	-	0	n/a	-
Eastern Wheatbelt HD												
Kellerberrin (S)	3	58.3	(0.0 - 124.0)	2.63	(0.21 - 6.14)	-*	3	37.9	(0.0 - 86.3)	3.41	(0.28 - 7.97)	-*
Koorda (S)	0	-	-	-	-	-	0	-	-	-	-	-
Merredin (S)	2	13.2	(0.0 - 31.9)	0.87	(0.01 - 2.43)	-*	3	28.4	(0.0 - 60.8)	1.87	(0.15 - 4.37)	-*
Mount Marshall (S)	0	-	-	-	-	-	0	-	-	-	-	-
Mukinbudin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Narembeen (S)	2	60.8	(0.0 - 145.0)	2.82	(0.04 - 7.87)	-*	0	-	-	0	n/a	-
Nungarin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Trayning (S)	1	22.7	(0.0 - 66.8)	2.91	(0.00 - 10.75)	-*	0	-	-	-	-	-
Westonia (S)	0	-	-	-	-	-	0	-	-	-	-	-
Wyalkatchem (S)	1	32.6	(0.0 - 96.2)	1.76	(0.00 - 6.50)	-*	1	12.5	(0.0 - 36.7)	2.79	(0.00 - 10.30)	-*
Yilgam (S)	1	18.9	(0.0 - 55.7)	1.10	(0.00 - 4.05)	-*	0	-	-	0	n/a	-
Avon HD												
Northam (S)	4	42.5	(0.0 - 88.5)	1.74	(0.27 - 3.81)	-*	0	-	-	0	n/a	-
Northam (T)	8	26.8	(7.0 - 46.6)	1.70	(0.60 - 3.07)	-	6	13.6	(0.0 - 27.3)	1.45	(0.39 - 2.82)	-*
Toodyay (S)	4	28.2	(0.2 - 56.3)	1.50	(0.23 - 3.28)	-*	2	15.8	(0.0 - 38.2)	1.31	(0.02 - 3.64)	-*
York (S)	4	23.1	(0.0 - 46.8)	1.47	(0.23 - 3.22)	-*	1	8.4	(0.0 - 24.8)	0.53	(0.00 - 1.95)	-*
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	1	24.6	(0.0 - 72.6)	0.86	(0.00 - 3.16)	-*	0	-	-	0	n/a	-
Kalgoorlie/Boulder (C) - Pt A	15	29.6	(14.1 - 45.0)	1.55	(0.79 - 2.42)	-	8	17.2	(4.4 - 29.9)	1.10	(0.39 - 1.98)	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	-	-	-	0	-	-	-	-	-
Laverton (S)	0	-	-	-	-	-	1	46.5	(0.0 - 137.3)	5.87	(0.00 - 21.65)	-*
Leonora (S)	1	57.1	(0.0 - 167.5)	1.33	(0.00 - 4.89)	-*	1	33.3	(0.0 - 96.5)	4.01	(0.00 - 14.78)	-*
Menzies (S)	0	-	-	-	-	-	0	-	-	-	-	-
Ngaanyatjarraku (S)	0	-	-	-	-	-	0	-	-	-	-	-
South East Coastal HD												
Dundas (S)	1	26.3	(0.0 - 76.5)	1.34	(0.00 - 4.96)	-*	0	-	-	-	-	-
Esperance (S)	14	33.8	(15.9 - 51.6)	1.80	(0.89 - 2.85)	-	6	12.5	(1.9 - 23.1)	1.09	(0.30 - 2.12)	-
Ravensthorpe (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	21	29.2	(15.1 - 43.3)	1.42	(0.83 - 2.09)	-	18	16.3	(6.8 - 25.9)	1.32	(0.73 - 2.00)	-
Albany (C) Bal	4	8.3	(0.1 - 16.5)	0.43	(0.07 - 0.95)	V	4	10.8	(0.1 - 21.5)	0.79	(0.12 - 1.72)	-
Cranbrook (S)	1	21.2	(0.0 - 62.6)	1.15	(0.00 - 4.23)	-*	0	-	-	-	-	-
Denmark (S)	1	3.4	(0.0 - 10.2)	0.25	(0.00 - 0.94)	V*	4	19.3	(0.0 - 39.1)	1.60	(0.25 - 3.51)	-*
Jerramungup (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Plantagenet (S)	5	29.6	(3.7 - 55.6)	1.48	(0.32 - 3.03)	-*	2	10.1	(0.0 - 25.1)	0.86	(0.01 - 2.41)	-*
Central Great Southern HD												
Broomehill (S)	1	59.7	(0.0 - 175.8)	3.21	(0.00 - 11.83)	-*	0	-	-	-	-	-
Gnowangerup (S)	2	51.8	(0.0 - 123.4)	2.12	(0.03 - 5.90)	-*	1	12.0	(0.0 - 35.5)	1.50	(0.00 - 5.55)	-*
Katanning (S)	3	15.5	(0.0 - 34.3)	1.12	(0.09 - 2.62)	-*	1	2.7	(0.0 - 8.1)	0.46	(0.00 - 1.71)	-*
Kent (S)	0	-	-	-	-	-	0	-	-	-	-	-
Kojonup (S)	2	28.5	(0.0 - 67.8)	1.17	(0.01 - 3.26)	-*	4	39.5	(0.0 - 80.8)	3.40	(0.53 - 7.46)	-*
Tambellup (S)	0	-	-	-	-	-	0	-	-	-	-	-
Woodanilling (S)	0	-	-	-	-	-	0	-	-	-	-	-
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	7	19.5	(3.8 - 35.2)	1.08	(0.34 - 2.02)	-	3	10.2	(0.0 - 21.9)	0.67	(0.05 - 1.58)	-*
Busselton (S)	16	16.8	(8.2 - 25.5)	0.95	(0.50 - 1.47)	-	15	14.3	(6.4 - 22.3)	1.13	(0.57 - 1.76)	-
Warren-Blackwood HD												
Boyup Brook (S)	0	-	-	0	n/a	-	2	21.1	(0.0 - 54.3)	1.89	(0.02 - 5.27)	-*
Bridgetown-Greenbushes (S)	0	-	-	0	n/a	-	2	11.3	(0.0 - 27.5)	1.00	(0.01 - 2.79)	-*
Manjimup (S)	7	18.9	(4.7 - 33.1)	1.02	(0.32 - 1.91)	-	6	14.1	(1.7 - 26.4)	1.32	(0.36 - 2.56)	-
Nannup (S)	2	34.7	(0.0 - 82.7)	2.40	(0.03 - 6.67)	-*	0	-	-	0	n/a	-
Bunbury HD												
Bunbury (C)	18	14.8	(7.4 - 22.1)	0.88	(0.48 - 1.33)	-	15	11.2	(4.5 - 17.9)	0.87	(0.44 - 1.36)	-
Capel (S) - Pt A	2	18.8	(0.0 - 44.7)	1.89	(0.02 - 5.25)	-*	0	-	-	0	n/a	-
Capel (S) - Pt B	2	14.7	(0.0 - 35.3)	0.76	(0.01 - 2.11)	-*	2	16.7	(0.0 - 39.7)	1.30	(0.02 - 3.62)	-*
Dardanup (S) - Pt A	5	32.4	(3.7 - 61.0)	1.88	(0.41 - 3.85)	-*	0	-	-	0	n/a	-
Dardanup (S) - Pt B	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Wellington HD												

Cancer type: Colorectal cancer 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	8	19.5	(5.4 - 33.5)	1.29	(0.45 - 2.32)	-	3	7.1	(0.0 - 15.3)	0.69	(0.06 - 1.60)	-*
Donnybrook-Balingup (S)	4	21.6	(0.3 - 43.0)	1.34	(0.21 - 2.94)	-*	3	14.4	(0.0 - 31.1)	1.49	(0.12 - 3.49)	-*
Harvey-Yarloop HD												
Harvey (S) - Pt A	7	23.7	(5.6 - 41.9)	1.45	(0.46 - 2.71)	-	2	8.9	(0.0 - 21.3)	0.65	(0.01 - 1.82)	-*
Harvey (S) - Pt B	4	14.3	(0.0 - 28.6)	0.74	(0.11 - 1.61)	-	3	11.0	(0.0 - 23.8)	0.78	(0.06 - 1.82)	-*
Total State	1159	18.0	(16.9 - 19.1)	1.00	(0.94 - 1.06)	-	929	11.5	(10.6 - 12.3)	1.00	(0.94 - 1.07)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (DOH Areas)

Cancer type: Prostate gland 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	18	11.6	(6.1 - 17.1)	0.98	(0.54 - 1.48)	-	0	-	-	-	-	.
Claremont (T)	9	15.3	(4.6 - 26.1)	1.18	(0.45 - 2.08)	-	0	-	-	-	-	.
Cottesloe (T)	4	7.7	(0.1 - 15.3)	0.80	(0.12 - 1.76)	-	0	-	-	-	-	.
Joondalup (C) - North	11	10.6	(4.3 - 16.9)	0.97	(0.42 - 1.62)	-	0	-	-	-	-	.
Joondalup (C) - South	41	12.4	(8.4 - 16.4)	0.97	(0.68 - 1.29)	-	0	-	-	-	-	.
Mosman Park (T)	6	15.9	(2.5 - 29.4)	1.08	(0.29 - 2.09)	-	0	-	-	-	-	.
Nedlands (C)	14	8.8	(3.7 - 13.8)	0.83	(0.41 - 1.31)	-	0	-	-	-	-	.
Peppermint Grove (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Stirling (C) - Central	49	10.4	(7.4 - 13.4)	0.82	(0.59 - 1.06)	-	0	-	-	-	-	.
Stirling (C) - Coastal	44	14.8	(10.3 - 19.3)	1.15	(0.82 - 1.52)	-	0	-	-	-	-	.
Subiaco (C)	6	9.6	(1.6 - 17.6)	0.74	(0.20 - 1.44)	-	0	-	-	-	-	.
Wanneroo (C) - North-East	10	19.3	(7.2 - 31.4)	1.23	(0.51 - 2.11)	-	0	-	-	-	-	.
Wanneroo (C) - North-West	9	12.8	(4.0 - 21.5)	0.98	(0.38 - 1.72)	-	0	-	-	-	-	.
Wanneroo (C) - South	7	8.1	(2.1 - 14.2)	0.70	(0.22 - 1.31)	-	0	-	-	-	-	.
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	17	13.0	(6.5 - 19.6)	0.84	(0.45 - 1.28)	-	0	-	-	-	-	.
Canning (C)	37	14.7	(9.8 - 19.5)	1.10	(0.75 - 1.48)	-	0	-	-	-	-	.
South Perth (C)	25	13.3	(7.4 - 19.2)	0.98	(0.60 - 1.39)	-	0	-	-	-	-	.
Victoria Park (T)	27	16.1	(8.5 - 23.7)	1.15	(0.72 - 1.62)	-	0	-	-	-	-	.
Inner City HD												
Perth (C) - Inner	0	-	-	-	-	.	0	-	-	-	-	.
Perth (C) - Remainder	9	27.6	(8.6 - 46.5)	1.90	(0.73 - 3.33)	-	0	-	-	-	-	.
Stirling (C) - South-Eastern	18	13.2	(6.8 - 19.5)	1.28	(0.71 - 1.94)	-	0	-	-	-	-	.
Vincent (T)	13	9.6	(4.2 - 15.0)	0.77	(0.37 - 1.23)	-	0	-	-	-	-	.
Kalamunda HD												
Kalamunda (S)	26	15.6	(9.5 - 21.7)	1.16	(0.72 - 1.64)	-	0	-	-	-	-	.
Swan HD												
Bassendean (T)	6	10.3	(1.9 - 18.6)	0.73	(0.20 - 1.43)	-	0	-	-	-	-	.
Bayswater (C)	23	9.6	(5.5 - 13.7)	0.64	(0.38 - 0.92)	V	0	-	-	-	-	.
Mundaring (S)	11	9.1	(3.6 - 14.6)	0.73	(0.32 - 1.22)	-	0	-	-	-	-	.
Swan (C)	27	12.9	(8.0 - 17.9)	0.98	(0.61 - 1.38)	-	0	-	-	-	-	.
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	17	10.0	(5.2 - 14.9)	0.80	(0.43 - 1.22)	-	0	-	-	-	-	.
Gosnells (C)	23	9.7	(5.7 - 13.8)	0.79	(0.47 - 1.14)	-	0	-	-	-	-	.
Serpentine-Jarrahdale (S)	2	6.5	(0.0 - 15.4)	0.52	(0.01 - 1.44)	-*	0	-	-	-	-	.
Fremantle HD												
Cockburn (C)	25	13.1	(7.9 - 18.4)	1.01	(0.62 - 1.44)	-	0	-	-	-	-	.
East Fremantle (T)	3	9.7	(0.0 - 21.4)	0.65	(0.05 - 1.52)	-	0	-	-	-	-	.
Fremantle (C) - Inner	0	-	-	0	n/a	-	0	-	-	-	-	.
Fremantle (C) - Remainder	20	15.7	(8.7 - 22.7)	1.18	(0.67 - 1.75)	-	0	-	-	-	-	.
Melville (C)	61	12.2	(8.9 - 15.4)	0.98	(0.75 - 1.26)	-	0	-	-	-	-	.
Rockingham-Kwinana HD												
Kwinana (T)	6	8.1	(1.5 - 14.7)	0.71	(0.19 - 1.39)	-	0	-	-	-	-	.
Rockingham (C)	34	11.7	(7.6 - 15.7)	0.91	(0.61 - 1.24)	-	0	-	-	-	-	.
Peel HD												
Mandurah (C)	47	16.0	(11.2 - 20.8)	1.23	(0.88 - 1.60)	-	0	-	-	-	-	.
Murray (S)	6	10.1	(1.9 - 18.2)	0.84	(0.23 - 1.64)	-	0	-	-	-	-	.
Waroona (S)	3	18.8	(0.0 - 39.9)	1.49	(0.12 - 3.48)	-*	0	-	-	-	-	.
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	2	11.3	(0.0 - 27.1)	0.83	(0.01 - 2.31)	-*	0	-	-	-	-	.
Derby-West Kimberley (S)	1	8.3	(0.0 - 24.6)	0.49	(0.00 - 1.81)	-*	0	-	-	-	-	.
Halls Creek (S)	1	21.3	(0.0 - 62.8)	1.02	(0.00 - 3.77)	-*	0	-	-	-	-	.
Wyndham-East Kimberley (S)	3	20.5	(0.0 - 45.0)	2.01	(0.16 - 4.69)	-*	0	-	-	-	-	.
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Roebourne (S)	0	-	-	0	n/a	-	0	-	-	-	-	.

Cancer type: Prostate gland 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	6	23.2	(4.5 - 41.9)	1.94	(0.52 - 3.77)	-*	0	-	-	-	-	.
Exmouth (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Shark Bay (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
East Pilbara HD												
East Pilbara (S)	1	21.7	(0.0 - 64.1)	1.08	(0.00 - 4.00)	-*	0	-	-	-	-	.
Port Hedland (T)	2	14.0	(0.0 - 33.6)	0.98	(0.01 - 2.73)	-*	0	-	-	-	-	.
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	0	-	-	-	-	.	0	-	-	-	-	.
Chapman Valley (S)	0	-	-	-	-	.	0	-	-	-	-	.
Coorow (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Irwin (S)	3	21.8	(0.0 - 47.6)	1.59	(0.13 - 3.72)	-*	0	-	-	-	-	.
Mingenew (S)	0	-	-	-	-	.	0	-	-	-	-	.
Morawa (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mullewa (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northampton (S)	1	6.9	(0.0 - 20.5)	0.48	(0.00 - 1.79)	-*	0	-	-	-	-	.
Perenjori (S)	0	-	-	-	-	.	0	-	-	-	-	.
Three Springs (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murchison HD												
Cue (S)	0	-	-	-	-	.	0	-	-	-	-	.
Meekatharra (S)	1	41.7	(0.0 - 119.9)	3.14	(0.00 - 11.59)	-*	0	-	-	-	-	.
Mount Magnet (S)	0	-	-	-	-	.	0	-	-	-	-	.
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	0	-	-	-	-	.	0	-	-	-	-	.
Geraldton HD												
Geraldton (C)	13	15.5	(7.0 - 24.0)	1.17	(0.56 - 1.89)	-	0	-	-	-	-	.
Greenough (S) - Pt A	1	4.5	(0.0 - 13.3)	0.37	(0.00 - 1.37)	-*	0	-	-	-	-	.
Greenough (S) - Pt B	2	44.9	(0.0 - 107.2)	3.50	(0.04 - 9.76)	-*	0	-	-	-	-	.
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	1	9.3	(0.0 - 27.6)	0.76	(0.00 - 2.82)	-*	0	-	-	-	-	.
Bruce Rock (S)	2	29.3	(0.0 - 70.0)	2.56	(0.03 - 7.14)	-*	0	-	-	-	-	.
Corrigin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Cunderdin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Quairading (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Tammin (S)	1	87.0	(0.0 - 253.6)	4.07	(0.00 - 15.00)	-*	0	-	-	-	-	.
Upper Great Southern HD												
Boddington (S)	1	35.7	(0.0 - 105.1)	1.61	(0.00 - 5.94)	-*	0	-	-	-	-	.
Brookton (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Cuballing (S)	0	-	-	-	-	.	0	-	-	-	-	.
Dumbleyung (S)	2	52.6	(0.0 - 123.6)	4.49	(0.06 - 12.50)	-*	0	-	-	-	-	.
Kondinin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kulin (S)	1	20.0	(0.0 - 58.4)	1.98	(0.00 - 7.30)	-*	0	-	-	-	-	.
Lake Grace (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Narrogin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Narrogin (T)	7	35.6	(8.1 - 63.2)	2.88	(0.90 - 5.36)	-*	0	-	-	-	-	.
Pingelly (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wagin (S)	1	8.8	(0.0 - 25.8)	0.68	(0.00 - 2.51)	-*	0	-	-	-	-	.
Wandering (S)	0	-	-	-	-	.	0	-	-	-	-	.
West Arthur (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Wickepin (S)	1	17.9	(0.0 - 52.2)	1.97	(0.00 - 7.27)	-*	0	-	-	-	-	.
Williams (S)	0	-	-	-	-	.	0	-	-	-	-	.
Western HD												
Chittering (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Dalwallinu (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Dandaragan (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Dowerin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Gingin (S)	4	23.3	(0.3 - 46.3)	1.91	(0.30 - 4.18)	-*	0	-	-	-	-	.
Goomalling (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Moora (S)	2	16.4	(0.0 - 38.9)	1.66	(0.02 - 4.61)	-*	0	-	-	-	-	.

Cancer type: Prostate gland 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	3	62.9	(0.0 - 136.3)	4.37	(0.35 - 10.19)	-*	0	-	-	-	-	-
Wongan-Ballidu (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Eastern Wheatbelt HD												
Kellerberrin (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Koorda (S)	1	50.0	(0.0 - 143.0)	4.41	(0.00 - 16.27)	-*	0	-	-	-	-	-
Merredin (S)	1	11.5	(0.0 - 34.1)	0.53	(0.00 - 1.97)	-*	0	-	-	-	-	-
Mount Marshall (S)	0	-	-	-	-	-	0	-	-	-	-	-
Mukinbudin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Narembeen (S)	2	37.4	(0.0 - 89.6)	3.40	(0.04 - 9.48)	-*	0	-	-	-	-	-
Nungarin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Trayning (S)	0	-	-	-	-	-	0	-	-	-	-	-
Westonia (S)	0	-	-	-	-	-	0	-	-	-	-	-
Wyalkatchem (S)	1	22.7	(0.0 - 66.8)	2.28	(0.00 - 8.42)	-*	0	-	-	-	-	-
Yilgam (S)	1	16.7	(0.0 - 49.1)	1.65	(0.00 - 6.08)	-*	0	-	-	-	-	-
Avon HD												
Northam (S)	2	14.6	(0.0 - 34.8)	1.34	(0.02 - 3.72)	-*	0	-	-	-	-	-
Northam (T)	6	16.5	(2.9 - 30.1)	1.47	(0.40 - 2.86)	-*	0	-	-	-	-	-
Toodyay (S)	1	6.6	(0.0 - 19.6)	0.57	(0.00 - 2.12)	-*	0	-	-	-	-	-
York (S)	5	30.8	(3.6 - 58.0)	2.16	(0.47 - 4.43)	-*	0	-	-	-	-	-
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Kalgoorlie/Boulder (C) - Pt A	5	9.4	(0.8 - 18.0)	0.77	(0.17 - 1.58)	-	0	-	-	-	-	-
Kalgoorlie/Boulder (C) - Pt B	1	222.2	(0.0 - 632.9)	6.39	(0.00 - 23.57)	-*	0	-	-	-	-	-
Laverton (S)	0	-	-	-	-	-	0	-	-	-	-	-
Leonora (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Menzies (S)	0	-	-	-	-	-	0	-	-	-	-	-
Ngaanyatjarraku (S)	0	-	-	-	-	-	0	-	-	-	-	-
South East Coastal HD												
Dundas (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Esperance (S)	9	19.4	(6.6 - 32.3)	1.49	(0.57 - 2.61)	-	0	-	-	-	-	-
Ravensthorpe (S)	2	29.6	(0.0 - 70.4)	2.66	(0.03 - 7.42)	-*	0	-	-	-	-	-
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	9	9.8	(2.7 - 17.0)	0.63	(0.24 - 1.11)	-	0	-	-	-	-	-
Albany (C) Bal	6	14.3	(2.9 - 25.8)	0.88	(0.24 - 1.70)	-	0	-	-	-	-	-
Cranbrook (S)	1	14.7	(0.0 - 43.3)	1.36	(0.00 - 5.03)	-*	0	-	-	-	-	-
Denmark (S)	6	22.1	(4.1 - 40.0)	1.83	(0.50 - 3.57)	-*	0	-	-	-	-	-
Jerramungup (S)	1	71.4	(0.0 - 201.0)	1.99	(0.00 - 7.33)	-*	0	-	-	-	-	-
Plantagenet (S)	5	27.7	(3.4 - 52.1)	1.94	(0.42 - 3.98)	-*	0	-	-	-	-	-
Central Great Southern HD												
Broomehill (S)	1	50.0	(0.0 - 143.0)	4.00	(0.00 - 14.74)	-*	0	-	-	-	-	-
Gnowangerup (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Katanning (S)	4	18.7	(0.1 - 37.2)	1.79	(0.28 - 3.91)	-*	0	-	-	-	-	-
Kent (S)	0	-	-	-	-	-	0	-	-	-	-	-
Kojonup (S)	3	20.3	(0.0 - 43.5)	2.09	(0.17 - 4.88)	-*	0	-	-	-	-	-
Tambellup (S)	0	-	-	-	-	-	0	-	-	-	-	-
Woodanilling (S)	0	-	-	-	-	-	0	-	-	-	-	-
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	7	15.4	(2.9 - 27.9)	1.25	(0.39 - 2.33)	-	0	-	-	-	-	-
Busselton (S)	18	15.0	(7.7 - 22.3)	1.24	(0.68 - 1.87)	-	0	-	-	-	-	-
Warren-Blackwood HD												
Boyup Brook (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Bridgetown-Greenbushes (S)	1	4.9	(0.0 - 14.6)	0.47	(0.00 - 1.74)	-*	0	-	-	-	-	-
Manjimup (S)	9	17.5	(6.0 - 29.0)	1.59	(0.61 - 2.79)	-	0	-	-	-	-	-
Nannup (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Bunbury HD												
Bunbury (C)	26	18.1	(10.8 - 25.3)	1.41	(0.88 - 2.01)	-	0	-	-	-	-	-
Capel (S) - Pt A	0	-	-	0	n/a	-	0	-	-	-	-	-
Capel (S) - Pt B	5	30.1	(3.7 - 56.6)	2.50	(0.55 - 5.13)	-*	0	-	-	-	-	-
Dardanup (S) - Pt A	2	16.0	(0.0 - 38.2)	1.05	(0.01 - 2.93)	-*	0	-	-	-	-	-
Dardanup (S) - Pt B	1	14.6	(0.0 - 43.2)	0.93	(0.00 - 3.42)	-*	0	-	-	-	-	-
Wellington HD												

Cancer type: Prostate gland 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	8	22.8	(6.5 - 39.1)	1.51	(0.53 - 2.72)	-	0	-	-	-	-	-
Donnybrook-Balingup (S)	5	29.2	(3.5 - 54.8)	2.23	(0.49 - 4.57)	-*	0	-	-	-	-	-
Harvey-Yarloop HD												
Harvey (S) - Pt A	2	5.7	(0.0 - 13.6)	0.57	(0.01 - 1.60)	-*	0	-	-	-	-	-
Harvey (S) - Pt B	10	31.8	(11.8 - 51.7)	2.30	(0.95 - 3.93)	-*	0	-	-	-	-	-
Total State	945	13.0	(12.2 - 13.9)	1.00	(0.94 - 1.07)	-	0	-	-	-	-	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates; "[^]" Significant excess of cases; "^v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (DOH Areas)
Cancer type: Melanoma (skin) 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	6	6.6	(1.1 - 12.2)	1.48	(0.40 - 2.87)	-*	2	1.5	(0.0 - 3.9)	0.74	(0.01 - 2.07)	-*
Claremont (T)	3	3.9	(0.0 - 8.3)	1.87	(0.15 - 4.36)	-*	3	9.1	(0.0 - 21.6)	2.31	(0.19 - 5.39)	-*
Cottesloe (T)	4	12.1	(0.0 - 24.3)	3.39	(0.52 - 7.43)	-*	1	5.0	(0.0 - 14.8)	1.25	(0.00 - 4.62)	-*
Joondalup (C) - North	1	0.9	(0.0 - 2.6)	0.26	(0.00 - 0.94)	V*	1	0.7	(0.0 - 2.1)	0.41	(0.00 - 1.53)	-*
Joondalup (C) - South	10	3.1	(1.1 - 5.2)	0.80	(0.33 - 1.36)	-	9	2.6	(0.8 - 4.4)	1.25	(0.48 - 2.20)	-
Mosman Park (T)	5	17.0	(1.7 - 32.3)	3.87	(0.84 - 7.93)	-*	1	1.3	(0.0 - 3.8)	1.11	(0.00 - 4.09)	-*
Nedlands (C)	4	5.1	(0.0 - 10.4)	1.13	(0.17 - 2.47)	-*	1	0.2	(0.0 - 0.6)	0.38	(0.00 - 1.39)	-*
Peppermint Grove (S)	0	-	-	-	-	.	0	-	-	-	-	.
Stirling (C) - Central	13	3.4	(1.5 - 5.4)	0.88	(0.42 - 1.41)	-	5	1.2	(0.1 - 2.4)	0.55	(0.12 - 1.12)	-
Stirling (C) - Coastal	11	4.2	(1.6 - 6.8)	1.19	(0.52 - 1.99)	-	9	3.2	(0.9 - 5.6)	1.51	(0.58 - 2.64)	-
Subiaco (C)	0	-	-	0	n/a	-	3	3.8	(0.0 - 9.3)	2.10	(0.17 - 4.90)	-*
Wanneroo (C) - North-East	3	5.2	(0.0 - 11.2)	1.30	(0.11 - 3.04)	-*	1	2.2	(0.0 - 6.5)	0.74	(0.00 - 2.75)	-*
Wanneroo (C) - North-West	3	4.0	(0.0 - 8.7)	1.14	(0.09 - 2.67)	-*	1	1.7	(0.0 - 4.9)	0.72	(0.00 - 2.65)	-*
Wanneroo (C) - South	2	2.0	(0.0 - 4.7)	0.61	(0.01 - 1.70)	-*	1	1.0	(0.0 - 3.0)	0.50	(0.00 - 1.83)	-*
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	6	5.2	(0.9 - 9.6)	1.24	(0.34 - 2.41)	-	2	1.5	(0.0 - 3.6)	0.68	(0.01 - 1.89)	-*
Canning (C)	3	1.5	(0.0 - 3.2)	0.33	(0.03 - 0.76)	V	4	1.1	(0.0 - 2.3)	0.69	(0.11 - 1.50)	-
South Perth (C)	8	5.7	(1.2 - 10.2)	1.42	(0.50 - 2.55)	-	2	1.1	(0.0 - 2.8)	0.48	(0.01 - 1.34)	-*
Victoria Park (T)	4	3.6	(0.0 - 7.9)	0.85	(0.13 - 1.86)	-	9	4.5	(0.3 - 8.7)	2.47	(0.95 - 4.33)	-*
Inner City HD												
Perth (C) - Inner	1	100.0	(0.0 - 275.3)	8.92	(0.00 - 32.92)	-*	0	-	-	-	-	.
Perth (C) - Remainder	2	5.9	(0.0 - 14.3)	1.75	(0.02 - 4.88)	-*	1	6.6	(0.0 - 19.5)	2.09	(0.00 - 7.71)	-*
Stirling (C) - South-Eastern	0	-	-	0	n/a	-	4	2.6	(0.0 - 6.1)	1.89	(0.29 - 4.15)	-*
Vincent (T)	4	3.1	(0.0 - 6.4)	1.01	(0.16 - 2.21)	-*	1	0.4	(0.0 - 1.3)	0.40	(0.00 - 1.47)	-*
Kalamunda HD												
Kalamunda (S)	11	7.0	(2.7 - 11.3)	1.76	(0.77 - 2.95)	-	6	2.8	(0.3 - 5.2)	1.61	(0.43 - 3.12)	-*
Swan HD												
Bassendean (T)	4	5.2	(0.0 - 10.4)	1.95	(0.30 - 4.28)	-*	2	4.4	(0.0 - 10.5)	1.57	(0.02 - 4.36)	-*
Bayswater (C)	7	3.7	(0.9 - 6.5)	0.80	(0.25 - 1.49)	-	5	2.0	(0.1 - 3.9)	0.94	(0.20 - 1.92)	-
Mundaring (S)	4	3.3	(0.0 - 6.5)	0.93	(0.14 - 2.04)	-*	1	0.8	(0.0 - 2.3)	0.39	(0.00 - 1.45)	-*
Swan (C)	9	4.3	(1.4 - 7.2)	1.09	(0.42 - 1.91)	-	4	1.9	(0.0 - 3.8)	0.82	(0.13 - 1.79)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	7	4.3	(1.1 - 7.5)	1.15	(0.36 - 2.15)	-	6	3.7	(0.7 - 6.8)	1.67	(0.45 - 3.25)	-*
Gosnells (C)	5	2.3	(0.2 - 4.3)	0.57	(0.12 - 1.17)	-	5	1.9	(0.2 - 3.6)	0.96	(0.21 - 1.97)	-
Serpentine-Jarrahdale (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Fremantle HD												
Cockburn (C)	6	3.1	(0.6 - 5.7)	0.81	(0.22 - 1.57)	-	9	4.2	(1.4 - 6.9)	2.05	(0.79 - 3.59)	-*
East Fremantle (T)	1	2.2	(0.0 - 6.4)	0.95	(0.00 - 3.50)	-*	1	1.1	(0.0 - 3.1)	1.50	(0.00 - 5.53)	-*
Fremantle (C) - Inner	0	-	-	-	-	.	0	-	-	-	-	.
Fremantle (C) - Remainder	3	2.2	(0.0 - 4.8)	0.73	(0.06 - 1.71)	-*	0	-	-	0	n/a	-
Melville (C)	16	4.0	(1.9 - 6.0)	1.08	(0.57 - 1.68)	-	7	1.3	(0.1 - 2.5)	0.74	(0.23 - 1.38)	-
Rockingham-Kwinana HD												
Kwinana (T)	1	1.2	(0.0 - 3.4)	0.40	(0.00 - 1.49)	-*	0	-	-	0	n/a	-
Rockingham (C)	9	3.9	(1.3 - 6.4)	0.94	(0.36 - 1.64)	-	10	3.4	(1.2 - 5.7)	1.83	(0.76 - 3.13)	-
Peel HD												
Mandurah (C)	8	2.9	(0.8 - 5.0)	0.90	(0.32 - 1.62)	-	3	1.1	(0.0 - 2.4)	0.64	(0.05 - 1.50)	-
Murray (S)	2	8.5	(0.0 - 21.8)	1.06	(0.01 - 2.96)	-*	2	4.6	(0.0 - 11.4)	2.32	(0.03 - 6.46)	-*
Waroona (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	2	5.4	(0.0 - 13.0)	2.08	(0.03 - 5.79)	-*	0	-	-	-	-	.
Derby-West Kimberley (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Halls Creek (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyndham-East Kimberley (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	0	-	-	-	-	.	1	5.1	(0.0 - 15.1)	5.76	(0.00 - 21.24)	-*
Roebourne (S)	0	-	-	0	n/a	-	0	-	-	-	-	.

Cancer type: Melanoma (skin) 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Exmouth (S)	1	19.4	(0.0 - 57.4)	4.12	(0.00 - 15.19)	-*	0	-	-	-	-	-
Shark Bay (S)	0	-	-	-	-	-	0	-	-	-	-	-
Upper Gascoyne (S)	0	-	-	-	-	-	0	-	-	-	-	-
East Pilbara HD												
East Pilbara (S)	0	-	-	-	-	-	0	-	-	-	-	-
Port Hedland (T)	0	-	-	0	n/a	-	1	2.6	(0.0 - 7.7)	2.34	(0.00 - 8.61)	-*
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	0	-	-	-	-	-	1	71.4	(0.0 - 201.0)	24.09	(0.00 - 88.85)	-*
Chapman Valley (S)	0	-	-	-	-	-	0	-	-	-	-	-
Coorow (S)	0	-	-	-	-	-	0	-	-	-	-	-
Irwin (S)	1	6.2	(0.0 - 18.3)	2.02	(0.00 - 7.44)	-*	0	-	-	-	-	-
Mingenew (S)	0	-	-	-	-	-	0	-	-	-	-	-
Morawa (S)	0	-	-	-	-	-	0	-	-	-	-	-
Mullewa (S)	0	-	-	-	-	-	0	-	-	-	-	-
Murchison (S)	0	-	-	-	-	-	0	-	-	-	-	-
Northampton (S)	1	8.9	(0.0 - 26.2)	1.85	(0.00 - 6.82)	-*	0	-	-	-	-	-
Perenjori (S)	0	-	-	-	-	-	0	-	-	-	-	-
Three Springs (S)	0	-	-	-	-	-	0	-	-	-	-	-
Yalgoo (S)	0	-	-	-	-	-	0	-	-	-	-	-
Murchison HD												
Cue (S)	0	-	-	-	-	-	0	-	-	-	-	-
Meekatharra (S)	0	-	-	-	-	-	0	-	-	-	-	-
Mount Magnet (S)	0	-	-	-	-	-	0	-	-	-	-	-
Sandstone (S)	0	-	-	-	-	-	0	-	-	-	-	-
Wiluna (S)	0	-	-	-	-	-	0	-	-	-	-	-
Geraldton HD												
Geraldton (C)	10	12.8	(4.6 - 21.0)	3.63	(1.49 - 6.20)	^*	1	1.5	(0.0 - 4.4)	0.59	(0.00 - 2.19)	-*
Greenough (S) - Pt A	1	7.6	(0.0 - 22.3)	1.02	(0.00 - 3.76)	-*	0	-	-	0	n/a	-
Greenough (S) - Pt B	0	-	-	-	-	-	0	-	-	-	-	-
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	1	12.3	(0.0 - 36.5)	3.19	(0.00 - 11.76)	-*	0	-	-	-	-	-
Bruce Rock (S)	0	-	-	-	-	-	0	-	-	-	-	-
Corrigin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Cunderdin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Quairading (S)	0	-	-	-	-	-	0	-	-	-	-	-
Tammin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Upper Great Southern HD												
Boddington (S)	1	11.6	(0.0 - 34.2)	5.83	(0.00 - 21.52)	-*	0	-	-	-	-	-
Brookton (S)	0	-	-	-	-	-	0	-	-	-	-	-
Cuballing (S)	0	-	-	-	-	-	0	-	-	-	-	-
Dumbleyung (S)	1	29.9	(0.0 - 87.9)	8.49	(0.00 - 31.30)	-*	0	-	-	-	-	-
Kondinin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Kulin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Lake Grace (S)	0	-	-	-	-	-	0	-	-	-	-	-
Narrogin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Narrogin (T)	1	7.6	(0.0 - 22.4)	1.83	(0.00 - 6.73)	-*	0	-	-	-	-	-
Pingelly (S)	0	-	-	-	-	-	0	-	-	-	-	-
Wagin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Wandering (S)	0	-	-	-	-	-	0	-	-	-	-	-
West Arthur (S)	0	-	-	-	-	-	0	-	-	-	-	-
Wickepin (S)	0	-	-	-	-	-	0	-	-	-	-	-
Williams (S)	0	-	-	-	-	-	0	-	-	-	-	-
Western HD												
Chittering (S)	1	9.6	(0.0 - 28.3)	2.56	(0.00 - 9.46)	-*	0	-	-	-	-	-
Dalwallinu (S)	0	-	-	-	-	-	0	-	-	-	-	-
Dandaragan (S)	1	6.3	(0.0 - 18.5)	2.17	(0.00 - 7.99)	-*	1	10.9	(0.0 - 32.2)	5.17	(0.00 - 19.07)	-*
Dowerin (S)	1	42.6	(0.0 - 125.1)	9.09	(0.00 - 33.53)	-*	0	-	-	-	-	-
Gingin (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Goomalling (S)	0	-	-	-	-	-	0	-	-	-	-	-
Moora (S)	0	-	-	-	-	-	0	-	-	-	-	-

Cancer type: Melanoma (skin) 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wongan-Ballidu (S)	0	-	-	-	-	.	0	-	-	-	-	.
Eastern Wheatbelt HD												
Kellerberrin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Koorda (S)	0	-	-	-	-	.	0	-	-	-	-	.
Merredin (S)	0	-	-	-	-	.	1	10.0	(0.0 - 29.6)	3.87	(0.00 - 14.29)	-*
Mount Marshall (S)	0	-	-	-	-	.	0	-	-	-	-	.
Mukinbudin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Narembeen (S)	0	-	-	-	-	.	0	-	-	-	-	.
Nungarin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Trayning (S)	0	-	-	-	-	.	0	-	-	-	-	.
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	1	22.7	(0.0 - 66.8)	8.68	(0.00 - 32.01)	-*	0	-	-	-	-	.
Yilgam (S)	0	-	-	-	-	.	0	-	-	-	-	.
Avon HD												
Northam (S)	1	7.0	(0.0 - 20.6)	2.13	(0.00 - 7.85)	-*	1	8.4	(0.0 - 24.9)	4.41	(0.00 - 16.29)	-*
Northam (T)	3	10.5	(0.0 - 24.1)	3.10	(0.25 - 7.24)	-*	1	1.3	(0.0 - 3.9)	1.63	(0.00 - 6.02)	-*
Toodyay (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
York (S)	1	8.8	(0.0 - 25.9)	1.82	(0.00 - 6.70)	-*	2	13.8	(0.0 - 33.3)	6.81	(0.09 - 18.97)	-*
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	2	40.9	(0.0 - 98.6)	6.41	(0.08 - 17.86)	-*	0	-	-	-	-	.
Kalgoorlie/Boulder (C) - Pt A	2	3.6	(0.0 - 8.6)	0.84	(0.01 - 2.34)	-*	0	-	-	0	n/a	-
Kalgoorlie/Boulder (C) - Pt B	0	-	-	-	-	.	0	-	-	-	-	.
Laverton (S)	0	-	-	-	-	.	0	-	-	-	-	.
Leonora (S)	0	-	-	-	-	.	0	-	-	-	-	.
Menzies (S)	0	-	-	-	-	.	0	-	-	-	-	.
Ngaanyatjarraku (S)	0	-	-	-	-	.	0	-	-	-	-	.
South East Coastal HD												
Dundas (S)	0	-	-	-	-	.	0	-	-	-	-	.
Esperance (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Ravensthorpe (S)	0	-	-	-	-	.	0	-	-	-	-	.
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	4	5.6	(0.0 - 11.9)	1.34	(0.21 - 2.93)	-*	3	4.1	(0.0 - 9.4)	1.54	(0.12 - 3.59)	-*
Albany (C) Bal	2	4.0	(0.0 - 9.5)	1.04	(0.01 - 2.90)	-*	1	2.3	(0.0 - 6.7)	1.13	(0.00 - 4.15)	-*
Cranbrook (S)	0	-	-	-	-	.	0	-	-	-	-	.
Denmark (S)	1	4.6	(0.0 - 13.7)	1.26	(0.00 - 4.66)	-*	1	3.1	(0.0 - 9.0)	2.52	(0.00 - 9.31)	-*
Jerramungup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Plantagenet (S)	0	-	-	0	n/a	-	1	3.2	(0.0 - 9.3)	2.73	(0.00 - 10.06)	-*
Central Great Southern HD												
Broomehill (S)	0	-	-	-	-	.	0	-	-	-	-	.
Gnowangerup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Katanning (S)	2	17.1	(0.0 - 41.2)	3.51	(0.04 - 9.79)	-*	1	2.7	(0.0 - 8.1)	2.95	(0.00 - 10.88)	-*
Kent (S)	0	-	-	-	-	.	0	-	-	-	-	.
Kojonup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Tambellup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Woodanilling (S)	0	-	-	-	-	.	0	-	-	-	-	.
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	1	1.5	(0.0 - 4.5)	0.73	(0.00 - 2.68)	-*	1	1.3	(0.0 - 3.7)	1.39	(0.00 - 5.13)	-*
Busselton (S)	3	3.3	(0.0 - 7.1)	0.87	(0.07 - 2.03)	-*	3	4.0	(0.0 - 8.6)	1.49	(0.12 - 3.47)	-*
Warren-Blackwood HD												
Boyup Brook (S)	0	-	-	-	-	.	0	-	-	-	-	.
Bridgetown-Greenbushes (S)	1	4.9	(0.0 - 14.6)	1.69	(0.00 - 6.24)	-*	0	-	-	-	-	.
Manjimup (S)	2	5.3	(0.0 - 12.8)	1.40	(0.02 - 3.89)	-*	0	-	-	0	n/a	-
Nannup (S)	0	-	-	-	-	.	0	-	-	-	-	.
Bunbury HD												
Bunbury (C)	5	6.0	(0.7 - 11.3)	1.16	(0.25 - 2.38)	-*	2	1.5	(0.0 - 3.9)	0.77	(0.01 - 2.13)	-*
Capel (S) - Pt A	1	15.9	(0.0 - 46.9)	4.21	(0.00 - 15.54)	-*	0	-	-	-	-	.
Capel (S) - Pt B	0	-	-	0	n/a	-	0	-	-	-	-	.
Dardanup (S) - Pt A	1	5.1	(0.0 - 15.1)	1.70	(0.00 - 6.27)	-*	1	3.7	(0.0 - 10.9)	3.05	(0.00 - 11.24)	-*
Dardanup (S) - Pt B	0	-	-	-	-	.	0	-	-	-	-	.
Wellington HD												

Cancer type: Melanoma (skin) 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Donnybrook-Balingup (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Harvey-Yarloop HD												
Harvey (S) - Pt A	1	2.6	(0.0 - 7.8)	0.95	(0.00 - 3.52)	-*	0	-	-	0	n/a	-
Harvey (S) - Pt B	2	7.5	(0.0 - 17.8)	1.77	(0.02 - 4.93)	-*	1	3.9	(0.0 - 11.5)	1.64	(0.00 - 6.06)	-*
Total State	246	3.8	(3.3 - 4.3)	1.00	(0.88 - 1.14)	-	147	2.0	(1.7 - 2.4)	1.00	(0.85 - 1.18)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (DOH Areas)

Cancer type: Lung, bronchus & trachea 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	25	17.2	(9.9 - 24.5)	0.68	(0.42 - 0.98)	V	17	11.8	(5.0 - 18.5)	0.86	(0.46 - 1.32)	-
Claremont (T)	13	27.0	(9.8 - 44.1)	0.90	(0.43 - 1.45)	-	8	7.7	(1.2 - 14.2)	0.85	(0.30 - 1.54)	-
Cottesloe (T)	5	15.4	(0.8 - 30.0)	0.49	(0.11 - 1.00)	-	4	3.7	(0.1 - 7.2)	0.68	(0.10 - 1.48)	-
Joondalup (C) - North	30	32.7	(20.6 - 44.8)	0.96	(0.62 - 1.33)	-	21	21.4	(11.9 - 30.9)	1.37	(0.80 - 2.01)	-
Joondalup (C) - South	87	27.5	(21.4 - 33.5)	0.83	(0.67 - 1.02)	-	42	11.5	(7.8 - 15.2)	0.84	(0.59 - 1.12)	-
Mosman Park (T)	13	39.5	(16.5 - 62.4)	1.13	(0.54 - 1.83)	-	1	0.6	(0.0 - 1.8)	0.16	(0.00 - 0.57)	V
Nedlands (C)	19	16.8	(8.4 - 25.3)	0.61	(0.34 - 0.92)	V	14	8.1	(2.4 - 13.8)	0.74	(0.36 - 1.17)	-
Peppermint Grove (S)	2	34.5	(0.0 - 81.9)	0.84	(0.01 - 2.35)	-*	1	5.4	(0.0 - 15.9)	0.92	(0.00 - 3.38)	-*
Stirling (C) - Central	153	37.7	(31.5 - 44.0)	1.12	(0.96 - 1.32)	-	61	12.6	(9.2 - 16.0)	0.88	(0.68 - 1.13)	-
Stirling (C) - Coastal	58	22.4	(16.4 - 28.5)	0.70	(0.53 - 0.91)	V	43	13.7	(9.2 - 18.1)	0.96	(0.68 - 1.27)	-
Subiaco (C)	22	41.8	(23.1 - 60.5)	1.31	(0.77 - 1.91)	-	12	17.2	(6.2 - 28.2)	1.20	(0.55 - 1.97)	-
Wanneroo (C) - North-East	30	51.4	(32.6 - 70.3)	1.53	(0.99 - 2.12)	-	13	19.9	(8.6 - 31.2)	1.39	(0.66 - 2.24)	-
Wanneroo (C) - North-West	14	21.7	(10.0 - 33.5)	0.60	(0.30 - 0.95)	V	14	18.0	(8.2 - 27.7)	1.45	(0.72 - 2.30)	-
Wanneroo (C) - South	32	39.2	(25.5 - 52.8)	1.18	(0.78 - 1.63)	-	13	13.6	(6.1 - 21.1)	0.98	(0.47 - 1.58)	-
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	64	44.3	(32.7 - 55.9)	1.42	(1.10 - 1.83)	^	20	10.2	(5.1 - 15.3)	0.88	(0.51 - 1.31)	-
Canning (C)	95	39.1	(31.0 - 47.1)	1.18	(0.96 - 1.45)	-	43	13.3	(9.1 - 17.6)	1.01	(0.71 - 1.34)	-
South Perth (C)	38	24.1	(15.5 - 32.7)	0.78	(0.53 - 1.04)	-	26	11.3	(5.9 - 16.8)	0.86	(0.53 - 1.22)	-
Victoria Park (T)	50	44.2	(29.8 - 58.6)	1.21	(0.88 - 1.57)	-	30	18.9	(9.8 - 28.1)	1.14	(0.74 - 1.58)	-
Inner City HD												
Perth (C) - Inner	3	180.1	(0.0 - 386.9)	3.26	(0.26 - 7.60)	-*	0	-	-	-	-	-
Perth (C) - Remainder	11	41.8	(16.8 - 66.8)	1.12	(0.49 - 1.86)	-	2	8.9	(0.0 - 22.6)	0.58	(0.01 - 1.61)	-*
Stirling (C) - South-Eastern	31	42.9	(25.4 - 60.4)	1.27	(0.83 - 1.76)	-	12	9.0	(2.3 - 15.7)	0.80	(0.36 - 1.31)	-
Vincent (T)	45	44.2	(29.9 - 58.5)	1.31	(0.93 - 1.72)	-	13	8.1	(3.1 - 13.2)	0.72	(0.34 - 1.16)	-
Kalamunda HD												
Kalamunda (S)	47	28.3	(20.1 - 36.6)	0.85	(0.61 - 1.11)	-	19	10.2	(5.4 - 15.0)	0.71	(0.40 - 1.07)	-
Swan HD												
Bassendean (T)	26	48.0	(29.0 - 67.0)	1.39	(0.87 - 1.98)	-	12	19.3	(7.5 - 31.1)	1.24	(0.57 - 2.04)	-
Bayswater (C)	81	33.2	(25.6 - 40.7)	1.03	(0.82 - 1.29)	-	37	10.7	(6.8 - 14.7)	0.94	(0.64 - 1.27)	-
Mundaring (S)	25	21.5	(12.9 - 30.2)	0.67	(0.41 - 0.95)	V	14	9.3	(4.2 - 14.3)	0.79	(0.39 - 1.25)	-
Swan (C)	84	41.5	(32.5 - 50.5)	1.21	(0.97 - 1.51)	-	33	14.4	(9.3 - 19.5)	1.01	(0.67 - 1.38)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	53	33.8	(24.6 - 43.0)	1.00	(0.76 - 1.32)	-	34	17.5	(11.3 - 23.6)	1.33	(0.89 - 1.82)	-
Gosnells (C)	75	34.8	(26.8 - 42.8)	1.02	(0.81 - 1.28)	-	27	10.1	(6.2 - 14.1)	0.75	(0.47 - 1.06)	-
Serpentine-Jarrahdale (S)	11	33.7	(13.6 - 53.8)	1.01	(0.44 - 1.69)	-	3	8.8	(0.0 - 19.0)	0.68	(0.06 - 1.60)	-*
Fremantle HD												
Cockburn (C)	69	36.5	(27.8 - 45.2)	1.08	(0.85 - 1.38)	-	40	19.3	(13.1 - 25.5)	1.31	(0.91 - 1.75)	-
East Fremantle (T)	7	22.6	(4.6 - 40.6)	0.76	(0.24 - 1.41)	-	2	2.3	(0.0 - 5.4)	0.42	(0.01 - 1.16)	-
Fremantle (C) - Inner	0	-	-	0	n/a	-	1	74.1	(0.0 - 216.5)	3.21	(0.00 - 11.85)	-*
Fremantle (C) - Remainder	45	41.8	(29.0 - 54.6)	1.20	(0.85 - 1.58)	-	21	16.8	(8.8 - 24.8)	1.11	(0.65 - 1.63)	-
Melville (C)	121	30.2	(24.5 - 35.9)	0.90	(0.75 - 1.09)	-	60	11.6	(8.3 - 14.9)	0.84	(0.64 - 1.08)	-
Rockingham-Kwinana HD												
Kwinana (T)	32	50.1	(32.3 - 67.8)	1.47	(0.97 - 2.02)	-	15	18.9	(9.0 - 28.7)	1.55	(0.79 - 2.42)	-
Rockingham (C)	96	36.6	(29.1 - 44.2)	1.09	(0.89 - 1.34)	-	41	13.7	(9.3 - 18.1)	1.01	(0.71 - 1.34)	-
Peel HD												
Mandurah (C)	73	28.3	(21.4 - 35.3)	0.84	(0.66 - 1.06)	-	48	17.5	(12.1 - 23.0)	1.28	(0.92 - 1.67)	-
Murray (S)	15	26.1	(12.7 - 39.5)	0.82	(0.42 - 1.28)	-	16	33.2	(16.8 - 49.7)	2.45	(1.29 - 3.79)	^
Waroona (S)	1	6.0	(0.0 - 17.7)	0.21	(0.00 - 0.77)	V	0	-	-	0	n/a	-
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	2	7.8	(0.0 - 18.8)	0.28	(0.00 - 0.78)	V	2	8.9	(0.0 - 21.4)	0.77	(0.01 - 2.13)	-*
Derby-West Kimberley (S)	9	65.5	(22.4 - 108.6)	1.81	(0.70 - 3.17)	-	3	28.3	(0.0 - 60.8)	1.66	(0.13 - 3.88)	-*
Halls Creek (S)	1	15.6	(0.0 - 46.2)	0.44	(0.00 - 1.61)	-*	0	-	-	0	n/a	-
Wyndham-East Kimberley (S)	5	34.3	(3.0 - 65.6)	1.23	(0.27 - 2.52)	-*	0	-	-	0	n/a	-
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	1	26.3	(0.0 - 77.7)	0.44	(0.00 - 1.62)	-*	1	5.5	(0.0 - 16.2)	1.39	(0.00 - 5.14)	-*
Roebourne (S)	9	56.4	(13.1 - 99.8)	1.68	(0.64 - 2.94)	-	3	27.2	(0.0 - 62.1)	1.50	(0.12 - 3.49)	-*

Cancer type: Lung, bronchus & trachea 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	6	29.4	(5.7 - 53.2)	0.79	(0.21 - 1.54)	-	4	20.8	(0.0 - 41.9)	1.54	(0.24 - 3.37)	-*
Exmouth (S)	2	28.7	(0.0 - 68.8)	1.00	(0.01 - 2.78)	-*	0	-	-	0	n/a	-
Shark Bay (S)	1	24.8	(0.0 - 73.4)	0.63	(0.00 - 2.33)	-*	0	-	-	-	-	.
Upper Gascoyne (S)	0	-	-	-	-	.	0	-	-	-	-	.
East Pilbara HD												
East Pilbara (S)	3	36.4	(0.0 - 82.7)	1.07	(0.09 - 2.51)	-*	0	-	-	0	n/a	-
Port Hedland (T)	7	34.2	(5.8 - 62.5)	1.15	(0.36 - 2.14)	-	1	5.9	(0.0 - 17.3)	0.47	(0.00 - 1.73)	-*
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	0	-	-	0	n/a	-	1	46.9	(0.0 - 138.0)	3.60	(0.00 - 13.29)	-*
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	2.17	(0.03 - 6.04)	-*	0	-	-	-	-	.
Coorow (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Irwin (S)	8	55.6	(16.0 - 95.2)	1.69	(0.59 - 3.04)	-	1	7.0	(0.0 - 20.7)	0.61	(0.00 - 2.26)	-*
Mingenew (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Morawa (S)	1	28.8	(0.0 - 85.1)	0.73	(0.00 - 2.68)	-*	0	-	-	-	-	.
Mullewa (S)	1	27.6	(0.0 - 81.5)	0.94	(0.00 - 3.45)	-*	0	-	-	-	-	.
Murchison (S)	0	-	-	-	-	.	0	-	-	-	-	.
Northampton (S)	6	43.4	(8.1 - 78.7)	1.18	(0.32 - 2.29)	-	1	4.3	(0.0 - 12.7)	0.54	(0.00 - 1.98)	-*
Perenjori (S)	2	132.9	(0.0 - 316.1)	3.54	(0.04 - 9.85)	-*	0	-	-	-	-	.
Three Springs (S)	1	44.4	(0.0 - 131.1)	0.93	(0.00 - 3.42)	-*	0	-	-	-	-	.
Yalgoo (S)	0	-	-	-	-	.	0	-	-	-	-	.
Murchison HD												
Cue (S)	3	373.2	(0.0 - 792.4)	8.86	(0.71 - 20.68)	-*	2	301.8	(0.0 - 720.5)	16.67	(0.21 - 46.45)	-*
Meekatharra (S)	2	77.8	(0.0 - 185.3)	1.96	(0.02 - 5.47)	-*	1	46.2	(0.0 - 135.9)	2.50	(0.00 - 9.21)	-*
Mount Magnet (S)	0	-	-	0	n/a	-	1	58.8	(0.0 - 170.7)	5.20	(0.00 - 19.17)	-*
Sandstone (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wiluna (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Geraldton HD												
Geraldton (C)	47	64.0	(45.3 - 82.7)	1.85	(1.32 - 2.41)	^	17	19.0	(9.1 - 28.8)	1.35	(0.73 - 2.07)	-
Greenough (S) - Pt A	6	22.3	(4.1 - 40.5)	0.75	(0.20 - 1.45)	-	9	43.9	(14.8 - 73.0)	2.85	(1.09 - 4.99)	^*
Greenough (S) - Pt B	1	16.1	(0.0 - 47.5)	0.69	(0.00 - 2.54)	-*	0	-	-	-	-	.
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	1	9.3	(0.0 - 27.6)	0.34	(0.00 - 1.27)	-*	0	-	-	0	n/a	-
Bruce Rock (S)	1	11.9	(0.0 - 35.0)	0.59	(0.00 - 2.18)	-*	1	10.6	(0.0 - 31.3)	1.33	(0.00 - 4.92)	-*
Corrigin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Cunderdin (S)	2	37.2	(0.0 - 88.3)	1.11	(0.01 - 3.09)	-*	1	21.3	(0.0 - 62.9)	1.25	(0.00 - 4.62)	-*
Quairading (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Tammin (S)	2	173.9	(0.0 - 404.2)	3.75	(0.05 - 10.45)	-*	0	-	-	-	-	.
Upper Great Southern HD												
Boddington (S)	1	45.5	(0.0 - 133.9)	0.72	(0.00 - 2.66)	-*	0	-	-	0	n/a	-
Brookton (S)	3	60.6	(0.0 - 134.5)	1.61	(0.13 - 3.77)	-*	1	13.3	(0.0 - 39.3)	1.50	(0.00 - 5.53)	-*
Cuballing (S)	1	38.2	(0.0 - 112.9)	1.16	(0.00 - 4.27)	-*	0	-	-	-	-	.
Dumbleyung (S)	1	37.0	(0.0 - 109.2)	0.94	(0.00 - 3.48)	-*	0	-	-	-	-	.
Kondinin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Kulin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Lake Grace (S)	2	53.0	(0.0 - 128.3)	1.29	(0.02 - 3.60)	-*	3	61.5	(0.0 - 129.9)	4.81	(0.39 - 11.22)	-*
Narrogin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Narrogin (T)	7	44.7	(9.0 - 80.5)	1.45	(0.46 - 2.70)	-	3	20.4	(0.0 - 46.3)	1.16	(0.09 - 2.70)	-*
Pingelly (S)	3	50.6	(0.0 - 106.7)	1.49	(0.12 - 3.48)	-*	1	22.7	(0.0 - 67.0)	1.14	(0.00 - 4.21)	-*
Wagin (S)	9	91.5	(20.4 - 162.5)	3.12	(1.20 - 5.47)	^*	2	39.0	(0.0 - 92.9)	1.39	(0.02 - 3.88)	-*
Wandering (S)	1	75.0	(0.0 - 220.2)	2.55	(0.00 - 9.40)	-*	0	-	-	-	-	.
West Arthur (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Wickepin (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Williams (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Western HD												
Chittering (S)	7	59.4	(15.3 - 103.5)	1.91	(0.60 - 3.56)	-*	1	10.2	(0.0 - 30.2)	0.84	(0.00 - 3.10)	-*
Dalwallinu (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Dandaragan (S)	4	29.3	(0.5 - 58.2)	0.92	(0.14 - 2.01)	-*	0	-	-	0	n/a	-
Dowerin (S)	0	-	-	0	n/a	-	1	25.0	(0.0 - 73.7)	2.05	(0.00 - 7.56)	-*
Gingin (S)	5	27.6	(3.2 - 52.0)	0.81	(0.18 - 1.65)	-	1	6.7	(0.0 - 19.7)	0.44	(0.00 - 1.62)	-*
Goomalling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Moora (S)	4	66.5	(1.2 - 131.7)	1.48	(0.23 - 3.25)	-*	0	-	-	0	n/a	-

Cancer type: Lung, bronchus & trachea 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	3	67.7	(0.0 - 144.2)	2.01	(0.16 - 4.69)	-*	0	-	-	-	-	.
Wongan-Ballidu (S)	4	101.5	(1.3 - 201.6)	2.64	(0.41 - 5.79)	-*	2	30.2	(0.0 - 74.5)	2.77	(0.03 - 7.72)	-*
Eastern Wheatbelt HD												
Kellerberrin (S)	1	13.2	(0.0 - 38.6)	0.46	(0.00 - 1.71)	-*	0	-	-	0	n/a	-
Koorda (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Merredin (S)	3	29.5	(0.0 - 63.2)	0.70	(0.06 - 1.63)	-*	5	45.0	(4.3 - 85.7)	2.70	(0.59 - 5.54)	-*
Mount Marshall (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Mukinbudin (S)	1	23.5	(0.0 - 69.4)	1.04	(0.00 - 3.84)	-*	0	-	-	-	-	.
Narembeen (S)	1	15.2	(0.0 - 44.4)	0.76	(0.00 - 2.80)	-*	1	10.6	(0.0 - 31.3)	1.75	(0.00 - 6.45)	-*
Nungarin (S)	0	-	-	-	-	.	0	-	-	-	-	.
Trayning (S)	0	-	-	0	n/a	-	1	47.6	(0.0 - 139.8)	3.47	(0.00 - 12.80)	-*
Westonia (S)	0	-	-	-	-	.	0	-	-	-	-	.
Wyalkatchem (S)	2	69.5	(0.0 - 166.7)	1.86	(0.02 - 5.18)	-*	0	-	-	-	-	.
Yilgam (S)	3	52.2	(0.0 - 111.2)	1.79	(0.14 - 4.17)	-*	0	-	-	0	n/a	-
Avon HD												
Northam (S)	5	38.1	(4.8 - 71.5)	1.14	(0.25 - 2.34)	-*	3	28.7	(0.0 - 61.1)	1.89	(0.15 - 4.42)	-*
Northam (T)	12	50.1	(19.9 - 80.4)	1.34	(0.61 - 2.20)	-	5	16.8	(0.5 - 33.0)	1.07	(0.23 - 2.20)	-
Toodyay (S)	5	31.6	(3.9 - 59.3)	0.99	(0.22 - 2.03)	-	2	12.0	(0.0 - 28.6)	1.08	(0.01 - 3.01)	-*
York (S)	5	39.8	(4.9 - 74.8)	0.98	(0.21 - 2.02)	-	2	6.3	(0.0 - 15.0)	0.93	(0.01 - 2.59)	-*
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Kalgoorlie/Boulder (C) - Pt A	27	58.4	(36.1 - 80.8)	1.57	(0.99 - 2.22)	-	16	28.9	(13.5 - 44.2)	1.99	(1.05 - 3.08)	^
Kalgoorlie/Boulder (C) - Pt B	1	187.5	(0.0 - 543.3)	2.83	(0.00 - 10.44)	-*	1	166.7	(0.0 - 464.9)	12.84	(0.00 - 47.36)	-*
Laverton (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Leonora (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Menzies (S)	0	-	-	-	-	.	0	-	-	-	-	.
Ngaanyatjarraku (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
South East Coastal HD												
Dundas (S)	1	19.2	(0.0 - 56.9)	0.74	(0.00 - 2.74)	-*	0	-	-	-	-	.
Esperance (S)	9	22.6	(7.8 - 37.4)	0.62	(0.24 - 1.09)	-	8	19.2	(5.5 - 32.8)	1.25	(0.44 - 2.25)	-
Ravensthorpe (S)	2	32.7	(0.0 - 77.9)	1.04	(0.01 - 2.89)	-*	0	-	-	0	n/a	-
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	26	42.8	(25.2 - 60.4)	0.93	(0.58 - 1.32)	-	15	17.4	(7.0 - 27.8)	0.99	(0.50 - 1.55)	-
Albany (C) Bal	9	17.5	(6.0 - 29.1)	0.52	(0.20 - 0.90)	V	7	14.2	(3.6 - 24.7)	1.10	(0.35 - 2.06)	-
Cranbrook (S)	1	30.8	(0.0 - 90.8)	0.61	(0.00 - 2.25)	-*	0	-	-	-	-	.
Denmark (S)	7	31.4	(7.9 - 54.9)	0.94	(0.30 - 1.75)	-	3	12.7	(0.0 - 27.5)	1.00	(0.08 - 2.33)	-*
Jerramungup (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Plantagenet (S)	4	21.2	(0.2 - 42.2)	0.62	(0.10 - 1.36)	-	1	2.6	(0.0 - 7.7)	0.37	(0.00 - 1.37)	-*
Central Great Southern HD												
Broomehill (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Gnowangerup (S)	1	24.2	(0.0 - 71.4)	0.57	(0.00 - 2.11)	-*	0	-	-	0	n/a	-
Katanning (S)	5	38.4	(4.1 - 72.6)	1.01	(0.22 - 2.07)	-	4	29.6	(0.5 - 58.8)	1.64	(0.25 - 3.58)	-*
Kent (S)	1	74.1	(0.0 - 216.5)	1.89	(0.00 - 6.97)	-*	0	-	-	-	-	.
Kojonup (S)	1	5.7	(0.0 - 16.9)	0.31	(0.00 - 1.16)	-*	0	-	-	0	n/a	-
Tambellup (S)	0	-	-	0	n/a	-	0	-	-	-	-	.
Woodanilling (S)	0	-	-	-	-	.	0	-	-	-	-	.
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	7	20.1	(4.4 - 35.7)	0.58	(0.18 - 1.08)	-	7	14.6	(2.7 - 26.6)	1.38	(0.44 - 2.58)	-
Busselton (S)	23	23.2	(13.4 - 33.1)	0.72	(0.43 - 1.04)	-	23	20.2	(11.2 - 29.1)	1.50	(0.90 - 2.17)	-
Warren-Blackwood HD												
Boyup Brook (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bridgetown-Greenbushes (S)	5	32.4	(3.9 - 60.8)	0.94	(0.20 - 1.92)	-	4	25.3	(0.1 - 50.5)	1.70	(0.26 - 3.73)	-*
Manjimup (S)	12	29.0	(12.1 - 45.8)	0.93	(0.43 - 1.53)	-	1	3.6	(0.0 - 10.8)	0.19	(0.00 - 0.69)	V
Nannup (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Bunbury HD												
Bunbury (C)	44	41.9	(28.7 - 55.0)	1.15	(0.81 - 1.51)	-	25	22.6	(13.1 - 32.2)	1.29	(0.79 - 1.84)	-
Capel (S) - Pt A	1	17.2	(0.0 - 50.7)	0.52	(0.00 - 1.90)	-*	0	-	-	0	n/a	-
Capel (S) - Pt B	4	23.7	(0.6 - 46.9)	0.81	(0.13 - 1.78)	-	1	7.3	(0.0 - 21.6)	0.54	(0.00 - 2.01)	-*
Dardanup (S) - Pt A	5	33.1	(3.7 - 62.5)	1.02	(0.22 - 2.09)	-	2	11.4	(0.0 - 27.3)	0.90	(0.01 - 2.52)	-*
Dardanup (S) - Pt B	2	27.4	(0.0 - 67.6)	0.72	(0.01 - 1.99)	-*	1	20.8	(0.0 - 60.8)	1.07	(0.00 - 3.94)	-*
Wellington HD												

Cancer type: Lung, bronchus & trachea 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	15	46.3	(21.7 - 70.8)	1.29	(0.66 - 2.02)	-	4	13.2	(0.0 - 26.5)	0.77	(0.12 - 1.69)	-
Donnybrook-Balingup (S)	4	26.8	(0.6 - 53.0)	0.72	(0.11 - 1.58)	-	2	15.3	(0.0 - 36.4)	0.87	(0.01 - 2.42)	-*
Harvey-Yarloop HD												
Harvey (S) - Pt A	5	17.6	(1.9 - 33.2)	0.55	(0.12 - 1.13)	-	9	36.0	(12.1 - 59.9)	2.37	(0.91 - 4.16)	-*
Harvey (S) - Pt B	7	22.9	(5.7 - 40.1)	0.69	(0.22 - 1.28)	-	1	2.0	(0.0 - 5.8)	0.23	(0.00 - 0.85)	V*
Total State	2166	33.6	(32.1 - 35.0)	1.00	(0.96 - 1.04)	-	1058	13.9	(13.0 - 14.8)	1.00	(0.94 - 1.06)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.

W.A. Cancer by SLA (DOH Areas)
Cancer type: All cancers 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
NORTH METRO HEALTH REGION												
North Metro HD												
Cambridge (T)	127	108.1	(87.0 - 129.1)	0.84	(0.70 - 1.00)	-	117	83.8	(65.5 - 102.1)	0.91	(0.76 - 1.09)	-
Claremont (T)	59	143.7	(102.6 - 184.9)	0.97	(0.75 - 1.26)	-	59	77.4	(50.1 - 104.8)	0.92	(0.71 - 1.20)	-
Cottesloe (T)	42	126.4	(85.6 - 167.3)	0.98	(0.68 - 1.29)	-	25	54.9	(18.3 - 91.4)	0.65	(0.40 - 0.94)	V
Joondalup (C) - North	124	129.5	(106.0 - 153.1)	0.95	(0.80 - 1.14)	-	125	113.5	(93.0 - 134.1)	1.25	(1.04 - 1.49)	^
Joondalup (C) - South	362	115.0	(102.7 - 127.3)	0.83	(0.75 - 0.92)	V	304	81.5	(71.7 - 91.3)	0.96	(0.85 - 1.07)	-
Mosman Park (T)	49	138.7	(97.7 - 179.7)	1.03	(0.74 - 1.34)	-	36	63.8	(35.9 - 91.7)	0.83	(0.56 - 1.13)	-
Nedlands (C)	124	109.2	(87.4 - 130.9)	0.93	(0.78 - 1.12)	-	155	94.9	(75.0 - 114.8)	1.21	(1.03 - 1.41)	^
Peppermint Grove (S)	8	128.5	(37.2 - 219.7)	0.82	(0.29 - 1.48)	-	8	81.6	(15.0 - 148.1)	1.15	(0.40 - 2.07)	-
Stirling (C) - Central	575	146.3	(133.8 - 158.8)	1.04	(0.96 - 1.13)	-	413	82.7	(73.9 - 91.5)	0.96	(0.87 - 1.05)	-
Stirling (C) - Coastal	338	131.6	(116.7 - 146.5)	0.99	(0.89 - 1.10)	-	266	87.4	(75.7 - 99.2)	0.94	(0.83 - 1.06)	-
Subiaco (C)	81	158.5	(122.0 - 195.0)	1.14	(0.91 - 1.42)	-	79	94.1	(69.0 - 119.3)	1.20	(0.95 - 1.50)	-
Wanneroo (C) - North-East	93	158.0	(125.3 - 190.6)	1.15	(0.93 - 1.41)	-	63	91.1	(67.2 - 115.0)	1.05	(0.81 - 1.35)	-
Wanneroo (C) - North-West	82	119.2	(92.6 - 145.8)	0.88	(0.70 - 1.09)	-	56	78.5	(57.4 - 99.6)	0.94	(0.71 - 1.22)	-
Wanneroo (C) - South	115	137.2	(111.9 - 162.5)	1.03	(0.86 - 1.25)	-	77	79.4	(61.3 - 97.6)	0.90	(0.71 - 1.13)	-
EAST METRO HEALTH REGION												
Bentley HD												
Belmont (C)	217	161.2	(138.3 - 184.1)	1.19	(1.04 - 1.37)	^	135	86.7	(70.1 - 103.2)	0.96	(0.81 - 1.14)	-
Canning (C)	330	135.9	(120.9 - 150.8)	1.00	(0.90 - 1.12)	-	256	80.8	(70.2 - 91.4)	0.95	(0.84 - 1.08)	-
South Perth (C)	192	123.3	(103.9 - 142.7)	0.93	(0.80 - 1.07)	-	189	86.4	(70.7 - 102.1)	0.94	(0.82 - 1.09)	-
Victoria Park (T)	227	193.7	(163.4 - 224.0)	1.29	(1.13 - 1.47)	^	182	91.0	(71.9 - 110.1)	1.02	(0.88 - 1.18)	-
Inner City HD												
Perth (C) - Inner	5	301.6	(57.0 - 546.3)	1.33	(0.29 - 2.72)	-*	1	83.3	(0.0 - 245.5)	0.58	(0.00 - 2.14)	-*
Perth (C) - Remainder	57	198.4	(145.1 - 251.8)	1.38	(1.06 - 1.80)	^	18	73.6	(34.7 - 112.5)	0.81	(0.45 - 1.23)	-
Stirling (C) - South-Eastern	112	126.8	(98.5 - 155.2)	1.07	(0.88 - 1.29)	-	109	84.4	(61.6 - 107.3)	1.06	(0.87 - 1.28)	-
Vincent (T)	145	137.3	(112.9 - 161.7)	1.01	(0.86 - 1.20)	-	99	72.3	(54.5 - 90.1)	0.84	(0.69 - 1.03)	-
Kalamunda HD												
Kalamunda (S)	227	138.8	(120.4 - 157.2)	1.01	(0.88 - 1.15)	-	162	83.3	(69.7 - 96.8)	0.95	(0.82 - 1.12)	-
Swan HD												
Bassendean (T)	91	167.9	(132.3 - 203.6)	1.20	(0.97 - 1.48)	-	78	125.6	(94.9 - 156.4)	1.30	(1.03 - 1.63)	^
Bayswater (C)	291	125.0	(110.0 - 140.0)	0.90	(0.80 - 1.02)	-	268	92.1	(79.6 - 104.6)	1.07	(0.94 - 1.20)	-
Mundaring (S)	135	122.1	(101.1 - 143.1)	0.88	(0.74 - 1.05)	-	118	84.7	(68.8 - 100.6)	1.04	(0.86 - 1.25)	-
Swan (C)	290	140.5	(124.1 - 156.9)	1.02	(0.90 - 1.14)	-	217	90.3	(77.8 - 102.9)	1.03	(0.90 - 1.18)	-
SOUTH METRO HEALTH REGION												
Armadale HD												
Armadale (C)	188	118.7	(101.6 - 135.9)	0.87	(0.75 - 1.01)	-	177	99.1	(83.8 - 114.3)	1.10	(0.94 - 1.27)	-
Gosnells (C)	308	139.6	(123.8 - 155.4)	1.02	(0.91 - 1.14)	-	217	83.5	(71.9 - 95.1)	0.95	(0.83 - 1.08)	-
Serpentine-Jarrahdale (S)	40	120.7	(82.8 - 158.7)	0.91	(0.63 - 1.21)	-	18	56.8	(30.3 - 83.4)	0.64	(0.35 - 0.96)	V
Fremantle HD												
Cockburn (C)	287	153.1	(135.3 - 171.0)	1.10	(0.98 - 1.24)	-	211	95.6	(82.3 - 109.0)	1.09	(0.95 - 1.25)	-
East Fremantle (T)	31	108.9	(68.6 - 149.1)	0.80	(0.52 - 1.10)	-	29	61.4	(33.2 - 89.6)	0.93	(0.59 - 1.29)	-
Fremantle (C) - Inner	1	33.9	(0.0 - 100.1)	0.17	(0.00 - 0.63)	V	1	74.1	(0.0 - 216.5)	0.51	(0.00 - 1.87)	-*
Fremantle (C) - Remainder	166	153.6	(129.4 - 177.9)	1.09	(0.93 - 1.27)	-	128	100.7	(80.4 - 120.9)	1.06	(0.89 - 1.26)	-
Melville (C)	502	123.9	(112.4 - 135.4)	0.91	(0.84 - 1.00)	-	418	76.9	(68.4 - 85.3)	0.92	(0.84 - 1.02)	-
Rockingham-Kwinana HD												
Kwinana (T)	112	168.4	(136.7 - 200.1)	1.27	(1.05 - 1.54)	^	63	90.5	(67.5 - 113.4)	1.04	(0.81 - 1.34)	-
Rockingham (C)	392	152.8	(137.1 - 168.4)	1.10	(1.00 - 1.22)	-	271	94.0	(82.1 - 105.9)	1.08	(0.95 - 1.22)	-
Peel HD												
Mandurah (C)	350	139.9	(124.1 - 155.6)	1.01	(0.91 - 1.13)	-	230	86.7	(74.2 - 99.1)	1.01	(0.89 - 1.15)	-
Murray (S)	63	126.5	(91.3 - 161.7)	0.87	(0.68 - 1.13)	-	59	135.2	(99.2 - 171.2)	1.47	(1.13 - 1.91)	^
Waroona (S)	14	107.2	(47.5 - 167.0)	0.72	(0.36 - 1.15)	-	16	127.8	(62.9 - 192.6)	1.26	(0.66 - 1.95)	-
KIMBERLEY HEALTH REGION												
Kimberley HD												
Broome (S)	21	96.8	(54.0 - 139.6)	0.70	(0.41 - 1.03)	-	16	67.9	(32.9 - 103.0)	0.91	(0.48 - 1.40)	-
Derby-West Kimberley (S)	29	192.5	(121.4 - 263.6)	1.37	(0.88 - 1.91)	-	14	114.9	(52.1 - 177.7)	1.13	(0.56 - 1.79)	-
Halls Creek (S)	10	146.2	(51.9 - 240.4)	1.02	(0.42 - 1.75)	-	7	116.3	(26.4 - 206.1)	1.17	(0.37 - 2.18)	-
Wyndham-East Kimberley (S)	13	87.9	(36.4 - 139.4)	0.74	(0.35 - 1.19)	-	8	68.1	(17.1 - 119.0)	0.84	(0.30 - 1.52)	-
PILBARA-GASCOYNE HEALTH REGION												
West Pilbara HD												
Ashburton (S)	4	63.5	(0.0 - 137.6)	0.38	(0.06 - 0.84)	V	6	124.6	(5.6 - 243.6)	1.11	(0.30 - 2.16)	-
Roebourne (S)	23	131.0	(66.9 - 195.0)	0.95	(0.57 - 1.37)	-	8	38.8	(2.3 - 75.2)	0.54	(0.19 - 0.97)	V

Cancer type: All cancers 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Gascoyne HD												
Carnarvon (S)	34	144.7	(95.6 - 193.7)	1.10	(0.74 - 1.50)	-	11	60.1	(23.9 - 96.3)	0.66	(0.29 - 1.10)	-
Exmouth (S)	6	121.9	(8.8 - 234.9)	0.74	(0.20 - 1.44)	-	6	96.7	(16.9 - 176.4)	1.30	(0.35 - 2.53)	-
Shark Bay (S)	1	24.8	(0.0 - 73.4)	0.16	(0.00 - 0.59)	V	1	48.8	(0.0 - 143.8)	0.33	(0.00 - 1.23)	-*
Upper Gascoyne (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
East Pilbara HD												
East Pilbara (S)	10	139.3	(46.4 - 232.2)	0.79	(0.33 - 1.35)	-	4	53.3	(0.0 - 112.9)	0.59	(0.09 - 1.29)	-
Port Hedland (T)	24	118.7	(65.4 - 172.1)	0.89	(0.54 - 1.27)	-	14	78.2	(35.4 - 121.1)	0.92	(0.46 - 1.46)	-
MIDWEST MURCHISON HEALTH REGION												
Midwest HD												
Carnamah (S)	2	89.3	(0.0 - 211.6)	0.63	(0.01 - 1.77)	-*	2	118.3	(0.0 - 276.8)	1.12	(0.01 - 3.13)	-*
Chapman Valley (S)	2	60.0	(0.0 - 145.0)	0.53	(0.01 - 1.49)	-*	3	95.1	(0.0 - 208.7)	1.43	(0.12 - 3.33)	-*
Coorow (S)	6	126.5	(24.6 - 228.5)	0.88	(0.24 - 1.71)	-	2	35.7	(0.0 - 88.5)	0.53	(0.01 - 1.47)	-*
Irwin (S)	24	172.0	(101.9 - 242.1)	1.28	(0.78 - 1.84)	-	10	88.7	(33.1 - 144.3)	0.99	(0.41 - 1.70)	-
Mingenew (S)	2	105.3	(0.0 - 249.2)	0.79	(0.01 - 2.20)	-*	1	60.6	(0.0 - 177.6)	0.64	(0.00 - 2.35)	-*
Morawa (S)	4	118.1	(2.5 - 233.6)	0.71	(0.11 - 1.56)	-	2	52.5	(0.0 - 132.7)	0.68	(0.01 - 1.89)	-*
Mullewa (S)	4	126.6	(2.3 - 251.0)	0.89	(0.14 - 1.96)	-*	2	121.1	(0.0 - 304.9)	0.88	(0.01 - 2.44)	-*
Murchison (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Northampton (S)	20	147.2	(81.5 - 213.0)	0.99	(0.56 - 1.46)	-	7	46.6	(12.0 - 81.3)	0.61	(0.19 - 1.14)	-
Perenjori (S)	3	175.9	(0.0 - 377.3)	1.27	(0.10 - 2.97)	-*	1	33.3	(0.0 - 97.6)	0.56	(0.00 - 2.08)	-*
Three Springs (S)	5	147.0	(12.4 - 281.7)	1.11	(0.24 - 2.27)	-	4	126.3	(0.0 - 265.2)	1.55	(0.24 - 3.41)	-*
Yalgoo (S)	1	62.5	(0.0 - 184.2)	0.77	(0.00 - 2.83)	-*	0	-	-	0	n/a	-
Murchison HD												
Cue (S)	3	373.2	(0.0 - 792.4)	2.07	(0.17 - 4.83)	-*	3	478.3	(0.0 - 1,018.1)	3.52	(0.28 - 8.22)	-*
Meekatharra (S)	8	273.5	(81.4 - 465.5)	1.87	(0.66 - 3.37)	-*	4	164.9	(3.9 - 325.8)	1.53	(0.24 - 3.35)	-*
Mount Magnet (S)	0	-	-	0	n/a	-	1	58.8	(0.0 - 170.7)	0.77	(0.00 - 2.83)	-*
Sandstone (S)	0	-	-	0	n/a	-	0	-	-	-	-	-
Wiluna (S)	1	24.0	(0.0 - 70.9)	0.40	(0.00 - 1.47)	-*	2	195.8	(0.0 - 476.2)	2.16	(0.03 - 6.03)	-*
Geraldton HD												
Geraldton (C)	149	198.5	(166.1 - 231.0)	1.45	(1.23 - 1.70)	^	96	109.5	(85.5 - 133.5)	1.21	(0.99 - 1.49)	-
Greenough (S) - Pt A	33	129.9	(84.4 - 175.3)	1.00	(0.67 - 1.37)	-	23	102.6	(59.8 - 145.5)	1.11	(0.67 - 1.61)	-
Greenough (S) - Pt B	4	81.2	(1.1 - 161.3)	0.67	(0.10 - 1.47)	-	2	54.8	(0.0 - 130.4)	0.72	(0.01 - 2.01)	-*
WHEATBELT HEALTH REGION												
Central Wheatbelt HD												
Beverley (S)	7	80.0	(20.3 - 139.6)	0.59	(0.19 - 1.10)	-	4	27.9	(0.0 - 55.8)	0.55	(0.08 - 1.19)	-
Bruce Rock (S)	9	168.2	(55.0 - 281.4)	1.30	(0.50 - 2.27)	-	4	70.2	(0.0 - 145.1)	0.86	(0.13 - 1.89)	-
Corrigin (S)	4	57.9	(0.0 - 116.2)	0.52	(0.08 - 1.13)	-	7	128.9	(28.1 - 229.7)	1.21	(0.38 - 2.25)	-
Cunderdin (S)	4	78.3	(2.2 - 154.5)	0.54	(0.08 - 1.17)	-	6	108.9	(13.3 - 204.5)	1.16	(0.31 - 2.25)	-
Quairading (S)	5	112.1	(13.9 - 210.4)	0.81	(0.18 - 1.66)	-	7	132.7	(21.7 - 243.8)	1.38	(0.43 - 2.57)	-
Tammin (S)	4	310.9	(20.3 - 601.4)	1.78	(0.27 - 3.89)	-*	2	48.8	(0.0 - 114.8)	1.31	(0.02 - 3.64)	-*
Upper Great Southern HD												
Boddington (S)	5	126.2	(2.2 - 250.1)	0.85	(0.19 - 1.75)	-	4	115.5	(1.2 - 229.8)	1.17	(0.18 - 2.57)	-*
Brookton (S)	7	133.5	(26.2 - 240.7)	0.88	(0.28 - 1.64)	-	8	161.6	(35.9 - 287.3)	1.84	(0.65 - 3.32)	-*
Cuballing (S)	4	148.8	(3.5 - 294.1)	1.17	(0.18 - 2.56)	-*	2	86.5	(0.0 - 206.3)	0.98	(0.01 - 2.72)	-*
Dumbleyung (S)	6	172.1	(35.1 - 309.1)	1.39	(0.38 - 2.71)	-*	0	-	-	0	n/a	-
Kondinin (S)	2	58.9	(0.0 - 140.7)	0.46	(0.01 - 1.27)	-*	2	84.1	(0.0 - 199.9)	0.82	(0.01 - 2.29)	-*
Kulin (S)	3	72.4	(0.0 - 156.7)	0.62	(0.05 - 1.44)	-	2	62.3	(0.0 - 148.8)	0.67	(0.01 - 1.86)	-*
Lake Grace (S)	8	180.9	(53.4 - 308.4)	1.26	(0.44 - 2.27)	-	6	138.4	(25.0 - 251.8)	1.51	(0.41 - 2.93)	-*
Narrogin (S)	0	-	-	0	n/a	V	0	-	-	0	n/a	V
Narrogin (T)	34	209.1	(133.5 - 284.8)	1.67	(1.12 - 2.28)	^	20	120.6	(58.2 - 183.0)	1.19	(0.68 - 1.76)	-
Pingelly (S)	9	188.2	(53.4 - 323.0)	1.11	(0.42 - 1.94)	-	7	120.4	(22.2 - 218.6)	1.24	(0.39 - 2.31)	-
Wagin (S)	15	153.1	(60.3 - 245.8)	1.24	(0.63 - 1.94)	-	11	131.1	(44.6 - 217.5)	1.22	(0.53 - 2.04)	-
Wandering (S)	1	75.0	(0.0 - 220.2)	0.62	(0.00 - 2.28)	-*	1	83.3	(0.0 - 232.4)	1.04	(0.00 - 3.84)	-*
West Arthur (S)	1	20.4	(0.0 - 60.0)	0.18	(0.00 - 0.65)	V	0	-	-	0	n/a	-
Wickepin (S)	3	99.7	(0.0 - 223.9)	0.66	(0.05 - 1.54)	-	2	80.9	(0.0 - 192.5)	0.78	(0.01 - 2.18)	-*
Williams (S)	1	34.5	(0.0 - 101.7)	0.22	(0.00 - 0.81)	V	4	167.4	(4.6 - 330.2)	1.39	(0.21 - 3.04)	-*
Western HD												
Chittering (S)	19	169.4	(92.0 - 246.9)	1.33	(0.75 - 1.99)	-	3	27.4	(0.0 - 58.6)	0.40	(0.03 - 0.93)	V
Dalwallinu (S)	8	129.3	(40.1 - 218.4)	0.95	(0.33 - 1.71)	-	1	10.6	(0.0 - 31.3)	0.18	(0.00 - 0.65)	V
Dandaragan (S)	14	102.5	(48.5 - 156.5)	0.82	(0.41 - 1.31)	-	7	73.4	(18.7 - 128.1)	0.80	(0.25 - 1.49)	-
Dowerin (S)	3	109.0	(0.0 - 238.4)	0.77	(0.06 - 1.79)	-*	2	54.4	(0.0 - 128.6)	0.68	(0.01 - 1.88)	-*
Gingin (S)	32	186.4	(120.7 - 252.1)	1.33	(0.87 - 1.83)	-	12	74.3	(32.3 - 116.3)	0.85	(0.39 - 1.39)	-
Goomalling (S)	1	25.0	(0.0 - 72.8)	0.18	(0.00 - 0.65)	V	1	15.4	(0.0 - 45.3)	0.26	(0.00 - 0.94)	V*
Moora (S)	10	139.8	(49.5 - 230.2)	0.88	(0.36 - 1.51)	-	4	48.9	(0.0 - 104.2)	0.50	(0.08 - 1.10)	-

Cancer type: All cancers 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Victoria Plains (S)	8	171.6	(52.0 - 291.3)	1.29	(0.45 - 2.33)	-	1	62.5	(0.0 - 181.1)	0.39	(0.00 - 1.43)	-*
Wongan-Ballidu (S)	8	193.3	(57.2 - 329.5)	1.30	(0.46 - 2.34)	-	7	122.2	(20.9 - 223.4)	1.51	(0.47 - 2.81)	-
Eastern Wheatbelt HD												
Kellerberrin (S)	7	112.6	(27.9 - 197.3)	0.80	(0.25 - 1.49)	-	10	138.5	(38.7 - 238.2)	1.63	(0.67 - 2.78)	-
Koorda (S)	2	121.4	(0.0 - 280.9)	0.78	(0.01 - 2.16)	-*	1	62.5	(0.0 - 183.1)	0.60	(0.00 - 2.20)	-*
Merredin (S)	18	138.5	(72.1 - 204.8)	1.02	(0.56 - 1.54)	-	19	162.2	(87.0 - 237.3)	1.62	(0.91 - 2.43)	-
Mount Marshall (S)	1	43.5	(0.0 - 128.1)	0.34	(0.00 - 1.24)	-*	0	-	-	0	n/a	-
Mukinbudin (S)	1	23.5	(0.0 - 69.4)	0.27	(0.00 - 1.00)	-*	0	-	-	0	n/a	-
Narembeen (S)	7	156.8	(37.0 - 276.6)	1.29	(0.40 - 2.40)	-	1	10.6	(0.0 - 31.3)	0.27	(0.00 - 1.00)	-*
Nungarin (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Trayning (S)	3	168.1	(0.0 - 376.3)	1.13	(0.09 - 2.64)	-*	2	95.2	(0.0 - 224.1)	1.07	(0.01 - 2.98)	-*
Westonia (S)	1	102.0	(0.0 - 300.0)	0.68	(0.00 - 2.50)	-*	0	-	-	0	n/a	-
Wyalkatchem (S)	5	147.6	(16.1 - 279.0)	1.17	(0.25 - 2.39)	-*	3	105.4	(0.0 - 236.7)	1.17	(0.09 - 2.74)	-*
Yilgam (S)	10	195.1	(73.6 - 316.7)	1.46	(0.60 - 2.49)	-	2	44.2	(0.0 - 105.4)	0.48	(0.01 - 1.33)	-*
Avon HD												
Northam (S)	18	145.4	(74.6 - 216.1)	1.05	(0.58 - 1.58)	-	8	73.2	(22.5 - 123.8)	0.81	(0.28 - 1.46)	-
Northam (T)	44	179.2	(122.3 - 236.1)	1.21	(0.86 - 1.60)	-	41	108.1	(68.4 - 147.7)	1.39	(0.97 - 1.85)	-
Toodyay (S)	20	130.3	(73.2 - 187.3)	1.00	(0.57 - 1.48)	-	14	96.7	(45.3 - 148.1)	1.20	(0.59 - 1.90)	-
York (S)	20	146.9	(81.1 - 212.6)	0.96	(0.55 - 1.43)	-	14	77.8	(32.7 - 122.8)	1.02	(0.51 - 1.63)	-
GOLDFIELDS-SOUTH EAST COASTAL HEALTH REGION												
Northern Goldfields HD												
Coolgardie (S)	7	113.9	(21.5 - 206.4)	0.79	(0.25 - 1.48)	-	6	83.2	(9.5 - 156.9)	1.22	(0.33 - 2.37)	-
Kalgoorlie/Boulder (C) - Pt A	88	169.5	(133.1 - 205.9)	1.20	(0.96 - 1.48)	-	67	114.7	(84.9 - 144.6)	1.22	(0.95 - 1.56)	-
Kalgoorlie/Boulder (C) - Pt B	3	597.2	(0.0 - 1,233.6)	1.99	(0.16 - 4.66)	-*	2	357.1	(0.0 - 828.0)	3.71	(0.05 - 10.33)	-*
Laverton (S)	1	38.1	(0.0 - 112.7)	0.27	(0.00 - 0.99)	V*	1	46.5	(0.0 - 137.3)	0.76	(0.00 - 2.79)	-*
Leonora (S)	5	142.6	(0.0 - 290.5)	0.87	(0.19 - 1.78)	-	1	33.3	(0.0 - 96.5)	0.49	(0.00 - 1.80)	-*
Menzies (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
Ngaanyatjarraku (S)	0	-	-	0	n/a	V	1	32.0	(0.0 - 94.5)	0.38	(0.00 - 1.39)	-*
South East Coastal HD												
Dundas (S)	5	124.0	(17.5 - 230.5)	0.89	(0.19 - 1.83)	-	2	61.2	(0.0 - 147.6)	0.63	(0.01 - 1.74)	-*
Esperance (S)	54	129.0	(94.4 - 163.7)	0.91	(0.69 - 1.20)	-	39	88.5	(59.9 - 117.2)	0.96	(0.66 - 1.29)	-
Ravensthorpe (S)	4	62.3	(1.4 - 123.1)	0.51	(0.08 - 1.12)	-	4	87.1	(0.7 - 173.6)	0.91	(0.14 - 2.00)	-*
GREAT SOUTHERN HEALTH REGION												
Lower Great Southern HD												
Albany (C) - Central	114	157.6	(125.4 - 189.8)	0.99	(0.82 - 1.19)	-	87	83.7	(61.8 - 105.6)	0.91	(0.73 - 1.13)	-
Albany (C) Bal	41	83.3	(57.3 - 109.3)	0.58	(0.41 - 0.78)	V	43	92.9	(64.8 - 121.0)	1.10	(0.78 - 1.45)	-
Cranbrook (S)	5	106.9	(10.6 - 203.2)	0.75	(0.16 - 1.53)	-	3	69.5	(0.0 - 151.0)	0.94	(0.08 - 2.20)	-*
Denmark (S)	22	92.3	(53.0 - 131.7)	0.73	(0.43 - 1.07)	-	20	92.5	(50.1 - 134.9)	1.09	(0.62 - 1.61)	-
Jerramungup (S)	1	71.4	(0.0 - 201.0)	0.18	(0.00 - 0.68)	V	1	22.8	(0.0 - 67.5)	0.35	(0.00 - 1.31)	-*
Plantagenet (S)	30	170.2	(109.2 - 231.3)	1.17	(0.76 - 1.62)	-	15	77.2	(35.8 - 118.6)	0.89	(0.45 - 1.39)	-
Central Great Southern HD												
Broomehill (S)	2	109.7	(0.0 - 258.5)	0.83	(0.01 - 2.32)	-*	0	-	-	0	n/a	-
Gnowangerup (S)	7	167.8	(44.9 - 290.7)	0.97	(0.30 - 1.81)	-	2	24.1	(0.0 - 57.1)	0.41	(0.01 - 1.15)	-
Katanning (S)	23	148.3	(85.8 - 210.8)	1.12	(0.67 - 1.62)	-	17	85.4	(41.0 - 129.8)	1.09	(0.58 - 1.66)	-
Kent (S)	1	74.1	(0.0 - 216.5)	0.46	(0.00 - 1.68)	-*	0	-	-	0	n/a	-
Kojonup (S)	12	105.9	(43.0 - 168.7)	0.92	(0.42 - 1.50)	-	10	72.1	(23.3 - 120.9)	1.18	(0.48 - 2.01)	-
Tambellup (S)	2	92.6	(0.0 - 220.7)	0.64	(0.01 - 1.78)	-*	1	50.0	(0.0 - 147.4)	0.50	(0.00 - 1.83)	-*
Woodanilling (S)	0	-	-	0	n/a	-	0	-	-	0	n/a	-
SOUTH WEST HEALTH REGION												
Vasse-Leeuwin HD												
Augusta-Margaret River (S)	49	122.5	(86.1 - 159.0)	0.98	(0.71 - 1.27)	-	22	51.9	(28.6 - 75.3)	0.68	(0.40 - 0.99)	V
Busselton (S)	122	120.0	(97.6 - 142.4)	0.94	(0.78 - 1.12)	-	102	93.3	(73.2 - 113.4)	1.06	(0.87 - 1.30)	-
Warren-Blackwood HD												
Boyup Brook (S)	2	17.4	(0.0 - 41.3)	0.20	(0.00 - 0.56)	V	7	74.8	(7.7 - 141.9)	0.93	(0.29 - 1.73)	-
Bridgetown-Greenbushes (S)	19	127.2	(67.9 - 186.4)	0.88	(0.49 - 1.32)	-	14	78.5	(36.3 - 120.6)	0.95	(0.47 - 1.50)	-
Manjimup (S)	59	152.5	(112.3 - 192.7)	1.12	(0.86 - 1.45)	-	29	70.5	(43.1 - 97.9)	0.86	(0.55 - 1.21)	-
Nannup (S)	4	77.3	(2.4 - 152.2)	0.63	(0.10 - 1.39)	-	1	13.5	(0.0 - 39.6)	0.24	(0.00 - 0.89)	V*
Bunbury HD												
Bunbury (C)	164	149.5	(124.9 - 174.1)	1.03	(0.88 - 1.21)	-	122	94.0	(75.2 - 112.9)	0.99	(0.82 - 1.18)	-
Capel (S) - Pt A	6	106.4	(13.4 - 199.5)	0.76	(0.20 - 1.47)	-	1	21.7	(0.0 - 64.2)	0.19	(0.00 - 0.71)	V
Capel (S) - Pt B	22	144.0	(83.8 - 204.2)	1.10	(0.65 - 1.60)	-	10	78.8	(29.2 - 128.5)	0.86	(0.35 - 1.46)	-
Dardanup (S) - Pt A	24	166.2	(99.1 - 233.2)	1.19	(0.72 - 1.71)	-	8	44.3	(12.7 - 75.9)	0.57	(0.20 - 1.03)	-
Dardanup (S) - Pt B	7	83.9	(19.3 - 148.5)	0.62	(0.19 - 1.16)	-	5	75.0	(8.0 - 141.9)	0.86	(0.19 - 1.76)	-
Wellington HD												

Cancer type: All cancers 1998-2002: mortality(1)

Area	Males						Females					
	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)	Cases	ASR	95% c.i.	SRR	95% c.i.	Sig(2)
Collie (S)	48	142.1	(100.0 - 184.1)	1.00	(0.72 - 1.30)	-	30	85.9	(52.8 - 119.0)	0.93	(0.60 - 1.29)	-
Donnybrook-Balingup (S)	17	99.4	(51.9 - 146.8)	0.75	(0.40 - 1.15)	-	14	82.6	(37.8 - 127.4)	0.94	(0.47 - 1.50)	-
Harvey-Yarloop HD												
Harvey (S) - Pt A	32	119.6	(76.4 - 162.8)	0.87	(0.57 - 1.20)	-	29	114.8	(72.3 - 157.2)	1.22	(0.78 - 1.71)	-
Harvey (S) - Pt B	49	160.8	(115.4 - 206.2)	1.18	(0.85 - 1.54)	-	26	77.7	(45.2 - 110.2)	0.93	(0.58 - 1.33)	-
Total State	8892	137.0	(134.1 - 139.9)	1.00	(0.98 - 1.02)	-	6757	87.4	(85.1 - 89.6)	1.00	(0.98 - 1.02)	-

NOTES (refer also to "Statistical Methods"): (1) Does not include BCC/SCC; (2) "-" Statistically similar to State rates;

"^" Significant excess of cases; "v" Significant deficit of cases; "." no assessment possible.

* SRR calculations based on less than 5 expected cases. Comparisons and assessment of SRRs should take note of 95% c.i.

It should be noted that even "statistically-significant" results may be misleading when numbers of cases are small.